PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Nakamura, H; Komatsu, K; Ayaki, M; Kawamoto, S; Murakami, M; Uoshima, N; Yagi, T; Hasegawa, T; Yasumi, M; Karasuno, T; Teshima, H; Hiraoka, A; Masaoka, T				Nakamura, H; Komatsu, K; Ayaki, M; Kawamoto, S; Murakami, M; Uoshima, N; Yagi, T; Hasegawa, T; Yasumi, M; Karasuno, T; Teshima, H; Hiraoka, A; Masaoka, T			Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-best disease after allogeneic bone marrow transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on New Trends in Immunopharmacology 1998	JUL   25, 1998	TOKYO, JAPAN			allogeneic bone marrow transplantation; acute graft-versus-host disease; soluble IL-2 receptor; IL-12; IL-18; IFN-gamma	HOST DISEASE; INTERLEUKIN-2 RECEPTORS; CYTOKINE; CELLS; INTERFERON	Background: Acute graft-versus-host disease still represents the major factor that limits successful allogeneic bone marrow transplantation. Cytokines released by type 1 T-helper cells are thought to play a pivotal role in acute graft-versus-host disease. Objective: This study was performed to investigate whether the serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma were associated with the manifestation of acute graft-versus-host disease. Methods: Serum cytokine levels were measured by sandwich ELISA in 18 patients who underwent allogeneic bone marrow transplantation. Results: Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma were increased in patients in whom acute graft-versus-host disease developed. However, only serum soluble IL-2 receptor levels were significantly related to disease severity. Serum levels of IL-12 and IL-18, both of which are mainly produced by activated macrophages, were increased in different phases of acute graft-versus-host disease, especially grade I. Serum levels of soluble IL-2 receptor and IFN-gamma were significantly elevated in patients with fever. Conclusion: Serum levels of soluble IL-2 receptor were more closely related to the severity of acute graft-versus-host disease than those of IL-12, IL-18, and IFN-gamma.	Osaka Med Ctr Canc & Cardiovasc Dis, Dept Tumor Biochem, Higashinari Ku, Osaka 5378511, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Med 5, Higashinari Ku, Osaka 5378511, Japan	Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Medical Center for Cancer & Cardiovascular Diseases	Nakamura, H (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Tumor Biochem, Higashinari Ku, 3-3 Nakamichi 1-Chome, Osaka 5378511, Japan.							ADAMS DH, 1989, LANCET, V1, P469; Bonnotte B, 1996, EUR CYTOKINE NETW, V7, P389; BUNJES D, 1995, BONE MARROW TRANSPL, V15, P727; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Ferrara JLM, 1996, STEM CELLS, V14, P473, DOI 10.1002/stem.140473; Fujimori Y, 1998, BLOOD, V92, p332B; FUKUDA H, 1994, BONE MARROW TRANSPL, V13, P181; GRANELLIPIPERNO A, 1990, J EXP MED, V171, P533, DOI 10.1084/jem.171.2.533; Krenger W, 1996, J Hematother, V5, P3, DOI 10.1089/scd.1.1996.5.3; Krenger W, 1997, TRANSPLANTATION, V64, P553, DOI 10.1097/00007890-199708270-00001; NIEDERWIESER D, 1990, TRANSPLANTATION, V50, P620, DOI 10.1097/00007890-199010000-00019; Okamura H, 1998, ADV IMMUNOL, V70, P281, DOI 10.1016/S0065-2776(08)60389-2; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; RUBIN LA, 1985, J IMMUNOL, V135, P3172; SIEGERT W, 1990, BONE MARROW TRANSPL, V6, P97; STORB R, 1995, TRANSPLANT P, V27, P2649; SYKES M, 1995, BLOOD, V86, P2429, DOI 10.1182/blood.V86.6.2429.bloodjournal8662429; SYKES M, 1990, P NATL ACAD SCI USA, V87, P5633, DOI 10.1073/pnas.87.15.5633; Taniguchi M, 1997, J IMMUNOL METHODS, V206, P107, DOI 10.1016/S0022-1759(97)00094-X; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; Williamson E, 1997, J IMMUNOL, V159, P1208	21	67	73	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	2	S			S45	S50		10.1067/mai.2000.106774	http://dx.doi.org/10.1067/mai.2000.106774			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	339NF	10887333				2022-12-18	WOS:000088482600006
J	Hamid, QA; Minshall, EM				Hamid, QA; Minshall, EM			Molecular pathology of allergic disease - I: Lower airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						bronchial asthma; eosinophils; T lymphocytes; cytokines; chemokines	BRONCHOALVEOLAR LAVAGE FLUID; MESSENGER-RNA EXPRESSION; HEMATOPOIETIC PROGENITOR CELLS; TRANSCRIPTION FACTOR GATA-3; BRONCHIAL BIOPSY SPECIMENS; COLONY-STIMULATING FACTOR; CYTOKINE GENE-EXPRESSION; LATE ASTHMATIC REACTIONS; RECEPTOR ALPHA-SUBUNIT; CD4(+) T-CELLS	Asthma is a complex disorder associated with eosinophil infiltration and the activation of T lymphocytes within the airways, Recent advances in the pathophysiologic mechanisms of asthma point to the importance of eosinophil-basophil progenitor cells and a family of transcription factors that underlie the development of T-H(2)-type responses. Further research is needed to address the development of chronic inflammatory changes, the role of profibrotic cytokines, and especially their reliance on eosinophils in the lungs.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada	McGill University	Hamid, QA (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.							AALBERS R, 1993, CHEST, V103, P1178, DOI 10.1378/chest.103.4.1178; Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Andrew DP, 1998, J IMMUNOL, V161, P5027; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; CAMERON L, IN PRESS J IMMUNOL; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738, DOI 10.1165/ajrcmb.13.6.7576712; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; DEL PG, 1988, J IMMUNOL, V140, P4193; DEMOLY P, 1992, AM J RESP CELL MOL, V7, P128, DOI 10.1165/ajrcmb/7.2.128; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENBURG JA, 1985, BLOOD, V66, P312; DIAZ I, 1989, REV MED PANAMA, V14, P79; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747, DOI 10.1165/ajrcmb.19.5.3166; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EILSON JW, 1992, AM REV RESPIR DIS, V135, P958; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; Fajac I, 1997, EUR RESPIR J, V10, P633; FAVRE C, 1990, BLOOD, V75, P67; FILLEY WV, 1982, LANCET, V2, P11; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331, DOI 10.1164/ajrccm/143.2.331; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; GRATZIOU C, 1992, AM REV RESPIR DIS, V145, P1259, DOI 10.1164/ajrccm/145.6.1259; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; HAMID Q, 1994, INT ARCH ALLER A IMM, V94, P169; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Himmelrich H, 1998, J IMMUNOL, V161, P6156; HOWARTH PH, 1991, INT ARCH ALLER A IMM, V94, P266, DOI 10.1159/000235379; Huang J, 1999, AM J RESP CRIT CARE, V160, P725, DOI 10.1164/ajrccm.160.2.9809040; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Jayaraman S, 1999, J IMMUNOL, V162, P1717; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; Kapsenberg ML, 1999, CLIN EXP ALLERGY, V29, P33, DOI 10.1046/j.1365-2222.1999.00006.x-i2; KIMATA H, 1994, EUR J IMMUNOL, V24, P2910, DOI 10.1002/eji.1830241149; Kotsimbos TC, 1998, J ALLERGY CLIN IMMUN, V102, P859, DOI 10.1016/S0091-6749(98)70029-6; Krejsek J, 1998, ALLERGY, V53, P73, DOI 10.1111/j.1398-9995.1998.tb03776.x; Kroegel C, 1996, EUR RESPIR J, V9, P899, DOI 10.1183/09031936.96.09050899; Krug N, 1999, J ALLERGY CLIN IMMUN, V103, P649, DOI 10.1016/S0091-6749(99)70238-1; Laberge S, 1999, INT ARCH ALLERGY IMM, V119, P120, DOI 10.1159/000024186; Laberge S, 1997, AM J RESP CELL MOL, V17, P193, DOI 10.1165/ajrcmb.17.2.2750; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376, DOI 10.5271/sjweh.1383; Mashikian MV, 1998, J ALLERGY CLIN IMMUN, V101, P786, DOI 10.1016/S0091-6749(98)70403-8; Mautino G, 1999, AM J RESP CRIT CARE, V160, P324, DOI 10.1164/ajrccm.160.1.9808087; Metzger W J, 1987, Agents Actions Suppl, V21, P151; MOSMANN TR, 1991, IMMUNOL RES, V10, P183, DOI 10.1007/BF02919690; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845, DOI 10.1164/ajrccm.155.3.9117015; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469, DOI 10.1164/ajrccm/145.6.1469; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; PARE CS, 1998, EUR RESPIR J, V12, P872; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1999, J ALLERGY CLIN IMMUN, V103, P9; ROCHE WR, 1989, LANCET, V1, P520; Rogge L, 1999, J IMMUNOL, V162, P3926; ROSSI GA, 1991, AM REV RESPIR DIS, V144, P379, DOI 10.1164/ajrccm/144.2.379; SALVATO G, 1968, THORAX, V23, P168, DOI 10.1136/thx.23.2.168; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P1818, DOI 10.1164/ajrccm.157.6.9710023; Simon HU, 1997, INT ARCH ALLERGY IMM, V113, P206, DOI 10.1159/000237548; Spinozzi F, 1998, FASEB J, V12, P1747, DOI 10.1096/fasebj.12.15.1747; Spinozzi F, 1996, ANN INTERN MED, V124, P223, DOI 10.7326/0003-4819-124-2-199601150-00005; Stanciu LA, 1997, J ALLERGY CLIN IMMUN, V100, P373, DOI 10.1016/S0091-6749(97)70251-3; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; Taha RA, 1999, AM J RESP CRIT CARE, V160, P1119, DOI 10.1164/ajrccm.160.4.9807120; Taha RA, 1999, J ALLERGY CLIN IMMUN, V103, P476, DOI 10.1016/S0091-6749(99)70474-4; Teran LM, 1999, AM J RESP CELL MOL, V20, P777, DOI 10.1165/ajrcmb.20.4.3508; TILL S, 1995, EUR J IMMUNOL, V25, P2727, DOI 10.1002/eji.1830251002; Venge J, 1996, J ALLERGY CLIN IMMUN, V97, P1110, DOI 10.1016/S0091-6749(96)70265-8; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; Wood JJ, 1998, AM J RESP CRIT CARE, V157, P99, DOI 10.1164/ajrccm.157.1.9704125; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; YANG-YEN H-F, 1990, New Biologist, V2, P351; Yasruel Z, 1997, AM J RESP CRIT CARE, V155, P1413, DOI 10.1164/ajrccm.155.4.9105087; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153; Ying S, 1997, J IMMUNOL, V158, P3539; ZANGRILLI JG, 1995, AM J RESP CRIT CARE, V151, P1346, DOI 10.1164/ajrccm.151.5.7537586; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zhang JQ, 1996, J OBJECT-ORIENT PROG, V9, P6; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	108	67	69	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				20	36		10.1016/S0091-6749(00)90172-6	http://dx.doi.org/10.1016/S0091-6749(00)90172-6			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629448				2022-12-18	WOS:000084992100003
J	Hartl, A; Kiesslich, J; Weiss, R; Bernhaupt, A; Mostbock, S; Scheiblhofer, S; Edner, C; Ferreira, F; Thalhamer, J				Hartl, A; Kiesslich, J; Weiss, R; Bernhaupt, A; Mostbock, S; Scheiblhofer, S; Edner, C; Ferreira, F; Thalhamer, J			Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bet v 1a; DNA immunization; birch pollen allergen; immunotherapy; Balb/c	MHC CLASS-I; INTRADERMAL GENE IMMUNIZATION; CYTOTOXIC T-LYMPHOCYTES; INTERFERON-GAMMA; IMMUNOGLOBULIN-E; CPG MOTIFS; IGG ANTIBODIES; VIRAL PROTEIN; IMMUNOTHERAPY; CELLS	Background: Immunization with plasmid DNA encoding various antigens is a promising method in vaccine research. Recent studies also indicate that DNA-based immunization might represent a potential approach in allergen-specific immunotherapy. Objective: In this study we have characterized the immune responses induced by recombinant Bet V 1a and plasmid DNA encoding for Bet v Ia, the major allergen of birch pollen in a mouse system. Methods: Balb/c mice were injected intraperitoneally with recombinant Bet v 1a and intradermally with plasmid DNA encoding for the gene Bet v 1a (pCMV-Bet). In addition, the effect of immunostimulatory DNA sequences was investigated by appending CpG motifs to the gene of Bet v 1a, coinjecting CpG-oligodeoxynucleotides together with the pCMV-Bet construct, or both. IgE and IgG antibody responses, as well as IgG subclasses, were measured by ELISA in sera after each immunization. IFN-gamma and IL-4 levels were also measured by ELISA in sera and supernatants of allergen-stimulated spleen cells. Results: The primary humoral response to a single treatment with pCMV-Bet was very weak, but the reaction could be boosted to higher levels by 2 additional injections. On the other hand, proliferation assays of spleen cells and measurements of cytokine levels already indicated a cellular response after the first injection of plasmid DNA. After 2 immunizations with pCMV-Bet, the ratio of IgG1 to IgG2a pointed to a T-K1 subclass profile. IgE was not detectable in any group at any time during the immune reaction. Accordingly, IL-4 levels were markedly reduced in the serum, as well as in the supernatants, of stimulated spleen cells. Animals immunized with pCMV-Bet containing appended CpG motifs at the 3' end of the Bet v 1a gene and/or with the CpG-ODN GCTAGACGTTAGCGT plus pCMV-Bet displayed reduced humoral responses against Bet v 1a when compared with animals injected with pCMV-Bet alone. The levels of IFN-gamma measured after allergen stimulation of isolated spleen cells were significantly higher in animals immunized with pCMV-Bet plus CpG motifs than with pCMV-Bet alone. Immunization with recombinant Bet v 1a protein elicited a strong T-K2-type response, including IgE production, a high titer of IgG1, and IL-4 production in both serum and supernatants of proliferation cultures. Conclusion: In contrast to immunization with protein, DNA immunization induces a storng T-K1-type response against a relevant inhalant allergen. Our data support the concept of developing a novel type of allergen immunotherapy based on plasmid DNA immunization. (J Allergy Clin Immunol 1999:103:107-13.)	Salzburg Univ, Inst Chem & Biochem, A-5020 Salzburg, Austria; Univ Vienna, Inst Gen & Expt Pathol, A-1010 Vienna, Austria; Salzburg Univ, Inst Genet & Gen Biol, A-5020 Salzburg, Austria	Salzburg University; University of Vienna; Salzburg University	Thalhamer, J (corresponding author), Salzburg Univ, Inst Chem & Biochem, Hellbrunnerstr 34, A-5020 Salzburg, Austria.		Thalhamer, Josef/E-5787-2011; Ferreira, Fatima/E-4889-2011; Weiss, Richard/N-7279-2013; Ferreira, Fatima/AAB-4321-2019	Thalhamer, Josef/0000-0003-2285-6400; Ferreira, Fatima/0000-0003-0989-2335; Weiss, Richard/0000-0003-3185-7253; Ferreira, Fatima/0000-0003-0989-2335; Scheiblhofer, Sandra/0000-0003-2867-9054; Hartl, Arnulf/0000-0001-9626-6425; Mostbock, Sven/0000-0003-1301-7875				Barry MA, 1997, VACCINE, V15, P788, DOI 10.1016/S0264-410X(96)00265-4; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; DAVIS HL, 1993, HUM GENE THER, V4, P733, DOI 10.1089/hum.1993.4.6-733; Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Feltquate DM, 1997, J IMMUNOL, V158, P2278; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; GACYNSKA M, 1993, NATURE, V365, P264; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Huang AYC, 1996, IMMUNITY, V4, P349, DOI 10.1016/S1074-7613(00)80248-4; Jahn-Schmid B, 1997, INT IMMUNOL, V9, P1867, DOI 10.1093/intimm/9.12.1867; JAROLIM E, 1989, INT ARCH ALLER A IMM, V88, P180, DOI 10.1159/000234778; JUTEL M, 1995, J IMMUNOL, V154, P4187; Klinman DM, 1997, J IMMUNOL, V158, P3635; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; Pertmer TM, 1996, J VIROL, V70, P6119, DOI 10.1128/JVI.70.9.6119-6125.1996; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; RENZ H, 1994, J IMMUNOL, V152, P351; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Slater J. E., 1997, Journal of Allergy and Clinical Immunology, V99, pS504; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Ulmer JB, 1996, IMMUNOLOGY, V89, P59, DOI 10.1046/j.1365-2567.1996.d01-718.x; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144	35	67	71	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				107	113		10.1016/S0091-6749(99)70533-6	http://dx.doi.org/10.1016/S0091-6749(99)70533-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893193				2022-12-18	WOS:000078112300017
J	Macy, E				Macy, E			Elective penicillin skin testing and amoxicillin challenge: Effect on outpatient antibiotic use, cost, and clinical outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adverse reaction; allergy; amoxicillin; antibiotic use; cephalosporin; challenge; cost; health care use; penicillin; skin test	ALLERGY; DIAGNOSIS	Background: Elective penicillin skin testing in advance of acute antibiotic need and amoxicillin challenge in patients with negative skin test responses have not been evaluated, Methods: I reviewed 236 patients previously entered in a study of new penicillin reagents who received at least 1 prescription drug over a 2-year period. Antibiotic use, outpatient visit rate, and adverse reactions to antibiotics during the year before and after skin testing were evaluated. Results: Forty (17%) of the 236 subjects had positive responses. Antibiotic courses dispensed to the 236 subjects fell 28% from 779 the year before testing to 558 the year after testing. The total cost for antibiotics dispensed fell 32% from $17,211.88 to $11,648.27, with a 5.5% reduction in the average cost per antibiotic. Outpatient visit rate did not change but shifted from primary to specialty departments in subjects with both positive and negative skin test responses. In 93 subjects with negative skin test responses, a total of 188 therapeutic courses of penicillin during the year after testing resulted in 3 (3.2%) unrechallenged mild adverse reactions. Optional amoxicillin challenge in 146 of the subjects with negative skin test responses resulted in complaints of an adverse reaction in 6 of these subjects. Four of these received a penicillin analogue in the next year without reaction. Conclusions: Elective penicillin skin testing done by an allergist was associated with unexpected declines in the number and cost of antibiotics used the year after testing but only modestly lowered the average cost per antibiotic. Adverse reactions to penicillins in subjects with negative skin test responses were infrequent, and amoxicillin challenge did not affect outcomes.	Univ Calif San Diego, Sch Med, Kaiser Permanente, San Diego Med Ctr,Dept Allergy, San Diego, CA USA	Kaiser Permanente; University of California System; University of California San Diego	Macy, E (corresponding author), 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.			Macy, Eric/0000-0002-5857-9444				ANNE S, 1995, ANN ALLERG ASTHMA IM, V74, P167; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; KERR JR, 1994, BRIT J CLIN PRACT, V48, P5; Macy E, 1997, J ALLERGY CLIN IMMUN, V100, P586, DOI 10.1016/S0091-6749(97)70159-3; Macy E. M., 1996, Journal of Allergy and Clinical Immunology, V97, P347, DOI 10.1016/S0091-6749(96)80878-5; Markowitz M, 1996, PEDIATRICS, V97, P981; MARKOWITZ M, 1991, LANCET, V337, P1308; MENDELSON LM, 1984, J ALLERGY CLIN IMMUN, V73, P76, DOI 10.1016/0091-6749(84)90487-1; PARKER PJ, 1991, J ALLERGY CLIN IMMUN, V88, P213, DOI 10.1016/0091-6749(91)90331-H; PRESTON SL, 1994, AM J HOSP PHARM, V51, P79, DOI 10.1093/ajhp/51.1.79; RESSLER C, 1987, ANN ALLERGY, V59, P167; SARTI W, 1985, ANN ALLERGY, V55, P157; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; VANARSDEL PP, 1986, WESTERN J MED, V144, P311	15	67	67	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1998	102	2					281	285		10.1016/S0091-6749(98)70097-1	http://dx.doi.org/10.1016/S0091-6749(98)70097-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	113EH	9723673				2022-12-18	WOS:000075537100022
J	Barnes, PJ				Barnes, PJ			Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inhaled corticosteroids; inflammation; asthma; side effects; airway hyperresponsiveness	LONG-TERM TREATMENT; NEWLY DIAGNOSED ASTHMA; EXHALED NITRIC-OXIDE; AIRWAY INFLAMMATION; MOLECULAR MECHANISMS; CONTROLLED TRIAL; CLINICAL ASTHMA; INDUCED SPUTUM; BETA-AGONISTS; LUNG-FUNCTION	Airway inflammation appears to be present even in the mildest of asthma, and inhaled corticosteroids now form the mainstay of asthma therapy. Inhaled corticosteroids largely avoid the adverse effects associated with oral steroids and are now recommended in newly detected disease. Inhaled corticosteroids reduce airway inflammation, airway hyperresponsiveness, and the symptoms of asthma and improve lung function, irrespective of the patient's age or asthma severity. Several different inhaled corticosteroids are available as therapeutic options for the treatment of asthma, and these include fluticasone propionate, beclomethasone dipropionate, and budesonide. The efficacy and safety of inhaled corticosteroids are compared in this article, and inhaled corticosteroid therapy is also compared with other therapies. Recently, there has been a consensus that the optimal use of inhaled corticosteroids for asthma management is using a "start high--go low" approach, and the reasons for this are discussed.	Imperial Coll, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Imperial Coll, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.			Barnes, Peter/0000-0002-5122-4018				Adcock IM, 1996, AM J RESP CRIT CARE, V154, P771, DOI 10.1164/ajrccm.154.3.8810618; Agertoft L, 1994, RESPIR MED, V5, P369; BARNES PJ, 1993, ANNU REV MED, V44, P229, DOI 10.1146/annurev.me.44.020193.001305; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BARNES PJ, 1994, AM J RESP CRIT CARE, V150, pS42, DOI 10.1164/ajrccm/150.5_Pt_2.S42; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; Barnes PJ, 1996, THORAX, V51, P218, DOI 10.1136/thx.51.2.218; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; Barnes PJ, 1996, RESP MED, V90, P379, DOI 10.1016/S0954-6111(96)90108-0; Barnes PJ, 1996, J ALLERGY CLIN IMMUN, V97, P159, DOI 10.1016/S0091-6749(96)80216-8; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BARNES PJ, 1990, AM REV RESPIR DIS, V141, pS70; BARNES PJ, 1995, CLIN EXP ALLERGY S2, V27, P46; BARNES PJ, 1992, ASTHMA BASIC MECH CL, P343; BEL EH, 1991, AM REV RESPIR DIS, V143, P109, DOI 10.1164/ajrccm/143.1.109; BOSLEY CM, 1994, EUR RESPIR J, V7, P504, DOI 10.1183/09031936.94.07030504; BRATTSAND R, 1992, NEW DRUGS ASTHMA, V2, P192; *BRIT THOR SOC, 1993, THORAX, V48, pS1; BURKE C, 1992, EUR RESPIR J, V5, P73; CHUNG KF, 1995, EUR RESPIR J, V8, P1203, DOI 10.1183/09031936.95.08071203; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P699; DOMPELING E, 1992, EUR RESPIR J, V5, P945; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HUMMEL S, 1992, LANCET, V340, P1483, DOI 10.1016/0140-6736(92)92750-A; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; JONES AH, 1994, RESP MED, V88, P293, DOI 10.1016/0954-6111(94)90059-0; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773, DOI 10.1164/ajrccm.153.6.8665033; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; KNOX AJ, 1994, CLIN SCI, V86, P647, DOI 10.1042/cs0860647; KONIG P, 1988, J ALLERGY CLIN IMMUN, V82, P297, DOI 10.1016/0091-6749(88)91015-9; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; MANOLITSAS ND, 1995, AM J RESP CRIT CARE, V151, P1925, DOI 10.1164/ajrccm.151.6.7767541; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; SHEFFER AL, 1992, CLIN EXP ALLERGY S1, V22, P1; SHEFFER AL, 1991, J ALLERGY CLIN IMMUN, V88, P425; THOMSON NC, 1989, RESP MED, V83, P269, DOI 10.1016/S0954-6111(89)80195-7; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17, DOI 10.1164/ajrccm.150.1.8025745; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	61	67	70	2	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1998	101	4	2	S			S427	S433		10.1016/S0091-6749(98)70154-X	http://dx.doi.org/10.1016/S0091-6749(98)70154-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZK101	9563367				2022-12-18	WOS:000073285000001
J	Yagami, T; Sato, M; Nakamura, A; Komiyama, T; Kitagawa, K; Akasawa, A; Ikezawa, Z				Yagami, T; Sato, M; Nakamura, A; Komiyama, T; Kitagawa, K; Akasawa, A; Ikezawa, Z			Plant defense-related enzymes as latex antigens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; antigen; cross-reactivity; serologic relationship; defense-related protein; hydrolytic enzyme; immunoblotting; ELISA	PATHOGENESIS-RELATED PROTEINS; HEVEA-BRASILIENSIS LATEX; BIRCH POLLEN ALLERGEN; RUBBER-TREE; BETA-1,3-GLUCANASE ISOZYMES; GENE FAMILY; IN-VITRO; BET-V-1; IDENTIFICATION; LYSOZYME	Background: Latex allergy is an increasing hazard to people who frequently come into contact with latex products. Of interest concerning this immediate-type allergy is the crossreactivity to various vegetable foods and pollen. Despite its high prevalence, no adequate explanation has been provided for the cross-reactive antigens. Objective: We have hypothesized that a series of plant defense-related proteins act as latex allergens, as well as vegetable food allergens. To evaluate this hypothesis, hydrolytic enzymes that are very likely to take on defensive roles in rubber trees were examined for their antigenicity. Methods: By applying chromatographic procedures, defense-related enzymes were separated from nonammoniated latex (NAL). Their antigenicity was examined by immunoblotting and ELISA with sera containing IgE antibodies to crude latex proteins. Results: Three kinds of hydrolytic enzymes (basic beta-1,3-glucanases [35, 36.5, and 38 kd], a basic chitinase/lysozyme [29.5 kd], and an acidic esterase [44 kd]) were separated from NAL. They were recognized by IgE antibodies from a significant number of patients allergic to latex. The basic beta-1,3-glucanases and the acidic esterase were also strongly recognized by IgE antibodies from several atopic subjects who were allergic to various vegetable foods rather than latex products. Conclusion: It was ascertained that the three defense-related enzymes separated from NAL constituted part of the latex antigens. Taking together the well-known serologic or immunologic relationships and amino acid sequence similarities of defense-related proteins coming from phylogenetically distant plant species, we can suspect their universal antigenicity and cross-reactivity.	Natl Inst Hlth Sci, Div Med Devices, Setagaya Ku, Tokyo 158, Japan; Niigata Coll Pharm, Niigata 95021, Japan; Natl Childrens Hosp, Tokyo 154, Japan; Yokohama City Univ, Urafune Hosp, Yokohama, Kanagawa 232, Japan	National Institute of Health Sciences - Japan; National Center for Child Health & Development - Japan; Yokohama City University	Yagami, T (corresponding author), Natl Inst Hlth Sci, Div Med Devices, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 158, Japan.							ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; Alenius H, 1996, J IMMUNOL, V156, P1618; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; AUDY P, 1989, COMP BIOCHEM PHYS B, V92, P523, DOI 10.1016/0305-0491(89)90126-0; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; BOL JF, 1990, ANNU REV PHYTOPATHOL, V28, P113, DOI 10.1146/annurev.py.28.090190.000553; BOLLER T, 1987, PLANT MICROBE INTERA, V2, P385; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; CHURNGCHOW N, 1995, PHYTOCHEMISTRY, V39, P505, DOI 10.1016/0031-9422(95)00974-C; CHYE ML, 1995, PLANT MOL BIOL, V29, P397, DOI 10.1007/BF00043663; DAUZAC J, 1993, CURR PLANT SCI BIOT, V16, P205; DAUZAC J, 1995, PLANT PHYSIOL BIOCH, V33, P765; DICKINSON H, 1994, NATURE, V367, P517, DOI 10.1038/367517a0; DURING K, 1993, PLANT MOL BIOL, V23, P209, DOI 10.1007/BF00021432; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KURUP VP, 1992, ALLERGY PROC, V13, P329, DOI 10.2500/108854192778816915; KUSH A, 1990, P NATL ACAD SCI USA, V87, P1787, DOI 10.1073/pnas.87.5.1787; LAVAUD F, 1995, J ALLERGY CLIN IMMUN, V95, P557, DOI 10.1016/S0091-6749(95)70318-7; LEE HI, 1995, BRAZ J MED BIOL RES, V28, P743; LINTHORST HJM, 1991, CRIT REV PLANT SCI, V10, P123, DOI 10.1080/07352689109382309; Loon L. C. van, 1994, Plant Molecular Biology Reporter, V12, P245, DOI 10.1007/BF02668748; LYNN KR, 1986, PHYTOCHEMISTRY, V25, P2279, DOI 10.1016/S0031-9422(00)81679-9; MONEO I, 1995, ANN ALLERG ASTHMA IM, V75, P440; PAN SQ, 1989, ANAL BIOCHEM, V182, P136, DOI 10.1016/0003-2697(89)90730-6; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; SANDIFORD CP, 1995, CLIN EXP ALLERGY, V25, P340, DOI 10.1111/j.1365-2222.1995.tb01052.x; Shewry PR, 1997, ADV BOT RES, V26, P135, DOI 10.1016/S0065-2296(08)60120-2; STINTZI A, 1993, BIOCHIMIE, V75, P687, DOI 10.1016/0300-9084(93)90100-7; STRICKLAND JA, 1995, PLANT PHYSIOL, V109, P667, DOI 10.1104/pp.109.2.667; Subroto T, 1996, PHYTOCHEMISTRY, V43, P29, DOI 10.1016/0031-9422(96)00196-3; SUNDERASAN E, 1995, J RUBBER RES, V10, P82; SWOBODA I, 1994, BBA-GENE STRUCT EXPR, V1219, P457, DOI 10.1016/0167-4781(94)90072-8; SWOBODA I, 1995, PLANT CELL ENVIRON, V18, P865, DOI 10.1111/j.1365-3040.1995.tb00595.x; Swoboda I, 1996, PHYSIOL PLANTARUM, V96, P433, DOI 10.1111/j.1399-3054.1996.tb00455.x; SWOBODA I, 1995, PROTOPLASMA, V187, P103, DOI 10.1007/BF01280237; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332, DOI 10.1111/j.1365-2222.1995.tb01051.x; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VANPARIJS J, 1991, PLANTA, V183, P258, DOI 10.1007/BF00197797; WILLIAMS PB, 1995, J ALLERGY CLIN IMMUN, V95, P88, DOI 10.1016/S0091-6749(95)70156-7; Yagami T, 1996, FOOD AGR IMMUNOL, V8, P121, DOI 10.1080/09540109609354910; YAGAMI T, 1995, J ALLERGY CLIN IMMUN, V96, P677, DOI 10.1016/S0091-6749(95)70267-9; YAGAMI T, 1995, J RUBBER RES, V10, P100; YAGAMI T, 1994, P LAT ALL S TOR CAN	45	67	72	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					379	385		10.1016/S0091-6749(98)70251-9	http://dx.doi.org/10.1016/S0091-6749(98)70251-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525455				2022-12-18	WOS:000072593900016
J	Bissonnette, EY; Befus, AD				Bissonnette, EY; Befus, AD			Anti-inflammatory effect of beta(2)-agonists: Inhibition of TNF-alpha release from human mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; TNF-alpha; beta(2)-agonist; allergic reactions histamine; asthma	TUMOR-NECROSIS-FACTOR; BETA-ADRENERGIC RECEPTORS; SENSITIZED LUNG-TISSUE; GUINEA-PIG SKIN; SODIUM CROMOGLYCATE; HISTAMINE-SECRETION; DOWN-REGULATION; MESSENGER-RNA; SALMETEROL; IGE	beta(2)-Agonists inhibit the release of preformed mediators such as histamine and newly synthesized mediators such as prostaglandin D-2 from mast cells. However, although mast cells have been identified as an important source of several cytokines including tumor necrosis factor-alpha (TNF-alpha), there is no information about their regulation by beta(2)-agonists. Thus given the importance of TNF-alpha in inflammation and the widespread use of beta(2)-agonists, we investigated the effect of long-acting (salmeterol) and short-acting (salbutamol) beta(2)-agonists on the secretion of TNF-alpha from human skin mast cells. Treatment of mast cells with salmeterol or salbutamol (100 nmol/L) inhibited the IgE-dependent release of TNF-alpha (82% and 74%, respectively). Moreover, 2-hour treatment with salmeterol, isoproterenol, or salbutamol inhibited mast cell cytotoxicity against a TNF-alpha-sensitive cell line, WEHI-164, with an IC50 of 71, 50, and 29 nmol/L, respectively. Specificity for beta-adrenergic receptors was shown with propranolol. The inhibitory effect of beta(2)-agonists was observed after only 20 minutes of treatment but was lost by 24 hours after removal of salbutamol and isoproterenol (7% and 11% inhibition remaining, respectively). In contrast, the inhibition of TNF-alpha release was increased 1 hour after removal of salmeterol and remained significant 24 hours later. Furthermore, beta(2)-agonists did not show tachyphylaxis for the inhibition of TNF-alpha release. Thus selective beta(2)-agonists demonstrate anti-inflammatory activity by inhibiting the release of TNF-alpha from mast cells stimulated through their IgE receptor or by a tumor target cell. This inhibitory effect of beta-agonists may be important in their mode of action in the treatment of allergic diseases.	Univ Alberta, Dept Med, Pulm Res Grp, Edmonton, AB T6G 2S2, Canada	University of Alberta	Bissonnette, EY (corresponding author), Univ Alberta, Dept Med, Pulm Res Grp, HMRC 574, Edmonton, AB T6G 2S2, Canada.		Befus, Dean/C-5561-2009	Befus, Dean/0000-0002-1611-2897				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, P838, DOI 10.1164/ajrccm.152.3.7663795; BENYON RC, 1991, J IMMUNOL, V147, P2253; BENYON RC, 1989, ASTHMA REV, V2, P151; BISSONNETTE BY, 1996, AM J RESP CELL MOL B, V14, P620; BISSONNETTE EY, 1995, CLIN EXP IMMUNOL, V102, P78; BISSONNETTE EY, 1990, J IMMUNOL, V145, P3385; BORISH L, 1992, MED CLIN N AM, V76, P765, DOI 10.1016/S0025-7125(16)30325-X; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471, DOI 10.1165/ajrcmb.10.5.8179909; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; BUSSE WW, 1984, J ALLERGY CLIN IMMUN, V73, P404, DOI 10.1016/0091-6749(84)90416-0; BUTCHERS PR, 1991, BRIT J PHARMACOL, V104, P672, DOI 10.1111/j.1476-5381.1991.tb12487.x; CHONG LK, 1995, AM J RESP CELL MOL, V13, P540, DOI 10.1165/ajrcmb.13.5.7576689; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; Coleman RA, 1996, TRENDS PHARMACOL SCI, V17, P324, DOI 10.1016/S0165-6147(96)10040-7; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; DIDIER M, 1987, J IMMUNOL, V139, P1179; ERJEFALT I, 1991, AM REV RESPIR DIS, V143, P1008, DOI 10.1164/ajrccm/143.5_Pt_1.1008; FELDMAN RD, 1987, J IMMUNOL, V139, P3355; Foss HD, 1996, J PATHOL, V179, P60; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; Green SA, 1996, J BIOL CHEM, V271, P24029, DOI 10.1074/jbc.271.39.24029; GRONNEBERG R, 1992, CLIN EXP ALLERGY, V21, P257; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HETIER E, 1991, EXP BRAIN RES, V86, P407; KIPS JC, 1993, CLIN EXP ALLERGY, V23, P247, DOI 10.1111/j.1365-2222.1993.tb00317.x; MEYER JM, 1993, ANN PHARMACOTHER, V27, P1478, DOI 10.1177/106002809302701214; MUNOZ NM, 1994, J PHARMACOL EXP THER, V268, P1339; NIALS AT, 1993, BRIT J PHARMACOL, V108, P507, DOI 10.1111/j.1476-5381.1993.tb12833.x; NIALS AT, 1994, EUR J PHARMACOL, V251, P127, DOI 10.1016/0014-2999(94)90392-1; Nilsson G., 1995, ASTHMA RHINITIS, P195; NISHIKAWA M, 1994, AM J RESP CELL MOL, V10, P91, DOI 10.1165/ajrcmb.10.1.8292387; OCONNOR BJ, 1994, AM J RESP CRIT CARE, V150, P381, DOI 10.1164/ajrccm.150.2.8049819; OHKAWARA Y, 1992, AM J RESP CELL MOL, V7, P385, DOI 10.1165/ajrcmb/7.4.385; OHNO I, 1990, AM J RESP CELL MOL, V3, P285, DOI 10.1165/ajrcmb/3.4.285; OKAYAMA Y, 1992, INT ARCH ALLERGY IMM, V97, P216, DOI 10.1159/000236122; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PAGE CP, 1993, J ASTHMA, V30, P155, DOI 10.3109/02770909309054513; PEARCE FL, 1984, J ALLERGY CLIN IMMUN, V73, P819, DOI 10.1016/0091-6749(84)90453-6; PEARCE FL, 1982, J IMMUNOL, V128, P2481; PROSS HF, 1981, J CLIN IMMUNOL, V1, P51, DOI 10.1007/BF00915477; REDINGTON AE, 1995, CHEM IMMUNOL, V62, P22; SCHLEIMER RP, 1991, AM REV RESPIR DIS, V143, P1169, DOI 10.1164/ajrccm/143.5_Pt_1.1169; SEKUT L, 1995, CLIN EXP IMMUNOL, V99, P461; SELDON PM, 1995, MOL PHARMACOL, V48, P747; SEVERN A, 1992, J IMMUNOL, V148, P3441; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; STRIETER RM, 1993, CRIT CARE MED, V21, pS447, DOI 10.1097/00003246-199310001-00006; TEIXEIRA MM, 1995, EUR J PHARMACOL, V272, P185, DOI 10.1016/0014-2999(94)00643-L; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76, DOI 10.1164/ajrccm.152.1.7599866; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WHELAN CJ, 1993, BRIT J PHARMACOL, V110, P613, DOI 10.1111/j.1476-5381.1993.tb13855.x; Yamada N, 1995, J ALLERGY CLIN IMMUN, V96, P1069, DOI 10.1016/S0091-6749(95)70192-3	54	67	67	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				825	831		10.1016/S0091-6749(97)70280-X	http://dx.doi.org/10.1016/S0091-6749(97)70280-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438493				2022-12-18	WOS:000071353600017
J	Naclerio, RM; Proud, D; Moylan, B; Balcer, S; Freidhoff, L; KageySobotka, A; Lichtenstein, LM; Creticos, PS; Hamilton, RG; Norman, PS				Naclerio, RM; Proud, D; Moylan, B; Balcer, S; Freidhoff, L; KageySobotka, A; Lichtenstein, LM; Creticos, PS; Hamilton, RG; Norman, PS			A double-blind study of the discontinuation of ragweed immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ragweed immunotherapy; discontinuation of immunotherapy; IgE antibodies; IgG antibodies; allergic rhinitis	INDUCED ALLERGIC RHINITIS; NASAL AIRWAY CHALLENGE; VENOM IMMUNOTHERAPY; FOLLOW-UP; INFLAMMATORY MEDIATORS; HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; STING CHALLENGE; HAY-FEVER; ANTIGEN	Background: Immunotherapy effectively treats the symptoms of allergic rhinitis and improves its pathophysiology. We studied whether the effects of immunotherapy on the early response to nasal challenge with antigen and seasonal symptoms persist after discontinuation. Methods: Twenty subjects with ragweed allergy who were receiving immunotherapy and who had nasal challenges performed before initiation of treatment were selected. The patients had been receiving maintenance therapy with aqueous ragweed extract at a dose of 12 mu g of Amb a 1 equivalent for a minimum of 3 years, at which point they were randomized to receive either placebo injections or to continue with the maintenance dose. Nasal challenges were performed before and 1 year after randomization. Nasal challenges were monitored by counting the number of sneezes and measuring histamine, N-alpha-tosyl-L-arginine methyl ester-esterase activity, and kinins in recovered nasal lavages. In the same year symptom diaries were collected during the ragweed season. Results: The initial immunotherapy significantly reduced responses to nasal challenge in both groups. The group continuing to receive active treatment showed no significant changes from the response before randomization. In contrast, the group randomized to placebo treatment showed a partial return of histamine, kinins, and N-alpha-tosyl-L-arginine methyl ester-esterase in nasal secretions and the numbers of sneezes. IgG antibodies to ragweed declined only in the group switched to placebo treatment, Seasonal rises of IgE antibodies to ragweed did not return during the first season after treatment was stopped. Symptoms reported during the ragweed season were not different between the groups. Conclusions: One year after discontinuation of ragweed immunotherapy, nasal challenges showed partial recrudescence of mediator responses even though reports during the season appeared to indicate continued suppression of symptoms.	JOHNS HOPKINS UNIV, SCH MED, DIV CLIN IMMUNOL, BALTIMORE, MD USA	Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, U01AI031867, R37AI008270, U19AI031867] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31867, AI33135, AI08270] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALAM R, 1989, J IMMUNOL, V143, P2280; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V83, P273; Hamilton RG, 1992, MANUAL CLIN LABORATO, P702; HAMILTON RG, 1992, MANUAL CLIN IMMUNOLO, P689; HAUGAARD L, 1991, J ALLERGY CLIN IMMUN, V87, P699, DOI 10.1016/0091-6749(91)90391-Z; Hedlin G, 1995, J ALLERGY CLIN IMMUN, V96, P879, DOI 10.1016/S0091-6749(95)70223-7; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; IMANARI T, 1976, DHEW NIH76791 PUBL, P205; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MAJCHEL AM, 1993, J ALLERGY CLIN IMMUN, V92, P767, DOI 10.1016/0091-6749(93)90021-7; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; NORMAN PS, 1989, J ALLERGY CLIN IMMUN, V84, P438, DOI 10.1016/0091-6749(89)90355-2; NORMAN PS, 1988, J ALLERGY CLIN IMMUN, V81, P294, DOI 10.1016/0091-6749(88)90737-3; NORMAN PS, 1978, IMMUNOLOGICAL DISEAS, P832; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; PATTERSON R, 1978, ALLERGY PRINCIPLES P, P877; PENG ZK, 1992, J ALLERGY CLIN IMMUN, V89, P519, DOI 10.1016/0091-6749(92)90318-V; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SVENSSON C, 1992, CLIN EXP ALLERGY, V22, P411, DOI 10.1111/j.1365-2222.1992.tb03103.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; WATASE T, 1986, Rhinology (Utrecht), V24, P181	39	67	70	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					293	300		10.1016/S0091-6749(97)70240-9	http://dx.doi.org/10.1016/S0091-6749(97)70240-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314339				2022-12-18	WOS:A1997XX47900004
J	Heiss, S; Fischer, S; Muller, WD; Weber, B; Hirschwehr, R; Spitzauer, S; Kraft, D; Valenta, R				Heiss, S; Fischer, S; Muller, WD; Weber, B; Hirschwehr, R; Spitzauer, S; Kraft, D; Valenta, R			Identification of a 60 kd cross-reactive allergen in pollen and plant-derived food	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cross-reactive allergens; pollen allergy; food allergy; IgE; IgE inhibition	GRASS PHLEUM-PRATENSE; MAJOR ALLERGEN; BIRCH POLLEN; SEQUENCE ANALYSIS; CDNA CLONING; TREE-POLLEN; PROFILIN; CELERY; SENSITIVITY; BINDING	Background: Cross-reactive IgE antibodies were found to be responsible for allergic reactions in patients allergic to pollen on ingestion of food (oral allergy syndrome). So far, the major birch pollen allergen Bet nu 1 and birch profilin (Bet nu 2) were identified as relevant cross-reactive allergens. Objective: In this study we attempted to identify additional cross-reactive plant allergens, which could be responsible for food intolerance in patients allergic to pollen. Methods: Monoclonal antibodies specific for the major mugwort pollen allergen, Art nu 1, representing a 60 kd glycoprotein, were used to defect cross-reactive allergens in other pollens and plant-derived food. The amino acid compositions of the cross-reactive structure were determined, and their resistance against trypsin treatment was investigated. In addition, IgE immunoblot inhibitions were done with the 60 kd mugwort pollen allergen. Results: Monoclonal antibodies specific for the major mugwort pollen allergen, Art nu 1, cross-reacted with proteins of comparable molecular weight in fruit and vegetables. Preadsorption of patients' sera with the 60 kd mugwort allergen led to a reduction of IgE binding to components of a similar molecular weight present in different pollen (birch, timothy grass), fruit (apple, peanuts), and vegetable (celery) extracts and reduced IgE binding to apple, kiwi, and celery as determined by RAST inhibitions. Conclusion: A cross-reactive plant panallergen, possibly identical to the major mugwort pollen allergen, Art nu 1, is described. The allergen represents a protein of approximately 60 kd present in various pollen and plant foods, which is distinct from Bet nu 1 and profilin and hence may represent a nor el cross-reactive allergen in the oral allergy syndrome.	UNIV VIENNA,INST GEN & EXPT PATHOL,AKH,A-1090 VIENNA,AUSTRIA; UNIV JENA,INST CLIN IMMUNOL,D-6900 JENA,GERMANY; ALLERGOPHARMA JOACHIM GANZER KG,REINBEK,GERMANY; UNIV VIENNA,INST CLIN CHEM & LAB DIAGNOST,AKH,A-1090 VIENNA,AUSTRIA	University of Vienna; Friedrich Schiller University of Jena; Allergopharma; University of Vienna				Valenta, Rudolf/0000-0001-5944-3365				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; DEBLAY F, 1991, ALLERGY PROC, V12, P313, DOI 10.2500/108854191778879151; DELAHOZ F, 1990, MOL IMMUNOL, V27, P651, DOI 10.1016/0161-5890(90)90008-N; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; HALMEPURO L, 1985, ALLERGY, V40, P264, DOI 10.1111/j.1398-9995.1985.tb00231.x; HANNUKSELA M, 1977, ALLERGY, V33, P143; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; JILEK A, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P39; KREMSER M, 1983, WIEN KLIN WOCHENSCHR, V95, P838; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; LAHTI A, 1980, ALLERGY, V35, P297, DOI 10.1111/j.1398-9995.1980.tb01770.x; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; PAULI G, 1992, ACI NEWS, V4, P43; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SAVONIUS B, 1993, ALLERGY, V48, P215, DOI 10.1111/j.1398-9995.1993.tb00718.x; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; TAKEUCHI Y, 1991, J MOL BIOL, V221, P309, DOI 10.1016/0022-2836(91)80221-F; TAKEUCHI Y, 1993, P NATL ACAD SCI USA, V89, P4407; THIEL C, 1988, ALLERGOLOGIE, V11, P397; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; VALENTA R, 1993, J BIOL CHEM, V268, P22777; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171; VRTALA S, 1993, J IMMUNOL, V151, P4773; WUTHRICH B, 1985, SCHWEIZ MED WOCHENSC, V115, P258	36	67	68	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	1				938	947		10.1016/S0091-6749(96)80010-8	http://dx.doi.org/10.1016/S0091-6749(96)80010-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VU764	8939157				2022-12-18	WOS:A1996VU76400010
J	Steinman, HA				Steinman, HA			''Hidden'' allergens in foods	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SOYBEAN-SENSITIVE INDIVIDUALS; FATAL ANAPHYLACTIC REACTIONS; LEGUME BOTANICAL FAMILY; BIRD-EGG SYNDROME; OCCUPATIONAL ASTHMA; ATOPIC-DERMATITIS; BAKERS ASTHMA; HENS EGG; CROSS-ALLERGENICITY; PEANUT ALLERGY				Steinman, HA (corresponding author), UNIV CAPE TOWN,SCH MED,DEPT CLIN SCI & IMMUNOL,ALLERGOL UNIT,ANZIO RD,ZA-7925 CAPE TOWN,SOUTH AFRICA.							ADKINS FM, 1988, J ALLERGY CLIN IMMUN, V82, P242; AICKEN R, 1994, BMJ SA, V3, P55; ANET J, 1985, INT ARCH ALLER A IMM, V77, P364, DOI 10.1159/000233846; ANNIBARRO B, 1993, J ALLERGY CLIN IMMUN, V92, P628; ARMENTIA A, 1993, CLIN EXP ALLERGY, V23, P410, DOI 10.1111/j.1365-2222.1993.tb00347.x; *ASS DIET SO AFR, S AFR FOOD INT DAT; BALDO BA, 1982, PROG ALLERGY, V30, P1; BALDO BA, 1978, CLIN ALLERGY, V8, P109, DOI 10.1111/j.1365-2222.1978.tb00456.x; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; BERNAOLA G, 1994, ALLERGY, V49, P189, DOI 10.1111/j.1398-9995.1994.tb00824.x; BERNHISEL-BROADBENT J, 1990, Journal of Allergy and Clinical Immunology, V85, P270; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BERNSTEIN DI, 1987, J ALLERGY CLIN IMMUN, V80, P791, DOI 10.1016/S0091-6749(87)80267-1; BERNSTEIN JA, 1993, CHEST, V103, P532, DOI 10.1378/chest.103.2.532; BOCK SA, 1985, J PEDIATR-US, V107, P676, DOI 10.1016/S0022-3476(85)80391-7; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1983, ALLERGY PRINCIPLES P, P1515; BUCKLEY RH, 1982, JAMA-J AM MED ASSOC, V248, P2627, DOI 10.1001/jama.248.20.2627; BUSH RK, 1989, ALLERGY PROC, V10, P261, DOI 10.2500/108854189778959975; BUSH RK, 1985, J ALLERGY CLIN IMMUN, V76, P242, DOI 10.1016/0091-6749(85)90709-2; CARMONA JGB, 1992, ALLERGY, V47, P190, DOI 10.1111/j.1398-9995.1992.tb00964.x; CHIARAMONTE LT, 1988, FOOD ALLERGY PRACTIC; CICLITIRA PJ, 1984, BRIT MED J, V289, P83, DOI 10.1136/bmj.289.6437.83; COURT J, 1984, ARCH DIS CHILD, V59, P908, DOI 10.1136/adc.59.9.908-a; DAVID TJ, 1989, ALLERGY, V44, P101, DOI 10.1111/j.1398-9995.1989.tb02464.x; DAVID TJ, 1984, ARCH DIS CHILD, V59, P983, DOI 10.1136/adc.59.10.983; DAVID TJ, 1993, FOOD FOOD ADITIVE IN; DAVID TJ, 1993, FOOD FOOD ADDITIVE I, P137; DAVID TJ, 1993, FOOD FOOD ADDITIVE I, P111; DEBLAY F, 1994, ALLERGY PROC, V15, P77, DOI 10.2500/108854194778703017; DOKE S, 1989, AGR BIOL CHEM TOKYO, V53, P1231, DOI 10.1080/00021369.1989.10869477; DONOVAN KL, 1990, BRIT MED J, V300, P1378, DOI 10.1136/bmj.300.6736.1378; EDWARDS JH, 1983, CLIN ALLERGY, V13, P427, DOI 10.1111/j.1365-2222.1983.tb02618.x; EVANS S, 1988, CAN MED ASSOC J, V139, P231; FOX BA, 1986, FOOD SCI KCHEM APPRO; FRIEDMAN HM, 1994, ALLERGY PROC, V15, P217, DOI 10.2500/108854194778702801; FRIES JH, 1982, ANN ALLERGY, V48, P220; GOTHE CJ, 1983, ALLERGY, V38, P155; GUNN RA, 1980, J FOOD PROTECT, V43, P525, DOI 10.4315/0362-028X-43.7.525; HAPGOOD F., 1987, NATL GEOGR, V172, P66; HEFLE SL, 1994, J ALLERGY CLIN IMMUN, V94, P167, DOI 10.1016/0091-6749(94)90036-1; HIDE DW, 1995, J PAEDIATR MED, V8, P4; HILL DJ, 1987, ANN ALLERGY, V59, P141; HIYAMA DT, 1989, JPEN-PARENTER ENTER, V13, P318, DOI 10.1177/0148607189013003318; HOFFMAN DR, 1994, J ALLERGY CLIN IMMUN, V93, P801, DOI 10.1016/0091-6749(94)90262-3; HOFFMAN DR, 1975, IMMUNOCHEMISTRY, V12, P535, DOI 10.1016/0019-2791(75)90080-4; JONES RT, 1992, ANN ALLERGY, V68, P223; KALLIEL JN, 1989, ALLERGY PROC, V10, P259, DOI 10.2500/108854189778960018; KASARDA DD, 1978, PERSPECTIVES COELIAC; KEATING MU, 1990, J ALLERGY CLIN IMMUN, V86, P44; KLURFELD DM, 1987, LIPIDS, V22, P667, DOI 10.1007/BF02533947; KOERNER CB, 1994, FOOD ALLERGY NEWS, V3; KOERNER CB, 1991, FOOD ALLERGY ADVERSE, V3, P333; KUSHIMOTO H, 1985, ARCH DERMATOL, V121, P355, DOI 10.1001/archderm.121.3.355; LANGELAND T, 1983, ALLERGY, V38, P399, DOI 10.1111/j.1398-9995.1983.tb05083.x; LANGELAND T, 1982, ALLERGY, V37, P521, DOI 10.1111/j.1398-9995.1982.tb02335.x; LANGELAND T, 1987, FOOD ALLERGY INTOLER, P367; LOZA C, 1995, CLIN EXP ALLERGY, V25, P493, DOI 10.1111/j.1365-2222.1995.tb01086.x; MANDALLAZ MM, 1988, INT ARCH ALLER A IMM, V87, P143, DOI 10.1159/000234664; METCALF D, 1991, FOOD ALLERGY ADVERSE; Moneret-Vautrin D A, 1994, Pediatr Allergy Immunol, V5, P184, DOI 10.1111/j.1399-3038.1994.tb00236.x; MONERETVAUTRIN DA, 1991, LANCET, V338, P1149, DOI 10.1016/0140-6736(91)92008-P; MOROZ LA, 1980, NEW ENGL J MED, V302, P1126, DOI 10.1056/NEJM198005153022005; Natarajan K R, 1980, Adv Food Res, V26, P215, DOI 10.1016/S0065-2628(08)60319-5; NORGAARD A, 1992, CLIN EXP ALLERGY, V22, P940, DOI 10.1111/j.1365-2222.1992.tb02068.x; ONEIL C, 1993, CLIN REV ALLERG, V11, P183; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; PICHLER WJ, 1992, ANN ALLERGY, V69, P521; PORRAS O, 1985, INT ARCH ALLER A IMM, V78, P30, DOI 10.1159/000233858; RAGNO V, 1993, EUR J PEDIATR, V152, P760, DOI 10.1007/BF01953996; ROSENTHAL E, 1991, ACTA PAEDIATR SCAND, V80, P958, DOI 10.1111/j.1651-2227.1991.tb11760.x; RUGO E, 1992, CLIN EXP ALLERGY, V22, P635, DOI 10.1111/j.1365-2222.1992.tb00180.x; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SANTIAGO AV, 1988, ALLERGOL IMMUNOPATH, V16, P309; SETTIPANE GA, 1989, ALLERGY PROC, V10, P271, DOI 10.2500/108854189778960036; SMITH T, 1990, BRIT MED J, V300, P1354, DOI 10.1136/bmj.300.6736.1354; STEINMAN HA, UNPUB EVALUATION CAS; SUTTON R, 1984, CLIN ALLERGY, V14, P93, DOI 10.1111/j.1365-2222.1984.tb02196.x; TATTRIE NH, 1973, J I CAN SCI TECHNOL, V6, P289; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; WAHN U, 1992, J PEDIATR-US, V121, pS80, DOI 10.1016/S0022-3476(05)81412-X; WALSH BJ, 1985, J ALLERGY CLIN IMMUN, V76, P23, DOI 10.1016/0091-6749(85)90799-7; Yamada T, 1993, Arerugi, V42, P136; YUNGINGER JW, 1994, ALLERGY PROC, V15, P219, DOI 10.2500/108854194778702810; YUNGINGER JW, 1992, NEW ENGL J MED, V327, P421, DOI 10.1056/NEJM199208063270611; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; YUNGINGER JW, 1989, ALLERGY PROC, V10, P249, DOI 10.2500/108854189778959993	92	67	68	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					241	250		10.1016/S0091-6749(96)70146-X	http://dx.doi.org/10.1016/S0091-6749(96)70146-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757199	Bronze			2022-12-18	WOS:A1996VC99500001
J	Kita, H				Kita, H			The eosinophil: A cytokine-producing cell?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							COLONY-STIMULATING FACTOR; INSITU HYBRIDIZATION; MESSENGER-RNA; INTERLEUKIN-5; NEUTROPHIL; EXPRESSION; CHALLENGE; SURVIVAL				Kita, H (corresponding author), MAYO CLIN & MAYO FDN, DEPT IMMUNOL, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839; BRAUN RK, 1993, EUR J IMMUNOL, V23, P956, DOI 10.1002/eji.1830230429; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BROIDE DH, 1991, J CLIN INVEST, V88, P1048, DOI 10.1172/JCI115366; BRUIJNZEEL PLB, 1993, J INVEST DERMATOL, V100, P137, DOI 10.1111/1523-1747.ep12462781; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1994, SAMTERS IMMUNOLOGICA, P205; JOHNSTON NW, 1974, J IMMUNOL METHODS, V4, P189, DOI 10.1016/0022-1759(74)90060-X; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; LEVISCHAFFER F, 1995, BLOOD, V85, P2579, DOI 10.1182/blood.V85.9.2579.bloodjournal8592579; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MOQBEL R, 1991, J EXP MED, V174, P749, DOI 10.1084/jem.174.3.749; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; PATTERSON S, 1989, J VIROL METHODS, V23, P105, DOI 10.1016/0166-0934(89)90124-9; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673	20	67	69	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1996	97	4					889	892		10.1016/S0091-6749(96)80061-3	http://dx.doi.org/10.1016/S0091-6749(96)80061-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UG086	8655882				2022-12-18	WOS:A1996UG08600001
J	Ikagawa, S; Matsushita, S; Chen, YZ; Ishikawa, T; Nishimura, Y				Ikagawa, S; Matsushita, S; Chen, YZ; Ishikawa, T; Nishimura, Y			Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cell epitope; analog peptide; IFN-gamma; IL-4 TCR antagonism; HLA-DR, cedar; pollen allergen	II HISTOCOMPATIBILITY ANTIGEN; CRYPTOMERIA-JAPONICA POLLEN; HLA-D SPECIFICITIES; DUST MITE ALLERGEN; MAJOR ALLERGEN; MONOCLONAL-ANTIBODIES; SEROLOGIC DISSECTION; CYTOKINE PRODUCTION; CLONES; PROLIFERATION	We generated T cell clones specific to a Japanese cedar pollen allergen (Cry j 1) and investigated effects of altered T cell receptor (TCR) ligand on changes of T cell responses. One of these Cry j 1-specific T cell clones established from patients with Japanese cedar pollinosis, ST1.9, recognized an antigenic peptide Cry j 1 p335-346 in the contest of HLA-DRA +DRB3*0301 molecules and secreted interleukin-4 dominantly, with a smaller amount of interferon-gamma. ST1.9 represented one of the major T cell clones specific to Cry j 1 in the donor, because a short-term cultured polyclonal T cell line specific to Cry j 1 cuhibited the same character as the ST1.9. We synthesized various analog peptides derived from Cry j 1 p335-346 with single amino acid substitutions and determined key residues for interactions between TCR of ST1.9 and HLA-DR molecules. We also analyzed changes in the responses of ST1.9 to Cry j 1 p335-346-derived analog peptides. Of interest was that the substitution of (339)threonine to valine resulted in a significant increase in interferon-gamma production, with no remarkable changes either ill proliferative response or interleukin-4 production. Analog peptides carrying the substitutions of (339)threonine to glycine ol glutamine revealed TCR antagonism, without changes in their binding affinities to the DR molecule. Therefore single amino acid substitutions on an allergen peptide carrying the T cell epitope may suppress helper-T-dependent class switch pressure to IgE in B cells either by inducing increased interferon-gamma production or by inhibiting proliferative responses in helper-T cells.	KUMAMOTO UNIV,GRAD SCH MED SCI,DEPT NEUROSCI & IMMUNOL,DIV IMMUNOGENET,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT OTORHINOLARYNGOL,KUMAMOTO 860,JAPAN	Kumamoto University; Kumamoto University								BETZ M, 1991, J IMMUNOL, V146, P108; BODNER JG, 1994, HUM IMMUNOL, V41, P1; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHAN SC, 1993, J IMMUNOL, V151, P3345; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; EBNER C, 1993, J IMMUNOL, V150, P1047; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FUKUI Y, 1990, J IMMUNOGENET, V16, P445; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; GRIFFITH IJ, 1993, J ALLERGY CLIN IMMUN, V91, P339; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HIRAYAMA K, 1986, J IMMUNOL, V137, P924; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; ISHIKAWA N, 1987, IMMUNOGENETICS, V26, P143, DOI 10.1007/BF00365903; KAMIKAWAJI N, 1991, J IMMUNOL, V146, P2560; KASAHARA M, 1983, IMMUNOGENETICS, V17, P485, DOI 10.1007/BF00696872; KASAHARA M, 1983, IMMUNOGENETICS, V18, P525, DOI 10.1007/BF00364393; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MATSUSHITA S, 1994, J EXP MED, V180, P873, DOI 10.1084/jem.180.3.873; MATSUSHITA S, 1987, J IMMUNOL, V138, P109; NISHIMURA Y, 1992, HLA 1991, P693; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; SCHAMBOECK A, 1983, NUCLEIC ACIDS RES, V11, P8663, DOI 10.1093/nar/11.24.8663; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; SOLOWAY P, 1991, J EXP MED, V174, P847, DOI 10.1084/jem.174.4.847; SONE T, 1994, BIOCHEM BIOPH RES CO, V199, P619, DOI 10.1006/bbrc.1994.1273; SONE T, 1985, J IMMUNOL, V135, P1288; SPIEGELBERG HL, 1994, J IMMUNOL, V152, P4706; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; WIERENGA EA, 1990, EUR J IMMUNOL, V20, P1519, DOI 10.1002/eji.1830200717; YASUEDA H, 1983, J ALLERGY CLIN IMMUN, V71, P77, DOI 10.1016/0091-6749(83)90550-X; YSSEL H, 1992, J IMMUNOL, V148, P738	39	67	75	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				53	64		10.1016/S0091-6749(96)70283-X	http://dx.doi.org/10.1016/S0091-6749(96)70283-X			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568138				2022-12-18	WOS:A1996TR94700008
J	AHRENS, R; LUX, C; BAHL, T; HAN, SH				AHRENS, R; LUX, C; BAHL, T; HAN, SH			CHOOSING THE METERED-DOSE INHALER SPACER OR HOLDING CHAMBER THAT MATCHES THE PATIENTS NEED - EVIDENCE THAT THE SPECIFIC DRUG BEING DELIVERED IS AN IMPORTANT CONSIDERATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PRESSURIZED AEROSOL INHALERS; IMPROVEMENT; AEROCHAMBER; NEBUHALER		UNIV IOWA,DEPT PREVENT MED & ENVIRONM HLTH,DIV BIOSTAT,IOWA CITY,IA 52242	University of Iowa	AHRENS, R (corresponding author), UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242, USA.							AGERTOFT L, 1994, ARCH DIS CHILD, V71, P217, DOI 10.1136/adc.71.3.217; CHAPMAN BJ, 1990, EUR RESPIR J, V3, P584; CHUA HL, 1995, J AEROSOL MED, V8, P89; CRIMI N, 1987, EUR J RESPIR DIS, V71, P153; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; DOLOVICH M, 1993, AEROSOL SCI TECH, V18, P230, DOI 10.1080/02786829308959600; DOLOVICH M, 1995, J ALLERGY CLIN IMMUN, V95, P229; DOLOVICH M, 1994, J ALLERGY CLIN IMMUN, V93, P169; EPSTEIN SW, 1979, CAN MED ASSOC J, V120, P813; JUNE DS, 1994, PHARM TECHNOL    OCT, P40; KONIG P, 1985, CHEST, V88, P276, DOI 10.1378/chest.88.2.276; LEE H, 1987, CHEST, V91, P366, DOI 10.1378/chest.91.3.366; LEE HS, 1983, CLIN PEDIATR, V22, P440; NELSON HS, 1994, ANN ALLERGY, V72, P337; NEWMAN SP, 1984, THORAX, V39, P935, DOI 10.1136/thx.39.12.935; NEWMAN SP, 1991, THORAX, V46, P712, DOI 10.1136/thx.46.10.712; SALZMAN GA, 1988, J ALLERGY CLIN IMMUN, V81, P424, DOI 10.1016/0091-6749(88)90911-6; USPNF31246 STAND	18	67	70	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					288	294		10.1016/S0091-6749(95)70208-3	http://dx.doi.org/10.1016/S0091-6749(95)70208-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636073				2022-12-18	WOS:A1995RQ00100028
J	WOODFOLK, JA; HAYDEN, ML; MILLER, JD; ROSE, G; CHAPMAN, MD; PLATTSMILLS, TAE				WOODFOLK, JA; HAYDEN, ML; MILLER, JD; ROSE, G; CHAPMAN, MD; PLATTSMILLS, TAE			CHEMICAL TREATMENT OF CARPETS TO REDUCE ALLERGEN - A DETAILED STUDY OF THE EFFECTS OF TANNIC-ACID ON INDOOR ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TANNIC ACID; DUST MITE ALLERGEN; CAT ALLERGEN; ELISA; INHIBITION; ALBUMIN	HOUSE-DUST MITES; FEL-D-I; BRONCHIAL HYPERREACTIVITY; MONOCLONAL-ANTIBODIES; ENVIRONMENTAL-CONTROL; ASTHMA; AVOIDANCE; ACARICIDE; EXPOSURE; INVITRO	Tannic acid (TA), a protein-denaturing agent, has been reported to reduce allergen levels in house dust and is marketed for that purpose as 1% and 3% solutions. We investigated the effects of TA on dust allergens by using monoclonal antibody-based ELISAs for mite (Der p I, Der fl, and group II) and cat (Fel d I) allergens. Initial studies confirmed that TA reduced allergen levels in carpet dust. However, when dust samples from treated carpets are extracted in saline solution residual TA redissolves and may interfere with the assessment of allergens. In the laboratory, concentrations of TA as low as 0.1% inhibited the assays, but this effect may be prevented by addition of 5% bovine serum albumin (BSA). After treatment of dust samples in the laboratory with 3% TA, the apparent reductions in Der p I and Der f I levels were 89% and 96% respectively, but when the samples were extracted in 5% BSA the reductions were 74% and 92%. Similar effects were seen with dust samples from carpets treated with TA. In an extreme case in which a carpet had been repeatedly treated with TA, the apparent concentration of Der p I was <0.05 mu g/gm without BSA and 2.1 and 8.4 mu g/gm when extracted in the presence of 1% and 5% BSA, respectively. Our testing of the ability of TA to denature Fel d I demonstrated an 80% reduction in allergen but only in samples with an initial concentration of less than 200 mu g Fel d I/gm dust. In samples with high levels of Fel d T (similar to 1 mg/gm) TA had little effect. The interpretation of this was that Fel d I itself could block the effects of TA. In keeping with this, Fel d I inhibited the effect of TA on Der p I. The results confirmed the profound denaturing effects of TA, but demonstrated that high levels of protein blocked the effect of TA on dust allergens. In addition, without added protein, residual TA in dust samples could interfere with the assay of allergens in vitro.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MED, DIV CLIN IMMUNOL & ALLERGY, CHARLOTTESVILLE, VA 22908 USA	University of Virginia				Chapman, Martin/0000-0002-0845-3632; Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI-20565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565, R01AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; COLLOFF MJ, 1986, CLIN ALLERGY, V16, P41, DOI 10.1111/j.1365-2222.1986.tb01952.x; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; GREEN WF, 1984, LANCET, V2, P160; GREEN WF, 1989, CLIN EXP ALLERGY, V19, P203, DOI 10.1111/j.1365-2222.1989.tb02365.x; HART BJ, 1992, CLIN EXP ALLERGY, V22, P923, DOI 10.1111/j.1365-2222.1992.tb02065.x; HAYDEN ML, 1992, J ALLERGY CLIN IMMUN, V89, P536, DOI 10.1016/0091-6749(92)90320-2; HELLERHAUPT A, 1974, J MED ENTOMOL, V11, P551; HORIGOME T, 1988, BRIT J NUTR, V60, P275, DOI 10.1079/BJN19880099; LONGSTAFF MA, 1991, BRIT J NUTR, V66, P139, DOI 10.1079/BJN19910017; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MAKKAR HPS, 1988, BRIT J NUTR, V60, P287, DOI 10.1079/BJN19880100; MAY KR, 1945, J SCI INSTRUM, V22, P187, DOI 10.1088/0950-7671/22/10/303; MILLER JD, 1989, J ALLERGY CLIN IMMUN, V83, P262; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MURRAY AB, 1983, PEDIATRICS, V71, P418; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; OVSYANNIKOVA I, 1992, J ALLERGY CLIN IMMUN, V89, P217; PENAUD A, 1975, Clinical Allergy, V5, P109, DOI 10.1111/j.1365-2222.1975.tb01842.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; SAINTGEORGESGRI.D, 1988, NOTES PRELIMINAIRE R, V28, P131; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P711, DOI 10.1136/adc.49.9.711; THOMPSON PJ, 1993, J ALLERGY CLIN IMMUN, V91, P251; TOVEY ER, 1992, CLIN EXP ALLERGY, V22, P67, DOI 10.1111/j.1365-2222.1992.tb00116.x; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; VOORHORST P, 1969, HOUSE DUST MITE ATOP; WALSHAW MJ, 1986, Q J MED, V58, P199	34	67	71	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					19	26		10.1016/0091-6749(94)90066-3	http://dx.doi.org/10.1016/0091-6749(94)90066-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027494				2022-12-18	WOS:A1994NX39300003
J	VALENTA, R; SPERR, WR; FERREIRA, F; VALENT, P; SILLABER, C; TEJKL, M; DUCHENE, M; EBNER, C; LECHNER, K; KRAFT, D; SCHEINER, O				VALENTA, R; SPERR, WR; FERREIRA, F; VALENT, P; SILLABER, C; TEJKL, M; DUCHENE, M; EBNER, C; LECHNER, K; KRAFT, D; SCHEINER, O			INDUCTION OF SPECIFIC HISTAMINE-RELEASE FROM BASOPHILS WITH PURIFIED NATURAL AND RECOMBINANT BIRCH POLLEN ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RECOMBINANT ALLERGENS; BET-V-I; PROFILIN; IGE; HISTAMINE RELEASE; FCE-RECEPTOR; DESENSITIZATION OF BASOPHILS	DESENSITIZATION; ANTIBODIES; PROFILIN; PROTEINS; IGE	As much as 15% of the population in industrialized countries suffers from type I allergic symptoms (rhinitis, conjunctivitis, and bronchial asthma). One approach toward this disease involves the production of recombinant allergens in Escherichia coli and their purification for diagnostic and therapeutic purposes. In this study we compared the IgE-binding capacity of natural and recombinant birth allergens with their functional ability to release histamine from allergic patients' basophils via cross-linking of high-affinity Fc(epsilon)-receptors. The recombinant as well as pollen-derived Bet v I and birch profilin (Bet v II) were purified and tested in parallel on IgE immunoblots and in in vitro histamine release tests (n = 21). We observed an exellent correlation between allergen-induced histamine release and birch pollen RAST (r = 0.881, p < 0.002). Nonspecific histamine release as a result of a cell toxic effect of the allergen preparations was never observed from basophils of donors without birch pollen allergy. The specificity of the presented effector model is also documented by the specific desensitization of patients' basophils with the recombinant allergens. These data may provide a basis for the use of purified recombinant allergens in sensitive and specific in vitro allergy tests monitoring the effector situation in allergic patients, which therefore may represent a possible alternative for in vivo diagnostic methods.	UNIV VIENNA,AKH-E 20L,A-1010 VIENNA,AUSTRIA; UNIV VIENNA,AKH,DIV HEMATOL & HEMOSTASEOL,A-1010 VIENNA,AUSTRIA	University of Vienna; University of Vienna	VALENTA, R (corresponding author), UNIV VIENNA,AKH,INST GEN & EXPTL PATHOL,WAHRINGERGURTEL 18-20,A-1090 VIENNA,AUSTRIA.		Sperr, Mast/V-4767-2019; Duchêne, Michael/G-6659-2019; Gamperl, Susi/V-2715-2019; Ferreira, Fatima/E-4889-2011; Test, Test/Y-7921-2019; Ferreira, Fatima/AAB-4321-2019; Valent, Peter/B-8533-2016; Test, PV/U-9451-2019	Sperr, Mast/0000-0002-7778-5219; Duchêne, Michael/0000-0003-1232-3600; Gamperl, Susi/0000-0003-0456-5095; Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Valent, Peter/0000-0003-0456-5095; Valenta, Rudolf/0000-0001-5944-3365; Sperr, Wolfgang/0000-0003-3288-8027				BREITENBACH M, 1990, EPITOPES ATOPIC ALLE, P57; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; DEMBO M, 1980, CELL, V22, P59, DOI 10.1016/0092-8674(80)90154-3; HIRAI K, 1988, J IMMUNOL, V141, P3958; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; KAZIMIERCZAK W, 1984, J IMMUNOL, V132, P399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; MACGLASHAN DW, 1981, J IMMUNOL, V127, P2410; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SEGAL DM, 1977, P NATL ACAD SCI USA, V41, P457; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; SWOBODA I, 1992, IN PRESS MOL BIOL IM; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135	20	67	71	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	1				88	97		10.1016/0091-6749(93)90300-5	http://dx.doi.org/10.1016/0091-6749(93)90300-5			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK044	7678614				2022-12-18	WOS:A1993KK04400007
J	KUEHR, J; FRISCHER, T; KARMAUS, W; MEINERT, R; BARTH, R; HERRMANKUNZ, E; FORSTER, J; URBANEK, R				KUEHR, J; FRISCHER, T; KARMAUS, W; MEINERT, R; BARTH, R; HERRMANKUNZ, E; FORSTER, J; URBANEK, R			EARLY-CHILDHOOD RISK-FACTORS FOR SENSITIZATION AT SCHOOL AGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CHILDHOOD; RISK; SENSITIZATION; FAMILIAL; SMOKING; GENDER	SKIN-TEST REACTIVITY; CORD SERUM IGE; ATOPIC DISEASE; ALLERGIC DISEASES; FAMILY HISTORY; FINNISH ADOLESCENTS; CHILDREN; PREVALENCE; POPULATION; INFANTS	Early childhood risk factors for current sensitization were investigated by use of cross-sectional data of a longitudinal study in Southwest Germany. Information was gathered by questionnaires from 1812 families of whom 1470 children 6 to 8 years old were tested by means of a skin prick test (SPT) with seven aeroallergens. Groups with sensitization (n = 201; positive SPT to grass pollens 6.6%, Dermatophagoides pteronyssinus 6.5%, Dermatophagoides farinae 4.4%, cat dander 4.6%, any of the tested allergens 13.7%) are compared with children without sensitization (n = 1269). As risk factors for any sensitization parental atopy (odds ratio [OR]/95% confidence interval [95%CI]: unilateral 1.9/1.3 to 2.6; bilateral 2.8/1.5 to 5.2), low gestational age (1.9/1.1 to 3.2), and male gender (1.6/1.2 to 2.3) are statistically significant in multiple logistic regression. Former cat ownership is significantly related to sensitization to cat dander (2.7/1.4 to 5.5). Breast feeding, maternal smoking habits after the child's birth, prior exposure to pets, and social class are not important. In conclusion, our data suggest parental atopy, low gestational age, and male gender as independent risk factors for sensitization to aeroallergens at school age.	NORDIG INST HLTH RES & PREVENT,HAMBURG,GERMANY; UNIV VIENNA,CHILDRENS HOSP,A-1010 VIENNA,AUSTRIA	University of Vienna	KUEHR, J (corresponding author), UNIV FREIBURG,CHILDRENS HOSP,MATHILDENSTR 1,W-7800 FREIBURG,GERMANY.							ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; Angioni A M, 1989, Paediatr Perinat Epidemiol, V3, P248, DOI 10.1111/j.1365-3016.1989.tb00376.x; ARORA S, 1970, INT ARCH ALLER A IMM, V37, P357, DOI 10.1159/000230798; ASTARITA C, 1988, CLIN ALLERGY, V18, P341, DOI 10.1111/j.1365-2222.1988.tb02881.x; BACKMAN A, 1984, ALLERGY, V39, P309, DOI 10.1111/j.1398-9995.1984.tb00867.x; BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BELIN L, 1985, ALLERGY S4, V40, P60; BJORKSTEN F, 1976, CLIN ALLERGY, V6, P165, DOI 10.1111/j.1365-2222.1976.tb01894.x; BROWN EB, 1969, AM J DIS CHILD, V117, P693, DOI 10.1001/archpedi.1969.02100030695013; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; CEDERQVIST LL, 1984, AM J OBSTET GYNECOL, V148, P1123, DOI 10.1016/0002-9378(84)90639-2; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; CRONER S, 1989, PEDIATR ALLERGY IMMU, V2, P14; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GREENBERG RS, 1985, ANNU REV PUBL HEALTH, V6, P223; HAAHTELA T, 1980, ALLERGY, V35, P433, DOI 10.1111/j.1398-9995.1980.tb01790.x; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; HAPPLE R, 1982, INT ARCH ALLER A IMM, V68, P90, DOI 10.1159/000233072; HARELL FE, 1985, 10TH P ANN SAS US GR; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P601, DOI 10.1111/j.1651-2227.1976.tb04939.x; KJELLMANN NIM, 1976, THESIS LINKOPING U L; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LINNA O, 1983, ALLERGY, V38, P513, DOI 10.1111/j.1398-9995.1983.tb02360.x; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; MENSINGA TT, 1990, J ALLERGY CLIN IMMUN, V86, P99, DOI 10.1016/S0091-6749(05)80129-0; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; PEAT JK, 1987, CLIN ALLERGY, V17, P283, DOI 10.1111/j.1365-2222.1987.tb02016.x; POYSA L, 1989, ACTA PAEDIATR SCAND, V78, P902, DOI 10.1111/j.1651-2227.1989.tb11172.x; RONCHETTI R, 1990, J ALLERGY CLIN IMMUN, V86, P400, DOI 10.1016/S0091-6749(05)80104-6; RUGTVEIT J, 1990, ALLERGY, V45, P154, DOI 10.1111/j.1398-9995.1990.tb00474.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SMITH JM, 1965, AM REV RESPIR DIS, V92, P16; SMITH JM, 1988, ALLERGY PRINCIPLES P, V2, P919; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573; 1990, SAS STAT SOFTWARE CA	45	67	67	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				358	363		10.1016/S0091-6749(05)80015-6	http://dx.doi.org/10.1016/S0091-6749(05)80015-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527318				2022-12-18	WOS:A1992JP52000013
J	BOSCHETTO, P; FABBRI, LM; ZOCCA, E; MILANI, G; PIVIROTTO, F; DALVECCHIO, A; PLEBANI, M; MAPP, CE				BOSCHETTO, P; FABBRI, LM; ZOCCA, E; MILANI, G; PIVIROTTO, F; DALVECCHIO, A; PLEBANI, M; MAPP, CE			PREDNISONE INHIBITS LATE ASTHMATIC REACTIONS AND AIRWAY INFLAMMATION INDUCED BY TOLUENE DIISOCYANATE IN SENSITIZED SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PADUA, INST OCCUPAT MED, I-35100 PADUA, ITALY; ORTHOPED HOSP, ANESTHESIOL UNIT, Padua, ITALY; ROVIGO GEN HOSP, PULM DIS SECT, Padua, ITALY; UNIV PADUA, INST CLIN CHEM, I-35100 PADUA, ITALY	University of Padua; University of Padua			Boschetto, Piera/AAM-3247-2020; Fabbri, Leonardo M/I-4055-2012; Plebani, Mario/AAF-4953-2020	Boschetto, Piera/0000-0003-3889-1681; Fabbri, Leonardo M/0000-0001-8894-1689; 				ALTMAN LC, 1981, J CLIN INVEST, V67, P28, DOI 10.1172/JCI110024; AXELROD L, 1983, LANCET, V1, P904; BARNES PJ, 1986, LANCET, V1, P242; BOOYNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344; BOSCHETTO P, 1986, J ALLERGY CLIN IMMUN, V77, P244; BUTCHER B T, 1985, Folia Allergologica et Immunologica Clinica, V32, P29; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHUNG KF, 1985, J APPL PHYSIOL, V58, P1347, DOI 10.1152/jappl.1985.58.4.1347; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1979, CAN MED ASSOC J, V121, P602; DAVIES AO, 1983, J CLIN INVEST, V71, P565, DOI 10.1172/JCI110801; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; Fabbri L M, 1985, Prog Biochem Pharmacol, V20, P18; FABBRI LM, 1985, B EUR PHYSIOPATH RES, V21, P421; FABBRI LM, 1985, AM REV RESPIR DIS, V132, P1010; FABBRI LM, 1984, AM REV RESPIR DIS, V129, P288; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; GORDON T, 1985, AM REV RESPIR DIS, V132, P1106; HOGG JC, 1981, J ALLERGY CLIN IMMUN, V67, P421, DOI 10.1016/0091-6749(81)90094-4; HOLTZMAN MJ, 1983, BIOCHEM BIOPH RES CO, V114, P1071, DOI 10.1016/0006-291X(83)90671-X; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149; KAY AB, 1985, ASTHMA PHYSL PHARM T, P211; KEEN H, 1963, LANCET, V2, P913; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; Mapp C, 1979, Med Lav, V70, P203; MAPP C, 1985, AM REV RESPIR DIS, V132, P292; MAPP CE, 1986, EUR J RESPIR DIS, V69, P276; MAPP CE, 1986, EUR J RESPIR DIS, V68, P89; MAPP CE, 1985, J ALLERGY CLIN IMMUN, V75, P568, DOI 10.1016/0091-6749(85)90031-4; MAROM Z, 1984, AM REV RESPIR DIS, V129, P62; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; MORRIS HG, 1985, J ALLERGY CLIN IMMUN, V75, P1, DOI 10.1016/0091-6749(85)90002-8; MURLAS C, 1985, J APPL PHYSIOL, V58, P1630, DOI 10.1152/jappl.1985.58.5.1630; MURLAS CG, 1985, AM REV RESPIR DIS, V131, P314; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; NADEL JA, 1984, ANNU REV MED, V35, P451, DOI 10.1146/annurev.med.35.1.451; NADEL JA, 1985, ASTHMA PHYSL PHARM T, P129; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; OERTEL H, 1981, J ALLERGY CLIN IMMUN, V68, P238, DOI 10.1016/0091-6749(81)90190-1; PAUWELS R, 1986, CLIN ALLERGY, V16, P281, DOI 10.1111/j.1365-2222.1986.tb01959.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PERSSON CGA, 1986, B EUR PHYSIOPATHOL R, V22, P32; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; SIRACUSA A, 1978, CLIN ALLERGY, V8, P195, DOI 10.1111/j.1365-2222.1978.tb00464.x; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; 1971, TABLES REFERENCE EXA	49	67	68	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				261	267		10.1016/0091-6749(87)90028-5	http://dx.doi.org/10.1016/0091-6749(87)90028-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	3040835	Bronze			2022-12-18	WOS:A1987K103600004
J	SHAPIRO, GG; FURUKAWA, CT; PIERSON, WE; GILBERTSON, E; BIERMAN, CW				SHAPIRO, GG; FURUKAWA, CT; PIERSON, WE; GILBERTSON, E; BIERMAN, CW			BLINDED COMPARISON OF MAXILLARY SINUS RADIOGRAPHY AND ULTRASOUND FOR DIAGNOSIS OF SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ASTHMA INC,SEATTLE,WA; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; CHILDRENS ORTHOPED HOSP & MED CTR,DIV ALLERGY,SEATTLE,WA 98105	University of Washington; University of Washington Seattle								AXELSSON A, 1970, ACTA OTO-LARYNGOL, V69, P302, DOI 10.3109/00016487009123368; BERGER A, 1984, ANN ALLERGY, V52, P233; MANN W, 1979, ORL J OTO-RHINO-LARY, V41, P168, DOI 10.1159/000275455; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RACHELEFSKY GS, 1980, ALLERGIC DISORDERS I, P526; Revonta M, 1980, Acta Otolaryngol Suppl, V370, P1; ROHR AS, 1984, ANN ALLERGY, V52, P233; VUORINEN P, 1962, J Laryngol Otol, V76, P359, DOI 10.1017/S0022215100059442; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; WATTBOOLSEN S, 1977, CLIN OTOLARYNGOL, V2, P41, DOI 10.1111/j.1365-2273.1977.tb01333.x	10	67	67	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1986	77	1	1				59	64		10.1016/0091-6749(86)90324-6	http://dx.doi.org/10.1016/0091-6749(86)90324-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AZD36	3511125				2022-12-18	WOS:A1986AZD3600012
J	BIAGINI, RE; BERNSTEIN, IL; GALLAGHER, JS; MOORMAN, WJ; BROOKS, S; GANN, PH				BIAGINI, RE; BERNSTEIN, IL; GALLAGHER, JS; MOORMAN, WJ; BROOKS, S; GANN, PH			THE DIVERSITY OF REAGINIC IMMUNE-RESPONSES TO PLATINUM AND PALLADIUM METALLIC SALTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,231 BETHESDA AVE,CINCINNATI,OH 45267; UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH SCI,CINCINNATI,OH 45267; NEW JERSEY STATE DEPT HLTH,TRENTON,NJ; CTR DIS CONTROL,NIOSH,DIV BIOMED & BEHAV SCI,EXPTL TOXICOL BRANCH,CINCINNATI,OH	University of Cincinnati; University of Cincinnati; New Jersey Department of Health & Senior Services; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)					PHS HHS [211-79-0041, 211-80-0021] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ADKINSON NF, 1981, J ALLERGY CLIN IMMUN, V67, P87, DOI 10.1016/0091-6749(81)90001-4; BERNSTEIN DI, 1984, J ALLERGY CLIN IMMUN, V74, P794, DOI 10.1016/0091-6749(84)90181-7; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V49, P219; BIAGINI RE, 1982, FED PROC, V41, P827; BIAGINI RE, 1983, TOXICOL APPL PHARM, V69, P377, DOI 10.1016/0041-008X(83)90261-2; BRUEVICH TS, 1980, GIG T PROF ZABOL, V5, P42; CLEARE MJ, 1976, CLIN ALLERGY, V6, P183, DOI 10.1111/j.1365-2222.1976.tb01897.x; CROMWELL O, 1979, CLIN ALLERGY, V9, P109, DOI 10.1111/j.1365-2222.1979.tb01529.x; DALLEY MB, 1980, AM REV RESPIR DIS S, V4, P230; FEINBERG SM, 1968, ANN ALLERGY, V26, P99; FREEDMAN SO, 1968, J ALLERGY, V42, P233, DOI 10.1016/S0021-8707(68)90118-4; FRIEDMAN ME, 1971, BIOCHIM BIOPHYS ACTA, V250, P286, DOI 10.1016/0005-2744(71)90185-9; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; HUGHES EG, 1980, J SOC OCCUP MED, V30, P27; HUNTER D, 1945, BRIT J IND MED, V2, P92; LEROY AF, 1977, BIOCHEM MED METAB B, V18, P184, DOI 10.1016/0006-2944(77)90089-8; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; MOLLER DR, 1985, J ALLERGY CLIN IMMUN, V75, P663, DOI 10.1016/0091-6749(85)90091-0; MURDOCH RD, 1984, CLIN EXP IMMUNOL, V57, P107; Pepys J, 1972, Clin Allergy, V2, P391, DOI 10.1111/j.1365-2222.1972.tb01303.x; PEPYS J, 1979, CLIN ALLERGY, V9, P99, DOI 10.1111/j.1365-2222.1979.tb01528.x; PERERA MG, 1975, AM REV RESPIR DIS, V111, P605; ROBERTS F, 1951, ARCH IND HYG, V4, P549; TOMILETS V A, 1979, Fiziologicheskii Zhurnal (Kiev), V25, P653; TOMILETS VA, 1980, ARCH IMMUNOL THER EX, V28, P953; TOMILETS VA, 1979, FARMAKOL TOKSIKOL, V42, P170; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9; 1977, PLATINUM GROUP METAL, P125	30	67	67	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1985	76	6					794	802		10.1016/0091-6749(85)90750-X	http://dx.doi.org/10.1016/0091-6749(85)90750-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AWX93	2933442				2022-12-18	WOS:A1985AWX9300006
J	WALSH, BJ; WRIGLEY, CW; MUSK, AW; BALDO, BA				WALSH, BJ; WRIGLEY, CW; MUSK, AW; BALDO, BA			A COMPARISON OF THE BINDING OF IGE IN THE SERA OF PATIENTS WITH BAKERS ASTHMA TO SOLUBLE AND INSOLUBLE WHEAT-GRAIN PROTEINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									QUEEN ELIZABETH II MED CTR,NEDLANDS,WA 6009,AUSTRALIA; KOLLING INST MED RES,ST LEONARDS,AUSTRALIA	University of Western Australia; University of Sydney; Kolling Institute of Medical Research	WALSH, BJ (corresponding author), CSIRO,WHEAT RES UNIT,PRIVATE BAG PO,N RYDE,NSW 2113,AUSTRALIA.		Wrigley, Colin/Q-7771-2019	Walsh, Brad/0000-0003-3571-4399				Baldo B. A., 1984, Advances in Cereal Science and Technology, V6, P289; BALDO BA, 1978, CLIN ALLERGY, V8, P109, DOI 10.1111/j.1365-2222.1978.tb00456.x; BALDO BA, 1980, ALLERGY, V35, P45, DOI 10.1111/j.1398-9995.1980.tb01716.x; BLANDS J, 1976, INT ARCH ALLER A IMM, V52, P392, DOI 10.1159/000231706; CHANYEUNG M, 1979, CHEST, V75, P461, DOI 10.1378/chest.75.4.461; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HENDRICK DJ, 1976, CLIN ALLERGY, V6, P241, DOI 10.1111/j.1365-2222.1976.tb01903.x; MINK JT, 1980, CHEST, V77, P28, DOI 10.1378/chest.77.1.28; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; STRESEMANN E, 1967, ACTA ALLERGOL, VS 22, P99; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; SUTTON R, 1982, CLIN ALLERGY, V12, P63, DOI 10.1111/j.1365-2222.1982.tb03127.x; SUTTON R, 1984, CLIN ALLERGY, V14, P93, DOI 10.1111/j.1365-2222.1984.tb02196.x; THIEL H, 1982, RESPIRATION, V43, P208, DOI 10.1159/000194486; WALSH BJ, 1984, J IMMUNOL METHODS, V73, P139, DOI 10.1016/0022-1759(84)90039-5; WALSH BJ, 1984, J IMMUNOL METHODS, V66, P99, DOI 10.1016/0022-1759(84)90252-7; WARREN P, 1974, J ALLERGY CLIN IMMUN, V53, P139, DOI 10.1016/0091-6749(74)90002-5; WRAITH DG, 1979, CLIN ALLERGY, V9, P25, DOI 10.1111/j.1365-2222.1979.tb01519.x; WRIGLEY CW, 1979, INT S GRAIN DUST, P81	19	67	67	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					23	28		10.1016/0091-6749(85)90799-7	http://dx.doi.org/10.1016/0091-6749(85)90799-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	3839248				2022-12-18	WOS:A1985AMV8400002
J	WARING, NP; DAUL, CB; DESHAZO, RD; MCCANTS, ML; LEHRER, SB				WARING, NP; DAUL, CB; DESHAZO, RD; MCCANTS, ML; LEHRER, SB			HYPERSENSITIVITY REACTIONS TO INGESTED CRUSTACEA - CLINICAL-EVALUATION AND DIAGNOSTIC STUDIES IN SHRIMP-SENSITIVE INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV,SCH MED,DEPT MED,CLIN IMMUNOL & ALLERGY SECT,1700 PERDIDO ST,NEW ORLEANS,LA 70112; TULANE UNIV,MED CTR,DEPT PEDIAT,CLIN IMMUNOL SECT,NEW ORLEANS,LA 70118	Tulane University; Tulane University					NIAID NIH HHS [AI-19266-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019266] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P210, DOI 10.1016/0091-6749(72)90084-X; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; HOFFMAN DR, 1981, ANN ALLERGY, V47, P17; KARR RM, 1978, J ALLERGY CLIN IMMUN, V62, P143, DOI 10.1016/0091-6749(78)90098-2; LEHRER S B, 1984, Journal of Allergy and Clinical Immunology, V73, P114; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; MAY CD, 1978, ALLERGY PRINCIPLES P, P1159; WARING NP, 1983, J ALLERGY CLIN IMMUN, V71, P111, DOI 10.1016/0091-6749(83)90213-0	11	67	70	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					440	445		10.1016/0091-6749(85)90724-9	http://dx.doi.org/10.1016/0091-6749(85)90724-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	4031316				2022-12-18	WOS:A1985ARC0900004
J	TURK, J; OATES, JA; ROBERTS, LJ				TURK, J; OATES, JA; ROBERTS, LJ			INTERVENTION WITH EPINEPHRINE IN HYPOTENSION ASSOCIATED WITH MASTOCYTOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NIGMS NIH HHS [GM15431] Funding Source: Medline; PHS HHS [MO1R R0095] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHORD JL, 1980, AM J MED, V69, P610, DOI 10.1016/0002-9343(80)90476-3; ANHUT H, 1978, PROSTAGLANDINS, V15, P889, DOI 10.1016/0090-6980(78)90156-9; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BROGREN N, 1959, ACTA MED SCAND, V163, P223; CLUTTER WE, 1980, J CLIN INVEST, V66, P94, DOI 10.1172/JCI109840; Dale HH, 1919, J PHYSIOL-LONDON, V52, P355; DEMIS DJ, 1963, ANN INTERN MED, V59, P194, DOI 10.7326/0003-4819-59-2-194; DODD NJ, 1979, J CLIN PATHOL, V32, P31, DOI 10.1136/jcp.32.1.31; ELLIS CK, 1979, J BIOL CHEM, V254, P4152; FITZGERALD GA, 1980, EUR J CLIN INVEST, V10, P401, DOI 10.1111/j.1365-2362.1980.tb00052.x; GERRARD JW, 1979, J PEDIATR-US, V94, P843, DOI 10.1016/S0022-3476(79)80177-8; GOLDENBERG M, 1950, ARCH INTERN MED, V86, P823, DOI 10.1001/archinte.1950.00230180028003; HUBBARD WC, 1976, PROSTAGLANDINS, V12, P21, DOI 10.1016/S0090-6980(76)80004-4; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; LEVINE RJ, 1974, DUNCANS DISEASES MET, P1651; LEWIS RA, 1980, FED PROC, V39, P905; MAJNO G, 1967, CIRC RES, V21, P833, DOI 10.1161/01.RES.21.6.833; PLATSHON LF, 1978, J CLIN INVEST, V62, P1113, DOI 10.1172/JCI109230; PLESKOW WW, 1980, J ALLERGY CLIN IMMUN, V65, P226; Roberts L J 2nd, 1982, Adv Shock Res, V8, P145; ROBERTS LJ, 1982, METHOD ENZYMOL, V86, P559; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; ROBERTS PL, 1968, AM J MED, V45, P638, DOI 10.1016/0002-9343(68)90178-2; SOTER NA, 1979, NEW ENGL J MED, V301, P465, DOI 10.1056/NEJM197908303010903; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; WASSERMAN MA, 1977, PROSTAGLANDINS, V13, P255, DOI 10.1016/0090-6980(77)90007-7; WATT JB, 1978, AM J MED, V64, P1093, DOI 10.1016/0002-9343(78)90482-5	27	67	67	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	2					189	192		10.1016/0091-6749(83)90098-2	http://dx.doi.org/10.1016/0091-6749(83)90098-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC188	6296213				2022-12-18	WOS:A1983QC18800003
J	HALONEN, M; BARBEE, RA; LEBOWITZ, MD; BURROWS, B				HALONEN, M; BARBEE, RA; LEBOWITZ, MD; BURROWS, B			AN EPIDEMIOLOGIC-STUDY OF THE INTERRELATIONSHIPS OF TOTAL SERUM IMMUNOGLOBULIN-E, ALLERGY SKIN-TEST REACTIVITY, AND EOSINOPHILIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HALONEN, M (corresponding author), UNIV ARIZONA, COLL MED, DIV RESP SCI, WESTEND LABS, TUCSON, AZ 85724 USA.			Halonen, Marilyn/0000-0001-9606-935X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014136] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 14136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBEE RA, 1976, ANN INTERN MED, V84, P129, DOI 10.7326/0003-4819-84-2-129; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1980, AM REV RESPIR DIS, V122, P709, DOI 10.1164/arrd.1980.122.5.709; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; GERRARD JW, 1980, ANN ALLERGY, V44, P261; HOURI M, 1972, Clinical Allergy, V2, P285, DOI 10.1111/j.1365-2222.1972.tb01292.x; LEBOWITZ MD, 1975, AM J EPIDEMIOL, V102, P137, DOI 10.1093/oxfordjournals.aje.a112141; LEHRER SB, 1980, AM REV RESPIR DIS, V121, P168; LOEFFLER JA, 1973, ANN ALLERGY, V31, P331; WARREN CPW, 1974, CAN MED ASSOC J, V110, P425	13	67	68	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	2					221	228		10.1016/0091-6749(82)90103-8	http://dx.doi.org/10.1016/0091-6749(82)90103-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NC581	7056953				2022-12-18	WOS:A1982NC58100009
J	SACHS, MI; JONES, RT; YUNGINGER, JW				SACHS, MI; JONES, RT; YUNGINGER, JW			ISOLATION AND PARTIAL CHARACTERIZATION OF A MAJOR PEANUT ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MINNESOTA,MAYO GRAD SCH MED,ROCHESTER,MN 55901	Mayo Clinic; University of Minnesota System; University of Minnesota Rochester	SACHS, MI (corresponding author), MAYO CLIN & MAYO FDN,DEPT PEDIAT,ALLERG DIS RES LAB,200 1ST ST SW,ROCHESTER,MN 55901, USA.				NIAID NIH HHS [AI-00107] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAS K, 1973, Clinical Allergy, V3, P255, DOI 10.1111/j.1365-2222.1973.tb01331.x; AAS K, 1969, INT ARCH ALLER A IMM, V36, P152, DOI 10.1159/000230735; AAS K, 1967, INT ARCH ALLER A IMM, V32, P1, DOI 10.1159/000229911; AWDEH ZL, 1968, NATURE, V219, P66, DOI 10.1038/219066a0; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P477, DOI 10.1016/0091-6749(76)90191-3; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P299, DOI 10.1016/0091-6749(76)90135-4; DAUSSANT J, 1969, PLANT PHYSIOL, V44, P480, DOI 10.1104/pp.44.4.480; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DECHARY JM, 1961, NATURE, V190, P1125, DOI 10.1038/1901125b0; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GILLESPIE DN, 1976, J ALLERGY CLIN IMMUN, V57, P302, DOI 10.1016/0091-6749(76)90086-5; GLEICH GJ, 1976, MANUAL CLIN IMMUNOLO, P575; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P210, DOI 10.1016/0091-6749(72)90084-X; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; Johns CO, 1916, J BIOL CHEM, V28, P77; JOHNSON P, 1965, EUR POLYM J, V1, P63; KABAT EA, 1967, EXPERIMENTAL IMMUNOC, P476; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MAY CD, 1978, ALLERGY PRINCIPLES P, P1159; MOROZ LA, 1980, NEW ENGL J MED, V302, P1126, DOI 10.1056/NEJM198005153022005; NEUCERE NJ, 1969, ANAL BIOCHEM, V27, P15, DOI 10.1016/0003-2697(69)90215-2; SHIBASAKI M, 1980, INT ARCH ALLER A IMM, V61, P441, DOI 10.1159/000232472	26	67	72	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	1					27	34		10.1016/0091-6749(81)90041-5	http://dx.doi.org/10.1016/0091-6749(81)90041-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KZ173	6161143				2022-12-18	WOS:A1981KZ17300006
J	BORUM, P; MYGIND, N				BORUM, P; MYGIND, N			INHIBITION OF THE IMMEDIATE ALLERGIC REACTION IN THE NOSE BY THE BETA-2 ADRENOSTIMULANT FENOTEROL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BORUM, P (corresponding author), UNIV COPENHAGEN,RIGSHOSP,OTOPATHOL LAB,DK-2100 COPENHAGEN O,DENMARK.							ANGGARD A, 1974, ACTA OTO-LARYNGOL, V77, P131, DOI 10.3109/00016487409124608; ASSEM ESK, 1969, NATURE, V224, P1028, DOI 10.1038/2241028a0; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; COX JSG, 1970, RESPIRATION, V27, P292, DOI 10.1159/000192762; FUGNER A, 1977, INT ARCH ALLER A IMM, V54, P78, DOI 10.1159/000231810; HASTIE R, 1979, LAB INVEST, V40, P554; HILEY CR, 1978, ACTA OTO-LARYNGOL, V85, P444; JORDE W, 1975, MED KLIN, V70, P1314; JORDE W, 1976, ARZNEIMITTEL-FORSCH, V26, P2103; KALINER M, 1973, NEW ENGL J MED, V289, P277, DOI 10.1056/NEJM197308092890601; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; MALM L, 1974, ACTA OTO-LARYNGOL, V78, P242, DOI 10.3109/00016487409126350; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V58, P563, DOI 10.1016/0091-6749(76)90202-5; Mygind N., 1979, NASAL ALLERGY; OKUDA M, 1978, ARCH OHREN NASEN KEH, V221, P215, DOI 10.1007/BF01886298; OKUDA M, 1980, TOPICAL STEROID TREA; PATTERSON R, 1974, CLIN EXP IMMUNOL, V16, P223; ROSENTHAL RR, 1978, CHEST, V73, P977; SHILD HO, 1936, QUART J EXP PHYSIOL, V26, P165; SORENBY L, 1975, EUR J PHARMACOL, V30, P140, DOI 10.1016/0014-2999(75)90092-8; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; TOWNLEY RG, 1978, CHEST, V73, P974	22	67	67	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	1					25	32		10.1016/0091-6749(80)90134-7	http://dx.doi.org/10.1016/0091-6749(80)90134-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JZ541	7381123				2022-12-18	WOS:A1980JZ54100004
J	GLEICH, GJ; HULL, WM				GLEICH, GJ; HULL, WM			MEASUREMENT OF HISTAMINE - A QUALITY-CONTROL STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO MED SCH,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT MED,ROCHESTER,MN 55901; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55901	Mayo Clinic; Mayo Clinic; Mayo Clinic	GLEICH, GJ (corresponding author), MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011483] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 42546, AI 11483] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AXELROD J, 1962, J PHARMACOL EXP THER, V138, P28; Beaven MA., 1975, HDB PSYCHOPHARMACOLO, V1, P253; BEAVEN MA, 1978, HDB EXPT PHARMACOLOG, V18, P151; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P393; SNYDER SH, 1972, PERSPECTIVES NEUROPH, P43	7	67	68	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	4					295	298		10.1016/0091-6749(80)90024-X	http://dx.doi.org/10.1016/0091-6749(80)90024-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KM254	7419831				2022-12-18	WOS:A1980KM25400006
J	CROPP, GJA				CROPP, GJA			EXERCISE BRONCHOPROVOCATION TEST - STANDARDIZATION OF PROCEDURES AND EVALUATION OF RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY, DEPT PEDIAT, BUFFALO, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; SUNY Maritime College	CROPP, GJA (corresponding author), CHILDRENS HOSP, CHILDRENS LUNG CTR, BUFFALO, NY 14222 USA.							ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; [Anonymous], 1979, AM REV RESPIR DIS, V119, P831; BIERMAN CW, 1975, PEDIATRICS, V56, P843; CHEN WY, 1976, PHYSIOLOGIST, V19, P152; CROPP GJA, 1975, PEDIATRICS, V56, P868; CROPP GJA, 1975, PEDIATRICS, V56, P860; CROPP GJA, 1975, PEDIATR CLIN N AM, V22, P63; CROPP GJA, 1977, MUSCULAR EXERCISE LU, P265; FITCH KD, 1975, PEDIATRICS, V56, P904; MACKLEM PT, 1974, PROCEDURES STANDARDI; SHTURMANELLSTEIN R, 1978, AM REV RESPIR DIS, V118, P65; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P419, DOI 10.1136/adc.47.253.419; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402	13	67	67	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					627	633		10.1016/0091-6749(79)90026-5	http://dx.doi.org/10.1016/0091-6749(79)90026-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	512259				2022-12-18	WOS:A1979HX84300014
J	DUNSKY, EH; ZWEIMAN, B; FISCHLER, E; LEVY, DA				DUNSKY, EH; ZWEIMAN, B; FISCHLER, E; LEVY, DA			EARLY EFFECTS OF CORTICOSTEROIDS ON BASOPHILS, LEUKOCYTE HISTAMINE, AND TISSUE HISTAMINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM HOSP,PHILADELPHIA,PA 19104; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21218	Johns Hopkins University	DUNSKY, EH (corresponding author), UNIV PENN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,PHILADELPHIA,PA 19174, USA.		Levy, David/GPS-4945-2022					ANDERSEN V, 1969, CELL TISSUE KINET, V2, P139, DOI 10.1111/j.1365-2184.1969.tb01000.x; AVIADO DM, 1970, J CLIN PHARMACOL N D, V10, P3; BISHOP CR, 1968, J CLIN INVEST, V47, P249, DOI 10.1172/JCI105721; BORSEILA AA, 1963, ANN NY ACAD SCI, V103, P394; BRORASMUSSEN F, 1973, ACTA PATH MICRO IM A, VA 81, P593; BUOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344; CHAI H, 1973, J ALLERGY CLIN IMMUN, V51, P65, DOI 10.1016/S0091-6749(73)80001-6; CODE CF, 1954, P STAFF M MAYO CLIN, V29, P200; DALE DC, 1976, J LAB CLIN MED, V87, P487; DUNSKY E, 1976, J ALLERGY CLIN IMMUN, V57, P189; DUNSKY EH, 1977, J ALLERGY CLIN IMMUN, V59, P142, DOI 10.1016/0091-6749(77)90216-0; ESELLIER AF, 1954, BLOOD, V9, P531; FELARCA AB, 1969, J ALLERGY, V43, P114, DOI 10.1016/0021-8707(69)90131-2; GOETZL EJ, 1975, ARCH PATHOL, V99, P1; GREAVES MW, 1974, IMMUNOLOGY, V27, P359; HALPERN BN, 1952, BRIT J PHARM CHEMOTH, V7, P287, DOI 10.1111/j.1476-5381.1952.tb01324.x; ISHIZAKA T, 1972, J IMMUNOL, V108, P1000; LEVY DA, 1973, J LAB CLIN MED, V81, P291; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MOORE JE, 1953, P SOC EXP BIOL MED, V82, P601; OTTOLENGHI A, 1974, J PHARMACOL EXP THER, V189, P303; PARKER CW, 1973, J CLIN INVEST, V52, P1342, DOI 10.1172/JCI107306; SCHAYER RW, 1954, P SOC EXP BIOL MED, V87, P590; SLOTT RI, 1975, J ALLERGY CLIN IMMUN, V55, P232, DOI 10.1016/0091-6749(75)90142-6; SLOTT RI, 1974, J ALLERGY CLIN IMMUN, V54, P229, DOI 10.1016/0091-6749(74)90065-7; WEINER SL, 1975, J CLIN INVEST, V56, P679; ZWEIMAN B, 1976, J ALLERGY CLIN IMMUN, V58, P657, DOI 10.1016/0091-6749(76)90177-9	27	67	69	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	6					426	432		10.1016/0091-6749(79)90217-3	http://dx.doi.org/10.1016/0091-6749(79)90217-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GY514	87408	Bronze			2022-12-18	WOS:A1979GY51400010
J	NOVEY, HS; MARCHIOLI, LE; SOKOL, WN; WELLS, ID				NOVEY, HS; MARCHIOLI, LE; SOKOL, WN; WELLS, ID			PAPAIN-INDUCED ASTHMA - PHYSIOLOGICAL AND IMMUNOLOGICAL FEATURES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE,DEPT MED,DIV ALLERGY IMMUNOL,ORANGE,CA 92668	University of California System; University of California Irvine								ARNON R, 1967, BIOCHEMISTRY, V6, P3951; BEECHER WL, 1931, ILL MED J, P343; BOYDE TRC, 1968, CLIN CHIM ACTA, V21, P9, DOI 10.1016/0009-8981(68)90003-X; DAVIES RJ, 1977, J ALLERGY CLIN IMMUN, V60, P93, DOI 10.1016/0091-6749(77)90032-X; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DOLOVICH J, 1977, ANN ALLERGY, V38, P382; DRENTH J, 1968, NATURE, V218, P929, DOI 10.1038/218929a0; FISHER MJ, 1976, J APPL PHYSIOL, V41, P174, DOI 10.1152/jappl.1976.41.2.174; FLINDT MLH, 1978, LANCET, V1, P430; HATCH TF, 1961, BACTERIOL REV, V25, P237, DOI 10.1128/MMBR.25.3.237-240.1961; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; KILBURN KH, 1971, ARCH INTERN MED, V127, P884, DOI 10.1001/archinte.127.5.884; MARTORANA PA, 1976, AM REV RESPIR DIS, V113, P607; MILNE J, 1975, BRIT J IND MED, V32, P302; MURPHY RLH, 1976, BRONCHIAL ASTHMA MEC, P517; Nava C, 1969, Med Lav, V60, P732; NOVEY HS, 1969, ISRAEL J MED SCI, V5, P270; OSGOOD H, 1945, J ALLERGY, V16, P245, DOI 10.1016/0021-8707(45)90005-0; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; PEPYS J, 1975, NEW ENGL J MED, V293, P758; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; WIDE L, 1967, LANCET, V2, P1105	22	67	68	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	2					98	103		10.1016/0091-6749(79)90198-2	http://dx.doi.org/10.1016/0091-6749(79)90198-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GJ748	759468	Bronze			2022-12-18	WOS:A1979GJ74800006
J	PARKER, CW				PARKER, CW			PROSTAGLANDINS AND SLOW-REACTING SUBSTANCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOWARD HUGHES MED INST,MIAMI,FL	Howard Hughes Medical Institute	PARKER, CW (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV ALLERGY & IMMUNOL,ST LOUIS,MO 63110, USA.							ANGGARD E, 1963, ACTA PHYSIOL SCAND, V59, P97, DOI 10.1111/j.1748-1716.1963.tb02727.x; Anturane Reinfarction Trial Research Group, 1978, N Engl J Med, V298, P289; APPLETON RA, 1977, J MED CHEM, V20, P371, DOI 10.1021/jm00213a012; AUGSTEIN J, 1973, NATURE-NEW BIOL, V245, P215, DOI 10.1038/newbio245215a0; BACH MK, 1977, PROSTAGLANDINS, V14, P21, DOI 10.1016/0090-6980(77)90154-X; BACH MK, 1974, J IMMUNOL, V113, P2040; BRASHLER JR, 1976, FED PROC, V35, P864; BROCKLEHURST WE, 1960, J PHYSIOL-LONDON, V151, P416, DOI 10.1113/jphysiol.1960.sp006449; BROCKLEHURST WE, 1962, PROG ALLERGY, V6, P539, DOI 10.1159/000313810; BURKA JF, 1975, INT ARCH ALLER A IMM, V49, P774, DOI 10.1159/000231461; COLLIER HOJ, 1966, J PHYSIOL-LONDON, V185, pP71; CONROY MC, 1976, J IMMUNOL, V116, P1677; CROSSLEY NS, 1976, CHEM IND LONDON, V1976, P334; DAWSON W, 1974, NATURE, V250, P331, DOI 10.1038/250331a0; ENGINEER DM, 1976, BRIT J PHARMACOL, V57, pP460; Feldberg W, 1938, J PHYSIOL-LONDON, V94, P187, DOI 10.1113/jphysiol.1938.sp003674; FUSTER V, 1978, J CLIN INVEST, V61, P722, DOI 10.1172/JCI108985; GILL JR, 1976, AM J MED, V61, P43, DOI 10.1016/0002-9343(76)90029-2; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; GRANT JA, 1974, J IMMUNOL, V112, P897; HERXHEIMER H, 1963, J PHYSIOL-LONDON, V165, pP78; HEYMANN MA, 1976, NEW ENGL J MED, V295, P530, DOI 10.1056/NEJM197609022951004; HORTON EW, 1975, SCOT MED J, V20, P155, DOI 10.1177/003693307502000406; HYMAN AL, 1978, AM REV RESPIR DIS, V117, P111; ISHIZAKA T, 1971, J IMMUNOL, V106, P1267; JAFFE BM, 1973, J CLIN INVEST, V52, P398, DOI 10.1172/JCI107196; JAKSCHIK B, 1977, FED PROC, V36, P1328; JAKSCHIK B, 1976, CLIN RES, V24, pA575; JAKSCHIK BA, 1977, J IMMUNOL, V119, P618; JAKSCHIK BA, 1977, P NATL ACAD SCI USA, V74, P4577, DOI 10.1073/pnas.74.10.4577; JAKSCHIK BA, 1978, FED PROC, V37, P384; KALINER M, 1977, J ALLERGY CLIN IMMUN, V60, P204, DOI 10.1016/0091-6749(77)90125-7; KAY AB, 1976, IMMUNOLOGY, V30, P83; Kellaway CH, 1940, Q J EXP PHYSIOL CMS, V30, P121; LEWIS RA, 1975, J IMMUNOL, V114, P87; LEWIS RA, 1974, J EXP MED, V140, P1133, DOI 10.1084/jem.140.5.1133; LEWIS RA, 1977, FED PROC, V36, P2676; MATHE AA, 1976, ACTA PHYSL SCAN S441; MILTON AS, 1971, J PHYSIOL-LONDON, V218, P325, DOI 10.1113/jphysiol.1971.sp009620; NIJKAMP FP, 1976, NATURE, V263, P479, DOI 10.1038/263479a0; ORANGE RP, 1975, J IMMUNOL, V114, P182; ORANGE RP, 1976, J IMMUNOL, V117, P2191; ORANGE RP, 1973, J IMMUNOL, V110, P760; ORANGE RP, 1975, J IMMUNOL, V115, P1072; ORANGE RP, 1976, J IMMUNOL, V116, P392; ORANGE RP, 1969, ADV IMMUNOL, V10, P106; Parker C W, 1974, Adv Cyclic Nucleotide Res, V4, P1; PARKER CW, 1977, ASTHMA PHYSL IMMUNOP, P301; PARKER CW, 1978, 12TH P LEUK CULT C; PATTERSON R, 1971, J IMMUNOL, V106, P1274; PELUS LM, 1977, LIFE SCI, V20, P903, DOI 10.1016/0024-3205(77)90274-0; RUSSELL PT, 1975, CLIN CHEM, V21, P653; SAMUELSSON B, 1975, ANNU REV BIOCHEM, V44, P669, DOI 10.1146/annurev.bi.44.070175.003321; SEYBERTH HW, 1975, NEW ENGL J MED, V293, P1278, DOI 10.1056/NEJM197512182932502; SNIDER DE, 1978, ALLERGY PRINCIPLES P; STRANDBE.K, 1971, ACTA PHYSIOL SCAND, V82, P358, DOI 10.1111/j.1748-1716.1971.tb04977.x; TAKAHASHI H, 1976, J IMMUNOL, V117, P1039; TASHJIAN AH, 1975, NEW ENGL J MED, V293, P1317, DOI 10.1056/NEJM197512182932511; TASHJIAN AH, 1975, NATURE, V258, P739, DOI 10.1038/258739a0; TURNBULL LS, 1976, IMMUNOLOGY, V31, P813; VANE JR, 1969, BRIT J PHARMACOL, V35, P209, DOI 10.1111/j.1476-5381.1969.tb07982.x; WASSERMAN SI, 1976, J CLIN INVEST, V57, P738, DOI 10.1172/JCI108332; WASSERMAN SI, 1975, J IMMUNOL, V114, P645; YECIES LD, 1978, J ALLERGY CLIN IMMUN, V61, P131, DOI 10.1016/0091-6749(78)90246-4	64	67	67	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	1					1	14		10.1016/0091-6749(79)90155-6	http://dx.doi.org/10.1016/0091-6749(79)90155-6			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GE110	82564				2022-12-18	WOS:A1979GE11000001
J	RACHELEFSKY, GS; OPELZ, G; MICKEY, MR; KIUCHI, M; TERASAKI, PI; SIEGEL, SC; STIEHM, ER				RACHELEFSKY, GS; OPELZ, G; MICKEY, MR; KIUCHI, M; TERASAKI, PI; SIEGEL, SC; STIEHM, ER			DEFECTIVE T CELL-FUNCTION IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,SCH MED,DEPT SURG,LOS ANGELES,CA; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOMATH,LOS ANGELES,CA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BAER RL, 1959, MED CLIN N AM, V43, P765, DOI 10.1016/S0025-7125(16)34141-4; BAKER PJ, 1970, J IMMUNOL, V105, P1581; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1974, J ALLERGY CLIN IMMUN, V53, P72; CLENDENNING WE, 1973, J INVEST DERMATOL, V61, P233, DOI 10.1111/1523-1747.ep12676481; CORMANE RH, 1974, BRIT J DERMATOL, V90, P597, DOI 10.1111/j.1365-2133.1974.tb06687.x; DIXON W.J., 1975, BMDP BIOMEDICAL COMP; FJELDE A, 1967, ACTA DERM-VENEREOL, V47, P168; GUDJONSSON H, 1966, ACTA DERM-VENEREOL, V46, P159; HILL HR, 1974, LANCET, V2, P617; JARRETT E, 1974, NATURE, V250, P420, DOI 10.1038/250420a0; KERBEL RS, 1972, EUR J IMMUNOL, V2, P114, DOI 10.1002/eji.1830020204; LAWLOR GJ, 1973, J ALLERGY CLIN IMMUN, V52, P31, DOI 10.1016/0091-6749(73)90118-8; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; MICHAEL JG, 1973, J IMMUNOL, V111, P1600; OKUMURA K, 1971, J IMMUNOL, V107, P1682; OKUMURA K, 1971, J IMMUNOL, V106, P1019; PERNIS B, 1970, J EXP MED, V132, P1001, DOI 10.1084/jem.132.5.1001; PETERSON RDA, 1965, J PEDIATR, V66, P224; PILOT ML, 1950, AM J CLIN PATHOL, V20, P870, DOI 10.1093/ajcp/20.9_ts.870; POLMAR SH, 1972, AM J PATHOL, V69, P499; RAJKA G, 1967, ACTA DERM VENER, V47, P159; REED WB, 1966, J AMER MED ASSOC, V195, P746, DOI 10.1001/jama.195.9.746; ROSTENBERG A, 1959, ARCH DERMATOL, V79, P692, DOI 10.1001/archderm.1959.01560180066017; SENGAR DPS, 1971, TRANSPLANTATION, V11, P260, DOI 10.1097/00007890-197103000-00004; Stiehm E R, 1967, Clin Exp Immunol, V2, P179; TADA T, 1971, J IMMUNOL, V106, P1012; TADA T, 1973, ACTA PATHOL JAPON, V23, P907; WALDMANN TA, 1974, J IMMUNOL, V113, P379; WALDMANN TA, 1972, J IMMUNOL, V109, P304; WYBRAN J, 1973, LANCET, V1, P126	32	67	67	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	6					569	576		10.1016/0091-6749(76)90008-7	http://dx.doi.org/10.1016/0091-6749(76)90008-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BV054	1084358	Bronze			2022-12-18	WOS:A1976BV05400008
J	MIYAMOTO, T; JOHANSSON, SG; ITO, K; HORIUCHI, Y				MIYAMOTO, T; JOHANSSON, SG; ITO, K; HORIUCHI, Y			ATOPIC ALLERGY IN JAPANESE SUBJECTS - STUDIES PRIMARILY WITH RADIOALLERGOSORBENT TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TOKYO, SCH MED, DEPT PHYS THERAPY & INTERN MED, TOKYO, JAPAN; UNIV HOSP UPPSALA, BLOOD CTR, UPPSALA, SWEDEN	University of Tokyo; Uppsala University; Uppsala University Hospital								BENNICH H, 1970, VOX SANG, V19, P1, DOI 10.1111/j.1423-0410.1970.tb01490.x; BENNICH HH, 1968, B WORLD HEALTH ORGAN, V38, P151; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; BERNSTEIN IL, 1970, J ALLERGY, V45, P116; BERNTON HS, 1969, J ALLERGY, V43, P158; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; ISHIZAKA T, 1972, FED PROC, V31, P2998; Johansson S G, 1972, Prog Clin Immunol, V1, P157; JOHANSSON SG, 1971, INT ARCH ALLER A IMM, V41, P443, DOI 10.1159/000230538; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; JOHANSSON SGO, 1967, 3 NOB S GAMM GLOB ST, P193; KAWAI T, 1972, J ALLERGY CLIN IMMUN, V50, P117, DOI 10.1016/0091-6749(72)90007-3; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; MIYAMOTO T, 1970, ANN ALLERGY, V28, P405; MIYAMOTO T, 1968, JAP J ALLERGY, V17, P91; PEPYS J, 1968, LANCET, V1, P1270; STENIUS B, 1969, LANCET, V2, P455; Voorhorst R., 1964, Allergie Asthma, V10, P329; WIDE L, 1967, LANCET, V2, P1105; WIDE L, 1966, BIOCHIM BIOPHYS ACTA, V130, P257, DOI 10.1016/0304-4165(66)90032-8	21	67	67	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	1					9	19		10.1016/0091-6749(74)90094-3	http://dx.doi.org/10.1016/0091-6749(74)90094-3			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R8075	4855558				2022-12-18	WOS:A1974R807500002
J	Bachert, C; Han, JK; Wagenmann, M; Hosemann, W; Lee, SE; Backer, V; Mullol, J; Gevaert, P; Klimek, L; Prokopakis, E; Knill, A; Cavaliere, C; Hopkins, C; Hellings, P				Bachert, Claus; Han, Joe K.; Wagenmann, Martin; Hosemann, Werner; Lee, Stella E.; Backer, Vibeke; Mullol, Joaquim; Gevaert, Philippe; Klimek, Ludger; Prokopakis, Emanuel; Knill, Andrew; Cavaliere, Carlo; Hopkins, Claire; Hellings, Peter			EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; nasal polyps; endotypes; type 2 inflammation; sinus surgery; biologics; indication; patient selection		Uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) is the most bothersome phenotype of chronic rhinosinusitis; it is typically characterized by a type 2 inflammatory reaction and by comorbidities, including asthma, nonsteroidal anti-inflammatory drug-exacerbated respiratory disease, and allergies. Here, the European Forum for Research and Education in Allergy and Airway Diseases proposes structured definitions to enable communication between clinicians and provides a practical algorithm to define type 2 inflammation in CRSwNP in daily clinical practice. A rational approach for the treatment of uncontrolled severe CRSwNP is discussed; it consists of evaluating the perspective and risks of surgery and efficacy and adverse events of biologics on the basis of currently available data. Further, possible combinations of surgery and biologics are discussed, and a rationale is provided. Here, it is of importance to adequately counsel the patient about both approaches to enable a decision-making process with an informed patient. Criteria for the selection of a biologic drug are provided, as several biologics for uncontrolled severe CRSwNP will be available in many countries within a short time. Further, suggestions for monitoring of the drug effects that support recognition of responders to the therapy and, subsequently, the decision regarding continuation or discontinuation of the biologic are proposed.	[Bachert, Claus; Gevaert, Philippe] Univ Ghent, Upper Airways Res Lab, Ghent, Belgium; [Bachert, Claus; Gevaert, Philippe] Univ Ghent, Dept Otorhinolaryngol, Ghent, Belgium; [Bachert, Claus] Univ Stockholm, Karolinska Inst, Div ENT Dis, CLINTEC, Stockholm, Sweden; [Bachert, Claus] Sun Yat Sen Univ, Int Airway Res Ctr, Affiliated Hosp 1, Guangzhou, Peoples R China; [Han, Joe K.] Eastern Virginia Med Sch, Dept Otolaryngol Head & Neck Surg, Norfolk, VA 23501 USA; [Wagenmann, Martin] Univ Klinikum Dusseldorf, Dept Otorhinolaryngol, HNO Klin, Dusseldorf, Germany; [Hosemann, Werner] Ernst Moritz Arndt Univ Greifswald, Dept Otorhinolaryngol Head & Neck Surg, Greifswald, Germany; [Lee, Stella E.] Univ Pittsburgh, Sch Med, Dept Otolaryngol Head & Neck Surg, Div Sinonasal Disorders & Allergy, Pittsburgh, PA 15261 USA; [Backer, Vibeke] Univ Copenhagen, Rigshosp, ENT Dept, Copenhagen, Denmark; [Mullol, Joaquim] Univ Barcelona, Hosp Clin, ENT Dept, Rhinol Unit,IDIBAPS,CIBERES, Barcelona, Spain; [Mullol, Joaquim] Univ Barcelona, Hosp Clin, ENT Dept, Smell Clin,IDIBAPS,CIBERES, Barcelona, Spain; [Klimek, Ludger] Ctr Rhinol & Allergol, Wiesbaden, Germany; [Prokopakis, Emanuel] Univ Crete, Dept Otorhinolaryngol, Sch Med, Iraklion, Greece; [Knill, Andrew] Opus Commun, London, England; [Cavaliere, Carlo] Sapienza Univ, Dept Oral & Maxillofacial Sci, Rome, Italy; [Hopkins, Claire] Guys & St Thomas NHS Fdn Trust, London, England; [Hellings, Peter] Univ Hosp Leuven, Dept Otorhinolaryngol Head & Neck Surg, Leuven, Belgium	Ghent University; Ghent University; Karolinska Institutet; Stockholm University; Sun Yat Sen University; Eastern Virginia Medical School; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Ernst Moritz Arndt Universitat Greifswald; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Rigshospitalet; University of Copenhagen; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Crete; Sapienza University Rome; Guy's & St Thomas' NHS Foundation Trust; KU Leuven; University Hospital Leuven	Bachert, C (corresponding author), Ghent Univ Hosp, Upper Airways Res Lab, C Heymanslaan 10, B-9000 Ghent, Belgium.; Bachert, C (corresponding author), Ghent Univ Hosp, Dept Otorhinolaryngol, C Heymanslaan 10, B-9000 Ghent, Belgium.	claus.bachert@ugent.be	Gevaert, Philippe/ABA-4588-2021; Backer, Vibeke/AAQ-9379-2021; Cavaliere, Carlo/B-3031-2018; Bachert, Claus/J-8825-2012	Cavaliere, Carlo/0000-0002-0378-8935; Gevaert, Philippe/0000-0002-1629-8468	EUFOREA	EUFOREA	This was an initiative of and sponsored by EUFOREA.	Alsharif S, 2019, LARYNGOSCOPE, V129, P1286, DOI 10.1002/lary.27815; Anderson P, 2009, LARYNGOSCOPE, V119, P1828, DOI 10.1002/lary.20565; Bachert C, 2020, J ALLERGY CLIN IMMUN, V145, P725, DOI 10.1016/j.jaci.2020.01.020; Bachert C, 2019, LANCET, V394, P1638, DOI 10.1016/S0140-6736(19)31881-1; Bachert C, 2015, J ALLERGY CLIN IMMUN, V136, P1431, DOI 10.1016/j.jaci.2015.10.010; Bhattacharyya N, 2009, ANN OTO RHINOL LARYN, V118, P185, DOI 10.1177/000348940911800305; Blomgren K, 2018, CLIN OTOLARYNGOL, V43, P7, DOI 10.1111/coa.12894; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Chang JR, 2015, JAMA OPHTHALMOL, V133, P850, DOI 10.1001/jamaophthalmol.2015.0706; DeConde AS, 2017, LARYNGOSCOPE, V127, P550, DOI 10.1002/lary.26391; Draf W., 1991, OPER TECH OTOLAYNGOL, V2, P234, DOI [10.1016/S1043-1810(10)80087-9, DOI 10.1016/S1043-1810(10)80087-9]; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fokkens WJ, 2019, ALLERGY, V74, P2312, DOI 10.1111/all.13875; Georgalas C, 2011, RHINOLOGY, V49, P195, DOI [10.4193/Rhin10.153, 10.4193/Rhino10.153]; Gevaert P, 2020, J ALLERGY CLIN IMMUN, V146, P595, DOI 10.1016/j.jaci.2020.05.032; Hopkins C, 2009, LARYNGOSCOPE, V119, P2459, DOI 10.1002/lary.20653; Hosemann W, 2013, GMS Curr Top Otorhinolaryngol Head Neck Surg, V12, pDoc06, DOI 10.3205/cto000098; Jankowski R, 2018, EUR ANN OTORHINOLARY, V135, P327, DOI 10.1016/j.anorl.2018.05.006; Jankowski R, 1995, J FR DOTO RHINO LARY, V44, P221; Jian L, 2020, J ALLERGY CLIN IMMUN, V146, P67, DOI 10.1016/j.jaci.2020.04.030; Khan A, 2019, RHINOLOGY, V57, P343, DOI 10.4193/Rhin19.158; Khan A, 2019, RHINOLOGY, V57, P32, DOI 10.4193/Rhin17.255; Kowalski ML, 2019, ALLERGY, V74, P28, DOI 10.1111/all.13599; Loftus CA, 2020, INT FORUM ALLERGY RH, V10, P199, DOI 10.1002/alr.22487; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS3, DOI 10.1002/alr.21694; Ramakrishnan VR, 2012, INT FORUM ALLERGY RH, V2, P34, DOI 10.1002/alr.20101; Satyanarayana Rao K H, 2008, J Cutan Aesthet Surg, V1, P33, DOI 10.4103/0974-2077.41159; Schick B, 2009, RHINOLOGY FACIAL PLA, P567; Shirazi MA, 2007, LARYNGOSCOPE, V117, P765, DOI 10.1097/MLG.0b013e3180337d7b; Siedek V, 2013, EUR ARCH OTO-RHINO-L, V270, P141, DOI 10.1007/s00405-012-1973-z; Smith KA, 2015, LARYNGOSCOPE, V125, P1547, DOI 10.1002/lary.25180; STAMMBERGER H, 1990, EUR ARCH OTO-RHINO-L, V247, P63; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Toppila-Salmi S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022173; Van Zele T, 2018, RHINOLOGY, V56, P178, DOI 10.4193/Rhin17.078; Velez F, 2018, VALUE HEALTH, V21, P1; Wang ET, 2014, WORLD J CLIN CASES, V2, P873, DOI 10.12998/wjcc.v2.i12.873; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; WIGAND ME, 1981, HNO, V29, P215; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008; Zhang Y, 2017, J ALLERGY CLIN IMMUN, V140, P1230, DOI 10.1016/j.jaci.2017.09.009	41	66	70	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					29	36		10.1016/j.jaci.2020.11.013	http://dx.doi.org/10.1016/j.jaci.2020.11.013		JAN 2021	8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	33227318	Bronze			2022-12-18	WOS:000613645900003
J	Kohn, DB; Hershfield, MS; Puck, JM; Aiuti, A; Blincoe, A; Gaspar, HB; Notarangelo, LD; Grunebaum, E				Kohn, Donald B.; Hershfield, Michael S.; Puck, Jennifer M.; Aiuti, Alessandro; Blincoe, Annaliesse; Gaspar, H. Bobby; Notarangelo, Luigi D.; Grunebaum, Eyal			Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Adenosine deaminase deficiency; enzyme replacement therapy; gene therapy; hematopoietic stem cell transplantation; lentivirus; severe combined immune deficiency	SEVERE COMBINED IMMUNODEFICIENCY; STEM-CELL TRANSPLANTATION; ENZYME-REPLACEMENT THERAPY; GENE-THERAPY; T-CELL; ADA-DEFICIENCY; BONE-MARROW; BEHAVIORAL ABNORMALITIES; SENSORINEURAL DEAFNESS; MYELOID DYSPLASIA	Inherited defects in adenosine deaminase (ADA) cause a subtype of severe combined immunodeficiency (SCID) known as severe combined immune deficiency caused by adenosine deaminase defects (ADA-SCID). Most affected infants can receive a diagnosis while still asymptomatic by using an SCID newborn screening test, allowing early initiation of therapy. We review the evidence currently available and propose a consensus management strategy. In addition to treatment of the immune deficiency seen in patients with ADA-SCID, patients should be followed for specific noninfectious respiratory, neurological, and biochemical complications associated with ADA deficiency. All patients should initially receive enzyme replacement therapy (ERT), followed by definitive treatment with either of 2 equal first-line options. If an HLA-matched sibling donor or HLA-matched family donor is available, allogeneic hematopoietic stem cell transplantation (HSCT) should be pursued. The excellent safety and efficacy observed in more than 100 patients with ADA-SCID who received gammaretrovirus-or lentivirus-mediated autologous hematopoietic stem cell gene therapy (HSC-GT) since 2000 now positions HSC-GT as an equal alternative. If HLA-matched sibling donor/HLA-matched family donor HSCT or HSC-GT are not available or have failed, ERT can be continued or reinstituted, and HSCT with alternative donors should be considered. The outcomes of novel HSCT, ERT, and HSC-GT strategies should be evaluated prospectively in "real-life'' conditions to further inform these management guidelines.	[Kohn, Donald B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Kohn, Donald B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Hematol & Oncol, Los Angeles, CA 90095 USA; [Hershfield, Michael S.] Duke Univ, Med Ctr, Dept Med & Biochem, Durham, NC 27706 USA; [Puck, Jennifer M.] Univ Calif San Francisco, Dept Pediat, Div Allergy Immunol & Bone Marrow Transplantat, San Francisco, CA USA; [Aiuti, Alessandro] Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy, Milan, Italy; [Aiuti, Alessandro] Univ Vita Salute San Raffaele, Milan, Italy; [Blincoe, Annaliesse] Univ Montreal, Dept Pediat, CHU St Justine, Montreal, PQ, Canada; [Gaspar, H. Bobby] UCL Great Ormond St Inst Child Hlth, Infect Immun Inflammat Mol & Cellular Immunol Sec, London, England; [Notarangelo, Luigi D.] NIAID, Lab Clin Immunol & Microbiol, Div Intramural Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Grunebaum, Eyal] Hosp Sick Children, Div Immunol & Allergy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada; [Grunebaum, Eyal] Hosp Sick Children, Dept Pediat, Res Inst, Dev & Stem Cell Biol Program, Toronto, ON, Canada	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Duke University; University of California System; University of California San Francisco; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; University of London; University College London; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Grunebaum, E (corresponding author), Hosp Sick Children, Div Immunol & Allergy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	eyal.grunebaum@sickkids.ca			Thomson, Inc; Campbell Chair for Immunology Research, University of Toronto; Hospital for Sick Children Foundation, Toronto, Ontario; Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, Md [U54-AI082973, R13-AI094943]; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Enzon Pharmaceuticals; Leadiant Biosciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001222, R13AI094943, U01AI100801, U54AI082973] Funding Source: NIH RePORTER; MRC [G0600773, MR/K015427/1, G0802483] Funding Source: UKRI	Thomson, Inc; Campbell Chair for Immunology Research, University of Toronto; Hospital for Sick Children Foundation, Toronto, Ontario; Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID); Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, Md; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Enzon Pharmaceuticals; Leadiant Biosciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The meeting was supported by unrestricted educational grants by Thomson, Inc, and Campbell Chair for Immunology Research, University of Toronto, and The Hospital for Sick Children Foundation, Toronto, Ontario (to E.G.). E.G. is supported by the Campbell Chair for Immunology Research, University of Toronto. D.B.K., J.M.P. and L.D.N acknowledge support from the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases (NIAID), and the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, Md: U54-AI082973 (PI: J.M.P) and R13-AI094943 (PI: J.M.P). L.D.N. is supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. M.S.H. is supported by grants from Enzon Pharmaceuticals, and since 2010, from Leadiant Biosciences.	Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Aiuti A, 2017, EMBO MOL MED, V9, P737, DOI 10.15252/emmm.201707573; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Albuquerque W, 2004, J PEDIATR-US, V144, P278, DOI 10.1016/j.jpeds.2003.10.055; Arredondo-Vega FX, 1998, AM J HUM GENET, V63, P1049, DOI 10.1086/302054; Baffelli R, 2015, J CLIN IMMUNOL, V35, P624, DOI 10.1007/s10875-015-0191-z; Bertaina A, 2014, BLOOD, V124, P822, DOI 10.1182/blood-2014-03-563817; BLAESE RM, 1993, HUM GENE THER, V4, P521, DOI 10.1089/hum.1993.4.4-521; Bollinger ME, 1996, NEW ENGL J MED, V334, P1367, DOI 10.1056/NEJM199605233342104; Booth C, 2012, J CLIN IMMUNOL, V32, P449, DOI 10.1007/s10875-012-9658-3; Booth C, 2007, CLIN IMMUNOL, V123, P139, DOI 10.1016/j.clim.2006.12.009; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Bradford KL, 2017, J CLIN IMMUNOL, V37, P626, DOI 10.1007/s10875-017-0433-3; Brodsky RA, 2008, BONE MARROW TRANSPL, V42, P523, DOI 10.1038/bmt.2008.203; Cagdas D, 2018, J CLIN IMMUNOL, V38, P484, DOI 10.1007/s10875-018-0496-9; Cancrini C, 2010, HAEMATOL-HEMATOL J, V95, P1778, DOI 10.3324/haematol.2010.025098; Candotti F, 2012, BLOOD, V120, P3635, DOI 10.1182/blood-2012-02-400937; Carapito R, 2016, BLOOD, V128, P1979, DOI 10.1182/blood-2016-05-719070; Carbonaro DA, 2012, BLOOD, V120, P3677, DOI 10.1182/blood-2012-02-408591; CEDERBAUM SD, 1976, J PEDIATR-US, V89, P737, DOI 10.1016/S0022-3476(76)80793-7; CHAFFEE S, 1992, J CLIN INVEST, V89, P1643, DOI 10.1172/JCI115761; CHAKRAVARTI VS, 1991, PEDIATR RADIOL, V21, P447, DOI 10.1007/BF02026688; Chan B, 2005, CLIN IMMUNOL, V117, P133, DOI 10.1016/j.clim.2005.07.006; Cicalese MP, 2018, MOL THER, V26, P917, DOI 10.1016/j.ymthe.2017.12.022; Cicalese MP, 2016, BLOOD, V128, P45, DOI 10.1182/blood-2016-01-688226; Dalal I, 2011, CLIN IMMUNOL, V140, P284, DOI 10.1016/j.clim.2011.04.011; Flinn AM, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0807-5; Gangi-Peterson L, 1999, J CLIN INVEST, V103, P833, DOI 10.1172/JCI4320; Gaspar HB, 2011, SCI TRANSL MED, V3, DOI [10.1126/scitranslmed.3002716, 10.1126/scitranslmed.3002715]; Gaspar HB, 2009, BLOOD, V114, P3524, DOI 10.1182/blood-2009-06-189209; GIBLETT ER, 1972, LANCET, V2, P1067; Griffith LM, 2009, J ALLERGY CLIN IMMUN, V124, P1152, DOI 10.1016/j.jaci.2009.10.022; Grunebaum E, 2013, CURR OPIN ALLERGY CL, V13, P630, DOI 10.1097/ACI.0000000000000006; Grunebaum E, 2012, J ALLERGY CLIN IMMUN, V129, P1588, DOI 10.1016/j.jaci.2012.02.003; Hassan A, 2012, BLOOD, V120, P3615, DOI 10.1182/blood-2011-12-396879; Heimall J, 2017, BLOOD, V130, P2718, DOI 10.1182/blood-2017-05-781849; Heimall J, 2017, BIOL BLOOD MARROW TR, V23, P1229, DOI 10.1016/j.bbmt.2017.04.026; Hershfield M., 1993, GENEREVIEWS; Hershfield M., 2004, IMMUNOLOGIC DISORDER, P480; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; Hershfield MS., 2001, METABOLIC MOL BASES, V8th, P2585; Hershfield MS, 1993, PEDIATR RES, V33, pS4248; Husain M, 2007, J PEDIATR-US, V151, P93, DOI 10.1016/j.jpeds.2007.03.059; Joachims ML, 2008, J IMMUNOL, V181, P8153, DOI 10.4049/jimmunol.181.11.8153; KAPOOR N, 1986, J PEDIATR-US, V108, P435, DOI 10.1016/S0022-3476(86)80892-7; Kaufman DA, 2005, PEDIATRICS, V116, pE876, DOI 10.1542/peds.2005-1068; Kesserwan C, 2012, J ALLERGY CLIN IMMUN, V129, P762, DOI 10.1016/j.jaci.2011.10.028; Kim VHD, 2019, J ALLERGY CLIN IMMUN, V143, P403, DOI 10.1016/j.jaci.2018.04.029; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kohn DB, 2018, J CLIN IMMUNOL, V38, P364; Kohn DB, 2017, J CLIN IMMUNOL, V37, P351, DOI 10.1007/s10875-017-0373-y; Kohn DB, 2017, J ALLERGY CLIN IMMUN, V139, P726, DOI 10.1016/j.jaci.2017.01.007; Komarow HD, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0365-z; Kuhl JS, 2011, KLIN PADIATR, V223, P85, DOI 10.1055/s-0030-1269916; Kuo CY, 2018, J CLIN IMMUNOL, V38, P342; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; la Marca G, 2013, J ALLERGY CLIN IMMUN, V131, P1604, DOI 10.1016/j.jaci.2012.08.054; Lee SJ, 2007, BLOOD, V110, P4576, DOI 10.1182/blood-2007-06-097386; Malacarne F, 2005, EUR J IMMUNOL, V35, P3376, DOI 10.1002/eji.200526248; Manson D, 2013, PEDIATR RADIOL, V43, P589, DOI 10.1007/s00247-012-2564-2; Marciano BE, 2014, J ALLERGY CLIN IMMUN, V133, P1134, DOI 10.1016/j.jaci.2014.02.028; Maury S, 2007, HAEMATOL-HEMATOL J, V92, P589, DOI 10.3324/haematol.10899; Migliavacca M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00113; Modell V, 2014, IMMUNOL RES, V60, P145, DOI 10.1007/s12026-014-8485-4; Nikolajeva O, 2015, J CLIN IMMUNOL, V35, P366, DOI 10.1007/s10875-015-0158-0; Nofech-Mozes Y, 2007, PEDIATR NEUROL, V37, P218, DOI 10.1016/j.pediatrneurol.2007.03.011; Nomura K, 2013, PEDIATR BLOOD CANCER, V60, P885, DOI 10.1002/pbc.24353; OCHS HD, 1992, BLOOD, V80, P1163; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Patel NC, 2010, NEW ENGL J MED, V362, P314, DOI 10.1056/NEJMoa0904485; Pham-Huy A., 2015, LYMPHOSIGN J, V2, P195, DOI [10.14785/lpsn-2015-0010, DOI 10.14785/LPSN-2015-0010]; POLMAR SH, 1976, NEW ENGL J MED, V295, P1337, DOI 10.1056/NEJM197612092952402; RATECH H, 1985, AM J PATHOL, V120, P157; Rogers MH, 2001, J PEDIATR-US, V139, P44, DOI 10.1067/mpd.2001.115023; Roifman CM, 2008, J ALLERGY CLIN IMMUN, V121, P1056, DOI 10.1016/j.jaci.2007.12.1148; Sauer AV, 2017, SCI REP-UK, V7, DOI 10.1038/srep40136; Sauer AV, 2012, J CLIN INVEST, V122, P2141, DOI 10.1172/JCI61788; Sauer AV, 2012, BLOOD, V119, P1428, DOI 10.1182/blood-2011-07-366781; Sauer AV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00265; Scott O, 2017, J CLIN IMMUNOL, V37, P582, DOI 10.1007/s10875-017-0421-7; Selleri S, 2011, J ALLERGY CLIN IMMUN, V127, P1368, DOI 10.1016/j.jaci.2011.03.004; Serana F, 2010, J IMMUNOL, V185, P7713, DOI 10.4049/jimmunol.1001770; Shaw KL, 2017, J CLIN INVEST, V127, P1689, DOI 10.1172/JCI90367; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Sokolic R, 2011, BLOOD, V118, P2688, DOI 10.1182/blood-2011-01-329359; Somech R, 2009, J ALLERGY CLIN IMMUN, V124, P848, DOI 10.1016/j.jaci.2009.07.003; Speckmann C, 2012, J ALLERGY CLIN IMMUN, V130, P991, DOI 10.1016/j.jaci.2012.04.004; Tanaka C, 1996, BRAIN DEV-JPN, V18, P304, DOI 10.1016/0387-7604(96)00014-9; Tartibi HM, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2169; Titman P, 2008, BLOOD, V112, P3907, DOI 10.1182/blood-2008-04-151332; Tucci F, 2018, HEPATOLOGY, V68, P2434, DOI 10.1002/hep.30160; WEINBERG K, 1993, J CLIN INVEST, V92, P596, DOI 10.1172/JCI116626; Whitmore KV, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00314	94	66	67	1	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2019	143	3					852	863		10.1016/j.jaci.2018.08.024	http://dx.doi.org/10.1016/j.jaci.2018.08.024			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN6CQ	30194989	Green Accepted, Bronze			2022-12-18	WOS:000460272900004
J	Blom, WM; Michelsen-Huisman, AD; van Os-Medendorp, H; van Duijn, G; de Zeeuw-Brouwer, ML; Versluis, A; Castenmiller, JJM; Noteborn, HPJM; Kruizinga, AG; Knulst, AC; Houben, GF				Blom, W. Marty; Michelsen-Huisman, Anouska D.; van Os-Medendorp, Harmieke; van Duijn, Gert; de Zeeuw-Brouwer, Mary-lane; Versluis, Astrid; Castenmiller, Jacqueline J. M.; Noteborn, Hubert P. J. M.; Kruizinga, Astrid G.; Knulst, Andre C.; Houben, Geert F.			Accidental food allergy reactions: Products and undeclared ingredients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Accidental allergic reaction; allergen management; allergen labeling; allergen intake; food allergy; food product; precautionary allergen labeling; reference dose; undeclared allergen	RISK-ASSESSMENT; PEANUT; EXPOSURES; RELEVANT; COOKIES; HEALTH; TRACES; LABELS; MODEL	Background: Accidental allergic reactions to food are frequent and can be severe and even fatal. Objective: We sought to analyze the culprit food products and levels of unexpected allergens in accidental reactions. Methods: A prospective cohort study was conducted in adults (n = 157) with a physician-confirmed diagnosis of food allergy. During a 1-year follow-up, 73 patients reported accidental allergic reactions and the culprit food products. Food samples received (n = 51) were analyzed for a wide range of suspected noningredient allergens, and risk was quantified. Results: A very diverse range of food products was responsible for the unexpected allergic reactions. Thirty-seven percent (19/51) of products analyzed had 1 to 4 culprit allergens identified that were not supposed to be present according to the ingredient declaration. Concentrations varied from 1 to 5000 mg of protein of the allergenic food per kilogram of food product and were greatest for peanut, milk, and sesame. Milk proteins posed the highest estimated risk for objective allergic reactions. The intake of culprit allergens by patients varied considerably. For those cases in which culprit allergens were detected, the intake of at least 1 allergen exceeded the reference dose or a culprit allergen with a yet unknown reference dose was present. Both patient neglect of precautionary allergen labeling statements and omission of using a precautionary allergen labeling statement by food manufacturers seem to contribute to accidental reactions. Conclusion: A wide range of food products are causing accidental reactions in patients with food allergy. Eight different allergens not declared on the ingredient lists were detected in the culprit food products, all of which were representative of allergens regulated in the European Union.	[Blom, W. Marty; de Zeeuw-Brouwer, Mary-lane; Kruizinga, Astrid G.; Houben, Geert F.] Netherlands Org Appl Sci Res TNO, Zeist, Netherlands; [Blom, W. Marty; Michelsen-Huisman, Anouska D.; van Os-Medendorp, Harmieke; Versluis, Astrid; Knulst, Andre C.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands; [Houben, Geert F.] Univ Utrecht, Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands; [van Duijn, Gert] Triskelion BV, Zeist, Netherlands; [Castenmiller, Jacqueline J. M.; Noteborn, Hubert P. J. M.] Netherlands Food & Consumer Prod Safety Author, Utrecht, Netherlands	Netherlands Organization Applied Science Research; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Blom, WM (corresponding author), Netherlands Org Appl Sci Res TNO, Dept RAPID, Utrechtseweg 48,POB 360, NL-3700 AJ Zeist, Netherlands.	marry.blom@tno.nl		Blom, W.M./0000-0002-6853-0900; Knulst, Andre/0000-0002-1056-3179; Houben, Geert/0000-0001-7261-3912	Netherlands Food and Consumer Product Safety Authority; Dutch Governmental TNO Research Cooperation Funds	Netherlands Food and Consumer Product Safety Authority; Dutch Governmental TNO Research Cooperation Funds	Supported by the Netherlands Food and Consumer Product Safety Authority. W.M.B. and G.F.H. were also funded in part by the Dutch Governmental TNO Research Cooperation Funds.	Allen KJ, 2018, J ALLER CL IMM-PRACT, V6, P400, DOI 10.1016/j.jaip.2017.12.025; Allen KJ, 2014, J ALLERGY CLIN IMMUN, V133, P156, DOI 10.1016/j.jaci.2013.06.042; Anibarro B, 2007, J INVEST ALLERG CLIN, V17, P168; Crevel RWR, 2007, FOOD CHEM TOXICOL, V45, P691, DOI 10.1016/j.fct.2006.09.005; Crotty MP, 2010, J ALLERGY CLIN IMMUN, V125, P935, DOI 10.1016/j.jaci.2009.12.003; Cucu T, 2013, J AGR FOOD CHEM, V61, P5624, DOI 10.1021/jf303337z; Decastelli L, 2012, FOOD ADDIT CONTAM B, V5, P160, DOI 10.1080/19393210.2012.679318; DunnGalvin A, 2015, ALLERGY, V70, P1039, DOI 10.1111/all.12614; Fleischer DM, 2012, PEDIATRICS, V130, pE25, DOI 10.1542/peds.2011-1762; Ford LS, 2010, J ALLERGY CLIN IMMUN, V126, P384, DOI 10.1016/j.jaci.2010.05.034; Gendel SM, 2013, J FOOD PROTECT, V76, P1933, DOI 10.4315/0362-028X.JFP-13-171; Hefle SL, 2007, J ALLERGY CLIN IMMUN, V120, P171, DOI 10.1016/j.jaci.2007.04.013; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; Khuda S, 2012, J AGR FOOD CHEM, V60, P4195, DOI 10.1021/jf3001839; Khuda SE, 2016, FOOD ADDIT CONTAM A, V33, P1265, DOI 10.1080/19440049.2016.1198051; Kruizinga AG, 2008, FOOD CHEM TOXICOL, V46, P1437, DOI 10.1016/j.fct.2007.09.109; Michelsen-Huisman AD, 2018, ALLERGY; Nha UNL, 2012, PEDIAT ALLERG IMM-UK, V23, P134, DOI 10.1111/j.1399-3038.2011.01235.x; Nwaru BI, 2014, ALLERGY, V69, P992, DOI 10.1111/all.12423; Pele M, 2007, FOOD ADDIT CONTAM A, V24, P1334, DOI 10.1080/02652030701458113; Remington BC, 2015, ALLERGY, V70, P813, DOI 10.1111/all.12625; Remington BC, 2013, FOOD CHEM TOXICOL, V62, P179, DOI 10.1016/j.fct.2013.08.030; Sheth SS, 2010, ANN ALLERG ASTHMA IM, V104, P60, DOI 10.1016/j.anai.2009.11.008; Spanjersberg MQI, 2007, FOOD CHEM TOXICOL, V45, P49, DOI 10.1016/j.fct.2006.07.018; Spanjersberg MQI, 2010, FOOD ADDIT CONTAM A, V27, P169, DOI 10.1080/19440040903317513; Taylor SL, 2014, FOOD CHEM TOXICOL, V63, P9, DOI 10.1016/j.fct.2013.10.032; Trendelenburg V, 2015, ALLERGY, V70, P591, DOI 10.1111/all.12588; Turner PJ, 2016, ALLERGY, V71, P1505, DOI 10.1111/all.12961; Turner PJ, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6180; van der Heijden L, 2013, INFORMATORIUM VOEDIN, P732; Van Rossum C.T.M., DUTCH NATL FOOD CONS; Versluis A, 2015, CLIN EXP ALLERGY, V45, P347, DOI 10.1111/cea.12328; Walker MJ, 2016, ANALYST, V141, P24, DOI [10.1039/c5an01457c, 10.1039/C5AN01457C]	33	66	67	4	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					865	875		10.1016/j.jaci.2018.04.041	http://dx.doi.org/10.1016/j.jaci.2018.04.041			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29908992	Bronze			2022-12-18	WOS:000443726500019
J	Wisniewski, JA; Muehling, LM; Eccles, JD; Capaldo, BJ; Agrawal, R; Shirley, DA; Patrie, JT; Workman, LJ; Schuyler, AJ; Lawrence, MG; Teague, WG; Woodfolk, JA				Wisniewski, Julia A.; Muehling, Lyndsey M.; Eccles, Jacob D.; Capaldo, Brian J.; Agrawal, Rachana; Shirley, Debbie-Ann; Patrie, James T.; Workman, Lisa J.; Schuyler, Alexander J.; Lawrence, Monica G.; Teague, W. Gerald; Woodfolk, Judith A.			T(H)1 signatures are present in the lower airways of children with severe asthma, regardless of allergic status	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; allergic; IgE; IFN-gamma; IL-4; IL-5; IL-23; IL-33; IL-28A; T(H)1 cells; T(H)2 cells; T(H)17 cells; type 2 innate lymphoid cells	STEROID-RESISTANT ASTHMA; PEDIATRIC SEVERE ASTHMA; INTERFERON-GAMMA; T-CELLS; IFN-GAMMA; DENDRITIC CELLS; CYTOKINE PRODUCTION; BEHCETS-DISEASE; INFLUENZA-VIRUS; FLOW-CYTOMETRY	Background: The pathogenesis of severe asthma in childhood remains poorly understood. Objective: We sought to construct the immunologic landscape in the airways of children with severe asthma. Methods: Comprehensive analysis of multiple cell types and mediators was performed by using flow cytometry and a multiplex assay with bronchoalveolar lavage (BAL) specimens (n = 68) from 52 highly characterized allergic and nonallergic children (0.5-17 years) with severe treatment-refractory asthma. Multiple relationships were tested by using linear mixed-effects modeling. Results: Memory CCR5(+) T(H)1 cells were enriched in BAL fluid versus blood, and pathogenic respiratory viruses and bacteria were readily detected. IFN-gamma(+) IL-17(+) and IFN-gamma(-) 2 IL-17(+) subsets constituted secondary T-H types, and BAL fluid CD8 1 T cells were almost exclusively IFN-gamma(+). The T(H)17-associated mediators IL-23 and macrophage inflammatory protein 3 alpha/CCL20 were highly expressed. Despite low T(H)2 numbers, T(H)2 cytokines were detected, and T(H)2 skewing correlated with total IgE levels. Type 2 innate lymphoid cells and basophils were scarce in BAL fluid. Levels of IL-5, IL-33, and IL-28A/IFN-lambda 2 were increased in multisensitized children and correlated with IgE levels to dust mite, ryegrass, and fungi but not cat, ragweed, or food sources. Additionally, levels of IL-5, but no other cytokine, increased with age and correlated with eosinophil numbers in BAL fluid and blood. Both plasmacytoid and IgE 1 FceRI 1 myeloid dendritic cells were present in BAL fluid. Conclusions: The lower airways of children with severe asthma display a dominant T(H)1 signature and atypical cytokine profiles that link to allergic status. Our findings deviate from established paradigms and warrant further assessment of the pathogenicity of T(H)1 cells in patients with severe asthma.	[Wisniewski, Julia A.; Muehling, Lyndsey M.; Eccles, Jacob D.; Agrawal, Rachana; Workman, Lisa J.; Schuyler, Alexander J.; Lawrence, Monica G.; Woodfolk, Judith A.] Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA; [Wisniewski, Julia A.; Shirley, Debbie-Ann; Teague, W. Gerald] Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA; [Capaldo, Brian J.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA; [Patrie, James T.] Univ Virginia, Sch Med, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Woodfolk, JA (corresponding author), Univ Virginia Hlth Syst, Div Allergy, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu		Muehling, Lyndsey/0000-0003-3203-3264; Capaldo, Brian/0000-0003-1244-8884; ECCLES, Jacob/0000-0002-4202-0355	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [R01 AI-052196]; NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01 AR-059058]; NIH/NIAID [T32 AI-007496]; NIH/National Heart, Lung, and Blood Institute [U10 HL 109250]; University of Virginia Ivy Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL109250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007496, U01AI100799, R01AI052196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); University of Virginia Ivy Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) R01 AI-052196 and NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases R01 AR-059058 (to J.A.W.), NIH/NIAID T32 AI-007496 (to L.M.M.), and NIH/National Heart, Lung, and Blood Institute U10 HL 109250 and the University of Virginia Ivy Foundation (to W.G.T.).	Agrawal R, 2014, CLIN EXP ALLERGY, V44, P1266, DOI 10.1111/cea.12390; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Alcaide P, 2012, J IMMUNOL, V188, P1421, DOI 10.4049/jimmunol.1101647; Andersson CK, 2017, J ALLERGY CLIN IMMUN, V139, P1819, DOI 10.1016/j.jaci.2016.09.022; Bassis CM, 2015, MBIO, V6, DOI 10.1128/mBio.00037-15; Baumann C, 2015, P NATL ACAD SCI USA, V112, P4056, DOI 10.1073/pnas.1418549112; Baumgarth N, 2000, J IMMUNOL METHODS, V243, P77, DOI 10.1016/S0022-1759(00)00229-5; Boniface K, 2010, J IMMUNOL, V185, P679, DOI 10.4049/jimmunol.1000366; Bosco A, 2012, J ALLERGY CLIN IMMUN, V129, P88, DOI 10.1016/j.jaci.2011.10.038; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Breen EC, 2011, CLIN VACCINE IMMUNOL, V18, P1229, DOI 10.1128/CVI.05032-11; Campbell JJ, 2001, J IMMUNOL, V166, P2842, DOI 10.4049/jimmunol.166.4.2842; Castanhinha S, 2015, J ALLERGY CLIN IMMUN, V136, P312, DOI 10.1016/j.jaci.2015.01.016; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; CELADA A, 1987, J IMMUNOL, V139, P147; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; Chae SC, 2007, J HUM GENET, V52, P355, DOI 10.1007/s10038-007-0123-8; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chung KF, 2015, LANCET, V386, P1086, DOI 10.1016/S0140-6736(15)00157-9; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Clarke DC, 2013, MOL CELL PROTEOMICS, V12, P245, DOI 10.1074/mcp.M112.018655; de Blic J, 2004, J ALLERGY CLIN IMMUN, V113, P94, DOI 10.1016/j.jaci.2003.10.045; Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC; Draijer C, 2017, J ALLERGY CLIN IMMUN, V140, P280, DOI 10.1016/j.jaci.2016.11.020; Dreymueller D, 2015, AM J PHYSIOL-LUNG C, V308, pL325, DOI 10.1152/ajplung.00294.2014; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Fong Y, 2015, NCAL NONLINEAR CALIB; Froidure A, 2015, THORAX, V70, P967, DOI 10.1136/thoraxjnl-2014-206364; Galkina E, 2005, J CLIN INVEST, V115, P3473, DOI 10.1172/JCI24482; Gauthier M, 2015, AM J RESP CRIT CARE, V192, P660, DOI 10.1164/rccm.201504-0763PP; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Henault J, 2016, NAT IMMUNOL, V17, P196, DOI 10.1038/ni.3326; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Hong GH, 2016, J IMMUNOL, V196, P2021, DOI 10.4049/jimmunol.1500747; Hosoki K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126035; Huse M, 2006, NAT IMMUNOL, V7, P247, DOI 10.1038/ni1304; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Jackson DJ, 2016, J ALLERGY CLIN IMMUN, V137, P659, DOI 10.1016/j.jaci.2016.01.002; Jirapongsananuruk O, 2000, J ALLERGY CLIN IMMUN, V106, P981, DOI 10.1067/mai.2000.110101; Kanzaki H, 2016, SCI REP-UK, V6, DOI 10.1038/srep32259; Kaur M, 2014, INT IMMUNOPHARMACOL, V23, P581, DOI 10.1016/j.intimp.2014.10.008; Kebir H, 2009, ANN NEUROL, V66, P390, DOI 10.1002/ana.21748; Kohlmeier JE, 2008, IMMUNITY, V29, P101, DOI 10.1016/j.immuni.2008.05.011; Koltsida O, 2011, EMBO MOL MED, V3, P348, DOI 10.1002/emmm.201100142; Komai-Koma M, 2016, IMMUNOBIOLOGY, V221, P412, DOI 10.1016/j.imbio.2015.11.013; Kreutz C, 2007, BIOINFORMATICS, V23, P2747, DOI 10.1093/bioinformatics/btm397; Lazarski CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071949; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Li B, 2014, CELL IMMUNOL, V290, P116, DOI 10.1016/j.cellimm.2014.06.003; Loza MJ, 2008, J ALLERGY CLIN IMMUN, V121, P750, DOI 10.1016/j.jaci.2007.10.036; Maecker HT, 2006, CYTOM PART A, V69A, P1037, DOI 10.1002/cyto.a.20333; Mao Jian-hua, 2004, Zhejiang Da Xue Xue Bao Yi Xue Ban, V33, P155; MOLLER BK, 1990, FEBS LETT, V276, P59, DOI 10.1016/0014-5793(90)80506-E; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Nagakumar P, 2016, J ALLERGY CLIN IMMUN, V137, P624, DOI 10.1016/j.jaci.2015.06.038; Newcomb DC, 2015, J ALLERGY CLIN IMMUN, V136, P1025, DOI 10.1016/j.jaci.2015.05.046; Neyt K, 2016, MUCOSAL IMMUNOL, V9, P999, DOI 10.1038/mi.2015.91; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; R Core Team, R LANG ENV STAT COMP; Raundhal M, 2015, J CLIN INVEST, V125, P3037, DOI 10.1172/JCI80911; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Romeo MJ, 2014, J ALLERGY CLIN IMMUN, V133, P952, DOI 10.1016/j.jaci.2013.08.006; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Shikotra A, 2017, J IMMUNOL, V198, P3307, DOI 10.4049/jimmunol.1600606; Shimizu J, 2012, CLIN EXP IMMUNOL, V168, P68, DOI 10.1111/j.1365-2249.2011.04543.x; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Tham R, 2017, J ALLERGY CLIN IMMUN, V139, P1140, DOI 10.1016/j.jaci.2016.06.046; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wisniewski JA, 2015, CLIN EXP ALLERGY, V45, P1201, DOI 10.1111/cea.12537; Won JH, 2012, P NATL ACAD SCI USA, V109, P2848, DOI 10.1073/pnas.1112599109; Xie M, 2015, J ALLERGY CLIN IMMUN, V135, P386, DOI 10.1016/j.jaci.2014.08.023; Yang M, 2009, J IMMUNOL, V182, P5107, DOI 10.4049/jimmunol.0803468	74	66	67	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2048	+		10.1016/j.jaci.2017.08.020	http://dx.doi.org/10.1016/j.jaci.2017.08.020			26	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	28939412	Green Accepted, Bronze			2022-12-18	WOS:000434701600012
J	Prencipe, G; Caiello, I; Pascarella, A; Grom, AA; Bracaglia, C; Chatel, L; Ferlin, WG; Marasco, E; Strippoli, R; de Min, C; De Benedetti, F				Prencipe, Giusi; Caiello, Ivan; Pascarella, Antonia; Grom, Alexei A.; Bracaglia, Claudia; Chatel, Laurence; Ferlin, Walter G.; Marasco, Emiliano; Strippoli, Raffaele; de Min, Cristina; De Benedetti, Fabrizio			Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Macrophage activation syndrome; hemophagocytic lymphohistiocytosis; IFN-gamma	JUVENILE IDIOPATHIC ARTHRITIS; CYTOKINE-DIRECTED THERAPIES; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; INTERFERON-GAMMA; MICE; RECEPTOR; INTERLEUKIN-6; PATHOGENESIS; EXPRESSION; GENE	Background: The pathogenesis of macrophage activation syndrome (MAS) is not clearly understood: a large body of evidence supports the involvement of mechanisms similar to those implicated in the setting of primary hemophagocytic lymphohistiocytosis. Objective: We sought to investigate the pathogenic role of IFN-gamma and the therapeutic efficacy of IFN-gamma neutralization in an animal model of MAS. Methods: We used an MAS model established in mice transgenic for human IL-6 (IL-6TG mice) challenged with LPS (MAS mice). Levels of IFN-gamma and IFN-gamma-inducible chemokines were evaluated by using real-time PCR in the liver and spleen and by means of ELISA in plasma. IFN-gamma neutralization was achieved by using the anti-IFN-gamma antibody XMG1.2 in vivo. Results: Mice with MAS showed a significant upregulation of the IFN-gamma pathway, as demonstrated by increased mRNA levels of Ifng and higher levels of phospho-signal transducer and activator of transcription 1 in the liver and spleen and increased expression of the IFN-gamma-inducible chemokines Cxcl9 and Cxcl10 in the liver and spleen, as well as in plasma. A marked increase in Il12a and Il12b expression was also found in livers and spleens of mice with MAS. In addition, mice with MAS had a significant increase in numbers of liver CD68(+) macrophages. Mice with MAS treated with an anti-IFN-gamma antibody showed a significant improvement in survival and body weight recovery associated with a significant amelioration of ferritin, fibrinogen, and alanine aminotransferase levels. In mice with MAS, treatment with the anti-IFN-gamma antibody significantly decreased circulating levels of CXCL9, CXCL10, and downstream proinflammatory cytokines. The decrease in CXCL9 and CXCL10 levels paralleled the decrease in serum levels of proinflammatory cytokines and ferritin. Conclusion: These results provide evidence for a pathogenic role of IFN-gamma in the setting of MAS.	[Prencipe, Giusi; Caiello, Ivan; Pascarella, Antonia; Bracaglia, Claudia; Marasco, Emiliano; De Benedetti, Fabrizio] IRCCS, Bambino Gesu Childrens Hosp, Div Rheumatol, Rome, Italy; [Grom, Alexei A.] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, ML 4010, Cincinnati, OH 45229 USA; [Chatel, Laurence; Ferlin, Walter G.; de Min, Cristina] NovImmune SA, Geneva, Switzerland; [Strippoli, Raffaele] Sapienza Univ Rome, Dept Cellular Biotechnol & Haematol, Rome, Italy	IRCCS Bambino Gesu; Cincinnati Children's Hospital Medical Center; NovImmune SA; Sapienza University Rome	Prencipe, G (corresponding author), Bambino Gesu Pediat Hosp, Div Rheumatol, Viale S Paolo 15, I-00146 Rome, Italy.	giusi.prencipe@opbg.net	Bracaglia, Claudia/AAF-7969-2021; Marasco, Emiliano/J-3627-2016; prencipe, giusi/K-5829-2016; de benedetti, fabrizio/J-9577-2018; Strippoli, Raffaele/J-2129-2018; Bracaglia, Claudia/K-6886-2016	Bracaglia, Claudia/0000-0002-9834-9619; Marasco, Emiliano/0000-0001-5346-3357; prencipe, giusi/0000-0003-1152-9041; de benedetti, fabrizio/0000-0001-8749-8232; Strippoli, Raffaele/0000-0003-3483-8381; 	Italian Ministry of Health (Rome, Italy) [GR-2011-02347874]; Grant FIGHT-HLH [306124]; National Institutes of Health [R01-AR059049]	Italian Ministry of Health (Rome, Italy)(Ministry of Health, Italy); Grant FIGHT-HLH; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by the Italian Ministry of Health (Rome, Italy) Young Investigator Grants (GR-2011-02347874; to G.P.), by the FP7 Grant FIGHT-HLH (agreement no. 306124; to F.D.B. and C.d.M.), and by National Institutes of Health grant R01-AR059049 (to A.A.G.).	Avau A, 2014, ARTHRITIS RHEUMATOL, V66, P1340, DOI 10.1002/art.38359; Behrens EM, 2011, J CLIN INVEST, V121, P2264, DOI 10.1172/JCI43157; Billiau AD, 2005, BLOOD, V105, P1648, DOI 10.1182/blood-2004-08-2997; Bracaglia C, 2017, ANN RHEUM DIS, V76, P166, DOI 10.1136/annrheumdis-2015-209020; Brisse E, 2016, J IMMUNOL, V196, P3124, DOI 10.4049/jimmunol.1501035; Buatois V, 2017, TRANSL RES, V180, P37, DOI 10.1016/j.trsl.2016.07.023; Canna SW, 2013, ARTHRITIS RHEUM-US, V65, P1764, DOI 10.1002/art.37958; de Benedetti F, 2005, ARTHRITIS RHEUM-US, V52, P687, DOI 10.1002/art.20946; De Benedetti F, 2012, NEW ENGL J MED, V367, P2385, DOI 10.1056/NEJMoa1112802; DeBenedetti F, 1997, J CLIN INVEST, V99, P643, DOI 10.1172/JCI119207; Fall N, 2007, ARTHRITIS RHEUM-US, V56, P3793, DOI 10.1002/art.22981; Freeman HR, 2011, ARCH DIS CHILD, V96, P688, DOI 10.1136/adc.2009.176610; Grom AA, 2003, J PEDIATR-US, V142, P292, DOI 10.1067/mpd.2003.110; Grom AA, 2016, NAT REV RHEUMATOL, V12, P259, DOI 10.1038/nrrheum.2015.179; Hu XY, 2009, IMMUNITY, V31, P539, DOI 10.1016/j.immuni.2009.09.002; Jordan M, 2015, 57 ASH ANN M EXP LBA; Jordan MB, 2004, BLOOD, V104, P735, DOI 10.1182/blood-2003-10-3413; Kaufman KM, 2014, ARTHRITIS RHEUMATOL, V66, P3486, DOI 10.1002/art.38793; Ogilvie EM, 2007, ARTHRITIS RHEUM-US, V56, P1954, DOI 10.1002/art.22644; Pachlopnik SJ, 2009, EMBO MOL MED, V1, P112, DOI DOI 10.1002/EMMM.200900009; Put K, 2015, RHEUMATOLOGY, V54, P1507, DOI 10.1093/rheumatology/keu524; Ravelli A, 2012, GENES IMMUN, V13, P289, DOI 10.1038/gene.2012.3; Reinhardt RL, 2015, J IMMUNOL, V194, P2358, DOI 10.4049/jimmunol.1401992; Risma K, 2012, CURR OPIN PEDIATR, V24, P9, DOI 10.1097/MOP.0b013e32834ec9c1; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schulert GS, 2015, ANNU REV MED, V66, P145, DOI 10.1146/annurev-med-061813-012806; Schulert GS, 2014, BEST PRACT RES CL RH, V28, P277, DOI 10.1016/j.berh.2014.03.002; Sepulveda FE, 2016, BLOOD, V127, P2113, DOI 10.1182/blood-2015-12-688960; Sikora KA, 2012, ARTHRITIS RHEUM-US, V64, P3799, DOI 10.1002/art.34604; Strippoli R, 2013, J RHEUMATOL, V40, P761, DOI 10.3899/jrheum.121233; Strippoli R, 2012, ARTHRITIS RHEUM-US, V64, P1680, DOI 10.1002/art.33496; Takada H, 2003, CLIN EXP IMMUNOL, V133, P448, DOI 10.1046/j.1365-2249.2003.02237.x; Tesi B, 2015, J ALLERGY CLIN IMMUN, V135, P1638, DOI 10.1016/j.jaci.2014.11.030; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Vastert SJ, 2014, NAT REV RHEUMATOL, V10, P640, DOI 10.1038/nrrheum.2014.143; Vastert SJ, 2010, RHEUMATOLOGY, V49, P441, DOI 10.1093/rheumatology/kep418; Wulffraat NM, 2003, RHEUMATOLOGY, V42, P375, DOI 10.1093/rheumatology/keg074; Xu XJ, 2012, J PEDIATR-US, V160, P984, DOI 10.1016/j.jpeds.2011.11.046; Zhang K, 2008, ARTHRITIS RHEUM, V58, P2892, DOI 10.1002/art.23734; Zhang MC, 2014, CURR RHEUMATOL REP, V16, DOI 10.1007/s11926-014-0439-2; Zoller EE, 2011, J EXP MED, V208, P1203, DOI 10.1084/jem.20102538	41	66	68	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1439	1449		10.1016/j.jaci.2017.07.021	http://dx.doi.org/10.1016/j.jaci.2017.07.021			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28807602	Bronze, Green Published			2022-12-18	WOS:000429197800029
J	Unger, S; Seidl, M; van Schouwenburg, P; Rakhmanov, M; Bulashevska, A; Frede, N; Grimbacher, B; Pfeiffer, J; Schrenk, K; Munoz, L; Hanitsch, L; Stumpf, I; Kaiser, F; Hausmann, O; Kollert, F; Goldacker, S; van der Burg, M; Keller, B; Warnatz, K				Unger, Susanne; Seidl, Maximilian; van Schouwenburg, Pauline; Rakhmanov, Mirzokhid; Bulashevska, Alla; Frede, Natalie; Grimbacher, Bodo; Pfeiffer, Jens; Schrenk, Klaudia; Munoz, Luis; Hanitsch, Leif; Stumpf, Ina; Kaiser, Fabian; Hausmann, Oliver; Kollert, Florian; Goldacker, Sigune; van der Burg, Mirjam; Keller, Baerbel; Warnatz, Klaus			The T(H)1 phenotype of follicular helper T cells indicates an IFN-gamma-associated immune dysregulation in patients with CD21low common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Follicular helper T cells; common variable immunodeficiency; IFN-gamma; germinal center; CD21(low) B cells; T-bet	SYSTEMIC-LUPUS-ERYTHEMATOSUS; MEMORY B-CELLS; PERIPHERAL-BLOOD; INTERFERON-GAMMA; TFH CELLS; BET EXPRESSION; PLASMA-CELLS; MALARIA; LYMPHADENOPATHY; DEFICIENCY	Background: A subgroup of patients with common variable immunodeficiency (CVID) experience immune dysregulation manifesting as autoimmunity, lymphoproliferation, and organ inflammation and thereby increasing morbidity and mortality. Therefore treatment of these complications demands a deeper comprehension of their cause and pathophysiology. Objectives: On the basis of the identification of an interferon signature in patients with CVID with secondary complications and a skewed follicular helper T-cell differentiation in defined monogenic immunodeficiencies, we sought to determine the profile of CD4 memory T cells in blood and secondary lymphatic tissues of these patients. Methods: We quantified T(H)1/T(H)2/T(H)17 CD4 memory T cells in blood and lymph nodes of patients with CVID using flow cytometry, analyzed their function, and correlated all findings to the burden of immune dysregulation. Results: Patients with CVID with immune dysregulation had a skewed memory CD4 T-cell differentiation toward a CXCR3(+)CCR6(-) T(H)1 phenotype both in blood and lymph nodes. Consistent with our phenotypic findings, we observed a higher IFN-gamma production in peripheral CD4 memory T cells and lymph node-derived follicular helper T cells of patients with CVID compared with those of healthy control subjects. Increased IFN-gamma production was accompanied by a poor germinal center output, an accumulation of T-box transcription factor (T-bet)(+) B cells in lymph nodes, and an accumulation of T-bet(+)CD21(low) B cells in peripheral blood of affected patients. Conclusion: Identification of excessive IFN-gamma production by blood and lymph node-derived T cells of patients with CVID with immune dysregulation will offer new therapeutic avenues for this subgroup. CD21(low) B cells might serve as a marker of this IFN-gamma-associated dysregulation.	[Unger, Susanne; Seidl, Maximilian; Bulashevska, Alla; Frede, Natalie; Grimbacher, Bodo; Schrenk, Klaudia; Stumpf, Ina; Goldacker, Sigune; Keller, Baerbel; Warnatz, Klaus] Univ Freiburg, Fac Med, Med Ctr, Ctr Chron Immunodeficiency CCI, Freiburg, Germany; [Unger, Susanne] Univ Freiburg, Fac Biol, Freiburg, Germany; [Pfeiffer, Jens] Univ Freiburg, Dept Otorhinolaryngol Head & Neck Surg, Freiburg, Germany; [Seidl, Maximilian; Schrenk, Klaudia] Univ Med Ctr Freiburg, Inst Surg Pathol, Freiburg, Germany; [Kollert, Florian] Univ Med Ctr Freiburg, Dept Rheumatol & Clin Immunol, Freiburg, Germany; [van Schouwenburg, Pauline; Kaiser, Fabian; van der Burg, Mirjam] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Kaiser, Fabian] Univ Med Ctr Rotterdam, Erasmus MC, Dept Pediat, Rotterdam, Netherlands; [Rakhmanov, Mirzokhid] Ctr Human Genet & Lab Diagnost AHC, Martinsried, Germany; [Munoz, Luis] Friedrich Alexander Univ Erlangen Nurnberg, Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany; [Hanitsch, Leif] Charite Univ Med Berlin, Inst Med Immunol, Campus Virchow, Berlin, Germany; [Hausmann, Oliver] Lowenpraxis, Luzern, Switzerland; [Hausmann, Oliver] Klin St Anna, Luzern, Switzerland	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Erlangen Nuremberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Warnatz, K (corresponding author), Univ Freiburg, Med Ctr, Ctr Chron Immunodeficiency, Breisacher Str 115, D-79106 Freiburg, Germany.	klaus.warnatz@uniklinik-freiburg.de	Seidl, Maxmilian/ABF-3322-2021; Rakhmanov, Mirzokhid/P-8351-2019; Munoz, Luis E/E-7725-2010; Bulashevska, Alla/C-4910-2019; Rakhmanov, Mirzokhid/GMW-5383-2022; Warnatz, Klaus/AAD-3464-2022	Seidl, Maxmilian/0000-0002-5559-4980; Munoz, Luis E/0000-0002-5395-804X; Unger, Susanne/0000-0001-6916-7544; Hanitsch, Leif G./0000-0002-8181-0093; van Schouwenburg, Pauline/0000-0003-2779-1415	German Federal Ministry of Education and Research [BMBF 01EO1303]; Deutsche Forschungsgemeinschaft [DFG TRR130 p07]	German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	Supported by the German Federal Ministry of Education and Research (BMBF 01EO1303) and Deutsche Forschungsgemeinschaft (DFG TRR130 p07; to K. W.).	AUCOUTURIER P, 1986, CLIN EXP IMMUNOL, V63, P234; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Barnett BE, 2016, J IMMUNOL, V197, P1017, DOI 10.4049/jimmunol.1500368; Bateman EAL, 2012, CLIN EXP IMMUNOL, V170, P202, DOI 10.1111/j.1365-2249.2012.04643.x; Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Camacho FI, 2001, AM J PATHOL, V158, P1363, DOI 10.1016/S0002-9440(10)64087-4; Carvalho LJM, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-59; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Chevalier N, 2011, J IMMUNOL, V186, P5556, DOI 10.4049/jimmunol.1002828; Cols M, 2016, J ALLERGY CLIN IMMUN, V137, pe1; Cols M, 2016, J ALLERGY CLIN IMMUN, V137, P1206, DOI 10.1016/j.jaci.2015.09.013; Crum-Cianflone NF, 2012, CLIN EXP IMMUNOL, V168, P135, DOI 10.1111/j.1365-2249.2011.04550.x; Cubas R, 2015, J IMMUNOL, V195, P5625, DOI 10.4049/jimmunol.1501524; Ehrhardt GRA, 2008, J EXP MED, V205, P1807, DOI 10.1084/jem.20072682; Giovannetti A, 2007, J IMMUNOL, V178, P3932, DOI 10.4049/jimmunol.178.6.3932; Gosselin A, 2010, J IMMUNOL, V184, P1604, DOI 10.4049/jimmunol.0903058; Haas C, 1998, J IMMUNOL, V160, P3713; Heninger AK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf8848; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Johrens K, 2005, HAEMATOLOGICA, V90, P1070; Johrens K, 2006, HISTOPATHOLOGY, V48, P343, DOI 10.1111/j.1365-2559.2005.02305.x; Kim JR, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-3; KIM T, 1987, CLIN EXP IMMUNOL, V70, P562; Kojima M, 2010, PATHOL RES PRACT, V206, P361, DOI 10.1016/j.prp.2009.12.010; Lee SK, 2012, IMMUNITY, V37, P880, DOI 10.1016/j.immuni.2012.10.010; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; Ma CS, 2015, J ALLERGY CLIN IMMUN, V136, P993, DOI 10.1016/j.jaci.2015.05.036; Mannon PJ, 2006, GASTROENTEROLOGY, V131, P748, DOI 10.1053/j.gastro.2006.06.022; MAYUMI M, 1983, J IMMUNOL, V130, P671; Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Muehlenbachs A, 2007, J IMMUNOL, V179, P557, DOI 10.4049/jimmunol.179.1.557; Obeng-Adjei N, 2015, CELL REP, V13, P425, DOI 10.1016/j.celrep.2015.09.004; OZMEN L, 1995, EUR J IMMUNOL, V25, P6, DOI 10.1002/eji.1830250103; Park J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074893; Peng SL, 1997, J CLIN INVEST, V99, P1936, DOI 10.1172/JCI119361; Portugal S, 2015, ELIFE, V4, DOI 10.7554/eLife.07218; PREBLE OT, 1982, SCIENCE, V216, P429, DOI 10.1126/science.6176024; Rakhmanov M, 2009, P NATL ACAD SCI USA, V106, P13451, DOI 10.1073/pnas.0901984106; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; RAYMOND J, 1990, J CLIN MICROBIOL, V28, P1434, DOI 10.1128/JCM.28.6.1434-1437.1990; Raziorrouh B, 2016, GASTROENTEROLOGY, V150, P696, DOI 10.1053/j.gastro.2015.11.005; Resnick ES, 2012, CURR OPIN ALLERGY CL, V12, P595, DOI 10.1097/ACI.0b013e32835914b9; Rubtsov AV, 2011, BLOOD, V118, P1305, DOI 10.1182/blood-2011-01-331462; Rubtsova K, 2015, J IMMUNOL, V195, P1933, DOI 10.4049/jimmunol.1501209; Rubtsova K, 2013, P NATL ACAD SCI USA, V110, pE3216, DOI 10.1073/pnas.1312348110; Ryg-Cornejo V, 2016, CELL REP, V14, P68, DOI 10.1016/j.celrep.2015.12.006; Saadoun D, 2004, J HEPATOL, V41, P1031, DOI 10.1016/j.jhep.2004.08.011; SEVERINSON E, 1990, EUR J IMMUNOL, V20, P1079, DOI 10.1002/eji.1830200520; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; Terrier B, 2011, J IMMUNOL, V187, P6550, DOI 10.4049/jimmunol.1102022; Tipton CM, 2015, NAT IMMUNOL, V16, P755, DOI 10.1038/ni.3175; TURNER RR, 1987, AM J SURG PATHOL, V11, P625, DOI 10.1097/00000478-198708000-00006; Unger S, 2014, J CLIN IMMUNOL, V34, P615, DOI 10.1007/s10875-014-0052-1; Varzaneh FN, 2014, J CLIN IMMUNOL, V34, P524, DOI 10.1007/s10875-014-0053-0; Velu V, 2016, J IMMUNOL, V197, P1832, DOI 10.4049/jimmunol.1600143; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Wehr C, 2004, CLIN IMMUNOL, V113, P161, DOI 10.1016/j.clim.2004.05.010; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Weiss GE, 2009, J IMMUNOL, V183, P2176, DOI 10.4049/jimmunol.0901297; Wirsum C, 2016, J CLIN IMMUNOL, V36, P406, DOI 10.1007/s10875-016-0264-7	63	66	66	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					730	740		10.1016/j.jaci.2017.04.041	http://dx.doi.org/10.1016/j.jaci.2017.04.041			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28554560	Bronze			2022-12-18	WOS:000424410800029
J	Kaustio, M; Haapaniemi, E; Goos, H; Hautala, T; Park, G; Syrjanen, J; Einarsdottir, E; Sahu, B; Kilpinen, S; Rounioja, S; Fogarty, CL; Glumoff, V; Kulmala, P; Katayama, S; Tamene, F; Trotta, L; Morgunova, E; Krjutskov, K; Nurmi, K; Eklund, K; Lagerstedt, A; Helminen, M; Martelius, T; Mustjoki, S; Taipale, J; Saarela, J; Kere, J; Varjosalo, M; Seppanen, M				Kaustio, Meri; Haapaniemi, Emma; Goos, Helka; Hautala, Timo; Park, Giljun; Syrjanen, Jaana; Einarsdottir, Elisabet; Sahu, Biswajyoti; Kilpinen, Sanna; Rounioja, Samuli; Fogarty, Christopher L.; Glumoff, Virpi; Kulmala, Petri; Katayama, Shintaro; Tamene, Fitsum; Trotta, Luca; Morgunova, Ekaterina; Krjutskov, Kaarel; Nurmi, Katariina; Eklund, Kari; Lagerstedt, Anssi; Helminen, Merja; Martelius, Timi; Mustjoki, Satu; Taipale, Jussi; Saarela, Janna; Kere, Juha; Varjosalo, Markku; Seppanen, Mikko			Damaging heterozygous mutations in NFKB1 lead to diverse immunologic phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nuclear factor k light-chain enhancer of activated B cells; hypogammaglobulinemia; autoinflammation; Behcet disease; NFKB1; p50; p105; B cell	NF-KAPPA-B; COMMON VARIABLE IMMUNODEFICIENCY; ANHIDROTIC ECTODERMAL DYSPLASIA; T-CELLS; BEHCETS-DISEASE; AUTOINFLAMMATORY DISEASE; INTESTINAL HOMEOSTASIS; BACTERIAL-INFECTIONS; DENDRITIC CELLS; P50 SUBUNIT	Background: The nuclear factor kappa light-chain enhancer of activated B cells (NF-kappa B) signaling pathway is a key regulator of immune responses. Accordingly, mutations in several NF-kappa B pathway genes cause immunodeficiency. Objective: We sought to identify the cause of disease in 3 unrelated Finnish kindreds with variable symptoms of immunodeficiency and autoinflammation. Methods: We applied genetic linkage analysis and next-generation sequencing and functional analyses of NFKB1 and its mutated alleles. Results: In all affected subjects we detected novel heterozygous variants in NFKB1, encoding for p50/p105. Symptoms in variant carriers differed depending on the mutation. Patients harboring a p.I553M variant presented with antibody deficiency, infection susceptibility, and multiorgan autoimmunity. Patients with a p.H67R substitution had antibody deficiency and experienced autoinflammatory episodes, including aphthae, gastrointestinal disease, febrile attacks, and small-vessel vasculitis characteristic of Behc, et disease. Patients with a p.R157X stop-gain experienced hyperinflammatory responses to surgery and showed enhanced inflammasome activation. In functional analyses the p.R157X variant caused proteasome-dependent degradation of both the truncated and wild-type proteins, leading to a dramatic loss of p50/p105. The p.H67R variant reduced nuclear entry of p50 and showed decreased transcriptional activity in luciferase reporter assays. The p.I553M mutation in turn showed no change in p50 function but exhibited reduced p105 phosphorylation and stability. Affinity purification mass spectrometry also demonstrated that both missense variants led to altered protein-protein interactions. Conclusion: Our findings broaden the scope of phenotypes caused by mutations in NFKB1 and suggest that a subset of autoinflammatory diseases, such as Behcet disease, can be caused by rare monogenic variants in genes of the NF-kappa B pathway.	[Kaustio, Meri; Trotta, Luca; Saarela, Janna] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland; [Goos, Helka; Varjosalo, Markku] Univ Helsinki, Inst Biotechnol, Helsinki, Finland; [Park, Giljun] Univ Helsinki, Hematol Res Unit Helsinki, Dept Clin Chem & Hematol, Helsinki, Finland; [Sahu, Biswajyoti] Univ Helsinki, Res Programs Unit, Genomescale Biol Program, Helsinki, Finland; [Fogarty, Christopher L.] Univ Helsinki, Res Programs Unit, Diabet & Obes, Helsinki, Finland; [Einarsdottir, Elisabet; Kere, Juha] Univ Helsinki, Res Programs Unit, Mol Neurol, Helsinki, Finland; [Haapaniemi, Emma; Einarsdottir, Elisabet; Fogarty, Christopher L.; Krjutskov, Kaarel; Kere, Juha] Folkhalsan Inst Genet, Helsinki, Finland; [Haapaniemi, Emma; Einarsdottir, Elisabet; Katayama, Shintaro; Morgunova, Ekaterina; Krjutskov, Kaarel; Taipale, Jussi; Kere, Juha] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Hautala, Timo] Oulu Univ Hosp, Dept Internal Med, Oulu, Finland; [Syrjanen, Jaana] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland; [Kilpinen, Sanna; Lagerstedt, Anssi] Tampere Univ Hosp, Fimlab Labs, Tampere, Finland; [Rounioja, Samuli; Helminen, Merja] Tampere Univ Hosp, Tampere Ctr Child Hlth Res, Tampere, Finland; [Kilpinen, Sanna] Jyvaskyla Cent Hosp, Dept Internal Med, Jyvaskyla, Finland; [Fogarty, Christopher L.] Univ Helsinki, Abdominal Ctr Nephrol, Helsinki, Finland; [Nurmi, Katariina; Eklund, Kari] Univ Helsinki, Dept Rheumatol, Helsinki, Finland; [Martelius, Timi] Univ Helsinki, Adult Immunodeficiency Unit, Infect Dis, Inflammat Ctr, Helsinki, Finland; [Seppanen, Mikko] Univ Helsinki, Childrens Hosp, Rare Dis Ctr, Helsinki, Finland; [Seppanen, Mikko] Helsinki Univ Hosp, Helsinki, Finland; [Glumoff, Virpi; Kulmala, Petri] Univ Oulu, Res Unit Biomed, Oulu, Finland; [Kulmala, Petri] Oulu Univ Hosp, Res Unit Pediat Pediat Neurol Pediat Surg Child P, Oulu, Finland; [Kulmala, Petri] Oulu Univ Hosp, MRC Oulu, Oulu, Finland; [Kulmala, Petri] Univ Oulu, Oulu, Finland; [Krjutskov, Kaarel] Competence Ctr Hlth Technol, Tartu, Estonia; [Mustjoki, Satu] Univ Helsinki, Cent Hosp, Comprehens Canc Ctr, Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Karolinska Institutet; University of Oulu; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital; Central Finland Central Hospital; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Helsinki; Helsinki University Central Hospital	Kere, J (corresponding author), Dept Biosci & Nutr, Halsovagen 7, S-SE14183 Huddinge, Sweden.	juha.kere@ki.se	Rounioja, Samuli/D-4195-2014; Sahu, Biswajyoti/U-6724-2017; Kere, Juha/AAX-9117-2021; Kere, Juha/A-9179-2008; Morgunova, Ekaterina/G-2479-2018; Katayama, Shintaro/F-2958-2010; Glumoff, Virpi/AHD-7811-2022; Mustjoki, Satu/AAD-9974-2020; Varjosalo, Markku/K-6424-2015	Sahu, Biswajyoti/0000-0001-6576-5440; Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Morgunova, Ekaterina/0000-0002-7754-9021; Katayama, Shintaro/0000-0001-7581-5157; Glumoff, Virpi/0000-0003-3461-6471; Mustjoki, Satu/0000-0002-0816-8241; Varjosalo, Markku/0000-0002-1340-9732; Martelius, Timi/0000-0002-3678-958X; Hautala, Timo/0000-0001-7889-1614; Goos, Helka/0000-0002-6175-4872; Einarsdottir, Elisabet/0000-0003-3101-2285; Seppanen, Mikko/0000-0001-9733-3650; Rounioja, Samuli/0000-0001-7713-0610; Syrjanen, Jaana/0000-0002-7335-573X; Haapaniemi, Emma/0000-0002-6693-8208; Saarela, Janna/0000-0002-0853-6219	Academy of Finland [288475, 294173]; Sigrid Juselius Foundation; Emil Aaltonen Foundation; Finnish Medical Foundation; Jane and Aatos Erkko Foundation; Alma and K.A. Snellman Foundation; Biocentrum Helsinki; Instrumentarium Science Foundation; Finnish Cancer Institute; Foundation for Pediatric Research; Biomedicum Helsinki Foundation; Integrative Life Science Doctoral Program (ILS); Doctoral Programme in Biomedicine of the University of Helsinki; Karolinska Institutet Distinguished Professor Award; Strategic Research Program for Diabetes Funding at Karolinska Institutet; Swedish Research Council	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Emil Aaltonen Foundation; Finnish Medical Foundation; Jane and Aatos Erkko Foundation; Alma and K.A. Snellman Foundation; Biocentrum Helsinki; Instrumentarium Science Foundation; Finnish Cancer Institute; Foundation for Pediatric Research; Biomedicum Helsinki Foundation; Integrative Life Science Doctoral Program (ILS); Doctoral Programme in Biomedicine of the University of Helsinki; Karolinska Institutet Distinguished Professor Award; Strategic Research Program for Diabetes Funding at Karolinska Institutet; Swedish Research Council(Swedish Research CouncilEuropean Commission)	Supported by the Academy of Finland (nos. 288475 and 294173), the Sigrid Juselius Foundation, the Emil Aaltonen Foundation, the Finnish Medical Foundation, the Jane and Aatos Erkko Foundation, the Alma and K.A. Snellman Foundation, Biocentrum Helsinki, the Instrumentarium Science Foundation, the Finnish Cancer Institute, the Foundation for Pediatric Research, the Biomedicum Helsinki Foundation, the Integrative Life Science Doctoral Program (ILS) and Doctoral Programme in Biomedicine of the University of Helsinki, Karolinska Institutet Distinguished Professor Award, the Strategic Research Program for Diabetes Funding at Karolinska Institutet, and the Swedish Research Council.	Artis D, 2005, J IMMUNOL, V174, P7154, DOI 10.4049/jimmunol.174.11.7154; Artis D, 2002, J IMMUNOL, V169, P4481, DOI 10.4049/jimmunol.169.8.4481; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bhardwaj R, 2015, J IMMUNOL, V194, P2862, DOI 10.4049/jimmunol.1400874; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; Boztug H, 2016, J CLIN IMMUNOL, V36, P533, DOI 10.1007/s10875-016-0306-1; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Cao SJ, 2006, J BIOL CHEM, V281, P26041, DOI 10.1074/jbc.M602222200; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Cheng LE, 2009, CLIN IMMUNOL, V132, P124, DOI 10.1016/j.clim.2009.03.514; Collins PE, 2014, J BIOL CHEM, V289, P7059, DOI 10.1074/jbc.M114.551986; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; D'Assante R, 2016, INT REV IMMUNOL, V35, P25, DOI 10.3109/08830185.2015.1010724; Dannappel M, 2014, NATURE, V513, P90, DOI 10.1038/nature13608; de Valle E, 2016, J EXP MED, V213, P621, DOI 10.1084/jem.20151182; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Dissanayake D, 2011, NAT MED, V17, P1663, DOI 10.1038/nm.2556; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fliegauf M, 2015, AM J HUM GENET, V97, P389, DOI 10.1016/j.ajhg.2015.07.008; FUJIMOTO K, 1995, GENE, V165, P183, DOI 10.1016/0378-1119(95)00507-3; Gadjeva M, 2004, J IMMUNOL, V173, P5786, DOI 10.4049/jimmunol.173.9.5786; Gadjeva M, 2007, EUR J IMMUNOL, V37, P2509, DOI 10.1002/eji.200737186; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gasparini C, 2013, CYTOKINE, V61, P736, DOI 10.1016/j.cyto.2012.12.029; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; Grundstrom S, 2004, J BIOL CHEM, V279, P8460, DOI 10.1074/jbc.M312398200; Gugasyan R, 2012, EMBO J, V31, P692, DOI 10.1038/emboj.2011.435; Haapaniemi EM, 2015, BLOOD, V125, P639, DOI 10.1182/blood-2014-04-570101; Han W, 2009, AM J PHYSIOL-LUNG C, V296, pL320, DOI 10.1152/ajplung.90485.2008; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; Hung YH, 2010, DIS MARKERS, V28, P55, DOI [10.1155/2010/305953, 10.3233/DMA-2010-0684]; Inan MS, 2000, AM J PHYSIOL-GASTR L, V279, pG1282, DOI 10.1152/ajpgi.2000.279.6.G1282; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Janssens S, 2014, NAT IMMUNOL, V15, P910, DOI 10.1038/ni.2991; Karban AS, 2004, HUM MOL GENET, V13, P35, DOI 10.1093/hmg/ddh008; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Klemann C, 2016, CLIN IMMUNOL, V164, P52, DOI 10.1016/j.clim.2016.01.010; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Oakley F, 2005, AM J PATHOL, V166, P695, DOI 10.1016/S0002-9440(10)62291-2; Pannicke U, 2013, NEW ENGL J MED, V369, P2504, DOI 10.1056/NEJMoa1309199; Patel MN, 2015, P NATL ACAD SCI USA, V112, P506, DOI 10.1073/pnas.1414536112; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Roux Kyle J, 2013, Curr Protoc Protein Sci, V74, DOI 10.1002/0471140864.ps1923s74; Savinova OV, 2009, MOL CELL, V34, P591, DOI 10.1016/j.molcel.2009.04.033; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shih VFS, 2012, NAT IMMUNOL, V13, P1162, DOI 10.1038/ni.2446; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Snapper CM, 1996, J IMMUNOL, V156, P183; Song L, 2016, GASTROENTEROLOGY, V150, P499, DOI 10.1053/j.gastro.2015.10.017; Stanic AK, 2004, J IMMUNOL, V172, P2265, DOI 10.4049/jimmunol.172.4.2265; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Takada H, 2010, CLIN GENET, V78, P575, DOI 10.1111/j.1399-0004.2010.01432.x; Takahashi N, 2014, NATURE, V513, P95, DOI 10.1038/nature13706; Todaro M, 2005, ARTHRITIS RHEUM-US, V52, P2179, DOI 10.1002/art.21145; Turunen M, 2014, CELL REP, V7, P654, DOI 10.1016/j.celrep.2014.03.047; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Varjosalo M, 2013, CELL REP, V3, P1306, DOI 10.1016/j.celrep.2013.03.027; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Willmann KL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6360; Yazici H, 2007, NAT CLIN PRACT RHEUM, V3, P148, DOI 10.1038/ncprheum0436; Yenmis G, 2015, SCAND J IMMUNOL, V81, P81, DOI 10.1111/sji.12251; Yoshioka T, 2013, J CLIN IMMUNOL, V33, P1165, DOI 10.1007/s10875-013-9924-z; Zheng SS, 2013, MOL CELL BIOL, V33, P4857, DOI 10.1128/MCB.00797-13; Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057; Zhou Q, 2016, NAT GENET, V48, P67, DOI 10.1038/ng.3459; Zilberman-Rudenko J, 2016, P NATL ACAD SCI USA, V113, P1612, DOI 10.1073/pnas.1518163113	70	66	68	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					782	796		10.1016/j.jaci.2016.10.054	http://dx.doi.org/10.1016/j.jaci.2016.10.054			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28115215	Bronze, Green Published			2022-12-18	WOS:000409241500017
J	Wang, ZP; Mascarenhas, N; Eckmann, L; Miyamoto, Y; Sun, XJ; Kawakami, T; Di Nardo, A				Wang, Zhenping; Mascarenhas, Nicholas; Eckmann, Lars; Miyamoto, Yukiko; Sun, Xiaojun; Kawakami, Toshiaki; Di Nardo, Anna			Skin microbiome promotes mast cell maturation by triggering stem cell factor production in keratinocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; microbiome; germ free; SCF; keratinocyte; LTA	COMMENSAL BACTERIA; ACTIVATION; MIGRATION; SURVIVAL; VIRUS; MOUSE; MICE	Background: Mast cell (MC) progenitors leave the bone marrow, enter the circulation, and settle in the skin and other tissues. Their maturation in tissues is influenced by the surrounding microenvironment. Objective: We tested the hypothesis that environmental factors play a role in MC maturation in the skin. Methods: MCs were numerically, phenotypically, and functionally compared between germ-free (GF), specific pathogen-free, and GF mice reconstituted with microbiota. The maturity of MCs was then correlated with skin levels of stem cell factor (SCF), a critical MC differentiation factor, and lipoteichoic acid (LTA), a Toll-like receptor 2 ligand. MCs were also evaluated in mice with keratinocyte-specific deletion of Scf. Results: We found that GF mice express abnormally low amounts of SCF, a critical MC differentiation factor, and contain MCs that are largely undifferentiated. Reconstituting the GF microbiota reverted this MC phenotype to normal, indicating that the phenotype is related to ongoing interactions of the microbiota and skin. Consistent with the immaturity of GF MCs, degranulation-provoking compound 48/80 induced less edema in the skin of GF mice than in conventional mice. Our results show that the skin microbiome drives SCF production in keratinocytes, which triggers the differentiation of dermal MCs. Because the skin microbiome is a rich source of LTA, a Toll-like receptor 2 ligand, we mimicked the GF microbiome's effect on MCs by applying LTA to the skin of GF mice. We also demonstrated that MC migration within the skin depends exclusively on keratinocyte-produced SCF. Conclusion: This study has revealed a novel mechanism by which the skin microbiota signals the recruitment and maturation of MCs within the dermis through SCF production by LTA-stimulated keratinocytes.	[Wang, Zhenping; Mascarenhas, Nicholas; Sun, Xiaojun; Di Nardo, Anna] Univ Calif San Diego, Sch Med, Dept Dermatol, La Jolla, CA 92093 USA; [Eckmann, Lars; Miyamoto, Yukiko] Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; [Kawakami, Toshiaki] La Jolla Inst Allergy & Immunol, Div Cell Biol, La Jolla, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; La Jolla Institute for Immunology	Di Nardo, A (corresponding author), 9500 Gilman Dr 0869, La Jolla, CA 92093 USA.	adinardo@ucsd.edu	Wang, Zhenping/B-4863-2016; SUN, XIAOJUN/I-8018-2014; di nardo, anna/AAI-1629-2020	Wang, Zhenping/0000-0003-3360-3775; SUN, XIAOJUN/0000-0003-3710-8560; di nardo, anna/0000-0002-5575-9968; Miyamoto, Yukiko/0000-0001-5650-699X	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases through NIH grant [5R01AI106874]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL124283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI093957, R01AI106874, R21AI123729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR064418] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases through NIH grant; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	A.D.N.'s laboratory is supported by the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases through NIH grant 5R01AI106874.	Aasen T, 2010, NAT PROTOC, V5, P371, DOI 10.1038/nprot.2009.241; Aoki R, 2013, J INVEST DERMATOL, V133, P2170, DOI 10.1038/jid.2013.150; BESMER P, 1993, DEVELOPMENT, P125; BURTON AL, 1964, ANAT REC, V150, P265, DOI 10.1002/ar.1091500308; Chatterjea D, 2012, BIOCHEM BIOPH RES CO, V425, P237, DOI 10.1016/j.bbrc.2012.07.074; Flo TH, 2000, J IMMUNOL, V164, P2064, DOI 10.4049/jimmunol.164.4.2064; Galli SJ, 2000, CURR OPIN HEMATOL, V7, P32, DOI 10.1097/00062752-200001000-00007; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Goo SY, 2007, J BIOL CHEM, V282, P27647, DOI 10.1074/jbc.M701876200; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Halova I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00119; Henz BM, 2008, EXP DERMATOL, V17, P91, DOI 10.1111/j.1600-0625.2007.00658.x; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Ito T, 2012, J IMMUNOL, V188, P5428, DOI 10.4049/jimmunol.1103366; Kirshenbaum Arnold S, 2006, Methods Mol Biol, V315, P105; KITAMURA Y, 1993, AM J MED SCI, V306, P185, DOI 10.1097/00000441-199309000-00011; Kunii J, 2011, IMMUNOBIOLOGY, V216, P692, DOI 10.1016/j.imbio.2010.10.007; Kunisada T, 1998, J EXP MED, V187, P1565, DOI 10.1084/jem.187.10.1565; Kurashima Y, 2014, IMMUNITY, V40, P530, DOI 10.1016/j.immuni.2014.01.014; Lai YP, 2009, NAT MED, V15, P1377, DOI 10.1038/nm.2062; Liu CX, 2010, MOL BIOL REP, V37, P1993, DOI 10.1007/s11033-009-9650-z; Luu-The V, 2005, BIOTECHNIQUES, V38, P287, DOI 10.2144/05382RR05; Mashiko S, 2015, J ALLERGY CLIN IMMUN, V136, P351, DOI 10.1016/j.jaci.2015.01.033; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Meng GX, 2004, J CLIN INVEST, V113, P1473, DOI 10.1172/JCI200420762; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Moller C, 2007, EXP HEMATOL, V35, P385, DOI 10.1016/j.exphem.2006.11.008; Nahid MA, 2011, J IMMUNOL, V186, P1723, DOI 10.4049/jimmunol.1002311; Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152; Nakamizo S, 2015, SEMIN IMMUNOPATHOL, V37, P73, DOI 10.1007/s00281-014-0452-6; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Nakatsuji T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2441; Okayama Y, 2006, IMMUNOL RES, V34, P97, DOI 10.1385/IR:34:2:97; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pivarcsi A., 2004, Acta Microbiologica et Immunologica Hungarica, V51, P303, DOI 10.1556/AMicr.51.2004.3.8; Prussin Calman, 2003, Journal of Allergy and Clinical Immunology, V111, pS486; Wang Z, 2010, J INVEST DERMATOL, V130, pS124; Wang ZP, 2012, J IMMUNOL, V189, P1551, DOI 10.4049/jimmunol.1200471; Wang ZP, 2012, J IMMUNOL, V188, P345, DOI 10.4049/jimmunol.1101703; WELKER P, 1995, INT ARCH ALLERGY IMM, V107, P139, DOI 10.1159/000236956; Williams MR, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0567-4; YAMAZAKI M, 1994, BLOOD, V83, P3509; Yoshida H, 2001, J INVEST DERM SYMP P, V6, P1, DOI 10.1046/j.0022-202x.2001.00006.x	43	66	68	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1205	+		10.1016/j.jaci.2016.09.019	http://dx.doi.org/10.1016/j.jaci.2016.09.019			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27746235	Bronze, Green Accepted			2022-12-18	WOS:000398771800016
J	Maggi, L; Montaini, G; Mazzoni, A; Rossettini, B; Capone, M; Rossi, MC; Santarlasci, V; Liotta, F; Rossi, O; Gallo, O; De Palma, R; Maggi, E; Cosmi, L; Romagnani, S; Annunziato, F				Maggi, Laura; Montaini, Gianni; Mazzoni, Alessio; Rossettini, Beatrice; Capone, Manuela; Rossi, Maria Caterina; Santarlasci, Veronica; Liotta, Francesco; Rossi, Oliviero; Gallo, Oreste; De Palma, Raffaele; Maggi, Enrico; Cosmi, Lorenzo; Romagnani, Sergio; Annunziato, Francesco			Human circulating group 2 innate lymphoid cells can express CD154 and promote IgE production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Group 2 innate lymphoid cell; TH2; IL-4; IL-13; IL-5; CD154; IgE; Toll-like receptor	T-LYMPHOCYTES; NASAL POLYPS; INFLAMMATION; ILC2S; IL-25; TH1	Background: Protection against helminths consists of adaptive responses by TH2 cells and innate responses by group 2 innate lymphoid cells (ILC2s), with these latter being well characterized in mice but less so in human subjects. Objective: We sought to characterize human circulating ILC2s and compare their functional profile with that of autologous TH2 cells. Methods: Circulating ILC2s and TH2 cells were isolated by means of fluorescence-activated cell sorting and magnetic cell sorting and expanded in vitro. ILC2s were then stimulated with phorbol 12-myristate 13-acetate plus ionomycin, IL-25 plus IL-33 (IL-25/IL-33), or a mixture of Toll-like receptor ligands to evaluate their ability to produce cytokines, express CD154, and induce IgE production by autologous B cells. Cytokines and transcription factor gene methylation were assessed. Results: ILC2s expressed GATA-3, retinoic acid orphan receptor (RORC) 2, and RORa; were able to produce IL-5, IL-13, and IL-4; and, accordingly, were characterized by demethylation of IL4, IL13, IL5, GATA3, and RORC2, whereas the IFNG, IFNG promoter, and TBX21 regions of interest were methylated. ILC2s expressed TLR1, TLR4, and TLR6, and TLR stimulation induced IL-5 and IL-13 production. Moreover, ILC2s expressed CD154 in response to phorbol 12-myristate 13-acetate plus ionomycin, IL-25/ IL-33, or a mixture of TLR ligands. Stimulated ILC2s also induced IgM, IgG, IgA, and IgE production by B cells. Finally, circulating ILC2s from atopic patients were not different in numbers and frequency but expressed higher IL-4 levels than those from nonatopic subjects. Conclusion: This study provides the first evidence that human ILC2s can express CD154 and stimulate the production of IgE by B lymphocytes through IL-25/ IL-33 stimulation or TLR triggering.	[Maggi, Laura; Montaini, Gianni; Mazzoni, Alessio; Rossettini, Beatrice; Capone, Manuela; Rossi, Maria Caterina; Santarlasci, Veronica; Liotta, Francesco; Maggi, Enrico; Cosmi, Lorenzo; Romagnani, Sergio; Annunziato, Francesco] Dept Expt & Clin Med, Florence, Italy; [Maggi, Laura; Montaini, Gianni; Mazzoni, Alessio; Rossettini, Beatrice; Capone, Manuela; Rossi, Maria Caterina; Santarlasci, Veronica; Liotta, Francesco; Maggi, Enrico; Cosmi, Lorenzo; Romagnani, Sergio; Annunziato, Francesco] DENOTHE Ctr, Florence, Italy; [De Palma, Raffaele] Univ Naples 2, Dept Clin & Expt Med, Naples, Italy; [De Palma, Raffaele] Univ Naples 2, Ctr Biomol Studies Supporting Human Hlth, Naples, Italy; [Liotta, Francesco; Rossi, Oliviero; Maggi, Enrico; Cosmi, Lorenzo; Annunziato, Francesco] Azienda Osped Careggi, Regenerat Med Unit, Florence, Italy; [Liotta, Francesco; Rossi, Oliviero; Maggi, Enrico; Cosmi, Lorenzo; Annunziato, Francesco] Azienda Osped Careggi, Immunol & Cellular Therapy Unit, Florence, Italy; [Gallo, Oreste] Univ Florence, Dept Surg & Translat Med, Florence, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence	Annunziato, F (corresponding author), Univ Florence, Dept Expt & Clin Med, Viale Pieraccini 6, I-50134 Florence, Italy.	francesco.annunziato@unifi.it	Maggi, Enrico/AAA-8045-2019; Mazzoni, Alessio/AAB-4311-2019; Maggi, Laura/B-6693-2013	Maggi, Enrico/0000-0002-1824-3583; Mazzoni, Alessio/0000-0001-7768-3805; Maggi, Laura/0000-0003-2862-9591; Annunziato, Francesco/0000-0001-8798-7589; Gallo, Oreste/0000-0003-3426-7179	AIRC; MIUR	AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR))	The experiments reported in this paper were performed with grants from AIRC and MIUR.	Annunziato F, 2007, J EXP MED, V204, P1849, DOI 10.1084/jem.20070663; Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Finkelman FD, 2001, J ALLERGY CLIN IMMUN, V107, P772, DOI 10.1067/mai.2001.114989; Ho J, 2015, CLIN EXP ALLERGY, V45, P394, DOI 10.1111/cea.12462; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Kim BS, 2013, CURR OPIN IMMUNOL, V25, P738, DOI 10.1016/j.coi.2013.07.013; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kotas ME, 2015, CELL, V160, P816, DOI 10.1016/j.cell.2015.02.010; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Magri G, 2014, NAT IMMUNOL, V15, P354, DOI 10.1038/ni.2830; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Mazzoni A, 2015, J IMMUNOL, V194, P3116, DOI 10.4049/jimmunol.1401303; Miljkovic D, 2014, ALLERGY, V69, P1154, DOI 10.1111/all.12440; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nagakumar P, 2016, J ALLERGY CLIN IMMUN, V137, P624, DOI 10.1016/j.jaci.2015.06.038; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; Peebles RS, 2015, J LEUKOCYTE BIOL, V97, P469, DOI 10.1189/jlb.3BT0814-383R; Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sandler NG, 2003, J IMMUNOL, V171, P3655, DOI 10.4049/jimmunol.171.7.3655; Smith SG, 2016, J ALLERGY CLIN IMMUN, V137, P75, DOI 10.1016/j.jaci.2015.05.037; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2351, DOI 10.1038/jid.2014.146; Walford HH, 2014, CLIN IMMUNOL, V155, P126, DOI 10.1016/j.clim.2014.09.007; Walker JA, 2013, CURR OPIN IMMUNOL, V25, P148, DOI 10.1016/j.coi.2013.02.010; Yu S, 2014, J ALLERGY CLIN IMMUN, V133, P943, DOI 10.1016/j.jaci.2014.02.015	33	66	67	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2017	139	3					964	+		10.1016/j.jaci.2016.06.032	http://dx.doi.org/10.1016/j.jaci.2016.06.032			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EP3QC	27576126	Bronze			2022-12-18	WOS:000397295800028
J	Frick, M; Fischer, J; Helbling, A; Rueff, F; Wieczorek, D; Ollert, M; Pfutzner, W; Muller, S; Huss-Marp, J; Dorn, B; Biedermann, T; Lidholm, J; Ruecker, G; Bantleon, F; Miehe, M; Spillner, E; Jakob, T				Frick, Marcel; Fischer, Joerg; Helbling, Arthur; Rueff, Franziska; Wieczorek, Dorothea; Ollert, Markus; Pfuetzner, Wolfgang; Mueller, Sabine; Huss-Marp, Johannes; Dorn, Britta; Biedermann, Tilo; Lidholm, Jonas; Ruecker, Gerta; Bantleon, Frank; Miehe, Michaela; Spillner, Edzard; Jakob, Thilo			Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Apis mellifera; Hymenoptera venom allergy; HBV allergy; recombinant allergen; allergen-specific immunotherapy; treatment failure	MOLECULAR-CLONING; EXPRESSION; ALLERGEN	Background: Component resolution recently identified distinct sensitization profiles in honey bee venom (HBV) allergy, some of which were dominated by specific IgE to Api m 3 and/or Api m 10, which have been reported to be underrepresented in therapeutic HBV preparations. Objective: We performed a retrospective analysis of component-resolved sensitization profiles in HBV-allergic patients and association with treatment outcome. Methods: HBV-allergic patients who had undergone controlled honey bee sting challenge after at least 6 months of HBV immunotherapy (n = 115) were included and classified as responder (n = 79) or treatment failure (n = 36) on the basis of absence or presence of systemic allergic reactions upon sting challenge. IgE reactivity to a panel of HBV allergens was analyzed in sera obtained before immunotherapy and before sting challenge. Results: No differences were observed between responders and nonresponders regarding levels of IgE sensitization to Api m 1, Api m 2, Api m 3, and Api m 5. In contrast, Api m 10 specific IgE was moderately but significantly increased in nonresponders. Predominant Api m 10 sensitization (>50% of specific IgE to HBV) was the best discriminator (specificity, 95%; sensitivity, 25%) with an odds ratio of 8.444 (2.127-33.53; P = .0013) for treatment failure. Some but not all therapeutic HBV preparations displayed a lack of Api m 10, whereas Api m 1 and Api m 3 immunoreactivity was comparable to that of crude HBV. In line with this, significant Api m 10 sIgG(4) induction was observed only in those patients who were treated with HBV in which Api m 10 was detectable. Conclusions: Component-resolved sensitization profiles in HBV allergy suggest predominant IgE sensitization to Api m 10 as a risk factor for treatment failure in HBV immunotherapy.	[Frick, Marcel; Dorn, Britta; Jakob, Thilo] Justus Liebig Univ, Univ Med Ctr Giessen Marburg, Dept Dermatol & Allergol, Gaffkystr 14, D-35395 Giessen, Germany; [Frick, Marcel; Mueller, Sabine; Huss-Marp, Johannes; Dorn, Britta; Jakob, Thilo] Univ Freiburg, Med Ctr, Dept Dermatol, Allergy Res Grp, Freiburg, Germany; [Fischer, Joerg; Biedermann, Tilo] Univ Med Ctr Tubingen, Dept Dermatol & Allergol, Tubingen, Germany; [Helbling, Arthur] Spital Netz Bern, Allergy Unit Zieglerspital, Dept Internal Med, Bern, Switzerland; [Rueff, Franziska] Ludwig Maximilian Univ Munich, Dept Dermatol & Allergol, Munich, Germany; [Wieczorek, Dorothea] Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany; [Ollert, Markus] LIH, Dept Infect & Immun, Esch Sur Alzette, Luxembourg; [Ollert, Markus] Univ Southern Denmark, Odense Res Ctr Anaphylaxis, Dept Dermatol, Odense, Denmark; [Ollert, Markus] Univ Southern Denmark, Odense Res Ctr Anaphylaxis, Allergy Ctr, Odense, Denmark; [Pfuetzner, Wolfgang] Philipps Univ, Univ Med Ctr Giessen Marburg, Dept Dermatol & Allergol, Marburg, Germany; [Biedermann, Tilo] Tech Univ Munich, Dept Dermatol & Allergol, Munich, Germany; [Lidholm, Jonas] Thermo Fisher Sci, Uppsala, Sweden; [Ruecker, Gerta] Univ Freiburg, Med Ctr, Inst Med Biometry & Stat, Freiburg, Germany; [Bantleon, Frank; Miehe, Michaela; Spillner, Edzard] Aarhus Univ, Immunol Engn, Dept Engn, Aarhus, Denmark	Justus Liebig University Giessen; University Hospital of Giessen & Marburg; University of Freiburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Munich; Hannover Medical School; Luxembourg Institute of Health; University of Southern Denmark; University of Southern Denmark; Philipps University Marburg; University Hospital of Giessen & Marburg; Technical University of Munich; Thermo Fisher Scientific; University of Freiburg; Aarhus University	Jakob, T (corresponding author), Justus Liebig Univ, Univ Med Ctr Giessen Marburg, Dept Dermatol & Allergol, Gaffkystr 14, D-35395 Giessen, Germany.	thilo.jakob@derma.med.uni-giessen.de	Rücker, Gerta/B-2965-2009	Rücker, Gerta/0000-0002-2192-2560; Lidholm, Jonas/0000-0002-7779-3411; Biedermann, Tilo/0000-0002-5352-5105; spillner, edzard/0000-0003-0999-5254; Ollert, Markus W./0000-0002-8055-0103	Thermo Fisher Scientific, Freiburg	Thermo Fisher Scientific, Freiburg	This work was supported in part by a research grant of Thermo Fisher Scientific, Freiburg, to T.J.	Adolph J, 1986, Z Erkr Atmungsorgane, V166, P119; ARBESMAN CE, 1976, CLIN ALLERGY, V6, P587, DOI 10.1111/j.1365-2222.1976.tb01945.x; Armbruster David A, 2008, Clin Biochem Rev, V29 Suppl 1, pS49; Bilo BM, 2008, CURR OPIN ALLERGY CL, V8, P330, DOI 10.1097/ACI.0b013e32830638c5; Bilo MB, 2009, ANN ALLERG ASTHMA IM, V103, P57, DOI 10.1016/S1081-1206(10)60144-5; Bilo MB, 2012, J ALLERGY CAIRO, V2012; Blank S, 2011, ALLERGY, V66, P1322, DOI 10.1111/j.1398-9995.2011.02667.x; Blank S, 2010, J IMMUNOL, V184, P5403, DOI 10.4049/jimmunol.0803709; Boyle RJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008838.pub2; De Olano DG, 2008, J ALLERGY CLIN IMMUN, V121, P519, DOI 10.1016/j.jaci.2007.11.010; Gonzalez-de-Olano D, 2011, IMMUNOTHERAPY-UK, V3, P637, DOI [10.2217/IMT.11.44, 10.2217/imt.11.44]; Grunwald T, 2006, J ALLERGY CLIN IMMUN, V117, P848, DOI 10.1016/j.jaci.2005.12.1331; Hockenhull J, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16120; Kohler J, 2014, J ALLERGY CLIN IMMUN, V133, P1383, DOI 10.1016/j.jaci.2013.10.060; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller UR, 1988, INSEKTENSTICHALLERGI; Peiren N, 2006, FEBS LETT, V580, P4895, DOI 10.1016/j.febslet.2006.08.005; RING J, 1977, LANCET, V1, P466; Rueff F, 2014, CLIN EXP ALLERGY, V44, P736, DOI 10.1111/cea.12275; Rueff F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063233; Seismann H, 2010, MOL IMMUNOL, V47, P799, DOI 10.1016/j.molimm.2009.10.005; Spillner E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00077; Team R.C, 2015, R LANG ENV STAT COMP	23	66	68	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1663	+		10.1016/j.jaci.2016.04.024	http://dx.doi.org/10.1016/j.jaci.2016.04.024			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27372568	Green Published, hybrid			2022-12-18	WOS:000390019300022
J	Xia, MC; Viera-Hutchins, L; Garcia-Lloret, M; Rivas, MN; Wise, P; McGhee, SA; Chatila, ZK; Daher, N; Sioutas, C; Chatila, TA				Xia, Mingcan; Viera-Hutchins, Loida; Garcia-Lloret, Maria; Rivas, Magali Noval; Wise, Petra; McGhee, Sean A.; Chatila, Zena K.; Daher, Nancy; Sioutas, Constantinos; Chatila, Talal A.			Vehicular exhaust particles promote allergic airway inflammation through an aryl hydrocarbon receptor-notch signaling cascade	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Traffic-related particulate matter; diesel exhaust particles; ultrafine particles; asthma; allergic airway inflammation; Jagged 1; Notch; aryl hydrocarbon receptor; airway hyper-responsiveness	AMBIENT PARTICULATE MATTER; ULTRAFINE PARTICLES; OXIDATIVE STRESS; TRANSCRIPTION FACTOR; DENDRITIC CELLS; ASTHMA; POLLUTION; CHEMICALS; NRF2; HEALTH	Background: Traffic-related particulate matter (PM) has been linked to a heightened incidence of asthma and allergic diseases. However, the molecular mechanisms by which PM exposure promotes allergic diseases remain elusive. Objective: We sought to determine the expression, function, and regulation of pathways involved in promotion of allergic airway inflammation by PM. Methods: We used gene expression transcriptional profiling, in vitro culture assays, and in vivo murine models of allergic airway inflammation. Results: We identified components of the Notch pathway, most notably Jagged 1 (Jag1), as targets of PM induction in human monocytes and murine dendritic cells. PM, especially ultrafine particles, upregulated T-H cytokine levels, IgE production, and allergic airway inflammation in mice in a Jag1- and Notch-dependent manner, especially in the context of the proasthmatic IL-4 receptor allele Il4raR576. PM-induced Jag1 expression was mediated by the aryl hydrocarbon receptor (AhR), which bound to and activated AhR response elements in the Jag1 promoter. Pharmacologic antagonism of AhR or its lineage-specific deletion in CD11c(+) cells abrogated the augmentation of airway inflammation by PM. Conclusion: PM activates an AhR-Jag1-Notch cascade to promote allergic airway inflammation in concert with proasthmatic alleles.	[Xia, Mingcan; Rivas, Magali Noval; Chatila, Zena K.; Chatila, Talal A.] Harvard Univ, Sch Med, Dept Pediat, Div Immunol,Boston Childrens Hosp, Boston, MA 02115 USA; [Viera-Hutchins, Loida; Garcia-Lloret, Maria] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Immunol Allergy & Rheumatol, Los Angeles, CA 90095 USA; [Wise, Petra] Childrens Hosp Los Angeles, Dept Hematol Oncol & Bone Marrow Transplant, Los Angeles, CA USA; [McGhee, Sean A.] Stanford Univ, Sch Med, Div Immunol & Allergy, Stanford, CA 94305 USA; [Daher, Nancy; Sioutas, Constantinos] Univ So Calif, Dept Civil & Environm Engn, Los Angeles, CA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Children's Hospital Los Angeles; Stanford University; University of Southern California	Chatila, TA (corresponding author), Harvard Univ, Sch Med, Dept Pediat, Div Immunol,Boston Childrens Hosp, Boston, MA 02115 USA.	talal.chatila@childrens.harvard.edu	Sioutas, Constantinos/R-1968-2019; Noval Rivas, Magali/R-4987-2016	Noval Rivas, Magali/0000-0001-5570-8928; Chatila, Zena/0000-0002-4383-6305; Chatila, Talal/0000-0001-7439-2762; Sioutas, Constantinos/0000-0001-5146-0857	National Institutes of Health [2R01AI065617]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM075776] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health grant 2R01AI065617 (to T.A.C.).	Amsen D, 2009, CURR OPIN IMMUNOL, V21, P153, DOI 10.1016/j.coi.2009.03.010; Amsen D, 2009, NAT REV IMMUNOL, V9, P116, DOI 10.1038/nri2488; [Anonymous], 2011, MMWR MORB MORTAL WKL, V60, P547; Araujo JA, 2008, CIRC RES, V102, P589, DOI 10.1161/CIRCRESAHA.107.164970; Bailis W, 2013, IMMUNITY, V39, P148, DOI 10.1016/j.immuni.2013.07.006; Blaeser F, 2003, J EXP MED, V198, P1189, DOI 10.1084/jem.20030471; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chan RCF, 2006, J ALLERGY CLIN IMMUN, V118, P455, DOI 10.1016/j.jaci.2006.06.006; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Ford JG, 2001, J IMMUNOL, V167, P1769, DOI 10.4049/jimmunol.167.3.1769; Gong KW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r149; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Halonen JI, 2008, THORAX, V63, P635, DOI 10.1136/thx.2007.091371; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pa.35.040195.001515; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hiura TS, 1999, J IMMUNOL, V163, P5582; Inoue K, 2009, EXP BIOL MED, V234, P200, DOI 10.3181/0809-RM-285; Ji H, 2012, J ALLERGY CLIN IMMUN, V129, P33, DOI 10.1016/j.jaci.2011.11.008; Kang XD, 2010, PROTEOMICS, V10, P520, DOI 10.1002/pmic.200900573; Kittelson DB, 1998, J AEROSOL SCI, V29, P575, DOI 10.1016/S0021-8502(97)10037-4; Knol AB, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-19; Kumar Sushil, 2013, Reviews on Environmental Health, V28, P117, DOI 10.1515/reveh-2013-0008; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li N, 2008, FREE RADICAL BIO MED, V44, P1689, DOI 10.1016/j.freeradbiomed.2008.01.028; Li N, 2010, AM J PHYSIOL-LUNG C, V299, pL374, DOI 10.1152/ajplung.00115.2010; Li N, 2009, ENVIRON HEALTH PERSP, V117, P1116, DOI 10.1289/ehp.0800319; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; McMillan SJ, 2005, J IMMUNOL, V174, P5774, DOI 10.4049/jimmunol.174.9.5774; Misra C, 2002, J AEROSOL SCI, V33, P735, DOI 10.1016/S0021-8502(01)00210-5; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Porter M, 2007, AM J RESP CELL MOL, V37, P706, DOI 10.1165/rcmb.2007-0199OC; Provoost S, 2011, J IMMUNOL, V187, P3331, DOI 10.4049/jimmunol.1004062; Provoost S, 2010, J IMMUNOL, V184, P426, DOI 10.4049/jimmunol.0902564; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Sioutas C, 2005, ENVIRON HEALTH PERSP, V113, P947, DOI 10.1289/ehp.7939; Stanley P, 2007, CURR OPIN STRUC BIOL, V17, P530, DOI 10.1016/j.sbi.2007.09.007; Tachdjian R, 2009, J EXP MED, V206, P2191, DOI 10.1084/jem.20091480; Tan AM, 2010, J IMMUNOL, V184, P3535, DOI 10.4049/jimmunol.0900340; van Voorhis M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082545; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; Wakabayashi N, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000762; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560; Williams MA, 2008, J IMMUNOL, V181, P4545, DOI 10.4049/jimmunol.181.7.4545; Xia T, 2004, ENVIRON HEALTH PERSP, V112, P1347, DOI 10.1289/ehp.7167; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200	50	66	68	0	34	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					441	453		10.1016/j.jaci.2015.02.014	http://dx.doi.org/10.1016/j.jaci.2015.02.014			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25825216	Green Accepted			2022-12-18	WOS:000359004900026
J	Harden, JL; Johnson-Huang, LM; Chamian, MF; Lee, E; Pearce, T; Leonardi, CL; Haider, A; Lowes, MA; Krueger, JG				Harden, Jamie L.; Johnson-Huang, Leanne M.; Chamian, Maria Francesca; Lee, Edmund; Pearce, Tillman; Leonardi, Craig L.; Haider, Asifa; Lowes, Michelle A.; Krueger, James G.			Humanized anti-IFN-gamma (HuZAF) in the treatment of psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SUPPRESSES; ACTIVATION; VULGARIS; MODERATE; THERAPY; ALPHA		[Harden, Jamie L.; Johnson-Huang, Leanne M.; Chamian, Maria Francesca; Lee, Edmund; Haider, Asifa; Lowes, Michelle A.; Krueger, James G.] Rockefeller Univ, Lab Investigat Dermatol, New York, NY 10021 USA; [Pearce, Tillman] Prot Design Lab, Fremont, CA USA; [Leonardi, Craig L.] St Louis Univ, Dept Dermatol, St Louis, MO 63103 USA	Rockefeller University; Saint Louis University	Harden, JL (corresponding author), Rockefeller Univ, Lab Investigat Dermatol, 1230 York Ave, New York, NY 10021 USA.	jgk@rockefeller.edu	Lowes, Michelle A/G-9585-2016	Lowes, Michelle A/0000-0003-4256-478X	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR060222] Funding Source: NIH RePORTER; NIAMS NIH HHS [1R01AR060222] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Austin LM, 1999, J INVEST DERMATOL, V113, P752, DOI 10.1046/j.1523-1747.1999.00749.x; Chodorowska G, 1998, J EUR ACAD DERMATOL, V10, P147, DOI 10.1016/S0926-9959(97)00182-7; Hommes DW, 2006, GUT, V55, P1131, DOI 10.1136/gut.2005.079392; Johnson-Huang LM, 2012, DIS MODEL MECH, V5, P423, DOI 10.1242/dmm.009092; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Lew W, 2004, TRENDS IMMUNOL, V25, P295, DOI 10.1016/j.it.2004.03.006; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Thakur AB, 1999, MOL IMMUNOL, V36, P1107, DOI 10.1016/S0161-5890(99)00096-6; UYEMURA K, 1993, J INVEST DERMATOL, V101, P701, DOI 10.1111/1523-1747.ep12371679; VALLAT VP, 1994, J EXP MED, V180, P283, DOI 10.1084/jem.180.1.283; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046	11	66	73	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					553	+		10.1016/j.jaci.2014.05.046	http://dx.doi.org/10.1016/j.jaci.2014.05.046			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25085340	Bronze			2022-12-18	WOS:000349372300031
J	Bochenek, G; Kuschill-Dziurda, J; Szafraniec, K; Plutecka, H; Szczeklik, A; Nizankowska-Mogilnicka, E				Bochenek, Grazyna; Kuschill-Dziurda, Joanna; Szafraniec, Krystyna; Plutecka, Hanna; Szczeklik, Andrzej; Nizankowska-Mogilnicka, Ewa			Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin; aspirin-exacerbated respiratory disease; asthma phenotype; latent class analysis; nonsteroidal anti-inflammatory drugs	NATURAL-HISTORY; ASTHMA; RHINOSINUSITIS; SENSITIVITY; INTOLERANCE; PHENOTYPES; ATOPY; LIFE	Background: Aspirin-exacerbated respiratory disease (AERD) is recognized as a distinct asthma phenotype. It usually has a severe course accompanied by chronic hyperplastic eosinophilic sinusitis with nasal polyps, blood eosinophilia, and increased concentrations of urinary leukotriene E-4 (LTE4). More insightful analysis of individual patients shows this group to be nonhomogeneous. Objective: We sought to identify any likely subphenotypes in a cohort of patients with AERD through the application of latent class analysis (LCA). Methods: Clinical data from 201 patients with AERD (134 women) were collected from questionnaires. Standard spirometry, atopy traits, blood eosinophilia, and urinary LTE4 concentrations were evaluated. LCA was applied to identify possible AERD subphenotypes. Results: Four classes (subphenotypes) within the AERD phenotype were identified as follows: class 1, asthma with a moderate course, intensive upper airway symptoms, and blood eosinophilia (18.9% of patients); class 2, asthma with a mild course, relatively well controlled, and with low health care use (34.8% of patients); class 3, asthma with a severe course, poorly controlled, and with severe exacerbations and airway obstruction (41.3% of patients); and class 4, poorly controlled asthma with frequent and severe exacerbations in female subjects (5.0% of patients). Atopic status did not affect class membership. Patients with particularly intensive upper airway symptoms had the highest levels of blood eosinophilia and the highest concentrations of urinary LTE4. Conclusions: LCA revealed unique AERD subphenotypes, thus corroborating the heterogeneity of this population. Such discrimination might facilitate more individualized treatment in difficult-to-treat patients.	[Bochenek, Grazyna; Kuschill-Dziurda, Joanna; Plutecka, Hanna; Szczeklik, Andrzej; Nizankowska-Mogilnicka, Ewa] Jagiellonian Univ, Coll Med, Dept Internal Med, Inst Publ Hlth, PL-31066 Krakow, Poland; [Szafraniec, Krystyna] Jagiellonian Univ, Coll Med, Dept Epidemiol & Populat Studies, Inst Publ Hlth, PL-31066 Krakow, Poland	Jagiellonian University; Collegium Medicum Jagiellonian University; Jagiellonian University; Collegium Medicum Jagiellonian University	Bochenek, G (corresponding author), Jagiellonian Univ, Coll Med, Dept Internal Med, Skawinska 8, PL-31066 Krakow, Poland.	mmbochen@cyf-kr.edu.pl			Polish Ministry of Science and Higher Education; Jagiellonian University [K/ZDS/001022]	Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); Jagiellonian University	Supported by a grant from the Polish Ministry of Science and Higher Education and Jagiellonian University (K/ZDS/001022).	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474, DOI 10.1016/S1081-1206(10)62084-4; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Bochenek G, 1996, ALLERGY, V51, P16, DOI 10.1111/j.1398-9995.1996.tb00004.x; Chhabra SK, 2011, J ASTHMA, V48, P609, DOI 10.3109/02770903.2011.587577; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fukutomi Y, 2012, CLIN EXP ALLERGY, V42, P738, DOI 10.1111/j.1365-2222.2011.03880.x; Hagenars JA, 2002, APPL LATENT CLASS AN; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Higashi N, 2004, J ALLERGY CLIN IMMUN, V113, P277, DOI 10.1016/j.jaci.2003.10.068; Hu Y, 2012, LARYNGOSCOPE, V122, P498, DOI 10.1002/lary.22507; Kowalski ML, 2011, ALLERGY, V66, P32, DOI 10.1111/j.1398-9995.2010.02379.x; Kumlin M, 2000, AM J RESP CRIT CARE, V161, pS102, DOI 10.1164/ajrccm.161.supplement_1.ltta-20; Lanza ST, 2007, STRUCT EQU MODELING, V14, P671, DOI 10.1080/10705510701575602; Mascia K, 2005, ANN ALLERG ASTHMA IM, V94, P652, DOI 10.1016/S1081-1206(10)61323-3; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; Mikos M, 2009, RESPIRATION, V77, P381, DOI 10.1159/000141652; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; Nizankowska-Mogilnicka E, 2007, ALLERGY, V62, P1111, DOI 10.1111/j.1398-9995.2007.01409.x; Ponte EV, 2008, ALLERGY, V63, P564, DOI 10.1111/j.1398-9995.2007.01624.x; Rowe BH, 2009, CHEST, V135, P57, DOI 10.1378/chest.07-3041; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M, 2010, ALLERGY, V65, P663, DOI 10.1111/j.1398-9995.2009.02206.x; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Szefler SJ, 2012, J ALLERGY CLIN IMM S, V129, pS9; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Williamson PA, 2011, CLIN EXP ALLERGY, V41, P1379, DOI 10.1111/j.1365-2222.2011.03793.x; Yoshimine F, 2005, RESPIROLOGY, V10, P477, DOI 10.1111/j.1440-1843.2005.00740.x	36	66	66	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					98	+		10.1016/j.jaci.2013.07.004	http://dx.doi.org/10.1016/j.jaci.2013.07.004			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23993879	Green Submitted			2022-12-18	WOS:000329105700013
J	Pescatore, AM; Dogaru, CM; Duembgen, L; Silverman, M; Gaillard, EA; Spycher, BD; Kuehni, CE				Pescatore, Anina M.; Dogaru, Cristian M.; Duembgen, Lutz; Silverman, Michael; Gaillard, Erol A.; Spycher, Ben D.; Kuehni, Claudia E.			A simple asthma prediction tool for preschool children with wheeze or cough	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; wheeze; cough; children; prediction; prognosis; persistence; longitudinal; cohort study	OBSTRUCTIVE AIRWAYS DISEASE; 1ST 6 YEARS; LUNG-FUNCTION; LONG-TERM; CHILDHOOD ASTHMA; SCHOOL-AGE; PHENOTYPES; RISK; QUESTIONNAIRE; ASSOCIATIONS	Background: Many preschool children have wheeze or cough, but only some have asthma later. Existing prediction tools are difficult to apply in clinical practice or exhibit methodological weaknesses. Objective: We sought to develop a simple and robust tool for predicting asthma at school age in preschool children with wheeze or cough. Methods: From a population-based cohort in Leicestershire, United Kingdom, we included 1- to 3-year-old subjects seeing a doctor for wheeze or cough and assessed the prevalence of asthma 5 years later. We considered only noninvasive predictors that are easy to assess in primary care: demographic and perinatal data, eczema, upper and lower respiratory tract symptoms, and family history of atopy. We developed a model using logistic regression, avoided overfitting with the least absolute shrinkage and selection operator penalty, and then simplified it to a practical tool. We performed internal validation and assessed its predictive performance using the scaled Brier score and the area under the receiver operating characteristic curve. Results: Of 1226 symptomatic children with follow-up information, 345 (28%) had asthma 5 years later. The tool consists of 10 predictors yielding a total score between 0 and 15: sex, age, wheeze without colds, wheeze frequency, activity disturbance, shortness of breath, exercise-related and aeroallergen-related wheeze/cough, eczema, and parental history of asthma/bronchitis. The scaled Brier scores for the internally validated model and tool were 0.20 and 0.16, and the areas under the receiver operating characteristic curves were 0.76 and 0.74, respectively. Conclusion: This tool represents a simple, low-cost, and noninvasive method to predict the risk of later asthma in symptomatic preschool children, which is ready to be tested in other populations.	[Pescatore, Anina M.; Dogaru, Cristian M.; Duembgen, Lutz; Spycher, Ben D.; Kuehni, Claudia E.] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Duembgen, Lutz] Univ Bern, Inst Math Stat & Actuarial Sci, CH-3012 Bern, Switzerland; [Silverman, Michael; Gaillard, Erol A.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 7RH, Leics, England	University of Bern; University of Bern; University of Leicester	Kuehni, CE (corresponding author), Inst Social & Prevent Med, Finkenhubelweg 11, CH-3012 Bern, Switzerland.	kuehni@ispm.unibe.ch	Dogaru, Cristian/I-1861-2019; Spycher, Ben D/B-3308-2008; Dogaru, Cristian/N-6290-2015	Dogaru, Cristian/0000-0002-0722-6147; Spycher, Ben D/0000-0002-1430-5695; Dogaru, Cristian/0000-0002-0722-6147; Duembgen, Lutz/0000-0003-0172-9285; Gaillard, Erol/0000-0003-0996-8133; Kuehni, Claudia E./0000-0001-8957-2002	Swiss National Science Foundation [PDFMP3-123162, 3200B0-122341]; Asthma UK [07/048]; European Respiratory Society/Marie Curie Joint Research Fellowship [MC 1614-2010]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Asthma UK; European Respiratory Society/Marie Curie Joint Research Fellowship	Supported by the Swiss National Science Foundation (PDFMP3-123162 and 3200B0-122341) and Asthma UK 07/048. B. D. S. is the recipient of a European Respiratory Society/Marie Curie Joint Research Fellowship (MC 1614-2010).	ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Austin PC, 2004, J CLIN EPIDEMIOL, V57, P1138, DOI 10.1016/j.jclinepi.2004.04.003; Balemans WAF, 2006, J CLIN EPIDEMIOL, V59, P1207, DOI 10.1016/j.jclinepi.2006.02.011; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Carlsen KCL, 2010, ALLERGY, V65, P1134, DOI 10.1111/j.1398-9995.2010.02344.x; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Caudri D, 2011, PEDIAT ALLERG IMM-UK, V22, P652, DOI 10.1111/j.1399-3038.2011.01193.x; Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616; Dogaru CM, 2012, AM J RESP CRIT CARE, V185, P874, DOI 10.1164/rccm.201108-1490OC; Eysink PED, 2005, BRIT J GEN PRACT, V55, P125; Frank PI, 2008, BRIT MED J, V336, P1423, DOI 10.1136/bmj.39568.623750.BE; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Galant SP, 2007, J PEDIATR-US, V151, P457, DOI 10.1016/j.jpeds.2007.05.004; Harrell F. E., 2001, REGRESSION MODELING; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Hosmer DW, 1997, STAT MED, V16, P965; Korppi M, 2010, EUR RESPIR J, V36, P221, DOI 10.1183/09031936.00036710; Kuehni CE, 2007, INT J EPIDEMIOL, V36, P977, DOI 10.1093/ije/dym090; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Leonardi NA, 2011, J ALLERGY CLIN IMMUN, V127, P1466, DOI 10.1016/j.jaci.2011.03.001; Lowe L, 2004, CURR ALLERGY ASTHM R, V4, P159, DOI 10.1007/s11882-004-0062-9; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; Matricardi PM, 2010, EUR RESPIR J, V35, P701, DOI 10.1183/09031936.00163709; Midodzi WK, 2008, RESPIROLOGY, V13, P537, DOI 10.1111/j.1440-1843.2008.01284.x; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Piippo-Savolainen E, 2008, ACTA PAEDIATR, V97, P5, DOI 10.1111/j.1651-2227.2007.00558.x; Robertson CF, 2007, AM J RESP CRIT CARE, V175, P323, DOI 10.1164/rccm.200510-1546OC; Rodriguez-Martinez CE, 2011, PEDIATR PULM, V46, P1175, DOI 10.1002/ppul.21493; Savenije OEM, 2012, J ALLERGY CLIN IMMUN, V130, P325, DOI 10.1016/j.jaci.2012.05.007; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Spycher BD, 2010, CLIN EXP ALLERGY, V40, P1130, DOI 10.1111/j.1365-2222.2010.03541.x; Spycher BD, 2009, PEDIATRICS, V123, P944, DOI 10.1542/peds.2008-0115; Stevens CA, 2003, EUR RESPIR J, V21, P1000, DOI 10.1183/09031936.03.00057002; Steyerberg E., 2008, CLIN PREDICTION MODE; Strippoli MPF, 2007, ARCH DIS CHILD, V92, P861, DOI 10.1136/adc.2007.117978; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Van Bever HP, 2002, PEDIATR ALLERGY IMMU, V13, P77, DOI 10.1034/j.1399-3038.2002.00093.x; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	43	66	74	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					111	+		10.1016/j.jaci.2013.06.002	http://dx.doi.org/10.1016/j.jaci.2013.06.002			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23891353				2022-12-18	WOS:000329105700015
J	Bublin, M; Kostadinova, M; Radauer, C; Hafner, C; Szepfalusi, Z; Varga, EM; Maleki, SJ; Hoffmann-Sommergruber, K; Breiteneder, H				Bublin, Merima; Kostadinova, Maria; Radauer, Christian; Hafner, Christine; Szepfalusi, Zsolt; Varga, Eva-Maria; Maleki, Soheila J.; Hoffmann-Sommergruber, Karin; Breiteneder, Heimo			IgE cross-reactivity between the major peanut allergen Ara h 2 and the nonhomologous allergens Ara h 1 and Ara h 3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergens; food allergy; IgE cross-reactivity; peanut allergy	IMMUNOGLOBULIN-E-BINDING; MICROARRAY IMMUNOASSAY; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; ARACHIS-HYPOGAEA; EPITOPES; PROTEIN; SEVERITY; CHILDREN; IDENTIFICATION	Background: Ara h 1, a vicilin; Ara h 2, a 2S albumin; and Ara h 3, a legumin, are major peanut allergens. Ara h 2 is an important predictor of clinical reactivity to peanut, but cosensitization to all 3 allergens is correlated with the severity of patients' symptoms. Objective: We investigated whether cosensitization to these 3 allergens is caused by IgE cross-reactivity, despite the fact that they do not display obvious structural or sequence similarities. Methods: IgE cross-inhibitions were performed with purified Ara h 1, Ara h 2, and Ara h 3 and IgG-depleted sera from 10 patients with peanut allergy. After an in silico search for similar peptides, IgE ELISA inhibition assays with synthetic peptides were performed. Results: Ara h 2 inhibited IgE binding to Ara h 1 (average, 86% +/- 13%) and Ara h 3 (average, 96% +/- 6%). IgE binding to Ara h 2 was inhibited by Ara h 1 by 78% +/- 15% and by Ara h 3 by 80% +/- 6%. A subsequent sequence comparison showed that these nonhomologous allergens contained several similar surface-exposed peptides. IgE binding to Ara h 2-derived peptides was completely inhibited by Ara h 1 and Ara h 3. A mixture of these peptides reduced IgE binding to Ara h 1 and Ara h 3 by 20% to 60% and to Ara h 2 by 49% to 89%. Conclusion: Occurrence of similar sequences in the 3 major peanut allergens accounts for the high extent of cross-reactivity among them.	[Bublin, Merima; Kostadinova, Maria; Radauer, Christian; Hoffmann-Sommergruber, Karin; Breiteneder, Heimo] Med Univ Vienna, Dept Pathophysiol & Allergy Res, A-1090 Vienna, Austria; [Hafner, Christine] Karl Landsteiner Inst Dermatol Res, St Polten, Austria; [Szepfalusi, Zsolt] Med Univ Vienna, Dept Paediat & Adolescent Med, A-1090 Vienna, Austria; [Varga, Eva-Maria] Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria; [Maleki, Soheila J.] ARS, USDA, So Reg Res Ctr, New Orleans, LA USA	Medical University of Vienna; Medical University of Vienna; Medical University of Graz; United States Department of Agriculture (USDA)	Bublin, M (corresponding author), Med Univ Vienna, Dept Pathophysiol & Allergy Res, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	merima.bublin@meduniwien.ac.at	Radauer, Christian/AAN-6260-2021	Radauer, Christian/0000-0001-9920-4449; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X; Szepfalusi, Zsolt/0000-0003-4852-3102; Bublin, Merima/0000-0002-7191-9431	BRIDGE Grant from the Austrian Research Promotion Agency (FFG) [820127]; Roche; Bristol-Myers Squibb; Phadia Austria; Thermo Fisher Diagnostics AB; SNF	BRIDGE Grant from the Austrian Research Promotion Agency (FFG); Roche(Roche Holding); Bristol-Myers Squibb(Bristol-Myers Squibb); Phadia Austria(Phadia); Thermo Fisher Diagnostics AB; SNF	Supported by BRIDGE Grant 820127 from the Austrian Research Promotion Agency (FFG; to H.B.).; C. Hafner has received lecture fees from Roche, Bristol-Myers Squibb, and Phadia Austria. K. Hoffmann-Sommergruber has received consulting fees from Thermo Fisher Diagnostics AB, has received fees for participation in a reviewer board from SNF, has received royalties from CRD Press for coediting Managing Allergens in Food (2007), and has received travel support for EAACI Meetings in relation to the Interest Group for Food Allergy. The rest of the authors declare that they have no relevant conflicts of interest.	Aalberse RC, 2011, ALLERGY, V66, P1261, DOI 10.1111/j.1398-9995.2011.02656.x; Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Albrecht M, 2009, J ALLERGY CLIN IMMUN, V124, P328, DOI 10.1016/j.jaci.2009.05.031; Asarnoj A, 2010, ALLERGY, V65, P1189, DOI 10.1111/j.1398-9995.2010.02334.x; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Blanc F, 2009, CLIN EXP ALLERGY, V39, P1277, DOI 10.1111/j.1365-2222.2009.03294.x; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Cabanos C, 2011, MOL IMMUNOL, V49, P115, DOI 10.1016/j.molimm.2011.08.004; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Eswar Narayanan, 2008, V426, P145, DOI 10.1007/978-1-60327-058-8_8; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jin T, 2009, MOL IMMUNOL, V46, P1796, DOI 10.1016/j.molimm.2009.01.023; King N, 2005, MOL NUTR FOOD RES, V49, P963, DOI 10.1002/mnfr.200500073; Koppelman SJ, 2005, CLIN EXP ALLERGY, V35, P490, DOI 10.1111/j.1365-2222.2005.02204.x; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Krause S, 2010, MOL NUTR FOOD RES, V54, P381, DOI 10.1002/mnfr.200900072; Kulis M, 2012, CLIN EXP ALLERGY, V42, P326, DOI 10.1111/j.1365-2222.2011.03934.x; Lehmann K, 2006, BIOCHEM J, V395, P463, DOI 10.1042/BJ20051728; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; Lin J, 2012, J ALLERGY CLIN IMMUN, V129, P1321, DOI 10.1016/j.jaci.2012.02.012; Maleki SJ, 2011, ALLERGY, V66, P1522, DOI 10.1111/j.1398-9995.2011.02692.x; Marsh J, 2008, MOL NUTR FOOD RES, V52, pS272, DOI 10.1002/mnfr.200700524; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Palmer GW, 2005, CLIN IMMUNOL, V115, P302, DOI 10.1016/j.clim.2005.02.011; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Porterfield HS, 2009, CLIN EXP ALLERGY, V39, P1099, DOI 10.1111/j.1365-2222.2009.03273.x; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; Rouge P, 2009, MOL IMMUNOL, V46, P1067, DOI 10.1016/j.molimm.2008.09.030; Schein CH, 2005, J AGR FOOD CHEM, V53, P8752, DOI 10.1021/jf051148a; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010	44	66	70	1	50	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					118	U212		10.1016/j.jaci.2013.01.022	http://dx.doi.org/10.1016/j.jaci.2013.01.022			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23465659	Green Published			2022-12-18	WOS:000321052300016
J	Kauffmann, F; Demenais, F				Kauffmann, Francine; Demenais, Florence			Gene-environment interactions in asthma and allergic diseases: Challenges and perspectives	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Gene; environment; gene-environment interaction; asthma; allergy	GENOME-WIDE ASSOCIATION; CHILDHOOD ASTHMA; SMOKING EXPOSURE; PUBLIC-HEALTH; LUNG-FUNCTION; BRONCHIAL HYPERRESPONSIVENESS; STATISTICAL-METHODS; PATHWAY ANALYSIS; CLUSTER-ANALYSIS; ETHICAL-ISSUES	The concept of gene-environment (GxE) interactions has dramatically evolved in the last century and has now become a central theme in studies that assess the causes of human disease. Despite the numerous efforts to discover genes associated in asthma and allergy through various approaches, including the recent genome-wide association studies, investigation of GxE interactions has been mainly limited to candidate genes, candidate environmental exposures, or both. This review discusses the various strategies from hypothesis-driven strategies to the full agnostic search of GxE interactions with an illustration from recently published articles. Challenges raised by each piece of the puzzle (ie, phenotype, environment, gene, and analysis of GxE interaction) are put forward, and tentative solutions are proposed. New perspectives to integrate various types of data generated by new sequencing technologies and to progress toward a systems biology approach of disease are outlined. The future of a molecular network-based approach of disease to which GxE interactions are related requires space for innovative and multidisciplinary research. Assembling the various parts of a puzzle in a complex system could well occur in a way that might not necessarily follow the rules of logic. (J Allergy Clin Immunol 2012;130:1229-40.)	[Demenais, Florence] Fdn Jean Dausset CEPH, INSERM, UMR 946, F-75010 Paris, France; [Kauffmann, Francine] INSERM, CESP Ctr Res Epidemiol & Populat Hlth, U1018, Resp & Environm Epidemiol Team, Villejuif, France; [Kauffmann, Francine] Univ Paris 11, UMRS 1018, Villejuif, France; [Demenais, Florence] INSERM, U946, Genet Variat & Human Dis Unit, Paris, France; [Demenais, Florence] Univ Paris Diderot, Inst Univ Hematol, Paris, France	Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Demenais, F (corresponding author), Fdn Jean Dausset CEPH, INSERM, UMR 946, 27 Rue Juliette Dodu, F-75010 Paris, France.	florence.demenais@inserm.fr	Demenais, Florence/G-3298-2013	Demenais, Florence/0000-0001-8361-0936	French National Agency for Research [ANR-2010-PRSP-003 IAGO, ANR-11-BSV1-027-01-GWIS-AM]	French National Agency for Research(French National Research Agency (ANR))	Supported by grants from the French National Agency for Research (ANR-2010-PRSP-003 IAGO and ANR-11-BSV1-027-01-GWIS-AM).	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Aschard H, 2009, GENES IMMUN, V10, P559, DOI 10.1038/gene.2009.46; Aschard H, 2012, HUM GENET, V131, P1591, DOI 10.1007/s00439-012-1192-0; Aschard H, 2010, HUM HERED, V70, P292, DOI 10.1159/000323318; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Barouki R, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-42; Bookman EB, 2011, GENET EPIDEMIOL, V35, P217, DOI 10.1002/gepi.20571; Borzelleca JF, 2000, THORAX, V53, P2; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Brauner EV, 2012, GENES IMMUN, V13, P94, DOI 10.1038/gene.2011.51; Bunyavanich S, 2012, CLIN EXP ALLERGY, V42, P229, DOI 10.1111/j.1365-2222.2011.03874.x; Candelaria PV, 2010, ALLERGY, V65, P229, DOI 10.1111/j.1398-9995.2009.02145.x; Cantor RM, 2010, AM J HUM GENET, V86, P6, DOI 10.1016/j.ajhg.2009.11.017; Castro-Giner F, 2009, ENVIRON HEALTH PERSP, V117, P1919, DOI 10.1289/ehp.0900589; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Cordell HJ, 2009, NAT REV GENET, V10, P392, DOI 10.1038/nrg2579; Curjuric I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040175; Dai JY, 2012, AM J EPIDEMIOL, V176, P164, DOI 10.1093/aje/kwr521; Descartes Rene, 1637, DISCOURS METHODE BIE; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; Dizier MH, 2007, EUR J HUM GENET, V15, P810, DOI 10.1038/sj.ejhg.5201830; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Forno E, 2012, J ALLERGY CLIN IMMUN, V130, P83, DOI 10.1016/j.jaci.2012.03.020; Gene, 2006, ENV HLTH IN; Ghazalpour A, 2006, PLOS GENET, V2, P1182, DOI 10.1371/journal.pgen.0020130; Halapi E, 2009, J ALLERGY CLIN IMMUN, V124, P605; Haldane John Burdon Sanderson, 1938, HEREDITY POLITICS; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hamza TH, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002237; Han MK, 2012, THORAX, V67, P456, DOI 10.1136/thoraxjnl-2011-201183; Herrington D, 2005, CIRCULATION, V112, P2081, DOI 10.1161/CIRCULATIONAHA.105.570069; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Holmans P, 2010, ADV GENET, V72, P141, DOI [10.1016/S0065-2660(10)72007-1, 10.1016/B978-0-12-380862-2.00007-2]; HOWELL WM, 1995, THORAX, V50, P815, DOI 10.1136/thx.50.8.815; Hsu L, 2012, GENET EPIDEMIOL, V36, P183, DOI 10.1002/gepi.21610; Hung RJ, 2004, CANCER EPIDEM BIOMAR, V13, P1013; Hwang BF, 2012, ANN EPIDEMIOL, V22, P250, DOI 10.1016/j.annepidem.2012.01.008; Kabesch M, 2010, EUR RESPIR J, V36, P950, DOI 10.1183/09031936.00019310; Kauffmann F, 2010, PROG INFLAMM RES SER, P205, DOI 10.1007/978-3-7643-8556-9_12; Kauffmann F, 2010, J EPIDEMIOL COMMUN H, V64, P188, DOI 10.1136/jech.2008.086199; Khoury MJ, 1997, AM J MED GENET, V71, P289, DOI 10.1002/(SICI)1096-8628(19970822)71:3<289::AID-AJMG8>3.0.CO;2-P; Khoury MJ, 2011, GENET EPIDEMIOL, V35, P845, DOI 10.1002/gepi.20634; Khoury MJ, 2009, AM J EPIDEMIOL, V169, P227, DOI 10.1093/aje/kwn351; Kim JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013818; Kim SH, 2009, CLIN EXP ALLERGY, V39, P203, DOI 10.1111/j.1365-2222.2008.03117.x; Knoppers BM, 2008, EUR J HUM GENET, V16, P664, DOI 10.1038/ejhg.2008.55; Kooperberg C, 2008, GENET EPIDEMIOL, V32, P255, DOI 10.1002/gepi.20300; Koppelman GH, 2007, J ALLERGY CLIN IMMUN, V120, P1266, DOI 10.1016/j.jaci.2007.10.007; Koppelman GH, 2011, CURR OPIN ALLERGY CL, V11, P414, DOI 10.1097/ACI.0b013e32834a9573; Kraft P, 2007, HUM HERED, V63, P111, DOI 10.1159/000099183; Le Souef PN, 2009, CURR OPIN ALLERGY CL, V9, P123, DOI 10.1097/ACI.0b013e3283292283; Lee JY, 2012, INT ARCH ALLERGY IMM, V157, P363, DOI 10.1159/000328778; Lewis S, 1998, LANCET, V351, P1220, DOI 10.1016/S0140-6736(98)22017-4; Li DL, 2009, AM J EPIDEMIOL, V169, P497, DOI 10.1093/aje/kwn339; Liu ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025099; London SJ, 2009, ANNU REV PUBL HEALTH, V30, P55, DOI 10.1146/annurev.publhealth.031308.100151; Manning AK, 2011, GENET EPIDEMIOL, V35, P11, DOI 10.1002/gepi.20546; Marenne G, 2011, HUM MUTAT, V32, P240, DOI 10.1002/humu.21398; Martinez FD, 2007, EUR RESPIR J, V29, P179, DOI 10.1183/09031936.00087906; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Mechanic LE, 2012, GENET EPIDEMIOL, V36, P22, DOI 10.1002/gepi.20652; Meyers DA, 2005, J ALLERGY CLIN IMMUN, V115, P1169, DOI 10.1016/j.jaci.2005.01.070; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Mukherjee B, 2008, BIOMETRICS, V64, P685, DOI 10.1111/j.1541-0420.2007.00953.x; Mukherjee B, 2012, AM J EPIDEMIOL, V175, P177, DOI 10.1093/aje/kwr367; Munoz B, 2012, ENVIRON TOXICOL PHAR, V33, P226, DOI 10.1016/j.etap.2011.12.007; Murcray CE, 2011, GENET EPIDEMIOL, V35, P201, DOI 10.1002/gepi.20569; Neuman A., 2012, AM J RESP CRIT CARE; Ober C, 2011, TRENDS GENET, V27, P107, DOI 10.1016/j.tig.2010.12.004; OTTMAN R, 1990, GENET EPIDEMIOL, V7, P177, DOI 10.1002/gepi.1370070302; Ramanan VK, 2012, TRENDS GENET, V28, P323, DOI 10.1016/j.tig.2012.03.004; Ramasamy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044008; Renz H, 2011, NAT IMMUNOL, V12, P273, DOI 10.1038/ni0411-273; Ritchie MD, 2005, PHARMACOGENOMICS, V6, P823, DOI 10.2217/14622416.6.8.823; Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774; Roeder K, 2009, STAT SCI, V24, P398, DOI 10.1214/09-STS289; Romieu I, 2004, THORAX, V59, P8; Romieu Isabelle, 2010, Proc Am Thorac Soc, V7, P116, DOI 10.1513/pats.200909-097RM; Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454; Schork NJ, 1997, AM J RESP CRIT CARE, V156, pS103, DOI 10.1164/ajrccm.156.4.12-tac-5; SCHULTE PA, 1989, ENVIRON RES, V48, P129, DOI 10.1016/S0013-9351(89)80029-5; Schulte PA, 1999, J OCCUP ENVIRON MED, V41, P639, DOI 10.1097/00043764-199908000-00005; Schwartz DA, 2012, J ALLERGY CLIN IMMUN; Schwartz DA, 2009, PEDIATRICS, V123, pS151, DOI 10.1542/peds.2008-2233E; Sharp RR, 2003, ENVIRON HEALTH PERSP, V111, P1786, DOI 10.1289/ehp.6778; Shostak S, 2003, SOC SCI MED, V56, P2327, DOI 10.1016/S0277-9536(02)00231-9; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Sly PD, 2011, CURR OPIN ALLERGY CL, V11, P127, DOI 10.1097/ACI.0b013e32834487c6; Smit LAM, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-26; Su MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030694; SUTTON GC, 1980, ANN HUM BIOL, V7, P449, DOI 10.1080/03014468000004561; Thomas D, 2010, ANNU REV PUBL HEALTH, V31, P21, DOI 10.1146/annurev.publhealth.012809.103619; Thomas D, 2010, NAT REV GENET, V11, P259, DOI 10.1038/nrg2764; Thomas DC, 2012, GENET EPIDEMIOL, V36, P179, DOI 10.1002/gepi.21612; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Ungvari I, 2012, J COMMUN GENET, V3, P25, DOI 10.1007/s12687-011-0075-8; van der Valk RJP, 2012, ALLERGY, V67, P767, DOI 10.1111/j.1398-9995.2012.02819.x; Varraso R, 2012, AM J CLIN NUTR, V96, P1079, DOI 10.3945/ajcn.112.038109; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Vercelli D, 2010, CURR OPIN ALLERGY CL, V10, P145, DOI 10.1097/ACI.0b013e32833653d7; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; Weiss ST, 2012, J ALLERGY CLIN IMMUN, V129, P327, DOI 10.1016/j.jaci.2011.12.971; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wild CP, 2012, INT J EPIDEMIOL, V41, P24, DOI 10.1093/ije/dyr236; Willis-Owen SAG, 2009, J ALLERGY CLIN IMMUN, V123, P14, DOI 10.1016/j.jaci.2008.09.016; Yang IV, 2012, AM J RESP CRIT CARE; Yu W, 2008, NAT GENET, V40, P124, DOI 10.1038/ng0208-124; Zhang GC, 2011, PEDIAT ALLERG IMM-UK, V22, P621, DOI 10.1111/j.1399-3038.2011.01186.x; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154	114	66	67	0	49	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1229	1240		10.1016/j.jaci.2012.10.038	http://dx.doi.org/10.1016/j.jaci.2012.10.038			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23195523				2022-12-18	WOS:000311641100001
J	Hauck, F; Randriamampita, C; Martin, E; Gerart, S; Lambert, N; Lim, A; Soulier, J; Maciorowski, Z; Touzot, F; Moshous, D; Quartier, P; Heritier, S; Blanche, S; Rieux-Laucat, F; Brousse, N; Callebaut, I; Veillette, A; Hivroz, C; Fischer, A; Latour, S; Picard, C				Hauck, Fabian; Randriamampita, Clotilde; Martin, Emmanuel; Gerart, Stephane; Lambert, Nathalie; Lim, Annick; Soulier, Jean; Maciorowski, Zosia; Touzot, Fabien; Moshous, Despina; Quartier, Pierre; Heritier, Sebastien; Blanche, Stephane; Rieux-Laucat, Frederic; Brousse, Nicole; Callebaut, Isabelle; Veillette, Andre; Hivroz, Claire; Fischer, Alain; Latour, Sylvain; Picard, Capucine			Primary T-cell immunodeficiency with immunodysregulation caused by autosomal recessive LCK deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD4; lymphopenia; autoinflammation; recurrent infections; LCK; SRC tyrosine kinase; genetic defect; immunodeficiency; T-cell receptor signaling	PROTEIN-TYROSINE KINASES; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; DOCK8 DEFICIENCY; MICE LACKING; ACTIVATION; MUTATION; FYN; P56(LCK); COMPLEX	Background: Signals emanating from the antigen T-cell receptor (TCR) are required for T-cell development and function. The T lymphocyte-specific protein tyrosine kinase (Lck) is a key component of the TCR signaling machinery. On the basis of its function, we considered LCK a candidate gene in patients with combined immunodeficiency. Objective: We identify and describe a child with a T-cell immunodeficiency caused by a homozygous missense mutation of the LCK gene (c.1022T>C) resulting from uniparental disomy. Methods: Genetic, molecular, and functional analyses were performed to characterize the Lck deficiency, and the associated clinical and immunologic phenotypes are reported. Results: The mutant LCK protein (p.L341P) was weakly expressed with no kinase activity and failed to reconstitute TCR signaling in LCK-deficient T cells. The patient presented with recurrent respiratory tract infections together with predominant early-onset inflammatory and autoimmune manifestations. The patient displayed CD4(+) T-cell lymphopenia and low levels of CD4 and CD8 expression on the T-cell surface. The residual T lymphocytes had an oligoclonal T-cell repertoire and exhibited a profound TCR signaling defect, with only weak tyrosine phosphorylation signals and no Ca2+ mobilization in response to TCR stimulation. Conclusion: We report a new form of T-cell immunodeficiency caused by a LCK gene defect, highlighting the essential role of Lck in human T-cell development and responses. Our results also point out that defects in the TCR signaling cascade often result in abnormal T-cell differentiation and functions, leading to an important risk factor for inflammation and autoimmunity. (J Allergy Clin Immunol 2012;130:1144-52.)	[Hauck, Fabian; Martin, Emmanuel; Gerart, Stephane; Rieux-Laucat, Frederic; Fischer, Alain; Latour, Sylvain] Hop Necker Enfants Malad, INSERM 768, Lab Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France; [Hauck, Fabian; Quartier, Pierre; Heritier, Sebastien; Blanche, Stephane; Brousse, Nicole; Fischer, Alain; Picard, Capucine] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Paris, France; [Randriamampita, Clotilde] Inst Cochin, CNRS UMR 8104, INSERM 567, Paris, France; [Lambert, Nathalie; Picard, Capucine] Hop Necker Enfants Malad, AP HP, Ctr Etud Deficits Immunitaires, F-75015 Paris, France; [Lim, Annick] Inst Pasteur, Unite Regulat Immunitaire & Vaccinol, Paris, France; [Soulier, Jean] Hop St Louis, AP HP, INSERM 944, CNRS UMR 7212, Paris, France; [Maciorowski, Zosia] Inst Curie, Flow Cytometry Core Facil, Paris, France; [Touzot, Fabien; Moshous, Despina; Quartier, Pierre; Heritier, Sebastien; Blanche, Stephane; Fischer, Alain] Hop Necker Enfants Malad, AP HP, Unite Immunol & Hematol Pediat, F-75015 Paris, France; [Brousse, Nicole] Hop Necker Enfants Malad, AP HP, Serv Anat & Cytol Pathol, F-75015 Paris, France; [Callebaut, Isabelle] Univ Paris 06, CNRS UMR 7590, Inst Mineral & Phys Milieux Condenses, Paris, France; [Callebaut, Isabelle] Univ Paris Diderot, Paris, France; [Veillette, Andre] Inst Rech Clin Montreal, Mol Oncol Res Unit, Montreal, PQ H2W 1R7, Canada; [Hivroz, Claire] Inst Curie, INSERM 932, Paris, France; [Picard, Capucine] Necker Enfants Malades Branch, Lab Human Genet Infect Dis, INSERM 980, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Latour, S (corresponding author), Hop Necker Enfants Malad, INSERM 768, Lab Dev Normal & Pathol Syst Immunitaire, 149 Rue Sevres, F-75015 Paris, France.	sylvain.latour@inserm.fr	Touzot, Fabien/T-7797-2018; Hauck, Fabian/H-5556-2016; Martin, Emmanuel/F-9743-2016; Picard, Capucine/H-3914-2017; Heritier, Sebastien/D-8139-2017; Moshous, Despina/B-7507-2017; Latour, Sylvain/H-3652-2017; Rieux-Laucat, Frederic/A-7916-2017	Touzot, Fabien/0000-0002-0889-4905; Martin, Emmanuel/0000-0003-4211-7373; Picard, Capucine/0000-0001-8788-5056; Heritier, Sebastien/0000-0003-0384-6370; Hauck, Fabian/0000-0001-9644-2003; Hivroz, Claire/0000-0002-6794-2890; Randriamampita, Clotilde/0000-0001-8594-7831; Moshous, Despina/0000-0001-6719-3693; Latour, Sylvain/0000-0001-8238-4391; Quartier, Pierre/0000-0002-1769-549X; Rieux-Laucat, Frederic/0000-0001-7858-7866	INSERM, Agence Nationale de la Recherche (France) [ANR-08-MIEN-012-01]; European Research Council [ERC-2009-AdG_20090506]; Centre National de la Recherche Scientifique (France); German Research Council/DFG [HA 5967/1 1]; Fondation IMAGINE (France); Ministere de la Recherche and l'Ecole Polytechnique (France); Fondation ARC pour la Recherche sur le Cancer (ARC) (France); ANR (France); Robert A. Good/Jeffrey Modell fellowship	INSERM, Agence Nationale de la Recherche (France)(French National Research Agency (ANR)); European Research Council(European Research Council (ERC)European Commission); Centre National de la Recherche Scientifique (France)(Centre National de la Recherche Scientifique (CNRS)); German Research Council/DFG(German Research Foundation (DFG)); Fondation IMAGINE (France); Ministere de la Recherche and l'Ecole Polytechnique (France); Fondation ARC pour la Recherche sur le Cancer (ARC) (France); ANR (France)(French National Research Agency (ANR)); Robert A. Good/Jeffrey Modell fellowship	Supported by grants from INSERM, Agence Nationale de la Recherche (ANR-08-MIEN-012-01, France), and the European Research Council (ERC-2009-AdG_20090506 no. FP7-249816). S.L. is a senior scientist at the Centre National de la Recherche Scientifique (France) and F.H. is a clinician at the University Children's Hospital of Dresden (Germany) and holds fellowships from the German Research Council/DFG (HA 5967/1 1) and the Fondation IMAGINE (France). S.G. holds a fellowship from the Ministere de la Recherche and l'Ecole Polytechnique (France) and the Fondation ARC pour la Recherche sur le Cancer (ARC) (France). E.M. is supported by the ANR (France). D.M. received a Robert A. Good/Jeffrey Modell fellowship.	Abdollahpour H, 2012, BLOOD, V119, P3450, DOI 10.1182/blood-2011-09-378158; ARNAIZVILLENA A, 1992, NEW ENGL J MED, V327, P529, DOI 10.1056/NEJM199208203270805; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Bueno C, 2006, IMMUNITY, V25, P67, DOI 10.1016/j.immuni.2006.04.012; Byun M, 2010, J EXP MED, V207, P2307, DOI 10.1084/jem.20101597; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Clappier E, 2007, BLOOD, V110, P1251, DOI 10.1182/blood-2006-12-064683; Conche C, 2009, IMMUNITY, V30, P33, DOI 10.1016/j.immuni.2008.10.020; DAVIDSON D, 1994, MOL CELL BIOL, V14, P4554, DOI 10.1128/MCB.14.7.4554; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2010, CLIN IMMUNOL, V135, P169, DOI 10.1016/j.clim.2010.01.011; Fischer A, 2005, CURR OPIN ALLERGY CL, V5, P491, DOI 10.1097/01.all.0000191886.12645.79; Fischer A, 2007, IMMUNITY, V27, P835, DOI 10.1016/j.immuni.2007.11.012; Fischer A, 2010, SEMIN IMMUNOPATHOL, V32, P107, DOI 10.1007/s00281-010-0196-x; Fujise S, 1996, J IMMUNOL, V157, P247; Goldman FD, 1998, J CLIN INVEST, V102, P421, DOI 10.1172/JCI3205; Hubert P, 2000, INT IMMUNOL, V12, P449, DOI 10.1093/intimm/12.4.449; Huck K, 2009, J CLIN INVEST, V119, P1350, DOI 10.1172/JCI37901; Katamura K, 1999, CLIN EXP IMMUNOL, V115, P124; Kotzot D, 2001, J MED GENET, V38, P497, DOI 10.1136/jmg.38.8.497; Latour S, 2001, NAT IMMUNOL, V2, P681, DOI 10.1038/90615; Li FY, 2011, NATURE, V475, P471, DOI 10.1038/nature10246; Lim A, 2002, J IMMUNOL METHODS, V261, P177, DOI 10.1016/S0022-1759(02)00004-2; Linka RM, 2012, LEUKEMIA, V26, P963, DOI 10.1038/leu.2011.371; Lovatt M, 2006, MOL CELL BIOL, V26, P8655, DOI 10.1128/MCB.00168-06; Mateo V, 2007, BLOOD, V110, P4285, DOI 10.1182/blood-2007-05-088286; McCarl CA, 2009, J ALLERGY CLIN IMMUN, V124, P1311, DOI 10.1016/j.jaci.2009.10.007; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Morgan NV, 2011, J CLIN INVEST, V121, P695, DOI 10.1172/JCI41931; Nehme NT, 2012, BLOOD, V119, P3458, DOI 10.1182/blood-2011-09-378364; Ouederni M, 2011, BLOOD, V118, P5108, DOI 10.1182/blood-2011-05-352716; Pacheco-Castro A, 1998, J IMMUNOL, V161, P3152; Page ST, 1997, EUR J IMMUNOL, V27, P554, DOI 10.1002/eji.1830270229; PENNINGER J, 1993, SCIENCE, V260, P358, DOI 10.1126/science.8469988; Picard C, 2009, EUR J IMMUNOL, V39, P1966, DOI 10.1002/eji.200939385; Picard C, 2009, NEW ENGL J MED, V360, P1971, DOI 10.1056/NEJMoa0900082; Prando C, 2010, AM J MED GENET A, V152A, P622, DOI 10.1002/ajmg.a.33291; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Randriamampita C, 2003, EUR J IMMUNOL, V33, P1215, DOI 10.1002/eji.200323844; Recio MJ, 2007, J IMMUNOL, V178, P2556, DOI 10.4049/jimmunol.178.4.2556; Rigaud S, 2006, NATURE, V444, P110, DOI 10.1038/nature05257; Roifman CM, 2010, J ALLERGY CLIN IMMUN, V126, P1226, DOI 10.1016/j.jaci.2010.07.029; Salmond RJ, 2009, IMMUNOL REV, V228, P9, DOI 10.1111/j.1600-065X.2008.00745.x; Sawabe T, 2001, INT J MOL MED, V7, P609; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Snow AL, 2010, IMMUNOL REV, V236, P68, DOI 10.1111/j.1600-065X.2010.00917.x; Sprent J, 2011, NAT IMMUNOL, V12, P478, DOI 10.1038/ni.2018; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Su HC, 2010, CURR OPIN ALLERGY CL, V10, P515, DOI 10.1097/ACI.0b013e32833fd718; Tewari K, 2006, P NATL ACAD SCI USA, V103, P16388, DOI 10.1073/pnas.0602565103; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791; Wiegers GJ, 2011, IMMUNOL CELL BIOL, V89, P33, DOI 10.1038/icb.2010.127; Willinger T, 2005, J IMMUNOL, V175, P5895, DOI 10.4049/jimmunol.175.9.5895	60	66	68	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1144	+		10.1016/j.jaci.2012.07.029	http://dx.doi.org/10.1016/j.jaci.2012.07.029			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	030LE	22985903				2022-12-18	WOS:000310571400016
J	Fukutomi, Y; Itagaki, Y; Taniguchi, M; Saito, A; Yasueda, H; Nakazawa, T; Hasegawa, M; Nakamura, H; Akiyama, K				Fukutomi, Yuma; Itagaki, Yasuharu; Taniguchi, Masami; Saito, Akemi; Yasueda, Hiroshi; Nakazawa, Takuya; Hasegawa, Maki; Nakamura, Hiroyuki; Akiyama, Kazuo			Rhinoconjunctival sensitization to hydrolyzed wheat protein in facial soap can induce wheat-dependent exercise-induced anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GLIADIN; HYPERSENSITIVITIES; IDENTIFICATION; SENSITIVITY		[Fukutomi, Yuma; Taniguchi, Masami; Saito, Akemi; Yasueda, Hiroshi; Nakazawa, Takuya; Hasegawa, Maki; Akiyama, Kazuo] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan; [Fukutomi, Yuma; Nakamura, Hiroyuki] Kanazawa Univ, Grad Sch Med Sci, Dept Environm & Prevent Med, Kanazawa, Ishikawa, Japan; [Itagaki, Yasuharu] Hokkaido Bunkyo Univ, Fac Human Sci, Dept Hlth & Nutr, Eniwa, Japan; [Itagaki, Yasuharu] Kanagawa Acad Sci & Technol, Food Safety & Reliabil Project, Kawasaki, Kanagawa, Japan	Kanazawa University; Kanagawa Academy Science & Technology	Fukutomi, Y (corresponding author), Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan.	y-fukutomi@sagamihara-hosp.gr.jp	Fukutomi, Yuma/AFQ-4306-2022	Fukutomi, Yuma/0000-0001-9913-4524				Fujimura T, 2007, ALLERGY, V62, P547, DOI 10.1111/j.1398-9995.2007.01331.x; Lauriere M, 2007, ALLERGY, V62, P890, DOI 10.1111/j.1398-9995.2007.01456.x; Lauriere M, 2006, CONTACT DERMATITIS, V54, P283, DOI 10.1111/j.0105-1873.2006.00830.x; Matsuo H, 2008, ALLERGY, V63, P233, DOI 10.1111/j.1398-9995.2007.01504.x; Matsuo H, 2005, CLIN EXP ALLERGY, V35, P461, DOI 10.1111/j.1365-2222.2005.02213.x; Palosuo K, 1999, J ALLERGY CLIN IMMUN, V103, P912, DOI 10.1016/S0091-6749(99)70438-0; Sandiford CP, 1997, CLIN EXP ALLERGY, V27, P1120, DOI 10.1046/j.1365-2222.1997.1310936.x; Snegaroff J, 2006, INT ARCH ALLERGY IMM, V139, P201, DOI 10.1159/000091165; Yasueda H, 1998, BIOCHEM BIOPH RES CO, V248, P240, DOI 10.1006/bbrc.1998.8944	9	66	68	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					531	533		10.1016/j.jaci.2010.09.035	http://dx.doi.org/10.1016/j.jaci.2010.09.035			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21094523				2022-12-18	WOS:000286808000033
J	Barton, SJ; Koppelman, GH; Vonk, JM; Browning, CA; Nolte, IM; Stewart, CE; Bainbridge, S; Mutch, S; Rose-Zerilli, MJ; Postma, DS; Maniatis, N; Henry, AP; Hall, IP; Holgate, ST; Tighe, P; Holloway, JW; Sayers, I				Barton, Sheila J.; Koppelman, Gerard H.; Vonk, Judith M.; Browning, Claudia A.; Nolte, Ilja M.; Stewart, Ceri E.; Bainbridge, Sue; Mutch, Stacey; Rose-Zerilli, Matthew J.; Postma, Dirkje S.; Maniatis, Nikolas; Henry, Amanda P.; Hall, Ian P.; Holgate, Stephen T.; Tighe, Patrick; Holloway, John W.; Sayers, Ian			PLAUR polymorphisms are associated with asthma, PLAUR levels, and lung function decline	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; susceptibility; PLAUR; remodeling	GENOME-WIDE SEARCH; PLASMINOGEN-ACTIVATOR; SUSCEPTIBILITY LOCI; FOUNDER POPULATION; ADAM33 GENE; FRENCH EGEA; SCREEN; FAMILIES; ATOPY; KERATINOCYTES	Background: Several studies have suggested that chromosome 19q13.1-3 contains asthma susceptibility genes. Objective: Linkage and association analyses using 587 United Kingdom and Dutch asthma families (n = 2819 subjects) were used to investigate this region. Methods: A 3-phase procedure was used: (1) linkage and association analyses using 15 microsatellite markers spanning 14.4 mega base pairs (Mbps) on 19q13, (2) fine mapping of the refined region using 26 haplotype tagging single nucleotide polymorphisms (SNPs), and (3) dense gene analyses using 18 SNPs evaluated for association with asthma, bronchial hyperresponsiveness (BHR), FEV1, plasma urokinase plasminogen activator receptor (PLAUR), and rate of annual FEV1 decline in subjects with asthma. Results: The microsatellite analyses provided tentative support for an asthma/lung function susceptibility locus (48.9-49.1Mbps), and fine mapping localized modest association to the PLAUR gene. PLAUR SNPs in the 5' region, intron 3, and 3' region are associated with asthma and BHR susceptibility and predict FEV1 and plasma PLAUR levels. SNPs in the 5' region showed association for asthma (2 populations), FEV1 (2 populations), and BHR (2 populations) phenotypes. SNPs in intron 3 showed association with asthma (2 populations) and BHR (3 populations). Importantly, the same 5' region and intron 3 SNPs were associated with plasma PLAUR levels. The same 5' region and 3' region SNPs were found to he determinants of FEV1 decline in subjects with asthma. Conclusion: This study represents the first report to identify PLAUR as a potential asthma susceptibility gene and determine PLAUR regions underlying this association, including a role in influencing plasma PLAUR levels. Finally, the association of PLAUR with lung function decline supports a role for PLAUR in airway remodeling in asthma. (J Allergy Clin Immunol 2009;123:1391-400.)	[Browning, Claudia A.; Stewart, Ceri E.; Henry, Amanda P.; Hall, Ian P.; Sayers, Ian] Univ Nottingham Hosp, Div Therapeut & Mol Med, Nottingham NG7 2UH, England; [Bainbridge, Sue; Mutch, Stacey; Tighe, Patrick] Univ Nottingham Hosp, Div Immunol, Nottingham NG7 2UH, England; [Barton, Sheila J.; Rose-Zerilli, Matthew J.; Holgate, Stephen T.; Holloway, John W.] Univ Southampton, Sch Med, Div Infect Inflammat & Immun, Southampton SO9 5NH, Hants, England; [Rose-Zerilli, Matthew J.; Holloway, John W.] Univ Southampton, Sch Med, Div Human Genet, Southampton SO9 5NH, Hants, England; [Koppelman, Gerard H.] Beatrix Childrens Hosp, Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, Groningen, Netherlands; [Vonk, Judith M.; Nolte, Ilja M.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 AB Groningen, Netherlands; [Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9700 AB Groningen, Netherlands; [Maniatis, Nikolas] UCL, Dept Biol, London WC1E 6BT, England	University of Nottingham; University of Nottingham; University of Southampton; University of Southampton; University of Groningen; University of Groningen; University of Groningen; University of London; University College London	Sayers, I (corresponding author), Univ Nottingham Hosp, Div Therapeut & Mol Med, Nottingham NG7 2UH, England.	ian.sayers@nottingham.ac.uk	Koppelman, Gerard/AAG-9187-2020; Vonk, Judith/K-8477-2019; Vonk, Judith M/ABA-3009-2020; Holloway, John W/B-5424-2009	Vonk, Judith/0000-0001-7531-4547; Vonk, Judith M/0000-0001-7531-4547; Holloway, John W/0000-0001-9998-0464; Tighe, Patrick/0000-0001-8326-093X; Stewart, Ceri/0000-0002-6214-2237; Maniatis, Nikolas/0000-0002-6567-5936; Barton, Sheila/0000-0003-4963-4242; Koppelman, Gerard/0000-0001-8567-3252; Hall, Ian/0000-0001-9933-3216; Sayers, Ian/0000-0001-5601-5410; Rose-Zerilli, Matthew/0000-0002-1064-5350; Henry, Amanda/0000-0001-6299-7676	Medical Research Council; Netherlands Asthma Foundation; MRC [G0400283, G0800766] Funding Source: UKRI; Medical Research Council [G0400283, G0800766, U1475000004] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Netherlands Asthma Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	I.S. is supported by the Medical Research Council (New Investigator Award), and the Dutch family studies were supported by The Netherlands Asthma Foundation. The Southampton Asthma Family Cohort was originally recruited in collaboration with Genome Therapeutics Corp and Schering-Plough.	Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Begin P, 2007, AM J RESP CRIT CARE, V175, P1109, DOI 10.1164/rccm.200607-1012OC; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Bouzigon E, 2004, HUM MOL GENET, V13, P3103, DOI 10.1093/hmg/ddh340; Brooks AM, 2006, AM J RESP CELL MOL, V35, P503, DOI 10.1165/rcmb.2006-0113OC; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P212, DOI 10.1067/mai.2001.117260; Chu EK, 2006, AM J RESP CELL MOL, V35, P628, DOI 10.1165/rcmb.2006-0040OC; de Arellano-Lopez AR, 1998, MAT SCI ENG A-STRUCT, V252, P93, DOI 10.1016/S0921-5093(98)00654-6; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812, DOI 10.1164/ajrccm.162.5.2002113; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.1938.x; JORDAN H, 1999, FOCUS, V21, P4; Koppelman GH, 2006, CURR ALLERGY ASTHM R, V6, P103, DOI 10.1007/s11882-006-0047-y; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Marsh DG, 1997, NAT GENET, V15, P389; MCNEILL H, 1990, CELL REGUL, V1, P843, DOI 10.1091/mbc.1.11.843; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; Postma DS, 2005, AM J RESP CRIT CARE, V172, P446, DOI 10.1164/rccm.200407-864OC; ROMER J, 1994, J INVEST DERMATOL, V102, P519, DOI 10.1111/1523-1747.ep12373187; Sayers I, 2003, THORAX, V58, P417, DOI 10.1136/thorax.58.5.417; SAYERS I, 2002, GENETICS ASTHMA WHAT, P138; SUSOL E, 2000, SNP MICROSATELLITE G, P49; Tapper W, 2005, P NATL ACAD SCI USA, V102, P11835, DOI 10.1073/pnas.0505262102; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Venanzi S, 2001, CLIN EXP ALLERGY, V31, P1220, DOI 10.1046/j.1365-2222.2001.01132.x; Wang IM, 2008, AM J RESP CRIT CARE, V177, P402, DOI 10.1164/rccm.200703-390OC; Xiao W, 2005, CHEST, V128, P2316, DOI 10.1378/chest.128.4.2316; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589	32	66	68	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1391	1400		10.1016/j.jaci.2009.03.014	http://dx.doi.org/10.1016/j.jaci.2009.03.014			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19443020				2022-12-18	WOS:000266799100034
J	von Gunten, S; Smith, DF; Cummings, RD; Riedel, S; Miescher, S; Schaub, A; Hamilton, RG; Bochner, BS				von Gunten, Stephan; Smith, David F.; Cummings, Richard D.; Riedel, Stefan; Miescher, Sylvia; Schaub, Alexander; Hamilton, Robert G.; Bochner, Bruce S.			Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG(2) subclass	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgG subclasses; gamma-globulin; anticarbohydrate antibodies; glycans; IgG(2); glycan microarray	INFLUENZAE TYPE-B; STREPTOCOCCUS-PNEUMONIAE; POLYSACCHARIDE ANTIGENS; CAPSULAR POLYSACCHARIDE; MARKERS	Background: Specificities for carbohydrate IgG antibodies, thought to be predominantly of the IgG(2) subclass, have never been broadly examined in healthy human subjects. Objective: To examine commercial intravenous immunoglobulin (IVIG) preparations for their ability to recognize a wide range of glycans and to determine the contribution of IgG(2) to the binding pattern observed. Methods: We used a glycan microarray to evaluate IVIG preparations and a control mix of similar proportions of human myeloma IgG, and IgG(2) for binding to 377 glycans, courtesy of the Consortium for Functional Glycomics Core H. Glycans recognized were categorized using public databases for their likely cellular sources. IgG(2) was depleted from IVIG by using immunoaffinity chromatography, and depletion was confirmed by using nephelometry and surface plasmon resonance. Results: Nearly half of the glycans bound IgG. Some of the glycans with the greatest antibody binding can be found in structures of human pathogenic bacteria (eg, Streptococcus pneumoniae, Mycobacterium tuberculosis, Vibrio cholera) and nonpathogenic bacteria, including LPS and lipoteichoic acid, capsular polysaccharides, and exopolysaccharides. Surprisingly, depletion of IgG(2) had only a modest effect on anticarbohydrate recognition patterns compared with the starting IVIG preparation. Little to no binding activity was detected to human endogenous glycans, including tumor-associated antigens. Conclusions: This novel, comprehensive analysis provides evidence that IVIG contains a much wider range than previously appreciated of anticarbohydrate IgG antibodies, including those recognizing both pathogenic and non-pathogen-associated prokaryotic glycans. (J Allergy Clin Immunol 2009; 123:1268-76.)	[von Gunten, Stephan; Hamilton, Robert G.; Bochner, Bruce S.] Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol,Dept Med, Baltimore, MD 21224 USA; [Riedel, Stefan; Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21224 USA; [Smith, David F.; Cummings, Richard D.] Emory Univ, Sch Med, Dept Biochem, Protein Carbohydrate Interact Core H Consortium F, Atlanta, GA 30322 USA; [Miescher, Sylvia; Schaub, Alexander] CSL Behring AG, Res & Dev, Bern, Switzerland	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Emory University; CSL	Bochner, BS (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol,Dept Med, 5501 Hopkins Bayview Circle,Room 2B-71, Baltimore, MD 21224 USA.	bbochner@jhmi.edu	Riedel, Stefan/ABF-4206-2021	von Gunten, Stephan/0000-0002-2753-8738	Swiss National Foundation [GM62116, PBBEB-113394]; Johns Hopkins University; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Johns Hopkins University(Johns Hopkins University); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grant number GM62116 to the Consortium for Functional Glycomics and grant number PBBEB-113394 from the Swiss National Foundation to Stephan von Gunten. B.S. Buchner received support from the Johns Hopkins University Department of Medicine as a Cosner Scholar in Translational Research.d	BARRETT DJ, 1986, CLIN EXP IMMUNOL, V63, P127; Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; Dube DH, 2005, NAT REV DRUG DISCOV, V4, P477, DOI 10.1038/nrd1751; HAMMARSTROM L, 1983, CLIN EXP IMMUNOL, V51, P600; JEFFERIS R, 1992, IMMUNOL LETT, V31, P143, DOI 10.1016/0165-2478(92)90141-A; LUCAS AH, 2008, VACCINE         0609, DOI DOI 10.1016/J.VACCINE.2008.05.055; Mikolajczyk MG, 2004, CLIN DIAGN LAB IMMUN, V11, P1158, DOI 10.1128/CDLI.11.6.1158-1164.2004; Paulson JC, 2006, NAT CHEM BIOL, V2, P238, DOI 10.1038/nchembio785; RIESEN WF, 1976, SCAND J IMMUNOL, V5, P383, DOI 10.1111/j.1365-3083.1976.tb00292.x; Schauer U, 2003, CLIN DIAGN LAB IMMUN, V10, P202, DOI 10.1128/CDLI.10.2.202-207.2003; SIBER GR, 1980, NEW ENGL J MED, V303, P178, DOI 10.1056/NEJM198007243030402; Snapper CM, 2006, CURR PROTEIN PEPT SC, V7, P295; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; von Gunten S, 2007, J ALLERGY CLIN IMMUN, V119, P1005, DOI 10.1016/j.jaci.2007.01.023; Wang DN, 2002, NAT BIOTECHNOL, V20, P275, DOI 10.1038/nbt0302-275; YOUNT WJ, 1968, J EXP MED, V127, P633, DOI 10.1084/jem.127.3.633	16	66	69	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1268	1276		10.1016/j.jaci.2009.03.013	http://dx.doi.org/10.1016/j.jaci.2009.03.013			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19443021	Green Accepted			2022-12-18	WOS:000266799100017
J	Steckelbroeck, S; Ballmer-Weber, BK; Vieths, S				Steckelbroeck, Stephan; Ballmer-Weber, Barbara K.; Vieths, Stefan			Potential, pitfalls, and prospects of food allergy diagnostics with recombinant allergens or synthetic sequential epitopes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						food hypersensitivity; component-resolved diagnosis; recombinant food allergen; sequential epitope; immunoblot inhibition; skin prick test; IgE quantification; sensitivity; specificity; cross-reactivity	SKIN PRICK TEST; LIPID TRANSFER PROTEIN; IGE-BINDING EPITOPES; IN-VITRO DIAGNOSIS; MILK-SPECIFIC IGE; COWS MILK; BIRCH-POLLEN; CROSS-REACTIVITY; DOUBLE-BLIND; PEANUT ALLERGEN	This article aims to critically review developments in food allergy diagnostics with regard to the verification of specific IgE antibodies and the identification of the responsible allergens. Results of IgE-binding tests with food extracts are hampered by cross-reactive proteins, low-quality test agents, or both. Specificity can be increased by defining adequate cutoff values, whereas sensitivity can be improved by using high-quality test agents. IgE-binding tests with purified allergens enabled reliable quantification of allergen-specific IgE titers, with higher levels found in individuals with food allergy compared with individuals without food allergy. However, the overlap in individual test reactivity between allergic and nonallergic subjects complicates interpretation. Recombinant allergens and synthetic sequential epitopes enabled detection of sensitization profiles, with IgE specific to several allergens and substructures now being suggested as markers of severity, persistence, or both. However, high-power quantitative studies with larger numbers of patients are required to confirm these markers. IgE-binding tests merely indicate sensitization, whereas the final proof of clinical relevance still relies on family/case history, physical examinations, and provocation tests. Novel technologies promise superior diagnostics. Microarray technology permits simultaneous measurement of multiple IgE reactivities regarding specificity, abundance, reactivity, or interaction. Improved functional tests might enable reliable estimation of the clinical relevance of IgE sensitizations at justifiable expenses.	[Steckelbroeck, Stephan; Vieths, Stefan] Paul Ehrlich Inst, Dept Allergol, D-63225 Langen, Germany; [Ballmer-Weber, Barbara K.] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland	Paul Ehrlich Institute; University of Zurich; University Zurich Hospital	Vieths, S (corresponding author), Paul Ehrlich Inst, Dept Allergol, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	viest@pei.de						AALBERSE RC, 1991, EUR RESPIR J, V4, pS78; Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Aalberse Rob C, 2007, Clin Mol Allergy, V5, P2, DOI 10.1186/1476-7961-5-2; AAS K, 1978, CLIN ALLERGY, V8, P39, DOI 10.1111/j.1365-2222.1978.tb00446.x; Akkerdaas JH, 2003, INT ARCH ALLERGY IMM, V132, P132, DOI 10.1159/000073714; *AM AC ALL IMM, 1992, J ALLERGY CLIN IMMUN, V90, P263; Andersson K, 2007, ALLERGY, V62, P897, DOI 10.1111/j.1398-9995.2007.01450.x; Asero R, 1996, J ALLERGY CLIN IMMUN, V97, P611, DOI 10.1016/S0091-6749(96)70306-8; Asero R, 1998, J ALLERGY CLIN IMMUN, V101, P427, DOI 10.1016/S0091-6749(98)70261-1; Asero R, 2007, MOL NUTR FOOD RES, V51, P135, DOI 10.1002/mnfr.200600132; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Ballmer-Weber BK, 2007, J ALLERGY CLIN IMMUN, V119, P1489, DOI 10.1016/j.jaci.2007.01.049; Ballmer-Weber BK, 2005, CLIN EXP ALLERGY, V35, P970, DOI 10.1111/j.1365-2222.2005.02294.x; Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Bannon GA, 2006, MOL NUTR FOOD RES, V50, P638, DOI 10.1002/mnfr.200500276; BARNETT D, 1983, J ALLERGY CLIN IMMUN, V72, P61, DOI 10.1016/0091-6749(83)90053-2; Battais F, 2005, ALLERGY, V60, P815, DOI 10.1111/j.1398-9995.2005.00795.x; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; Beyer K, 2005, J ALLERGY CLIN IMMUN, V116, P704, DOI 10.1016/j.jaci.2005.05.007; BIRK HW, 1987, ANAL BIOCHEM, V164, P12, DOI 10.1016/0003-2697(87)90360-5; Bohle B, 2004, MOL NUTR FOOD RES, V48, P424, DOI 10.1002/mnfr.200400003; Bohle B, 2003, EUR J IMMUNOL, V33, P3303, DOI 10.1002/eji.200324321; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Bonds RS, 2008, CURR OPIN ALLERGY CL, V8, P82, DOI 10.1097/ACI.0b013e3282f4177e; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Chen HD, 1996, ALLERGY ASTHMA PROC, V17, P143, DOI 10.2500/108854196779165058; CHUA YY, 1976, J ALLERGY CLIN IMMUN, V58, P477, DOI 10.1016/0091-6749(76)90191-3; CRESPO JF, 1994, ALLERGY PROC, V15, P73, DOI 10.2500/108854194778703099; Crespo JF, 2004, MOL NUTR FOOD RES, V48, P347, DOI 10.1002/mnfr.200400019; DANNAEUS A, 1979, ACTA PAEDIATR SCAND, V68, P377, DOI 10.1111/j.1651-2227.1979.tb05023.x; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; Deinhofer K, 2004, METHODS, V32, P249, DOI 10.1016/j.ymeth.2003.08.018; Dias RP, 2008, PEDIATR ALLERGY IMMU, V19, P86, DOI 10.1111/j.1399-3038.2007.00582.x; DOUGLASS JA, 2006, MED J AUSTRALIA, V21, P228; Ebo DG, 2001, ACTA CLIN BELG, V56, P234, DOI 10.1179/acb.2001.035; Eiwegger T, 2006, CLIN EXP ALLERGY, V36, P1281, DOI 10.1111/j.1365-2222.2006.02565.x; El-Khouly F, 2007, PEDIAT ALLERG IMM-UK, V18, P607, DOI 10.1111/j.1399-3038.2007.00542.x; Erdmann SM, 2005, INT ARCH ALLERGY IMM, V136, P230, DOI 10.1159/000083949; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P423, DOI 10.1016/j.jaci.2007.10.009; Gamboa PM, 2007, ALLERGY, V62, P408, DOI 10.1111/j.1398-9995.2006.01284.x; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Grodzinsky E, 2001, CLIN DIAGN LAB IMMUN, V8, P564, DOI 10.1128/CDLI.8.3.564-570.2001; HAAHTELA TMK, 1979, CLIN ALLERGY, V9, P53, DOI 10.1111/j.1365-2222.1979.tb01522.x; Hansen TK, 1997, ANN ALLERG ASTHMA IM, V78, P187, DOI 10.1016/S1081-1206(10)63386-8; HARWANEGG C, 2006, ALLERG IMMUNOL PARIS, V38, P232; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193, DOI 10.1159/000235213; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; Hoffmann-Sommergruber K, 1999, J ALLERGY CLIN IMMUN, V104, P478, DOI 10.1016/S0091-6749(99)70397-0; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; James JM, 1997, ANN ALLERG ASTHMA IM, V79, P131, DOI 10.1016/S1081-1206(10)63099-2; Jarvinen KM, 2001, INT ARCH ALLERGY IMM, V126, P111, DOI 10.1159/000049501; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Kagan R, 2003, ANN ALLERG ASTHMA IM, V90, P640, DOI 10.1016/S1081-1206(10)61869-8; KALACH N, 2007, ALLERG IMMUNOL PARIS, V39, P51; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; Kim TE, 2002, YONSEI MED J, V43, P613, DOI 10.3349/ymj.2002.43.5.613; KJELLMAN NIM, 1982, ALLERGY, V37, P463; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.128946; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; LESSOF MH, 1980, CLIN ALLERGY, V10, P115, DOI 10.1111/j.1365-2222.1980.tb02088.x; Liccardi G, 2006, J INVEST ALLERG CLIN, V16, P75; Lidholm J, 2006, CURR OPIN ALLERGY CL, V6, P234, DOI 10.1097/01.all.0000225166.90768.d6; Lin J, 2007, CLIN EXP ALLERGY, V37, P1854, DOI 10.1111/j.1365-2222.2007.02803.x; Mari A, 2005, CURR OPIN ALLERGY CL, V5, P267, DOI 10.1097/01.all.0000168793.27948.b0; Matsuo H, 2005, J IMMUNOL, V175, P8116, DOI 10.4049/jimmunol.175.12.8116; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; Mine Y, 2002, BIOCHEM BIOPH RES CO, V292, P1070, DOI 10.1006/bbrc.2002.6725; Mittag D, 2006, MOL IMMUNOL, V43, P268, DOI 10.1016/j.molimm.2005.02.008; Mittag D, 2004, MOL NUTR FOOD RES, V48, P380, DOI 10.1002/mnfr.200400016; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; Mondoulet L, 2005, J AGR FOOD CHEM, V53, P4547, DOI 10.1021/jf050091p; Neudecker P, 2003, BIOCHEM J, V376, P97, DOI 10.1042/BJ20031057; Neudecker P, 2001, J BIOL CHEM, V276, P22756, DOI 10.1074/jbc.M101657200; Niggemann B, 2005, ALLERGY, V60, P865, DOI 10.1111/j.1398-9995.2005.00828.x; Niggemann B, 2004, J INVEST ALLERG CLIN, V14, P98; NORGAARD A, 1995, ALLERGY, V50, P636, DOI 10.1111/j.1398-9995.1995.tb02580.x; Nowak-Wegrzyn A, 2007, NESTLE NUTR WORKS SE, V59, P17, DOI 10.1159/000098510; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; Osterballe M, 2003, J ALLERGY CLIN IMMUN, V112, P196, DOI 10.1067/mai.2003.1603; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Pastorello EA, 2004, MOL NUTR FOOD RES, V48, P356, DOI 10.1002/mnfr.200400047; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Petersen AB, 2004, CLIN BIOCHEM, V37, P882, DOI 10.1016/j.clinbiochem.2004.06.010; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Ramesh S, 2008, CLIN REV ALLERG IMMU, V34, P217, DOI 10.1007/s12016-007-8034-1; Rance F, 1997, ALLERGY, V52, P1031, DOI 10.1111/j.1398-9995.1997.tb02427.x; Reese G, 2001, J CHROMATOGR B, V756, P157, DOI 10.1016/S0378-4347(01)00104-9; Reuter A, 2006, CLIN EXP ALLERGY, V36, P815, DOI 10.1111/j.1365-2222.2006.2492.x; Ricci G, 2003, ALLERGY, V58, P38, DOI 10.1034/j.1398-9995.2003.23761.x; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; ROGER A, 1994, J INVEST ALLERG CLIN, V4, P178; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; RUDESCHKO O, 1995, ALLERGY, V50, P575, DOI 10.1111/j.1398-9995.1995.tb01202.x; Saarinen KM, 2005, J ALLERGY CLIN IMMUN, V116, P869, DOI 10.1016/j.jaci.2005.06.018; Saarinen KM, 2001, CLIN EXP ALLERGY, V31, P423, DOI 10.1046/j.1365-2222.2001.01015.x; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Scheurer S, 2004, J ALLERGY CLIN IMMUN, V114, P900, DOI 10.1016/j.jaci.2004.06.017; Schmid-Grendelmeier P, 2001, INT ARCH ALLERGY IMM, V125, P96, DOI 10.1159/000053803; Schocker F, 2004, J ALLERGY CLIN IMMUN, V113, P141, DOI 10.1016/j.jaci.2003.09.013; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; SMITH TF, 1992, ANN ALLERGY, V68, P293; Son DY, 1999, EUR J NUTR, V38, P201, DOI 10.1007/s003940050063; Spuergin P, 1996, ALLERGY, V51, P306, DOI 10.1111/j.1398-9995.1996.tb00090.x; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; Valent P, 2004, METHODS, V32, P265, DOI 10.1016/j.ymeth.2003.08.006; Van Ree R, 2008, ALLERGY, V63, P310, DOI 10.1111/j.1398-9995.2007.01612.x; Vassilopoulou E, 2006, J ALLERGY CLIN IMMUN, V118, P473, DOI 10.1016/j.jaci.2006.04.057; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Vieths S, 1998, ALLERGY, V53, P65, DOI 10.1111/j.1398-9995.1998.tb04965.x; Visco V, 1996, J IMMUNOL, V157, P956; Wedemeyer J, 2000, BRIT MED BULL, V56, P936, DOI 10.1258/0007142001903616; Wickman M, 2005, ALLERGY, V60, P650, DOI 10.1111/j.1398-9995.2004.00764.x; WIDE L, 1967, LANCET, V2, P1105; Yman L, 1985, Allergy, V40 Suppl 4, P8, DOI 10.1111/j.1398-9995.1985.tb04163.x	141	66	70	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1323	1330		10.1016/j.jaci.2008.04.008	http://dx.doi.org/10.1016/j.jaci.2008.04.008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18472149	Green Accepted			2022-12-18	WOS:000256771700003
J	Kim, HJ; Barajas, B; Wang, MY; Nel, AE				Kim, Hyon-Jeen; Barajas, Berenice; Wang, Meiying; Nel, Andre E.			Nrf2 activation by sulforaphane restores the age-related decrease of T(H)1 immunity: Role of dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aging; redox equilibrium; cellular immunity; dendritic cells; Nrf2; glutathione; N-acetyl cysteine; sulforaphane	DELAYED-TYPE HYPERSENSITIVITY; EXHAUST PARTICLE CHEMICALS; ANTIGEN-PRESENTING CELLS; T-CELLS; CONTACT SENSITIZERS; DISEASE; MICE; DIFFERENTIATION; ANTIOXIDANTS; MATURATION	Background: The decrease in cellular immunity with aging is of considerable public health importance. Recent studies suggest that the redox equilibrium of dendritic cells (DCs) is a key factor in maintaining protective cellular immunity and that a disturbance of this homeostatic mechanism could contribute to immune senescence. Objectives: We sought (1) to elucidate the role of DC redox equilibrium in the decrease of contact hypersensitivity (CHS) and T(H)1 immunity during aging and (2) to determine how restoration of glutathione (GSH) levels by the Nrf2-mediated antioxidant defense pathway affects this decrease. Methods: We assessed the effect of Nrf2 deficiency and boosting of GSH levels by the Nrf2 agonist sulforaphane or the thiol precursor N-acetyl cysteine (NAC) on the CHS response to contact antigens in old mice. We studied the effect of SFN and NAC on restoring T(H)1 immunity by treating DCs ex vivo before adoptive transfer and in vivo challenge. Results: Aging was associated with a decreased CHS response that was accentuated by Nrf2 deficiency. Systemic SFN treatment reversed this decrease through Nrf2-mediated antioxidant enzyme expression and GSH synthesis. Adoptive transfer of DCs from old animals induced a weakened CHS response in recipient animals. Treatment of DCs from old animals with SFN or NAC ex vivo restored the in vivo challenge response. Conclusion: SFN and NAC upregulate T(H)1 immunity in aging through a restoration of redox equilibrium.	[Kim, Hyon-Jeen; Barajas, Berenice; Wang, Meiying; Nel, Andre E.] Univ Calif Los Angeles, Dept Med, Div NanoMed, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Nel, AE (corresponding author), Univ Calif Los Angeles, Dept Med, Div NanoMed, Los Angeles, CA 90095 USA.	anel@mednet.ucla.edu	Nel, Andre E/J-2808-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028748, R01AG014992] Funding Source: NIH RePORTER; NIAID NIH HHS [U19 AI070453] Funding Source: Medline; NIA NIH HHS [5P30 AG028748, R01 AG014992, P30 AG028748, R01 AG14992] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; Becker D, 2003, J INVEST DERMATOL, V120, P233, DOI 10.1046/j.1523-1747.2003.12026.x; Bruchhausen S, 2003, J INVEST DERMATOL, V121, P1039, DOI 10.1046/j.1523-1747.2003.12510.x; CHAN K, 1997, P NATL ACAD SCI USA, V96, P12731; Chan RCF, 2006, J ALLERGY CLIN IMMUN, V118, P455, DOI 10.1016/j.jaci.2006.06.006; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; Fulop T, 2003, ARTHRITIS RES THER, V5, P290, DOI 10.1186/ar1019; GASPARI AA, 2003, CURRENT PROTOCOLS IM; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hirayama A, 2003, FREE RADICAL BIO MED, V34, P1236, DOI 10.1016/S0891-5849(03)00073-X; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kantengwa S, 2003, AM J RESP CRIT CARE, V167, P431, DOI 10.1164/rccm.200205-425OC; Kim HJ, 2005, J IMMUNOL, V175, P2948, DOI 10.4049/jimmunol.175.5.2948; Kim HJ, 2007, J ALLERGY CLIN IMMUN, V119, P1225, DOI 10.1016/j.jaci.2007.01.016; Lane N, 2003, J THEOR BIOL, V225, P531, DOI 10.1016/S0022-5193(03)00304-7; Li J, 2004, PHYSIOL GENOMICS, V18, P261, DOI 10.1152/physiolgenomics.00209.2003; Lung TL, 2000, VACCINE, V18, P1606, DOI 10.1016/S0264-410X(99)00494-6; Meydani M, 1998, ANN NY ACAD SCI, V854, P352, DOI 10.1111/j.1749-6632.1998.tb09915.x; Miller Carla, 1994, Aging Immunology and Infectious Disease, V5, P249; Pawelec G, 1998, J LEUKOCYTE BIOL, V64, P703, DOI 10.1002/jlb.64.6.703; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Rivollier A, 2006, MOL CELL PROTEOMICS, V5, P726, DOI 10.1074/mcp.M500262-MCP200; Sarnstrand B, 1999, J PHARMACOL EXP THER, V288, P1174; Shih PH, 2007, BIOGERONTOLOGY, V8, P71, DOI 10.1007/s10522-006-9033-y; Shurin MR, 2007, CRIT REV ONCOL HEMAT, V64, P90, DOI 10.1016/j.critrevonc.2007.03.002; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790; Thoren FB, 2007, J IMMUNOL, V179, P21, DOI 10.4049/jimmunol.179.1.21; Wallet MA, 2005, CLIN MED RES, V3, P166, DOI 10.3121/cmr.3.3.166; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200	31	66	71	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1255	1261		10.1016/j.jaci.2008.01.016	http://dx.doi.org/10.1016/j.jaci.2008.01.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18325578	Green Accepted			2022-12-18	WOS:000255961700027
J	Wershil, BK; Furuta, GT				Wershil, Barry K.; Furuta, Glenn T.			Gastrointestinal mucosal immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mucosal immunity; oral tolerance	DENDRITIC CELLS; INTESTINAL IGA; T-CELLS; TOLERANCE; RESPONSES; ANTIGEN	Mucosal surfaces constitute a large host-environmental interface that must be protected from pathogenic organisms. The mucosal immune system has evolved as a distinct immune organ functioning independently from its systemic counterpart. The mucosal immune system has the difficult task of mounting protective responses to invading microorganisms while maintaining a state of nonresponsiveness to commensal bacteria and food antigens. The system has unique cellular components and functional aspects that permit it to carry out this dual role.	[Wershil, Barry K.] Childrens Hosp, Div Pediat Gastroenterol & Nutr, Albert Einstein Coll Med, Bronx, NY USA; [Furuta, Glenn T.] Univ Colorado, Sch Med, Denver, CO 80202 USA; [Furuta, Glenn T.] Childrens Hosp, Sect Pediat Gastroenterol, Denver, CO USA	Yeshiva University; Albert Einstein College of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado	Furuta, GT (corresponding author), Childrens Hosp, 13123 E Colfax Ave B290, Aurora, CO 80045 USA.	furuta.glenn@tchden.org						Allez M, 2002, GASTROENTEROLOGY, V123, P1516, DOI 10.1053/gast.2002.36588; Bilsborough J, 2004, GASTROENTEROLOGY, V127, P300, DOI 10.1053/j.gastro.2004.01.028; Bowman EP, 2002, J EXP MED, V195, P269, DOI 10.1084/jem.20010670; Chen YP, 2002, P NATL ACAD SCI USA, V99, P14338, DOI 10.1073/pnas.212290499; Cheroutre H, 2004, ANNU REV IMMUNOL, V22, P217, DOI 10.1146/annurev.immunol.22.012703.104522; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Dahan S, 2007, IMMUNOL REV, V215, P243, DOI 10.1111/j.1600-065X.2006.00484.x; Debard N, 2001, GASTROENTEROLOGY, V120, P1173, DOI 10.1053/gast.2001.22476; Ericksen B, 2005, ANTIMICROB AGENTS CH, V49, P269, DOI 10.1128/AAC.49.1.269-275.2005; Fagarasan S, 2004, CURR OPIN IMMUNOL, V16, P277, DOI 10.1016/j.coi.2004.03.005; Fagarasan S, 2003, NAT REV IMMUNOL, V3, P63, DOI 10.1038/nri982; FU YX, 1999, ANNU REV IMMUNOL, V17, P173; Jang MH, 2004, P NATL ACAD SCI USA, V101, P6110, DOI 10.1073/pnas.0400969101; Koon HW, 2006, ANN NY ACAD SCI, V1088, P23, DOI 10.1196/annals.1366.024; Kunkel D, 2003, EUR J IMMUNOL, V33, P1292, DOI 10.1002/eji.200323383; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Mestecky J, 1999, GUT, V44, P2, DOI 10.1136/gut.44.1.2; Miller H, 2007, WORLD J GASTROENTERO, V13, P1477, DOI 10.3748/wjg.v13.i10.1477; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Neutra MR, 2001, NAT IMMUNOL, V2, P1004, DOI 10.1038/ni1101-1004; Niess JH, 2006, CURR OPIN GASTROEN, V22, P354, DOI 10.1097/01.mog.0000231807.03149.54; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x	25	66	74	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		2			S380	S383		10.1016/j.jaci.2007.10.023	http://dx.doi.org/10.1016/j.jaci.2007.10.023			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266IB	18241686				2022-12-18	WOS:000253426600005
J	Leynaert, B; Guilloud-Bataille, M; Soussan, D; Benessiano, J; Guenegou, A; Pin, I; Neukirch, F				Leynaert, Benedicte; Guilloud-Bataille, Monique; Soussan, David; Benessiano, Joelle; Guenegou, Armelle; Pin, Isabelle; Neukirch, Francoise			Association between farm exposure and atopy, according to the CD14 C-159T polymorphism	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						gene; asthma; allergic rhinitis; immunologic sensitization; epidemiologic studies	HOUSE-DUST ENDOTOXIN; SOLUBLE CD14; PROMOTER POLYMORPHISM; EARLY-LIFE; ASTHMA; GENE; CHILDREN; ALLERGY; IGE; SENSITIZATION	Background: A higher exposure to bacterial compounds is purported to explain the lower prevalence of allergy in farm children, but responsiveness to bacterial compounds is modulated by genetic factors. Objective: To assess whether the protective effect of farm exposure on atopy is influenced by a CD14 promoter functional polymorphism. Methods: We administered a detailed questionnaire on farm exposure in childhood and genotyped the CD14 C-159T polymorphism in 2 French centers participating in the European Community Respiratory Health Survey (ECRHS)-II. Results: Six hundred randomly selected young adults provided blood samples for IgE measurements and had CD14 C-159T genotyped. Exposure to a farming environment in early life was associated with a reduced risk of nasal allergies (odds ratio [OR], 0.54; 95% CI, 0.29-1.00) and atopic sensitization (OR, 0.47; 95% CI, 0.24-0.93) in adulthood. A lower risk of allergic rhinitis and atopy was also observed in carriers of the CD14-159TT genotype compared with -159CC subjects (OR, 0.52; 95% CI, 0.30-0.88; and OR, 0.54; 95% CI, 0.31-0.92, respectively). When farm exposure and CD14 C-159T were considered together, the risk of nasal allergies and atopy was the most reduced in the subjects who combined both an early-life exposure to a farming environment and the -159TT genotype (OR, 0.26; 95% CI, 0.07-0.94; and OR, 0.21; 95% CI, 0.05-0.93, respectively, vs nonexposed -159CC+CT subjects). The results were consistent in the 2 centers, supporting the validity of the results. Conclusion: A gene-by-environment interaction between CD14 C-159T and environmental exposure in childhood may modify the development of atopy. Clinical implications: This polymorphism should be considered in interventions studies that use microbial stimuli to reduce sensitization.	Univ Paris 07, INSERM, Unite Epidemiol 700, F-75018 Paris, France; Hop Xavier Bichat, APHP, Ctr Invest Clin, Paris, France; CHU Grenoble, Dept Pediat, F-38043 Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Leynaert, B (corresponding author), Univ Paris 07, INSERM, Unite Epidemiol 700, 16 Rue Henri Huchard, F-75018 Paris, France.	leynaert@bichat.inserm.fr	Leynaert, Benedicte/N-5251-2018; PIN, Isabelle/N-3020-2013; ARNOUX, Armelle GUENEGOU/AAL-8094-2021	ARNOUX, Armelle GUENEGOU/0000-0003-3427-7086; Leynaert, Benedicte/0000-0001-5045-2492				AMELUNG PJ, 2000, AM J RESP CRIT CARE, V161, pA927; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Baldini M, 2002, ALLERGY, V57, P188, DOI 10.1034/j.1398-9995.2002.1r152.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Buckova D, 2003, ALLERGY, V58, P1023, DOI 10.1034/j.1398-9995.2003.00271.x; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Gehring U, 2003, AM J RESP CRIT CARE, V167, P91, DOI 10.1164/ajrccm.167.1.363; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Jones CA, 2002, J ALLERGY CLIN IMMUN, V109, P858, DOI 10.1067/mai.2002.123535; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Kedda MA, 2005, THORAX, V60, P211, DOI 10.1136/thx.2004.028449; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Leung TF, 2003, PEDIAT ALLERG IMM-UK, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829, DOI 10.1164/ajrccm.164.10.2103137; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P1056, DOI 10.1016/j.jaci.2005.02.006; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Matricardi PM, 2003, CLIN EXP ALLERGY, V33, P717, DOI 10.1046/j.1365-2222.2003.01695.x; O'Donnell AR, 2004, AM J RESP CRIT CARE, V169, P615, DOI 10.1164/rccm.200302-278OC; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; Tulic MK, 2004, LANCET, V363, P1689, DOI 10.1016/S0140-6736(04)16253-3; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	34	66	66	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					658	665		10.1016/j.jaci.2006.06.015	http://dx.doi.org/10.1016/j.jaci.2006.06.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950285				2022-12-18	WOS:000240649000019
J	Rossi, AB; Herlaar, E; Braselmann, S; Huynh, S; Taylor, V; Frances, R; Issakani, SD; Argade, A; Singh, R; Payan, DG; Masuda, ES				Rossi, Alexander B.; Herlaar, Ellen; Braselmann, Sylvia; Huynh, Stacey; Taylor, Vanessa; Frances, Roy; Issakani, Sarkiz D.; Argade, Ankush; Singh, Rajinder; Payan, Donald G.; Masuda, Esteban S.			Identification of the Syk kinase inhibitor R112 by a human mast cell screen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Syk; Fc receptors; IgE; histamine; tryptase; cytokines; mast cells; allergic rhinitis; small molecule inhibitor; steroids	SIGNAL-TRANSDUCTION; IGE; DEGRANULATION; FAMILY	Background: Activation of the IgE receptor, Fc epsilon RI, in mast cells is the key mechanism initiating and propagating pathophysiological responses in allergic rhinitis. Objective: Identify and characterize a small molecule inhibitor of IgE-dependent mast cell activation for the treatment of allergic diseases. Methods: A cell-based high-throughput screen for small molecules that block IgE signaling was performed in cultured human mast cells. A potent inhibitor, referred to as R112, was selected and characterized by using biochemical and cell-based assays. R112 effects on IgE-dependent degranulation and cytokine production was measured in mast cells and basophils and compared with other mast cell inhibitors. Results: R112 inhibited degranulation induced by anti-IgE cross-linking in mast cells (tryptase release, effective concentration for 50% inhibition [EC50] = 353 nmol/L) or basophils (histamine release, EC50 = 280 mnol/L), and by allergen (dust mile) in basophils (histamine release, EC50 = 490 muol/L). R112 also blocked leukotriene C4 production and all proinflammatory cytokines tested. Subsequent molecular characterization indicated that R112 is an ATP-competitive spleen tyrosine kinase (Syk) inhibitor (inhibitory constant [K-i] = 96 muol/L). Its onset of action was immediate, and the inhibition was reversible. Incubation of mast cells with R112 showed that cytokine production in mast cells was dependent on sustained activation of the Fc epsilon RI-Lyn-spleen tyrosine kinase pathway. Unlike other mast cell inhibitors, R112 was able to completely inhibit all three IgE-induced mast cell functions: degranulation, lipid mediator production, and cytokine production. Conclusion: R112 potently, completely, and rapidly abrogated all mast cell activation cascades triggered by IgE receptor cross-linking. Clinical implications: R112 and its analogues offer a new modality in the treatment of allergic rhinitis.	Rigel Pharmaceut, San Francisco, CA 94080 USA		Masuda, ES (corresponding author), Rigel Pharmaceut, 1180 Vet Blvd, San Francisco, CA 94080 USA.	emasuda@rigel.com		Masuda, Esteban/0000-0002-3175-2868				BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; Bingham CO, 2000, J ALLERGY CLIN IMMUN, V105, pS527, DOI 10.1016/S0091-6749(00)90056-3; Boyce JA, 2003, J ALLERGY CLIN IMMUN, V111, P24, DOI 10.1067/mai.2003.60; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HIDE I, 1993, J CELL BIOL, V123, P585, DOI 10.1083/jcb.123.3.585; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Holgate ST, 2003, NAT REV DRUG DISCOV, V2, P903, DOI 10.1038/nrd1224; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Law CL, 1996, MOL CELL BIOL, V16, P1305; MacGlashan D, 2005, ANN NY ACAD SCI, V1050, P73, DOI 10.1196/annals.1313.009; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V115, P791, DOI 10.1016/j.jaci.2005.01.040; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Nadler MJS, 2002, NAT IMMUNOL, V3, P707, DOI 10.1038/ni0802-707; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; SAITO H, 1995, INT ARCH ALLERGY IMM, V107, P63, DOI 10.1159/000236932; Saitoh S, 2003, J EXP MED, V198, P831, DOI 10.1084/jem.20030574; SAYAMA K, 2002, BMC IMMUNOL, V3, P1; Siraganian RP, 2003, CURR OPIN IMMUNOL, V15, P639, DOI 10.1016/j.coi.2003.09.010; Wong BR, 2004, EXPERT OPIN INV DRUG, V13, P743, DOI 10.1517/13543784.13.7.743; Yamamoto N, 2003, J PHARMACOL EXP THER, V306, P1174, DOI 10.1124/jpet.103.052316	25	66	78	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					749	755		10.1016/j.jaci.2006.05.023	http://dx.doi.org/10.1016/j.jaci.2006.05.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950297				2022-12-18	WOS:000240649000033
J	Murphy, S; Roberts, R				Murphy, S; Roberts, R			"Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food and Drug Administration; adverse drug reactions; MedWatch; "black box" warning; drug labeling; drug benefit/risk; risk management; postmarketing surveillance; drug development	BLACK-BOX WARNINGS; PRESCRIPTION; SURVEILLANCE; WITHDRAWALS; SAFETY; IMPACT	A prominently displayed boxed warning, the so-called "black box," is added to the labeling of drugs or drug products by the Food and Drug Administration when serious adverse reactions or special problems occur, particularly those that may lead to death or serious injury. Healthcare providers are often not knowledgeable about the origin, meaning, and implications of these "black box" warnings. In this review, our goal is to provide insight into how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. We discuss drug labeling, the emphasis on safety throughout the drug approval process, legislative initiatives for safe use of drugs in children, and postmarketing safety surveillance. In addition, we encourage health care providers to report drug reactions to the Food and Drug Administration's MedWatch program. A discussion of new Food and Drug Administration initiatives to improve drug safety processes and methods to serve the public better are highlighted.	US FDA, Ctr Drug Evaluat & Res, Off Counter Terrorism & Pediat Drug Dev, Silver Spring, MD USA	US Food & Drug Administration (FDA)	Murphy, S (corresponding author), 10903 New Hampshire Ave,Bldg 21, Silver Spring, MD 20993 USA.	murphys@cder.fda.gov						Ahmad SR, 2003, J GEN INTERN MED, V18, P57, DOI 10.1046/j.1525-1497.2003.20130.x; Avorn J, 2005, NEW ENGL J MED, V353, P969, DOI 10.1056/NEJMp058174; Beach JE, 1998, FOOD DRUG LAW J, V53, P403; CDER, 2004, REP NAT IMPR PUBL HL; Fontanarosa PB, 2004, JAMA-J AM MED ASSOC, V292, P2647, DOI 10.1001/jama.292.21.2647; Hasford J, 2002, J CLIN EPIDEMIOL, V55, P945, DOI 10.1016/S0895-4356(02)00450-X; Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215; Shatin D, 2005, PHARMACOEPIDEM DR S, V14, P149, DOI 10.1002/pds.961; Temple RJ, 2002, JAMA-J AM MED ASSOC, V287, P2273, DOI 10.1001/jama.287.17.2273; Trontell A, 2004, NEW ENGL J MED, V351, P1385, DOI 10.1056/NEJMp048187; *US FDA, 2005, MPH BEF COMM GOVT RE; Weatherby LB, 2002, CLIN PHARMACOL THER, V72, P735, DOI 10.1067/mcp.2002.129503; Willy ME, 2004, PHARMACOEPIDEM DR S, V13, P201, DOI 10.1002/pds.856; Wysowski DK, 2005, ARCH INTERN MED, V165, P1363, DOI 10.1001/archinte.165.12.1363	14	66	68	1	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					34	39		10.1016/j.jaci.2005.10.031	http://dx.doi.org/10.1016/j.jaci.2005.10.031			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387581	Bronze			2022-12-18	WOS:000235687100006
J	Busse, PJ; Zhang, TF; Srivastava, K; Lin, BP; Schofield, B; Sealfon, SC; Li, XM				Busse, PJ; Zhang, TF; Srivastava, K; Lin, BP; Schofield, B; Sealfon, SC; Li, XM			Chronic exposure to TNF-alpha increases airway mucus gene expression in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; mucus; MUC-5AC; gob-5; TNF-alpha	NECROSIS-FACTOR-ALPHA; GOBLET CELL HYPERPLASIA; INDUCIBLE NITRIC-OXIDE; LUNG EPITHELIAL-CELLS; MUCIN HYPERSECRETION; ASTHMA; MICE; INFLAMMATION; ACTIVATION; RESPONSES	Background: Hypersecretion of mucus plays an important role in the pathogenesis and severity of asthma. The primary proteins in mucus are mucin glycoproteins; MUC-5AC is the primary airway mucin gene. The calcium chloride-activated channel gene hCLCA1 (gob-5 in the mouse) has been suggested to increase MUC-5AC gene expression, and both are increased in asthmatic patients and murine models. TNF-alpha increases the expression of these genes in vitro but has not been investigated in vivo. Objective: We sought to determine whether TNF-a increases gene expression of gob-5 and MUC-5AC and induces mucus cell metaplasia in vivo. Methods: Naive BALB/c mice received 50 ng of recombinant murine TNF-alpha (rmTNF-alpha) intratracheally daily for 1, 2, or 3 weeks; another group received the same dose of intratracheal rmTNF-alpha daily for 3 weeks and then alternate-day treatment for 3 additional weeks (total of 6 weeks). AKR mice received 50 ng of rmTNF-alpha intratracheally for 3 or 6 weeks daily. Naive nontreated mice were used as control animals. Airway gene products for gob-5 and MUC-5AC were determined by means of real-time PCR. Lung tissue sections were stained with periodic acid-Schiff/Alcian blue to assess mucus cell metaplasia. Results: rmTNF-alpha significantly increased gene expression of airway gob-5 and MUC-5AC after 2 weeks in the BALB/c mice. There was noticeable mucus staining in all mice treated for at least 3 weeks with TNF-a and in 80% of the mice receiving 2 weeks of treatment. After 3 weeks of treatment, the AKR mice also showed increased gob-5 expression. Conclusions: This study demonstrates for the first time that TNF-a alone in vivo is sufficient to increase airway mucus gene expression in 2 murine strains.	CUNY Mt Sinai Sch Med, Div Clin Immunol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pediat Allergy & Immunol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, Baltimore, MD USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Busse, PJ (corresponding author), CUNY Mt Sinai Sch Med, Div Clin Immunol, 1425 Madison Ave,Room 11-20, New York, NY 10029 USA.	paula.busse@mssm.edu		SEALFON, Stuart/0000-0001-5791-1217				AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Alimam MZ, 2000, AM J RESP CELL MOL, V22, P253, DOI 10.1165/ajrcmb.22.3.3768; Amrani Y, 2000, Respir Res, V1, P49, DOI 10.1186/rr12; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549, DOI 10.1152/ajplung.1999.276.4.L549; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150, DOI 10.1164/ajrccm.160.4.9806034; CARDELL BS, 1956, INT ARCH ALLER A IMM, V9, P189, DOI 10.1159/000228332; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291, DOI 10.1164/ajrccm/147.2.291; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Dewas C, 2003, J IMMUNOL, V171, P4392, DOI 10.4049/jimmunol.171.8.4392; Eyles JE, 2001, J PHARM PHARMACOL, V53, P601, DOI 10.1211/0022357011775929; Eyles JE, 1999, INT J PHARM, V189, P75, DOI 10.1016/S0378-5173(99)00239-2; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Gonzalez-Maeso J, 2003, J NEUROSCI, V23, P8836; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768, DOI 10.1164/ajrccm/146.3.768; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; Groneberg DA, 2002, HISTOPATHOLOGY, V40, P367, DOI 10.1046/j.1365-2559.2002.01378.x; Hauber HP, 2005, J ALLERGY CLIN IMMUN, V115, P266, DOI 10.1016/j.jaci.2004.09.039; *I LAB AN RES COMM, 1996, NIH PUBL, V8623; Kohri K, 2002, AM J PHYSIOL-LUNG C, V283, pL531, DOI 10.1152/ajplung.00455.2001; KRISHNASWAMY G, 1993, AM J RESP CELL MOL, V9, P279, DOI 10.1165/ajrcmb/9.3.279; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Leverkoehne I, 2002, J HISTOCHEM CYTOCHEM, V50, P829, DOI 10.1177/002215540205000609; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; Li XM, 1996, J IMMUNOL, V157, P3216; Li YH, 2001, AM J RESP CELL MOL, V25, P644, DOI 10.1165/ajrcmb.25.5.4485; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; LUKACS NW, 1995, J IMMUNOL, V154, P5411; Luttmann W, 1999, AM J RESP CELL MOL, V20, P474, DOI 10.1165/ajrcmb.20.3.3326; Nadel JA, 2000, CHEST, V117, p262S, DOI 10.1378/chest.117.5_suppl_1.262S-a; NAGAKI M, 1995, RESP PHYSIOL, V102, P89, DOI 10.1016/0034-5687(95)00042-C; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V198, P835, DOI 10.1006/bbrc.1994.1119; Rogers DF, 2002, CLIN EXP ALLERGY, V32, P1124, DOI 10.1046/j.1365-2745.2002.01474.x; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; SLUNGAARD A, 1990, J EXP MED, V171, P2025, DOI 10.1084/jem.171.6.2025; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; STARCHER B, 1989, LAB ANIM, V23, P234, DOI 10.1258/002367789780810536; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Takeyama K, 2001, AM J RESP CRIT CARE, V163, P511, DOI 10.1164/ajrccm.163.2.2001038; Tanaka H, 2002, INFLAMM RES, V51, P307, DOI 10.1007/PL00000309; Temann UA, 1997, AM J RESP CELL MOL, V16, P471, DOI 10.1165/ajrcmb.16.4.9115759; Toda M, 2002, J ALLERGY CLIN IMMUN, V109, P246, DOI 10.1067/mai.2002.121555; TRILIHEFF A, 2001, CLIN EXP ALLERGY, V31, P934; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	49	66	70	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1256	1263		10.1016/j.jaci.2005.08.059	http://dx.doi.org/10.1016/j.jaci.2005.08.059			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337454				2022-12-18	WOS:000235687000013
J	Levy, H; Raby, BA; Lake, S; Tantisira, KG; Kwiatkowski, D; Lazarus, R; Silverman, EK; Richter, B; Klimecki, WT; Vercelli, D; Martinez, FD; Weiss, ST				Levy, H; Raby, BA; Lake, S; Tantisira, KG; Kwiatkowski, D; Lazarus, R; Silverman, EK; Richter, B; Klimecki, WT; Vercelli, D; Martinez, FD; Weiss, ST			Association of defensin beta-1 gene polymorphisms with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma genetics; defensin; association studies	OBSTRUCTIVE PULMONARY-DISEASE; ADULT-ONSET ASTHMA; BODY-MASS INDEX; HUMAN BETA-DEFENSIN-1; LINKAGE DISEQUILIBRIUM; CHILDHOOD ASTHMA; UNIFIED APPROACH; HOST-DEFENSE; POPULATION; TESTS	Background: Defensins are antimicrobial peptides that may take part in airway inflammation and hyperresponsiveness. Objective: We characterized the genetic diversity in the defensin beta-1 (DEFB1) locus and tested for an association between common genetic variants and asthma diagnosis. Methods: To identify single nucleotide polymorphisms (SNPs), we resequenced this gene in 23 self-defined European Americans and 24 African Americans. To test whether DEFB1 genetic variants are associated with asthma, we genotyped 4 haplotype-tag SNPs in 517 asthmatic and 519 control samples from the Nurses' Health Study (NHS) and performed a case-control association analysis. To replicate these findings, we evaluated the DEFB1 polymorphisms in a second cohort from the Childhood Asthma Management Program. Results: Within the NHS, single SNP testing suggested an association between asthma diagnosis and a 5' genomic SNP (g. - 1816 T>C; P = .025) and intronic SNP (IVS + 692 G>A; P = .054). A significant association between haplotype (Adenine, Cytosine, Thymine, Adenine [ACTA]) and asthma (P = .024) was also identified. Associations between asthma diagnosis and both DEFB1 polymorphisms were observed in Childhood Asthma Management Program, a second cohort: g. - 1816 T>C and IVS + 692 G>A demonstrated significant transmission distortion (P = .05 and .007, respectively). Transmission distortion was not observed in male subjects. The rare alleles (- 1816C and + 692A) were undertransmitted to offspring with asthma, suggesting a protective effect, contrary to the findings in the NHS cohort. Similar effects were evident at the haplotype level: ACTA was undertransmitted (P = .04) and was more prominent in female subjects (P = .007). Conclusion: Variation in DEFB1 contributes to asthma diagnosis, with apparent gender-specific effects.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Childrens Hosp, Div Pulm Med, Boston, MA 02115 USA; Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; Harvard Partners Ctr Genet & Genom, Boston, MA USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; University of Arizona; Harvard University; Harvard University; Brigham & Women's Hospital	Levy, H (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	Hara.levy@childrens.harvard.edu	Raby, Benjamin/AAK-3866-2021	lazarus, ross/0000-0003-3939-1961	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067664, K23HL074202, U01HL066795] Funding Source: NIH RePORTER; NHLBI NIH HHS [K23 HL074202, K23 HL074202-01, N01HR16044, P01 HL067664, U01 HL066795, 1U01 HL66795-21, P01 HL67664] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Barr RG, 2004, ARCH INTERN MED, V164, P379, DOI 10.1001/archinte.164.4.379; Barr RG, 2002, ARCH INTERN MED, V162, P1761, DOI 10.1001/archinte.162.15.1761; Barr RG, 2002, AM J EPIDEMIOL, V155, P965, DOI 10.1093/aje/155.10.965; Barr RG, 2001, CHEST, V120, P1474, DOI 10.1378/chest.120.5.1474; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P48, DOI 10.1093/oxfordjournals.aje.a114223; Diamond G, 1998, CLIN IMMUNOL IMMUNOP, V88, P221, DOI 10.1006/clin.1998.4587; Dork T, 1998, MOL CELL PROBE, V12, P171, DOI 10.1006/mcpr.1998.0165; Gabrijelcic J, 2003, EUR RESPIR J, V22, P290, DOI 10.1183/09031936.03.00098102; Ganz T, 1999, SCIENCE, V286, P420, DOI 10.1126/science.286.5439.420; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; HIBBERT M, 1995, PEDIATR PULM, V19, P129, DOI 10.1002/ppul.1950190208; HILL WG, 1974, HEREDITY, V33, P229, DOI 10.1038/hdy.1974.89; Hsu FC, 2003, GENET EPIDEMIOL, V25, P1, DOI 10.1002/gepi.10241; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Jurevic RJ, 2002, GENET TEST, V6, P261, DOI 10.1089/10906570260471787; Kaiser V, 2000, J LEUKOCYTE BIOL, V68, P779; Keselman HJ, 2002, BRIT J MATH STAT PSY, V55, P27, DOI 10.1348/000711002159680; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.3.CO;2-D; LEWITTER FI, 1984, AM J EPIDEMIOL, V120, P518, DOI 10.1093/oxfordjournals.aje.a113912; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Liu Andrew H, 2004, Paediatr Respir Rev, V5 Suppl A, pS65, DOI 10.1016/S1526-0542(04)90013-9; Liu LD, 1997, GENOMICS, V43, P316, DOI 10.1006/geno.1997.4801; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Martinez FD, 2002, PEDIATRICS, V109, P362; Matsushita I, 2002, BIOCHEM BIOPH RES CO, V291, P17, DOI 10.1006/bbrc.2002.6395; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; NIEMINEN MM, 1991, CHEST, V100, P70, DOI 10.1378/chest.100.1.70; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; PANYUTICH AV, 1995, AM J RESP CELL MOL, V12, P351, DOI 10.1165/ajrcmb.12.3.7873202; Peters SP, 2003, AM J MED, V115, p49S, DOI 10.1016/S0002-9343(03)00193-1; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; RICE WG, 1987, BLOOD, V70, P757; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Sebastiani P, 2003, P NATL ACAD SCI USA, V100, P9900, DOI 10.1073/pnas.1633613100; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Siroux V, 2004, J ALLERGY CLIN IMMUN, V114, P491, DOI 10.1016/j.jaci.2004.05.027; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Szefler S, 2000, NEW ENGL J MED, V343, P1054; van Wetering S, 1999, J ALLERGY CLIN IMMUN, V104, P1131, DOI 10.1016/S0091-6749(99)70004-7; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525	47	66	73	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					252	258		10.1016/j.jaci.2004.11.013	http://dx.doi.org/10.1016/j.jaci.2004.11.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696078	Green Accepted			2022-12-18	WOS:000227043600007
J	Ibarrola, I; Arilla, MC; Martinez, A; Asturias, JA				Ibarrola, I; Arilla, MC; Martinez, A; Asturias, JA			Identification of a polygalacturonase as a major allergen (Pla a 2) from Platanus acerifolia pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						London planetree; major allergen; Platanus acerifolia; polygalacturonase; three-dimensional structure; molecular modeling	JAPANESE CEDAR POLLEN; POLLINOSIS; PURIFICATION; SEQUENCE; ASTHMA	Background: Planetree pollen allergy is a clinical disorder affecting human populations in cities of the United States and Western Europe, but little is known about its relevant allergens. Objective: We sought to purify, characterize, and clone the 43-kd allergen from Platanus acerifolia. Methods: P acerifolia pollen extract was fractionated by using ion-exchange and gel-permeation chromatography. Analyses were carried out by using ELISA, SDS-PAGE, isoelectrofocusing, and immunoblotting. Partial amino acid sequence was obtained by means of Edman sequencing of cyanogen bromide-digested peptides. Specific cDNA was cloned by using reverse transcription, followed by PCR, with amino acid sequences from peptides of the allergen. Results: The allergen isolated from P acerifolia pollen, Pla a 2, is a glycoprotein with an observed molecular mass of 43 kd and an isoelectric point value of 9.3. It is involved in the allergic responses of 84% of patients with planetree-induced pollinosis and represented 52% of the total IgE-binding capacity of the P acerifolia extract. Pla a 2 displays polygalacturonase (PG) activity, being the first PG with functional enzyme activity from an angiosperm plant pollen described as an allergen. The cDNA allergen sequence codified for a 372-residue protein with 56% and 42% sequence identity to PGs from pollen and fruits, respectively. Western blot analysis showed that Pla a 2 is present in pollen and stems and has IgG cross-reactivity with a PG from tomato and pectate lyases from Cupressaceae pollen. Conclusion: Pla a 2, a major allergen of P acerifolia pollen with PG activity has been purified, characterized, and cloned.	Bial Aristegui, Dept Res & Dev, Bilbao 48008, Spain		Asturias, JA (corresponding author), Bial Aristegui, Dept Res & Dev, Alameda Urquijo 27, Bilbao 48008, Spain.			Asturias, Juan/0000-0001-9570-522X				Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Asturias JA, 2003, CLIN EXP ALLERGY, V33, P978, DOI 10.1046/j.1365-2222.2003.01707.x; Asturias JA, 2002, ALLERGY, V57, P221, DOI 10.1034/j.1398-9995.2002.03406.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Cadot P, 2000, J ALLERGY CLIN IMMUN, V105, P286, DOI 10.1016/S0091-6749(00)90078-2; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Chardin H, 2003, ALLERGY, V58, P407, DOI 10.1034/j.1398-9995.2003.00094.x; Charpin J., 1974, ATLAS EUROPEAN ALLER; COHEN FE, 1993, SCIENCE, V260, P1444, DOI 10.1126/science.8502989; DYGERT S, 1965, ANAL BIOCHEM, V13, P367, DOI 10.1016/0003-2697(65)90327-1; ELKON KB, 1898, HDB IMMUNOBLOTTING P, P51; Enrique E, 2002, ALLERGY, V57, P351, DOI 10.1034/j.1398-9995.2002.1s3509.x; Hadfield KA, 1998, PLANT PHYSIOL, V117, P337, DOI 10.1104/pp.117.2.337; Huecas S, 2001, J BIOL CHEM, V276, P27959, DOI 10.1074/jbc.M103041200; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; Kondo Y, 2001, INT ARCH ALLERGY IMM, V126, P294, DOI 10.1159/000049526; NAMBA M, 1994, FEBS LETT, V353, P124, DOI 10.1016/0014-5793(94)01022-6; OHTSUKI T, 1995, ALLERGY, V50, P483, DOI 10.1111/j.1398-9995.1995.tb01183.x; Petersen A, 2001, J ALLERGY CLIN IMMUN, V107, P856, DOI 10.1067/mai.2001.114114; Pickersgill R, 1998, J BIOL CHEM, V273, P24660, DOI 10.1074/jbc.273.38.24660; Sone T, 1998, J IMMUNOL, V161, P448; SUBIZA J, 1994, CLIN EXP ALLERGY, V24, P1123, DOI 10.1111/j.1365-2222.1994.tb03317.x; Tamura Y, 2003, CLIN EXP ALLERGY, V33, P211, DOI 10.1046/j.1365-2222.2003.01579.x; TANIGUCHI Y, 1995, ALLERGY, V50, P90, DOI 10.1111/j.1398-9995.1995.tb02489.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Varela S, 1997, J ALLERGY CLIN IMMUN, V100, P748, DOI 10.1016/S0091-6749(97)70268-9	27	66	73	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1185	1191		10.1016/j.jaci.2004.02.031	http://dx.doi.org/10.1016/j.jaci.2004.02.031			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208603				2022-12-18	WOS:000222091000027
J	Echigo, T; Hasegawa, M; Shimada, Y; Takehara, K; Sato, S				Echigo, T; Hasegawa, M; Shimada, Y; Takehara, K; Sato, S			Expression of fractalkine and its receptor, CX(3)CR1, in atopic dermatitis: Possible contribution to skin inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic derniatitis; chemokine; fractalkine; CX(3)CR1; endothelial cell; leukocyte activation; adhesion molecule; skin inflammation	INTERCELLULAR-ADHESION MOLECULE-1; ACTIVATION-REGULATED CHEMOKINE; MACROPHAGE-DERIVED CHEMOKINE; MEMBRANE-BOUND CHEMOKINE; L-SELECTIN EXPRESSION; T-CELLS; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; LESIONAL SKIN	Background: Fractalkine (FKN) induces activation and adhesion of leukocytes expressing its receptor, CX(3)CR1. FKN is released from the cell surface through proteolytic cleavage as soluble FKN (sFKN). Objective: We sought to assess FKN and CX(3)CR1 expression in the skin, serum sFKN levels, and CX(3)CR1 expression on blood leukocytes in patients with atopic dermatitis (AD). Methods: FKN and CX(3)CR1 expression in the skin was examined immunohistochemically. mRNA expression of FKN, thymus and activation-regulated chemokine, and macrophage-derived chemokine in the skin was assessed by means of real-time RT-PCR. Serum sFKN levels were assessed by using ELISA. Blood leukocytes were stained for CX(3)CR1 by means of flow cytometric analysis. Results: FKN was strongly expressed on endothelial cells in skin lesions of patients with AD and psoriasis but not in normal skin. FKN mRNA levels in AD lesional skin increased to a similar extent to thymus and activation-regulated chemokine and macrophage-derived chemokine mRNA levels. CX(3)CR1-expressing cells in the affected skin of patients with AD or psoriasis increased compared with those in normal skin. Serum sFKN levels were increased in patients with AD but not in patients with psoriasis relative to levels in healthy control subjects. Serum sFKN levels were associated with the disease severity and decreased with the improvement of skin lesions in patients with AD. CX(3)CR1(+) cell frequencies and CX(3)CR1 expression levels were decreased in CD8(+) T cells, monocytes, and natural killer cells from patients with AD, but this was not observed in patients with psoriasis. Conclusions: These results suggest that through functions in both membrane-bound and soluble forms, FKN plays an important role in the trafficking of CX(3)CR1(+) leukocytes during the inflammation caused by AD.	Kanazawa Univ, Grad Sch Med Sci, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University	Sato, S (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Dermatol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.							Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BOS JD, 1992, ARCH DERMATOL, V128, P1509, DOI 10.1001/archderm.128.11.1509; D'Ambrosio D, 2000, IMMUNOL TODAY, V21, P183, DOI 10.1016/S0167-5699(00)01590-5; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Fraticelli P, 2001, J CLIN INVEST, V107, P1173, DOI 10.1172/JCI11517; Galli G, 2000, EUR J IMMUNOL, V30, P204, DOI 10.1002/1521-4141(200001)30:1<204::AID-IMMU204>3.0.CO;2-G; Garton KJ, 2001, J BIOL CHEM, V276, P37993; GEARING AJH, 1992, ANN NY ACAD SCI, V667, P324, DOI 10.1111/j.1749-6632.1992.tb51633.x; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1982, J AM ACAD DERMATOL, V6, P1, DOI 10.1016/S0190-9622(82)70001-5; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; HART DNJ, 1988, J EXP MED, V168, P157, DOI 10.1084/jem.168.1.157; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Katoh N, 2002, CLIN EXP IMMUNOL, V127, P283, DOI 10.1046/j.1365-2249.2002.01740.x; LEEUWENBERG JFM, 1992, IMMUNOLOGY, V77, P543; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung DYM, 1999, J ALLERGY CLIN IMMUN, V104, pS99, DOI 10.1016/S0091-6749(99)70051-5; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; Meijerink J, 2001, J MOL DIAGN, V3, P55, DOI 10.1016/S1525-1578(10)60652-6; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nagaoka T, 2000, AM J PATHOL, V157, P237, DOI 10.1016/S0002-9440(10)64534-8; Nakatani T, 2001, J ALLERGY CLIN IMMUN, V107, P353, DOI 10.1067/mai.2001.112601; Nakazawa M, 1997, J ALLERGY CLIN IMMUN, V99, P673, DOI 10.1016/S0091-6749(97)70030-7; Nanki T, 2002, ARTHRITIS RHEUM, V46, P2878, DOI 10.1002/art.10622; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Papadopoulos EJ, 2000, EUR J IMMUNOL, V30, P2355, DOI 10.1002/1521-4141(2000)30:8<2355::AID-IMMU2355>3.0.CO;2-#; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; Ruth JH, 2001, ARTHRITIS RHEUM, V44, P2750, DOI 10.1002/1529-0131(200112)44:12<2750::AID-ART462>3.0.CO;2-C; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; Sato A, 1998, J INVEST DERMATOL, V111, P1079, DOI 10.1046/j.1523-1747.1998.00454.x; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; Suomela S, 2001, EXP DERMATOL, V10, P175, DOI 10.1034/j.1600-0625.2001.010003175.x; Tang MLK, 1998, J IMMUNOL, V160, P5113; TEDDER TF, 1990, J IMMUNOL, V144, P532; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P764, DOI 10.1016/0091-6749(94)90185-6; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Umehara H, 2001, IMMUNOL CELL BIOL, V79, P298, DOI 10.1046/j.1440-1711.2001.01004.x; Umehara H, 2001, TRENDS IMMUNOL, V22, P602, DOI 10.1016/S1471-4906(01)02051-8; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; Yoneda O, 2000, J IMMUNOL, V164, P4055, DOI 10.4049/jimmunol.164.8.4055; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	59	66	72	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					940	948		10.1016/S0091-6749(04)01061-9	http://dx.doi.org/10.1016/S0091-6749(04)01061-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131578	Green Submitted, Bronze			2022-12-18	WOS:000221269000018
J	Maestrelli, P; Zanolla, L; Pozzan, M; Fabbri, LM				Maestrelli, P; Zanolla, L; Pozzan, M; Fabbri, LM			Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchodilators; corticosteroids; allergens; lung function; prevention	MILD PERSISTENT ASTHMA; DERMATOPHAGOIDES-PTERONYSSINUS; DOUBLE-BLIND; BRONCHIAL HYPERRESPONSIVENESS; SUBLINGUAL IMMUNOTHERAPY; POLLEN IMMUNOTHERAPY; CLINICAL-EFFICACY; CONTROLLED TRIAL; POSITION PAPER; CHILDREN	Background: Although several studies support the efficacy of specific immunotherapy in allergic asthma, its benefit compared with that of standardized pharmacologic intervention remains unknown. Objective: A double-blind, placebo-controlled trial in 72 patients with mild-to-moderate asthma and allergy to house dust mite (HDM; Dermatophagoides species) was conducted to assess the effects of specific immunotherapy added to guideline-adjusted pharmacologic treatment and allergen avoidance. Methods: After 1 observational year of pharmacologic treatment and standard measures of HDM avoidance, 2 groups of asthmatic subjects were randomly assigned to receive specific immunotherapy consisting of subcutaneous injections of either a mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae vaccine (n = 41) or placebo (n = 31) for 3 years. Medications were adjusted every 3 months according to the Global Initiative for Asthma guidelines. Results: The adjustment of treatment was associated with a reduction in asthma symptom scores in all subjects. The addition of specific immunotherapy was associated with a decrease in the number of subjects requiring rescue bronchodilators, an increase in morning and evening peak expiratory flow, and a reduced skin sensitivity to HDM extracts. The addition of specific immunotherapy had no significant effects on the cumulative dose of inhaled corticosteroids, asthma symptoms, lung volumes, or bronchial responsiveness to methacholine. Conclusion: These results suggest that specific immunotherapy added to pharmacologic treatment and HDM avoidance provides marginal but statistically significant clinical benefits, possibly by reducing the allergic response of asthmatic patients sensitized to HDM.	Univ Padua, Dipartimento Med Ambientale & Sanita Pubbl, I-35128 Padua, Italy; Gen Hosp, Verona, Italy; Allergol Clin, Dept Hlth, Padua, Italy; Univ Modena, I-41100 Modena, Italy; Study Grp Ric Sanitaria Finalizzata, Regione Veneto, Italy	University of Padua; Universita di Modena e Reggio Emilia	Maestrelli, P (corresponding author), Univ Padua, Dipartimento Med Ambientale & Sanita Pubbl, Via Giustiniani 2, I-35128 Padua, Italy.		Murer, Luisa LM/I-8830-2018; Senna, Gianenrico/AAC-5201-2022; Fabbri, Leonardo M/I-4055-2012	Murer, Luisa LM/0000-0002-3010-2337; Senna, Gianenrico/0000-0003-4172-3216; Fabbri, Leonardo M/0000-0001-8894-1689; Zanolla, Luisa/0000-0002-3626-9699; Crivellaro, Maria Angiola/0000-0002-8013-0627				Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; *COMM COMM EUR, 1972, COMM REL QUEST CECA; Crescioli S, 1996, ANN ALLERG ASTHMA IM, V77, P106, DOI 10.1016/S1081-1206(10)63495-3; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048, DOI 10.1164/ajrccm.162.6.9909087; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; MACHIELS JJ, 1990, J CLIN INVEST, V85, P1024, DOI 10.1172/JCI114532; Maestrelli P, 2001, CLIN EXP ALLERGY, V31, P715, DOI 10.1046/j.1365-2222.2001.01020.x; MALLING HJ, 1993, ALLERGY, V48, P9; MALLING HJ, 1987, ALLERGY, V42, P391, DOI 10.1111/j.1398-9995.1987.tb02226.x; MAPP CE, 1985, J ALLERGY CLIN IMMUN, V75, P568, DOI 10.1016/0091-6749(85)90031-4; MINELLI M, 1997, ITAL J ALLERGY CLIN, V7, P218; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Olaguibel JM, 1997, ALLERGY, V52, P168, DOI 10.1111/j.1398-9995.1997.tb00971.x; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; PEAT JK, 1994, J CLIN EPIDEMIOL, V47, P1099, DOI 10.1016/0895-4356(94)90096-5; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1982, LANCET, V2, P675; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VENTAS P, 1990, REV ESP ALERGOL IMMU, V5, P71; WARNER JO, 1978, LANCET, V2, P912	33	66	71	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					643	649		10.1016/j.jaci.2003.12.586	http://dx.doi.org/10.1016/j.jaci.2003.12.586			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100667				2022-12-18	WOS:000220956600009
J	Aleman, A; Sastre, J; Quirce, S; de las Heras, M; Carnes, J; Fernandez-Caldas, E; Pastor, C; Blazquez, AB; Vivanco, F; Cuesta-Herranz, J				Aleman, A; Sastre, J; Quirce, S; de las Heras, M; Carnes, J; Fernandez-Caldas, E; Pastor, C; Blazquez, AB; Vivanco, F; Cuesta-Herranz, J			Allergy to kiwi: A double-blind, placebo-controlled food challenge study in patients from a birch-free area	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; double-blind; placebo-controlled food challenge; kiwi fruit allergy; oral allergy syndrome	CROSS-REACTIVITY; ADVERSE-REACTIONS; FRUIT; POLLEN; LATEX; IDENTIFICATION; TIMOTHY; CARROT	Background: Allergy to kiwi fruit is being increasingly reported, but it has never been evaluated by means of a double-blind, placebo-controlled food challenge (DBPCFC) study. Objective: We sought to assess kiwi allergy on the basis of a DBPCFC and identify the patterns of allergen recognition in sensitized patients from a birch-free area. Methods: Forty-three patients with allergy symptoms who were sensitized to kiwi were evaluated by means of clinical history, skin tests, IgE determinations, and DBPCFCs. The pattern of allergen recognition was assessed by means of IgE immunoblotting. Sequence analysis of IgE-binding bands was performed by using Edman degradation. Results: DBPCFCs were performed in 33 patients; 4 patients had experienced severe anaphylaxis, and 6 patients declined informed consent. DBPCFC results were positive in 23 patients and negative in 10 patients. The most frequent clinical manifestation was oral allergy syndrome. Twenty-one percent of the patients were not allergic to pollen. Forty-six percent of patients experienced systemic symptoms, and this happened with higher frequency in patients not allergic to pollen (100 %). Twenty-eight percent of the patients were sensitized to latex. The IgE-binding bands in kiwi extract more frequently recognized by patient sera were those of 30, 24, 66, and 12 kd, and they could not be associated with any pattern of kiwi-induced allergic reactions. Conclusion: The results provide evidence that kiwi allergy is not a homogeneous disorder because several clinical subgroups can be established. No definite allergen-recognition pattern was associated with the type of allergic reactions to kiwi. One of 5 patients with kiwi allergy was not allergic to pollen, and these patients had the highest risk of systemic reactions to kiwi.	Fdn Jimenez Diaz, Serv Alergia, Dept Allergy, E-28040 Madrid, Spain; Fdn Jimenez Diaz, Dept Immunol, E-28040 Madrid, Spain; CBF Leti, R&D, Leti, Spain		Sastre, J (corresponding author), Fdn Jimenez Diaz, Serv Alergia, Dept Allergy, Av Reyes Catolicos 2, E-28040 Madrid, Spain.		Pastor Vargas, Carlos/B-4112-2010; s, q/AAD-7171-2020; Vivanco, Fernando/Q-6866-2016	Pastor Vargas, Carlos/0000-0002-4678-7967; 				Akasawa A, 1996, J BIOL CHEM, V271, P25389, DOI 10.1074/jbc.271.41.25389; Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Blanco C, 2003, CURR ALLERGY ASTHM R, V3, P47, DOI 10.1007/s11882-003-0012-y; Cuesta-Herranz J, 1999, J ALLERGY CLIN IMMUN, V104, P688, DOI 10.1016/S0091-6749(99)70343-X; Cuesta-Herranz J, 1998, ALLERGY, V53, P78, DOI 10.1111/j.1398-9995.1998.tb03777.x; Cuesta-Herranz J, 2003, CLIN EXP ALLERGY, V33, P827, DOI 10.1046/j.1365-2222.2003.01680.x; Cuesta-Herranz J, 1998, J ALLERGY CLIN IMMUN, V102, P275, DOI 10.1016/S0091-6749(98)70096-X; Cuesta-Herranz J, 2000, CLIN EXP ALLERGY, V30, P1411, DOI 10.1046/j.1365-2222.2000.00868.x; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P448, DOI 10.1046/j.1365-2222.2002.01306.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Duffort OA, 2002, J AGR FOOD CHEM, V50, P7738, DOI 10.1021/jf0258398; Fahlbusch B, 1998, J INVEST ALLERG CLIN, V8, P325; Figueredo E, 2003, ANN ALLERG ASTHMA IM, V91, P303, DOI 10.1016/S1081-1206(10)63534-X; FINE AJ, 1981, J ALLERGY CLIN IMMUN, V68, P235, DOI 10.1016/0091-6749(81)90189-5; GALL H, 1994, J ALLERGY CLIN IMMUN, V94, P70, DOI 10.1016/0091-6749(94)90073-6; Gavrovic-Jankulovic M, 2002, J ALLERGY CLIN IMMUN, V110, P805, DOI 10.1067/mai.2002.128947; JENSEN J, 1989, ALLERGY, V44, P52, DOI 10.1111/j.1398-9995.1989.tb00446.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moller M, 1998, ALLERGY, V53, P289, DOI 10.1111/j.1398-9995.1998.tb03889.x; Ortolani C, 2000, J ALLERGY CLIN IMMUN, V105, P577, DOI 10.1067/mai.2000.103052; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; Pastorello EA, 1996, J ALLERGY CLIN IMMUN, V98, P601, DOI 10.1016/S0091-6749(96)70094-5; Patil SP, 2001, ANN ALLERG ASTHMA IM, V87, P140, DOI 10.1016/S1081-1206(10)62209-0; Poon AW, 1998, AM J MANAG CARE, V4, P969; Quirce S, 2001, ALLERGY, V56, P754, DOI 10.1034/j.1398-9995.2001.056008754.x; Quirce S, 2000, ALLERGY, V55, P896, DOI 10.1034/j.1398-9995.2000.00744.x; Rodriguez J, 2000, J ALLERGY CLIN IMMUN, V106, P183, DOI 10.1067/mai.2000.106927; Rodriguez J, 2000, J ALLERGY CLIN IMMUN, V106, P968, DOI 10.1067/mai.2000.110467; Rudeschko O, 1998, J INVEST ALLERG CLIN, V8, P78; SUBIZA J, 1995, J ALLERGY CLIN IMMUN, V96, P15, DOI 10.1016/S0091-6749(95)70028-5; Voitenko V, 1997, ALLERGY, V52, P136, DOI 10.1111/j.1398-9995.1997.tb00967.x	33	66	68	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					543	550		10.1016/j.jaci.2003.11.043	http://dx.doi.org/10.1016/j.jaci.2003.11.043			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007359				2022-12-18	WOS:000220144200029
J	Wallin, A; Sue-Chu, M; Bjermer, L; Ward, J; Sandstrom, T; Lindberg, A; Lundback, B; Djukanovic, R; Holgate, S; Wilson, S				Wallin, A; Sue-Chu, M; Bjermer, L; Ward, J; Sandstrom, T; Lindberg, A; Lundback, B; Djukanovic, R; Holgate, S; Wilson, S			Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; randomized controlled trial; bronchoscopy; fluticasone propionate; salmeterol; inflammation	BRONCHOALVEOLAR LAVAGE; PROPIONATE; BUDESONIDE; CELLS; FORMOTEROL; EXPRESSION; SYMPTOMS; PLACEBO	Background: The clinical benefit of combining long-acting beta(2)-agonists with inhaled corticosteroids rather than doubling the dose of corticosteroid has been well-documented. However, there are concerns that this might result in a masking of underlying airway inflammation. Objective: The aim of this study was to test the hypothesis that the addition of the long-acting beta(2)-agonist salmeterol (SALM) to a low dose of the inhaled corticosteroid fluticasone propionate (FP) has a steroid-sparing effect and does not result in a worsening of bronchial inflammation compared to doubling the dose of inhaled corticosteroid. Methods: Fifty-six asthmatic subjects, previously not well-controlled on inhaled corticosteroids, were randomized to receive 3 months of treatment with inhaled FP 500 mug twice a day (FP 1000) or FP 200 mug twice a day plus SALM 50 mug twice a day (FP 400 + SALM). Fluticasone propionate 200 mug twice a day served as the control (FP400). Bronchial mucosal biopsy specimens, bronchial washings (BW), and bronchoalveolar lavage were obtained before and after treatment. The primary end points for the study were submucosal mast cell and eosinophil counts. Results: There was a significant improvement in FEV1 in the FP400 + SALM group compared to both the FP400 and FP1000 groups. This was accompanied by a significant improvement in peak expiratory flow in the FP400 + SALM group in both the morning and evening compared to the FP1000 group. There were no significant between treatment differences in the change in the number of submucosal mast cells or eosinophils. However, in the FP400 + SALM group there was a significant decrease in submucosal mast cells after 12 weeks of treatment. The addition of SALM to FP was not associated with any increases in airway inflammation in the biopsy specimens, bronchoalveolar lavage, or bronchial washings. Conclusion: These findings confirm that addition of SALM to FP has clinical benefits but does not mask or exacerbate airway inflammation and suggest that long-acting beta(2)-adrenoceptor agonists might influence mast cell numbers.	Univ Umea Hosp, Dept Resp Med & Allergy, S-90185 Umea, Sweden; Dept Lung Med, Trondheim, Norway; Lund Univ, Dept Resp Med & Allergol, Lund, Sweden; Univ Southampton, Sch Med, Dept Infect Inflammat & Repair, Southampton, Hants, England; Boden Hosp, Dept Pulm Med, Boden, Sweden; Karolinska Inst, Stockholm, Sweden	Umea University; Lund University; University of Southampton; Karolinska Institutet	Wilson, S (corresponding author), Southampton Gen Hosp, Mailpoint 810 RCMB,Level D,Ctr Block,Tremona Rd, Southampton SO16 6YD, Hants, England.		Bjermer, Leif H/I-4899-2014; Sue-Chu, Malcolm/D-8671-2016	Bjermer, Leif H/0000-0002-3441-8099; Ward, Jon/0000-0002-9278-0002; Djukanovic, Ratko/0000-0001-6039-5612; Sue-Chu, Malcolm/0000-0002-3301-1983; Lindberg, Anne/0000-0002-3292-7471				ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Brutsche MH, 2000, LANCET, V356, P556, DOI 10.1016/S0140-6736(00)02581-2; Condemi JJ, 1999, ANN ALLERG ASTHMA IM, V82, P383, DOI 10.1016/S1081-1206(10)63288-7; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; Faul JL, 1998, THORAX, V53, P753, DOI 10.1136/thx.53.9.753; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Hart L, 2000, AM J RESP CRIT CARE, V161, P224, DOI 10.1164/ajrccm.161.1.9809019; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Jarjour NN, 1998, AM J RESP CRIT CARE, V157, P692, DOI 10.1164/ajrccm.157.3.9705020; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Li X, 1999, AM J RESP CRIT CARE, V160, P1493, DOI 10.1164/ajrccm.160.5.9811052; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; van Noord JA, 1999, THORAX, V54, P207, DOI 10.1136/thx.54.3.207; Vermetten FAAM, 1999, J ASTHMA, V36, P97, DOI 10.3109/02770909909065153; Wallin A, 1999, AM J RESP CRIT CARE, V159, P79, DOI 10.1164/ajrccm.159.1.9801007; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; [No title captured]	25	66	66	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					72	78		10.1067/mai.2003.1518	http://dx.doi.org/10.1067/mai.2003.1518			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847482	Bronze			2022-12-18	WOS:000184010600013
J	Eum, SY; Maghni, K; Hamid, G; Eidelman, DH; Campbell, H; Isogai, S; Martin, JG				Eum, SY; Maghni, K; Hamid, G; Eidelman, DH; Campbell, H; Isogai, S; Martin, JG			Inhibition of allergic airways inflammation and airway hyperresponsiveness in mice by dexamethasone: Role of eosinophils, IL-5, eotaxin, and IL-13	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; glucocorticoid; eotaxin; IL-5; murine model	MURINE MODEL; TISSUE EOSINOPHILIA; EXPERIMENTAL ASTHMA; CHEMOKINE EOTAXIN; CC-CHEMOKINES; IN-VIVO; INTERLEUKIN-5; LUNG; HYPERREACTIVITY; EXPRESSION	Background: Glucocorticoids inhibit allergen-induced airway eosinophilia and airway hyperresponsiveness (AHR). Whether gIucocorticoids mediate their effects on AHR by inhibiting eotaxin and IL-5, 2 of the principal mediators of eosinophilia, or through IL-13, an important mediator of AHR, has not been established. Objective: We sought to investigate the effects of glucocorticoids on airway eosinophilia and the expression of IL-5, eotaxin, and IL-13 in relation to the induction of AHR in a murine model of allergic asthma. Methods: Dexamethasone (4 mg/kg) and mAbs against eotaxin (80 mug/kg) and IL-5 (100 mug/kg) singly and in combination were administered to immunized mice before antigen challenge. Airway responsiveness to methacholine was measured in anesthetized and mechanically ventilated animals. Eotaxin, IL-5, and IL-13 in bronchoalveolar lavage fluid (BALF), lung homogenates, or both were measured by means of ELISA. Results: A single antigen challenge induced AHR that lasted at least 10 days. Eotaxin protein and mRNA levels increased in lung tissue but not in BALF after challenge. IL-5 protein and mRNA levels increased both in BALF and in lung tissue. Dexamethasone reduced airway eosinophilia, AHR, and protein and mRNA for eotaxin and IL-5. Anti-murine eotaxin and anti-IL-5 antibodies alone and in combination reduced the ovalbumin-induced airway eosinophilia significantly but failed to inhibit AHR. Both dexamethasone and anti-IL-5/anti-eotaxin inhibited the increases in lung IL-13 levels after ovalbumin challenge to a similar extent. Conclusion: These findings suggest that the inhibition of AHR by the glueocorticoid dexamethasone does not appear to be explained by effects on eosinophilia, eotaxin, IL-5, or IL-13.	McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada	McGill University	Martin, JG (corresponding author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 Rue St Urbain, Montreal, PQ H2X 2P2, Canada.			Martin, James/0000-0001-7574-5363				BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BERKMAN N, 1995, AM J PHYSIOL-LUNG C, V269, pL443, DOI 10.1152/ajplung.1995.269.4.L443; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Braun CM, 1997, J ALLERGY CLIN IMMUN, V100, P400, DOI 10.1016/S0091-6749(97)70255-0; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Eum SY, 1995, P NATL ACAD SCI USA, V92, P12290, DOI 10.1073/pnas.92.26.12290; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hakonarson H, 1999, J CLIN INVEST, V104, P657, DOI 10.1172/JCI7137; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325, DOI 10.1165/ajrcmb.16.3.9070618; Hogan SP, 1998, J IMMUNOL, V161, P1501; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KUNG TT, 1995, AM J RESP CELL MOL, V13, P360, DOI 10.1165/ajrcmb.13.3.7654390; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; LEUNG DYM, 2003, J ALLERGY CLIN IMMUN, V111; Li D, 1997, EUR RESPIR J, V10, P1946, DOI 10.1183/09031936.97.10091946; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Mathur M, 1999, AM J RESP CRIT CARE, V159, P580, DOI 10.1164/ajrccm.159.2.9712018; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Mould AW, 2000, J IMMUNOL, V164, P2142, DOI 10.4049/jimmunol.164.4.2142; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Pitzalis C, 1997, J IMMUNOL, V158, P5007; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; SPORN PHS, 2000, AM J RESP CRIT CARE, V161, pA709; STELLATO C, 1995, J IMMUNOL, V155, P410; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; Yang M, 2001, AM J RESP CELL MOL, V25, P522, DOI 10.1165/ajrcmb.25.4.4620	40	66	74	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1049	1061		10.1067/mai.2003.1416	http://dx.doi.org/10.1067/mai.2003.1416			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743570	Bronze			2022-12-18	WOS:000182904500020
J	Muro, S; Taha, R; Tsicopoulos, A; Olivenstein, R; Tonnel, AB; Christodoulopoulos, P; Wallaert, B; Hamid, Q				Muro, S; Taha, R; Tsicopoulos, A; Olivenstein, R; Tonnel, AB; Christodoulopoulos, P; Wallaert, B; Hamid, Q			Expression of IL-15 in inflammatory pulmonary diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-15; IL-2; sarcoidosis; tuberculosis; chronic bronchitis; neutrophils; natural killer cells	BRONCHOALVEOLAR LAVAGE FLUID; CD4+ T-CELLS; INTERLEUKIN-15 IL-15; GENE-EXPRESSION; MESSENGER-RNA; IN-VITRO; IFN-GAMMA; CYTOKINE; SPUTUM; RECEPTORS	Background: IL-15 is a T(H)1-related cytokine that shares many biologic activities with IL-2. Both cytokines bind a specific alpha subunit, and they share the same beta and gamma common receptor subunits for signal transduction. IL-15 has recently been shown to be upregulated in T cell-mediated inflammatory disorders, such as rheumatoid arthritis and inflammatory bowel diseases. However, the role and expression of IL-15 in inflammatory lung disease has not been investigated. Objective: In the present study we have evaluated the expression of IL-15 mRNA and protein in bronchial biopsy specimens obtained from patients with sarcoidosis (n = 8), tuberculosis (n = 7), chronic bronchitis (n = 10), and bronchial asthma (n = 8) and compared its expression with that seen in normal control subjects (n = 11). Methods: In situ hybridization and immunocytochemistry were used to detect the number of cells expressing IL-15 mRNA and protein, respectively, within sections of bronchial tissues from all subject groups. In addition, double immunocytochemistry was used to characterize the cellular source of IL-15. Results: The number of IL-15(+) cells was significantly higher within tissue from patients with sarcoidosis, tuberculosis, and chronic bronchitis compared with that in asthmatic patients and normal control subjects. Similar results were obtained for IL-15 immunoreactivity by using immunohistochemistry. Furthermore, double immunostaining revealed that neutrophils and macrophages are the major source of IL-15. Conclusion: These results suggest that the expression of IL-15 may be associated with T(H)1-mediated chronic inflammatory diseases of the lung.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Montreal Chest Res Inst, Montreal, PQ, Canada; Inst Pasteur, F-59019 Lille, France	McGill University; McGill University; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Tsicopoulos, Anne/C-2260-2019	Tsicopoulos, Anne/0000-0002-1579-2763				Agostini C, 1996, J IMMUNOL, V157, P910; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Badolato R, 1997, BLOOD, V90, P2804, DOI 10.1182/blood.V90.7.2804.2804_2804_2809; BENSASSON SZ, 1990, J IMMUNOL, V145, P1127; Capelli A, 1999, EUR RESPIR J, V14, P160, DOI 10.1034/j.1399-3003.1999.14a27.x; CRYSTAL RG, 1981, ANN INTERN MED, V94, P73, DOI 10.7326/0003-4819-94-1-73; Girard D, 1998, CLIN IMMUNOL IMMUNOP, V88, P232, DOI 10.1006/clin.1998.4576; Girard D, 1996, BLOOD, V88, P3176, DOI 10.1182/blood.V88.8.3176.bloodjournal8883176; GIRGIS RE, 1995, AM J RESP CRIT CARE, V152, P71, DOI 10.1164/ajrccm.152.1.7599865; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hill AT, 1999, AM J RESP CRIT CARE, V160, P893, DOI 10.1164/ajrccm.160.3.9901091; HOSHI H, 1995, CLIN EXP ALLERGY, V25, P720, DOI 10.1111/j.1365-2222.1995.tb00009.x; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HUNNINGHAKE GW, 1981, NEW ENGL J MED, V305, P429, DOI 10.1056/NEJM198108203050804; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; Liu ZJ, 2000, J IMMUNOL, V164, P3608, DOI 10.4049/jimmunol.164.7.3608; McDonald PP, 1998, BLOOD, V92, P4828, DOI 10.1182/blood.V92.12.4828.424k09_4828_4835; Minshall EM, 1997, EUR RESPIR J, V10, P2034, DOI 10.1183/09031936.97.10092034; Mori A, 1996, J IMMUNOL, V156, P2400; Perera LP, 1999, J IMMUNOL, V162, P2606; RICHMANEISENSTAT JBY, 1993, AM J PHYSIOL, V264, pL413, DOI 10.1152/ajplung.1993.264.4.L413; Seder RA, 1996, J IMMUNOL, V156, P2413; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; Tagaya Y, 1996, EMBO J, V15, P4928, DOI 10.1002/j.1460-2075.1996.tb00873.x; Taha RA, 1997, AM J RESP CRIT CARE, V155, P1135, DOI 10.1164/ajrccm.155.3.9116999; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; ZHANG YH, 1995, J CLIN INVEST, V95, P586, DOI 10.1172/JCI117702; Zissel G, 2000, EUR CYTOKINE NETW, V11, P105	30	66	70	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					970	975		10.1067/mai.2001.119556	http://dx.doi.org/10.1067/mai.2001.119556			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742275				2022-12-18	WOS:000172938400013
J	Roorda, RJ; Mezei, G; Bisgaard, H; Maden, C				Roorda, RJ; Mezei, G; Bisgaard, H; Maden, C			Response of preschool children with asthma symptoms to fluticasone propionate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; fluticasone propionate; Babyhaler spacer; preschool children; placebo	INHALED BUDESONIDE; EARLY-CHILDHOOD; YOUNG-CHILDREN; EFFICACY; INFANTS	Background: Many uncertainties remain in the diagnosis and treatment of preschool children with asthma symptoms. Objective: We sought to determine the subgroups of preschool children (aged 12-47 months) with recurrent asthma symptoms most likely to respond to inhaled fluticasone propionate (200 mug/d). Methods: Subgroups of pooled data from 2 similar 12-week multicenter studies were analyzed. Results: Children with frequent symptoms (symptoms on greater than or equal to3 days per week and a total of greater than or equal to 75% days with symptoms during the 4-week run-in period; n = 169) showed a significantly greater increase in days without symptoms after fluticasone propionate treatment (0% to 45%) compared with after placebo treatment (0% to 25 %, P = .005). Children with a family history of asthma (n = 213) also had a significantly greater increase in days without symptoms after fluticasone propionate (11% to 54%) compared with after placebo (7% to 35%, P = .002) and a significantly higher proportion of exacerbation-free patients (61% to 76%, P = .02). Children with less frequent symptoms, no family history of asthma, or both showed no significant treatment effect. There seemed to be no association between response to fluticasone propionate and history of rhinitis or eczema or the number of previous exacerbations. Conclusions: Children with frequent symptoms, a family history of asthma, or both showed the greatest response to fluticasone propionate treatment. These findings may help to predict treatment outcome and guide the management of preschool children with recurrent asthma symptoms.	De Weezenlanden Hosp, Isala Klinieken, Dept Pediat, NL-8000 GM Zwolle, Netherlands; Semmelweis Univ, Dept Pediat 1, Budapest, Hungary; Copenhagen Univ Hosp, Dept Pediat, Copenhagen, Denmark; GlaxoSmithKline Res & Dev, Uxbridge, Middx, England	Isala Clinics; Semmelweis University; University of Copenhagen; GlaxoSmithKline	Roorda, RJ (corresponding author), De Weezenlanden Hosp, Isala Klinieken, Dept Pediat, POB 10500, NL-8000 GM Zwolle, Netherlands.		Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592				BISGAARD H, 1990, LANCET, V336, P649, DOI 10.1016/0140-6736(90)92147-A; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P126, DOI 10.1164/ajrccm.160.1.9811024; CONNETT G, 1993, ARCH DIS CHILD, V68, P85, DOI 10.1136/adc.68.1.85; CONNETT GJ, 1993, ARCH DIS CHILD, V69, P351, DOI 10.1136/adc.69.3.351; deBenedictis FM, 1996, PEDIATR PULM, V21, P310, DOI 10.1002/(SICI)1099-0496(199605)21:5<310::AID-PPUL6>3.0.CO;2-Q; deBlic J, 1996, J ALLERGY CLIN IMMUN, V98, P14, DOI 10.1016/S0091-6749(96)70221-X; Dodge R, 1996, J ALLERGY CLIN IMMUN, V98, P48, DOI 10.1016/S0091-6749(96)70225-7; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; GLEESON JGA, 1988, BRIT MED J, V297, P163, DOI 10.1136/bmj.297.6642.163; Hollander M, 1973, NONPARAMETRIC STAT M; ILLANGOVAN P, 1993, ARCH DIS CHILD, V68, P356; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mellon M, 1999, J ALLERGY CLIN IMMUN, V104, pS191, DOI 10.1016/S0091-6749(99)70061-8; SILVERMAN M, 1995, CHILDHOOD ASTHMA OTH; Warner JO, 1998, CLIN EXP ALLERGY, V28, P71; Williams J, 1998, REV CONTEMP PHARMACO, V9, P581; WILSON N, 1995, ARCH DIS CHILD, V72, P317, DOI 10.1136/adc.72.4.317; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407	18	66	69	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					540	546		10.1067/mai.2001.118789	http://dx.doi.org/10.1067/mai.2001.118789			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	485NK	11590379				2022-12-18	WOS:000171760300012
J	Tanaka, H; Miyazaki, N; Oashi, K; Tanaka, S; Ohmichi, M; Abe, S				Tanaka, H; Miyazaki, N; Oashi, K; Tanaka, S; Ohmichi, M; Abe, S			Sputum matrix metalloproteinase-9: Tissue inhibitor of metalloproteinase-1 ratio in acute asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						matrix metalloproteinase; tissue inhibitor of metalloproteinase; acute asthma; sputum; glucocorticosteroid	BRONCHOALVEOLAR LAVAGE FLUID; HUMAN ALVEOLAR MACROPHAGES; AIR-FLOW OBSTRUCTION; BASEMENT-MEMBRANE; IV COLLAGENASE; GELATINASE-B; IN-VITRO; INFLAMMATION; FIBROSIS; MATRIX-METALLOPROTEINASE-9	Background: The ratio of matrix metalloproteinase-9 (MMP-9) and its inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1) map be a marker of the balance between airway tissue destruction and repair. TIMP-1 may potentially contribute to the pathogenesis of increased submucosal extracellular matrix deposition in asthma. Objective: Our purpose was to assess the variation in sputum MMP-9 and TIMP-1 during acute asthma, Methods: We evaluated the MMP-9 and TIMP-1 balance in sputa of 16 asthmatic patients admitted with spontaneous exacerbation, conducting measurement before (day 1) and after methylprednisolone infusion therapy (days 2, 3, 5, and 7), and on remission days. Results: Peak expiratory flow and eosinophilic cationic protein levels were significantly (P < .05) improved within 7 days in all patients. Sputum MMP-9 revels on day 2 tended to be lower than on day 1, but not significantly Zymography revealed that the main enzyme was identified immunologically as MMP-9, and gelatinase activity on day I had a tendency to decrease for the following 7 days. The TIMP-1 levels gradually increased until day 5, were significantly (P < .05) high on day 5, and decreased on day 7. The MMP-9/TIMP-1 molar ratios were significantly (P < .05) decreased on days 2, 3, 5, and 7 compared with day 1. Sputum levels of MMP-9 and TIMP-1 and the MMP-9/TIMP-1 molar ratios on day 1 were significantly higher (P < .02) than those on remission days. Conclusions: An imbalance between MMP-9 and TIMP-1 was present in acute asthma, with an excess of MMP-9 resulting in a high ratio of MMP-9/TIMP-1 before treatment, and over time with glucocorticosteroid the TIMP-1 levels rose, dropping the ratio of MMP-9/TIMP-1. It was suggested that overproduction of MMP-9 and TIMP-1 after asthma exacerbation might contribute significantly to airway tissue remodeling and that TIMP-1 production in acute asthma might not be suppressed by glucocorticosteroid.	Sapporo Med Univ, Sch Med, Dept Internal Med 3, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Hokkaido Railway Co, Sapporo Hosp, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo City General Hospital	Tanaka, H (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 3, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Bosse M, 1999, AM J RESP CRIT CARE, V159, P596, DOI 10.1164/ajrccm.159.2.9802045; CORBRIDGE TC, 1995, AM J RESP CRIT CARE, V151, P1296, DOI 10.1164/ajrccm.151.5.7735578; DEAN DD, 1989, J CLIN INVEST, V84, P678, DOI 10.1172/JCI114215; DELACOURT C, 1995, AM J RESP CRIT CARE, V152, P765, DOI 10.1164/ajrccm.152.2.7633740; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; HAYAKAWA T, 1994, CELL STRUCT FUNCT, V19, P109, DOI 10.1247/csf.19.109; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; LACRAZ S, 1992, J CLIN INVEST, V90, P382, DOI 10.1172/JCI115872; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298, DOI 10.1164/ajrccm.159.4.9708080; LEPPERT D, 1995, J IMMUNOL, V154, P4379; MARTRISIAN LM, 1990, TRENDS GENET, V6, P121; Mattos WL, 1999, AM J RESP CRIT CARE, V159, pA325; Mautino G, 1999, AM J RESP CRIT CARE, V160, P324, DOI 10.1164/ajrccm.160.1.9808087; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; Mercer PF, 1999, AM J RESP CRIT CARE, V159, pA189; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; *NIH, 1995, GLOB STRAT ASTHM MAN, P77; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; ROCHE WR, 1989, LANCET, V1, P520; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; Shute JK, 1997, INT ARCH ALLERGY IMM, V113, P366, DOI 10.1159/000237604; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; THURLBECK WM, 1990, CHEST, V97, pS6, DOI 10.1378/chest.97.2.6S; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; Warner JA, 1997, INT ARCH ALLERGY IMM, V113, P318, DOI 10.1159/000237587; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Xia MH, 1996, J IMMUNOL, V156, P160; Yao PM, 1996, J BIOL CHEM, V271, P15580, DOI 10.1074/jbc.271.26.15580	35	66	77	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					900	905		10.1067/mai.2000.105316	http://dx.doi.org/10.1067/mai.2000.105316			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808169				2022-12-18	WOS:000087185000007
J	Belsito, DV				Belsito, DV			The diagnostic evaluation, treatment. and prevention of allergic contact dermatitis in the new millennium	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergic contact dermatitis; common allergens; clinical manifestations; diagnostic evaluation; immunoregulation; treatment; prevention	ORAL LICHENOID LESIONS; LYMPH-NODE ACTIVATION; PATCH TEST REACTIONS; TATTOO REACTION; METAL-SALTS; SENSITIZATION; HYPERSENSITIVITY; NICKEL; SKIN; AGE	Identifying the etiology of allergic contact dermatitis is a rewarding yet challenging endeavor. Not all allergic contact reactions are eczematous in appearance. The most reliable clinical clue to the allergic nature of the dermatitis is its geographic distribution. Once a list of culprit allergens has been identified by patch testing, the practitioner must identify the relevant allergen(s) and counsel the patient in avoidance. For most individuals, allergen avoidance results in resolution of the dermatitis; however, some patients will require continuing symptomatic therapy despite avoidance. For those patients unable to avoid known allergens, immunosuppressant therapies (including phototherapy) or barriers ran be beneficial. Currently, hyposensitization is not a viable alternative for the treatment of allergic contact dermatitis.	Univ Kansas, Med Ctr, Div Dermatol, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center	Belsito, DV (corresponding author), Univ Kansas, Med Ctr, Div Dermatol, Kansas City, KS 66103 USA.							ADAMS RM, 1999, OCCUPTATIONAL SKIN D; ADDY JH, 1991, INT J DERMATOL, V30, P271, DOI 10.1111/j.1365-4362.1991.tb04636.x; Amann U, 1997, HAUTARZT, V48, P410, DOI 10.1007/s001050050603; ANCONA A, 1982, CONTACT DERMATITIS, V8, P91, DOI 10.1111/j.1600-0536.1982.tb04152.x; *ASS SCH PUBL HLTH, 1988, PROP NAT STRAT PREV, P65; BAER RL, 1979, DERMATOLOGY GENERAL, P512; Balato N, 1996, CONTACT DERMATITIS, V34, P153, DOI 10.1111/j.1600-0536.1996.tb02159.x; BASKETTER DA, 1994, FOOD CHEM TOXICOL, V32, P543, DOI 10.1016/0278-6915(94)90112-0; Belsito D V, 1992, AM J CONTACT DERMATI, V3, P193; BELSITO DV, 1993, CUTIS, V52, P291; BELSITO DV, 1988, J INVEST DERMATOL, V90, P546; BELSITO DV, 1987, ARCH DERMATOL RES, V279, pS76, DOI 10.1007/BF00585926; BELSITO DV, 1989, CLIN REV ALLERG, V7, P347; Belsito DV, 1999, DERMATOL CLIN, V17, P705, DOI 10.1016/S0733-8635(05)70117-0; BELSITO DV, 1997, 8 INT P EHRL SEM STU, P195; BELSITO DV, 1999, FITZPATRICKS DERMATO, P1447; BERMAN B, 1983, BRIT J DERMATOL, V109, P553, DOI 10.1111/j.1365-2133.1983.tb07678.x; Bloch B, 1926, ARCH DERMATOL SYPH-G, V152, P283, DOI 10.1007/BF01828376; BRANCACCIO RR, 1993, J AM ACAD DERMATOL, V28, P827, DOI 10.1016/0190-9622(93)70110-F; Bruynzeel D P, 1982, Derm Beruf Umwelt, V30, P16; Castelli D, 1998, CONTACT DERMATITIS, V38, P123, DOI 10.1111/j.1600-0536.1998.tb05676.x; Cederbrant K, 1997, INT ARCH ALLERGY IMM, V112, P212, DOI 10.1159/000237456; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; Cohen DE, 1997, J AM ACAD DERMATOL, V36, P914, DOI 10.1016/S0190-9622(97)80272-1; Cohen DE, 1997, DERMATOL CLIN, V15, P137, DOI 10.1016/S0733-8635(05)70421-6; CUMBERBATCH M, 1993, TOXICOLOGY, V77, P181, DOI 10.1016/0300-483X(93)90148-L; Dang M, 1998, INT J DERMATOL, V37, P860, DOI 10.1046/j.1365-4362.1998.00593.x; Daoud MS, 1997, J AM ACAD DERMATOL, V36, P178, DOI 10.1016/S0190-9622(97)70276-7; Dearman RJ, 1996, FUND APPL TOXICOL, V33, P24, DOI 10.1006/faat.1996.0139; DeGroot A., 1986, PATCH TESTING TEST C; Dupuis G., 1982, ALLERGIC CONTACT DER; ELMETS CA, 1983, J EXP MED, V158, P781, DOI 10.1084/jem.158.3.781; Enk AH, 1997, MOL MED TODAY, V3, P423, DOI 10.1016/S1357-4310(97)01087-3; EPSTEIN St., 1956, DERMATOLOGICA, V113, P191; EPSTEIN WL, 1982, ARCH DERMATOL RES, V272, P279, DOI 10.1007/BF00509057; FISHER AA, 1974, CUTIS, V14, P25; FOUSSEREAU J, 1988, CONTACT DERMATITIS, V18, P183, DOI 10.1111/j.1600-0536.1988.tb04518.x; Freeman S, 1997, CONTACT DERMATITIS, V36, P247, DOI 10.1111/j.1600-0536.1997.tb00211.x; FUNK JO, 1994, J AM ACAD DERMATOL, V31, P999, DOI 10.1016/S0190-9622(94)70272-1; Gaspari A A, 1996, Am J Contact Dermat, V7, P212, DOI 10.1016/S1046-199X(96)90052-4; Geier J, 1999, CONTACT DERMATITIS, V40, P119, DOI 10.1111/j.1600-0536.1999.tb06008.x; GONCALO S, 1992, CONTACT DERMATITIS, V26, P112, DOI 10.1111/j.1600-0536.1992.tb00894.x; Guerder S, 1995, Int Rev Immunol, V13, P135, DOI 10.3109/08830189509061743; GUIN JD, 1995, PRACTICAL CONTACT DE; HALBERT AR, 1992, CONTACT DERMATITIS, V27, P214, DOI 10.1111/j.1600-0536.1992.tb03248.x; Heylings JR, 1996, TOXICOLOGY, V109, P57, DOI 10.1016/0300-483X(96)03304-5; HOGAN DJ, 1990, SEMIN DERMATOL, V9, P233; *INT COORD COMM VA, 1999, 994494 NIH PUBLICATI; JADASSOHN J, 1895, VERHANDLUNGEN DTSCH, P103; JAMES WD, 1992, J AM ACAD DERMATOL, V26, P991, DOI 10.1016/0190-9622(92)70145-6; KATZ DH, 1971, J EXP MED, V134, P201, DOI 10.1084/jem.134.1.201; KAUPPINEN K, 1976, ANN CLIN RES, V8, P232; KIEFFER M, 1979, CONTACT DERMATITIS, V5, P398, DOI 10.1111/j.1600-0536.1979.tb04913.x; Kimber I, 1995, TOXICOLOGY, V103, P63, DOI 10.1016/0300-483X(95)03114-U; Kimber I, 1999, FOOD CHEM TOXICOL, V37, P553, DOI 10.1016/S0278-6915(99)00048-4; KLIGMAN AM, 1958, ARCH DERMATOL, V78, P47, DOI 10.1001/archderm.1958.01560070051008; KOCH P, 1995, CONTACT DERMATITIS, V33, P323, DOI 10.1111/j.1600-0536.1995.tb02046.x; Krasteva M, 1999, EUR J DERMATOL, V9, P144; KRASTEVA M, 1996, OBJECTIF PEAU, V4, P442; KWANGSUKSTITH C, 1995, CONTACT DERMATITIS, V33, P289, DOI 10.1111/j.1600-0536.1995.tb02041.x; Laine J, 1997, CONTACT DERMATITIS, V36, P141, DOI 10.1111/j.1600-0536.1997.tb00396.x; Landsteiner K, 1941, J EXP MED, V73, P431, DOI 10.1084/jem.73.3.431; Larsen W, 1998, Am J Contact Dermat, V9, P202; LEMBO G, 1987, CONTACT DERMATITIS, V17, P122, DOI 10.1111/j.1600-0536.1987.tb02684.x; Lips R, 1996, CONTACT DERMATITIS, V34, P268, DOI 10.1111/j.1600-0536.1996.tb02198.x; LOMBARDI P, 1983, CONTACT DERMATITIS, V9, P520, DOI 10.1111/j.1600-0536.1983.tb04483.x; MARCUSSEN PV, 1963, ARCH DERMATOL, V87, P378, DOI 10.1001/archderm.1963.01590150094017; Marks JG, 1998, J AM ACAD DERMATOL, V38, P911, DOI 10.1016/S0190-9622(98)70587-0; MARKS JG, 1987, ARCH DERMATOL, V123, P476, DOI 10.1001/archderm.123.4.476; MARKS JG, 1990, AM J CONTACT DERMATI, V1, P157; MARKS JG, 1996, IN PRESS ARCH DERMAT; MITCHELL JC, 1977, CONTACT DERMATITIS, V3, P315, DOI 10.1111/j.1600-0536.1977.tb03695.x; Mizoguchi S, 1998, DERMATOLOGY, V196, P268, DOI 10.1159/000017891; MORK NJ, 1983, ACTA DERM-VENEREOL, V63, P87; MORTON CA, 1995, CONTACT DERMATITIS, V32, P281, DOI 10.1111/j.1600-0536.1995.tb00781.x; MUSTAIN EL, 1986, J IMMUNOL, V136, P4372; NALEFSKI EA, 1993, J IMMUNOL, V150, P3806; NOSSAL GJV, 1991, EUR J BIOCHEM, V202, P729, DOI 10.1111/j.1432-1033.1991.tb16427.x; OLERUP O, 1988, IMMUNOGENETICS, V28, P310, DOI 10.1007/BF00364228; OLIVER E. A., 1939, Journal of the American Medical Association, V113, P927; PARKER D, 1983, J INVEST DERMATOL, V81, P198, DOI 10.1111/1523-1747.ep12517692; PARODI G, 1987, LICHENOID PHOTOCONTA, V16, P136; Penagos H, 1996, CONTACT DERMATITIS, V35, P214, DOI 10.1111/j.1600-0536.1996.tb02360.x; PRYCE DW, 1989, CONTACT DERMATITIS, V21, P28, DOI 10.1111/j.1600-0536.1989.tb04681.x; PRZYBILLA B, 1983, DERMATOLOGICA, V167, P1, DOI 10.1159/000249735; REES JL, 1990, BRIT J DERMATOL, V122, P29, DOI 10.1111/j.1365-2133.1990.tb08236.x; Rietschel R.L., 1995, FISHERS CONTACT DERM; RIETSCHEL RL, 1990, AM J CONTACT DERMATI, V1, P53; ROBERTS DL, 1981, ARCH DERMATOL, V117, P273, DOI 10.1001/archderm.117.5.273; ROLDAN FP, 1992, REV CLIN ESP, V191, P501; Schamberg JF, 1919, J AMER MED ASSOC, V73, P1213, DOI 10.1001/jama.1919.02610420041014; SCHIRMER RH, 1987, Z HAUTKRANKHEITEN, V62, P792; SCHUBERT H, 1987, B DERMATOLOGIA ALLER, V2, P35; Sharma VK, 1999, CONTACT DERMATITIS, V41, P40, DOI 10.1111/j.1600-0536.1999.tb06206.x; SilvennoinenKassinen S, 1997, INT ARCH ALLERGY IMM, V114, P94, DOI 10.1159/000237650; SILVENNOINENKASSINEN S, 1979, TISSUE ANTIGENS, V14, P459; SKOG E, 1958, Acta Derm Venereol, V38, P1; Slavin RG, 1999, ALLERGY ASTHMA PROC, V20, P229, DOI 10.2500/108854199778339044; SOMMER G, 1975, IMMUNOLOGY, V29, P517; STRAUS HENRY W., 1931, JOUR ALLERGY, V2, P137, DOI 10.1016/S0021-8707(31)90341-9; STRICKLER A, 1923, JAMA-J AM MED ASSOC, V80, P1588; Sulzberger M B, 1975, Contact Dermatitis, V1, P117, DOI 10.1111/j.1600-0536.1975.tb05337.x; Sulzberger MB, 1929, ARCH DERMATOL SYPH, V20, P669, DOI 10.1001/archderm.1929.01440050079007; Tresukosol P, 1997, CONTACT DERMATITIS, V36, P176, DOI 10.1111/j.1600-0536.1997.tb00416.x; VALSECCHI R, 1982, ARCH DERMATOL, V118, P533, DOI 10.1001/archderm.118.7.533; VEIEN NK, 1983, CONTACT DERMATITIS, V9, P402, DOI 10.1111/j.1600-0536.1983.tb04437.x; VONPIRQUET C, ALLERGIE; WALKER FB, 1967, INT ARCH ALLER A IMM, V32, P453, DOI 10.1159/000229956; WARSHAWSHKI L, 1981, CONTACT DERMATITIS, V7, P351, DOI 10.1111/j.1600-0536.1981.tb04112.x; WHITE IR, 1984, BRIT DENT J, V156, P259, DOI 10.1038/sj.bdj.4805333; WHITE SI, 1986, BRIT J DERMATOL, V115, P663, DOI 10.1111/j.1365-2133.1986.tb06646.x; WOLF R, 1987, DERMATOLOGICA, V174, P285, DOI 10.1159/000249200; YASUDA H, 1983, Hokkaido Journal of Medical Science, V58, P617	113	66	68	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					409	420		10.1067/mai.2000.104937	http://dx.doi.org/10.1067/mai.2000.104937			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	347UC	10719287				2022-12-18	WOS:000088946700002
J	Niggemann, B; Buck, D; Michael, T; Wahn, U				Niggemann, B; Buck, D; Michael, T; Wahn, U			Latex provocation tests in patients with spine bifida: Who is at risk of becoming symptomatic?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; provocation test; spina bifida	ALLERGY; CHILDREN; HYPERSENSITIVITY	Background: Although there is accepted information on the prevalence rates of sensitization to latex in patients with spina bifida, little is known about the clinical relevance of this sensitization. Methods: We performed provocation tests with latex gloves in 159 patients with spina bifida (median age, 10 years). Results: Eighty-eight patients (55.3%) were sensitized to Latex in terms of a positive skin prick test response, specific IgE to latex in serum, or both. Fifty-five patients (34.6% of all patients or 62.5% of Latex-sensitized patients) showed clinical symptoms on provocation. Specific IgE to latex was significantly higher in patients with a positive provocation test response (P<.0001), The total number of operations and degree of sensitization showed a significant correlation. More than 8 operations significantly increased the risk of sensitization (P<.0001), and more than 9 operations increased the risk of allergy to latex (P<.0001), One hundred seventeen (75%) patients had a ventricular shunt system, Specific IgE in these patients was significantly higher than in patients without (P<.0001), and the odds ratio for the existence of a shunt system in terms of a positive provocation was 3.9. Patients with a shunt system were significantly more often sensitized and had positive provocation results (P<.0001). Seventy-two patients (45.3%) were classified as atopic; they were significantly more often sensitized and clinically symptomatic (P<.0001), and the odds ratio for having a positive provocation response was 3.2 for atopic subjects. History of symptoms on contact with material containing latex had a sensitivity of 53.7% and specificity of 94.2%. Conclusions: Our results indicate that an atopic disposition, number of operations, and presence of a shunt system increase the risk of becoming not only sensitized but also allergic to latex. Our results strongly support the necessity that patients with spina bifida as a high-risk group for latex allergy should remain latex-free from the first day of life.	Humboldt Univ, Virchow Clin, Dept Pediat, D-13353 Berlin, Germany	Humboldt University of Berlin	Niggemann, B (corresponding author), Humboldt Univ, Childrens Hosp Charite, Div Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.							AXEN RE, 1988, NEW ENG REG ALLERGY, V9, P503; BANTA JV, 1993, DEV MED CHILD NEUROL, V35, P540; Baur X, 1997, ALLERGY, V52, P661, DOI 10.1111/j.1398-9995.1997.tb01046.x; BEAUDOUIN E, 1994, EUR J PEDIATR SURG, V4, P90, DOI 10.1055/s-2008-1066075; Bode CP, 1996, PEDIATR ALLERGY IMMU, V7, P157, DOI 10.1111/j.1399-3038.1996.tb00125.x; DASTOUS J, 1992, J BONE JOINT SURG AM, V74A, P1084, DOI 10.2106/00004623-199274070-00016; DeSwert LFA, 1997, CLIN EXP ALLERGY, V27, P1067; DORMANS JP, 1994, J BONE JOINT SURG AM, V76A, P1688, DOI 10.2106/00004623-199411000-00012; ELLSWORTH PI, 1993, J UROLOGY, V150, P691, DOI 10.1016/S0022-5347(17)35587-8; ERIKSSON NE, 1990, ALLERGY, V45, P285, DOI 10.1111/j.1398-9995.1990.tb00497.x; Hamilton RG, 1997, ANN ALLERG ASTHMA IM, V79, P266, DOI 10.1016/S1081-1206(10)63013-X; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V94, P53, DOI 10.1016/0091-6749(94)90071-X; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; Liebke C, 1996, PEDIATR ALLERGY IMMU, V7, P103, DOI 10.1111/j.1399-3038.1996.tb00115.x; Mazon A, 1997, J ALLERGY CLIN IMMUN, V99, P600, DOI 10.1016/S0091-6749(97)70019-8; Michael T, 1996, CLIN EXP ALLERGY, V26, P934; Nieto A, 1996, J ALLERGY CLIN IMMUN, V98, P501, DOI 10.1016/S0091-6749(96)70082-9; Niggemann B, 1997, PEDIATR ALLERGY IMMU, V8, P51, DOI 10.1111/j.1399-3038.1997.tb00143.x; Niggemann B, 1997, J ALLERGY CLIN IMMUN, V100, P849, DOI 10.1016/S0091-6749(97)70284-7; SLATER JE, 1991, J UROLOGY, V146, P578, DOI 10.1016/S0022-5347(17)37860-6; TOSI LL, 1993, J PEDIATR ORTHOPED, V13, P709, DOI 10.1097/01241398-199311000-00003; YASSIN MS, 1992, ANN ALLERGY, V69, P207	22	66	70	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				665	670		10.1016/S0091-6749(98)70285-4	http://dx.doi.org/10.1016/S0091-6749(98)70285-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802377				2022-12-18	WOS:000076600400019
J	Peden, DB; Berger, WE; Noonan, MJ; Thomas, MR; Hendricks, VL; Hamedani, AG; Mahajan, P; House, KW				Peden, DB; Berger, WE; Noonan, MJ; Thomas, MR; Hendricks, VL; Hamedani, AG; Mahajan, P; House, KW			Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting of the European-Respiratory-Society	SEP 20-24, 1997	BERLIN, GERMANY	European Resp Soc		asthma; children; Diskhaler; Diskus; fluticasone propionate	MODERATE ASTHMA; BECLOMETHASONE DIPROPIONATE; CHILDREN; AEROSOL; TRIAL; CORTICOSTEROIDS; CHILDHOOD; LIFE	Background: Inhaled corticosteroids are increasingly being used to treat mild-to-moderate asthma in children. However, data regarding therapy with this class of compounds, especially in children under age 6 years, is limited. Fluticasone propionate is a third generation inhaled corticosteroid with an optimal therapeutic index, Few large prospective clinical trials have been conducted to evaluate the efficacy and safety of fluticasone propionate powder in children. Objective: We sought to determine the efficacy and safety of fluticasone propionate powder administered by means of the Diskus and Diskhaler multidose powder inhalers in pediatric patients with persistent asthma, Methods: Fluticasone propionate powder (50 mu g or 100 mu g twice daily) or placebo was administered by means of the Diskus or Diskhaler inhalers to 437 children (4 to 11 years old) with persistent asthma for 12 weeks in a randomized, double-blind, parallel-group, multi-center trial. Patients were stratified according to whether they were receiving prior treatment with inhaled corticosteroids or cromolyn or beta(2)-agonists alone. Results: Fluticasone propionate powder administered by means of Diskus or Diskhaler significantly improved FEV1 (mean increase from baseline of 0.22 to 0.24 L: p less than or equal to 0.023), ic morning peak expiratory flow (mean increase from baseline of 48 to 55 L/min; p less than or equal to 0.006), patient-measured morning (p less than or equal to 0.001) and evening (p less than or equal to 0.003) peak expiratory flow; and asthma symptom scores (in all but the 50 mu g Diskus group; p less than or equal to 0.036), as well as reduced albuterol use (p less than or equal to 0.002) and nighttime awakenings (p less than or equal to 0.019) at endpoint, Efficacy parameters were not significantly different between the two doses with either device. More placebo-treated patients discontinued the study because of lack of efficacy than patients in any fluticasone propionate group (p < 0.001). Fluticasone propionate did not suppress morning plasma cortisol concentrations and did not affect 24-hour urinary free-cortisol excretion. Adverse events were primarily pharmacologic effects of inhaled corticosteroids, and those related to the study drug occurred with low frequency. Patient satisfaction with both the Diskus and Diskhaler devices was high, with a majority of patients (> 80%) rating them favorably. Conclusion: This study demonstrated that fluticasone propionate powder, at the conventional recommended doses of up to 200 mu g/day administered by means of Diskus or Diskhaler, was well tolerated and improved lung function in children even as young as 4 and 5 years old regardless of whether they were previously treated with inhaled corticosteroids or cromolyn or beta(2)-agonists alone.	Univ N Carolina, Dept Pediat, Div Pulm Med & Allergy, Chapel Hill, NC USA; So Calif Res Ctr, Mission Viejo, CA USA; Allergy Associates, Portland, OR USA; Midwest Allergy & Asthma Clin Inc, Omaha, NE USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline	Peden, DB (corresponding author), CEMLB, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.			Peden, David/0000-0003-4526-4627				AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; *AM THOR SOC, 1987, AM REV RESPIR DIS, V36, P225; BROWN PH, 1991, RESP MED, V85, P511, DOI 10.1016/S0954-6111(06)80269-6; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; DEBLAQUIERE P, 1989, AM REV RESPIR DIS, V140, P910, DOI 10.1164/ajrccm/140.4.910; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Dodge R, 1996, J ALLERGY CLIN IMMUN, V98, P48, DOI 10.1016/S0091-6749(96)70225-7; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; GADDIE J, 1973, LANCET, V2, P280; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; Hoekstra MO, 1996, AM J RESP CRIT CARE, V154, P1039, DOI 10.1164/ajrccm.154.4.8887604; Hoekx JCM, 1996, EUR RESPIR J, V9, P2263, DOI 10.1183/09031936.96.09112263; HUMMEL S, 1992, LANCET, V340, P1483, DOI 10.1016/0140-6736(92)92750-A; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V98, pS3, DOI 10.1016/S0091-6749(96)80122-9; Lipworth BJ, 1997, THORAX, V52, P686, DOI 10.1136/thx.52.8.686; MACKENZIE CA, 1993, EUR J PEDIATR, V152, P856, DOI 10.1007/BF02073387; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; *NIH, 1992, US DEP HHS PUBL; *NIH NAT HEART LUN, 1997, NIH PUBL; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; POLGAR G, 1971, PULMONARY FUNCTION T, P12; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; TOOGOOD JH, 1977, J ALLERGY CLIN IMMUN, V59, P298, DOI 10.1016/0091-6749(77)90051-3; Wasserman SI, 1996, J ASTHMA, V33, P265, DOI 10.3109/02770909609055367; Wright AL, 1996, AM J RESP CRIT CARE, V153, P1259, DOI 10.1164/ajrccm.153.4.8616551	27	66	67	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					32	38		10.1016/S0091-6749(98)70052-1	http://dx.doi.org/10.1016/S0091-6749(98)70052-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	102DX	9679845				2022-12-18	WOS:000074909500007
J	Storms, W; Meltzer, EO; Nathan, RA; Selner, JC				Storms, W; Meltzer, EO; Nathan, RA; Selner, JC			The economic impact of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; pharmacoeconomics; survey	UNITED-STATES; ASTHMA	Allergic rhinitis is the most common chronic allergic disease. Symptoms include continuous or periodic nasal congestion, rhinorrhea, sneezing, itching of the nose and eyes, generalized malaise, irritability, and fatigue. We conducted an evaluation of the costs related to management of allergic rhinitis in a U.S. population. Data are based on self-reported trends in medication and health care services usage from a nationwide population sample selected from a base of 15,000 households. The average per-patient expenditure for prescription medications was $56 yearly. The mean per-patient expenditure for nonprescription medications was $56 yearly. Based on the findings of this study, the estimated total annual medication cost associated with allergic rhinitis in the United States is $2.4 billion. Because 63% of our study population had consulted a physician within the last 12 months, we estimate that a further $1.1 billion is associated with physician billing. The cost of the comorbid conditions of asthma and sinusitis originating from or exacerbated by allergic rhinitis could significantly alter these figures. If management of these conditions were allowed to contribute, even in part, to the indirect cost, the financial impact of this disease would be more properly appreciated.	ASTHMA & ALLERGY ASSOCIATES,COLORADO SPRINGS,CO; ALLERGY & ASTHMA MED GRP & RES CTR,SAN DIEGO,CA; ALLERGY RESP INST COLORADO,DENVER,CO									*BUR CENS, 1992, STAT ABSTR US 1992, P21; DRUCE HM, 1993, ALLERGY PRINCIPLES P, P1433; FAGIN J, 1981, PEDIATR CLIN N AM, V28, P797; LEVIT KR, 1994, HEALTH AFFAIR, V13, P14, DOI 10.1377/hlthaff.13.5.14; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V82, P950, DOI 10.1016/0091-6749(88)90038-3; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; YOUNG P, 1980, 80388 NIH PUBL; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T	11	66	66	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	2	S			S820	S824		10.1016/S0091-6749(97)80042-5	http://dx.doi.org/10.1016/S0091-6749(97)80042-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XJ363					2022-12-18	WOS:A1997XJ36300004
J	Kanazawa, H; Shoji, S; Yamada, M; Fujii, T; Kawaguchi, T; Kudoh, S; Hirata, K; Yoshikawa, J				Kanazawa, H; Shoji, S; Yamada, M; Fujii, T; Kawaguchi, T; Kudoh, S; Hirata, K; Yoshikawa, J			Increased levels of nitric oxide derivatives in induced sputum in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nitric oxide; induced sputum; bronchial asthma; eosinophil cationic protein; epithelial shedding	CIGARETTE SMOKERS; EPITHELIAL-CELLS; EXHALED AIR; LUNG; PEROXYNITRITE; MECHANISMS; SUPEROXIDE; AIRWAYS; DISEASE; INJURY	Background: Nitric oxide (NO) plays an important role as an inflammatory mediator in the airways. However, because direct measurement of endogenous NO has been difficult in who, the exact pathologic roles of NO in human airway inflammation have remained unclear, Objective: This study was designed to determine whether NO may be harmful by amplifying allergic inflammation in asthmatic airways. Methods: In (his study we examined the concentration of stable end products of NO, nitrite and nitrate! in induced sputum in 18 patients with asthma and 10 normal control subjects and evaluated the relationship between levels of NO derivatives in sputum and cellular and biochemical profiles, the degree of airflow obstruction, and the cytotoxic activities for epithelial cells. Results: The concentration of NO derivatives in induced sputum was significantly higher in patients with asthma than in normal control subjects (1086 +/- 325 mu mol/L, 577 +/- 115 mu mol/L; p < 0.05). Percentages of eosinophil counts and eosinophil cationic protein levels in sputum were also significantly higher in patients with asthma. Moreover, percentages of eosinophil counts and eosinophil cationic protein levels in sputum in patients with asthma were: significantly correlated with the concentration of NO derivatives in sputum (r = 0.63, p < 0.01; r = 0.56, p < 0.05. respectively), In addition, we found that the concentration of KO derivatives in sputum in patients with asthma was significantly correlated with the degree of airflow obstruction (FEV1/forced vital capacity) (r = -0.62, p < 0.01) and dth percentages of shedding epithelial cells (r = 0.61, p < 0.01). Conclusion: We bare shown that a higher concentration of NO derivatives was found in induced sputum of patients with asthma as compared with normal subjects. The clinical implication of our findings is that measurement of NO derivatives in induced sputum mag he useful fur assessing allergic inflammation in airways.			Kanazawa, H (corresponding author), OSAKA CITY UNIV,SCH MED,DEPT INTERNAL MED 1,ABENO KU,1-5-7 ASAHI MACHI,OSAKA 545,JAPAN.							ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; ALVING K, 1992, ACTA PHYSIOL SCAND, V146, P407, DOI 10.1111/j.1748-1716.1992.tb09439.x; BARNES PJ, 1993, EUR RESPIR J, V6, P163; BARNES PJ, 1993, THORAX, V48, P1034, DOI 10.1136/thx.48.10.1034; BARNES PJ, 1986, LANCET, V1, P242; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; GALDSTON M, 1984, AM REV RESPIR DIS, V129, P258; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; KUO HP, 1992, EUR J PHARMACOL, V221, P385; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; MCGOWAN SE, 1984, J LAB CLIN MED, V104, P127; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; PACHT ER, 1986, J CLIN INVEST, V77, P789, DOI 10.1172/JCI112376; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; PHIZACKERLEY PJR, 1983, ANAL BIOCHEM, V131, P242, DOI 10.1016/0003-2697(83)90161-6; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; REDOWSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V198, P1027; SARAN M, 1990, FREE RADICAL RES COM, V10, P221, DOI 10.3109/10715769009149890; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; TUCKER JF, 1990, BRIT J PHARMACOL, V100, P663, DOI 10.1111/j.1476-5381.1990.tb14072.x; UNTERSEE P, 1971, RESP PHYSIOL, V13, P171, DOI 10.1016/0034-5687(71)90088-0; WHITE CW, 1985, EXP LUNG RES, V8, P81, DOI 10.3109/01902148509057515	29	66	71	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					624	629		10.1016/S0091-6749(97)70024-1	http://dx.doi.org/10.1016/S0091-6749(97)70024-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155829				2022-12-18	WOS:A1997WY60000010
J	Riccio, MM; Proud, D				Riccio, MM; Proud, D			Evidence that enhanced nasal reactivity to bradykinin in patients with symptomatic allergy is mediated by neural reflexes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bradykinin; allergic rhinitis; atropine; neural reflexes; cholinergic; glandular secretion; lactoferrin; albumin; vascular permeability; sneezing	ANTIGEN CHALLENGE; PATHO-PHYSIOLOGY; RHINITIS; RESPONSES; PROVOCATION; SECRETIONS; HISTAMINE; AIRWAYS; INTERLEUKIN-1; PERMEABILITY	Objective: The aim of this study was to determine whether allergic inflammation induces nasal hyperreactivity to bradykinin by enhancing neuronal responsiveness. Methods: We compared the response to localized, unilateral nasal challenge with bradykinin in patients with perennial allergic rhinitis and nonallergic subjects, and in patients with seasonal allergic rhinitis challenged in and out of season. Weights of secretions from each nostril were recorded, and levels of albumin and lactoferrin in secretions recovered from each nostril were assayed. Contralateral administration of atropine (0.32 mg) was used to evaluated the role of cholinergic reflexes in nasal hyperresponsiveness to bradykinin. Results: In patients with symptomatic allergy, bradykinin induced greater symptoms scores than in asymptomatic atopic or nonallergic control subjects. Moreover, bradykinin caused sneezing in a majority of patients with symptomatic allergy but in none of the asymptomatic atopic or nonallergic control subjects. Only patients with symptomatic allergy showed dose-dependent bilateral increases in secretion weights and levels of the serous glandular maker, lactoferrin. In contrast, bradykinin induced similar increases in ipsilateral, but not contralateral, levels of albumin in all patient populations. Atropine inhibited contralateral secretion and lactoferrin production (p < 0.05) in patients with symptomatic allergy. Conclusion: The induction of sneezing and of atropine-inhibitable contralateral glandular secretion demonstrates that allergic inflammation causes nasal hyperreactivity to bradykinin, at least in part, by enhancing neuronal responsiveness.	JOHNS HOPKINS ASTHMA & ALLERGY CTR,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [HL 32272] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032272] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARANIUK JN, 1994, CLIN EXP ALLERGY, V24, P724, DOI 10.1111/j.1365-2222.1994.tb00982.x; BARANIUK JN, 1994, INT ARCH ALLERGY IMM, V103, P202, DOI 10.1159/000236628; BARNES PJ, 1992, THORAX, V47, P979, DOI 10.1136/thx.47.11.979; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661, DOI 10.1152/jappl.1993.74.6.2661; BATHON JM, 1992, J PHARMACOL EXP THER, V260, P384; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; ELLIS JL, 1992, J PHARMACOL EXP THER, V262, P646; FOX AJ, 1993, J PHYSIOL-LONDON, V469, P21, DOI 10.1113/jphysiol.1993.sp019802; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; HERXHEIMER H, 1961, J PHYSIOL-LONDON, V158, P38; HOLMBERG K, 1990, EUR J PHARMACOL, V175, P35, DOI 10.1016/0014-2999(90)90149-Z; KAUFMAN MP, 1980, J APPL PHYSIOL, V48, P511, DOI 10.1152/jappl.1980.48.3.511; KONNO A, 1979, ANN OTO RHINOL LARYN, V88, P258, DOI 10.1177/000348947908800219; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MOLIMARD M, 1994, AM J RESP CRIT CARE, V149, P123, DOI 10.1164/ajrccm.149.1.7509245; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; RAJAKULASINGAM K, 1991, J PHYSIOL-LONDON, V437, P557; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; RICCIO MM, 1995, IN PRESS AM J RESP C; SVENSJO E, 1985, PROG RESPIR RES, V19, P173; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; VARONIER HS, 1968, INT ARCH ALLER A IMM, V34, P293, DOI 10.1159/000230120; WAGENMANN M, 1994, J ALLERGY CLIN IMMUN, V93, P594, DOI 10.1016/S0091-6749(94)70071-0; WILLIAMS TJ, 1990, AM REV RESPIR DIS, V141, pS39	30	66	67	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1252	1263		10.1016/S0091-6749(96)70193-8	http://dx.doi.org/10.1016/S0091-6749(96)70193-8			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648021	hybrid			2022-12-18	WOS:A1996VD60700013
J	Bauer, L; Kohlich, A; Hirschwehr, R; Siemann, U; Ebner, H; Scheiner, O; Kraft, D; Ebner, C				Bauer, L; Kohlich, A; Hirschwehr, R; Siemann, U; Ebner, H; Scheiner, O; Kraft, D; Ebner, C			Food allergy to honey: Pollen or bee products? Characterization of allergenic proteins in honey by means of immunoblotting	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy honey; IgE inhibition; honeybee heads; bee venom	BIRCH POLLEN; ANTIBODIES; IDENTIFICATION; PURIFICATION; PROFILIN; CELERY; VENOM; IGE	Objective: To characterize the allergenic components of honey, 23 patients allergic to honey were investigated All displayed allergic symptoms after ingestion of honey or honey-containing products. ranging from itching in the oral mucosa to severe systemic symptoms to anaphylactic shock. Methods and results: Immunoblot analyses of the patients' sein revealed IgE binding to proteins at a molecular mass of 54 kd, 60 kd, 72 kd, or to a 30 kd/33 kd double band, or to both in sunflower honey extracts. The three bands corresponding to higher molecular mass proteins could also be detected in the three other kinds of honey (locust tree, European chestnut and forest honey) that were tested and represented bee products because IgE binding to these proteins was inhibited by extracts of honeybee heads and extracts of isolated bee venom sacs. The 30 kd/33 kd bands could be identified as sunflower honey-specific. When resting sera from patients allergic to bee venom with honey extract, in seven of 10 cases IgE binding to bee-specific components could be observed. Conclusion: Both proteins derived from secretions of pharyngeal and salivary glands of honeybee heads and pollen proteins contained in the honey cause allergic reactions to honey.	UNIV VIENNA,AKH,INST GEN & EXPTL PATHOL,A-1090 VIENNA,AUSTRIA; INST BEE RES,BAD VOSLAU,AUSTRIA; ALLERGY CLIN REUMANNPL,VIENNA,AUSTRIA	University of Vienna								AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; BIRNBAUM J, 1989, CLIN EXP ALLERGY, V19, P229, DOI 10.1111/j.1365-2222.1989.tb02369.x; BOUSQUET J, 1984, ALLERGY, V39, P73, DOI 10.1111/j.1398-9995.1984.tb01936.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; FERNANDEZ C, 1993, J ALLERGY CLIN IMMUN, V92, P660, DOI 10.1016/0091-6749(93)90008-4; HAUSEN BM, 1987, CONTACT DERMATITIS, V17, P163, DOI 10.1111/j.1600-0536.1987.tb02699.x; HELBLING A, 1987, ALLERGOLOGIE, V10, P252; HELBLING A, 1992, ALLERGY, V47, P41, DOI 10.1111/j.1398-9995.1992.tb02248.x; HOFER T, 1985, SCHWEIZ MED WSCHR, V115, P1437; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; REISMAN RE, 1988, ALLERGY PRINCIPLES P, P1345; Stanley RG., 1974, POLLEN, DOI [10.1007/978-3-642-65905-8, DOI 10.1007/978-3-642-65905-8]; STREM E, 1958, ANN ALLERGY, P375; STUWE HT, 1989, NATURWISSENSCHAFTEN, V76, P426, DOI 10.1007/BF00366169; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; Zander E, 1975, HONIG HERKUNFT GEWIN, V2	25	66	71	1	24	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1996	97	1	1				65	73		10.1016/S0091-6749(96)70284-1	http://dx.doi.org/10.1016/S0091-6749(96)70284-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TR947	8568139				2022-12-18	WOS:A1996TR94700009
J	PHILIP, G; BAROODY, FM; PROUD, D; NACLERIO, RM; TOGIAS, AG				PHILIP, G; BAROODY, FM; PROUD, D; NACLERIO, RM; TOGIAS, AG			THE HUMAN NASAL RESPONSE TO CAPSAICIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CAPSAICIN; NEUROGENIC MECHANISMS; NASAL SECRETION; NASAL LAVAGE; TOTAL PROTEIN; ALBUMIN; LACTOFERRIN	NEUROGENIC PLASMA EXTRAVASATION; VASOMOTOR RHINITIS; ANTIGEN CHALLENGE; AFFERENT NEURONS; MEDIATOR RELEASE; CIGARETTE-SMOKE; SENSORY NEURONS; AIRWAY MUCOSA; SUBSTANCE-P; SECRETION	Airway sensory nerves play a role in reactions to inhaled allergens, irritants, and physical stimuli. Capsaicin, the pungent principle of hot peppers, stimulates a subcategory of sensory nerves. To study the consequences of selective activation of airway sensory nerves in the human nose, we administered capsaicin nasal challenges to eight volunteers (four normal subjects and four subjects with perennial allergic rhinitis). Capsaicin (20 mu mol/L), when sprayed into the nose, induced burning, rhinorrhea, and lacrimation. Capsaicin also induced a significant increase in total protein content of nasal lavage fluid after challenge compared with vehicle (increase from before challenge to 1 minute after challenge, 172 +/- 55 vs 46 +/- 29 mu g/ml, p < 0.001). In contrast to many animal studies, capsaicin did not increase vascular permeability in the airway, because albumin content of nasal lavage fluid was not increased (p = 0.86). On the other hand, lactoferrin, a marker of glandular secretion, was increased (p < 0.005). Repetitive capsaicin challenge every 10 minutes led to tachyphylaxis of symptoms, total protein secretion, and lactoferrin secretion. Compared with vehicle, unilateral capsaicin (6 mmol/L) disk challenge induced significant secretion both ipsilateral (21.3 +/- 4.2 vs 4.9 +/- 2.2 mg, p < 0.01) and contralateral (18.2 +/- 4.4 vs 7.4 +/- 1.9 mg, p < 0.04) to challenge. Thus we have shown that capsaicin challenge to the human nose leads to airway sensory nerve activation. Further, we have demonstrated that capsaicin stimulates a predominantly central neuronal response and that the induced secretory response is of glandular rather than vascular origin.	JOHNS HOPKINS ASTHMA & ALLERGY CTR, DEPT OTOLARYNGOL HEAD & NECK SURG, BALTIMORE, MD 21224 USA; JOHNS HOPKINS ASTHMA & ALLERGY CTR, DEPT MED, DIV RESP & CRIT CARE MED, BALTIMORE, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	PHILIP, G (corresponding author), JOHNS HOPKINS ASTHMA & ALLERGY CTR, DEPT MED, DIV CLIN IMMUNOL, OFF UNIT 7, BALTIMORE, MD 21224 USA.				NHLBI NIH HHS [R29 HL-48248, HL-32272] Funding Source: Medline; NIAID NIH HHS [AI-33135] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048248, R01HL032272] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARANIUK JN, 1991, PULM PHARMACOL THER, V4, P20, DOI 10.1016/0952-0600(91)90035-2; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661, DOI 10.1152/jappl.1993.74.6.2661; BASCOM R, 1991, J PHARMACOL EXP THER, V259, P1323; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BORSON DB, 1991, AM J PHYSIOL, V260, pL212, DOI 10.1152/ajplung.1991.260.4.L212; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUNSTEIN G, 1991, AM REV RESPIR DIS, V144, P630, DOI 10.1164/ajrccm/144.3_Pt_1.630; CHURCH MK, 1982, J IMMUNOL, V129, P2116; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; Eccles R., 1982, NOSE UPPER AIRWAY PH, P191; GAMSE R, 1981, N-S ARCH PHARMACOL, V317, P140, DOI 10.1007/BF00500070; GEPPETTI P, 1988, BRIT J PHARMACOL, V93, P509, DOI 10.1111/j.1476-5381.1988.tb10305.x; HAYES EC, 1983, J IMMUNOL, V131, P429; HOLTZER P, 1991, PHARMACOL REV, V43, P143; LACROIX JS, 1991, CLIN EXP ALLERGY, V21, P595, DOI 10.1111/j.1365-2222.1991.tb00852.x; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LEE LY, 1989, J APPL PHYSIOL, V66, P2032, DOI 10.1152/jappl.1989.66.5.2032; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0; LUNDBLAD L, 1984, ACTA PHYSIOL SCAND, P1; MAGGI CA, 1991, J AUTONOM NERV SYST, V33, P1, DOI 10.1016/0165-1838(91)90013-S; MARABINI S, 1991, EUR ARCH OTO-RHINO-L, V248, P191; MCDONALD DM, 1992, AM REV RESPIR DIS, V146, pS40, DOI 10.1164/ajrccm/146.5_Pt_2.S40; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; PETERSSON G, 1989, BRIT J PHARMACOL, V98, P930, DOI 10.1111/j.1476-5381.1989.tb14623.x; PETERSSON G, 1993, J PHARMACOL EXP THER, V264, P509; RAJAKULASINGAM K, 1992, J APPL PHYSIOL, V72, P1418, DOI 10.1152/jappl.1992.72.4.1418; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V87, P457, DOI 10.1016/0091-6749(91)90001-5; STJARNE P, 1989, BRIT J PHARMACOL, V96, P693, DOI 10.1111/j.1476-5381.1989.tb11870.x; STJARNE P, 1991, ACTA PHYSIOL SCAND, V142, P1; Stjarne P, 1991, AM J RHINOL ALLERGY, V5, P145, DOI [10.2500/105065891781874992, DOI 10.2500/105065891781874992]; UNDEM BJ, 1991, INT ARCH ALLER A IMM, V94, P319, DOI 10.1159/000235394; WELLS UM, 1992, PULM PHARMACOL, V5, P183, DOI 10.1016/0952-0600(92)90039-J	35	66	92	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				1035	1045		10.1016/0091-6749(94)90122-8	http://dx.doi.org/10.1016/0091-6749(94)90122-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7798536	Bronze			2022-12-18	WOS:A1994PY23000012
J	HACZKU, A; ALEXANDER, A; BROWN, P; ASSOUFI, B; LI, BQ; KAY, AB; CORRIGAN, C				HACZKU, A; ALEXANDER, A; BROWN, P; ASSOUFI, B; LI, BQ; KAY, AB; CORRIGAN, C			THE EFFECT OF DEXAMETHASONE, CYCLOSPORINE, AND RAPAMYCIN ON T-LYMPHOCYTE PROLIFERATION IN-VITRO - COMPARISON OF CELLS FROM PATIENTS WITH GLUCOCORTICOID-SENSITIVE AND GLUCOCORTICOID-RESISTANT CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; THERAPY; GLUCOCORTICOID RESISTANCE; T LYMPHOCYTES; IMMUNOSUPPRESSANTS	MESSENGER-RNA; GROWTH-FACTOR; BRONCHIAL BIOPSIES; DISEASE SEVERITY; ATOPIC ASTHMA; ACTIVATION; INHIBITION; EOSINOPHILIA; EXPRESSION; RECEPTOR	Inhibition of T-lymphocyte activation may provide a useful approach to the treatment of chronic severe asthma. We compared rapamycin, a novel immunosuppressive drug, with cyclosporine and dexamethasone for its effects in inhibiting proliferation of T lymphocytes from patients with glucocorticoid-resistant and glucocorticoid-sensitive asthma. Phytohemagglutinin-stimulated peripheral blood T lymphocytes from 11 patients with clinically glucocorticoid-resistant and 8 patients with glucocorticoid-sensitive chronic asthma were tested for sensitivity to these drugs in a highly reproducible proliferation assay. All drugs inhibited proliferation in a dose-dependent manner (10(-6) to 10(-10) mol/L). T lymphocytes from the patients with glucocorticoid-resistant asthma were significantly less sensitive (p < 0.01) to dexamethasone than those of patients with glucocorticoid-sensitive asthma over a wide concentration range. In contrast, cyclosporine and rapamycin inhibited cells from both patient groups to an equivalent extent. The presence of exogenous interleukin-2 abrogated the inhibitory effect of dexamethasone bur not that of cyclosporine or rapamycin, suggesting that dexamethasone may act principally by inhibition of interleukin-2 production, whereas the latter drugs exert distinct or additional inhibitory effects. Stimulation of peripheral blood T lymphocytes with phytohemagglutinin for 24 hours before addition of the drugs abolished the inhibitory effect of dexamethasone and significantly reduced that of cyclosporine. The Inhibitory effect of rapamycin was, however unaltered These data suggest that dexamethasone and cyclosporine evert their effects only at an early stage of T-lymphocyte activation whereas rapamycin is able to inhibit lymphoblasts. The fact that the inhibitory mechanisms of these drugs are different might explain why cyclsoporine and rapamycin are effective in inhibiting T lymphocytes from both patients with glucocorticoid-sensitive and those with glucocorticoid-resistant asthma. The data further suggest that cyclosporine and rapamycin may be effective for the therapy of glucocorticoid-resistant asthma.	NATL HEART & LUNG INST,DEPT ALLERGY & CLIN IMMUNOL,LONDON SW3 6LY,ENGLAND; WESTERN GEN HOSP,EDINBURGH,SCOTLAND	Imperial College London; University of Edinburgh			HACZKU, ANGELA/A-8486-2013	HACZKU, ANGELA/0000-0002-1301-4941; Brown, Penelope/0000-0001-8487-7106; Corrigan, Chris/0000-0002-0706-6534				ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ALVAREZ J, 1992, J ALLERGY CLIN IMMUN, V89, P714, DOI 10.1016/0091-6749(92)90379-G; ARYA SK, 1984, J IMMUNOL, V133, P273; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BLOEMENA E, 1989, EUR J IMMUNOL, V19, P943, DOI 10.1002/eji.1830190524; CARMICHAEL J, 1981, BRIT MED J, V282, P1419, DOI 10.1136/bmj.282.6274.1419; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1988, LANCET, V1, P1129; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1026, DOI 10.1164/ajrccm/144.5.page; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FRYER J, 1993, TRANSPLANTATION, V55, P340, DOI 10.1097/00007890-199302000-00021; GILLIS S, 1979, J IMMUNOL, V123, P1624; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LASSALLE P, 1992, CLIN EXP IMMUNOL, V87, P266; METCALFE SM, 1990, TRANSPLANTATION, V49, P798, DOI 10.1097/00007890-199004000-00028; POZNANSKY MC, 1985, CLIN EXP IMMUNOL, V61, P135; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SEGHAL SN, 1990, TRANSPLANT IMMUNOL L, V7, P12; VANOERS RHJ, 1985, TRANSPLANT P, V17, P2700; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALKER KB, 1987, CLIN EXP IMMUNOL, V68, P162; WU J, 1991, TRANSPLANT P, V23, P238	26	66	68	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					510	519		10.1016/0091-6749(94)90361-1	http://dx.doi.org/10.1016/0091-6749(94)90361-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	8120277	Bronze, Green Published			2022-12-18	WOS:A1994MY58100013
J	DIETEMANN, A; BESSOT, JC; HOYET, C; OTT, M; VEROT, A; PAULI, G				DIETEMANN, A; BESSOT, JC; HOYET, C; OTT, M; VEROT, A; PAULI, G			A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SOLIDIFIED BENZYL BENZOATE APPLIED IN DWELLINGS OF ASTHMATIC-PATIENTS SENSITIVE TO MITES - CLINICAL EFFICACY AND EFFECT ON MITE ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MITES; MITE ALLERGENS; ASTHMA PREVENTION; ACARICIDES	DERMATOPHAGOIDES-PTERONYSSINUS ALLERGENS; HOUSE DUST SAMPLES; DER-P-I; AVOIDANCE MEASURES; F-I; CHILDREN; GUANINE; REDUCTION; CHILDHOOD; ACARICIDE	Background: The aim of this double-blind, randomized study was to investigate the effectiveness of an acaricidal cleaning product in modifying both clinical symptoms and mite allergen levels over a period of at least 1 year. Methods: Twenty-six asthmatic patients with proven Dermatophagoides pteronyssinus (Dp) asthma were selected; three were withdrawn from the trial. The patients' homes were divided into two groups; 11 homes were treated with solidified benzyl benzoate and tenside agents (A), and 12 were treated with a placebo (P). Two applications were performed at the beginning of the trial and at least 6 months later. Patients were examined 1 month before the trial, at the beginning of the trial, and every 3 months over a period of 1 year. Indoor mite exposure was evaluated by three methods: semiquantitative guanine determinations, quantitative guanine determinations, and the measurement of Der p I + Der f I (antigen P, of Dp + antigen F1 of D. farinae) levels. Results: The symptom scores established at the beginning of the trial and 12 months later showed a statistically significant improvement only in the A group (p < 0.01). The visual analog scale also showed a statistically significant difference both in the A (p < 0.05) and P groups (p < 0.01). No statistical differences were found between medication scores in the A or P groups. A statistically significant increase was also observed for forced expiratory volume in 1 second and maximal expiratory flow rate 25 / 75 in the two groups (p < 0.05 for P group; p < 0.01 for A group). The mean decreases in Der p I + Der f I in patient mattresses between the beginning of the trial and after 12 months were 20% for the acaricide group and 17% for the placebo group, respectively (NS). For house dust samples with origins other than the patients' mattresses we found significant decreases in Der p I + Der f I in the A group (p < 0.01 for carpets and p < 0.05 for upholstery elements).	HOP UNIV STRASBOURG, HOP CIVIL, PAVILLON LAENNEC, SERV PNEUMOL, BP426, F-67091 STRASBOURG, FRANCE	CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								BISCHOFF E, 1984, ALLERGOLOGIE, V7, P446; BISCHOFF E, 1987, ADV AEROBIOLOGY, P189; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; CHARPIN D, 1990, REV FR ALLERGOL, V30, P149, DOI 10.1016/S0335-7457(05)80229-1; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; ELIXMANN JH, 1988, ALLERGOLOGIE, V11, P274; HOYET C, 1991, J ALLERGY CLIN IMMUN, V88, P678, DOI 10.1016/0091-6749(91)90162-H; KERSTEN W, 1988, ALLERGOLOGIE, V11, P371; KNIEST FM, 1991, CLIN EXP ALLERGY, V21, P39, DOI 10.1111/j.1365-2222.1991.tb00802.x; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; LAUSCHADENDORF S, 1991, J ALLERGY CLIN IMMUN, V87, P41, DOI 10.1016/0091-6749(91)90211-6; LEMAO J, 1989, J ALLERGY CLIN IMMUN, V83, P926, DOI 10.1016/0091-6749(89)90107-3; LEMAO J, 1980, J ALLERGY CLIN IMMUN, V65, P381, DOI 10.1016/0091-6749(80)90217-1; LEMAO J, 1992, INDOOR ENVIRON, V1, P212; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MURRAY AB, 1983, PEDIATRICS, V71, P418; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PAULI G, 1985, EUR J RESPIR DIS, V67, P369; PAULI G, 1989, REV FR ALLERGOL, V29, P175, DOI 10.1016/S0335-7457(89)80014-0; PAULI G, 1988, CLIN ALLERGY, V18, P383, DOI 10.1111/j.1365-2222.1988.tb02886.x; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P716, DOI 10.1136/adc.49.9.716; Siegel S., 1956, NONPARAMETRIC STAT B; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; WALSHAW MJ, 1986, Q J MED, V58, P199	30	66	68	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1993	91	3					738	746		10.1016/0091-6749(93)90193-J	http://dx.doi.org/10.1016/0091-6749(93)90193-J			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KU203	8454796	Bronze			2022-12-18	WOS:A1993KU20300006
J	KELLY, WJW; HUDSON, I; PHELAN, PD; PAIN, MCF; OLINSKY, A				KELLY, WJW; HUDSON, I; PHELAN, PD; PAIN, MCF; OLINSKY, A			ATOPY IN SUBJECTS WITH ASTHMA FOLLOWED TO THE AGE OF 28 YEARS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROYAL CHILDRENS HOSP,DEPT THORAC MED,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT THORAC MED,PARKVILLE,VIC 3050,AUSTRALIA	Royal Children's Hospital Melbourne; Royal Melbourne Hospital				Hudson, Irene/0000-0002-9000-9556				BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BRODER I, 1962, J ALLERGY, V33, P524, DOI 10.1016/0021-8707(62)90020-5; BRODER I, 1962, J ALLERGY, V33, P513, DOI 10.1016/0021-8707(62)90019-9; BRYANT DH, 1976, CLIN ALLERGY, V6, P373, DOI 10.1111/j.1365-2222.1976.tb01919.x; BRYANT DH, 1976, CLIN ALLERGY, V6, P523, DOI 10.1111/j.1365-2222.1976.tb01937.x; BUFFUM WP, 1966, AM J DIS CHILD, V112, P214, DOI 10.1001/archpedi.1966.02090120082007; BULLEN SS, 1929, NEW YORK STATE J MED, V29, P545; CADE JF, 1971, AUST NZ J MED, V1, P22, DOI 10.1111/j.1445-5994.1971.tb02256.x; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; FINK JN, 1969, J ALLERGY, V43, P167; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; MARTIN AJ, 1981, MED J AUSTRALIA, V2, P470, DOI 10.5694/j.1326-5377.1981.tb112942.x; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MCNICHOL KN, 1973, BRIT MED J, V4, P12, DOI 10.1136/bmj.4.5883.12; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; NEALE A V, 1963, Med Hist, V7, P247; OGILVIE A. G., 1962, THORAX, V17, P183, DOI 10.1136/thx.17.3.183; PATTERSO.R, 1965, J CLIN INVEST, V44, P140, DOI 10.1172/JCI105120; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; WOOLCOCK AJ, 1978, CLIN ALLERGY, V8, P155, DOI 10.1111/j.1365-2222.1978.tb00460.x; 1987, BR J DIS CHEST, V81, P30	27	66	67	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1990	85	3					548	557		10.1016/0091-6749(90)90092-I	http://dx.doi.org/10.1016/0091-6749(90)90092-I			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CU668	2312990	Bronze			2022-12-18	WOS:A1990CU66800003
J	COCKCROFT, DW; MURDOCK, KY; GORE, BP; OBYRNE, PM; MANNING, P				COCKCROFT, DW; MURDOCK, KY; GORE, BP; OBYRNE, PM; MANNING, P			THEOPHYLLINE DOES NOT INHIBIT ALLERGEN-INDUCED INCREASE IN AIRWAY RESPONSIVENESS TO METHACHOLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,MED CTR,AMBROSE CARDIORESP UNIT,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University	COCKCROFT, DW (corresponding author), UNIV HOSP SASKATOON,RESP MED SECT,SASKATOON S7N 0X0,SASKATCHEWAN,CANADA.			O'Byrne, Paul/0000-0003-0979-281X				ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BLEECKER E R, 1981, American Review of Respiratory Disease, V123, P53; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHUNG KF, 1986, AM REV RESPIR DIS, V134, P258; CHUNG KF, 1985, J APPL PHYSIOL, V58, P1347, DOI 10.1152/jappl.1985.58.4.1347; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COCKCROFT DW, 1987, ANN ALLERGY, V59, P405; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, IN PRESS LATE PHASE; COCKCROFT DW, IN PRESS BRONCHITIS, V4; CRESCIOLI S, 1988, American Review of Respiratory Disease, V137, P35; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DORSCH W, 1980, PRAX KLIN PNEUMOL, V34, P461; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KERREBIJN KF, 1986, EUR J RESPIR DIS, V69, P98; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MAPP CE, 1987, AM REV RESPIR DIS, V16, P1403; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; NISSIM JE, 1980, J ALLERGY CLIN IMMUN, V65, P180; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PAUWELS R, 1987, CHEST, V92, pS32, DOI 10.1378/chest.92.1_Supplement.32S; PEEL ET, 1980, AM REV RESPIR DIS, V121, P973; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; Steel R.G., 1980, PRINCIPLES PROCEDURE, V2nd, P102; STEEL RGD, 1980, PRINCIPLES PROCEDURE, P544	36	66	66	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					913	920		10.1016/0091-6749(89)90105-X	http://dx.doi.org/10.1016/0091-6749(89)90105-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2497168				2022-12-18	WOS:A1989U716100011
J	KLOPROGGE, E; DELEEUW, AJ; DEMONCHY, JGR; KAUFFMAN, HF				KLOPROGGE, E; DELEEUW, AJ; DEMONCHY, JGR; KAUFFMAN, HF			HYPODENSE EOSINOPHILIC GRANULOCYTES IN NORMAL INDIVIDUALS AND PATIENTS WITH ASTHMA - GENERATION OF HYPODENSE CELL-POPULATIONS INVITRO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GRONINGEN HOSP,INTERNAL MED CLIN,DEPT ALLERGOL,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen								BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BEESON PB, 1980, EOSINOPHIL HLTH DISE, P313; BOOYNOORD H, 1972, CLIN ALLERGY, V2, P43; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P738; BUTTERWORTH AE, 1975, NATURE, V256, P727, DOI 10.1038/256727a0; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; DAHL R, 1982, EUR J RESPIR DIS, V122, P23; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DESIMONE C, 1982, CLIN EXP IMMUNOL, V48, P249; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GARTNER I, 1980, IMMUNOLOGY, V40, P133; GLEICH GJ, 1986, 12 P INT C ALL CLIN, P124; HOFFBRAND AV, 1985, ESSENTIAL HAEMATOLOG; KAUFFMAN HF, 1987, J ALLERGY CLIN IMMUN, V79, P611, DOI 10.1016/S0091-6749(87)80157-4; KLOPROGGE E, 1983, THROMB RES, V29, P595, DOI 10.1016/0049-3848(83)90214-1; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; MIGLER R, 1978, BIOCHEM MED METAB B, V19, P16, DOI 10.1016/0006-2944(78)90003-0; OLSEN RL, 1983, BIOCHEM J, V209, P781, DOI 10.1042/bj2090781; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; PARILLO JE, 1978, BLOOD, V51, P457; POPPER H, 1983, FOLIA ALLERGOL IM S4, P92; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; RAMESH KS, 1987, BIOCHIM BIOPHYS ACTA, V923, P241, DOI 10.1016/0304-4165(87)90009-2; ROBERTS RL, 1985, BLOOD, V65, P433; ROOS D, 1970, BIOCHIM BIOPHYS ACTA, V222, P565, DOI 10.1016/0304-4165(70)90182-0; Roos D, 1986, Methods Enzymol, V132, P225; ROTHENBERG ME, 1987, SCIENCE, V237, P645, DOI 10.1126/science.3110954; SPRY CJF, 1985, IMMUNOL TODAY, V6, P332, DOI 10.1016/0167-5699(85)90130-6; STRATH M, 1985, J IMMUNOL METHODS, V83, P209, DOI 10.1016/0022-1759(85)90242-X; VADAS MA, 1979, J IMMUNOL, V122, P1228; VENGE P, 1983, IMMUNOBIOLOGY EOSINO, P163; WALSH PN, 1972, BRIT J HAEMATOL, V22, P205, DOI 10.1111/j.1365-2141.1972.tb08801.x; WASSERMAN SI, 1976, J CLIN INVEST, V57, P738, DOI 10.1172/JCI108332; WELLER PF, 1985, BLOOD, V65, P1269; WELLER PF, 1983, J CLIN INVEST, V71, P114, DOI 10.1172/JCI110739; WINQVIST I, 1981, IMMUNOLOGY, V51, P1; YAZDANBAKHSH M, 1987, IMMUNOLOGY, V60, P123	39	66	68	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				393	400		10.1016/0091-6749(89)90124-3	http://dx.doi.org/10.1016/0091-6749(89)90124-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2537351				2022-12-18	WOS:A1989T448900005
J	WASS, U; BELIN, L				WASS, U; BELIN, L			IMMUNOLOGICAL SPECIFICITY OF ISOCYANATE-INDUCED IGE ANTIBODIES IN SERUM FROM 10 SENSITIZED WORKERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											WASS, U (corresponding author), SAHLGRENS HOSP,ASTHMA & ALLERGY RES CTR,DEPT MED 1,S-41345 GOTHENBURG,SWEDEN.							BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; BUTCHER BT, 1983, CLIN ALLERGY, V13, P31, DOI 10.1111/j.1365-2222.1983.tb02563.x; CALLAGHER JS, 1981, J OCCUP MED, V23, P610; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; DANKS JM, 1981, CLIN ALLERGY, V11, P161, DOI 10.1111/j.1365-2222.1981.tb01580.x; DEWAIR M, 1983, INT ARCH OCC ENV HEA, V52, P257, DOI 10.1007/BF00526524; DEWAIR MA, 1982, J CLIN CHEM CLIN BIO, V20, P337; DILLER W, 1980, ZENTRALBL ARBEITSMED, V4, P100; GAME CJA, 1982, AM IND HYG ASSOC J, V43, P759, DOI 10.1202/0002-8894(1982)043<0759:ATWSAF>2.3.CO;2; GRUNEWALDER E, 1986, ALLERGY, V41, P203, DOI 10.1111/j.1398-9995.1986.tb00301.x; HANNA N, 1972, P SOC EXP BIOL MED, V140, P89; HENSCHLER D, 1984, GESUNDHEITSSCHADLICH; KAROL MH, 1979, J OCCUP ENVIRON MED, V21, P354; KAROL MH, 1980, CLIN ALLERGY, V10, P101, DOI 10.1111/j.1365-2222.1980.tb02086.x; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P546, DOI 10.1080/0002889778507807; MALO JL, 1983, J ALLERGY CLIN IMMUN, V72, P413, DOI 10.1016/0091-6749(83)90508-0; MAPP CE, 1985, ANN ALLERGY, V54, P424; MCKAY RT, 1983, AM REV RESPIR DIS, V128, P50, DOI 10.1164/arrd.1983.128.1.50; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; PAGGIARO PL, 1983, CLIN ALLERGY, V13, P75, DOI 10.1111/j.1365-2222.1983.tb02570.x; PEZZINI A, 1984, CLIN ALLERGY, V14, P453, DOI 10.1111/j.1365-2222.1984.tb02229.x; ROY N, 1979, CLIN LABORATORY STAT, P105; TSE CST, 1979, TOXICOL APPL PHARM, V51, P39, DOI 10.1016/0041-008X(79)90006-1; TSE KS, 1985, ALLERGY, V40, P314, DOI 10.1111/j.1398-9995.1985.tb00242.x; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	29	66	66	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					126	135		10.1016/0091-6749(89)90487-9	http://dx.doi.org/10.1016/0091-6749(89)90487-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2536411	Bronze			2022-12-18	WOS:A1989T041900018
J	DEGROOT, H; VANSWIETEN, P; VANLEEUWEN, J; LIND, P; AALBERSE, RC				DEGROOT, H; VANSWIETEN, P; VANLEEUWEN, J; LIND, P; AALBERSE, RC			MONOCLONAL-ANTIBODIES TO THE MAJOR FELINE ALLERGEN FEL-D-I .1. SEROLOGIC AND BIOLOGIC ACTIVITY OF AFFINITY-PURIFIED FEL-D-I AND OF FEL-D-I-DEPLETED EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COPENHAGEN,PROT LAB,DK-1168 COPENHAGEN K,DENMARK; ALK RES GRP,COPENHAGEN,DENMARK; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL,AMSTERDAM,NETHERLANDS; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,POB 9406,1006 AK AMSTERDAM,NETHERLANDS	University of Copenhagen; University of Amsterdam								Aalberse R C, 1983, Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M, P137; Aalberse R C, 1978, Acta Otorhinolaryngol Belg, V32, P25; ASTALDI GCB, 1980, J IMMUNOL, V125, P1411; BRYANT DH, 1976, MED J AUSTRALIA, V1, P918, DOI 10.5694/j.1326-5377.1976.tb141170.x; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KURATA JH, 1976, ANN ALLERGY, V37, P398; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; LOWENSTEIN H, 1981, ALLERGOLOGIE, V4, P265; LOWENSTEIN H, 1978, PROG ALLERGY, V25, P62; OHMAN JL, 1974, J IMMUNOL, V113, P1668; SARSFIELD JK, 1976, ARCH DIS CHILD, V51, P186, DOI 10.1136/adc.51.3.186; SCHWARTZ B, 1984, J ALLERGY CLIN IMM S, V74, P156; SIRAGANIAN RP, 1975, J IMMUNOL METHODS, V7, P283, DOI 10.1016/0022-1759(75)90025-3; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; Sutherland C, 1942, Br Med J, V2, P280; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3	22	66	67	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				778	786		10.1016/0091-6749(88)90079-6	http://dx.doi.org/10.1016/0091-6749(88)90079-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	2461402				2022-12-18	WOS:A1988R170800011
J	OBYRNE, PM				OBYRNE, PM			ALLERGEN-INDUCED AIRWAY HYPERRESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											OBYRNE, PM (corresponding author), MCMASTER UNIV,HLTH SCI CTR,DEPT MED,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA.			O'Byrne, Paul/0000-0003-0979-281X				AIZAWA H, 1985, J APPL PHYSIOL, V59, P1918, DOI 10.1152/jappl.1985.59.6.1918; ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BOSCHETTO P, 1986, J ALLERGY CLIN IMMUN, V77, P244; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BUTCHERS PR, 1979, BRIT J PHARMACOL, V67, P23; CAMUSSI G, 1983, AM J PATHOL, V112, P78; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHUNG KF, 1986, J PHARMACOL EXP THER, V236, P580; CHUNG KF, 1986, AM REV RESPIR DIS, V134, P258; CHUNG KF, 1985, J APPL PHYSIOL, V58, P1347, DOI 10.1152/jappl.1985.58.4.1347; COCKCROFT DW, 1987, THORAX, V42, P302, DOI 10.1136/thx.42.4.302; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1983, LANCET, V2, P253; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; CUSS FM, 1986, LANCET, V2, P189; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENJEAN A, 1983, J APPL PHYSIOL, V55, P799, DOI 10.1152/jappl.1983.55.3.799; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FABBRI LM, 1985, AM REV RESPIR DIS, V132, P1010; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GORDON T, 1985, AM REV RESPIR DIS, V132, P1106; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HEGARDT B, 1981, ALLERGY, V36, P115, DOI 10.1111/j.1398-9995.1981.tb04105.x; HENSON PM, 1977, J IMMUNOL, V119, P2179; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; KIRBY JG, 1987, AM REV RESPIR DIS, V135, pA12; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LANES S, 1986, J APPL PHYSIOL, V61, P864, DOI 10.1152/jappl.1986.61.3.864; LEE HK, 1985, AM REV RESPIR DIS, V132, P1005; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MORRIS HG, 1985, CHEST, V88, pS133, DOI 10.1378/chest.88.2.133S; MUITTARI A, 1978, CLIN ALLERGY, V8, P281, DOI 10.1111/j.1365-2222.1978.tb03225.x; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; NAKAMURA T, 1987, INT ARCH ALLER A IMM, V82, P57, DOI 10.1159/000234290; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P220; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; OBYRNE PM, 1985, J APPL PHYSIOL, V59, P1941, DOI 10.1152/jappl.1985.59.6.1941; PATTERSON R, 1984, J LAB CLIN MED, V104, P340; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PEPYS J, 1968, LANCET, V2, P134; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; SHEPHARD EG, 1985, BRIT J CLIN PHARMACO, V19, P459, DOI 10.1111/j.1365-2125.1985.tb02671.x; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; STEINBERG DR, 1987, J ALLERGY CLIN IMMUN, V79, P249; STEVENS FRANKLIN A., 1934, JOUR ALLERGY, V5, P285, DOI 10.1016/S0021-8707(34)90226-4; Taylor G, 1973, Clin Allergy, V3, P103, DOI 10.1111/j.1365-2222.1973.tb01314.x; THOMPSON PJ, 1984, AM REV RESPIR DIS, V129, P3; THORPE J, 1986, AM REV RESPIR DIS, V133, P93	56	66	67	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					119	127		10.1016/0091-6749(88)90230-8	http://dx.doi.org/10.1016/0091-6749(88)90230-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3276757				2022-12-18	WOS:A1988M027400019
J	VENABLES, KM; TOPPING, MD; NUNN, AJ; HOWE, W; TAYLOR, AJN				VENABLES, KM; TOPPING, MD; NUNN, AJ; HOWE, W; TAYLOR, AJN			IMMUNOLOGICAL AND FUNCTIONAL CONSEQUENCES OF CHEMICAL (TETRACHLOROPHTHALIC ANHYDRIDE)-INDUCED ASTHMA AFTER 4 YEARS OF AVOIDANCE OF EXPOSURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BROMPTON HOSP,MRC,TB & CHEST DIS UNIT,LONDON SW3 6HP,ENGLAND; HLTH & SAFETY EXECUT,OCCUPAT MED & HYG LAB,LONDON,ENGLAND	Royal Brompton Hospital	VENABLES, KM (corresponding author), BROMPTON HOSP,DEPT OCCUPAT MED,FULHAM RD,LONDON SW3 6HP,ENGLAND.							BERNSTEIN DI, 1984, J ALLERGY CLIN IMMUN, V74, P794, DOI 10.1016/0091-6749(84)90181-7; COCKCROFT DW, 1982, CHEST, V82, P572, DOI 10.1378/chest.82.5.572; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTES JE, 1979, LUNG FUNCTION ASSESS; GLEICH GJ, 1977, J ALLERGY CLIN IMMUN, V60, P188, DOI 10.1016/0091-6749(77)90123-3; HOLT PG, 1984, CELL IMMUNOL, V89, P281, DOI 10.1016/0008-8749(84)90330-7; HOWE W, 1983, J ALLERGY CLIN IMMUN, V71, P5, DOI 10.1016/0091-6749(83)90539-0; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; MCGRATH KG, 1984, J OCCUP ENVIRON MED, V26, P671; NAWATA Y, 1984, CLIN EXP IMMUNOL, V58, P348; OGAWA M, 1971, AM J MED, V51, P193, DOI 10.1016/0002-9343(71)90238-5; PLATTSMILLS TAE, 1982, LANCET, V2, P675; SCHLUETER DP, 1978, J OCCUP ENVIRON MED, V20, P183, DOI 10.1097/00043764-197803000-00006; TOPPING MD, 1986, J ALLERGY CLIN IMMUN, V77, P834, DOI 10.1016/0091-6749(86)90381-7; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; YEUNG M, 1985, THORAX, V40, P241, DOI 10.1136/thx.40.4.241; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1983, ANN INTERN MED, V98, P8, DOI 10.7326/0003-4819-98-1-8; 1977, MATERIAL SAFETY DATA	19	66	66	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					212	218		10.1016/0091-6749(87)90131-X	http://dx.doi.org/10.1016/0091-6749(87)90131-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	3611542				2022-12-18	WOS:A1987J657500013
J	SVENDSEN, UG; FROLUND, L; MADSEN, F; NIELSEN, NH; HOLSTEINRATHLOU, NH; WEEKE, B				SVENDSEN, UG; FROLUND, L; MADSEN, F; NIELSEN, NH; HOLSTEINRATHLOU, NH; WEEKE, B			A COMPARISON OF THE EFFECTS OF SODIUM CROMOGLYCATE AND BECLOMETHASONE DIPROPIONATE ON PULMONARY-FUNCTION AND BRONCHIAL HYPERREACTIVITY IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SVENDSEN, UG (corresponding author), RIGSHOSPITALET,DEPT MED TTA,ALLERGY UNIT 7511,TAGENSVEJ 20,DK-2200 COPENHAGEN N,DENMARK.		Holstein-Rathlou, Niels-Henrik/B-2781-2008	Madsen, Flemming/0000-0002-9911-0175				ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BERGLUND E, 1963, ACTA MED SCAND, V173, P185; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; CLARKE PS, 1982, J ASTHMA, V19, P91, DOI 10.3109/02770908209104741; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; CORDIER R, 1984, CLIN TRIALS J, V21, P487; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; DICKSON W, 1970, DISODIUM CROMOGLYCAT, P47; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; JUNIPER E F, 1980, American Review of Respiratory Disease, V121, P76; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MADSEN F, 1985, EUR J RESPIR DIS, V67, P193; MADSEN F, 1985, SCAND J CLIN LAB INV, V45, P453, DOI 10.3109/00365518509155243; ROCCHICCIOLI IL, 1984, THORAX, V39, P406; SIMONSSO BG, 1965, ACTA ALLERGOL, V20, P325, DOI 10.1111/j.1398-9995.1965.tb03068.x; STAFFORD WP, 1984, ANN ALLERGY, V52, P401; 1962, AM REV RESPIR DIS, V85, P762	20	66	66	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1987	80	1					68	74						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J2194	3110248				2022-12-18	WOS:A1987J219400011
J	LICHTENSTEIN, LM; MACGLASHAN, DW				LICHTENSTEIN, LM; MACGLASHAN, DW			THE CONCEPT OF BASOPHIL RELEASABILITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material											LICHTENSTEIN, LM (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,5601 LOCH RAVEN BLVD,BALTIMORE,MD 21239, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI008270, R01AI008270] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08270, AI07290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1979, J IMMUNOL, V122, P965; ASKENASE PW, 1979, J ALLERGY CLIN IMMUN, V64, P79, DOI 10.1016/0091-6749(79)90041-1; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; CONROY MC, 1982, FED PROC, V41, P376; CONROY MC, 1977, J IMMUNOL, V118, P1317; CZARNETZKI BM, 1976, J INVEST DERMATOL, V67, P276, DOI 10.1111/1523-1747.ep12514261; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FOREMAN JC, 1980, BIOCHIM BIOPHYS ACTA, V629, P587, DOI 10.1016/0304-4165(80)90164-6; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KAZIMIERCZAK W, 1984, J IMMUNOL, V132, P399; KENNERLY DA, 1979, J IMMUNOL, V122, P152; KERN F, 1976, J CLIN INVEST, V57, P1369, DOI 10.1172/JCI108405; LICHTENSTEIN LM, 1971, J IMMUNOL, V107, P1122; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; LICHTENSTEIN LM, MAST CELL DIFFERENTI; LICHTENSTEIN LM, 1977, ALLERGY CLIN IMMUNOL, P109; MACGLASHAN D, 1983, J IMMUNOL, V130, P2337; MACGLASHAN DW, 1981, J IMMUNOL, V127, P2410; MACGLASHAN DW, J IMMUNOL; MAEYAMA R, 1985, FED P, V44, P1917; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MARONE G, 1985, INT ARCH ALLER A IMM, V77, P103, DOI 10.1159/000233761; MARONE G, 12 P INT C ALL CLIN; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PETERS SP, 1981, NATURE, V292, P455, DOI 10.1038/292455a0; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; PLAUT M, J ALLERGY CLIN IMMUN; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SIRAGANIAN RP, 1976, J IMMUNOL, V116, P639; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; TUNG R, 1982, J IMMUNOL, V128, P2067	37	66	67	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1986	77	2					291	294		10.1016/S0091-6749(86)80106-3	http://dx.doi.org/10.1016/S0091-6749(86)80106-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A0899	2418091	Bronze			2022-12-18	WOS:A1986A089900004
J	DJURUP, R; MALLING, HJ; SONDERGAARD, I; WEEKE, B				DJURUP, R; MALLING, HJ; SONDERGAARD, I; WEEKE, B			THE IGE AND IGG SUBCLASS ANTIBODY-RESPONSE IN PATIENTS ALLERGIC TO YELLOW JACKET VENOM UNDERGOING DIFFERENT REGIMENS OF VENOM IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											DJURUP, R (corresponding author), RIGSHOSP,DEPT MED TA 7542,MED ALLERGOL,TAGENSVEJ 20,DK-2200 COPENHAGEN,DENMARK.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; BERNSTEIN IL, 1979, INT ARCH ALLER A IMM, V58, P30; BOREL Y, 1976, TRANSPLANT REV, V31, P3; CLAYTON WF, 1983, CLIN ALLERGY, V13, P301, DOI 10.1111/j.1365-2222.1983.tb02604.x; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; DJURUP R, 1984, ALLERGY, V39, P51, DOI 10.1111/j.1398-9995.1984.tb01933.x; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GRAFT DF, 1984, J ALLERGY CLIN IMMUN, V73, P61, DOI 10.1016/0091-6749(84)90485-8; GRANT JA, 1981, J ALLERGY CLIN IMMUN, V68, P112, DOI 10.1016/0091-6749(81)90168-8; HAMILTON RG, 1981, J ALLERGY CLIN IMMUN, V67, P14, DOI 10.1016/0091-6749(81)90039-7; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V72, P376, DOI 10.1016/0091-6749(83)90503-1; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; LEE WY, 1978, IMMUNOL REV, V41, P200, DOI 10.1111/j.1600-065X.1978.tb01466.x; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; MALLING HJ, ALLERGY; NIELSSON D, 1976, ACTA PAEDIATR, V65, P33; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; Siegel S., 1956, NONPARAMETRIC STAT B; SINCLAIR NRS, 1978, TRANSPLANT P, V10, P349	20	66	66	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					46	55		10.1016/0091-6749(85)90803-6	http://dx.doi.org/10.1016/0091-6749(85)90803-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	4008813				2022-12-18	WOS:A1985AMV8400006
J	GRAMMER, LC; SHAUGHNESSY, MA; PATTERSON, R				GRAMMER, LC; SHAUGHNESSY, MA; PATTERSON, R			MODIFIED FORMS OF ALLERGEN IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University				Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERRENS L, 1973, CLIN ALLERGY, V3, P449, DOI 10.1111/j.1365-2222.1973.tb01352.x; BUTTERFIELD JH, 1981, J ALLERGY CLIN IMMUN, V67, P272, DOI 10.1016/0091-6749(81)90021-X; CHIORAZZI N, 1976, P NATL ACAD SCI USA, V73, P2091, DOI 10.1073/pnas.73.6.2091; Freeman J, 1911, LANCET, V2, P814; FUCHS AM, 1959, J ALLERGY, V30, P66, DOI 10.1016/0021-8707(59)90060-7; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P160, DOI 10.1016/0091-6749(83)90524-9; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V73, P484, DOI 10.1016/0091-6749(84)90359-2; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P448, DOI 10.1016/0091-6749(83)90580-8; GRAMMER LC, 1982, J ALLERGY CLIN IMMUN, V69, P494, DOI 10.1016/0091-6749(82)90173-7; HENDRIX SG, 1980, J ALLERGY CLIN IMMUN, V66, P486, DOI 10.1016/0091-6749(80)90010-X; ISHIZAKA K, 1975, J IMMUNOL, V114, P110; JOHANSSON SG, 1974, CLIN ALLERGY, V4, P255, DOI 10.1111/j.1365-2222.1974.tb01383.x; JUNIPER EF, 1983, J ALLERGY CLIN IMMUN, V71, P119, DOI 10.1016/0091-6749(83)90247-6; LEE WY, 1977, NATURE, V267, P618, DOI 10.1038/267618a0; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; LIU FT, 1979, P NATL ACAD SCI USA, V76, P1430, DOI 10.1073/pnas.76.3.1430; LOVELESS MH, 1957, J IMMUNOL, V79, P68; MARSH DG, 1970, IMMUNOLOGY, V18, P705; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; METZGER WJ, 1981, J ALLERGY CLIN IMMUN, V68, P442, DOI 10.1016/0091-6749(81)90198-6; NORMAN PS, 1972, J ALLERGY CLIN IMMUN, V50, P31, DOI 10.1016/0091-6749(72)90077-2; NORMAN PS, 1967, J ALLERGY, V39, P82, DOI 10.1016/0021-8707(67)90114-1; NORMAN PS, 1984, J ALLERGY CLIN IMMUN, V73, P782, DOI 10.1016/0091-6749(84)90448-2; NORMAN PS, 1980, J ALLERGY CLIN IMMUN, V66, P336, DOI 10.1016/0091-6749(80)90030-5; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; NORMAN PS, 1979, J ALLERGY CLIN IMMUN, V63, P167; NORMAN PS, 1971, IMMUNOLOGIC DISEASES, V2, P840; PARKER CW, 1980, CLIN IMMUNOLOGY, V2, P1372; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1983, J ALLERGY CLIN IMMUN, V72, P129, DOI 10.1016/0091-6749(83)90519-5; PATTERSON R, 1981, J ALLERGY CLIN IMMUN, V68, P85, DOI 10.1016/0091-6749(81)90163-9; PATTERSON R, 1984, INT ARCH ALLER A IMM, V73, P1, DOI 10.1159/000233427; PATTERSON R, 1973, J IMMUNOL, V110, P1413; PATTERSON R, 1983, ALLERGY PRINCIPLES P, V2, P1119; REISMAN RE, 1965, INT ARCH ALLER A IMM, V28, P353, DOI 10.1159/000229681; SEHON AH, 1978, J ALLERGY CLIN IMMUN, V62, P257, DOI 10.1016/0091-6749(78)90155-0; ZEISS CR, 1979, J ALLERGY CLIN IMMUN, V63, P273, DOI 10.1016/0091-6749(79)90112-X; ZEISS CR, 1979, ALLERGY CLIN IMMUNOL, P616; 1967, FACT SHEET CARCINOGE	40	66	69	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					397	401		10.1016/0091-6749(85)90661-X	http://dx.doi.org/10.1016/0091-6749(85)90661-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	3926854				2022-12-18	WOS:A1985APE8900025
J	HOLGATE, ST; EMANUEL, MB; HOWARTH, PH				HOLGATE, ST; EMANUEL, MB; HOWARTH, PH			ASTEMIZOLE AND OTHER H-1-ANTIHISTAMINIC DRUG-TREATMENT OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JANSSEN PHARMACEUT LTD, WANTAGE, OXON, ENGLAND	Johnson & Johnson; Janssen Pharmaceuticals	HOLGATE, ST (corresponding author), SOUTHAMPTON GEN HOSP, CTR BLOCK, LEVEL D, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.			Howarth, Peter/0000-0003-0619-7927				ATKINS PC, 1980, J ALLERGY CLIN IMMUN, V66, P478, DOI 10.1016/0091-6749(80)90009-3; ATKINS PC, 1984, J ALLERGY CLIN IMMUN, V73, P341, DOI 10.1016/0091-6749(84)90406-8; BARNES PJ, 1982, CLIN SCI, V62, P661, DOI 10.1042/cs0620661; Best CH, 1927, J PHYSIOL-LONDON, V52, P397; BOOIJNOO.H, 1970, J ALLERGY, V46, P1, DOI 10.1016/0021-8707(70)90055-9; BRUCE C, 1976, THORAX, V31, P724, DOI 10.1136/thx.31.6.724; BRYANT DH, 1976, CLIN ALLERGY, V6, P523, DOI 10.1111/j.1365-2222.1976.tb01937.x; CHURCH MK, 1980, BRIT J PHARMACOL, V69, P663, DOI 10.1111/j.1476-5381.1980.tb07919.x; CLEE MD, 1984, BRIT J DIS CHEST, V78, P180, DOI 10.1016/0007-0971(84)90120-7; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; Code CF, 1937, J PHYSIOL-LONDON, V89, P257, DOI 10.1113/jphysiol.1937.sp003476; Dale HH, 1929, LANCET, V1, P1285; Dale HH, 1929, LANCET, V1, P1233; Dale HH, 1929, LANCET, V1, P1179; Dragstedt CA, 1936, J PHARMACOL EXP THER, V57, P419; DURHAM SR, 1983, THORAX, V38, P224; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; EISER NM, 1981, CLIN SCI, V60, P363, DOI 10.1042/cs0600363; FEINBERG SM, 1950, ANTIHISTAMINES, P112; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; GROGGINS RC, 1979, BRIT J DIS CHEST, V73, P297, DOI 10.1016/0007-0971(79)90056-1; HEGARDT B, 1982, ALLERGY, V37, P407, DOI 10.1111/j.1398-9995.1982.tb02319.x; HERXHEIMER H, 1949, BMJ-BRIT MED J, V2, P901, DOI 10.1136/bmj.2.4633.901; HOWARTH PH, 1984, J ALLERGY CLIN IMMUN, V73, P391, DOI 10.1016/0091-6749(84)90414-7; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; HOWARTH PH, RESPIRATION; IND PW, 1982, AGENTS ACTIONS, V12, P12, DOI 10.1007/BF01965099; LADURON PM, 1982, MOL PHARMACOL, V21, P294; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; MANN JS, 1984, THORAX, V39, P230; MCFADDEN ER, 1984, J ALLERGY CLIN IMMUN, V73, P413, DOI 10.1016/0091-6749(84)90347-6; NATHAN RA, 1979, AM REV RESPIR DIS, V120, P1251; NOGRADY SG, 1978, THORAX, V33, P700, DOI 10.1136/thx.33.6.700; PARTRIDGE MR, 1979, THORAX, V34, P771, DOI 10.1136/thx.34.6.771; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PHILLIPS MJ, 1984, THORAX, V39, P345, DOI 10.1136/thx.39.5.345; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; SCHILD HO, 1951, LANCET, V261, P376; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; THOMSON NC, 1980, THORAX, V35, P428, DOI 10.1136/thx.35.6.428; WHITE J, 1983, BRIT J DIS CHEST, V77, P215; Windaus A, 1907, BER DTSCH CHEM GES, V40, P3691, DOI 10.1002/cber.190704003164; 1982, MERCK INDEX, P2398	43	66	66	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					375	380		10.1016/0091-6749(85)90657-8	http://dx.doi.org/10.1016/0091-6749(85)90657-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	2862178				2022-12-18	WOS:A1985APE8900021
J	BOUSQUET, J; MENARDO, JL; AZNAR, R; ROBINETLEVY, M; MICHEL, FB				BOUSQUET, J; MENARDO, JL; AZNAR, R; ROBINETLEVY, M; MICHEL, FB			CLINICAL AND IMMUNOLOGICAL SURVEY IN BEEKEEPERS IN RELATION TO THEIR SENSITIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CTR TRANSFUS SANGUINE HERAULT,MALAD RESP CLIN,MONTPELLIER,FRANCE; CTR TRANSFUS SANGUINE HERAULT,PROT LAB,MONTPELLIER,FRANCE									ADKINSON NF, 1981, J ALLERGY CLIN IMMUN, V67, P87, DOI 10.1016/0091-6749(81)90001-4; BOUSQUET J, 1982, CLIN ALLERGY, V12, P331, DOI 10.1111/j.1365-2222.1982.tb02537.x; CASE RL, 1981, J ALLERGY CLIN IMMUN, V68, P399, DOI 10.1016/0091-6749(81)90139-1; GOLDEN D B K, 1982, Journal of Allergy and Clinical Immunology, V69, P124; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; GRANT AJ, 1981, J ALLERGY CLIN IMMUN, V58, P112; HAMILTON RG, 1979, J IMMUNOL, V122, P1073; HOFFMAN DR, 1979, ANN ALLERGY, V43, P811; JARISCH R, 1980, ARCH DERMATOL RES, V217, P269; JARISCH R, ARCH DERMATOL RES; KAGEYSOBOTKA A, 1981, MONOGRAPH INSECT ALL, P31; KEMENY DM, 1982, INT ARCH ALLER A IMM, V68, P268, DOI 10.1159/000233110; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; LESSOF MH, 1976, J ALLERGY CLIN IMMUN, V57, P246; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LIGHT WC, 1975, CLIN ALLERGY, V5, P383; MIYACHI S, 1979, INT ARCH ALLER A IMM, V60, P148, DOI 10.1159/000232336; MOROZ LA, 1982, J ALLERGY CLIN IMMUN, V70, P315, DOI 10.1016/0091-6749(82)90073-2; MUELLER HL, 1959, NEW ENGL J MED, V261, P374, DOI 10.1056/NEJM195908202610803; MULLER U, 1977, CLIN ALLERGY, V7, P147, DOI 10.1111/j.1365-2222.1977.tb01435.x; MULLER U, 1978, CLIN ALLERGY, V8, P267, DOI 10.1111/j.1365-2222.1978.tb03223.x; REID MJ, 1982, J ALLERGY CLIN IMMUN, V70, P191, DOI 10.1016/0091-6749(82)90041-0; REISMAN RE, 1983, 10TH P INT C ALL CLI, P459; SANTRACH PJ, 1980, ANN ALLERGY, V45, P130; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; SHIMIZU MM, 1976, J IMMUNOL METHODS, V19, P317; SOBOTKA AK, 1976, J IMMUNOL, V117, P84; VALENTINE MD, 1981, MONOGRAPH INSECT ALL, P47; VERVLOET D, 1974, Clinical Allergy, V4, P359, DOI 10.1111/j.1365-2222.1974.tb01397.x; YUNGINGER JW, 1978, J ALLERGY CLIN IMMUN, V61, P93, DOI 10.1016/0091-6749(78)90231-2; ZELEZNICK LD, 1977, J ALLERGY CLIN IMMUN, V59, P2, DOI 10.1016/0091-6749(77)90169-5; ZIMMERMANN EM, 1980, J ALLERGY CLIN IMMUN, V66, P386, DOI 10.1016/0091-6749(80)90118-9	32	66	66	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					332	340		10.1016/0091-6749(84)90405-6	http://dx.doi.org/10.1016/0091-6749(84)90405-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6699314				2022-12-18	WOS:A1984SK15500006
J	GREENBERGER, PA				GREENBERGER, PA			ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											GREENBERGER, PA (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,CHICAGO,IL 60611, USA.				NIAID NIH HHS [AI-11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA K, 1984, CHEST, V85, P699, DOI 10.1378/chest.85.5.699; BASICH JE, 1981, J ALLERGY CLIN IMMUN, V68, P98, DOI 10.1016/0091-6749(81)90165-2; BINDER RE, 1982, MEDICINE, V61, P109, DOI 10.1097/00005792-198203000-00005; CHANYEUN.M, 1971, CHEST, V59, P33, DOI 10.1378/chest.59.1.33; GEHA RS, 1977, J ALLERGY CLIN IMMUN, V60, P357, DOI 10.1016/0091-6749(77)90066-5; GHORY AC, 1980, INT ARCH ALLER A IMM, V62, P285, DOI 10.1159/000232524; GHORY AC, 1980, CLIN EXP IMMUNOL, V40, P581; GLEICH GJ, 1975, SCIENCE, V190, P1106, DOI 10.1126/science.1188389; GRAVES TS, 1978, ANN INTERN MED, V91, P378; GREENBERGER PA, 1980, J ALLERGY CLIN IMMUN, V66, P327, DOI 10.1016/0091-6749(80)90029-9; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; GREENBERGER PA, 1983, ARCH INTERN MED, V143, P2003, DOI 10.1001/archinte.143.10.2003; HALWIG JM, 1984, J ALLERGY CLIN IMMUN, V74, P738, DOI 10.1016/0091-6749(84)90238-0; HALWIG JM, UNPUB ALLERGIC BRONC; HENDRICK DJ, 1982, AM REV RESPIR DIS, V126, P935; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; IMBEAU SA, 1977, AM J DIS CHILD, V131, P1127, DOI 10.1001/archpedi.1977.02120230073013; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P243, DOI 10.1016/0091-6749(78)90214-2; ISHIZAKA T, 1976, J ALLERGY CLIN IMMUN, V58, P523, DOI 10.1016/0091-6749(76)90196-2; JOHANSSON S G O, 1970, British Journal of Dermatology, V82, P10, DOI 10.1111/j.1365-2133.1970.tb02185.x; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; LAUFER P, 1984, J ALLERGY CLIN IMMUN, V73, P44, DOI 10.1016/0091-6749(84)90482-2; MARX JJ, 1976, J ALLERGY CLIN IMMUN, V57, P328, DOI 10.1016/0091-6749(76)90089-0; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; MINTZER RA, 1978, RADIOLOGY, V127, P301, DOI 10.1148/127.2.301; NICHOLS D, 1979, AM J MED, V67, P631, DOI 10.1016/0002-9343(79)90246-8; PATTERSON R, 1982, ANN INTERN MED, V96, P286, DOI 10.7326/0003-4819-96-3-286; PATTERSON R, 1980, CLIN EXP IMMUNOL, V42, P395; PATTERSON R, 1977, AM J MED, V63, P257, DOI 10.1016/0002-9343(77)90240-6; PATTERSON R, 1979, J CLIN LAB IMMUNOL, V2, P199; PATTERSON R, 1968, University of Michigan Medical Center Journal, V34, P8; PATTERSON R, 1983, ANN INTERN MED, V99, P18, DOI 10.7326/0003-4819-99-1-18; RADIN RC, 1983, CLIN ALLERGY, V13, P271, DOI 10.1111/j.1365-2222.1983.tb02598.x; RICKETTI AJ, 1984, J ALLERGY CLIN IMMUN, V74, P68, DOI 10.1016/0091-6749(84)90089-7; RICKETTI AJ, 1983, J ALLERGY CLIN IMMUN, V71, P541, DOI 10.1016/0091-6749(83)90434-7; RICKETTI AJ, 1983, J ALLERGY CLIN IMMUN, V72, P386, DOI 10.1016/0091-6749(83)90504-3; RICKETTI AJ, 1984, INT ARCH ALLER A IMM, V73, P283, DOI 10.1159/000233483; RINALDI MG, 1983, REV INFECT DIS, V5, P1061; ROSENBERG IL, 1984, CHEST, V85, P123, DOI 10.1378/chest.85.1.123; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; ROSENBERG M, 1977, CHEST, V72, P597, DOI 10.1378/chest.72.5.597; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SCADDING JG, 1967, SCAND J RESPIR DIS, V48, P372; SCHWARTZ HJ, 1978, J ALLERGY CLIN IMMUN, V62, P8; SETTIPANE GA, 1978, J ALLERGY, V62, P163; SLAVIN R G, 1970, Journal of Pediatrics, V76, P416, DOI 10.1016/S0022-3476(70)80482-6; SLAVIN RG, 1978, INT ARCH ALLER A IMM, V56, P325, DOI 10.1159/000232038; SOLOMON WR, 1978, J ALLERGY CLIN IMMUN, V62, P56, DOI 10.1016/0091-6749(78)90073-8; VERNON DRH, 1980, CLIN ALLERGY, V10, P217, DOI 10.1111/j.1365-2222.1980.tb02100.x; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917; WANG JLF, 1979, AM REV RESPIR DIS, V120, P87	52	66	66	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	5					645	653		10.1016/0091-6749(84)90223-9	http://dx.doi.org/10.1016/0091-6749(84)90223-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT169	6438210				2022-12-18	WOS:A1984TT16900001
J	HIRATANI, M; MUTO, K; OSHIDA, Y; ITO, S; KASEI, M				HIRATANI, M; MUTO, K; OSHIDA, Y; ITO, S; KASEI, M			LYMPHOCYTE RESPONSIVENESS TO DERMATOPHAGOIDES-FARINAE EXTRACT IN MITE-SENSITIVE PATIENTS - EFFECT OF IMMUNOTHERAPY ON CELLULAR PROLIFERATIVE RESPONSE AND SPECIFIC IMMUNOGLOBULIN-E ANTIBODY (RAST SCORE)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											HIRATANI, M (corresponding author), KANAZAWA UNIV,SCH MED,DEPT PEDIAT,KANAZAWA,ISHIKAWA 920,JAPAN.							AHLSTEDT S, 1977, INT ARCH ALLER A IMM, V55, P400, DOI 10.1159/000231951; ASSEM E S K, 1973, Clinical Allergy, V3, P161, DOI 10.1111/j.1365-2222.1973.tb01319.x; ASSEM ESK, 1970, BRIT MED J, V2, P504, DOI 10.1136/bmj.2.5708.504; BROSTOFF J, 1969, LANCET, V2, P1269; BUCKLEY RH, 1977, J ALLERGY CLIN IMMUN, V59, P70, DOI 10.1016/0091-6749(77)90180-4; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GEHA RS, 1975, J CLIN INVEST, V56, P386, DOI 10.1172/JCI108103; GIRARD JP, 1967, J ALLERGY, V39, P65, DOI 10.1016/0021-8707(67)90113-X; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; ITO K, 1976, Japanese Journal of Allergology, V25, P815; KISHIMOTO T, 1979, J IMMUNOL, V64, P266; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; MAINI RN, 1971, CLIN EXP IMMUNOL, V9; MATHEWS KP, 1977, CELL IMMUNOL, V32, P120, DOI 10.1016/0008-8749(77)90187-3; MAUNSELL K, 1968, LANCET, V1, P1267; MIYAMOTO T, 1969, J ALLERGY, V44, P228, DOI 10.1016/0021-8707(69)90089-6; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; NAGAYA H, 1977, ANN ALLERGY, V39, P246; OWNBY DR, 1979, J ALLERGY CLIN IMMUN, V63, P65, DOI 10.1016/0091-6749(79)90164-7; REISMAN RE, 1975, INT ARCH ALLER A IMM, V48, P721, DOI 10.1159/000231360; RICHTER M, 1968, J ALLERGY, V41, P140, DOI 10.1016/0021-8707(68)90054-3; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; ROMAGNANI S, 1973, Clinical Allergy, V3, P51, DOI 10.1111/j.1365-2222.1973.tb01309.x; YOO TJ, 1977, ACTA ALLERGOL, V32, P227, DOI 10.1111/j.1398-9995.1977.tb01355.x; ZEITZ SJ, 1966, J ALLERGY, V38, P321, DOI 10.1016/0021-8707(66)90030-X	27	66	66	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	3					205	211		10.1016/0091-6749(81)90185-8	http://dx.doi.org/10.1016/0091-6749(81)90185-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG544	7021642				2022-12-18	WOS:A1981MG54400007
J	COHEN, SH; YUNGINGER, JW; ROSENBERG, N; FINK, JN				COHEN, SH; YUNGINGER, JW; ROSENBERG, N; FINK, JN			ACUTE ALLERGIC REACTION AFTER COMPOSITE POLLEN INGESTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT MED,ALLERGY SECT,MILWAUKEE,WI 53233; MAYO CLIN & MAYO FDN,ALLERG DIS RES LAB,ROCHESTER,MN 55901	Medical College of Wisconsin; Mayo Clinic	COHEN, SH (corresponding author), MILWAUKEE CTY MED COMPLEX,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.								0	66	69	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	4					270	274		10.1016/0091-6749(79)90143-X	http://dx.doi.org/10.1016/0091-6749(79)90143-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HQ469	479479				2022-12-18	WOS:A1979HQ46900007
J	HOFFMAN, DR; SHIPMAN, WH; BABIN, D				HOFFMAN, DR; SHIPMAN, WH; BABIN, D			ALLERGENS IN BEE VENOM .2. 2 NEW HIGH MOLECULAR-WEIGHT ALLERGENIC SPECIFICITIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV,SCH MED,DEPT PATHOL,OMAHA,NB 68178; CREIGHTON UNIV,DEPT BIOCHEM,OMAHA,NB 68178; USN,UNDERSEA CTR,SAN DIEGO,CA	Creighton University; Creighton University; United States Department of Defense; United States Navy								HABERMANN E, 1967, H-S Z PHYSIOL CHEM, V348, P37, DOI 10.1515/bchm2.1967.348.1.37; HOFFMAN DR, 1975, J ALLERGY CLIN IMMUN, V55, P73; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; HOFFMAN DR, 1976, J ALLERGY CLIN IMMUN, V58, P551, DOI 10.1016/0091-6749(76)90201-3; HOFFMAN DR, 1974, PEDIATRICS, V54, P151; HOFFMAN DR, 1972, J IMMUNOL, V108, P18; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; Light W. C., 1975, Advances in diagnosis of allergy: RAST (Editor R. Evans, III)., P137; MAGEE WL, 1960, BIOCHEM J, V77, P526, DOI 10.1042/bj0770526; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; SCHROEDER WA, 1963, BIOCHEMISTRY-US, V2, P992, DOI 10.1021/bi00905a016; SHEPHERD GW, 1974, PREP BIOCHEM, V4, P71, DOI 10.1080/00327487408068187; SHIPOLIN.RA, 1971, EUR J BIOCHEM, V20, P459, DOI 10.1111/j.1432-1033.1971.tb01414.x; SOBOTKA A, 1974, J ALLERGY CLIN IMMUN, V53, P103; SOBOTKA AK, 1976, J ALLERGY CLIN IMMUN, V57, P29, DOI 10.1016/0091-6749(76)90076-2; TOLKSDORF S, 1949, J LAB CLIN MED, V34, P74	16	66	69	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					147	153		10.1016/0091-6749(77)90217-2	http://dx.doi.org/10.1016/0091-6749(77)90217-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	401840				2022-12-18	WOS:A1977CV62200009
J	LEIFERMAN, KM; GLEICH, GJ; JONES, RT				LEIFERMAN, KM; GLEICH, GJ; JONES, RT			CROSS-REACTIVITY OF IGE ANTIBODIES WITH POLLEN ALLERGENS .2. ANALYSES OF VARIOUS SPECIES OF RAGWEED AND OTHER FALL WEED POLLENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO FDN, DEPT MED, ROCHESTER, MN 55901 USA; MAYO CLIN & MAYO FDN, DEPT IMMUNOL, ROCHESTER, MN 55901 USA; MAYO CLIN & MAYO FDN, DEPT MICROBIOL, ROCHESTER, MN 55901 USA; MAYO CLIN & MAYO FDN, SCH MED, ALLERGIC DIS RES LAB, ROCHESTER, MN 55901 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GOLDFARB A R, 1972, Journal of Asthma Research, V9, P139, DOI 10.3109/02770907209104714; GOLDFARB AR, 1961, INT ARCH ALLER A IMM, V19, P86, DOI 10.1159/000229199; GOLDFARB AR, 1961, J IMMUNOL, V86, P83; KING TP, 1973, EXCERPTA MEDICA  323, P394; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; NELSON RS, COMMUNICATION; WIDE L, 1967, LANCET, V2, P1105; WODEHOUSE ROGER P., 1957, ANN ALLERGY, V15, P527; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P109, DOI 10.1016/0091-6749(72)90006-1	11	66	67	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					140	148		10.1016/0091-6749(76)90149-4	http://dx.doi.org/10.1016/0091-6749(76)90149-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX744	956554				2022-12-18	WOS:A1976BX74400003
J	Bedard, A; Basagana, X; Anto, JM; Garcia-Aymerich, J; Devillier, P; Arnavielhe, S; Bedbrook, A; Onorato, GL; Czarlewski, W; Murray, R; Almeida, R; Fonseca, J; Costa, E; Malva, J; Morais-Almeida, M; Pereira, AM; Todo-Bom, A; Menditto, E; Stellato, C; Ventura, MT; Cruz, AA; Stelmach, R; da Silva, J; Larenas-Linnemann, D; Fuentes-Perez, JM; Huerta-Villalobos, YR; Emuzyte, R; Kvedariene, V; Valiulis, A; Kuna, P; Samolinski, B; Klimek, L; Mosges, R; Pfaar, O; Shamai, S; Annesi-Maesano, I; Bosse, I; Demoly, P; Fontaine, JF; Cardona, V; Mullol, J; Valero, A; Roller-Wirnsberger, RE; Tomazic, PV; Chavannes, NH; Fokkens, WJ; Reitsma, S; Bewick, M; Ryan, D; Sheikh, A; Haahtela, T; Toppila-Salmi, S; Valovirta, E; Makris, M; Papadopoulos, NG; Prokopakis, EP; Psarros, F; Cingi, C; Gemicioglu, B; Yorgancioglu, A; Bosnic-Anticevich, S; O'Hehir, RE; Bachert, C; Hellings, PW; Pugin, B; Bindslev-Jensen, C; Eller, E; Kull, I; Melen, E; Wickman, M; De Vries, G; van Eerd, M; Agache, I; Ansotegui, IJ; Dykewicz, MS; Casale, T; Wallace, D; Waserman, S; Laune, D; Bousquet, J				Bedard, Annabelle; Basagana, Xavier; Anto, Josep M.; Garcia-Aymerich, Judith; Devillier, Philippe; Arnavielhe, Sylvie; Bedbrook, Anna; Onorato, Gabrielle L.; Czarlewski, Wienczyslawa; Murray, Ruth; Almeida, Rute; Fonseca, Joao; Costa, Elisio; Malva, Joao; Morais-Almeida, Mario; Pereira, Ana Margarida; Todo-Bom, Ana; Menditto, Enrica; Stellato, Cristiana; Ventura, Maria Teresa; Cruz, Alvaro A.; Stelmach, Rafael; da Silva, Jane; Larenas-Linnemann, Desiree; Fuentes-Perez, Jose M.; Huerta-Villalobos, Yunuen R.; Emuzyte, Regina; Kvedariene, Violeta; Valiulis, Arunas; Kuna, Piotr; Samolinski, Boleslaw; Klimek, Ludger; Mosges, Ralph; Pfaar, Oliver; Shamai, Sara; Annesi-Maesano, Isabelle; Bosse, Isabelle; Demoly, Pascal; Fontaine, Jean-Francois; Cardona, Vicky; Mullol, Joaquim; Valero, Antonio; Roller-Wirnsberger, Regina E.; Tomazic, Peter Valentin; Chavannes, Niels H.; Fokkens, Wytske J.; Reitsma, Sietze; Bewick, Mike; Ryan, Dermot; Sheikh, Aziz; Haahtela, Tari; Toppila-Salmi, Sanna; Valovirta, Erkka; Makris, Michael; Papadopoulos, Nikos G.; Prokopakis, Emmanuel P.; Psarros, Fotis; Cingi, Cemal; Gemicioglu, Bilun; Yorgancioglu, Arzu; Bosnic-Anticevich, Sinthia; O'Hehir, Robyn E.; Bachert, Claus; Hellings, Peter W.; Pugin, Benoit; Bindslev-Jensen, Carsten; Eller, Esben; Kull, Ingrid; Melen, Erik; Wickman, Magnus; De Vries, Gert; van Eerd, Michiel; Agache, Ioana; Ansotegui, Ignacio J.; Dykewicz, Mark S.; Casale, Thomas; Wallace, Dana; Waserman, Susan; Laune, Daniel; Bousquet, Jean		MASK Study Grp	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; antihistamines; asthma; conjunctivitis; corticosteroids; mobile health; MASK; treatment	GUIDED SELF-MANAGEMENT; VISUAL ANALOG SCALE; TRADITIONAL TREATMENT; WORK PRODUCTIVITY; ASTHMA; IMPACT; AZELASTINE; FLUTICASONE; THERAPY; QUALITY	Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H-1-antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid-treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H-1-antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible.	[Bedard, Annabelle; Basagana, Xavier; Anto, Josep M.; Garcia-Aymerich, Judith] ISGlobal, Barcelona, Spain; [Bedard, Annabelle; Basagana, Xavier; Anto, Josep M.; Garcia-Aymerich, Judith] UPF, Barcelona, Spain; [Bedard, Annabelle; Basagana, Xavier; Anto, Josep M.; Garcia-Aymerich, Judith] CIBERESP, Barcelona, Spain; [Devillier, Philippe] Univ Paris Saclay, Hop Foch, UPRES EA220, Pole Malad Voies Resp, Suresnes, France; [Arnavielhe, Sylvie; Laune, Daniel] INNOV, KYomed, Montpellier, France; [Bedbrook, Anna; Onorato, Gabrielle L.; Bousquet, Jean] MACVIA France, Fdn Partenariale FMC VIA LR, Montpellier, France; [Czarlewski, Wienczyslawa] Med Consulting Czarlewski, Levallois Perret, France; [Murray, Ruth] MedScript, Med Commun Consultant, Dundalk, Ireland; [Murray, Ruth] OPC, Cambridge, England; [Almeida, Rute; Fonseca, Joao] Univ Porto, Fac Med, Ctr Hlth Technol & Serv Res CINTESIS, Porto, Portugal; [Almeida, Rute; Fonseca, Joao] Medida, Porto, Portugal; [Costa, Elisio] Univ Porto, Porto4Ageing, Fac Pharm, REQUINTE,UCIBIO, Porto, Portugal; [Costa, Elisio] Univ Porto, Porto4Ageing, Competence Ctr Act & Hlth Ageing, Porto, Portugal; [Malva, Joao] Univ Coimbra, Fac Med, IBILI, Coimbra, Portugal; [Malva, Joao] Ageing Coimbra EIP AHA Reference Site, Coimbra, Portugal; [Morais-Almeida, Mario] CUF Descobertas Hosp, Allergy Ctr, Lisbon, Portugal; [Pereira, Ana Margarida] CUF Porto Hosp & Inst, Allergy Unit, Porto, Portugal; [Pereira, Ana Margarida] Univ Porto, CINTESIS, Ctr Res Hlth Technol & Informat Syst, Porto, Portugal; [Todo-Bom, Ana] Ctr Hosp Univ Coimbra, Imunoalergol, Coimbra, Portugal; [Todo-Bom, Ana] Univ Coimbra, Fac Med, Coimbra, Portugal; [Menditto, Enrica] Univ Naples Federico II, CIRFF, Naples, Italy; [Stellato, Cristiana] Univ Salerno, Dept Med Surg & Dent, Scuola Med Salernitana, Salerno, Italy; [Ventura, Maria Teresa] Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Bari, Italy; [Cruz, Alvaro A.] Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil; [Cruz, Alvaro A.] WHO GARD Planning Grp, Salvador, BA, Brazil; [Stelmach, Rafael] Univ Sao Paulo, Fac Med, Hosp Clin, Heart Inst InCor,Pulm Div, Sao Paulo, Brazil; [da Silva, Jane] Univ Fed Santa Catarina, Dept Internal Med, Florianopolis, SC, Brazil; [da Silva, Jane] Univ Fed Santa Catarina, Allergy Clin, Florianopolis, SC, Brazil; [da Silva, Jane] Univ Fed Santa Catarina, Sao Thiago Univ Hosp, Florianopolis, SC, Brazil; [Larenas-Linnemann, Desiree] Hosp Med Sur, Ctr Excellence Asthma & Allergy, Mexico City, DF, Mexico; [Fuentes-Perez, Jose M.; Huerta-Villalobos, Yunuen R.] Hosp Gen Reg 1, Dr Carlos Mc Gregor Sanchez Navarro IMSS, Mexico City, DF, Mexico; [Emuzyte, Regina] Vilnius Univ, Fac Med, Clin Childrens Dis, Vilnius, Lithuania; [Kvedariene, Violeta] Vilnius Univ, Fac Med, Vilnius, Lithuania; [Valiulis, Arunas] Vilnius Univ, Inst Clin Med, Clin Childrens Dis, Vilnius, Lithuania; [Valiulis, Arunas] Inst Hlth Sci, Dept Publ Hlth, Vilnius, Lithuania; [Valiulis, Arunas] EAP UEMS SP, Brussels, Belgium; [Kuna, Piotr] Med Univ Lodz, Barlicki Univ Hosp, Div Internal Med Asthma & Allergy, Lodz, Poland; [Samolinski, Boleslaw] Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland; [Klimek, Ludger] Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg,Ctr Rhinol, Mannheim, Germany; [Mosges, Ralph; Shamai, Sara] Univ Cologne, Fac Med, Inst Med Stat & Computat Biol, Cologne, Germany; [Mosges, Ralph; Shamai, Sara] CRI Clin Res Int, Hamburg, Germany; [Bousquet, Jean] Univ Hosp, Montpellier, France; [Pfaar, Oliver] Phillipps Univ, Univ Hosp Marburg, Sect Rhinol & Allergy, Dept Otorhinolaryngol Head & Neck Surg, Marburg, Germany; [Annesi-Maesano, Isabelle] INSERM, Dept Inst Pierre Louis Epidemiol & Publ Hlth, Epidemiol Allerg & Resp Dis, Paris, France; [Annesi-Maesano, Isabelle] UPMC Sorbonne Univ, Med Sch St Antoine, Paris, France; [Demoly, Pascal] Montpellier Univ Hosp, Dept Resp Dis, Montpellier, France; [Cardona, Vicky] Hosp Valle De Hebron, Dept Internal Med, Allergy Sect, Barcelona, Spain; [Cardona, Vicky] ARADyAL Res Network, Barcelona, Spain; [Mullol, Joaquim] Univ Barcelona, Hosp Clin, ENT Dept, Rhinol Unit, Barcelona, Spain; [Mullol, Joaquim] Univ Barcelona, Hosp Clin, ENT Dept, Smell Clin, Barcelona, Spain; [Mullol, Joaquim] Univ Barcelona, CIBERES, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain; [Valero, Antonio] Univ Barcelona, CIBERES, Pneumol & Allergy Dept, Barcelona, Spain; [Valero, Antonio] Univ Barcelona, IDIBAPS, Clin & Expt Resp Immunoallergy, Barcelona, Spain; [Roller-Wirnsberger, Regina E.] Med Univ Graz, Dept Internal Med, Graz, Austria; [Tomazic, Peter Valentin] Med Univ Graz, Dept ENT, Graz, Austria; [Chavannes, Niels H.] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands; [Fokkens, Wytske J.; Reitsma, Sietze] Univ Amsterdam, Med Ctr, AMC, Dept Otorhinolaryngol, Amsterdam, Netherlands; [Bewick, Mike] iQ4U Consultants, London, England; [Ryan, Dermot] Univ Edinburgh, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland; [Sheikh, Aziz] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Haahtela, Tari; Toppila-Salmi, Sanna] Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland; [Valovirta, Erkka] Univ Turku, Dept Lung Dis & Clin Immunol, Turku, Finland; [Valovirta, Erkka] Terveystalo Allergy Clin, Turku, Finland; [Makris, Michael] Univ Athens, Attikon Univ Hosp, Dept Dermatol & Venereol 2, Allergy Unit D Kalogeromitros, Athens, Greece; [Papadopoulos, Nikos G.] Univ Manchester, Royal Manchester Childrens Hosp, Inst Human Dev, Ctr Pediat & Child Hlth, Manchester, Lancs, England; [Papadopoulos, Nikos G.] Univ Athens, Athens Gen Childrens Hosp P&A Kyriakou, Pediat Clin 2, UK Allergy Dept, Athens, Greece; [Prokopakis, Emmanuel P.] Univ Crete, Sch Med, Dept Otorhinolaryngol, Iraklion, Greece; [Psarros, Fotis] Athens Naval Hosp, Dept Allergy, Athens, Greece; [Cingi, Cemal] Eskisehir Osmangazi Univ, Fac Med, ENT Dept, Eskisehir, Turkey; [Gemicioglu, Bilun] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Pulm Dis, Istanbul, Turkey; [Yorgancioglu, Arzu] Celal Bayar Univ, Fac Med, Dept Pulm Dis, Manisa, Turkey; [Bosnic-Anticevich, Sinthia] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW, Australia; [Bosnic-Anticevich, Sinthia] Woolcock Emphysema Ctr & Local Hlth Dist, Glebe, NSW, Australia; [O'Hehir, Robyn E.] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia; [O'Hehir, Robyn E.] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia; [O'Hehir, Robyn E.] Monash Univ, Dept Immunol, Melbourne, Vic, Australia; [Bachert, Claus] Ghent Univ Hosp, ENT Dept, Upper Airways Res Lab, Ghent, Belgium; [Hellings, Peter W.] Univ Hosp Leuven, Dept Otorhinolaryngol, Leuven, Belgium; [Hellings, Peter W.] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands; [Hellings, Peter W.] Euforea, Brussels, Belgium; [Pugin, Benoit] European Forum Res & Educ Allergy & Airway Dis EU, Brussels, Belgium; [Bindslev-Jensen, Carsten; Eller, Esben] Odense Univ Hosp, ORCA, Dept Dermatol, Odense, Denmark; [Bindslev-Jensen, Carsten; Eller, Esben] Odense Univ Hosp, ORCA, Allergy Ctr, Odense, Denmark; [Kull, Ingrid] Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden; [Kull, Ingrid] Sachs Children & Youth Hosp, Sodersjukhuset, Stockholm, Sweden; [Melen, Erik] Sachs Children & Youth Hosp, Sodersjukhuset, Stockholm, Sweden; [Melen, Erik] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Wickman, Magnus] Uppsala Univ, Ctr Clin Res Sormland, Eskilstuna, Sweden; [De Vries, Gert; van Eerd, Michiel] Peercode BV, Geldermalsen, Netherlands; [Agache, Ioana] Transylvania Univ Brasov, Brasov, Romania; [Ansotegui, Ignacio J.; Dykewicz, Mark S.] Hosp Quiron Bizkaia, Dept Allergy & Immunol, Erandio, Spain; [Dykewicz, Mark S.] St Louis Univ, Sch Med, Sect Allergy & Immunol, St Louis, MO USA; [O'Hehir, Robyn E.] Univ S Florida, Div Allergy Immunol, Tampa, FL USA; [Wallace, Dana] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA; [Waserman, Susan] McMaster Univ, Dept Med Clin Immunol & Allergy, Hamilton, ON, Canada; [Bousquet, Jean] INSERM, U1168, VIMA Ageing & Chron Dis Epidemiol & Publ Hlth App, Villejuif, France; [Bousquet, Jean] Univ Versailles St Quentin en Yvelines, Montigny Le Bretonneux, France; [Bousquet, Jean] Euforea, Brussels, Belgium	ISGlobal; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Hospital Foch; UDICE-French Research Universities; Universite Paris Saclay; Universite de Montpellier; Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade de Coimbra; Universidade do Porto; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra; University of Naples Federico II; University of Salerno; Universita degli Studi di Bari Aldo Moro; Universidade Federal da Bahia; Universidade de Sao Paulo; Universidade Federal de Santa Catarina (UFSC); Universidade Federal de Santa Catarina (UFSC); Universidade Federal de Santa Catarina (UFSC); Tecnologico de Monterrey; Vilnius University; Vilnius University; Vilnius University; Medical University Lodz; Medical University of Warsaw; Ruprecht Karls University Heidelberg; University of Cologne; Universite de Montpellier; CHU de Montpellier; University Hospital of Giessen & Marburg; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite de Montpellier; CHU de Montpellier; Hospital Universitari Vall d'Hebron; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Medical University of Graz; Medical University of Graz; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; University of Edinburgh; University of Edinburgh; University of Helsinki; Helsinki University Central Hospital; University of Turku; National & Kapodistrian University of Athens; University Hospital Attikon; Royal Manchester Children's Hospital; University of Manchester; National & Kapodistrian University of Athens; University of Crete; Eskisehir Osmangazi University; Istanbul University - Cerrahpasa; Celal Bayar University; University of Sydney; Woolcock Institute of Medical Research; Florey Institute of Neuroscience & Mental Health; Monash University; Monash University; Ghent University; Ghent University Hospital; KU Leuven; University Hospital Leuven; University of Amsterdam; Academic Medical Center Amsterdam; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Sodersjukhuset Hospital; Sodersjukhuset Hospital; Karolinska Institutet; Uppsala University; Transylvania University of Brasov; Saint Louis University; State University System of Florida; University of South Florida; Nova Southeastern University; McMaster University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Bousquet, J (corresponding author), CHU Arnaud Villeneuve, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France.	jean.bousquet@orange.f	Kvedarienė, Violeta/GON-7937-2022; Fokkens, Wytske WJ/ABF-2185-2020; Bachert, Claus/J-8825-2012; N.G., Papadopoulos/L-8670-2013; Pereira, Ana Margarida/K-3343-2014; Todo Bom, Ana/AHD-3630-2022; Pugin, Benoit/X-2984-2018; Chavannes, Niels/F-1148-2011; Cingi, Cemal/AAA-1951-2021; Agache, Ioana/AAP-7403-2020; Bédard, Annabelle/ABB-9803-2020; Basagaña, Xavier/C-3901-2017; Yorgancioglu, Arzu/AAC-7548-2020; Ryan, Dermot/AAJ-2329-2021; Almeida, Rute/Q-1621-2019; Cardona, Victoria/GRX-4196-2022; Gemicioglu, Bilun/AAH-6927-2019; Toppila-Salmi, Sanna/ABF-5840-2020; Anto, J M/H-2676-2014; Bindslev-Jensen, Carsten/H-1877-2011; Bosnic-Anticevich, Sinthia/AAD-2526-2021; stelmach, rafael/AAH-1638-2019; J, Garcia-Aymerich/G-6867-2014; Fonseca, João A./B-7562-2008; Demoly, Pascal/Y-9938-2019; Costa, Elisio/K-1990-2013; Malva, Joao/L-3557-2014; O'Hehir, Robyn/H-3627-2011	Kvedarienė, Violeta/0000-0002-6119-211X; N.G., Papadopoulos/0000-0002-4448-3468; Pereira, Ana Margarida/0000-0002-5468-0932; Pugin, Benoit/0000-0001-7132-9477; Chavannes, Niels/0000-0002-8607-9199; Bédard, Annabelle/0000-0002-7842-8889; Basagaña, Xavier/0000-0002-8457-1489; Ryan, Dermot/0000-0002-4115-7376; Almeida, Rute/0000-0001-7755-5002; Gemicioglu, Bilun/0000-0001-5953-4881; Toppila-Salmi, Sanna/0000-0003-0890-6686; Anto, J M/0000-0002-4736-8529; Bindslev-Jensen, Carsten/0000-0002-8940-038X; Bosnic-Anticevich, Sinthia/0000-0001-5077-8329; stelmach, rafael/0000-0002-5132-1934; J, Garcia-Aymerich/0000-0002-7097-4586; Fonseca, João A./0000-0002-0887-8796; Demoly, Pascal/0000-0001-7827-7964; Psarros, Fotis/0000-0002-2928-150X; yorgancioglu, arzu/0000-0002-4032-0944; Onorato, Gabrielle Laura/0000-0002-7867-5345; Costa, Elisio/0000-0003-1158-1480; Kuna, Piotr/0000-0003-2401-0070; Malva, Joao/0000-0002-5438-4447; VENTURA, Maria Teresa/0000-0002-2637-4583; orlando, valentina/0000-0002-8209-8878; Bousquet, Jean/0000-0002-4061-4766; Cardona, Victoria/0000-0003-2197-9767; menditto, enrica/0000-0001-8633-5650; O'Hehir, Robyn/0000-0002-3489-7595; Reitsma, Sietze/0000-0003-1734-2632	Sanofi Aventis; GlaxoSmithKline; North Portugal Regional Operational Programme; European Regional Development Fund (ERDF); Mundipharm; Teva Pharma; AstraZeneca; Boehringer Ingelheim; Chiesi; MEDA Pharma; Sao Paulo Research Foundation; Novartis; Chiesi, DBV Technologies; UCB; Sanofi; Adamed; FAES, Berlin Chemie; ALK-Abello; Allergopharma, Allergy Therapeutics; Servier; ASIT biotech; Hulka; Leti and Stallergenes; Roxall, Atmos, Bionorica; ALK-Abello, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics; Biomay, Nuvo, Circassia; Novartis Pharma; Mundipharma; Roche; Erkko Foundation; Hal Allergy B. V.; Teva; Meda, Stallergenes; Cipla; Mundipharma, Mylan; Sanofi-Aventis	Sanofi Aventis(Sanofi-Aventis); GlaxoSmithKline(GlaxoSmithKline); North Portugal Regional Operational Programme; European Regional Development Fund (ERDF)(European Commission); Mundipharm; Teva Pharma(Teva Pharmaceutical Industries); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); Chiesi(Chiesi Pharmaceuticals Inc); MEDA Pharma; Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Novartis(Novartis); Chiesi, DBV Technologies(Chiesi Pharmaceuticals Inc); UCB(UCB Pharma SA); Sanofi; Adamed; FAES, Berlin Chemie; ALK-Abello; Allergopharma, Allergy Therapeutics; Servier(Servier); ASIT biotech; Hulka; Leti and Stallergenes; Roxall, Atmos, Bionorica; ALK-Abello, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics; Biomay, Nuvo, Circassia; Novartis Pharma; Mundipharma; Roche(Roche Holding); Erkko Foundation; Hal Allergy B. V.; Teva(Teva Pharmaceutical Industries); Meda, Stallergenes; Cipla; Mundipharma, Mylan; Sanofi-Aventis(Sanofi-Aventis)	P. Devillier reports personal fees from Sanofi Aventis, GlaxoSmithKline, AstraZeneca, Chiesi, Meda Pharma, and Menarini outside the submitted work. R. Almeida reports grants from Project NORTE-01-0145-FEDER-000016 (NanoSTIMA) by the North Portugal Regional Operational Programme (NORTE 2020) under the Portugal 2020 Partnership Agreement and through the European Regional Development Fund (ERDF) during the conduct of the study. A. Todo-Bom reports grants and personal fees from GlaxoSmithKline, Mundipharm, and Novartis; personal fees from Teva Pharma and AstraZeneca; and grants from Leti and Bial outside the submitted work. A. A. Cruz reports grants and personal fees from AstraZeneca; grants from GlaxoSmithKline; personal fees from Boehringer Ingelheim, Chiesi, Novartis, Eurofarma, MEDA Pharma, and Boston Scientific outside the submitted work. R. Stelmach reports grants from the Sao Paulo Research Foundation and MSD; grants and personal fees from Novartis, grants, personal fees, and nonfinancial support from AstraZeneca and Chiesi; and personal fees and nonfinancial support from Boehringer Ingelheim outside the submitted work. D. Larenas-Linnemann reports personal fees from Armstrong, AstraZeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GlaxoSmithKline, MEDA, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, and UCB and grants from Sanofi, AstraZeneca, Novartis, UCB, GlaxoSmithKline, TEVA, Boehringer Ingelheim, and Chiesi outside the submitted work. V. Kvedariene has received payment for consultancy from GlaxoSmithKline and for lectures from StallergensGreer and Berlin-Chemie outside the submitted work. P. Kuna reports personal fees from Adamed, Boehringer Ingelheim, AstraZeneca, Chiesi, FAES, Berlin Chemie, Novartis, Polpharma, and Allergopharma outside the submitted work. R. Mosges reports personal fees from ALK-Abello, Allergopharma, Allergy Therapeutics, Hexal, Servier, Klosterfrau, Stada, UCB, and Friulchem; grants from ASIT biotech, Nuvo, Bayer, FAES, GlaxoSmithKline, MSD, Johnson & Johnson, Meda, Optima, Ursapharm, BitopAG, and Hulka; grants and personal fees from Bencard; grants from Leti and Stallergenes; grants, personal fees and nonfinancial support from Lofarma; nonfinancial support from Roxall, Atmos, Bionorica, Otonomy, and Ferrero; and personal fees and nonfinancial support from Novartis outside the submitted work. O. Pfaar reports grants and personal fees from ALK-Abello, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, and Lofarma; grants from Biomay, Nuvo, Circassia, and GlaxoSmithKline; and personal fees from Novartis Pharma, MEDA Pharma, Indoor Biotechnologies, and Pohl-Boskamp outside the submitted work. T. Haahtela reports personal fees from Mundipharma, Novartis, and Orion Pharma outside the submitted work. S. Toppila-Salmi reports other support from Biomedical Systems and Roche and grants from the Erkko Foundation outside the submitted work. N. G. Papadopoulos reports grants from Gerolymatos and personal fees from Hal Allergy B. V., Novartis Pharma AG, Menarini, Hal Allergy B. V., and Mylan outside the submitted work. S. Bosnic-Anticevich reports personal fees from Teva, Boehringer Ingelheim, Sanofi, GlaxoSmithKline, and AstraZeneca outside the submitted work. C. Bachert reports personal fees from Meda, Stallergenes, and ALK-Abello (speaker). I. J. Ansotegui reports personal fees from Hikma, Roxall, AstraZeneca, Menarini, UCB, Faes Farma, Sanofi, and Mundipharma outside the submitted work. D.; Wallace reports other from Mylan Pharmaceutical Company outside the submitted work being co-chair of the AAAAI/ACAAI Joint Task Force on Practice Parameters. J. Bousquet reports personal fees and other support from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, and Uriach outside the submitted work and other support from Kyomed. The rest of the authors declare that they have no relevant conflicts of interest.	Bachert C, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0210-2; Bonini M, 2017, CURR OPIN PULM MED, V23, P21, DOI 10.1097/MCP.0000000000000336; Bosnic-Anticevich S, 2018, J ASTHMA, V55, P684, DOI 10.1080/02770903.2017.1353611; Bourret Rodolphe, 2015, World Hosp Health Serv, V51, P36; Bousquet J, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0227-6; Bousquet J, 2018, ALLERGY, V73, P1763, DOI 10.1111/all.13406; Bousquet J, 2018, J INVEST ALLERG CLIN, V28, P42, DOI 10.18176/jiaci.0197; Bousquet J, 2018, ALLERGY, V73, P505, DOI 10.1111/all.13307; Bousquet J, 2017, ALLERGY, V72, P1475, DOI 10.1111/all.13177; Bousquet J, 2017, ALLERGY, V72, P857, DOI 10.1111/all.13125; Bousquet J, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0137-4; Bousquet J, 2015, ALLERGY, V70, P1372, DOI 10.1111/all.12686; Bousquet J, 2019, J ALLERGY CLIN IMMUN, V143, P864, DOI 10.1016/j.jaci.2018.08.049; Bousquet J, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0221-z; Bousquet J, 2018, J ALLER CL IMM-PRACT, V6, P1726, DOI 10.1016/j.jaip.2018.01.031; Bousquet J, 2016, J ALLERGY CLIN IMMUN, V138, P367, DOI 10.1016/j.jaci.2016.03.025; Brozek JL, 2017, J ALLERGY CLIN IMMUN, V140, P950, DOI 10.1016/j.jaci.2017.03.050; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Caimmi D, 2017, CLIN EXP ALLERGY, V47, P1526, DOI 10.1111/cea.13025; Carr W, 2012, J ALLERGY CLIN IMMUN, V129, P1282, DOI 10.1016/j.jaci.2012.01.077; Dykewicz MS, 2017, ANN ALLERG ASTHMA IM, V119, P489, DOI 10.1016/j.anai.2017.08.012; Hampel FC, 2010, ANN ALLERG ASTHMA IM, V105, P168, DOI 10.1016/j.anai.2010.06.008; KOPPKUBEL S, 1995, B WORLD HEALTH ORGAN, V73, P275; Kremer B, 1999, ARZNEIMITTEL-FORSCH, V49, P912; Lahdensuo A, 1998, BRIT MED J, V316, P1138, DOI 10.1136/bmj.316.7138.1138; Lahdensuo A, 1996, BRIT MED J, V312, P748; McDonald V M, 2006, Chron Respir Dis, V3, P29, DOI 10.1191/1479972306cd090ra; Meltzer EO, 2016, J ALLER CL IMM-PRACT, V4, P682, DOI 10.1016/j.jaip.2016.02.006; Ohta K, 2013, J ASTHMA, V50, P514, DOI 10.3109/02770903.2013.786726; Pizzulli A, 2014, CLIN EXP ALLERGY, V44, P1246, DOI 10.1111/cea.12386; Price D, 2015, EXPERT REV CLIN IMMU, V11, P1205, DOI 10.1586/1744666X.2015.1081814; Salo T, 2016, ASIA PAC ALLERGY, V6, P133, DOI 10.5415/apallergy.2016.6.2.133; Samreth D, 2018, WORLD ALLERGY ORGAN, V11, DOI 10.1186/s40413-018-0194-3; Sherman RE, 2016, NEW ENGL J MED, V375, P2293, DOI 10.1056/NEJMsb1609216; Tan Rachel, 2017, Asthma Res Pract, V3, P8, DOI 10.1186/s40733-017-0036-z; Travers J, 2007, THORAX, V62, P219, DOI 10.1136/thx.2006.066837; Wustenberg E, 2017, ALLERGO J, V26, P14	37	65	68	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					135	+		10.1016/j.jaci.2019.01.053	http://dx.doi.org/10.1016/j.jaci.2019.01.053			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	30951790	Green Published, Bronze, Green Submitted, Green Accepted			2022-12-18	WOS:000473432800017
J	Werfel, T; Layton, G; Yeadon, M; Whitlock, L; Osterloh, I; Jimenez, P; Liu, W; Lynch, V; Asher, A; Tsianakas, A; Purkins, L				Werfel, Thomas; Layton, Gary; Yeadon, Michael; Whitlock, Lyndsey; Osterloh, Ian; Jimenez, Pablo; Liu, Wai; Lynch, Victoria; Asher, Aliya; Tsianakas, Athanasios; Purkins, Lynn			Efficacy and safety of the histamine H-4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Atopic dermatitis; atopic eczema; eczema; histamine 4 receptor antagonist; Eczema Area and Severity Index; SCORAD; Investigator's Global Assessment; pruritus	TASK-FORCE; PRURITUS; STIMULATION; DUPILUMAB; PLACEBO; ADULTS; INDEX	Background: H-4 receptor antagonists are potential novel treatments for inflammatory skin diseases, including atopic dermatitis (AD). Objective: We sought to study the efficacy and safety of ZPL-3893787 (a selective H-4 receptor antagonist) in patients with moderate-to-severe AD. Methods: A randomized, double-blind, placebo-controlled, parallel-group study was conducted to evaluate ZPL-3893787 (30 mg) once-daily oral therapy in adults with moderate-tosevere AD. Patients were randomized (2:1) to ZPL-3893787 (n = 65) or placebo (n = 33) for 8 weeks. Patients had a history of AD for more than 12 months, Eczema Area and Severity Index (EASI) scores of 12 or greater and 48 or less, Investigator's Global Assessment (IGA) scores of 3 or greater, pruritus scores of = or greater (0- to 10-point scale), and AD on 10% or greater of body surface area. Efficacy parameters included EASI, IGA, SCORAD, and pruritus assessment. Results: Treatment with oral ZPL-3893787 showed a 50% reduction in EASI score compared with 27% for placebo. The placebo-adjusted reduction in EASI score at week 8 was 5.1 (1-sided P = .01). Clear or almost-clear IGA scores were 18.5% with ZPL-3893787 versus 9.1% with placebo. SCORAD scores exhibited 41% reduction with ZPL-3893787 versus 26% with placebo (placebo-adjusted reduction of 10.0, P = .004). There was a 3-point reduction (scale, 1-10) in pruritus with ZPL-3893787, but there was a similar reduction with placebo, resulting in a nonsignificant difference (P 5.249). Patient-reported pruritus subscores obtained from SCORAD were reduced with ZPL-3893787 compared with placebo at week 8 (nonsignificant). ZPL-3893787 was well tolerated. Conclusion: For the first time, these results showed that ZPL-3893787 improved inflammatory skin lesions in patients with AD, confirming H-4 receptor antagonism as a novel therapeutic option.	[Werfel, Thomas] Hannover Med Sch, Klin Dermatol Allergol & Venerol, Hannover, Germany; [Layton, Gary] ParamStat, Ash, England; [Yeadon, Michael; Whitlock, Lyndsey; Jimenez, Pablo; Liu, Wai; Purkins, Lynn] Ziarco Pharma, Discovery Pk, Sandwich, Kent, England; [Osterloh, Ian] Ostermed, Birmingham Business Pk, Birmingham, W Midlands, England; [Lynch, Victoria] MAC Clin Res, Leeds, W Yorkshire, England; [Asher, Aliya] MAC Clin Res, Manchester, Lancs, England; [Tsianakas, Athanasios] Univ Hosp Muenster, Dept Dermatol, Munster, Germany	Hannover Medical School; University of Munster	Werfel, T (corresponding author), Hannover Med Sch, Dept Dermatol & Allergy, D-30625 Hannover, Germany.	Werfel.Thomas@mh-hannover.de	Werfel, Thomas/B-6921-2012		Ziarco Pharma	Ziarco Pharma	This study was funded by Ziarco Pharma, who were involved in the study design, collection, analysis, and interpretation of the data; writing of the report; and the decision to submit the article for publication.	Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Dijkstra D, 2008, J INVEST DERMATOL, V128, P1696, DOI 10.1038/sj.jid.5701250; Dunford PJ, 2007, J ALLERGY CLIN IMMUN, V119, P176, DOI 10.1016/j.jaci.2006.08.034; Eichenfield LF, 2017, J ALLERGY CLIN IMMUN, V139, pS49, DOI 10.1016/j.jaci.2017.01.009; Glatzer F, 2013, J ALLERGY CLIN IMMUN, V132, P1358, DOI 10.1016/j.jaci.2013.06.023; Gutzmer R, 2005, J IMMUNOL, V174, P5224, DOI 10.4049/jimmunol.174.9.5224; Gutzmer R, 2009, J ALLERGY CLIN IMMUN, V123, P619, DOI 10.1016/j.jaci.2008.12.1110; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Kini SP, 2011, ARCH DERMATOL, V147, P1153, DOI 10.1001/archdermatol.2011.178; Kollmeier A, 2014, J PHARMACOL EXP THER, V350, P181, DOI 10.1124/jpet.114.215749; Liu WL, 2014, DRUG DISCOV TODAY, V19, P1222, DOI 10.1016/j.drudis.2014.05.007; Mowbray CE, 2011, BIOORG MED CHEM LETT, V21, P6596, DOI 10.1016/j.bmcl.2011.07.125; Murata Y, 2015, J DERMATOL, V42, P129, DOI 10.1111/1346-8138.12726; Panula P, 2015, PHARMACOL REV, V67, P601, DOI 10.1124/pr.114.010249; Rossbach K, 2016, ALLERGY, V71, P189, DOI 10.1111/all.12779; Rossbach K, 2009, EXP DERMATOL, V18, P57, DOI 10.1111/j.1600-0625.2008.00762.x; Schaper K, 2016, PHARMACOL RES, V113, P209, DOI 10.1016/j.phrs.2016.08.001; Sher LG, 2012, ACTA DERM-VENEREOL, V92, P455, DOI 10.2340/00015555-1360; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Steinhoff M, 2003, J NEUROSCI, V23, P6176; Thurmond RL, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00065; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Werfel T, 2016, J DTSCH DERMATOL GES, V14, P92, DOI [10.1111/ddg.12871, 10.1111/ddg.12884]; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043	25	65	66	2	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2019	143	5					1830	+		10.1016/j.jaci.2018.07.047	http://dx.doi.org/10.1016/j.jaci.2018.07.047			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HW6FP	30414855	Bronze			2022-12-18	WOS:000466784600019
J	Schmid, C; Delacher, M; Huehn, J; Feuerer, M				Schmid, Christian; Delacher, Michael; Huehn, Jochen; Feuerer, Markus			Epigenetic mechanisms regulating T-cell responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Epigenetics; gene regulation; enhancer; promoter; chromatin accessibility; histone modifications; DNA methylation; transcription factor binding; T-cell development; T-cell function; T-cell exhaustion; regulatory T cells; tissue specificity	NOVO DNA METHYLATION; CHROMATIN ACCESSIBILITY; TRANSCRIPTION FACTORS; FOXP3 EXPRESSION; GENE-EXPRESSION; CIS-ELEMENT; ENHANCER; DIFFERENTIATION; MEMORY; CD4	During the last decade, advances in sequencing technologies allowed production of a wealth of information on epigenetic modifications in T cells. Epigenome maps, in combination with mechanistic studies, have demonstrated that T cells undergo extensive epigenome remodeling in response to signals, which has a strong effect on phenotypic stability and function of lymphocytes. In this review we focus on DNA methylation, histone modifications, and chromatin structure as important epigenetic mechanisms involved in controlling T-cell responses. In particular, we discuss epigenetic processes in light of the development, activation, and differentiation of CD4(+) T helper (T-H), regulatory T, and CD8(+) T cells. As central aspects of the adaptive immune system, we review mechanisms that ensure molecular memory, stability, plasticity, and exhaustion of T cells. We further discuss the effect of the tissue environment on imprinting T-cell epigenomes with potential implications for immunotherapy.	[Schmid, Christian; Delacher, Michael; Feuerer, Markus] Univ Regensburg, Regensburg Ctr Intervent Immunol RCI, Regensburg, Germany; [Delacher, Michael; Feuerer, Markus] Univ Regensburg, Chair Immunol, Regensburg, Germany; [Delacher, Michael; Feuerer, Markus] Univ Med Ctr Regensburg, Regensburg, Germany; [Huehn, Jochen] Helmholtz Ctr Infect Res, Expt Immunol, Braunschweig, Germany	University of Regensburg; University of Regensburg; University of Regensburg; Helmholtz Association; Helmholtz-Center for Infection Research	Feuerer, M (corresponding author), Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	markus.feuerer@ukr.de	Schmidl, Christian/HDO-6299-2022; Delacher, Michael/AAA-5224-2019; Delacher, Michael/AAM-9710-2021	Schmidl, Christian/0000-0002-0522-202X; 	European Research Council (ERC-CoG) [648145 REGiREG]; German Research Foundation (DFG) [SFB/Transregio 221B8, SFB738-C7]	European Research Council (ERC-CoG); German Research Foundation (DFG)(German Research Foundation (DFG))	Supported by grants from the European Research Council (ERC-CoG, #648145 REGiREG to M.F.) and the German Research Foundation (DFG) SFB/Transregio 221B8 to M.F. and SFB738-C7 to J.H.	Akondy RS, 2017, NATURE, V552, P362, DOI 10.1038/nature24633; Ali N, 2017, CELL, V169, P1119, DOI 10.1016/j.cell.2017.05.002; Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59; Allison KA, 2016, ELIFE, V5, DOI 10.7554/eLife.10134; Aznar MA, 2018, CANCER IMMUNOL RES, V6, P69, DOI 10.1158/2326-6066.CIR-17-0159; Araki Y, 2009, IMMUNITY, V30, P912, DOI 10.1016/j.immuni.2009.05.006; Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Barski A, 2017, SCI REP-UK, V7, DOI 10.1038/srep39785; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Bevington SL, 2016, EMBO J, V35, P515, DOI 10.15252/embj.201592534; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Boucheron N, 2014, NAT IMMUNOL, V15, P439, DOI 10.1038/ni.2864; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; Buenostro JD, 2015, NATURE, V523, P486, DOI 10.1038/nature14590; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Cheung P, 2018, CELL, V173, P1385, DOI 10.1016/j.cell.2018.03.079; Chong MMW, 2010, GENE DEV, V24, P659, DOI 10.1101/gad.1901610; Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016; Cipolletta D, 2012, NATURE, V486, P549, DOI 10.1038/nature11132; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Crompton JG, 2016, CELL MOL IMMUNOL, V13, P502, DOI 10.1038/cmi.2015.32; Cusanovich DA, 2015, SCIENCE, V348, P910, DOI 10.1126/science.aab1601; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Delacher M, 2017, NAT IMMUNOL, V18, P1160, DOI 10.1038/ni.3799; Delacher M, 2014, CURR TOP MICROBIOL, V381, P83, DOI 10.1007/82_2014_373; Dombrowski Y, 2017, NAT NEUROSCI, V20, P674, DOI 10.1038/nn.4528; Dominguez-Villar M, 2011, NAT MED, V17, P673, DOI 10.1038/nm.2389; DuPage M, 2015, IMMUNITY, V42, P227, DOI 10.1016/j.immuni.2015.01.007; Durek P, 2016, IMMUNITY, V45, P1148, DOI 10.1016/j.immuni.2016.10.022; Egawa T, 2011, P NATL ACAD SCI USA, V108, P14873, DOI 10.1073/pnas.1112293108; Eizenberg-Magar I, 2017, P NATL ACAD SCI USA, V114, pE6447, DOI 10.1073/pnas.1615590114; Farlik M, 2015, CELL REP, V10, P1386, DOI 10.1016/j.celrep.2015.02.001; Feng YQ, 2014, CELL, V158, P749, DOI 10.1016/j.cell.2014.07.031; Feuerer M, 2009, IMMUNITY, V31, P654, DOI 10.1016/j.immuni.2009.08.023; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Ghisletti S, 2010, IMMUNITY, V32, P317, DOI 10.1016/j.immuni.2010.02.008; Ghoneim HE, 2017, CELL, V170, DOI 10.1016/j.cell.2017.06.007; Gialitakis M, 2012, CURR TOP MICROBIOL, V356, P165, DOI 10.1007/82_2011_175; Hashimoto S, 2013, J IMMUNOL, V190, P4076, DOI 10.4049/jimmunol.1202267; Hawkins RD, 2013, IMMUNITY, V38, P1271, DOI 10.1016/j.immuni.2013.05.011; He B, 2016, IMMUNITY, V45, P1341, DOI 10.1016/j.immuni.2016.11.009; Hegazy AN, 2010, IMMUNITY, V32, P116, DOI 10.1016/j.immuni.2009.12.004; Heinz S, 2015, NAT REV MOL CELL BIO, V16, P144, DOI 10.1038/nrm3949; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Hirahara K, 2013, J ALLERGY CLIN IMMUN, V131, P1276, DOI 10.1016/j.jaci.2013.03.015; Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hu GQ, 2018, IMMUNITY, V48, P227, DOI 10.1016/j.immuni.2018.01.013; Iwata A, 2017, NAT IMMUNOL, V18, P563, DOI 10.1038/ni.3714; Jabeen R, 2013, J CLIN INVEST, V123, P4641, DOI 10.1172/JCI69489; Johnson JL, 2018, IMMUNITY, V48, P243, DOI 10.1016/j.immuni.2018.01.012; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kagoya Y, 2016, J CLIN INVEST, V126, P3479, DOI 10.1172/JCI86437; Kaplan MH, 2017, SEMIN IMMUNOPATHOL, V39, P11, DOI 10.1007/s00281-016-0600-2; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kitagawa Y, 2017, NAT IMMUNOL, V18, P173, DOI 10.1038/ni.3646; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Ladle BH, 2016, P NATL ACAD SCI USA, V113, P10631, DOI 10.1073/pnas.1524490113; Lara-Astiaso D, 2014, SCIENCE, V345, P943, DOI 10.1126/science.1256271; Lavin Y, 2014, CELL, V159, P1312, DOI 10.1016/j.cell.2014.11.018; Levine M, 2014, CELL, V157, P13, DOI 10.1016/j.cell.2014.02.009; Li XD, 2014, CELL, V158, P734, DOI 10.1016/j.cell.2014.07.030; Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369; Lio CWJQ, 2008, IMMUNITY, V28, P100, DOI 10.1016/j.immuni.2007.11.021; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Liu B, 2010, SCIENCE, V330, P521, DOI 10.1126/science.1193787; Liu YY, 2017, CELL REP, V19, P1283, DOI 10.1016/j.celrep.2017.04.067; Lu KT, 2011, IMMUNITY, V35, P622, DOI 10.1016/j.immuni.2011.07.015; Maunakea AK, 2013, CELL RES, V23, P1256, DOI 10.1038/cr.2013.110; Mognol GP, 2017, P NATL ACAD SCI USA, V114, pE2776, DOI 10.1073/pnas.1620498114; Moskowitz DM, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag0192; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Mumbach MR, 2017, NAT GENET, V49, P1602, DOI 10.1038/ng.3963; Neph S, 2012, NATURE, V489, P83, DOI 10.1038/nature11212; Ohkura N, 2012, IMMUNITY, V37, P785, DOI 10.1016/j.immuni.2012.09.010; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Panzer M, 2012, J IMMUNOL, V188, P615, DOI 10.4049/jimmunol.1101164; Pauken KE, 2016, SCIENCE, V354, P1160, DOI 10.1126/science.aaf2807; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Qu K, 2017, CANCER CELL, V32, P27, DOI 10.1016/j.ccell.2017.05.008; Qu K, 2015, CELL SYST, V1, P51, DOI 10.1016/j.cels.2015.06.003; Rendeiro AF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11938; Richards DM, 2015, PROG MOL BIOL TRANSL, V136, P175, DOI 10.1016/bs.pmbts.2015.07.014; Roychoudhuri R, 2015, VACCINE, V33, P914, DOI 10.1016/j.vaccine.2014.10.007; Rui JX, 2012, J IMMUNOL, V189, P1380, DOI 10.4049/jimmunol.1201077; Russ BE, 2017, CELL REP, V21, P3624, DOI 10.1016/j.celrep.2017.11.097; Russ BE, 2014, IMMUNITY, V41, P853, DOI 10.1016/j.immuni.2014.11.001; Scharer CD, 2017, J IMMUNOL, V198, P2238, DOI 10.4049/jimmunol.1602086; Scharer CD, 2013, J IMMUNOL, V191, P3419, DOI 10.4049/jimmunol.1301395; Schlenner SM, 2012, J EXP MED, V209, P1529, DOI 10.1084/jem.20112646; Schmidl C, 2014, BLOOD, V123, pE68, DOI 10.1182/blood-2013-02-486944; Schmidl C, 2011, EUR J IMMUNOL, V41, P1491, DOI 10.1002/eji.201041067; Schmidl C, 2009, GENOME RES, V19, P1165, DOI 10.1101/gr.091470.109; Schmidt C, 2015, NAT METHODS, V12, P963, DOI [10.1038/NMETH.3542, 10.1038/nmeth.3542]; Schubeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192; Scott-Browne JP, 2016, IMMUNITY, V45, P1327, DOI 10.1016/j.immuni.2016.10.028; Sefik E, 2015, SCIENCE, V349, P993, DOI 10.1126/science.aaa9420; Sen DR, 2016, SCIENCE, V354, P1165, DOI 10.1126/science.aae0491; Seumois G, 2014, NAT IMMUNOL, V15, P777, DOI 10.1038/ni.2937; Shevach EM, 2014, IMMUNOL REV, V259, P88, DOI 10.1111/imr.12160; Speiser DE, 2016, NAT REV IMMUNOL, V16, P500, DOI 10.1038/nri.2016.80; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Stadhouders R, 2018, NAT GENET, V50, P238, DOI 10.1038/s41588-017-0030-7; Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Taniuchi I, 2004, ONCOGENE, V23, P4341, DOI 10.1038/sj.onc.1207671; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Taniuchi I, 2002, MOL CELL, V10, P1083, DOI 10.1016/S1097-2765(02)00735-9; Thomas RM, 2012, J BIOL CHEM, V287, P22900, DOI 10.1074/jbc.M111.312785; Thomson JP, 2010, NATURE, V464, P1082, DOI 10.1038/nature08924; Toker A, 2013, J IMMUNOL, V190, P3180, DOI 10.4049/jimmunol.1203473; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Tserel L, 2015, SCI REP-UK, V5, DOI 10.1038/srep13107; Tumes DJ, 2013, IMMUNITY, V39, P819, DOI 10.1016/j.immuni.2013.09.012; Tyrakis PA, 2016, NATURE, V540, P236, DOI 10.1038/nature20165; Vahedi G, 2015, NATURE, V520, P558, DOI 10.1038/nature14154; Vahedi G, 2012, CELL, V151, P981, DOI 10.1016/j.cell.2012.09.044; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184; Walker JA, 2018, NAT REV IMMUNOL, V18, P121, DOI 10.1038/nri.2017.118; Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wilson CB, 2009, NAT REV IMMUNOL, V9, P91, DOI 10.1038/nri2487; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Xiong YN, 2012, J BIOL CHEM, V287, P34372, DOI 10.1074/jbc.M111.325332; Xu T, 2017, NATURE, V548, P228, DOI 10.1038/nature23475; Yin YM, 2017, SCIENCE, V356, DOI 10.1126/science.aaj2239; Yoshimoto M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051587; Youngblood B, 2017, NATURE, V552, P404, DOI 10.1038/nature25144; Youngblood B, 2011, IMMUNITY, V35, P400, DOI 10.1016/j.immuni.2011.06.015; Yu BF, 2017, NAT IMMUNOL, V18, P573, DOI 10.1038/ni.3706; Yue XJ, 2016, J EXP MED, V213, P377, DOI 10.1084/jem.20151438; Zhang TY, 2015, EMBO REP, V16, P1467, DOI 10.15252/embr.201540945; Zhao ED, 2016, NAT IMMUNOL, V17, P95, DOI 10.1038/ni.3313; Zhao M, 2016, SCI REP-UK, V6, DOI 10.1038/srep38411; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750	149	65	65	5	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					728	743		10.1016/j.jaci..2018.07.014	http://dx.doi.org/10.1016/j.jaci..2018.07.014			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	30195378				2022-12-18	WOS:000443726500003
J	Karasuyama, H; Miyake, K; Yoshikawa, S; Yamanishi, Y				Karasuyama, Hajime; Miyake, Kensuke; Yoshikawa, Soichiro; Yamanishi, Yoshinori			Multifaceted roles of basophils in health and disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Basophil; mast cell; development; allergy; anaphylaxis; inflammation; autoimmune disease; infection; antigen presentation; IL-4; protease	THYMIC STROMAL LYMPHOPOIETIN; ANTIGEN-PRESENTING CELLS; CHRONIC MYELOID-LEUKEMIA; CD4(+) T-CELLS; FC-EPSILON-RI; CHRONIC ALLERGIC INFLAMMATION; CLASS-II COMPLEXES; MAST-CELLS; IN-VIVO; SPONTANEOUS URTICARIA	Until recently, basophils had often been neglected in immunologic studies because of their minority status among immune cells or confused with tissue-resident mast cells because of some phenotypic similarities between them in spite of different anatomic localization. It is now appreciated that basophils and mast cells are distinct cell lineages and that basophils play important and nonredundant roles distinct from those played by mast cells. On the one hand, basophils contribute beneficially to protective immunity, particularly against parasitic infections. On the other hand, basophils are involved in the development of various disorders, including allergy and autoimmune disease. Basophils interact with other immune cells and nonhematopoietic cells through cell-to-cell contact or basophil-derived factors, such as cytokines and proteases, contributing to the regulation of immune and allergic responses. In this review article we highlight recent advances in our understanding of basophil pathophysiology in human subjects and animal models by consolidating research findings reported during the past 5 years. Further studies on basophils and their products will help identify suitable targets for novel therapeutics in allergy and effective vaccines against parasitic infection.	[Karasuyama, Hajime; Miyake, Kensuke; Yoshikawa, Soichiro; Yamanishi, Yoshinori] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Immune Regulat, Tokyo, Japan	Tokyo Medical & Dental University (TMDU)	Karasuyama, H (corresponding author), 1-5-45 Yushima,Bunkyo Ku, Tokyo 1138519, Japan.	karasuyama.mbeh@tmd.ac.jp	Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836; Miyake, Kensuke/0000-0003-1149-3755	Ministry of Education, Culture, Sports, Science and Technology; Grants-in-Aid for Scientific Research [15H05786, 17K15719] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology.	Akasaki S, 2016, INT IMMUNOL, V28, P65, DOI 10.1093/intimm/dxv055; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Baba T, 2016, BLOOD, V127, P2607, DOI 10.1182/blood-2015-10-673087; Baba T, 2013, J EXP MED, V210, P2661, DOI 10.1084/jem.20130112; Beer PA, 2015, BLOOD, V125, P504, DOI 10.1182/blood-2014-06-581173; Beutier H, 2017, J ALLERGY CLIN IMMUN, V139, P269, DOI 10.1016/j.jaci.2016.03.028; Bischof A, 2014, J INFECT DIS, V210, P14, DOI 10.1093/infdis/jiu056; Bleriot C, 2015, IMMUNITY, V42, P145, DOI 10.1016/j.immuni.2014.12.020; BROWN SJ, 1982, J IMMUNOL, V129, P790; Campbell IK, 2014, J IMMUNOL, V192, P5031, DOI 10.4049/jimmunol.1301611; Cerny-Reiterer S, 2012, NEOPLASIA, V14, P572, DOI 10.1593/neo.12724; Chapuy L, 2014, J ALLERGY CLIN IMMUN, V134, P978, DOI 10.1016/j.jaci.2014.05.025; Charles N, 2010, NAT MED, V16, P701, DOI 10.1038/nm.2159; Chen K, 2009, NAT IMMUNOL, V10, P889, DOI 10.1038/ni.1748; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; DVORAK HF, 1976, J ALLERGY CLIN IMMUN, V58, P229, DOI 10.1016/0091-6749(76)90159-7; DVORAK HF, 1979, J EXP MED, V150, P322, DOI 10.1084/jem.150.2.322; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Eckl-Dorna J, 2012, ALLERGY, V67, P601, DOI 10.1111/j.1398-9995.2012.02792.x; Egawa M, 2013, IMMUNITY, V38, P570, DOI 10.1016/j.immuni.2012.11.014; Falcone FH, 2011, CLIN EXP ALLERGY, V41, P939, DOI 10.1111/j.1365-2222.2011.03781.x; Falcone FH, 2005, INFLAMM RES, V54, pS13, DOI 10.1007/s00011-004-0405-y; Finkelman FD, 2016, J ALLERGY CLIN IMMUN, V137, P1674, DOI 10.1016/j.jaci.2016.02.015; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; Giacomin PR, 2012, J IMMUNOL, V189, P4371, DOI 10.4049/jimmunol.1200691; Gorgens A, 2013, CELL REP, V3, P1539, DOI 10.1016/j.celrep.2013.04.025; Gomez MR, 2014, MUCOSAL IMMUNOL, V7, P188, DOI 10.1038/mi.2013.38; Grundstrom J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048308; Haenuki Y, 2012, J ALLERGY CLIN IMMUN, V130, P184, DOI 10.1016/j.jaci.2012.02.013; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hashimoto T, 2015, J IMMUNOL, V194, P4631, DOI 10.4049/jimmunol.1401032; Hermann FJ, 2015, IMMUNOLOGY, V145, P202, DOI 10.1111/imm.12436; Huang H, 2016, SEMIN IMMUNOPATHOL, V38, P539, DOI 10.1007/s00281-016-0562-4; Hussain M, 2017, J ALLERGY CLIN IMMUN; Iki M, 2016, BLOOD, V128, P2909, DOI 10.1182/blood-2016-07-729392; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; Ito Y, 2011, ALLERGY, V66, P1107, DOI 10.1111/j.1398-9995.2011.02570.x; Jiang AP, 2015, J VIROL, V89, P8050, DOI 10.1128/JVI.01021-15; Jonsson F, 2011, J CLIN INVEST, V121, P1484, DOI 10.1172/JCI45232; JUHLIN L, 1977, LANCET, V1, P1233; Kambayashi T, 2014, NAT REV IMMUNOL, V14, P719, DOI 10.1038/nri3754; KATZ SI, 1978, J INVEST DERMATOL, V71, P70, DOI 10.1111/1523-1747.ep12544415; Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053, DOI 10.1164/ajrccm.164.6.2102025; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V132, P1375, DOI 10.1016/j.jaci.2013.09.008; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; KleinJan A, 2000, J ALLERGY CLIN IMMUN, V106, P677, DOI 10.1067/mai.2000.109621; Korosec P, 2017, J ALLERGY CLIN IMMUN, V140, P750, DOI 10.1016/j.jaci.2016.12.989; Koshino T, 1996, J ASTHMA, V33, P89, DOI 10.3109/02770909609054536; Leyva-Castillo JM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3847; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; Metz M, 2017, THERANOSTICS, V7, P1266, DOI 10.7150/thno.18304; Meulenbroeks C, 2015, J INVEST DERMATOL, V135, P222, DOI 10.1038/jid.2014.329; Miyake K, 2017, P NATL ACAD SCI USA, V114, P1111, DOI 10.1073/pnas.1615973114; Motakis E, 2014, BLOOD, V123, pE58, DOI 10.1182/blood-2013-02-483792; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Mukai K, 2005, IMMUNITY, V23, P191, DOI 10.1016/j.immuni.2005.06.011; Mukai K, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00053-17; Muto T, 2014, INT IMMUNOL, V26, P539, DOI 10.1093/intimm/dxu058; Nakashima C, 2014, J ALLERGY CLIN IMMUN, V134, P100, DOI 10.1016/j.jaci.2014.02.026; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Nouri-Aria KT, 2001, J ALLERGY CLIN IMMUN, V108, P205, DOI 10.1067/mai.2001.117175; Obata K, 2007, BLOOD, V110, P913, DOI 10.1182/blood-2007-01-068718; Obata-Ninomiya K, 2013, J EXP MED, V210, P2583, DOI 10.1084/jem.20130761; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Pan QJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00348; Pellefigues C, 2013, CURR OPIN IMMUNOL, V25, P704, DOI 10.1016/j.coi.2013.10.003; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Phythian-Adams AT, 2010, J EXP MED, V207, P2089, DOI 10.1084/jem.20100734; Qi XP, 2013, IMMUNITY, V39, P97, DOI 10.1016/j.immuni.2013.06.012; Reber LL, 2013, J ALLERGY CLIN IMMUN, V132, P881, DOI 10.1016/j.jaci.2013.06.008; Reimer JM, 2006, ALLERGY, V61, P1063, DOI 10.1111/j.1398-9995.2006.01149.x; Reitz M, 2017, MUCOSAL IMMUNOL, V10, P481, DOI 10.1038/mi.2016.56; Saini SS, 2015, J INVEST DERMATOL, V135, P67, DOI 10.1038/jid.2014.306; Sanjuan MA, 2016, J ALLERGY CLIN IMMUN, V137, P1651, DOI 10.1016/j.jaci.2016.04.007; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P1123, DOI 10.1016/j.jaci.2012.05.039; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; Schiechl G, 2016, AM J TRANSPLANT, V16, P2574, DOI 10.1111/ajt.13764; Schroeder JT, 2011, IMMUNOL REV, V242, P144, DOI 10.1111/j.1600-065X.2011.01023.x; Schwartz C, 2014, P NATL ACAD SCI USA, V111, pE5169, DOI 10.1073/pnas.1412663111; Sektioglu IM, 2017, CANCER RES, V77, P291, DOI 10.1158/0008-5472.CAN-16-0993; Shiraishi Y, 2013, J IMMUNOL, V190, P539, DOI 10.4049/jimmunol.1202049; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Stephen-Victor E, 2017, HAEMATOLOGICA, V102, pE233, DOI 10.3324/haematol.2016.163451; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Sullivan BM, 2011, NAT IMMUNOL, V12, P527, DOI 10.1038/ni.2036; Torrero MN, 2013, VACCINE, V31, P3675, DOI 10.1016/j.vaccine.2013.06.010; Tsai SH, 2015, IMMUNITY, V42, P279, DOI 10.1016/j.immuni.2015.01.015; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Tsutsui H, 2017, J BIOL CHEM, V292, P1061, DOI 10.1074/jbc.M116.754648; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; van Beek AA, 2013, INT ARCH ALLERGY IMM, V160, P7, DOI 10.1159/000341633; Venturelli N, 2016, J ALLERGY CLIN IMMUN, V138, P1367, DOI 10.1016/j.jaci.2016.02.034; Voskamp AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081777; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Wakahara K, 2012, BLOOD, V120, P4761, DOI 10.1182/blood-2012-04-424226; Watanabe T, 2013, J GASTROENTEROL, V48, P247, DOI 10.1007/s00535-012-0626-8; Yazawa Naoki, 2015, Tokai J Exp Clin Med, V40, P141; Ying S, 2002, J ALLERGY CLIN IMMUN, V109, P694, DOI 10.1067/mai.2002.123236; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Yousefi S, 2015, ALLERGY, V70, P1184, DOI 10.1111/all.12662; Yuk CM, 2017, SCI REP-UK, V7, DOI 10.1038/srep41744	106	65	66	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					370	380		10.1016/j.jaci.2017.10.042	http://dx.doi.org/10.1016/j.jaci.2017.10.042			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29247714	Bronze			2022-12-18	WOS:000440664400004
J	Turner, JH; Chandra, RK; Li, P; Bonnet, K; Schlundt, DG				Turner, Justin H.; Chandra, Rakesh K.; Li, Ping; Bonnet, Kemberlee; Schlundt, David G.			Identification of clinically relevant chronic rhinosinusitis endotypes using cluster analysis of mucus cytokines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							GENE-EXPRESSION; NASAL POLYPS; PROFILES		[Turner, Justin H.; Chandra, Rakesh K.; Li, Ping] Vanderbilt Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Nashville, TN 37212 USA; [Bonnet, Kemberlee; Schlundt, David G.] Vanderbilt Univ, Sch Arts & Sci, Dept Psychol Sci, 221 Kirkland Hall, Nashville, TN 37235 USA; [Bonnet, Kemberlee; Schlundt, David G.] Vanderbilt Ctr Qualitat Res, Nashville, TN USA	Vanderbilt University; Vanderbilt University	Turner, JH (corresponding author), Vanderbilt Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Nashville, TN 37212 USA.	justin.h.turner@vanderbilt.edu	Turner, Justin/AAD-8607-2020	Turner, Justin/0000-0002-5501-9900; Chandra, Rakesh/0000-0002-3612-0026	National Institutes of Health (NIH) [RO3 DC014809, L30 AI113795]; Clinical and Translational Science Award from the National Center for Advancing Translational Sciences [UL1TR000445]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC014809] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Clinical and Translational Science Award from the National Center for Advancing Translational Sciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This project was supported by the National Institutes of Health (NIH; grant no. RO3 DC014809 to J.H.T. and grant no. L30 AI113795 to J.H.T.), and Clinical and Translational Science Award UL1TR000445 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the NIH.	[Anonymous], 1983, FACTOR ANAL; Doty R.L., 2013, SMELL IDENTIFICATION; DOTY RL, 1984, LARYNGOSCOPE, V94, P176, DOI 10.1288/00005537-198402000-00004; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Hauser LJ, 2017, INT FORUM ALLERGY RH, V7, P957, DOI 10.1002/alr.21994; Hinks TSC, 2016, J ALLERGY CLIN IMMUN, V138, P61, DOI 10.1016/j.jaci.2015.11.020; Hopkins C, 2009, CLIN OTOLARYNGOL, V34, P447, DOI 10.1111/j.1749-4486.2009.01995.x; Konig K, 2015, ALLERGY ASTHMA CL IM, V11, DOI 10.1186/s13223-015-0093-x; Kuo CHS, 2017, AM J RESP CRIT CARE, V195, P443, DOI 10.1164/rccm.201512-2452OC; O'Rourke N, 2013, STEP BY STEP APPROAC; Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS22, DOI 10.1002/alr.21695; Oyer SL, 2013, LARYNGOSCOPE, V123, pE72, DOI 10.1002/lary.24305; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Platt MP, 2011, OTOLARYNG HEAD NECK, V145, P171, DOI 10.1177/0194599811402030; Scavuzzo MC, 2003, BIOMED PHARMACOTHER, V57, P366, DOI 10.1016/S0753-3322(03)00097-0; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; Tan BK, 2017, J ALLERGY CLIN IMMUN, V139, P699, DOI 10.1016/j.jaci.2016.06.063; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Wang BF, 2016, INT FORUM ALLERGY RH, V6, P1013, DOI 10.1002/alr.21799; Weibman AR, 2017, INT FORUM ALLERGY RH, V7, P1058, DOI 10.1002/alr.22005; Wu J, 2018, LARYNGOSCOPE, V128, pE304, DOI 10.1002/lary.27112	21	65	70	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1895	+		10.1016/j.jaci.2018.02.002	http://dx.doi.org/10.1016/j.jaci.2018.02.002			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29452200	Bronze, Green Accepted			2022-12-18	WOS:000432148200036
J	Admiraal, R; de Koning, CCH; Lindemans, CA; Bierings, MB; Wensing, AMJ; Versluys, AB; Wolfs, TFW; Nierkens, S; Boelens, JJ				Admiraal, Rick; de Koning, Coco C. H.; Lindemans, Caroline A.; Bierings, Marc B.; Wensing, Annemarie M. J.; Versluys, A. Birgitta; Wolfs, Tom F. W.; Nierkens, Stefan; Boelens, Jaap Jan			Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Viral reactivations; hematopoietic cell transplantation; immune reconstitution; clinical outcomes	ALLOGENEIC BONE-MARROW; VERSUS-HOST-DISEASE; HERPES-VIRUS 6; CLINICAL-OUTCOMES; CMV REACTIVATION; MORTALITY; CYTOMEGALOVIRUS; RECOVERY; SURVIVAL; IMPACT	Background: Viral reactivations (VRs) after hematopoietic cell transplantation (HCT) contribute to significant morbidity and mortality. Timely immune reconstitution (IR) is suggested to prevent VR. Objectives: We studied the relation between IR (as a continuous predictor over time) and VR (as a time-varying predictor) and the relation between VR and other clinical outcomes. Methods: In this retrospective analysis all patients receiving a first HCT between January 2004 and September 2014 were included. IR (CD3/CD4/CD8 T, natural killer, and B cells) was measured biweekly until 12 weeks and monthly thereafter. Main outcomes of interest were VR of adenovirus, EBV, human herpesvirus 6 (HHV6), cytomegalovirus (CMV), and BK virus screened weekly. Clinical outcomes included overall survival (OS), event-free-survival, nonrelapse mortality (NRM), and graft-versus-host disease. Cox proportional hazard and Fine and Gray competing risk models were used. Results: Two hundred seventy-three patients (age, 0.1-22.7 years; median follow-up, 58 months) were included. Delayed CD4 reconstitution predicted reactivation of adenovirus (hazard ratio [HR], 0.995; P =.022), EBV (HR, 0.994; P =.029), and HHV6 (HR, 0.991; P =.012) but not CMV (P =.31) and BK virus (P =.27). Duration of adenovirus reactivation was shorter with timely CD4 reconstitution, which was defined as 50 x 10(6) cells/L or greater within 100 days. Adenovirus reactivation predicted lower OS (HR, 2.17; P =.0039) and higher NRM (HR, 2.96; P =.0008). Concomitant CD4 reconstitution abolished this negative effect of adenovirus reactivation (OS, P =.67; NRM, P =.64). EBV and HHV6 reactivations were predictors for the occurrence of graft-versus-host disease, whereas CMV and BK virus reactivation did not predict clinical outcomes. Conclusion: These results stress the importance of timely CD4 reconstitution. Strategies to improve CD4 reconstitution can improve HCT outcomes, including survival, and reduce the need for toxic antiviral therapies.	[Admiraal, Rick; de Koning, Coco C. H.; Nierkens, Stefan; Boelens, Jaap Jan] Univ Med Ctr Utrecht, Lab Translat Immunol, Utrecht, Netherlands; [Admiraal, Rick; Lindemans, Caroline A.; Bierings, Marc B.; Versluys, A. Birgitta; Boelens, Jaap Jan] Univ Med Ctr Utrecht, Pediat Blood & Marrow Transplantat Program, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands; [Wensing, Annemarie M. J.] Univ Med Ctr Utrecht, Virol, Dept Med Microbiol, Utrecht, Netherlands; [Wolfs, Tom F. W.] Univ Med Ctr Utrecht, Dept Pediat Infect Dis, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Boelens, JJ (corresponding author), Univ Med Ctr Utrecht, Pediat Blood & Marrow Transplantat Program, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	j.j.boelens@umcutrecht.nl	Nierkens, Stefan/AAQ-5564-2021	Nierkens, Stefan/0000-0003-3406-817X; de Koning, Coco/0000-0003-3992-8570	Dutch Organization for Scientific Research (ZonMW) [40-41500-98-11044]; Dutch foundation Children Cancerfree (KiKa) [142]; American Foundation for AIDS Research Consortium on HIV Eradication (amfAR ARCHE) [109293]	Dutch Organization for Scientific Research (ZonMW)(Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Health Research and Development); Dutch foundation Children Cancerfree (KiKa); American Foundation for AIDS Research Consortium on HIV Eradication (amfAR ARCHE)	Supported by a Rational Pharmacotherapy Programme grant from the Dutch Organization for Scientific Research (ZonMW; grant no. 40-41500-98-11044 to R. A.), and the Dutch foundation Children Cancerfree (KiKa; project no. 142 to C.d.K.). A.M.J.W. was supported by the American Foundation for AIDS Research Consortium on HIV Eradication (amfAR ARCHE; grant no. 109293 [EPISTEM]).	Admiraal R, 2016, BLOOD, V128, P2734, DOI 10.1182/blood-2016-06-721936; Admiraal R, 2015, LANCET HAEMATOL, V2, pE194, DOI 10.1016/S2352-3026(15)00045-9; Auger S, 2014, EUR J HAEMATOL, V92, P421, DOI 10.1111/ejh.12260; Bartelink IH, 2013, BIOL BLOOD MARROW TR, V19, P305, DOI 10.1016/j.bbmt.2012.10.010; Berger M, 2008, BONE MARROW TRANSPL, V41, P55, DOI 10.1038/sj.bmt.1705870; Boeckh M, 2003, BLOOD, V101, P407, DOI 10.1182/blood-2002-03-0993; Broers AEC, 2000, BLOOD, V95, P2240, DOI 10.1182/blood.V95.7.2240.007k08_2240_2245; Bruno B, 2003, BIOL BLOOD MARROW TR, V9, P341, DOI 10.1016/S1083-8791(03)00102-2; Buhlmann L, 2011, BONE MARROW TRANSPL, V46, P1357, DOI 10.1038/bmt.2010.306; Chiesa R, 2012, BRIT J HAEMATOL, V156, P656, DOI 10.1111/j.1365-2141.2011.08994.x; de Koning C, 2016, BLOOD, V128, P2607, DOI 10.1182/blood-2016-06-724005; de Pagter PJA, 2013, BONE MARROW TRANSPL, V48, P1460, DOI 10.1038/bmt.2013.78; Fedele R, 2012, BLOOD TRANSFUS-ITALY, V10, P174, DOI 10.2450/2012.0034-11; Gilis L, 2014, BONE MARROW TRANSPL, V49, P664, DOI 10.1038/bmt.2013.235; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Gotoh M, 2014, TRANSPL INFECT DIS, V16, P440, DOI 10.1111/tid.12229; Green ML, 2013, BLOOD, V122, P1316, DOI 10.1182/blood-2013-02-487074; Hiwarkar P, 2013, BONE MARROW TRANSPL, V48, P803, DOI 10.1038/bmt.2012.221; Jaskula E, 2010, TRANSPL P, V42, P3273, DOI 10.1016/j.transproceed.2010.07.027; Kim DH, 2006, BONE MARROW TRANSPL, V37, P1119, DOI 10.1038/sj.bmt.1705381; Nadal E, 2004, EXP HEMATOL, V32, P218, DOI 10.1016/j.exphem.2003.10.016; Nierkens S, 2015, CYTOTHERAPY, V17, P1667, DOI 10.1016/j.jcyt.2015.09.008; Perruccio K, 2010, ANN NY ACAD SCI, V1194, P153, DOI 10.1111/j.1749-6632.2010.05486.x; Peters SG, 2005, CLIN CHEST MED, V26, P561, DOI 10.1016/j.ccm.2005.06.009; Pourgheysari B, 2009, BONE MARROW TRANSPL, V43, P853, DOI 10.1038/bmt.2008.403; Ritter J, 2015, AM J TRANSPLANT, V15, P2170, DOI 10.1111/ajt.13241; Schmidt-Hieber M, 2013, BLOOD, V122, P3359, DOI 10.1182/blood-2013-05-499830; Seggewiss R, 2007, SEMIN HEMATOL, V44, P203, DOI 10.1053/j.seminhematol.2007.04.009; Servais S, 2014, BIOL BLOOD MARROW TR, V20, P507, DOI 10.1016/j.bbmt.2014.01.001; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; Teira P, 2016, BLOOD, V127, P2427, DOI 10.1182/blood-2015-11-679639; Velardi E, 2014, J EXP MED, V211, P2341, DOI 10.1084/jem.20131289; Violago L, 2015, PEDIATR TRANSPLANT, V19, P737, DOI 10.1111/petr.12572; Zerr DM, 2005, CLIN INFECT DIS, V40, P932, DOI 10.1086/428060	34	65	65	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1643	+		10.1016/j.jaci.2016.12.992	http://dx.doi.org/10.1016/j.jaci.2016.12.992			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28392330	Bronze			2022-12-18	WOS:000417206000019
J	Hollams, EM; Teo, SM; Kusel, M; Holt, BJ; Holt, KE; Inouye, M; De Klerk, NH; Zhang, GC; Sly, PD; Hart, PH; Holt, PG				Hollams, Elysia M.; Teo, Shu Mei; Kusel, Merci; Holt, Barbara J.; Holt, Kathryn E.; Inouye, Michael; De Klerk, Nicholas H.; Zhang, Guicheng; Sly, Peter D.; Hart, Prue H.; Holt, Patrick G.			Vitamin D over the first decade and susceptibility to childhood allergy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; asthma; allergy; respiratory infections; microbiome; Streptococcus; longitudinal birth cohort; childhood	RECEPTOR GENE POLYMORPHISMS; REGULATORY T-CELLS; RESPIRATORY-INFECTIONS; CLINICAL-RELEVANCE; AIRWAY; ATOPY; RISK; ASSOCIATION; PATHOGENESIS; MODULATION	Background: Vitamin D (25(OH) D) deficiency has been implicated as a possible risk factor for asthma development, but studies at selected time points measuring 25(OH) D levels during childhood have yielded conflicting findings. Prospective studies tracking 25(OH) D levels during the initiation phase of asthma in early childhood have not been reported. Objective: We sought to elucidate relationships between 25(OH) D levels from birth to age 10 years and susceptibility to allergic sensitization, respiratory tract infections, and asthma. Methods: Asthma-, allergy-, and respiratory tract infection-associated phenotypes (including pathogen identification) were characterized in a high-risk birth cohort. Plasma 25(OH) D concentrations were quantified at birth and at clinical follow-ups at the ages of 0.5, 1, 2, 3, 4, 5, and 10 years, and relationships with clinical outcomes were examined. Results: Cross-sectional analyses demonstrated inverse associations between 25(OH) D concentrations and the risk for concurrent sensitization at age 0.5, 2, and 3 years, and mixed-effects regression demonstrated inverse longitudinal associations of 25(OH) D levels with both sensitization and eczema. Multivariate regression modeling suggested that the number of 25(OH) D-deficient follow-ups was positively associated with risk for asthma/wheeze, eczema, and sensitization at 10 years; adjustment for sensitization (particularly by 2 years) in the asthma/wheeze models reduced 25(OH) D associations with these latter outcomes. 25(OH) D levels were also inversely associated with early nasopharyngeal colonization with Streptococcus species and age of first febrile lower respiratory illness, both of which are known asthma risk factors. Conclusion: 25(OH) D deficiency in early childhood is associated with increased risk for persistent asthma, potentially through modulating susceptibility to early allergic sensitization, upper respiratory tract colonization with bacterial pathogens, or both. These relationships are only evident if 25(OH) D status is monitored prospectively and longitudinally.	[Hollams, Elysia M.; Kusel, Merci; Holt, Barbara J.; De Klerk, Nicholas H.; Hart, Prue H.; Holt, Patrick G.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia; [Teo, Shu Mei; Holt, Kathryn E.; Inouye, Michael] Univ Melbourne, Ctr Syst Genom, Melbourne, Vic, Australia; [Teo, Shu Mei; Holt, Kathryn E.] Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Melbourne, Vic, Australia; [Zhang, Guicheng] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia; [Sly, Peter D.; Holt, Patrick G.] Univ Queensland, Brisbane, Qld, Australia	Telethon Kids Institute; University of Western Australia; University of Melbourne; University of Melbourne; Curtin University; University of Queensland	Holt, PG (corresponding author), Telethon Kids Inst, POB 855, Perth, WA 6872, Australia.	Patrick.Holt@telethonkids.org.au	Sly, Peter D/F-1486-2010; Zhang, Brad/AAF-8719-2021; Holt, Kathryn E/A-8108-2012; de Klerk, Nicholas/D-8388-2016; Holt, Patrick/H-1548-2011	Sly, Peter D/0000-0001-6305-2201; Holt, Kathryn E/0000-0003-3949-2471; Inouye, Michael/0000-0001-9413-6520; Zhang, Guicheng/0000-0001-9888-5385; de Klerk, Nicholas/0000-0001-9223-0767; Hollams, Elysia/0000-0002-3481-6396; Holt, Patrick/0000-0003-1193-0935	Asthma Australia (Australian Heart Foundation) [1026411, 1049539, 1061409, 1061435]; Western Australian Department of Health (Australian Heart Foundation) [1026411, 1049539, 1061409, 1061435]; NHMRC of Australia (Australian Heart Foundation) [1026411, 1049539, 1061409, 1061435]	Asthma Australia (Australian Heart Foundation); Western Australian Department of Health (Australian Heart Foundation); NHMRC of Australia (Australian Heart Foundation)(National Health and Medical Research Council (NHMRC) of Australia)	Supported by Asthma Australia, the Western Australian Department of Health, and the NHMRC of Australia, including project grants #1026411 and #1049539 and fellowships #1061409 (to K.E.H.) and #1061435 (to M.I., cofunded with the Australian Heart Foundation).	Adorini L, 2003, J CELL BIOCHEM, V88, P227, DOI 10.1002/jcb.10340; Albarhani AA, 2015, CLIN BIOCHEM, V48, P1105, DOI 10.1016/j.clinbiochem.2015.04.014; Bailey D, 2013, CLIN BIOCHEM, V46, P190, DOI 10.1016/j.clinbiochem.2012.10.037; Berraies A, 2014, J ASTHMA ALLERGY, V7, P23, DOI 10.2147/JAA.S46944; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bosse Y, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-98; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Britt RD, 2015, J CELL PHYSIOL, V230, P1189, DOI 10.1002/jcp.24814; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Cantorna MT, 2014, ANN NY ACAD SCI, V1317, P70, DOI 10.1111/nyas.12408; Carlberg C, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00167; Cassim R, 2015, ALLERGY, V70, P339, DOI 10.1111/all.12583; Chambers ES, 2014, IMMUNOLOGY, V143, P52, DOI 10.1111/imm.12289; Clarke MW, 2013, METABOLOMICS, V9, P1031, DOI 10.1007/s11306-013-0518-9; da Silva FP, 2012, PEPTIDES, V36, P308, DOI 10.1016/j.peptides.2012.05.014; Du R, 2012, J ALLERGY CLIN IMMUN, V129, P368, DOI 10.1016/j.jaci.2011.09.034; Greiller CL, 2015, NUTRIENTS, V7, P4240, DOI 10.3390/nu7064240; Hansdottir S, 2010, J IMMUNOL, V184, P965, DOI 10.4049/jimmunol.0902840; Hart PH, 2015, PEDIATRICS, V135, pE167, DOI 10.1542/peds.2014-1860; Hart PH, 2011, NAT REV IMMUNOL, V11, P584, DOI 10.1038/nri3045; Hollams EM, 2011, EUR RESPIR J, V38, P1320, DOI 10.1183/09031936.00029011; Holt PG, 2011, CHEST, V139, P1165, DOI 10.1378/chest.10-2397; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Hossein-nezhad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058725; Jackson DJ, 2010, IMMUNOL ALLERGY CLIN, V30, P513, DOI 10.1016/j.iac.2010.08.004; Kerley CP, 2015, PULM PHARMACOL THER, V32, P75, DOI 10.1016/j.pupt.2015.02.010; Kongsbak M, 2014, BMC IMMUNOL, V15, DOI 10.1186/s12865-014-0035-2; Kusel MMH, 2012, EUR RESPIR J, V39, P876, DOI 10.1183/09031936.00193310; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Leung TF, 2015, PEDIAT ALLERG IMM-UK, V26, P375, DOI 10.1111/pai.12392; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6; Mirzakhani H, 2015, CLIN EXP ALLERGY, V45, P114, DOI 10.1111/cea.12430; Navas-Nazario A, 2014, ANN ALLERG ASTHMA IM, V112, P519, DOI 10.1016/j.anai.2014.03.017; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Penna G, 2007, J IMMUNOL, V178, P145, DOI 10.4049/jimmunol.178.1.145; Peters SAE, 2012, J CLIN EPIDEMIOL, V65, P686, DOI 10.1016/j.jclinepi.2011.11.012; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Ramankutty P, 2014, J PAEDIATR CHILD H, V50, P713, DOI 10.1111/jpc.12657; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Tizaoui K, 2014, LUNG, V192, P955, DOI 10.1007/s00408-014-9648-8; van der Mei IAF, 2007, J NEUROL, V254, P581, DOI 10.1007/s00415-006-0315-8; Vimaleswaran KS, 2012, ALLERGY, V67, P1033, DOI 10.1111/j.1398-9995.2012.02856.x; Walker ML, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00447; Yu SL, 2015, SCI REP-UK, V5, DOI 10.1038/srep14636	46	65	71	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					472	+		10.1016/j.jaci.2016.07.032	http://dx.doi.org/10.1016/j.jaci.2016.07.032			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27726947				2022-12-18	WOS:000397002400013
J	Brick, T; Schober, Y; Bocking, C; Pekkanen, J; Genuneit, J; Loss, G; Dalphin, JC; Riedler, J; Lauener, R; Nockher, WA; Renz, H; Vaarala, O; Braun-Fahrlander, C; von Mutius, E; Ege, MJ; Pfefferle, PI				Brick, Tabea; Schober, Yvonne; Boecking, Christian; Pekkanen, Juha; Genuneit, Jon; Loss, Georg; Dalphin, Jean-Charles; Riedler, Josef; Lauener, Roger; Nockher, Wolfgang Andreas; Renz, Harald; Vaarala, Outi; Braun-Fahrlander, Charlotte; von Mutius, Erika; Ege, Markus Johannes; Pfefferle, Petra Ina		PASTURE Study Grp	omega-3 fatty acids contribute to the asthma-protective effect of unprocessed cow's milk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy protection; farm milk effect; omega-3 fatty acid; asthma	FISH-OIL SUPPLEMENTATION; HIGH-PRESSURE HOMOGENIZATION; POLYUNSATURATED FATTY-ACIDS; CHILDHOOD ASTHMA; INVERSE ASSOCIATION; HIGH-RISK; FARM; CONSUMPTION; INFANTS; ALLERGY	Background: Living on a farm has repeatedly been shown to protect children from asthma and allergies. A major factor involved in this effect is consumption of unprocessed cow's milk obtained directly from a farm. However, this phenomenon has never been shown in a longitudinal design, and the responsible milk components are still unknown. Objectives: We sought to assess the asthma-protective effect of unprocessed cow's milk consumption in a birth cohort and to determine whether the differences in the fatty acid (FA) composition of unprocessed farm milk and industrially processed milk contributed to this effect. Methods: The Protection Against Allergy-Study in Rural Environments (PASTURE) study followed 1133 children living in rural areas in 5 European countries from birth to age 6 years. In 934 children milk consumption was assessed by using yearly questionnaires, and samples of the ``usually'' consumed milk and serum samples of the children were collected at age 4 years. Doctor-diagnosed asthma was parent reported at age 6 years. In a nested case-control study of 35 asthmatic and 49 nonasthmatic children, 42 FAs were quantified in milk samples. Results: The risk of asthma at 6 years of age was reduced by previous consumption of unprocessed farm milk compared with shop milk (adjusted odds ratio for consumption at 4 years, 0.26; 95% CI,0.10-0.67). Part of the effect was explained by the higher fat content of farm milk, particularly the higher levels of omega-3 polyunsaturated FAs (adjusted odds ratio, 0.29; 95% CI,0.11-0.81). Conclusion: Continuous farm milk consumption in childhood protects against asthma at school age partially by means of higher intake of omega-3 polyunsaturated FAs, which are precursors of anti-inflammatory mediators.	[Brick, Tabea; Loss, Georg; von Mutius, Erika; Ege, Markus Johannes] Univ Munich, Dr von Hauner Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany; [Schober, Yvonne; Boecking, Christian; Nockher, Wolfgang Andreas; Renz, Harald; Pfefferle, Petra Ina] Univ Marburg, Inst Lab Med Pathobiochem & Mol Diagnost, Marburg, Germany; [Pfefferle, Petra Ina] Univ Marburg, Fac Med, Comprehens Biomat Bank Marburg, CBBMR, Marburg, Germany; [Pekkanen, Juha] Univ Eastern Finland, Natl Inst Hlth & Welf, Dept Environm Hlth, Kuopio, Finland; [Pekkanen, Juha] Univ Eastern Finland, Publ Hlth & Clin Nutr, Kuopio, Finland; [Genuneit, Jon] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Loss, Georg] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; [Dalphin, Jean-Charles] Univ Hosp Besancon, Dept Resp Dis, UMR CNRS Chronoenvironm 6249, Besancon, France; [Riedler, Josef] Childrens Hosp Schwarzach, Schwarzach, Austria; [Lauener, Roger] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Lauener, Roger] Childrens Hosp Eastern Switzerland, St Gallen, Switzerland; [Vaarala, Outi] Univ Helsinki, Inst Clin Med, Helsinki, Finland; [Braun-Fahrlander, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Braun-Fahrlander, Charlotte] Univ Basel, Basel, Switzerland; [von Mutius, Erika; Ege, Markus Johannes] German Ctr Lung Res, CPC M, Munich, Germany	University of Munich; Philipps University Marburg; Philipps University Marburg; Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; Ulm University; University of California System; University of California San Diego; Universite de Franche-Comte; CHU Besancon; University of Helsinki; University of Basel; Swiss Tropical & Public Health Institute; University of Basel	Ege, MJ (corresponding author), Univ Munich, Dr von Hauner Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	markus.ege@med.lmu.de	Jurassien, LTER Jurassian Arc Zone atelier Arc/C-1946-2016; Genuneit, Jon/I-9323-2012; Schaub, Bianca/B-9935-2019; Loss, Georg/AAE-7296-2019; Lauener, Roger P/O-8612-2016; riedler, josef/AAQ-4666-2020; Ege, Markus/C-1962-2012	Genuneit, Jon/0000-0001-5764-1528; Schaub, Bianca/0000-0003-1652-8873; Loss, Georg/0000-0003-1090-812X; Lauener, Roger P/0000-0002-8412-606X; Ege, Markus/0000-0001-6643-3923; von Mutius, Erika/0000-0002-8893-4515				[Anonymous], 2013, KENNZ MILCH WELCH IN; [Anonymous], 2001, MILKS FLUID; Bocking C, 2010, CLIN CHEM LAB MED, V48, P1757, DOI 10.1515/CCLM.2010.350; D'Vaz N, 2012, PEDIATRICS, V130, P674, DOI 10.1542/peds.2011-3104; De La Fuente LF, 2009, J DAIRY SCI, V92, P3791, DOI 10.3168/jds.2009-2151; de Roos B, 2009, BRIT J PHARMACOL, V158, P413, DOI 10.1111/j.1476-5381.2009.00189.x; Depner M, 2014, AM J RESP CRIT CARE, V189, P129, DOI 10.1164/rccm.201307-1198OC; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Grainger JR, 2013, NAT MED, V19, P713, DOI 10.1038/nm.3189; Hayes MG, 2003, J DAIRY RES, V70, P297, DOI 10.1017/S0022029903006320; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Kirchner B, 2015, J ALLERGY CLIN IMMUN; Lauritzen L, 2005, LIPIDS, V40, P669, DOI 10.1007/s11745-005-1429-6; Leiber F, 2005, LIPIDS, V40, P191, DOI 10.1007/s11745-005-1375-3; Let MB, 2007, J AGR FOOD CHEM, V55, P1773, DOI 10.1021/jf062391s; Loss G, 2015, J ALLERGY CLIN IMMUN, V135, P56, DOI 10.1016/j.jaci.2014.08.044; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Miyata J, 2015, ALLERGOL INT, V64, P27, DOI 10.1016/j.alit.2014.08.003; Palmer DJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e184; Pereda J, 2008, J AGR FOOD CHEM, V56, P7125, DOI 10.1021/jf800972m; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Schubert R, 2009, INT ARCH ALLERGY IMM, V148, P321, DOI 10.1159/000170386; van Neerven RJJ, 2012, J ALLERGY CLIN IMMUN, V130, P853, DOI 10.1016/j.jaci.2012.06.050; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wall R, 2010, NUTR REV, V68, P280, DOI 10.1111/j.1753-4887.2010.00287.x; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567; Wlasiuk G, 2012, CURR OPIN ALLERGY CL, V12, P461, DOI 10.1097/ACI.0b013e328357a3bc; Zaslona Z, 2014, J ALLERGY CLIN IMMUN, V133, P379, DOI 10.1016/j.jaci.2013.07.037	37	65	65	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1699	+		10.1016/j.jaci.2015.10.042	http://dx.doi.org/10.1016/j.jaci.2015.10.042			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26792208	Bronze, Green Published			2022-12-18	WOS:000377527200008
J	Harden, JL; Lewis, SM; Lish, SR; Suarez-Farinas, M; Gareau, D; Lentini, T; Johnson-Huang, LM; Krueger, JG; Lowes, MA				Harden, Jamie L.; Lewis, Steven M.; Lish, Samantha R.; Suarez-Farinas, Mayte; Gareau, Daniel; Lentini, Tim; Johnson-Huang, Leanne M.; Krueger, James G.; Lowes, Michelle A.			The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis vulgaris; tryptophan metabolism; L-kynureninase; inflammation	ARYL-HYDROCARBON RECEPTOR; NITRIC-OXIDE SYNTHASE; INDOLEAMINE 2,3-DIOXYGENASE; ATOPIC-DERMATITIS; GENE-EXPRESSION; DENDRITIC CELLS; SKIN-LESIONS; IFN-GAMMA; T-CELLS; IMMUNITY	Background: Many human diseases arise from or have pathogenic contributions from a dysregulated immune response. One pathway with immunomodulatory ability is the tryptophan metabolism pathway, which promotes immune suppression through the enzyme indoleamine 2,3-dioxygenase (IDO) and subsequent production of kynurenine. However, in patients with chronic inflammatory skin disease, such as psoriasis and atopic dermatitis (AD), another tryptophan metabolism enzyme downstream of IDO, L-kynureninase (KYNU), is heavily upregulated. The role of KYNU has not been explored in patients with these skin diseases or in general human immunology. Objective: We sought to explore the expression and potential immunologic function of the tryptophan metabolism enzyme KYNU in inflammatory skin disease and its potential contribution to general human immunology. Methods: Psoriatic skin biopsy specimens, as well as normal human skin, blood, and primary cells, were used to investigate the immunologic role of KYNU and tryptophan metabolites. Results: Here we show that KYNU 1 cells, predominantly of myeloid origin, infiltrate psoriatic lesional skin. KYNU expression positively correlates with disease severity and inflammation and is reduced on successful treatment of psoriasis or AD. Tryptophan metabolites downstream of KYNU upregulate several cytokines, chemokines, and cell adhesions. By mining data on several human diseases, we found that in patients with cancer, IDO is preferentially upregulated compared with KYNU, whereas in patients with inflammatory diseases, such as AD, KYNU is preferentially upregulated compared with IDO. Conclusion: Our results suggest that tryptophan metabolism might dichotomously modulate immune responses, with KYNU as a switch between immunosuppressive versus inflammatory outcomes. Although tryptophan metabolism is increased in many human diseases, how tryptophan metabolism is proceeding might qualitatively affect the immune response in patients with that disease.	[Harden, Jamie L.; Lewis, Steven M.; Lish, Samantha R.; Suarez-Farinas, Mayte; Gareau, Daniel; Lentini, Tim; Johnson-Huang, Leanne M.; Krueger, James G.; Lowes, Michelle A.] Rockefeller Univ, Lab Invest Dermatol, New York, NY 10065 USA; [Suarez-Farinas, Mayte] Rockefeller Univ, Ctr Clin & Translat Sci, New York, NY 10065 USA; [Lowes, Michelle A.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Dermatol, Bronx, NY 10467 USA; [Suarez-Farinas, Mayte] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA	Rockefeller University; Rockefeller University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai	Harden, JL (corresponding author), Rockefeller Univ, Lab Invest Dermatol, New York, NY 10065 USA.	jharden@rockefeller.edu	; Lowes, Michelle A/G-9585-2016	Lewis, Steven/0000-0002-1979-0554; Lowes, Michelle A/0000-0003-4256-478X	National Institutes of Health (NIH) [1R01AR060222]; National Psoriasis Foundation Discovery grant; Linda and Leonard Berkowitz Postdoctoral Fellowship; Milstein Foundation; Robertson Therapeutics Fund; National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program [UL1 TR000043]; Rockefeller University Center for Clinical and Translational Science [ULTR000043]; Robertson Therapeutics Development fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000043] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR060222] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Psoriasis Foundation Discovery grant; Linda and Leonard Berkowitz Postdoctoral Fellowship; Milstein Foundation; Robertson Therapeutics Fund; National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program; Rockefeller University Center for Clinical and Translational Science; Robertson Therapeutics Development fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by National Institutes of Health (NIH) grant 1R01AR060222 (full or partial supported to M.A.L., J.L.H., and M.S-.F.). T.L. was supported by the National Psoriasis Foundation Discovery grant (awarded to M.A.L.). L.M.J.-H. was supported by the Linda and Leonard Berkowitz Postdoctoral Fellowship. D.G. was supported by the Milstein Foundation and the Robertson Therapeutics Fund. This research was supported in part by grant no. UL1 TR000043 from the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program. This research was also supported by the Rockefeller University Center for Clinical and Translational Science (grant award no. ULTR000043) and the Robertson Therapeutics Development fund (both awarded to J.L.H.).	Asp L, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-25; Carruthers R, 1968, Med J Aust, V1, P493; Chen YQ, 2010, NEUROTOX RES, V18, P132, DOI 10.1007/s12640-009-9129-7; Chiricozzi A, 2011, J INVEST DERMATOL, V131, P677, DOI 10.1038/jid.2010.340; Colonna M, 2014, IMMUNITY, V40, P863, DOI 10.1016/j.immuni.2014.06.001; Daubener W, 2009, THROMB HAEMOSTASIS, V102, P1110, DOI 10.1160/TH09-04-0250; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Darcy CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021185; Davidovici BB, 2010, J INVEST DERMATOL, V130, P1785, DOI 10.1038/jid.2010.103; Di Meglio P, 2014, IMMUNITY, V40, P989, DOI 10.1016/j.immuni.2014.04.019; Dowlatshahi EA, 2014, J INVEST DERMATOL, V134, P1542, DOI 10.1038/jid.2013.508; Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752; Fuentes-Duculan J, 2010, J INVEST DERMATOL, V130, P2412, DOI 10.1038/jid.2010.165; Gu T, 2010, CANCER RES, V70, P129, DOI 10.1158/0008-5472.CAN-09-3170; Gudjonsson JE, 2010, J INVEST DERMATOL, V130, P1829, DOI 10.1038/jid.2010.36; Gudjonsson JE, 2009, J INVEST DERMATOL, V129, P2795, DOI 10.1038/jid.2009.173; Gulati N, 2014, J INVEST DERMATOL, V134, P2531, DOI 10.1038/jid.2014.196; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Harden JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111255; Harden JL, 2012, IMMUNOL INVEST, V41, P738, DOI 10.3109/08820139.2012.676122; Harden JL, 2011, J IMMUNOL, V187, P126, DOI 10.4049/jimmunol.1100168; Ito M, 2004, J DERMATOL SCI, V36, P157, DOI 10.1016/j.jdermsci.2004.08.012; Jensen JM, 2012, ALLERGY, V67, P413, DOI 10.1111/j.1398-9995.2011.02747.x; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Julliard W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00458; Kennedy-Crispin M, 2012, J INVEST DERMATOL, V132, P105, DOI 10.1038/jid.2011.262; Kwidzinski E, 2007, J MOL MED, V85, P1351, DOI 10.1007/s00109-007-0229-7; Lee JS, 2012, NAT IMMUNOL, V13, P144, DOI 10.1038/ni.2187; Lowes MA, 2005, P NATL ACAD SCI USA, V102, P19057, DOI 10.1073/pnas.0509736102; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Mellor AL, 1999, IMMUNOL TODAY, V20, P469, DOI 10.1016/S0167-5699(99)01520-0; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Mitsui H, 2012, J INVEST DERMATOL, V132, P1615, DOI 10.1038/jid.2012.33; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Perera GK, 2012, ANNU REV PATHOL-MECH, V7, P385, DOI 10.1146/annurev-pathol-011811-132448; Prendergast GC, 2014, CANCER IMMUNOL IMMUN, V63, P721, DOI 10.1007/s00262-014-1549-4; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Riol-Blanco L, 2014, NATURE, V510, P157, DOI 10.1038/nature13199; Roberson EDO, 2012, J INVEST DERMATOL, V132, P583, DOI 10.1038/jid.2011.348; SPIERA H, 1967, LANCET, V2, P137; Stone TW, 2002, NAT REV DRUG DISCOV, V1, P609, DOI 10.1038/nrd870; Suarez-Farinas M, 2011, J INVEST DERMATOL, V131, P391, DOI 10.1038/jid.2010.280; Suarez-Farinas M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010247; Tian SY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044274; Vecsei L, 2013, NAT REV DRUG DISCOV, V12, P64, DOI 10.1038/nrd3793; Wang YT, 2010, NAT MED, V16, P279, DOI 10.1038/nm.2092; Zaba LC, 2009, J ALLERGY CLIN IMMUN, V124, P1022, DOI 10.1016/j.jaci.2009.08.046; Zaba LC, 2009, J INVEST DERMATOL, V129, P302, DOI 10.1038/jid.2008.225	50	65	72	2	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1830	1840		10.1016/j.jaci.2015.09.055	http://dx.doi.org/10.1016/j.jaci.2015.09.055			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26725996	Green Accepted, Bronze			2022-12-18	WOS:000377527200025
J	Hayashi, H; Mitsui, C; Nakatani, E; Fukutomi, Y; Kajiwara, K; Watai, K; Sekiya, K; Tsuburai, T; Akiyama, K; Hasegawa, Y; Taniguchi, M				Hayashi, Hiroaki; Mitsui, Chihiro; Nakatani, Eiji; Fukutomi, Yuma; Kajiwara, Keiichi; Watai, Kentaro; Sekiya, Kiyoshi; Tsuburai, Takahiro; Akiyama, Kazuo; Hasegawa, Yoshinori; Taniguchi, Masami			Omalizumab reduces cysteinyl leukotriene and 9 alpha,11 beta-prostaglandin F-2 overproduction in aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ASTHMATIC-PATIENTS; CELL		[Hayashi, Hiroaki; Mitsui, Chihiro; Fukutomi, Yuma; Kajiwara, Keiichi; Watai, Kentaro; Sekiya, Kiyoshi; Tsuburai, Takahiro; Akiyama, Kazuo; Taniguchi, Masami] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan; [Hayashi, Hiroaki; Hasegawa, Yoshinori] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi 4648601, Japan; [Nakatani, Eiji] Fdn Biomed Res & Innovat, Translat Res Informat Ctr, Kobe, Hyogo, Japan; [Watai, Kentaro] Juntendo Univ, Grad Sch Med, Dept Allergy & Clin Immunol, Tokyo, Japan	Nagoya University; Institute for Biomedical Research & Innovation (IBRI); Juntendo University	Taniguchi, M (corresponding author), Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan.	m-taniguchi@sagamihara-hosp.gr.jp	Nakatani, Eiji/O-2782-2013; Fukutomi, Yuma/AFQ-4306-2022	Nakatani, Eiji/0000-0002-4876-446X; 				Cahill KN, 2015, J ALLERGY CLIN IMMUN, V135, P245, DOI 10.1016/j.jaci.2014.07.031; Chang TW, 2015, J ALLERGY CLIN IMMUN, V135, P337, DOI 10.1016/j.jaci.2014.04.036; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Higashi N, 2004, J ALLERGY CLIN IMMUN, V113, P277, DOI 10.1016/j.jaci.2003.10.068; Higashi N, 2010, J ALLERGY CLIN IMMUN, V125, P1084, DOI 10.1016/j.jaci.2009.12.977; Holgate ST, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-17; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019	13	65	68	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1585	1587		10.1016/j.jaci.2015.09.034	http://dx.doi.org/10.1016/j.jaci.2015.09.034			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26559322	Bronze			2022-12-18	WOS:000376180200035
J	Simon, Q; Pers, JO; Cornec, D; Le Pottier, L; Mageed, RA; Hillion, S				Simon, Quentin; Pers, Jacques-Olivier; Cornec, Divi; Le Pottier, Laetitia; Mageed, Rizgar A.; Hillion, Sophie			In-depth characterization of CD24(high)CD38(high) transitional human B cells reveals different regulatory profiles	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Transitional B cells; immune regulation; chronic inflammatory diseases; autoimmunity	PERIPHERAL-BLOOD; T-CELLS; SUBSETS; MEMORY; IDENTIFICATION; POPULATIONS; COMPARTMENT; ANERGY; MOUSE	Background: CD24(high)CD38(high) transitional B cells represent cells at a key stage in their developmental pathway. In addition, these B cells have been widely ascribed regulatory functions and involvement in the control of chronic inflammatory diseases. However, the phenotypic and functional overlap between these cells and regulatory B cells remains controversial. Objective: In this study we wanted to explore the regulatory properties of CD24(high)CD38(high) human B cells. Methods: We used multicolor flow cytometry in combination with bioinformatics and functional studies to show that CD24(high)CD38(high) B cells can be distinguished into multiple subsets with different regulatory functions. Results: For the first time, the study reveals that human transitional B cells encompass not only transitional type 1 and type 2 B cells, as previously suggested, but also distinct anergic type 3 B cells, as well as IL-10-producing CD27(+) transitional B cells. Interestingly, the latter 2 subsets differentially regulate CD4(+) T-cell proliferation and polarization toward T(H)1 effector cells. Additional analyses reveal that the percentage of type 3 B cells is reduced and the frequency of CD27(+) transitional B cells is increased in patients with autoimmune diseases compared with those in matched healthy subjects. Conclusion: This study provides evidence for the existence of different transitional B-cell subsets, each displaying unique phenotypic and regulatory functional profiles. Furthermore, the study indicates that altered distribution of transitional B-cell subsets highlights different regulatory defects in patients with different autoimmune diseases.	[Simon, Quentin; Pers, Jacques-Olivier; Cornec, Divi; Le Pottier, Laetitia; Hillion, Sophie] Univ Brest, EA2216, INSERM ESPRI, ERI29, Brest, France; [Simon, Quentin; Pers, Jacques-Olivier; Cornec, Divi; Le Pottier, Laetitia; Hillion, Sophie] LabEx IGO, Brest, France; [Cornec, Divi] CHRU Brest Morvan, Dept Rheumatol, Brest, France; [Mageed, Rizgar A.] Queen Mary Univ London, William Harvey Res Inst, London, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale; CHU Brest; University of London; Queen Mary University London	Hillion, S (corresponding author), CHRU Brest, Immunol Lab, BP824, F-29609 Brest, France.	sophie.hillion@univ-brest.fr	HILLION, Sophie/I-9747-2019; Simon, Quentin/AAW-8810-2020; Pers, Jacques-Olivier/AGG-7221-2022	Simon, Quentin/0000-0002-2383-2809; Hillion, Sophie/0000-0002-3354-0981	LabEX IGO program [ANR-11 LABX 0016 0]	LabEX IGO program	Supported by the LabEX IGO program through investment of the future program ANR-11 LABX 0016 0.	Allman D, 2001, J IMMUNOL, V167, P6834, DOI 10.4049/jimmunol.167.12.6834; Anolik JH, 2007, ARTHRITIS RHEUM, V56, P3044, DOI 10.1002/art.22810; Aviszus K, 2012, J IMMUNOL, V189, P4275, DOI 10.4049/jimmunol.1201818; Bao WL, 2013, AM J HEMATOL, V88, P736, DOI 10.1002/ajh.23488; Benitez A, 2014, J IMMUNOL, V192, P4610, DOI 10.4049/jimmunol.1300692; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Bouaziz JD, 2010, EUR J IMMUNOL, V40, P2686, DOI 10.1002/eji.201040673; Browne CD, 2009, IMMUNITY, V31, P749, DOI 10.1016/j.immuni.2009.08.026; Dalai SK, 2008, J IMMUNOL, V181, P3221, DOI 10.4049/jimmunol.181.5.3221; Duggal NA, 2013, AGING CELL, V12, P873, DOI 10.1111/acel.12114; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; Genestier L, 2007, J IMMUNOL, V178, P7779, DOI 10.4049/jimmunol.178.12.7779; Giltiay NV, 2013, J EXP MED, V210, P2773, DOI 10.1084/jem.20122798; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Khoder A, 2014, BLOOD, V124, P2034, DOI 10.1182/blood-2014-04-571125; Lemoine S, 2011, J AUTOIMMUN, V36, P228, DOI 10.1016/j.jaut.2011.01.005; Li XJ, 2012, BLOOD, V120, P3318, DOI 10.1182/blood-2012-05-432575; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Matsumoto M, 2014, IMMUNITY, V41, P1040, DOI 10.1016/j.immuni.2014.10.016; Merrell KT, 2006, IMMUNITY, V25, P953, DOI 10.1016/j.immuni.2006.10.017; Nouel A, 2015, J AUTOIMMUN, V59, P53, DOI 10.1016/j.jaut.2015.02.004; Nouel A, 2014, KIDNEY INT, V85, P590, DOI 10.1038/ki.2013.457; Palanichamy A, 2009, J IMMUNOL, V182, P5982, DOI 10.4049/jimmunol.0801859; Petro JB, 2002, J BIOL CHEM, V277, P48009, DOI 10.1074/jbc.M200305200; Pillai S, 2005, ANNU REV IMMUNOL, V23, P161, DOI 10.1146/annurev.immunol.23.021704.115728; Qian Y, 2010, CYTOM PART B-CLIN CY, V78B, pS69, DOI 10.1002/cyto.b.20554; Quach TD, 2011, J IMMUNOL, V186, P4640, DOI 10.4049/jimmunol.1001946; Rosser EC, 2015, IMMUNITY, V42, P607, DOI 10.1016/j.immuni.2015.04.005; Seite JF, 2014, J ALLERGY CLIN IMMUN, V133, P181, DOI 10.1016/j.jaci.2013.08.042; Sims GP, 2005, BLOOD, V105, P4390, DOI 10.1182/blood-2004-11-4284; Tedder TF, 2015, J IMMUNOL, V194, P1395, DOI 10.4049/jimmunol.1401329; Ueda Y, 2007, J IMMUNOL, V178, P3593, DOI 10.4049/jimmunol.178.6.3593; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Wirths S, 2005, EUR J IMMUNOL, V35, P3433, DOI 10.1002/eji.200535364; Yurasov S, 2005, J EXP MED, V201, P703, DOI 10.1084/jem.20042251	35	65	66	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2016	137	5					1577	+		10.1016/j.jaci.2015.09.014	http://dx.doi.org/10.1016/j.jaci.2015.09.014			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DM2MF	26525227	Green Submitted, Bronze			2022-12-18	WOS:000376180200034
J	Patil, SU; Ogunniyi, AO; Calatroni, A; Tadigotla, VR; Ruiter, B; Ma, A; Moon, J; Love, JC; Shreffler, WG				Patil, Sarita U.; Ogunniyi, Adebola O.; Calatroni, Agustin; Tadigotla, Vasisht R.; Ruiter, Bert; Ma, Alex; Moon, James; Love, J. Christopher; Shreffler, Wayne G.			Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; antigen-specific B cells; peanut allergy; food allergy; antibody repertoire	TREE NUT ALLERGY; IGE; RESPONSES; ANTIBODIES; PREVALENCE; SIGNATURES; SEVERITY; CHILDREN; IGG4	Background: Peanut oral immunotherapy (PNOIT) induces persistent tolerance to peanut in a subset of patients and induces specific antibodies that might play a role in clinical protection. However, the contribution of induced antibody clones to clinical tolerance in PNOIT is unknown. Objective: We hypothesized that PNOIT induces a clonal, allergen-specific B-cell response that could serve as a surrogate for clinical outcomes. Methods: We used a fluorescent Ara h 2 multimer for affinity selection of Ara h 2-specific B cells and subsequent single-cell immunoglobulin amplification. The diversity of related clones was evaluated by means of next-generation sequencing of immunoglobulin heavy chains from circulating memory B cells with 2x250 paired-end sequencing on the Illumina MiSeq platform. Results: Expression of class-switched antibodies from Ara h 2-positive cells confirms enrichment for Ara h 2 specificity. PNOIT induces an early and transient expansion of circulating Ara h 2-specific memory B cells that peaks at week 7. Ara h 2-specific sequences from memory cells have rates of nonsilent mutations consistent with affinity maturation. The repertoire of Ara h 2-specific antibodies is oligoclonal. Next-generation sequencing-based repertoire analysis of circulating memory B cells reveals evidence for convergent selection of related sequences in 3 unrelated subjects, suggesting the presence of similar Ara h 2-specific B-cell clones. Conclusions: Using a novel affinity selection approach to identify antigen-specific B cells, we demonstrate that the early PNOIT-induced Ara h 2-specific B-cell receptor repertoire is oligoclonal and somatically hypermutated and shares similar clonal groups among unrelated subjects consistent with convergent selection.	[Patil, Sarita U.; Ruiter, Bert; Ma, Alex; Moon, James; Shreffler, Wayne G.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; [Patil, Sarita U.; Ruiter, Bert; Ma, Alex; Moon, James; Shreffler, Wayne G.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA; [Patil, Sarita U.; Ruiter, Bert; Shreffler, Wayne G.] Massachusetts Gen Hosp, Food Allergy Ctr, Boston, MA 02114 USA; [Patil, Sarita U.; Ruiter, Bert; Shreffler, Wayne G.] MassGen Hosp Children, Boston, MA USA; [Patil, Sarita U.; Ogunniyi, Adebola O.; Love, J. Christopher] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Calatroni, Agustin] Rho, Chapel Hill, NC USA; [Tadigotla, Vasisht R.] Boston Univ, Dept Phys, Boston, MA 02215 USA; [Love, J. Christopher] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA; [Love, J. Christopher] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Rho; Boston University; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Harvard Medical School	Patil, SU (corresponding author), 55 Fruit St,Cox 201, Boston, MA 02114 USA.	Sarita.patil@mgh.harvard.edu	; moon, james/F-1031-2014	Moon, James/0000-0001-8246-931X; Love, John/0000-0003-0921-3144; Ruiter, Bert/0000-0003-3945-3202; Shreffler, Wayne/0000-0001-6465-137X; moon, james/0000-0001-8071-1491	National Institute of Allergy and Infectious Diseases (NIAID) [U19 AI087881, U19 AI095261]; National Institutes of Health grant [1S10RR023440-01A1]; Koch Institute Support (core) grant [P30-CA14051]; Keck Foundation; Bill and Melinda Gates Foundation; NIAID [F32 AI104182]; AAAAI/Food Allergy Research & Education Howard Gittis Memorial Research Award; Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award) [UL1 TR001102]; Harvard University; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR023440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095261, F32AI104182, U01AI087881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Koch Institute Support (core) grant; Keck Foundation(W.M. Keck Foundation); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); AAAAI/Food Allergy Research & Education Howard Gittis Memorial Research Award; Harvard Clinical and Translational Science Center (National Center for Research Resources)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award); Harvard University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by contracts with the National Institute of Allergy and Infectious Diseases (NIAID U19 AI087881 and NIAID U19 AI095261), National Institutes of Health grant 1S10RR023440-01A1, and in part by Koch Institute Support (core) grant P30-CA14051. Research was also supported by the Keck Foundation and the Bill and Melinda Gates Foundation. S.U.P. is supported by NIAID F32 AI104182 and 2013 AAAAI/Food Allergy Research & Education Howard Gittis Memorial Research Award. J.C.L is a Camile Dreyfus Teacher-Scholar. Clinical studies were supported in part by the Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102), and financial contributions from Harvard University and its affiliated academic health care centers.	Alamyar Eltaf, 2012, Methods Mol Biol, V882, P569, DOI 10.1007/978-1-61779-842-9_32; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; Franz B, 2011, BLOOD, V118, P348, DOI 10.1182/blood-2011-03-341917; Frolich D, 2010, J IMMUNOL, V185, P3103, DOI 10.4049/jimmunol.1000911; Garcia-Bates TM, 2013, J IMMUNOL, V190, P80, DOI 10.4049/jimmunol.1103350; Giudicelli Veronique, 2011, Cold Spring Harb Protoc, V2011, P695, DOI 10.1101/pdb.prot5633; Glanville J, 2011, P NATL ACAD SCI USA, V108, P20066, DOI 10.1073/pnas.1107498108; Jackson KJL, 2014, CELL HOST MICROBE, V16, P105, DOI 10.1016/j.chom.2014.05.013; James LK, 2012, J ALLERGY CLIN IMMUN, V130, P663, DOI 10.1016/j.jaci.2012.04.006; Jiang N, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004794; Jiang N, 2011, P NATL ACAD SCI USA, V108, P5348, DOI 10.1073/pnas.1014277108; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Jones Stacie M, 2009, J Allergy Clin Immunol, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Klemans RJB, 2013, J ALLERGY CLIN IMMUN, V131, P157, DOI 10.1016/j.jaci.2012.08.010; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; LANZAVECCHIA A, 1987, IMMUNOL REV, V99, P39, DOI 10.1111/j.1600-065X.1987.tb01171.x; Lee JH, 2010, CELL IMMUNOL, V262, P44, DOI 10.1016/j.cellimm.2009.12.006; Lefranc MP, 2009, NUCLEIC ACIDS RES, V37, pD1006, DOI 10.1093/nar/gkn838; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Morris L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023532; Newman J, 2003, J IMMUNOL METHODS, V272, P177, DOI 10.1016/S0022-1759(02)00499-4; Ogunniyi AO, 2014, VACCINE, V32, P2866, DOI 10.1016/j.vaccine.2014.02.020; Parameswaran P, 2013, CELL HOST MICROBE, V13, P691, DOI 10.1016/j.chom.2013.05.008; R Core Team R, 2022, R LANG ENV STAT COMP; Rogosch T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00176; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Thyagarajan A, 2012, CLIN EXP ALLERGY, V42, P1197, DOI 10.1111/j.1365-2222.2012.04028.x; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wang XW, 2000, J IMMUNOL METHODS, V244, P217, DOI 10.1016/S0022-1759(00)00260-X; Wood S., 2006, GEN ADDITIVE MODELS, DOI DOI 10.1201/9781315370279; Wu XL, 2011, SCIENCE, V333, P1593, DOI 10.1126/science.1207532	47	65	65	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2015	136	1					125	U253		10.1016/j.jaci.2015.03.026	http://dx.doi.org/10.1016/j.jaci.2015.03.026			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM2WE	25985925	Green Published, Bronze, Green Accepted			2022-12-18	WOS:000357542200014
J	Wang, CS; Lou, HF; Wang, XD; Wang, Y; Fan, EZ; Li, Y; Wang, H; Bachert, C; Zhang, L				Wang, Chengshuo; Lou, Hongfei; Wang, Xiangdong; Wang, Yang; Fan, Erzhong; Li, Ying; Wang, Hong; Bachert, Claus; Zhang, Luo			Effect of budesonide transnasal nebulization in patients with eosinophilic chronic rhinosinusitis with nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic chronic rhinosinusitis; nasal polyps; tissue remodeling; inflammatory cytokine; T-cell subsets; budesonide; transnasal nebulization	COLLAGEN DEPOSITION; TISSUE INHIBITOR; ORAL STEROIDS; CORTICOSTEROIDS; METALLOPROTEINASE-1; TOLERABILITY; INFLAMMATION; IRRIGATIONS; SUPPRESSION; EXPRESSION	Background: There is little evidence on the efficacy of glucocorticoid transnasal nebulization therapy in patients with eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP). Objective: We sought to evaluate the immunologic and remodeling effects of budesonide transnasal nebulization in patients with eosinophilic CRSwNP. Methods: Sixty patients with eosinophilic CRSwNP were randomized to receive budesonide or placebo treatment for 14 days by means of transnasal nebulization in a double-blind manner. Endoscopic polyp size scores (maximum 5 6 points, Kennedy score) and visual analog scale scores for nasal symptoms were assessed before and after treatment. Similarly, polyp samples were evaluated for inflammatory cytokines, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs) by using an immunoassay; collagen by using histochemistry; eosinophils by using hematoxylin and eosin stain; and T-cell subsets by using flow cytometry. Results: Budesonide transnasal nebulization significantly reduced polyp size compared with placebo (mean difference between groups, 20.73 units; 95% CI, -1.15 to -0.32 units; P = .002) and improved symptoms. Polyp IL-5 and eotaxin expression decreased significantly, whereas TGF-beta and IL-10 expression increased. Expression of IFN-gamma and IL-17 was not altered. Budesonide transnasal nebulization consistently reduced eosinophil infiltration and T(H)2 cell frequency and increased natural regulatory T-cell and type 1 regulatory T-cell frequencies. Indices of remodeling, including albumin, MMP-2, MMP-7, MMP-8, and MMP-9, were significantly decreased, whereas collagen deposition and TIMP-1, TIMP-2, and TIMP-4 levels were significantly increased. Budesonide transnasal nebulization did not suppress the hypothalamicpituitary-adrenal axis or cause any serious side effects. Conclusion: Short-term budesonide transnasal nebulization is an effective and safe treatment option in patients with eosinophilic CRSwNP, achieving clinical improvement by regulating remodeling, cytokine expression, and T-cell subset distribution.	[Wang, Chengshuo; Lou, Hongfei; Wang, Xiangdong; Zhang, Luo] Capital Med Univ, Beijing TongRen Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Wang, Chengshuo; Lou, Hongfei; Wang, Xiangdong; Wang, Yang; Fan, Erzhong; Li, Ying; Wang, Hong; Zhang, Luo] Minist Educ China, Beijing Inst Otolaryngol, Key Lab Otolaryngol Head & Neck Surg, Beijing, Peoples R China; [Bachert, Claus] Ghent Univ Hosp, Dept Otorhinolaryngol, Upper Airways Res Lab, Ghent, Belgium	Capital Medical University; Ministry of Education, China; Ghent University; Ghent University Hospital	Zhang, L (corresponding author), Beijing Inst Otolaryngol, 17 HouGouHuTong, Beijing 100005, Peoples R China.	dr.luozhang@gmail.com	Bachert, Claus/J-8825-2012; wang, xiao/HGB-7081-2022; Wang, Xiangdong/AAF-9148-2020	wang, xiao/0000-0002-4088-3341; Zhang, Luo/0000-0002-0910-9884	Program for Changjiang Scholars and Innovative Research Team [IRT13082]; National Science Fund for Distinguished Young Scholars [81025007, 81420108009]; Beijing Natural Science Foundation [7131006]; Ministry of Health Foundation [201202005]; Capital Health Research and Development Special Fund [2011-1017-06]; Special Fund of Sanitation Elite Reconstruction of Beijing [2009-2007]; Beijing Health Bureau Program for High Level Talents [2011-3-043]; National Science Foundation; Beijing Natural Science Foundation; Ministry of Health Foundation; Ministry of Education; Capital Health Research and Development; Special Fund of Sanitation Elite Reconstruction of Beijing; Beijing Health Bureau	Program for Changjiang Scholars and Innovative Research Team(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); National Science Fund for Distinguished Young Scholars(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Ministry of Health Foundation; Capital Health Research and Development Special Fund; Special Fund of Sanitation Elite Reconstruction of Beijing; Beijing Health Bureau Program for High Level Talents; National Science Foundation(National Science Foundation (NSF)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Ministry of Health Foundation; Ministry of Education; Capital Health Research and Development; Special Fund of Sanitation Elite Reconstruction of Beijing; Beijing Health Bureau	Supported by grants from the Program for Changjiang Scholars and Innovative Research Team (IRT13082), the National Science Fund for Distinguished Young Scholars and for the Major International Joint Research Program (81025007 and 81420108009), the Beijing Natural Science Foundation (7131006), the Ministry of Health Foundation (201202005), the Capital Health Research and Development Special Fund (2011-1017-06), the Special Fund of Sanitation Elite Reconstruction of Beijing (2009-2007), and the Beijing Health Bureau Program for High Level Talents (2011-3-043).r Disclosure of potential conflict of interest: L. Zhang's institution has received funding from the National Science Foundation, the Beijing Natural Science Foundation, the Ministry of Health Foundation, the Ministry of Education, the Capital Health Research and Development, the Special Fund of Sanitation Elite Reconstruction of Beijing, and the Beijing Health Bureau. The rest of the authors declare that they have no relevant conflicts of interest.	Bachert C, 2000, AM J RHINOL, V14, P279, DOI 10.2500/105065800781329573; Basu K, 2009, ANN ALLERG ASTHMA IM, V103, P436, DOI 10.1016/S1081-1206(10)60365-1; Bhalla RK, 2008, J OTOLARYNGOL-HEAD N, V37, P821, DOI 10.2310/7070.2008.OA0186; Bruni FM, 2009, NEUROIMMUNOMODULAT, V16, P353, DOI 10.1159/000216193; Cao PP, 2009, J ALLERGY CLIN IMMUN, V124, P478, DOI 10.1016/j.jaci.2009.05.017; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Fokkens W, 2007, RHINOLOGY, P1; Hamilos DL, 2011, J ALLERGY CLIN IMMUN, V128, P693, DOI 10.1016/j.jaci.2011.08.004; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hvizdos KM, 2000, DRUGS, V60, P1141, DOI 10.2165/00003495-200060050-00010; Jankowski R, 2001, ARCH OTOLARYNGOL, V127, P447, DOI 10.1001/archotol.127.4.447; Keith P, 2000, CLIN EXP ALLERGY, V30, P1460, DOI 10.1046/j.1365-2222.2000.00932.x; Lee YM, 2003, J KOREAN MED SCI, V18, P97; Li HB, 2008, CLIN IMMUNOL, V129, P394, DOI 10.1016/j.clim.2008.07.031; Li XY, 2010, J ALLERGY CLIN IMMUN, V125, P1061, DOI 10.1016/j.jaci.2010.02.023; Mastruzzo C, 2003, J ALLERGY CLIN IMMUN, V112, P37, DOI 10.1067/mai.2003.1586; Molet SM, 2003, LARYNGOSCOPE, V113, P1803, DOI 10.1097/00005537-200310000-00027; Namba M, 2004, ACTA OTO-LARYNGOL, V124, P964, DOI 10.1080/00016480310016947; Sachanandani NS, 2009, ARCH OTOLARYNGOL, V135, P303, DOI 10.1001/archoto.2008.555; Small CB, 2008, J ALLERGY CLIN IMMUN, V121, P928, DOI 10.1016/j.jaci.2007.11.018; Steinke JW, 2009, J ALLERGY CLIN IMMUN, V124, P1352, DOI 10.1016/j.jaci.2009.09.018; Vaidyanathan S, 2011, ANN INTERN MED, V154, P293, DOI 10.7326/0003-4819-154-5-201103010-00003; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Zele T, 2010, J ALLERGY CLIN IMMUN, V125, P1069, DOI 10.1016/j.jaci.2010.02.020; Welch KC, 2010, AMJ RHINOL ALLERGY, V24, P26, DOI 10.2500/ajra.2010.24.3418; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Yigit O, 2011, LARYNGOSCOPE, V121, P667, DOI 10.1002/lary.21462; Zhang N, 2008, J ALLERGY CLIN IMMUN, V122, P961, DOI 10.1016/j.jaci.2008.07.008	29	65	86	1	23	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					922	+		10.1016/j.jaci.2014.10.018	http://dx.doi.org/10.1016/j.jaci.2014.10.018			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25483598	Green Published, hybrid			2022-12-18	WOS:000352238600013
J	Glatzer, F; Gschwandtner, M; Ehling, S; Rossbach, K; Janik, K; Klos, A; Baumer, W; Kietzmann, M; Werfel, T; Gutzmer, R				Glatzer, Franziska; Gschwandtner, Maria; Ehling, Sarah; Rossbach, Kristine; Janik, Katrin; Klos, Andreas; Baeumer, Wolfgang; Kietzmann, Manfred; Werfel, Thomas; Gutzmer, Ralf			Histamine induces proliferation in keratinocytes from patients with atopic dermatitis through the histamine 4 receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Histamine; keratinocyte; proliferation; histamine 4 receptor; human; mouse; atopic dermatitis	PROTEIN-KINASE-C; H-4 RECEPTOR; EPIDERMAL DIFFERENTIATION; MURINE KERATINOCYTES; MOLECULAR-CLONING; GROWTH-FACTOR; CELL-LINE; SKIN; PSORIASIS; EXPRESSION	Background: Epidermal hyperproliferation resulting in acanthosis is an important clinical observation in patients with atopic dermatitis, and its underlying mechanisms are not completely understood. Objective: Because increased levels of histamine are present in lesional skin, we investigated the effect of histamine, especially with regard to histamine 4 receptor (H4R) activation, on the proliferation of human and murine keratinocytes. Methods: The expression of H4R on human and murine keratinocytes was detected by using real-time PCR. Keratinocyte proliferation was evaluated by using different in vitro cell proliferation assays, scratch assays, and measurement of the epidermal thickness of murine skin. Results: We detected H4R mRNA on foreskin keratinocytes and on outer root sheath keratinocytes; H4R mRNA was more abundant in keratinocytes from patients with atopic dermatitis compared with those from nonatopic donors. Stimulation of foreskin keratinocytes, atopic dermatitis outer root sheath keratinocytes, and H4R-transfected HaCaT cells with histamine and H4R agonist resulted in an increase in proliferation, which was blocked with the H4R-specific antagonist JNJ7777120. Abdominal epidermis of H4R-deficient mice was significantly thinner, and the in vitro proliferation of keratinocytes derived from H4R-deficient mice was lower compared with that seen in control mice. Interestingly, we only detected H4R expression on murine keratinocytes after stimulation with LPS and peptidoglycan. Conclusion: H4R is highly expressed on keratinocytes from patients with atopic dermatitis, and its stimulation induces keratinocyte proliferation. This might represent a mechanism that contributes to the epidermal hyperplasia observed in patients with atopic dermatitis.	[Glatzer, Franziska; Gschwandtner, Maria; Werfel, Thomas; Gutzmer, Ralf] Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, D-30625 Hannover, Germany; [Janik, Katrin; Klos, Andreas] Hannover Med Sch, Inst Med Microbiol & Hosp Epidemiol, D-30625 Hannover, Germany; [Gschwandtner, Maria] Med Univ Vienna, Dept Dermatol, Res Div Biol & Pathobiol Skin, Vienna, Austria; [Ehling, Sarah; Rossbach, Kristine; Baeumer, Wolfgang; Kietzmann, Manfred] Univ Vet Med, Inst Pharmacol Toxicol & Pharm, Hannover, Germany	Hannover Medical School; Hannover Medical School; Medical University of Vienna; University of Veterinary Medicine Hannover, Foundation	Glatzer, F (corresponding author), Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Glatzer.Franziska@mh-hannover.de	Werfel, Thomas/B-6921-2012; Janik, Katrin/U-2525-2019	Janik, Katrin/0000-0003-0878-7402; Baumer, Wolfgang/0000-0002-4346-5911; Gschwandtner, Maria/0000-0002-7944-7475	DFG (Deutsche Forschungsgemeinschaft) [Gu434/5-2, BA 2071/2-2]; Austrian Science Fund (FWF) [T545-B19]; European Community COST Action [BM0806]; Austrian Science Fund (FWF) [T 545] Funding Source: researchfish	DFG (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); European Community COST Action; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by grants from the DFG (Deutsche Forschungsgemeinschaft; Gu434/5-2 and BA 2071/2-2), from the Austrian Science Fund (FWF; T545-B19), and from the European Community COST Action BM0806 (Recent Advances in histamine H4 receptor research).	Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x; Bertero T, 2011, FASEB J, V25, P3092, DOI 10.1096/fj.10-168401; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRAUNSTEIN S, 1994, J INVEST DERMATOL, V103, P601, DOI 10.1111/1523-1747.ep12396936; Buddenkotte J, 2010, ADV EXP MED BIOL, V709, P73; Caldelari R, 2010, METHODS MOL BIOL, V633, P125, DOI 10.1007/978-1-59745-019-5_10; Carmi-Levy I, 2011, CLIN REV ALLERG IMMU, V41, P245, DOI 10.1007/s12016-010-8239-6; Caruso R, 2009, NAT MED, V15, P1013, DOI 10.1038/nm.1995; Chan JR, 2006, J EXP MED, V203, P2577, DOI 10.1084/jem.20060244; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; Davenas E, 2008, J PHARMACOL EXP THER, V326, P406, DOI 10.1124/jpet.107.135368; Dijkstra D, 2008, J INVEST DERMATOL, V128, P1696, DOI 10.1038/sj.jid.5701250; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; FURSTENBERGER G, 1985, CARCINOGENESIS, V6, P289, DOI 10.1093/carcin/6.2.289; Giustizieri ML, 2004, J ALLERGY CLIN IMMUN, V114, P1176, DOI 10.1016/j.jaci.2004.07.054; Gschwandtner M, 2013, ALLERGY, V68, P37, DOI 10.1111/all.12051; Guttman-Yassky E, 2009, J ALLERGY CLIN IMMUN, V124, P1235, DOI 10.1016/j.jaci.2009.09.031; Gutzmer Ralf, 2011, Front Biosci (Schol Ed), V3, P985; Gutzmer R, 2009, J ALLERGY CLIN IMMUN, V123, P619, DOI 10.1016/j.jaci.2008.12.1110; Hoffjan S, 2007, BRIT J DERMATOL, V157, P441, DOI 10.1111/j.1365-2133.2007.07999.x; Hofstra CL, 2003, J PHARMACOL EXP THER, V305, P1212, DOI 10.1124/jpet.102.046581; Ikawa Y, 2008, J TOXICOL SCI, V33, P503, DOI 10.2131/jts.33.503; Jensen JM, 2004, J INVEST DERMATOL, V122, P1423, DOI 10.1111/j.0022-202X.2004.22621.x; JOHNSON CL, 1990, CELL SIGNAL, V2, P105, DOI 10.1016/0898-6568(90)90014-2; Kanda N, 2004, J INVEST DERMATOL, V122, P863, DOI 10.1111/j.0022-202X.2004.22432.x; Kohda F, 2002, J DERMATOL SCI, V28, P34, DOI 10.1016/S0923-1811(01)00147-5; Krogstad AL, 1997, J INVEST DERMATOL, V109, P632, DOI 10.1111/1523-1747.ep12337620; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lim HD, 2005, J PHARMACOL EXP THER, V314, P1310, DOI 10.1124/jpet.105.087965; Lin TK, 2013, J INVEST DERMATOL, V133, P469, DOI 10.1038/jid.2012.335; Maurer M, 1997, J DERMATOL SCI, V16, P79, DOI 10.1016/S0923-1811(97)00043-1; Nakamura T, 2000, BIOCHEM BIOPH RES CO, V279, P615, DOI 10.1006/bbrc.2000.4008; Oda T, 2000, J BIOL CHEM, V275, P36781, DOI 10.1074/jbc.M006480200; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PANETTIERI RA, 1990, AM J PHYSIOL, V259, pL365, DOI 10.1152/ajplung.1990.259.6.L365; Romanowska M, 2008, J INVEST DERMATOL, V128, P110, DOI 10.1038/sj.jid.5700943; Schneider Elke, 2011, Front Biosci (Schol Ed), V3, P467, DOI 10.2741/s165; Wang D, 2008, ARTHRITIS RHEUM, V58, P3205, DOI 10.1002/art.23868; Werfel T, 2009, J INVEST DERMATOL, V129, P1878, DOI 10.1038/jid.2009.71; Wittmann M, 2005, J INVEST DERMATOL, V124, P1225, DOI 10.1111/j.0022-202X.2005.23715.x; Yu B, 2010, BRIT J DERMATOL, V162, P1038, DOI 10.1111/j.1365-2133.2010.09675.x	41	65	66	1	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2013	132	6					1358	1367		10.1016/j.jaci.2013.06.023	http://dx.doi.org/10.1016/j.jaci.2013.06.023			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	259PG	23932072	Green Accepted			2022-12-18	WOS:000327538200015
J	Papi, A; Contoli, M; Adcock, IM; Bellettato, C; Padovani, A; Casolari, P; Stanciu, LA; Barnes, PJ; Johnston, SL; Ito, K; Caramori, G				Papi, Alberto; Contoli, Marco; Adcock, Ian M.; Bellettato, Cinzia; Padovani, Anna; Casolari, Paolo; Stanciu, Luminita A.; Barnes, Peter J.; Johnston, Sebastian L.; Ito, Kazuhiro; Caramori, Gaetano			Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor kappa B and c-Jun N-terminal kinase activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; viral respiratory tract infections; glucocorticoids; transcription factors; kinases	ADHESION MOLECULE-1 ICAM-1; TRANSCRIPTIONAL ACTIVATION; INHALED CORTICOSTEROIDS; ASTHMA EXACERBATIONS; UP-REGULATION; MECHANISMS; INFLAMMATION; EXPRESSION; CHILDREN; COPD	Background: Although inhaled glucocorticoids are the mainstays of asthma treatment, they are poorly effective at treating and preventing virus-induced asthma exacerbations. The major viruses precipitating asthma exacerbations are rhinoviruses. Objective: We sought to evaluate whether rhinovirus infection interferes with the mechanisms of action of glucocorticoids. Methods: Cultured primary human bronchial or transformed (A549) respiratory epithelial cells were infected with rhinovirus 16 (RV-16) before dexamethasone exposure. Glucocorticoid receptor (GR) alpha nuclear translocation, glucocorticoid response element (GRE) binding, and transactivation/transrepression functional readouts were evaluated by using immunocytochemistry, Western blotting, DNA binding assays, real-time quantitative PCR, coimmunoprecipitation, and ELISA techniques. Specific inhibitors of c-Jun N-terminal kinase (JNK) and of I kappa B kinase (IKK) were used to investigate the involvement of intracellular signaling pathways. Results: RV-16 infection impaired dexamethasone-dependent (1) inhibition of IL-1 beta-induced CXCL8 release, (2) induction of mitogen-activated protein kinase phosphatase 1 gene expression, and (3) binding of GR to GREs in airway epithelial cells. This was associated with impaired GR alpha nuclear translocation, as assessed by means of both immunochemistry (54.0% +/- 6.8% vs 24.7% +/- 3.8% GR-positive nuclei after 10 nmol/L dexamethasone treatment in sham- or RV-16-infected cells, respectively; P < .01) and Western blotting. RV-16 infection induced nuclear factor kappa B activation and GR alpha phosphorylation, which were prevented by inhibitors of IKK2 and JNK, respectively. In rhinovirus-infected cells the combination of JNK and IKK2 inhibitors totally restored dexamethasone suppression of CXCL8 release, induction of mitogen-activated protein kinase phosphatase 1 gene expression, and GR alpha nuclear translocation. Conclusion: RV-16 infection of human airway epithelium induces glucocorticoid resistance. Inhibition of RV-16-induced JNK and nuclear factor kappa B activation fully reversed rhinovirus impairment of both GR alpha nuclear translocation and the transactivation/transrepression activities of glucocorticoids.	[Papi, Alberto; Contoli, Marco; Bellettato, Cinzia; Padovani, Anna; Casolari, Paolo; Caramori, Gaetano] Univ Ferrara, Sect Resp Dis, Dept Med Sci, I-44121 Ferrara, Italy; [Adcock, Ian M.; Barnes, Peter J.; Ito, Kazuhiro] Univ London Imperial Coll Sci Technol & Med, Airways Dis Sect, Natl Heart & Lung Inst, London SW7 2AZ, England; [Bellettato, Cinzia; Stanciu, Luminita A.; Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, MRC, London SW7 2AZ, England; [Bellettato, Cinzia; Stanciu, Luminita A.; Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Asthma UK Ctr Allerg Mech Asthma, Ctr Resp Infect, Natl Heart & Lung Inst, London SW7 2AZ, England	University of Ferrara; Imperial College London; Imperial College London; Imperial College London; University of London; King's College London	Papi, A (corresponding author), Univ Ferrara, Sez Malattie Apparato Resp, Via Savonarola 9, I-44121 Ferrara, Italy.	ppa@unife.it	Ito, Kazuhiro/AAF-5994-2019; Adcock, Ian/L-3217-2019; Johnston, Sebastian Lennox/I-2423-2012; Caramori, Gaetano/AAS-8611-2020; Stanciu, Luminita A/B-8384-2012; Papi, alberto/AAC-1888-2019; Contoli, Marco/K-3947-2018	Johnston, Sebastian Lennox/0000-0003-3009-9200; Caramori, Gaetano/0000-0002-9807-327X; Contoli, Marco/0000-0002-2731-5809; Adcock, Ian/0000-0003-2101-8843; PAPI, ALBERTO/0000-0002-6924-4500; Barnes, Peter/0000-0002-5122-4018	Ministry of Education and Scientific Research (Italy); University of Ferrara (Italy); Chiesi Foundation (Parma, Italy); Chair from Asthma UK [CH11SJ]; MRC Centre [G1000758]; ERC [233015]; Wellcome Programme grant [093080/Z/10/Z]; Medical Research Council [G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10148] Funding Source: researchfish	Ministry of Education and Scientific Research (Italy); University of Ferrara (Italy); Chiesi Foundation (Parma, Italy)(Chiesi Pharmaceuticals Inc); Chair from Asthma UK; MRC Centre(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); ERC(European Research Council (ERC)European Commission); Wellcome Programme grant; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by the Ministry of Education and Scientific Research (Italy) and the University of Ferrara (Italy). The Section of Respiratory Diseases of the University of Ferrara has received an unrestricted grant to support its research from Chiesi Foundation (Parma, Italy). S.L.J. was supported by a Chair from Asthma UK (CH11SJ). This work was also supported in part by MRC Centre Grant G1000758 and ERC FP7 Advanced grant 233015 (to S.L.J) and by Wellcome Programme grant 093080/Z/10/Z (to I.M.A. and P.J.B.).	Adcock IM, 2006, CURR DRUG TARGETS, V7, P649, DOI 10.2174/138945006777435344; Adcock IM, 2010, CURR PHARM DESIGN, V16, P3554; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Beck IME, 2009, ENDOCR REV, V30, P830, DOI 10.1210/er.2009-0013; Bossios A, 2008, CLIN EXP ALLERGY, V38, P1615, DOI 10.1111/j.1365-2222.2008.03058.x; Caramori G, 2003, THORAX, V58, P348, DOI 10.1136/thorax.58.4.348; Caramori G, 2006, CURR MED CHEM, V13, P2267, DOI 10.2174/092986706777935159; Chu SJ, 2006, AM J PHYSIOL-LUNG C, V291, pL983, DOI 10.1152/ajplung.00454.2005; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; de Kluijver J, 2003, CLIN EXP ALLERGY, V33, P1415, DOI 10.1046/j.1365-2222.2003.01770.x; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; Ducharme FM, 2009, NEW ENGL J MED, V360, P1674; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Eddleston J, 2011, AM J RESP CELL MOL, V44, P118, DOI 10.1165/rcmb.2009-0266OC; Edwards MR, 2006, AM J RESP CELL MOL, V34, P616, DOI 10.1165/rcmb.2005-0385OC; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; Frelin C, 2003, ONCOGENE, V22, P8187, DOI 10.1038/sj.onc.1206963; Global Initiative for Asthma (GINA), GLOB STRAT ASTHM MAN; Grunberg K, 2000, CLIN EXP ALLERGY, V30, P1015; Grunberg K, 2001, AM J RESP CRIT CARE, V164, P1816; Gustafson LM, 1996, J ALLERGY CLIN IMMUN, V97, P1009, DOI 10.1016/S0091-6749(96)80077-7; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Iordanov MS, 1999, J BIOL CHEM, V274, P25801, DOI 10.1074/jbc.274.36.25801; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K., 2001, FASEB Journal, V15, P1110; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Jiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101; Johnston SL, 1998, J IMMUNOL, V160, P6172; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1995, DIAGNOSTIC PROCEDURE, P553; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Kobayashi Y, 2012, PULM PHARMACOL THER, V25, P201, DOI 10.1016/j.pupt.2012.02.005; Mallia P, 2007, CURR PHARM DESIGN, V13, P73, DOI 10.2174/138161207779313777; Marwick JA, 2009, AM J RESP CRIT CARE, V179, P542, DOI 10.1164/rccm.200810-1570OC; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; Mercado N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041582; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Neubig RR, 2003, PHARMACOL REV, V55, P597, DOI 10.1124/pr.55.4.4; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Panickar J, 2009, NEW ENGL J MED, V360, P329, DOI 10.1056/NEJMoa0804897; Papi A, 2002, FASEB J, V16, P1934, DOI 10.1096/fj.02-0118fje; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Papi A, 2000, J ALLERGY CLIN IMMUN, V105, P318, DOI 10.1016/S0091-6749(00)90082-4; Papi A, 2008, J BIOL CHEM, V283, P28595, DOI 10.1074/jbc.M805766200; Pfeffer LM, 2011, J INTERF CYTOK RES, V31, P553, DOI 10.1089/jir.2011.0028; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Szatmary Z, 2004, J BIOL CHEM, V279, P43708, DOI 10.1074/jbc.M406568200; Tchen CR, 2010, J BIOL CHEM, V285, P2642, DOI 10.1074/jbc.M109.037309; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; Wiehler S, 2007, AM J PHYSIOL-LUNG C, V293, pL505, DOI 10.1152/ajplung.00066.2007	56	65	69	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1075	+		10.1016/j.jaci.2013.05.028	http://dx.doi.org/10.1016/j.jaci.2013.05.028			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23871663	Green Published, Green Submitted			2022-12-18	WOS:000326235600006
J	Amoah, AS; Obeng, BB; Larbi, IA; Versteeg, SA; Aryeetey, Y; Akkerdaas, JH; Zuidmeer, L; Lidholm, J; Fernandez-Rivas, M; Hartgers, FC; Boakye, DA; van Ree, R; Yazdanbakhsh, M				Amoah, Abena S.; Obeng, Benedicta B.; Larbi, Irene A.; Versteeg, Serge A.; Aryeetey, Yvonne; Akkerdaas, Jaap H.; Zuidmeer, Laurian; Lidholm, Jonas; Fernandez-Rivas, Montserrat; Hartgers, Franca C.; Boakye, Daniel A.; van Ree, Ronald; Yazdanbakhsh, Maria			Peanut-specific IgE antibodies in asymptomatic Ghanaian children possibly caused by carbohydrate determinant cross-reactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; skin prick testing; IgE; Sub-Saharan Africa; IgE cross-reactivity; cross-reactive carbohydrate determinants; helminth infections; basophil histamine release; EuroPrevall	FOOD ALLERGY; SKIN PRICK; HELMINTH INFECTION; PREVALENCE; SENSITIZATION; DIAGNOSIS; CHALLENGE; RELEVANCE; PROTECT	Background: The prevalence of peanut allergy has increased in developed countries, but little is known about developing countries with high peanut consumption and widespread parasitic infections. Objective: We sought to investigate peanut allergy in Ghana. Methods: In a cross-sectional survey among Ghanaian schoolchildren (n = 1604), data were collected on reported adverse reactions to peanut, peanut sensitization (serum specific IgE and skin reactivity), consumption patterns, and parasitic infections. In a subset (n = 43) IgE against Ara h 1, 2, 3, and 9 as well as cross-reactive carbohydrate determinants (CCDs) was measured by using ImmunoCAP. Cross-reactivity and biological activity were investigated by means of ImmunoCAP inhibition and basophil histamine release, respectively. Results: Adverse reactions to peanut were reported in 1.5%, skin prick test reactivity in 2.0%, and IgE sensitization (>= 0.35 kU/L) in 17.5% of participants. Moreover, 92.4% of those IgE sensitized to peanut (>= 0.35 kU/L) had negative peanut skin prick test responses. Schistosoma haematobium infection was positively associated with IgE sensitization (adjusted odds ratio, 2.29; 95% CI, 1.37-3.86). In the subset IgE titers to Ara h 1, 2, 3, and 9 were low (<1.3 kU/L), except for 6 moderately strong reactions to Ara h 9. IgE against peanut was strongly correlated with IgE against CCDs (r = 0.89, P < .0001) and could be almost completely inhibited by CCDs, as well as S haematobium soluble egg antigen. Moreover, IgE to peanut showed poor biological activity. Conclusions: Parasite-induced IgE against CCDs might account largely for high IgE levels to peanut in our study population of Ghanaian schoolchildren. No evidence of IgE-mediated peanut allergy was found.	[Amoah, Abena S.; Obeng, Benedicta B.; Larbi, Irene A.; Aryeetey, Yvonne; Boakye, Daniel A.] Noguchi Mem Inst Med Res, Dept Parasitol, Accra, Ghana; [Amoah, Abena S.; Obeng, Benedicta B.; Hartgers, Franca C.; Yazdanbakhsh, Maria] Leiden Univ, Med Ctr, Dept Parasitol, NL-2333 ZA Leiden, Netherlands; [Versteeg, Serge A.; Akkerdaas, Jaap H.; Zuidmeer, Laurian; van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands; [Versteeg, Serge A.; Akkerdaas, Jaap H.; Zuidmeer, Laurian; van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands; [Lidholm, Jonas] Thermo Fisher Sci, Uppsala, Sweden; [Fernandez-Rivas, Montserrat] Hosp Clin San Carlos, Serv Alergia, Madrid, Spain	University of Ghana; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Thermo Fisher Scientific; Hospital Clinico San Carlos	Yazdanbakhsh, M (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	M.Yazdanbakhsh@lumc.nl	Yazdanbakhsh, Maria/AAI-3996-2020	Yazdanbakhsh, Maria/0000-0002-7666-1441; Ashong, Yvonne Aryeetey/0000-0003-3305-223X; Larbi, Irene/0000-0003-4275-5738; Amoah, Abena/0000-0003-2270-1871; Zuidmeer-Jongejan, Laurian/0000-0003-3245-5555; Lidholm, Jonas/0000-0002-7779-3411	EuroPrevall [FOOD-CT-2005-514000]; GLOFAL [FOOD-CT-2005-517812]; Wellcome Trust [075791/Z/04/Z]; European Union; Wellcome Trust; European Commission; Instituto de Salud Carlos III; ALK-Abello	EuroPrevall; GLOFAL; Wellcome Trust(Wellcome TrustEuropean Commission); European Union(European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); European Commission(European CommissionEuropean Commission Joint Research Centre); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); ALK-Abello	Supported by EuroPrevall (FOOD-CT-2005-514000), GLOFAL (FOOD-CT-2005-517812), and the Wellcome Trust (075791/Z/04/Z).; A. S. Amoah has received grants from the European Union and the Wellcome Trust. B. B. Obeng, I. A. Larbi, S. A. Versteeg, Y. Aryeetey, J. Akkerdaas, L. Zuidmeer, F. C. Hartgers, D. A. Boakye, and M. Yazdanbakhsh have received grants from the European Union. J. Lidholm is employed by Thermo Fisher Scientific. M. Fernandez-Rivas has received a grant and travel support from the European Commission, is employed by the Hospital Clinico San Carlos, has received grants from the European Commission and Instituto de Salud Carlos III, has received payment for lectures from ALK-Abello, and has received travel support from the European Academy of Allergology and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. R. van Ree has received grants from the European Union and has consultant arrangements with HAL Allergy BV.	Acevedo N, 2011, PARASITE IMMUNOL, V33, P309, DOI 10.1111/j.1365-3024.2011.01288.x; Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; Belyhun Y, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-21; Ben-Shoshan M, 2012, CURR ALLERGY ASTHM R, V12, P346, DOI 10.1007/s11882-012-0274-3; Ben-Shoshan M, 2009, J ALLERGY CLIN IMMUN, V123, P783, DOI 10.1016/j.jaci.2009.02.004; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; Budde IK, 2001, INT ARCH ALLERGY IMM, V126, P277, DOI 10.1159/000049524; Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; Codreanu F, 2011, INT ARCH ALLERGY IMM, V154, P216, DOI 10.1159/000321108; Cooper PJ, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-33; DREBORG S, 1989, J AM ACAD DERMATOL, V21, P820, DOI 10.1016/S0190-9622(89)70256-5; Eller E, 2013, ALLERGY, V68, P190, DOI 10.1111/all.12075; Flohr C, 2006, J ALLERGY CLIN IMMUN, V118, P1305, DOI 10.1016/j.jaci.2006.08.035; Hong X, 2012, ALLERGY, V67, P1538, DOI 10.1111/all.12047; Hussaarts L, 2011, J ALLERGY CLIN IMMUN, V128, P733, DOI 10.1016/j.jaci.2011.05.012; Institute of Food Research, PREV COST BAS FOOD A; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Krause S, 2009, J ALLERGY CLIN IMMUN, V124, P771, DOI 10.1016/j.jaci.2009.06.008; Kummeling I, 2009, ALLERGY, V64, P1493, DOI 10.1111/j.1398-9995.2009.02046.x; Lauer I, 2009, CLIN EXP ALLERGY, V39, P1427, DOI 10.1111/j.1365-2222.2009.03312.x; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; Mari A, 2002, INT ARCH ALLERGY IMM, V129, P286, DOI 10.1159/000067591; Mari A, 2008, ALLERGY, V63, P891, DOI 10.1111/j.1398-9995.2008.01703.x; Ministry of Food and Agriculture, 2010, STAT; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Obeng BB, 2011, INT ARCH ALLERGY IMM, V155, P63, DOI 10.1159/000318704; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; PETERS PA, 1976, B WORLD HEALTH ORGAN, V54, P159; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Santiago HC, 2011, J ALLERGY CLIN IMMUN, V127, P479, DOI 10.1016/j.jaci.2010.11.007; Shek LPC, 2010, J ALLERGY CLIN IMMUN, V126, P324, DOI 10.1016/j.jaci.2010.06.003; Sicherer SH, 2012, J ALLERGY CLIN IMMUN, V129, P76, DOI 10.1016/j.jaci.2011.11.016; Smits HH, 2010, CURR ALLERGY ASTHM R, V10, P3, DOI 10.1007/s11882-009-0085-3; US Department of Agriculture, 2012, FOOD AV PER CAP DAT; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010; Wong G., 2011, CLIN TRANSL ALLERG S, V1, pS6; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zarei M, 2004, ANN ALLERG ASTHMA IM, V92, P604, DOI 10.1016/S1081-1206(10)61425-1	40	65	65	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					639	647		10.1016/j.jaci.2013.04.023	http://dx.doi.org/10.1016/j.jaci.2013.04.023			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23763976	Green Published, hybrid			2022-12-18	WOS:000323612000016
J	Vos, B; Kohler, J; Muller, S; Stretz, E; Rueff, F; Jakob, T				Vos, Byrthe; Koehler, Julian; Mueller, Sabine; Stretz, Eva; Rueff, Franziska; Jakob, Thilo			Spiking venom with rVes v 5 improves sensitivity of IgE detection in patients with allergy to Vespula venom	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							API M 1; DISTINGUISH BEE; DIAGNOSIS; SUFFICIENT		[Koehler, Julian; Mueller, Sabine; Jakob, Thilo] Univ Med Ctr, Dept Dermatol, Allergy Res Grp, Freiburg, Germany; [Vos, Byrthe; Stretz, Eva; Rueff, Franziska] Univ Munich, Dept Dermatol, Allergy Unit, D-80539 Munich, Germany	University of Freiburg; University of Munich	Vos, B (corresponding author), Univ Munich, Dept Dermatol, Allergy Unit, Frauenlobstr 9-11, D-80539 Munich, Germany.	thilo.jakob@uniklinik-freiburg.de						Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V128, P248, DOI 10.1016/j.jaci.2011.02.020; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V127, P265, DOI 10.1016/j.jaci.2010.06.042; Jakob T, 2012, J ALLERGY CLIN IMMUN, V130, P276, DOI 10.1016/j.jaci.2012.03.048; Korosec P, 2012, J ALLERGY CLIN IMMUN, V129, P1406, DOI 10.1016/j.jaci.2011.12.975; Korosec P, 2011, J ALLERGY CLIN IMMUN, V128, P671, DOI 10.1016/j.jaci.2011.03.012; Mittermann I, 2010, J ALLERGY CLIN IMMUN, V125, P1300, DOI 10.1016/j.jaci.2010.03.017; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Sturm GJ, 2011, J ALLERGY CLIN IMMUN, V128, P247, DOI 10.1016/j.jaci.2011.02.021	9	65	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1225	1227		10.1016/j.jaci.2012.07.041	http://dx.doi.org/10.1016/j.jaci.2012.07.041			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23006544				2022-12-18	WOS:000317187200033
J	Kucuksezer, UC; Palomares, O; Ruckert, B; Jartti, T; Puhakka, T; Nandy, A; Gemicioglu, B; Fahrner, HB; Jung, A; Deniz, G; Akdis, CA; Akdis, M				Kucuksezer, Umut Can; Palomares, Oscar; Rueckert, Beate; Jartti, Tuomas; Puhakka, Tuomo; Nandy, Andreas; Gemicioglu, Bilun; Fahrner, Heinz B.; Jung, Andreas; Deniz, Gunnur; Akdis, Cezmi A.; Akdis, Muebeccel			Triggering of specific Toll-like receptors and proinflammatory cytokines breaks allergen-specific T-cell tolerance in human tonsils and peripheral blood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peripheral tolerance; tonsils; proinflammatory cytokines; IL-1 beta; IL-6; Toll-like receptors; allergen-specific T cells; myeloid dendritic cells	DENDRITIC CELLS; REGULATORY CELLS; IMMUNITY; INNATE; IMMUNOTHERAPY; CROSSTALK; RESPONSES; SUPPRESSION; INDIVIDUALS; MECHANISMS	Background: The generation and maintenance of allergen-specific T-cell tolerance is a key step in healthy immune responses to allergens and successful allergen-specific immunotherapy. Breaking of peripheral T-cell tolerance to allergens can lead to the development of allergies, but the mechanisms are not completely understood. Objective: We sought to identify molecular mechanisms that break allergen-specific T-cell tolerance in human subjects. Methods: Proliferative responses of allergen-specific T cells from tonsils and peripheral blood were measured by using tritiated thymidine incorporation and carboxyfluorescein succinimidyl ester (CFSE) dilution experiments. Cytokine levels in cell-free supernatants were quantified by using the cytometric bead array, and mRNA expression of transcription factors and cytokines was determined by using quantitative PCR. Myeloid dendritic cells (DCs) were characterized by using flow cytometry. Results: In allergic patients the immune profile of the tonsils represents the atopic status of patients, with low expression of the T(H)1 cell-specific transcription factor T-bet and the cytokine IFN-gamma, as well as IL-10. Human tonsils show very low levels of allergen-induced T-cell proliferation, thus representing a very suitable in vivo model to assess mechanisms of breaking allergen-specific T-cell tolerance. Triggering of Toll-like receptor (TLR) 4 or TLR8 and the proinflammatory cytokines IL-1 beta or IL-6 break allergen-specific T-cell tolerance in human tonsils and peripheral blood through a mechanism dependent on the adaptor molecule myeloid differentiation primary response gene (88) (MyD88). In particular, myeloid DCs and stimulations that activate them broke the tolerance of allergen-specific CD4(+) T cells, whereas plasmacytoid DCs and stimulations that activate them, such as TLR7 and TLR9, did not have any effect. Tolerance-breaking conditions induced by different molecular mechanisms were associated with a mixed cytokine profile with a tendency toward increased levels of IL-13 and IL-17, which are T(H)2 and T(H)17 cytokines, respectively. Conclusion: Certain innate immune response signals and proinflammatory cytokines break allergen-specific CD4(+) T-cell tolerance in normally unresponsive subjects, which might lead to the development or exacerbation of allergic diseases after encountering microbes or inflammatory conditions. (J Allergy Clin Immunol 2013;131:875-85.)	[Kucuksezer, Umut Can; Palomares, Oscar; Rueckert, Beate; Jung, Andreas; Akdis, Cezmi A.; Akdis, Muebeccel] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Kucuksezer, Umut Can; Deniz, Gunnur] Istanbul Univ, Inst Expt Med DETAE, Dept Immunol, Istanbul, Turkey; [Palomares, Oscar] Complutense Univ Madrid UCM, Dept Biochem & Mol Biol, Sch Chem, Madrid, Spain; [Jartti, Tuomas] Turku Univ Hosp, Dept Pediat, Turku, Finland; [Puhakka, Tuomo] Turku Univ Hosp, Dept Otorhinolaryngol, Turku, Finland; [Puhakka, Tuomo] Satakunta Cent Hosp, Dept Otorhinolaryngol, Pori, Finland; [Nandy, Andreas] Joachim Ganzer KG, Allergopharma, Reinbek, Germany; [Gemicioglu, Bilun] Istanbul Univ, Cerrahpasa Med Fac, Dept Pulm Dis, Istanbul, Turkey; [Fahrner, Heinz B.] Kantonsspital Graubunden, Dept ENT, Chur, Switzerland; [Jung, Andreas] Hochgebirgsklinik, Davos, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Istanbul University; Complutense University of Madrid; University of Turku; University of Turku; Satakunta Central Hospital; Allergopharma; Istanbul University; Istanbul University - Cerrahpasa; Kantonsspital Graubunden	Akdis, M (corresponding author), Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	akdism@siaf.uzh.ch	Deniz, Gunnur/AAC-2909-2020; Akdis, Cezmi/AAV-4844-2020; Palomares, Oscar/ABG-5229-2020; Gemicioglu, Bilun/AAH-6927-2019; kucuksezer, umut/AAD-5168-2020	Akdis, Cezmi/0000-0001-8020-019X; Gemicioglu, Bilun/0000-0001-5953-4881; Palomares, Oscar/0000-0003-4516-0369	Swiss National Foundation [32-125249, 320030-132899]; Christine Kuhne-Center for Allergy Research and Education (CK-CARE); European 7th frame work project MeDALL: Mechanisms of the Development of Allergy [261357]; European 7th frame work project PREDICTA: Post-Infectious Immune Reprogramming and Its Association with Persistence and Chronicity of Respiratory Allergic Diseases [260895]; European Respiratory Society (ERS) Long Term Research Fellowship [288]; MINECO; European Social Fund; University of Istanbul, Research Fund [2826]; Academy of Finland; Sigrid Juselius Foundation; Novartis; PREDICTA; Swiss National Science Foundation; MeDALL; Global Allergy and Asthma European Network; Christine Kuhne-Center for Allergy Research and Education	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Christine Kuhne-Center for Allergy Research and Education (CK-CARE); European 7th frame work project MeDALL: Mechanisms of the Development of Allergy; European 7th frame work project PREDICTA: Post-Infectious Immune Reprogramming and Its Association with Persistence and Chronicity of Respiratory Allergic Diseases; European Respiratory Society (ERS) Long Term Research Fellowship; MINECO(Spanish Government); European Social Fund(European Social Fund (ESF)); University of Istanbul, Research Fund(Istanbul University); Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Novartis(Novartis); PREDICTA; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); MeDALL; Global Allergy and Asthma European Network; Christine Kuhne-Center for Allergy Research and Education	Supported by Swiss National Foundation grants 32-125249 and 320030-132899, the Christine Kuhne-Center for Allergy Research and Education (CK-CARE), European 7th frame work projects MeDALL: Mechanisms of the Development of Allergy (no. 261357), and PREDICTA: Post-Infectious Immune Reprogramming and Its Association with Persistence and Chronicity of Respiratory Allergic Diseases (no. 260895). U.C.K. was funded by a European Respiratory Society (ERS) Long Term Research Fellowship (no. 288), and O.P. is a Ramon y Cajal Scholar funded by MINECO and the European Social Fund. U.C.K. is supported by University of Istanbul, Research Fund (no. 2826).; T. Jartti has received research support from the Academy of Finland and Sigrid Juselius Foundation. C.A. Akdis has received research support from Novartis, PREDICTA, the Swiss National Science Foundation, MeDALL, the Global Allergy and Asthma European Network, and the Christine Kuhne-Center for Allergy Research and Education; has provided consultation for Actellion, Aventis, Stallergenes, and Allergopharma; is president of the European Academy of Allergy and Clinical Immunology; is a fellow and interest group member for the American Academy of Allergy, Asthma & Immunology; is a former committee member of the Global Allergy and Asthma European Network; and is director of the Christine Kuhne-Center for Allergy Research and Education. M. Akdis has received research support from the Swiss National Science Foundation, Predicta, and MeDALL. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis CA, 2000, FASEB J, V14, P1666; Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Akdis M, 2012, NAT IMMUNOL, V13, P312, DOI 10.1038/ni.2266; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bonasio R, 2006, CURR OPIN IMMUNOL, V18, P503, DOI 10.1016/j.coi.2006.05.011; Burgler S, 2010, J IMMUNOL, V184, P6161, DOI 10.4049/jimmunol.0903243; Burgler S, 2009, J ALLERGY CLIN IMMUN, V123, P588, DOI 10.1016/j.jaci.2008.12.017; Campbell JD, 2009, J EXP MED, V206, P1535, DOI 10.1084/jem.20082901; Cervantes JL, 2011, P NATL ACAD SCI USA, V108, P3683, DOI 10.1073/pnas.1013776108; Chen WJ, 2006, FRONT BIOSCI-LANDMRK, V11, P1360, DOI 10.2741/1889; Darrasse-Jeze G, 2009, J EXP MED, V206, P1853, DOI 10.1084/jem.20090746; EBNER C, 1995, J IMMUNOL, V154, P1932; Fehervari Z, 2004, INT IMMUNOL, V16, P1769, DOI 10.1093/intimm/dxh178; Fogal B, 2011, J IMMUNOL, V187, P6268, DOI 10.4049/jimmunol.1003774; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Gill MA, 2012, J ALLERGY CLIN IMMUN, V129, P889, DOI 10.1016/j.jaci.2012.02.028; Gujer C, 2011, IMMUNOLOGY, V134, P257, DOI 10.1111/j.1365-2567.2011.03484.x; Hammad H, 2011, ALLERGY, V66, P579, DOI 10.1111/j.1398-9995.2010.02528.x; Hirota JA, 2012, J ALLERGY CLIN IMMUN, V129, P1116, DOI 10.1016/j.jaci.2011.11.033; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Ito T, 2006, BLOOD, V107, P2423, DOI 10.1182/blood-2005-07-2709; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kupz A, 2012, NAT IMMUNOL, V13, P162, DOI 10.1038/ni.2195; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Leavy O, 2012, NAT REV IMMUNOL, V12, P232, DOI 10.1038/nri3196; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McCartney SA, 2009, IMMUNOL REV, V227, P87, DOI 10.1111/j.1600-065X.2008.00726.x; McClory S, 2012, J CLIN INVEST, V122, P1403, DOI 10.1172/JCI46125; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Novak N, 2012, J ALLERGY CLIN IMMUN, V129, P879, DOI 10.1016/j.jaci.2012.01.062; Novak N, 2010, J ALLERGY CLIN IMMUN, V125, P50, DOI 10.1016/j.jaci.2009.11.019; Oberg HH, 2011, EUR J CELL BIOL, V90, P582, DOI 10.1016/j.ejcb.2010.11.012; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Palomares O, 2011, J ALLERGY CLIN IMMUN, V127, P1541, DOI 10.1016/j.jaci.2011.04.002; Palomares O, 2010, EUR J IMMUNOL, V40, P1232, DOI 10.1002/eji.200940045; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Peng GY, 2005, SCIENCE, V309, P1380, DOI 10.1126/science.1113401; Pulendran B, 2008, CURR OPIN IMMUNOL, V20, P61, DOI 10.1016/j.coi.2007.10.009; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Ruiter B, 2012, J ALLERGY CLIN IMMUN, V129, P921, DOI 10.1016/j.jaci.2012.01.080; Sancho D, 2012, ANNU REV IMMUNOL, V30, P491, DOI 10.1146/annurev-immunol-031210-101352; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Wehrens EJ, 2011, BLOOD, V118, P3538, DOI 10.1182/blood-2010-12-328187; Wills-Karp M, 2010, CURR OPIN IMMUNOL, V22, P777, DOI 10.1016/j.coi.2010.10.011	53	65	71	0	41	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					875	+		10.1016/j.jaci.2012.10.051	http://dx.doi.org/10.1016/j.jaci.2012.10.051			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23265862				2022-12-18	WOS:000315587800032
J	Martinez-Gallo, M; Radigan, L; Almejun, MB; Martinez-Pomar, N; Matamoros, N; Cunningham-Rundles, C				Martinez-Gallo, Monica; Radigan, Lin; Almejun, Maria Belen; Martinez-Pomar, Natalia; Matamoros, Nuria; Cunningham-Rundles, Charlotte			TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CVID; TACI; hypogammaglobulinemia; activation-induced cytidine deaminase; Toll-like receptor 9	COMMON VARIABLE IMMUNODEFICIENCY; ANTIBODY-DEFICIENCY SYNDROME; SELECTIVE IGA DEFICIENCY; TRANSMEMBRANE ACTIVATOR; TNFRSF13B VARIANTS; BAFF-R; APRIL; SURVIVAL; DISEASE; BINDING	Background: Mutations in the gene coding for the transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) are found in 8% to 10% of subjects with common variable immunodeficiency (CVID). Although heterozygous mutations may coincide with immunodeficiency in a few families, most mutation-bearing relatives are not hypogammaglobulinemic. Thus, the role of TACI mutations in producing the immune defect remains unclear. Objective: This study examined the expression and function of TACI mutations in healthy heterozygous relatives. Methods: We examined the surface and intracellular expression of TACI protein in EBV-transformed B cells of patients and relatives with mutations in 7 families, binding of a proliferation-inducing ligand, and secretion of IgG and IgA by ligand-activated B cells. We tested whether Toll-like receptor 9 agonists increased TACI expression and whether an agonistic anti-TACI antibody could induce activation-induced cytidine deaminase mRNA in those with mutations. Results: Intracellular and extracellular TACI expression was defective for B cells of all subjects with mutations, including subjects with CVID and relatives. Although Toll-like receptor 9 triggering normally up-regulates B-cell TACI expression, this was defective for all subjects with mutations. Triggering TACI by an agonistic antibody showed loss of activation-induced cytidine deaminase mRNA induction in all mutation-bearing B cells. However, ligand-induced IgG and IgA production was normal for healthy relatives but not for subjects with CVID. Conclusion: Thus, B cells of relatives of subjects with CVID who have mutations in TACI but normal immune globulin levels still have detectable in vitro B-cell defects. (J Allergy Clin Immunol 2013;131:468-76.)	[Martinez-Gallo, Monica; Radigan, Lin; Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Dept Med, New York, NY USA; [Martinez-Gallo, Monica; Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Dept Pediat, New York, NY USA; [Martinez-Gallo, Monica; Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Inst Immunol, New York, NY USA; [Martinez-Gallo, Monica] Vall Hebron Univ Hosp, Serv Inmunol, Barcelona, Spain; [Almejun, Maria Belen] Hosp Nacl Pediat Prof Dr Juan P Garrahan, Serv Inmunol & Reumatol, Buenos Aires, DF, Argentina; [Martinez-Pomar, Natalia; Matamoros, Nuria] Son Espases Univ Hosp, Serv Immunol, Palma de Mallorca, Spain	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Hospital Universitari Vall d'Hebron; Hospital de Pediatria Doctor Juan Garrahan; Hospital Universitari Son Espases	Cunningham-Rundles, C (corresponding author), Mt Sinai Med Ctr, Dept Med, 1425 Madison Ave, New York, NY 10029 USA.	Charlotte.Cunningham-Rundles@MSSM.edu	Martinez-Gallo, Monica/S-1368-2019	Martinez-Gallo, Monica/0000-0002-7340-2161; Almejun, Maria Belen/0000-0003-3138-736X	National Institutes of Health [AI-101093, AI-467320, AI-48693]; National Institute of Allergy and Infectious Diseases [03-22]; Ministerio de Sanidad y Consumo of Spain [CM05/00145]; National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI061093, R18AI048693, R21AI101093] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Ministerio de Sanidad y Consumo of Spain(Spanish Government); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institutes of Health AI-101093, AI-467320, and AI-48693 and National Institute of Allergy and Infectious Diseases Contract 03-22 (C.C.-R.). M.M.-G. was recipient of a fellowship (CM05/00145) from the Ministerio de Sanidad y Consumo of Spain.; C. Cunningham-Rundles has received grants from the National Institutes of Health and has received royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	Bonhomme D, 2000, J IMMUNOL, V165, P4725, DOI 10.4049/jimmunol.165.8.4725; Bossen C, 2008, BLOOD, V111, P1004, DOI 10.1182/blood-2007-09-110874; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Chinen J, 2011, J ALLERGY CLIN IMMUN, V127, P1579, DOI 10.1016/j.jaci.2011.02.046; Cunningham-Rundles C, 2001, Curr Allergy Asthma Rep, V1, P421, DOI 10.1007/s11882-001-0027-1; Garibyan L, 2007, J CLIN INVEST, V117, P1550, DOI 10.1172/JCI31023; Goldacker S, 2005, CURR OPIN ALLERGY CL, V5, P504, DOI 10.1097/01.all.0000191888.97397.b3; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; He B, 2010, NAT IMMUNOL, V11, P836, DOI 10.1038/ni.1914; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Kaur K, 2007, BLOOD, V110, P2948, DOI 10.1182/blood-2007-01-069245; Kuijpers TW, 2010, J CLIN INVEST, V120, P214, DOI 10.1172/JCI40231; Lee JJ, 2010, J ALLERGY CLIN IMMUN, V126, P1234, DOI 10.1016/j.jaci.2010.08.017; Lee JJ, 2009, BLOOD, V114, P2254, DOI 10.1182/blood-2008-11-189720; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Martinez-Pomar N, 2009, BLOOD, V114, P2846, DOI 10.1182/blood-2009-05-213025; Ochtrop MLG, 2011, BLOOD, V118, P309, DOI 10.1182/blood-2010-11-321695; Orange JS, 2011, J ALLERGY CLIN IMMUN, V127, P1360, DOI 10.1016/j.jaci.2011.02.039; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2009, BLOOD, V113, P1967, DOI 10.1182/blood-2008-02-141937; Schneider P, 2005, CURR OPIN IMMUNOL, V17, P282, DOI 10.1016/j.coi.2005.04.005; Schroeder HW, 2004, J INVEST MED, V52, P90, DOI 10.1136/jim-52-02-17; Thiel J, 2012, J ALLERGY CLIN IMMUN, V129, P801, DOI 10.1016/j.jaci.2011.09.027; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; VORECHOVSKY I, 1995, CLIN IMMUNOL IMMUNOP, V77, P185, DOI 10.1006/clin.1995.1142; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Warnatz K, 2009, P NATL ACAD SCI USA, V106, P13945, DOI 10.1073/pnas.0903543106; Zhang L, 2007, J ALLERGY CLIN IMMUN, V120, P1178, DOI 10.1016/j.jaci.2007.10.001	34	65	67	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					468	476		10.1016/j.jaci.2012.10.029	http://dx.doi.org/10.1016/j.jaci.2012.10.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23237420	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000314661500026
J	Chen, KW; Blatt, K; Thomas, WR; Swoboda, I; Valent, P; Valenta, R; Vrtala, S				Chen, Kuan-Wei; Blatt, Katharina; Thomas, Wayne R.; Swoboda, Ines; Valent, Peter; Valenta, Rudolf; Vrtala, Susanne			Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergen; specific immunotherapy; recombinant hypoallergen; house dust mite allergy	IGE-BINDING; RECOMBINANT ALLERGENS; DER-P-1; EXPRESSION; REDUCTION; MUTATION; ANTIGEN; FUTURE	Background: More than 50% of allergic patients have house dust mite (HDM) allergy. Group 1 and 2 allergens are the major HDM allergens. Objective: We sought to produce and perform preclinical characterization of a recombinant hypoallergenic combination vaccine for specific immunotherapy of HDM allergy. Methods: Synthetic genes coding for 2 hybrid proteins consisting of reassembled Der p 1 and Der p 2 fragments with (recombinant Der p 2 [rDer p 2]/1C) and without (rDer p 2/1S) cysteines were expressed in Escherichia coli and purified to homogeneity by means of affinity chromatography. Protein fold was determined by using circular dichroism analysis, allergenic activity was determined by testing IgE reactivity and using basophil activation assays, and the presence of T-cell epitopes was determined based on lymphoproliferation in allergic patients. Mice and rabbits were immunized to study the molecules' ability to induce an allergic response and whether they induce allergen-specific IgG capable of inhibiting allergic patients' IgE binding to the allergens, respectively. Results: rDer p 2/1C and rDer p 2/1S were expressed in large amounts in E coli as soluble and folded proteins. Because of the lack of disulfide bonds, rDer p 2/1S did not form aggregates and was obtained as a monomeric protein, whereas rDer p 2/1C did form aggregates. Both hypoallergens lacked relevant IgE reactivity and had reduced ability to induce allergic inflammation and allergic responses but induced similar T-cell proliferation as the wild-type allergens. Immunization with the hypoallergens (rDer p 2/1S > rDer p 2/1C) induced IgG antibodies in rabbits that inhibited the IgE reactivity of patients with HDM allergy to Der p 1 and Der p 2. Conclusion: The preclinical characterization indicates that particularly rDer p 2/1S can be used as a safe hypoallergenic molecule for both tolerance and vaccination approaches to treat HDM allergy. (J Allergy Clin Immunol 2012;130:435-43.)	[Chen, Kuan-Wei; Valenta, Rudolf; Vrtala, Susanne] Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, A-1090 Vienna, Austria; [Blatt, Katharina; Valent, Peter] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, A-1090 Vienna, Austria; [Thomas, Wayne R.] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Crawley, Australia; [Swoboda, Ines; Valenta, Rudolf] Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol & Allergy Res, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Telethon Kids Institute; University of Western Australia; Medical University of Vienna	Vrtala, S (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	susanne.vrtala@meduniwien.ac.at	Valent, Peter/B-8533-2016; Test, PV/U-9451-2019; Test, Test/Y-7921-2019; Gamperl, Susi/V-2715-2019	Valent, Peter/0000-0003-0456-5095; Gamperl, Susi/0000-0003-0456-5095; Vrtala, Susanne/0000-0003-4250-8243; Swoboda, Ines/0000-0002-9164-1721; Valenta, Rudolf/0000-0001-5944-3365; Chen, Kuan-Wei/0000-0001-5899-5766	Austrian Science Fund [F1803, F1815, F1820, F4602, F4605, F4611]; Christian Doppler Research Association; Biomay AG, Vienna, Austria	Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Association; Biomay AG, Vienna, Austria	Supported by grants F1803, F1815, F1820, F4602, F4605, and F4611 of the Austrian Science Fund, by the Christian Doppler Research Association, and by a grant from Biomay AG, Vienna, Austria.; W. R. Thomas has received research support from the Australian National Health and Medical Research Council. P. Valent has received research support from Biomay. R. Valenta has received research support from the Austrian Science Fund, the Christian Doppler Research Association, Biomay, and Phadia and has received consultancy fees from Phadia and Biomay. S. Vrtala has received research support from the Austrian Science Fund, Phadia, Uppsala, Sweden, and Biomay, Vienna, Austria. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Asturias JA, 2009, CLIN EXP ALLERGY, V39, P1088, DOI 10.1111/j.1365-2222.2009.03264.x; Bussieres L, 2010, INT ARCH ALLERGY IMM, V153, P141, DOI 10.1159/000312631; Campana R, 2010, J ALLERGY CLIN IMMUN, V126, P1024, DOI 10.1016/j.jaci.2010.05.023; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; Chen KW, 2008, MOL IMMUNOL, V45, P2486, DOI 10.1016/j.molimm.2008.01.006; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Hales BJ, 2006, J ALLERGY CLIN IMMUN, V118, P361, DOI 10.1016/j.jaci.2006.04.001; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P934, DOI 10.1046/j.1365-2222.2000.00901.x; Hauswirth AW, 2002, J ALLERGY CLIN IMMUN, V110, P102, DOI 10.1067/mai.2002.125257; Jacquet A, 2002, CLIN EXP ALLERGY, V32, P1048, DOI 10.1046/j.1365-2222.2002.01437.x; Korematsu S, 2000, J IMMUNOL, V165, P2895, DOI 10.4049/jimmunol.165.5.2895; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Mellerup MT, 2000, CLIN EXP ALLERGY, V30, P1423, DOI 10.1046/j.1365-2222.2000.00910.x; MEYER CH, 1994, CLIN EXP ALLERGY, V24, P1041, DOI 10.1111/j.1365-2222.1994.tb02741.x; Nakazawa T, 2005, FEBS LETT, V579, P1988, DOI 10.1016/j.febslet.2005.01.088; PECOUD A, 1990, ALLERGY, V45, P386, DOI 10.1111/j.1398-9995.1990.tb00516.x; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Suzuki K, 2009, INT ARCH ALLERGY IMM, V149, P21, DOI 10.1159/000210649; Takai T, 2000, EUR J BIOCHEM, V267, P6650, DOI 10.1046/j.1432-1327.2000.01760.x; Takai T, 1999, MOL IMMUNOL, V36, P1055, DOI 10.1016/S0161-5890(99)00098-X; Takai T, 2002, FEBS LETT, V531, P265, DOI 10.1016/S0014-5793(02)03534-2; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Thomas WR, 2010, TRENDS MOL MED, V16, P321, DOI 10.1016/j.molmed.2010.04.008; TINKELMAN DG, 1995, J ALLERGY CLIN IMMUN, V95, P8, DOI 10.1016/S0091-6749(95)70146-X; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2011, J ALLERGY CLIN IMMUN, V127, P860, DOI 10.1016/j.jaci.2011.02.016; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; von Bubnoff D, 2002, J IMMUNOL, V169, P1810, DOI 10.4049/jimmunol.169.4.1810; Vrtala S, 2011, VACCINE, V29, P2140, DOI 10.1016/j.vaccine.2010.12.080; Walgraffe D, 2009, J ALLERGY CLIN IMMUN, V123, P1150, DOI 10.1016/j.jaci.2008.11.038	34	65	77	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					435	+		10.1016/j.jaci.2012.05.035	http://dx.doi.org/10.1016/j.jaci.2012.05.035			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22789398	Green Accepted			2022-12-18	WOS:000307002200025
J	Chruszcz, M; Chapman, MD; Osinski, T; Solberg, R; Demas, M; Porebski, PJ; Majorek, KA; Pomes, A; Minor, W				Chruszcz, Maksymilian; Chapman, Martin D.; Osinski, Tomasz; Solberg, Robert; Demas, Matthew; Porebski, Przemyslaw J.; Majorek, Karolina A.; Pomes, Anna; Minor, Wladek			Alternaria alternata allergen Alt a 1: A unique beta-barrel protein dimer found exclusively in fungi	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergens; molds; Alt a 1; Alternaria species; x-ray crystallography; protein structure; oligomeric structure	CRYSTAL-STRUCTURE; MAJOR ALLERGEN; WEB SERVER; ASTHMA; SENSITIZATION; MODEL; SEQUENCE; EXPOSURE; IGE; DIFFRACTION	Background: Alternaria species is one of the most common molds associated with allergic diseases, and 80% of Alternaria species-sensitive patients produce IgE antibodies to a major protein allergen, Alt a 1. The structure and function of Alt a 1 is unknown. Objective: We sought to obtain a high-resolution structure of Alt a 1 using x-ray crystallography and to investigate structural relationships between Alt a 1 and other allergens and proteins reported in the Protein Data Bank. Methods: X-ray crystallography was used to determine the structure of Alt a 1 by using a custom-designed set of crystallization conditions. An initial Alt a 1 model was determined by the application of a Ta6Br122+ cluster and single-wavelength anomalous diffraction. Bioinformatic analyses were used to compare the Alt a 1 sequence and structure with that of other proteins. Results: Alt a 1 is a unique beta-barrel comprising 11 beta-strands and forms a "butterfly-like" dimer linked by a single disulfide bond with a large (1345 angstrom(2)) dimer interface. Intramolecular disulfide bonds are conserved among Alt a 1 homologs. Currently, the Alt a 1 structure has no equivalent in the Protein Data Bank. Bioinformatics analyses suggest that the structure is found exclusively in fungi. Four previously reported putative IgE-binding peptides have been located on the Alt a 1 structure. Conclusions: Alt a 1 has a unique, dimeric beta-barrel structure that appears to define a new protein family with unknown function found exclusively in fungi. The location of IgE antibody-binding epitopes is in agreement with the structural analysis of Alt a 1. The Alt a 1 structure will allow mechanistic structure/function studies and immunologic studies directed toward new forms of immunotherapy for Alternaria species-sensitive allergic patients. (J Allergy Clin Immunol 2012; 130:241-7.)	[Chruszcz, Maksymilian; Osinski, Tomasz; Solberg, Robert; Demas, Matthew; Porebski, Przemyslaw J.; Majorek, Karolina A.; Minor, Wladek] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; [Chapman, Martin D.; Pomes, Anna] Indoor Biotechnol Inc, Charlottesville, VA 22903 USA	University of Virginia; INDOOR Biotechnologies	Chruszcz, M (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, 1340 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	maks@iwonka.med.virginia.edu; mdc@inbio.com; wladek@iwonka.med.virginia.edu	Pomés, Anna/H-7010-2019; Porebski, Przemyslaw/D-9661-2018; Minor, Wladek/F-3096-2014; Chruszcz, Maksymilian/E-6407-2011	Pomés, Anna/0000-0002-8729-1829; Porebski, Przemyslaw/0000-0001-8012-5791; Minor, Wladek/0000-0001-7075-7090; Chruszcz, Maksymilian/0000-0001-7521-5485; Osinski, Tomasz/0000-0001-9933-346X; Chapman, Martin/0000-0002-0845-3632	National Institutes of Health [GM53163]; US Department of Energy, Office of Biological and Environmental Research [DE-AC02-06CH11357]; Michigan Technology Tri-Corridor [085P1000817]; National Institute of Allergy and Infectious Diseases [R01AI077653]; National Institute for Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053163] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Energy, Office of Biological and Environmental Research(United States Department of Energy (DOE)); Michigan Technology Tri-Corridor; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute for Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health grant GM53163. The structural results shown in this report are derived from work performed at Argonne National Laboratory at the Structural Biology Center of the Advanced Photon Source. Argonne is operated by University of Chicago Argonne, LLC, for the US Department of Energy, Office of Biological and Environmental Research, under contract DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor for the support of this research program (grant 085P1000817). A.P. and M.D.C. were funded in part by grant R01AI077653 from the National Institute of Allergy and Infectious Diseases.; Disclosure of potential conflict of interest: M. D. Chapman is President and CEO of Indoor Biotechnologies and has ownership positions with Indoor Biotechnologies, Inc, and Indoor Biotechnologies Ltd; has received research support from the National Institute for Environmental Health Sciences and the National Institute of Allergy and Infectious Diseases; and is on the Board of Directors for the Virginia Biotechnology Association. A. Pomes is employed by Indoor Biotechnologies Ltd and has received research support from the National Institute of Allergy and Infectious Diseases. The rest of the authors declare that they have no relevant conflicts of interest.	ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P133, DOI 10.1016/j.jaci.2005.04.022; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barnes C, 2006, ANN ALLERG ASTHMA IM, V97, P350, DOI 10.1016/S1081-1206(10)60800-9; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bush RK, 2001, J ALLERGY CLIN IMMUN, V107, pS430, DOI 10.1067/mai.2001.113669; Chan-Yeung M, 2010, ALLERGY, V65, P1404, DOI 10.1111/j.1398-9995.2010.02399.x; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; Cramer RA, 2003, APPL ENVIRON MICROB, V69, P2361, DOI 10.1128/AEM.69.4.2361-2364.2003; Cymborowski M., 2010, Journal of Structural and Functional Genomics, V11, P211, DOI 10.1007/s10969-010-9092-9; DEARDS MJ, 1991, MOL IMMUNOL, V28, P409, DOI 10.1016/0161-5890(91)90154-C; DeLano W. L, 2002, PYMOL MOL GENETICS G; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622, DOI 10.2307/3433608; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.1016/S0022-2836(02)00027-X; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385, DOI 10.1159/000237397; Dolinsky TJ, 2007, NUCLEIC ACIDS RES, V35, pW522, DOI 10.1093/nar/gkm276; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455, DOI 10.1164/ajrccm.164.3.2008042; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fernandez C, 2011, CLIN EXP ALLERGY, V41, P649, DOI 10.1111/j.1365-2222.2010.03645.x; Flower DR, 1996, BIOCHEM J, V318, P1; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366; Holst M, 2000, J COMPUT CHEM, V21, P1319, DOI 10.1002/1096-987X(20001130)21:15<1319::AID-JCC1>3.0.CO;2-8; Hong SG, 2005, FUNGAL GENET BIOL, V42, P119, DOI 10.1016/j.fgb.2004.10.009; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Kuna P, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Kuna P, 2011, J ALLERGY CLIN IMMUN, V127, P502, DOI 10.1016/j.jaci.2010.11.036; Kurup VP, 2003, PEPTIDES, V24, P179, DOI 10.1016/S0196-9781(03)00024-X; Laskowski RA, 2005, NUCLEIC ACIDS RES, V33, pW89, DOI 10.1093/nar/gki414; Li M, 2008, J BIOL CHEM, V283, P22806, DOI 10.1074/jbc.M800937200; Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158; Lo WC, 2009, NUCLEIC ACIDS RES, V37, pW545, DOI 10.1093/nar/gkp291; Marks GB, 2007, J ALLERGY CLIN IMMUN, V120, P530, DOI 10.1016/j.jaci.2007.07.012; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314; O'Connor GT, 2004, J ALLERGY CLIN IMMUN, V114, P599, DOI 10.1016/j.jaci.2004.05.064; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pei JM, 2008, NUCLEIC ACIDS RES, V36, P2295, DOI 10.1093/nar/gkn072; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Randriamanantany ZA, 2010, ALLERGY, V65, P368, DOI 10.1111/j.1398-9995.2009.02210.x; Rosenbaum G, 2006, J SYNCHROTRON RADIAT, V13, P30, DOI 10.1107/S0909049505036721; Rouvinen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009037; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Schoch CL, 2009, PERSOONIA, V22, P129, DOI 10.3767/003158509X461486; Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI [10.1107/S0108767307043930, 10.1107/S2053229614024218]; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Terwilliger T, 2004, J SYNCHROTRON RADIAT, V11, P49, DOI 10.1107/S0909049503023938; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; Twaroch TE, 2012, J ALLERGY CLIN IMMUN, V129, P1148, DOI 10.1016/j.jaci.2011.10.008; Unger A, 1999, INT ARCH ALLERGY IMM, V118, P220, DOI 10.1159/000024076; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; Vailes LD, 2001, CLIN EXP ALLERGY, V31, P1891, DOI 10.1046/j.1365-2222.2001.00745.x; Wang J, 2009, CLIN EXP ALLERGY, V39, P1381, DOI 10.1111/j.1365-2222.2009.03225.x; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; Yang HW, 2004, ACTA CRYSTALLOGR D, V60, P1833, DOI 10.1107/S0907444904019419; Ye YZ, 2004, NUCLEIC ACIDS RES, V32, pW582, DOI 10.1093/nar/gkh430; Zimmerman M, 2005, ACTA CRYSTALLOGR A, V61, pC178, DOI 10.1107/S0108767305092391	69	65	66	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					241	+		10.1016/j.jaci.2012.03.047	http://dx.doi.org/10.1016/j.jaci.2012.03.047			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22664167	Green Accepted			2022-12-18	WOS:000306644800033
J	Herczenik, E; van Haren, SD; Wroblewska, A; Kaijen, P; van den Biggelaar, M; Meijer, AB; Martinez-Pomares, L; ten Brinke, A; Voorberg, J				Herczenik, Eszter; van Haren, Simon D.; Wroblewska, Aleksandra; Kaijen, Paul; van den Biggelaar, Maartje; Meijer, Alexander B.; Martinez-Pomares, Luisa; ten Brinke, Anja; Voorberg, Jan			Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hemophilia; coagulation factor VIII; dendritic cells; endocytosis; antibody formation	RECEPTOR-RELATED PROTEIN; VON-WILLEBRAND-FACTOR; HEMOPHILIA-A PATIENT; INHIBITOR DEVELOPMENT; FACTOR IXA; ENDOGENOUS LIGANDS; MURINE HEMOPHILIA; MANNOSE RECEPTOR; HUMAN-ANTIBODIES; IMMUNE-RESPONSE	Background: The uptake and processing of blood coagulation factor VIII (FVIII) by antigen-presenting cells and the subsequent presentation of FVIII-derived peptides to CD4(+) T cells direct the immune response to FVIII in patients with hemophilia A. Multiple receptors including mannose receptor and low-density lipoprotein receptor-related protein-1 (LRP1) have been implicated in FVIII uptake. Objective: This work studies the involvement of receptor candidates in FVIII uptake by dendritic cells (DCs). Furthermore, we explore FVIII residues that mediate endocytosis. Methods: FVIII uptake was performed with human monocyte-derived and murine bone marrow-derived DCs. To investigate FVIII endocytosis, competition assays with soluble receptor ligands, binding studies with recombinant receptor fragments, and small-interfering RNA-induced gene silencing were performed. In addition, FVIII-targeting monoclonal antibodies KM33 and VK34 were used. To confirm in vitro results, hemophilic E17 knockout mice were pretreated with antibodies prior to FVIII injections and anti-FVIII titers were determined. Results: Upon treatment of DCs with mannan or LRP ligand alpha 2-macroglobulin, we observed only a minor decrease in FVIII internalization. In addition, small interfering RNA-mediated knockdown of LRP, mannose receptor, or DC-SIGN expression in monocyte-derived dendritic cells did not prevent FVIII uptake. Binding studies using Fc chimeras revealed that LRP, DC-SIGN, and mannose receptor can bind to FVIII; however, we did not observe a critical role for these receptors in FVIII uptake. Previous studies have shown that human antibodies targeting the C1 (KM33) and A2 (VK34) domains of FVIII interfere with binding to endocytic receptors. Preincubation of FVIII with VK34 did not influence FVIII uptake; however, KM33 completely inhibited FVIII endocytosis by both monocyte-derived dendritic cells and bone marrow-derived dendritic cells. Accordingly, anti-FVIII antibody titers were greatly reduced following the preadministration of KM33 in vivo. Conclusion: Together, our observations emphasize the physiological significance of KM33-targeted residues within the C1 domain in the uptake of FVIII by DCs in vitro and in vivo. (J Allergy Clin Immunol 2012;129:501-9.)	[Herczenik, Eszter; van Haren, Simon D.; Wroblewska, Aleksandra; Kaijen, Paul; van den Biggelaar, Maartje; Meijer, Alexander B.; Voorberg, Jan] Sanquin AMC Landsteiner Lab, Dept Plasma Prot, Amsterdam, Netherlands; [Herczenik, Eszter; van Haren, Simon D.; Wroblewska, Aleksandra; Kaijen, Paul; van den Biggelaar, Maartje; Meijer, Alexander B.; Voorberg, Jan] Van Creveld Lab, Amsterdam, Netherlands; [Martinez-Pomares, Luisa] Univ Nottingham, Sch Mol Med Sci, Queens Med Ctr, Nottingham NG7 2RD, England; [ten Brinke, Anja] Sanquin AMC Landsteiner Lab, Dept Immunopathol, Amsterdam, Netherlands	University of Amsterdam; University of Nottingham; University of Amsterdam	Voorberg, J (corresponding author), Sanquin Res, Dept Plasma Prot, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	j.voorberg@sanquin.nl	van Haren, Simon/K-7066-2019	van Haren, Simon/0000-0002-1791-0161; Voorberg, Jan/0000-0003-4585-2621; Martinez-Pomares, Luisa/0000-0002-2331-127X; ten Brinke, Anja/0000-0002-0135-7496; Wroblewska, Aleksandra/0000-0003-2059-6158				Amini-Nekoo A, 2001, BRIT J HAEMATOL, V113, P537, DOI 10.1046/j.1365-2141.2001.02752.x; Bi L, 1996, BLOOD, V88, P3446, DOI 10.1182/blood.V88.9.3446.bloodjournal8893446; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; Bovenschen N, 2006, J THROMB HAEMOST, V4, P1487, DOI 10.1111/j.1538-7836.2006.01965.x; Bovenschen N, 2005, BLOOD, V106, P906, DOI 10.1182/blood-2004-11-4230; Bovenschen N, 2003, J BIOL CHEM, V278, P9370, DOI 10.1074/jbc.M212053200; Bovenschen N, 2003, BLOOD, V101, P3933, DOI 10.1182/blood-2002-07-2081; Brinkman HJM, 2002, ARTERIOSCL THROM VAS, V22, P511, DOI 10.1161/hq0302.105359; Burgdorf S, 2008, CURR OPIN IMMUNOL, V20, P89, DOI 10.1016/j.coi.2007.12.002; Dasgupta S, 2007, HAEMATOLOGICA, V93, P83, DOI 10.3324/haematol.11535; Dasgupta S, 2007, P NATL ACAD SCI USA, V104, P8965, DOI 10.1073/pnas.0702120104; Dimichele D, 2007, J THROMB HAEMOST, V5, P143, DOI 10.1111/j.1538-7836.2007.02474.x; Fijnvandraat K, 2003, SEMIN THROMB HEMOST, V29, P61, DOI 10.1055/s-2003-37940; Garcia-Vallejo JJ, 2009, IMMUNOL REV, V230, P22, DOI 10.1111/j.1600-065X.2009.00786.x; Gouw SC, 2007, BLOOD, V109, P4648, DOI 10.1182/blood-2006-11-056291; Jacquemin MG, 1998, BLOOD, V92, P496, DOI 10.1182/blood.V92.2.496.414k16_496_506; Kempton CL, 2009, BLOOD, V113, P11, DOI 10.1182/blood-2008-06-160432; Kessler M, 2006, NEPHROL DIAL TRANSPL, V21, P9, DOI 10.1093/ndt/gfl476; Lacroix-Desmazes S, 2008, BLOOD, V112, P240, DOI 10.1182/blood-2008-02-124941; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; Linehan SA, 2001, EUR J IMMUNOL, V31, P1857, DOI 10.1002/1521-4141(200106)31:6<1857::AID-IMMU1857>3.0.CO;2-D; Lollar P, 2004, J THROMB HAEMOST, V2, P1082, DOI 10.1111/j.1538-7836.2004.00802.x; Mannucci PM, 2001, NEW ENGL J MED, V344, P1773, DOI 10.1056/NEJM200106073442307; Martinez-Pomares L, 2006, EUR J IMMUNOL, V36, P1074, DOI 10.1002/eji.200535685; Mebius RE, 2005, NAT REV IMMUNOL, V5, P606, DOI 10.1038/nri1669; Medzihradszky KF, 1997, ANAL CHEM, V69, P3986, DOI 10.1021/ac970372z; Meems H, 2009, BLOOD, V114, P3938, DOI 10.1182/blood-2009-01-197707; Meijer AB, 2007, BBA-PROTEINS PROTEOM, V1774, P714, DOI 10.1016/j.bbapap.2007.04.003; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Muchitsch EM, 1999, THROMB HAEMOSTASIS, V82, P1371; Navarrete A, 2009, J THROMB HAEMOST, V7, P1816, DOI 10.1111/j.1538-7836.2009.03571.x; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Pavlova A, 2009, J THROMB HAEMOST, V7, P976, DOI 10.1111/j.1538-7836.2009.03346.x; Pfistershammer K, 2006, THROMB HAEMOSTASIS, V96, P309, DOI 10.1160/TH05-11-0729; Qadura M, 2008, J THROMB HAEMOST, V6, P2095, DOI 10.1111/j.1538-7836.2008.03165.x; Qian JH, 2000, BLOOD, V95, P1324, DOI 10.1182/blood.V95.4.1324.004k25_1324_1329; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Reding MT, 2000, THROMB HAEMOSTASIS, V84, P643, DOI 10.1055/s-0037-1614081; Reipert BM, 2000, THROMB HAEMOSTASIS, V84, P826, DOI 10.1055/s-0037-1614124; Ronnmark J, 2002, J IMMUNOL METHODS, V261, P199, DOI 10.1016/S0022-1759(01)00563-4; Saenko EL, 1999, J BIOL CHEM, V274, P37685, DOI 10.1074/jbc.274.53.37685; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; ten Brinke A, 2007, VACCINE, V25, P7145, DOI 10.1016/j.vaccine.2007.07.031; Van den Biggelaar M, 2007, J THROMB HAEMOST, V5, P2235, DOI 10.1111/j.1538-7836.2007.02737.x; van den Brink EN, 2000, BLOOD, V96, P540; van den Brink EN, 2002, BLOOD, V99, P2828, DOI 10.1182/blood.V99.8.2828; van den Brink EN, 2001, BLOOD, V97, P966, DOI 10.1182/blood.V97.4.966; van Haren SD, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002246; van Helden PMW, 2008, BRIT J HAEMATOL, V142, P644, DOI 10.1111/j.1365-2141.2008.07232.x; Waters B, 2009, BLOOD, V113, P193, DOI 10.1182/blood-2008-04-151597	51	65	65	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					501	U341		10.1016/j.jaci.2011.08.029	http://dx.doi.org/10.1016/j.jaci.2011.08.029			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	21962992	Bronze			2022-12-18	WOS:000299951700030
J	Harduar-Morano, L; Simon, MR; Watkins, S; Blackmore, C				Harduar-Morano, Laurel; Simon, Michael R.; Watkins, Sharon; Blackmore, Carina			A population-based epidemiologic study of emergency department visits for anaphylaxis in Florida	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; epidemiology; emergency; International Classification of Diseases; Ninth Revision; Clinical Modification	UNITED-STATES; ALLERGY; HOSPITALIZATIONS; PRESCRIPTIONS; EPINEPHRINE; ANESTHESIA; CHILDREN; RISK; LIFE	Background: Previous population-based analyses of emergency department (ED) visits for anaphylaxis have been limited to small populations in limited geographic areas and focused on children or have included patients who had allergic conditions other than anaphylaxis. Objective: We sought to describe the epidemiology and risk factors among patients with anaphylaxis presenting to Florida EDs. Methods: Two thousand seven hundred fifty-one patients with anaphylaxis were identified for 2005-2006 within ED records by using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and a validated ICD-9-CM-based algorithm. Age-and sex-specific rates were calculated. Regression analyses were used to determine relative risks for anaphylaxis caused by various triggers (food, venom, and medication) and risk factors (age, sex, race, and ethnicity). Results: The highest observed rates were among the youngest male subjects (8.2/100,000 Floridians aged 0-4 years) and among adult female subjects (15-54 years) grouped in 10-year age categories (9.9-10.9/100,000 Floridians). Male and black subjects were 20% and 25%, respectively, more likely to have a food trigger than female and white subjects. White, male, and older subjects were more likely to have an anaphylaxis-related ED visit caused by insect stings. Venom-induced anaphylaxis was more likely in August through October. Children were less likely than those older than 70 years (referent) to have medication-induced anaphylaxis (P < .03). Conclusion: This is the only ED-based population study in a US lower-latitude state. The overall rate is considerably lower than other US ED-based population studies. The rates of anaphylaxis by age group differed by sex. Male and black subjects were more likely to have a food trigger. (J Allergy Clin Immunol 2011;128:594-600.)	[Simon, Michael R.] William Beaumont Hosp, Div Allergy & Clin Immunol, Royal Oak, MI 48073 USA; [Harduar-Morano, Laurel; Watkins, Sharon; Blackmore, Carina] Bur Environm Publ Hlth Med, Div Environm Hlth, Florida Dept Hlth, Tallahassee, FL USA; [Simon, Michael R.] Wayne State Univ, Sch Med, Dept Internal Med & Pediat, Detroit, MI USA	Beaumont Health; Florida Department of Health; Wayne State University	Simon, MR (corresponding author), William Beaumont Hosp, Allergy & Immunol Sect, Royal Oak, MI 48073 USA.	mrsimonmd@sbcglobal.net			NIEHS NIH HHS [T32 ES007018] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007018] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agresti A., 2003, CATEGORICAL DATA ANA, V482, DOI DOI 10.1002/0471249688; [Anonymous], TECHN APP VIT STAT U; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Braganza SC, 2006, ARCH DIS CHILD, V91, P159, DOI 10.1136/adc.2004.069914; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Chong YY, 2008, SINGAP MED J, V49, P483; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Clark S, 2007, IMMUNOL ALLERGY CLIN, V27, P145, DOI 10.1016/j.iac.2007.03.002; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Hannaway PJ, 2005, ANN ALLERG ASTHMA IM, V95, P143, DOI 10.1016/S1081-1206(10)61203-3; Harduar-Morano L, 2010, J ALLERGY CLIN IMMUN, V126, P98, DOI 10.1016/j.jaci.2010.04.017; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; Laxenaire MC, 2001, BRIT J ANAESTH, V87, P549, DOI 10.1093/bja/87.4.549; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Macy E, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2009.01.034; Moneret-Vautrin D A, 2004, Eur Ann Allergy Clin Immunol, V36, P46; Moneret-Vautrin D A, 2002, Allerg Immunol (Paris), V34, P194; Moneret-Vautrin DA, 2005, ALLERGY, V60, P443, DOI 10.1111/j.1398-9995.2005.00785.x; Moneret-Vautrin DA, 2007, B ACAD NAT MED PARIS, V191, P807, DOI 10.1016/S0001-4079(19)33018-3; Mulla ZD, 2007, INT ARCH ALLERGY IMM, V144, P128, DOI 10.1159/000103224; Mulla ZD, 2011, CURR ALLERGY ASTHM R, V11, P37, DOI 10.1007/s11882-010-0154-7; Mulla ZD, 2009, J ALLERGY CLIN IMMUN, V123, P1194, DOI 10.1016/j.jaci.2009.02.035; Mullins RJ, 2009, ANN ALLERG ASTHMA IM, V103, P488, DOI 10.1016/S1081-1206(10)60265-7; Pastorello EA, 2001, J CHROMATOGR B, V756, P11, DOI 10.1016/S0378-4347(01)00067-6; Robbins AS, 2002, ANN EPIDEMIOL, V12, P452, DOI 10.1016/S1047-2797(01)00278-2; Rudders SA, 2010, ANN ALLERG ASTHMA IM, V104, P413, DOI 10.1016/j.anai.2010.01.022; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sheikh A, 2001, CLIN EXP ALLERGY, V31, P1571, DOI 10.1046/j.1365-2222.2001.01203.x; Simon MR, 2008, ALLERGY, V63, P1077, DOI 10.1111/j.1398-9995.2008.01737.x; Smit DV, 2005, J EMERG MED, V28, P381, DOI 10.1016/j.jemermed.2004.11.028; Stokes ME, 2000, CATEGORICAL DATA ANA, V2nd, P469; The Florida Legislature Office of Economic and Demographic Research, POP EST ACC FLOR COM; West SL, 2007, PHARMACOEPIDEM DR S, V16, P1255, DOI 10.1002/pds.1502; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	37	65	66	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					594	U239		10.1016/j.jaci.2011.04.049	http://dx.doi.org/10.1016/j.jaci.2011.04.049			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21714994	Green Accepted			2022-12-18	WOS:000294283400019
J	Leonardi, NA; Spycher, BD; Strippoli, MPF; Frey, U; Silverman, M; Kuehni, CE				Leonardi, Nora A.; Spycher, Ben D.; Strippoli, Marie-Pierre F.; Frey, Urs; Silverman, Michael; Kuehni, Claudia E.			Validation of the Asthma Predictive Index and comparison with simpler clinical prediction rules	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; wheeze; children; prognosis; prediction; longitudinal; cohort study; validation	OBSTRUCTIVE AIRWAYS DISEASE; PRESCHOOL-CHILDREN; CHILDHOOD ASTHMA; YOUNG-CHILDREN; RISK; WHEEZE; QUESTIONNAIRE; SEVERITY; INFANCY; DESIGN	Background: The loose and stringent Asthma Predictive Indices (API), developed in Tucson, are popular rules to predict asthma in preschool children. To be clinically useful, they require validation in different settings. Objective: To assess the predictive performance of the API in an independent population and compare it with simpler rules based only on preschool wheeze. Methods: We studied 1954 children of the population-based Leicester Respiratory Cohort, followed up from age 1 to 10 years. The API and frequency of wheeze were assessed at age 3 years, and we determined their association with asthma at ages 7 and 10 years by using logistic regression. We computed test characteristics and measures of predictive performance to validate the API and compare it with simpler rules. Results: The ability of the API to predict asthma in Leicester was comparable to Tucson: for the loose API, odds ratios for asthma at age 7 years were 5.2 in Leicester (5.5 in Tucson), and positive predictive values were 26% (26%). For the stringent API, these values were 8.2 (9.8) and 40% (48%). For the simpler rule early wheeze, corresponding values were 5.4 and 21%; for early frequent wheeze, 6.7 and 36%. The discriminative ability of all prediction rules was moderate (c statistic <= 0.7) and overall predictive performance low (scaled Brier score < 20%). Conclusion: Predictive performance of the API in Leicester, although comparable to the original study, was modest and similar to prediction based only on preschool wheeze. This highlights the need for better prediction rules. (J Allergy Clin Immunol 2011;127:1466-72.)	[Leonardi, Nora A.; Spycher, Ben D.; Strippoli, Marie-Pierre F.; Kuehni, Claudia E.] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Frey, Urs] Univ Basel, Univ Childrens Hosp Basel, Basel, Switzerland; [Silverman, Michael] Univ Leicester, Div Child Hlth, Dept Infect Immun & Inflammat, Leicester, Leics, England	University of Bern; University of Basel; University of Leicester	Kuehni, CE (corresponding author), Univ Bern, Inst Social & Prevent Med, Finkenhubelweg 11, CH-3012 Bern, Switzerland.	kuehni@ispm.unibe.ch	Strippoli, Marie-Pierre F/K-8164-2013; Spycher, Ben D/B-3308-2008	Strippoli, Marie-Pierre F/0000-0003-3053-484X; Spycher, Ben D/0000-0002-1430-5695; Kuehni, Claudia E./0000-0001-8957-2002	Swiss National Science Foundation [PDFMP3-123162, 823B-046481, 3200B0-122341]; Asthma UK [07/048]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Asthma UK	Supported by the Swiss National Science Foundation (PDFMP3-123162, 823B-046481, 3200B0-122341) and Asthma UK (07/048).	[Anonymous], 1997, P AM STAT ASS BIOM S; [Anonymous], 2009, GINA REP GLOB STRAT; Becker AB, 2008, J ALLERGY CLIN IMMUN, V122, P1136, DOI 10.1016/j.jaci.2008.10.038; Borrego LM, 2009, THORAX, V64, P203, DOI 10.1136/thx.2008.099903; Brand PLP, 2011, J ALLERGY CLIN IMMUN, V127, P293, DOI 10.1016/j.jaci.2010.10.012; Carlsen KCL, 2010, ALLERGY, V65, P1134, DOI 10.1111/j.1398-9995.2010.02344.x; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez JA, 2010, J ALLERGY CLIN IMMUN, V126, P212, DOI 10.1016/j.jaci.2010.06.032; Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045; Devulapalli CS, 2008, THORAX, V63, P8, DOI 10.1136/thx.2006.060616; Eysink PED, 2005, BRIT J GEN PRACT, V55, P125; GRAHAM R, 2009, J ALLERGY CLIN IMMUN, V124, P911; Guilbert TW, 2010, J ALLERGY CLIN IMMUN, V126, P417, DOI 10.1016/j.jaci.2010.06.024; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Harrell F. E., 2001, REGRESSION MODELING; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F; Kuehni CE, 2005, SWISS MED WKLY, V135, P95; Kuehni CE, 2007, INT J EPIDEMIOL, V36, P977, DOI 10.1093/ije/dym090; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Ly NP, 2006, PEDIATRICS, V117, pE1132, DOI 10.1542/peds.2005-2271; Marenholz I, 2009, J ALLERGY CLIN IMMUN, V123, P911, DOI 10.1016/j.jaci.2009.01.051; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Michel G, 2006, EUR RESPIR J, V28, P1124, DOI 10.1183/09031936.06.00008406; Moeller A, 2008, J ALLERGY CLIN IMMUN, V121, P705, DOI 10.1016/j.jaci.2007.11.008; National Asthma Education and Prevention Program, 2007, 3 NIH NAT ASTHM ED P; Ruotsalainen M, 2010, ALLERGY, V65, P503, DOI 10.1111/j.1398-9995.2009.02212.x; SCHONBERGER H, 2004, EUR J GEN PRACT, V10, P51; Schonberger Hubert, 2004, Eur J Gen Pract, V10, P138; Spahn JD, 2008, J ALLERGY CLIN IMMUN, V121, P548, DOI 10.1016/j.jaci.2008.01.012; Spycher BD, 2010, CLIN EXP ALLERGY, V40, P1130, DOI 10.1111/j.1365-2222.2010.03541.x; Steyerberg E., 2008, CLIN PREDICTION MODE; Strippoli MPF, 2007, ARCH DIS CHILD, V92, P861, DOI 10.1136/adc.2007.117978; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162	37	65	70	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1466	U225		10.1016/j.jaci.2011.03.001	http://dx.doi.org/10.1016/j.jaci.2011.03.001			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21453960				2022-12-18	WOS:000291048500023
J	Kwok, WW; Roti, M; DeLong, JH; Tan, V; Wambre, E; James, EA; Robinson, D				Kwok, William W.; Roti, Michelle; DeLong, Jonathan H.; Tan, Venus; Wambre, Erik; James, Eddie A.; Robinson, David			Direct ex vivo analysis of allergen-specific CD4(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CLASS-II TETRAMERS; FEL D 1; EPITOPES; CAT; IDENTIFICATION; PEPTIDES; FEL-D-1		[Kwok, William W.; Roti, Michelle; DeLong, Jonathan H.; Tan, Venus; Wambre, Erik; James, Eddie A.] Virginia Mason, Benaroya Res Inst, Seattle, WA USA; [Kwok, William W.] Univ Washington, Dept Immunol, Seattle, WA 98195 USA; [Robinson, David] Virginia Mason Med Ctr, Seattle, WA 98101 USA	Benaroya Research Institute; Virginia Mason Medical Center; University of Washington; University of Washington Seattle; Virginia Mason Medical Center	Kwok, WW (corresponding author), Virginia Mason, Benaroya Res Inst, Seattle, WA USA.	bkwok@benaroyaresearch.org	James, Eddie/V-4929-2019	James, Eddie/0000-0002-7217-5729	NIAID NIH HHS [HHSN272200700046C] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bateman EAL, 2008, CLIN EXP ALLERGY, V38, P1760, DOI 10.1111/j.1365-2222.2008.03098.x; Bateman EAL, 2006, J ALLERGY CLIN IMMUN, V118, P1350, DOI 10.1016/j.jaci.2006.07.040; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Counsell CM, 1996, J ALLERGY CLIN IMMUN, V98, P884, DOI 10.1016/S0091-6749(96)80004-2; Day CL, 2003, J CLIN INVEST, V112, P831, DOI 10.1172/JCI200318509; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; Haselden BM, 2001, J ALLERGY CLIN IMMUN, V108, P349, DOI 10.1067/mai.2001.117461; Novak EJ, 1999, J CLIN INVEST, V104, pR63, DOI 10.1172/JCI8476; Novak EJ, 2001, J IMMUNOL, V166, P6665, DOI 10.4049/jimmunol.166.11.6665; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763	10	65	71	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1407	1409		10.1016/j.jaci.2010.03.037	http://dx.doi.org/10.1016/j.jaci.2010.03.037			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20513526	Green Accepted			2022-12-18	WOS:000278831000037
J	Michels, AW; Eisenbarth, GS				Michels, Aaron W.; Eisenbarth, George S.			Immunologic endocrine disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Type 1 diabetes; HLA; autoantibodies; immunotherapy; Addison disease; autoimmune polyendocrine syndrome type 1; autoimmune polyendocrine syndrome type 2; Graves disease; polyendocrine autoimmunity; iatrogenic autoimmunity	MONOCLONAL-ANTIBODY RITUXIMAB; POLYENDOCRINE SYNDROME TYPE-1; BETA-CELL AUTOIMMUNITY; GRAVES-DISEASE; 21-HYDROXYLASE AUTOANTIBODIES; ISLET AUTOIMMUNITY; DIABETES-MELLITUS; MEDICAL PROGRESS; DQ HAPLOTYPES; MAJOR TARGET	Autoimmunity affects multiple glands in the endocrine system. Animal models and human studies highlight the importance of alleles in HLA-like molecules determining tissue-specific targeting that, with the loss of tolerance, leads to organ-specific autoimmunity. Disorders such as type 1A diabetes, Graves disease, Hashimoto thyroiditis, Addison disease, and many others result from autoimmune-mediated tissue destruction. Each of these disorders can be divided into stages beginning with genetic susceptibility, environmental triggers, active autoimmunity, and finally metabolic derangements with overt symptoms of disease. With an increased understanding of the immunogenetics and immunopathogenesis of endocrine autoimmune disorders, immunotherapies are becoming prevalent, especially in patients with type 1A diabetes. Immunotherapies are being used more in multiple subspecialty fields to halt disease progression. Although therapies for autoimmune disorders stop the progress of an immune response, immunomodulatory therapies for cancer and chronic infections can also provoke an unwanted immune response. As a result, there are now iatrogenic autoimmune disorders arising from the treatment of chronic viral infections and malignancies. (J Allergy Clin Immunol 2010;125:S226-37.)	[Michels, Aaron W.] Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Dept Med, Aurora, CO 80045 USA; [Eisenbarth, George S.] Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Dept Pediat, Aurora, CO 80045 USA; [Eisenbarth, George S.] Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Dept Immunol, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Michels, AW (corresponding author), Univ Colorado Denver, Barbara Davis Ctr Childhood Diabet, Dept Med, 1775 Aurora Ct,MSB140,POB 6511, Aurora, CO 80045 USA.	Aaron.Michels@ucdenver.edu		Michels, Aaron/0000-0003-3766-5244	National Institutes of Health [DK32083, DK32493, DK057538]; Autoimmunity Prevention Center [AI50964]; Diabetes Endocrine Research Center [P30 DK57516]; Clinical Research Centers [MO1 RR00069, MO1 RR00051]; Immune Tolerance Network [AI15416]; American Diabetes Association; Juvenile Diabetes Research Foundation; Brehm Coalition; Children's Diabetes Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR000069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057516, R37DK032083, R01DK032083, R01DK032493, R01DK057538, R37DK032493] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Autoimmunity Prevention Center; Diabetes Endocrine Research Center; Clinical Research Centers; Immune Tolerance Network; American Diabetes Association(American Diabetes Association); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Brehm Coalition; Children's Diabetes Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants from the National Institutes of Health (DK32083, DK32493, and DK057538) Autoimmunity Prevention Center (AI50964), Diabetes Endocrine Research Center (P30 DK57516), and Clinical Research Centers (MO1 RR00069 and MO1 RR00051); the Immune Tolerance Network (AI15416); the American Diabetes Association; the Juvenile Diabetes Research Foundation; the Brehm Coalition, and the Children's Diabetes Foundation.	Achenbach P, 2006, DIABETOLOGIA, V49, P2969, DOI 10.1007/s00125-006-0451-9; Achenbach Peter, 2005, Curr Diab Rep, V5, P98, DOI 10.1007/s11892-005-0035-y; Alimohammadi M, 2008, NEW ENGL J MED, V358, P1018, DOI 10.1056/NEJMoa0706487; Allen HF, 1999, DIABETES CARE, V22, P1703, DOI 10.2337/diacare.22.10.1703; Amer Diabet Assoc, 2008, DIABETES CARE, V31, pS55, DOI 10.2337/dc08-S055; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; Bakalov VK, 2005, FERTIL STERIL, V84, P958, DOI 10.1016/j.fertnstert.2005.04.060; Ban Y, 2003, P NATL ACAD SCI USA, V100, P15119, DOI 10.1073/pnas.2434175100; Ban Y, 2003, GENES IMMUN, V4, P586, DOI 10.1038/sj.gene.6364018; Barker JM, 2005, DIABETES CARE, V28, P850, DOI 10.2337/diacare.28.4.850; Betterle C, 1997, J CLIN ENDOCR METAB, V82, P939, DOI 10.1210/jc.82.3.939; Blansfield JA, 2005, J IMMUNOTHER, V28, P593, DOI 10.1097/01.cji.0000178913.41256.06; Bonifacio E, 2008, DIABETOLOGIA, V51, P1245, DOI 10.1007/s00125-008-1022-z; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Caturegli P, 2008, AUTOIMMUN REV, V7, P631, DOI 10.1016/j.autrev.2008.04.016; Chen F, 2005, MEDICINE, V84, P98, DOI 10.1097/01.md.0000159082.45703.90; Chen QY, 1999, J CLIN ENDOCR METAB, V84, P3182, DOI 10.1210/jc.84.9.3182; Creange A, 2008, NAT CLIN PRACT NEURO, V4, P686, DOI 10.1038/ncpneuro0942; EISENBARTH GS, 1979, ANN INTERN MED, V91, P528, DOI 10.7326/0003-4819-91-4-528; Eisenbarth GS, 2004, NEW ENGL J MED, V350, P2068, DOI 10.1056/NEJMra030158; El Fassi D, 2007, J CLIN ENDOCR METAB, V92, P1769, DOI 10.1210/jc.2006-2388; ELLIOTT RB, 1991, DIABETOLOGIA, V34, P362, DOI 10.1007/BF00405010; Erlich H, 2008, DIABETES, V57, P1084, DOI 10.2337/db07-1331; Farrell RJ, 2002, NEW ENGL J MED, V346, P180, DOI 10.1056/NEJMra010852; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Gambelunghe G, 1999, J CLIN ENDOCR METAB, V84, P3701, DOI 10.1210/jc.84.10.3701; Gillis D, 1998, J PEDIATR ENDOCR MET, V11, P467; Grant SFA, 2009, DIABETES, V58, P290, DOI 10.2337/db08-1022; Harjutsalo V, 2008, LANCET, V371, P1777, DOI 10.1016/S0140-6736(08)60765-5; Herold KC, 2005, DIABETES, V54, P1763, DOI 10.2337/diabetes.54.6.1763; HILL JA, 1990, AM J OBSTET GYNECOL, V162, P534, DOI 10.1016/0002-9378(90)90425-7; Hue S, 2003, J IMMUNOL, V171, P1909, DOI 10.4049/jimmunol.171.4.1909; Hutton JC, 2003, P NATL ACAD SCI USA, V100, P8626, DOI 10.1073/pnas.1633447100; JENNER M, 1992, DIABETOLOGIA, V35, P884, DOI 10.1007/BF00399937; Jones JL, 2008, NEURODEGENER DIS, V5, P27, DOI 10.1159/000109935; Keymeulen B, 2005, NEW ENGL J MED, V352, P2598, DOI 10.1056/NEJMoa043980; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kifor O, 2003, J CLIN ENDOCR METAB, V88, P60, DOI 10.1210/jc.2002-020249; Kristof RA, 1999, J NEUROL NEUROSUR PS, V67, P398, DOI 10.1136/jnnp.67.3.398; Kumar PG, 2002, ENDOCRIN METAB CLIN, V31, P321, DOI 10.1016/S0889-8529(01)00011-1; Le Bras S, 2006, J CLIN INVEST, V116, P1473, DOI 10.1172/JCI28880; Lie BA, 2000, AM J HUM GENET, V66, P740, DOI 10.1086/302780; Ludvigsson J, 2008, NEW ENGL J MED, V359, P1909, DOI 10.1056/NEJMoa0804328; Maasho K, 2005, J IMMUNOL, V174, P4480, DOI 10.4049/jimmunol.174.8.4480; Maker AV, 2006, J IMMUNOTHER, V29, P455, DOI 10.1097/01.cji.0000208259.73167.58; Marga M, 2001, AM J MED GENET, V102, P188, DOI 10.1002/ajmg.1431; Martin A, 1997, J CLIN ENDOCR METAB, V82, P3361, DOI 10.1210/jc.82.10.3361; Mazzolari E, 2005, BONE MARROW TRANSPL, V35, P1033, DOI 10.1038/sj.bmt.1704954; Meager A, 2006, PLOS MED, V3, P1152, DOI 10.1371/journal.pmed.0030289; Meyer G, 2001, CLIN ENDOCRINOL, V54, P335, DOI 10.1046/j.1365-2265.2001.01230.x; Michels AW, 2009, J INTERN MED, V265, P530, DOI 10.1111/j.1365-2796.2009.02091.x; Moriyama H, 2002, P NATL ACAD SCI USA, V99, P5539, DOI 10.1073/pnas.082120099; Murphy R, 2008, NAT CLIN PRACT ENDOC, V4, P200, DOI 10.1038/ncpendmet0778; Norris JM, 2007, JAMA-J AM MED ASSOC, V298, P1420, DOI 10.1001/jama.298.12.1420; Norris JM, 2003, JAMA-J AM MED ASSOC, V290, P1713, DOI 10.1001/jama.290.13.1713; Patel DD, 2001, J CLIN INVEST, V107, P155, DOI 10.1172/JCI11966; PERHEENTUPA J, 2002, AUTOIMMUNE POLYENDOC, P295; Perros P, 2000, DIABETIC MED, V17, P749, DOI 10.1046/j.1464-5491.2000.00373.x; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Redondo MJ, 2008, NEW ENGL J MED, V359, P2849, DOI 10.1056/NEJMc0805398; Redondo MJ, 2004, J AUTOIMMUN, V23, P275, DOI 10.1016/j.jaut.2004.07.001; Rewers M, 2004, ENDOCRIN METAB CLIN, V33, P197, DOI 10.1016/j.ecl.2003.12.007; REWERS M, 2004, ENDOCRIN METAB CLIN, V33, pR11; Russo MW, 2003, GASTROENTEROLOGY, V124, P1711, DOI 10.1016/S0016-5085(03)00394-9; Salvi M, 2007, EUR J ENDOCRINOL, V156, P33, DOI 10.1530/eje.1.02325; Schreuder TCMA, 2008, LIVER INT, V28, P39, DOI 10.1111/j.1478-3231.2007.01610.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Silverstein J, 2005, DIABETES CARE, V28, P186, DOI 10.2337/diacare.28.1.186; Singh N, 2007, BLOOD, V110, P1199, DOI 10.1182/blood-2006-10-054585; SOMMERS SC, 2002, ADRENAL GLANDS ANDER, P1429; Staeva-Vieira T, 2007, CLIN EXP IMMUNOL, V148, P17, DOI 10.1111/j.1365-2249.2007.03328.x; Starkey KJ, 2003, J MOL ENDOCRINOL, V30, P369, DOI 10.1677/jme.0.0300369; Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068; UCHIGATA Y, 1993, J CLIN ENDOCR METAB, V77, P249, DOI 10.1210/jc.77.1.249; Umpierrez GE, 2003, DIABETES CARE, V26, P1181, DOI 10.2337/diacare.26.4.1181; Uusitalo L, 2008, DIABETOLOGIA, V51, P773, DOI 10.1007/s00125-008-0959-2; Vang T, 2005, NAT GENET, V37, P1317, DOI 10.1038/ng1673; Verge CF, 1996, DIABETES, V45, P926, DOI 10.2337/diabetes.45.7.926; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Weetman AP, 2000, NEW ENGL J MED, V343, P1236, DOI 10.1056/NEJM200010263431707; WEIJL NI, 1993, J CLIN ONCOL, V11, P1376, DOI 10.1200/JCO.1993.11.7.1376; Wenzlau JM, 2007, P NATL ACAD SCI USA, V104, P17040, DOI 10.1073/pnas.0705894104; Wenzlau JM, 2008, ANN NY ACAD SCI, V1150, P256, DOI 10.1196/annals.1447.029; Willcox A, 2009, CLIN EXP IMMUNOL, V155, P173, DOI 10.1111/j.1365-2249.2008.03860.x; Yu LP, 1999, J CLIN ENDOCR METAB, V84, P328, DOI 10.1210/jc.84.1.328; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547	88	65	71	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S226	S237		10.1016/j.jaci.2009.09.053	http://dx.doi.org/10.1016/j.jaci.2009.09.053			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20176260	Green Accepted, Bronze			2022-12-18	WOS:000280170600020
J	Oliveira, JB; Fleisher, TA				Oliveira, Joao B.; Fleisher, Thomas A.			Laboratory evaluation of primary immunodeficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiency; laboratory assessment; immunologic diagnosis; immunity	AUTOIMMUNE-LYMPHOPROLIFERATIVE-SYNDROME; CHRONIC GRANULOMATOUS-DISEASE; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; FLOW-CYTOMETRY; IMMUNE-DEFICIENCY; CLINICAL FINDINGS; FOLLOW-UP; MUTATIONS; DEFECTS; SUSCEPTIBILITY	Primary immunodeficiencies are congenital disorders caused by defects in different elements of the immune system. Affected patients usually present clinically with recurrent infections, severe infections, or both, as well as autoimmune phenomena that are associated with many of these disorders. Early diagnosis is essential for referral to specialized care centers and the prompt initiation of appropriate therapy. In this article the authors describe a general approach for the investigation of the most common primary immunodeficiencies, outlining the typical clinical symptoms and most appropriate laboratory investigations. (J Allergy Clin Immunol 2010;125:S297-305.)	[Oliveira, Joao B.; Fleisher, Thomas A.] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Fleisher, TA (corresponding author), Bldg 10,Room 2C306,10 Ctr Dr,MSC 1508, Bethesda, MD 20892 USA.	TFleishe@cc.nih.gov	Oliveira, João/GXN-3304-2022; Oliveira, Joao Bosco/AAC-9947-2021	Oliveira, Joao Bosco/0000-0001-9388-8173	CLINICAL CENTER [ZIACL010304] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA CL010304-11] Funding Source: Medline	CLINICAL CENTER; Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Al-Muhsen S, 2008, J ALLERGY CLIN IMMUN, V122, P1043, DOI 10.1016/j.jaci.2008.10.037; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; Bi LL, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-41; Botto M, 2009, MOL IMMUNOL, V46, P2774, DOI 10.1016/j.molimm.2009.04.029; Boztug K, 2008, IMMUNOL ALLERGY CLIN, V28, P259, DOI 10.1016/j.iac.2008.01.007; Casanova JL, 2008, J INTERN MED, V264, P115, DOI 10.1111/j.1365-2796.2008.01971.x; Casrouge A, 2006, SCIENCE, V314, P308, DOI 10.1126/science.1128346; Chan K, 2005, J ALLERGY CLIN IMMUN, V115, P391, DOI 10.1016/j.jaci.2004.10.012; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Conley ME, 2002, J PEDIATR-US, V141, P566, DOI 10.1067/mpd.2002.127711; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; ERSOY F, 1991, TURKISH J PEDIATR, V33, P205; Etzioni A, 2007, ADV EXP MED BIOL, V601, P51; Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010; Filipovich AH, 2008, IMMUNOL ALLERGY CLIN, V28, P293, DOI 10.1016/j.iac.2008.01.010; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Fleisher TA, 2004, J ALLERGY CLIN IMMUN, V114, P227, DOI 10.1016/j.jaci.2004.06.001; Fleisher TA, 1999, CLIN IMMUNOL, V90, P425, DOI 10.1006/clim.1998.4654; Grimbacher B, 2005, IMMUNOL REV, V203, P244, DOI 10.1111/j.0105-2896.2005.00228.x; Hanson EP, 2008, J ALLERGY CLIN IMMUN, V122, P1169, DOI 10.1016/j.jaci.2008.08.018; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Holzelova E, 2004, NEW ENGL J MED, V351, P1409, DOI 10.1056/NEJMoa040036; Jirapongsananuruk O, 2003, J ALLERGY CLIN IMMUN, V111, P374, DOI 10.1067/mai.2003.58; Jouanguy E, 1999, NAT GENET, V21, P370, DOI 10.1038/7701; Kawai S, 2002, J IMMUNOL METHODS, V260, P195, DOI 10.1016/S0022-1759(01)00549-X; Kogawa K, 2002, BLOOD, V99, P61, DOI 10.1182/blood.V99.1.61; Magerus-Chatinet A, 2009, BLOOD, V113, P3027, DOI 10.1182/blood-2008-09-179630; Marcenaro S, 2006, BLOOD, V108, P2316, DOI 10.1182/blood-2006-04-015693; Marsh RA, 2009, CYTOM PART B-CLIN CY, V76B, P334, DOI 10.1002/cyto.b.20473; Martire B, 2008, CLIN IMMUNOL, V126, P155, DOI 10.1016/j.clim.2007.09.008; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Moraes-Vasconcelos D, 2008, J CLIN IMMUNOL, V28, pS11, DOI 10.1007/s10875-008-9176-5; Muller SM, 2001, BLOOD, V98, P1847, DOI 10.1182/blood.V98.6.1847; Nichols KE, 2005, IMMUNOL REV, V203, P180, DOI 10.1111/j.0105-2896.2005.00230.x; Notarangelo LD, 2000, IMMUNOL REV, V178, P39, DOI 10.1034/j.1600-065X.2000.17812.x; OCHS HD, 1992, BLOOD, V80, P1163; Oliveira JB, 2004, CURR OPIN ALLERGY CL, V4, P497, DOI 10.1097/00130832-200412000-00005; Oliveira JB, 2008, CURR OPIN ALLERGY CL, V8, P499, DOI 10.1097/ACI.0b013e328312c790; Ozcan E, 2008, J ALLERGY CLIN IMMUN, V122, P1054, DOI 10.1016/j.jaci.2008.10.023; Picard C, 2007, IMMUNOL RES, V38, P347, DOI 10.1007/s12026-007-0006-2; Pilch H, 2002, CLIN DIAGN LAB IMMUN, V9, P257, DOI 10.1128/CDLI.9.2.257-266.2002; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Rosenzweig SD, 2004, J ALLERGY CLIN IMMUN, V113, P620, DOI 10.1016/j.jaci.2004.02.001; Routes JM, 2009, J ALLERGY CLIN IMMUN, V123, pS68, DOI 10.1016/j.jaci.2008.12.229; Sancho-Shimizu V, 2007, CURR OPIN ALLERGY CL, V7, P495, DOI 10.1097/ACI.0b013e3282f151d2; Shinozaki K, 2002, INT IMMUNOL, V14, P1215, DOI 10.1093/intimm/dxf084; Sullivan KE, 2008, IMMUNOL ALLERGY CLIN, V28, P353, DOI 10.1016/j.iac.2008.01.003; Torgerson TR, 2007, J ALLERGY CLIN IMMUN, V120, P744, DOI 10.1016/j.jaci.2007.08.044; Truedsson L, 2007, AUTOIMMUNITY, V40, P560, DOI 10.1080/08916930701510673; Villa A, 2008, J ALLERGY CLIN IMMUN, V122, P1082, DOI 10.1016/j.jaci.2008.09.037; von Bernuth H, 2005, CLIN INFECT DIS, V41, pS436, DOI 10.1086/431994; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298; von Bernuth H, 2006, PEDIATRICS, V118, P2498, DOI 10.1542/peds.2006-1845; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Yong PFK, 2008, IMMUNOL ALLERGY CLIN, V28, P691, DOI 10.1016/j.iac.2008.06.003; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522	61	65	70	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S297	S305		10.1016/j.jaci.2009.08.043	http://dx.doi.org/10.1016/j.jaci.2009.08.043			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	629CC	20042230	Green Accepted			2022-12-18	WOS:000280170600027
J	Flory, JH; Sleiman, PM; Christie, JD; Annaiah, K; Bradfield, J; Kim, CE; Glessner, J; Imielinski, M; Li, HZ; Frackelton, EC; Hou, CP; Otieno, G; Thomas, K; Smith, R; Glaberson, W; Garris, M; Chiavacci, R; Allen, J; Spergel, J; Grundmeier, R; Grunstein, M; Magnusson, M; Grant, SFA; Bonnelykke, K; Bisgaard, H; Hakonarson, H				Flory, James H.; Sleiman, Patrick M.; Christie, Jason D.; Annaiah, Kiran; Bradfield, Jonathan; Kim, Cecilia E.; Glessner, Joseph; Imielinski, Marcin; Li, Hongzhe; Frackelton, Edward C.; Hou Cuiping; Otieno, George; Thomas, Kelly; Smith, Ryan; Glaberson, Wendy; Garris, Maria; Chiavacci, Rosetta; Allen, Julian; Spergel, Jonathan; Grundmeier, Robert; Grunstein, Michael; Magnusson, Michael; Grant, Struan F. A.; Bonnelykke, Klaus; Bisgaard, Hans; Hakonarson, Hakon			17q12-21 variants interact with smoke exposure as a risk factor for pediatric asthma but are equally associated with early-onset versus late-onset asthma in North Americans of European ancestry	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GENE		[Flory, James H.; Sleiman, Patrick M.; Annaiah, Kiran; Bradfield, Jonathan; Kim, Cecilia E.; Glessner, Joseph; Imielinski, Marcin; Li, Hongzhe; Frackelton, Edward C.; Hou Cuiping; Otieno, George; Thomas, Kelly; Smith, Ryan; Glaberson, Wendy; Garris, Maria; Chiavacci, Rosetta; Grant, Struan F. A.; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA; [Allen, Julian; Grunstein, Michael] Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA; [Spergel, Jonathan] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA; [Grundmeier, Robert] Childrens Hosp Philadelphia, Dept Bioinformat, Philadelphia, PA 19104 USA; [Magnusson, Michael] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Christie, Jason D.] Univ Penn, Dept Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Dept Hlth Sci, Copenhagen, Denmark	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Copenhagen	Flory, JH (corresponding author), Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA.	hakonarson@CHOP.EDU	Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Glessner, Joseph/0000-0001-5131-2811; Bonnelykke, Klaus/0000-0003-2003-1018; Spergel, Jonathan/0000-0002-4658-5353				Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Hakonarson H, 2007, NATURE, V448, P591, DOI 10.1038/nature06010; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Sleiman PMA, 2008, J ALLERGY CLIN IMMUN, V122, P1225, DOI 10.1016/j.jaci.2008.06.041	8	65	67	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					605	607		10.1016/j.jaci.2009.05.047	http://dx.doi.org/10.1016/j.jaci.2009.05.047			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19660801				2022-12-18	WOS:000274315900033
J	Musaad, SMA; Patterson, T; Ericksen, M; Lindsey, M; Dietrich, K; Succop, P; Hershey, GKK				Musaad, Salma M. A.; Patterson, Tia; Ericksen, Mark; Lindsey, Mark; Dietrich, Kim; Succop, Paul; Hershey, Gurjit K. Khurana			Comparison of anthropometric measures of obesity in childhood allergic asthma: Central obesity is most relevant	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; obesity; children; body mass index percentiles; waist circumference	BODY-MASS INDEX; TO-HEIGHT RATIO; WAIST CIRCUMFERENCE; INCIDENT ASTHMA; RESPIRATORY SYMPTOMS; ABDOMINAL ADIPOSITY; PROSPECTIVE COHORT; PHYSICAL-ACTIVITY; UNITED-STATES; YOUNG-ADULTS	Background: Established indicators of central obesity include waist circumference, waist/height ratio, and the conicity index. Studies using such measures (as opposed to body mass index [BMI] percentiles) to characterize the association between obesity and asthma are lacking, despite the fact that these measures have been shown to be most relevant for many other chronic diseases. Objectives: We sought to examine measures assessing the distribution of obesity in the context of childhood allergic rhinitis and asthma and to elucidate the association of obesity, including central obesity, with allergic asthma in children. Methods: Children with allergic rhinitis with (cases) or without (control subjects) asthma were recruited. BMI percentiles were derived by using national growth charts. Waist circumference, waist/height ratio, and conicity index values were obtained. Results: Central obesity was associated with asthma, asthma severity, lower lung function, and reduced atopy in asthmatic subjects. Conclusion: Measures of central obesity are more associated with the presence of asthma and asthma severity in children with allergic rhinitis when compared with standard BMI measures. (J Allergy Clin Immunol 2009;123:1321-7.)	[Musaad, Salma M. A.; Patterson, Tia; Ericksen, Mark; Lindsey, Mark; Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp, Med Ctr, Div Asthma Res & Allergy & Immunol, Cincinnati, OH 45229 USA; [Musaad, Salma M. A.; Patterson, Tia; Ericksen, Mark; Lindsey, Mark; Hershey, Gurjit K. Khurana] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45221 USA; [Musaad, Salma M. A.; Dietrich, Kim; Succop, Paul] Univ Cincinnati, Coll Med, Dept Environm Hlth, Div Epidemiol & Biostat, Cincinnati, OH 45221 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Asthma Res, 3333 Burnet Ave,MLC 7037, Cincinnati, OH 45229 USA.	Gurjit.Hershey@cchmc.org		Khurana Hershey, Gurjit/0000-0001-6663-977X	National Institutes of Health [U19A170235-01]; University of Cincinnati and Molecular Epidemiology in Children's Environmental Health Institutional National Institute of Environmental Health Sciences [T32 ES10957]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES010957] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Cincinnati and Molecular Epidemiology in Children's Environmental Health Institutional National Institute of Environmental Health Sciences; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health grant U19A170235-01 (G. K. Khurana Hershey) and University of Cincinnati and Molecular Epidemiology in Children's Environmental Health Institutional National Institute of Environmental Health Sciences grant T32 ES10957 (S. M. A. Musaad).	Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; Appleton SL, 2006, J ALLERGY CLIN IMMUN, V118, P1284, DOI 10.1016/j.jaci.2006.08.011; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Ashwell M, 2005, INT J FOOD SCI NUTR, V56, P303, DOI 10.1080/09637480500195066; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Bibi H, 2004, J ASTHMA, V41, P403, DOI 10.1081/JAS-120026097; Boulet LP, 2007, CAN RESPIR J, V14, P217, DOI 10.1155/2007/101640; Cassol VE, 2006, J ASTHMA, V43, P57, DOI 10.1080/02770900500448597; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Chen Y, 2005, CHEST, V128, P3048, DOI 10.1378/chest.128.4.3048; Daniels SR, 1997, PEDIATRICS, V99, P804, DOI 10.1542/peds.99.6.804; Del-Rio-Navarro BE, 2003, J INVEST ALLERG CLIN, V13, P118; Ford ES, 2005, J ASTHMA, V42, P91, DOI 10.1081/JAS-51328; Ford ES, 2004, EUR RESPIR J, V24, P740, DOI 10.1183/09031936.04.00088003; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Gunnbjomsdottir MI, 2004, EUR RESPIR J, V24, P116, DOI 10.1183/09031936.04.00042603; Hasler G, 2006, INT J OBESITY, V30, P1111, DOI 10.1038/sj.ijo.0803215; Kahn HS, 2005, J PEDIATR-US, V146, P482, DOI 10.1016/j.jpeds.2004.12.028; Kilpelainen M, 2006, RESP MED, V100, P1518, DOI 10.1016/j.rmed.2006.01.011; KOENKER R, 1978, ECONOMETRICA, V46, P33, DOI 10.2307/1913643; Kronander UN, 2004, RESP MED, V98, P1108, DOI 10.1016/j.rmed.2004.03.022; Lazarus R, 1996, AM J CLIN NUTR, V63, P500, DOI 10.1093/ajcn/63.4.500; Lofgren I, 2004, J NUTR, V134, P1071, DOI 10.1093/jn/134.5.1071; Luder E, 2004, RESP MED, V98, P29, DOI 10.1016/j.rmed.2003.08.004; Mannino DM, 2006, INT J OBESITY, V30, P6, DOI 10.1038/sj.ijo.0803145; Mannucci Pier M, 2002, Hematology Am Soc Hematol Educ Program, P1; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moreno LA, 2001, INT J OBESITY, V25, P1656, DOI 10.1038/sj.ijo.0801803; Muthen L., 2017, STAT ANAL LATENT VAR, V8th; *NAT HEART LUNG BL, 2007, NAT I HLTH PUBL; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; Oddy WH, 2004, AM J PUBLIC HEALTH, V94, P1531, DOI 10.2105/AJPH.94.9.1531; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304; Stanley AH, 2005, J ASTHMA, V42, P97, DOI 10.1081/JAS-51338; Sulit LG, 2005, AM J RESP CRIT CARE, V171, P659, DOI 10.1164/rccm.200403-398OC; Tantisira KG, 2001, THORAX, V56, P64; Tsai HJ, 2007, J ASTHMA, V44, P397, DOI 10.1080/02770900701364304; *US DEP HHS, 2005, CTR DIS CONTR PREV A; VALDEZ R, 1993, INT J OBESITY, V17, P77; VALDEZ R, 1991, J CLIN EPIDEMIOL, V44, P955, DOI 10.1016/0895-4356(91)90059-I; Wang Y, 2004, INT J OBESITY, V28, pS21, DOI 10.1038/sj.ijo.0802801; Wickens K, 2005, THORAX, V60, P7, DOI 10.1136/thx.2002.001529; SAS PROGRAM CDC GROW	45	65	67	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1321	1327		10.1016/j.jaci.2009.03.023	http://dx.doi.org/10.1016/j.jaci.2009.03.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19439348	Green Accepted			2022-12-18	WOS:000266799100024
J	Bonnelykke, K; Pipper, CB; Bisgaard, H				Bonnelykke, Klaus; Pipper, Christian Bressen; Bisgaard, Hans			Sensitization does not develop in utero	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sensitization; cord blood; infant; intrauterine; atopy	CORD-BLOOD; ATOPIC DISEASE; BIRTH COHORT; IGE LEVELS; LIFE; AGE; IMMUNOGLOBULINS; AVOIDANCE; PREGNANCY; RESPONSES	Background: Intrauterine sensitization has been suggested to play a role in the development of atopic disease in children, and this has led to current guidelines recommending allergen avoidance during pregnancy. Objective: To investigate the relevance of allergen-specific IgE in cord blood to sensitization in early infancy and the origin of such IgE. Methods: Inhalant and food allergen-specific IgE in cord blood was analyzed and compared with specific IgE in infant blood at 6 months of age and in parental blood. Cord blood IgA was measured to detect maternal blood contamination of cord blood. Results: Allergen-specific IgE, primarily against inhalant allergens, was detected in 14% of cord blood samples. However, corresponding specific IgE was not found in infant blood at 6 months of age. Specific IgE in cord blood completely matched specific IgE in maternal blood with respect to allergen specificity, level of specific IgE, and ratio of total IgE/specific IgE. Finally, there was a correlation between specific IgE and IgA in cord blood. Conclusion: Allergen-specific IgE in cord blood does not reflect intrauterine sensitization but seems to be the result of transfer of maternal IgE to the fetus.	[Bonnelykke, Klaus; Pipper, Christian Bressen; Bisgaard, Hans] Univ Copenhagen Hosp, Dept Pediat, Pediat Asthma Ctr, DK-2900 Hellerup, Denmark	University of Copenhagen	Bonnelykke, K (corresponding author), Univ Copenhagen Hosp, Dept Pediat, Pediat Asthma Ctr, Gentofte,Niels Ansersens Vej 65, DK-2900 Hellerup, Denmark.	kb@copsac.dk	Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592; Pipper, Christian Bressen/0000-0003-0261-616X; Bonnelykke, Klaus/0000-0003-2003-1018	Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden)		AVRECH OM, 1994, INT ARCH ALLERGY IMM, V103, P160, DOI 10.1159/000236622; Baker SS, 2000, PEDIATRICS, V106, P346; Ballardini N, 2006, ALLERGY, V61, P337, DOI 10.1111/j.1398-9995.2005.00936.x; Bertino E, 2006, PEDIATR ALLERGY IMMU, V17, P484, DOI 10.1111/j.1399-3038.2006.00449.x; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; CAIN TW, 2006, ALLERGY CLIN IMMUNOL, P1; *DEP HLTH COMM TOX, 1998, CONS PROD ENV ADV RE; Edenharter G, 1998, CLIN EXP ALLERGY, V28, P671; Hansen L G, 1993, Pediatr Allergy Immunol, V4, P34, DOI 10.1111/j.1399-3038.1993.tb00063.x; Herrmann ME, 1996, EUR J PEDIATR, V155, P770, DOI 10.1007/BF02002904; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Jones CA, 2000, ALLERGY, V55, P2, DOI 10.1034/j.1398-9995.2000.00109.x; LILJA G, 1990, ALLERGY, V45, P436, DOI 10.1111/j.1398-9995.1990.tb01094.x; LILJA G, 1992, ALLERGY, V47, P522, DOI 10.1111/j.1398-9995.1992.tb00676.x; Lima JO, 2000, J ALLERGY CLIN IMMUN, V106, P911, DOI 10.1067/mai.2000.110228; Malek A, 1996, AM J REPROD IMMUNOL, V36, P248; MiguezBurbano MJ, 1997, LANCET, V350, P782, DOI 10.1016/S0140-6736(05)62566-4; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1111/j.1365-2222.1996.tb00608.x; MILLER DL, 1973, FED PROC, P1013; Nambu M, 2003, BIOL NEONATE, V83, P102, DOI 10.1159/000067961; ODELRAM H, 1995, ALLERGY, V50, P585, DOI 10.1111/j.1398-9995.1995.tb01204.x; Ownby DR, 1996, PEDIATR ALLERGY IMMU, V7, P125, DOI 10.1111/j.1399-3038.1996.tb00119.x; Paganelli R, 1998, ALLERGY, V53, P763; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Thornton CA, 2004, J IMMUNOL, V173, P3084, DOI 10.4049/jimmunol.173.5.3084; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC	29	65	65	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					646	651		10.1016/j.jaci.2007.12.1149	http://dx.doi.org/10.1016/j.jaci.2007.12.1149			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18328892				2022-12-18	WOS:000253918900016
J	Peeters, KABM; Nordlee, JA; Penninks, AH; Chen, L; Goodman, RE				Peeters, Kim A. B. M.; Nordlee, Julie A.; Penninks, Andre H.; Chen, Lingyun; Goodman, Richard E.			Lupine allergy: Not simply cross-reactivity with peanut or soy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lupine allergy; cross-reactivity; legumes; allergens; IgE immunoblotting; amino acid sequencing; skin prick tests; doubleblind; placebo-controlled,food challenge; eliciting dose; peanut	ALBUS CV MULTOLUPA; FLOUR; ANAPHYLAXIS; ALLERGENICITY; PROTEINS; ARA-H-1; BINDING; FOODS; CHILD; IGE	Background: Reports of lupine allergy are increasing as its use in food products increases. Lupine allergy might be the consequence of cross-reactivity after sensitization to peanut or other legumes or de novo sensitization. Lupine allergens have not been completely characterized. Objectives: We sought to identify allergens associated with lupine allergy, evaluate potential cross-reactivity with peanut, and determine eliciting doses (EDs) for lupine allergy by using double-blind, placebo-controlled food challenges. Methods: Six patients with a history of allergic reactions to lupine flour were evaluated by using skin prick tests, CAP tests, and double-blind, placebo-controlled food challenges. Three of these patients were also allergic to peanut. Lupine allergens were characterized by means of IgE immunoblotting and peptide sequencing. Results: In all 6 patients the ED for lupine flour was 3 mg or less for subjective symptoms and 300 mg or more for objective symptoms. The low ED and moderate-to-severe historical symptoms indicate significant allergenicity of lupine flour. Two patients allergic to lupine but not to peanut displayed IgE binding predominantly to approximately 66-kd proteins and weak binding to 14- and 24-kd proteins, whereas patients with peanut allergy and lupine allergy showed weak binding to lupine proteins of about 14 to 21 or 66 kd. Inhibition of binding was primarily species specific. Conclusion: Lupine allergy can occur either separately or together with peanut allergy, as demonstrated by 3 patients who are cosensitized to peanut and lupine. Clinical implications: Lupine flour is allergenic and potentially cross-reactive with peanut allergen, thus posing some risk if used as a replacement for soy flour.	Univ Utrecht, Med Ctr, Dept Dermatol Allergol G02 124, NL-3508 GA Utrecht, Netherlands; Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE USA; TNO Qual Life, Zeist, Netherlands	Utrecht University; University of Nebraska System; University of Nebraska Lincoln; Netherlands Organization Applied Science Research	Peeters, KABM (corresponding author), Univ Utrecht, Med Ctr, Dept Dermatol Allergol G02 124, POB 85 500, NL-3508 GA Utrecht, Netherlands.	K.A.B.M.Peeters@umcutrecht.nl						BALLESTER D, 1984, J FOOD SCI, V49, P14, DOI 10.1111/j.1365-2621.1984.tb13657.x; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; Barre A, 2005, BIOCHIMIE, V87, P499, DOI 10.1016/j.biochi.2005.02.011; BEMHISELBROADBE.J, 1989, J ALLERGY CLIN IMMUN, V83, P435; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEPENNA EW, 1987, J FOOD SCI, V52, P1434; HEFLE SL, 1994, J ALLERGY CLIN IMMUN, V94, P167, DOI 10.1016/0091-6749(94)90036-1; Holden L, 2005, J AGR FOOD CHEM, V53, P5866, DOI 10.1021/jf050631i; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lifrani A, 2005, INT IMMUNOPHARMACOL, V5, P1427, DOI 10.1016/j.intimp.2005.03.018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matheu V, 1999, ANN ALLERG ASTHMA IM, V83, P406, DOI 10.1016/S1081-1206(10)62838-4; Moneret-Vautrin DA, 1999, J ALLERGY CLIN IMMUN, V104, P883, DOI 10.1016/S0091-6749(99)70303-9; Moreno-Ancillo A, 2005, PEDIAT ALLERG IMM-UK, V16, P542, DOI 10.1111/j.1399-3038.2005.00299.x; Mueller H L, 1966, J Asthma Res, V3, P331; Novembre E, 1999, J ALLERGY CLIN IMMUN, V103, P1214, DOI 10.1016/S0091-6749(99)70203-4; Parisot L, 2001, ALLERGY, V56, P918, DOI 10.1034/j.1398-9995.2001.00254.x; Radcliffe M, 2005, LANCET, V365, P1360, DOI 10.1016/S0140-6736(05)61036-7; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; Smith WB, 2004, MED J AUSTRALIA, V181, P219, DOI 10.5694/j.1326-5377.2004.tb06242.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wensing M, 2003, J ALLERGY CLIN IMMUN, V111, P420, DOI 10.1067/mai.2003.61; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Wensing M, 2002, CLIN EXP ALLERGY, V32, P1757, DOI 10.1046/j.1365-2222.2002.01555.x	24	65	65	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					647	653		10.1016/j.jaci.2007.05.032	http://dx.doi.org/10.1016/j.jaci.2007.05.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17637469	Green Published			2022-12-18	WOS:000249505400025
J	Zanini, A; Chetta, A; Saetta, M; Baraldo, S; D'Ippolito, R; Castagnaro, A; Neri, M; Olivieri, D				Zanini, Andrea; Chetta, Alfredo; Saetta, Marina; Baraldo, Simonetta; D'Ippolito, Raffaele; Castagnaro, Antonio; Neri, Margherita; Olivieri, Dario			Chymase-positive mast cells play a role in the vascular component of airway remodeling in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; bronchial asthma; vascular remodeling	LUNG-FUNCTION; TRYPTASE; MCTC; IMMUNOHISTOCHEMISTRY; ANGIOGENESIS; EOSINOPHILS; PROTEINASE; EXPRESSION	Background: There is increasing evidence to support a role for total mast cells (MCTOT) in the vascular component of airway remodeling in asthma. On the contrary, up to now, no study has addressed the role of chymase-positive mast cells (MCTC) in microvasculature changes. Objective: We sought to assess the role of MCTC in the vascular component of airway remodeling in asthma. Methods: We recruited 8 patients with mild-to-moderate asthma and 8 healthy volunteers as a control group. Fiberoptic bronchoscopy with endobronchial biopsy was successfully performed in all subjects. Immunostaining was performed for quantification of vessels, vascular endothelial growth factor (VEGF)-positive Cells, MCTOT, and MCTC. Results: Compared with those from healthy subjects, endobronchial biopsy specimens from asthmatic patients showed increased numbers of MCTOT and MCTC and VEGF(+) cells (P < .05). In asthmatic patients the number of vessels and the vascular area was also greater than in healthy subjects (P < .05). Additionally, in asthmatic patients the number of MCTC was significantly related to the vascular area (r(s) = 0.74, P < .01) and to the number of VEGF(+) cells (r(s) = 0.78, P < .01). Moreover, a colocalization study revealed that MCTC were a relevant cellular source of VEGF. Finally, a 6-week treatment with inhaled fluticasone propionate was able to reduce MCTC numbers. Conclusion: MCTC can play a role in the vascular component of airway remodeling in asthma, possibly through induction of VEGF. Clinical implications: Specific targeting of MCTC might be a toot for treating vascular remodeling in asthma.	IRCCS, Fdn Salvatore Maugeri, Div Pneumol, Inst Rehabil Tradate, I-21049 Tradate, Italy; Univ Parma, Sect Resp Dis, Dept Clin Sci, Parma, Italy; Univ Padua, Sect Resp Dis, Dept Cardiothorac & Vasc Sci, I-35100 Padua, Italy	Istituti Clinici Scientifici Maugeri IRCCS; University of Parma; University of Padua	Zanini, A (corresponding author), IRCCS, Fdn Salvatore Maugeri, Div Pneumol, Inst Rehabil Tradate, Via Roncaccio 16, I-21049 Tradate, Italy.	azanini@fsm.it	Saetta, Marina/D-1924-2009; Baraldo, Simonetta/AAE-3862-2021	Baraldo, Simonetta/0000-0001-8923-7511; Chetta, Alfredo/0000-0002-0416-5334; SAETTA, MARINA/0000-0002-1547-2102				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Berger P, 1999, CLIN EXP ALLERGY, V29, P804; Blair RJ, 1997, J CLIN INVEST, V99, P2691, DOI 10.1172/JCI119458; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Chetta A, 2005, CLIN EXP ALLERGY, V35, P1437, DOI 10.1111/j.1365-2222.2005.02360.x; Chetta A, 2003, AM J RESP CRIT CARE, V167, P751, DOI 10.1164/rccm.200207-710OC; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58, DOI 10.1016/S0091-6749(97)70195-7; Groneberg DA, 2005, ALLERGY, V60, P90, DOI 10.1111/j.1398-9995.2004.00628.x; Hamada H, 1999, AM J RESP CRIT CARE, V160, P1303, DOI 10.1164/ajrccm.160.4.9810058; Ibaraki T, 2005, EUR J CARDIO-THORAC, V28, P617, DOI 10.1016/j.ejcts.2005.06.020; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; IRANI AMA, 1991, J IMMUNOL, V147, P247; Johnson PRA, 1997, EUR RESPIR J, V10, P38, DOI 10.1183/09031936.97.10010038; JULIUSSON S, 1995, ALLERGY, V50, P15, DOI 10.1111/j.1398-9995.1995.tb02478.x; Kanbe N, 1999, EUR J IMMUNOL, V29, P2645; Kim S, 2000, PHARMACOL REV, V52, P11; MATIN R, 1992, J HISTOCHEM CYTOCHEM, V40, P781, DOI 10.1177/40.6.1588024; McDonald DM, 2001, AM J RESP CRIT CARE, V164, pS39, DOI 10.1164/ajrccm.164.supplement_2.2106065; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Muramatsu M, 2000, EUR J PHARMACOL, V402, P181, DOI 10.1016/S0014-2999(00)00350-2; Nagata M, 2003, VIRCHOWS ARCH, V443, P565, DOI 10.1007/s00428-003-0842-y; Norrby K, 2002, APMIS, V110, P355, DOI 10.1034/j.1600-0463.2002.100501.x; Oskeritzian CA, 2005, J ALLERGY CLIN IMMUN, V115, P1162, DOI 10.1016/j.jaci.2005.02.022; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; Schwartz Lawrence B, 2006, Methods Mol Biol, V315, P53; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Wilson J, 2000, CLIN EXP ALLERGY, V30, P51; Wilson JW, 2006, CURR OPIN ALLERGY CL, V6, P51, DOI 10.1097/01.all.0000200505.54425.47	34	65	70	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					329	333		10.1016/j.jaci.2007.04.021	http://dx.doi.org/10.1016/j.jaci.2007.04.021			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17559912				2022-12-18	WOS:000248654900017
J	Romagnani, S				Romagnani, Sergio			Coming back to a missing immune deviation as the main explanatory mechanism for the hygiene hypothesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						hygiene hypothesis; TLR; pathogen-associated molecular pattern; Delta-4; jagged-1; notch; IL-12; T(H)1; T(H)2; immune deviation	T-CELLS; ALLERGY; AUTOIMMUNE; RESPONSES; ASTHMA		Univ Florence, Dept Internal Med, I-50134 Florence, Italy	University of Florence	Romagnani, S (corresponding author), Univ Florence, Dept Internal Med, Viale Morgagni 85, I-50134 Florence, Italy.	s.romagnani@dmi.unifi.it						Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Brugnolo F, 2003, J ALLERGY CLIN IMMUN, V111, P380, DOI 10.1067/mai.2003.102; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Fili L, 2006, J ALLERGY CLIN IMMUN, V118, P511, DOI 10.1016/j.jaci.2006.05.027; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; HURTADO A, 2005, KIDNEY INT S, V97, P62; Linehan MF, 2007, J ALLERGY CLIN IMMUN, V119, P1079, DOI 10.1016/j.jaci.2006.12.672; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; STEM DA, 2007, J ALLERGY CLIN IMMUN, V119, P351; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tirosh A, 2006, ANN INTERN MED, V144, P877, DOI 10.7326/0003-4819-144-12-200606200-00004; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	20	65	68	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1511	1513		10.1016/j.jaci.2007.04.005	http://dx.doi.org/10.1016/j.jaci.2007.04.005			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17556059				2022-12-18	WOS:000247232800029
J	Rand, C; Bilderback, A; Schiller, K; Edelman, JM; Hustad, CM; Zeiger, RS				Rand, Cynthia; Bilderback, Andrew; Schiller, Kathleen; Edelman, Jonathan M.; Hustad, Carolyn M.; Zeiger, Robert S.		MIAMI Study Res Grp	Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adherence; compliance; dose-response; mild persistent asthma; leukotriene receptor antagonist; montelukast; inhaled corticosteroids; fluticasone; clinical trial	PATIENT COMPLIANCE; PERSISTENT ASTHMA; MEDICATION	Background: Nonadherence with asthma therapy is common and may contribute to poor clinical outcomes. Objective: To examine the effect of dosing frequency and mode of delivery of therapy on adherence and clinical outcomes. Methods: We examined adherence in patients with mild persistent asthma (15-85 years) enrolled in a randomized study of montelukast (10 mg once daily) or fluticasone (88 mu g, 2 puffs twice daily) during a 12-week double-blind treatment period (DB), followed by a 36-week open-label trial (OL). Adherence was monitored using eDEM for montelukast/placebo and MDILog devices for fluticasone/placebo. Results: Participants used at least I puff of inhaled therapy on 83.3% DB/76.8% OL of days and at least I dose of oral therapy on 77.5%/71.4% of days (P <.0001). Subjects used inhaled therapy less than prescribed on 49.5%/57.5% of days, compared with 22.5%/28.6% of days for oral therapy (P <.0001). In the DB, a dose-response relationship was observed with fluticasone and asthma rescue-free days (P =.02) and FEV1 percent predicted (P <.01) only for patients with FEV1 <= 86%. In the OL period, a dose-response relationship was observed with fluticasone and FEV1 percent predicted (P <.001).	Johns Hopkins Sch Med, JHAAC, Baltimore, MD 21224 USA; Merck & Co Inc, West Point, PA 19486 USA; Kaiser Permanente, San Diego, CA USA	Johns Hopkins University; Johns Hopkins Medicine; Merck & Company; Kaiser Permanente	Rand, C (corresponding author), Johns Hopkins Sch Med, JHAAC, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	crand@mail.jhmi.edu		Zeiger, Robert/0000-0001-5788-5063				Apter AJ, 2001, ANN ALLERG ASTHMA IM, V86, P421, DOI 10.1016/S1081-1206(10)62488-X; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; Global Initiative for Asthma, NIH PUBL, V02-3659; Iskedjian M, 2002, CLIN THER, V24, P302, DOI 10.1016/S0149-2918(02)85026-3; Julius SM, 2002, CHEST, V121, P871, DOI 10.1378/chest.121.3.871; KOREN G, 1991, PEDIATR RES, V29, pA61; MANN M, 1992, CHEST, V101, P496, DOI 10.1378/chest.101.2.496; Mason BJ, 1996, WESTERN J MED, V164, P182; Morningstar BA, 2002, J CLIN PHARM THER, V27, P213, DOI 10.1046/j.1365-2710.2002.00411.x; *NAT ASTHM ED PREV, 2003, NIH PUBL; OLIVIERI NF, 1991, ARCH DIS CHILD, V66, P1399, DOI 10.1136/adc.66.12.1399; Rand CS, 1998, HDB HLTH BEHAV CHANG, P114; RAND CS, 2002, LUNG BIOL HEALTH DIS, V163, P491; Riekert KA, 2002, J CLIN PSYCHOL MED S, V9, P25, DOI 10.1023/A:1014131928789; Sherman J, 2001, PHARMACOTHERAPY, V21, P1464, DOI 10.1592/phco.21.20.1464.34485; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; Urquhart J, 2000, PHARMACOEPIDEM DR S, V9, P565, DOI 10.1002/pds.540; Urquhart J, 1998, ADV DRUG DELIVER REV, V33, P207, DOI 10.1016/S0169-409X(98)00029-5; Zeiger RS, 2005, AM J MED, V118, P649, DOI 10.1016/j.amjmed.2005.03.003; Zeiger RS, 2004, RESP MED, V98, P898, DOI 10.1016/j.rmed.2004.02.016	21	65	66	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					916	923		10.1016/j.jaci.2006.12.664	http://dx.doi.org/10.1016/j.jaci.2006.12.664			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17349681				2022-12-18	WOS:000245729500021
J	Le, LQ; Mahler, V; Lorenz, Y; Scheurer, S; Biemelt, S; Vieths, S; Sonnewald, U				Le, Lien Quynh; Mahler, Vera; Lorenz, Yvonne; Scheurer, Stephan; Biemelt, Sophia; Vieths, Stefan; Sonnewald, Uwe			Reduced allergenicity of tomato fruits harvested from Lyc e 1-silenced transgenic tomato plants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Lyc e 1; RNA interference; tomato allergy; allergen avoidance	COMPONENT-RESOLVED DIAGNOSIS; CROSS-REACTIVITY; LYCOPERSICON-ESCULENTUM; BIRCH POLLEN; FOOD ALLERGENS; PROFILIN; CLONING; PROTEINS; IGE; TRANSFORMATION	Background: Profilin is a small actin-binding protein that contributes to the allergenic potency of many fruits and vegetables, including tomato. Two highly similar genes encoding tomato profilin have been isolated and designated as allergen Lyc a 1.01 and Lye a 1.02. Objective: The aim of the study was to generate profilin-reduced hypoallergenic tomato fruits by silencing of both genes in transgenic tomato plants by means of RNA interference (RNAi). Methods: The efficiency of gene silencing was documented by means of Northern blotting, immunoblotting, and skin prick testing. Results: Quantification of the remaining protein revealed that profilin accumulation in transgenic fruits was decreased 10-fold compared with that seen in untransformed controls. This decrease was sufficient to cause a reduced allergenic reactivity in patients with tomato allergy, as determined with skin prick tests. Because most patients with tomato allergy are not monosensitized to profilin, the IgE reactivity to the profilin-silenced tomato fruits in vivo varied widely between individuals tested. Conclusion: We could demonstrate the efficient silencing of both profilin genes in transgenic tomato plants using RNAi This resulted in Lyc a 1-diminished tomato fruits, providing proof of concept and demonstrating that RNAi can be used to design allergen-reduced food. However, simultaneous silencing of multiple allergens will be required to design hypoallergenic tomatoes. Clinical implications: Our findings demonstrate the feasibility of creating low-allergenic food by using RNAL This concept constitutes a novel approach to allergen avoidance.	Univ Erlangen Nurnberg, Lehrstuhl Biochem, Dept Biochem, D-91058 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Dermatol, Univ Hosp, D-8520 Erlangen, Germany; Paul Ehrlich Inst, Langen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; Paul Ehrlich Institute	Sonnewald, U (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Biochem, Dept Biochem, Staudtstr 5, D-91058 Erlangen, Germany.	usonne@biologie.uni-erlangen.de	Scheurer, Stephan/A-6509-2019; Sonnewald, Uwe/J-7875-2012	Scheurer, Stephan/0000-0002-2859-562X; Sonnewald, Uwe/0000-0003-1835-5339				Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Bolhaar STHP, 2005, INT ARCH ALLERGY IMM, V136, P45, DOI 10.1159/000082584; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Crespo JF, 2006, MOL NUTR FOOD RES, V50, P282, DOI 10.1002/mnfr.200500200; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; Dreborg S., 1989, ALLERGY S10, V44, P31; Foetisch K, 2001, EUR FOOD RES TECHNOL, V213, P259, DOI 10.1007/s002170100343; Gilissen LJWJ, 2005, J ALLERGY CLIN IMMUN, V115, P364, DOI 10.1016/j.jaci.2004.10.014; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; Herman EM, 2003, PLANT PHYSIOL, V132, P36, DOI 10.1104/pp.103.021865; *INT UN IMM SOC, OFF LIST ALL MAINT; Kandasamy MK, 2002, CELL MOTIL CYTOSKEL, V52, P22, DOI 10.1002/cm.10029; Karimi M, 2002, TRENDS PLANT SCI, V7, P193, DOI 10.1016/S1360-1385(02)02251-3; Kondo Y, 2001, INT ARCH ALLERGY IMM, V126, P294, DOI 10.1159/000049526; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE QL, 2006, J PLANT BIOTECHNOL, V4, P231; Ling HQ, 1998, PLANT CELL REP, V17, P843, DOI 10.1007/s002990050495; Mahler V, 2000, CLIN EXP ALLERGY, V30, P509; McKinney EC, 2001, PLANT CELL, V13, P1179, DOI 10.1105/tpc.13.5.1179; Ramachandran S, 2000, PLANT PHYSIOL, V124, P1637, DOI 10.1104/pp.124.4.1637; Reindl J, 2002, INT ARCH ALLERGY IMM, V128, P105, DOI 10.1159/000059400; Rodriguez-Perez R, 2003, ALLERGY, V58, P635, DOI 10.1034/j.1398-9995.2003.00198.x; Scheurer S, 2000, CLIN EXP ALLERGY, V30, P962, DOI 10.1046/j.1365-2222.2000.00821.x; Scheurer S, 2001, J CHROMATOGR B, V756, P315, DOI 10.1016/S0378-4347(01)00090-1; SLATER A, 1985, PLANT MOL BIOL, V5, P137, DOI 10.1007/BF00015677; Tada Y, 1996, FEBS LETT, V391, P341, DOI 10.1016/0014-5793(96)00773-9; Vidya CSS, 1999, J BIOSCIENCE, V24, P287, DOI 10.1007/BF02941242; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; Westphal S, 2003, EUR J BIOCHEM, V270, P1327, DOI 10.1046/j.1432-1033.2003.03503.x; Westphal S, 2004, ALLERGY, V59, P526, DOI 10.1046/j.1398-9995.2003.00413.x; Willerroider M, 2003, INT ARCH ALLERGY IMM, V131, P245, DOI 10.1159/000072136	32	65	69	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1176	1183		10.1016/j.jaci.2006.06.031	http://dx.doi.org/10.1016/j.jaci.2006.06.031			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137GY	17088146				2022-12-18	WOS:000244282300026
J	Laforest, L; Van Ganse, E; Devouassoux, G; Bousquet, J; Chretin, S; Bauguil, G; Pacheco, Y; Chamba, G				Laforest, Laurent; Van Ganse, Eric; Devouassoux, Gilles; Bousquet, Jean; Chretin, Stephanie; Bauguil, Gisele; Pacheco, Yves; Chamba, Genevieve			Influence of patients' characteristics and disease management on asthma control	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; control; therapy; sex; smoking; primary care	QUALITY-OF-LIFE; CIGARETTE-SMOKING; CARE; ADULTS; PROPIONATE; REDUCTION; INHALER; WEIGHT	Background: Although asthma control is a major outcome in disease management, little is known about its determinants. Objectives: We sought to study the relationships between asthma control and patient characteristics or asthma management. Methods: Asthmatic patients (age 18-50 years) who were regular customers of pharmacies and had a prescription for an antiasthma medication were recruited consecutively. Patients completed a questionnaire, which was complemented by computerized pharmacy records of previously dispensed medications. Asthma control (adequate/inadequate) was assessed with the Asthma Control Test. Determinants of asthma control were identified by means of multivariate logistic regression analysis. Results: The mean age of the 1351 patients included was 36.8 years (SD, 9.8), and 55.8% were women. A minority of patients were considered to have had their symptoms adequately controlled. Smoking, female sex, and a body mass index of greater than 30 kg/m(2) were all independent determinants of inadequate control. Compared with patients receiving inhaled corticosteroid monotherapy, those who were dispensed fixed combinations of inhaled corticosteroids and long-acting agonists presented with a significantly lower risk of inadequate asthma control (odds ratio, 0.58; 95% CI, 0.35-0.96). Conclusion: Asthma control varied according to both the patients' characteristics and therapy. Clinical implications: Our results strongly support the need to improve asthma control, especially in primary care and in women. A regular use of fixed controller combinations, helping patients to quit smoking, or addressing weight issues might contribute to improvement in asthma control.	Unit Pharmacoepidemiol, EA 3091, Oullins, France; Resp Med, EA 3091, Oullins, France; Resp Med, Montpellier, France; Univ Lyon 1, Fac Pharm, F-69365 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Van Ganse, E (corresponding author), Fac Med Lyon Sud, Unite Pharmacoepidemiol, EA 3091, 165 Chemin Grand Revoyet,BP 12, F-69921 Oullins, France.	eric.vanganse@recherche.univ-lyon1.fr	VAN GANSE, Eric/D-5876-2015; Bousquet, Jean/O-4221-2019	VAN GANSE, Eric/0000-0002-7463-9187; 				Adams RJ, 2003, J ALLERGY CLIN IMMUN, V112, P445, DOI 10.1067/mai.2003.1625; [Anonymous], GLOB IN ASTHM GLOB S; Aubier M, 1999, RESP MED, V93, P876, DOI 10.1016/S0954-6111(99)90053-7; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chinn S, 2003, J ASTHMA, V40, P1, DOI 10.1081/JAS-120017202; de Marco R, 2003, ALLERGY, V58, P221, DOI 10.1034/j.1398-9995.2003.00059.x; Floreani A A, 1999, Curr Opin Pulm Med, V5, P38, DOI 10.1097/00063198-199901000-00007; Krishnan JA, 2004, AM J RESP CRIT CARE, V170, P1281, DOI 10.1164/rccm.200403-409OC; Laforest L, 2006, EUR RESPIR J, V27, P42, DOI 10.1183/09031936.06.00035805; Laforest L, 2005, ALLERGY, V60, P1505, DOI 10.1111/j.1398-9995.2005.00923.x; Laforest L, 2005, ANN ALLERG ASTHMA IM, V94, P473, DOI 10.1016/S1081-1206(10)61118-0; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nelson HS, 2003, J ALLERGY CLIN IMMUN, V112, P29, DOI 10.1067/mai.2003.1558; Osborne ML, 1998, AM J RESP CRIT CARE, V157, P123, DOI 10.1164/ajrccm.157.1.9612063; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Santillan AA, 2003, INT J OBESITY, V27, P1430, DOI 10.1038/sj.ijo.0802395; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P564, DOI 10.1016/j.jaci.2004.12.005; Sippel JM, 1999, CHEST, V115, P691, DOI 10.1378/chest.115.3.691; Soriano JB, 2003, J ASTHMA, V40, P803, DOI 10.1081/JAS-120023572; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Suzuki K, 2003, J ASTHMA, V40, P243, DOI 10.1081/JAS-120018317; Tonnesen P, 2005, NICOTINE TOB RES, V7, P139, DOI 10.1080/14622200412331328411; Van Ganse E, 2002, EUR RESPIR J, V20, P260, DOI 10.1183/09031936.02.02542001; Van Ganse E, 2001, J ASTHMA, V38, P637, DOI 10.1081/JAS-100107541; Vollmer WM, 2004, ANN ALLERG ASTHMA IM, V93, P409, DOI 10.1016/S1081-1206(10)61406-8; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Weiner P, 2002, CHEST, V122, P197, DOI 10.1378/chest.122.1.197; Young SYN, 2001, ARCH INTERN MED, V161, P1605, DOI 10.1001/archinte.161.13.1605	28	65	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1404	1410		10.1016/j.jaci.2006.03.007	http://dx.doi.org/10.1016/j.jaci.2006.03.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751004				2022-12-18	WOS:000238332300030
J	Castigli, E; Geha, RS				Castigli, E; Geha, RS			Molecular basis of common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						common variable immunodeficiency; IgA deficiency; TNF receptor; B cells; transmembrane activator and calcium-modulator and cyclophilin lignad interactor mutations	CELL-ACTIVATING FACTOR; B-CELLS; BAFF RECEPTOR; TNF FAMILY; SOMATIC HYPERMUTATION; AFFINITY MATURATION; IGA EXPRESSION; MICE LACKING; TACI; APRIL	Common variable immunodeficiency (CVID) is the most prevalent human primary immunodeficiency requiring medical attention. Until recently, the only known genetic defect specific to CVID was the inducible costimulatory receptor (ICOS) deficiency, which accounts for less than 1% of the patients. Recently, mutations in the TNF receptor family member transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI), which mediates isotype switching in B cells, were found to be present in 10% to 20% of patients with CVID. Mutations in TACI were also found in relatives of patients with CVID who had IgA deficiency (IgAD),as well as in a patient with isolated IgAD. In the majority of patients described to date, only one TACI allele is mutated, showing an autosomal dominant transmission of the disease. B cells from individuals with TACI mutations did not produce IgG and IgA in response to the TACI ligand a proliferation-inducing ligand (APRIL), probably reflecting impaired isotype switching. These results suggest (hat TACI mutations can lead to CVID and IgAD.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Castigli, E (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	emanuela.castigli@childrens.harvard.edu						Ahonen CL, 2002, NAT IMMUNOL, V3, P451, DOI 10.1038/ni792; Andersen P, 2005, BLOOD, V105, P511, DOI 10.1182/blood-2003-12-4359; Asano T, 2004, CLIN EXP IMMUNOL, V136, P284, DOI 10.1111/j.1365-2249.2004.02440.x; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Bonhomme D, 2000, J IMMUNOL, V165, P4725, DOI 10.4049/jimmunol.165.8.4725; Burrows PD, 1997, ADV IMMUNOL, V65, P245, DOI 10.1016/S0065-2776(08)60744-0; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Castigli E, 2004, P NATL ACAD SCI USA, V101, P3903, DOI 10.1073/pnas.0307348101; Cunningham-Rundles C, 2001, J CLIN IMMUNOL, V21, P303, DOI 10.1023/A:1012241117984; Di Renzo M, 2004, CLIN EXP MED, V3, P211, DOI 10.1007/s10238-004-0027-2; Eastwood D, 2004, CLIN EXP IMMUNOL, V137, P584, DOI 10.1111/j.1365-2249.2004.02581.x; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Gross JA, 2001, IMMUNITY, V15, P289, DOI 10.1016/S1074-7613(01)00183-2; He B, 2004, J IMMUNOL, V173, P4479, DOI 10.4049/jimmunol.173.7.4479; Hendriks J, 2005, CELL DEATH DIFFER, V12, P637, DOI 10.1038/sj.cdd.4401647; Hymowitz SG, 2005, J BIOL CHEM, V280, P7218, DOI 10.1074/jbc.M411714200; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; ISLAM KB, 1991, INT IMMUNOL, V3, P1099, DOI 10.1093/intimm/3.11.1099; ISLAM KB, 1994, J IMMUNOL, V152, P1442; Jabara HH, 2005, J ALLERGY CLIN IMMUN, V115, P856, DOI 10.1016/j.jaci.2005.01.020; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Kokron CM, 2004, AN ACAD BRAS CIENC, V76, P707, DOI 10.1590/S0001-37652004000400007; Kralovicova J, 2000, Bratisl Lek Listy, V101, P24; Levy Y, 1998, P NATL ACAD SCI USA, V95, P13135, DOI 10.1073/pnas.95.22.13135; LIN YCA, 1992, J IMMUNOL, V149, P2914; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Lopez-Fraga M, 2001, EMBO REP, V2, P945, DOI 10.1093/embo-reports/kve198; Mackay F, 2002, CURR OPIN IMMUNOL, V14, P783, DOI 10.1016/S0952-7915(02)00407-7; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Mao C, 2001, J IMMUNOL, V167, P1522, DOI 10.4049/jimmunol.167.3.1522; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood-2004-11-4512; Ni CZ, 2004, J IMMUNOL, V173, P7394, DOI 10.4049/jimmunol.173.12.7394; NILSSON L, 1995, INT IMMUNOL, V7, P1191, DOI 10.1093/intimm/7.8.1191; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Park SR, 2001, EUR J IMMUNOL, V31, P1706, DOI 10.1002/1521-4141(200106)31:6<1706::AID-IMMU1706>3.0.CO;2-Z; Qiu G, 1998, J IMMUNOL, V161, P2906; Rahman ZSM, 2003, J EXP MED, V198, P1157, DOI 10.1084/jem.20030495; Reyes-Moreno C, 2004, J BIOL CHEM, V279, P7799, DOI 10.1074/jbc.M313168200; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; Salzer U, 2005, CURR OPIN ALLERGY CL, V5, P496, DOI 10.1097/01.all.0000191887.89773.cc; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2004, CLIN IMMUNOL, V113, P234, DOI 10.1016/j.clim.2004.07.002; Sasaki Y, 2004, J IMMUNOL, V173, P2245, DOI 10.4049/jimmunol.173.4.2245; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schroeder HW, 2004, J INVEST MED, V52, P90, DOI 10.1136/jim-52-02-17; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Shi MJ, 2001, INT IMMUNOL, V13, P733, DOI 10.1093/intimm/13.6.733; Shulga-Morskaya S, 2004, J IMMUNOL, V173, P2331, DOI 10.4049/jimmunol.173.4.2331; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Tafuri A, 2001, NATURE, V409, P105, DOI 10.1038/35051113; von Bulow GU, 2000, MAMM GENOME, V11, P628, DOI 10.1007/s003350010125; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Wang ZG, 1999, CLIN IMMUNOL, V91, P263, DOI 10.1006/clim.1999.4702; WARNATZ K, 2005, BLOOD           1229; Weston SA, 2001, CLIN EXP IMMUNOL, V124, P465, DOI 10.1046/j.1365-2249.2001.01556.x; Wong SC, 2003, BLOOD, V102, P1381, DOI 10.1182/blood-2002-08-2416; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790; Yang M, 2005, J IMMUNOL, V175, P2814, DOI 10.4049/jimmunol.175.5.2814; Zelazowski P, 1997, J IMMUNOL, V159, P3133; Zhang X, 2005, INT IMMUNOL, V17, P779, DOI 10.1093/intimm/dxh259	68	65	70	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					740	746		10.1016/j.jaci.2006.01.038	http://dx.doi.org/10.1016/j.jaci.2006.01.038			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630927				2022-12-18	WOS:000236862800002
J	Tavernier, G; Fletcher, G; Gee, I; Watson, A; Blacklock, G; Francis, H; Fletcher, A; Frank, T; Frank, P; Pickering, CA; Niven, R				Tavernier, G; Fletcher, G; Gee, I; Watson, A; Blacklock, G; Francis, H; Fletcher, A; Frank, T; Frank, P; Pickering, CA; Niven, R			IPEADAM study: Indoor endotoxin exposure, family status, and some housing characteristics in English children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						childhood asthma; Der p 1; endotoxin; indoor pollutants; dampness; environmental tobacco smoke; volatile organic compound; nitrogen dioxide; formaldehyde	VOLATILE ORGANIC-COMPOUNDS; DUST MITE ALLERGEN; CHILDHOOD ASTHMA; MANCHESTER ASTHMA; HOME-ENVIRONMENT; YOUNG-CHILDREN; TOBACCO-SMOKE; GERMAN HOMES; EARLY-LIFE; RISK	Background: Many environmental factors have been investigated to determine their involvement in the asthma epidemic. Objective: We sought to investigate the indoor environment of English children. Method: The Indoor Pollutants, Endotoxin, Allergens, Damp and Asthma in Manchester (IPEADAM) study recruited 200 asthmatic and age-, sex-, and sibship size-matched nonasthmatic children after a questionnaire-based community screening epidemiology survey. Their homes were sampled for several indoor air factors, and reservoir dust samples were obtained. Endotoxin, Der p 1, and dampness levels were assayed. Questionnaires were administered to record housing characteristics. Indoor pollutants, including environmental tobacco smoke, volatile organic compounds, nitrogen dioxide, formaldehyde, temperature., and relative humidity, were investigated. STATA univariate and multivariate analyses were used to compare the indoor environments of the children. Results: The levels of endotoxin (adjusted odds ratio, 1.88; 95% CI, 1.11-3.18; P = .018), living in a single-parent family (adjusted odds ratio, 3.89; 95% CI, 1.25-12.1; P = .019), redecoration in the living room (adjusted odds ratio, 3.15; 95% CI, 1.36-7.33; P = .008), and self-reported absence of dampness (adjusted odds ratio, 0.36; 95% CI, 0.14-0.91; P = .030) were all independent predictive factors of asthma. There was no difference between asthmatic and healthy children in their exposure to Der p 1, objective measurements of dampness, guardian's smoking habits, pet ownership, house type or age, time in residence, central heating systems, insulation types, glazing systems, floor types, and age and measurements of several indoor pollutants. Conclusion: The IPEADAM study has shown that there were very few differences in the indoor environments of English asthmatic and nonasthmatic children. However, once asthma has been established, the presence of endotoxin is positively associated with an asthmatic child's living room carpet reservoir dust. Clinical implications: There are no direct clinical implications of this research, although it needs interpreting with other clinical data on endotoxin exposure in epidemiologic settings.	Wythenshawe Hosp, NW Lung Res Ctr, Manchester M23 9LT, Lancs, England; Manchester Metropolitan Univ, ARIC, Dept Geog & Environm Sci, Manchester M15 6BH, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Manchester Metropolitan University	Niven, R (corresponding author), Wythenshawe Hosp, NW Lung Res Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.	Robert.niven@smuht.nwest.nhs.uk	Gee, Ivan/GZL-8287-2022	Niven, Robert/0000-0003-2249-960X; Frank, Timothy/0000-0002-1580-8980; Gee, Ivan/0000-0001-7684-3563				ASTM C., 2002, ANN BOOK ASTM, V4, P349; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Baker D, 1999, J EPIDEMIOL COMMUN H, V53, P636, DOI 10.1136/jech.53.10.636; Bischof W, 2002, INDOOR AIR, V12, P2, DOI 10.1034/j.1600-0668.2002.120102.x; BOUSHEY HA, 1995, ENVIRON HEALTH PERSP, V103, P229, DOI 10.2307/3432378; Butland BK, 1997, THORAX, V52, P618, DOI 10.1136/thx.52.7.618; Carrington J, 2001, INDOOR BUILT ENVIRON, V10, P214; Carter PM, 2003, ANN ALLERG ASTHMA IM, V90, P41, DOI 10.1016/S1081-1206(10)63612-5; Cooper JF, 1997, PDA J PHARM SCI TECH, V51, P2; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Dennekamp M, 2001, OCCUP ENVIRON MED, V58, P511, DOI 10.1136/oem.58.8.511; Diez U, 2003, INT J HYG ENVIR HEAL, V206, P173, DOI 10.1078/1438-4639-00218; Feijen M, 2000, BRIT MED BULL, V56, P894, DOI 10.1258/0007142001903580; FRANK TI, 1999, INDOOR AIR, V2, P564; Frank TL, 1999, EUR RESPIR J, V14, P1190, DOI 10.1183/09031936.99.14511909; Gee IL, 1998, CHEMOSPHERE, V36, P2497, DOI 10.1016/S0045-6535(97)10217-X; Gehring U, 2004, INDOOR AIR, V14, P284, DOI 10.1111/j.1600-0668.2004.00244.x; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Gomzi M, 1999, ATMOS ENVIRON, V33, P4081, DOI 10.1016/S1352-2310(99)00149-1; HARRISON PTC, 1998, ISSUES ENV SCI TECHN, V10, P101; Joesch JM, 1997, SOC BIOL, V44, P159; Jones AP, 2000, J ASTHMA, V37, P103, DOI 10.3109/02770900009055434; KALRA S, 1992, THORAX, V47, P928, DOI 10.1136/thx.47.11.928; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; LEIKAUF GD, 1995, ENVIRON HEALTH PERSP, V103, P253, DOI 10.2307/3432382; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641, DOI 10.1164/ajrccm.154.6.8970348; MITCHELL EA, 1989, INT J EPIDEMIOL, V18, P888, DOI 10.1093/ije/18.4.888; *NAT ASTHM CAMP, 2002, ASTHMA J, V8; Niven R, 2003, CLIN EXP ALLERGY, V33, P273, DOI 10.1046/j.1365-2745.2003.01618.x; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388, DOI 10.1136/oem.52.6.388; Ormstad H, 2000, TOXICOLOGY, V152, P53, DOI 10.1016/S0300-483X(00)00292-4; Pilotto LS, 1997, INT J EPIDEMIOL, V26, P788, DOI 10.1093/ije/26.4.788; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; Rumchev KB, 2002, EUR RESPIR J, V20, P403, DOI 10.1183/09031936.02.00245002; SCHOBINGER R, 1992, J PSYCHOSOM RES, V36, P743, DOI 10.1016/0022-3999(92)90132-L; Shooter D, 1997, ENVIRON TECHNOL, V18, P243, DOI 10.1080/09593331808616534; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; STRACHAN DP, 1989, J EPIDEMIOL COMMUN H, V43, P7, DOI 10.1136/jech.43.1.7; TAVEMIER G, 2004, EUR RESPIR J, V24, pS268; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; von Mutius E, 2001, CLIN EXP ALLERGY, V31, P1651, DOI 10.1046/j.1365-2222.2001.01272.x; Wamboldt FS, 2002, J PEDIATR-US, V141, P109, DOI 10.1067/mpd.2002.125490; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; [No title captured]	47	65	67	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					656	662		10.1016/j.jaci.2005.12.1311	http://dx.doi.org/10.1016/j.jaci.2005.12.1311			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522467				2022-12-18	WOS:000236263100023
J	Juhn, YJ; Weaver, A; Katusic, S; Yunginger, J				Juhn, YJ; Weaver, A; Katusic, S; Yunginger, J			Mode of delivery at birth and development of asthma: A population-based cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mode of delivery; childhood asthma; wheezing episode; birth cohort; cesarean section	DAY-CARE ATTENDANCE; SCHOOL-AGE; ALLERGIC DISEASE; RESPIRATORY-INFECTIONS; CESAREAN DELIVERY; EARLY EXPOSURE; LUNG-FUNCTION; RISK-FACTOR; CHILDREN; ATOPY	Background: To test the hygiene hypothesis, previous studies have assessed the relationship between mode of delivery at birth and asthma incidence, but the results have been inconsistent because of potential selection and ascertainment biases. Objective: To assess the relationship between mode of delivery at birth and asthma by following all children born in Rochester, Minn, between 1976 and 1982. Methods: From the birth certificate, we determined mode of delivery (cesarean section vs vaginal delivery). Asthma status during the first 7 years of life was ascertained from comprehensive medical record reviews. The association between mode of delivery and asthma status was evaluated in a proportional hazards model adjusted for sex, birth weight, maternal education, and maternal age. Results: The cumulative incidence rates of asthma among children who were born by cesarean section and vaginal delivery were 3.2% versus 2.6%, 4.6% versus 4.6%, 4.6% versus 5.8%, and 5.7% versus 6.7% at the 1st, 3rd, 5th, and 7th years of life, respectively. The adjusted hazard ratios for cesarean section in predicting asthma and wheezing episode were 0.93 (95% CI, 0.6-1.4; P =.71) and 0.93 (95% CI, 0.7-1.3; P = .67), respectively. Conclusion: Mode of delivery is not associated with subsequent risk of developing childhood asthma or wheezing episodes. Because the effect of mode of delivery on a risk of developing asthma or wheezing episodes varies over time (ie, age), selection of the study subjects according to their ages may have influenced the findings of previous studies with a shorter follow-up period.	Mayo Clin, Dept Pediat & Adolescent Med, Div Community Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Juhn, YJ (corresponding author), Mayo Clin, Dept Pediat & Adolescent Med, Div Community Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.	juhn.young@mayo.edu						Annesi-Maesano I, 2001, ALLERGY, V56, P491, DOI 10.1034/j.1398-9995.2001.056006491.x; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BRAVEMAN P, 1995, AM J PUBLIC HEALTH, V85, P625, DOI 10.2105/AJPH.85.5.625; *BUR CENS, PHC802305 BUR CENS; Carlisle DM, 1996, J HEALTH CARE POOR U, V7, P308; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1022; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; GERGEN PJ, 1988, PEDIATRICS, V81, P1; Gern JE, 2003, J PEDIATR-US, V142, pS9, DOI 10.1067/mpd.2003.20; Gern JE, 2003, PEDIATR CLIN N AM, V50, P555, DOI 10.1016/S0031-3955(03)00040-3; Gern JE, 2003, J PEDIAT, V142, pS13; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Guyatt GH, 1997, PEDIATRICS, V99, P165, DOI 10.1542/peds.99.2.165; Hin L Y, 1994, Asia Oceania J Obstet Gynaecol, V20, P389; JOHNSON NP, 1995, NEW ZEAL MED J, V108, P511; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Katusic SK, 2001, MAYO CLIN PROC, V76, P1081, DOI 10.4065/76.11.1081; Katusic SK, 1996, AM J MENT RETARD, V100, P335; Katusic SK, 1998, MAYO CLIN PROC, V73, P1053, DOI 10.4065/73.11.1053; Kero J, 2002, PEDIATR RES, V52, P6, DOI 10.1023/01.PDR.0000017263.01840.F0; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; Lemanske RF, 2003, CHEST, V123, p385S, DOI 10.1378/chest.123.3_suppl.385S-a; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Lwebuga-Mukasa JS, 2000, J URBAN HEALTH, V77, P745, DOI 10.1007/BF02344035; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; MARIAN J, 1979, MOL PHARMACOL, V16, P196; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P800, DOI 10.1067/mai.2002.124046; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MILLER J, 2001, EARLY CHILDHOOD CHRO; Nafstad P, 2000, J ALLERGY CLIN IMMUN, V106, P867, DOI 10.1067/mai.2000.110558; Nafstad P, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e38; Nja F, 2003, ARCH DIS CHILD, V88, P566, DOI 10.1136/adc.88.7.566; Nystad W, 1999, INT J EPIDEMIOL, V28, P882, DOI 10.1093/ije/28.5.882; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romagnani S, 1998, ALLERGY, V53, P12, DOI 10.1111/j.1398-9995.1998.tb04951.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Shy K, 2000, AM J OBSTET GYNECOL, V182, P1363, DOI 10.1067/mob.2000.106175; Sotir M, 2003, ENVIRON HEALTH PERSP, V111, P657, DOI 10.1289/ehp.5824; STROPE GL, 1991, AM REV RESPIR DIS, V144, P655, DOI 10.1164/ajrccm/144.3_Pt_1.655; Svanes C, 2002, THORAX, V57, P945, DOI 10.1136/thorax.57.11.945; Taffel S M, 1994, Vital Health Stat 21, P1; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Umetsu DT, 2004, NAT MED, V10, P232, DOI 10.1038/nm0304-232; VANENK A, 1990, INT J GYNECOL OBSTET, V33, P307, DOI 10.1016/0020-7292(90)90515-M; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189, DOI 10.1001/archpedi.1990.02150350021016; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; Xu BZ, 2000, J ASTHMA, V37, P589, DOI 10.3109/02770900009090814; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	61	65	65	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					510	516		10.1016/j.jaci.2005.05.043	http://dx.doi.org/10.1016/j.jaci.2005.05.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159617	Bronze			2022-12-18	WOS:000235686500006
J	Schedel, M; Carr, D; Klopp, N; Woitsch, B; Illig, T; Stachel, D; Schmid, I; Fritzsch, C; Weiland, SK; von Mutius, E; Kabesch, M				Schedel, M; Carr, D; Klopp, N; Woitsch, B; Illig, T; Stachel, D; Schmid, I; Fritzsch, C; Weiland, SK; von Mutius, E; Kabesch, M			A signal transducer and activator of transcription 6 haplotype influences the regulation of serum IgE levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						STAT6; atopy; IgE; IL-4 pathway; SNP	GENE; STAT6; POLYMORPHISM; ASSOCIATION; LINKAGE; ASTHMA; CHILDREN	Background: Because of its central role in the IL-4/IL,43 pathway, the intracellular signaling molecule signal transducer and activator of transcription 6 (STAT6) may be crucial for IgE production in asthma and allergy. Objective: We analyzed the association between polymorphisms in the STAT6 gene and the regulation of serum IgE levels. Methods: In a population of 1120 German schoolchildren (age 9-11 years), we genotyped 6 previously identified polymorphisms spanning the STAT6 gene by using the matrix-assisted laser desorption ionization-time of flight mass spectrometry method. Haplotypes were estimated and population-derived IgE percentiles (50% IgE > 60 IU/mL, 66% IgE > 115 IU/mL, and 90% IgE > 457 IU/mL) were modeled as outcome variables in haplotype-trend regression analysis. Results: Polymorphisms located in intron 2 (C2892T) and the 3' untranslated region (T12888C) significantly and consistently contributed to elevated total serum IgE levels. One STAT6 haplotype showed increased odds ratios of 1.58 (95% CI, 1.08-2.32; P = .020), 1.82 (95% Cl, 1.19-2.77; P =.006), and 3.92 (95% CI, 1.93-7.96; P = .0002) for elevated IgE levels at percentiles 50%, 66%, and 90%, respectively. Because C2892T is located within a nuclear factor kappaB transcription factor binding site, a functional role of this polymorphism is very likely. Conclusion: The data indicate that within the IL-4/IL,43 pathway, genetic variants in the STAT6 gene significantly contribute to the regulation of serum IgE levels.	Univ Munich, Childrens Hosp, D-80337 Munich, Germany; GSF, Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Univ Childrens Hosp, Erlangen, Germany; Univ Childrens Hosp, Leipzig, Germany; Univ Ulm, Inst Epidemiol, Ulm, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Erlangen Nuremberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University	Kabesch, M (corresponding author), Univ Munich, Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Michael.Kabesch@med.uni-muenchen.de	Kabesch, Michael/AAB-5701-2020; Kabesch, Michael/GZM-1583-2022; Schedel, Michaela/B-3065-2019	Schedel, Michaela/0000-0001-8465-2986; von Mutius, Erika/0000-0002-8893-4515				Abecasis GR, 2001, AM J HUM GENET, V68, P191, DOI 10.1086/316944; Barnes KC, 1999, J ALLERGY CLIN IMMUN, V104, P485, DOI 10.1016/S0091-6749(99)70398-2; Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; Botto LD, 2001, AM J EPIDEMIOL, V153, P1016, DOI 10.1093/aje/153.10.1016; Di Marco S, 2001, NUCLEIC ACIDS RES, V29, P863, DOI 10.1093/nar/29.4.863; Duetsch G, 2002, HUM MOL GENET, V11, P613, DOI 10.1093/hmg/11.6.613; Gao PS, 2000, J MED GENET, V37, P380; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V112, P893, DOI 10.1016/j.jaci.2003.08.033; Kaplan MH, 1999, J IMMUNOL, V163, P6536; Kelly-Welch AE, 2003, SCIENCE, V300, P1527, DOI 10.1126/science.1085458; Marsh DG, 1997, NAT GENET, V15, P389; MEYERS DA, 1987, AM J HUM GENET, V41, P51; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; *SAS, 2002, SAS 2 SAS GEN US GUI; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Stutz AM, 1999, J IMMUNOL, V163, P4383; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Tamura K, 2001, CLIN EXP ALLERGY, V31, P1509, DOI 10.1046/j.1365-2222.2001.01191.x; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	26	65	70	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1100	1105		10.1016/j.jaci.2004.07.048	http://dx.doi.org/10.1016/j.jaci.2004.07.048			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536416				2022-12-18	WOS:000225047800016
J	Quarcoo, D; Weixler, S; Groneberg, D; Joachim, R; Ahrens, B; Wagner, AH; Hecker, M; Hamelmann, E				Quarcoo, D; Weixler, S; Groneberg, D; Joachim, R; Ahrens, B; Wagner, AH; Hecker, M; Hamelmann, E			Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD40; vascular cell adhesion molecule 1; asthma; bronchial hyperreactivity	B-CELL ACTIVATION; FACTOR-KAPPA-B; INTERFERON-GAMMA; MOUSE MODEL; CD40 LIGAND; DECOY OLIGODEOXYNUCLEOTIDE; ADHESION MOLECULES; ENDOTHELIAL-CELLS; GENE-EXPRESSION; GROWTH-FACTOR	Background: Transcriptional factors of the signal transducer and activator of transcription (STAT) family play an important role in orchestrating immune reactions. Objective: The aim of the current study was to investigate the role of STAT-1 in murine allergen-induced sensitization and development of airway inflammation (At) and airway hyperreactivity (AHR), cardinal features of bronchial asthma. Methods: BALB/c mice were systemically sensitized to ovalbumin and challenged with ovalbumin through the airways. Decoy oligonucleotide (ODN) specific for STAT-I was applied once locally to the airways of sensitized animals before allergen airway challenges. Results: Single application of decoy ODN markedly and significantly reduced numbers of eosinophils and lymphocytes in bronchoalveolar lavage fluids compared with those seen in sensitized and challenged animals receiving mutant control ODN. Associated with this decrease in eosinophilic AI were significantly reduced levels of IL-5 in BAL fluid, of CD40 expression in peribronchial infiltrates, and of vascular cell adhesion molecule 1 expression in vascular endothelial cells, respectively. In addition, development of AHR after allergen sensitization and airway challenges was effectively abolished after local STAT-1 decoy ODN treatment. Conclusion: The data indicate that a decoy ODN neutralizing STAT-1 effectively inhibits allergen-induced All and AHR, probably by attenuating upregulation of costimulatory and adhesion molecules, and suggest a significant role of STAT-1 in asthma pathology.	Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Humboldt Univ, Charite, Dept Internal Med, D-13353 Berlin, Germany; Univ Gottingen, Dept Cardiovasc Physiol, D-3400 Gottingen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Gottingen	Hamelmann, E (corresponding author), Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	eckard.hamelmann@charite.de	Hamelmann, Eckard/AAJ-9124-2021; Groneberg, David/A-5132-2018	Groneberg, David/0000-0001-8551-6556; Quarcoo, David/0000-0001-6398-2118				Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Blotta MH, 1996, J IMMUNOL, V156, P3133; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; Braun A, 1998, EUR J IMMUNOL, V28, P3240, DOI 10.1002/(SICI)1521-4141(199810)28:10<3240::AID-IMMU3240>3.0.CO;2-U; Buchwald AB, 2002, J AM COLL CARDIOL, V39, P732, DOI 10.1016/S0735-1097(01)01797-1; Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291, DOI 10.1164/ajrccm/147.2.291; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; DAMELL JE, 1994, SCIENCE, V264, P1415; De Caterina R, 2001, ARTERIOSCL THROM VAS, V21, P227, DOI 10.1161/01.ATV.21.2.227; De Vita L, 1998, EUR J IMMUNOL, V28, P3552; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; GOSSET P, 1995, INT ARCH ALLERGY IMM, V106, P69, DOI 10.1159/000236892; Groneberg DA, 2001, AM J PATHOL, V158, P707, DOI 10.1016/S0002-9440(10)64013-8; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V120, P8, DOI 10.1159/000024215; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325, DOI 10.1165/ajrcmb.16.3.9070618; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Kelkenberg U, 2002, ARTERIOSCL THROM VAS, V22, P949, DOI 10.1161/01.ATV.0000017198.16727.27; Krzesz R, 1999, FEBS LETT, V453, P191, DOI 10.1016/S0014-5793(99)00683-3; Kudlacz E, 2002, J PHARMACOL EXP THER, V301, P747, DOI 10.1124/jpet.301.2.747; Lei XF, 1998, J CLIN INVEST, V101, P1342, DOI 10.1172/JCI1662; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Miyata S, 1999, CLIN EXP ALLERGY, V29, P114; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; PELLETIER RP, 1992, J IMMUNOL, V149, P2473; Peng XH, 1996, EUR J IMMUNOL, V26, P1621, DOI 10.1002/eji.1830260732; Popper HH, 2002, VIRCHOWS ARCH, V440, P172, DOI 10.1007/s004280100507; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283, DOI 10.1164/ajrccm.160.4.9809065; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Wagner AH, 2002, BLOOD, V99, P520, DOI 10.1182/blood.V99.2.520	45	65	76	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					288	295		10.1016/j.jaci.2004.03.055	http://dx.doi.org/10.1016/j.jaci.2004.03.055			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316505				2022-12-18	WOS:000223405600012
J	Plotz, SG; Traidl-Hoffman, C; Feussner, L; Kasche, A; Feser, M; Ring, J; Jakob, T; Behrendt, H				Plotz, SG; Traidl-Hoffman, C; Feussner, L; Kasche, A; Feser, M; Ring, J; Jakob, T; Behrendt, H			Chemotaxis and activation of human peripheral blood eosinophils induced by pollen-associated lipid mediators	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil granlocytes; chemotaxis; pollen; lipid mediators	LEUKOTRIENE B-4 RECEPTOR; ACID; RELEASE; HEALTH	Background: Eosinophil accumulation at sites of allergic inflammation is largely regulated by chemokines and lipid mediators released by a variety of cells of the local microenvironment. Recent studies have shown that pollen grains, apart from their function as allergen carriers, are a rich exogenous source of eicosanoid-like lipid mediators that are rapidly released on contact with the aqueous phase and thus may contribute to the generation of local inflammatory responses. Objective: Here we analyze the biological activity of pollen-associated lipid mediators (PALMs) on peripheral human blood eosinophils. Methods: Human eosinophils were coincubated with pollen grains and analyzed by electron microscopy. The lipid mediator composition of aqueous pollen extracts (APEs) was analyzed by HPLC. Human eosinophils were exposed to APEs or lipid fractions from pollen. Effects on eosinophils were tested by transwell migration and surface expression of CD11b. Results: In vitro experiments showed adhesion of eosinophils to Phleum pratense pollen. In chemotaxis assays eosinophils displayed significant directed migration to APEs. HPLC analysis of APEs from Phleum pratense and Betula alba pollen demonstrated the occurrence of linoleic and alpha-linolenic acid as well as their monohydroxylated derivatives. Moreover, total lipid extracts from pollen and RP-HPLC fractions containing monohydroxylated derivatives of linoleic and alpha-linolenic acid induced similar migratory responses, although to a lesser degree than APEs. In addition, APEs and lipid extracts induced up-regulation of CD11b surface expression and secretion of eosinophil cationic protein. APE-induced chemotaxis was blocked by the leukotriene B-4 receptor antagonist LY293111, suggesting that PALMs may serve as ligands for LTB4 receptors. Conclusion: Pollen grains release lipid mediators that recruit and activate eosinophils in vitro. Similar mechanisms may be effective under natural exposure conditions, in which PALMs may play a role in the recruitment of eosinophils to the site of allergic inflammation.	Tech Univ Munich, Ctr Allergy & Environm, Div Environm Dermatol & Allergy GSF TUM, D-80802 Munich, Germany; Univ Gottingen, Albrecht Von Haller Int Plant Sci, Dept Plant Biochem, D-3400 Gottingen, Germany; Tech Univ Munich, Dept Dermatol & Allergy, D-80802 Munich, Germany	Technical University of Munich; University of Gottingen; Technical University of Munich	Behrendt, H (corresponding author), Tech Univ Munich, Ctr Allergy & Environm, Div Environm Dermatol & Allergy GSF TUM, Biedersteiner Str 29, D-80802 Munich, Germany.	heidrun.behrendt@lrz.tuni.de	Jakob, Thilo/J-1621-2012; Ring, Johannes/GLN-4341-2022; Feussner, Ivo/H-9320-2013	Ring, Johannes/0000-0001-8236-3152; Feussner, Ivo/0000-0002-9888-7003; Traidl-Hoffmann, Claudia/0000-0001-5085-5179				Angeli W, 2001, EUR J IMMUNOL, V31, P2751, DOI 10.1002/1521-4141(200109)31:9&lt;2751::AID-IMMU2751&gt;3.0.CO;2-4; Behrendt H, 2001, INT ARCH ALLERGY IMM, V124, P121, DOI 10.1159/000053688; Behrendt H, 2001, CURR OPIN IMMUNOL, V13, P709, DOI 10.1016/S0952-7915(01)00283-7; Bianchi E, 1997, IMMUNOL TODAY, V18, P586, DOI 10.1016/S0167-5699(97)01162-6; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; Bock C., 1987, BEITR ELEKTRONENMIKR, V20, P209; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brunekreef B, 2000, LANCET, V355, P1517, DOI 10.1016/S0140-6736(00)02168-1; Engels F, 1996, PROSTAGLANDINS, V52, P117, DOI 10.1016/0090-6980(96)00057-3; Feussner I, 2002, ANNU REV PLANT BIOL, V53, P275, DOI 10.1146/annurev.arplant.53.100301.135248; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; HENRICKS PAJ, 1991, EUR J PHARMACOL, V197, P233, DOI 10.1016/0014-2999(91)90530-4; Jackson WT, 1999, J PHARMACOL EXP THER, V288, P286; Kayaba H, 2001, J IMMUNOL, V167, P995, DOI 10.4049/jimmunol.167.2.995; Liu XH, 1996, CANCER LETT, V109, P223, DOI 10.1016/S0304-3835(96)04462-X; MACKAY JA, 1986, ALLERGY, V41, P169, DOI 10.1111/j.1398-9995.1986.tb00297.x; MULLER MJ, 1998, CHEM BIOL, V12, P323; Plotz SG, 2001, BLOOD, V97, P235, DOI 10.1182/blood.V97.1.235; Schroder JM, 2002, J BIOL CHEM, V277, P27887, DOI 10.1074/jbc.M202998200; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SIEGEL I, 1970, J ALLERGY, V45, P133, DOI 10.1016/0021-8707(70)90123-1; Simon HU, 2000, J IMMUNOL, V165, P4069, DOI 10.4049/jimmunol.165.7.4069; Simon HU, 2000, ALLERGY, V55, P791, DOI 10.1034/j.1398-9995.2000.00030.x; Toborek M, 1997, J LIPID RES, V38, P2155; Traidl-Hoffmann C, 2003, INT ARCH ALLERGY IMM, V131, P1, DOI 10.1159/000070428; Traidl-Hoffmann C, 2002, J ALLERGY CLIN IMMUN, V109, P831, DOI 10.1067/mai.2002.124655; Wang DY, 2000, AM J RHINOL, V14, P325, DOI 10.2500/105065800781329483; Weichert H, 1999, FEBS LETT, V464, P133, DOI 10.1016/S0014-5793(99)01697-X; Yokomizo T, 2001, J BIOL CHEM, V276, P12454, DOI 10.1074/jbc.M011361200	31	65	70	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1152	1160		10.1016/j.jaci.2004.03.011	http://dx.doi.org/10.1016/j.jaci.2004.03.011			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208598	Bronze			2022-12-18	WOS:000222091000022
J	Vissers, JLM; van Esch, BCAM; Hofman, GA; Kapsenberg, ML; Weller, FR; van Oosterhout, AJM				Vissers, JLM; van Esch, BCAM; Hofman, GA; Kapsenberg, ML; Weller, FR; van Oosterhout, AJM			Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; immunotherapy; IL-10; IgE; hyper-responsiveness; eosinophilia; T(H)2 lymphocytes; regulatory T cells; suppression	AIRWAY EOSINOPHILIA; MURINE MODEL; T-CELLS; INDUCTION; ANTIGEN; HYPERRESPONSIVENESS; LYMPHOCYTES; GAMMA	Background: Human studies have demonstrated that allergen immunotherapy induces memory suppressive responses and IL-10 production by allergen-specific T cells. Previously, we established a mouse model in which allergen immunotherapy was effective in the suppression of allergen-induced asthma manifestations. Objective: In this study, we examined whether immunotherapy induces a long-lasting effect and investigated the role of IL-10 in successful immunotherapy. Methods: Ovalbumin-sensitized BALB/c mice were treated with 3 injections of ovalbumin (1 mg, subcutaneous) on alternate days. After a short interval (1 week) and after a long interval (5 weeks), mice were challenged by ovalbumin inhalation, and subsequently, airway reactivity, airway eosinophilia, ovalbumin-specific IgE, and T(H)2 cytokine profile were measured. Flow cytometry and blocking of IL-10 receptors in vivo were used to gain insight in the role of IL-10 in the beneficial effects of allergen immunotherapy. Results: After a long interval between ovalbumin immunotherapy and ovalbumin challenge, the development of airway eosinophilia and hyperresponsiveness to methacholine were as strongly suppressed as after a short interval. These suppressive effects coincided with significantly reduced serum ovalbumin-specific IgE levels and T(H)2 cytokine production. On immunotherapy, the IL-5:IL-10 ratio in the bronchoalveolar lavage fluid shifted toward IL-10. In ovalbumin-restimulated lung cell and thoracic lymph node cultures from these mice, IL-5 levels dramatically decreased, whereas the percentage of IL-10(+)CD4(+) T cells was not affected. Finally, in mice treated with mAb against IL-10 receptors, the beneficial effects of immunotherapy were largely abrogated. Conclusion: These data demonstrate that allergen immunotherapy induces a memory suppressive effect in which IL-10 is essential.	Univ Utrecht, Fac Pharmaceut Sci, Dept Pharmacol & Pathobiol, NL-3584 CA Utrecht, Netherlands; Asthmactr Davos, Hilversum, Netherlands; Asthmactr Heideheuvel, Hilversum, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Histol & Cell Biol, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van Oosterhout, AJM (corresponding author), Univ Utrecht, Fac Pharmaceut Sci, Dept Pharmacol & Pathobiol, Sorbonnelaan 16, NL-3584 CA Utrecht, Netherlands.	A.J.M.vanOosterhout@pharm.uu.nl		van Esch, Betty/0000-0001-9961-750X				ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Barnes PJ, 1996, NEW ENGL J MED, V334, P531, DOI 10.1056/NEJM199602223340811; Becker C, 2001, NAT MED, V7, P1159, DOI 10.1038/nm1001-1159; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P1, DOI 10.1016/0091-6749(94)90064-7; Castro AG, 2000, J EXP MED, V192, P1529, DOI 10.1084/jem.192.10.1529; de Bie JJ, 2000, EXP LUNG RES, V26, P491; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; FINKELMAN FD, 1989, J IMMUNOL, V142, P403; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS712; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325, DOI 10.1165/ajrcmb.16.3.9070618; Hofstra CL, 1999, INFLAMM RES, V48, P602, DOI 10.1007/s000110050510; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nicklas W, 2002, LAB ANIM-UK, V36, P20, DOI 10.1258/0023677021911740; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; SCHWEIZER RC, 1994, BLOOD, V83, P3697; Shevach EM, 2001, J EXP MED, V193, pF41, DOI 10.1084/jem.193.11.F41; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Van Oosterhout AJM, 1998, AM J RESP CELL MOL, V19, P622, DOI 10.1165/ajrcmb.19.4.3112m; Wachholz PA, 2003, CLIN EXP ALLERGY, V33, P1171, DOI 10.1046/j.1365-2222.2003.01765.x	25	65	68	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1204	1210		10.1016/j.jaci.2004.02.041	http://dx.doi.org/10.1016/j.jaci.2004.02.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208606	Bronze			2022-12-18	WOS:000222091000030
J	Chisholm, D; Libet, L; Hayashi, T; Horner, AA				Chisholm, D; Libet, L; Hayashi, T; Horner, AA			Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						toll-like receptor 2; toll-like receptor 9; peptidoglycan; immostimulatory sequence oligodeoxynucleotide; CpG motif; asthma; intranasal vaccination; hygiene hypothesis	TOLL-LIKE RECEPTOR-2; INDUCE DIFFERENT CLASSES; IMMUNE-RESPONSES; CUTTING EDGE; MURINE MODEL; OX40 LIGAND; MOUSE MODEL; CELLS; INFLAMMATION; ANTIGEN	Background: Environmental exposures to toll-like receptor (TLR) ligands have been suggested to provide immunologic protection against allergic diseases. However, some TLRs use unique intracellular signaling pathways, suggesting that ambi-ent TLR ligand exposures might induce a range of host responses. Objective: These investigations compared to peptidglycan (PGN; TLR2)-induced and immunostimulatory sequence DNA oligodeoxynucleotide (ISS-ODN; TLR9)-induced innate responses and determined how airway exposures to these TLR ligands affect adaptive immunity and the asthmatic phenotype. Methods: In in vitro and in vivo studies innate responses to PGN and ISS-ODN, and adaptive immune profiles and responses to airway OVA challenge were assessed. Results: PGN and ISS-ODN induced divergent innate responses predictive of their haveing T(H)2- and T(H)1-biasing adjuvant potential, respectively.Consistent with these findings, mice intrasanally immunized with OVA alone had relatively weak adaptive responses, whereas intrasanal OVA/PGN- and OVA-ISS-ODN-coimmunized mice had much stronger humoral and cellular responses that were T(H)2 and T(H)1 biased, respectively. Finally, on airway allergen challenge, mice intrasanally immunized with OVA alone had modest T(H)2- biased airway hypersensitivity responses, whereas airway responses were greatly exaggerated for intrasanal OVA/PGN-immunized mice. In contrast, intrasanal OVA/ISS-ODN-immunized mice had little evidence of airway hypersensitivity after airway allergen challenge. Conclusions: Considered in a larger context, these results suggest that inspired air is likely to contain TLR ligands capable of both preventing and preciptitating the asthmatic phentype.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Horner, AA (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI040682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047360] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40682] Funding Source: Medline; NIAMS NIH HHS [AR47360] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akbari O, 2003, INT ARCH ALLERGY IMM, V130, P108, DOI 10.1159/000069012; Akiba H, 2000, J EXP MED, V191, P375, DOI 10.1084/jem.191.2.375; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Bradley LM, 1996, J IMMUNOL, V157, P1350; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Broide D, 1998, J IMMUNOL, V161, P7054; Cameron MJ, 2003, ADV EXP MED BIOL, V520, P8; Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026; Dobrovolskaia MA, 2003, J IMMUNOL, V170, P508, DOI 10.4049/jimmunol.170.1.508; Dodge IL, 2003, J IMMUNOL, V170, P4457, DOI 10.4049/jimmunol.170.9.4457; Dziarski R, 2003, CELL MOL LIFE SCI, V60, P1793, DOI 10.1007/s00018-003-3019-6; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Goriely S, 2001, J IMMUNOL, V166, P2141, DOI 10.4049/jimmunol.166.3.2141; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horner AA, 2001, J IMMUNOL, V167, P1584, DOI 10.4049/jimmunol.167.3.1584; Hoshino A, 2003, EUR J IMMUNOL, V33, P861, DOI 10.1002/eji.200323455; Iwaki D, 2002, J BIOL CHEM, V277, P24315, DOI 10.1074/jbc.M107057200; Kline JN, 1998, J IMMUNOL, V160, P2555; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; Pulendran B, 2001, J IMMUNOL, V167, P5067, DOI 10.4049/jimmunol.167.9.5067; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Rharbaoui F, 2002, EUR J IMMUNOL, V32, P2857, DOI 10.1002/1521-4141(2002010)32:10<2857::AID-IMMU2857>3.0.CO;2-R; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Ruedl C, 2000, EUR J IMMUNOL, V30, P2056, DOI 10.1002/1521-4141(200007)30:7<2056::AID-IMMU2056>3.0.CO;2-S; Sin JI, 1999, J IMMUNOL, V162, P2912; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Sur S, 1999, J IMMUNOL, V162, P6284; Takabayashi K, 2003, J IMMUNOL, V170, P3898, DOI 10.4049/jimmunol.170.7.3898; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579	34	65	72	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					448	454		10.1016/j.jaci.2003.12.011	http://dx.doi.org/10.1016/j.jaci.2003.12.011			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007346				2022-12-18	WOS:000220144200016
J	Tinghino, R; Twardosz, A; Barletta, B; Puggioni, EMR; Iacovacci, P; Butteroni, C; Afferni, C; Mari, A; Hayek, B; Di Felice, G; Focke, M; Westritschnig, K; Valenta, R; Pini, C				Tinghino, R; Twardosz, A; Barletta, B; Puggioni, EMR; Iacovacci, P; Butteroni, C; Afferni, C; Mari, A; Hayek, B; Di Felice, G; Focke, M; Westritschnig, K; Valenta, R; Pini, C			Molecular, structural, and immunologic relationships between different families of recombinant calcium-binding pollen allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						calcium-binding allergens; pollen allergy; crossreactivity; recombinant allergens; molecular modeling	BERMUDA GRASS-POLLEN; CROSS-REACTIVITY; IGE-BINDING; PROTEIN; EXPRESSION; RECOGNITION; BET-V-4; CLONING; THERAPY; CA2+	Background: Calcium-binding plant allergens can be grouped in different families according to the number of calcium-binding domains (EF hands). Objective: We sought to identify pollens containing cross. reactive calcium-binding allergens and to investigate structural and immunologic similarities of members belonging to different families of calcium-binding allergens. Methods: By means of multiple sequence alignment and molecular modeling, we searched for structural similarities among pollen allergens with 2 (Phi p 7, timothy grass; Aln g 4, alder), 3 (Bet v 3, birch) and 4 EF hands (Jun o 4, prickly juniper). Purified recombinant Aln g 4 and Jun o 4 were used to determine the prevalence of IgE recognition in 210 patients sensitized to different pollens and to search, by means of ELISA competition, for the presence of cross-reactive epitopes in pollens from 16 unrelated plant species. IgE cross-reactivity among the allergen families was studied with purified rPhI p 7, rAln g 4, rBet v 3, and rJun o 4 and 2 synthetic peptides comprising the N-terminal and C-terminal EF hands of Phi p 7 by means of ELISA competition. Results: Structural similarities were found by using molecular modeling among the allergens with 2, 3, and 4 EF hands. Pollens from 16 unrelated plants contained Aln g 4- and Jun o 4-related epitopes. Twenty-two percent of the patients with multiple pollen sensitization reacted to at least one of the calcium-binding allergens. A hierarchy of IgE cross-reactivity (rPhI p7 > rAln g 4 > rJun o 4 > rBet v 3) could be established that identified rPhI p 7 as the EF-hand allergen containing most IgE epitopes in the population studied. Conclusion: The demonstration that members of different families of calcium-binding plant allergens share similarities suggests that it may be possible to use representative molecules for the diagnosis and therapy of allergies to Er-hand allergens.	Univ Vienna, Vienna Gen Hosp, Dept Pathophysiol, Mol Immunopathol Grp, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Dermatol, Div Immunodermatol, A-1090 Vienna, Austria; Ist Super Sanita, Dept Immunol, I-00161 Rome, Italy; Univ Vienna, Vienna Gen Hosp, Dept Internal Med 4, Div Pulmol, A-1090 Vienna, Austria; Natl Hlth Serv, Allergy Unit, Rome, Italy	University of Vienna; University of Vienna; Istituto Superiore di Sanita (ISS); University of Vienna	Valenta, R (corresponding author), Univ Vienna, Vienna Gen Hosp, Dept Pathophysiol, Mol Immunopathol Grp, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		BARLETTA, BIANCA/B-9980-2016; BUTTERONI, CINZIA/B-9981-2016; Di Felice, Gabriella/B-9985-2016; AFFERNI, CLAUDIA/B-9978-2016	BUTTERONI, CINZIA/0000-0002-3919-5752; Di Felice, Gabriella/0000-0001-7387-9683; AFFERNI, CLAUDIA/0000-0002-8567-7365; Valenta, Rudolf/0000-0001-5944-3365				Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; Engel E, 1997, J BIOL CHEM, V272, P28630, DOI 10.1074/jbc.272.45.28630; Hayek B, 1998, J IMMUNOL, V161, P7031; Ledesma A, 2000, FEBS LETT, V466, P192, DOI 10.1016/S0014-5793(99)01790-1; Mari A, 2001, INT ARCH ALLERGY IMM, V125, P57, DOI 10.1159/000053797; Marlovits TC, 1998, FASEB J, V12, P695, DOI 10.1096/fasebj.12.9.695; MUCCI N, 1992, ALLERGY, V47, P424, DOI 10.1111/j.1398-9995.1992.tb02083.x; Niederberger V, 1999, FASEB J, V13, P843, DOI 10.1096/fasebj.13.8.843; Seiberler S, 1999, INT ARCH ALLERGY IMM, V120, P117, DOI 10.1159/000024229; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; Smith PM, 1997, INT ARCH ALLERGY IMM, V114, P265, DOI 10.1159/000237678; Suphioglu C, 1997, FEBS LETT, V402, P167, DOI 10.1016/S0014-5793(96)01520-7; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tinghino R, 1998, J ALLERGY CLIN IMMUN, V101, P772, DOI 10.1016/S0091-6749(98)70306-9; Toriyama K, 1995, PLANT MOL BIOL, V29, P1157, DOI 10.1007/BF00020459; Twardosz A, 1997, BIOCHEM BIOPH RES CO, V239, P197, DOI 10.1006/bbrc.1997.6860; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; Valenta R, 1997, IGE REGULATION MOL M, P225; VALENTA R, 2000, CALCIUM MOL BASIS CA, P36577; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	23	65	69	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2					314	320		10.1067/mai.2002.121528	http://dx.doi.org/10.1067/mai.2002.121528			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	528EZ	11842303	Bronze			2022-12-18	WOS:000174232600018
J	Goh, DLM; Chua, KY; Chew, FT; Seow, TK; Ou, KL; Yi, FC; Lee, BW				Goh, DLM; Chua, KY; Chew, FT; Seow, TK; Ou, KL; Yi, FC; Lee, BW			Immunochemical characterization of edible bird's nest allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						collocalia species; swiftlets; bird's nest; anaphylaxis; allergen; IgE; protein; food allergy; immunochemical	INDUCED ANAPHYLAXIS; COLLOCALIA NEST; EXTRACTS; CARBOHYDRATE; ANTIGENS; PROTEINS; CHILDREN; IGE	Background: We have previously described anaphylaxis induced by edible bird's nest (BN) and demonstrated that this condition is IgE mediated. Objectives: This study aimed at describing the immunochemical properties of the BN allergens. Comparative studies between 3 commercially available sources (according to the country of origin) of BN were also made. Methods: Crude extracts of commercially available processed BN from Sarawak (Malaysia), Thailand, and Indonesia and fresh unprocessed BN from the caves of Sarawak were obtained by means of aqueous extraction. Specific IgE toward these sources were determined by using fluorescence allergosorbent tests (FASTs), Cross-reactivity studies between the 3 sources of commercially available processed BN were carried out by means of FAST inhibition. Immunochemical characterization by means of IgE immunoblot, periodate treatment, and heat stability studies were carried out on fresh unprocessed BN from Sarawak, Results: Serum from allergic patients showed differences in IgE binding to the 3 sources of commercially available BN, with the highest levels of specific IgE recorded with the Sarawak source (P < .0001). Of these, only the Sarawak and Thailand sources showed considerable cross-reactivity, Further work on the unprocessed fresh Sarawak source identified a putative 66-kd major allergen containing several isoforms. Periodate treatment resulted in loss of IgE binding. Despite a progressive decline in the molecular weights of allergens on SDS-PAGE with increasing periods of boiling, IgE binding, as assessed by means of FAST, was not affected. N-terminal sequence of the major putative allergen (66 kd) showed homology to a domain of an ovoinhibitor precursor in chicken (SWISS-PROT accession No. P10184). Conclusions: We have described the immunochemical properties of BN allergens. Edible BN from different sources are allergenically dissimilar. The putative major allergen is a 66-kd protein.	Natl Univ Singapore, Dept Paediat, Singapore 119074, Singapore; Natl Univ Singapore, Ctr Bioproc Technol, Singapore, Singapore	National University of Singapore; National University of Singapore	Lee, BW (corresponding author), Natl Univ Singapore, Dept Paediat, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.		Seow, Teck Keong/I-1198-2012; Goh, Denise/D-8486-2015; Chew, Fook Tim/E-7259-2010	Chew, Fook Tim/0000-0003-1337-5146				BrummerKorvenkontio H, 1997, INT ARCH ALLERGY IMM, V112, P169, DOI 10.1159/000237450; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Goh DLM, 2000, J PEDIATR-US, V137, P277, DOI 10.1067/mpd.2000.107108; Goh DLM, 1999, ALLERGY, V54, P84, DOI 10.1034/j.1398-9995.1999.00925.x; KATHAN RH, 1969, ARCH BIOCHEM BIOPHYS, V134, P572, DOI 10.1016/0003-9861(69)90319-1; KONG YC, 1987, COMP BIOCHEM PHYS B, V87, P221, DOI 10.1016/0305-0491(87)90133-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau SM., 1994, INT TRADE SWIFTLET N; MCCORMACK DR, 1995, ANN ALLERG ASTHMA IM, V74, P39; NG MH, 1986, BIOCHEM INT, V13, P521; ONG EK, 1990, INT ARCH ALLER A IMM, V93, P338, DOI 10.1159/000235263; Peng ZK, 1996, INT ARCH ALLERGY IMM, V110, P46, DOI 10.1159/000237309; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Seow TK, 2000, ELECTROPHORESIS, V21, P1787, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1787::AID-ELPS1787>3.3.CO;2-1; SZEPFALUSI Z, 1994, J ALLERGY CLIN IMMUN, V93, P932, DOI 10.1016/0091-6749(94)90388-3; TAUERREICH I, 1994, ALLERGY, V49, P448, DOI 10.1111/j.1398-9995.1994.tb00838.x	16	65	70	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1082	1088		10.1067/mai.2001.114342	http://dx.doi.org/10.1067/mai.2001.114342			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398089				2022-12-18	WOS:000169454800023
J	Gergen, PJ				Gergen, PJ			Understanding the economic burden of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cost-of-illness study; direct costs; incidence; indirect costs; prevalence	INDIRECT COSTS; CHILDREN; THERAPY	The economic impact of asthma is large and growing, and the use of economic outcomes is increasing. Such outcomes serve as the basis for studies of the efficiency of care and are being reported increasingly as outcomes of clinical trials. This article presents the basic components of a cost-of-illness study, the influences that have an impact on these components, the relation of economic indicators to clinical outcomes, and the relative importance of the economic factors for differing groups in society.	Agcy Healthcare Res & Qual, Ctr Primary Care & Res, Rockville, MD 20852 USA	Agency for Healthcare Research & Quality	Gergen, PJ (corresponding author), Agcy Healthcare Res & Qual, Ctr Primary Care & Res, 6010 Execut Blvd,Suite 201, Rockville, MD 20852 USA.							BENSON V, 1998, VITAL HLTH STAT, V10, P78; BOLTON MB, 1991, J GEN INTERN MED, V6, P401, DOI 10.1007/BF02598160; Chew FT, 1999, AUST NZ J MED, V29, P228, DOI 10.1111/j.1445-5994.1999.tb00688.x; Cowie RL, 1997, CHEST, V112, P1534, DOI 10.1378/chest.112.6.1534; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; Halterman JS, 2000, PEDIATRICS, V105, P272; HODGKINSON DP, 1983, RADIOACT WASTE MANAG, V4, P129; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; MARION RJ, 1985, ANN ALLERGY, V54, P31; MELLIS CM, 1991, MED J AUSTRALIA, V155, P522, DOI 10.5694/j.1326-5377.1991.tb93888.x; Nash DR, 1999, PEDIATRICS, V104, P310, DOI 10.1542/peds.104.2.310; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P408, DOI 10.1016/S0091-6749(99)70464-1; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; Stempel DA, 1996, ARCH FAM MED, V5, P36, DOI 10.1001/archfami.5.1.36; Szucs TD, 1999, EUR RESPIR J, V13, P281, DOI 10.1034/j.1399-3003.1999.13b10.x; VANCE VJ, 1971, ANN ALLERGY, V29, P455; vonderSchulenburg JMG, 1996, MED KLIN, V91, P670; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; 1997, STAT B METROP I CO, V78, P26	23	65	66	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5		S			S445	S448		10.1067/mai.2001.114992	http://dx.doi.org/10.1067/mai.2001.114992			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	435RD	11344373				2022-12-18	WOS:000168894200002
J	Barnes, PJ				Barnes, PJ			New directions in allergic diseases: Mechanism-based anti-inflammatory therapies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; atopic dermatitis; rhinitis; cytokines; antagonists; immunotherapy	ACTIVATED PROTEIN-KINASE; INDUCED AIRWAY HYPERRESPONSIVENESS; GRASS-POLLEN IMMUNOTHERAPY; COLONY-STIMULATING FACTOR; NITRIC-OXIDE SYNTHASE; CHRONIC SEVERE ASTHMA; MONOCLONAL-ANTIBODY; HUMAN EOSINOPHILS; INTERFERON-GAMMA; T-CELLS	Advances in our understanding of allergic inflammation have led to the development of several novel anti-inflammatory drugs that target specific aspects of the inflammatory process. These treatments are based on improvements in existing therapies or on a better understanding of the cellular and molecular mechanisms involved in atopic diseases. Although most attention has been focused on asthma, treatments that inhibit the atopic disease profess would have application to all atopic diseases, which often coincide. Specific agents that are now in development for the treatment of allergic inflammation include inhibitors of eosinophilic inflammation (eg, anti-IL-5, CCR3 antagonists, and very late antigen 4 inhibitors), drugs that may inhibit allergen presentation, and inhibitors of T(H)2 cells. More general anti-inflammatory approaches include novel corticosteroids, phosphodiesterase inhibitors, and mitogen-activated protein kinase inhibitors, Most of the new therapies in development are aimed at inhibiting or suppressing components of the allergic inflammatory response, but in the future, there are possibilities for development of preventive and curative treatments.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.			Barnes, Peter/0000-0002-5122-4018				Abraham WM, 1999, AM J RESP CRIT CARE, V159, P1205, DOI 10.1164/ajrccm.159.4.9806002; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Barnes PJ, 1996, CLIN EXP ALLERGY, V26, P738; BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; Barnes PJ, 1999, NATURE, V402, pB31, DOI 10.1038/35037026; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Barnes PJ, 1999, NEW ENGL J MED, V341, P2006, DOI 10.1056/NEJM199912233412610; Barnes PJ, 1998, MOL MED TODAY, V4, P452, DOI 10.1016/S1357-4310(98)01335-5; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V102, P531, DOI 10.1016/S0091-6749(98)70268-4; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BARNES PJ, 1993, THORAX, V48, P195, DOI 10.1136/thx.48.3.195; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; BIANCO S, 1993, EUR RESPIR J, V6, P130; Bieber T, 1998, J ALLERGY CLIN IMMUN, V102, P555, DOI 10.1016/S0091-6749(98)70270-2; BOGUNIEWICZ M, 1995, J ALLERGY CLIN IMMUN, V95, P133, DOI 10.1016/S0091-6749(95)70162-1; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816, DOI 10.1164/ajrccm.160.6.9808146; BRYAN S, 2000, IN PRESS AM J RESP C; Caramori G, 1999, AM J RESP CRIT CARE, V159, pA908; CHAN SC, 1993, J LAB CLIN MED, V121, P44; Chomarat P, 1998, Int Rev Immunol, V17, P1, DOI 10.3109/08830189809084486; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; Costello PS, 1996, ONCOGENE, V13, P2595; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Dasic G, 1999, EUR J IMMUNOL, V29, P2957, DOI 10.1002/(SICI)1521-4141(199909)29:09<2957::AID-IMMU2957>3.0.CO;2-4; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Egan RW, 1996, ALLERGY, V51, P71, DOI 10.1111/j.1398-9995.1996.tb00038.x; Elsner J, 1997, EUR J IMMUNOL, V27, P2892, DOI 10.1002/eji.1830271122; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Feldman M, 1998, TRANSPLANT P, V30, P4126, DOI 10.1016/S0041-1345(98)01365-7; Foster PS, 1999, CLIN EXP ALLERGY, V29, P12; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Grunewald SM, 1998, J IMMUNOL, V160, P4004; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haczku A, 1999, AM J RESP CRIT CARE, V159, P1638, DOI 10.1164/ajrccm.159.5.9711040; Harbinson PL, 1997, EUR RESPIR J, V10, P1008, DOI 10.1183/09031936.97.10051008; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hay DWP, 1996, AM J RESP CRIT CARE, V154, P1594, DOI 10.1164/ajrccm.154.6.8970340; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HEINKE S, 1995, BRIT J PHARMACOL, V115, P1393, DOI 10.1111/j.1476-5381.1995.tb16629.x; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Hogan SP, 1998, J IMMUNOL, V161, P1501; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kim MK, 1998, AM J RESP CELL MOL, V19, P836, DOI 10.1165/ajrcmb.19.5.3032; Kim TS, 1997, J IMMUNOL, V158, P4137; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; KRISHNA MT, 1998, AM J RESP CRIT CARE, V157, pA456; Lack G, 1996, J IMMUNOL, V157, P1432; Leckie MJ, 1999, AM J RESP CRIT CARE, V159, pA624; Leonard JP, 1997, BLOOD, V90, P2541; Li L, 1999, J IMMUNOL, V162, P2477; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Losman JA, 1999, J IMMUNOL, V162, P3770; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Lynch OT, 1999, BRIT J PHARMACOL, V128, P1149, DOI 10.1038/sj.bjp.0702892; LYNCH OT, 2000, IN PRESS BLOOD; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; MORLEY J, 1992, J AUTOIMMUN, V5, P265, DOI 10.1016/0896-8411(92)90042-O; Muller T, 1996, TRENDS PHARMACOL SCI, V17, P294, DOI 10.1016/0165-6147(96)10035-3; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Mygind N, 1997, ALLERGY, V52, P39, DOI 10.1111/j.1398-9995.1997.tb04883.x; NIZANKOWSKA E, 1995, EUR RESPIR J, V8, P1091, DOI 10.1183/09031936.95.08071091; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; PILEWSKI JM, 1995, AM J RESP CELL MOL, V12, P1; Pretolani M, 1997, IMMUNOL TODAY, V18, P277, DOI 10.1016/S0167-5699(97)80023-0; Pullerits T, 1999, AM J RESP CRIT CARE, V159, P1814, DOI 10.1164/ajrccm.159.6.9810016; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rosenwasser LJ, 1998, J ALLERGY CLIN IMMUN, V102, P344; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Schafer PH, 1999, J IMMUNOL, V162, P7110; Schwarze J, 1999, J IMMUNOL, V162, P4207; Seldon Paul M., 1998, Cell Biochemistry and Biophysics, V29, P179, DOI 10.1007/BF02737835; SELIG W, 1992, EUR J PHARMACOL, V213, P331, DOI 10.1016/0014-2999(92)90621-A; Seybold J, 1998, J BIOL CHEM, V273, P20575, DOI 10.1074/jbc.273.32.20575; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; SUN J, 1994, INT ARCH ALLERGY IMM, V104, P291, DOI 10.1159/000236679; Sur S, 1999, J IMMUNOL, V162, P6284; Taylor DA, 1999, AM J RESP CRIT CARE, V160, P237, DOI 10.1164/ajrccm.160.1.9809046; THOMSON AW, 1993, IMMUNOL REV, V136, P71, DOI 10.1111/j.1600-065X.1993.tb00655.x; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Van Neerven RJJ, 1998, CLIN EXP ALLERGY, V28, P808; vanDeventer SJH, 1997, GASTROENTEROLOGY, V113, P383, DOI 10.1053/gast.1997.v113.pm9247454; VanGanse E, 1997, EUR RESPIR J, V10, P2216, DOI 10.1183/09031936.97.10102216; VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/ajrcmb.17.3.2679; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; WALSH GM, 1994, CLIN EXP ALLERGY, V24, P81, DOI 10.1111/j.1365-2222.1994.tb00921.x; Wang CC, 1998, IMMUNOLOGY, V93, P307; Wang LH, 1999, EUR J PHARMACOL, V371, P241, DOI 10.1016/S0014-2999(99)00179-X; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; Wheeler MA, 1997, J CLIN INVEST, V99, P110, DOI 10.1172/JCI119121; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xing Z, 1996, J CLIN INVEST, V97, P1102, DOI 10.1172/JCI118503; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; YSSEL H, 1994, CURR OPIN IMMUNOL, V6, P847, DOI 10.1016/0952-7915(94)90003-5; Yuan Q, 1996, BIOCHEM J, V318, P591, DOI 10.1042/bj3180591; Zhang ZJ, 1997, DNA CELL BIOL, V16, P73, DOI 10.1089/dna.1997.16.73; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	121	65	77	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				5	16		10.1067/mai.2000.107930	http://dx.doi.org/10.1067/mai.2000.107930			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887299				2022-12-18	WOS:000088393300001
J	Finn, PW; Boudreau, JO; He, HZ; Wang, YS; Chapman, MD; Vincent, C; Burge, HA; Weiss, ST; Perkins, DL; Gold, DR				Finn, PW; Boudreau, JO; He, HZ; Wang, YS; Chapman, MD; Vincent, C; Burge, HA; Weiss, ST; Perkins, DL; Gold, DR			Children at risk for asthma: Home allergen levels, lymphocyte proliferation, and wheeze	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; T lymphocytes; proliferation; home allergen levels; allergy; asthma; cockroach; Bla g 2; Der f 1; Fel d 1	ENVIRONMENTAL ENDOTOXIN MEASUREMENT; LOWER RESPIRATORY ILLNESS; HOUSE-DUST MITES; T-CELL MEMORY; EARLY-CHILDHOOD; INHALANT ALLERGENS; NATURAL-HISTORY; LIMULUS ASSAY; EXPOSURE; CAT	Background: Allergic asthma is a common childhood disease. Although T-lymphocyte activation plays a critical role in allergic asthma, the environmental factors promoting lymphocyte activation in children are not well defined. Objective: In a cohort of children at risk for asthma (n = 114), we determined whether the levels of cockroach (Bla g 1 or 2), house dust mite (Der f 1), and cat allergen (Fel d 1) in the home during infancy mas associated with subsequent allergen-specific lymphocyte proliferation in later life. Methods: Dust samples from multiple sites in the home were collected at 3 months of age and were measured for allergen levels. Serial questionnaires were applied. At a median age of 2 years, PBMCs were isolated and lymphocyte proliferation to the home allergens and PHA was determined. Results: Increased lymphocyte proliferative responses to Bla g 2 were associated with higher home levels of Bla g 1 or 2 (P for trend with kitchen Bla g levels = .011), in analyses adjusting for cold in the past week. Proliferative responses to Der fl were higher in homes with family room levels of Der f 1 greater than or equal to 10 mu g/g dust than in homes with Der f 1 <2 mu g/g, but differences were not significant in analyses adjusting for cold (P = .15). Repeated wheeze in the first 2 years of life was associated with increased allergen-specific and PHA proliferative responses. Conclusion: Early-life cockroach allergen exposure at 3 months of age predicts allergen-specific lymphocyte proliferative responses at a median of 2 years of age.	Brigham & Womens Hosp, Div Resp & Crit Care, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Beth Israel Hosp, Div Pulm, Boston, MA 02215 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; University of Virginia	Finn, PW (corresponding author), Brigham & Womens Hosp, Div Resp & Crit Care, 75 Francis St, Boston, MA 02115 USA.			Chapman, Martin/0000-0002-0845-3632	AHRQ HHS [HS45007, HS35786] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; Bergmann R, 1998, EUR RESPIR J, V12, p9S; Bjorksten B, 1996, CLIN EXP ALLERGY, V26, P775, DOI 10.1111/j.1365-2222.1996.tb00607.x; Boner A, 1998, CLIN EXP ALLERGY, V28, P50; Chan-Yeung M, 1999, CLIN EXP ALLERGY, V29, P762; CHANYEUNG M, 1995, CLIN EXP ALLERGY, V25, P240, DOI 10.1111/j.1365-2222.1995.tb01035.x; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536, DOI 10.1164/ajrccm.157.5.9708011; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; Custovic A, 1999, ALLERGY, V54, P612, DOI 10.1034/j.1398-9995.1999.00062.x; Donovan CE, 1999, THORAX, V54, P938, DOI 10.1136/thx.54.10.938; GOLD DR, 1989, AM REV RESPIR DIS, V140, P877, DOI 10.1164/ajrccm/140.4.877; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Holgate ST, 1997, CIBA F SYMP, V206, P5; HOLT PG, 1987, IMMUNOLOGY, V60, P97; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; KANG B, 1985, CLIN REV ALLERG, V3, P363, DOI 10.1007/BF02993001; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; Lara-Marquez ML, 1998, J ALLERGY CLIN IMMUN, V101, P699, DOI 10.1016/S0091-6749(98)70180-0; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; MILTON DK, 1992, ENVIRON RES, V57, P212, DOI 10.1016/S0013-9351(05)80081-7; Mowat A M, 1987, Adv Exp Med Biol, V216A, P709; OWNBY DR, 1990, J ALLERGY CLIN IMMUN, V86, P279, DOI 10.1016/S0091-6749(05)80088-0; Parvaneh S, 1999, ALLERGY, V54, P229, DOI 10.1034/j.1398-9995.1999.00855.x; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PlattsMills TAE, 1997, CIBA F SYMP, V206, P173; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1997, INT ARCH ALLERGY IMM, V113, P75, DOI 10.1159/000237512; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SCHRIER RD, 1986, J INFECT DIS, V153, P1084, DOI 10.1093/infdis/153.6.1084; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; van der Heide S, 1998, ALLERGY, V53, P104, DOI 10.1111/j.1398-9995.1998.tb05009.x; Vollmer WM, 1998, AM J RESP CRIT CARE, V157, P1079, DOI 10.1164/ajrccm.157.4.9704140; Weiss ST, 1998, CLIN EXP ALLERGY, V28, P29; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7	45	65	65	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					933	942		10.1067/mai.2000.106546	http://dx.doi.org/10.1067/mai.2000.106546			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	316TW	10808174				2022-12-18	WOS:000087185000012
J	Bernstein, IL				Bernstein, IL			Is the use of benzalkonium chloride as a preservative for nasal formulations a safety concern? A cautionary note based on compromised mucociliary transport	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; topical nasal drugs; preservatives; benzalkonium chloride; mucociliary transport	CILIARY BEAT FREQUENCY; HUMAN RESPIRATORY MUCOSA; IN-VIVO; ALLERGIC RHINITIS; CLEARANCE; STEROIDS; SPRAYS; VITRO; DROPS; RAT	Background: Topical nasal solution and suspension delivery systems are available for short- and long-acting vasoconstrictors, ipratropium, cromolyn, azelastine, and glucocorticosteroids. The use of intranasal glucocorticosteroids has increased substantially because the efficacy of these agents has been well established for the treatment of perennial and seasonal allergic rhinitis, Adverse local effects of burning, irritation, and dryness are occasionally associated with glucocorticosteroid nasal preparations. Benzalkonium chloride (BKC) is a quaternary ammonium antimicrobial agent included in some nasal solutions (including glucocorticosteroids) to prevent the growth of bacteria, Some reports suggest that BKC in nasal sprays may cause adverse effects, including reduced mucociliary transport, rhinitis medicamentosa, and neutrophil dysfunction. Objective: This article summarizes recent literature about possible adverse biologic effects associated with BKC as a nasal spray preservative by examining its effects on the following properties of mucociliary transport: ciliary motion, ciliary form, ciliary beat frequency, electron microscopy, and particle movement/saccharin clearance tests. Conclusion: Both animal and human in vitro data suggest that BKC promotes ciliostasis and reduction in mucociliary transport that may be partially masked by absorption and dilution effects occurring in respiratory mucus. These possible confounding factors may account for several disparate human in vivo results. The use of BKC-free glucocorticosteroid formulations should be considered, particularly in patients who complain of nasal burning, dryness, or irritation.	Univ Cincinnati, Coll Med, Div Immunol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Bernstein, IL (corresponding author), Univ Cincinnati, Coll Med, Div Immunol, 231 Bethesda Ave,ML 536, Cincinnati, OH 45267 USA.							AINGE G, 1994, DRUG INVEST, V8, P127, DOI 10.1007/BF03259428; BATTS AH, 1989, J PHARM PHARMACOL, V41, P156, DOI 10.1111/j.2042-7158.1989.tb06420.x; Beasley R, 1998, PHARMACOTHERAPY, V18, P130; Berg OH, 1997, ALLERGY, V52, P627, DOI 10.1111/j.1398-9995.1997.tb01041.x; BERG OH, 1995, PHARMACOL TOXICOL, V76, P245, DOI 10.1111/j.1600-0773.1995.tb00137.x; BERNSTEIN JA, 1994, J ALLERGY CLIN IMMUN, V94, P257, DOI 10.1016/0091-6749(94)90048-5; BRAAT JPM, 1995, CLIN EXP ALLERGY, V25, P957, DOI 10.1111/j.1365-2222.1995.tb00398.x; DEJONG C, 1994, GRAEF ARCH CLIN EXP, V232, P221, DOI 10.1007/BF00184009; Graf P, 1996, LARYNGOSCOPE, V106, P605, DOI 10.1097/00005537-199605000-00016; GRAF P, 1995, CLIN EXP ALLERGY, V25, P395, DOI 10.1111/j.1365-2222.1995.tb01069.x; HAKANSSON B, 1989, PHARMACOL TOXICOL, V64, P321, DOI 10.1111/j.1600-0773.1989.tb00656.x; HARVEY SC, 1985, PHARMACOL BASIS THER, P971; Hofmann T, 1998, HNO, V46, P146; Joki S, 1996, AM J RHINOL, V10, P181, DOI 10.2500/105065896781794932; KLEIN GF, 1991, CONTACT DERMATITIS, V25, P269, DOI 10.1111/j.1600-0536.1991.tb01869.x; Kuboyama Yasumasa, 1997, Journal of Toxicological Sciences, V22, P153; Lale AM, 1998, CLIN OTOLARYNGOL, V23, P388, DOI 10.1046/j.1365-2273.1998.00173.x; McMahon C, 1997, CLIN OTOLARYNGOL, V22, P318, DOI 10.1046/j.1365-2273.1997.00042.x; Mygind N, 1996, CLIN EXP ALLERGY, V26, P2, DOI 10.1111/j.1365-2222.1996.tb00652.x; PIPKORN U, 1983, ALLERGY, V38, P125, DOI 10.1111/j.1398-9995.1983.tb01596.x; RICHARDS RME, 1976, J PHARM SCI, V65, P76, DOI 10.1002/jps.2600650115; RUTLAND J, 1981, THORAX, V36, P654, DOI 10.1136/thx.36.9.654; RUTLAND J, 1980, LANCET, V2, P564; STAFANGER G, 1987, ALLERGY, V42, P507, DOI 10.1111/j.1398-9995.1987.tb00373.x; STANLEY PJ, 1985, THORAX, V40, P607, DOI 10.1136/thx.40.8.607; Steinsvag SK, 1996, ACTA OTO-LARYNGOL, V116, P868, DOI 10.3109/00016489609137943; van de Donk H J, 1980, Rhinology, V18, P119; van de Donk H J, 1982, Rhinology, V20, P127; van de Donk H J, 1981, Rhinology, V19, P215; WEINER M, 1989, ADVERSE REACTIONS DR, P178	30	65	76	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				39	44		10.1016/S0091-6749(00)90175-1	http://dx.doi.org/10.1016/S0091-6749(00)90175-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629450				2022-12-18	WOS:000084992100005
J	Ward, GW; Woodfolk, JA; Hayden, ML; Jackson, S; Platts-Mills, TAE				Ward, GW; Woodfolk, JA; Hayden, ML; Jackson, S; Platts-Mills, TAE			Treatment of late-onset asthma with fluconazole	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						trichophyton; late-onset asthma; dermatophytosis; fluconazole; steroid use; bronchial provocation	DELAYED-HYPERSENSITIVITY; TRICHOPHYTON-TONSURANS; CHRONIC SINUSITIS; DEPENDENT ASTHMA; IGE ANTIBODIES; SINGLE PROTEIN; IMMEDIATE; EOSINOPHILIA; RHINITIS; ALLERGY	Background: Although the etiology of intrinsic or late-onset asthma is generally not known, some eases are associated with overt dermatophyte infection and immediate hypersensitivity to proteins derived from fungi of the genus Trichophyton. Objective: We sought to test the efficacy of oral antifungal treatment for Trichophyton-induced asthma by using fluconazole in a placebo-controlled trial. Methods: Eleven patients with severe or moderately severe asthma were randomized to treatment with fluconazole 100 mg daily or placebo for 5 months (phase 1); during the following 5 months, all patients received active drug (phase 2). Subjects were evaluated by skin tests, bronchial provocation tests, and measurement of serum antibodies to Trichophyton species antigens. Clinical response was monitored by changes in peak flow values measured during a 2-week period at the end of each phase and by changes in bronchial sensitivity, symptoms, and steroid requirements. Results: At the end of the first 5 months of active treatment, there was a highly significant decrease in bronchial sensitivity to Trichophyton (P = .012) and in oral steroid requirement (P = .01), At the end of phase 2, mean peak expiratory flow rates increased in 9 of II patients. An improvement in symptoms, peak flow, and steroid use was maintained up to 36 months after starting fluconazole in patients who continued to receive treatment. Conclusion: The results show that fluconazole can be useful in the treatment of patients with severe or moderately severe asthma who have dermatophytosis. These findings are consistent with the argument that proteins derived from fungi on the skin and nails can contribute to allergic disease.	Univ Virginia, Ctr Asthma & Allerg Dis, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Ctr Asthma & Allerg Dis, Box 225, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X	NCRR NIH HHS [RR-00847] Funding Source: Medline; NIAID NIH HHS [AI-30840, U01 AI-34607] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030840, U01AI034607] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; Bates DV, 1964, RESP FUNCTION DIS; BEENTENS JR, 1986, BIOCHEM PHARMACOL, V35, P883; BERNSTEIN DI, 1988, J ALLERGY CLIN IMMUN, V81, P6, DOI 10.1016/0091-6749(88)90213-8; DAVIES RR, 1983, CLIN ALLERGY, V13, P309, DOI 10.1111/j.1365-2222.1983.tb02605.x; DeCoster R, 1996, J STEROID BIOCHEM, V56, P133, DOI 10.1016/0960-0760(95)00230-8; DENNER K, 1995, PHARMACOGENETICS, V5, P89, DOI 10.1097/00008571-199504000-00005; DEUELL B, 1991, J IMMUNOL, V147, P96; GUMOWSKI P, 1987, ANN ALLERGY, V59, P48; JAMES JM, 1994, AM J RESP CRIT CARE, V149, P59, DOI 10.1164/ajrccm.149.1.8111598; JARJOUR N, 1996, SEVERE ASTHMA PATHOG, P333; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; MINGS R, 1988, AM J RHINOL, V71, P123; MULLARKEY MF, 1990, ANN INTERN MED, V112, P577, DOI 10.7326/0003-4819-112-8-577; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; PEPYS J, 1959, AM REV RESPIR DIS, V80, P167; PHILLIPS CD, 1995, AM J ROENTGENOL, V164, P185, DOI 10.2214/ajr.164.1.7998536; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P40, DOI 10.1016/S0091-6749(87)80014-3; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Slunt JB, 1996, J IMMUNOL, V157, P5192; STEVENSON DD, 1988, ALLERGY PRINCIPLES P, P1537; WARD GW, 1989, LANCET, V1, P859; Wise F, 1930, J AMER MED ASSOC, V95, P1504, DOI 10.1001/jama.1930.27210200002011a; Woodfolk JA, 1996, J IMMUNOL, V156, P1695; Woodfolk JA, 1998, J BIOL CHEM, V273, P29489, DOI 10.1074/jbc.273.45.29489; YU M, 1993, CRIT CARE MED, V21, P1335	27	65	68	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				541	546		10.1016/S0091-6749(99)70321-0	http://dx.doi.org/10.1016/S0091-6749(99)70321-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482825				2022-12-18	WOS:000082870000013
J	Kinoshita, M; Shiraishi, T; Koga, T; Ayabe, M; Rikimaru, T; Oizumi, K				Kinoshita, M; Shiraishi, T; Koga, T; Ayabe, M; Rikimaru, T; Oizumi, K			Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Kurume Univ, Sch Med, Dept Med 1, Kurume, Fukuoka 8300011, Japan	Kurume University	Kinoshita, M (corresponding author), Kurume Univ, Sch Med, Dept Med 1, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.							Churg J, 1998, JAMA-J AM MED ASSOC, V279, P1949; Holloway Jennifer, 1998, Journal of the American Osteopathic Association, V98, P275; Katz RS, 1998, JAMA-J AM MED ASSOC, V279, P1949, DOI 10.1001/jama.279.24.1949; Knoell DL, 1998, CHEST, V114, P332, DOI 10.1378/chest.114.1.332; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455	5	65	67	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				534	535		10.1016/S0091-6749(99)70483-5	http://dx.doi.org/10.1016/S0091-6749(99)70483-5			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069892				2022-12-18	WOS:000079175700027
J	Kotsimbos, TC; Ghaffar, O; Minshall, EM; Humbert, M; Durham, SR; Pfister, R; Menz, G; Kay, AB; Hamid, QA				Kotsimbos, TC; Ghaffar, O; Minshall, EM; Humbert, M; Durham, SR; Pfister, R; Menz, G; Kay, AB; Hamid, QA			Expression of the IL-4 receptor alpha-subunit is increased in bronchial biopsy specimens from atopic and nonatopic asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic asthma; intrinsic asthma; IL-4 receptor; IL-4; IgE	CYTOKINE MESSENGER-RNA; T-CELLS; BRONCHOALVEOLAR LAVAGE; INTERFERON-GAMMA; EPITHELIAL-CELLS; GENE-EXPRESSION; ENDOTHELIAL-CELLS; HUMAN EOSINOPHILS; INTRINSIC ASTHMA; LYMPHOCYTES-T	Background: Recent studies have provided evidence for increased IL-4 expression in the airways of atopic and nonatopic asthmatic subjects. IL-4 is believed to perform important regulatory roles in asthma: however, the expression of the IL-4 receptor has not been investigated. In this study we examined the mRNA and protein expression of the specific alpha-subunit of the IL-4 receptor (alpha IL-1R) in bronchial biopsy specimens obtained from atopic and nonatopic asthmatic subjects. Methods: Asthmatic subjects and nonasthmatic control subjects were recruited, and lung function measurements were performed before bronchoscopy, Endobronchial biopsy specimens were examined for the presence of alpha IL-1R mRNA and immunoreactivity by using in situ hybridization and immunocytochemistry, respectively. Results: alpha IL-4R mRNA-positive and immunoreactive cells were detected in the epithelium and subepithelium in biopsy specimens from all subjects. Expression of alpha IL-4R mRNA and protein was significantly increased in the epithelium and subepithelium of biopsy; specimens from atopic asthmatic subjects compared with atopic control subjects (P < .05 and r < .001, respectively). Epithelial alpha IL-4R mRNA expression and immunoreactivity did not differ significantly between nonatopic asthmatic subjects and nonatopic control subjects. Although the numbers of alpha IL-4R mRNA-positive cells were augmented in the submucosa of intrinsic asthmatic subjects compared with nonatopic control subjects (P < .05), alpha IL-4R immunoreactivity did not differ significantly between these groups. Increased alpha IL-4R immunoreactive signals were also detected in the endothelial cell layer in both atopic and intrinsic asthmatic subjects compared with atopic and nonatopic control subjects, respectively (P < .05). Combined in situ hybridization immunocytochemistry performed on biopsy sections from asthmatic and control subjects demonstrated alpha IL-4R mRNA expression in CD3-positive T cells and tryptase-positive e mast cells, with T cells comprising the larger proportion of alpha IL-4R mRNA-positive cells. Numbers of alpha IL-4R mRNA-positive or immunoreactive cells did not correlate with CD3-positive cell numbers, numbers of IL-4 mRNA-positive cells, or indices of pulmonary function. Conclusion: These results demonstrate constitutive alpha IL-4R expression in normal airways and enhanced expression in airway tissue from asthmatic individuals.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Natl Heart & Lung Inst, Dept Allergy & Clin Immunol, London, England; Hochgebirgsklin Davos, Asthma & Allergy Clin, Davos, Switzerland	McGill University; Imperial College London	Hamid, QA (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.			Humbert, Marc/0000-0003-0703-2892				ARMITAGE RJ, 1990, INT IMMUNOL, V2, P1039, DOI 10.1093/intimm/2.11.1039; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; CABRILLAT H, 1987, BIOCHEM BIOPH RES CO, V149, P995, DOI 10.1016/0006-291X(87)90507-9; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; DELPRETE G, 1988, J IMMUNOL, V140, P4193; FERNANDEZBOTRAN R, 1986, P NATL ACAD SCI USA, V83, P9689, DOI 10.1073/pnas.83.24.9689; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GORRONE P, 1991, EUR J IMMUNOL, V21, P1365; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1992, BLOOD, V80, P1496; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Kotsimbos ATC, 1997, J ALLERGY CLIN IMMUN, V99, P666, DOI 10.1016/S0091-6749(97)70029-0; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526, DOI 10.1165/ajrcmb.10.5.8179915; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MOZO L, 1993, J IMMUNOL, V150, P4261; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; Nakamura Y, 1996, AM J RESP CELL MOL, V15, P680, DOI 10.1165/ajrcmb.15.5.8918375; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Schnyder B, 1996, BLOOD, V87, P4286, DOI 10.1182/blood.V87.10.4286.bloodjournal87104286; STELLATO C, 1995, J IMMUNOL, V155, P410; Toru H, 1996, INT IMMUNOL, V8, P1367; XAUBET A, 1994, CLIN EXP ALLERGY, V24, P307, DOI 10.1111/j.1365-2222.1994.tb00240.x; Yasruel Z, 1997, AM J RESP CRIT CARE, V155, P1413, DOI 10.1164/ajrccm.155.4.9105087; Ying S, 1997, J IMMUNOL, V158, P3539; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	36	65	67	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					859	866		10.1016/S0091-6749(98)70029-6	http://dx.doi.org/10.1016/S0091-6749(98)70029-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819306				2022-12-18	WOS:000077033400023
J	Bieber, T				Bieber, T			Topical tacrolimus (FK 506): A new milestone in the management of atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							OINTMENT; FK-506; FK506; CELLS		Univ Bonn, Dept Dermatol, Bonn, Germany	University of Bonn	Bieber, T (corresponding author), Univ Bonn, Dept Dermatol, Bonn, Germany.							[Anonymous], 1996, Arch Dermatol, V132, P419; AOYAMA H, 1995, BRIT J DERMATOL, V133, P494, DOI 10.1111/j.1365-2133.1995.tb02691.x; Bieber T, 1997, IMMUNOL TODAY, V18, P311, DOI 10.1016/S0167-5699(97)01046-3; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; BOS JD, 1993, IMMUNOL TODAY, V14, P75, DOI 10.1016/0167-5699(93)90062-P; DEPAULIS A, 1992, J INVEST DERMATOL, V99, P723, DOI 10.1111/1523-1747.ep12614216; LAUERMA AI, 1992, LANCET, V340, P556, DOI 10.1016/0140-6736(92)91757-Y; NAKAGAWA H, 1994, LANCET, V344, P883, DOI 10.1016/S0140-6736(94)92855-X; REITAMO S, 1998, IN PRESS J INVEST DE; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHULZ BS, 1993, J IMMUNOL, V151, P4399	12	65	70	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				555	557		10.1016/S0091-6749(98)70270-2	http://dx.doi.org/10.1016/S0091-6749(98)70270-2			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802361				2022-12-18	WOS:000076600400003
J	Hizawa, N; Freidhoff, LR; Ehrlich, E; Chiu, YF; Duffy, DL; Schou, C; Dunston, GM; Beaty, TH; Marsh, DG; Barnes, KC; Huang, SK				Hizawa, N; Freidhoff, LR; Ehrlich, E; Chiu, YF; Duffy, DL; Schou, C; Dunston, GM; Beaty, TH; Marsh, DG; Barnes, KC; Huang, SK		Collaborative Study Genetics Asthma CSGA	Genetic influences of chromosomes 5q31-q33 and 11q13 on specific IgE responsiveness to common inhaled allergens among African American families	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; skin prick test; chromosome 5q31-q33; chromosome 11q13; multipoint linkage analysis	LINKAGE ANALYSIS; SERUM IGE; UNDERLYING ASTHMA; ATOPY; LOCALIZATION; SENSITIVITY; RESPONSES; MARKERS; DENSITY	Background: We have recently conducted a genome-wide screening for genes influencing Dermatophagoides pteronyssinus-specific IgE responsiveness as a part of the Collaborative Study on the Genetics of Asthma (CSGA), which showed evidence for linkage in some regions, including chromosomes 5q31-q33 and 11q13 in African American families. Objectives: To clarify relative contributions of these regions to atopy in the same African American population, we have conducted further genetic linkage studies of specific IgE responses toward common inhaled allergens. Methods: We studied 328 individuals in 58 African American families participating in the CSGA, Specific IgE responses toward Dermatophagoides farinae, cat, dog, American cockroach, rye grass, and Bermuda grass, as measured by skin tests, were used for multipoint linkage analysis with polymorphic markers on chromosomes 5q31-q33 and 11q13. Results: Specific IgE response toward American cockroach showed evidence for linkage to chromosomes 5q31-q33 (P =.0050) and 11q13 (P =.017). Specific IgE response toward dog showed evidence for linkage with chromosome 5q31-q33 (P =.0043). Evidence for linkage with chromosome 11q13 was obtained for specific IgE responses toward Dermatophagoides farinae (P =.012), cat (P =.035), and Bermuda grass (P =.017). The presence of a positive ST response for at least 1 of 30 common allergens showed evidence for linkage to chromosomes 5q31-q33 (P =.017) and 11q13 (P =.00058). Conclusions: These data support that genes on both chromosomes 5q31-q33 and 11q13 confer susceptibility to upregulated IgE-mediated immune responses in this African American population. The putative genes on chromosomes 5q31-q33 and 11q13, however, showed contrasting effects on atopy, which may result from strong gene-environmental interactions.	Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Baltimore, MD 21224 USA; Johns Hopkins Sch Hyg, Dept Biostat, Baltimore, MD USA; Johns Hopkins Sch Hyg, Dept Epidemiol, Baltimore, MD USA; Queensland Inst Med Res, Brisbane, Qld 4006, Australia; ALK Labs, Horsholm, Denmark; Howard Univ, Coll Med, Dept Microbiol, Washington, DC USA; NHLBI, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; QIMR Berghofer Medical Research Institute; Howard University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Huang, SK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Huang, Shau-Ku/F-5509-2010; Duffy, David L/B-7392-2013; Chiu, Yen-Feng/E-3847-2010	Duffy, David L/0000-0001-7227-632X; 	NHLBI NIH HHS [HL/AI 49612] Funding Source: Medline; NIAID NIH HHS [AI20059] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020059] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLUMENTHAL MN, 1995, CLIN EXP ALLERGY, V25, P29, DOI 10.1111/j.1365-2222.1995.tb00416.x; BLUMENTHAL MN, 1987, CHEST, V91, pS176, DOI 10.1378/chest.91.6.176S; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; FREIDHOFF LR, 1983, J ALLERGY CLIN IMMUN, V72, P274, DOI 10.1016/0091-6749(83)90032-5; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HIZAWA N, 1992, CLIN EXP ALLERGY, V22, P1065, DOI 10.1111/j.1365-2222.1992.tb00131.x; HIZAWA N, 1998, J ALLERGY CLIN IMMUN, V102, P435; Inglehearn CF, 1997, NAT GENET, V16, P15, DOI 10.1038/ng0597-15; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; Palmer LJ, 1997, AM J HUM GENET, V61, P182, DOI 10.1086/513888; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHIRAKAWA T, 1994, CLIN GENET, V46, P125	24	65	67	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1998	102	3					449	453		10.1016/S0091-6749(98)70134-4	http://dx.doi.org/10.1016/S0091-6749(98)70134-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	124ZN	9768587	hybrid			2022-12-18	WOS:000076212800020
J	Asturias, JA; Arilla, MC; GomezBayon, N; Martinez, J; Martinez, A; Palacios, R				Asturias, JA; Arilla, MC; GomezBayon, N; Martinez, J; Martinez, A; Palacios, R			Cloning and expression of the panallergen profilin and the major allergen (Ole e 1) from olive tree pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ole e 1; profilin; recombinant allergens; olive tree pollen; cDNA cloning; expression; IgE binding	TOBACCO NICOTIANA-TABACUM; POLYMERASE CHAIN-REACTION; HIGH-LEVEL EXPRESSION; BIRCH POLLEN; CDNA CLONING; E-I; RECOMBINANT ALLERGENS; SEQUENCE-ANALYSIS; CROSS-REACTIVITY; ESCHERICHIA-COLI	Background: Olive tree (Olea europaea) pollen allergy is one of the main causes of allergy in Mediterranean countries and some areas of North America. Objective: To clone olive allergens and to characterize immunologically the purified recombinant allergens. Methods: Full-length complementary deoxyribonucleic acid (cDNA) strands encoding olive allergens (Ole e 1) were cloned by polymerase chain reaction amplification and sequenced. Recombinant proteins were produced in Escherichia coli by the use of two different expression systems. Immunoreactivity of the recombinant proteins was tested by ELISA and Western blot with serum from patients with allergy to olive. Results: Significant sequence polymorphism was found in both allergens, The panallergen profilin was expressed as a nonfusion protein and was purified to homogeneity after a single step of affinity chromatography with a poly-1-proline Sepharose column. One cDNA encoding an Ole e 1 isoform was expressed as a fusion protein consisting of the glutathione S-transferase of Schistosoma japonicum and Ole e 1. The fusion protein was purified to homogeneity by gel filtration chromatography and affinity chromatography with a glutathione-Sepharose column, and digested with thrombin. Both recombinant allergens shared B cell epitopes with the corresponding natural allergens. Conclusion: IgE-reactive Ole e 1 and olive profilin expressed in bacteria were purified after simple chromatographic procedures and may be useful for diagnostic purposes.			Asturias, JA (corresponding author), ARISTEGUI,IFIDESA,R&D DEPT,ALAMEDA URQUIJO 27,BILBAO 48008,SPAIN.			MARTINEZ, JORGE/0000-0001-7002-0056; Asturias, Juan/0000-0001-9570-522X				Baatout S, 1996, EUR J CLIN CHEM CLIN, V34, P575; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; Cardaba B, 1996, CLIN EXP ALLERGY, V26, P316, DOI 10.1111/j.1365-2222.1996.tb00097.x; Christensen HEM, 1996, PLANT J, V10, P269, DOI 10.1046/j.1365-313X.1996.10020269.x; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GRIFFITH IJ, 1991, INT ARCH ALLER A IMM, V96, P296, DOI 10.1159/000235512; JIMENEZ A, 1994, INT ARCH ALLERGY IMM, V105, P297, DOI 10.1159/000236772; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; LINDBERG U, 1988, BIOCHIM BIOPHYS ACTA, V967, P391, DOI 10.1016/0304-4165(88)90102-X; LOMBARDERO M, 1994, CLIN EXP ALLERGY, V24, P765, DOI 10.1111/j.1365-2222.1994.tb00988.x; MARTINEZ A, 1995, ACI NEWS, V7, P85; MITTERMANN I, 1995, PLANT MOL BIOL, V27, P137, DOI 10.1007/BF00019185; Mittermann I, 1996, SEX PLANT REPROD, V9, P133, DOI 10.1007/BF02221392; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Possee RD., 1992, BACULOVIRUS EXPRESSI; RIHS HP, 1994, INT ARCH ALLERGY IMM, V105, P190, DOI 10.1159/000236824; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; VIDALI L, 1995, PLANT PHYSIOL, V108, P115, DOI 10.1104/pp.108.1.115; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; VRTALA S, 1995, INT ARCH ALLERGY IMM, V107, P290, DOI 10.1159/000237005; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WHEELER AW, 1990, MOL IMMUNOL, V27, P631, DOI 10.1016/0161-5890(90)90005-K	43	65	77	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1997	100	3					365	372		10.1016/S0091-6749(97)70250-1	http://dx.doi.org/10.1016/S0091-6749(97)70250-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XX479	9314349				2022-12-18	WOS:A1997XX47900014
J	Borish, L; Rosenwasser, L				Borish, L; Rosenwasser, L			T-H1/T-H2 lymphocytes: Doubt some more	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							INTERFERON-GAMMA PRODUCTION; CD4+ T-CELLS; CYTOKINE PRODUCTION; STIMULATORY FACTOR; IMMUNE-RESPONSES; CLONAL ANERGY; IL-12; IMMUNOTHERAPY; INTERLEUKIN-4; PROLIFERATION				Borish, L (corresponding author), UNIV COLORADO, HLTH SCI CTR, NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, 1400 JACKSON ST, DENVER, CO 80206 USA.							BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257, DOI 10.1165/ajrcmb.13.3.7544594; BORISH L, 1993, J ALLERGY CLIN IMMUN, V92, P123, DOI 10.1016/0091-6749(93)90046-I; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; DEKRUYFF RH, 1995, J IMMUNOL, V154, P2578; DING L, 1993, J IMMUNOL, V151, P1224; Gaglani B, 1996, J ALLERGY CLIN IMMUN, V97, P474; GURKA G, 1989, J ALLERGY CLIN IMMUN, V83, P945, DOI 10.1016/0091-6749(89)90110-3; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hawrylowicz CM, 1996, J ALLERGY CLIN IMMUN, V97, P707, DOI 10.1016/S0091-6749(96)70318-4; HIGGINS JA, 1992, J ALLERGY CLIN IMMUN, V90, P749, DOI 10.1016/0091-6749(92)90098-M; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Ikagawa S, 1996, J ALLERGY CLIN IMMUN, V97, P53, DOI 10.1016/S0091-6749(96)70283-X; IMADA M, 1995, IMMUNOLOGY, V85, P373; JUTEL M, 1995, J IMMUNOL, V154, P4187; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KUBIN M, 1994, J EXP MED, V180, P211, DOI 10.1084/jem.180.1.211; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MARSHALL JD, 1995, J IMMUNOL, V155, P111; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; MCKNIGHT AJ, 1994, J IMMUNOL, V152, P2172; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; OHEHIR RE, 1990, P NATL ACAD SCI USA, V87, P8884, DOI 10.1073/pnas.87.22.8884; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SALLUSTO F, 1993, ALLERGY, V48, P37, DOI 10.1111/j.1398-9995.1993.tb02172.x; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; Slunt J. B., 1996, Journal of Allergy and Clinical Immunology, V97, P408, DOI 10.1016/S0091-6749(96)81121-3; SPITERI MA, 1994, EUR RESPIR J, V7, P1431, DOI 10.1183/09031936.94.07081431; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	37	65	66	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					161	164		10.1016/S0091-6749(97)70090-3	http://dx.doi.org/10.1016/S0091-6749(97)70090-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042039				2022-12-18	WOS:A1997WH83100002
J	VANOOSTERHOUT, AJM; FATTAH, D; VANARK, I; HOFMAN, G; BUCKLEY, TL; NIJKAMP, FP				VANOOSTERHOUT, AJM; FATTAH, D; VANARK, I; HOFMAN, G; BUCKLEY, TL; NIJKAMP, FP			EOSINOPHIL INFILTRATION PRECEDES DEVELOPMENT OF AIRWAY HYPERREACTIVITY AND MUCOSAL EXUDATION AFTER INTRANASAL ADMINISTRATION OF INTERLEUKIN-5 TO MICE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HYPERREACTIVITY; RESPIRATORY AIRWAYS; INTERLEUKIN-5; EOSINOPHIL; ASTHMA; MUCOSAL EXUDATION	MAJOR BASIC-PROTEIN; RECOMBINANT HUMAN INTERLEUKIN-5; ALLERGEN-INDUCED INCREASE; COLONY-STIMULATING FACTOR; MESSENGER-RNA; BRONCHOALVEOLAR LAVAGE; SMOOTH-MUSCLE; BRONCHIAL BIOPSIES; HISTAMINE-RELEASE; INVITRO RESPONSES	Recently, we demonstrated that antibody to interleukin-5 (IL-5) prevents the infiltration of eosinophils in the respiratory airways and the development of bronchial hyperreactivity in an animal model of allergic asthma. In this study we investigated the influence of long-term intranasal administration of IL-5 on airway responsiveness in vitro, the infiltration of inflammatory-leukocytes, and mucosal exudation. Mice (BALB/c) received 1 mu g of recombinant human IL-5 in 30 mu l of saline solution or vehicle alone twice a day for 1, 3, and 7 days. At 3 and 7 days after IL-5 administration, the number of bronchoalveolar lavage eosinophils increased approximately fourfold and sixfold, respectively. Blood eosinophil numbers showed a similar increase. In addition 7 days after IL-5 treatment, total lung eosinophil peroxidase activity was significantly increased by 170% as compared with controls. The maximal responsiveness of the trachea in vitro to methacholine was significantly increased by 34%, as compared with controls, only at 7 days after IL-5 administration. Furthermore, mucosal exudation was also only increased significantly at 7 days after IL-5 administration. It can be concluded that the IL-5-induced eosinophil infiltration precedes the development of airway hyperreactivity and mucosal exudation.	GLAXO GRP RES LTD, DEPT CELLULAR SCI, GREENFORD UB6 0HE, MIDDX, ENGLAND	GlaxoSmithKline	VANOOSTERHOUT, AJM (corresponding author), UNIV UTRECHT, UTRECHT INST PHARMACEUT SCI, DEPT PHARMACOL, POB 80082, 3508 TB UTRECHT, NETHERLANDS.							ANDERSON G P, 1992, American Review of Respiratory Disease, V145, pA239; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BISCHOFF SC, 1990, J EXP MED, V172, P1577, DOI 10.1084/jem.172.6.1577; BLACK JL, 1991, AM REV RESPIR DIS, V143, P1177, DOI 10.1164/ajrccm/143.5_Pt_1.1177; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BRUSASCO V, 1990, J APPL PHYSIOL, V69, P2209, DOI 10.1152/jappl.1990.69.6.2209; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAND N, 1992, EUR J PHARMACOL, V211, P121, DOI 10.1016/0014-2999(92)90273-7; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COLLINS DS, 1993, AM REV RESPIR DIS, V147, P677, DOI 10.1164/ajrccm/147.3.677; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540, DOI 10.1164/ajrccm/147.3.540; DEJONGSTE JC, 1987, EUR J RESPIR DIS, V71, P23; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; FATTAH D, 1990, Cytokine, V2, P112, DOI 10.1016/1043-4666(90)90005-E; FILLEY WV, 1982, LANCET, V2, P11; FRIGAS E, 1981, MAYO CLIN PROC, V56, P345; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263, DOI 10.1164/ajrccm/146.1.263; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HERBERT CA, 1993, BRIT J PHARMACOL, V110, P840, DOI 10.1111/j.1476-5381.1993.tb13889.x; HESSEL EM, 1994, AM J RESP CRIT CARE, V149, pA754; HIRAI K, 1990, J EXP MED, V172, P1525, DOI 10.1084/jem.172.5.1525; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; KITA H, 1992, J IMMUNOL, V149, P629; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MARINI M, 1992, CHEST, V102, P661, DOI 10.1378/chest.102.3.661; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623, DOI 10.1164/ajrccm/148.6_Pt_1.1623; MOSER R, 1992, BLOOD, V79, P2937; NAGASAWA M, 1991, CELL IMMUNOL, V133, P317, DOI 10.1016/0008-8749(91)90107-M; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469, DOI 10.1164/ajrccm/145.6.1469; OHNISHI T, 1993, AM REV RESPIR DIS, V147, P901, DOI 10.1164/ajrccm/147.4.901; RAMOS T, 1989, IMMUNOL LETT, V21, P277, DOI 10.1016/0165-2478(89)90020-5; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROSSI GA, 1991, AM REV RESPIR DIS, V144, P379, DOI 10.1164/ajrccm/144.2.379; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHELLENBERG RR, 1984, INT ARCH ALLER A IMM, V75, P237, DOI 10.1159/000233622; STRATH M, 1985, J IMMUNOL METHODS, V83, P209, DOI 10.1016/0022-1759(85)90242-X; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TERADA N, 1992, J ALLERGY CLIN IMMUN, V90, P160, DOI 10.1016/0091-6749(92)90067-C; UCHIDA DA, 1993, AM REV RESPIR DIS, V147, P982, DOI 10.1164/ajrccm/147.4.982; VANOOSTERHOUT AJM, 1993, PULM PHARMACOL THER, V6, P225, DOI 10.1006/pulp.1993.1030; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548, DOI 10.1164/ajrccm/147.3.548; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; YOSHIKAWA S, 1993, AM REV RESPIR DIS, V147, P914, DOI 10.1164/ajrccm/147.4.914	51	65	65	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1995	96	1					104	112		10.1016/S0091-6749(95)70039-0	http://dx.doi.org/10.1016/S0091-6749(95)70039-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RK383	7622752				2022-12-18	WOS:A1995RK38300014
J	LOMBARDERO, M; QUIRCE, S; DUFFORT, O; BARBER, D; CARPIZO, J; CHAMORRO, MJ; LEZAUN, A; CARREIRA, J				LOMBARDERO, M; QUIRCE, S; DUFFORT, O; BARBER, D; CARPIZO, J; CHAMORRO, MJ; LEZAUN, A; CARREIRA, J			MONOCLONAL-ANTIBODIES AGAINST OLEA-EUROPAEA MAJOR ALLERGEN - ALLERGENIC ACTIVITY OF AFFINITY-PURIFIED ALLERGEN AND DEPLETED EXTRACT AND DEVELOPMENT OF A RADIOIMMUNOASSAY FOR THE QUANTITATION OF THE ALLERGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						OLEA-EUROPAEA; MAJOR ALLERGEN; MONOCLONAL ANTIBODY; EPITOPES; ALLERGEN DEPLETION; AFFINITY CHROMATOGRAPHY; RADIOIMMUNOASSAY; STANDARDIZATION; MASS UNITS		Several monoclonal antibodies (MAbs) were raised against Olea europaea pollen-extract components. Two of these antibodies, named OL 2 and OL 7, recognize two nonoverlapping, nonrepeating epitopes on the olive-allergen Ole e I, as demonstrated by different techniques. The allergen was purified in a single step by MAb-based affinity chromatography, and the allergen revealed a band at molecular weight 20 kd as well as a minor band at 18 kd on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The contribution of allergen Ole e I to the allergenic activity of O. europaea pollen extracts was determined from the effect of allergen depletion by affinity chromatography on skin reactivity and a histamine-release test. The removal of allergen caused a large reduction in the activity of the preparation in 25 monospecific olive-allergic patients. In agreement, the affinity-purified allergen demonstrated a similar response when it was compared with the whole extract in these assays. The results indicated that Ole e I is by far the most important olive-pollen allergen. A two-site solid-phase radioimmunoassay was developed for the quantitation of the allergen Ole e I in mass units. The assay was based on the MAbs, OL 2 and OL 7, and had a detection limit in the nanogram range. A good correlation was found between allergenic activity, as determined by RAST inhibition, and allergen content in 18 olive-pollen extracts. This result indicates that the assay can be a good alternative to RAST inhibition for the standardization of O. europaea extracts.	ALERGIA & INMUNOL ABELLO SA, DEPT ANALYT, MADRID, SPAIN; HOSP RAMON Y CAJAL, MADRID, SPAIN	Hospital Universitario Ramon y Cajal	LOMBARDERO, M (corresponding author), ALERGIA INMUNOL ABELLO SA, RES DEPT, MIGUEL FLETA 19, E-28037 MADRID, SPAIN.		s, q/AAD-7171-2020; Barber, Domingo/Y-9516-2019	Barber, Domingo/0000-0002-5488-5700				BARBER D, 1990, ANN ALLERGY, V64, P43; BLANCA M, 1983, CLIN ALLERGY, V13, P473, DOI 10.1111/j.1365-2222.1983.tb02624.x; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; FINNEY DJ, 1978, STATISTICAL METHODS; GONZALEZ RM, 1987, REV ESP ALERGOL IMMU, V2, P18; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Jimeno Nogales L, 1990, Int Arch Allergy Appl Immunol, V92, P175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUZURICA P, 1988, MOL IMMUNOL, V25, P337, DOI 10.1016/0161-5890(88)90028-4; LEY V, 1985, J IMMUNOL METHODS, V84, P265, DOI 10.1016/0022-1759(85)90433-8; LOMBARDERO M, 1986, ALLERGOL IMMUNOPATH, V14, P189; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; MONEO I, 1980, ALLERGOL IMMUNOPAT S, V7, P311; OHMAN JL, 1974, J IMMUNOL, V113, P1668; REIK LM, 1987, J IMMUNOL METHODS, V100, P123, DOI 10.1016/0022-1759(87)90180-3; RIVAS MF, 1990, ALLERGOL IMMUNOPATH, V18, P79; RUBIO N, 1987, J CHROMATOGR, V403, P312, DOI 10.1016/S0021-9673(00)96369-6; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; TAMIR R, 1991, CLIN EXP ALLERGY, V21, P329, DOI 10.1111/j.1365-2222.1991.tb01664.x; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; VELA C, 1982, INT ARCH ALLER A IMM, V68, P289, DOI 10.1159/000233116; VILLALBA M, 1990, BIOCHEM BIOPH RES CO, V172, P523, DOI 10.1016/0006-291X(90)90704-Q; WHEELER AW, 1990, MOL IMMUNOL, V27, P631, DOI 10.1016/0161-5890(90)90005-K; WOLF P, 1983, ANAL BIOCHEM, V129, P145, DOI 10.1016/0003-2697(83)90062-3; Yman L, 1975, Dev Biol Stand, V29, P151; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2; [No title captured]	30	65	67	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					884	894		10.1016/0091-6749(92)90445-8	http://dx.doi.org/10.1016/0091-6749(92)90445-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1373162				2022-12-18	WOS:A1992HN86000015
J	VENGE, P; HENRIKSEN, J; DAHL, R				VENGE, P; HENRIKSEN, J; DAHL, R			EOSINOPHILS IN EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHILS; EOSINOPHIL CATIONIC PROTEIN; EXERCISE; ASTHMA	NEUTROPHIL CHEMOTACTIC ACTIVITY; CATIONIC PROTEIN; BRONCHIAL-ASTHMA; HISTAMINE; CHALLENGE; MEDIATORS; SERUM	The variations in serum levels of eosinophil cationic protein (ECP) have been measured after exercise challenge of 13 patients with asthma with exercise-induced asthma (EIA) and nine patients with asthma without EIA. The patients were treated before exercise in a randomized and blinded fashion with inhalation of one dose of either disodium chromoglycate, terbutaline, or budesonide and in an open study with 4 weeks of inhaled budesonide. In the group with EIA, there was, in some patients, an initial increase in serum levels of ECP after exercise, but 60 minutes after exercise, the levels were significantly reduced (p < 0.001). Disodium chromoglycate and 4 weeks of budesonide treatment inhibited this reduction. Histamine challenge of the group with EIA produced a similar fall in serum ECP levels (p < 0.001). The group without EIA had initially lower levels of ECP than the group with EIA (p < 0.05 to p < 0.01), and ECP stayed unaltered after exercise. The preexercise serum ECP levels correlated significantly to the maximal fall in peak expiratory flow in the untreated group (r = 0.91; p < 0.001) and in the group receiving one dose of budesonide (r = 0.62; p < 0.05). The blood eosinophil counts were unchanged after challenge and not related to lung function. The results suggest that the ECP content in serum reflects the degree of allergic inflammation in the lungs and thereby the degree of bronchial hyperreactivity.	AARHUS UNIV HOSP,DEPT LUNG MED,DK-8000 AARHUS,DENMARK	Aarhus University	VENGE, P (corresponding author), UNIV HOSP UPPSALA,DEPT CLIN CHEM,INFLAMMAT RES LAB,S-75185 UPPSALA,SWEDEN.		Dahl, Ronahl/F-8170-2013					ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; BELCHER NG, 1988, J ALLERGY CLIN IMMUN, V81, P100, DOI 10.1016/0091-6749(88)90227-8; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; CLARK RAF, 1977, J IMMUNOL, V118, P137; DAHL R, 1978, ALLERGY, V33, P211, DOI 10.1111/j.1398-9995.1978.tb01536.x; GODFREY S, 1986, EUR J RESPIR DIS, V68, P81; IIKURA Y, 1985, J ALLERGY CLIN IMMUN, V75, P285, DOI 10.1016/0091-6749(85)90059-4; KOWNATZKI E, 1977, NATURE, V270, P67, DOI 10.1038/270067a0; LEE TH, 1985, THORAX, V40, P481, DOI 10.1136/thx.40.7.481; LEE TH, 1984, AM REV RESPIR DIS, V129, P409; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; NAGAKURA T, 1983, AM REV RESPIR DIS, V128, P294; PETERSON CGB, 1987, BIOCHEM J, V245, P781, DOI 10.1042/bj2450781; PINCUS SH, 1982, J INVEST DERMATOL, V79, P53, DOI 10.1111/1523-1747.ep12510590; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; REES PJ, 1985, THORAX, V40, P603, DOI 10.1136/thx.40.8.603; TURNBULL LW, 1977, IMMUNOLOGY, V32, P57; TURNBULL LW, 1976, IMMUNOLOGY, V31, P797; VENGE P, 1989, European Respiratory Journal, V2, p430S; VENGE P, 1988, INT ARCH ALLER A IMM, V87, P306, DOI 10.1159/000234690; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; VENGE P, 1990, J ALLERGY CLIN IMMUN, V85, P498, DOI 10.1016/0091-6749(90)90161-V; Venge P, 1989, EOSINOPHILS ASTHMA, P163; 1983, B EUR PHYSIOPATHOL R, V19, P495	25	65	65	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					699	704		10.1016/0091-6749(91)90175-N	http://dx.doi.org/10.1016/0091-6749(91)90175-N			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1955630				2022-12-18	WOS:A1991GQ45200003
J	MONERETVAUTRIN, DA; GUEANT, JL; KAMEL, L; LAXENAIRE, MC; ELKHOLTY, S; NICOLAS, JP				MONERETVAUTRIN, DA; GUEANT, JL; KAMEL, L; LAXENAIRE, MC; ELKHOLTY, S; NICOLAS, JP			ANAPHYLAXIS TO MUSCLE-RELAXANTS - CROSS-SENSITIVITY STUDIED BY RADIOIMMUNOASSAYS COMPARED TO INTRADERMAL TESTS IN 34 CASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FAC MED NANCY,BIOCHIM MED & PEDIAT LAB,F-54019 NANCY,FRANCE; HOP CENT,DEPT ANESTHESIOL,NANCY,FRANCE	Universite de Lorraine; CHU de Nancy	MONERETVAUTRIN, DA (corresponding author), FAC MED NANCY,SERV IMMUNO ALLERGOL,BP 184,F-54505 VANDOEUVRE NANCY,FRANCE.		garcia, waynice np/K-3914-2015					BALDO BA, 1983, MOL IMMUNOL, V20, P1393, DOI 10.1016/0161-5890(83)90171-2; BALDO BA, 1983, NATURE, V306, P262, DOI 10.1038/306262a0; BALDO BA, 1983, ANAESTH INTENS CARE, V11, P194, DOI 10.1177/0310057X8301100302; BOOIJ LHDJ, 1980, ACTA ANAESTH SCAND, V24, P393; Clarke R S, 1985, Ann Fr Anesth Reanim, V4, P146, DOI 10.1016/S0750-7658(85)80190-8; DIDIER A, 1987, J ALLERGY CLIN IMMUN, V79, P578, DOI 10.1016/S0091-6749(87)80152-5; FISHER M, 1982, ANESTH INTENSIVE CAR, V10, P152; FISHER MM, 1980, ANAESTH INTENS CARE, V8, P211, DOI 10.1177/0310057X8000800222; FISHER MM, 1981, ANAESTH INTENS CARE, V9, P226, DOI 10.1177/0310057X8100900304; FISHER MM, 1983, ANESTH ANALG, V62, P559; FISHER MM, 1979, ANAESTH INTENS CARE, V7, P58, DOI 10.1177/0310057X7900700110; GALLETLY DC, 1985, ANAESTH INTENS CARE, V13, P305, DOI 10.1177/0310057X8501300311; GUEANT J L, 1986, Annales Francaises d'Anesthesie et de Reanimation, V5, P570, DOI 10.1016/S0750-7658(86)80064-8; HARLE DG, 1985, BRIT J ANAESTH, V57, P1073, DOI 10.1093/bja/57.11.1073; HARLE DG, 1985, J IMMUNOL METHODS, V78, P293, DOI 10.1016/0022-1759(85)90087-0; HARLE DG, 1984, LANCET, V1, P930; IOLLENAERE JP, 1979, ATLAS 3 DIMENSIONAL, P56; Lavery G G, 1985, Ann Fr Anesth Reanim, V4, P180, DOI 10.1016/S0750-7658(85)80196-9; Laxenaire M C, 1982, Ann Fr Anesth Reanim, V1, P29, DOI 10.1016/S0750-7658(82)80073-7; Laxenaire M C, 1985, Ann Fr Anesth Reanim, V4, P158, DOI 10.1016/S0750-7658(85)80192-1; LAXENAIRE MC, 1985, INT ANESTHESIOLOGY C, P145; LEVINE BB, 1968, J CLIN INVEST, V47, P555; Moneret-Vautrin D A, 1985, Ann Fr Anesth Reanim, V4, P186, DOI 10.1016/S0750-7658(85)80198-2; MONERET-VAUTRIN D A, 1984, Annales Francaises d'Anesthesie et de Reanimation, V3, P467, DOI 10.1016/S0750-7658(84)80150-1; MONERETVAUTRIN DA, 1981, CLIN ALLERGY, V11, P175, DOI 10.1111/j.1365-2222.1981.tb01582.x; MONERETVAUTRIN DA, 1978, NOUV PRESSE MED, V7, P3371; MOSS J, 1983, ANESTHESIOLOGY, V59, P330, DOI 10.1097/00000542-198310000-00011; PANNING B, 1985, ANAESTHESIST, V34, P211; Vervloet D, 1985, Ann Fr Anesth Reanim, V4, P184, DOI 10.1016/S0750-7658(85)80197-0; VERVLOET D, 1985, J ALLERGY CLIN IMMUN, V75, P338, DOI 10.1016/0091-6749(85)90069-7; VERVLOET D, 1979, J ALLERGY CLIN IMMUN, V63, P348, DOI 10.1016/0091-6749(79)90130-1; VERVLOET D, 1986, 12 P INT C ALL CLIN, P69; WATKINS J, 1985, INT ANESTHESIOLOGY C, P17; Wood M, 1985, Ann Fr Anesth Reanim, V4, P176, DOI 10.1016/S0750-7658(85)80195-7; YOUNGMAN PR, 1983, LANCET, V2, P597	35	65	66	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				745	752		10.1016/0091-6749(88)90074-7	http://dx.doi.org/10.1016/0091-6749(88)90074-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	2903875				2022-12-18	WOS:A1988R170800006
J	MOLER, FW; HURWITZ, ME; CUSTER, JR				MOLER, FW; HURWITZ, ME; CUSTER, JR			IMPROVEMENT IN CLINICAL ASTHMA SCORE AND PACO2 IN CHILDREN WITH SEVERE ASTHMA TREATED WITH CONTINUOUSLY NEBULIZED TERBUTALINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MOLER, FW (corresponding author), UNIV MICHIGAN,CS MOTT CHILDRENS HOSP,MED CTR,DEPT PEDIAT,PEDIAT INTENS CARE & PULM SECT,ANN ARBOR,MI 48109, USA.							AGGARWAL J, 1986, J ALLERGY CLIN IMMUN, V77, P185; BIERMAN CW, 1986, CRITICALLY ILL CHILD, P299; BLOOMFIELD P, 1979, BRIT MED J, V1, P848, DOI 10.1136/bmj.1.6167.848; BOHN D, 1984, CRIT CARE MED, V12, P892, DOI 10.1097/00003246-198410000-00012; COTTON EK, 1975, PEDIATR CLIN N AM, V22, P163; CUSHLEY MJ, 1983, THORAX, V38, P908, DOI 10.1136/thx.38.12.908; DAVIES DS, 1984, EUR J RESPIR DIS, V65, P141; ELLIS EF, 1983, NELSONS TXB PEDIATRI, P544; ESTELLE F, 1977, AM J DIS CHILD, V131, P1097; GOODMAN W, 1985, PHARM BASIS THERAPEU, P172; HEIMER D, 1980, J ALLERGY CLIN IMMUN, V66, P75, DOI 10.1016/0091-6749(80)90141-4; HULTQUIST C, 1984, EUR J RESPIR DIS, V65, P195; INGEMARSSON I, 1985, OBSTET GYNECOL, V66, P176; KADAR D, 1974, CLIN PHARMACOL THER, V16, P789; KURLAND G, 1979, J ALLERGY CLIN IMMUN, V63, P407, DOI 10.1016/0091-6749(79)90214-8; LAWFORD P, 1978, BRIT MED J, V1, P84, DOI 10.1136/bmj.1.6105.84; MAGUIRE JF, 1986, J ALLERGY CLIN IMM 2, V77, pA109; MATSON JR, 1978, J PEDIATR-US, V92, P776, DOI 10.1016/S0022-3476(78)80150-4; MCCUBBIN M, 1987, AM REV RESPIR DIS, V145, pA229; MCFADDEN ER, 1981, J ALLERGY CLIN IMMUN, V68, P91, DOI 10.1016/0091-6749(81)90164-0; NEWHOUSE MT, 1986, NEW ENGL J MED, V315, P870, DOI 10.1056/NEJM198610023151406; NICHOLS DG, 1987, TXB PEDIATRIC INTENS, P84; PARRY WH, 1976, AM J DIS CHILD, V130, P39, DOI 10.1001/archpedi.1976.02120020041006; PATERSON JW, 1968, LANCET, V2, P426; PIERCE RJ, 1981, CHEST, V79, P506, DOI 10.1378/chest.79.5.506; RICHIE D, 1979, NZ MED J, V89, P332; ROBERTSON CF, 1985, J PEDIATR-US, V106, P672, DOI 10.1016/S0022-3476(85)80101-3; SHENFIELD GM, 1973, AM REV RESPIR DIS, V108, P501; STEMPEL DA, 1983, PEDIATR CLIN N AM, V31, P879; SVEDMYR N, 1985, BRONCHIAL ASTHMA, P640; TASHKIN DP, 1985, BRONCHIAL ASTHMA, P611; THIRINGER G, 1976, SCAND J RESPIR DIS, V57, P17; WEISS CB, 1968, ANN ALLERGY, V26, P545; WILLIAMS SJ, 1981, THORAX, V36, P629, DOI 10.1136/thx.36.8.629; WOOD DW, 1968, J ALLERGY, V42, P261, DOI 10.1016/0021-8707(68)90020-8; WOOD DW, 1972, AM J DIS CHILD, V123, P227, DOI 10.1001/archpedi.1972.02110090097011; WOOD DW, 1973, ANN ALLERGY, V31, P607; WOOD DW, 1972, J ALLERGY CLIN IMMUN, V50, P75, DOI 10.1016/0091-6749(72)90002-4; ZEIGER RS, 1983, J ASTHMA, V20, P341, DOI 10.3109/02770908309077377; ZWERDLING RG, 1986, PEDIATR ANN, V15, P105, DOI 10.3928/0090-4481-19860201-08; 1987, MED LETT, V29, P11	41	65	65	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1988	81	6					1101	1109		10.1016/0091-6749(88)90876-7	http://dx.doi.org/10.1016/0091-6749(88)90876-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P0023	3132498				2022-12-18	WOS:A1988P002300006
J	KLAUSTERMEYER, WB; NORITAKE, DT; KWONG, FK				KLAUSTERMEYER, WB; NORITAKE, DT; KWONG, FK			CHRYSOTHERAPY IN THE TREATMENT OF CORTICOSTEROID-DEPENDENT ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM WADSWORTH MED CTR,DEPT RES,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	KLAUSTERMEYER, WB (corresponding author), VET ADM WADSWORTH MED CTR,DEPT MED,DIV ALLERGY & IMMUNOL 691W111R,WILSHIRE & SAWTELLE BLVD,LOS ANGELES,CA 90073, USA.							[Anonymous], 1960, ANN RHEUM DIS, V19, P95; CARROLL MP, 1985, J ALLERGY CLIN IMMUN, V75, P290, DOI 10.1016/0091-6749(85)90060-0; DAVIS P, 1979, J RHEUMATOL S5, V1, P6; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FABBRI LM, 1984, AM REV RESPIR DIS, V129, P288; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HOGG JC, 1983, ALLERGY PRINCIPLES P, P833; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; LEE LY, 1977, J APPL PHYSIOL, V43, P626, DOI 10.1152/jappl.1977.43.4.626; METZGER WJ, 1985, CLIN REV ALLERG, V3, P145, DOI 10.1007/BF02992980; MURANAKA M, 1974, J ALLERGY CLIN IMMUN, V54, P32, DOI 10.1016/S0091-6749(74)80006-0; MURANAKA M, 1978, ANN ALLERGY, V40, P132; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P350, DOI 10.1016/0091-6749(81)90079-8; OBYRNE P, 1983, PHYSIOLOGIST, V26, pA35; PENNEYS NS, 1979, J AM ACAD DERMATOL, V1, P315, DOI 10.1016/S0190-9622(79)80020-1; SCHEEL LD, 1959, J APPL PHYSIOL, V14, P67, DOI 10.1152/jappl.1959.14.1.67; SOKAL RR, 1969, BIOMETRY, P598; SUZUKI S, 1983, J ALLERGY CLIN IMMUN, V72, P469, DOI 10.1016/0091-6749(83)90583-3; VANARSDEL PP, 1981, J ALLERGY CLIN IMMUN, V67, P348, DOI 10.1016/0091-6749(81)90078-6; WALSH JJ, 1961, ARCH INTERN MED, V108, P376, DOI 10.1001/archinte.1961.03620090048006; YAMAUCHI N, 1984, J ALLERGY CLIN IMMUN, V74, P802, DOI 10.1016/0091-6749(84)90182-9; 1975, CHEST, V67, P383	24	65	65	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1987	79	5					720	725		10.1016/0091-6749(87)90202-8	http://dx.doi.org/10.1016/0091-6749(87)90202-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H4349	3106448				2022-12-18	WOS:A1987H434900005
J	BEDARD, PM; BRUNET, C; PELLETIER, G; HEBERT, J				BEDARD, PM; BRUNET, C; PELLETIER, G; HEBERT, J			INCREASED COMPOUND 48/80 INDUCED LOCAL HISTAMINE-RELEASE FROM NONLESIONAL SKIN OF PATIENTS WITH CHRONIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BEDARD, PM (corresponding author), CHU LAVAL,CTR RECH IMMUNOL & PHUMATOL,2705 BOUL LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA.							ATKINS PC, 1981, J ALLERGY CLIN IMMUN, V68, P286, DOI 10.1016/0091-6749(81)90153-6; DAVIS KC, 1984, J ALLERGY CLIN IMMUN, V73, P810, DOI 10.1016/0091-6749(84)90451-2; DUNSKY EH, 1978, J ALLERGY CLIN IMMUN, V62, P127, DOI 10.1016/0091-6749(78)90091-X; DUNSKY EH, 1979, J ALLERGY CLIN IMMUN, V63, P426, DOI 10.1016/0091-6749(79)90217-3; KAPLAN A P, 1984, Journal of Allergy and Clinical Immunology, V73, P120; KAPLAN AP, 1983, POSTGRAD MED, V74, P209, DOI 10.1080/00325481.1983.11698427; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAPLAN AP, 1978, ALLERGY PRINCIPLES P, P1080; LEVINSON AI, 1984, POSTGRAD MED, V76, P183, DOI 10.1080/00325481.1984.11698674; Lewis T., 1927, BLOOD VESSELS HUMAN; MATHEWS KP, 1978, J ALLERGY CLIN IMMUN, V61, P347, DOI 10.1016/0091-6749(78)90112-4; MEKORI YA, 1983, J ALLERGY CLIN IMMUN, V72, P681, DOI 10.1016/0091-6749(83)90629-2; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; PHANUPHAK P, 1980, J ALLERGY CLIN IMMUN, V65, P371, DOI 10.1016/0091-6749(80)90215-8; SALARI H, 1985, J EXP MED, V162, P1904, DOI 10.1084/jem.162.6.1904; TING S, 1981, J ALLERGY CLIN IMMUN, V68, P65, DOI 10.1016/0091-6749(81)90125-1; VERBURG KM, 1983, LIFE SCI, V32, P2855, DOI 10.1016/0024-3205(83)90322-3; ZWEIMAN B, 1976, J ALLERGY CLIN IMMUN, V58, P657, DOI 10.1016/0091-6749(76)90177-9	18	65	66	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1121	1125		10.1016/0091-6749(86)90260-5	http://dx.doi.org/10.1016/0091-6749(86)90260-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	2431027				2022-12-18	WOS:A1986F302600006
J	MAURICE, F; RIVORY, JP; LARSSON, PH; JOHANSSON, SGO; BOUSQUET, J				MAURICE, F; RIVORY, JP; LARSSON, PH; JOHANSSON, SGO; BOUSQUET, J			ANAPHYLACTIC SHOCK CAUSED BY FORMALDEHYDE IN A PATIENT UNDERGOING LONG-TERM HEMODIALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP AIGUELONGUE,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE; CTR HEMODIALYSE LANGUEDOC ROUSSILLON,MONTPELLIER,FRANCE; KAROLINSKA INST,INST KLIN IMMUNOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet			Bousquet, Jean/O-4221-2019					ANDERSEN KE, 1982, ALLERGIC REACTIONS D, P313; BHAT K, 1984, ANN ALLERGY, V52, P282; BOUSQUET J, 1982, ALLERGY, V37, P397, DOI 10.1111/j.1398-9995.1982.tb02318.x; DAHLQUIST I, 1978, CONTACT DERMATITIS, V4, P173, DOI 10.1111/j.1600-0536.1978.tb03775.x; DOLOVICH J, 1978, J ALLERGY CLIN IMMUN, V62, P30, DOI 10.1016/0091-6749(78)90069-6; EVANS S, 1983, J ALLERGY CLIN IMMUN, V71, P158, DOI 10.1016/0091-6749(83)90403-7; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V74, P544, DOI 10.1016/0091-6749(84)90392-0; HENDRICK DJ, 1975, BRIT MED J, V1, P607, DOI 10.1136/bmj.1.5958.607; HOEY JR, 1984, CAN MED ASSOC J, V130, P115; JOHANSSON SGO, 1975, J CLIN PATHOL S, V28, P33; MAURICE F, 1982, NEPHROLOGIE, V67, P3; Molina C, 1971, Rev Fr Allergol, V11, P11, DOI 10.1016/S0035-2845(71)80004-5; NICHOLLS AJ, 1982, BRIT MED J, V285, P1607, DOI 10.1136/bmj.285.6355.1607; Pepys J., 1975, BR J HOSP MED, V14, P412; PORTER JAH, 1975, LANCET, V2, P603; VILLARROEL F, 1984, ARTIF ORGANS, V8, P278, DOI 10.1111/j.1525-1594.1984.tb04290.x	16	65	67	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					594	597		10.1016/0091-6749(86)90351-9	http://dx.doi.org/10.1016/0091-6749(86)90351-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	3958388				2022-12-18	WOS:A1986A938100011
J	GJESING, B; JAGER, L; MARSH, DG; LOWENSTEIN, H				GJESING, B; JAGER, L; MARSH, DG; LOWENSTEIN, H			THE INTERNATIONAL COLLABORATIVE STUDY ESTABLISHING THE 1ST INTERNATIONAL STANDARD FOR TIMOTHY (PHLEUM-PRATENSE) GRASS-POLLEN ALLERGENIC EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COPENHAGEN,PROT LAB,SIGURDSGADE 34,DK-2200 COPENHAGEN N,DENMARK; JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,BALTIMORE,MD 21239; FRIEDRICH SCHILLER UNIV,BEREICH MED,INST KLIN IMMUNOL,DDR-6900 JENA,GER DEM REP	University of Copenhagen; Johns Hopkins University; Friedrich Schiller University of Jena					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019727, R55AI019727] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19727] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERRENS L, 1973, INT ARCH ALLER A IMM, V45, P30, DOI 10.1159/000230996; BJERRUM OJ, 1975, SCAND J IMMUNOL   S2, V4, P89; CALAM DH, 1982, CHROMATOGRAPHIA, V16, P216, DOI 10.1007/BF02258905; CAMPBELL PJ, 1974, J BIOL STAND, V2, P259, DOI 10.1016/0092-1157(74)90034-1; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CLARKE H. G. MINCHIN, 1967, PROTIDES BIOL FLUIDS, V14, P503; FINNEY DJ, 1978, STATISTICAL METHOD B; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; HALD A, 1953, STATISTICAL METHODS; Kirkwood TBL, 1979, BIOMETRICS, V35, P908; LEGGETTBAILEY J, 1962, TECHNIQUES PROTEIN C, P73; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOWENSTEIN H, 1978, ALLERGY, V33, P30, DOI 10.1111/j.1398-9995.1978.tb01504.x; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; OSTERBALLE O, 1983, J ALLERGY CLIN IMMUN, V71, P40, DOI 10.1016/0091-6749(83)90545-6; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; Voller A., 1976, AM SOC MICROBIOL, V17, P506; WEBER K, 1975, PROTEINS, V1, pCH13; 1978, WHO TECHNICAL REPORT, V626	21	65	67	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					258	267		10.1016/0091-6749(85)90055-7	http://dx.doi.org/10.1016/0091-6749(85)90055-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	2578495				2022-12-18	WOS:A1985ABZ0500005
J	MCGRATH, KG; ZEFFREN, B; ALEXANDER, J; KAPLAN, K; PATTERSON, R				MCGRATH, KG; ZEFFREN, B; ALEXANDER, J; KAPLAN, K; PATTERSON, R			ALLERGIC REACTIONS TO STREPTOKINASE CONSISTENT WITH ANAPHYLACTIC OR ANTIGEN-ANTIBODY COMPLEX-MEDIATED DAMAGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,303 & CHICAGO AVE,CHICAGO,IL 60611; NORTHWESTERN UNIV,SCH MED,DEPT MED,CARDIOL SECT,CHICAGO,IL 60611	Northwestern University; Northwestern University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BURROW CR, 1984, ANN INTERN MED, V100, P237, DOI 10.7326/0003-4819-100-2-237; CROWLEY MJ, 1981, AM HEART J, V102, P1149; JARVINEN P, 1978, KLIN WOCHENSCHR, V56, P801, DOI 10.1007/BF01489713; JOHANSSON L, 1979, ACTA MED SCAND, V206, P93; KAKKAR VV, 1969, BRIT J SURG, V56, P178, DOI 10.1002/bjs.1800560307; KOHNER EM, 1976, BRIT MED J, V1, P550, DOI 10.1136/bmj.1.6009.550; MARBET GA, 1982, THROMB HAEMOSTASIS, V48, P196; MARDER VJ, 1977, J LAB CLIN MED, V89, P1018; MASON D, 1981, AM HEART J, V102, P1123; MCGRATH KG, 1984, JAMA-J AM MED ASSOC, V252, P1314, DOI 10.1001/jama.252.10.1314; Oppenheim J. J., 1976, MANUAL CLIN IMMUNOLO, P81; OUCHTERLONY O, 1978, PROG ALLERGY, V5, P1; REICHLE FA, 1977, J SURG RES, V22, P202, DOI 10.1016/0022-4804(77)90135-4; SELPUVEDA R, 1979, CLIN ALLERGY, V9, P359; SHARMA GVRK, 1982, NEW ENGL J MED, V306, P1268; SIX P, 1976, BLUTGERINNUNG ANTIKO, P111; STRAUB PW, 1974, SCHWEIZ MED WSCHR, V104, P1891; THAYER CF, 1981, CURR THER RES CLIN E, V30, P129; THORSBY E, 1970, HISTOCOMPATIBILITY T, P655; TOTTY WG, 1982, AM J ROENTGENOL, V138, P143, DOI 10.2214/ajr.138.1.143; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55	21	65	66	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					453	457		10.1016/0091-6749(85)90726-2	http://dx.doi.org/10.1016/0091-6749(85)90726-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	3928729				2022-12-18	WOS:A1985ARC0900006
J	MURRAY, AB; FERGUSON, AC; MORRISON, BJ				MURRAY, AB; FERGUSON, AC; MORRISON, BJ			SENSITIZATION TO HOUSE DUST MITES IN DIFFERENT CLIMATIC AREAS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA, DEPT HLTH CARE & EPIDEMIOL, VANCOUVER V6H 3V4, BC, CANADA	University of British Columbia	MURRAY, AB (corresponding author), UNIV BRITISH COLUMBIA, DEPT PEDIAT, DIV ALLERGY, VANCOUVER V6H 3V4, BC, CANADA.			Ferguson, Alexander C./0000-0002-3143-5619				ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1983, J MED ENTOMOL, V20, P99, DOI 10.1093/jmedent/20.1.99; ARLIAN LG, 1978, J MED ENTOMOL, V15, P35, DOI 10.1093/jmedent/15.1.35; ARLIAN LG, 1979, COMP BIOCHEM PHYS A, V64, P191, DOI 10.1016/0300-9629(79)90650-9; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BRANDT RL, 1976, J MED ENTOMOL, V13, P327, DOI 10.1093/jmedent/13.3.327; CHAPMAN JD, 1956, BRIT COLUMBIA ATLAS, P15; DAILEY F, 1982, Journal of Allergy and Clinical Immunology, V69, P127; DUSBABEK F, 1975, Folia Parasitologica (Ceske Budejovice), V22, P219; HODGMAN CS, 1956, HDB CHEM PHYSICS, P2302; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; LANG JD, 1977, ENVIRON ENTOMOL, V6, P213, DOI 10.1093/ee/6.2.213; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281, DOI 10.1093/ee/7.2.281; MARYGABRIEL SX, 1977, CLIN ALLERGY, V7, P325; MURRAY AB, 1983, CAN MED ASSOC J, V129, P828; MURRAY AB, 1983, PEDIATRICS, V71, P418; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P21, DOI 10.1016/0091-6749(83)90542-0; ORDMAN D, 1971, South African Medical Journal, V45, P739; PEPYS J, 1968, LANCET, V1, P1270; PRICE JF, 1982, CLIN EXP IMMUNOL, V47, P587; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P711, DOI 10.1136/adc.49.9.711; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; VANASPEREN PP, 1980, MED J AUSTRALIA, V2, P266; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; WARNER JO, 1978, LANCET, V2, P912; 1959, CLIMATIC NORMALS, V4, P1	28	65	66	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	1					108	112		10.1016/0091-6749(85)90812-7	http://dx.doi.org/10.1016/0091-6749(85)90812-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AMV84	4008808				2022-12-18	WOS:A1985AMV8400015
J	VALENTINE, MD				VALENTINE, MD			INSECT VENOM ALLERGY - DIAGNOSIS AND TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											VALENTINE, MD (corresponding author), JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV ALLERGY & CLIN IMMUNOL,BALTIMORE,MD 21239, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015443] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENSON RL, 1930, J ALLERGY, V1, P105; BERNTON HS, 1965, J ALLERGY, V36, P315, DOI 10.1016/0021-8707(65)90038-9; BRAUN L. I. B., 1925, SOUTH AFRICAN MEDICAL RECORD, V23, P408; BUSSE WW, 1975, JAMA-J AM MED ASSOC, V231, P1154, DOI 10.1001/jama.231.11.1154; FOUBERT EL, 1958, J ALLERGY, V29, P13, DOI 10.1016/0021-8707(58)90050-9; GOLDEN D B K, 1982, Journal of Allergy and Clinical Immunology, V69, P124; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; GOLDEN DBK, 1983, J CLIN IMMUNOASSAY, V6, P172; GRAFT DF, 1984, J ALLERGY CLIN IMMUN, V73, P61, DOI 10.1016/0091-6749(84)90485-8; HAMILTON RG, 1981, J ALLERGY CLIN IMMUN, V67, P14, DOI 10.1016/0091-6749(81)90039-7; HOFFMAN DR, 1982, ANN ALLERGY, V48, P78; HUNT KJ, 1976, ANN INTERN MED, V85, P56, DOI 10.7326/0003-4819-85-1-56; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; KING TP, CLIN REV ALLERGY ALL; LANGLOIS C, 1965, J ALLERGY, V36, P109, DOI 10.1016/0021-8707(65)90160-7; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; LOVELESS MARY HEWITT, 1956, ANN ALLERGY, V14, P347; LOVELESS MH, 1962, J IMMUNOL, V89, P204; REISMAN RE, 1979, J ALLERGY CLIN IMMUN, V64, P3, DOI 10.1016/0091-6749(79)90074-5; SCHUBERTH KC, 1983, J PEDIATR-US, V102, P361, DOI 10.1016/S0022-3476(83)80649-0; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; SCHWARTZ HJ, 1965, JAMA-J AM MED ASSOC, V194, P113; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; SHIPOLIN.RA, 1974, EUR J BIOCHEM, V48, P465, DOI 10.1111/j.1432-1033.1974.tb03787.x; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SOBOTKA AK, 1974, J ALLERGY CLIN IMMUN, V53, P170, DOI 10.1016/0091-6749(74)90005-0; TORSNEY PJ, 1973, J ALLERGY CLIN IMMUN, V52, P303, DOI 10.1016/0091-6749(73)90049-3; VALENTINE MD, 1976, J ALLERGY CLIN IMMUN, V57, P247; VERHEIJ HM, 1983, BIOCHIM BIOPHYS ACTA, V747, P93, DOI 10.1016/0167-4838(83)90126-7; ZELEZNICK LD, 1977, J ALLERGY CLIN IMMUN, V59, P2, DOI 10.1016/0091-6749(77)90169-5	32	65	66	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					299	304		10.1016/0091-6749(84)90397-X	http://dx.doi.org/10.1016/0091-6749(84)90397-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6366028				2022-12-18	WOS:A1984SK15500001
J	NACLERIO, R; MIZRAHI, EA; ADKINSON, NF				NACLERIO, R; MIZRAHI, EA; ADKINSON, NF			IMMUNOLOGICAL OBSERVATIONS DURING DESENSITIZATION AND MAINTENANCE OF CLINICAL TOLERANCE TO PENICILLIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP, SCH MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21239 USA	Johns Hopkins University					NIAID NIH HHS [AI 11936] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1977, P A BENZON S, V10, P123; ADKINSON NF, 1980, MANUAL CLIN IMMUNOLO, P794; BROWN BC, 1964, JAMA-J AM MED ASSOC, V189, P599; BROWN LA, 1982, J ALLERGY CLIN IMMUN, V69, P51, DOI 10.1016/0091-6749(82)90087-2; CLUFF L, 1974, HARRISONS PRINCIPLES, P381; DEWECK AL, 1978, IMMUNOLOGICAL DISEAS, P432; FELLNER MJ, 1970, J ALLERGY, V45, P55, DOI 10.1016/0021-8707(70)90017-1; GANIER M, 1977, JAMA-J AM MED ASSOC, V237, P1852; GILLMAN S A, 1972, Clinical Allergy, V2, P63, DOI 10.1111/j.1365-2222.1972.tb01268.x; GRAYBILL JR, 1974, SOUTH MED J, V67, P62, DOI 10.1097/00007611-197401000-00017; GREEN GR, 1971, J ALLERGY CLIN IMMUN, V48, P331, DOI 10.1016/0091-6749(71)90079-0; KRAFT D, 1977, CLIN ALLERGY, V7, P21, DOI 10.1111/j.1365-2222.1977.tb01420.x; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; ODONOVAN WJ, 1946, LANCET, V251, P444; ODRISCOLL J, 1955, BMJ-BRIT MED J, V2, P473, DOI 10.1136/bmj.2.4937.473; PEDERSEN.J, 1969, ACTA ALLERGOL, V24, P333, DOI 10.1111/j.1398-9995.1969.tb03748.x; REISMAN RE, 1962, J ALLERGY, V33, P178, DOI 10.1016/0021-8707(62)90007-2; SCHELLENBERG RR, 1975, J IMMUNOL, V49, P428; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P500, DOI 10.1016/0091-6749(82)90174-9; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P275, DOI 10.1016/S0091-6749(82)80004-3	21	65	66	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	3					294	301		10.1016/0091-6749(83)90083-0	http://dx.doi.org/10.1016/0091-6749(83)90083-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH188	6826989				2022-12-18	WOS:A1983QH18800005
J	DOPICO, GA; FLAHERTY, D; BHANSALI, P; CHAVAJE, N				DOPICO, GA; FLAHERTY, D; BHANSALI, P; CHAVAJE, N			GRAIN FEVER SYNDROME INDUCED BY INHALATION OF AIRBORNE GRAIN DUST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,DEPT PREVENT MED,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,JOHN RANKIN LAB PULM MED,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					PHS HHS [210-76-0176] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALDO BA, 1978, CLIN ALLERGY, V8, P109, DOI 10.1111/j.1365-2222.1978.tb00456.x; BASS H, 1973, CHEST, V63, P171, DOI 10.1378/chest.63.2.171; BECKLAKE MR, 1980, OCCUPATIONAL PULMONA, P189; BHANSALI PV, 1979, J APPL PHYSIOL, V47, P161, DOI 10.1152/jappl.1979.47.1.161; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHANYEUNG M, 1980, AM REV RESPIR DIS, V121, P329; CHANYEUNG M, 1979, CHEST, V75, P461, DOI 10.1378/chest.75.4.461; COTTON DJ, 1978, ANN INTERN MED, V88, P840, DOI 10.7326/0003-4819-88-6-840; DICKIE HA, 1958, JAMA-J AM MED ASSOC, V167, P1069, DOI 10.1001/jama.1958.02990260011004; DOPICO GA, 1977, AM REV RESPIR DIS, V115, P915; DOPICO GA, 1982, CHEST, V81, P55, DOI 10.1378/chest.81.1.55; Dosman J. A., 1980, OCCUPATIONAL PULMONA, P417; EMMANUEL DA, 1975, CHEST, V67, P293; FLAHERTY DK, 1974, J LAB CLIN MED, V84, P298; GOETZ O, 1971, J EXP MED, V134, P90; KABAT EA, 1961, EXPERIMENTAL IMMUNOC, P476; LUNN JA, 1968, BRIT J IND MED, V24, P158; MANCINI C, 1964, PROTIDES BIOL FLUIDS, P37; MARDINEY MR, 1965, J IMMUNOL, V94, P877; MARX JJ, 1976, J ALLERGY CLIN IMMUN, V57, P328, DOI 10.1016/0091-6749(76)90089-0; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; NICHOLS D, 1979, AM J MED, V67, P631, DOI 10.1016/0002-9343(79)90246-8; OGILVIE CM, 1957, J CLIN INVEST, V36, P1, DOI 10.1172/JCI103402; OLENCHOCK SA, 1980, OCCUPATIONAL PULMONA, P263; PATTERSO.R, 1974, CLIN ALLERGY, V4, P79, DOI 10.1111/j.1365-2222.1974.tb01365.x; PERNIS B, 1961, BRIT J IND MED, V18, P120; WARREN P, 1974, J ALLERGY CLIN IMMUN, V53, P139, DOI 10.1016/0091-6749(74)90002-5; WHIDDEN MP, 1979, P INT S GRAIN DUST, P73; WILLIAMS NORMAN, 1964, J OCCUP MED, V6, P319, DOI 10.1097/00043764-196408000-00001; 1978, AM REV RESPIR DIS 2, V118, P55	30	65	65	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	5					435	443		10.1016/0091-6749(82)90118-X	http://dx.doi.org/10.1016/0091-6749(82)90118-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NP934	7076983				2022-12-18	WOS:A1982NP93400005
J	GRAMMER, LC; ZEISS, CR; SUSZKO, IM; SHAUGHNESSY, MA; PATTERSON, R				GRAMMER, LC; ZEISS, CR; SUSZKO, IM; SHAUGHNESSY, MA; PATTERSON, R			A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF POLYMERIZED WHOLE RAGWEED FOR IMMUNOTHERAPY OF RAGWEED ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University				Grammer, Leslie/0000-0001-6860-2014	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACAL E, 1978, J ALLERGY CLIN IMMUN, V62, P289, DOI 10.1016/0091-6749(78)90160-4; HENDRIX S, 1980, J ALLERGY CLIN IMMUN, V65, P57, DOI 10.1016/0091-6749(80)90177-3; HENDRIX SG, 1980, J ALLERGY CLIN IMMUN, V66, P486, DOI 10.1016/0091-6749(80)90010-X; HENDRIX SG, 1981, J ALLERGY CLIN IMMUN, V67, P124, DOI 10.1016/0091-6749(81)90007-5; KELLY JF, 1980, J ALLERGY CLIN IMMUN, V65, P50, DOI 10.1016/0091-6749(80)90176-1; LEVINE MI, 1979, J ALLERGY CLIN IMMUN, V63, P209; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; MELAM H, 1980, ALLERGIC DISEASES, P326; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1979, J ALLERGY CLIN IMMUN, V63, P47, DOI 10.1016/0091-6749(79)90161-1; PATTERSON R, 1978, ALLERGY PRINCIPLES P, P881; WISE PJ, 1979, J ALLERGY CLIN IMMUN, V63, P216; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1968; ZEISS CR, 1979, J ALLERGY CLIN IMMUN, V63, P273, DOI 10.1016/0091-6749(79)90112-X; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1978, J ALLERGY CLIN IMMUN, V61, P216	18	65	65	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	6					494	499		10.1016/0091-6749(82)90173-7	http://dx.doi.org/10.1016/0091-6749(82)90173-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT025	7042799				2022-12-18	WOS:A1982NT02500004
J	RACHELEFSKY, GS; KATZ, RM; SIEGEL, SC				RACHELEFSKY, GS; KATZ, RM; SIEGEL, SC			CHRONIC SINUSITIS IN CHILDREN WITH RESPIRATORY ALLERGY - THE ROLE OF ANTI-MICROBIALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,DEPT PEDIAT,DIV ALLERGY & IMMUNOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles								AXELSSON A, 1973, LARYNGOSCOPE, V83, P2003, DOI 10.1288/00005537-197312000-00011; AXELSSON A, 1972, ACTA OTO-LARYNGOL, V74, P118, DOI 10.3109/00016487209128430; BJORKWALL T, 1950, FINSKA LAK SALLSK HA, V93, P38; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FREDERICK J, 1974, NEW ENGL J MED, V290, P135, DOI 10.1056/NEJM197401172900304; GROTE JJ, 1980, J LARYNGOL OTOL, V94, P177, DOI 10.1017/S0022215100088642; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; KALM O, 1975, SCAND J INFECT DIS, V7, P209, DOI 10.3109/inf.1975.7.issue-3.10; KOGUTT MS, 1973, PEDIATRICS, V52, P121; MANN W, 1977, ARCH OTO-RHINO-LARYN, V215, P67, DOI 10.1007/BF00463193; NICKMAN JN, 1978, LARYNGOSCOPE, V88, P117; NYLEN O, 1972, Scandinavian Journal of Infectious Diseases, V4, P43; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; REVONTA M, 1979, LANCET, V1, P320; SIEGEL SC, 1979, OTITIS MEDIA, P25; SPECTOR SL, 1981, J ALLERGY CLIN IMMUN, V67, P22, DOI 10.1016/0091-6749(81)90040-3; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302	17	65	65	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	69	4					382	387		10.1016/0091-6749(82)90150-6	http://dx.doi.org/10.1016/0091-6749(82)90150-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NL280	7069074				2022-12-18	WOS:A1982NL28000009
J	FINE, AJ				FINE, AJ			HYPERSENSITIVITY REACTION TO KIWI FRUIT (CHINESE GOOSEBERRY, ACTINIDIA-CHINENSIS)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ASTHMA & HAY FEVER CLIN INC,CLEVELAND,OH									ASTRIDGE SJ, 1975, ECON BOT, V29, P357, DOI 10.1007/BF02862182; CARNE A, 1978, BIOCHEM J, V173, P78; DEZACKS RL, 1979, HORTICULTURE, V57, P52; SIMMONS AF, 1972, GROWING UNUSUAL FRUI, P83	4	65	66	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	3					235	237		10.1016/0091-6749(81)90189-5	http://dx.doi.org/10.1016/0091-6749(81)90189-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG544	7264104				2022-12-18	WOS:A1981MG54400011
J	LASSER, EC; LANG, JH; LYON, SG; HAMBLIN, AE				LASSER, EC; LANG, JH; LYON, SG; HAMBLIN, AE			COMPLEMENT AND CONTRAST MATERIAL REACTORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LASSER, EC (corresponding author), UNIV CALIF SAN DIEGO HOSP, MED CTR, SCH MED, DEPT RADIOL, SAN DIEGO, CA 92103 USA.							ASGHAR SS, 1976, CLIN EXP IMMUNOL, V25, P244; AUSMAN J I, 1964, J Surg Res, V4, P349, DOI 10.1016/S0022-4804(64)80082-2; BRASCH RC, 1976, INVEST RADIOL, V11, P1, DOI 10.1097/00004424-197601000-00001; BRASCH RC, 1976, INVEST RADIOL, V11, P347, DOI 10.1097/00004424-197609000-00002; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1964, J CLIN INVEST, V43, P2204, DOI 10.1172/JCI105094; DONALDSON VH, 1968, J EXP MED, V127, P411, DOI 10.1084/jem.127.3.411; DONALDSON VH, 1976, J LAB CLIN MED, V68, P359; HADJIYANNAKI K, 1971, Clinical Allergy, V1, P221, DOI 10.1111/j.1365-2222.1971.tb03021.x; HARPEL PC, 1975, PROTEASES BIOL CONTR, P387; HAUPTMANN G, 1976, BLUT, V32, P195, DOI 10.1007/BF00995913; KOLB WP, 1978, J IMMUNOL, V121, P1232; LANG JH, 1971, J MED CHEM, V14, P233, DOI 10.1021/jm00285a014; LANG JH, 1958, J AM CHEM SOC, V80, P4923, DOI 10.1021/ja01551a041; LANG JH, 1976, INVEST RADIOL, V11, P303, DOI 10.1097/00004424-197607000-00007; Lasser E C, 1966, Invest Radiol, V1, P237; LASSER EC, 1962, AMER J ROENTGENOL RA, V87, P338; LASSER EC, 1971, RADIOLOGY, V100, P683, DOI 10.1148/100.3.683; LASSER EC, 1974, RADIOLOGY, V110, P49, DOI 10.1148/110.1.49; LASSER EC, 1968, RADIOLOGY, V91, P63, DOI 10.1148/91.1.63; LASSER EC, 1979, AM J ROENTGENOL, V132, P171, DOI 10.2214/ajr.132.2.171; LASSER EC, 1976, RADIOLOGY, V119, P91, DOI 10.1148/119.1.91; LASSER EC, 1974, INVEST RADIOL, V9, pA6, DOI 10.1097/00004424-197407000-00001; LAURELL AB, 1976, CLIN IMMUNOL IMMUNOP, V5, P308, DOI 10.1016/0090-1229(76)90038-6; LEPOW IRWIN H., 1965, CIBA FOUND SYMP, P74, DOI 10.1002/9780470719381.ch4; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MAYER MM, 1971, EXPT IMMUNOCHEMISTRY, P130; NAISH PF, 1977, IMMUNOLOGY, V33, P517; NILSSON IM, 1970, THROMB DIATH HAEMO, V30, P232; OGSTON D, 1962, LANCET, V2, P521; PALMBLAD J, 1977, J PSYCHOSOM RES, V21, P87, DOI 10.1016/0022-3999(77)90030-7; RITCHIE WGM, 1975, BRIT J RADIOL, V48, P945; ROCKOFF SD, 1972, INVEST RADIOL, V7, P177; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; SCHREIBER AD, 1976, BLOOD, V48, P567; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; TANNENBAUM H, 1975, J ALLERGY CLIN IMMUN, V56, P226, DOI 10.1016/0091-6749(75)90094-9; TILL G, 1978, INT ARCH ALLER A IMM, V56, P543, DOI 10.1159/000232070; VROON DH, 1970, IMMUNOCHEMISTRY, V7, P43, DOI 10.1016/0019-2791(70)90029-7; WALDRON RL, 1974, AM J ROENTGENOL, V122, P469, DOI 10.2214/ajr.122.3.469; WATKINS J, 1978, BRIT J ANAESTH, V50, P73; WATKINS J, 1976, BRIT J ANAESTH, V48, P457, DOI 10.1093/bja/48.5.457; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832	44	65	65	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	2					105	112		10.1016/0091-6749(79)90043-5	http://dx.doi.org/10.1016/0091-6749(79)90043-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG426	458054				2022-12-18	WOS:A1979HG42600003
J	LAWLOR, GJ; STIEHM, ER; KAPLAN, MS; SENGAR, DPS; TERASAKI, PI				LAWLOR, GJ; STIEHM, ER; KAPLAN, MS; SENGAR, DPS; TERASAKI, PI			PHYTOHEMAGGLUTININ (PHA) SKIN-TEST IN DIAGNOSIS OF CELLULAR IMMUNODEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF,SCH MED,DEPT SURG,LOS ANGELES,CA 90024; UNIV CALIF,CTR HLTH SCI,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								AIRO R, 1967, LANCET, V1, P899; AISENBERG AC, 1962, J CLIN INVEST, V41, P1964, DOI 10.1172/JCI104654; BELLANTI JA, 1971, PEDIATR CLIN N AM, V18, P49; BONFORTE RJ, 1972, J PEDIATR-US, V81, P775, DOI 10.1016/S0022-3476(72)80101-X; BURGIO GR, 1971, PEDIATR RES, V5, P88, DOI 10.1203/00006450-197102000-00029; CATALONA W J, 1972, New England Journal of Medicine, V286, P399, DOI 10.1056/NEJM197202242860804; GATTI RA, 1971, LANCET, V1, P1351; JOHNSON MW, 1971, NEW ENGL J MED, V284, P1255, DOI 10.1056/NEJM197106032842210; NASPITZ CK, 1968, PROG ALLERGY, V12, P1, DOI 10.1159/000287256; OPPENHEIM JJ, 1970, J IMMUNOL, V104, P835; OPPENHEIM JJ, 1968, FED PROC, V27, P21; PARK BH, 1972, P NATL ACAD SCI USA, V69, P371, DOI 10.1073/pnas.69.2.371; SCHREK R, 1963, FED PROC, V22, P428; SENGAR DPS, 1971, TRANSPLANTATION, V11, P260, DOI 10.1097/00007890-197103000-00004; SHANNON DC, 1966, NEW ENGL J MED, V275, P690, DOI 10.1056/NEJM196609292751302; [No title captured]	16	65	64	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	1					31	37		10.1016/0091-6749(73)90118-8	http://dx.doi.org/10.1016/0091-6749(73)90118-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q1826	4715272				2022-12-18	WOS:A1973Q182600004
J	Tesch, VK; Abolhassani, H; Shadur, B; Zobel, J; Mareika, Y; Sharapova, S; Karakoc-Aydiner, E; Riviere, JG; Garcia-Prat, M; Moes, N; Haerynck, F; Gonzales-Granado, LI; Perez, JLS; Mukhina, A; Shcherbina, A; Aghamohammadi, A; Hammarstrom, L; Dogu, F; Haskologlu, S; Ikinciogullari, AI; Bal, SK; Baris, S; Kilic, SS; Karaca, NE; Kutukculer, N; Girschick, H; Kolios, A; Keles, S; Uygun, V; Stepensky, P; Worth, A; van Montfrans, JM; Peters, AMJ; Meyts, I; Adeli, M; Marzollo, A; Padem, N; Khojah, AM; Chavoshzadeh, Z; Stefanija, MA; Bakhtiar, S; Florkin, B; Meeths, M; Gamez, L; Grimbacher, B; Seppanen, MRJ; Lankester, A; Gennery, AR; Seidel, MG				Tesch, Victoria Katharina; Abolhassani, Hassan; Shadur, Bella; Zobel, Joachim; Mareika, Yuliya; Sharapova, Svetlana; Karakoc-Aydiner, Elif; Riviere, Jacques G.; Garcia-Prat, Marina; Moes, Nicolette; Haerynck, Filomeen; Gonzales-Granado, Luis I.; Santos Perez, Juan Luis; Mukhina, Anna; Shcherbina, Anna; Aghamohammadi, Asghar; Hammarstrom, Lennart; Dogu, Figen; Haskologlu, Sule; Ikinciogullari, Aydan I.; Bal, Sevgi Kostel; Baris, Safa; Kilic, Sara Sebnem; Karaca, Neslihan Edeer; Kutukculer, Necil; Girschick, Hermann; Kolios, Antonios; Keles, Sevgi; Uygun, Vedat; Stepensky, Polina; Worth, Austen; van Montfrans, Joris M.; Peters, Anke M. J.; Meyts, Isabelle; Adeli, Mehdi; Marzollo, Antonio; Padem, Nurcicek; Khojah, Amer M.; Chavoshzadeh, Zahra; Stefanija, Magdalena Avbelj; Bakhtiar, Shahrzad; Florkin, Benoit; Meeths, Marie; Gamez, Laura; Grimbacher, Bodo; Seppanen, Mikko R. J.; Lankester, Arjan; Gennery, Andrew R.; Seidel, Markus G.		European Soc Blood; European Soc Immunodeficiencies	Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Inborn error of immunity; primary immunodeficiency disorder; immune dysregulation; clinical score; performance scale; hematopoietic stem cell transplantation; CTLA4; abatacept; sirolimus; combined immunodeficiency	MUTATIONS	Background: Recent findings strongly support hematopoietic stem cell transplantation (HSCT) in patients with severe presentation of LPS-responsive beige-like anchor protein (LRBA) deficiency, but long-term follow-up and survival data beyond previous patient reports or meta-reviews are scarce for those patients who do not receive a transplant. Objective: This international retrospective study was conducted to elucidate the longitudinal clinical course of patients with LRBA deficiency who do and do not receive a transplant. Method: We assessed disease burden and treatment responses with a specially developed immune deficiency and dysregulation activity score, reflecting the sum and severity of organ involvement and infections, days of hospitalization, supportive care requirements, and performance indices. Results: Of 76 patients with LRBA deficiency from 29 centers (median follow-up, 10 years; range, 1-52), 24 underwent HSCT from 2005 to 2019. The overall survival rate after HSCT (median follow-up, 20 months) was 70.8% (17 of 24 patients); all deaths were due to nonspecific, early, transplant-related mortality. Currently, 82.7% of patients who did not receive a transplant (43 of 52; age range, 3-69 years) are alive. Of 17 HSCT survivors, 7 are in complete remission and 5 are in good partial remission without treatment (together, 12 of 17 [70.6%]). In contrast, only 5 of 43 patients who did not receive a transplant (11.6%) are without immunosuppression. Immune deficiency and dysregulation activity scores were significantly lower in patients who survived HSCT than in those receiving conventional treatment (P = .005) or in patients who received abatacept or sirolimus as compared with other therapies, and in patients with residual LRBA expression. Higher disease burden, longer duration before HSCT, and lung involvement were associated with poor outcome. Conclusion: The lifelong disease activity, implying a need for immunosuppression and risk of malignancy, must be weighed against the risks of HSCT.	[Tesch, Victoria Katharina; Seidel, Markus G.] Med Univ Graz, Res Unit Pediat Hematol & Immunol, Graz, Austria; [Tesch, Victoria Katharina; Seidel, Markus G.] Med Univ Graz, Div Pediat Hematooncol, Graz, Austria; [Zobel, Joachim] Med Univ Graz, Dept Pediat & Adolescent Med, Div Gen Pediat, Graz, Austria; [Abolhassani, Hassan; Hammarstrom, Lennart] Karolinska Univ, Huddinge Hosp, Karolinska Inst, Div Clin Immunol,Dept Lab Med, Stockholm, Sweden; [Shadur, Bella; Stepensky, Polina] Hebrew Univ Jerusalem, Med Ctr, Dept Bone Marrow Transplantat, Jerusalem, Israel; [Mareika, Yuliya] Belarusian Res Ctr Pediat Oncol Hematol & Immunol, Bone Marrow Transplantat Unit, Minsk, BELARUS; [Sharapova, Svetlana] Belarusian Res Ctr Pediat Oncol Hematol & Immunol, Res Dept, Minsk, BELARUS; [Karakoc-Aydiner, Elif; Baris, Safa] Marmara Univ, Fac Med, Pediat Immunol & Allergy Div, Istanbul, Turkey; [Karakoc-Aydiner, Elif; Baris, Safa] Istanbul Jeffrey Modell Diagnost & Res Ctr Primar, Istanbul, Turkey; [Riviere, Jacques G.; Garcia-Prat, Marina] Univ Autonoma Barcelona, Pediat Infect Dis & Immunodeficiencies Unit, Hosp Univ Vall Hebron, Vall Hebron Res Inst, Barcelona, Spain; [Riviere, Jacques G.; Garcia-Prat, Marina] Jeffrey Modell Fdn Excellence Ctr, Barcelona, Spain; [Moes, Nicolette] Antwerp Univ Hosp, Dept Pediat Gastroenterol, Edegem, Belgium; [Moes, Nicolette] Univ Antwerp, Fac Med & Hlth Sci, Lab Expt Med & Pediat, Antwerp, Belgium; [Haerynck, Filomeen] Ghent Univ Hosp, Primary Immune Deficiency Res Lab, Ghent, Belgium; [Haerynck, Filomeen] Ghent Univ Hosp, Jeffrey Modell Diag & Res Ctr, Dept Internal Med & Pediat, Ctr Primary Immunodeficiency Ghent, Ghent, Belgium; [Gonzales-Granado, Luis I.] Hosp 12 Octubre, Res Inst, Immunodeficiencies Unit, Madrid, Spain; [Santos Perez, Juan Luis] Hosp Univ Virgen Nieves, Serv Pediat, Infect Dis & Immunodeficiencies Unit, Granada, Spain; [Mukhina, Anna; Shcherbina, Anna] Dmitry Rogachev Natl Med Ctr Pediat Hematol Oncol, Immunol, Moscow, Russia; [Abolhassani, Hassan; Aghamohammadi, Asghar] Univ Tehran Med Sci, Pediat Ctr Excellence, Res Ctr Immunodeficiencies, Childrens Med Ctr, Tehran, Iran; [Dogu, Figen; Haskologlu, Sule; Ikinciogullari, Aydan I.; Bal, Sevgi Kostel] Ankara Univ, Dept Pediat Immunol & Allergy, Sch Med, Ankara, Turkey; [Bal, Sevgi Kostel] Ludwig Boltzmann Inst Rare & Undiagnosed Dis, Vienna, Austria; [Bal, Sevgi Kostel] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria; [Kilic, Sara Sebnem] Uludag Univ, Dept Pediat, Fac Med, Pediat Immunol Rheumatol, Bursa, Turkey; [Karaca, Neslihan Edeer; Kutukculer, Necil] Ege Univ, Fac Med, Dept Pediat Immunol, Izmir, Turkey; [Girschick, Hermann] Vivantes Berlin Friedrichshain, Childrens Hosp, Berlin, Germany; [Kolios, Antonios] Univ Hosp Zurich, Dept Immunol, Zurich, Switzerland; [Kolios, Antonios] Univ Zurich, Zurich, Switzerland; [Keles, Sevgi; Uygun, Vedat] Necmettin Erbakan Univ, Div Pediat Allergy & Immunol, Meram Med Fac, Konya, Turkey; [Worth, Austen] UCL, Inst Child Hlth, London, England; [van Montfrans, Joris M.] UMC Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Immunol & Infect Dis, Utrecht, Netherlands; [Peters, Anke M. J.] Univ Freiburg, Med Ctr, Dept Pediat Hematol & Oncol, Ctr Pediat, Freiburg, Germany; [Meyts, Isabelle] Univ Hosp Leuven, Dept Pediat, Leuven, Belgium; [Meyts, Isabelle] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Lab Inborn Errors Immun, Leuven, Belgium; [Adeli, Mehdi] Hamad Med Corp, Sidra Med, Doha, Qatar; [Marzollo, Antonio] Univ Padua, Azienda Osped, Dept Womens & Childrens Hlth, Pediat Hematol Oncol Unit, Padua, Italy; [Padem, Nurcicek; Khojah, Amer M.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Chavoshzadeh, Zahra] Shahid Beheshti Univ Med Sci, Mofid Children Hosp, Tehran, Iran; [Stefanija, Magdalena Avbelj] Univ Med Ctr Ljubljana, Univ Childrens Hosp, Dept Pediat Endocrinol Diabet & Metab, Ljubljana, Slovenia; [Bakhtiar, Shahrzad] Univ Hosp Frankfurt, Div Stem Cell Transplantat & Immunol, Frankfurt, Germany; [Florkin, Benoit] CHR Citadelle, Serv Pediat, Immuno Hematorhumatol Pediat, Liege, Belgium; [Meeths, Marie] Karolinska Univ, Hosp Solna, Childhood Canc Res Unit, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Meeths, Marie] Karolinska Univ, Hosp Solna, Clin Genet Unit, Dept Mol Med & Surg, Stockholm, Sweden; [Meeths, Marie] Karolinska Univ, Hosp Solna, Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; [Gamez, Laura; Grimbacher, Bodo] Albert Ludwigs Univ Freiburg, Inst Immunodeficiency, Ctr Chron Immunodeficiency, Med Ctr,Fac Med, Freiburg, Germany; [Grimbacher, Bodo] Satellite Ctr Freiburg, DZIF German Ctr Infect Res, Freiburg, Germany; [Grimbacher, Bodo] Albert Ludwigs Univ, Ctr Integrat Biol Signalling Studies, Freiburg, Germany; [Grimbacher, Bodo] Satellite Ctr Freiburg, Hanover Med Sch, RESIST Cluster Excellence 2155, Freiburg, Germany; [Seppanen, Mikko R. J.] Univ Helsinki, Rare Dis Ctr, Helsinki, Finland; [Seppanen, Mikko R. J.] Univ Helsinki, Pediat Res Ctr, Children & Adolescents, Helsinki, Finland; [Seppanen, Mikko R. J.] HUS Helsinki Univ Hosp, Helsinki, Finland; [Seppanen, Mikko R. J.] Univ Helsinki, Adult Immunodeficiency Unit, Inflammat Ctr, Helsinki, Finland; [Seppanen, Mikko R. J.] Univ Helsinki, Translat Immunol Res Programs Unit & Clinicum, Helsinki, Finland; [Lankester, Arjan] Leiden Univ, Med Ctr, Dept Pediat, Leiden, Netherlands; [Gennery, Andrew R.] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England; [Shadur, Bella] Garvan Inst Med Res, Dept Immunol, Darlinghurst, NSW, Australia	Medical University of Graz; Medical University of Graz; Medical University of Graz; Karolinska Institutet; Karolinska University Hospital; Hebrew University of Jerusalem; Marmara University; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Antwerp; University of Antwerp; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Hospital Universitario 12 de Octubre; Hospital Universitario Virgen de las Nieves; Tehran University of Medical Sciences; Ankara University; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; Uludag University; Ege University; University of Zurich; University Zurich Hospital; University of Zurich; Necmettin Erbakan University; Selcuk University; University of London; University College London; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; University of Freiburg; KU Leuven; University Hospital Leuven; KU Leuven; Hamad Medical Corporation; Sidra Medical & Research Center; University of Padua; Azienda Ospedaliera - Universita di Padova; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Shahid Beheshti University Medical Sciences; University Medical Centre Ljubljana; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; University of Freiburg; German Center for Infection Research; University of Freiburg; Hannover Medical School; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Newcastle University - UK; Garvan Institute of Medical Research	Seidel, MG (corresponding author), Med Univ Graz, Dept Pediat & Adolescent Med, Div Pediat Hematooncol, Auen bruggerpl 38, A-8036 Graz, Austria.	markus.seidel@medunigraz.at	uygun, vedat/AGH-4534-2022; Rivière, Jacques G./ABH-8867-2020; Abolhassani, Hassan/B-3465-2014; Marzollo, Antonio/J-3579-2018; Moes, Nicolette/GXN-4667-2022; chavoshzadeh, zahra/AAU-8508-2021; khojah, Amer/AAS-6015-2021; Sharapova, Svetlana/ABF-3330-2020; Ba, Sha/HGB-9711-2022; İkinciogullari, Aydan/AAQ-3841-2020; Haerynck, Filomeen/AAD-6761-2020; Kilic, Sara Sebnem/AAH-1658-2021; Karaca, Neslihan/AAW-1924-2020; Seidel, Markus G/N-9951-2017	uygun, vedat/0000-0003-3257-7798; Rivière, Jacques G./0000-0003-1055-2063; Abolhassani, Hassan/0000-0002-4838-0407; Marzollo, Antonio/0000-0003-2177-8500; khojah, Amer/0000-0002-4120-5307; İkinciogullari, Aydan/0000-0003-1145-0843; Karaca, Neslihan/0000-0002-2202-7082; kilic, sara sebnem/0000-0001-8571-2581; Dogu, Figen/0000-0002-7869-4941; Seidel, Markus G/0000-0003-0981-8661; Garcia-Prat, Marina/0000-0001-5387-1908; Haerynck, Filomeen/0000-0001-9161-7361; Seppanen, Mikko/0000-0001-9733-3650; khojah, amer/0000-0003-3357-4863; Avbelj Stefanija, Magdalena/0000-0002-0836-5114; Kolios, Antonios/0000-0002-3897-4578	Styrian Children's Cancer Aid Foundation; Slovenian Research Agency [P3-0343]; Jonas S_oderquist Foundation; Scientific and Technological Research Council of Turkey [217S847, 318S202]; Deutsche Forschungsgemeinschaft under Germany's Excellence Strategy [390939984, 39087428]; E-Rare program of the European Union by the Deutsche Forschungsgemeinschaft [GR1617/14-1/iPAD]; Netzwerke Seltener Erkrankungen of the German Ministry of Education and Research [GAIN_ 01GM1910A]; Finnish Foundation for Pediatric Research and Pediatric Research Center, HUS Helsinki University Hospital; Graduate Research Training Scholarship of the Australian government; Hadassah Australia; ERN-RITA network [739543]	Styrian Children's Cancer Aid Foundation; Slovenian Research Agency(Slovenian Research Agency - Slovenia); Jonas S_oderquist Foundation; Scientific and Technological Research Council of Turkey(Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)); Deutsche Forschungsgemeinschaft under Germany's Excellence Strategy(German Research Foundation (DFG)); E-Rare program of the European Union by the Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Netzwerke Seltener Erkrankungen of the German Ministry of Education and Research; Finnish Foundation for Pediatric Research and Pediatric Research Center, HUS Helsinki University Hospital; Graduate Research Training Scholarship of the Australian government; Hadassah Australia; ERN-RITA network	M.G. Seidel and the Research Unit for Pediatric Hematology and Immunology are supported in part by the Styrian Children's Cancer Aid Foundation. M. Avbeli Stefanija was supported by the Slovenian Research Agency (grant P3-0343). H. Abolhassani was supported by the Jonas S_oderquist Foundation. S. Baris was supported by the Scientific and Technological Research Council of Turkey for the diagnosis of patients with LRBA deficiency (grants 217S847 and 318S202). B. Grimbacher receives support through the Deutsche Forschungsgemeinschaft under Germany's Excellence Strategy (CIBSS-EXC-2189-Project ID 390939984 and RESIST-EXC 2155-Project ID 39087428); through the E-Rare program of the European Union, managed by the Deutsche Forschungsgemeinschaft (grant GR1617/14-1/iPAD); and through the Netzwerke Seltener Erkrankungen of the German Ministry of Education and Research (grant GAIN_ 01GM1910A). M.R.J. Sepp_anen was supported by the Finnish Foundation for Pediatric Research and Pediatric Research Center, HUS Helsinki University Hospital. I. Meyts is a member of the ERN-RITA network (project identification number 739543). B. Shadur is supported by a Graduate Research Training Scholarship of the Australian government and by Hadassah Australia.	Al Sukaiti N, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.20; Alkhairy OK, 2016, J CLIN IMMUNOL, V36, P33, DOI 10.1007/s10875-015-0224-7; Azizi G, 2018, J INVEST ALLERG CLIN, V28, P48, DOI 10.18176/jiaci.0205; Azizi G, 2017, PEDIAT ALLERG IMM-UK, V28, P478, DOI 10.1111/pai.12735; Bakhtiar S, 2016, FRONT PEDIATR, V4, DOI 10.3389/fped.2016.00098; Bal SK, 2017, J CLIN IMMUNOL, V37, P790, DOI 10.1007/s10875-017-0446-y; Barzaghi F, 2018, J ALLERGY CLIN IMMUN, V141, P1036, DOI 10.1016/j.jaci.2017.10.041; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Bratanic N, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0682-5; Cagdas D, 2019, J CLIN IMMUNOL, V39, P726, DOI 10.1007/s10875-019-00677-6; Egg D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02012; Eren Akarcan Sanem, 2018, JMM Case Rep, V5, pe005167, DOI 10.1099/jmmcr.0.005167; Gamez-Diaz L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00720; Gamez-Diaz L, 2016, J ALLERGY CLIN IMMUN, V137, P223, DOI 10.1016/j.jaci.2015.09.025; Habibi S, 2019, J ALLER CL IMM-PRACT, V7, P2379, DOI 10.1016/j.jaip.2019.04.011; Karnofsky DA, 1949, EVALUATION CHEMOTHER, P149; Kiykim A, 2019, J ALLER CL IMM-PRACT, V7, P2790, DOI 10.1016/j.jaip.2019.06.011; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; LANSKY SB, 1987, CANCER, V60, P1651, DOI 10.1002/1097-0142(19871001)60:7<1651::AID-CNCR2820600738>3.0.CO;2-J; Lo B, 2016, BLOOD, V128, P1037, DOI 10.1182/blood-2016-04-712612; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Jaramillo CM, 2018, COLOMB MEDICA, V49, P236, DOI [10.25100/cm.v49i2.3802, 10.25100/cm.v49i3.3802]; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Seidel MG, 2018, J ALLERGY CLIN IMMUN, V141, P770, DOI 10.1016/j.jaci.2017.04.023; Seidel MG, 2015, J ALLERGY CLIN IMMUN, V135, P1384, DOI 10.1016/j.jaci.2014.10.048; Shamriz O, 2018, EUR J PEDIATR, V177, P1163, DOI 10.1007/s00431-018-3171-5; Speckmann C, 2017, J ALLERGY CLIN IMMUN, V139, P1302, DOI 10.1016/j.jaci.2016.07.040	28	64	65	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2020	145	5					1452	1463		10.1016/j.jaci.2019.12.896	http://dx.doi.org/10.1016/j.jaci.2019.12.896			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LK7TB	31887391	Green Published, Green Accepted, hybrid			2022-12-18	WOS:000531063400017
J	Pavel, AB; Song, T; Kim, HJ; Del Duca, E; Krueger, JG; Dubin, C; Peng, XY; Xu, H; Zhang, N; Estrada, YD; Denis, L; Rao, N; Gupta, S; Zammit, DJ; Bissonnette, R; Guttman-Yassky, E				Pavel, Ana B.; Song, Teresa; Kim, Hyun-Je; Del Duca, Ester; Krueger, James G.; Dubin, Celina; Peng, Xiangyu; Xu, Hui; Zhang, Ning; Estrada, Yeriel D.; Denis, Louis; Rao, Niranjan; Gupta, Sandeep; Zammit, David J.; Bissonnette, Robert; Guttman-Yassky, Emma			Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; ASN002; Janus kinase; spleen tyrosine kinase; Janus kinase inhibitors; spleen tyrosine kinase inhibitors; tyrosine kinase; T(H)2; T(H)22; T(H)17; barrier	DOWN-REGULATES FILAGGRIN; SYK TYROSINE KINASE; DIFFERENTIATION COMPLEX; PROPIONIBACTERIUM-ACNES; ALOPECIA-AREATA; DUPILUMAB; MODERATE; ACTIVATION; EXPRESSION; SKIN	Background: Moderate-to-severe atopic dermatitis (AD) has been associated with significant disease burden and systemic abnormalities and often requires systemic treatments. Currently, safe and effective oral systemic treatments for moderate-to-severe AD are not yet available. ASN002 is an oral inhibitor of the Janus kinase/spleen tyrosine kinase signaling pathways, targeting several cytokine axes (T(H)2/T(H)22/T(H)17/T(H)1) and epidermal differentiation. Objective: We sought to evaluate the effect of ASN002 on the cellular and molecular biomarker profile of patients with moderate-to-severe AD and to correlate changes in biomarkers to improvements in clinical severity measures and pruritus. Methods: Thirty-six patients with moderate-to-severe AD were randomized to groups with dose escalation of ASN002 (20, 40, and 80 mg) and a placebo group. Skin biopsy specimens were performed at baseline, day 15, and day 29. Gene expression studies were conducted by using microarray and quantitative RT-PCR, and cellular infiltrates and protein expression were studied by using immunohistochemistry. Results: ASN002 reversed the lesional skin transcriptome toward a nonlesional phenotype. It also rapidly and significantly suppressed key inflammatory pathways implicated in AD pathogenesis, including T(H)2 (IL4 receptor [IL4R], IL13, CCL13/monocyte chemoattractant protein 4, CCL17/thymus and activation-regulated chemokine, CCL18/pulmonary and activation-regulated chemokine, CCL22/macrophage-derived chemokine, and CCL26/eotaxin-3), T(H)17/T(H)22 (lipocalins, PI3/elafin, CCL20, S100A7/S100A8/S100A9, and IL36G/IL36RN), and T(H)1 (IFNG, CXCL9/CXCL11, and MX1) axes and barrier-related measures (filaggrin [FLG] and CLDN23). Significant improvements in AD gene signatures were observed predominantly in the 40- and 80-mg groups. Smaller and largely nonsignificant molecular changes were seen in the 20-mg and placebo groups. Conclusion: The Janus kinase/spleen tyrosine kinase inhibitor ASN002 significantly suppressed key AD inflammatory pathways, corresponding to clinical response. ASN002 might be an effective novel therapeutic agent for moderate-to-severe AD.	[Pavel, Ana B.; Song, Teresa; Kim, Hyun-Je; Del Duca, Ester; Dubin, Celina; Peng, Xiangyu; Xu, Hui; Zhang, Ning; Estrada, Yeriel D.; Guttman-Yassky, Emma] Icahn Sch Med Mt Sinai, Dept Dermatol, Lab Inflammatory Skin Dis, New York, NY 10029 USA; [Krueger, James G.] Rockefeller Univ, Lab Invest Dermatol, 1230 York Ave, New York, NY 10021 USA; [Denis, Louis; Rao, Niranjan; Gupta, Sandeep; Zammit, David J.] Asana Biosci, Princeton, NJ USA; [Bissonnette, Robert] Innovaderm Res, Montreal, PQ, Canada	Icahn School of Medicine at Mount Sinai; Rockefeller University; Innovaderm Research Inc.	Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Dept Dermatol, 5 E 98th St, New York, NY 10029 USA.; Guttman-Yassky, E (corresponding author), Icahn Sch Med Mt Sinai, Med Ctr, Lab Inflammatory Skin Dis, 5 E 98th St, New York, NY 10029 USA.	emma.guttman@mountsinai.org	Del Duca, Ester/AAC-2711-2022	Del Duca, Ester/0000-0001-7948-8536; , Ana Brandusa/0000-0002-8155-8553	Asana BioSciences	Asana BioSciences	This study was funded by Asana BioSciences.	Akahane K, 2017, BRIT J HAEMATOL, V177, P271, DOI 10.1111/bjh.14563; Akita K, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00084; Barbarot S, 2018, ALLERGY, V73, P1284, DOI 10.1111/all.13401; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Berekmeri A, 2018, J ALLERGY CLIN IMMUN, V142, P988, DOI 10.1016/j.jaci.2018.04.031; Betz RC, 2007, J INVEST DERMATOL, V127, P2539, DOI 10.1038/sj.jid.5700915; Bissonnette R, 2016, BRIT J DERMATOL, V175, P902, DOI 10.1111/bjd.14871; Bissonnette R, 2019, BR J DERMATOL; Blauvelt A, 2017, LANCET, V389, P2287, DOI 10.1016/S0140-6736(17)31191-1; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Brunner PM, 2019, ANN ALLERG ASTHMA IM, V122, P449, DOI 10.1016/j.anai.2018.11.015; Brunner PM, 2019, J ALLERGY CLIN IMMUN, V143, P142, DOI 10.1016/j.jaci.2018.07.028; Brunner PM, 2018, J ALLERGY CLIN IMMUN, V141, P2094, DOI 10.1016/j.jaci.2018.02.040; Brunner PM, 2018, ANN ALLERG ASTHMA IM, V120, P34, DOI 10.1016/j.anai.2017.09.055; Brunner PM, 2016, J ALLERGY CLIN IMMUN, V138, P169, DOI 10.1016/j.jaci.2015.12.1323; Chan TC, 2018, J ALLERGY CLIN IMMUN, V142, P1013, DOI 10.1016/j.jaci.2018.06.016; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Czarnowicki T, 2019, J ALLERGY CLIN IMMUN, V143, P1, DOI 10.1016/j.jaci.2018.10.032; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V140, P134, DOI 10.1016/j.jaci.2016.09.060; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Czarnowicki T, 2016, J ALLERGY CLIN IMMUN, V137, P1091, DOI 10.1016/j.jaci.2015.08.013; Dennehy KM, 2008, EUR J IMMUNOL, V38, P500, DOI 10.1002/eji.200737741; Dhingra N, 2014, J ALLERGY CLIN IMMUN, V134, P362, DOI 10.1016/j.jaci.2014.03.009; Draaisma E, 2015, PEDIAT ALLERG IMM-UK, V26, P359, DOI 10.1111/pai.12388; Elloso MM, 2012, J LEUKOCYTE BIOL, V92, P1187, DOI 10.1189/jlb.0212101; Esaki H, 2016, J ALLERGY CLIN IMMUN, V138, P1639, DOI 10.1016/j.jaci.2016.07.013; Eshtiaghi P, 2018, CORE EVID, V13, P13, DOI 10.2147/CE.S133661; Ewald DA, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0133-x; Friedberg JW, 2010, BLOOD, V115, P2578, DOI 10.1182/blood-2009-08-236471; Fukuyama T, 2017, J ALLERGY CLIN IMMUN, V140, P306, DOI 10.1016/j.jaci.2016.12.960; Gittler JK, 2013, J ALLERGY CLIN IMMUN, V131, P300, DOI 10.1016/j.jaci.2012.06.048; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Gooderham M, 2018, ARTHRITIS RHEUMATOL, V70; Gooderham M, 2017, J CUTAN MED SURG, V21, P31, DOI 10.1177/1203475416670364; Gutowska-Owsiak D, 2011, BRIT J DERMATOL, V165, P492, DOI 10.1111/j.1365-2133.2011.10400.x; Gutowska-Owsiak D, 2012, EXP DERMATOL, V21, P104, DOI 10.1111/j.1600-0625.2011.01412.x; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, pAB127, DOI 10.1016/j.jaci.2018.12.385; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V144, P482, DOI 10.1016/j.jaci.2018.11.053; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Guttman-Yassky E, 2019, J AM ACAD DERMATOL, V80, P913, DOI 10.1016/j.jaad.2018.01.018; Guttman-Yassky E, 2017, J ALLERGY CLIN IMMUN, V140, P1032, DOI 10.1016/j.jaci.2017.01.027; Guttman-Yassky E, 2017, CURR OPIN IMMUNOL, V48, P68, DOI 10.1016/j.coi.2017.08.008; Guttman-Yassky E, 2017, SEMIN CUTAN MED SURG, V36, P100, DOI 10.12788/j.sder.2017.036; Guttman-Yassky E, 2018, EXP DERMATOL, V27, P409, DOI 10.1111/exd.13336; Guttman-Yassky E, 2016, J ALLERGY CLIN IMMUN, V137, P301, DOI 10.1016/j.jaci.2015.11.001; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1420, DOI 10.1016/j.jaci.2011.01.054; Guttman-Yassky E, 2011, J ALLERGY CLIN IMMUN, V127, P1110, DOI 10.1016/j.jaci.2011.01.053; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Hartman J, 2014, CARDIOL REV, V22, P147, DOI 10.1097/CRD.0000000000000021; Hoffjan S, 2007, BRIT J DERMATOL, V157, P441, DOI 10.1111/j.1365-2133.2007.07999.x; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2018, ANN ALLERG ASTHMA IM, V120, P367, DOI 10.1016/j.anai.2018.02.012; Kaufman BP, 2018, EXP DERMATOL, V27, P340, DOI 10.1111/exd.13514; Kelhala HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105238; Khattri S, 2017, EXP DERMATOL, V26, P28, DOI 10.1111/exd.13112; Khattri S, 2014, J ALLERGY CLIN IMMUN, V133, P1626, DOI 10.1016/j.jaci.2014.03.003; Kim J, 2016, J INVEST DERMATOL, V136, P2173, DOI 10.1016/j.jid.2016.04.032; Kim J, 2015, DERMATOL CLIN, V33, P13, DOI 10.1016/j.det.2014.09.002; Kistowska M, 2015, J INVEST DERMATOL, V135, P110, DOI 10.1038/jid.2014.290; Kremer JM, 2016, ARTHRITIS RHEUMATOL, V68, P2867, DOI 10.1002/art.39801; Krueger J, 2016, J ALLERGY CLIN IMMUN, V137, P1079, DOI 10.1016/j.jaci.2015.12.1318; Krueger JG, 2016, J ALLERGY CLIN IMMUN, V138, P321; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Lee DE, 2018, J DERMATOL TREAT, V29, P364, DOI 10.1080/09546634.2017.1373736; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levy LL, 2015, J AM ACAD DERMATOL, V73, P395, DOI 10.1016/j.jaad.2015.06.045; Liu BS, 2006, SPECTROSC SPECT ANAL, V26, P306; Llop-Guevara A, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0866-0; Malajian D, 2015, CYTOKINE, V73, P311, DOI 10.1016/j.cyto.2014.11.023; Malik K, 2019, J ALLERGY CLIN IMMUN, V143, P604, DOI 10.1016/j.jaci.2018.03.021; Meyer DM, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-41; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Morelli M, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/7897263; Mortz CG, 2015, ALLERGY, V70, P836, DOI 10.1111/all.12619; Noda S, 2015, J ALLERGY CLIN IMMUN, V136, P1254, DOI 10.1016/j.jaci.2015.08.015; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Oh J, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/781375; Patel D, 2018, INT IMMUNOPHARMACOL, V54, P375, DOI 10.1016/j.intimp.2017.11.026; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Renert-Yuval Y, 2018, CURR OPIN ALLERGY CL, V18, P356, DOI 10.1097/ACI.0000000000000455; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Sanyal RD, 2019, ANN ALLERG ASTHMA IM, V122, P99, DOI 10.1016/j.anai.2018.08.024; Sardana K, 2017, INDIAN J DERMATOL, V62, P392, DOI 10.4103/ijd.IJD_483_16; Schwartz Daniella M, 2017, Nat Rev Drug Discov, V17, P78, DOI 10.1038/nrd.2017.267; Simpson EL, 2019, J INVEST DERMATOL, V139, P1063, DOI 10.1016/j.jid.2018.10.043; Simpson EL, 2016, J AM ACAD DERMATOL, V74, P491, DOI 10.1016/j.jaad.2015.10.043; Stemmler S, 2009, INT J IMMUNOGENET, V36, P217, DOI 10.1111/j.1744-313X.2009.00858.x; Strong CD, 2010, HUM MOL GENET, V19, P1453, DOI 10.1093/hmg/ddq019; Suarez-Farinas M, 2015, J ALLERGY CLIN IMMUN, V136, P1277, DOI 10.1016/j.jaci.2015.06.032; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Tamari M, 2014, J DERMATOL, V41, P213, DOI 10.1111/1346-8138.12321; Thomi R, 2018, JAMA DERMATOL, V154, P592, DOI 10.1001/jamadermatol.2018.0141; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Ungar B, 2017, J INVEST DERMATOL, V137, P603, DOI 10.1016/j.jid.2016.09.037; Weidinger S, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0001-z; Werfel T, 2016, J ALLERGY CLIN IMMUN, V138, P336, DOI 10.1016/j.jaci.2016.06.010; Whiteley J, 2016, CURR MED RES OPIN, V32, P1645, DOI 10.1080/03007995.2016.1195733; Wittkowski KM, 2004, STAT MED, V23, P1579, DOI 10.1002/sim.1778; Wu NL, 2016, J INVEST DERMATOL, V136, P192, DOI 10.1038/JID.2015.381; Wu NL, 2015, J INVEST DERMATOL, V135, P490, DOI 10.1038/jid.2014.383; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; Zhou LS, 2019, J ALLERGY CLIN IMMUN, V144, P144, DOI 10.1016/j.jaci.2019.01.015	104	64	67	3	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					1011	1024		10.1016/j.jaci.2019.07.013	http://dx.doi.org/10.1016/j.jaci.2019.07.013			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31356921	Bronze			2022-12-18	WOS:000488803900017
J	Cepika, AM; Sato, Y; Liu, JMH; Uyeda, MJ; Bacchetta, R; Roncarolo, MG				Cepika, Alma-Martina; Sato, Yohei; Liu, Jeffrey Mao-Hwa; Uyeda, Molly Javier; Bacchetta, Rosa; Roncarolo, Maria Grazia			Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Autoimmunity; BACH2; CD25; CTLA-4; FOXP3; gain of function; hematopoietic stem cell transplantation; IL-10; IL-2; immune dysregulation; inborn error of immunity; IPEX; LRBA; monogenic disease; primary immunodeficiency; regulatory T (Treg) cell; STAT3 GOF; T(R)1; Tregopathy; type 1 regulatory T cell	GROWTH-HORMONE INSENSITIVITY; INFLAMMATORY-BOWEL-DISEASE; OF-FUNCTION MUTATIONS; HEMATOPOIETIC PROGENITOR CELLS; X-LINKED SYNDROME; IMMUNE DYSREGULATION; GENE-THERAPY; CUTTING EDGE; B-CELLS; PRIMARY IMMUNODEFICIENCY	Monogenic diseases of the immune system, also known as inborn errors of immunity, are caused by single-gene mutations resulting in immune deficiency and dysregulation. More than 350 diseases have been described to date, and the number is rapidly expanding, with increasing availability of next-generation sequencing facilitating the diagnosis. The spectrum of immune dysregulation is wide, encompassing deficiencies in humoral, cellular, innate, and adaptive immunity; phagocytosis; and the complement system, which lead to autoinflammation and autoimmunity. Multiorgan autoimmunity is a dominant symptom when genetic mutations lead to defects in molecules essential for the development, survival, and/or function of regulatory T (Treg) cells. Studies of "Tregopathies'' are providing critical mechanistic information on Treg cell biology, the role of Treg cell-associated molecules, and regulation of peripheral tolerance in human subjects. The pathogenic immune networks underlying these diseases need to be dissected to apply and develop immunomodulatory treatments and design curative treatments using cell and gene therapy. Here we review the pathogenetic mechanisms, clinical presentation, diagnosis, and current and future treatments of major known Tregopathies caused by mutations in FOXP3, CD25, cytotoxic T lymphocyte-associated antigen 4 (CTLA4), LPS-responsive and beige-like anchor protein (LRBA), and BTB domain and CNC homolog 2 (BACH2) and gain-of-function mutations in signal transducer and activator of transcription 3 (STAT3). We also discuss deficiencies in genes encoding STAT5b and IL-10 or IL-10 receptor as potential Tregopathies.	[Cepika, Alma-Martina; Sato, Yohei; Liu, Jeffrey Mao-Hwa; Uyeda, Molly Javier; Bacchetta, Rosa; Roncarolo, Maria Grazia] Stanford Sch Med, Div Stem Cell Transplantat & Regenerat Med, Dept Pediat, Stanford, CA USA; [Uyeda, Molly Javier; Roncarolo, Maria Grazia] Stanford Sch Med, Stanford Inst Stem Cell Biol & Regenerat Med, Stanford, CA USA	Stanford University; Stanford University	Bacchetta, R; Roncarolo, MG (corresponding author), Lorry I Lokey Stem Cell Res Bldg, Stanford, CA 94305 USA.	rosab@stanford.edu; mg1@stanford.edu		Sato, Yohei/0000-0002-8042-0069; Bacchetta, Rosa/0000-0002-0606-6268; Cepika, Alma-Martina/0000-0003-2862-1901; Liu, Jeffrey/0000-0003-0129-8569	National Institute of Allergy and Infectious Diseases [R21 AI123896]; California Institute for Regenerative Medicine [DISC2-09526]; Stanford's SPARK Translational Research Program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI123896] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); Stanford's SPARK Translational Research Program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institute of Allergy and Infectious Diseases (R21 AI123896 to R.B.), the California Institute for Regenerative Medicine (DISC2-09526 to R.B.), Stanford's SPARK Translational Research Program (to R.B.), and a generous gift to Stanford's Center for Genetic Immune Diseases (with M.G.R. as executive and R.B. as associate director).	Abbas AK, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat1482; Abbas AK, 2013, NAT IMMUNOL, V14, P307, DOI 10.1038/ni.2554; Afzali B, 2017, NAT IMMUNOL, V18, P813, DOI 10.1038/ni.3753; Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151; Alfen JS, 2018, J ALLERGY CLIN IMMUN, V142, P1537, DOI 10.1016/j.jaci.2017.12.984; Ali MA, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf7779; Alroqi FJ, 2018, J ALLERGY CLIN IMMUN, V141, P1050, DOI 10.1016/j.jaci.2017.05.022; Arif S, 2004, J CLIN INVEST, V113, P451, DOI 10.1172/JCI200419585; Astier AL, 2006, J CLIN INVEST, V116, P3252, DOI 10.1172/JCI29251; Azizi G, 2016, CELL IMMUNOL, V310, P14, DOI 10.1016/j.cellimm.2016.08.012; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; Bacchetta R, 2018, ANN NY ACAD SCI, V1417, P5, DOI 10.1111/nyas.13011; Bak RO, 2018, NAT PROTOC, V13, P358, DOI 10.1038/nprot.2017.143; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737594; Baron U, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan3508; Barzaghi F, 2012, J AUTOIMMUN, V38, P49, DOI 10.1016/j.jaut.2011.12.009; Barzaghi F, 2018, J ALLERGY CLIN IMMUN, V141, P1036, DOI 10.1016/j.jaci.2017.10.041; Battaglia M, 2006, J IMMUNOL, V177, P8338, DOI 10.4049/jimmunol.177.12.8338; Bernasconi A, 2006, PEDIATRICS, V118, pE1584, DOI 10.1542/peds.2005-2882; Besnard C, 2018, CLIN IMMUNOL, V188, P52, DOI 10.1016/j.clim.2017.12.009; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bezrodnik L, 2014, CLIN EXP IMMUNOL, V175, P227, DOI 10.1111/cei.12214; Bezrodnik L, 2015, J CLIN IMMUNOL, V35, P264, DOI 10.1007/s10875-015-0145-5; BORDIGNON C, 1995, SCIENCE, V270, P470, DOI 10.1126/science.270.5235.470; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Bousfiha AA, 2013, J CLIN IMMUNOL, V33, P1, DOI 10.1007/s10875-012-9751-7; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Braun CJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007280; Brockmann L, 2017, J IMMUNOL, V198, P1130, DOI 10.4049/jimmunol.1601045; Caramalho I, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00395; Casanova JL, 2014, J EXP MED, V211, P2137, DOI 10.1084/jem.20140520; Cassani B, 2010, J ALLERGY CLIN IMMUN, V125, P209, DOI 10.1016/j.jaci.2009.10.023; Caudy AA, 2007, J ALLERGY CLIN IMMUN, V119, P482, DOI 10.1016/j.jaci.2006.10.007; Chandrasekaran P, 2016, J ALLERGY CLIN IMMUN, V138, P1222, DOI 10.1016/j.jaci.2016.05.007; Charbonnier LM, 2015, J ALLERGY CLIN IMMUN, V135, P217, DOI 10.1016/j.jaci.2014.10.019; Chase NM, 2013, J CLIN IMMUNOL, V33, P30, DOI 10.1007/s10875-012-9755-3; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; Cohen AC, 2006, J IMMUNOL, V177, P2770, DOI 10.4049/jimmunol.177.5.2770; Collison LW, 2011, METHODS MOL BIOL, V707, P21, DOI 10.1007/978-1-61737-979-6_2; d'Hennezel E, 2009, NEW ENGL J MED, V361, P1710, DOI 10.1056/NEJMc0907093; De Benedetti F, 2006, CLIN GASTROENTEROL H, V4, P653, DOI 10.1016/j.cgh.2005.12.014; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Deenick EK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00168; Dever DP, 2017, CURR OPIN HEMATOL, V24, P481, DOI 10.1097/MOH.0000000000000385; Dever DP, 2016, NATURE, V539, P384, DOI 10.1038/nature20134; Di Cesare S, 2015, PEDIAT ALLERG IMM-UK, V26, P591, DOI 10.1111/pai.12420; Engelhardt KR, 2013, J ALLERGY CLIN IMMUN, V131, P825, DOI 10.1016/j.jaci.2012.09.025; Ferrando-Martinez S, 2014, J PEDIATR-US, V164, P882, DOI 10.1016/j.jpeds.2013.12.013; Ferrua F, 2017, HUM GENE THER, V28, P972, DOI 10.1089/hum.2017.175; Fischer A, 2013, GENE, V525, P170, DOI 10.1016/j.gene.2013.03.092; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, NAT IMMUNOL, V6, P1142, DOI 10.1038/ni1263; Friederich E, 1999, J BIOL CHEM, V274, P26751, DOI 10.1074/jbc.274.38.26751; Gagliani N, 2013, NAT MED, V19, P739, DOI 10.1038/nm.3179; Gagliani N, 2010, DIABETES, V59, P433, DOI 10.2337/db09-1168; Gambineri Eleonora, 2008, J Allergy Clin Immunol, V122, P1105, DOI 10.1016/j.jaci.2008.09.027; Gamez-Diaz L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00720; Gamez-Diaz L, 2016, J ALLERGY CLIN IMMUN, V137, P223, DOI 10.1016/j.jaci.2015.09.025; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Glocker EO, 2011, ANN NY ACAD SCI, V1246, P102, DOI 10.1111/j.1749-6632.2011.06339.x; Glocker EO, 2010, LANCET, V376, P1272, DOI 10.1016/S0140-6736(10)61008-2; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Gobert D, 2011, BRIT J HAEMATOL, V155, P498, DOI 10.1111/j.1365-2141.2011.08880.x; Goudy K, 2013, CLIN IMMUNOL, V146, P248, DOI 10.1016/j.clim.2013.01.004; Gregori S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00233; Gregori S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00030; Gregori S, 2010, BLOOD, V116, P935, DOI 10.1182/blood-2009-07-234872; Grimbert P, 2017, TRANSPL INT, V30, P647, DOI 10.1111/tri.12975; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Gundry MC, 2016, CELL REP, V17, P1453, DOI 10.1016/j.celrep.2016.09.092; Gutierrez M, 2018, MOL CELL ENDOCRINOL, V473, P166, DOI 10.1016/j.mce.2018.01.016; Haapaniemi EM, 2015, BLOOD, V125, P639, DOI 10.1182/blood-2014-04-570101; Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313; Hatada S, 2000, P NATL ACAD SCI USA, V97, P13807, DOI 10.1073/pnas.240462897; Hendel A, 2015, NAT BIOTECHNOL, V33, P985, DOI 10.1038/nbt.3290; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hou TZ, 2017, BLOOD, V129, P1458, DOI 10.1182/blood-2016-10-745174; Hutchins AP, 2013, BRIEF FUNCT GENOMICS, V12, P489, DOI 10.1093/bfgp/elt028; Huynh A, 2015, NAT IMMUNOL, V16, P188, DOI 10.1038/ni.3077; Hwa V, 2005, J CLIN ENDOCR METAB, V90, P4260, DOI 10.1210/jc.2005-0515; Hwa V, 2007, HORM RES, V68, P218, DOI 10.1159/000101334; Hwa V, 2016, GROWTH HORM IGF RES, V28, P16, DOI 10.1016/j.ghir.2015.12.006; Hwang JL, 2018, PEDIATR DIABETES, V19, P388, DOI 10.1111/pedi.12612; Igarashi K, 2014, IMMUNOL REV, V261, P116, DOI 10.1111/imr.12201; Iikuni N, 2009, J IMMUNOL, V183, P1518, DOI 10.4049/jimmunol.0901163; Jeddane L, 2017, J CLIN IMMUNOL, V37, P1, DOI 10.1007/s10875-016-0354-6; Johnson MB, 2017, DIABETES, V66, P2316, DOI 10.2337/db17-0040; Jyonouchi S, 2017, CLIN IMMUNOL, V179, P47, DOI 10.1016/j.clim.2017.02.001; Kanai T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00234; Kemper C, 2003, NATURE, V421, P388, DOI 10.1038/nature01315; Kennedy-Nasser AA, 2014, CLIN CANCER RES, V20, P2215, DOI 10.1158/1078-0432.CCR-13-3205; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Khoury T, 2017, CLIN THER, V39, P444, DOI 10.1016/j.clinthera.2017.01.004; Kim EH, 2014, J IMMUNOL, V192, P985, DOI 10.4049/jimmunol.1302378; Kim J, 2018, J INVEST DERMATOL; Kinnunen T, 2013, BLOOD, V121, P1595, DOI 10.1182/blood-2012-09-457465; Kleindienst P, 2005, IMMUNOLOGY, V115, P556, DOI 10.1111/j.1365-2567.2005.02196.x; Kobayashi I, 1999, GASTROENTEROLOGY, V117, P823, DOI 10.1016/S0016-5085(99)70340-9; Kobayashi I, 2011, CLIN IMMUNOL, V141, P83, DOI 10.1016/j.clim.2011.05.010; Kobbe R, 2016, GENE, V586, P234, DOI 10.1016/j.gene.2016.04.006; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kotlarz D, 2012, GASTROENTEROLOGY, V143, P347, DOI 10.1053/j.gastro.2012.04.045; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lampasona V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078664; Lee CH, 2014, J CROHNS COLITIS, V8, P1551, DOI 10.1016/j.crohns.2014.04.004; Lee S, 2016, J ALLERGY CLIN IMMUN, V137, P327, DOI 10.1016/j.jaci.2015.08.036; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Lim HW, 2005, J IMMUNOL, V175, P4180, DOI 10.4049/jimmunol.175.7.4180; Lio CWJQ, 2008, IMMUNITY, V28, P100, DOI 10.1016/j.immuni.2007.11.021; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Lo B, 2016, BLOOD, V128, P1037, DOI 10.1182/blood-2016-04-712612; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lombardo A, 2007, NAT BIOTECHNOL, V25, P1298, DOI 10.1038/nbt1353; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Lutz M, 2016, BRIT J CLIN PHARMACO, V82, P1171, DOI 10.1111/bcp.13022; MacArthur DG, 2014, NATURE, V508, P469, DOI 10.1038/nature13127; Maccari ME, 2017, CLIN IMMUNOL, V183, P273, DOI 10.1016/j.clim.2017.09.011; Magg T, 2012, EUR J IMMUNOL, V42, P1627, DOI 10.1002/eji.201141838; Martinez-Forero I, 2008, EUR J IMMUNOL, V38, P576, DOI 10.1002/eji.200737271; Meyer S, 2016, CELL, V166, P582, DOI 10.1016/j.cell.2016.06.024; Miano M, 2016, BRIT J HAEMATOL, V172, P524, DOI 10.1111/bjh.13866; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Miyao T, 2012, IMMUNITY, V36, P262, DOI 10.1016/j.immuni.2011.12.012; Muto A, 2004, NATURE, V429, P566, DOI 10.1038/nature02596; Nabhani S, 2017, CLIN IMMUNOL, V181, P32, DOI 10.1016/j.clim.2017.05.021; Neven B, 2013, BLOOD, V122, P3713, DOI 10.1182/blood-2013-06-508267; Olfat M, 2015, LUPUS, V24, P966, DOI 10.1177/0961203315578764; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; Passerini L., 2018, J ALLERGY CLIN IMMUN; Passerini L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01282; Passerini L, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007320; Patel CH, 2017, CURR OPIN IMMUNOL, V46, P82, DOI 10.1016/j.coi.2017.04.006; Picard C, 2018, J CLIN IMMUNOL, V38, P96, DOI 10.1007/s10875-017-0464-9; Pillemer BBL, 2007, EUR J IMMUNOL, V37, P2082, DOI 10.1002/eji.200737193; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; Pot C, 2009, J IMMUNOL, V183, P797, DOI 10.4049/jimmunol.0901233; Pugliese-Pires PN, 2010, EUR J ENDOCRINOL, V163, P349, DOI 10.1530/EJE-10-0272; Qureshi OS, 2011, SCIENCE, V332, P600, DOI 10.1126/science.1202947; Rao VK, 2009, PEDIATR BLOOD CANCER, V52, P847, DOI 10.1002/pbc.21965; Rodero MP, 2016, J EXP MED, V213, P2527, DOI 10.1084/jem.20161596; Romano M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01625; Roncarolo MG, 2014, CURR TOP MICROBIOL, V380, P39, DOI 10.1007/978-3-662-43492-5_3; Rosenberg JM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00544; Roth TL, 2018, NATURE, V559, P405, DOI 10.1038/s41586-018-0326-5; Rowe JH, 2018, BLOOD, V131, P2335, DOI 10.1182/blood-2018-02-835561; Roychoudhuri R, 2016, NAT IMMUNOL, V17, P851, DOI 10.1038/ni.3441; Roychoudhuri R, 2013, NATURE, V498, P506, DOI 10.1038/nature12199; Rudensky AY, 2011, IMMUNOL REV, V241, P260, DOI 10.1111/j.1600-065X.2011.01018.x; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Samstein RM, 2012, CELL, V150, P29, DOI 10.1016/j.cell.2012.05.031; Sanda S, 2008, CLIN IMMUNOL, V127, P138, DOI 10.1016/j.clim.2007.12.003; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Sauer S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI 10.1073/pnas.0800928105; Scaglia PA, 2012, J CLIN ENDOCR METAB, V97, pE830, DOI 10.1210/jc.2011-2554; Schildberg FA, 2016, IMMUNITY, V44, P955, DOI 10.1016/j.immuni.2016.05.002; Schiroli G, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0820; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schwab C, 2018, J ALLERGY CLIN IMMUN, V142, P1932, DOI 10.1016/j.jaci.2018.02.055; Seghezzo S, 2017, J PEDIATR-US, V186, P183, DOI 10.1016/j.jpeds.2017.03.051; Seidel MG, 2018, J ALLERGY CLIN IMMUN, V141, P770, DOI 10.1016/j.jaci.2017.04.023; Serris A, 2018, AM J HEMATOL, V93, P424, DOI 10.1002/ajh.24999; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Sharfe N, 1997, P NATL ACAD SCI USA, V94, P3168, DOI 10.1073/pnas.94.7.3168; Shevach EM, 2014, IMMUNOL REV, V259, P88, DOI 10.1111/imr.12160; Shouval DS, 2017, INFLAMM BOWEL DIS, V23, P1950, DOI 10.1097/MIB.0000000000001270; Shouval DS, 2014, ADV IMMUNOL, V122, P177, DOI 10.1016/B978-0-12-800267-4.00005-5; Slatter MA, 2018, EXPERT REV CLIN IMMU, V14, P103, DOI 10.1080/1744666X.2018.1424627; Sockolosky JT, 2018, SCIENCE, V359, P1037, DOI 10.1126/science.aar3246; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; Tiemessen MM, 2007, P NATL ACAD SCI USA, V104, P19446, DOI 10.1073/pnas.0706832104; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Touzot F, 2015, J ALLERGY CLIN IMMUN, V135, P1303, DOI 10.1016/j.jaci.2014.08.019; Tree TIM, 2010, DIABETES, V59, P1451, DOI 10.2337/db09-0503; Tsukumo S, 2013, P NATL ACAD SCI USA, V110, P10735, DOI 10.1073/pnas.1306691110; Uzel G, 2013, J ALLERGY CLIN IMMUN, V131, P1611, DOI 10.1016/j.jaci.2012.11.054; Vahedi G, 2015, NATURE, V520, P558, DOI 10.1038/nature14154; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102; Vasiljevic A, 2015, LANCET, V385, P2120, DOI 10.1016/S0140-6736(15)60773-5; Veenbergen S, 2008, ARTHRITIS RHEUM-US, V58, P3742, DOI 10.1002/art.24072; Verpy E, 2000, NAT GENET, V26, P51, DOI 10.1038/79171; Vidarsdottir S, 2006, J CLIN ENDOCR METAB, V91, P3482, DOI 10.1210/jc.2006-0368; Walenkamp MJE, 2007, EUR J ENDOCRINOL, V156, P155, DOI 10.1530/eje.1.02327; Walker LSK, 2017, IMMUNOL LETT, V184, P43, DOI 10.1016/j.imlet.2017.02.007; Walter JE, 2016, J ALLER CL IMM-PRACT, V4, P1089, DOI 10.1016/j.jaip.2016.08.004; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Weinreich MA, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00049; Wienke J, 2015, ONCOTARGET, V6, P20037, DOI 10.18632/oncotarget.5042; Xavier-Da-Silva MM, 2015, CLIN IMMUNOL, V156, P131, DOI 10.1016/j.clim.2014.12.007; Yamashita M, 2018, INT IMMUNOL, V30, P397, DOI 10.1093/intimm/dxy020; Yanagi T, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0424-5; Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995; Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756; Ye CX, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-017-0002-5; Yoon SI, 2010, STRUCTURE, V18, P638, DOI 10.1016/j.str.2010.02.009; Zama D, 2014, ITAL J PEDIATR, V40, DOI 10.1186/s13052-014-0068-4; Zhou XY, 2008, J EXP MED, V205, P1983, DOI 10.1084/jem.20080707; Zhou Y, 2016, CLIN REV ALLERG IMMU, V50, P345, DOI 10.1007/s12016-016-8538-7; Zhu L, 2017, GASTROENTEROL RES, V10, P65, DOI 10.14740/gr740w	212	64	66	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1679	1695		10.1016/j.jaci.2018.10.026	http://dx.doi.org/10.1016/j.jaci.2018.10.026			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	30527062				2022-12-18	WOS:000452315800001
J	Niederberger, V; Neubauer, A; Gevaert, P; Zidarn, M; Worm, M; Aberer, W; Mailing, HJ; Pfaar, O; Klimek, L; Pfutzner, W; Ring, J; Darsow, U; Novak, N; van Wijk, RG; Eckl-Dorna, J; Focke-Tejkl, M; Weber, M; Muller, HH; Klinger, J; Stolz, F; Breit, N; Henning, R; Valenta, R				Niederberger, Verena; Neubauer, Angela; Gevaert, Philippe; Zidarn, Mihaela; Worm, Margitta; Aberer, Werner; Mailing, Hans Jorgen; Pfaar, Oliver; Klimek, Ludger; Pfuetzner, Wolfgang; Ring, Johannes; Darsow, Ulf; Novak, Natalija; van Wijk, Roy Gerth; Eckl-Dorna, Julia; Focke-Tejkl, Margarete; Weber, Milena; Mueller, Hans-Helge; Klinger, Joachim; Stolz, Frank; Breit, Nora; Henning, Rainer; Valenta, Rudolf			Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; grass pollen allergy; allergen; allergen immunotherapy; recombinant allergen; B-cell epitope-based immunotherapy; efficacy; hypoallergenic; clinical trial; safety	ALLERGEN-SPECIFIC IMMUNOTHERAPY; CONTIGUOUS OVERLAPPING PEPTIDES; BET V 1; THERAPEUTIC VACCINES; BLOCKING ANTIBODIES; POSITION PAPER; RHINOCONJUNCTIVITIS; MECHANISMS; RESPONSES; RHINITIS	Background: BM32 is a grass pollen allergy vaccine based on recombinant fusion proteins consisting of nonallergenic peptides from the IgE-binding sites of the 4 major grass pollen allergens and the hepatitis B preS protein. Objective: We sought to study the safety and clinical efficacy of immunotherapy (allergen immunotherapy) with BM32 in patients with grass pollen-induced rhinitis and controlled asthma. Methods: A double-blind, placebo-controlled, multicenter allergen immunotherapy field study was conducted for 2 grass pollen seasons. After a baseline season, subjects (n = 181) were randomized and received 3 preseasonal injections of either placebo (n = 58) or a low dose (80 mu g, n = 60) or high dose (160 mu g, n = 63) of BM32 in year 1, respectively, followed by a booster injection in autumn. In the second year, all actively treated subjects received 3 preseasonal injections of the BM32 low dose, and placebo-treated subjects continued with placebo. Clinical efficacy was assessed by using combined symptom medication scores, visual analog scales, Rhinoconjunctivitis Quality of Life Questionnaires, and asthma symptom scores. Adverse events were graded according to the European Academy of Allergy and Clinical Immunology. Allergen-specific antibodies were determined by using ELISA, ImmunoCAP, and ImmunoCAP ISAC. Results: Although statistical significance regarding the primary end point was not reached, BM32-treated subjects, when compared with placebo-treated subjects, showed an improvement regarding symptom medication, visual analog scale, Rhinoconjunctivitis Quality of Life Questionnaire, and asthma symptom scores in both treatment years. This was accompanied by an induction of allergen-specific IgG without induction of allergen-specific IgE and a reduction in the seasonally induced increase in allergen-specific IgE levels in year 2. In the first year, more grade 2 reactions were observed in the active (n = 6) versus placebo (n = 1) groups, whereas there was almost no difference in the second year. Conclusions: Injections of BM32 induced allergen-specific IgG, improved clinical symptoms of seasonal grass pollen allergy, and were well tolerated.	[Niederberger, Verena; Eckl-Dorna, Julia] Med Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria; [Neubauer, Angela; Stolz, Frank; Breit, Nora; Henning, Rainer] Biomay AG, Vienna, Austria; [Gevaert, Philippe] Ghent Univ Hosp, Dept Otorhinolaryngol, Ghent, Belgium; [Zidarn, Mihaela] Univ Clin Resp & Allerg Dis, Golnik, Slovenia; [Worm, Margitta] Charite, Allergy Ctr, Berlin, Germany; [Aberer, Werner] Med Univ Graz, Dept Dermatol & Venerol, Graz, Austria; [Mailing, Hans Jorgen] Copenhagen Univ Hosp, Allergy Clin, Gentofte, Denmark; [Pfaar, Oliver; Klimek, Ludger] Ctr Rhinol Allergol, Wiesbaden, Germany; [Pfaar, Oliver] Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Heidelberg, Germany; [Pfuetzner, Wolfgang] Med Ctr Giessen & Marburg GmbH, Dept Dermatol & Allergol, Marburg, Germany; [Ring, Johannes; Darsow, Ulf] TUM, Dept Dermatol & Allergy Biederstein, Munich, Germany; [Ring, Johannes; Darsow, Ulf] ZAUM Ctr Allergy & Environm, Munich, Germany; [Novak, Natalija] Univ Bonn, Clin Dermatol & Allergol, Bonn, Germany; [van Wijk, Roy Gerth] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands; [Focke-Tejkl, Margarete; Weber, Milena; Valenta, Rudolf] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Div Immunopathol, Vienna, Austria; [Mueller, Hans-Helge] Ludwig Maximilians Univ Munchen, Inst Med Informat Technol Biometr & Epidemiol, Munich, Germany; [Mueller, Hans-Helge] Philipps Univ, Inst Med Biometry & Epidemiol, Marburg, Germany; [Klinger, Joachim] SynteractHCR Deutschland GmbH, Munich, Germany; [Valenta, Rudolf] NRC Inst Immunol FMBA Russia, Moscow, Russia	Medical University of Vienna; Ghent University; Ghent University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Medical University of Graz; University of Copenhagen; Ruprecht Karls University Heidelberg; Technical University of Munich; University of Bonn; Erasmus University Rotterdam; Erasmus MC; Medical University of Vienna; University of Munich; Philipps University Marburg; NRC Institute of Immunology FMBA of Russia	Valenta, R (corresponding author), Med Univ Vienna, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, Div Immunopathol, Waehringer Guertel 18-20,3Q, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Gevaert, Philippe/ABA-4588-2021; Ring, Johannes/GLN-4341-2022; Gevaert, Philippe/AAP-1892-2020; Eckl-Dorna, Julia/AAY-6371-2020	Ring, Johannes/0000-0001-8236-3152; Gevaert, Philippe/0000-0002-1629-8468; Valenta, Rudolf/0000-0001-5944-3365; Worm, Margitta/0000-0002-3449-1245; Eckl-Dorna, Julia/0000-0001-5981-1607; Zidarn, Mihaela/0000-0003-0515-5207	Biomay AG, Vienna, Austria; Austrian Science Fund (FWF) [F4605, F4613]; Megagrant of the Government of the Russian Federation [14.W03.31.0024]	Biomay AG, Vienna, Austria; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Megagrant of the Government of the Russian Federation	Supported by Biomay AG, Vienna, Austria, and research grants F4605 and F4613 of the Austrian Science Fund (FWF). R.V. is recipient of a Megagrant of the Government of the Russian Federation, grant number 14.W03.31.0024.	Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Cornelius C, 2016, EBIOMEDICINE, V11, P58, DOI 10.1016/j.ebiom.2016.07.023; Cox L, 2015, CURR OPIN OTOLARYNGO, V23, P247, DOI 10.1097/MOO.0000000000000150; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Focke-Tejkl M, 2015, J ALLERGY CLIN IMMUN, V135, P1207, DOI 10.1016/j.jaci.2014.09.012; Gerlich WH, 2016, EBIOMEDICINE, V11, P5, DOI 10.1016/j.ebiom.2016.07.032; GOIDL EA, 1968, J IMMUNOL, V100, P371; Gonzalez-Fernandez A, 1998, IMMUNOLOGY, V93, P149; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; Jutel M, 2016, J ALLERGY CLIN IMMUN, V137, P358, DOI 10.1016/j.jaci.2015.12.1300; Kahlert H, 2008, INT ARCH ALLERGY IMM, V145, P193, DOI 10.1159/000109288; Kristiansen M, 2017, PEDIAT ALLERG IMM-UK, V28, P18, DOI 10.1111/pai.12661; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.1093/biomet/63.3.655; Marth K, 2013, J IMMUNOL, V190, P3068, DOI 10.4049/jimmunol.1202441; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 2015, J ALLERGY CLIN IMMUN, V136, P1101, DOI 10.1016/j.jaci.2015.03.034; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pellaton Celine, 2013, Clin Transl Allergy, V3, P17, DOI 10.1186/2045-7022-3-17; Pfaar O, 2014, ALLERGY, V69, P854, DOI 10.1111/all.12383; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Spertini F, 2016, J ALLERGY CLIN IMMUN, V138, P162, DOI 10.1016/j.jaci.2016.02.044; Spertini F, 2014, J ALLERGY CLIN IMMUN, V134, P239, DOI 10.1016/j.jaci.2014.04.001; Valenta R, 2012, J INTERN MED, V272, P144, DOI 10.1111/j.1365-2796.2012.02556.x; Valenta R, 2016, J ALLERGY CLIN IMMUN, V137, P351, DOI 10.1016/j.jaci.2015.12.1299; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Westman M, 2015, J ALLERGY CLIN IMMUN, V135, P1199, DOI 10.1016/j.jaci.2014.10.042; Worm M, 2011, J ALLERGY CLIN IMMUN, V127, P89, DOI 10.1016/j.jaci.2010.11.029; Zieglmayer P, 2016, EBIOMEDICINE, V11, P43, DOI 10.1016/j.ebiom.2016.08.022	40	64	65	1	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2018	142	2					497	+		10.1016/j.jaci.2017.09.052	http://dx.doi.org/10.1016/j.jaci.2017.09.052			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GP2LN	29361332	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000440664400018
J	Hornsby, E; Pfeffer, PE; Laranjo, N; Cruikshank, W; Tuzova, M; Litonjua, AA; Weiss, ST; Carey, VJ; O'Connor, G; Hawrylowicz, C				Hornsby, Eve; Pfeffer, Paul E.; Laranjo, Nancy; Cruikshank, William; Tuzova, Marina; Litonjua, Augusto A.; Weiss, Scott T.; Carey, Vincent J.; O'Connor, George; Hawrylowicz, Catherine			Vitamin D supplementation during pregnancy: Effect on the neonatal immune system in a randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; asthma; innate immunity; pregnancy	REGULATORY T-CELLS; CORD BLOOD; 1,25-DIHYDROXYVITAMIN D-3; CLINICAL-TRIAL; IFN-GAMMA; RESPIRATORY ILLNESSES; CHILDHOOD ASTHMA; BIRTH COHORT; 1ST YEAR; RESPONSES	Background: Programming of the immune system during fetal development can influence asthma-related risk factors and outcomes in later life. Vitamin D is a well-recognized immune modulator, and deficiency of this nutrient during pregnancy is hypothesized to influence disease development in offspring. Objective: We sought to investigate the effect on neonatal immunity of maternal supplementation with 4400 IU/d vitamin D-3 during the second and third trimesters of pregnancy by using a subset of cord blood samples from a randomized, double-blind, placebo-controlled clinical trial (the Vitamin D Antenatal Asthma Reduction Trial). Methods: Cord blood samples from neonates born to mothers supplemented with 4400 IU/d (n=26) or 400 IU/d (n=25) of vitamin D-3 were analyzed for immune cell composition by flow cytometry, Toll-like receptor (TLR) expression by quantitative PCR, and cytokine secretion after stimulation with mitogenic, TLR, and T-cell stimuli by cytometric bead array. Responsiveness to the glucocorticoid dexamethasone was determined. Results: Supplementation of mothers with 4400 IU of vitamin D-3 resulted in an enhanced broad-spectrum proinflammatory cytokine response of cord blood mononuclear cells to innate and mitogenic stimuli (P=.0009), with an average 1.7- to 2.1-fold increase in levels of several proinflammatory cytokines (GMCSF, IFN-gamma, IL-1 beta, IL-6, and IL-8) across stimuli, a higher gene expression level of TLR2 (P=.02) and TLR9 (P=.02), a greater than 4-fold increase in IL-17A (P=.03) production after polyclonal T-cell stimulation, and an enhanced IL-10 response of cord blood mononuclear cells to dexamethasone treatment in culture (P=.018). Conclusion: Vitamin D exposure during fetal development influences the immune system of the neonate, which can contribute to protection from asthma-related, including infectious, outcomes in early life.	[Hornsby, Eve; Pfeffer, Paul E.; Hawrylowicz, Catherine] Kings Coll London, MRC & Asthma UK Ctr Allerg Mech Asthma, London, England; [Laranjo, Nancy; Litonjua, Augusto A.; Weiss, Scott T.; Carey, Vincent J.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA; [Cruikshank, William; Tuzova, Marina; O'Connor, George] Boston Univ, Sch Med, Dept Med, Ctr Pulm, Boston, MA 02118 USA; [Litonjua, Augusto A.; Weiss, Scott T.; Carey, Vincent J.] Harvard Med Sch, Boston, MA USA; [Hornsby, Eve] Queen Mary Univ London, Blizard Inst, London, England; [Pfeffer, Paul E.] Queen Mary Univ London, William Harvey Res Inst, London, England	University of London; King's College London; Harvard University; Brigham & Women's Hospital; Boston University; Harvard University; Harvard Medical School; University of London; Queen Mary University London; University of London; Queen Mary University London	Hawrylowicz, C (corresponding author), Asthma Allergy & Lung Biol, 5th Floor Tower Wing,Guys Hosp Campus, London SE1 9RT, England.	catherine.hawrylowicz@kcl.ac.uk	Hawrylowicz, Catherine/Q-8483-2017	Hawrylowicz, Catherine/0000-0002-2337-7463; Pfeffer, Paul/0000-0003-0369-2885	National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS Foundation Trust; NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; King's College London; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091528] Funding Source: NIH RePORTER; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; Asthma UK [08/019, MRC-AsthmaUKCentre, MRC-Asthma UK Centre] Funding Source: researchfish	National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS Foundation Trust; NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; King's College London; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	We thank the Boston University clinical site of VDAART for their work on this project and in particular the women who participated in this trial. We thank the Antony Nolan Trust staff at King's College Hospital for provision of cord blood samples for pilot studies. This research was also supported by the National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS Foundation Trust and NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.	Amoudruz P, 2005, J ALLERGY CLIN IMMUN, V115, P1304, DOI 10.1016/j.jaci.2005.02.036; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Chambers ES, 2015, J ALLERGY CLIN IMMUN, V136, P628, DOI 10.1016/j.jaci.2015.01.026; Chawes BL, 2016, JAMA-J AM MED ASSOC, V315, P353, DOI 10.1001/jama.2015.18318; Chi A, 2011, CLIN EXP ALLERGY, V41, P842, DOI 10.1111/j.1365-2222.2011.03712.x; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Gold DR, 2009, J ALLERGY CLIN IMMUN, V124, P1078, DOI 10.1016/j.jaci.2009.08.021; Goldberg MR, 2013, PEDIATR RES, V74, P211, DOI 10.1038/pr.2013.74; Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com; Hamzaoui A, 2014, IMMUNOBIOLOGY, V219, P873, DOI 10.1016/j.imbio.2014.07.009; Hand DJ, 1987, MULTIVARIATE ANAL VA, DOI [10.1007/978-94-009-3143-5, DOI 10.1007/978-94-009-3143-5]; Hewison M, 2011, NAT REV ENDOCRINOL, V7, P336, DOI 10.1038/nrendo.2010.226; Hollis BW, 2011, J BONE MINER RES, V26, P2341, DOI 10.1002/jbmr.463; Jeffery LE, 2009, J IMMUNOL, V183, P5458, DOI 10.4049/jimmunol.0803217; Jones AP, 2015, CLIN EXP ALLERGY, V45, P220, DOI 10.1111/cea.12449; Kollmann TR, 2012, IMMUNITY, V37, P771, DOI 10.1016/j.immuni.2012.10.014; Lavoie PM, 2010, J INFECT DIS, V202, P1754, DOI 10.1086/657143; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; LEMIRE JM, 1995, J NUTR, V125, pS1704, DOI 10.1093/jn/125.suppl_6.1704S; Litonjua AA, 2016, JAMA-J AM MED ASSOC, V315, P362, DOI 10.1001/jama.2015.18589; Litonjua AA, 2014, CONTEMP CLIN TRIALS, V38, P37, DOI 10.1016/j.cct.2014.02.006; Litonjua AA, 2009, CURR OPIN ALLERGY CL, V9, P202, DOI 10.1097/ACI.0b013e32832b36cd; Ly NP, 2007, PEDIATRICS, V119, pE171, DOI 10.1542/peds.2006-0524; Ly NP, 2006, PEDIATRICS, V117, pE1132, DOI 10.1542/peds.2005-2271; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Martinez FD, 1999, ALLERGY, V54, P24, DOI 10.1111/j.1398-9995.1999.tb04384.x; McAleer JP, 2014, IMMUNOL REV, V260, P129, DOI 10.1111/imr.12183; Nadeau K, 2010, PEDIATR RES, V67, P375, DOI 10.1203/PDR.0b013e3181d23656; Nanzer AM, 2013, J ALLERGY CLIN IMMUN, V132, P297, DOI 10.1016/j.jaci.2013.03.037; Pinheiro J., 2000, MIXED EFFECTS MODELS; Ramsey CD, 2007, J ALLERGY CLIN IMMUN, V119, P150, DOI 10.1016/j.jaci.2006.09.012; Reece P, 2011, J ALLERGY CLIN IMMUN, V127, P447, DOI 10.1016/j.jaci.2010.11.006; REICHEL H, 1987, P NATL ACAD SCI USA, V84, P3385, DOI 10.1073/pnas.84.10.3385; Schaub B, 2005, J CLIN IMMUNOL, V25, P329, DOI 10.1007/s10875-005-4180-5; Sevgican U, 2012, J ALLERGY CLIN IMMUN, V129, P567, DOI 10.1016/j.jaci.2011.09.032; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Sumino K, 2012, J ALLERGY CLIN IMMUN, V129, P1267, DOI 10.1016/j.jaci.2012.02.033; Unitt J, 2011, BIOCHEM PHARMACOL, V81, P1324, DOI 10.1016/j.bcp.2011.03.010; Urry Z, 2012, EUR J IMMUNOL, V42, P2697, DOI 10.1002/eji.201242370; Urry Z, 2009, J CLIN INVEST, V119, P387, DOI 10.1172/JCI32354; Visness CM, 2015, J ALLERGY CLIN IMMUN, V136, P1108, DOI 10.1016/j.jaci.2015.03.046; Wagner CL, 2013, J STEROID BIOCHEM, V136, P313, DOI 10.1016/j.jsbmb.2013.01.002; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; Zittermann A, 2004, PEDIAT ALLERG IMM-UK, V15, P242, DOI 10.1111/j.1399-3038.2004.00140.x	47	64	69	2	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					269	+		10.1016/j.jaci.2017.02.039	http://dx.doi.org/10.1016/j.jaci.2017.02.039			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28552588	Green Published, hybrid			2022-12-18	WOS:000419312200032
J	Joulia, R; L'Faqihi, FE; Valitutti, S; Espinosa, E				Joulia, Regis; L'Faqihi, Fatima-Ezzahra; Valitutti, Salvatore; Espinosa, Eric			IL-33 fine tunes mast cell degranulation and chemokine production at the single-cell level	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; degranulation; IL-33; time-lapse flow cytometry; avidin	INDIVIDUAL HUMAN BASOPHILS; FLOW-CYTOMETRIC ANALYSIS; DE-GRANULATION; ANAPHYLACTIC DEGRANULATION; DISTRIBUTIONAL BEHAVIOR; ALLERGIC SENSITIZATION; INNATE IMMUNITY; GRADED CHANGES; ACTIVATION; INFLAMMATION	Background: Mast cells are versatile key components of allergy and inflammation known to respond to both innate and adaptive immunologic stimuli. However, the response of individual mast cells to cumulative stimuli remains poorly understood. Objectives: We sought to dissect mast cell responses at the single-cell level and their potentiation by IL-33. Methods: We monitored mast cell degranulation in real time by exploiting the capacity of fluorochrome-labeled avidin to stain degranulating cells. During the degranulation process, the granule matrix is externalized and immediately bound by fluorochrome-labeled avidin present in the culture medium. The degranulation process is monitored by using either time-lapse microscopy or fluorescence-activated cell sorting analysis. Results: Single-cell analysis revealed a strong heterogeneity of individual mast cell degranulation responses. We observed that the number of degranulating mast cells was graded according to the FceRI stimulation strength, whereas the magnitude of individual mast cell degranulation remained unchanged, suggesting an all-or-none response of mast cells after Fc epsilon RI triggering. IL-33 pretreatment increased not only the number of degranulating and chemokine-producing mast cells but also the magnitude of individual mast cell degranulation and chemokine production. Conclusion: We illustrate the effect of IL-33 on mast cell biology at the single-cell level by showing that IL-33 potentiates IgE-mediated mast cell responses by both increasing the number of responding cells and enhancing the responses of individual mast cells.	INSERM, U1043, Toulouse, France; Univ Toulouse, UPS, CPTP, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Espinosa, E (corresponding author), CHU Purpan, CPTP, INSERM, U1043, BP3028, F-31024 Toulouse, France.	eric.espinosa@inserm.fr	espinosa, eric/E-4872-2013; Joulia, Régis/AAX-9773-2021; Valitutti, Salvatore/M-2999-2014	espinosa, eric/0000-0002-3512-0921; Valitutti, Salvatore/0000-0002-6432-4421; Joulia, Regis/0000-0002-7908-5670	Fondation ARC pour la Recherche sur le Cancer [EML2012090493]; Institut National du Cancer [INCa/DGOS 2012-054]; Laboratoire d'Excellence Toulouse Cancer (TOUCAN) [ANR11-LABX]; Region Midi-Pyrenees; Canceropole Grand Sud-Ouest [GSO-2015EXX]	Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Laboratoire d'Excellence Toulouse Cancer (TOUCAN); Region Midi-Pyrenees(Region OccitanieRegion Provence-Alpes-Cote d'Azur); Canceropole Grand Sud-Ouest	Supported by the Fondation ARC pour la Recherche sur le Cancer (grant EML2012090493), the Institut National du Cancer (INCa/DGOS 2012-054), and the Laboratoire d'Excellence Toulouse Cancer (TOUCAN, grant ANR11-LABX); and the Region Midi-Pyrenees and the Canceropole Grand Sud-Ouest (GSO-2015EXX).	Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Altschuler SJ, 2010, CELL, V141, P559, DOI 10.1016/j.cell.2010.04.033; Andrade MV, 2011, EUR J IMMUNOL, V41, P760, DOI 10.1002/eji.201040718; Andrews NL, 2009, IMMUNITY, V31, P469, DOI 10.1016/j.immuni.2009.06.026; Angleson JK, 1999, NAT NEUROSCI, V2, P440, DOI 10.1038/8107; [Anonymous], 2015, EUR J IMMUNOL; [Anonymous], 2015, J LEUKOE BIOL; [Anonymous], 2015, CELL REP; Bartemes KR, 2012, CLIN IMMUNOL, V143, P222, DOI 10.1016/j.clim.2012.03.001; Beltran CJ, 2010, INFLAMM BOWEL DIS, V16, P1097, DOI 10.1002/ibd.21175; BERGSTRESSER PR, 1984, J INVEST DERMATOL, V83, P214, DOI 10.1111/1523-1747.ep12263584; Byers DE, 2013, J CLIN INVEST, V123, P3967, DOI 10.1172/JCI65570; Cabeza JM, 2013, J BIOL CHEM, V288, P20293, DOI 10.1074/jbc.M113.459065; Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004; Cevikbas F, 2012, J INVEST DERMATOL, V132, P1326, DOI 10.1038/jid.2012.66; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Desplat V, 2004, CYTOM PART A, V62A, P35, DOI 10.1002/cyto.a.20030; DVORAK AM, 1991, BLOOD, V77, P569; DVORAK AM, 1981, LAB INVEST, V44, P174; Feinerman O, 2008, SCIENCE, V321, P1081, DOI 10.1126/science.1158013; Galli SJ, 2003, NAT IMMUNOL, V4, P1160, DOI 10.1038/ni1203-1160; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; GOMPERTS BD, 1994, ANN NY ACAD SCI, V710, P217, DOI 10.1111/j.1749-6632.1994.tb26630.x; Haenuki Y, 2012, J ALLERGY CLIN IMMUN, V130, P184, DOI 10.1016/j.jaci.2012.02.013; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; HIDE I, 1993, J CELL BIOL, V123, P585, DOI 10.1083/jcb.123.3.585; Ho LH, 2007, J LEUKOCYTE BIOL, V82, P1481, DOI 10.1189/jlb.0407200; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Iikura M, 2007, LAB INVEST, V87, P971, DOI 10.1038/labinvest.3700663; Joulia R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7174; Jung MY, 2013, J IMMUNOL, V190, P531, DOI 10.4049/jimmunol.1201576; Kassas A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109800; Kett WC, 2003, BBA-GEN SUBJECTS, V1620, P225, DOI 10.1016/S0304-4165(02)00539-1; Khazen R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10823; Krutzik PO, 2006, NAT METHODS, V3, P361, DOI 10.1038/NMETH872; Kunder CA, 2011, BLOOD, V118, P5383, DOI 10.1182/blood-2011-07-358432; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Liu YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060159; Lu Y, 2015, P NATL ACAD SCI USA, V112, pE607, DOI 10.1073/pnas.1416756112; Ma C, 2011, NAT MED, V17, P738, DOI 10.1038/nm.2375; MACGLASHAN D, 1989, J CELL BIOL, V109, P123, DOI 10.1083/jcb.109.1.123; MacGlashan D, 2010, CLIN EXP ALLERGY, V40, P1365, DOI 10.1111/j.1365-2222.2010.03572.x; MACGLASHAN DW, 1994, J LEUKOCYTE BIOL, V55, P13, DOI 10.1002/jlb.55.1.13; MACGLASHAN DW, 1995, J LEUKOCYTE BIOL, V58, P177, DOI 10.1002/jlb.58.2.177; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Muller S, 1999, IMMUNOLOGY, V97, P287; NAKAGAWA T, 1981, ALLERGY, V36, P39, DOI 10.1111/j.1398-9995.1981.tb01823.x; Niepel M, 2009, CURR OPIN CHEM BIOL, V13, P556, DOI 10.1016/j.cbpa.2009.09.015; Ohno T, 2012, ALLERGY, V67, P1203, DOI 10.1111/all.12004; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; PRUZANSKY JJ, 1980, IMMUNOLOGY, V40, P411; ROHLICH P, 1971, J CELL BIOL, V51, P465, DOI 10.1083/jcb.51.2.465; Saluja R, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0076-5; Saluja R, 2015, MOL IMMUNOL, V63, P80, DOI 10.1016/j.molimm.2014.06.018; Silver MR, 2010, INFLAMM RES, V59, P207, DOI 10.1007/s00011-009-0088-5; Sjoberg LC, 2015, ALLERGY, V70, P514, DOI 10.1111/all.12590; St John AL, 2013, J IMMUNOL, V190, P4458, DOI 10.4049/jimmunol.1203420; Tay S, 2010, NATURE, V466, P267, DOI 10.1038/nature09145; THARP MD, 1985, J HISTOCHEM CYTOCHEM, V33, P27, DOI 10.1177/33.1.2578142; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295	66	64	67	2	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					497	+		10.1016/j.jaci.2016.09.049	http://dx.doi.org/10.1016/j.jaci.2016.09.049			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	27876627	Bronze			2022-12-18	WOS:000406855500022
J	Bos, LD; Sterk, PJ; Fowler, SJ				Bos, Lieuwe D.; Sterk, Peter J.; Fowler, Stephen J.			Breathomics in the setting of asthma and chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; chronic obstructive pulmonary disease; Breathomics; breath analysis; volatile organic compounds	VOLATILE ORGANIC-COMPOUNDS; ELECTRONIC NOSE; EXHALED BREATH; CHILDHOOD ASTHMA; COPD PATIENTS; STEROID RESPONSIVENESS; PERSONALIZED MEDICINE; AIRWAY DISEASES; DISCRIMINATION; DIAGNOSIS	Exhaled breath contains thousands of volatile organic compounds that reflect the metabolic process occurring in the host both locally in the airways and systemically. They also arise from the environment and airway microbiome. Comprehensive analysis of breath volatile organic compounds (breathomics) provides opportunities for noninvasive biomarker discovery and novel mechanistic insights. Applications in patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease, include not only diagnostics (especially in children and other challenging diagnostic areas) but also identification of clinical treatable traits, such as airway eosinophilia and risk of infection/exacerbation, that are not specific to diagnostic labels. Although many aspects of breath sampling and analysis are challenging, proof-of-concept studies with mass spectrometry and electronic nose technologies have provided independent studies with moderate-to-good diagnostic and phenotypic accuracies. The present review evaluates the data obtained by using breathomics in (1) predicting the inception of asthma or chronic obstructive pulmonary disease, (2) inflammatory phenotyping, (3) exacerbation prediction, and (4) treatment stratification. The current findings merit the current efforts of large multicenter studies using standardized sampling, shared analytic methods, and databases, including external validation cohorts. This will position this noninvasive technology in the clinical assessment and monitoring of chronic airways diseases.	[Bos, Lieuwe D.; Sterk, Peter J.] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, M0-127,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Bos, Lieuwe D.; Sterk, Peter J.] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1012 WX Amsterdam, Netherlands; [Fowler, Stephen J.] Univ Manchester, Ctr Resp Med & Allergy, Manchester Acad Hlth Sci Ctr, Univ Hosp South Manchester NHS Fdn Trust, Manchester M13 9PL, Lancs, England	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Manchester; Wythenshawe Hospital NHS Foundation Trust	Bos, LD (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Resp Med, M0-127,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	l.d.bos@amc.nl	Sterk, P.J./AAK-8175-2020; Bos, Lieuwe/H-2578-2018	Bos, Lieuwe/0000-0003-2911-4549; Fowler, Stephen/0000-0002-4524-1663	Innovative Medicines Initiative	Innovative Medicines Initiative	P. Sterk has received a grant from Innovative Medicines Initiative. The rest of the authors declare that they have no relevant conflicts of interest.	Agusti A, 2016, EUR RESPIR J, V47, P410, DOI 10.1183/13993003.01359-2015; Agusti A, 2015, AM J RESP CRIT CARE, V191, P391, DOI 10.1164/rccm.201410-1935PP; ASHLEY DL, 1994, CLIN CHEM, V40, P1401; Basanta M, 2012, J BREATH RES, V6, DOI 10.1088/1752-7155/6/2/026002; Basanta M, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-72; Besa V, 2015, INT J CHRONIC OBSTR, V10, P399, DOI 10.2147/COPD.S76212; Bjerg A, 2013, CLIN EXP ALLERGY, V43, P1198, DOI 10.1111/cea.12192; Bofan M, 2013, J BREATH RES, V7, DOI 10.1088/1752-7155/7/1/017103; Boots AW, 2015, TRENDS MOL MED, V21, P633, DOI 10.1016/j.molmed.2015.08.001; Bos LDJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003311; Bousquet J, 2010, EUR RESPIR J, V36, P995, DOI 10.1183/09031936.00012610; Carraro S, 2007, AM J RESP CRIT CARE, V175, P986, DOI 10.1164/rccm.200606-769OC; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Chen R, 2012, CELL, V148, P1293, DOI 10.1016/j.cell.2012.02.009; Chung KF, 2016, J INTERN MED, V279, P192, DOI 10.1111/joim.12382; Chung KF, 2015, CURR OPIN ALLERGY CL, V15, P56, DOI 10.1097/ACI.0000000000000134; Collins GS, 2015, EUR UROL, V67, P1142, DOI 10.1016/j.eururo.2014.11.025; Cristescu SM, 2011, J BREATH RES, V5, DOI 10.1088/1752-7155/5/4/046009; Dallinga JW, 2010, CLIN EXP ALLERGY, V40, P68, DOI 10.1111/j.1365-2222.2009.03343.x; de Vries R, 2015, J BREATH RES, V9, DOI 10.1088/1752-7155/9/4/046001; Dragonieri S, 2007, J ALLERGY CLIN IMMUN, V120, P856, DOI 10.1016/j.jaci.2007.05.043; Dragonieri S, 2009, LUNG CANCER, V64, P166, DOI 10.1016/j.lungcan.2008.08.008; Faner R, 2015, EUR RESPIR J, V46, P1001, DOI 10.1183/13993003.00763-2015; Fens N, 2011, EUR RESPIR J, V38, P1301, DOI 10.1183/09031936.00032911; Fens N, 2011, CLIN EXP ALLERGY, V41, P1371, DOI 10.1111/j.1365-2222.2011.03800.x; Fens N, 2015, AM J RESP CRIT CARE, V191, P1086, DOI 10.1164/rccm.201411-2010LE; Fens N, 2009, AM J RESP CRIT CARE, V180, P1076, DOI 10.1164/rccm.200906-0939OC; Fowler SJ, 2015, THORAX, V70, P320, DOI 10.1136/thoraxjnl-2014-206273; Gahleitner F, 2013, BIOANALYSIS, V5, P2239, DOI 10.4155/bio.13.184; Gaida A, 2016, J BREATH RES, V10, DOI DOI 10.1097/SLA.0000000000001101; Hattesohl ADM, 2011, RESPIROLOGY, V16, P1258, DOI 10.1111/j.1440-1843.2011.02047.x; Hauschild AC, 2012, GENET MOL RES, V11, P2733, DOI 10.4238/2012.July.10.17; Ibrahim B, 2011, THORAX, V66, P804, DOI 10.1136/thx.2010.156695; Jackson DJ, 2016, J ALLERGY CLIN IMMUN, V137, P659, DOI 10.1016/j.jaci.2016.01.002; Klaassen EMM, 2015, AM J RESP CRIT CARE, V191, P201, DOI 10.1164/rccm.201408-1537OC; Lazar Z, 2010, SENSORS-BASEL, V10, P9127, DOI 10.3390/s101009127; Leopold JH, 2015, J BREATH RES, V9, DOI 10.1088/1752-7155/9/4/046002; Loymans RJB, 2015, EUR RESPIR J, V46, DOI 10.1183/13993003.congress-2015.PA2540; Matsunaga K, 2015, J ALLER CL IMM-PRACT, V3, P759, DOI 10.1016/j.jaip.2015.05.005; McShane LM, 2013, NATURE, V502, P317, DOI 10.1038/nature12564; Modak A, 2008, EXPERT REV MOL DIAGN, V8, P563, DOI 10.1586/14737159.8.5.563; Montuschi P, 2010, CHEST, V137, P790, DOI 10.1378/chest.09-1836; Pavord ID, 2008, LANCET, V372, P1017, DOI 10.1016/S0140-6736(08)61421-X; Petsky HL, 2012, THORAX, V67, P199, DOI 10.1136/thx.2010.135574; Phillips CO, 2012, J BREATH RES, V6, DOI 10.1088/1752-7155/6/3/036003; Phillips C, 2014, METABOLITES, V4, P300, DOI 10.3390/metabo4020300; Phillips M, 2000, J LAB CLIN MED, V136, P243, DOI 10.1067/mlc.2000.108943; Pleil JD, 2009, BIOMARKERS, V14, P560, DOI 10.3109/13547500903186460; Postma D, 2011, PRIM CARE RESP J, V20, P205, DOI 10.4104/pcrj.2011.00041; Rattray NJW, 2014, TRENDS BIOTECHNOL, V32, P538, DOI 10.1016/j.tibtech.2014.08.003; Reddel HK, 2015, EUR RESPIR J, V46, P622, DOI 10.1183/13993003.00853-2015; Robroeks CM, 2013, EUR RESPIR J, V42, P98, DOI 10.1183/09031936.00010712; Rubner FJ, 2016, J ALLERGY CLIN IMMUN; Rufo JC, 2016, ALLERGY, V71, P175, DOI 10.1111/all.12793; Schleich FN, 2016, J BREATH RES, V10, DOI 10.1088/1752-7155/10/1/016006; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; Shafiek H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135199; Sibila O, 2014, RESP MED, V108, P1608, DOI 10.1016/j.rmed.2014.09.008; Smolinska A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095668; Sohal SS, 2013, EXPERT REV RESP MED, V7, P275, DOI [10.1586/ERS.13.26, 10.1586/ers.13.26]; Su B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150586; Van Berkel JJBN, 2010, RESP MED, V104, P557, DOI 10.1016/j.rmed.2009.10.018; van der Schee MP, 2013, CLIN EXP ALLERGY, V43, P1217, DOI 10.1111/cea.12147; van der Schee MP, 2015, EUR RESPIR J, V45, P440, DOI 10.1183/09031936.00044414; van der Schee MP, 2015, CHEST, V147, P224, DOI 10.1378/chest.14-0781; Van Vliet D, 2016, J BREATH RES, V10, DOI 10.1088/1752-7155/10/1/016014; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Wedzicha JA, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-181; Wheelock CE, 2013, EUR RESPIR J, V42, P802, DOI 10.1183/09031936.00078812; Whiteson KL, 2014, ISME J, V8, P1247, DOI 10.1038/ismej.2013.229	70	64	64	4	44	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					970	976		10.1016/j.jaci.2016.08.004	http://dx.doi.org/10.1016/j.jaci.2016.08.004			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	27590400	Bronze, Green Submitted			2022-12-18	WOS:000385499400003
J	Riethmuller, C; McAleer, MA; Koppes, SA; Abdayem, R; Franz, J; Haftek, M; Campbell, LE; MacCallum, SF; McLean, WHI; Irvine, AD; Kezic, S				Riethmuller, Christoph; McAleer, Maeve A.; Koppes, Sjors A.; Abdayem, Rawad; Franz, Jonas; Haftek, Marek; Campbell, Linda E.; MacCallum, Stephanie F.; McLean, W. H. Irwin; Irvine, Alan D.; Kezic, Sanja			Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Skin barrier; transepidermal water loss; atopic dermatitis; filaggrin; corneocyte	STRATUM-CORNEUM; ELECTRON-MICROSCOPY; CELL-DEATH; SKIN; ECZEMA; FORCE; ABNORMALITIES; ENVELOPES; MODEL; SCORE	Background: Loss-of-function (LOF) mutations in the filaggrin gene (FLG) are a well-replicated risk factor for atopic dermatitis (AD) and are known to cause an epidermal barrier defect. The nature of this barrier defect is not fully understood. Patients with AD with FLG LOF mutations are known to have more persistent disease, more severe disease, and greater risk of food allergies and eczema herpeticum. Abnormalities in corneocyte morphology have been observed in patients with AD, including prominent villus-like projections (VP); however, these ultrastructural features have not been systematically studied in patients with AD in relation to FLG genotype and acute and convalescent status. Objective: We sought to quantitatively explore the relationship between FLG genotype, filaggrin breakdown products (natural moisturizing factor [NMF]), and corneocyte morphology in patients with AD. Methods: We studied 15 children at first presentation of AD and after 6 weeks of standard therapy. We applied atomic force microscopy to study corneocyte conformation in patients with AD stratified by FLG status and NMF level. By using a new quantitative methodology, the number of VPs per investigated corneocyte area was assessed and expressed as the Dermal Texture Index score. Corneocytes were also labeled with an anti-corneodesmosin antibody and visualized with scanning electron microscopy. Results: We found a strong correlation between NMF levels and Dermal Texture Index scores in both acute and convalescent states (respective r = -0.80 and -0.75, P <.001 and P = .002). Most, but not all, VPs showed the presence of corneodesmosin abundantly all over the cell surface in homozygous/compound heterozygous FLG patients and, to a lesser extent, in heterozygous and wild-type patients. Conclusions: NMF levels are highly correlated with corneocyte morphology in patients with AD. These corneocyte conformational changes shed further insight into the filaggrin-deficient phenotype and help explain the barrier defect in patients with AD with FLG LOF mutations.	[Riethmuller, Christoph; Franz, Jonas] Serend Ip GmbH, Munster, Germany; [McAleer, Maeve A.; Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Dermatol, Dublin, Ireland; [McAleer, Maeve A.; Irvine, Alan D.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin, Ireland; [Koppes, Sjors A.; Kezic, Sanja] Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat Hlth, NL-1105 AZ Amsterdam, Netherlands; [Abdayem, Rawad; Haftek, Marek] Univ Lyon 1, Fundamental Clin & Therapeut Aspects Skin Barrier, F-69365 Lyon, France; [Campbell, Linda E.; MacCallum, Stephanie F.; McLean, W. H. Irwin; Irvine, Alan D.] Univ Dundee, Coll Life Sci & Med, Ctr Dermatol & Genet Med, Div Mol Med, Dundee DD1 4HN, Scotland; [Campbell, Linda E.; MacCallum, Stephanie F.; McLean, W. H. Irwin; Irvine, Alan D.] Univ Dundee, Coll Dent, Ctr Dermatol & Genet Med, Div Mol Med, Dundee DD1 4HN, Scotland; [Campbell, Linda E.; MacCallum, Stephanie F.; McLean, W. H. Irwin; Irvine, Alan D.] Univ Dundee, Coll Nursing, Ctr Dermatol & Genet Med, Div Mol Med, Dundee DD1 4HN, Scotland; [Irvine, Alan D.] Univ Dublin Trinity Coll, Med Clin, Dublin 2, Ireland	National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; University of Amsterdam; Academic Medical Center Amsterdam; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Dundee; University of Dundee; University of Dundee; Trinity College Dublin	Kezic, S (corresponding author), Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat Hlth, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	irvinea@tcd.ie; s.kezic@amc.uva.nl	Irvine, Alan D/A-3982-2008	Irvine, Alan D/0000-0002-9048-2044; Franz, Jonas/0000-0001-7523-6622; Abdayem, Rawad/0000-0002-5295-2105	National Children's Research Centre Dublin, Ireland; Wellcome Trust Strategic Award [098439/Z/12/Z]; German Ministry of Research [01DJ13022A]; MRC [G0802780, G0700314] Funding Source: UKRI; Medical Research Council [G0700314, G0802780] Funding Source: researchfish	National Children's Research Centre Dublin, Ireland; Wellcome Trust Strategic Award(Wellcome Trust); German Ministry of Research; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by the National Children's Research Centre Dublin, Ireland (to A.D.I and M.A.M.). The Centre for Dermatology and Genetic Medicine, University of Dundee, is supported by a Wellcome Trust Strategic Award (098439/Z/12/Z to W.H.I.M). The work performed by Serend-ip was supported by the German Ministry of Research grant no. 01DJ13022A (to C.R.).	Angelova-Fischer I, 2014, ACTA DERM-VENEREOL, V94, P640, DOI 10.2340/00015555-1815; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Dapic I, 2013, ANAL LETT, V46, P2133, DOI 10.1080/00032719.2013.789881; DAWBER RPR, 1972, BRIT J DERMATOL, V86, P272, DOI 10.1111/j.1365-2133.1972.tb02228.x; Eckhart L, 2013, BBA-MOL CELL RES, V1833, P3471, DOI 10.1016/j.bbamcr.2013.06.010; Fluhr JW, 2014, BRIT J DERMATOL, V171, P978, DOI 10.1111/bjd.12880; Fredonnet J, 2014, J DERMATOL SCI, V75, P63, DOI 10.1016/j.jdermsci.2014.04.009; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; Harding C. R., 2003, International Journal of Cosmetic Science, V25, P157, DOI 10.1046/j.1467-2494.2003.00175.x; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Kezic S, 2011, ALLERGY, V66, P934, DOI 10.1111/j.1398-9995.2010.02540.x; KING CS, 1979, BRIT J DERMATOL, V100, P165, DOI 10.1111/j.1365-2133.1979.tb05556.x; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Leung DY, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Matsumoto K, 2005, SKIN RES TECHNOL, V11, P209, DOI 10.1111/j.1600-0846.2005.00106.x; McAleer MA, 2013, J ALLERGY CLIN IMMUN, V131, P280, DOI 10.1016/j.jaci.2012.12.668; Menon GK, 2012, INT J PHARMACEUT, V435, P3, DOI 10.1016/j.ijpharm.2012.06.005; MICHEL S, 1988, J INVEST DERMATOL, V91, P11, DOI 10.1111/1523-1747.ep12463281; Naoe Y, 2010, J DERMATOL SCI, V57, P192, DOI 10.1016/j.jdermsci.2009.12.014; Naoko O, 2013, SKIN RES TECHNOL, V19, P361, DOI 10.1111/srt.12044; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V126, P574, DOI 10.1016/j.jaci.2010.04.038; Rankl C, 2010, EXP DERMATOL, V19, P1014, DOI 10.1111/j.1600-0625.2010.01179.x; Rawlings AV, 2014, BRIT J DERMATOL, V171, P19, DOI 10.1111/bjd.13303; Riethmueller C, 2007, ULTRAMICROSCOPY, V107, P895, DOI 10.1016/j.ultramic.2007.04.007; Sandilands A, 2007, J INVEST DERMATOL, V127, P1282, DOI 10.1038/sj.jid.5700876; Schmitt J, 2007, J ALLERGY CLIN IMMUN, V120, P1389, DOI 10.1016/j.jaci.2007.08.011; Schmitt J, 2013, J ALLERGY CLIN IMMUN, V132, P1337, DOI 10.1016/j.jaci.2013.07.008; Simon M, 1996, BIOCHEM J, V317, P173, DOI 10.1042/bj3170173; Tang TS, 2014, J ALLERGY CLIN IMMUN, V133, P1615, DOI 10.1016/j.jaci.2013.12.1079; Thoelking G, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/26/265102; Watkinson A, 2002, COSMET SCI TECHNOL S, V25, P95; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wolkerstorfer A, 1999, ACTA DERM-VENEREOL, V79, P356	36	64	67	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1573	U223		10.1016/j.jaci.2015.04.042	http://dx.doi.org/10.1016/j.jaci.2015.04.042			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26071937	hybrid, Green Published			2022-12-18	WOS:000366044300019
J	Simpson, A; Lazic, N; Belgrave, DCM; Johnson, P; Bishop, C; Mills, C; Custovic, A				Simpson, Angela; Lazic, Nevena; Belgrave, Danielle C. M.; Johnson, Phil; Bishop, Christopher; Mills, Clare; Custovic, Adnan			Patterns of IgE responses to multiple allergen components and clinical symptoms at age 11 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; childhood; component-resolved diagnostics; latent variable modeling; allergens; asthma; wheeze; eczema; hay fever	MOLECULAR DIAGNOSIS; RESOLVED DIAGNOSIS; CHILDHOOD ASTHMA; PROTEIN FAMILIES; CHILDREN; SENSITIZATION; ISAAC; NOMENCLATURE; POPULATION; RATIONALE	Background: The relationship between sensitization to allergens and disease is complex. Objective: We sought to identify patterns of response to a broad range of allergen components and investigate associations with asthma, eczema, and hay fever. Methods: Serum specific IgE levels to 112 allergen components were measured by using a multiplex array (Immuno Solid-phase Allergen Chip) in a population-based birth cohort. Latent variable modeling was used to identify underlying patterns of component-specific IgE responses; these patterns were then related to asthma, eczema, and hay fever. Results: Two hundred twenty-one of 461 children had IgE to 1 or more components. Seventy-one of the 112 components were recognized by 3 or more children. By using latent variable modeling, 61 allergen components clustered into 3 component groups (CG1, CG2, and CG3); protein families within each CG were exclusive to that group. CG1 comprised 27 components from 8 plant protein families. CG2 comprised 7 components of mite allergens from 3 protein families. CG3 included 27 components of plant, animal, and fungal origin from 12 protein families. Each CG included components from different biological sources with structural homology and also nonhomologous proteins arising from the same biological source. Sensitization to CG3 was most strongly associated with asthma (odds ratio [OR], 8.20; 95% CI, 3.49-19.24; P < .001) and lower FEV1 (P < .001). Sensitization to CG1 was associated with hay fever (OR, 12.79; 95% CI, 6.84-23.90; P < .001). Sensitization to CG2 was associated with both asthma (OR, 3.60; 95% CI, 2.05-6.29) and hay fever (OR, 2.52; 95% CI, 1.38-4.61). Conclusions: Latent variable modeling with a large number of allergen components identified 3 patterns of IgE responses, each including different protein families. In 11-year-old children the pattern of response to components of multiple allergens appeared to be associated with current asthma and hay fever but not eczema.	[Simpson, Angela; Belgrave, Danielle C. M.; Johnson, Phil; Mills, Clare; Custovic, Adnan] Univ Manchester, Manchester Acad Hlth Sci Ctr, Inst Inflammat & Repair, Ctr Resp Med & Allergy, Manchester M23 9LT, Lancs, England; [Simpson, Angela; Belgrave, Danielle C. M.; Johnson, Phil; Mills, Clare; Custovic, Adnan] Univ S Manchester Hosp, Manchester, Lancs, England; [Lazic, Nevena; Bishop, Christopher] Microsoft Res Cambridge, Cambridge, England; [Belgrave, Danielle C. M.] Univ Manchester, Inst Populat Hlth, Ctr Hlth Informat, Manchester M23 9LT, Lancs, England; [Johnson, Phil; Mills, Clare] Univ Manchester, Manchester Inst Biotechnol, Inst Inflammat & Repair, Ctr Resp Med & Allergy, Manchester M23 9LT, Lancs, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Microsoft; University of Manchester; University of Manchester	Simpson, A (corresponding author), Univ Manchester, Univ S Manchester Hosp, ERC Bldg,Second Floor, Manchester M23 9LT, Lancs, England.	angela.simpson@manchester.ac.uk	Custovic, Adnan/A-2435-2012; Kuyucu, Semanur/K-5346-2015	Custovic, Adnan/0000-0001-5218-7071; Simpson, Angela/0000-0003-2733-6666	Asthma UK [301, 362, 01/012, 04/014]; JP Moulton Charitable Foundation; Medical Research Council [G0601361, MR/K002449/1]; North West Lung Centre Charity; MRC [MR/K002449/2, MR/K002449/1, G0601361] Funding Source: UKRI; Medical Research Council [MR/K002449/2] Funding Source: researchfish	Asthma UK; JP Moulton Charitable Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); North West Lung Centre Charity; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by Asthma UK (301, 362, 01/012, 04/014), the JP Moulton Charitable Foundation, the Medical Research Council (grants G0601361 and MR/K002449/1), and the North West Lung Centre Charity.	Antonicelli L, 2014, EUR ANN ALLERGY CLIN, V46, P30; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Belgrave DCM, 2013, J ALLERGY CLIN IMMUN, V132, P575, DOI 10.1016/j.jaci.2013.05.041; Bernard H, 2015, J ALLERGY CLIN IMMUN, V135, P1267, DOI 10.1016/j.jaci.2014.10.025; Bishop C., 1999, LEARNING GRAPHICAL M, P371, DOI DOI 10.1017/S0140525X10000798; Bishop CM, 2013, PHILOS T R SOC A, V371, DOI 10.1098/rsta.2012.0222; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Caubet JC, 2011, CURR OPIN ALLERGY CL, V11, P210, DOI 10.1097/ACI.0b013e3283464d1b; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2013, CURR OPIN ALLERGY CL, V13, P173, DOI 10.1097/ACI.0b013e32835e82b6; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, P631, DOI 10.1016/j.jaci.2011.01.026; Emara M, 2012, J BIOL CHEM, V287, P5756, DOI 10.1074/jbc.M111.312520; Flohr C, 2008, J ALLERGY CLIN IMMUN, V121, P141, DOI 10.1016/j.jaci.2007.08.066; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Heinzerling LM, 2009, ALLERGY, V64, P1498, DOI 10.1111/j.1398-9995.2009.02093.x; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kljaic-Bukvic B, 2014, PEDIAT ALLERG IMM-UK, V25, P552, DOI 10.1111/pai.12258; Konradsen JR, 2014, PEDIAT ALLERG IMM-UK, V25, P187, DOI 10.1111/pai.12198; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Melioli G, 2013, CURR OPIN ALLERGY CL, V13, P446, DOI 10.1097/ACI.0b013e32836274d8; Melioli G, 2011, CLIN BIOCHEM, V44, P1005, DOI 10.1016/j.clinbiochem.2011.05.007; Minka T.P., 2001, P 17 C UNC ART INT, P362; MUDDE GC, 1995, ALLERGY, V50, P193, DOI 10.1111/j.1398-9995.1995.tb01132.x; Nettis E, 2014, EUR ANN ALLERGY CLIN, V46, P68; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Nicolaou NC, 2008, J ALLERGY CLIN IMMUN, V122, P500, DOI 10.1016/j.jaci.2008.06.033; Nicolaou NC, 2006, AM J RESP CRIT CARE, V174, P254, DOI 10.1164/rccm.200601-140OC; Popa V, 2001, AM J RESP CRIT CARE, V163, P292, DOI 10.1164/ajrccm.163.1.16310b; Potaczek DP, 2012, CLIN EXP ALLERGY, V42, P852, DOI 10.1111/j.1365-2222.2011.03953.x; Prosperi MCF, 2014, PEDIAT ALLERG IMM-UK, V25, P71, DOI 10.1111/pai.12139; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; Radauer C, 2014, ALLERGY, V69, P413, DOI 10.1111/all.12348; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Scala E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024912; Sharquie IK, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-54; Simpson A, 2012, AM J RESP CRIT CARE, V185, P1197, DOI 10.1164/rccm.201112-2191OC; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Stanojevic S, 2009, AM J RESP CRIT CARE, V180, P547, DOI 10.1164/rccm.200903-0323OC; Treudler R, 2013, CURR ALLERGY ASTHM R, V13, P110, DOI 10.1007/s11882-012-0318-8; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Virtanen T, 2012, CLIN EXP ALLERGY, V42, P494, DOI 10.1111/j.1365-2222.2011.03903.x; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303	45	64	66	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1224	1231		10.1016/j.jaci.2015.03.027	http://dx.doi.org/10.1016/j.jaci.2015.03.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	25935108	Green Published, hybrid			2022-12-18	WOS:000364787200010
J	Oczypok, EA; Milutinovic, PS; Alcorn, JF; Khare, A; Crum, LT; Manni, ML; Epperly, MW; Pawluk, AM; Ray, A; Oury, TD				Oczypok, Elizabeth A.; Milutinovic, Pavle S.; Alcorn, John F.; Khare, Anupriya; Crum, Lauren T.; Manni, Michelle L.; Epperly, Michael W.; Pawluk, Adriane M.; Ray, Anuradha; Oury, Tim D.			Pulmonary receptor for advanced glycation end-products promotes asthma pathogenesis through IL-33 and accumulation of group 2 innate lymphoid cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; receptor for advanced glycation end-products; IL-33; group 2 innate lymphoid cells	LEUKOCYTE RECRUITMENT; ACUTE-INFLAMMATION; LUNG INFLAMMATION; EPITHELIAL-CELLS; TYPE-2 IMMUNITY; RAGE; EXPRESSION; MEDIATOR; SIGNALS; MICE	Background: Single nucleotide polymorphisms in the human gene for the receptor for advanced glycation end-products (RAGE) are associated with an increased incidence of asthma. RAGE is highly expressed in the lung and has been reported to play a vital role in the pathogenesis of murine models of asthma/allergic airway inflammation (AAI) by promoting expression of the type 2 cytokines IL-5 and IL-13. IL-5 and IL-13 are prominently secreted by group 2 innate lymphoid cells (ILC2s), which are stimulated by the proallergic cytokine IL-33. Objective: We sought to test the hypothesis that pulmonaryRAGE is necessary for allergen-induced ILC2 accumulation in the lung. Methods: AAI was induced in wild-type and RAGE knockout mice by using IL-33, house dust mite extract, or Alternaria alternata extract. RAGE's lung-specific role in type 2 responses was explored with bone marrow chimeras and induction of gastrointestinal type 2 immune responses. Results: RAGE was found to drive AAI by promoting IL-33 expression in response to allergen and by coordinating the inflammatory response downstream of IL-33. Absence of RAGE impedes pulmonary accumulation of ILC2s in models of AAI. Bone marrow chimera studies suggest that pulmonary parenchymal, but not hematopoietic, RAGE has a central role in promoting AAI. In contrast to the lung, the absence of RAGE does not affect IL-33-induced ILC2 influx in the spleen, type 2 cytokine production in the peritoneum, or mucus hypersecretion in the gastrointestinal tract. Conclusions: For the first time, this study demonstrates that a parenchymal factor, RAGE, mediates lung-specific accumulation of ILC2s.	[Oczypok, Elizabeth A.; Milutinovic, Pavle S.; Crum, Lauren T.; Pawluk, Adriane M.; Oury, Tim D.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Khare, Anupriya; Ray, Anuradha] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Alcorn, John F.; Manni, Michelle L.] Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA; [Epperly, Michael W.] Univ Pittsburgh, Dept Radiat Oncol, Inst Canc, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Oury, TD (corresponding author), S785 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	tdoury@pitt.edu			National Institutes of Health (NIH) [5R21HL095495-02, 1T32HL094295-01A2, 5T32HL094295-0304, 1F30ES024045-01, AI048927, HL113956]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL113956, R21HL095495, T32HL094295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F30ES024045] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by grant 5R21HL095495-02 (to T.D.O.), 1T32HL094295-01A2 (to P.S.M.), 5T32HL094295-03&04 (to E.A.O.), 1F30ES024045-01 (to E.A.O.), AI048927 (to A.R.), and HL113956 (to A.R.), all from the National Institutes of Health (NIH).	Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Akirav EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095678; Akirav EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034698; Alcorn JF, 2007, AM J RESP CRIT CARE, V176, P974, DOI 10.1164/rccm.200702-334OC; Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barlow JL, 2011, J LEUKOCYTE BIOL, V90, P867, DOI 10.1189/jlb.0311160; Barnig C, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004812; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Boitano S, 2004, AM J PHYSIOL-LUNG C, V287, pL455, DOI 10.1152/ajplung.00172.2004; Braach N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089422; BRETT J, 1993, AM J PATHOL, V143, P1699; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Chavakis T, 2003, J EXP MED, V198, P1507, DOI 10.1084/jem.20030800; Christianson CA, 2015, J ALLERGY CLIN IMMUN, V136, P59, DOI 10.1016/j.jaci.2014.11.037; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030; Curran CS, 2011, INT IMMUNOL, V23, P713, DOI 10.1093/intimm/dxr083; Dahlin K, 2004, AM J RESP CELL MOL, V31, P309, DOI 10.1165/rcmb.2003-0423OC; Demling N, 2006, CELL TISSUE RES, V323, P475, DOI 10.1007/s00441-005-0069-0; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Englert JM, 2008, AM J PATHOL, V172, P583, DOI 10.2353/ajpath.2008.070569; Everhart MB, 2005, J LEUKOCYTE BIOL, V77, P173, DOI 10.1189/jlb.1203647; Fehrenbach H, 1998, CELL MOL BIOL, V44, P1147; Frommhold D, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-56; Frommhold D, 2010, BLOOD, V116, P841, DOI 10.1182/blood-2009-09-244293; Gorfu G, 2009, CURR MOL MED, V9, P836, DOI 10.2174/156652409789105525; Halayko AJ, 2009, CAN J PHYSIOL PHARM, V87, P743, DOI 10.1139/Y09-054; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Hanford LE, 2003, AM J RESP CELL MOL, V29, pS77; Hara K, 2014, J IMMUNOL, V192, P4032, DOI 10.4049/jimmunol.1400110; Hardman CS, 2013, EUR J IMMUNOL, V43, P488, DOI 10.1002/eji.201242863; Hayakawa M, 2009, BIOCHEM BIOPH RES CO, V387, P218, DOI 10.1016/j.bbrc.2009.07.018; Humphreys NE, 2008, J IMMUNOL, V180, P2443, DOI 10.4049/jimmunol.180.4.2443; Isakson BE, 2003, AM J RESP CELL MOL, V29, P552, DOI 10.1165/rcmb.2002-0281OC; Kim HK, 2014, INT ARCH ALLERGY IMM, V163, P92, DOI 10.1159/000356341; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Koval M, 2002, AM J PHYSIOL-LUNG C, V283, pL875, DOI 10.1152/ajplung.00078.2002; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Llop-Guevara A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088714; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Manni ML, 2012, AM J PHYSIOL-LUNG C, V302, pL160, DOI 10.1152/ajplung.00360.2010; Milutinovic PS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088259; Milutinovic PS, 2012, AM J PATHOL, V181, P1215, DOI 10.1016/j.ajpath.2012.06.031; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; MOOLENBEEK C, 1981, LAB ANIM, V15, P57, DOI 10.1258/002367781780958577; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Neill DR, 2011, TRENDS PARASITOL, V27, P214, DOI 10.1016/j.pt.2011.01.001; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Robinson AB, 2012, AM J PHYSIOL-LUNG C, V302, pL1192, DOI 10.1152/ajplung.00099.2012; Scanlon ST, 2015, CLIN EXP ALLERGY, V45, P9, DOI 10.1111/cea.12464; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Schon MP, 1999, J IMMUNOL, V162, P6641; Shim EJ, 2012, CLIN EXP ALLERGY, V42, P958, DOI 10.1111/j.1365-2222.2012.03998.x; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Ullah MA, 2014, J ALLERGY CLIN IMMUN, V134, P440, DOI 10.1016/j.jaci.2013.12.1035; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Yamamoto Y, 2011, J IMMUNOL, V186, P3248, DOI 10.4049/jimmunol.1002253; Yasuda K, 2012, P NATL ACAD SCI USA, V109, P3451, DOI 10.1073/pnas.1201042109; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82	73	64	67	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					747	+		10.1016/j.jaci.2015.03.011	http://dx.doi.org/10.1016/j.jaci.2015.03.011			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25930197	Green Accepted, Bronze			2022-12-18	WOS:000360913300027
J	Alkhairy, OK; Rezaei, N; Graham, RR; Abolhassani, H; Borte, S; Hultenby, K; Wu, CL; Aghamohammadi, A; Williams, DA; Behrens, TW; Hammarstrom, L; Pan-Hammarstrom, Q				Alkhairy, Omar K.; Rezaei, Nima; Graham, Robert R.; Abolhassani, Hassan; Borte, Stephan; Hultenby, Kjell; Wu, Chenglin; Aghamohammadi, Asghar; Williams, David A.; Behrens, Timothy W.; Hammarstrom, Lennart; Pan-Hammarstrom, Qiang			RAC2 loss-of-function mutation in 2 siblings with characteristics of common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RHO GTPASE; T-CELLS; EXPRESSION		[Alkhairy, Omar K.; Abolhassani, Hassan; Borte, Stephan; Wu, Chenglin; Hammarstrom, Lennart; Pan-Hammarstrom, Qiang] Karolinska Inst, Div Clin Immunol & Transfus Med, Stockholm, Sweden; [Alkhairy, Omar K.; Abolhassani, Hassan; Borte, Stephan; Wu, Chenglin; Hammarstrom, Lennart; Pan-Hammarstrom, Qiang] Karolinska Inst, Clin Res Ctr, Dept Lab Med, Stockholm, Sweden; [Alkhairy, Omar K.; Abolhassani, Hassan; Borte, Stephan; Wu, Chenglin; Hammarstrom, Lennart; Pan-Hammarstrom, Qiang] Karolinska Univ Hosp Huddinge, Stockholm, Sweden; [Alkhairy, Omar K.] King Abdul Aziz Med City, Dept Pathol & Lab Med, Riyadh, Saudi Arabia; [Rezaei, Nima; Abolhassani, Hassan; Aghamohammadi, Asghar] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Childrens Med Ctr, Pediat Ctr Excellence, Tehran, Iran; [Rezaei, Nima] Univ Tehran Med Sci, Dept Immunol, Sch Med, Tehran, Iran; [Rezaei, Nima] Univ Tehran Med Sci, Mol Immunol Res Ctr, Tehran, Iran; [Graham, Robert R.; Behrens, Timothy W.] Genentech Inc, Immunol Biomarkers Grp, San Francisco, CA 94080 USA; [Borte, Stephan] Univ Leipzig, Translat Ctr Regenerat Med TRM, D-04109 Leipzig, Germany; [Williams, David A.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA; [Williams, David A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; King Abdulaziz Medical City; King Saud Bin Abdulaziz University for Health Sciences; King Abdulaziz Medical City - Riyadh; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Roche Holding; Genentech; Leipzig University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Alkhairy, OK (corresponding author), Karolinska Inst, Div Clin Immunol & Transfus Med, Stockholm, Sweden.	Qiang.Pan-Hammarstrom@ki.se	Rezaei, Nima/B-4245-2008; Abolhassani, Hassan/B-3465-2014; hammarstrom, qiang pan/ABA-4589-2021	Rezaei, Nima/0000-0002-3836-1827; Abolhassani, Hassan/0000-0002-4838-0407; pan-hammarstrom, qiang/0000-0003-1990-8804; Aghamohammadi, Asghar/0000-0002-9454-1603	European Research Council [242551] Funding Source: Medline; NIDDK NIH HHS [R01 DK062757, 5R01DK062757-12] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062757] Funding Source: NIH RePORTER	European Research Council(European Research Council (ERC)European Commission); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abolhassani H, 2014, J ALLERGY CLIN IMMUN, V134, P1375, DOI 10.1016/j.jaci.2014.04.042; Accetta D, 2011, J ALLERGY CLIN IMMUN, V127, P535, DOI 10.1016/j.jaci.2010.10.013; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; Arandi N, 2013, CELL IMMUNOL, V281, P129, DOI 10.1016/j.cellimm.2013.03.003; Boldt A, 2014, CYTOM PART B-CLIN CY, V86, P191, DOI 10.1002/cyto.b.21162; Buckley RH, 2005, J CLIN INVEST, V115, P2974, DOI 10.1172/JCI26956; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Gu Y, 2002, MOL CELL BIOL, V22, P7645, DOI 10.1128/MCB.22.21.7645-7657.2002; Gu Y, 2001, J BIOL CHEM, V276, P15929, DOI 10.1074/jbc.M010445200; Khan Mohammad Beigi P., 2007, J ALLERGY CLIN IMMUN, V120, P13, DOI [10.1007/978-3-319-47907-1_4, DOI 10.1007/978-3-319-47907-1_4]; Kurkchubasche AG, 2001, J PEDIATR-US, V139, P141, DOI 10.1067/mpd.2001.114718; Leavey PJ, 1998, BLOOD, V92, P4366, DOI 10.1182/blood.V92.11.4366.423k23_4366_4374; Oraei M, 2012, J INVEST ALLERG CLIN, V22, P160; Rezaei N, 2010, CLIN VACCINE IMMUNOL, V17, P524, DOI 10.1128/CVI.00389-09; Troeger A, 2013, EXP CELL RES, V319, P2375, DOI 10.1016/j.yexcr.2013.07.002; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Williams DA, 2000, BLOOD, V96, P1646	17	64	67	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1380	+		10.1016/j.jaci.2014.10.039	http://dx.doi.org/10.1016/j.jaci.2014.10.039			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25512081	Green Accepted, hybrid			2022-12-18	WOS:000353980700034
J	Bentley, JK; Chen, Q; Hong, JY; Popova, AP; Lei, J; Moore, BB; Hershenson, MB				Bentley, J. Kelley; Chen, Qiang; Hong, Jun Young; Popova, Antonia P.; Lei, Jing; Moore, Bethany B.; Hershenson, Marc B.			Periostin is required for maximal airways inflammation and hyperresponsiveness in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Periostin; asthma; mouse models; inflammation; matricellular protein; house dust mite; integrin; CD11b	ALLERGIC INFLAMMATION; ASTHMA; MODEL; METAPLASIA; FIBROSIS	Background: Periostin, a secreted extracellular matrix protein, has been localized to deposits of subepithelial fibrosis in asthmatic patients, and periostin levels have been linked to increases in IL-13. Objective: We hypothesized that periostin is required for airway inflammatory responses to a physiologic aeroallergen, house dust mite (HDM). Methods: We studied F4-F6 B6; 129-Postn(tm1Jmol)/J wild-type (Postn(+/+)) and null (Postn(-/-)) mice, as well as C57BL/6 mice treated with either IgM or OC-20 periostin neutralizing antibody. Mice were exposed to 5 doses of HDM intranasally over a 16-day period. Results: HDM increased airways responsiveness in Postn(+/+) but not Postn(-/-) mice. In addition, HDM-treated C57BL/6 mice injected with OC-20 had lower airways responsiveness than HDM-treated mice injected with IgM. Compared with Postn(+/+) mice, Postn(-/-) mice showed decreases in HDM-induced inflammation and mucous metaplasia, as well as reduced IL-4, IL-25, CD68, Gob5, and periostin mRNA expression. OC-20 antibody produced similar results. HDM exposure increased periostin expression in the airway epithelium, subepithelium, smooth muscle and inflammatory cells. OC-20 blocked the HDM-induced IgE response, and T cells incubated with dendritic cells (DCs) from Postn(-/-) mice or treated with OC-20 showed deficient DNA synthesis and IL-13 responses compared with T cells incubated with wild-type DCs. Finally, adoptive transfer of bone marrow-derived DCs from Postn(+/+) mice was sufficient to promote allergic responses in F6 Postn(-/-) littermates. Conclusions: In mice, periostin is required for maximal airways hyperresponsiveness and inflammation after HDM sensitization and challenge. Periostin is required for maximal HDM-induced T-cell responses.	[Bentley, J. Kelley; Chen, Qiang; Popova, Antonia P.; Lei, Jing; Hershenson, Marc B.] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA; [Hong, Jun Young; Hershenson, Marc B.] Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Moore, Bethany B.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hershenson, MB (corresponding author), Med Sci Res Bldg II,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	mhershen@umich.edu		Hong, Jun Young/0000-0002-4963-7147; Bentley, John Kelley/0000-0001-8865-7979; Moore, Bethany/0000-0003-3051-745X	Michigan Institute for Clinical and Health Research/National Institutes of Health [UL1TR000433, HL115618, HL079339]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000433] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL115618, K23HL109149, R01HL079339] Funding Source: NIH RePORTER	Michigan Institute for Clinical and Health Research/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the Michigan Institute for Clinical and Health Research/National Institutes of Health UL1TR000433 (to J.K.B.), HL115618 (to B.B.M), and HL079339 (to M.B.H.).	Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Bozyk PD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031336; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Erkan M, 2007, GASTROENTEROLOGY, V132, P1447, DOI 10.1053/j.gastro.2007.01.031; Gordon ED, 2012, CLIN EXP ALLERGY, V42, P144, DOI 10.1111/j.1365-2222.2011.03840.x; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; Hoersch S, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-30; Hur DG, 2012, ALLERGY ASTHMA IMMUN, V4, P222, DOI 10.4168/aair.2012.4.4.222; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Johansson MW, 2013, AM J RESP CELL MOL, V48, P503, DOI 10.1165/rcmb.2012-0150OC; Kanemitsu Y, 2013, J ALLERGY CLIN IMMUN, V132, P305, DOI 10.1016/j.jaci.2013.04.050; Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Lewkowich IP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003879; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Mesnil C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053242; Naik PK, 2012, AM J PHYSIOL-LUNG C, V303, pL1046, DOI 10.1152/ajplung.00139.2012; Newcomb DC, 2008, AM J RESP CRIT CARE, V177, P1111, DOI 10.1164/rccm.200708-1243OC; Nishiyama T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018410; Oh SY, 2007, J ALLERGY CLIN IMMUN, V119, P123, DOI 10.1016/j.jaci.2006.08.029; Oka T, 2007, CIRC RES, V101, P313, DOI 10.1161/CIRCRESAHA.107.149047; Orecchia P, 2011, EUR J CANCER, V47, P2221, DOI 10.1016/j.ejca.2011.04.026; Osterholzer JJ, 2009, J IMMUNOL, V183, P8044, DOI 10.4049/jimmunol.0902823; Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131-11144.2005; Schneider D, 2013, AM J PHYSIOL-LUNG C, V304, pL162, DOI 10.1152/ajplung.00182.2012; Schneider D, 2012, J IMMUNOL, V188, P2894, DOI 10.4049/jimmunol.1101391; Sehra S, 2011, J IMMUNOL, V186, P4959, DOI 10.4049/jimmunol.1002359; Snider P, 2008, CIRC RES, V102, P752, DOI 10.1161/CIRCRESAHA.107.159517; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Vi L, 2009, EXP CELL RES, V315, P3574, DOI 10.1016/j.yexcr.2009.07.015; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Yamashita O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079753	33	64	66	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1433	1442		10.1016/j.jaci.2014.05.029	http://dx.doi.org/10.1016/j.jaci.2014.05.029			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	24996263	Green Accepted			2022-12-18	WOS:000346075400027
J	Milara, J; Lluch, J; Almudever, P; Freire, J; Qian, XZ; Cortijo, J				Milara, Javier; Lluch, Javier; Almudever, Patricia; Freire, Jose; Qian Xiaozhong; Cortijo, Julio			Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Roflumilast; dexamethasone; corticosteroid resistance; neutrophil; chronic obstructive pulmonary disease	MIGRATION INHIBITORY FACTOR; GLUCOCORTICOID-RECEPTOR BETA; HISTONE DEACETYLASE ACTIVITY; BRONCHIAL EPITHELIAL-CELLS; PDE4 INHIBITOR; SYSTEMIC INFLAMMATION; AIRWAY INFLAMMATION; ENDOTHELIAL-CELLS; EXPRESSION; MECHANISM	Background: Glucocorticoid functions are markedly impaired in patients with chronic obstructive pulmonary disease (COPD). The phosphodiesterase 4 inhibitor roflumilast N-oxide (RNO) is the active metabolite of roflumilast approved as a treatment to reduce the risk of exacerbations in patients with severe COPD. Objective: We sought to characterize the differential effects of RNO versus corticosteroids and their potential additive/synergistic effect in neutrophils from patients with COPD, thus providing scientific rationale for the combination of roflumilast with corticosteroids in the clinic. Methods: Peripheral blood neutrophils were isolated from patients with COPD (n = 32), smokers (n = 7), and healthy nonsmokers (n = 25). Levels of IL-8, matrix metallopeptidase 9 (MMP-9), and biomarkers of glucocorticoid resistance were determined by using ELISA and RT-PCR. Neutrophils were incubated with dexamethasone (0.1 nmol/L to 1 mu mol/L), RNO (0.1 nmol/L to 1 mu mol/L), or the combination of 1nmol/L RNO plus 10 nmol/L DEX and stimulated with LPS (1 mu g/mL) or cigarette smoke extract 5%; levels of IL-8, MMP-9, and other biomarkers were measured at the end of the incubation period. Results: Peripheral neutrophils from patients with COPD showed a primed phenotype with an increased basal release of IL-8 and MMP-9 and expressed a corticosteroid resistance molecular profile characterized by an increase in phosphoinositide 3-kinase delta, macrophage migration inhibitory factor, and glucocorticoid receptor beta expression and a decrease in HDAC activity and mitogen-activated protein kinase phosphatase 1 expression. RNO demonstrated robust anti-inflammatory effects on neutrophils from patients with COPD, reversing their resistance to corticosteroids. The combination of RNO and dexamethasone showed additive/synergistic effects, which were consistent with the reversal of corticosteroid-resistant molecular markers by RNO. Conclusion: RNO reverses corticosteroid resistance and shows strong anti-inflammatory effects alone or in combination with corticosteroids on neutrophils from patients with COPD.	[Milara, Javier; Cortijo, Julio] Univ Gen Hosp Consortium, Clin Res Unit UIC, Valencia, Spain; [Milara, Javier] Univ Politecn Valencia, Dept Biotechnol, E-46071 Valencia, Spain; [Milara, Javier; Lluch, Javier; Almudever, Patricia; Cortijo, Julio] Res Fdn Gen Hosp Valencia, Valencia, Spain; [Almudever, Patricia; Cortijo, Julio] Univ Valencia, Fac Med, Dept Pharmacol, Valencia, Spain; [Lluch, Javier; Cortijo, Julio] Hlth Inst Carlos III, CIBERES, Valencia, Spain; [Freire, Jose; Qian Xiaozhong] Forest Res Inst, Jersey City, NJ USA	Universitat Politecnica de Valencia; University of Valencia; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Milara, J (corresponding author), Consorcio Hosp Gen Univ, Unidad Invest, Ave Tres Cruces S-N, E-46014 Valencia, Spain.	xmilara@hotmail.com		MILARA, JAVIER/0000-0001-6033-4211	CIBERES [CB06/06/0027]; Spanish government [ADE10/00020]; Regional Government [Prometeo II/2013/014]; Generalitat Valenciana; CENIT programme (Spanish Government);  [SAF2011-26443];  [FIS CP11/00293]	CIBERES; Spanish government(Spanish GovernmentEuropean Commission); Regional Government; Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission); CENIT programme (Spanish Government); ; 	Supported by grants SAF2011-26443 (to J.C.), FIS CP11/00293 (to J.M.), CIBERES (CB06/06/0027), ADE10/00020 (Spanish government), and research grants from the Regional Government (Prometeo II/2013/014 to J.C. and J.M.), "Generalitat Valenciana.'' Support from the CENIT programme (Spanish Government) was obtained as well.	Aeberli D, 2006, FEBS LETT, V580, P974, DOI 10.1016/j.febslet.2006.01.027; Ariga M, 2004, J IMMUNOL, V173, P7531, DOI 10.4049/jimmunol.173.12.7531; Baines KJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018426; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Barnes PJ, 2010, J STEROID BIOCHEM, V120, P76, DOI 10.1016/j.jsbmb.2010.02.018; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Coldren CD, 2006, AM J PHYSIOL-LUNG C, V291, pL1267, DOI 10.1152/ajplung.00097.2006; Cowburn AS, 2008, CHEST, V134, P606, DOI 10.1378/chest.08-0422; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; Daun JM, 2000, AM J PHYSIOL-REG I, V279, pR1043, DOI 10.1152/ajpregu.2000.279.3.R1043; Drost EM, 2005, THORAX, V60, P293, DOI 10.1136/thx.2004.027946; Elbim C, 2001, J CLIN VIROL, V20, P99, DOI 10.1016/S1386-6532(00)00133-5; Fermino ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026004; Gaber T, 2011, J IMMUNOL, V186, P764, DOI 10.4049/jimmunol.0903421; Grootendorst DC, 2007, THORAX, V62, P1081, DOI 10.1136/thx.2006.075937; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; Hatzelmann A, 2010, PULM PHARMACOL THER, V23, P235, DOI 10.1016/j.pupt.2010.03.011; Honda M, 2000, GASTROENTEROLOGY, V118, P859, DOI 10.1016/S0016-5085(00)70172-7; Ishiguro Y, 2006, CLIN IMMUNOL, V120, P335, DOI 10.1016/j.clim.2006.05.010; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Jones NA, 2005, PULM PHARMACOL THER, V18, P93, DOI 10.1016/j.pupt.2004.10.001; Korn SH, 1998, RESP MED, V92, P1102, DOI 10.1016/S0954-6111(98)90402-4; Kozaci DL, 2007, RHEUMATOLOGY, V46, P579, DOI 10.1093/rheumatology/kel276; Li LB, 2010, AM J RESP CRIT CARE, V182, P877, DOI 10.1164/rccm.201001-0015OC; Liu Ling-Yun, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P992; Martorana PA, 2005, AM J RESP CRIT CARE, V172, P848, DOI 10.1164/rccm.200411-1549OC; Marwick JA, 2009, AM J RESP CRIT CARE, V179, P542, DOI 10.1164/rccm.200810-1570OC; Milara J, 2012, BRIT J PHARMACOL, V166, P2243, DOI 10.1111/j.1476-5381.2012.01929.x; Milara J, 2010, BRIT J PHARMACOL, V161, P1599, DOI 10.1111/j.1476-5381.2010.00979.x; Milara J, 2012, RESPIRATION, V83, P147, DOI 10.1159/000332834; Moodley T, 2013, MOL PHARMACOL, V83, P894, DOI 10.1124/mol.112.083493; Muzaffar S, 2012, J CELL PHYSIOL, V227, P1941, DOI 10.1002/jcp.22922; Neeck G, 2002, ANN NY ACAD SCI, V966, P491, DOI 10.1111/j.1749-6632.2002.tb04252.x; Noguera A, 2001, THORAX, V56, P432, DOI 10.1136/thorax.56.6.432; O'Donnell RA, 2004, THORAX, V59, P837, DOI 10.1136/thx.2003.019349; Ortiz JL, 2013, ALLERGY, V68, P64, DOI 10.1111/all.12055; Oudijk EJD, 2005, THORAX, V60, P538, DOI 10.1136/thx.2004.034009; Oudijk EJD, 2003, EUR RESPIR J, V22, p5S, DOI 10.1183/09031936.03.00004603a; Pauwels RA, 2004, LANCET, V364, P613, DOI 10.1016/S0140-6736(04)16855-4; Plumb J, 2012, INT IMMUNOPHARMACOL, V12, P26, DOI 10.1016/j.intimp.2011.10.006; Pujols L, 2007, CURR ALLERGY ASTHM R, V7, P93, DOI 10.1007/s11882-007-0005-3; Quint JK, 2007, J ALLERGY CLIN IMMUN, V119, P1065, DOI 10.1016/j.jaci.2006.12.640; Rahman I, 2000, THORAX, V55, P189, DOI 10.1136/thorax.55.3.189; Rennard SI, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-18; Roche N, 2011, EUR RESPIR REV, V20, P175, DOI 10.1183/09059180.00004211; Roger T, 2005, EUR J IMMUNOL, V35, P3405, DOI 10.1002/eji.200535413; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; Santos LL, 2011, ARTHRITIS RHEUM-US, V63, P960, DOI 10.1002/art.30203; Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486; Sousa LP, 2009, BIOCHEM PHARMACOL, V78, P396, DOI 10.1016/j.bcp.2009.04.030; Stockley JA, 2013, INT IMMUNOPHARMACOL, V17, P1211, DOI 10.1016/j.intimp.2013.05.035; Strandberg K, 2010, PULM PHARMACOL THER, V23, P316, DOI 10.1016/j.pupt.2010.03.004; Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091; Suri S, 2008, BIOCHEM PHARMACOL, V76, P645, DOI 10.1016/j.bcp.2008.06.010; Terashima T, 1997, AM J RESP CRIT CARE, V155, P1021, DOI 10.1164/ajrccm.155.3.9116981; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Wang FF, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3828; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678	59	64	67	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					314	+	322.e9	10.1016/j.jaci.2014.02.001	http://dx.doi.org/10.1016/j.jaci.2014.02.001			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24636089				2022-12-18	WOS:000341370800009
J	Volpe, E; Pattarini, L; Martinez-Cingolani, C; Meller, S; Donnadieu, MH; Bogiatzi, SI; Fernandez, MI; Touzot, M; Bichet, JC; Reyal, F; Paronetto, MP; Chiricozzi, A; Chimenti, S; Nasorri, F; Cavani, A; Kislat, A; Homey, B; Soumelis, V				Volpe, Elisabetta; Pattarini, Lucia; Martinez-Cingolani, Carolina; Meller, Stephan; Donnadieu, Marie-Helene; Bogiatzi, Sofia I.; Fernandez, Maria I.; Touzot, Maxime; Bichet, Jean-Christophe; Reyal, Fabien; Paronetto, Maria Paola; Chiricozzi, Andrea; Chimenti, Sergio; Nasorri, Francesca; Cavani, Andrea; Kislat, Andreas; Homey, Bernhard; Soumelis, Vassili			Thymic stromal lymphopoietin links keratinocytes and dendritic cell-derived IL-23 in patients with psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; dendritic cells; IL-23; psoriasis; CD40 ligand; skin inflammation	HUMAN EPITHELIAL-CELLS; GROWTH-FACTOR-BETA; ATOPIC-DERMATITIS; CUTTING EDGE; CD40 LIGAND; IL-12 PRODUCTION; TSLP EXPRESSION; T-CELLS; INFLAMMATION; CYTOKINE	Background: Thymic stromal lymphopoietin (TSLP) is a major proallergic cytokine that promotes T(H)2 responses through dendritic cell (DC) activation. Whether it also plays a role in human autoimmune inflammation and associated pathways is not known. Objective: In this study we investigated the potential role of several epithelium-derived factors, including TSLP, in inducing IL-23 production by human DCs. We further dissected the role of TSLP in patients with psoriasis, an IL-23-associated skin autoimmune disease. Methods: The study was performed in human subjects using primary cells and tissue samples from patients with psoriasis and healthy donors. We analyzed the production of IL-23 in vitro by blood and skin DCs. We studied the function for TSLP and its interaction with other components of the inflammatory microenvironment in situ and ex vivo. Results: We found that TSLP synergized with CD40 ligand to promote DC activation and pathogenic IL-23 production by primary blood and skin DCs. In situ TSLP was strongly expressed by keratinocytes of untreated psoriatic lesions but not in normal skin. Moreover, we could demonstrate that IL-4, an important component of the TH2 inflammation seen in patients with atopic dermatitis, inhibited IL-23 production induced by TSLP and CD40 ligand in a signal transducer and activator of transcription 6-independent manner. Conclusion: Our results identify TSLP as a novel player within the complex psoriasis cytokine network. Blocking TSLP in patients with psoriasis might contribute to decreasing DC activation and shutting down the production of pathogenic IL-23.	[Volpe, Elisabetta; Pattarini, Lucia; Martinez-Cingolani, Carolina; Donnadieu, Marie-Helene; Bogiatzi, Sofia I.; Fernandez, Maria I.; Touzot, Maxime; Soumelis, Vassili] Inst Curie, Dept Immunol, Paris, France; [Pattarini, Lucia; Martinez-Cingolani, Carolina; Soumelis, Vassili] Inst Curie, Res Sect, Paris, France; [Reyal, Fabien] Inst Curie, Dept Surg, Paris, France; [Volpe, Elisabetta] Fdn Santa, Lab Neuroimmunol, Rome, Italy; [Pattarini, Lucia; Martinez-Cingolani, Carolina; Donnadieu, Marie-Helene; Bogiatzi, Sofia I.; Fernandez, Maria I.; Touzot, Maxime; Soumelis, Vassili] INSERM, U932, Paris, France; [Meller, Stephan; Kislat, Andreas; Homey, Bernhard] Univ Dusseldorf, Dept Dermatol, Dusseldorf, Germany; [Fernandez, Maria I.] CHU St Justine, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada; [Fernandez, Maria I.] Univ Montreal, Montreal, PQ H3C 3J7, Canada; [Fernandez, Maria I.] CHU St Justine Res Ctr, Montreal, PQ, Canada; [Bichet, Jean-Christophe] Hop La Pitie Salpetriere, Dept Chirurg, Paris, France; [Paronetto, Maria Paola] Fdn Santa Lucia, Lab Mol & Cellular Neurobiol, Rome, Italy; [Chiricozzi, Andrea; Chimenti, Sergio] Univ Roma Tor Vergata, Dept Dermatol, Rome, Italy; [Chiricozzi, Andrea] Rockefeller Univ, Lab Invest Dermatol, New York, NY 10021 USA; [Nasorri, Francesca; Cavani, Andrea] IDI IRCCS, Lab Expt Immunol, Rome, Italy	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; IRCCS Santa Lucia; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Heinrich Heine University Dusseldorf; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; IRCCS Santa Lucia; University of Rome Tor Vergata; Rockefeller University; IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Soumelis, V (corresponding author), 26 Rue Ulm, F-75248 Paris, France.	vassili.soumelis@curie.fr	Volpe, Elisabetta/J-8589-2016; Meller, Stephan/GYA-5568-2022; Paronetto, Maria Paola/A-9578-2012	Paronetto, Maria Paola/0000-0001-5324-0903; touzot, Maxime/0000-0002-0510-2431; Volpe, Elisabetta/0000-0001-7985-2422	European Union [261366]; European Community [014162]; Agence Nationale pour la Recherche (ANR); Fondation pour la Recherche Medicale (FRM); German Research Foundation [FOR-729]	European Union(European Commission); European Community(European Commission); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); German Research Foundation(German Research Foundation (DFG))	The research leading to these results has received funding from the European Union's Seventh Framework Programme FP7/2007-2013 under grant agreement no. 261366, a European Community FP6 Marie Curie Excellence Grant (014162), Agence Nationale pour la Recherche (ANR), Fondation pour la Recherche Medicale (FRM), and the German Research Foundation FOR-729.	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Arima K, 2010, SCI SIGNAL, V19, P105; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Bolognia JL, 2008, DERMATOLOGY, V2nd; Bowcock AM, 2005, NAT REV IMMUNOL, V5, P699, DOI 10.1038/nri1689; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; Eyerich S, 2011, NEW ENGL J MED, V365, P231, DOI 10.1056/NEJMoa1104200; FULEIHAN R, 1995, INT ARCH ALLERGY IMM, V107, P43, DOI 10.1159/000236925; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420, DOI 10.4049/jimmunol.181.10.7420; Hochrein H, 2000, J EXP MED, V192, P823, DOI 10.1084/jem.192.6.823; Krueger JG, 2002, J AM ACAD DERMATOL, V46, P1, DOI 10.1067/mjd.2002.120568; Lee HC, 2008, J IMMUNOL, V181, P5189, DOI 10.4049/jimmunol.181.8.5189; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Marchal-Somme J, 2006, J IMMUNOL, V176, P5735, DOI 10.4049/jimmunol.176.10.5735; Miyata M, 2008, EUR J IMMUNOL, V38, P1487, DOI 10.1002/eji.200737809; Ohta Y, 2004, DERMATOLOGY, V209, P21, DOI 10.1159/000078582; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Pasch MC, 2004, J PATHOL, V203, P839, DOI 10.1002/path.1581; Sato-Deguchi E, 2012, BRIT J DERMATOL, V167, P77, DOI 10.1111/j.1365-2133.2012.10917.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Surjit M, 2011, CELL, V145, P224, DOI 10.1016/j.cell.2011.03.027; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Watanabe N, 2005, BLOOD, V105, P4749, DOI 10.1182/blood-2004-09-3622; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	31	64	67	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					373	+		10.1016/j.jaci.2014.04.022	http://dx.doi.org/10.1016/j.jaci.2014.04.022			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24910175				2022-12-18	WOS:000341370800017
J	Holt, PG; Sly, PD; Sampson, HA; Robinson, P; Loh, R; Lowenstein, H; Calatroni, A; Sayre, P				Holt, Patrick G.; Sly, Peter D.; Sampson, Hugh A.; Robinson, Phil; Loh, Richard; Lowenstein, Henning; Calatroni, Agustin; Sayre, Peter			Prophylactic use of sublingual allergen immunotherapy in high-risk children: A pilot study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RESPONSES; SENSITIZATION; CELLS		[Holt, Patrick G.] Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; [Holt, Patrick G.] Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Sly, Peter D.] Univ Queensland, Queensland Childrens Med Res Inst, Royal Childrens Hosp, Brisbane, Qld, Australia; [Sampson, Hugh A.] Mt Sinai Sch Med, New York, NY USA; [Robinson, Phil] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Robinson, Phil] Univ Melbourne, Melbourne, Vic, Australia; [Loh, Richard] Princess Margaret Hosp, Child & Adolescent Hlth Serv, Subiaco, WA, Australia; [Lowenstein, Henning] ALK Abello AS, Horsholm, Denmark; [Calatroni, Agustin] Rho Fed Syst, Chapel Hill, NC USA; [Sayre, Peter] Immune Tolerance Network, San Francisco, CA USA; [Sayre, Peter] Univ Calif San Francisco, San Francisco, CA 94143 USA	Telethon Kids Institute; University of Western Australia; University of Western Australia; Royal Children's Hospital Brisbane; University of Queensland; Icahn School of Medicine at Mount Sinai; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; ALK-Abello AS; Immune Tolerance Network; University of California System; University of California San Francisco	Holt, PG (corresponding author), Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia.	patrick@ichr.uwa.edu.au	Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201				Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Holt PG, 2005, NAT IMMUNOL, V6, P957, DOI 10.1038/ni1005-957; Hoyne GF, 1996, INT IMMUNOL, V8, P335, DOI 10.1093/intimm/8.3.335; Jeal H, 2006, AM J RESP CRIT CARE, V174, P21, DOI 10.1164/rccm.200506-964OC; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Strickland DH, 2012, MUCOSAL IMMUNOL, V5, P332, DOI 10.1038/mi.2012.13; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC	9	64	65	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					991	993		10.1016/j.jaci.2013.04.049	http://dx.doi.org/10.1016/j.jaci.2013.04.049			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23768574				2022-12-18	WOS:000325096500034
J	Zhang, H; Nestor, CE; Zhao, SL; Lentini, A; Bohle, B; Benson, M; Wang, H				Zhang, Huan; Nestor, Colm E.; Zhao, Shuli; Lentini, Antonio; Bohle, Barbara; Benson, Mikael; Wang, Hui			Profiling of human CD4(+) T-cell subsets identifies the T(H)2-specific noncoding RNA GATA3-AS1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DIFFERENTIATION; EXPRESSION		[Zhang, Huan; Nestor, Colm E.; Lentini, Antonio; Benson, Mikael; Wang, Hui] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Linkoping, Sweden; [Zhang, Huan; Nestor, Colm E.; Lentini, Antonio; Benson, Mikael; Wang, Hui] Linkoping Univ, Fac Hlth Sci, CIMed, Ctr Individualised Med, Linkoping, Sweden; [Zhao, Shuli] Nanjing Med Univ, State Key Lab Reprod Med, Cent Lab, Nanjing Hosp 1, Nanjing, Jiangsu, Peoples R China; [Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Vienna, Austria; [Wang, Hui] Univ Gothenburg, Dept Pediat, Gothenburg, Sweden	Linkoping University; Linkoping University; Nanjing Medical University; Medical University of Vienna; University of Gothenburg	Wang, H (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Linkoping, Sweden.	mikael.benson@liu.se; hui.wang@gu.se	Lentini, Antonio/N-5684-2015	Lentini, Antonio/0000-0003-1239-5495; Bohle, Barbara/0000-0002-5105-7985				Banham AH, 2006, TRENDS IMMUNOL, V27, P541, DOI 10.1016/j.it.2006.10.002; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Cosmi L, 2008, J EXP MED, V205, P1903, DOI 10.1084/jem.20080397; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hansmann L, 2012, J IMMUNOL, V188, P1275, DOI 10.4049/jimmunol.1102288; Wei W, 2011, TRENDS GENET, V27, P267, DOI 10.1016/j.tig.2011.04.002; Wilson CB, 2009, NAT REV IMMUNOL, V9, P91, DOI 10.1038/nri2487; Woodfolk JA, 2007, J ALLERGY CLIN IMMUN, V119, P280, DOI 10.1016/j.jaci.2006.11.008; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001	9	64	66	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					1005	+		10.1016/j.jaci.2013.05.033	http://dx.doi.org/10.1016/j.jaci.2013.05.033			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23870669				2022-12-18	WOS:000325096500040
J	Belgrave, DCM; Simpson, A; Semic-Jusufagic, A; Murray, CS; Buchan, I; Pickles, A; Custovic, A				Belgrave, Danielle C. M.; Simpson, Angela; Semic-Jusufagic, Aida; Murray, Clare S.; Buchan, Iain; Pickles, Andrew; Custovic, Adnan			Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; asthma endotypes; wheeze phenotypes; longitudinal analysis	RESPIRATORY-SOCIETY STATEMENT; 1ST 6 YEARS; SEVERE ASTHMA; LUNG-FUNCTION; INHALED CORTICOSTEROIDS; PRESCHOOL-CHILDREN; CHILDHOOD ASTHMA; CLUSTER-ANALYSIS; PHENOTYPES; INFANTS	Background: Previous studies have suggested the presence of different childhood wheeze phenotypes through statistical modeling based on parentally reported wheezing. Objective: We sought to investigate whether joint modeling of observations from both medical records and parental reports helps to more accurately define wheezing disorders during childhood and whether incorporating information from medical records better characterizes severity. Methods: In a population-based birth cohort (n = 1184), we analyzed data from 2 sources (parentally reported current wheeze at 4 follow-ups and physician-confirmed wheeze from medical records in each year from birth to age 8 years) to determine classes of children who differ in wheeze trajectories. We tested the validity of these classes by examining their relationships with objective outcomes (lung function, airway hyperreactivity, and atopy), asthma medication, and severe exacerbations. Results: Longitudinal latent class modeling identified a 5-class model that best described the data. We assigned classes as follows: no wheezing (53.3%), transient early wheeze (13.7%), late-onset wheeze (16.7%), persistent controlled wheeze (13.1%), and persistent troublesome wheeze (PTW; 3.2%). Longitudinal trajectories of atopy and lung function differed significantly between classes. Patients in the PTW class had diminished lung function and more hyperreactive airways compared with all other classes. We observed striking differences in exacerbations, hospitalizations, and unscheduled visits, all of which were markedly higher in patients in the PTW class compared with those in the other classes. For example, the risk of exacerbation was much higher in patients in the PTW class compared with patients with persistent controlled wheeze (odds ratio [OR], 3.58; 95% CI, 1.27-10.09), late-onset wheeze (OR, 15.92; 95% CI, 5.61-45.15), and transient early wheeze (OR, 12.24; 95% CI, 4.28-35.03). Conclusion: We identified a novel group of children with persistent troublesome wheezing, who have markedly different outcomes compared with persistent wheezers with controlled disease.	[Belgrave, Danielle C. M.; Simpson, Angela; Semic-Jusufagic, Aida; Murray, Clare S.; Custovic, Adnan] Univ Manchester, Inst Inflammat & Repair, Ctr Resp Med & Allergy, Manchester M13 9PL, Lancs, England; [Belgrave, Danielle C. M.; Simpson, Angela; Semic-Jusufagic, Aida; Murray, Clare S.; Custovic, Adnan] Univ S Manchester Hosp, Manchester, Lancs, England; [Belgrave, Danielle C. M.; Buchan, Iain] Univ Manchester, Inst Populat Hlth, Ctr Hlth Informat, Manchester M13 9PL, Lancs, England; [Pickles, Andrew] Kings Coll London, Dept Biostat, London, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester; University of London; King's College London	Belgrave, DCM (corresponding author), Univ Manchester, Wythenshawe Hosp, ERC Bldg,2nd Floor, Manchester M23 9LT, Lancs, England.	danielle.belgrave@manchester.ac.uk	Pickles, Andrew/A-9625-2011; Custovic, Adnan/A-2435-2012; Buchan, Iain E/H-5767-2013	Pickles, Andrew/0000-0003-1283-0346; Custovic, Adnan/0000-0001-5218-7071; Buchan, Iain E/0000-0003-3392-1650; Simpson, Angela/0000-0003-2733-6666; Murray, Clare/0000-0002-8961-8055	JP Moulton Charitable Foundation; MRC [G0601361, MR/K002449/1]; National Institute for Health Research Clinical Research Facility at University Hospital of South Manchester NHS Foundation Trust; Asthma UK [04/014]; Medical Research Council; Asthma UK; GlaxoSmithKline; Research Council Grant from the University of Manchester; National Institute for Health; Moulton Charitable Foundation; Thermo Fisher Scientific; Airsonet; Novartis; Merck Sharp Dohme; ALK-Abello; MRC [MR/K006665/1] Funding Source: UKRI; Medical Research Council [MR/K002449/1, G0601361, MR/K006665/1, MC_PC_13042] Funding Source: researchfish	JP Moulton Charitable Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research Clinical Research Facility at University Hospital of South Manchester NHS Foundation Trust; Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; GlaxoSmithKline(GlaxoSmithKline); Research Council Grant from the University of Manchester; National Institute for Health; Moulton Charitable Foundation; Thermo Fisher Scientific; Airsonet; Novartis(Novartis); Merck Sharp Dohme(Merck & Company); ALK-Abello; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The Manchester Asthma and Allergy Study is supported by the JP Moulton Charitable Foundation, MRC Grants G0601361 and MR/K002449/1, the National Institute for Health Research Clinical Research Facility at University Hospital of South Manchester NHS Foundation Trust, and Asthma UK grant no. 04/014. This report is independent research supported by the National Institute for Health Research Clinical Research Facility at University Hospital of South Manchester NHS Foundation Trust. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the Department of Health.; A. Simpson has received grants from the Medical Research Council, Asthma UK, and the JP Moulton Charitable Foundation. C. S. Murray has received payment for lectures from GlaxoSmithKline. A. Pickles has received a Research Council Grant from the University of Manchester, has received grants from the Research Council and National Institute for Health, has received royalties for an autism screening questionnaire and statistical textbooks, has received payment for development of educational presentations for university lectures, and has received travel accommodations paid for under grant funding. A. Custovic has received grants from the Moulton Charitable Foundation and has received payment for lectures from GlaxoSmithKline, Thermo Fisher Scientific, Airsonet, Novartis, Merck Sharp & Dohme, and ALK-Abello. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 2006, LANCET, V368, P705; Beydon N, 2007, AM J RESP CRIT CARE, V175, P1304, DOI 10.1164/rccm.200605-642ST; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; Bush A, 2008, LANCET, V372, P1019, DOI 10.1016/S0140-6736(08)61422-1; Bush A, 2010, LANCET, V376, P814, DOI 10.1016/S0140-6736(10)61054-9; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Curran PJ, 2003, DEV PSYCHOPATHOL, V15, P581, DOI 10.1017/S0954579403000300; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2012, EXPERT REV RESP MED, V6, P301, DOI [10.1586/ERS.12.24, 10.1586/ers.12.24]; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fleming L, 2012, THORAX, V67, P675, DOI 10.1136/thoraxjnl-2011-201064; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Hedlin G, 2010, EUR RESPIR J, V36, P196, DOI 10.1183/09031936.00104809; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Just J, 2012, EUR RESPIR J, V40, P55, DOI 10.1183/09031936.00123411; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lowe L, 2004, ARCH DIS CHILD, V89, P540, DOI 10.1136/adc.2003.038539; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Lowe LA, 2004, ARCH PEDIAT ADOL MED, V158, P996, DOI 10.1001/archpedi.158.10.996; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Nicolaou NC, 2006, AM J RESP CRIT CARE, V174, P254, DOI 10.1164/rccm.200601-140OC; Pickles A, 2010, STAT METHODS MED RES, V19, P271, DOI 10.1177/0962280209105016; Rabe-Hesketh S, 2004, UC BERKELEY DIVISION, V2004; Rabe-Hesketh S, 2004, UC BERKELEY DIVISION, V2004; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Sharples J, 2012, EUR RESPIR J, V40, P264, DOI 10.1183/09031936.00209511; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Skrondal A., 2004, GEN LATENT VARIABLE; Smith JA, 2008, AM J RESP CRIT CARE, V177, P1358, DOI 10.1164/rccm.200709-1419OC; Stanojevic S, 2009, AM J RESP CRIT CARE, V180, P547, DOI 10.1164/rccm.200903-0323OC; WILSON NM, 1989, ARCH DIS CHILD, V64, P1194, DOI 10.1136/adc.64.8.1194	38	64	64	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					575	+		10.1016/j.jaci.2013.05.041	http://dx.doi.org/10.1016/j.jaci.2013.05.041			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23906378	Green Submitted, Bronze			2022-12-18	WOS:000323612000008
J	Kim, EH; Varshney, P; Steele, P; Kamilaris, J; Hiegel, AM; Carlisle, SK; Smith, PB; Scurlock, AM; Jones, SM; Burks, AW				Kim, Edwin H.; Varshney, Pooja; Steele, Pamela; Kamilaris, Janet; Hiegel, Anne M.; Carlisle, Suzanna K.; Smith, P. Brian; Scurlock, Amy M.; Jones, Stacie M.; Burks, A. Wesley			Sublingual versus oral immunotherapy for peanut-allergic children: A retrospective comparison	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD ALLERGY		[Varshney, Pooja] Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA; [Kim, Edwin H.; Steele, Pamela; Kamilaris, Janet; Burks, A. Wesley] Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27515 USA; [Hiegel, Anne M.; Carlisle, Suzanna K.; Scurlock, Amy M.; Jones, Stacie M.] Univ Arkansas Med Sci, Dept Pediat, Sect Allergy & Immunol, Little Rock, AR 72205 USA; [Smith, P. Brian] Duke Univ, Med Ctr, Dept Pediat, Duke Clin Res Inst, Durham, NC 27710 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Arkansas System; University of Arkansas Medical Sciences; Duke University	Kim, EH (corresponding author), Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27515 USA.	bvickery@email.unc.edu	Smith, Phillip B/I-5565-2014	Vickery, Brian/0000-0002-7243-5543	National Center for Complementary & Integrative Health [R01AT004435] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068074, K23AI099083] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT004435, R01-AT004435-03] Funding Source: Medline; NCRR NIH HHS [UL1RR024128, UL1 RR024128] Funding Source: Medline; NIAID NIH HHS [K23 AI099083, R01 AI068074, R01-AI06874-01A1, T32 AI007062] Funding Source: Medline	National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Narisety SD, 2012, DRUGS, V72, P1977, DOI 10.2165/11640800-000000000-00000; Novak N, 2011, ALLERGY, V66, P733, DOI 10.1111/j.1398-9995.2010.02535.x; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111	7	64	64	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					476	478		10.1016/j.jaci.2013.02.017	http://dx.doi.org/10.1016/j.jaci.2013.02.017			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23534975	Green Accepted			2022-12-18	WOS:000322631700027
J	Alcantara-Neves, NM; Veiga, RV; Dattoli, VCC; Fiaccone, RL; Esquivel, R; Cruz, AA; Cooper, PJ; Rodrigues, LC; Barreto, ML				Alcantara-Neves, Neuza Maria; Veiga, Rafael Valente; Cavalcante Dattoli, Vitor Camilo; Fiaccone, Rosimeire Leovigildo; Esquivel, Renata; Cruz, Alvaro Augusto; John Cooper, Philip; Rodrigues, Laura Cunha; Barreto, Mauricio Lima			The effect of single and multiple infections on atopy and wheezing in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; infections; pathogen exposure; allergen-specific IgE; skin prick test; wheezing illnesses; asthma	INTESTINAL PARASITE INFECTION; TOXOPLASMA-GONDII INFECTION; INVERSE ASSOCIATION; HELMINTH INFECTIONS; ANTIBODY-RESPONSES; LATIN-AMERICA; SCHOOL-AGE; HAY-FEVER; SKIN-TEST; ASTHMA	Background: The current epidemic of asthma and atopy has been explained by alterations in immune responses related to reduction in childhood infections. However, the findings of epidemiologic studies investigating the association between infection with atopy and asthma have been inconsistent. Objective: We sought to investigate the effect of single or multiple infections (pathogen burden) on atopy and wheeze in urban children from Latin America. Methods: Specific IgE against aeroallergens (sIgE) and skin prick test (SPT) reactivity for the most common local allergens were measured in 1128 children aged 4 to 11 years. Data on wheezing and potential confounders were collected by questionnaire. Infections by 8 pathogens were assessed by using serology and stool examination. Associations of wheeze and atopic outcomes with single and multiple infections were analyzed by means of logistic regression. Results: Negative results for Toxoplasma gondii were associated with a higher prevalence of sIgE (>= 0.70 kU/L), whereas negative results for Ascaris lumbricoides, T gondii, herpes simplex virus, and EBV were associated with a higher prevalence of SPT reactivity. Children with 3 or fewer infection markers had a higher prevalence of sIgE and SPT reactivity compared with those with 4 or more infection markers. However, isolated infections or pathogen burden were not associated with the prevalence of atopic or nonatopic wheeze. Conclusion: The findings provide support for the idea that the hygiene hypothesis is operating in an urban Latin American context, but its expression is thus far restricted to the atopic status of patients and not the perceived asthma symptoms. (J Allergy Clin Immunol 2012;129:359-67.)	[Alcantara-Neves, Neuza Maria; Veiga, Rafael Valente; Cavalcante Dattoli, Vitor Camilo] Univ Fed Bahia, Dept Ciencias Biointeracao, Inst Ciencias Saude, BR-40110100 Salvador, BA, Brazil; [Fiaccone, Rosimeire Leovigildo] Univ Fed Bahia, Inst Matemat, BR-40110100 Salvador, BA, Brazil; [Esquivel, Renata; Barreto, Mauricio Lima] Univ Fed Bahia, Inst Saude Colet, BR-40110100 Salvador, BA, Brazil; [John Cooper, Philip] Univ San Francisco Quito, Colegio Ciencias Salud, Quito, Ecuador; [Cruz, Alvaro Augusto] Univ Fed Bahia, ProAR Nucl Excelencia Asma, BR-40110100 Salvador, BA, Brazil; [John Cooper, Philip] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England; [Rodrigues, Laura Cunha] Univ London, London Sch Hyg & Trop Med, London WC1E 7HU, England	Universidade Federal da Bahia; Universidade Federal da Bahia; Universidade Federal da Bahia; Universidade Federal da Bahia; Liverpool School of Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Alcantara-Neves, NM (corresponding author), Univ Fed Bahia, Dept Ciencias Biointeracao, Inst Ciencias Saude, Ave Reitor Miguel Calmon, BR-40110100 Salvador, BA, Brazil.	neuzalcantara@gmail.com	RODRIGUES, LAURA CUNHA/AAO-4130-2021; Rodrigues, Laura/C-7196-2012; Barreto, Mauricio L/B-1752-2008; Cruz, Alvaro A/I-1676-2012	Barreto, Mauricio L/0000-0002-0215-4930; Cruz, Alvaro A/0000-0002-7403-3871; Rodrigues, Laura Cunha/0000-0001-9008-660X; Alcantara-Neves, Neuza Maria/0000-0002-2102-260X	Wellcome Trust [072405/Z/03/Z]; INCT/MCT/CNPq [57378620089]; CNPq; CAPES; FAPESB; Brazilian National Research Council (CNPq); Fundacao de Amparo a Pesquisa da Bahia, Brazil (FAPESB)	Wellcome Trust(Wellcome TrustEuropean Commission); INCT/MCT/CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FAPESB(Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)); Brazilian National Research Council (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa da Bahia, Brazil (FAPESB)	This study was conducted through the Social Change of Asthma and Allergy in Latin America (SCAALA) Programme and funded by the Wellcome Trust (grant no. 072405/Z/03/Z) and by the INCT/MCT/CNPq Programme (contract no. 57378620089). CNPq, CAPES, and FAPESB provided scholarships for some of the authors.; R. L. Fiaccone receives research support from Brazilian National Research Council (CNPq). A. A. Cruz receives research support from the Wellcome Trust, the Brazilian National Research Council (CNPq), and Fundacao de Amparo a Pesquisa da Bahia, Brazil (FAPESB) and is on the Board of Directors for the Global Initiative for Asthma (GINA) and Allergic Rhinitis and its Impact on Asthma. P. J. Cooper receives research support from the Wellcome Trust. The rest of the authors declare that they have no relevant conflicts of interest.	Acevedo N, 2009, ALLERGY, V64, P1635, DOI 10.1111/j.1398-9995.2009.02084.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Barreto Mauricio L, 2006, BMC Pulm Med, V6, P15, DOI 10.1186/1471-2466-6-15; Barreto ML, 2007, LANCET, V370, P1622, DOI 10.1016/S0140-6736(07)61638-9; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Behrendt H, 1995, PROG ALLER CLIN IMM, V3, P83; Belkaid Y, 2009, ANNU REV IMMUNOL, V27, P551, DOI 10.1146/annurev.immunol.021908.132723; Cam S, 2009, HELICOBACTER, V14, P1, DOI 10.1111/j.1523-5378.2009.00660.x; Cooper PJ, 2006, BRIT MED BULL, V79-80, P203, DOI 10.1093/bmb/ldl015; Cooper PJ, 2009, ALLERGY, V64, P5, DOI 10.1111/j.1398-9995.2008.01902.x; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; da Cunha SS, 2010, REV PANAM SALUD PUBL, V28, P405, DOI 10.1590/S1020-49892010001200001; Deniz G, 2008, J IMMUNOL, V180, P850, DOI 10.4049/jimmunol.180.2.850; Feary J, 2011, ALLERGY, V66, P569, DOI 10.1111/j.1398-9995.2010.02512.x; Fenoy I, 2009, CLIN EXP IMMUNOL, V155, P275, DOI 10.1111/j.1365-2249.2008.03813.x; Figueiredo CA, 2010, INFECT IMMUN, V78, P3160, DOI 10.1128/IAI.01228-09; Hales BJ, 2009, CLIN EXP ALLERGY, V39, P1170, DOI 10.1111/j.1365-2222.2009.03252.x; Hoffman W. A., 1934, PUERTO RICO J PUBLIC, V9, P281, DOI DOI 10.1590/S0037-86822012000300024; Hosmer W., 2000, APPL LOGISTIC REGRES, V2nd ed.; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Janson C, 2007, J ALLERGY CLIN IMMUN, V120, P673, DOI 10.1016/j.jaci.2007.05.003; Kamradt T, 2005, TRENDS IMMUNOL, V26, P260, DOI 10.1016/j.it.2005.03.009; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Kumar A, 2009, ANN ALLERG ASTHMA IM, V103, P181, DOI 10.1016/S1081-1206(10)60178-0; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; Linneberg A, 2003, J ALLERGY CLIN IMMUN, V111, P847, DOI 10.1067/mai.2003.1335; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; Michos A, 2011, PEDIAT ALLERG IMM-UK, V22, P243, DOI 10.1111/j.1399-3038.2010.01086.x; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Morgan MS, 1997, AM J TROP MED HYG, V57, P190, DOI 10.4269/ajtmh.1997.57.190; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Newcomb Dawn C, 2009, Proc Am Thorac Soc, V6, P266, DOI 10.1513/pats.200806-056RM; Nilsson C, 2005, J ALLERGY CLIN IMMUN, V116, P438, DOI 10.1016/j.jaci.2005.04.027; Pitrez PM, 2008, CURR OPIN ALLERGY CL, V8, P378, DOI 10.1097/ACI.0b013e32830fb911; Ponte JCM, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-34; Radon K, 2003, EUR J MED RES, V8, P147; Riffo-Vasquez Y, 2004, CLIN EXP ALLERGY, V34, P712, DOI 10.1111/j.1365-2222.2004.1931.x; Rodrigues LC, 2008, CLIN EXP ALLERGY, V38, P1769, DOI 10.1111/j.1365-2222.2008.03027.x; Santos ABR, 2008, J ALLERGY CLIN IMMUN, V121, P1040, DOI 10.1016/j.jaci.2007.12.1147; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Shi HZ, 2005, ALLERGY, V60, P986, DOI 10.1111/j.1398-9995.2005.00844.x; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Smits HH, 2007, ANN MED, V39, P428, DOI 10.1080/07853890701436765; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; von Hertzen LC, 2007, EUR RESPIR J, V30, P809, DOI 10.1183/09031936.00069807; von Hertzen LC, 2006, INT ARCH ALLERGY IMM, V140, P89, DOI 10.1159/000092251; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Weiss ST, 1997, CIBA F SYMP, V206, P244; Wilson MS, 2004, CLIN REV ALLERG IMMU, V26, P35, DOI 10.1385/CRIAI:26:1:35; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; Xu W, 2008, INT IMMUNOPHARMACOL, V8, P351, DOI 10.1016/j.intimp.2007.10.019	55	64	66	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					359	U134		10.1016/j.jaci.2011.09.015	http://dx.doi.org/10.1016/j.jaci.2011.09.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	887TC	22035877	Bronze, Green Published, Green Accepted			2022-12-18	WOS:000299951700009
J	Chen, E; Strunk, RC; Trethewey, A; Schreier, HMC; Maharaj, N; Miller, GE				Chen, Edith; Strunk, Robert C.; Trethewey, Alexandra; Schreier, Hannah M. C.; Maharaj, Nandini; Miller, Gregory E.			Resilience in low-socioeconomic-status children with asthma: Adaptations to stress	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Socioeconomic status; asthma; children; psychological; stress	CHILDHOOD ASTHMA; PSYCHOSOCIAL FACTORS; NATIONAL-INSTITUTES; INNER-CITY; IFN-GAMMA; HEALTH; ADOLESCENTS; PREVALENCE; OPTIMISM; CARE	Background: Low socioeconomic status (SES) is a strong predictor of many health problems, including asthma impairment; however, little is understood about why some patients defy this trend by exhibiting good asthma control despite living in adverse environments. Objective: This study sought to test whether a psychological characteristic, the shift-and-persist strategy (dealing with stressors by reframing them more positively while at the same time persisting in optimistic thoughts about the future), protects low-SES children with asthma. Methods: One hundred twenty-one children aged 9 to 18 years with a physician's diagnosis of asthma were recruited from medical practices and community advertisements (mean age, 12.6 years; 67% male; 61% white). Shift-and-persist scores and asthma inflammation (eosinophil counts and stimulated IL-4 cytokine production) were assessed at baseline, and asthma impairment (daily diary measures of rescue inhaler use and school absences) and daily peak flow were monitored at baseline and at a 6-month follow-up. Results: Children who came from low-SES backgrounds but who engaged in shift-and-persist strategies displayed less asthma inflammation at baseline (beta = 0.19, P < .05), as well as less asthma impairment (reduced rescue inhaler use and fewer school absences; beta = 0.32, P < .01) prospectively at the 6-month follow-up period. In contrast, shift-and-persist strategies were not beneficial among high-SES children with asthma. Conclusion: An approach that focuses on the psychological qualities that low-SES children develop to adapt to stressors might represent a practical and effective starting point for reducing health disparities. Moreover, the approaches that are effective in low-SES communities might be different from those that are optimal in a high-SES context. (J Allergy Clin Immunol 2011;128:970-6.)	[Chen, Edith; Trethewey, Alexandra; Schreier, Hannah M. C.; Maharaj, Nandini; Miller, Gregory E.] Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada; [Strunk, Robert C.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	University of British Columbia; Washington University (WUSTL)	Chen, E (corresponding author), Univ British Columbia, Dept Psychol, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.	echen@psych.ubc.ca			National Institutes of Health [HL073975]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073975] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant HL073975.	ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; Aiken L.S., 1991, MULTIPLE REGRESSION; [Anonymous], 2007, EXP PAN REP 3 GUID D; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Brady SS, 2002, J PEDIATR PSYCHOL, V27, P575, DOI 10.1093/jpepsy/27.7.575; Brotman DJ, 2007, LANCET, V370, P1089, DOI 10.1016/S0140-6736(07)61305-1; Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P529, DOI 10.1016/j.jaci.2010.01.036; Cesaroni G, 2003, EUR RESPIR J, V22, P619, DOI 10.1183/09031936.03.00091202; Chang EC, 2003, PERS INDIV DIFFER, V34, P867, DOI 10.1016/S0191-8869(02)00077-6; Chen E, 2004, CURR DIR PSYCHOL SCI, V13, P112, DOI 10.1111/j.0963-7214.2004.00286.x; Chen E, 2011, MOL PSYCHIATR, V16, P729, DOI 10.1038/mp.2010.53; Chen E, 2002, PSYCHOL BULL, V128, P295, DOI 10.1037/0033-2909.128.2.295; Chen E, 2011, SHIFT AND PERS UNPUB; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; Chen E, 2010, PSYCHOL SCI, V21, P31, DOI 10.1177/0956797609355566; Connor-Smith JK, 2000, J CONSULT CLIN PSYCH, V68, P976; Dales RE, 2002, THORAX, V57, P513, DOI 10.1136/thorax.57.6.513; Evans GW, 2007, DEV PSYCHOL, V43, P341, DOI 10.1037/0012-1649.43.2.341; Evans GW, 2004, AM PSYCHOL, V59, P77, DOI 10.1037/0003-066X.59.2.77; Everson-Rose SA, 2005, ANNU REV PUBL HEALTH, V26, P469, DOI 10.1146/annurev.publhealth.26.021304.144542; Garmezy N., 1985, J CHILD PSYCHOL PS S, P213; JUSTER FT, 1999, LABOUR ECON, V0006; Lachman ME, 1998, J PERS SOC PSYCHOL, V74, P763, DOI 10.1037/0022-3514.74.3.763; Lynch JW, 1997, SOC SCI MED, V44, P809, DOI 10.1016/S0277-9536(96)00191-8; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790, DOI 10.1164/ajrccm.161.6.9906130; Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037/0003-066X.56.3.227; MASTEN AS, 1988, J CHILD PSYCHOL PSYC, V29, P745, DOI 10.1111/j.1469-7610.1988.tb00751.x; Matthews KA, 2010, ANN NY ACAD SCI, V1186, P146, DOI 10.1111/j.1749-6632.2009.05332.x; Maziak W, 2004, PEDIAT ALLERG IMM-UK, V15, P166, DOI 10.1046/j.1399-3038.2003.00105.x; Miller GE, 2011, PSYCHOL SCI IN PRESS; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; Morozink JA, 2010, HEALTH PSYCHOL, V29, P626, DOI 10.1037/a0021360; Persky VW, 1998, ANN ALLERG ASTHMA IM, V81, P266, DOI 10.1016/S1081-1206(10)62824-4; Rozanski A, 2005, J AM COLL CARDIOL, V45, P637, DOI 10.1016/j.jacc.2004.12.005; RUTTER M, 1987, AM J ORTHOPSYCHIAT, V57, P316, DOI 10.1111/j.1939-0025.1987.tb03541.x; Scheier MF, 1999, ARCH INTERN MED, V159, P829, DOI 10.1001/archinte.159.8.829; SCHEIER MF, 1989, J PERS SOC PSYCHOL, V57, P1024, DOI 10.1037/0022-3514.57.6.1024; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; Schuerwegh AJ, 1999, CYTOKINE, V11, P783, DOI 10.1006/cyto.1998.0483; Simon PA, 2003, J ASTHMA, V40, P535, DOI 10.1081/JAS-120018788; Singer B, 1999, ANN NY ACAD SCI, V896, P96, DOI 10.1111/j.1749-6632.1999.tb08108.x; Szefler SJ, 2010, J ALLERGY CLIN IMMUN, V125, P521, DOI 10.1016/j.jaci.2010.01.025; Wadsworth ME, 2004, J COMMUNITY PSYCHOL, V32, P391, DOI 10.1002/jcop.20008; WERNER EE, 1995, CURR DIR PSYCHOL SCI, V4, P81, DOI 10.1111/1467-8721.ep10772327; Wood PR, 2002, AM J PUBLIC HEALTH, V92, P1446, DOI 10.2105/AJPH.92.9.1446	46	64	65	0	34	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					970	976		10.1016/j.jaci.2011.06.040	http://dx.doi.org/10.1016/j.jaci.2011.06.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	842FJ	21824649	Green Accepted			2022-12-18	WOS:000296578200008
J	Gagnon, R; Primeau, MN; Des Roches, A; Lemire, C; Kagan, R; Carr, S; Ouakki, M; Benoit, M; De Serres, G				Gagnon, Remi; Primeau, Marie Noel; Des Roches, Anne; Lemire, Chantal; Kagan, Rhoda; Carr, Stuart; Ouakki, Manale; Benoit, Melanie; De Serres, Gaston		PCIRN	Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vaccination; egg allergy; influenza vaccine; 2009 pandemic influenza A/H1N1 vaccine; Arepanrix	INFLUENZA VACCINE; CHILDREN	Background: Because influenza vaccine contains some residual egg protein, there is a theoretic risk of anaphylaxis when vaccinating patients with egg allergy. The objective of this study was to estimate the risk of anaphylaxis in children with egg allergy administered an adjuvanted monovalent 2009 pandemic influenza A/H1N1 influenza vaccine (Arepanrix; GlaxoSmithKline, Mississauga, Ontario, Canada). Methods: Patients with confirmed egg allergy with a history of respiratory or cardiovascular reactions after egg ingestion were vaccinated in 2 divided doses (10% and 90%) administered at a 30-minute interval, whereas children with other types of egg-induced allergic reactions were vaccinated with a single dose. All patients remained under observation for 60 minutes after vaccination. A 24-hour follow-up telephone call was made to detect any delayed reaction. The main outcome was the occurrence of an anaphylactic reaction according to criteria specified by the Brighton Collaboration. Results: Among the 830 patients with confirmed egg allergy, only 9% required the vaccine to be administered in divided doses. No patient had an anaphylactic reaction. Nine patients had minor allergic symptoms treated with an antihistamine (1 in the 60 minutes after vaccination and 8 in the following 23 hours), and 3 others received salbutamol (1 in the first 60 minutes after vaccination). Further vaccination of more than 3600 other children with reported egg allergy caused no anaphylaxis based on the criteria of the Brighton Collaboration, although 2 patients received epinephrine for symptoms compatible with allergy. Conclusion: Although anaphylaxis after influenza immunization is a theoretic risk, vaccination of patients with egg allergy with an adjuvanted monovalent pH1N1 influenza vaccine resulted in no cases of anaphylaxis and on that basis appears safe. (J Allergy Clin Immunol 2010;126:317-23.)	[Gagnon, Remi] Univ Laval, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada; [Primeau, Marie Noel] McGill Univ, Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada; [Des Roches, Anne] Univ Montreal, Hop Ste Justine, Montreal, PQ H3C 3J7, Canada; [Lemire, Chantal] Univ Sherbrooke, Ctr Hosp Univ Sherbrooke, Sherbrooke, PQ J1K 2R1, Canada; [Kagan, Rhoda] Univ Toronto, N York Gen Hosp, Toronto, ON M5S 1A1, Canada; [Carr, Stuart] Univ Alberta, Stollery Childrens Hosp, Edmonton, AB, Canada; [Ouakki, Manale; Benoit, Melanie; De Serres, Gaston] Inst Natl Sante Publ Quebec, Montreal, PQ, Canada	Laval University; McGill University; Universite de Montreal; University of Sherbrooke; University of Toronto; University Toronto Affiliates; North York General Hospital; Stollery Children's Hospital; University of Alberta; Institut national de sante publique du Quebec (INSPQ)	De Serres, G (corresponding author), 2400 Estimauville, Quebec City, PQ G1E 7G9, Canada.	gaston.deserres@ssss.gouv.qc.ca	Carr, Stuart/M-7044-2019		Canadian Institutes for Health Research (CIHR); Public Health Agency of Canada (PHAC) Influenza Research Network (PCIRN); Ministere de la sante et des services sociaux du Quebec; GlaxoSmithKline; Sanofi Pasteur	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Public Health Agency of Canada (PHAC) Influenza Research Network (PCIRN); Ministere de la sante et des services sociaux du Quebec; GlaxoSmithKline(GlaxoSmithKline); Sanofi Pasteur	Supported by the Canadian Institutes for Health Research (CIHR), the Public Health Agency of Canada (PHAC) Influenza Research Network (PCIRN), and the Ministere de la sante et des services sociaux du Quebec.; M. N. Primeau has received research support from the Canadian Institutes for Health Research (CIHR). G. De Serres has received research support from GlaxoSmithKline and Sanofi Pasteur. The rest of the authors have declared that they have no conflict of interest.	ANOLIK R, 1992, ANN ALLERGY, V68, P69; BIERMAN CW, 1977, J INFECT DIS, P568; *CAN SOC ALL CLIN, STAT ADM H1N1 SEAS I; Chung EY, 2010, PEDIATRICS, V125, pE1024, DOI 10.1542/peds.2009-2512; Dorsey MJ, 2005, J ALLERGY CLIN IMM S, V115, pS250; Erlewyn-Lajeunesse M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3680; Esposito S, 2008, VACCINE, V26, P4664, DOI 10.1016/j.vaccine.2008.06.095; HOTTE S, 2008, 2008 AM AC ASTHM ALL; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Li JT, 2009, ADMINISTERING H1N1 I; OBRIEN TC, 1971, APPL MICROBIOL, V21, P780, DOI 10.1128/AEM.21.4.780-782.1971; Park AY, 2008, J ALLERGY CLIN IMMUN, V121, pS240, DOI 10.1016/j.jaci.2007.12.949; Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064; Saltzman RW, 2009, J ALLERGY CLIN IMMUN, V123, pS175, DOI 10.1016/j.jaci.2008.12.659; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; WAIBEL KH, 2010, J ALLERGY CLIN IMMUN, V125, pE1; Waibel KH, 2010, J ALLERGY CLIN IMMUN, V125, P749, DOI 10.1016/j.jaci.2009.12.015; Wood RA, 2007, J ALLERGY CLIN IMMUN, V120, P478, DOI 10.1016/j.jaci.2007.04.035; Zeiger RS, 2002, J ALLERGY CLIN IMMUN, V110, P834, DOI 10.1067/mai.2002.129372	19	64	67	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					317	323		10.1016/j.jaci.2010.05.037	http://dx.doi.org/10.1016/j.jaci.2010.05.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20579720				2022-12-18	WOS:000281203800017
J	Harduar-Morano, L; Simon, MR; Watkins, S; Blackmore, C				Harduar-Morano, Laurel; Simon, Michael R.; Watkins, Sharon; Blackmore, Carina			Algorithm for the diagnosis of anaphylaxis and its validation using population-based data on emergency department visits for anaphylaxis in Florida	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; epidemiology; emergency; International Classification of Disease-Ninth Revision-Clinical Modification; underdiagnosis	EPIDEMIOLOGIC ANALYSIS; ALLERGY; HOSPITALIZATIONS; EPINEPHRINE	Background: Epidemiologic studies of anaphylaxis have been limited by significant underdiagnosis. Objective: The purpose of this study was to develop and validate a method for capturing previously unidentified anaphylaxis cases by using International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) based datasets. Methods: Florida emergency department data for the years 2005 and 2006 from the Florida Agency for Health Care Administration were used. Patients with anaphylaxis were identified by using ICD-9-CM codes specifically indicating anaphylaxis or an ICD-9-CM algorithm based on the definition of anaphylaxis proposed at the 2005 National Institute of Allergy and Infectious Disease and the Food Allergy and Anaphylaxis Network symposium. Cases ascertained with the algorithm were compared with the traditional case-ascertainment method. Comparisons included demographic and clinical risk factors, proportion of monthly visits, and age/sex-specific rates. Cases ascertained with anaphylaxis ICD-9-CM codes were excluded from those ascertained with the algorithm. Results: One thousand one hundred forty-nine patients were identified by using anaphylaxis ICD-9-CM codes, and 1,602 patients were identified with the algorithm. The clinical risk factors and demographics of cases were consistent between the 2 methods. However, the algorithm was more likely to identify older subjects (P<.0001), those with hypertension or heart disease (P<.0001), and subjects with venom-induced anaphylaxis (P<.0001). Conclusion: This study introduces and validates an ICD-9-CM based diagnostic algorithm for the diagnosis of anaphylaxis to capture subjects missed by using the ICD-9-CM anaphylaxis codes. Fifty-eight percent of anaphylaxis cases would be missed without the use of the algorithm, including 88% of venom-induced cases. (J Allergy Clin Immunol 2010;126:98-104.)	[Simon, Michael R.] William Beaumont Hosp, Allergy & Immunol Sect, Royal Oak, MI 48073 USA; [Harduar-Morano, Laurel; Watkins, Sharon; Blackmore, Carina] Bur Environm Publ Hlth Med, Div Environm Hlth, Florida Dept Hlth, Tallahassee, FL USA; [Simon, Michael R.] Wayne State Univ, Sch Med, Dept Internal Med, Detroit, MI 48201 USA; [Simon, Michael R.] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA	Beaumont Health; Florida Department of Health; Wayne State University; Wayne State University	Simon, MR (corresponding author), William Beaumont Hosp, Allergy & Immunol Sect, Royal Oak, MI 48073 USA.	mrsimonmd@sbcglobal.net			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007018] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES007018] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Agresti A., 2003, CATEGORICAL DATA ANA, V482, DOI DOI 10.1002/0471249688; [Anonymous], TECHN APP VIT STAT U; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Campbell RL, 2008, ANN ALLERG ASTHMA IM, V101, P631, DOI 10.1016/S1081-1206(10)60227-X; Clark S, 2007, IMMUNOL ALLERGY CLIN, V27, P145, DOI 10.1016/j.iac.2007.03.002; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; Fernandez J, 1999, CLIN EXP ALLERGY, V29, P1069, DOI 10.1046/j.1365-2222.1999.00614.x; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Grigoreas C, 1997, ALLERGY, V52, P51, DOI 10.1111/j.1398-9995.1997.tb02545.x; Haymore BR, 2005, ALLERGY ASTHMA PROC, V26, P361; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; Lieberman P, 2008, CURR OPIN ALLERGY CL, V8, P316, DOI 10.1097/ACI.0b013e3283036a69; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Mulla ZD, 2007, INT ARCH ALLERGY IMM, V144, P128, DOI 10.1159/000103224; O'Neil ME, 2007, PUBLIC HEALTH REP, V122, P764, DOI 10.1177/003335490712200608; Pastorello EA, 2001, J CHROMATOGR B, V756, P11, DOI 10.1016/S0378-4347(01)00067-6; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Simon MR, 2008, ALLERGY, V63, P1077, DOI 10.1111/j.1398-9995.2008.01737.x; Simon MR, 2008, INT ARCH ALLERGY IMM, V146, P89, DOI 10.1159/000112508; Simons FER, 2008, J ALLERGY CLIN IMMUN, V122, P1166, DOI 10.1016/j.jaci.2008.10.019; Weiler JM, 1999, J ALLERGY CLIN IMMUN, V104, P271, DOI 10.1016/S0091-6749(99)70363-5; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	22	64	64	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					98	104		10.1016/j.jaci.2010.04.017	http://dx.doi.org/10.1016/j.jaci.2010.04.017			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20541247	Green Accepted			2022-12-18	WOS:000280061800017
J	Golden, DBK; Kelly, D; Hamilton, RG; Craig, TJ				Golden, David B. K.; Kelly, Denise; Hamilton, Robert G.; Craig, Timothy J.			Venom immunotherapy reduces large local reactions to insect stings	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Insect sting; venom immunotherapy; large local reaction; Hymenoptera	GRASS-POLLEN IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; CONTROLLED TRIAL; NATURAL-HISTORY; DOUBLE-BLIND; HYPERSENSITIVITY; RESPONSES; ALLERGY; CHILDREN; IGE	Background: Large local reactions to insect stings cause significant morbidity and impair quality of life. Venom immunotherapy is not recommended because of a low risk for future systemic reaction and unproven efficacy in preventing large local reactions. Objective: To determine the feasibility of performing a controlled trial to examine the efficacy of venom immunotherapy in reducing the size and duration of large local reactions. Methods: Sting challenge in 41 patients with previous large local reactions and positive venom skin tests caused large local reactions 16 cm or larger in 34 patients, and 29 consented to treatment. Venom immunotherapy was initiated in 19, and 10 were untreated controls. Sting challenge was repeated after 7 to 11 weeks (control patients then began venom immunotherapy), and annually for as long as 4 years. Results: After 7 to 11 weeks of treatment, the size and duration of large local reactions decreased 42% and 53%, respectively, in treated patients and 18% in controls (P < .01 for both). The response was similar after 1 year, and improved after 2 to 4 years to 60% and 70%, respectively. Conclusions: Venom immunotherapy significantly reduced the size and duration of the large local reactions, and the efficacy improved over a period of 2 to 4 years of treatment. Further studies are needed to establish the safety and efficacy of venom immunotherapy for large local reactions, the optimal duration of treatment, and the mechanism for the differences in degree and rate of clinical response compared with venom immunotherapy in systemic reactors. (J Allergy Clin Immunol 2009;123:1371-5.)	[Golden, David B. K.; Kelly, Denise; Hamilton, Robert G.] Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine	Golden, DBK (corresponding author), 7939 Honeygo Blvd,219, Baltimore, MD 21236 USA.	dgolden1@jhmi.edu			National Institutes of Health [AI08270]; National Institutes of Health General Clinical Research Center [5MO1-RR02719]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI008270, R37AI008270] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grant AI08270 and National Institutes of Health General Clinical Research Center grant 5MO1-RR02719.	BOUSQUET J, 1984, J ALLERGY CLIN IMMUN, V73, P332, DOI 10.1016/0091-6749(84)90405-6; Brown SGA, 2003, LANCET, V361, P1001, DOI 10.1016/S0140-6736(03)12827-9; Golden DBK, 2009, ANN ALLERG ASTHMA IM, V102, P47, DOI 10.1016/S1081-1206(10)60107-X; Golden DBK, 2006, J ALLERGY CLIN IMMUN, V117, P670, DOI 10.1016/j.jaci.2005.12.1313; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; GOLDEN DBK, 2000, IMMUNOTHERAPY PRACTI, P553; GRAFT DF, 1984, J PEDIATR-US, V104, P664, DOI 10.1016/S0022-3476(84)80940-3; Graif Y, 2006, ANN ALLERG ASTHMA IM, V96, P24, DOI 10.1016/S1081-1206(10)61035-6; GREEN AW, 1980, J ALLERGY CLIN IMMUN, V66, P186, DOI 10.1016/0091-6749(80)90037-8; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hamilton RG, 2001, ANN ALLERG ASTHMA IM, V87, P134, DOI 10.1016/S1081-1206(10)62207-7; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LIGHT W C, 1975, Clinical Allergy, V5, P389, DOI 10.1111/j.1365-2222.1975.tb01878.x; LIGHT WC, 1977, J ALLERGY CLIN IMMUN, V59, P391, DOI 10.1016/0091-6749(77)90024-0; MAURIELLO PM, 1984, J ALLERGY CLIN IMMUN, V74, P494, DOI 10.1016/0091-6749(84)90384-1; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Muller UR, 2008, J ALLERGY CLIN IMMUN, V122, P1001, DOI 10.1016/j.jaci.2008.08.007; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; NASSER SMS, 1997, ALLERGY S37, V52, P88; Peng ZK, 2004, ANN ALLERG ASTHMA IM, V93, P553, DOI 10.1016/S1081-1206(10)61262-8; Rueff F, 2009, J ALLERGY CLIN IMMUN, V123, P272, DOI 10.1016/j.jaci.2008.10.028; SCHUBERTH K C, 1982, Journal of Allergy and Clinical Immunology, V69, P124; Severino MG, 2008, J ALLERGY CLIN IMMUN, V122, P44, DOI 10.1016/j.jaci.2008.03.031; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Walker R, 1999, J ALLERGY CLIN IMMUN, V103, pS180	26	64	64	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1371	1375		10.1016/j.jaci.2009.03.017	http://dx.doi.org/10.1016/j.jaci.2009.03.017			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	455WO	19443022				2022-12-18	WOS:000266799100031
J	Scranton, SE; Gonzalez, EG; Waibel, KH				Scranton, Stephen E.; Gonzalez, Erika G.; Waibel, Kirk H.			Incidence and characteristics of biphasic reactions after allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; biphasic; immunotherapy	ANAPHYLAXIS; PREDICTORS	Background: The reported incidence of biphasic anaphylactic reactions varies from 1% to 20%. Reported risk factors for biphasic reactions include a delay in epinephrine administration and a longer interval to initial improvement. To date, only 4 cases of biphasic reactions after allergen immunotherapy have been reported. Objective: We sought to determine the incidence, clinical characteristics, and risk factors for biphasic reactions after allergen-specific immunotherapy. Methods: Patients who were treated with epinephrine for systemic reactions after allergen immunotherapy were prospectively enrolled. Patients were assessed initially and at 24 hours by using a 31-symptom scoring system. Results: Sixty systemic reactions occurred in 55 patients; 14 (23%) biphasic reactions were reported. Patients experiencing biphasic reactions were more likely to be female (P = .03) and older (P = .01) and require greater than 1 dose of epinephrine (P = .001). There was no difference between groups (biphasic vs no biphasic reaction) regarding the type of immunotherapy, current asthma, initial symptom scores, or time to symptoms, initial epinephrine, or improvement. No specific symptom predicted biphasic reactions. Biphasic reactions were significantly less severe compared with the initial reaction (P < .001), did not occur in children, and did not require additional epinephrine. Conclusions: Twenty-three percent of patients requiring epinephrine for systemic reactions caused by allergen immunotherapy experienced biphasic symptoms. Patients treated promptly with epinephrine for systemic reactions should he cautioned regarding biphasic reactions; however, biphasic reactions after allergen immunotherapy were mild and did not require additional epinephrine. (J Allergy Clin Immunol 2009;123:493-8.)	[Scranton, Stephen E.] Landstuhl Reg Med Ctr, Dept Allergy & Immunol, Landstuhl, Germany; [Gonzalez, Erika G.] Wilford Hall USAF Med Ctr, Dept Allergy & Immunol, Lackland AFB, TX 78236 USA; [Waibel, Kirk H.] Brooke Army Med Ctr, Allergy Immunol Clin, Ft Sam Houston, TX 78234 USA	Landstuhl Regional Medical Center; United States Department of Defense; United States Air Force; San Antonio Military Medical Center; United States Department of Defense; United States Army	Scranton, SE (corresponding author), CMR 402,Box 1448, APO, AE 09180 USA.	scrantons@gmail.com						Brazil E, 1998, J ACCID EMERG MED, V15, P252; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Coifman RE, 2007, J ALLERGY CLIN IMMUN, V119, P1012, DOI 10.1016/j.jaci.2007.01.029; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; DOUGLAS DM, 1994, J ALLERGY CLIN IMMUN, V93, P977, DOI 10.1016/S0091-6749(94)70044-3; Ellis AK, 2007, ANN ALLERG ASTHMA IM, V98, P64, DOI 10.1016/S1081-1206(10)60861-7; Lee JM, 2000, PEDIATRICS, V106, P762, DOI 10.1542/peds.106.4.762; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217, DOI 10.1016/S1081-1206(10)61217-3; POPA VT, 1984, ANN ALLERGY, V53, P151; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Smit DV, 2005, J EMERG MED, V28, P381, DOI 10.1016/j.jemermed.2004.11.028; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; Tole JW, 2007, IMMUNOL ALLERGY CLIN, V27, P309, DOI 10.1016/j.iac.2007.03.011	13	64	66	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					493	498		10.1016/j.jaci.2008.10.026	http://dx.doi.org/10.1016/j.jaci.2008.10.026			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	409GU	19064282				2022-12-18	WOS:000263495000031
J	Stelmach, I; Grzelewski, T; Majak, P; Jerzynska, J; Stelmach, W; Kuna, P				Stelmach, Iwona; Grzelewski, Tornasz; Majak, Pawel; Jerzynska, Joanna; Stelmach, Wlodzimierz; Kuna, Piotr			Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; exercise; antiasthmatic treatment	DOSE INHALED BUDESONIDE; INDUCED BRONCHOSPASM; SALMETEROL TREATMENT; FORMOTEROL; METHACHOLINE; MONTELUKAST; CHALLENGE; BECLOMETHASONE; TERBUTALINE; GUIDELINES	Background: Exercise-induced bronchoconstriction occurs in a large proportion of children with asthma, limiting everyday activities important for their physical and social development. Objective: The purpose of this randomized, double-blind, placebo-controlled study was to compare the ability of different patterns of antiasthmatic treatment, recommended in childhood asthma, to protect patients from exercise-induced bronchoconstriction. Methods: Children 6 to 18 years of age with atopic asthma were randomized to a 4-week, placebo-controlled, double-blind trial. Patients were randomly allocated to receive daily 200 mu g budesonide (twice daily, 100 mu g per dose) + 9 mu g formoterol (twice daily, 4.5 mu g per dose; n = 20); 200 mu g budesonide + 5 or 10 mg montelukast (once daily at bedtime; n = 20); 5 or 10 mg montelukast (n = 20); 200 mu g budesonide (n = 20); or placebo (n = 20). A standardized treadmill exercise challenge was performed before and after treatment. Results: Exercise-induced bronchoconstriction, reflected by area under the curve for the FEV1 values from exercise over the 20-minute period and by maximum percent fall in FEV1 after exercise, was significantly diminished after 4 weeks in all active treatment groups, and compared with placebo. Exerciseinduced bronchoconstriction protection improved more significantly in the budesonide + montelukast and montelukast groups compared with other therapeutic options. Conclusion: These data indicate differences in effects on exercise-induced bronchoconstriction between therapeutic options recommended in childhood asthma. Control of childhood asthma with exercise-induced bronchoconstriction can be obtained by using regular controller treatment.	[Stelmach, Iwona; Grzelewski, Tornasz; Majak, Pawel; Jerzynska, Joanna; Stelmach, Wlodzimierz] N Copernicus Hosp, Dept Pediat & Allergy, PL-93513 Lodz, Poland; [Kuna, Piotr] Med Univ Lodz, Dept Allergy & Pneumonol, Lodz, Poland	Medical University Lodz	Stelmach, I (corresponding author), N Copernicus Hosp, Dept Pediat & Allergy, 62 Pabianicka St, PL-93513 Lodz, Poland.	alergol@kopernik.lodz.pl	Jerzynska, Joanna/S-9691-2016; Stelmach, Iwona/S-9796-2016	Kuna, Piotr/0000-0003-2401-0070; Stelmach, Iwona/0000-0002-1475-8221				ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; BONER AL, 1994, AM J RESP CRIT CARE, V149, P935, DOI 10.1164/ajrccm.149.4.7908246; Carlsen Kai-Hakon, 2002, Paediatr Respir Rev, V3, P154, DOI 10.1016/S1526-0550(02)00009-4; Carraro S, 2005, J ALLERGY CLIN IMMUN, V115, P764, DOI 10.1016/j.jaci.2004.10.043; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; de Benedictis FM, 2006, EUR RESPIR J, V28, P291, DOI 10.1183/09031936.06.00020606; Ferrari M, 2000, RESPIRATION, V67, P510, DOI 10.1159/000067465; FREEZER NJ, 1995, EUR RESPIR J, V8, P1488; Fuglsang G, 1998, PEDIATR PULM, V25, P314, DOI 10.1002/(SICI)1099-0496(199805)25:5<314::AID-PPUL5>3.0.CO;2-I; Garcia R, 2001, J INVEST ALLERG CLIN, V11, P176; Global Strategy for Asthma Management and Prevention, 2006, GLOB STRAT ASTHM MAN; Gronnerod TA, 2000, RESP MED, V94, P661, DOI 10.1053/rmed.2000.0789; Hermansen MN, 2006, CHEST, V129, P1203, DOI 10.1378/chest.129.5.1203; Hofstra WB, 2000, PEDIATR PULM, V29, P415, DOI 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7; Jonasson G, 2000, PEDIATR ALLERGY IMMU, V11, P120, DOI 10.1034/j.1399-3038.2000.00067.x; Jonasson G, 1998, EUR RESPIR J, V12, P1099, DOI 10.1183/09031936.98.12051099; Jonasson G, 2000, ALLERGY, V55, P740, DOI 10.1034/j.1398-9995.2000.00661.x; Kelly MM, 2006, J ALLERGY CLIN IMMUN, V117, P989, DOI 10.1016/j.jaci.2006.01.045; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Kim JH, 2005, PEDIATR PULM, V39, P162, DOI 10.1002/ppul.20156; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; Melo RE, 2003, J ALLERGY CLIN IMMUN, V111, P301, DOI 10.1067/mai.2003.66; MERKUS PJFM, 1992, THORAX, V47, P355, DOI 10.1136/thx.47.5.355; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Pearlman D, 2006, ANN ALLERG ASTHMA IM, V97, P382, DOI 10.1016/S1081-1206(10)60805-8; Petersen R, 2004, EUR RESPIR J, V24, P932, DOI 10.1183/09031936.04.00141303; Popa V, 2001, AM J RESP CRIT CARE, V163, P292, DOI 10.1164/ajrccm.163.1.16310b; QUANJER PH, 1989, EUR RESPIR J, V2, pS121; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Subbarao P, 2006, J ALLERGY CLIN IMMUN, V117, P1008, DOI 10.1016/j.jaci.2005.11.048; vanderHeide S, 1997, CLIN EXP ALLERGY, V27, P627, DOI 10.1111/j.1365-2222.1997.tb01189.x; Vidal C, 2001, ANN ALLERG ASTHMA IM, V86, P655, DOI 10.1016/S1081-1206(10)62294-6; WAALKENS JH, 1993, EUR RESPIR J, V6, P652; Weiler JM, 2007, J ALLERGY CLIN IMMUN, V119, P1349, DOI 10.1016/j.jaci.2007.02.041; WOUDE HJ, 2001, THORAX, V56, P529; Zarkovic J, 1998, CLIN DRUG INVEST, V15, P169, DOI 10.2165/00044011-199815030-00001	37	64	68	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					383	389		10.1016/j.jaci.2007.09.007	http://dx.doi.org/10.1016/j.jaci.2007.09.007			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	17980416				2022-12-18	WOS:000253337800016
J	Kerzl, R; Simonowa, A; Ring, J; Ollert, M; Mempel, M				Kerzl, Regina; Simonowa, Anna; Ring, Johannes; Ollert, Markus; Mempel, Martin			Life-threatening anaphylaxis to kiwi fruit: Protective sublingual allergen immunotherapy effect persists even after discontinuation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD ALLERGY; DOUBLE-BLIND; CHILDREN; EXTRACT; ASTHMA		Tech Univ Munich, Dept Dermatol & Allergy, D-8000 Munich, Germany; Tech Univ Munich, Div Environm Dermatol & Allergy, GSF Forschungszentrum Umwelt & Gesundheit, Natl Res Ctr Environm & Hlth, Neuherberg, Germany	Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Kerzl, R (corresponding author), Tech Univ Munich, Dept Dermatol & Allergy, D-8000 Munich, Germany.	m.mempel@lrz.tum.de	Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152; Ollert, Markus W./0000-0002-8055-0103				Bousquet J, 2006, ALLERGY, V61, P5, DOI 10.1111/j.1398-9995.2006.01183.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Mempel M, 2003, J ALLERGY CLIN IMMUN, V111, P1406, DOI 10.1067/mai.2003.1497; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x	7	64	66	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					507	508		10.1016/j.jaci.2006.09.041	http://dx.doi.org/10.1016/j.jaci.2006.09.041			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17125821	Bronze			2022-12-18	WOS:000244327900036
J	Schatz, M; Zeiger, RS; Drane, A; Harden, K; Cibildak, A; Oosterman, JE; Kosinski, M				Schatz, Michael; Zeiger, Robert S.; Drane, Alexandra; Harden, Kathleen; Cibildak, Aysel; Oosterman, Jon E.; Kosinski, Mark			Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma control; Asthma Control Test; asthma utilization; telephone follow-up; speech-recognition technology	HEALTH-CARE UTILIZATION; RESPONSIVENESS; ASSOCIATION; VALIDATION; ADHERENCE; SEVERITY; PHARMACY; ADULTS; RISK	Background: The Asthma Control Test (ACT) has been validated in a paper and pencil version but has not been validated for use by telephone. Objective: The purpose of this study was to provide validation data for the ACT administered by interactive telephone calls using speech recognition technology. Methods: The ACT was administered to patients who confirmed a diagnosis of physician-diagnosed asthma, and information regarding race/ethnicity, smoking, and asthma course was also obtained during the call. Asthma emergency department visits, hospitalizations, and oral corticosteroid and beta-agonist canister dispensings were assessed for the 12 months after the date of each patient's call. Internal consistency reliability and predictive validity were assessed. Results: Asthma Control Test scores (higher indicates better control) were completed by 2244 patients and were inversely related to black or Hispanic race/ethnicity and smoking. Reliability was 0.83. ACT scores were significantly related to emergency hospital care and oral corticosteroid and P-agonist dispensings over the period of the subsequent 6 and 12 months. After adjusting for demographic characteristics, a score <= 15 was associated significantly with an increased 12-month risk of emergency hospital care (odds ratio [OR], 2.5), oral corticosteroid dispensings (OR, 2.6) and dispensing of more than 6 beta-agonist canisters (OR, 6.8) compared with a score >= 20. Conclusion: These data support the reliability and predictive validity of the ACT administered by interactive telephone calls using speech recognition technology. Clinical implications: The ACT can be used for outreach or follow-up by means of interactive telephone calls using speech recognition technology.	Kaiser Permanente Med Ctr, Dept Allergy, San Diego, CA 92111 USA; Eliza Corp, Beverly, MA USA; Qual Metr Corp, Lincoln, NE USA	Kaiser Permanente	Schatz, M (corresponding author), Kaiser Permanente Med Ctr, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	michael.x.schatz@kp.org		Zeiger, Robert/0000-0001-5788-5063				CHISMAR W, 2002, P 36 HAW INT C SYST; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Giorgino T, 2005, INT J MED INFORM, V74, P159, DOI 10.1016/j.ijmedinf.2004.04.026; Gruffydd-Jones K, 2005, BRIT J GEN PRACT, V55, P918; Gruffydd-Jones K, 1999, ASTHMA GEN PRACT, V7, P36; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; LeNoir M, 2006, CURR MED RES OPIN, V22, P17, DOI 10.1185/030079905X74925; Li JT, 2005, J ALLERGY CLIN IMMUN, V116, pS3, DOI 10.1016/j.jaci.2005.08.017; Milgrom H, 2002, ANN ALLERG ASTHMA IM, V88, P429, DOI 10.1016/S1081-1206(10)62377-0; *NAT ASTHM ED PREV, 1997, NAT I HLTH PUBL; *NAT COMM QUAL ASS, 2001, HEDIS 2002, V2; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pinnock H, 2005, BRIT J GEN PRACT, V55, P119; Pinnock H, 2003, BMJ-BRIT MED J, V326, P477, DOI 10.1136/bmj.326.7387.477; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Schatz M, 2005, CHEST, V128, P1968, DOI 10.1378/chest.128.4.1968; Schatz M, 2006, J ASTHMA, V43, P225, DOI 10.1080/02770900600567049; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2005, J ALLERGY CLIN IMMUN, V115, P564, DOI 10.1016/j.jaci.2004.12.005; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P995, DOI 10.1016/j.jaci.2006.01.053; Sherman J, 2000, J PEDIATR-US, V136, P532, DOI 10.1016/S0022-3476(00)90019-2; Stoloff SW, 2006, J ALLERGY CLIN IMMUN, V117, P544, DOI 10.1016/j.jaci.2006.01.005; Streiner DL, 2000, HLTH MEASUREMENT SCA; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127	28	64	66	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					336	343		10.1016/j.jaci.2006.08.042	http://dx.doi.org/10.1016/j.jaci.2006.08.042			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17194469				2022-12-18	WOS:000244327900010
J	Akei, HS; Brandt, EB; Mishra, A; Strait, RT; Finkelman, FD; Warrier, MR; Hershey, GKK; Blanchard, C; Rothenberg, ME				Akei, Hiroko Saito; Brandt, Eric B.; Mishra, Anil; Strait, Richard T.; Finkelman, Fred D.; Warrier, Manoj R.; Hershey, Gurjit K. Khurana; Blanchard, Carine; Rothenberg, Marc E.			Epicutaneous aeroallergen exposure induces systemic T(H)2 immunity that predisposes to allergic nasal responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; atopic; dermatitis; eosinophilia; epicutaneous; lung; nose; sensitization; STAT6	IL-13 RECEPTOR ALPHA-2; MURINE MODEL; AIRWAY HYPERRESPONSIVENESS; TH2 RESPONSES; ASPERGILLUS-FUMIGATUS; ATOPIC-DERMATITIS; ASTHMA; CELLS; MICE; INFLAMMATION	Background: Atopic individuals are predisposed to mounting vigorous T(H)2-type immune responses to environmental allergens. The skin is often the first organ that manifests allergic disease and may provide an early entry point for antigen sensitization. Objective: We sought to determine whether epicutaneous exposure to the aeroallergen Aspergillus fumigatus induces nasal allergic responses. Furthermore, we aimed to examine the mechanism involved. Methods: Wild-type and signal transducer and activator of transcription 6 (STAT6)-deficient mice were exposed to epicutaneous A fumigatus and control antigen ovalbumin. Nasal inflammation and responsiveness to methacholine were monitored. Results: Exposure to epicutaneous A fumigatus antigen induced a marked atopic dermatitis-like phenotype in a manner significantly more efficient than epicutaneous ovalbumin. A single A fumigatus intranasal challenge induced clinical nasal responses and hyperresponsiveness to methacholine in the nose as manifested by nasal symptoms, accompanied by allergic airway and nasal inflammation. Mechanistic analysis using gene-targeted mice revealed that the clinical nasal responses and hyperresponsiveness were STAT6-dependent. Although STAT6 was required for changes in nasal responses, it was not required for epicutaneous pathology except eosinophilia. Conclusion: Epicutaneous exposure to the aeroallergen A fumigatus potently primes for STAT6-dependent nasal responses. These results draw attention to the cooperative interaction between the nasal tract and skin. Clinical implications: The skin is a potent site for antigen sensitization in the development of experimental allergic.	Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol,Dept Pediat,Coll Med, Cincinnati, OH 45229 USA; Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Coll Med,Div Emergency Med, Cincinnati, OH 45229 USA; Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat,Coll Med,Div Immunobiol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Div Allergy & Immunol,Dept Pediat,Coll Med, 3333 Burnet Ave,MLC 7028, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org	MISHRA, ANIL/S-7983-2017	MISHRA, ANIL/0000-0003-4266-4684; Brandt, Eric/0000-0003-0617-4100	NHLBI NIH HHS [HL 076383] Funding Source: Medline; NIAID NIH HHS [R01 AI 42242, AI 057803] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL076383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057803, R01AI042242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akaiwa M, 2001, CYTOKINE, V13, P75, DOI 10.1006/cyto.2000.0814; Akei HS, 2005, GASTROENTEROLOGY, V129, P985, DOI 10.1053/j.gastro.2005.06.027; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Beck Lisa A., 2000, Journal of Allergy and Clinical Immunology, V106, pS258; Blease K, 2002, AM J PATHOL, V160, P481, DOI 10.1016/S0002-9440(10)64867-5; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Corry DB, 2005, IMMUNOL RES, V33, P35, DOI 10.1385/IR:33:1:035; COULOT P, 1994, INFECT IMMUN, V62, P2169, DOI 10.1128/IAI.62.6.2169-2177.1994; David MD, 2003, ONCOGENE, V22, P3386, DOI 10.1038/sj.onc.1206352; Eichenfield LF, 2003, PEDIATRICS, V111, P608, DOI 10.1542/peds.111.3.608; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Finkelman FD, 1999, INT IMMUNOL, V11, P1811, DOI 10.1093/intimm/11.11.1811; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Foster PS, 2003, CLIN EXP ALLERGY, V33, P688, DOI 10.1046/j.1365-2222.2003.01647.x; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Herrick CA, 2000, J CLIN INVEST, V105, P765, DOI 10.1172/JCI8624; Herrick CA, 2003, J IMMUNOL, V170, P2488, DOI 10.4049/jimmunol.170.5.2488; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; Holgate ST, 2005, ARCH DIS CHILD, V90, P826, DOI 10.1136/adc.2004.053280; Huang TJ, 2001, J IMMUNOL, V166, P207, DOI 10.4049/jimmunol.166.1.207; Kagami S, 2005, CLIN EXP IMMUNOL, V141, P459, DOI 10.1111/j.1365-2249.2005.02875.x; Kelly EAB, 2004, AM J RESP CRIT CARE, V169, P551, DOI 10.1164/rccm.2312020; Konishi H, 2002, P NATL ACAD SCI USA, V99, P11340, DOI 10.1073/pnas.152337799; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; KURUP VP, 1992, J IMMUNOL, V148, P3783; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lee NA, 2001, J ALLERGY CLIN IMMUN, V107, P945, DOI 10.1067/mai.2001.116002; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V112, P12, DOI 10.1067/mai.2003.1624; Li L, 1998, J IMMUNOL, V161, P3128; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Mayer C, 1999, J EXP MED, V189, P1507, DOI 10.1084/jem.189.9.1507; Mentink-Kane MM, 2004, IMMUNOL REV, V202, P191, DOI 10.1111/j.0105-2896.2004.00210.x; Myou S, 2003, J EXP MED, V198, P1573, DOI 10.1084/jem.20030298; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Saito H, 2001, IMMUNOLOGY, V104, P226, DOI 10.1046/j.1365-2567.2001.01253.x; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65, DOI 10.1164/ajrccm.149.1.8111600; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 2005, CURR OPIN ALLERGY CL, V5, P17, DOI 10.1097/00130832-200502000-00005; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Wang LF, 1996, J IMMUNOL, V156, P4079; Zimmermann N, 2004, J IMMUNOL, V172, P1815, DOI 10.4049/jimmunol.172.3.1815	47	64	67	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					62	69		10.1016/j.jaci.2006.04.046	http://dx.doi.org/10.1016/j.jaci.2006.04.046			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815139				2022-12-18	WOS:000239184800007
J	Cockcroft, DW; Davis, BE				Cockcroft, Donald W.; Davis, Beth E.			The bronchoprotective effect of inhaling methacholine by using total lung capacity inspirations has a marked influence on the interpretation of the test result	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; methacholine challenge; deep inhalation; bronchoprotection	DEEP INSPIRATION; CHALLENGE; HISTAMINE; STANDARDIZATION; RESPONSIVENESS; DOSIMETER	Methacholine tests are widely used as a diagnostic aid for asthma. Their strength has been reputed to be the high sensitivity and very infrequent occurrence of false-negative test results (ie, high negative predictive value). There are 2 commonly used methods that have been outlined by the American Thoracic Society. These methods were thought to give equivalent results. However, in 3 investigations in which we have compared the 2 methods, we have demonstrated a marked lack of comparability. In subjects with borderline to mild airway responsiveness (tidal breathing, methacholine PC20 > 2 mg/mL), the 5 deep inhalations required of the dosimeter method produce marked bronchoprotection in some subjects with asthma. The result of this bronchoprotection is that in 55 subjects with asthma, 50% of those whose tidal breathing PC20 value was greater than 2 mg/mL and 25% of the total had negative methacholine challenge results. This indicates that the standardized dosimeter method has an unacceptable loss of diagnostic sensitivity. We recommend that the dosimeter method not be performed as outlined by the American Thoracic Society and that methacholine should be administered by means of submaximal inhalations or tidal breathing.	Univ Saskatchewan, Royal Univ Hosp, Div Respirol Crit Care & Sleep Med, Saskatoon, SK S7N 0W8, Canada	University of Saskatchewan	Cockcroft, DW (corresponding author), Univ Saskatchewan, Royal Univ Hosp, Div Respirol Crit Care & Sleep Med, 103 Hosp Dr,Ellis Hall,5th Floor, Saskatoon, SK S7N 0W8, Canada.	cockcroft@sask.usask.ca						Allen ND, 2005, CHEST, V128, P4018, DOI 10.1378/chest.128.6.4018; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Cockcroft DW, 2005, CHEST, V127, P839, DOI 10.1378/chest.127.3.839; COCKCROFT DW, 1983, CHEST, V84, P505, DOI 10.1378/chest.84.4.505; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1983, ANN ALLERGY, V51, P374; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; Cockeroft DW, 2001, CHEST, V120, P1857, DOI 10.1378/chest.120.6.1857; Davis BE, 2000, CHEST, V117, P881, DOI 10.1378/chest.117.3.881; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; Enright P, 2001, AM J RESP CRIT CARE, V163, P293; FABBRI LM, 1985, AIRWAY RESPONSIVENES, P29; FISH JE, 1981, J APPL PHYSIOL, V50, P1079, DOI 10.1152/jappl.1981.50.5.1079; FISH JE, 1979, J ALLERGY CLIN IMMUN, V64, P592, DOI 10.1016/0091-6749(79)90019-8; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; Kapsali T, 2000, J APPL PHYSIOL, V89, P711, DOI 10.1152/jappl.2000.89.2.711; OREHEK J, 1981, AM REV RESPIR DIS, V123, P269; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; Scichilone N, 2000, AM J RESP CRIT CARE, V162, P910, DOI 10.1164/ajrccm.162.3.9907048; Scichilone N, 2001, INT ARCH ALLERGY IMM, V124, P262, DOI 10.1159/000053728; SCICHILONE N, 2001, AM J RESP CRIT CARE, V163, pA829; Todd DC, 2004, J ALLERGY CLIN IMMUN, V114, P517, DOI 10.1016/j.jaci.2004.06.016; Wubbel C, 2004, CHEST, V125, P453, DOI 10.1378/chest.125.2.453	23	64	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1244	1248		10.1016/j.jaci.2006.02.038	http://dx.doi.org/10.1016/j.jaci.2006.02.038			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16750982				2022-12-18	WOS:000238332300007
J	Vanoirbeek, JAJ; Tarkowski, M; Vanhooren, HM; De Vooght, V; Nemery, B; Hoet, PHM				Vanoirbeek, Jeroen A. J.; Tarkowski, Maciej; Vanhooren, Hadewijch M.; De Vooght, Vanessa; Nemery, Benoit; Hoet, Peter H. M.			Validation of a mouse model of chemical-induced asthma using trimellitic anhydride, a respiratory sensitizer, and dinitrochlorobenzene, a dermal sensitizer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						trimellitic anhydride; 1-chloro-2; 4-dinitrobenzene; occupational asthma; murine model; T-lymphocytes subtypes; IL-4; IFN-gamma; macrophage inflammatory protein 2; TNF-alpha	BROWN-NORWAY RATS; LYMPH-NODE ASSAY; OCCUPATIONAL ASTHMA; MESSENGER-RNA; SERUM IGE; MICE; ALLERGENS; IDENTIFICATION; HYPERSENSITIVITY; PLETHYSMOGRAPHY	Background: Occupational asthma can be caused by chemicals. Previously, we established a murine model of immunologically mediated chemical-induced asthma using toluene diisocyanate. Objective: We sought to verify this model using trimellitic anhydride (TMA), a respiratory sensitizer, and 1-chloro-2,4-dinitrobenzene (DNCB), a dermal sensitizer. Methods: BALB/c mice received dermal applications (vehicle or chemical) on days 1 and 7. On day 10, they received an intranasal instillation (vehicle or chemical). Whole-body plethysmography (enhanced pause) was used to monitor changes in ventilatory function and methacholine reactivity. Pulmonary inflammation was assessed by using bronchoalveolar lavage (cells, TNF-alpha levels, and macrophage inflammatory protein 2 levels). Immunologic parameters included total serum IgE levels, lymphocyte distribution in auricular and cervical lymph nodes, and IL-4 and IFN-gamma levels in supernatants of lymph node cells incubated with or without concanavalin A. Results: Mice dermally treated and intranasally challenged with TMA experienced markedly increased enhanced pause immediately after intranasal challenge and increased methacholine reactivity (24 hours later). Mice similarly treated with DNCB did not show any ventilatory changes. Neutrophil influx and increased macrophage inflammatory protein 2 and TNF-alpha levels were found in bronchoalveolar lavage fluid in both TMA- and DNCB-treated mice. The proportion of CD19(+) B cells was increased in auricular and cervical lymph nodes of TMA-treated mice. IL-4 and IFN-gamma levels were increased in supernatants of concanavalin A-stimulated auricular and cervical lymph node cells of TMA- or DNCB-treated mice; however, the relative proportions of IL-4 and IFN-gamma levels differed between TMA- and DNCB-treated mice. Serum total IgE levels were increased in TMA-treated mice only. Conclusion: Both compounds induce a mixed T(H)1-T(H)2 response, but only TMA induced ventilatory changes. Clinical implications: In the workplace avoiding skin contact with chemical sensitizers might be advised to prevent chemical-induced asthma.	Katholieke Univ Leuven, Lab Pneumol, Unit Lung Toxicol, B-3000 Louvain, Belgium; Nofer Inst Occupat Med, Dept Immunotoxicol, Lodz, Poland	KU Leuven; Nofer Institute of Occupational Medicine	Nemery, B (corresponding author), Katholieke Univ Leuven, Lab Pneumol, Unit Lung Toxicol, Herestr 49 bus 706, B-3000 Louvain, Belgium.	ben.nemery@med.kuteuven.be	Vanoirbeek, Jeroen/D-5183-2016; Hoet, Peter/H-9987-2013; Nemery, Benoit/N-3155-2019; Nemery, Benoit/D-1224-2013	Vanoirbeek, Jeroen/0000-0001-5508-3518; Hoet, Peter/0000-0002-0292-6603; Nemery, Benoit/0000-0003-0571-4689; Tarkowski, Maciej Stanislaw/0000-0003-0061-9332				Arts JHE, 2004, INHAL TOXICOL, V16, P259, DOI 10.1080/08958370490427932; Arts JHE, 2003, TOXICOL APPL PHARM, V187, P38, DOI 10.1016/S0041-008X(02)00023-6; Banks DE, 2000, OCCUP MED-STATE ART, V15, P335; Bardana Emil J., 2003, Journal of Allergy and Clinical Immunology, V111, pS530; Bates JHT, 2003, J APPL PHYSIOL, V94, P1297, DOI 10.1152/japplphysiol.00706.2002; Becklake M, 2003, AM J RESP CRIT CARE, V167, P466; Bernstein IL, 1999, ASTHMA WORKPLACE; BRIATICOVANGOSA G, 1994, FUND APPL TOXICOL, V23, P145, DOI 10.1006/faat.1994.1093; Coquette A, 2003, TOXICOL IN VITRO, V17, P311, DOI 10.1016/S0887-2333(03)00019-5; De Raeve H, 1998, AM J IND MED, V34, P169, DOI 10.1002/(SICI)1097-0274(199808)34:2<169::AID-AJIM10>3.3.CO;2-N; Dearman RJ, 2003, J APPL TOXICOL, V23, P199, DOI 10.1002/jat.907; Dearman RJ, 2002, FOOD CHEM TOXICOL, V40, P1881, DOI 10.1016/S0278-6915(02)00179-5; Dearman RJ, 2001, J APPL TOXICOL, V21, P153, DOI 10.1002/jat.743; Farraj AK, 2004, TOXICOL SCI, V79, P315, DOI 10.1093/toxsci/kfh112; FAWCETT IW, 1977, CLIN ALLERGY, V7, P1, DOI 10.1111/j.1365-2222.1977.tb01418.x; Gerberick GF, 2004, CONTACT DERMATITIS, V50, P274, DOI 10.1111/j.0105-1873.2004.00290.x; Gerberick GF, 2002, TOXICOL SCI, V68, P420, DOI 10.1093/toxsci/68.2.420; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Kimber I, 2002, CONTACT DERMATITIS, V47, P315, DOI 10.1034/j.1600-0536.2002.470601.x; KUBY J, 1997, IMMUNOLOGY, P313; Lachowsky F, 2001, Curr Allergy Asthma Rep, V1, P587, DOI 10.1007/s11882-001-0070-y; Lee JK, 2004, ENVIRON TOXICOL PHAR, V17, P95, DOI 10.1016/j.etap.2004.03.006; LISBY S, 1995, INT IMMUNOL, V7, P343, DOI 10.1093/intimm/7.3.343; Lombardo LJ, 2000, ENVIRON HEALTH PERSP, V108, P697, DOI 10.2307/3454406; Lundblad LKA, 2002, J APPL PHYSIOL, V93, P1198, DOI 10.1152/japplphysiol.00080.2002; MAGNUSSON B, 1969, J INVEST DERMATOL, V52, P268, DOI 10.1038/jid.1969.42; Meuleman L, 1999, ALLERGY, V54, P752, DOI 10.1111/j.1398-9995.1999.00103.x; Mitzner W, 2003, J APPL PHYSIOL, V94, P828, DOI 10.1152/japplphysiol.00815.2002; Pauluhn J, 2003, TOXICOLOGY, V194, P1, DOI 10.1016/S0300-483X(03)00285-3; Pauluhn J, 2002, J APPL TOXICOL, V22, P89, DOI 10.1002/jat.831; Sallstad DM, 2003, TOXICOLOGY, V194, P147, DOI 10.1016/S030-483X(03)00338-X; Shen HHH, 2003, J IMMUNOL, V170, P3296, DOI 10.4049/jimmunol.170.6.3296; Van Och FMM, 2002, TOXICOL APPL PHARM, V184, P46, DOI 10.1006/taap.2002.9473; Vandebriel RJ, 2003, TOXICOLOGY, V188, P1, DOI 10.1016/S0300-483X(02)00742-4; Vanoirbeek JAJ, 2004, TOXICOL SCI, V80, P310, DOI 10.1093/toxsci/kfh155; Vanoirbeek JAJ, 2003, TOXICOL SCI, V76, P338, DOI 10.1093/toxsci/kfg235; Warbrick EV, 2002, J APPL TOXICOL, V22, P1, DOI 10.1002/jat.830; Whitehead GS, 2003, AM J PHYSIOL-LUNG C, V285, pL32, DOI 10.1152/ajplung.00390.2002; Zhang XD, 2004, J ALLERGY CLIN IMMUN, V113, P320, DOI 10.1016/j.jaci.2003.11.047	39	64	64	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1090	1097		10.1016/j.jaci.2006.01.027	http://dx.doi.org/10.1016/j.jaci.2006.01.027			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675337	Bronze, Green Published			2022-12-18	WOS:000237436300017
J	Anderson, SD; Sue-Chu, M; Perry, CP; Gratziou, C; Kippelen, P; McKenzie, DC; Beck, KC; Fitch, KD				Anderson, SD; Sue-Chu, M; Perry, CP; Gratziou, C; Kippelen, P; McKenzie, DC; Beck, KC; Fitch, KD			Bronchial challenges in athletes applying to inhale a beta(2)-agonist at the 2004 Summer Olympics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						athletes; asthma; beta(2)-agonist; bronchial provocation; exercise; eucapnic hyperpnea; methacholine	EXERCISE-INDUCED BRONCHOCONSTRICTION; AIRWAY HYPERRESPONSIVENESS; EUROPEAN-COMMUNITY; INDUCED ASTHMA; RESPONSIVENESS; CORTICOSTEROIDS; METHACHOLINE; INFLAMMATION; SALBUTAMOL; RESPONSES	Background: The International Olympic Committee Medical Commission required a medical justification for athletes to inhale a beta(2)-agonist before an event at the Summer Games in Athens in 2004. Objective: We sought to establish the percentage of athletes applying to use an inhaled beta(2)-agonist on the basis of the results of objective tests to establish a diagnosis of asthma or exercise-induced bronchoconstriction. We also sought to compare this percentage with the percentage of athletes simply notifying the intention to use a beta(2)-agonist at the previous Summer Games in Sydney in 2000. Methods: An analysis was made of tests that measured the change in FEV1 in response to a bronchodilator or in response to a provoking stimulus, such as exercise, eucapnic voluntary hyperpnea, hypertonic saline, or methacholine. Results: Ten thousand six hundred fifty-three athletes competed in Athens; 4.2% were approved to use a beta(2)-agonist, and 0.4% were rejected. This approval rate was 26% less than the notifications in 2000 in Sydney (5.7%). Compared with Sydney 2000, there was a significant reduction of submissions and approvals for athletes from the United States, New Zealand, Australia, and Canada and in triathlon and swimming sports. Conclusion: The need to provide objective testing has resulted in a reduction in the number of athletes seeking approval to use an inhaled beta(2)-agonist. Objective evidence has provided information for the doctor that is likely to improve the health of the athlete because many athletes appeared to be undertreated at the time of testing. Clinical implications: We show that documentation of airway narrowing in athletes, particularly in response to exercise or surrogate stimuli for exercise, aids in the diagnosis and management of asthma by providing evidence of bronchial hyperresponsiveness that will respond to treatment with inhaled corticosteroids and is usually associated with a reduction in respiratory symptoms on exercise.	Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia; Univ Trondheim Hosp, St Olavs Hosp, Dept Lung Med, Trondheim, Norway; Univ Athens, Sch Med, Ctr Asthma & Allergy, Pulm & Crit Care Dept, GR-11527 Athens, Greece; Univ British Columbia, Div Sports Med, Vancouver, BC V5Z 1M9, Canada; Guidant Corp, St Paul, MN USA; Univ Western Australia, Sch Human Movement & Exercise Sci, Nedlands, WA 6009, Australia	University of Sydney; Norwegian University of Science & Technology (NTNU); Athens Medical School; National & Kapodistrian University of Athens; University of British Columbia; Abbott Laboratories; University of Western Australia	Anderson, SD (corresponding author), Royal Prince Alfred Hosp, Dept Resp Med, E 11, Camperdown, NSW 2050, Australia.	sandya@med.usyd.edu.au	Kippelen, Pascale/ABH-2996-2020; Sue-Chu, Malcolm/D-8671-2016	Sue-Chu, Malcolm/0000-0002-3301-1983; Anderson, Sandra/0000-0002-6308-8770				Altman DG, 1990, PRACTICAL STAT MED R; Anderson Sandra D, 2004, Paediatr Drugs, V6, P161, DOI 10.2165/00148581-200406030-00003; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453, DOI 10.1067/mai.2000.109822; Anderson SD, 2005, CURR ALLERGY ASTHM R, V5, P116, DOI 10.1007/s11882-005-0084-y; Anderson SD, 2003, CLIN REV ALLERG IMMU, V24, P27, DOI 10.1385/CRIAI:24:1:27; Anderson SD, 2003, J ALLERGY CLIN IMMUN, V111, P45, DOI 10.1067/mai.2003.1; Anderson SD, 2002, MED J AUSTRALIA, V177, pS61, DOI 10.5694/j.1326-5377.2002.tb04821.x; Anderson SD, 2001, MED SCI SPORT EXER, V33, P893, DOI 10.1097/00005768-200106000-00007; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bonsignore MR, 2003, CLIN EXP ALLERGY, V33, P14, DOI 10.1046/j.1365-2222.2003.01557.x; Caillaud C, 2003, CAN J APPL PHYSIOL, V28, P793, DOI 10.1139/h03-059; Cave A, 1999, PHARMACOL THERAPEUT, V83, P153, DOI 10.1016/S0163-7258(99)00019-4; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; COX G, 1995, J IMMUNOL, V154, P4719; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; CRAPO RO, 1995, AM J RESP CRIT CARE, V152, P1107, DOI DOI 10.1164/AJRCCM.152.3.7663792; Dickinson JW, 2005, THORAX, V60, P629, DOI 10.1136/thx.2004.037499; Evans DW, 1997, THORAX, V52, P136, DOI 10.1136/thx.52.2.136; Helenius IJ, 1998, BRIT J SPORT MED, V32, P125, DOI 10.1136/bjsm.32.2.125; Holzer K, 2003, AM J RESP CRIT CARE, V167, P534, DOI 10.1164/rccm.200208-916OC; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479, DOI 10.1164/ajrccm.161.5.9909008; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; PERSSON CGA, 1991, CLIN EXP ALLERGY, V21, P17, DOI 10.1111/j.1365-2222.1991.tb00799.x; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Reddel HK, 2000, EUR RESPIR J, V16, P226, DOI 10.1034/j.1399-3003.2000.16b08.x; Rundell KW, 2004, CHEST, V125, P909, DOI 10.1378/chest.125.3.909; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; Scola AM, 2004, BRIT J PHARMACOL, V141, P163, DOI 10.1038/sj.bjp.0705599; SMITH CM, 1990, EUR RESPIR J, V3, P144; SOURK RL, 1983, AM REV RESPIR DIS, V128, P153, DOI 10.1164/arrd.1983.128.1.153; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Sue-Chu M, 2000, RESPIRATION, V67, P417, DOI 10.1159/000029541; van Grunsven PM, 1999, THORAX, V54, P316, DOI 10.1136/thx.54.4.316; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7	39	64	67	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					767	773		10.1016/j.jaci.2005.12.1355	http://dx.doi.org/10.1016/j.jaci.2005.12.1355			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630932				2022-12-18	WOS:000236862800007
J	Cardona, ID; Goleva, E; Ou, LS; Leung, DYM				Cardona, ID; Goleva, E; Ou, LS; Leung, DYM			Staphylococcal enterotoxin B inhibits regulatory T cells by inducing glucocorticoid-induced TNF receptor-related protein ligand on monocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inflammation; superantigens; T-regulatory cells; monocyteslmacrophages; GITR-L	IMMUNOLOGICAL SELF-TOLERANCE; MEDIATED SUPPRESSION; CUTTING EDGE; CD4(+)CD25(+); SUPERANTIGENS; GITR; IDENTIFICATION; COSTIMULATION; HOMEOSTASIS; EXPRESSION	Background: Superantigens inhibit naturally occurring CD4(+)CD25(+) regulatory T-cell (nTreg) activity, yet the mechanism for this is unknown. Objective: We tested the hypothesis that staphylococcal enterotoxin B (SEB), a prototypic superantigen, inhibits the ability of nTregs to suppress T-effector cell (Teff) proliferation by an antigen-p resenting cell-dependent cell contact mechanism and the induction of glucocorticoid-induced TNF receptor-related protein ligand (GITR-L) on monocytes. Methods: Cell proliferation assays were performed on immunomagnetic-bead separated CD4(+)CD25(+), CD4(+)CD25(-) cells and CD14(+) monocytes using anti-CD3, SEB, or a neutralizing anti-GITR-L antibody for stimulation. A cytokine permeable membrane insert separating cells in culture was used to evaluate the role of cell contact. Proliferation was measured by [H-3]-thymidine incorporation or a carboxyfluorescein diacetate succinimidyl ester assay. GITR-L expression was determined by RT-PCR and immnunostaining. Results: Antigen-presenting cell contact was required for proliferation of nTregs and loss of their ability to suppress Teff proliferation as confirmed by carboxyfluorescein diacetate succinimidyl ester. At baseline, monocytes expressed no GITR-L, but after SEB stimulation, GITR-L gene and protein expression increased significantly over a period of 24 hours (P < .05). When GITR-L activity was neutralized with blocking antibody, as opposed to isotype control, nTregs suppressed Teff proliferation despite the presence of SEB (P < .05). Likewise, loss of GITR-L at 48 hours was associated with restoration of nTreg activity (P <= .05). Conclusion: Staphylococcal enterotoxin B upregulates GITR-L on monocytes and inhibits nTreg ability to suppress Teff proliferation via a cell contact interaction. Clinical implications: Prevention of GITR-L induction on monocytes by SEB may be a novel target for control of inflammation in superantigen-driven diseases such as atopic dermatitis.	Natl Jewish Ctr Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Chang Gung Childrens Hosp, Dept Pediat, Taoyuan, Taiwan	Chang Gung Memorial Hospital	Leung, DYM (corresponding author), Natl Jewish Ctr Med & Res Ctr, Dept Pediat, Room K926I,1400 Jackson St, Denver, CO 80206 USA.	leungd@njc.org			NCRR NIH HHS [3M01 RR00051] Funding Source: Medline; NHLBI NIH HHS [HL37260, HL-36577] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, P01HL036577, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baecher-Allan C, 2004, SEMIN IMMUNOL, V16, P89, DOI 10.1016/j.smim.2003.12.005; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Chinen J, 2004, J ALLERGY CLIN IMMUN, V114, P398, DOI 10.1016/j.jaci.2004.05.036; Choi BK, 2004, J LEUKOCYTE BIOL, V75, P785, DOI 10.1189/jlb.1003491; Ehrenstein MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165; Fehervari Z, 2004, J CLIN INVEST, V114, P1209, DOI 10.1172/JCI200434495; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Goleva E, 2005, J ALLERGY CLIN IMMUN, V116, P1094, DOI 10.1016/j.jaci.2005.08.051; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Ji HB, 2004, J IMMUNOL, V172, P5823, DOI 10.4049/jimmunol.172.10.5823; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Kanamaru F, 2004, J IMMUNOL, V172, P7306, DOI 10.4049/jimmunol.172.12.7306; Kim BJ, 2004, INVEST OPHTH VIS SCI, V45, P3170, DOI 10.1167/iovs.03-0919; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Kriegel MA, 2004, J EXP MED, V199, P1285, DOI 10.1084/jem.20032158; Kwon BS, 1999, J BIOL CHEM, V274, P6056, DOI 10.1074/jbc.274.10.6056; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Proft T, 2003, CLIN EXP IMMUNOL, V133, P299, DOI 10.1046/j.1365-2249.2003.02203.x; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Seroogy CM, 2005, J ALLERGY CLIN IMMUN, V116, P996, DOI 10.1016/j.jaci.2005.07.015; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Stephens GL, 2004, J IMMUNOL, V173, P5008, DOI 10.4049/jimmunol.173.8.5008; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Tang QZ, 2003, J IMMUNOL, V171, P3348, DOI 10.4049/jimmunol.171.7.3348; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Valzasina B, 2005, BLOOD, V105, P2845, DOI 10.1182/blood-2004-07-2959; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579	33	64	73	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					688	695		10.1016/j.jaci.2005.11.037	http://dx.doi.org/10.1016/j.jaci.2005.11.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522472	Bronze			2022-12-18	WOS:000236263100028
J	Greenberger, PA				Greenberger, PA			Drug allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						drug; allergy; immunosuppressive; keratinocytes; Stevens-Johnson syndrome; toxic epidermal necrolysis; penicillin	TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; CROSS-REACTIVITY; MONOCLONAL-ANTIBODY; PENICILLIN ALLERGY; FOLLOW-UP; ASPIRIN; EVENTS; SAFETY; INHIBITOR	Drug reactions can be considered as being either predictable or unpredictable. A predictable reaction would be the result of the pharmacologic action of the medication. An unpredictable reaction might be idiosyncratic, might be drug intolerance, or might have or imply an immunologic basis, such as being IgE mediated. Immediate reactions that are not IgE mediated can be considered as pseudoallergic (non-IgE-mediated mast cell activation). This review will discuss allergic and immunologic reactions to immunomodulators, penicillins and cephalosporins, sulfonamides, aspirin, and nonselective nonsteroidal anti-inflammatory drugs and consider the serious drug-related conditions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The field of drug "allergy" has expanded to include adverse reactions associated with immunosuppressive medications, anticytokine therapies, and mAbs. The cytokine release reaction that occurs with anti-CD20 antibody infusions in patients with leukemia and white blood cell counts of greater than 50 x 10(9)/L is associated with high concentrations of TNF, IL-6, and IL-8. Because of the findings of fever, dyspnea, rigors, and hypotension, this reaction resembles the Jarisch-Herxheimer reaction that occurs 60 to 90 minutes after penicillin administration in patients with secondary syphilis. Furthermore, the care of the patient with penicillin allergy has been made more difficult in the absence of the major determinant, penicilloyi-polylysine, in that from 34% to 84% of patients who have positive skin test reactions to penicillin have exclusively positive reactions to the major determinant. SJS and TEN typically are caused by medications within I to 8 weeks of initiation of therapy. Evidence for death of the keratinocytes through (1) drug-specific cytotoxicity with the perforin-granzyme B-mediated killing and (2) activation of Fas on keratinocytes have provided explanations for the sloughing of skin. Unfortunately, intravenous immunoglobulin therapy for SJS and TEN has been disappointing.	Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Greenberger, PA (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Dept Med, 676 N St Clair St,14018, Chicago, IL 60611 USA.	p-greenberger@northwestern.edu	Greenberger, Paul/L-2770-2019; El-Owaidy, Rasha H/B-7609-2017	Greenberger, Paul/0000-0003-3882-8498; El-Owaidy, Rasha H/0000-0002-5609-4160				Abe R, 2003, AM J PATHOL, V162, P1515, DOI 10.1016/S0002-9440(10)64284-8; ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; Allam JP, 2004, EUR J DERMATOL, V14, P339; Amalberti R, 2005, ANN INTERN MED, V142, P756, DOI 10.7326/0003-4819-142-9-200505030-00012; Bachot N, 2003, ARCH DERMATOL, V139, P33, DOI 10.1001/archderm.139.1.33; Bennett CL, 2005, JAMA-J AM MED ASSOC, V293, P2131, DOI 10.1001/jama.293.17.2131; Bittner A, 2004, ALLERGY ASTHMA PROC, V25, P161; Blix HS, 2004, EUR J CLIN PHARMACOL, V60, P651, DOI 10.1007/s00228-004-0830-4; Brown NJ, 1997, JAMA-J AM MED ASSOC, V278, P232, DOI 10.1001/jama.278.3.232; Buchler M, 2003, CLIN TRANSPLANT, V17, P539, DOI 10.1046/j.1399-0012.2003.00102.x; Canaday BR, 1997, AM J HEALTH-SYST PH, V54, P2616, DOI 10.1093/ajhp/54.22.2616; Charles PJ, 2000, ARTHRITIS RHEUM, V43, P2383, DOI 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.3.CO;2-4; Cicardi M, 2004, ARCH INTERN MED, V164, P910, DOI 10.1001/archinte.164.8.910; Dimopoulos MA, 2004, AM J MED, V117, P508, DOI 10.1016/j.amjmed.2004.03.040; DITTO AM, 2002, PATTERSONS ALLERGIC, P295; Ebo DG, 2001, ANN ALLERG ASTHMA IM, V87, P243, DOI 10.1016/S1081-1206(10)62234-X; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gandhi TK, 2005, ANN INTERN MED, V142, P352, DOI 10.7326/0003-4819-142-5-200503010-00010; Gollapudi RR, 2004, JAMA-J AM MED ASSOC, V292, P3017, DOI 10.1001/jama.292.24.3017; GRAMMER L C, 1984, Journal of Allergy and Clinical Immunology, V73, P180; GRAMMER LC, 2003, DRUG ALLERGY PROTOCO, P1; GREENBERGER PA, 1991, J ALLERGY CLIN IMMUN, V87, P867, DOI 10.1016/0091-6749(91)90135-B; GREENBERGER PA, 2001, J INVEST MED, V49, pA303; GREENBERGER PA, 2002, PATTERSONS ALLERGIC, P335; GREENBERGER PA, 2005, J ALLERGY CLIN IMMUN, V115, pS182; Gruchalla Rebecca S., 2003, Journal of Allergy and Clinical Immunology, V111, pS548; Guillot B, 2004, DERMATOLOGY, V208, P49, DOI 10.1159/000075046; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Kelkar PS, 2001, NEW ENGL J MED, V345, P804, DOI 10.1056/NEJMra993637; Kohn LT, 2000, ERR IS HUMAN BUILDIN; Krause I, 2003, AM J MED, V115, P390, DOI 10.1016/S0002-9343(03)00390-5; Kuiper RAJ, 2000, ANN PHARMACOTHER, V34, P858; Lam Nga-Shuen, 2004, Journal of Microbiology Immunology and Infection, V37, P366; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; Macy E, 2003, J ALLERGY CLIN IMMUN, V111, P1111, DOI 10.1067/mai.2003.1385; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; Quiralte J, 2004, ANN ALLERG ASTHMA IM, V93, P360, DOI 10.1016/S1081-1206(10)61395-6; Romano A, 2004, ANN INTERN MED, V141, P16, DOI 10.7326/0003-4819-141-1-200407060-00010; Rzany B, 1999, LANCET, V353, P2190, DOI 10.1016/S0140-6736(98)05418-X; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAXON A, 1988, J ALLERGY CLIN IMMUN, V82, P213, DOI 10.1016/0091-6749(88)91001-9; Sellam J, 2005, JOINT BONE SPINE, V72, P48, DOI 10.1016/j.jbspin.2004.03.003; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; Solensky R, 2000, ANN ALLERG ASTHMA IM, V85, P195, DOI 10.1016/S1081-1206(10)62466-0; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; Strom BL, 2003, NEW ENGL J MED, V349, P1628, DOI 10.1056/NEJMoa022963; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; Tripathi A, 2000, ALLERGY ASTHMA PROC, V21, P101, DOI 10.2500/108854100778250914; TRIPATHI A, 2002, PATTERSONS ALLERGIC, P289; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Volcheck GW, 1998, ANN ALLERG ASTHMA IM, V80, P159, DOI 10.1016/S1081-1206(10)62949-3; Wadei H, 2004, AM J TRANSPLANT, V4, P1002, DOI 10.1111/j.1600-6143.2004.00429.x; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224; Winterstein AG, 2002, AM J HEALTH-SYST PH, V59, P1742, DOI 10.1093/ajhp/59.18.1742; Woessner KM, 2004, ANN ALLERG ASTHMA IM, V93, P339, DOI 10.1016/S1081-1206(10)61392-0	60	64	71	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		1			S464	S470		10.1016/j.jaci.2005.11.002	http://dx.doi.org/10.1016/j.jaci.2005.11.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VS	16455348				2022-12-18	WOS:000235865400009
J	Psarras, S; Volonaki, E; Skevaki, CL; Xatzipsalti, M; Bossios, A; Pratsinis, H; Tsigkos, S; Gourgiotis, D; Constantopoulos, AG; Papapetropoulos, A; Saxoni-Papageorgiou, P; Papadopoulos, NG				Psarras, S; Volonaki, E; Skevaki, CL; Xatzipsalti, M; Bossios, A; Pratsinis, H; Tsigkos, S; Gourgiotis, D; Constantopoulos, AG; Papapetropoulos, A; Saxoni-Papageorgiou, P; Papadopoulos, NG			Vascular endothelial growth factor-mediated induction of angiogenesis by human rhinoviruses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchial epithelial cells; airway remodeling.; endothelial cells; viral infection	BRONCHIAL EPITHELIAL-CELLS; PERMEABILITY FACTOR; ASTHMATIC SUBJECTS; LOWER AIRWAYS; IN-VITRO; EXPRESSION; INFECTION; ANGIOPOIETIN-1; CYTOKINES; IMMUNOREACTIVITY	Background: Human rhinoviruses, major precipitants of asthma exacerbations, infect the lower airway epithelium inducing inflammation. The possibility that viral infection may mediate angiogenesis, thus contributing to airway remodeling, has not been evaluated. Objective: To investigate whether epithelial infection with rhinovirus mediates angiogenesis in vitro, evaluate possible modulation by an atopic environment, and confirm angiogenic factor induction after in vivo rhinovirus infection. Methods: Bronchial epithelial cells were infected with rhinovirus and levels of vascular endothelial growth factor (VEGF), and angiopoietins were measured. The angiogenic effect of epithelial products was assessed in in vitro models of angiogenesis. PBMCs, obtained from patients with atopic asthma and normal controls, were exposed to rhinovirus; the ability of supernatants from these cultures differentially to affect rhinovirus-mediated epithelial VEGF production was evaluated. VEGF levels were measured in respiratory secretions from patients with asthma, before and during rhinovirus-induced exacerbations. Results: Epithelial infection with rhinovirus specifically stimulated mRNA expression and release of VEGF, but not angiopoietins, in a time-dependent and dose-dependent manner. Supernatants from these cultures were able to induce angiogenesis in vitro, significantly inhibited by a neutralizing anti-VEGF antibody. When bronchial cells were exposed to supernatants of rhinovirus-infected mononuclear cells from normal subjects or atopic patients with asthma, VEGF induction was significantly higher under the influence of the atopic environment. VEGF was elevated during rhinovirus-associated asthma exacerbations. Conclusion: Rhinovirus infection, a frequent event, induces VEGF production in bronchial epithelial cells and human airways, an effect enhanced in an atopic environment. Rhinovirus-associated, VEGF-mediated angiogenesis may contribute to airway remodeling in asthma.	Univ Athens, Dept Allergy, Pediat Clin 2, Athens, Greece; Natl Ctr Sci Res Demokritos, Lab Cell Proliferat & Ageing, Athens, Greece; Univ Athens, Dept Pulm & Crit Care Med, George P Livanos Lab, Athens, Greece; Univ Patras, Dept Pharm, Mol Pharmacol Lab, Patras, Greece	National & Kapodistrian University of Athens; National Centre of Scientific Research "Demokritos"; National & Kapodistrian University of Athens; University of Patras	Psarras, S (corresponding author), IIBEAA, Fdn Biomed Res Acad Athens, Ctr Basic Res, Cell Biol Lab, Athens, Greece.	spsarras@otenet.gr	Pratsinis, Harris/G-9861-2013; Papadopoulos, Nikolaos/ABE-1774-2021; Bossios, Apostolos/ABH-8262-2020; N.G., Papadopoulos/L-8670-2013; Andreas, Papapetropoulos/AAJ-3089-2020; Bossios, Apostolos/A-1720-2008	Pratsinis, Harris/0000-0001-7550-1975; Papadopoulos, Nikolaos/0000-0002-4448-3468; Bossios, Apostolos/0000-0002-0494-2690; N.G., Papadopoulos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-2508-3872; Papapetropoulos, Andreas/0000-0002-4253-5930				Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Asai K, 2003, CLIN EXP ALLERGY, V33, P595, DOI 10.1046/j.1365-2222.2003.01576.x; Boussat S, 2000, AM J PHYSIOL-LUNG C, V279, pL371, DOI 10.1152/ajplung.2000.279.2.L371; Caine GJ, 2003, EUR J CLIN INVEST, V33, P883, DOI 10.1046/j.1365-2362.2003.01243.x; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282; Chu HW, 2001, CHEST, V120, P416, DOI 10.1378/chest.120.2.416; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fiedler W, 1997, BLOOD, V89, P1870, DOI 10.1182/blood.V89.6.1870; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Ghildyal R, 2005, J MED VIROL, V75, P608, DOI 10.1002/jmv.20315; Griego SD, 2000, J IMMUNOL, V165, P5211, DOI 10.4049/jimmunol.165.9.5211; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hoshino M, 2003, EUR RESPIR J, V21, P804, DOI 10.1183/09031936.03.00082002; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Koyama S, 2002, EUR RESPIR J, V20, P1449, DOI 10.1183/09031936.02.00089802; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee CG, 2000, AM J RESP CELL MOL, V23, P662, DOI 10.1165/ajrcmb.23.5.4188; Lee YC, 2001, J ALLERGY CLIN IMMUN, V107, P1106, DOI 10.1067/mai.2001.115628; Lordan JL, 2002, J IMMUNOL, V169, P407, DOI 10.4049/jimmunol.169.1.407; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; Mosser AG, 2002, J INFECT DIS, V185, P734, DOI 10.1086/339339; Orsida BE, 1999, THORAX, V54, P289, DOI 10.1136/thx.54.4.289; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Papadopoulos NG, 1999, J VIROL METHODS, V80, P179, DOI 10.1016/S0166-0934(99)00045-2; Papadopoulos NG, 2001, CLIN EXP ALLERGY, V31, P1060, DOI 10.1046/j.1365-2222.2001.01112.x; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Parry DE, 2000, J ALLERGY CLIN IMMUN, V105, P692, DOI 10.1067/mai.2000.104785; Psarras S, 2002, ALLERGY, V57, P296; Richter A, 2001, AM J RESP CELL MOL, V25, P385, DOI 10.1165/ajrcmb.25.3.4437; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220, DOI 10.1165/ajrcmb.20.6.3261; Sedgwick JB, 2002, J ALLERGY CLIN IMMUN, V110, P752, DOI 10.1067/mai.2002.128581; Skoner DP, 1996, EUR RESPIR J, V9, P1402, DOI 10.1183/09031936.96.09071402; Tanaka H, 2003, AM J RESP CRIT CARE, V168, P1495, DOI 10.1164/rccm.200306-727OC; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Vignola AM, 2003, CHEST, V123, p417S, DOI 10.1378/chest.123.3_suppl.417S; XATZIPSALTI M, 2005, ALLERGY CLIN IMMUN S, V1, P547; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	42	64	68	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					291	297		10.1016/j.jaci.2005.11.005	http://dx.doi.org/10.1016/j.jaci.2005.11.005			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461129				2022-12-18	WOS:000235687300010
J	Salo, PM; Yin, M; Arbes, SJ; Cohn, RD; Sever, M; Muilenberg, M; Burge, HA; London, SJ; Zeldin, DC				Salo, PM; Yin, M; Arbes, SJ; Cohn, RD; Sever, M; Muilenberg, M; Burge, HA; London, SJ; Zeldin, DC			Dustborne Alternaria alternata antigens in US homes: Results from the National Survey of Lead and Allergens in Housing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alternaria alternata; allergen; antigen; indoor; exposure; asthma; allergy	AIRBORNE FUNGAL SPORES; RESPIRATORY HEALTH; EXPOSURE; OUTDOOR; INDOOR; ASTHMA; SENSITIZATION; CHILDREN; DUST; ENVIRONMENTS	Background: Alternaria alternata is one of the most common fungi associated with allergic disease. However, Alternaria exposure in indoor environments is not well characterized. Objective: The primary goals of this study were to examine the prevalence of Alternaria exposure and identify independent predictors of Alternaria antigen concentrations in US homes. Methods: Data for this cross-sectional study were obtained from the National Survey of Lead and Allergens in Housing. A nationally representative sample of 831 housing units in 75 different locations throughout the United States completed the survey. Information on housing and household characteristics was obtained by questionnaire and environmental assessments. Concentrations of A alternata antigens in dust collected from various indoor sites were assessed with a polyclonal anti-Alternaria antibody assay. Results: Alternaria antigens were detected in most (95% to 99%) of the dust samples. The geometric mean concentration, reflecting the average Alternaria concentration in homes, was 4.88 mu g/g (SEM, 0.13 mu g/g). In the multivariable linear regression analysis, the age of the housing unit, geographic region, urbanization, poverty, family race, observed mold and moisture problems, use of dehumidifier, and presence of cats and dogs were independent predictors of Alternaria antigen concentrations. Less frequent cleaning and smoking indoors also contributed to higher Alternaria antigen levels in homes. Conclusion: Exposure to A alternata antigens in US homes is common. Antigen levels in homes are influenced not only by regional factors but also by residential characteristics. Preventing mold and moisture problems, avoiding smoking indoors, and regular household cleaning may help reduce exposure to Alternaria antigens indoors.	NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Constella Grp Inc, Durham, England; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Cambridge, MA 02138 USA; EMLab Inc, San Bruno, CA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University; Harvard T.H. Chan School of Public Health	Zeldin, DC (corresponding author), NIEHS, NIH, 111 Alexander Dr Mail Drop D2-01, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Zeldin, Darryl C/Y-7091-2018; London, Stephanie/C-3734-2019	Zeldin, Darryl C/0000-0002-2087-7307; London, Stephanie/0000-0003-4911-5290; Sever, Michelle/0000-0002-2435-1214	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES049019, Z01ES025041, ZIAES043012, ZIAES025041, Z01ES025044, Z01ES043012, Z01ES049019] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andersson M, 2003, PEDIAT ALLERG IMM-UK, V14, P100, DOI 10.1034/j.1399-3038.2003.00031.x; Barnes C, 2001, ANN ALLERG ASTHMA IM, V86, P517, DOI 10.1016/S1081-1206(10)62899-2; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; Burge HA, 2000, ENVIRON HEALTH PERSP, V108, P653, DOI 10.2307/3454401; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Bush RK, 2001, J ALLERGY CLIN IMMUN, V107, pS430, DOI 10.1067/mai.2001.113669; Bush RK, 1999, J ALLERGY CLIN IMMUN, V104, P665, DOI 10.1016/S0091-6749(99)70340-4; Chew GL, 2003, ALLERGY, V58, P13, DOI 10.1034/j.1398-9995.2003.00013.x; CHRISTIAN JE, 1991, BUGS MOLD ROT, P59; *COMM ASS ASTHM IN, 2000, CLEAR AIR ASTHM IND, P105; Corden J.M., 2001, AEROBIOLOGIA, V17, P127, DOI [10.1023/A, DOI 10.1023/A:1010876917512, 10.1023/A:1010876917512]; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622, DOI 10.2307/3433608; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P1481, DOI 10.1046/j.1365-2222.1999.00640.x; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455, DOI 10.1164/ajrccm.164.3.2008042; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Fluckiger B, 2000, AEROBIOLOGIA, V16, P393, DOI 10.1023/A:1026573315573; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459, DOI 10.1046/j.1365-2222.1998.00255.x; Green BJ, 2003, J ALLERGY CLIN IMMUN, V111, P285, DOI 10.1067/mai.2003.57; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Hoog G. S. de, 1983, Fungi pathogenic for humans and animals (in three parts). Part A. Biology, P149; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; Leech JA, 2002, J EXPO ANAL ENV EPID, V12, P427, DOI 10.1038/sj.jea.7500244; Leech JA, 1999, CAN J PUBLIC HEALTH, V90, P244, DOI 10.1007/BF03404125; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; MARTYNY JW, 1999, BIOAEROSOLS ASSESSME; Mitakakis T., 1997, AEROBIOLOGIA, V13, P83, DOI [10.1007/BF02694423, DOI 10.1007/BF02694423]; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; Mitakakis TZ, 2000, CLIN EXP ALLERGY, V30, P1733, DOI 10.1046/j.1365-2222.2000.00966.x; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; O'Connor GT, 2004, J ALLERGY CLIN IMMUN, V114, P599, DOI 10.1016/j.jaci.2004.05.064; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626, DOI 10.1016/S0091-6749(98)70170-8; PORTNOY J, 1990, ANN ALLERGY, V65, P109; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P773, DOI 10.1016/0091-6749(93)90197-N; Ren P, 1999, J EXPO ANAL ENV EPID, V9, P560, DOI 10.1038/sj.jea.7500061; RIPE E, 1962, ACTA ALLERGOL, V17, P130, DOI 10.1111/j.1398-9995.1962.tb02935.x; SALO P, 1999, BIOAEROSOLS FUNGI MY, P561; SHAUGHNESSY RJ, 1999, BIOAEROSOLS ASSESSME; Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002; SNELLER MR, 1981, ANN ALLERGY, V46, P30; Sterling DA, 1998, ANN ALLERG ASTHMA IM, V80, P279, DOI 10.1016/S1081-1206(10)62971-7; Takahashi T, 1997, MYCOPATHOLOGIA, V139, P23, DOI 10.1023/A:1006831111595; Thomma BPHJ, 2003, MOL PLANT PATHOL, V4, P225, DOI [10.1046/j.1364-3703.2003.00173.x, 10.1046/J.1364-3703.2003.00173.X]; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527, DOI 10.1289/ehp.02110527; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	48	64	64	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					623	629		10.1016/j.jaci.2005.05.030	http://dx.doi.org/10.1016/j.jaci.2005.05.030			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IE	16159634	Bronze, Green Accepted			2022-12-18	WOS:000235686500024
J	Platts-Mills, JA; Custis, NJ; Woodfolk, JA; Platts-Mills, TAE				Platts-Mills, JA; Custis, NJ; Woodfolk, JA; Platts-Mills, TAE			Airborne endotoxin in homes with domestic animals: Implications for cat-specific tolerance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airborne endotoxin; cats; dogs	MODIFIED TH2 RESPONSE; HOUSE-DUST ENDOTOXIN; ION-CHARGING DEVICE; ALLERGIC SENSITIZATION; HIGH EXPOSURE; CHILDREN; ASTHMA; MITE; SCHOOL; RISK	Background: Although endotoxin is known to increase symptoms in allergic individuals, early exposure might decrease sensitization. Similarly, the presence of an animal in the home has been associated with decreased sensitization to animal allergens. It has been suggested that the effect of animals could be explained by increased endotoxin exposure. Objective: We sought to investigate the effects of domestic animals on airborne endotoxin. Methods: By using a silent particle collector, air was sampled over 24 hours in homes with or without animals. The total volume sampled was approximately 1000 m 3, which provides quantities of allergen and endotoxin that can easily be measured with standard assays. Results: The quantity of endotoxin ranged from less than 0.5 to more than 500 pg/m(3), whereas cat and dog allergen ranged from less than 0.002 to more than 5 ng/m(3). Overall, the quantity of airborne endotoxin was not higher in homes with at least one animal. However, airborne endotoxin levels were significantly lower in homes with a cat compared with homes with a dog (P < .001). In keeping with this, there was a significant correlation between airborne Can f 1 and airborne endotoxin (r = 0.509 P < .01) but not between endotoxin and Fel d 1 (r = 0.17, P = .27). Conclusions: The results demonstrate that endotoxin is present in the air of almost all homes. Although higher levels were seen in homes with a dog, similar levels might be present in homes with no animals. The results argue that the effects of cat ownership cannot be explained by increased exposure to endotoxin.	Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	University of Virginia	Platts-Mills, TAE (corresponding author), Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, R37AI020565, P01AI050989] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, P01-AI-50989] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexis NE, 2004, J ALLERGY CLIN IMMUN, V114, P1325, DOI 10.1016/j.jaci.2004.09.002; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Custis NJ, 2003, CLIN EXP ALLERGY, V33, P986, DOI 10.1046/j.1365-2222.2003.01706.x; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1111/j.1365-2222.1996.tb00521.x; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; El Sharif N, 2004, ALLERGY, V59, P623, DOI 10.1111/j.1398-9995.2004.00441.x; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Lewis SA, 2001, J ALLERGY CLIN IMMUN, V107, P615, DOI 10.1067/mai.2001.113523; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pacheco KA, 2003, AM J RESP CRIT CARE, V167, P983, DOI 10.1164/rccm.2112062; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills JA, 2005, CONTEMP TOP LAB ANIM, V44, P12; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Reefer AJ, 2004, J IMMUNOL, V172, P2763, DOI 10.4049/jimmunol.172.5.2763; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; SCHWEITZER JB, 2003, COMPARATIVE MED, V53, P486; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5	30	64	67	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					384	389		10.1016/j.jaci.2005.05.012	http://dx.doi.org/10.1016/j.jaci.2005.05.012			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083794				2022-12-18	WOS:000235686400022
J	Marogna, M; Spadolini, L; Massolo, A; Canonica, W; Passalacqua, G				Marogna, M; Spadolini, L; Massolo, A; Canonica, W; Passalacqua, G			Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: A 3-year randomized controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sublingual immunotherapy; birch; rhinitis; asthma; pulmonary function; eosinophil	CONTROLLED-TRIAL; BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY ALLERGY; RHINOCONJUNCTIVITIS; METHACHOLINE; ASTHMA; RESPONSIVENESS; INFLAMMATION; EFFICACY; CHILDREN	Background: Sublingual immunotherapy (SLIT) has been proved effective in allergic rhinitis, but there are few studies assessing its effects on inflammation and on the lower airways. Objective: We sought to evaluate at the same time the effects of SLIT on rhinitis symptoms, nasal inflammation, and lower airways function in patients with birch pollinosis. Methods: Adult patients with rhinitis and asthma monosensitized to birch were evaluated during a run-in pollen season and then randomized to receive openly either drugs alone or drugs plus SLIT and reevaluated in the subsequent 4 pollen seasons. Rhinitis symptoms and consumption of bronchodilators were assessed by means of diary card. A nasal smear for eosinophil count was carried out in and out of pollen seasons, and pulmonary function tests with methacholine challenge were performed at each season. Results: Of 79 enrolled patients, 27 dropped out, with a significantly higher rate of dropouts in the control group. There was a decrease in symptoms and bronchodilator use in the SLIT group versus the control group, becoming significant at the second and third pollen seasons, respectively (P < .01 at all times). Nasal eosinophils decreased significantly in the active group, starting from the third pollen season (P < .01). In the SLIT group a significant increase in FEV1, specific airways conductance, and maximal expiratory flow at 25% of forced vital capacity was seen starting from the second year and was associated with an increase in the methacholine threshold dose (P < .01). The differences were significant also at the intragroup comparison over time. Conclusion: SLIT achieved a significant clinical benefit in birch pollinosis, reduced the eosinophil infiltration in nasal mucosa, and significantly improved pulmonary function during the pollen seasons.	Macchi Hosp Fdn, Pneumol Unit, Varese, Italy; Anallergo SpA, Dept Med, Florence, Italy; Univ Florence, Inter Univ Ctr Wildlife Res & Environm Improvemen, I-50121 Florence, Italy	Ospedale Circolo & Fondazione Macchi; University of Florence; University of Florence	Passalacqua, G (corresponding author), Univ Genoa, DIMI, L R Benzi 10, I-16132 Genoa, Italy.	passalacqua@unige.it	Massolo, Alessandro/AAO-5344-2021; canonica, giorgio walter/ABF-2037-2020; Massolo, Alessandro/I-3437-2012	canonica, giorgio walter/0000-0001-8467-2557; Massolo, Alessandro/0000-0002-6333-4281				Bousquet J, 2005, ALLERGY, V60, P1, DOI 10.1111/j.1398-9995.2005.00700.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; Ciprandi G, 1999, CLIN EXP ALLERGY, V29, P49, DOI 10.1046/j.1365-2222.1999.00012.x; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Good P, 2000, PERMUTATION TESTS PR, V2; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048, DOI 10.1164/ajrccm.162.6.9909087; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Lombardi C, 2001, ALLERGY, V56, P989, DOI 10.1034/j.1398-9995.2001.00181.x; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; *NIH, 1997, NIH PUBL; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3, DOI 10.1016/S1081-1206(10)61440-8; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; Siegel S., 1988, NONPARAMETRIC STAT B, V2nd; Sokal R.R, 1995, INTRO BASIC STAT; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Wilson DR, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002893; [No title captured]; [No title captured]	27	64	69	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1184	1188		10.1016/j.jaci.2005.02.031	http://dx.doi.org/10.1016/j.jaci.2005.02.031			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940132				2022-12-18	WOS:000229815400012
J	Gao, PS; Mathias, RA; Plunkett, B; Togias, A; Barnes, KC; Beaty, TH; Huang, SK				Gao, PS; Mathias, RA; Plunkett, B; Togias, A; Barnes, KC; Beaty, TH; Huang, SK			Genetic variants of the T-cell immunoglobulin mucin 1 but not the T-cell immunoglobulin mucin 3 gene are associated with asthma in an African American population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; single nucleotide polymorphism; T-cell immnoglobulin mucin; haplotype; hepatitis A	FAMILY; DISEASE; IDENTIFICATION; INFORMATION; IMMUNITY; REGIONS; TESTS; TIM-1; LOCI	Background: The T-cell immunoglobulin mucin (TIM) proteins and their genetic variants have been suggested to play a role in regulating allergic diseases. Objective: Genetic association of the sequence variants for TIM-1 and TIM-3 genes with asthma in an African American population was investigated. Methods: Both case-control and family-based association analyses were performed for a total of 7 polymorphisms, including 3 single nucleotide polymorphism (SNPs) and I insertion/deletion polymorphism in the TIM-1 and 3 SNPs in the TIM-3 genes. The exposure to hepatitis A virus as judged by seropositivity was also examined. Results: In the case-control design, the frequencies of the TT genotype for SNP rs2277025 and the homozygous deletion variant (157deIMTTTVP) in the fourth exon of the TIM-1 gene were higher among patients with patients with asthma compared with the controls (odds ratio [OR], 2.779, P =.016; and OR, 3.09, P =.022, respectively). This association was substantiated by haplotype analysis of these and 2 additional SNPs (OR, 2.48; P =.004), and also by family-based tests for the allele and haplotype carrying 157deIMTTTVP (P =.009 and P =.048, respectively). Furthermore, this association seems to exist even in the hepatitis A virus-seronegative subjects in our data. None of the 3 variants in TIM-3 genes yielded significant association with either asthma or asthma-related phenotypes. Conclusion: Our findings suggest that the genetic variants of the TIM-1 but not the TIM-3 gene contribute to asthma susceptibility in this African-American population.	Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; NHGRI, Inherited Dis Res Branch, NIH, Bethesda, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Gao, PS (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	pgao1@jhmi.edu	Huang, Shau-Ku/F-5509-2010		NHLBI NIH HHS [HL-49612] Funding Source: Medline; NIAID NIH HHS [AI-52468] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL049612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052468] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barker DL, 2004, GENOME RES, V14, P901, DOI 10.1101/gr.1949704; Chae SC, 2003, HUM IMMUNOL, V64, P1177, DOI 10.1016/j.humimm.2003.09.011; Cookson W, 2002, IMMUNOL REV, V190, P195, DOI 10.1034/j.1600-065X.2002.19015.x; Fallin D, 2000, AM J HUM GENET, V67, P947, DOI 10.1086/303069; Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295; Huang JL, 2004, HUM MOL GENET, V13, P2691, DOI 10.1093/hmg/ddh279; Huang SK, 2003, HUM GENET, V113, P71, DOI 10.1007/s00439-003-0934-4; Kuchroo VK, 2003, NAT REV IMMUNOL, V3, P454, DOI 10.1038/nri1111; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; McIntire JJ, 2004, SPRINGER SEMIN IMMUN, V25, P335, DOI 10.1007/s00281-003-0141-3; McIntire JJ, 2003, NATURE, V425, P576, DOI 10.1038/425576a; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Noguchi E, 2003, GENES IMMUN, V4, P170, DOI 10.1038/sj.gene.6363935; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; Rohde K, 2001, HUM MUTAT, V17, P289, DOI 10.1002/humu.26; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; Silberstein E, 2003, J VIROL, V77, P8765, DOI 10.1128/JVI.77.16.8765-8774.2003; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589	21	64	72	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					982	988		10.1016/j.jaci.2005.01.035	http://dx.doi.org/10.1016/j.jaci.2005.01.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867855	Bronze			2022-12-18	WOS:000229055100013
J	Saadat, M; Saadat, I; Saboori, Z; Emad, A				Saadat, M; Saadat, I; Saboori, Z; Emad, A			Combination of CC16, GSTM1, and GSTT1 genetic polymorphisms is associated with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							STRESS; RISK		Shiraz Univ, Coll Sci, Dept Biol, Shiraz 71454, Iran; Khatam Univ, Tehran, Iran; Shiraz Univ Med Sci, Dept Internal Med, Div Resp Dis, Shiraz, Iran	Shiraz University; Shiraz University of Medical Science	Saadat, M (corresponding author), Shiraz Univ, Coll Sci, Dept Biol, Shiraz 71454, Iran.			Emad, Ali Farid/0000-0003-1398-9914; Saadat, Mostafa/0000-0002-0021-4055; Saadat, Iraj/0000-0002-8169-4707				BAMERS PJ, 1990, FREE RADIC BIOL MED, V9, P235; Emad A, 1997, CHEST, V112, P734, DOI 10.1378/chest.112.3.734; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437, DOI 10.1164/ajrccm.161.5.9903006; Gao PS, 1998, HUM GENET, V103, P57, DOI 10.1007/s004390050783; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Ivaschenko TE, 2002, J MOL MED, V80, P39, DOI 10.1007/s001090100274; Laing IA, 1998, J MED GENET, V35, P463, DOI 10.1136/jmg.35.6.463; Laing IA, 2000, AM J RESP CRIT CARE, V161, P124, DOI 10.1164/ajrccm.161.1.9904073; Mango GW, 1998, AM J PHYSIOL-LUNG C, V275, pL348, DOI 10.1152/ajplung.1998.275.2.L348; Soutar A, 1997, THORAX, V52, P166, DOI 10.1136/thx.52.2.166	10	64	64	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					996	998		10.1016/j.jaci.2004.02.007	http://dx.doi.org/10.1016/j.jaci.2004.02.007			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15148962				2022-12-18	WOS:000221269000027
J	Bender, BG; Berning, S; Dudden, R; Milgrom, H; Tran, ZV				Bender, BG; Berning, S; Dudden, R; Milgrom, H; Tran, ZV			Sedation and performance impairment of diphenhydramine and second-generation antihistamines: A meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; antihistamines; diphenhydramine; meta-analysis; sedation	CENTRAL-NERVOUS-SYSTEM; DRIVING PERFORMANCE; SLEEPINESS; YOUNG	Background: Antihistamines are among the most frequently used medications in the United States. Despite dramatically higher cost, second-generation antihistamines are replacing diphenhydramine because of the perception that they are not constrained by its sedating effects. Objective: We sought to examine, through meta-analytic procedures, the collective evidence regarding the sedating and performance-impairing effects of diphenhydramine relative to placebo and second-generation antihistamines. Methods: A search that began with the MEDLINE database was limited to those studies that included patients with atopic disease and control subjects, were blinded and randomized clinical trials, objectively examined alertness and psychomotor performance, reported means and variances, and were written in English. Information was systematically abstracted from the resulting 18 articles, and effect size was calculated. Results: Diphenhydramine impaired performance relative to placebo control and second-generation antihistamines, including acrivastine, astemizole, cetirizine, fexofenadine, loratadine, and terfenadine. However, results were quite varied, the average sedating effect of diphenhydramine was modest, and in some instances results of tests of performance in the diphenhydramine group showed less sedation than in the control or second-generation antihistamine groups. A significant (P < .05) average effect size indicated a mild sedating effect caused by second-generation antihistamines in comparison with placebo. Conclusion: The absence of a consistent finding of diphenhydramine-induced sedation is surprising given that most studies have been designed to increase the probability of this outcome, including administering a 50-mg dose. On the basis of this meta-analysis of performance-impairment trials, a clear and consistent distinction between sedating and nonsedating antihistamines does not exist.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	National Jewish Health	Bender, BG (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.							Adams P F, 1999, Vital Health Stat 10, P1; Bender BG, 2001, J PEDIATR-US, V138, P656, DOI 10.1067/mpd.2001.112647; BERLINGER WG, 1982, CLIN PHARMACOL THER, V32, P387, DOI 10.1038/clpt.1982.176; CARRUTHERS SG, 1978, CLIN PHARMACOL THER, V23, P375; GEBHART F, 2002, DRUG TOPICS, V6, P25; Hedges L.V., 2014, STAT METHODS META AN; Hindmarch I, 1999, BRIT J CLIN PHARMACO, V48, P200, DOI 10.1046/j.1365-2125.1999.00993.x; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; Kelley G A, 2001, Prev Cardiol, V4, P40, DOI 10.1111/j.1520-037X.2001.00812.x; MATTILA MJ, 1986, EUR J CLIN PHARMACOL, V31, P291, DOI 10.1007/BF00981126; *NRC COMM APPL THE, 1992, COMB INF STAT ISS OP; PHILPOT EE, 1993, MIL MED, V158, P654, DOI 10.1093/milmed/158.10.654; RAMAEKERS JG, 1994, EUR J CLIN PHARMACOL, V47, P261, DOI 10.1007/BF02570506; ROTH T, 1987, J ALLERGY CLIN IMMUN, V80, P94, DOI 10.1016/S0091-6749(87)80197-5; Sands L, 1997, AM J GERIAT PSYCHIAT, V5, P156; Scavone JM, 1998, J CLIN PHARMACOL, V38, P603, DOI 10.1002/j.1552-4604.1998.tb04466.x; SCHWEITZER PK, 1994, J ALLERGY CLIN IMMUN, V94, P716, DOI 10.1016/0091-6749(94)90179-1; Simons FER, 1995, ANN ALLERG ASTHMA IM, V75, P507; Simons FER, 1996, CLIN EXP ALLERGY, V26, P1092; THARION WJ, 1994, NEUROPSYCHOBIOLOGY, V29, P97, DOI 10.1159/000119069; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; Vuurman EFPM, 1996, ANN ALLERG ASTHMA IM, V76, P247, DOI 10.1016/S1081-1206(10)63435-7; Weiler JM, 2000, ANN INTERN MED, V132, P354, DOI 10.7326/0003-4819-132-5-200003070-00004; Wilken JA, 2002, ANN ALLERG ASTHMA IM, V89, P372, DOI 10.1016/S1081-1206(10)62038-8; WITEK TJ, 1995, ANN ALLERG ASTHMA IM, V74, P419; 1999, MARKETLETTER, V58	27	64	69	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					770	776		10.1067/mai.2003.1408	http://dx.doi.org/10.1067/mai.2003.1408			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704356				2022-12-18	WOS:000182258500016
J	Zheng, T; Zhu, Z; Liu, W; Lee, CG; Chen, QS; Homer, RJ; Elias, JA				Zheng, T; Zhu, Z; Liu, W; Lee, CG; Chen, QS; Homer, RJ; Elias, JA			Cytokine regulation of IL-13R alpha 2 and IL-13R alpha 1 in vivo and in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						interleukin 13; asthma; T(H)2 cytokine; IL-13 receptor; IL-4; IL-10; IL-13 transgenic mouse	IL-13 RECEPTOR ALPHA-2; INTERLEUKIN-13 RECEPTOR; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; B-CELLS; LUNG; CLONING; OVEREXPRESSION; INFLAMMATION; MECHANISM	Background: IL-13 signals via a high-affinity receptor that includes IL-4Ralpha and IL-13Ralpha1 and binds to the decoy receptor IL-13Ralpha2. The processes that regulate the expression of these receptor subunits, however, are poorly defined. Objective: These studies were designed to define the regulation of IL-13R components by T(H)2 and T(H)1 cytokines in vivo and in vitro. Methods: Northern analysis, in situ hybridization, RT-PCR analysis, and immunoprecipitation were used to define the expression of IL-13Ralpha1 and IL-13Ralpha2 in lungs from lung targeted overexpression mice and lung fragments and cells in culture. Results: IL-13Ralpha2 and IL-13Ralpha1 mRNA were detected at modest levels in lungs from control mice. In contrast, transgenic IL-13 caused a marked increase in IL-13Ralpha2 and IL-13Ralpha1 mRNA; this was most prominent in airway epithelial cells and macrophages. The effects of IL-13 on IL-13Ralpha2 were associated with comparable increases in protein production and were mediated by a blood leukocyte-independent and IL-4Ralpha-dependent mechanism. IL-13 stimulation of IL-13Ralpha1 was mediated via a blood leukocyte-dependent and partially IL-4Ralpha-dependent pathway. These effects were not specific for IL-13, because transgenic IL-4, IL-10, and IFN-gamma also stimulated IL-13Ra2 mRNA accumulation while stimulating-not altering and inhibiting-IL-13Ralpha1. mRNA accumulation, respectively. These regulatory events were mediated, at least in part, by direct effects of these cytokines, because IL-13, IL-4, and IFN-gamma had similar effects on IL-13Ralpha2 and/or IL-13Ralpha1 in epithelial cells and macrophages in in vitro culture. Conclusion: IL-13Ralpha2 and IL-13Ralpha1 are highly regulated in vivo and in vitro. These regulatory events might control IL-13 responses at sites of inflammation.	Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; VACT Hlt Care Syst, Pathol & Lab Med Serv, West Haven, CT USA	Yale University; Yale University	Elias, JA (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, 333 Cedar St 105 LCI,POB 208057, New Haven, CT 06520 USA.		homer, robert/P-3884-2019; Lee, Chun Geun/AAC-2838-2021	homer, robert/0000-0002-2055-5885; Lee, Chun Geun/0000-0002-9514-3658	NHLBI NIH HHS [R01-HL-66571, P50-HL-56389, R01-HL-64242, R01-HL-61904] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061904, R01HL066571, P50HL056389, R01HL064242] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Andrews RP, 2001, J IMMUNOL, V166, P1716, DOI 10.4049/jimmunol.166.3.1716; Blease K, 2001, J IMMUNOL, V166, P5219, DOI 10.4049/jimmunol.166.8.5219; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; Donaldson DD, 2001, PROG RESPIR RES, V31, P260; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Ford JG, 2001, J IMMUNOL, V167, P1769, DOI 10.4049/jimmunol.167.3.1769; Gao PS, 2000, CLIN EXP ALLERGY, V30, P1672, DOI 10.1046/j.1365-2222.2000.01011.x; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Johnson TR, 1999, J VIROL, V73, P8485, DOI 10.1128/JVI.73.10.8485-8495.1999; Kawakami K, 2001, J EXP MED, V194, P1743, DOI 10.1084/jem.194.12.1743; Kawakami M, 2001, ONCOL RES, V12, P459, DOI 10.3727/096504001108747468; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; Lee CG, 2002, J BIOL CHEM, V277, P35466, DOI 10.1074/jbc.M206395200; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Minty A, 1997, EUR CYTOKINE NETW, V8, P203; Murata T, 1998, INT J MOL MED, V1, P551; Ohshima K, 2001, HISTOPATHOLOGY, V38, P368, DOI 10.1046/j.1365-2559.2001.01083.x; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Rahaman SO, 2002, CANCER RES, V62, P1103; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yoon HJ, 1999, J IMMUNOL, V162, P7461; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; ZHENG T, 1994, J IMMUNOL, V153, P4742; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu Z, 2002, J IMMUNOL, V168, P2953, DOI 10.4049/jimmunol.168.6.2953; Zhu Z, 2001, J BIOL CHEM, V276, P25222, DOI 10.1074/jbc.M101512200; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	40	64	71	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					720	728		10.1067/mai.2003.1383	http://dx.doi.org/10.1067/mai.2003.1383			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	667WW	12704349				2022-12-18	WOS:000182258500008
J	Kuo, IC; Cheong, N; Trakultivakorn, M; Lee, BW; Chua, KY				Kuo, IC; Cheong, N; Trakultivakorn, M; Lee, BW; Chua, KY			An extensive study of human IgE cross-reactivity of Blo t 5 and Der p 5	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Blo t 5; cross-reactivity; Der p 5; IgE epitope	DUST-MITE ALLERGENS; DERMATOPHAGOIDES-PTERONYSSINUS; ASTHMATIC-PATIENTS; DOMESTIC MITES; ANTIBODY-BINDING; TROPICALIS; SENSITIZATION; IDENTIFICATION; CHILDREN; EPITOPES	Dual sensitization by Blomia tropicalis and Dermatophagoides pteronyssinus mites is common in tropical and subtropical countries. The human IgE cross-reactivity between clinical important group 5 allergens, Blo t 5 and Der p 5, remains controversial. Objective: This study was undertaken to assess the levels of the IgE cross-reactivity between Blo t 5 and Der p 5 by using sera from a large cohort of asthmatic children in subtropical and tropical countries. Methods: Purified recombinant Blo 15 and Der p 5 were produced in Pichia pastoris and tested against sera from 195 asthmatic children. The IgE cross-reactivity was examined by direct, inhibitory and competitive human IgE enzyme-linked immunosorbent assay as well as skin prick tests. Results: The Blo t 5 IgE responses were 91.8% (134 of 146) and 73.5% (36 of 49) for Taiwanese and Malaysian sera, respectively. The Blo t 5 specific IgE titers were significantly higher than those of Der p 5 (P <.02). The correlation of IgE reactivity between Blo t 5 and Der p 5 was low, and only limited cross-reactivity was observed. This was further confirmed by the dose-response inhibition studies. Skin prick tests performed on asthmatic children in Thailand also showed differential IgE response to Blo 15 and Der p 5. Conclusion: By using a large panel of asthmatic sera and a combination of in vitro and in vivo assays, the major allergen of B tropicalis in tropical and subtropical regions, Blo t 5, exhibits low levels of IgE cross-reactivity with homologous Der p 5. These findings suggest that highly specific clinical reagents are necessary for precise diagnosis and immunotherapeutic treatment of sensitization to group 5 mite allergens.	Natl Univ Singapore, Fac Med, Dept Paediat, Singapore 119074, Singapore; Natl Univ Singapore, Ctr Bioproc Technol, Singapore 119074, Singapore; Chiang Mai Univ, Fac Med, Dept Paediat, Chiang Mai 50000, Thailand	National University of Singapore; National University of Singapore; Chiang Mai University	Chua, KY (corresponding author), Natl Univ Singapore, Fac Med, Dept Paediat, 5 Lower Kent Ridge Rd, Singapore 119074, Singapore.							Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1042, DOI 10.1016/0091-6749(93)90218-5; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; Arruda LK, 1997, AM J RESP CRIT CARE, V155, P343, DOI 10.1164/ajrccm.155.1.9001334; ARRUDA LK, 1995, INT ARCH ALLERGY IMM, V107, P456, DOI 10.1159/000237080; Baratawidjaja IR, 1999, ASIAN PAC J ALLERGY, V17, P9; Caraballo L, 1998, J INVEST ALLERG CLIN, V8, P281; Caraballo L, 1996, J ALLERGY CLIN IMMUN, V98, P573, DOI 10.1016/S0091-6749(96)70091-X; Caraballo L, 1998, INT ARCH ALLERGY IMM, V117, P38, DOI 10.1159/000023988; Chew FT, 1999, ALLERGY, V54, P1150, DOI 10.1034/j.1398-9995.1999.00050.x; Chew FT, 1999, CLIN EXP ALLERGY, V29, P982, DOI 10.1046/j.1365-2222.1999.00543.x; FERNANDEZCALDAS E, 1993, J INVEST ALLERG CLIN, V3, P245; FernandezCaldas E, 1997, J INVEST ALLERG CLIN, V7, P402; Ferrandiz R, 1996, ALLERGY, V51, P501, DOI 10.1111/j.1398-9995.1996.tb04656.x; Ferrandiz R, 1998, INT ARCH ALLERGY IMM, V116, P206, DOI 10.1159/000023946; Goh LT, 2001, BIOTECHNOL LETT, V23, P661, DOI 10.1023/A:1010323611039; HAGEHAMSTEN M, 1995, CLIN EXP ALLERGY, V25, P905; Hakkaart GAJ, 1998, INT ARCH ALLERGY IMM, V115, P150, DOI 10.1159/000023895; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; Holt PG, 1999, NATURE, V402, pB12; Jimenez S, 1999, J ALLERGY CLIN IMMUN, V103, pS185; Johansson E, 1997, CLIN EXP ALLERGY, V27, P691, DOI 10.1111/j.1365-2222.1997.tb01198.x; Kuo IC, 1999, ASIAN PAC J ALLERGY, V17, P179; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P208, DOI 10.1080/00039899709602888; Li CS, 1996, J ALLERGY CLIN IMMUN, V97, P857, DOI 10.1016/S0091-6749(96)80166-7; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; LLERENA LP, 1991, J ALLERGY CLIN IMMUN, V88, P943, DOI 10.1016/0091-6749(91)90252-J; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; Morgan MS, 1996, ANN ALLERG ASTHMA IM, V77, P386, DOI 10.1016/S1081-1206(10)63337-6; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; Shek LPC, 1999, J ALLERGY CLIN IMMUN, V103, pS26; STANALAND BE, 1994, J ALLERGY CLIN IMMUN, V94, P452, DOI 10.1016/0091-6749(94)90200-3; Thomas WR, 1998, ALLERGY, V53, P821, DOI 10.1111/j.1398-9995.1998.tb03987.x; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; Tsai JJ, 1998, INT ARCH ALLERGY IMM, V115, P144, DOI 10.1159/000023894; Tsai LC, 2000, ALLERGY, V55, P141, DOI 10.1034/j.1398-9995.2000.00315.x; Yi FC, 2002, CLIN EXP ALLERGY, V32, P1203, DOI 10.1046/j.1365-2745.2002.01449.x	39	64	70	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					603	609		10.1067/mai.2003.167	http://dx.doi.org/10.1067/mai.2003.167			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642844				2022-12-18	WOS:000181639500025
J	McCusker, C; Chicoine, M; Hamid, Q; Mazer, B				McCusker, C; Chicoine, M; Hamid, Q; Mazer, B			Site-specific sensitization in a murine model of allergic rhinitis: Role of the upper airway in lower airways disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; animal models	BRONCHIAL RESPONSIVENESS; IMMUNOGLOBULIN-E; MAST-CELLS; INFLAMMATION; ASTHMA; HYPERRESPONSIVENESS; EXPOSURE; ANTIGEN; IGE; EOSINOPHILIA	Background: Allergic rhinitis (AR) is the most common atopic disease with strong links to asthma. We have developed a murine model of AR to study nasal, bronchial, and systemic immune response to local allergen stimulation. Objectives: The purpose of this study was to develop and characterize a murine model of AR. Methods: Six- to 8-week-old BALB/c mice were sensitized by means of intranasal (local) application of ovalbumin (OVA) or systemic intraperitoneal injection. They were then challenged with intranasal OVA, and allergic response was assessed. Results: Intranasal particle deposition was found to be exclusively in the nares. All sensitized animals showed increased levels of OVA-specific serum IgE and IgG after challenge, although the timing to maximal response varied with the route and dose of allergen used. Histology of the upper and lower airways showed marked eosinophilic infiltration, and analysis of bronchoalveolar lavage fluid showed increased IL-5 and PMN infiltrates after challenge. Conclusion: Using exclusive local sensitization and challenge of mouse nares, we were able to demonstrate inflammatory changes in both the upper and lower airways, even though, distribution of allergen particles appeared to be only in the nares of these animals. This provides further evidence for the importance of the upper airway in lower airways disease. We have shown that the route of administration greatly affects the characteristics of the subsequent immune responses.	Montreal Childrens Hosp, Div Allergy & Immunol, Res Inst, Montreal, PQ H3H 1P3, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ H3H 1P3, Canada	McGill University; McGill University	McCusker, C (corresponding author), McGill Univ, Meakins Christie Labs, 2300 Tupper St, Montreal, PQ H3H 1P3, Canada.							Almansouri HMSH, 1996, AM J MED SCI, V312, P202, DOI 10.1097/00000441-199611000-00002; Alvarez MJ, 2000, ALLERGY, V55, P531, DOI 10.1034/j.1398-9995.2000.00534.x; Alvarez MJ, 2000, ALLERGY, V55, P355, DOI 10.1034/j.1398-9995.2000.00312.x; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Barnes Kathleen C., 2000, Journal of Allergy and Clinical Immunology, V106, pS192; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051, DOI 10.1164/ajrccm.161.6.9906121; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150, DOI 10.1164/ajrccm.160.4.9806034; Campanella SG, 2001, PEDIATR PULM, V31, P165, DOI 10.1002/1099-0496(200102)31:2<165::AID-PPUL1025>3.0.CO;2-O; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; Donovan CE, 1999, THORAX, V54, P938, DOI 10.1136/thx.54.10.938; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Gleich GJ, 1997, P NATL ACAD SCI USA, V94, P2101, DOI 10.1073/pnas.94.6.2101; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Hellings PW, 2001, CLIN EXP ALLERGY, V31, P782, DOI 10.1046/j.1365-2222.2001.01081.x; Herz U, 1996, IMMUNOL CELL BIOL, V74, P209, DOI 10.1038/icb.1996.30; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325, DOI 10.1165/ajrcmb.16.3.9070618; Hurwitz B, 1997, J ASTHMA, V34, P427, DOI 10.3109/02770909709055385; Kips JC, 2000, AM J RESP CRIT CARE, V162, pS66, DOI 10.1164/ajrccm.162.supplement_2.ras-2; Kobayashi T, 2000, J IMMUNOL, V164, P3855, DOI 10.4049/jimmunol.164.7.3855; Lack G, 2001, J ALLERGY CLIN IMMUN, V108, pS9, DOI 10.1067/mai.2001.115562; Murphy Shirley, 1993, Current Opinion in Pediatrics, V5, P255; Okano M, 1999, ALLERGY, V54, P593, DOI 10.1034/j.1398-9995.1999.00063.x; Okano M, 2000, ALLERGY, V55, P723, DOI 10.1034/j.1398-9995.2000.00429.x; Passalacqua G, 2000, THORAX, V55, pS26, DOI 10.1136/thorax.55.suppl_2.S26; Polosa R, 2000, EUR RESPIR J, V15, P30, DOI 10.1034/j.1399-3003.2000.15a07.x; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; Saito H, 2002, J IMMUNOL, V168, P3017, DOI 10.4049/jimmunol.168.6.3017; Saito H, 2001, IMMUNOLOGY, V104, P226, DOI 10.1046/j.1365-2567.2001.01253.x; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65, DOI 10.1164/ajrccm.149.1.8111600; Sato J, 1999, INT ARCH ALLERGY IMM, V119, P197, DOI 10.1159/000024195; Schramm CM, 2000, AM J RESP CELL MOL, V22, P218, DOI 10.1165/ajrcmb.22.2.3620; Spector SL, 1997, J ALLERGY CLIN IMMUN, V99, pS773, DOI 10.1016/S0091-6749(97)70126-X; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Temelkovski J, 1998, THORAX, V53, P849, DOI 10.1136/thx.53.10.849; Togias A, 2000, J ALLERGY CLIN IMMUN, V105, pS599, DOI 10.1067/mai.2000.106885; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Tsitoura DC, 2000, J ALLERGY CLIN IMMUN, V106, P239; Van Cauwenberge P, 2000, THORAX, V55, pS20, DOI 10.1136/thorax.55.suppl_2.S20; van de Rijn M, 1998, J ALLERGY CLIN IMMUN, V102, P65, DOI 10.1016/S0091-6749(98)70056-9; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Wilder JA, 1999, AM J RESP CELL MOL, V20, P1326, DOI 10.1165/ajrcmb.20.6.3561; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Yiamouyiannis CA, 1999, AM J PATHOL, V154, P1911, DOI 10.1016/S0002-9440(10)65449-1; Zuberi RI, 2000, J IMMUNOL, V164, P2667, DOI 10.4049/jimmunol.164.5.2667	49	64	73	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					891	898		10.1067/mai.2002.130048	http://dx.doi.org/10.1067/mai.2002.130048			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	624TL	12464956				2022-12-18	WOS:000179777400012
J	Hirahara, K; Tatsuta, T; Takatori, T; Ohtsuki, M; Kirinaka, H; Kawaguchi, J; Serizawa, N; Taniguchi, Y; Saito, S; Sakaguchi, M; Inouye, S; Shiraishi, A				Hirahara, K; Tatsuta, T; Takatori, T; Ohtsuki, M; Kirinaka, H; Kawaguchi, J; Serizawa, N; Taniguchi, Y; Saito, S; Sakaguchi, M; Inouye, S; Shiraishi, A			Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Japanese cedar pollen; allergen; Cry j 1; Cry j 2; peptide; T-cell determinant; epitope; immunotherapy; IgE	CRYPTOMERIA-JAPONICA POLLEN; CRY-J-1; EPITOPES; IDENTIFICATION; POLLINOSIS; RESPONSES; MICE	Background: Peptide immunotherapy is a new approach to treating allergic diseases, but a therapeutic peptide for Japanese cedar pollinosis has not yet been developed. Objective: The aim or this study is to prepare and preclinically evaluate a hybrid peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. Methods: The recombinant hybrid peptide was prepared after immunodominance of 7 T-cell determinants was confirmed by means of PBMC proliferation assay in 113 volunteers with pollinosis. The hybrid peptide was compared with a mixture of the 7 T-cell determinants in a dose-dependent PBMC proliferation assay in 6 volunteers with pollinosis. PBMC proliferation and binding activity of serum IgE antibody against the hybrid peptide, Cry j 1, and Cry j 2 were investigated in 48 volunteers with pollinosis. Results: The hybrid peptide induced T-cell proliferation with an average 100-fold lower concentration than a mixture of the 7 peptides. PBMCs from 44 (92 %) of 48 volunteers proliferated against the hybrid peptide, with significant correlation (r = 0.87) in T-cell proliferation against Cry j 1 and Cry j 2. No serum IgE antibodies specific to Cry j 1 or Cry j 2 bound to the hybrid peptide. Conclusion: A hybrid peptide comprising 7 T-cell determinants has the potential for inducing T-cell proliferative responses that is superior to the potential of a mixture of the T-cell determinants and comparable with that of Cry j 1 and Cry j 2. The hybrid peptide will be of use in specific immunotherapy against Japanese cedar pollinosis.	Sankyo Co Ltd, Neurosci & Immunol Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; Hayashibara Biochem Labs Inc, Okayama, Japan; Jikei Univ, Sch Med, Tokyo, Japan; Natl Inst Infect Dis, Tokyo, Japan	Daiichi Sankyo Company Limited; Hayashibara Biochemical Laboratories, Inc.; Jikei University; National Institute of Infectious Diseases (NIID)	Shiraishi, A (corresponding author), Sankyo Co Ltd, Neurosci & Immunol Res Labs, Shinagawa Ku, 2-58 Hiromachi 1 Chome, Tokyo 1408710, Japan.		Inouye, Sharon/R-7216-2019					Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Ebner C, 1999, INT ARCH ALLERGY IMM, V119, P1, DOI 10.1159/000024168; Falk K, 2000, J EXP MED, V191, P717, DOI 10.1084/jem.191.4.717; Haselden BM, 2000, INT ARCH ALLERGY IMM, V122, P229, DOI 10.1159/000024403; Hashiguchi S, 1996, ALLERGY, V51, P621, DOI 10.1111/j.1398-9995.1996.tb04682.x; HASHIMOTO M, 1995, CLIN EXP ALLERGY, V25, P848, DOI 10.1111/j.1365-2222.1995.tb00027.x; Hirahara K, 1998, J ALLERGY CLIN IMMUN, V102, P961, DOI 10.1016/S0091-6749(98)70334-3; Ishikawa T, 1997, INT ARCH ALLERGY IMM, V113, P255, DOI 10.1159/000237563; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Muller UR, 1999, ALLERGY, V54, P45, DOI 10.1111/j.1398-9995.1999.tb04442.x; Nicodemus C, 1997, INT ARCH ALLERGY IMM, V113, P326, DOI 10.1159/000237590; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; RIA F, 1990, NATURE, V343, P381, DOI 10.1038/343381a0; ROGERS BL, 1994, MOL IMMUNOL, V31, P955, DOI 10.1016/0161-5890(94)90090-6; Saito S., 2000, ANN REP SANKYO RES L, V52, P49; SAKAGUCHI M, 1990, ALLERGY, V45, P309, DOI 10.1111/j.1398-9995.1990.tb00501.x; SAKAGUCHI M, 1986, Japanese Journal of Allergology, V35, P233; Sone T, 1998, J IMMUNOL, V161, P448; Sugimura K, 1996, ALLERGY, V51, P732; Tamura Y, 2000, INT ARCH ALLERGY IMM, V123, P228, DOI 10.1159/000024448; YASUEDA H, 1983, J ALLERGY CLIN IMMUN, V71, P77, DOI 10.1016/0091-6749(83)90550-X	22	64	73	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					94	100		10.1067/mai.2001.115481	http://dx.doi.org/10.1067/mai.2001.115481			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	458AN	11447388				2022-12-18	WOS:000170171200013
J	Abe, M; Kurosawa, M; Ishikawa, O; Miyachi, Y				Abe, M; Kurosawa, M; Ishikawa, O; Miyachi, Y			Effect of mast cell-derived mediators and mast cell-related neutral proteases on human dermal fibroblast proliferation and type I collagen production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on New Trends in Immunopharmacology 1998	JUL   25, 1998	TOKYO, JAPAN			mast cell; mediator; neutral protease; dermal fibroblast; proliferation; type I collagen	GROWTH-FACTOR-BETA; CULTURED FIBROBLASTS; LUNG FIBROBLASTS; HUMAN-SKIN; TRYPTASE; HISTAMINE; MITOGEN; CARBOXYPEPTIDASE; PURIFICATION; STIMULATION	Background: Possible involvement of mast cells in various fibrotic conditions has been suggested, hut the relative contribution of each mast cell mediator and neutral protease to fibroproliferative activity remains to be elucidated. Objective: We investigated the effect of mast cell-derived mediators and mast cell-related neutral proteases on type I collagen production and proliferation by human dermal fibroblasts. Methods: Mast cell-derived mediators or neutral proteases were added to cultured fibroblasts from normal dermis, and cell proliferation and type I collagen synthesis were assayed. Results: Fibroblast proliferation was increased by 2.8 x 10(-9) mol/L prostaglandin D-2 and 10 mu g/mL carboxypeptidase A, but not by leukotriene D-4 or cathepsin G at the concentrations studied. Proliferation was increased by tryptase in a concentration-dependent manner, and a significant increase was observed at concentrations of 1 and 10 mu g/mL. Production of type I collagen by fibroblasts was increased in the presence of 2.0 x 10(-9) mol/L leukotriene D-4 and 10 mu g/mL tryptase. Conclusion: Mast cell-derived mediators prostaglandin D-2 and Leukotriene D-4 and mast cell-related neutral proteases carboxypeptidase A and tryptase increase the proliferation and type I collagen production of human dermal fibroblasts in various manners.	Hirosaki Univ, Sch Med, Dept Geriatr Med, Hirosaki, Aomori 0368562, Japan; Gunma Univ, Sch Med, Dept Dermatol, Maebashi, Gumma 371, Japan; Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan	Hirosaki University; Gunma University; Kyoto University	Kurosawa, M (corresponding author), Hirosaki Univ, Sch Med, Dept Geriatr Med, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.			Ishikawa, Osamu/0000-0002-7655-0610				ALTER SC, 1987, BIOCHEM J, V248, P821, DOI 10.1042/bj2480821; BOUCEK RJ, 1973, P SOC EXP BIOL MED, V144, P929; BROWN JK, 1995, AM J RESP CELL MOL, V13, P227, DOI 10.1165/ajrcmb.13.2.7626290; Cairns JA, 1996, J IMMUNOL, V156, P275; DABROWSKI R, 1977, AGENTS ACTIONS, V7, P219, DOI 10.1007/BF01969976; DAYTON ET, 1989, J IMMUNOL, V142, P4307; FITZPATRICK DW, 1982, SURGERY, V97, P430; FRANZEN L, 1980, CELL TISSUE KINET, V13, P635, DOI 10.1111/j.1365-2184.1980.tb00502.x; GOLDSTEIN SM, 1987, J IMMUNOL, V139, P2724; GOLDSTEIN SM, 1989, J CLIN INVEST, V83, P1630, DOI 10.1172/JCI114061; GORDON JR, 1994, J EXP MED, V180, P2027, DOI 10.1084/jem.180.6.2027; Gruber BL, 1997, J IMMUNOL, V158, P2310; HATAMOCHI A, 1985, ARCH DERMATOL RES, V277, P60; IRANI AMA, 1992, ARTHRITIS RHEUM, V35, P933, DOI 10.1002/art.1780350813; JOHNSON CL, 1990, CELL SIGNAL, V2, P105, DOI 10.1016/0898-6568(90)90014-2; JORDANA M, 1988, THORAX, V43, P552, DOI 10.1136/thx.43.7.552; KANAYAMA N, 1992, GYNECOL OBSTET INVES, V34, P24, DOI 10.1159/000292719; KAWANAMI O, 1979, LAB INVEST, V40, P717; KIKUCHI K, 1995, DERMATOLOGY, V190, P4, DOI 10.1159/000246625; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVISCHAFFER F, 1995, J INVEST DERMATOL, V104, P999, DOI 10.1111/1523-1747.ep12606237; LEWIS RA, 1982, J IMMUNOL, V129, P1672; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; NISHIOKA K, 1987, ARCH DERMATOL, V123, P205, DOI 10.1001/archderm.123.2.205; OKEEFE RJ, 1992, J BONE MINER RES, V7, P397; PHAN SH, 1988, BIOCHEMISTRY-US, V27, P2846, DOI 10.1021/bi00408a028; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; RUSSELL JD, 1977, J CELL PHYSIOL, V93, P389, DOI 10.1002/jcp.1040930310; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SCHWARTZ LB, 1994, METHOD ENZYMOL, V244, P88; TOPOL BM, 1981, PLAST RECONSTR SURG, V68, P227, DOI 10.1097/00006534-198108000-00018; YAMASHITA Y, 1992, THORAX, V47, P634, DOI 10.1136/thx.47.8.634; YOSHIDA S, 1989, P SOC EXP BIOL MED, V191, P90; Zhou LJ, 1997, J DERMATOL SCI, V14, P217, DOI 10.1016/S0923-1811(96)00577-4	37	64	64	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	2	S			S78	S84		10.1067/mai.2000.106058	http://dx.doi.org/10.1067/mai.2000.106058			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	339NF	10887338				2022-12-18	WOS:000088482600011
J	Hauk, PJ; Wenzel, SE; Trumble, AE; Szefler, SJ; Leung, DYN				Hauk, PJ; Wenzel, SE; Trumble, AE; Szefler, SJ; Leung, DYN			Increased T-cell receptor V beta 8+T cells in bronchoalveolar lavage fluid of subjects with poorly controlled asthma: A potential role for microbial superantigens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; lymphocytes; superantigens	MYCOPLASMA-ARTHRITIDIS SUPERANTIGEN; CHLAMYDIA-PNEUMONIAE; RHEUMATOID-ARTHRITIS; DISEASE; PSORIASIS; ADULTS; EXACERBATION; EXPRESSION; INFECTION; MAM	Background: T cells are thought to play an important role in the pathogenesis of chronic asthma, The immunologic triggers that contribute to poorly controlled asthma are unknown but may include infectious agents. Superantigens (SAgs), which stimulate T cells expressing selected T-cell receptor (TCR) beta-chain variable (V beta) regions, are known to be an important mechanism by which microbes can contribute to T-cell activation and disease pathogenesis. Objective: We sought to determine the potential role of SAgs in T-cell activation of patients with poorly controlled asthma, Methods: We studied the TCR-V beta repertoire of bronchoalveolar lavage (BAL) cells and PBMCs from 9 subjects with poorly controlled asthma (FEV1 <75%), 7 subjects with well-controlled asthma (FEV1>80%), and 8 normal control subjects with the use of anti-TCR-V beta-specific mAbs and flow cytometry, Results: Subjects with poorly controlled asthma had a significantly higher expression of V beta 8(+) T cells in BAL fluid than subjects with well-controlled asthma and normal control subjects (P <.01) and autologous PBMCs (P <.05), Increased V beta 8(+) BAL T cells were present in CD4(+) (P <.01) and CD8(+) (P <.05) subsets, suggesting activation by SAgs, Conclusion: These results indicate that SAgs are a potential trigger of T-cell activation in poorly controlled asthma.	Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Div Pulm Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Clin Pharmacol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Allergy Immunol, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; National Jewish Health; National Jewish Health	Leung, DYN (corresponding author), Natl Jewish Med & Res Ctr, Div Allergy Immunol, 1400 Jackson St,Room K926, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, P01HL036577, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37260, HL36577] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE J, 1993, J EXP MED, V177, P791, DOI 10.1084/jem.177.3.791; ALLEGRA L, 1994, EUR RESPIR J, V7, P2165, DOI 10.1183/09031936.94.07122165; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BACCALA R, 1992, ARTHRITIS RHEUM-US, V35, P434, DOI 10.1002/art.1780350413; BERNSTEIN L, 1985, AM REV RESPIR DIS, V132, P180; BURASTERO SE, 1995, J IMMUNOL, V155, P5836; Chott A, 1996, J IMMUNOL, V156, P3024; COLE BC, 1993, ARTHRITIS RHEUM-US, V36, P994, DOI 10.1002/art.1780360717; Cole BC, 1996, J EXP MED, V183, P1105, DOI 10.1084/jem.183.3.1105; Cook PJ, 1998, THORAX, V53, P254, DOI 10.1136/thx.53.4.254; CORRIGAN CJ, 1991, INT ARCH ALLER A IMM, V94, P270, DOI 10.1159/000235380; FITZGERALD JE, 1995, J IMMUNOL, V154, P3538; FORRESTER JM, 1994, J IMMUNOL, V153, P4291; GulwaniAkolkar B, 1996, J CLIN INVEST, V98, P1344, DOI 10.1172/JCI118921; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; Herz U, 1998, J INVEST DERMATOL, V110, P224, DOI 10.1046/j.1523-1747.1998.00119.x; Hodtsev AS, 1998, J EXP MED, V187, P319, DOI 10.1084/jem.187.3.319; Hofer MF, 1995, CLIN EXP ALLERGY, V25, P1218, DOI 10.1111/j.1365-2222.1995.tb03046.x; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; LEUNG DYM, 1995, J CLIN INVEST, V96, P2106, DOI 10.1172/JCI118263; Matsumoto I, 1996, J CLIN INVEST, V97, P1969, DOI 10.1172/JCI118629; Neuber K, 1996, ACTA DERM-VENEREOL, V76, P214; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; SEGGEV JS, 1986, ANN ALLERGY, V57, P263; Valdimarsson H, 1997, CLIN EXP IMMUNOL, V107, P21; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I	29	64	67	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1999	104	1					37	45		10.1016/S0091-6749(99)70111-9	http://dx.doi.org/10.1016/S0091-6749(99)70111-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	221QZ	10400837	Bronze			2022-12-18	WOS:000081738900006
J	Shapiro, GG; Wighton, TG; Chinn, T; Zuckerman, J; Eliassen, AH; Picciano, JF; Platts-Mills, TAE				Shapiro, GG; Wighton, TG; Chinn, T; Zuckerman, J; Eliassen, AH; Picciano, JF; Platts-Mills, TAE			House dust mite avoidance for children with asthma in homes of low-income families	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; dust mite; bronchial hyperresponsiveness; environmental controls	BRONCHIAL RESPONSIVENESS; RESPIRATORY SYMPTOMS; PULMONARY-FUNCTION; ALLERGEN EXPOSURE; POPULATION; SEVERITY	Background: Home exposure to high levels of house dust mite allergen has been shown to aggravate airways reactivity and asthma. Objective: The purpose of this study was to determine whether specific house dust mite control measures could reduce exposure levels and asthma severity. Methods: This double-blinded, randomized trial compared asthma progression over 1 year in children whose homes received standard environmental control intervention with those whose homes received aggressive intervention for dust mite elimination. The primary end point was doubling in PD20 methacholine. Results: Symptom scores and quality-of-life scores were similar for the standard and aggressive intervention groups. PD20 methacholine doubling occurred in 9 members of the aggressive intervention group vs 4 control patients (P < .05). Dust mite levels decreased in the aggressive intervention homes compared with the standard intervention homes (P < .05). Conclusion: Aggressive dust mite intervention decreased dust mite levels and improved bronchial hyperresponsiveness.	ASTHMA Inc, Seattle, WA 98105 USA; Univ Virginia, Med Ctr, Div Allergy, Charlottesville, VA USA	University of Virginia	Shapiro, GG (corresponding author), ASTHMA Inc, 4540 Sand Point Way NE, Seattle, WA 98105 USA.			Eliassen, A Heather/0000-0002-3961-6609; Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034578, R01AI020565, R37AI020565, U01AI034607, U19AI034607] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20565, UO1 AI34578-01, AI/ES-34607] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; BURNEY PGJ, 1987, THORAX, V42, P38, DOI 10.1136/thx.42.1.38; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1302, DOI 10.1164/ajrccm.152.4.7551386; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805, DOI 10.1164/ajrccm.152.6.8520740; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1133, DOI 10.1136/adc.64.8.1133; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; MARKS GB, 1995, CLIN EXP ALLERGY, V25, P114, DOI 10.1111/j.1365-2222.1995.tb01015.x; MURRAY AB, 1983, PEDIATRICS, V71, P418; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; *NIH, 1997, NIH PUBL; PlattsMills TAE, 1996, J ALLERGY CLIN IMMUN, V98, pS297, DOI 10.1016/S0091-6749(96)80115-1; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; RIJCKEN B, 1987, B EUR PHYSIOPATH RES, V23, P391; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SPARROW D, 1987, AM REV RESPIR DIS, V135, P1255; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; WALSHAW MJ, 1986, Q J MED, V58, P199	21	64	64	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1069	1074		10.1016/S0091-6749(99)70181-8	http://dx.doi.org/10.1016/S0091-6749(99)70181-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359888				2022-12-18	WOS:000080929500015
J	van de Rijn, M; Mehlhop, PD; Judkins, A; Rothenberg, ME; Luster, AD; Oettgen, HC				van de Rijn, M; Mehlhop, PD; Judkins, A; Rothenberg, ME; Luster, AD; Oettgen, HC			A murine model of allergic rhinitis: Studies on the role of IgE in pathogenesis and analysis of the eosinophil influx elicited by allergen and eotaxin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; IgE; IL-5; eotaxin; mouse; model	ASPERGILLUS-FUMIGATUS ANTIGENS; VASCULAR ENDOTHELIAL-CELLS; NASAL-MUCOSA; IN-VIVO; AIRWAY HYPERRESPONSIVENESS; CHEMOATTRACTANT CYTOKINE; INFLAMMATORY CELLS; ANTIBODY-RESPONSE; DEFICIENT MICE; LYMPHOCYTES-T	Background: Allergic rhinitis is a prevalent disease with significant morbidity, Studies of its pathophysiology in human subjects have been limited. Nasal biopsy specimens are difficult to obtain, and nasal secretions incompletely reflect the cellular and molecular events in the mucosa, IgE-mediated mast cell activation and the elaboration of factors promoting eosinophil development and chemotaxis are likely to participate in pathogenesis. Objectives: We sought to develop a murine model of allergic rhinitis, to use it to assess the role of IgE in pathogenesis, and to study the effects of IL-5 and eotasin in the nasal mucosa, Methods: A protein extract of Aspergillus fumigatus (Af) was instilled intranasally in mice. Histologic changes were examined in wild-type and IgE-deficient (IgE(-/-)) animals. The effect of eotasin administration was assessed in wild-type and IL-5 transgenic mice. Results: Af-treated mice developed a nasal mucosal eosinophil influx comparable to that described for humans, This histology was distinct from that observed in a murine model Af-induced asthma, The pathology appeared over a time course similar to that reported for human subjects. There was no difference in the intensity of the mucosal inflammatory infiltrate of rif-treated IgE(-/-) mice compared with wild-type mice. Eotaxin mas able to recruit eosinophils to the mucosa but only in IL-5 transgenic animals, Conclusion: We describe a murine model for allergic rhinitis with an eosinophilic infiltrate comparable to that found in human disease and have demonstrated that rhinitis can arise in the absence of IgE, We have shown that the eosinophil influx can be induced by eotaxin in the presence of IL-5.	Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; Univ Penn, Med Syst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Childrens Hosp, Med Ctr, Div Pulm Med Allergy & Clin Immunol, Cincinnati, OH 45229 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Infect Dis Unit, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; University of Pennsylvania; Cincinnati Children's Hospital Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital	Oettgen, HC (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Enders 8,300 Longwood Ave, Boston, MA 02115 USA.		Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912; van de Rijn, Matt/0000-0002-1909-9739	NIAID NIH HHS [AI 40618] Funding Source: Medline; NICHD NIH HHS [2P30HD28827-06] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040618] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baraniuk JN, 1997, J ALLERGY CLIN IMMUN, V99, pS763, DOI 10.1016/S0091-6749(97)70125-8; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BEPPU T, 1994, ACTA OTO-LARYNGOL, P221; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; BurkeGaffney A, 1996, BIOCHEM BIOPH RES CO, V227, P35, DOI 10.1006/bbrc.1996.1463; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DRUCE HM, 1993, ALLERGY PRINCIPLES P, P1433; Eum SY, 1995, P NATL ACAD SCI USA, V92, P12290, DOI 10.1073/pnas.92.26.12290; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FOX PC, 1982, J IMMUNOL, V129, P314; FUJIWARA H, 1994, P NATL ACAD SCI USA, V91, P6835, DOI 10.1073/pnas.91.15.6835; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GARSSEN J, 1993, AM REV RESPIR DIS, V147, P307, DOI 10.1164/ajrccm/147.2.307; GARSSEN J, 1993, CHEST, V103, pS129; GUSTAVSSON S, 1994, J IMMUNOL, V152, P4793; HEYMAN B, 1993, EUR J IMMUNOL, V23, P1739, DOI 10.1002/eji.1830230754; IGARASHI Y, 1995, J ALLERGY CLIN IMMUN, V95, P716, DOI 10.1016/S0091-6749(95)70177-X; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; ISHIDA M, 1994, ANN ALLERGY, V72, P240; JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KATZ HR, 1992, J IMMUNOL, V148, P868; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; Kokron CM, 1997, J CLIN IMMUNOL, V17, P109, DOI 10.1023/A:1027322314256; KURUP VP, 1994, J LEUKOCYTE BIOL, V56, P593, DOI 10.1002/jlb.56.5.593; KURUP VP, 1992, J IMMUNOL, V148, P3783; KURUP VP, 1994, J ALLERGY CLIN IMMUN, V93, P1013, DOI 10.1016/S0091-6749(94)70050-8; KURUP VP, 1990, INT ARCH ALLER A IMM, V91, P145, DOI 10.1159/000235106; LACK C, 1995, AM J RESP CRIT CARE, V152, P1765, DOI 10.1164/ajrccm.152.6.8520735; LIM MC, 1995, AM J RESP CRIT CARE, V151, P136, DOI 10.1164/ajrccm.151.1.7812543; Luna L., 1986, AFIP MANUAL HISTOLOG; MacLean JA, 1996, J EXP MED, V184, P1461, DOI 10.1084/jem.184.4.1461; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Meltzer EO, 1997, J ALLERGY CLIN IMMUN, V99, pS815, DOI 10.1016/S0091-6749(97)80041-3; MerayoLloves J, 1996, J ALLERGY CLIN IMMUN, V97, P1129, DOI 10.1016/S0091-6749(96)70268-3; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; MUDDE GC, 1995, IMMUNOL TODAY, V16, P380, DOI 10.1016/0167-5699(95)80005-0; MURALI PS, 1993, J LEUKOCYTE BIOL, V53, P264, DOI 10.1002/jlb.53.3.264; MURALI PS, 1992, INFECT IMMUN, V60, P1952, DOI 10.1128/IAI.60.5.1952-1956.1992; NACLERIO RM, 1994, J ALLERGY CLIN IMMUN, V94, P1303, DOI 10.1016/0091-6749(94)90346-8; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; NUSSENZWEIG RS, 1964, J EXP MED, V120, P315, DOI 10.1084/jem.120.2.315; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; PIPKORN U, 1989, AM REV RESPIR DIS, V140, P729, DOI 10.1164/ajrccm/140.3.729; RENNICK DM, 1990, BLOOD, V76, P312; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631; SETTIPANE GA, 1986, OTOLARYNG HEAD NECK, V94, P470, DOI 10.1177/019459988609400411; TADA T, 1970, Journal of Immunology, V104, P377; TAKAHASHI N, 1990, J PHARMACOBIO-DYNAM, V13, P414, DOI 10.1248/bpb1978.13.414; TANAKA K, 1988, INT ARCH ALLER A IMM, V85, P392, DOI 10.1159/000234540; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; VAZ E M, 1970, International Archives of Allergy and Applied Immunology, V39, P459; WALSH GM, 1991, J IMMUNOL, V146, P3419; Wang D Y, 1994, Allergol Immunopathol (Madr), V22, P179; Wang Deyun, 1995, Rhinology (Utrecht), V33, P78; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561	64	64	66	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					65	74		10.1016/S0091-6749(98)70056-9	http://dx.doi.org/10.1016/S0091-6749(98)70056-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679849	hybrid			2022-12-18	WOS:000074909500011
J	Lack, G; Nelson, HS; Amran, D; Oshiba, A; Jung, T; Bradley, KL; Giclas, PC; Gelfand, EW				Lack, G; Nelson, HS; Amran, D; Oshiba, A; Jung, T; Bradley, KL; Giclas, PC; Gelfand, EW			Rush immunotherapy results in allergen-specific alterations in lymphocyte function and interferon-gamma productioni in CD4(+) T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rush immunotherapy; interferon-gamma; T cells; B cells; specificity	SUBCLASS ANTIBODY-RESPONSE; BEE VENOM IMMUNOTHERAPY; PERITONEAL MAST-CELLS; DOG-DANDER EXTRACTS; IFN-GAMMA; SUPPRESSOR CELLS; ATOPIC PATIENTS; DOUBLE-BLIND; CAT-DANDER; POLLEN	Background: Allergen immunotherapy results in a number of changes in clinical, inflammatory, and immunologic parameters. However; the basis for the specificity of this form of therapy is unknown, especially in the context of changes in T- and B-lymphocyte function after desensitization to specific allergens. Objective:This study was designed to determine the immunologic consequences of rush immunotherapy. Methods: We studied 10 patients who had positive skin test responses to the house dust mite Dermatophagoides pteronyssinus (Dpt) and eat dander extract. Each received rush immunotherapy to mite, but mot cat dander, over a 2- to 4-week period until maintenance was achieved. Patients were evaluated before and when maintenance was achieved for skin Best and nasal reactivity to mite and cat dander; antibody levels to the allergen were monitored, as were lymphocyte proliferative responses and cytokine production. Results: Rush immunotherapy to house dust mite resulted in a significant reduction in skin and nasal reactivity to mite allergen, but not to cat allergen, in 10 of a 10 patients. This was accompanied by a rise in serum anti-Dpt IgE, whereas anti-cat IgE was not altered (7 of 7 patients). In seven of seven patients there was an Increase in anti-Dpt IgG(4) levels. T-cell proliferative responses to mite antigen were suppressed, and numbers of CD8(+) T cells increased in frequency. There was a marked increase In interferon-gamma production particularly by CD4(+) T cells in 10 of 10 patients, The correlation between the increases in interferon-gamma production and the changes in cutaneous reactivity was highly significant. Conclusion: We show that rush immunotherapy is immunologically specific in eliciting changes in T- and B-cell responses to the desensitization antigen. The specificity and potential benefit of immunotherapy may be linked to the increase in interferon-gamma production by allergen-activated CH4(+) T lymphocytes.	NATL JEWISH CTR IMMUNOL & RESP MED, DIV BASIC SCI, DEPT PEDIAT, DENVER, CO 80206 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DIV ALLERGY & IMMUNOL, DEPT PEDIAT, DENVER, CO 80206 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DIV ALLERGY, DENVER, CO 80206 USA	National Jewish Health; National Jewish Health; National Jewish Health				Lack, Gideon/0000-0001-7350-4021	NHLBI NIH HHS [HL-36577] Funding Source: Medline; NIAID NIH HHS [AI-29704] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029704] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERSE RC, 1983, J IMMUNOL, V130, P722; ABED NS, 1994, CELL IMMUNOL, V153, P356, DOI 10.1006/cimm.1994.1034; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; CANONICA GW, 1979, J IMMUNOL, V123, P2669; COLEMAN JW, 1991, EUR J IMMUNOL, V21, P2559, DOI 10.1002/eji.1830211037; COLEMAN JW, 1991, INT ARCH ALLER A IMM, V94, P179, DOI 10.1159/000235356; DEKRUYFF RH, 1992, J IMMUNOL, V149, P3468; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; DJURUP R, 1985, J ALLERGY CLIN IMMUN, V76, P46, DOI 10.1016/0091-6749(85)90803-6; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; FUJISAWA T, 1990, J IMMUNOL, V144, P642; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; HAYGLASS KT, 1991, J EXP MED, V173, P279, DOI 10.1084/jem.173.2.279; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; JUTEL M, 1995, J IMMUNOL, V154, P4187; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LACK G, 1994, J IMMUNOL, V152, P2546; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; MALLING HJ, 1988, ALLERGY, V43, P60, DOI 10.1111/j.1398-9995.1988.tb02045.x; MOSS RB, 1987, J ALLERGY CLIN IMMUN, V79, P387, DOI 10.1016/0091-6749(87)90160-6; NAFZIGER J, 1990, EUR J IMMUNOL, V20, P113, DOI 10.1002/eji.1830200117; NAGATA M, 1993, INTERNAL MED, V32, P702, DOI 10.2169/internalmedicine.32.702; NOVELLI F, 1993, EUR J IMMUNOL, V23, P1226, DOI 10.1002/eji.1830230605; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; PARISH CR, 1972, J EXP MED, V135, P298, DOI 10.1084/jem.135.2.298; PENG ZK, 1992, J ALLERGY CLIN IMMUN, V89, P519, DOI 10.1016/0091-6749(92)90318-V; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; ROBINSON LD, 1993, J ALLERGY CLIN IMMUN, V91, P141; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; SALOGA J, 1993, J CLIN INVEST, V91, P133, DOI 10.1172/JCI116162; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; TAKAGI M, 1990, J IMMUNOL, V145, P1880; TAMIR R, 1987, J ALLERGY CLIN IMMUN, V79, P591, DOI 10.1016/S0091-6749(87)80154-9; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; TIPTON WR, 1982, J ALLERGY CLIN IMMUN, V69, P194, DOI 10.1016/0091-6749(82)90099-9; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; WIERENGA EA, 1990, J IMMUNOL, V144, P4651	46	64	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					530	538		10.1016/S0091-6749(97)70081-2	http://dx.doi.org/10.1016/S0091-6749(97)70081-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111499	Bronze			2022-12-18	WOS:A1997WU27400017
J	Sakaguchi, M; Yamanaka, T; Ikeda, K; Sano, Y; Fujita, H; Miura, T; Inouye, S				Sakaguchi, M; Yamanaka, T; Ikeda, K; Sano, Y; Fujita, H; Miura, T; Inouye, S			IgE-mediated systemic reactions to gelatin included in the varicella vaccine	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							MEASLES; MUMPS; CHILDREN		NISHIMACHI PEDIAT CLIN,SAPPORO,HOKKAIDO,JAPAN; SANO CLIN,NIIGATA,JAPAN; OSAKA UNIV,DIV RES & DEV,RES FDN MICROBIAL DIS,KANONJI,JAPAN; HAGA RED CROSS HOSP,DEPT PEDIAT,MOKA,JAPAN; PEDIAT CLIN TATSURU YAMANAKA,SAPPORO,HOKKAIDO,JAPAN	Osaka University	Sakaguchi, M (corresponding author), NATL INST HLTH,DEPT EPIDEMIOL,SHINJUKU KU,TOYAMA 1-23-1,TOKYO 162,JAPAN.		Inouye, Sharon/R-7216-2019					BUSINCO L, 1994, ANN ALLERGY, V72, P1; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; SAKAGUCHI M, IN PRESS J ALLERGY C; TAKAHASHI M, 1990, ADV EXP MED BIOL, V278, P49	5	64	70	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					263	264		10.1016/S0091-6749(97)70108-8	http://dx.doi.org/10.1016/S0091-6749(97)70108-8			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042057				2022-12-18	WOS:A1997WH83100020
J	DuBuske, LM				DuBuske, LM			Clinical comparison of histamine H-1-receptor antagonist drugs	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						H-1-receptor antagonists; allergy therapy; antihistamines	SEASONAL ALLERGIC RHINITIS; CELL-MEDIATOR RELEASE; DOUBLE-BLIND; ELECTROCARDIOGRAPHIC PHARMACODYNAMICS; NONSEDATING ANTIHISTAMINE; TERFENADINE SELDANE; PULMONARY-FUNCTION; THERAPEUTIC USE; INDUCED ASTHMA; CETIRIZINE	Nearly 40 million Americans have symptoms of upper respiratory allergies, making antihistamines among the most frequently used pharmacologic agents. Although there are mediators of allergic symptoms in addition to histamine, therapy for allergic rhinitis and urticaria has focused upon the use of antihistamines. The classic histamine H-1-receptor antagonists, however, are not selective for the H-1 site and produce a variety of dopaminergic, serotonergic, and cholinergic responses leading to considerable adverse effects in the central nervous system consequent to both their pharmacologic nonselectivity and their ability to penetrate the blood-brain barrier readily. The second-generation antihistamines were a major advance in the therapy of allergic rhinitis, because they do not penetrate the blood-brain barrier as rapidly and are also designed for greater specificity at H-1-receptor. Given their greater selectivity for the H-1-receptor, they cause fewer undesirable central nervous system actions, whereas their efficacy is similar to that of the classic antihistamines used in the treatment of allergic rhinitis. Selecting among these antihistamines for the treatment of allergic rhinitis has focused on their pharmacokinetics and adverse effect profiles. The potential cardiotoxic effects of some antihistamines when their metabolism is inhibited requires caution in prescribing these agents. The antiallergic and antiasthmatic effects of several newer antihistamines are being explored. For the clinician, making the therapeutic decision among H-1-receptor antagonists requires a comprehensive knowledge of their diverse effects.	HARVARD UNIV, SCH MED, CAMBRIDGE, MA 02138 USA	Harvard University	DuBuske, LM (corresponding author), IMMUNOL RES INST NEW ENGLAND, 955 SOUTH ST, FITCHBURG, MA 01420 USA.		DuBuske, Lawrence/AAV-3402-2020					ALFORD C, 1992, HUM PSYCHOPHARM CLIN, V7, P25, DOI 10.1002/hup.470070104; ARRANG JM, 1994, CELL MOL BIOL, V40, P275; BANTZ EW, 1987, ANN ALLERGY, V59, P341; BENDAVID J, 1993, LANCET, V341, P1578, DOI 10.1016/0140-6736(93)90708-O; Bernstein D., 1996, Journal of Allergy and Clinical Immunology, V97, P435, DOI 10.1016/S0091-6749(96)81228-0; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BOUSQUET J, 1990, ANN ALLERGY, V65, P504; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V86, P248, DOI 10.1016/S0091-6749(05)80072-7; BUSSE WW, 1994, ANN ALLERGY, V72, P371; BUTTMANN G, 1990, ANN ALLERGY, V64, P224; CANONICA GW, 1993, ALLERGY CLIN IMMUNOL, V5, P80; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CIMBURA G, 1982, J FORENSIC SCI, V27, P855; CIPRANDI G, 1995, J ALLERGY CLIN IMMUN, V95, P612, DOI 10.1016/S0091-6749(95)70324-1; CISTERO A, 1992, ANN ALLERGY, V69, P123; CLEE MD, 1984, BRIT J DIS CHEST, V78, P180, DOI 10.1016/0007-0971(84)90120-7; COHEN AF, 1985, CLIN PHARMACOL THER, V38, P381, DOI 10.1038/clpt.1985.191; COYLE AJ, 1991, BRIT J PHARMACOL, V103, P1520, DOI 10.1111/j.1476-5381.1991.tb09820.x; DAY CP, 1993, LANCET, V341, P1423; DEVOS C, 1987, ANN ALLERGY, V59, P278; DUBUSKE L, 1995, ANN ALLERG ASTHMA IM, V74, P345; ESTELLE F, 1994, DRUG SAFETY, V10, P350, DOI 10.2165/00002018-199410050-00002; FADEL R, 1991, INT ARCH ALLER A IMM, V95, P158; FINNERTY JP, 1989, AM REV RESPIR DIS, V140, P593, DOI 10.1164/ajrccm/140.3.593; Gilmore TM, 1996, AM J IND MED, V30, P234; GOETZ DW, 1991, ANN ALLERGY, V67, P448; GOETZ DW, 1989, J ALLERGY CLIN IMMUN, V84, P316, DOI 10.1016/0091-6749(89)90414-4; GOOD AP, 1994, AM J CARDIOL, V74, P207, DOI 10.1016/0002-9149(94)90108-2; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; GRANT SM, 1990, DRUGS, V40, P412, DOI 10.2165/00003495-199040030-00006; GROGGINS RC, 1979, BRIT J DIS CHEST, V73, P297, DOI 10.1016/0007-0971(79)90056-1; GUENGERICH FP, 1990, CARCINOGENESIS, V11, P2275, DOI 10.1093/carcin/11.12.2275; HANRAHAN JP, 1992, POST MARKETING SURVE, V6, P23; HOLGATE ST, 1989, ROLE INFLAMMATORY PR, P179; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; HONIG PK, 1993, CLIN PHARMACOL THER, V53, P630, DOI 10.1038/clpt.1993.83; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; JANSSENS MML, 1993, CLIN REV ALLERG, V11, P35; JUNIPER EF, 1988, J ALLERGY CLIN IMMUN, V82, P670, DOI 10.1016/0091-6749(88)90981-5; KARLIN JM, 1972, ANN ALLERGY, V30, P342; KOPFERSCHMITTKUBLER MC, 1990, ANN ALLERGY, V65, P501; LEWISTON NJ, 1982, J PEDIATR-US, V101, P458, DOI 10.1016/S0022-3476(82)80087-5; MASHETER HC, 1993, CLIN REV ALLERG, V11, P5; MAUSER PJ, 1990, EUR J PHARMACOL, V182, P125, DOI 10.1016/0014-2999(90)90500-6; MELTZER EO, 1990, J OCCUP ENVIRON MED, V32, P327, DOI 10.1097/00043764-199004000-00013; MELTZER EO, 1991, ANN ALLERGY, V67, P625; MELTZER EO, 1995, J ALLERGY CLIN IMMUN, V95, P1097, DOI 10.1016/S0091-6749(95)70213-X; MICHEL L, 1990, ANN ALLERGY, V65, P512; NACLERIO RM, 1993, OTOLARYNG HEAD NECK, V108, P723, DOI 10.1177/019459989310800615; NACLERIO RM, 1989, LARYNGOSCOPE, V99, P596; PANAYOTOPOULOS SM, 1990, ANN ALLERGY, V65, P146; PIEPHO RW, 1993, INTERN MED ALERT, V15, P126; POPA VT, 1977, J ALLERGY CLIN IMMUN, V59, P54, DOI 10.1016/0091-6749(77)90177-4; PRATT CM, 1994, IN PRESS AM J CARDIO; PRENKOWSKI MM, 1988, J ALLERGY CLIN IMMUN, V82, P95; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; REDIER H, 1992, J ALLERGY CLIN IMMUN, V90, P215, DOI 10.1016/0091-6749(92)90074-C; SALE ME, 1993, J ALLERGY CLIN IMMUN, V91, P258; SANDERS RL, 1992, J ALLERGY CLIN IMMUN, V89, P183; SCHULLER DE, 1983, J ALLERGY CLIN IMMUN, V72, P175, DOI 10.1016/0091-6749(83)90526-2; SEIDEL WF, 1990, J ALLERGY CLIN IMMUN, V86, P1029, DOI 10.1016/S0091-6749(05)80249-0; Simons F E, 1991, Clin Pharmacokinet, V21, P372; SIMONS FER, 1990, J ALLERGY CLIN IMMUN, V86, P540; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; SIMONS FER, 1988, J ALLERGY CLIN IMMUN, V82, P1068; SIMONS FER, 1994, J ALLERGY CLIN IMMUN, V93, P222; SMITH SJ, 1994, OTOLARYNG HEAD NECK, V111, P348, DOI 10.1177/01945998941113P203; SORKIN EM, 1985, DRUGS, V29, P34, DOI 10.2165/00003495-198529010-00002; SPECTOR SL, 1995, J ALLERGY CLIN IMMUN, V96, P174, DOI 10.1016/S0091-6749(95)70005-6; SPENCER CM, 1993, DRUGS, V46, P1055, DOI 10.2165/00003495-199346060-00008; STORMS W, 1985, J ALLERGY CLIN IMMUN, V75, P167, DOI 10.1016/0091-6749(85)90386-0; Thompson D, 1996, JAMA-J AM MED ASSOC, V275, P1339, DOI 10.1001/jama.275.17.1339; TOGIAS AG, 1989, ANN ALLERGY, V63, P465; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P225, DOI 10.1001/jama.255.2.225; TUCKER A, 1975, AM J PHYSIOL, V229, P1008, DOI 10.1152/ajplegacy.1975.229.4.1008; TURKELTAUB PC, 1991, ANN ALLERGY, V67, P147; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WALSH GM, 1991, INT ARCH ALLER A IMM, V95, P158, DOI 10.1159/000235422; WARREN R, 1981, ALCHOL DRUGS TRAFFIC, V1, P203; WASSERMAN SI, 1987, ANN ALLERGY, V59, P1; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8; WYNGAARDEN JB, 1951, JAMA-J AM MED ASSOC, V145, P277, DOI 10.1001/jama.1951.02920230001001; 1988, J ALLERGY CLIN IMMUN, V82, P481	84	64	65	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	3	S			S307	S318		10.1016/S0091-6749(96)80116-3	http://dx.doi.org/10.1016/S0091-6749(96)80116-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WC448	8977542				2022-12-18	WOS:A1996WC44800004
J	JUERGENS, UR; CHRISTIANSEN, SC; STEVENSON, DD; ZURAW, BL				JUERGENS, UR; CHRISTIANSEN, SC; STEVENSON, DD; ZURAW, BL			INHIBITION OF MONOCYTE LEUKOTRIENE B-4 PRODUCTION AFTER ASPIRIN DESENSITIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASPIRIN-SENSITIVE ASTHMA; ASPIRIN DESENSITIZATION; MONOCYTES; ARACHIDONIC ACID METABOLISM; LEUKOTRIENES	SENSITIVE RHINOSINUSITIS-ASTHMA; ARACHIDONIC-ACID METABOLISM; ANTI-INFLAMMATORY DRUGS; GLUCOCORTICOIDS INHIBIT; URINARY LEUKOTRIENE-E4; PROSTAGLANDIN; RELEASE; BIOSYNTHESIS; MACROPHAGES; HISTAMINE	Aspirin-sensitive patients may be desensitized through a graded series of exposures to aspirin. We investigated the underlying mechanism of aspirin desensitization by measuring the release of leukotrienes B-4 and C-4 from calcium ionophore-stimulated peripheral blood monocytes. Compared with monocytes from normal volunteers (n = 5), monocytes fr om patients with aspirin-sensitive asthma (n = 10) released increased amounts of thromboxane B-2 (1060 +/- 245 pg/ml vs 456 +/- 62 pg/ml), leukotriene B-4 (861 +/- 139 pg/ml vs 341 +/- 44 pg/ml), and leukotriene C-4 (147 +/- 31 pg/ml vs 56 +/- 6 pg/ml) at baseline. After aspirin desensitization, thromboxane B, release was almost completely suppressed in both groups. Leukotriene B, release was significantly decreased in the aspirin-sensitive group (484 +/- 85 pg/ml) but not in the normal subject group (466 +/- 55 pg/ml). The need for prednisone decreased significantly after patients were desensitized to aspirin (10.4 +/- 2.2 mg/day to 1.6 +/- 2.8 mg/day). These results demonstrate that desensitization to aspirin results in decreased monocyte leukotriene B, release. On the basis of the bronchospastic and inflammatory potential of leukotrienes, the decrease in leukotriene release may contribute to the clinical improvement seen after aspirin desensitization.	SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Scripps Research Institute				Zuraw, Bruce/0000-0003-0640-6768	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00833] Funding Source: Medline; NIAID NIH HHS [AI10386] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON S, 1985, P NATL ACAD SCI USA, V82, P7227, DOI 10.1073/pnas.82.21.7227; ARM JP, 1989, AM REV RESPIR DIS, V140, P148, DOI 10.1164/ajrccm/140.1.148; BALTER MS, 1988, AM REV RESPIR DIS, V138, P1134, DOI 10.1164/ajrccm/138.5.1134; BIGBY TD, 1987, J IMMUNOL, V138, P1546; BOYUM A, 1983, SCAND J IMMUNOL, V17, P429, DOI 10.1111/j.1365-3083.1983.tb00809.x; CHIU JT, 1983, J ALLERGY CLIN IMMUN, V71, P560, DOI 10.1016/0091-6749(83)90437-2; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1531, DOI 10.1164/ajrccm/146.6.1531; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; DEGEORGE JJ, 1987, J BIOL CHEM, V262, P9979; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; FULLER RW, 1984, CLIN SCI, V67, P653, DOI 10.1042/cs0670653; GASSAMADIAGNE A, 1990, J BIOL CHEM, V265, P4309; GOPPELTSTRUEBE M, 1992, BIOCHIM BIOPHYS ACTA, V1127, P163, DOI 10.1016/0005-2760(92)90273-X; HENDERSON WR, 1987, AM REV RESPIR DIS, V135, P1176; JUERGENS UR, 1992, J ALLERGY CLIN IMMUN, V90, P636, DOI 10.1016/0091-6749(92)90137-Q; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LOMBARDO VT, 1985, J CLIN INVEST, V76, P1950, DOI 10.1172/JCI112193; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NELSON RP, 1986, NEW ENGL REG ALLERGY, V7, P117; PIACENTINI GL, 1991, AM REV RESPIR DIS, V143, pS96; PRIDDY AR, 1990, J CLIN ENDOCR METAB, V71, P235, DOI 10.1210/jcem-71-1-235; RAIBLE D, 1990, CLIN RES, V38, pA791; RAULF M, 1990, IMMUNOPHARMACOLOGY, V19, P103, DOI 10.1016/0162-3109(90)90045-G; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; SIEGEL MI, 1979, P NATL ACAD SCI USA, V76, P3774, DOI 10.1073/pnas.76.8.3774; SLADEK K, 1993, EUR RESPIR J, V6, P391; STECHSCHULTE DJ, 1990, NEW ENGL J MED, V323, P1769, DOI 10.1056/NEJM199012203232511; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; SWEET JM, 1990, J ALLERGY CLIN IMMUN, V85, P59, DOI 10.1016/0091-6749(90)90222-P; SZCZEKLIK A, 1978, THORAX, V33, P664, DOI 10.1136/thx.33.5.664; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; TRAUTMANN M, 1991, EUR J PHARMACOL, V201, P53, DOI 10.1016/0014-2999(91)90322-H; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WENZEL SE, 1994, J ALLERGY CLIN IMMUN, V94, P870, DOI 10.1016/0091-6749(94)90155-4; WU KK, 1991, P NATL ACAD SCI USA, V88, P2384, DOI 10.1073/pnas.88.6.2384	42	64	66	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					148	156		10.1016/S0091-6749(95)70002-1	http://dx.doi.org/10.1016/S0091-6749(95)70002-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636051				2022-12-18	WOS:A1995RQ00100002
J	MEEKINS, CV; SULLIVAN, TJ; GRUCHALLA, RS				MEEKINS, CV; SULLIVAN, TJ; GRUCHALLA, RS			IMMUNOCHEMICAL ANALYSIS OF SULFONAMIDE DRUG ALLERGY - IDENTIFICATION OF SULFAMETHOXAZOLE-SUBSTITUTED HUMAN SERUM-PROTEINS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SULFAMETHOXAZOLE; HAPTENATION; CYTOCHROME P-450; IMMUNOBLOTTING; GEL ELECTROPHORESIS	HUMAN IGE; ANTIBODIES; HALOTHANE; HYPERSENSITIVITY; HYDROXYLAMINE; METABOLITE; HEPATITIS; TOXICITY	Background: Sulfonamides undergo oxidative metabolism to yield reactive metabolites that haptenate proteins readily. Although it has been shown that sulfonamide metabolites bind covalently to murine microsomes, sulfonamide-conjugated serum proteins have not been analyzed in the peripheral blood of treated individuals. Objective: We hypothesized that during treatment with sulfamethoxazole, intracellular proteins are haptenated by drug metabolites, and some of these are destined for secretion into the serum. Methods: Using antibodies specific for sulfamethoxazole and an alkaline phosphatase immunoblotting technique, we attempted to demonstrate the presence of sulfamethoxazole-substituted proteins in the serum of individuals during a course of treatment. Results: Five days into therapy, serum protein haptenation by sulfamethoxazole was demonstrated in two of the three individuals studied. In addition, Western blot analysis revealed that haptenation is not indiscriminate, but highly selctive. A single 30 kd protein is the target of haptenation in all instances. A kinetic analysis revealed that substituted proteins can be detected early, within hours of administration. Moreover, haptenated proteins remain detectable in the serum 48 hours after discontinuation of the drug. Conclusion: The results presented here constitute the first direct evidence that sulfonamides, on being metabolized covalently haptenate human serum proteins during a course of therapy.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV ALLERGY,DALLAS,TX 75235; EMORY UNIV,SCH MED,ATLANTA,GA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Emory University					NIAID NIH HHS [AI33711-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033711] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTOLONE JB, 1989, TOXICOL APPL PHARM, V99, P240, DOI 10.1016/0041-008X(89)90006-9; CARRINGTON DM, 1987, J ALLERGY CLIN IMMUN, V79, P442, DOI 10.1016/0091-6749(87)90361-7; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; GRUCHALLA RS, 1991, J ALLERGY CLIN IMMUN, V88, P784, DOI 10.1016/0091-6749(91)90186-R; GRUCHALLA RS, 1990, J ALLERGY CLIN IMMUN, V35, P157; HARLE DG, 1988, MOL IMMUNOL, V25, P1347, DOI 10.1016/0161-5890(88)90050-8; KENNA JG, 1988, J PHARMACOL EXP THER, V245, P1103; KENNA JG, 1987, J PHARMACOL EXP THER, V242, P733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leftwich WB, 1944, B JOHNS HOPKINS HOSP, V74, P26; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; Rich AR, 1942, B JOHNS HOPKINS HOSP, V71, P123; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; SATOH H, 1985, J PHARMACOL EXP THER, V233, P857; SHEAR NH, 1985, CAN J PHYSIOL PHARM, V63, P1370, DOI 10.1139/y85-225; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; WARRINGTON RJ, 1983, CLIN ALLERGY, V13, P235, DOI 10.1111/j.1365-2222.1983.tb02593.x	17	64	66	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				1017	1024		10.1016/0091-6749(94)90120-1	http://dx.doi.org/10.1016/0091-6749(94)90120-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7798534				2022-12-18	WOS:A1994PY23000010
J	RA, CS; YASUDA, M; YAGITA, H; OKUMURA, K				RA, CS; YASUDA, M; YAGITA, H; OKUMURA, K			FIBRONECTIN RECEPTOR INTEGRINS ARE INVOLVED IN MAST-CELL ACTIVATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1993 Conference	JUL   17, 1993	TOKYO, JAPAN			MAST CELL; ADHESION MOLECULE; INTEGRIN; FIBRONECTIN; LAMININ; FC-EPSILON-RI; CYTOKINE; DEGRANULATION; ALLERGY; MAST CELL SURVIVAL	AFFINITY IGE RECEPTOR; PROTEIN-TYROSINE KINASE; TRANSFECTED CELLS; PHOSPHORYLATION; AGGREGATION; EXPRESSION; ENGAGEMENT; ADHERENCE; CHAIN	Mast cells express fibronectin-receptor integrins on the cell surface which are involved in cellular activation. In this study rat and mouse mast cells adhered to fibronectin through very late antigen 4, 5 (beta 1 integrin) and vitronectin receptor (beta 3 integrin), and engagement of these receptors promoted cellular degranulation induced by, cross-linking of the high-affinity IgE receptor. Blocking of these adhesion molecules by monoclonal antibodies remarkably reduced passive cutaneous anaphylaxis reaction in vivo. On fibronectin, cytokine release from mast cells on IgE receptor aggregation was also enhanced but not the expression of cytokine genes, with the exception of interleukin-3. Interleukin-3 gene expression was constitutively observed in mouse-cultured mast cells and significantly increased on fibronectin with a prolonged survival of the cells, suggesting that the autocrine or paracrine system of interleukin-3 secretion contributes to the prolonged survival of mast cells on fibronectin. Our findings presented here clearly indicate that the engagement of fibronectin-receptor integrins on mast cells increases the sensitivity of the cells for cellular activation. Taking into consideration. the fact that mast cells in the microenvironment are actually surrounded by other cells and extracellular matrix proteins, we identified significant roles of adhesion molecules on mast cells in the allergic state and we hope to develop new strategies to manipulate these molecules for medical intervention in allergy.	JUNTENDO UNIV,SCH MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Juntendo University								BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; Busse WW, 1993, ALLERGY PRINCIPLES P, P105; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; EISEMAN E, 1992, NATURE, V355, P78; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; METZGER HK, 1989, IG MAST CELLS ALLERG, P93; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; THOMPSON HL, 1989, J IMMUNOL, V143, P4188; Yagita Hideo, 1993, P59	16	64	66	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1994	94	3	2	S			625	628		10.1016/0091-6749(94)90139-2	http://dx.doi.org/10.1016/0091-6749(94)90139-2			4	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PH235	8083471				2022-12-18	WOS:A1994PH23500008
J	SANTING, RE; OLYMULDER, CG; ZAAGSMA, J; MEURS, H				SANTING, RE; OLYMULDER, CG; ZAAGSMA, J; MEURS, H			RELATIONSHIPS AMONG ALLERGEN-INDUCED EARLY AND LATE-PHASE AIRWAY OBSTRUCTIONS, BRONCHIAL HYPERREACTIVITY, AND INFLAMMATION IN CONSCIOUS, UNRESTRAINED GUINEA-PIGS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EARLY AND LATE PHASE AIRWAY OBSTRUCTIONS; BRONCHIAL HYPERREACTIVITY; AIRWAY INFLAMMATION; UNRESTRAINED GUINEA PIGS; ALLERGIC ASTHMA	LATE ASTHMATIC RESPONSE; BRONCHOALVEOLAR LAVAGE; SMOOTH-MUSCLE; EOSINOPHIL ACCUMULATION; LEUKOCYTE INFILTRATION; INDUCED INCREASE; RESPONSIVENESS; CHALLENGE; HISTAMINE; ANTIGEN	The relationships among allergen-induced early asthmatic reactions (EARs) and late asthmatic reactions (LARs), early (between EAR and LAR) and lace (after LAR) changes in bronchial reactivity to histamine and infiltration of inflammatory cells into the airways were investigated with a new model of chronically instrumented, unrestrained, and ovalbumin-sensitized guinea pigs. Two different provocation strategies were examined. With the use of stepwise increasing allergen concentrations, all 21 animals responded with an EAR, which in 15 animals (71%) was followed by an LAR. By inhalation of a single allergen concentration for up to 15 minutes, II of 14 animals showed an EAR, which in 10 animals (71%) was followed by an LAR One animal did not respond, whereas the remaining two showed only an LAR. At 6 hours (after the EAR) and 24 hours (after the LAR) after allergen provocation, a significant bronchial hyperreactivity (BHR) toward histamine aerosol was observed in the dual responding animals (both protocols), but no significant changes were observed in animals with a single EAR or a single LAR. Significant correlations were found between the initial increase in airway obstruction after allergen provocation and the severity of the EAR and LAR as well as the early and late BHR; in addition, a significant correlation was found between the early and late BHR. In contrast, the severity of the LAR did not correlate with the BHR at 6 hours and 24 hoots. At 6 hours, there was a marked tendency to an increase in the number of eosinophils and a significant increase in the number of neutrophils in the bronchoalveolar lavage. At 24 hours after provocation, the number of eosinophils and neutrophils was significantly enhanced. These data suggest that early activation of mast cells and/or inflammatory leukocytes may determine the development of the LAR, as well as the early and late BHR, although there appears to be no causal relationship between the BHR at both time points and the severity of the LAR. The relationships among allergen-induced EAR and LAR, early and late BHR and airway inflammation observed in the new guinea pig model are strikingly similar to those observed in. patients with asthma.			SANTING, RE (corresponding author), UNIV GRONINGEN,CTR PHARM,DEPT PHARMACOL & THERAPEUT,A DUESINGLAAN 2,9713 AW GRONINGEN,NETHERLANDS.							AALBERS R, 1991, AM REV RESPIR DIS, V144, P352, DOI 10.1164/ajrccm/144.2.352; AALBERS R, 1993, CHEST, V103, P1178, DOI 10.1378/chest.103.4.1178; AMYOT R, 1986, ANESTHESIOLOGY, V64, P758, DOI 10.1097/00000542-198606000-00014; ANDERSSON P, 1988, INT ARCH ALLER A IMM, V87, P32, DOI 10.1159/000234645; ANDERSSON P, 1980, ALLERGY, V35, P65, DOI 10.1111/j.1398-9995.1980.tb01718.x; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; BARNES PJ, 1986, LANCET, V1, P242; BERNSTEIN DI, 1992, CHEST, V101, P437, DOI 10.1378/chest.101.2.437; BOICHOT E, 1991, CLIN EXP ALLERGY, V21, P67, DOI 10.1111/j.1365-2222.1991.tb00806.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1987, THORAX, V42, P302, DOI 10.1136/thx.42.4.302; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COYLE AJ, 1988, EUR J PHARMACOL, V148, P51, DOI 10.1016/0014-2999(88)90453-0; DAFFONCHIO L, 1988, BRIT J PHARMACOL, V94, P663, DOI 10.1111/j.1476-5381.1988.tb11573.x; Dahl R, 1988, ASTHMA BASIC MECHANI, P115; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DUNN CJ, 1988, AM REV RESPIR DIS, V137, P541, DOI 10.1164/ajrccm/137.3.541; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; FARMER SG, 1987, TRENDS PHARMACOL SCI, V8, P8, DOI 10.1016/0165-6147(87)90021-6; FLAVAHAN NA, 1985, J APPL PHYSIOL, V58, P834, DOI 10.1152/jappl.1985.58.3.834; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; HUTSON PA, 1988, AM REV RESPIR DIS, V137, P548, DOI 10.1164/ajrccm/137.3.548; IIJIMA H, 1987, AM REV RESPIR DIS, V136, P922, DOI 10.1164/ajrccm/136.4.922; JOHNS K, 1990, AM REV RESPIR DIS, V142, P138, DOI 10.1164/ajrccm/142.1.138; KALLOS P, 1984, INT ARCH ALLER A IMM, V73, P77, DOI 10.1159/000233441; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MEURS H, 1991, INFLAMMATORY CELLS M, P1; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; POPA V, 1973, J ALLERGY CLIN IMMUN, V51, P344, DOI 10.1016/0091-6749(73)90073-0; PRETOLANI M, 1988, AM REV RESPIR DIS, V138, P1572, DOI 10.1164/ajrccm/138.6.1572; SANJAR S, 1990, BRIT J PHARMACOL, V99, P679, DOI 10.1111/j.1476-5381.1990.tb12989.x; SANTING RE, 1992, PULM PHARMACOL, V5, P265, DOI 10.1016/0952-0600(92)90069-S; Smith H, 1989, Pulm Pharmacol, V2, P59, DOI 10.1016/0952-0600(89)90026-4; THORPE JE, 1987, CHEST, V91, P21, DOI 10.1378/chest.91.1.21; VANAMSTERDAM RGM, 1991, J PHARM PHARMACOL, V10, P694; VETTERMANN J, 1989, J APPL PHYSIOL, V66, P2698, DOI 10.1152/jappl.1989.66.6.2698; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WIESLANDER E, 1985, AGENTS ACTIONS, V16, P37, DOI 10.1007/BF01999639	39	64	72	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					1021	1030		10.1016/S0091-6749(94)70051-6	http://dx.doi.org/10.1016/S0091-6749(94)70051-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006307	Bronze			2022-12-18	WOS:A1994NT17200011
J	OBRIEN, RM; THOMAS, WR; WOOTTON, AM				OBRIEN, RM; THOMAS, WR; WOOTTON, AM			T-CELL RESPONSES TO THE PURIFIED MAJOR ALLERGENS FROM THE HOUSE DUST MITE DERMATOPHAGOIDES-PTERONYSSINUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HOUSE DUST MITE; DER P I; DER P II; DER F II; T-CELL PROLIFERATION; ASTHMA; ALLERGY	ATOPIC-DERMATITIS; IMMUNOGLOBULIN-E; MEDIATED-IMMUNITY; IGE SYNTHESIS; P-II; FARINAE; ASTHMA; HYPERSENSITIVITY; RESPONSIVENESS; LYMPHOCYTES	Proliferation assays were used to determine peripheral blood T cell responses to affinity-purified Der p I, Der p II, and Der f II allergens. Patients studied were sensitive to the house dust mite (HDM) either alone or in combination with other allergens. Control subjects were both nonatopic and atopic non-HDM sensitive. In general, only HDM-sensitive patients responded to the mite allergens. Mean stimulation indices (SI) were 10.2 +/- 2.8 (SEM) for Der p I and 10.0 +/- 2.2 for Der p II in HDM-sensitive individuals, and 2.0 +/- 0.2 and 2.8 +/- 0.6 for non-HDM sensitive control subjects (p < 0.001). Patients sensitive to HDM and other allergens had higher responses than subjects sensitive to HDM alone, and the degree of proliferation to Der p I and Der p II was well correlated in individual patients (r = 0. 71; p < 0.001). Total IgE levels were elevated in the allergic patients, and values were highly correlated with the SI for both Der p I and Der p II (p < 0.001). Responses to Der p II and Der f II were equivalent in 82% of individuals; however, in 18%, there was a marked discordance with strong responses to Der p II only. SIs were compared between different clinical groups of patients, and patients with asthma had significantly higher values to both Der p I and Der p II than patients with rhinitis alone (17.0 +/- 5.4 versus 5.7 +/- 1.0 for Der p I, p < 0.05; 14.3 +/- 6.8 versus 5.0 +/- 1.0 for Der p II, p < 0.05).	PRINCESS MARGARET HOSP,WESTERN AUSTRALIAN RES INST CHILD HLTH,PERTH,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT BIOCHEM,PARKVILLE,VIC 3050,AUSTRALIA	Telethon Kids Institute; University of Western Australia; Royal Melbourne Hospital	OBRIEN, RM (corresponding author), UNIV MELBOURNE,WESTERN HOSP,DEPT MED,GORDON ST,FOOTSCRAY,VIC 3011,AUSTRALIA.							BLACK PL, 1980, J ALLERGY CLIN IMMUN, V66, P394, DOI 10.1016/0091-6749(80)90119-0; CAVAILLON JM, 1988, ALLERGY, V43, P146, DOI 10.1111/j.1398-9995.1988.tb00409.x; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124, DOI 10.1159/000235102; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; COFFMAN RL, 1986, J IMMUNOL, V136, P949; ELLIOTT ST, 1979, ARCH DERMATOL, V115, P36, DOI 10.1001/archderm.115.1.36; ELLISTON WL, 1982, ARCH DERMATOL, V118, P26, DOI 10.1001/archderm.118.1.26; FREIDHOFF LR, 1984, J ALLERGY CLIN IMMUN, V73, P490, DOI 10.1016/0091-6749(84)90360-9; FRIEDHOFF LR, 1990, GENETIC ENV FACTORS, P53; GERRARD JW, 1978, AM J HUM GENET, V30, P46; HAENEY M, 1985, J ROY COLL PHYS LOND, V19, P147; HALVORSEN R, 1986, INT ARCH ALLER A IMM, V80, P62, DOI 10.1159/000234027; HIRATANI M, 1981, J ALLERGY CLIN IMMUN, V68, P205, DOI 10.1016/0091-6749(81)90185-8; HOVMARK A, 1977, ACTA DERM-VENEREOL, V57, P237; ISHIZAKA K, 1984, ANNU REV IMMUNOL, V2, P159, DOI 10.1146/annurev.immunol.2.1.159; KAPMEYER W, 1987, Annals of Clinical Biochemistry, V24, P188; KIMURA JY, 1990, IMMUNOLOGY, V70, P385; KRILIS S, 1985, AUST NZ J MED, V15, P421, DOI 10.1111/j.1445-5994.1985.tb02764.x; LEMAO J, 1981, IMMUNOLOGY, V44, P239; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; OHEHIR RE, 1989, IMMUNOLOGY, V66, P499; OHEHIR RE, 1987, IMMUNOLOGY, V62, P635; ORANGE RP, 1971, J EXP MED, V134, pS136; PARK HS, 1989, ANN ALLERGY, V63, P399; Pepys J., 1975, BR J HOSP MED, V14, P412; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROMAGNANI S, 1973, Clinical Allergy, V3, P51, DOI 10.1111/j.1365-2222.1973.tb01309.x; SMITH JM, 1969, BRIT MED J, V1, P723; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; THOMPSON SJ, 1988, IMMUNOLOGY, V64, P311; TOVEY ER, 1987, J ALLERGY CLIN IMMUN, V79, P93, DOI 10.1016/S0091-6749(87)80022-2; TRUDINGER M, 1991, CLIN EXP ALLERGY, V21, P33, DOI 10.1111/j.1365-2222.1991.tb00801.x; VANASPEREN PP, 1980, MED J AUSTRALIA, V2, P266; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; VICHYANOND P, 1990, ASIAN PAC J ALLERGY, V8, P1; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6; YOO TJ, 1977, ACTA ALLERGOL, V32, P227, DOI 10.1111/j.1398-9995.1977.tb01355.x; YUUKI T, 1990, Japanese Journal of Allergology, V39, P557	44	64	64	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1992	89	5					1021	1031		10.1016/0091-6749(92)90225-Q	http://dx.doi.org/10.1016/0091-6749(92)90225-Q			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HU542	1583244				2022-12-18	WOS:A1992HU54200013
J	BARANIUK, JN; KALINER, MA				BARANIUK, JN; KALINER, MA			NEUROPEPTIDES AND NASAL SECRETION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID, CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10, ROOM 11C205, BETHESDA, MD 20892 USA; NATL HEART & LUNG INST, LONDON, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Imperial College London				Baraniuk, James Nicholas/0000-0002-1866-4177				Andersen, 1982, NOSE UPPER AIRWAY PH, P45; BARANIUK JN, 1990, J CLIN INVEST, V85, P998, DOI 10.1172/JCI114577; BARANIUK JN, 1990, IMMUNOL ALLERGY CLIN, V10, P383; BARANIUK JN, 1990, AM REV RESPIR DIS, V141, P706, DOI 10.1164/ajrccm/141.3.706; BARANIUK JN, IN PRESS AM J PHYSL; BARANIUK JN, IN PRESS AM J RESPIR; BARANIUK JN, IN PRESS J CLIN INVE; BARNES PJ, 1987, AM REV RESPIR DIS, V136, pS77, DOI 10.1164/ajrccm/136.6_Pt_2.S77; BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; BRODFELDT S, 1986, AM REV RESPIR DIS, V133, P1138; BROWN DR, 1987, AM REV RESPIR DIS S, V136, pS44; CAUNA N, 1970, ANN OTO RHINOL LARYN, V79, P443, DOI 10.1177/000348947007900303; CAUNA N, 1969, ANN OTO RHINOL LARYN, V78, P865, DOI 10.1177/000348946907800418; COLES SJ, 1981, AM REV RESPIR DIS, V124, P531; COLES SJ, 1984, CIBA F SYMP, V109, P40, DOI 10.1002/9780470720905.ch4; DEVILLIER P, 1989, EUR J PHARMACOL, V168, P53, DOI 10.1016/0014-2999(89)90632-8; DEVILLIER P, 1988, EUR RESPIR J, V1, P356; Eccles R., 1982, NOSE UPPER AIRWAY PH, P191; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; EVANS TW, 1988, BRIT J CLIN PHARMACO, V25, P273, DOI 10.1111/j.1365-2125.1988.tb03302.x; GAMSE R, 1985, EUR J PHARMACOL, V114, P61, DOI 10.1016/0014-2999(85)90520-5; GEPPETTI P, 1988, BRIT J PHARMACOL, V93, P509, DOI 10.1111/j.1476-5381.1988.tb10305.x; GEPPETTI P, 1988, BRIT J PHARMACOL, V94, P288, DOI 10.1111/j.1476-5381.1988.tb11528.x; GEURKINK N, 1983, J ALLERGY CLIN IMMUN, V72, P123, DOI 10.1016/0091-6749(83)90518-3; GREENE R, 1988, J APPL PHYSIOL, V64, P2249, DOI 10.1152/jappl.1988.64.5.2249; HOLTZER P, 1988, NEUROSCIENCE, V24, P739; HUA XY, 1986, ACTA PHYSIOL SCAND, V127, P1; ILIOPOULOS O, 1988, AM J RHINOL, V2, P97; ITOH N, 1983, NATURE, V304, P547, DOI 10.1038/304547a0; JACQUES L, 1989, N-S ARCH PHARMACOL, V340, P170; JENEY E, 1989, J ALLERGY CLIN IMMUN, V83, P214; KARLSSON G, 1986, EUR J CLIN PHARMACOL, V30, P355, DOI 10.1007/BF00541544; KHALIL Z, 1988, EUR J PHARMACOL, V151, P281, DOI 10.1016/0014-2999(88)90809-6; KONNO A, 1979, ANN OTO RHINOL LARYN, V88, P258, DOI 10.1177/000348947908800219; LACROIX JS, 1989, ACTA PHYSIOL SCAND, V136, P1; LAITINEN LA, 1987, AM REV RESPIR DIS, V136, pS65; LAZARUS SC, 1987, INT ARCH ALLER A IMM, V82, P372, DOI 10.1159/000234230; LINDGREN BR, 1988, ACTA PHYSIOL SCAND, V133, P1; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; LUND J, 1989, ENDOCR RES, V15, P17, DOI 10.3109/01902148909069606; LUNDBERG JM, 1984, NEUROSCI LETT, V52, P37, DOI 10.1016/0304-3940(84)90347-1; LUNDBERG JM, 1987, AM REV RESPIR DIS, V136, pS16, DOI 10.1164/ajrccm/136.6_Pt_2.S16; LUNDBLAD L, 1984, ACTA PHYSIOL SCAND, P1; LUNDGREN JD, 1990, J ALLERGY CLIN IMMUN, V85, P399, DOI 10.1016/0091-6749(90)90147-V; MARTLING CR, 1987, ACTA PHYSIOL SCAND, V130, P1; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; MIADONNA A, 1988, ANN ALLERGY, V61, P220; PERNOW J, 1988, ACTA PHYSL SCAND S, V568, pS1; PETERSSON G, 1989, ANN ALLERGY, V62, P410; POTTER EK, 1988, PHARMACOL THERAPEUT, V37, P251, DOI 10.1016/0163-7258(88)90028-9; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1989, J CLIN INVEST, V84, P1528, DOI 10.1172/JCI114329; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; RAPHAEL GD, 1988, AM J RHINOL, V2, P8; RAPHAEL GD, IN PRESS J ALLERGY C; REPTKE H, 1988, AGENTS ACTIONS, V23, P207; RICHARDSON PS, 1987, AM REV RESPIR DIS, V136, pS72, DOI 10.1164/ajrccm/136.6_Pt_2.S72; ROGERS DF, 1989, LANCET, V1, P930; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330, DOI 10.1164/ajrccm/137.6.1330; SHIMURA S, 1988, J APPL PHYSIOL, V65, P2537, DOI 10.1152/jappl.1988.65.6.2537; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; STAMMBERGER H, 1988, ANN OTO RHINOL LARYN, V97, P3, DOI 10.1177/00034894880970S501; STEAD RH, 1987, IMMUNOL REV, V100, P333, DOI 10.1111/j.1600-065X.1987.tb00538.x; STERANKA LR, 1988, P NATL ACAD SCI USA, V85, P3245, DOI 10.1073/pnas.85.9.3245; STIMLERGERARD NP, 1987, J CLIN INVEST, V79, P1819, DOI 10.1172/JCI113023; STJARNE P, 1989, BRIT J PHARMACOL, V96, P693, DOI 10.1111/j.1476-5381.1989.tb11870.x; STRETTON CD, 1988, BRIT J PHARMACOL, V93, P672, DOI 10.1111/j.1476-5381.1988.tb10325.x; SUNDAY ME, 1988, LAB INVEST, V59, P5; TOGIAS A, 1988, J ALLERGY CLIN IMMUN, V81, P782, DOI 10.1016/0091-6749(88)90932-3; TONNESEN P, 1987, ALLERGY, V42, P146, DOI 10.1111/j.1398-9995.1987.tb02373.x; UDDMAN R, 1986, CLIN CHEST MED, V7, P201; WALKER KB, 1988, J CLIN IMMUNOL, V8, P108, DOI 10.1007/BF00917898; YOKOTA Y, IN PRESS J BIOL CHEM	76	64	65	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	2	S			620	627		10.1016/S0091-6749(05)80226-X	http://dx.doi.org/10.1016/S0091-6749(05)80226-X			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH093	2229824				2022-12-18	WOS:A1990EH09300007
J	GRIFFIN, P; FORD, AW; ALTERMAN, L; THOMPSON, J; PARKINSON, C; BLAINEY, AD; DAVIES, RJ; TOPPING, MD				GRIFFIN, P; FORD, AW; ALTERMAN, L; THOMPSON, J; PARKINSON, C; BLAINEY, AD; DAVIES, RJ; TOPPING, MD			ALLERGENIC AND ANTIGENIC RELATIONSHIP BETWEEN 3 SPECIES OF STORAGE MITE AND THE HOUSE DUST MITE, DERMATOPHAGOIDES-PTERONYSSINUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									OCCUPAT MED & HYG LAB,HLTH & SAFETY,403 EDGWARE RD,LONDON NW2 6LN,ENGLAND; NATL INST BIOL STANDARDS & CONTROL,POTTERSBAR,HERTS,ENGLAND; MAFF,SLOUGH,BERKS,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON EC1A 7BE,ENGLAND	National Institute for Biological Standards & Control; University of London; Queen Mary University London								AGHA M, 1981, CLIN ALLERGY, V11, P499, DOI 10.1111/j.1365-2222.1981.tb01625.x; ARLAIN LG, 1984, J ALLERGY CLIN IMMUN, V74, P172; ARLAIN LG, 1984, J ALLERGY CLIN IMMUN, V74, P166; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BLAINEY AD, 1986, J ALLERGY CLIN IMMUN, V77, P173; BLAINEY AD, 1988, THORAX, V43, P697, DOI 10.1136/thx.43.9.697; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CUTHBERT OD, 1984, CLIN ALLERGY, V14, P197, DOI 10.1111/j.1365-2222.1984.tb02653.x; CUTHBERT OD, 1979, CLIN ALLERGY, V9, P229, DOI 10.1111/j.1365-2222.1979.tb01547.x; GRIFFITHS DA, 1971, ANN APPL BIOL, V82, P180; HAGE-HAMSTEN M V, 1987, Clinical Allergy, V17, P23, DOI 10.1111/j.1365-2222.1987.tb02316.x; HAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P417; HARBOE N, 1973, Scandinavian Journal of Immunology, V2, P161; HILLERDAL G, 1982, ALLERGY, V37, P475, DOI 10.1111/j.1398-9995.1982.tb02330.x; INGRAM CG, 1979, LANCET, V2, P1330; KORSGAARD J, 1985, ALLERGOL IMMUNOPATH, V13, P143; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; LOWRY OH, 1951, J BIOL CHEM, V193, P265; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WARREN CPW, 1983, ANN ALLERGY, V50, P30; WRAITH DG, 1979, CLIN ALLERGY, V9, P545, DOI 10.1111/j.1365-2222.1979.tb00478.x	25	64	67	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1989	84	1					108	117		10.1016/0091-6749(89)90184-X	http://dx.doi.org/10.1016/0091-6749(89)90184-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG120	2754141				2022-12-18	WOS:A1989AG12000015
J	SCHUMACHER, MJ				SCHUMACHER, MJ			RHINOMANOMETRY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SCHUMACHER, MJ (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,DEPT PEDIAT,TUCSON,AZ 85724, USA.							ANCH AM, 1982, J APPL PHYSIOL, V53, P1158, DOI 10.1152/jappl.1982.53.5.1158; Arbour P, 1975, Can J Otolaryngol, V4, P333; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; CHABAN R, 1988, ARCH OTOLARYNGOL, V114, P413; CHADHA TS, 1987, CHEST, V92, P1037, DOI 10.1378/chest.92.6.1037; CHOWANETZ W, 1987, B EUR PHYSIOPATH RES, V23, P125; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P921; COLE P, 1979, ACTA OTO-LARYNGOL, V88, P148, DOI 10.3109/00016487909137154; COLE P, 1985, AM REV RESPIR DIS, V132, P1229; COLE P, 1986, ANN OTO RHINOL LARYN, V95, P233, DOI 10.1177/000348948609500305; COLE P, 1980, ACTA OTO-LARYNGOL, V90, P139, DOI 10.3109/00016488009131709; COLE P, 1988, ARCH OTOLARYNGOL, V114, P440; DALLIMORE NS, 1977, ACTA OTO-LARYNGOL, V84, P416, DOI 10.3109/00016487709123985; DEBONILLA JS, 1986, ANN OTO RHINOL LARYN, V95, P229, DOI 10.1177/000348948609500304; DVILLIER P, 1988, EUR RESPIR J, V1, P356; DVORACEK JE, 1985, J ALLERGY CLIN IMMUN, V76, P577, DOI 10.1016/0091-6749(85)90778-X; FULLTON JM, 1984, ANN OTO RHINOL LARYN, V93, P140, DOI 10.1177/000348948409300208; GHAEM A, 1985, B EUR PHYSIOPATH RES, V21, P11; HAIGHT JSJ, 1983, LARYNGOSCOPE, V93, P49; HARTGERINK DV, 1987, AM J ORTHOD DENTOFAC, V92, P381, DOI 10.1016/0889-5406(87)90258-7; HASEGAWA M, 1982, ANN OTO RHINOL LARYN, V91, P112, DOI 10.1177/000348948209100125; HAVAS TE, 1986, J ALLERGY CLIN IMMUN, V78, P856, DOI 10.1016/0091-6749(86)90230-7; Heetderks DR, 1927, AM J MED SCI, V174, P231, DOI 10.1097/00000441-192708000-00008; HERSHEY HG, 1976, AM J ORTHOD DENTOFAC, V69, P274, DOI 10.1016/0002-9416(76)90076-2; HOSHINO T, 1988, LARYNGOSCOPE, V98, P219; KENYON GS, 1987, J LARYNGOL OTOL, V101, P910, DOI 10.1017/S0022215100102968; Kern E B, 1973, Otolaryngol Clin North Am, V6, P863; MCCAFFREY TV, 1979, ARCH OTOLARYNGOL, V105, P542; MCLEAN JA, 1977, J ALLERGY CLIN IMMUN, V59, P165, DOI 10.1016/0091-6749(77)90220-2; MCNICHOLAS WT, 1982, AM REV RESPIR DIS, V126, P625; NIINIMAA V, 1979, J APPL PHYSIOL, V47, P1336, DOI 10.1152/jappl.1979.47.6.1336; OKUDA M, 1988, ANN ALLERGY, V60, P537; OLSON LG, 1987, AM REV RESPIR DIS, V135, P356; PESLIN R, 1985, AM REV RESPIR DIS, V132, P712; POLGAR G, 1965, J PEDIATR-US, V67, P557, DOI 10.1016/S0022-3476(65)80425-5; POLGAR G, 1967, BIOL NEONATORUM, V11, P1; RAO S, 1970, J APPL PHYSIOL, V28, P162, DOI 10.1152/jappl.1970.28.2.162; RICHERSON HB, 1968, J ALLERGY, V41, P269, DOI 10.1016/0021-8707(68)90032-4; RUNDCRANTZ H, 1969, ACTA OTO-LARYNGOL, V68, P435, DOI 10.3109/00016486909121582; SCHUMACHER MJ, 1979, J ALLERGY CLIN IMMUN, V64, P202, DOI 10.1016/0091-6749(79)90096-4; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V77, P241; SCHUMACHER MJ, 1985, COMPUT BIOL MED, V15, P187, DOI 10.1016/0010-4825(85)90060-5; SCHUMACHER MJ, 1987, IMMUNOL ALLERGY CLIN, V7, P15; STOCKS J, 1978, RESP PHYSIOL, V34, P233, DOI 10.1016/0034-5687(78)90031-2; STROHL KP, 1982, J APPL PHYSIOL, V52, P1432, DOI 10.1152/jappl.1982.52.6.1432; TONNESEN P, 1987, ALLERGY, V42, P447, DOI 10.1111/j.1398-9995.1987.tb00361.x; Unno T, 1986, Rhinology, V24, P49; VANCAUWENBERGE PB, 1984, ARCH OTOLARYNGOL, V110, P108; WALKER SB, 1985, J ALLERGY CLIN IMMUN, V76, P158, DOI 10.1016/0091-6749(85)90694-3	50	64	65	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					711	721		10.1016/0091-6749(89)90001-8	http://dx.doi.org/10.1016/0091-6749(89)90001-8			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2651505				2022-12-18	WOS:A1989U342000001
J	PAUWELS, RA				PAUWELS, RA			NEW ASPECTS OF THE THERAPEUTIC POTENTIAL OF THEOPHYLLINE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											PAUWELS, RA (corresponding author), STATE UNIV GHENT HOSP,DEPT RESP DIS,DE PINTELAAN 185,B-9000 GHENT,BELGIUM.							ANDERSSON P, 1985, ANTIASTHMA XANTHINES, P187; BUSSOLINO F, 1980, IMMUNOLOGY, V40, P367; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; JENNE JW, 1987, DRUG THERAPY ASTHMA, P297; KALINER M, 1974, BIOCHEM PHARMACOL, V23, P763, DOI 10.1016/0006-2952(74)90206-8; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; MAPP C, 1987, AM REV RESPIR DIS, V136, P1403, DOI 10.1164/ajrccm/136.6.1403; MARQUARDT DL, 1984, P NATL ACAD SCI USA, V81, P192; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; NADEL JA, 1984, J ALLERGY CLIN IMMUN, V73, P651, DOI 10.1016/0091-6749(84)90299-9; NELSON S, 1985, AM REV RESPIR DIS, V131, P923; NIELSON CP, 1988, AM REV RESPIR DIS, V137, P25, DOI 10.1164/ajrccm/137.1.25; NIELSON CP, 1986, J ALLERGY CLIN IMMUN, V78, P660, DOI 10.1016/0091-6749(86)90086-2; OBRYNE PM, 1987, AM REV RESPIR DIS, V136, P740; PAGE CP, 1986, EUR J RESPIR DIS, V68, P163; PAUWELS R, 1986, EUR J RESPIR DIS, V68, P137; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PAUWELS R, 1987, CHEST, V92, pS32, DOI 10.1378/chest.92.1_Supplement.32S; PAUWELS R, 1984, SUSTAINED RELEASE TH, P9; PAUWELS R, UNPUB EFFECT ENDOTOX; PAUWELS R, UNPUB EFFECT THEOPHY; PAVIA D, 1983, EUR J RESPIR DIS, V64, P304; PERRUCHOUD A P, 1984, Respiration, V46, P44; PERSSON CGA, 1979, ACTA PHARMACOL TOX, V44, P216; WEISSMAN.G, 1971, NATURE-NEW BIOL, V231, P131, DOI 10.1038/newbio231131a0; WELTON AF, 1980, BIOCHEM PHARMACOL, V29, P1085, DOI 10.1016/0006-2952(80)90400-1	29	64	64	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	2				548	553		10.1016/0091-6749(89)90036-5	http://dx.doi.org/10.1016/0091-6749(89)90036-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4491	2645351				2022-12-18	WOS:A1989T449100007
J	ROWNTREE, S; PLATTSMILLS, TAE; COGSWELL, JJ; MITCHELL, EB				ROWNTREE, S; PLATTSMILLS, TAE; COGSWELL, JJ; MITCHELL, EB			A SUBCLASS IGG4-SPECIFIC ANTIGEN-BINDING RADIOIMMUNOASSAY (RIA) - COMPARISON BETWEEN IGG AND IGG4 ANTIBODIES TO FOOD AND INHALED ANTIGENS IN ADULT ATOPIC-DERMATITIS AFTER DESENSITIZATION-TREATMENT AND DURING DEVELOPMENT OF ANTIBODY-RESPONSES IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWICK PK HOSP, CLIN RES CTR, HARROW HA1 3UJ, MIDDX, ENGLAND; UNIV VIRGINIA, DEPT MED, DIV ALLERGY & CLIN IMMUNOL, CHARLOTTESVILLE, VA 22903 USA; POOLE GEN HOSP, POOLE, DORSET, ENGLAND	Imperial College London; University of Virginia; Poole Hospital					NIAID NIH HHS [AI-20565] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020565, R01AI020565] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERSE RC, 1983, J IMMUNOL, V130, P722; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BRUYNZEEL PLB, 1979, INT ARCH ALLER A IMM, V58, P344, DOI 10.1159/000232211; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431, DOI 10.1159/000232471; DEVEY M E, 1975, Clinical Allergy, V5, P353, DOI 10.1111/j.1365-2222.1975.tb01874.x; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; EASTHAM EJ, 1979, GASTROENTEROLOGY, V76, P365; FAGAN DL, 1982, J ALLERGY CLIN IMMUN, V70, P399, DOI 10.1016/0091-6749(82)90031-8; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GOLDSTEIN GB, 1970, J ALLERGY, V46, P270, DOI 10.1016/0021-8707(70)90068-7; GWYNN CM, 1982, LANCET, V2, P1339; GWYNN CM, 1982, LANCET, V1, P254; HAMMARSTROM L, 1984, CLIN EXP IMMUNOL, V55, P593; LOWE J, 1982, IMMUNOLOGY, V47, P329; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MERRETT J, 1983, CLIN ALLERGY, V13, P397, DOI 10.1111/j.1365-2222.1983.tb02615.x; MERRETT J, 1984, CLIN EXP IMMUNOL, V56, P645; NAKAGAWA T, 1983, INT ARCH ALLER A IMM, V71, P122, DOI 10.1159/000233374; PARISH WE, 1970, LANCET, V2, P591; PARISH WE, 1981, BRIT J DERMATOL, V105, P223, DOI 10.1111/j.1365-2133.1981.tb01210.x; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; ROWNTREE S, 1986, INT ARCH ALLER A IMM, V79, P132, DOI 10.1159/000233960; SHAKIB F, 1980, RES CLIN LAB, V10, P463, DOI 10.1007/BF02938793; SHAKIB F, 1984, INT ARCH ALLER A IMM, V75, P107, DOI 10.1159/000233599; SHAKIB F, 1977, BRIT J DERMATOL, V97, P59, DOI 10.1111/j.1365-2133.1977.tb15428.x; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; VANTOORENENBERGEN AW, 1982, INT ARCH ALLER A IMM, V67, P117, DOI 10.1159/000233000; VIJAY HM, 1982, INT ARCH ALLER A IMM, V69, P489	32	64	64	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1987	80	4					622	630		10.1016/0091-6749(87)90017-0	http://dx.doi.org/10.1016/0091-6749(87)90017-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5224	3668126	Bronze			2022-12-18	WOS:A1987K522400017
J	BOUSQUET, J; HATTON, F; GODARD, P; MICHEL, FB				BOUSQUET, J; HATTON, F; GODARD, P; MICHEL, FB			ASTHMA MORTALITY IN FRANCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SERV INFORMAT CAUSES MED DECES,LE VESINET,FRANCE		BOUSQUET, J (corresponding author), CHU MONTPELLIER,MALAD RESP CLIN,AVE MAJOR FLANDRE,F-34059 MONTPELLIER,FRANCE.		Bousquet, Jean/O-4221-2019					ARNOLD AG, 1983, BR J DIS CHEST, V76, P157; BELLAMY D, 1979, THORAX, V34, P36, DOI 10.1136/thx.34.1.36; BURNEY PGJ, 1986, LANCET, V2, P323; CLUZEL M, 1986, J ALLERGY CLIN IMMUN, V77, P125; CUSHLEY MJ, 1983, J ROY SOC MED, V76, P662, DOI 10.1177/014107688307600808; DAVIS B, 1980, THORAX, V35, P111, DOI 10.1136/thx.35.2.111; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; GODARD P, IN PRESS HIGHLIGHTS; GRANT IWB, 1981, LANCET, V2, P36; HILLS E A, 1984, Thorax, V39, P505; INMAN WHW, 1969, LANCET, V2, P279; JACKSON RT, 1982, BRIT MED J, V285, P771, DOI 10.1136/bmj.285.6344.771; KLEBBA AJ, 1980, DHEW PHS801120 PUB S, V28; MCDONALD JB, 1976, BRIT MED J, V2, P721; NGUYEN MT, 1985, ANN ALLERGY, V55, P448; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; PAULOZZI LJ, 1986, ANN ALLERGY, V56, P392; REED CE, 1986, J ALLERGY CLIN IMMUN, V77, P537, DOI 10.1016/0091-6749(86)90342-8; SLY RM, 1984, ANN ALLERGY, V53, P20; SPEIZER FE, 1968, BRIT MED J, V1, P339, DOI 10.1136/bmj.1.5588.339; SPEIZER FE, 1968, BRIT MED J, V3, P245, DOI 10.1136/bmj.3.5612.245; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; SUTHERLAND DC, 1984, NEW ZEAL MED J, V97, P845; TATTERSFIELD AE, 1984, ASTHMA, P301; TROUSSEAU, 1867, LECTURES CLIN MED; WILSON JD, 1981, LANCET, V1, P1235; WOOD DW, 1976, CLIN PEDIATR, V15, P677, DOI 10.1177/000992287601500804; 1969, LANCET, V2, P305; 1982, BR MED J, V285, P1251; 1973, CAUSES DEATH DENMARK; 1969, CAUSES DEATHS	31	64	65	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			389	394		10.1016/0091-6749(87)90056-X	http://dx.doi.org/10.1016/0091-6749(87)90056-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037	3624689				2022-12-18	WOS:A1987K103700008
J	KINO, T; CHIHARA, J; FUKUDA, K; SASAKI, Y; SHOGAKI, Y; OSHIMA, S				KINO, T; CHIHARA, J; FUKUDA, K; SASAKI, Y; SHOGAKI, Y; OSHIMA, S			ALLERGY TO INSECTS IN JAPAN .3. HIGH-FREQUENCY OF IGE ANTIBODY-RESPONSES TO INSECTS (MOTH, BUTTERFLY, CADDIS FLY, AND CHIRONOMID) IN PATIENTS WITH BRONCHIAL-ASTHMA AND IMMUNOCHEMICAL QUANTITATION OF THE INSECT-RELATED AIRBORNE PARTICLES SMALLER THAN 10 MU-M IN DIAMETER	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											KINO, T (corresponding author), KYOTO UNIV, CHEST DIS RES INST, SAKYO KU, KYOTO 606, JAPAN.							AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V72, P40, DOI 10.1016/0091-6749(83)90050-7; AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; [Anonymous], 1966, HEALTH PHYS, V12, P173; BALYEAT RAY M., 1932, JOUR ALLERGY, V3, P227, DOI 10.1016/S0021-8707(32)90338-4; BAUR X, 1982, J ALLERGY CLIN IMMUN, V69, P66, DOI 10.1016/0091-6749(82)90090-2; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; ELRAB MOG, 1980, J ALLERGY CLIN IMMUN, V66, P190; IGARASHI T, 1985, ANN ALLERGY, V55, P375; ITO K, 1986, ANN ALLERGY, V57, P199; KINO T, 1978, J ALLERGY CLIN IMMUN, V61, P10, DOI 10.1016/0091-6749(78)90467-0; KINO T, 1979, J ALLERGY CLIN IMMUN, V64, P131, DOI 10.1016/0091-6749(79)90047-2; KINO T, 1978, JAP J ALLERGOL, V27, P31; MICHEL FB, 1977, AM REV RESPIR DIS, V115, P609; Parlato S.J., 1929, J ALLERGY, V1, P35; PERLMAN F, 1958, J ALLERGY, V29, P302, DOI 10.1016/0021-8707(58)90037-6	15	64	63	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1987	79	6					857	866		10.1016/0091-6749(87)90233-8	http://dx.doi.org/10.1016/0091-6749(87)90233-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	H9044	3294975				2022-12-18	WOS:A1987H904400005
J	MCFADDEN, ER				MCFADDEN, ER			NASAL-SINUS-PULMONARY REFLEXES AND BRONCHIAL-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									UNIV HOSP CLEVELAND,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106	University Hospitals of Cleveland; Case Western Reserve University	MCFADDEN, ER (corresponding author), UNIV HOSP CLEVELAND,CTR ASTHMA & ALLERG DIS,2074 ABINGDON RD,CLEVELAND,OH 44106, USA.							BROWN R, 1977, J APPL PHYSIOL, V42, P221, DOI 10.1152/jappl.1977.42.2.221; DALLIMORE NS, 1977, ACTA OTO-LARYNGOL, V84, P416, DOI 10.3109/00016487709123985; DAREMBERG C, 1854, OEUVRES ANATOMIQUES, V1; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DRETTNER B, 1970, ANN OTO RHINOL LARYN, V79, P499, DOI 10.1177/000348947007900311; FORSYTH RD, 1984, J APPL PHYSL, V55, P860; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; JUNTUNEN K, 1984, LARYNGOSCOPE, V94, P249, DOI 10.1288/00005537-198402000-00022; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KAUFMAN J, 1970, AM REV RESPIR DIS, V101, P768; KONNO A, 1985, ANN ALLERGY, V54, P50; MCFADDEN ER, 1984, J ALLERGY CLIN IMMUN, V73, P413, DOI 10.1016/0091-6749(84)90347-6; MYGIND N, 1979, NASAL ALLERGY, P1; OGURA JH, 1971, ACTA OTO-LARYNGOL, V71, P123, DOI 10.3109/00016487109125340; PROCTOR DF, 1983, EUR J RESPIR DIS, V64, P89; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RICHERSON HB, 1968, J ALLERGY, V41, P269, DOI 10.1016/0021-8707(68)90032-4; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; SCHNEIDER KV, 1660, LIBER PRIMUS CATARRH; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SERCER A., 1930, ADA OTO LARYNGOL, V14, P82, DOI 10.3109/00016483009121625; SLAVIN RG, 1980, J ALLERGY CLIN IMMUN, V66, P250, DOI 10.1016/0091-6749(80)90048-2; Sluder G, 1919, J AMER MED ASSOC, V73, P589, DOI 10.1001/jama.1919.02610340021006; SYABBALO NC, 1985, B EUR PHYSIOPATH RES, V21, P507; YAN K, 1983, EUR J RESPIR DIS, V64, P105	27	64	65	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				1	3		10.1016/0091-6749(86)90106-5	http://dx.doi.org/10.1016/0091-6749(86)90106-5			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3522705				2022-12-18	WOS:A1986D299600001
J	GRUNDBACHER, FJ; MASSIE, FS				GRUNDBACHER, FJ; MASSIE, FS			LEVELS OF IMMUNOGLOBULIN-G, IMMUNOGLOBULIN-M, IMMUNOGLOBULIN-A, AND IMMUNOGLOBULIN-E AT VARIOUS AGES IN ALLERGIC AND NONALLERGIC BLACK AND WHITE INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,PEDIAT ALLERGY CLIN,RICHMOND,VA 23298	Virginia Commonwealth University	GRUNDBACHER, FJ (corresponding author), UNIV ILLINOIS,COLL MED,DEPT BASIC SCI,POB 1649,PEORIA,IL 61656, USA.				NIAID NIH HHS [AI 12460] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BRODER I, 1974, J ALLERGY CLIN IMMUN, V53, P127, DOI 10.1016/0091-6749(74)90001-3; BUCKLEY RH, 1975, IMMUNODEFICIENCY MAN, P134; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; GOBLE FC, 1973, T NEW YORK ACAD SCI, V35, P325, DOI 10.1111/j.2164-0947.1973.tb01971.x; GRUNDBACHER FJ, 1972, SCIENCE, V176, P311, DOI 10.1126/science.176.4032.311; GRUNDBACHER FJ, 1974, AM J HUM GENET, V26, P1; GRUNDBACHER FJ, 1976, EXPERIENTIA, V32, P1063, DOI 10.1007/BF01933973; GRUNDBACHER FJ, 1980, EXPERIENTIA, V36, P1360, DOI 10.1007/BF01960097; GRUNDBACHER FJ, 1975, J ALLERGY CLIN IMMUN, V56, P104, DOI 10.1016/0091-6749(75)90114-1; JOHANSSON SGO, 1978, ALLERGY PRINCIPLES P, P551; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; ORGEL HA, 1974, J ALLERGY CLIN IMMUN, V53, P213, DOI 10.1016/0091-6749(74)90083-9; ROBERTS J, 1973, US VITAL HLTH STA 11, V129; SMITH JM, 1983, ALLERGY PRINCIPLES P, P771; THOMAS J, 1979, ANN ALLERGY, V43, P144; WASHBURN TC, 1965, PEDIATRICS, V35, P57; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3	20	64	64	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					651	658		10.1016/0091-6749(85)90089-2	http://dx.doi.org/10.1016/0091-6749(85)90089-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	4008794	Bronze			2022-12-18	WOS:A1985ALA8400004
J	ZETTERSTROM, O; NORDVALL, SL; BJORKSTEN, B; AHLSTEDT, S; STELANDER, M				ZETTERSTROM, O; NORDVALL, SL; BJORKSTEN, B; AHLSTEDT, S; STELANDER, M			INCREASED IGE ANTIBODY-RESPONSES IN RATS EXPOSED TO TOBACCO-SMOKE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV UPPSALA,DEPT PEDIAT,S-75105 UPPSALA,SWEDEN; UNIV UPPSALA,DEPT HYG,S-75105 UPPSALA,SWEDEN; LINKOPING UNIV,DEPT PEDIAT,S-58183 LINKOPING,SWEDEN; PHARMACIA AB,DEPT EXPTL ALLERGY RES,UPPSALA,SWEDEN; GOTHENBURG UNIV,DEPT CLIN IMMUNOL,S-41124 GOTHENBURG,SWEDEN	Uppsala University; Uppsala University; Linkoping University; Pfizer; Pharmacia Corporation; University of Gothenburg	ZETTERSTROM, O (corresponding author), KAROLINSKA HOSP,DEPT LUNG MED,S-10401 STOCKHOLM 60,SWEDEN.							AHLSTEDT S, 1983, IMMUNOLOGY, V48, P247; AHLSTEDT S, 1983, INT ARCH ALLER A IMM, V71, P293, DOI 10.1159/000233410; BAHNA SL, 1983, ALLERGY, V38, P57, DOI 10.1111/j.1398-9995.1983.tb00857.x; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; DALHAMN T, 1966, AM REV RESPIR DIS, V94, P799; DONTENWILL W, 1973, JNCI-J NATL CANCER I, V51, P1781, DOI 10.1093/jnci/51.6.1781; FRANCUS T, 1983, P NATL ACAD SCI-BIOL, V80, P3430, DOI 10.1073/pnas.80.11.3430; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; FRICK OL, 1981, CLIN IMMUNOL ALLERGY, P283; GERRARD JW, 1980, ANN ALLERGY, V44, P261; HALLGREN R, 1982, ACTA MED SCAND, V211, P269; HOLBROOK JB, 1983, HARRISONS PRINCIPLES, P1302; HULBERT WC, 1981, AM REV RESPIR DIS, V123, P320; JONES JG, 1980, LANCET, V1, P66; JONES R, 1972, BRIT MED J, V2, P142, DOI 10.1136/bmj.2.5806.142; LESKOWITZ S, 1972, Clinical Allergy, V2, P237, DOI 10.1111/j.1365-2222.1972.tb01288.x; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; OSEBOLD JW, 1980, J ENVIRON PATHOL TOX, V3, P221; SEDGWICK JD, 1983, IMMUNOLOGY, V50, P625; SIMANI AS, 1974, LAB INVEST, V31, P75; VANSELOW NA, 1970, J ALLERGY, V45, P302, DOI 10.1016/0021-8707(70)90036-5; WARNER JO, 1976, LANCET, V1, P990; WARREN CPW, 1975, CLIN ALLERGY, V1, P1; ZETTERSTROM O, 1981, ALLERGY, V36, P537, DOI 10.1111/j.1398-9995.1981.tb01871.x; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215	27	64	65	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	5					594	598		10.1016/0091-6749(85)90035-1	http://dx.doi.org/10.1016/0091-6749(85)90035-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AHV07	3989144				2022-12-18	WOS:A1985AHV0700009
J	KAGEN, SL; KURUP, VP; SOHNLE, PG; FINK, JN				KAGEN, SL; KURUP, VP; SOHNLE, PG; FINK, JN			MARIJUANA SMOKING AND FUNGAL SENSITIZATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MED COLL WISCONSIN,DEPT MED,ALLERGY SECT,MILWAUKEE,WI 53233; VET ADM MED CTR,RES SERV,WOOD,WI 53193	Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NHLBI NIH HHS [HL-15389] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CATES W, 1975, JAMA-J AM MED ASSOC, V234, P930; CHANG AE, 1979, ANN INTERN MED, V91, P812; CHMELIK F, 1975, AM REV RESPIR DIS, V111, P201; CHUSID MJ, 1975, ANN INTERN MED, V82, P682, DOI 10.7326/0003-4819-82-5-682; EDWARDS JH, 1972, J LAB CLIN MED, V79, P683; FINK JN, 1969, J IMMUNOL, V103, P244; FINK JN, 1978, ALLERGY PRINCIPLES P, P855; FRASER DW, 1979, JAMA-J AM MED ASSOC, V242, P1631, DOI 10.1001/jama.242.15.1631; FRYTAK S, 1979, ANN INTERN MED, V91, P825, DOI 10.7326/0003-4819-91-6-825; GOLDSTEIN RA, 1978, J ALLERGY CLIN IMMUN, V61, P229, DOI 10.1016/0091-6749(78)90190-2; HERMAN TS, 1979, NEW ENGL J MED, V300, P1295, DOI 10.1056/NEJM197906073002302; KAGEN SL, 1981, NEW ENGL J MED, V304, P483, DOI 10.1056/NEJM198102193040812; KAGEN SL, 1981, 37TH P ANN M AM AC A, P63; KRICK JA, 1976, CLIN HAEMATOL, V5, P249; KURUP VP, 1975, INT J SYST BACTERIOL, V25, P150, DOI 10.1099/00207713-25-2-150; KURUP VP, 1978, MICROBIOS, V19, P191; LEHRER RI, 1980, ANN INTERN MED, V93, P93, DOI 10.7326/0003-4819-93-1-93; LLAMAS R, 1978, CHEST, V73, P871, DOI 10.1378/chest.73.6.871; LLEWELLYN GC, 1977, MYCOPATHOLOGIA, V62, P109, DOI 10.1007/BF01259400; LUCAS VS, 1980, JAMA-J AM MED ASSOC, V243, P1241, DOI 10.1001/jama.243.12.1241; MAHONEY DH, 1979, J PEDIATR-US, V95, P70, DOI 10.1016/S0022-3476(79)80086-4; MCGLOTHLIN W, 1976, NATIONAL I DRUG ABUS, V14, P38; PRYSTOWSKY SD, 1976, NEW ENGL J MED, V295, P655, DOI 10.1056/NEJM197609162951206; RHEIN RW, 1980, MED WORLD NEWS  0428, P39; ROFFMAN RA, 1979, USING MARIJUANA REDU, P31; SALLAN SE, 1980, NEW ENGL J MED, V302, P135, DOI 10.1056/NEJM198001173020302; SALLAN SE, 1975, NEW ENGL J MED, V293, P795, DOI 10.1056/NEJM197510162931603; SOHNLE PG, 1978, J CLIN INVEST, V62, P45, DOI 10.1172/JCI109112; YOCUM MW, 1976, AM J MED, V61, P939, DOI 10.1016/0002-9343(76)90419-8; 1980, MED LETT, V22, P41; 1981, MORBIDITY MORTALITY, V30, P77	31	64	64	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	4					389	393		10.1016/0091-6749(83)90067-2	http://dx.doi.org/10.1016/0091-6749(83)90067-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	QL121	6833678				2022-12-18	WOS:A1983QL12100006
J	LAFORCE, CF; SZEFLER, SJ; MILLER, MF; EBLING, W; BRENNER, M				LAFORCE, CF; SZEFLER, SJ; MILLER, MF; EBLING, W; BRENNER, M			INHIBITION OF METHYLPREDNISOLONE ELIMINATION IN THE PRESENCE OF ERYTHROMYCIN THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP & RES CTR,DEPT PEDIAT,DENVER,CO 80206; SUNY BUFFALO,SCH MED & PHARM,DEPT PEDIAT,BUFFALO,NY 14260; SUNY BUFFALO,SCH MED & PHARM,DEPT PHARMACOL & THERAPEUT,BUFFALO,NY 14260; SUNY BUFFALO,SCH MED & PHARM,DEPT PHARMACEUT,BUFFALO,NY 14260	National Jewish Health; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NHLBI NIH HHS [HL-30513] Funding Source: Medline; NIAID NIH HHS [AI-14198] Funding Source: Medline; PHS HHS [24211] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		DANAN G, 1981, J PHARMACOL EXP THER, V218, P509; DJACZENKO W, 1977, CHEMOTHERAPY, V23, P167, DOI 10.1159/000221985; ENGEL MF, 1963, SOUTHERN MED J, V56, P1279, DOI 10.1097/00007611-196311000-00017; FOX JL, 1961, PENN MED J, V64, P634; GOLDSTEIN A, 1964, BIOSTATISTICS, P59; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; KAPLAN MA, 1959, ANTIBIOTICS ANN 1958, P273; LAFORCE CF, 1981, J PEDIATR-US, V99, P153, DOI 10.1016/S0022-3476(81)80983-3; LASSEN NA, 1979, TRACER KINETIC METHO, P76; ONG KS, 1978, J ALLERGY CLIN IMMUN, V62, P115, DOI 10.1016/0091-6749(78)90088-X; PESSAYRE D, 1981, BIOCHEM PHARMACOL, V30, P559, DOI 10.1016/0006-2952(81)90126-X; PESSAYRE D, 1981, BIOCHEM PHARMACOL, V30, P553, DOI 10.1016/0006-2952(81)90125-8; PRINCE RA, 1981, J ALLERGY CLIN IMMUN, V68, P427, DOI 10.1016/0091-6749(81)90196-2; ROBINSON MM, 1962, AM J MED SCI, V243, P502, DOI 10.1097/00000441-196204000-00012; ROSE JQ, 1979, J CHROMATOGR, V162, P273, DOI 10.1016/S0378-4347(00)81514-5; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; SZEFLER SJ, 1982, J ALLERGY CLIN IMMUN, V69, P455, DOI 10.1016/0091-6749(82)90121-X; TICKTIN HE, 1962, NEW ENGL J MED, V267, P964, DOI 10.1056/NEJM196211082671905; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; YEH KC, 1978, J PHARMACOKINET BIOP, V6, P79, DOI 10.1007/BF01066064; ZAROWITZ BJM, 1981, CLIN PHARMACOL THER, V29, P601, DOI 10.1038/clpt.1981.84; ZEIGER RS, 1980, J ALLERGY CLIN IMMUN, V66, P438, DOI 10.1016/0091-6749(80)90003-2	24	64	64	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	1					34	39		10.1016/0091-6749(83)90049-0	http://dx.doi.org/10.1016/0091-6749(83)90049-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QZ198	6602160				2022-12-18	WOS:A1983QZ19800004
J	REINBERG, A; GERVAIS, P; CHAUSSADE, M; FRABOULET, G; DUBURQUE, B				REINBERG, A; GERVAIS, P; CHAUSSADE, M; FRABOULET, G; DUBURQUE, B			CIRCADIAN CHANGES IN EFFECTIVENESS OF CORTICOSTEROIDS IN 8 PATIENTS WITH ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CNRS,ER CHRONOBIOL HUMAINE 105,F-75005 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	REINBERG, A (corresponding author), FDN A DE ROTHSCHILD,SERV MED INTERN & ALLERGOL,29 RUE MANIN,F-75940 PARIS 19,FRANCE.							ARNAUD A, 1977, NOUV PRESSE MED, V6, P45; BRODY AW, 1969, ANNU REV RESP DIS, V89, P214; CERESA F, 1969, J CLIN ENDOCR METAB, V29, P1074, DOI 10.1210/jcem-29-8-1074; DIRAIMONDA VC, 1956, AM J MED, V21, P231; FERRARI R, 1974, INT J CHRONOBIOL, V2, P17; GAULTIER C, 1977, RESP PHYSIOL, V31, P169, DOI 10.1016/0034-5687(77)90100-1; GERVAIS P, 1977, J ALLERGY CLIN IMMUN, V59, P207, DOI 10.1016/0091-6749(77)90151-8; GRANT SD, 1965, NEW ENGL J MED, V273, P1115, DOI 10.1056/NEJM196511182732101; HETZE MR, 1979, CHRONOPHARMACOLOGY, P213; KRIEGER DT, 1979, ENDOCRINE RHYTHMS; MCGOVERN J, 1977, CHRONOBIOLOGY ALLERG; NUTI R, 1983, THERAPIE WOCHE; REINBERG A, 1981, CHRONOBIOLOGIA, V8, P101; REINBERG A, 1971, CR ACAD SCI D NAT, V272, P1879; REINBERG A, 1977, CHRONOBIOLOGIA, V4, P295; REINBERG A, 1975, Folia Allergologica et Immunologica Clinica, V22, P559; REINBERG A, 1974, CHRONOBIOLOGIA, V1, P333; REINBERG A, 1981, BIOMEDICINE, V34, P171; Reinberg A, 1979, CHRONOBIOLOGIA S1, V6, P1; REINBERG A, 1978, EUR J CLIN PHARM, V14, P256; REINBERG A, 1983, J INT ENCY PHARM THE; Reindl K, 1969, Rass Neurol Veg, V23, P5; SERAFINI U, 1974, CHRONOBIOLOGIA S1, V1, P3977; Smolensky MH, 1974, CHRONOBIOLOGY, P197; Sothern R., 1972, PHYSIOL TEACH, V1, P1; SOUTAR CA, 1975, THORAX, V30, P436, DOI 10.1136/thx.30.4.436; TAMMELING CJ, 1977, CHRONOBIOLOGY ALLERG, P139	27	64	65	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	4					425	433		10.1016/0091-6749(83)90073-8	http://dx.doi.org/10.1016/0091-6749(83)90073-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QL121	6339595				2022-12-18	WOS:A1983QL12100012
J	DEDERICH, RA; SZEFLER, SJ; GREEN, ER				DEDERICH, RA; SZEFLER, SJ; GREEN, ER			INTRASUBJECT VARIATION IN SUSTAINED-RELEASE THEOPHYLLINE ABSORPTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP,DIV CLIN PHARMACOL & PHARMACOKINET,BUFFALO,NY 14222; SUNY BUFFALO,DEPT PHARM,BUFFALO,NY 14214; SUNY BUFFALO,DEPT PEDIAT,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								BELL T, 1978, PEDIATRICS, V62, P352; DASTA J, 1979, AM J HOSP PHARM, V36, P613, DOI 10.1093/ajhp/36.5.613; GIBALDI M, 1975, DRUGS PHARMACOKINETI, V1; HAMBLETON G, 1977, LANCET, V1, P381; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; JUSKO WJ, 1976, AM J HOSP PHARM, V33, P1193, DOI 10.1093/ajhp/33.11.1193; KELLY HW, 1979, AM J HOSP PHARM, V36, P1698, DOI 10.1093/ajhp/36.12.1698; RIEGELMAN S, 1979, 25TH P ANN C AM COLL; SPANGLER DL, 1978, ANN ALLERGY, V40, P6; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1978, NEW ENGL J MED, V299, P852, DOI 10.1056/NEJM197810192991603	11	64	64	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	6					465	471		10.1016/0091-6749(81)90100-7	http://dx.doi.org/10.1016/0091-6749(81)90100-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LU068	7346530				2022-12-18	WOS:A1981LU06800008
J	HENDERSON, LL; LARSON, JB; GLEICH, GJ				HENDERSON, LL; LARSON, JB; GLEICH, GJ			MAXIMAL RISE IN IGE ANTIBODY FOLLOWING RAGWEED POLLINATION SEASON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & FDN,ROCHESTER,MN 55901	Mayo Clinic								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; BERG T, 1971, INT ARCH ALLER A IMM, V41, P452, DOI 10.1159/000230539; GLEICH GJ, 1974, J ALLERGY CLIN IMMUN, V53, P158, DOI 10.1016/0091-6749(74)90004-9; GLEICH GJ, 1972, JUN P C BIOL ROL IMM; HENDERSON LL, 1973, J ALLERGY CLIN IMMUN, V52, P352, DOI 10.1016/0091-6749(73)90094-8; LEVY DA, 1967, J IMMUNOL, V99, P1068; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	10	64	64	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	1					10	15		10.1016/S0091-6749(75)80003-0	http://dx.doi.org/10.1016/S0091-6749(75)80003-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V2344	45925	Bronze			2022-12-18	WOS:A1975V234400002
J	SALVAGGIO, J; PHANUPHAK, P; STANFORD, R; BICE, D; CLAMAN, H				SALVAGGIO, J; PHANUPHAK, P; STANFORD, R; BICE, D; CLAMAN, H			EXPERIMENTAL PRODUCTION OF GRANULOMATOUS PNEUMONITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,MED CTR,DEPT PATHOL,DENVER,CO; UNIV COLORADO,MED CTR,DEPT MED,CLIN IMMUNOL DIV,DENVER,CO; TULANE UNIV,MED CTR,DEPT MED,NEW ORLEANS,LA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Tulane University								AREND WP, 1972, J EXP MED, V136, P514, DOI 10.1084/jem.136.3.514; BARTFELD H, 1969, TRANSPLANTATION, V7, P242; BIGUET J, 1964, ANN I PASTEUR PARIS, V107, P72; BLOOM BR, 1971, IN VITRO METHODS CEL; BOROS DL, 1973, IMMUNOLOGY, V24, P511; BOROS DL, 1970, J EXP MED, V132, P488, DOI 10.1084/jem.132.3.488; BOROS DL, 1971, NATURE, V229, P200, DOI 10.1038/229200a0; Cannon PR, 1941, AM J PATHOL, V17, P777; CANTELLA R, TO BE PUBLISHED; DAVID JR, 1965, J EXP MED, V122, P1125, DOI 10.1084/jem.122.6.1125; DAVID JR, 1964, J IMMUNOL, V93, P274; FARR RS, 1958, J INFECT DIS, V103, P239, DOI 10.1093/infdis/103.3.239; FINK J, 1972, ALLERGIC DISEASES; FINK JN, 1970, J ALLERGY, V46, P156, DOI 10.1016/0021-8707(70)90094-8; Fried BM, 1933, J EXP MED, V57, P111, DOI 10.1084/jem.57.1.111; GALINDO B, 1970, J IMMUNOL, V105, P227; GEORGE M, 1962, P SOC EXP BIOL MED, V111, P514; HENLEY G, 1974, ARCH PATHOL, V97, P33; KAWAI T, 1973, CHEST, V64, P420, DOI 10.1378/chest.64.4.420; KAWAI T, 1973, CLIN EXP IMMUNOL, V15, P123; KAWAI T, 1972, J ALLERGY CLIN IMMUN, V50, P276, DOI 10.1016/0091-6749(72)90026-7; KEMME HNB, 1966, ACTA OTORHINOLARYNGO, V28, P141; LAKE WW, 1971, HYPERSENSITIVITY PNE, V1; LEU RW, 1972, J EXP MED, V136, P589, DOI 10.1084/jem.136.3.589; MINDEN P, 1967, HDB EXPERIMENTAL IMM, pCH13; MIYAMOTO T, 1971, J ALLERGY, V47, P181, DOI 10.1016/S0091-6749(71)80296-8; MOORE RD, 1964, BRIT J EXP PATHOL, V45, P488; MOORE V L, 1970, Infection and Immunity, V2, P810; MOORE VL, 1973, INFECT IMMUN, V7, P764, DOI 10.1128/IAI.7.5.764-770.1973; MYRVIK QN, 1961, J IMMUNOL, V86, P133; MYRVIK QN, 1961, J IMMUNOL, V86, P128; OPIE EL, 1924, J IMMUNOL, V9, P321; PEPYS J, 1969, MONOGRAPHS ALLERGY, V4; RICHERSON HB, 1971, AM REV RESPIR DIS, V104, P568; RICHERSON HB, 1972, J LAB CLIN MED, V79, P745; ROCKLIN RE, 1971, IN VITRO METHODS CEL, P281; TUBERGEN DG, 1972, J EXP MED, V135, P255, DOI 10.1084/jem.135.2.255; UNANUE ER, 1973, AM J PATHOL, V71, P349; WALDMAN RH, 1971, J EXP MED, V134, P482, DOI 10.1084/jem.134.2.482	39	64	64	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	5					364	380		10.1016/0091-6749(75)90130-X	http://dx.doi.org/10.1016/0091-6749(75)90130-X			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW330	1102589				2022-12-18	WOS:A1975AW33000006
J	ARBESMAN, CE; WICHER, K; WYPYCH, JI; ITO, K				ARBESMAN, CE; WICHER, K; WYPYCH, JI; ITO, K			MEASUREMENT OF SERUM IGE BY A ONE-STEP SINGLE RADIAL RADIODIFFUSION METHOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ARBESMAN CE, 1971, J ALLERGY, V47, P85; BALL PAJ, 1971, BRIT MED J, V23, P210; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HEINER DC, 1970, J ALLERGY, V45, P30, DOI 10.1016/0021-8707(70)90014-6; ISHIZAKA K, 1970, J ALLERGY, V46, P197, DOI 10.1016/0021-8707(70)90023-7; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ITO K, 1971, J IMMUNOL, V106, P1130; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON SG, 1968, LANCET, V1, P1118; JOHANSSON SG, 1968, INT ARCH ALLER A IMM, V34, P1; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MIETENS C, 1971, KLIN WOCHENSCHR, V49, P256, DOI 10.1007/BF01485426; OGAWA M, 1971, ARCH DERMATOL, V103, P575, DOI 10.1001/archderm.103.6.575; OGAWA M, 1969, NEW ENGL J MED, V281, P1217, DOI 10.1056/NEJM196911272812204; ROWE DS, 1969, B WORLD HEALTH ORGAN, V40, P613; ROWE DS, 1970, INT ARCH ALLER A IMM, V39, P1; SALMON SE, 1970, CLIN RES, V18, P432; WITTIG HJ, 1959, J ALLERGY, V30, P19, DOI 10.1016/0021-8707(59)90054-1	22	64	64	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	2					72	&		10.1016/0091-6749(72)90058-9	http://dx.doi.org/10.1016/0091-6749(72)90058-9			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5997	4621500				2022-12-18	WOS:A1972L599700002
J	GREEN, GR; ROSENBLUM, A				GREEN, GR; ROSENBLUM, A			REPORT OF PENICILLIN STUDY GROUP - AMERICAN-ACADEMY-OF-ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BIERMAN CW, 1969, J ALLERGY, V43, P267, DOI 10.1016/0021-8707(69)90147-6; BROWN BC, 1964, JAMA-J AM MED ASSOC, V189, P599; DEWECK AL, 1965, INT ARCH ALLER A IMM, V27, P221, DOI 10.1159/000229614; FELLNER MJ, 1969, J AMER MED ASSOC, V210, P2061, DOI 10.1001/jama.1969.03160370045008; GREEN GR, 1967, ANN INTERN MED, V67, P235, DOI 10.7326/0003-4819-67-2-235; IDSOE O, 1968, B WORLD HEALTH ORGAN, V38, P159; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; PARKER CW, 1962, J EXP MED, V115, P821, DOI 10.1084/jem.115.4.821; RYTEL MW, 1963, JAMA-J AM MED ASSOC, V186, P894; SCHNEIDER CH, 1970, PENICILLIN ALLERGY C, pCH4; SCHNEIDER CH, 1970, PENICILLIN ALLERGY C, pCH2; VANDELLEN RG, 1971, J ALLERGY, V47, P230, DOI 10.1016/S0091-6749(71)80468-2; VOSS HE, 1966, J AMER MED ASSOC, V196, P679, DOI 10.1001/jama.1966.03100210049014	13	64	65	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	6					331	+		10.1016/0091-6749(71)90079-0	http://dx.doi.org/10.1016/0091-6749(71)90079-0			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L0384	5287035				2022-12-18	WOS:A1971L038400002
J	Maggi, E; Canonica, GW; Moretta, L				Maggi, Enrico; Canonica, Giorgio Walter; Moretta, Lorenzo			COVID-19: Unanswered questions on immune response and pathogenesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anti-SARS-CoV-2 immunity; COVID-19 pathogenesis; viral immune evasion	SARS; CORONAVIRUS; CELLS	The novel coronavirus disease 2019 has rapidly increased in pandemic scale since it first appeared in Wuhan, China, in December 2019. In these troubled days the scientific community is asking for rapid replies to prevent and combat the emergency. It is generally accepted that only achieving a better understanding of the interactions between the virus and the host immune response and of the pathogenesis of infection is crucial to identify valid therapeutic tools to control virus entry, replication, and spread as well as to impair its lethal effects. On the basis of recent research progress of severe acute respiratory syndrome coronavirus 2 and the results on previous coronaviruses, in this contribution we underscore some of the main unsolved problems, mostly focusing on pathogenetic aspects and host immunity to the virus. On this basis, we also touch important aspects regarding the immune response in asymptomatic subjects, the immune evasion of severe acute respiratory syndrome coronavirus 2 in severe patients, and differences in disease severity by age and sex.	[Maggi, Enrico; Moretta, Lorenzo] IRCCS, Bambino Gesu Children Hosp, Dept Immunol, Rome, Italy; [Canonica, Giorgio Walter] IRCCS, Humanitas Univ & Res Hosp, Asthma & Allergy Clin, Milan, Italy	IRCCS Bambino Gesu; Humanitas University	Maggi, E (corresponding author), IRCCS, Bambino Gesu Children Hosp, Via Bardelli 15, I-00146 Rome, Italy.	enrico.maggi@opbg.net	Moretta, Lorenzo/AAA-7239-2020; canonica, giorgio walter/ABF-2037-2020	Moretta, Lorenzo/0000-0003-4658-1747; canonica, giorgio walter/0000-0001-8467-2557	Ministero della Salute [RC-2020 OPBG]; Associazione Italiana per la Ricerca sul Cancro [5x1000 2018 Id 21147]	Ministero della Salute(Ministry of Health, Italy); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Ministero della Salute (grant no. RC-2020 OPBG to L.M. and E.M.) and from Associazione Italiana per la Ricerca sul Cancro (project no. 5x1000 2018 Id 21147 and project no. IG 2017 Id 19920 to L.M.).	Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876; Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7; Cohen AJ, 1996, J INFECT DIS, V174, P615, DOI 10.1093/infdis/174.3.615; Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E; Cossarizza A, 2020, CYTOM PART A, V97, P340, DOI 10.1002/cyto.a.24002; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; Fernandez-Atucha A, 2017, BIOL SEX DIFFER, V8, DOI 10.1186/s13293-017-0128-8; Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002; Grimsholm O, 2020, CELL REP, V30, P2963, DOI 10.1016/j.celrep.2020.02.022; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Kikkert M, 2020, J INNATE IMMUN, V12, P4, DOI 10.1159/000503030; Lee CH, 2004, J IMMUNOL, V172, P7841, DOI 10.4049/jimmunol.172.12.7841; Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490; Liao M., 2020, CUREUS, DOI [10.1101/2020.02.23.20026690, DOI 10.1038/S41591-020-0901-9, 10.1101/2020.02.23.20026690v1]; Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006; Locati M, 2020, ANNU REV PATHOL-MECH, V15, P123, DOI 10.1146/annurev-pathmechdis-012418-012718; Long Q, 2020, MEDRXIV, DOI 10.1101/2020.03.18.20038018; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732; Peters B, 2020, ANNU REV IMMUNOL, V38, P123, DOI 10.1146/annurev-immunol-082119-124838; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Shin HS, 2019, CLIN INFECT DIS, V68, P984, DOI 10.1093/cid/ciy595; Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829; Wang A, BIORXIV PREPRINT, DOI [10.1101/2020.04.12.037580, DOI 10.1101/2020.04.12.037580]; Yamaya M, 2020, RESPIR INVESTIG, V58, P155, DOI 10.1016/j.resinv.2019.12.005; Zhang JJ, 2020, ALLERGY, V75, P1809, DOI 10.1111/all.14316; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	29	63	68	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2020	146	1					18	22		10.1016/j.jaci.2020.05.001	http://dx.doi.org/10.1016/j.jaci.2020.05.001			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OC5BB	32389590	Green Published, hybrid			2022-12-18	WOS:000579170500003
J	Lee, PY; Kellner, ES; Huang, YL; Furutani, E; Huang, Z; Bainter, W; Alosaimi, MF; Stafstrom, K; Platt, CD; Stauber, T; Raz, S; Tirosh, I; Weiss, A; Jordan, MB; Krupski, C; Eleftheriou, D; Brogan, P; Sobh, A; Baz, Z; Lefranc, G; Irani, C; Kilic, SS; El-Owaidy, R; Lokeshwar, MR; Pimpale, P; Khubchandani, R; Chambers, EP; Chou, J; Geha, RS; Nigrovic, PA; Zhou, Q				Lee, Pui Y.; Kellner, Erinn S.; Huang, Yuelong; Furutani, Elissa; Huang, Zhengping; Bainter, Wayne; Alosaimi, Mohammed F.; Stafstrom, Kelsey; Platt, Craig D.; Stauber, Tali; Raz, Somech; Tirosh, Irit; Weiss, Aaron; Jordan, Michael B.; Krupski, Christa; Eleftheriou, Despina; Brogan, Paul; Sobh, Ali; Baz, Zeina; Lefranc, Gerard; Irani, Carla; Kilic, Sara S.; El-Owaidy, Rasha; Lokeshwar, M. R.; Pimpale, Pallavi; Khubchandani, Raju; Chambers, Eugene P.; Chou, Janet; Geha, Raif S.; Nigrovic, Peter A.; Zhou, Qing			Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adenosine deaminase 2; DADA2; vasculitis; pure red cell aplasia; bone marrow failure	CELL TRANSPLANTATION RESCUES; POLYARTERITIS-NODOSA; VASCULOPATHY; TYPE-2	Background: Deficiency of adenosine deaminase 2 (DADA2) is a syndrome with pleiotropic manifestations including vasculitis and hematologic compromise. A systematic definition of the relationship between adenosine deaminase 2 (ADA2) mutations and clinical phenotype remains unavailable. Objective: We sought to test whether the impact of ADA2 mutations on enzyme function correlates with clinical presentation. Methods: Patients with DADA2 with severe hematologic manifestations were compared with vasculitis-predominant patients. Enzymatic activity was assessed using expression constructs reflecting all 53 missense, nonsense, insertion, and deletion genotypes from 152 patients across the DADA2 spectrum. Results: We identified patients with DADA2 presenting with pure red cell aplasia (n = 5) or bone marrow failure (BMF, n = 10) syndrome. Most patients did not exhibit features of vasculitis. Recurrent infection, hepatosplenomegaly, and gingivitis were common in patients with BMF, of whom half died from infection. Unlike patients with DADA2 with vasculitis, patients with pure red cell aplasia and BMF proved largely refractory to TNF inhibitors. ADA2 variants associated with vasculitis predominantly reflected missense mutations with at least 3% residual enzymatic activity. In contrast, pure red cell aplasia and BMF were associated with missense mutations with minimal residual enzyme activity, nonsense variants, and insertions/deletions resulting in complete loss of function. Conclusions: Functional interrogation of ADA2 mutations reveals an association of subtotal function loss with vasculitis, typically responsive to TNF blockade, whereas more extensive loss is observed in hematologic disease, which may be refractory to treatment. These findings establish a genotype-phenotype spectrum in DADA2.	[Lee, Pui Y.; Bainter, Wayne; Alosaimi, Mohammed F.; Stafstrom, Kelsey; Platt, Craig D.; Chou, Janet; Geha, Raif S.; Nigrovic, Peter A.] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Lee, Pui Y.; Huang, Yuelong; Huang, Zhengping; Nigrovic, Peter A.] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, Boston, MA 02115 USA; [Kellner, Erinn S.] Cincinnati Childrens Hosp, Div Allergy Immunol, Cincinnati, OH USA; [Kellner, Erinn S.; Jordan, Michael B.] Univ Cincinnati, Cincinnati, OH USA; [Furutani, Elissa] Dana Farber & Boston Childrens Canc & Blood Disor, Boston, MA USA; [Huang, Zhengping] Guangdong Second Prov Gen Hosp, Dept Rheumatol & Immunol, Guangzhou, Peoples R China; [Alosaimi, Mohammed F.] King Saud Univ, Dept Pediat, Riyadh, Saudi Arabia; [Stauber, Tali; Raz, Somech] Jeffrey Modell Fdn, Sheba Med Ctr, Primary Immunodeficiency Clin, New York, NY USA; [Tirosh, Irit] Edmond & Lily Safra Childrens Hosp, Sheba Med Ctr, Pediat Rheumatol Serv, Tel Hashomer, Israel; [Weiss, Aaron] Maine Med Ctr, Dept Pediat, Portland, ME 04102 USA; [Jordan, Michael B.; Krupski, Christa] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA; [Jordan, Michael B.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Eleftheriou, Despina; Brogan, Paul] UCL, Great Ormond St Inst Child Hlth, London, England; [Sobh, Ali] Mansoura Univ, Fac Med, Mansoura Univ Childrens Hosp, Dept Pediat, Mansoura, Egypt; [Baz, Zeina] St George Hosp Univ, Med Ctr, Dept Pediat, Beirut, Lebanon; [Lefranc, Gerard] Univ Montpellier, CNRS, UMR 9002, Inst Genet Humaine, Montpellier, France; [Irani, Carla] St Joseph Univ, Hotel Dieu de France Hosp, Internal Med & Clin Immunol Dept, Beirut, Lebanon; [Kilic, Sara S.] Uludag Univ, Med Fac, Dept Pediat Immunol & Rheumatol, Bursa, Turkey; [El-Owaidy, Rasha] Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, Cairo, Egypt; [Lokeshwar, M. R.] Lilavati Hosp & Res Ctr, Dept Pediat, Mumbai, Maharashtra, India; [Pimpale, Pallavi; Khubchandani, Raju] SRCC Childrens Hosp, Mumbai, Maharashtra, India; [Chambers, Eugene P.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN USA; [Chambers, Eugene P.] DADA2 Fdn, Nashville, TN USA; [Zhou, Qing] Zhejiang Univ, Life Sci Inst, Hangzhou, Zhejiang, Peoples R China	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; King Saud University; Chaim Sheba Medical Center; Maine Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of London; University College London; Egyptian Knowledge Bank (EKB); Mansoura University; American University of Beirut; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Uludag University; Egyptian Knowledge Bank (EKB); Ain Shams University; Vanderbilt University; Zhejiang University	Lee, PY (corresponding author), Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	pui.lee@childrens.harvard.edu	Sobh, Ali/Q-6160-2016; El-Owaidy, Rasha H/B-7609-2017; Alosaimi, Mohammed F/AAY-5814-2021; Kilic, Sara Sebnem/AAH-1658-2021	Sobh, Ali/0000-0001-7047-076X; El-Owaidy, Rasha H/0000-0002-5609-4160; Alosaimi, Mohammed F/0000-0002-8025-3491; PIMPALE CHAVAN, PALLAVI/0000-0002-5124-6559; Khubchandani, Raju/0000-0003-0294-119X; kilic, sara sebnem/0000-0001-8571-2581; Brogan, Paul/0000-0001-6178-6893; Huang, Zhengping/0000-0002-2955-7385	National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [K08-AR074562, R01-AR065538, R01-AR073201, R01-AR075906, P30-AR070253]; Fundacion Bechara; Arbuckle Family Foundation for Arthritis Research; Rheumatology Research Foundation Investigator Award; Boston Children's Hospital Faculty Career Development Award; National Natural Science Foundation of China [31771548, 81971528]; Zhejiang Provincial Natural Science Foundation of China [LR19H100001]	National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Fundacion Bechara; Arbuckle Family Foundation for Arthritis Research; Rheumatology Research Foundation Investigator Award; Boston Children's Hospital Faculty Career Development Award; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province)	This work was supported by the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant no. K08-AR074562 to P.Y.L. and grant nos. R01-AR065538, R01-AR073201, R01-AR075906, and P30-AR070253 to P.A.N.), the Fundacion Bechara (P.A.N.), the Arbuckle Family Foundation for Arthritis Research (P.A.N.), the Rheumatology Research Foundation Investigator Award (P.Y.L.), Boston Children's Hospital Faculty Career Development Award (P.Y.L.), the National Natural Science Foundation of China (grant nos. 31771548 and 81971528 to Q.Z.), and the Zhejiang Provincial Natural Science Foundation of China (grant no. LR19H100001 to Q.Z.).	Alsultan A, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26912; Arts K, 2018, J CLIN IMMUNOL, V38, P836, DOI 10.1007/s10875-018-0565-0; Barzaghi F, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02767; Batu ED, 2015, J RHEUMATOL, V42, P1532, DOI 10.3899/jrheum.150024; Ben-Ami T, 2016, J PEDIATR-US, V177, P316, DOI 10.1016/j.jpeds.2016.06.058; Caorsi R, 2017, ANN RHEUM DIS, V76, P1648, DOI 10.1136/annrheumdis-2016-210802; Carmona-Rivera C, 2019, BLOOD, V134, P395, DOI 10.1182/blood.2018892752; Cipe FE, 2018, J CLIN IMMUNOL, V38, P273, DOI 10.1007/s10875-018-0487-x; Claassen D, 2018, CSH MOL CASE STUD, V4, DOI 10.1101/mcs.a003384; Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362; Ghurye RR, 2019, BRIT J HAEMATOL, V186, pE60, DOI 10.1111/bjh.15896; Gibson KM, 2019, ARTHRITIS RHEUMATOL, V71, P1747, DOI 10.1002/art.40913; Hashem H, 2017, BLOOD, V130, P2682, DOI 10.1182/blood-2017-07-798660; Hashem H, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0699-8; Hashem H, 2017, J PEDIAT HEMATOL ONC, V39, pE293, DOI 10.1097/MPH.0000000000000805; Hsu AP, 2016, J ALLERGY CLIN IMMUN, V138, P628, DOI 10.1016/j.jaci.2016.03.016; KYLE RA, 1970, MAYO CLIN PROC, V45, P494; Lamprecht P, 2018, CLIN EXP RHEUMATOL, V36, pS177; Lee PY, 2020, ANN RHEUM DIS, V79, P225, DOI 10.1136/annrheumdis-2019-216030; Lee PY, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00282; Lee PY, 2018, J ALLERGY CLIN IMMUN, V142, P1363, DOI 10.1016/j.jaci.2018.05.038; Meyts I, 2018, J CLIN IMMUNOL, V38, P569, DOI 10.1007/s10875-018-0525-8; Michniacki TF, 2018, J CLIN IMMUNOL, V38, P166, DOI 10.1007/s10875-018-0480-4; Nanthapisal S, 2016, ARTHRITIS RHEUMATOL, V68, P2314, DOI 10.1002/art.39699; Neishabury M, 2020, HAEMATOLOGICA, V105, pE1, DOI 10.3324/haematol.2019.216069; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Ombrello AK, 2019, NEW ENGL J MED, V380, P1582, DOI 10.1056/NEJMc1801927; Ozen S, 2020, J RHEUMATOL, V47, P117, DOI 10.3899/jrheum.181384; Rama M, 2018, EUR J HUM GENET, V26, P960, DOI 10.1038/s41431-018-0130-6; Sahin S, 2018, RHEUMATOL INT, V38, P129, DOI 10.1007/s00296-017-3740-3; Sasa GS, 2015, BLOOD, V126, P3615, DOI [10.1182/blood.V126.23.3615.3615, DOI 10.1182/BLOOD.V126.23.3615.3615]; Schepp J, 2017, ARTHRITIS RHEUMATOL, V69, P1689, DOI 10.1002/art.40147; Skrabl-Baumgartner A, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-017-0193-x; Springer JM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01361; Sundin M, 2019, J PEDIAT HEMATOL ONC, V41, P155, DOI 10.1097/MPH.0000000000001132; Trotta L, 2018, J ALLERGY CLIN IMMUN, V141, P1534, DOI 10.1016/j.jaci.2018.01.012; Ulirsch JC, 2018, AM J HUM GENET, V103, P930, DOI 10.1016/j.ajhg.2018.10.027; Van Eyck L, 2015, J ALLERGY CLIN IMMUN, V135, P283, DOI 10.1016/j.jaci.2014.10.010; Van Montfrans JM, 2016, RHEUMATOLOGY, V55, P902, DOI 10.1093/rheumatology/kev439; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361	40	63	64	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1664	+		10.1016/j.jaci.2019.12908	http://dx.doi.org/10.1016/j.jaci.2019.12908			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	31945408				2022-12-18	WOS:000539157800021
J	Chiang, D; Chen, XT; Jones, SM; Wood, RA; Sicherer, SH; Burks, AW; Leung, DYM; Agashe, C; Grishin, A; Dawson, P; Davidson, WF; Newman, L; Sebra, R; Merad, M; Sampson, HA; Losic, B; Berin, MC				Chiang, David; Chen, Xintong; Jones, Stacie M.; Wood, Robert A.; Sicherer, Scott H.; Burks, A. Wesley; Leung, Donald Y. M.; Agashe, Charuta; Grishin, Alexander; Dawson, Peter; Davidson, Wendy F.; Newman, Leah; Sebra, Robert; Merad, Miriam; Sampson, Hugh A.; Losic, Bojan; Berin, M. Cecilia			Single-cell profiling of peanut-responsive T cells in patients with peanut allergy reveals heterogeneous effector T(H)2 subsets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut allergy; T(H)2; regulatory T; tolerance	EXPERIMENTAL FOOD ALLERGY; ORAL IMMUNOTHERAPY; PERIPHERAL-BLOOD; GENE-EXPRESSION; DENDRITIC CELLS; TOLERANCE; CHILDREN; CONSUMPTION; ANAPHYLAXIS; INDUCTION	Background: The contribution of phenotypic variation of peanut-specific T cells to clinical allergy or tolerance to peanut is not well understood. Objectives: Our objective was to comprehensively phenotype peanut-specific T cells in the peripheral blood of subjects with and without peanut allergy (PA). Methods: We obtained samples from patients with PA, including a cohort undergoing baseline peanut challenges for an immunotherapy trial (Consortium of Food Allergy Research [CoFAR] 6). Subjectswere confirmed as having PA, or if they passed a 1-g peanut challenge, they were termed high-threshold subjects. Healthy control (HC) subjects were also recruited. PeanutresponsiveTcellswere identified based onCD154 expression after 6 to 18 hours of stimulation with peanut extract. Cells were analyzed by using flow cytometry and single-cell RNA sequencing. Results: Patients with PA had tissue-and follicle-homing peanutresponsive CD4 1 T cells with a heterogeneous pattern of TH2 differentiation, whereas control subjects had undetectable T-cell responses to peanut. The PA group had a delayed and IL-2-dependent upregulation of CD154 on cells expressing regulatory T (Treg) cell markers, which was absent in HC or high-threshold subjects. Depletion of Treg cells enhanced cytokine production in HC subjects and patients with PA in vitro, but cytokines associated with highly differentiated T(H)2 cells were more resistant to Treg cell suppression in patients with PA. Analysis of gene expression by means of single-cell RNA sequencing identified T cells with highly correlated expression of IL4, IL5, IL9, IL13, and the IL-25 receptor IL17RB. Conclusions: These results demonstrate the presence of highly differentiated T(H)2 cells producing T(H)2-associated cytokines with functions beyond IgE class-switching in patients with PA. A multifunctional T(H)2 response was more evident than a Treg cell deficit among peanut-responsive T cells.	[Chiang, David; Sicherer, Scott H.; Agashe, Charuta; Grishin, Alexander; Sampson, Hugh A.; Berin, M. Cecilia] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA; [Chen, Xintong; Newman, Leah; Sebra, Robert; Losic, Bojan] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Merad, Miriam] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.] Arkansas Childrens Hosp, Little Rock, AR USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Burks, A. Wesley] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27515 USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Dawson, Peter] EMMES Corp, Rockville, MD USA; [Davidson, Wendy F.] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital; Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill; National Jewish Health; Emmes Corporation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Berin, MC (corresponding author), Icahn Sch Med Mt Sinai, Pediat Allergy & Immunol, Box 1198,One Gustave L Levy Pl, New York, NY 10029 USA.; Losic, B (corresponding author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, Inst Genom & Multiscale Biol, 1425 Madison Ave,Box 1498, New York, NY 10029 USA.	bojan.losic@mssm.edu; cecilia.berin@mssm.edu	Agashe, Charuta/AAF-3847-2020; Chen, Xintong/I-4800-2019; Agashe, Charuta/AFP-8581-2022	Agashe, Charuta/0000-0001-8820-8655; Chen, Xintong/0000-0002-2536-165X; Chiang, David/0000-0002-3844-6126; berin, cecilia/0000-0002-9051-9249	David and Julia Koch Research Program in Food Allergy Therapeutics; NCI P30 Cancer Center Support Grant [P30 CA196521]; Food Allergy Research Education; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [U19AI066738, U01AI066560]; NIH/National Center for Advancing Translational Sciences [UL1 TR0001082, UL1 TR000067, UL1 TR000039, UL1 TR000083, UL1 TR000424]; DBV Technologies (Montrouge, France);  [U24AI118644]; NATIONAL CANCER INSTITUTE [P30CA196521] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082, UL1TR000424, UL1TR000083, UL1TR000039, UL1TR000067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI066738, UM1AI109565, U24AI118644, U01AI066560] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES023515] Funding Source: NIH RePORTER	David and Julia Koch Research Program in Food Allergy Therapeutics; NCI P30 Cancer Center Support Grant; Food Allergy Research Education; National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Center for Advancing Translational Sciences; DBV Technologies (Montrouge, France); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by U24AI118644 (to M.C.B. and M.M.) and the David and Julia Koch Research Program in Food Allergy Therapeutics (to H.A.S.). Facilities were supported by an NCI P30 Cancer Center Support Grant (P30 CA196521). MSSM PA cohort samples were kindly supplied by the Food Allergy Resource Initiative, which is supported by funding from Food Allergy Research & Education and maintained at the Elliot and Roslyn Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai. The clinical study (CoFAR6) providing samples for this study is registered with ClinicalTrials.gov with ID NCT01904604 and is supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grants U19AI066738 and U01AI066560. The project was also supported by NIH/National Center for Advancing Translational Sciences (NCATS) grant nos. UL1 TR0001082 (Colorado), UL1 TR000067 (Mount Sinai), UL1 TR000039 (Arkansas), UL1 TR000083 (North Carolina), and UL1 TR000424 (Johns Hopkins) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). Support for this trial was also provided by DBV Technologies (Montrouge, France) through funds provided to the Consortium of Food Allergy Research.	Bacher P, 2016, CELL, V167, P1067, DOI 10.1016/j.cell.2016.09.050; Blazquez AB, 2010, GASTROENTEROLOGY, V138, P275, DOI 10.1053/j.gastro.2009.09.016; Bray NL, 2016, NAT BIOTECHNOL, V34, P525, DOI 10.1038/nbt.3519; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P1329, DOI 10.1016/j.jaci.2014.06.032; Chen CY, 2015, IMMUNITY, V43, P788, DOI 10.1016/j.immuni.2015.08.020; DeLong JH, 2011, J ALLERGY CLIN IMMUN, V127, P1211, DOI 10.1016/j.jaci.2011.02.028; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Esterhazy D, 2016, NAT IMMUNOL, V17, P545, DOI 10.1038/ni.3408; Ewen C, 2001, J INTERF CYTOK RES, V21, P39, DOI 10.1089/107999001459141; Fayen JD, 2001, IMMUNOLOGY, V104, P299, DOI 10.1046/j.1365-2567.2001.01296.x; Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Han HW, 2014, J CLIN INVEST, V124, P5442, DOI 10.1172/JCI77798; Holt PG, 2016, J ALLERGY CLIN IMMUN, V137, P379, DOI 10.1016/j.jaci.2015.08.044; Jones SM, 2017, J ALLERGY CLIN IMMUN, V139, P1242, DOI 10.1016/j.jaci.2016.08.017; Kosoy R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163831; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lee JB, 2016, J ALLERGY CLIN IMMUN, V137, P1216, DOI 10.1016/j.jaci.2015.09.019; Leyva-Castillo JM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3847; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Litjens NHR, 2012, J IMMUNOL, V188, P1083, DOI 10.4049/jimmunol.1101974; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Mikhak Z, 2013, J EXP MED, V210, P1855, DOI 10.1084/jem.20130091; Mitson-Salazar A, 2016, J ALLERGY CLIN IMMUN, V137, P907, DOI 10.1016/j.jaci.2015.08.007; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Otani IM, 2013, J ALLERGY CLIN IMMUN, V131, P1576, DOI 10.1016/j.jaci.2013.02.042; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Rahman AH, 2016, CYTOM PART A, V89A, P601, DOI 10.1002/cyto.a.22826; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P639, DOI 10.1016/j.jaci.2016.06.003; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ryan JF, 2016, P NATL ACAD SCI USA, V113, pE1286, DOI 10.1073/pnas.1520180113; Scialdone A, 2015, METHODS, V85, P54, DOI 10.1016/j.ymeth.2015.06.021; Shayman JA, 2011, PROG LIPID RES, V50, P1, DOI 10.1016/j.plipres.2010.10.006; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Stubbington MJT, 2016, NAT METHODS, V13, P329, DOI [10.1038/NMETH.3800, 10.1038/nmeth.3800]; Su LF, 2016, P NATL ACAD SCI USA, V113, pE6192, DOI 10.1073/pnas.1611723113; Syed A, 2014, J ALLERGY CLIN IMMUN, V133, P500, DOI 10.1016/j.jaci.2013.12.1037; Tordesillas L, 2016, J ALLERGY CLIN IMMUN, V138, P1741, DOI 10.1016/j.jaci.2016.06.048; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wambre E, 2012, J ALLERGY CLIN IMMUN, V129, P544, DOI 10.1016/j.jaci.2011.08.034; Wisniewski JA, 2015, CLIN EXP ALLERGY, V45, P1201, DOI 10.1111/cea.12537; Yang J, 2007, P NATL ACAD SCI USA, V104, P19954, DOI 10.1073/pnas.0704397104; Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382	49	63	64	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2107	2120		10.1016/j.jaci.2017.11.060	http://dx.doi.org/10.1016/j.jaci.2017.11.060			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	29408715	Green Accepted, Bronze			2022-12-18	WOS:000434701600017
J	Jensen, ET; Kuhl, JT; Martin, LJ; Rothenberg, ME; Dellon, ES				Jensen, Elizabeth T.; Kuhl, Jonathan T.; Martin, Lisa J.; Rothenberg, Marc E.; Dellon, Evan S.			Prenatal, intrapartum, and postnatal factors are associated with pediatric eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; antibiotics; acid suppressant; breast-feeding; cesarean delivery; early-life factors; environment; eosinophilic esophagitis; furred pet; neonatal intensive care unit; acid-suppressive agents	CHILDHOOD ASTHMA; ALLERGIC DISEASE; CLINICAL-FEATURES; PROVIDES INSIGHT; CESAREAN-SECTION; UPPER ENDOSCOPY; UNITED-STATES; FOOD ALLERGY; RISK-FACTORS; BALB/C MICE	Background: Multiple lines of evidence point to the potential importance of early-life environmental factors in the rapid increase in the incidence of eosinophilic esophagitis (EoE), but potential exposures have not been extensively studied. Objective: We sought to assess the association between prenatal, intrapartum, and postnatal factors and the development of pediatric EoE using a case-control study. Methods: Patients with EoE were recruited from an existing registry at Cincinnati Children's Hospital Medical Center (CCHMC). Population-based community control subjects were identified from a separate CCHMC registry. Mothers of study subjects were contacted and completed a Web-based questionnaire. Crude and adjusted models were used to estimate associations. Results: Mothers of 127 cases and 121 control subjects were included. We observed a positive association between several early-life factors and EoE, including prenatal (maternal fever: adjusted odds ratio [aOR], 3.18; 95% CI, 1.27-7.98; preterm labor: aOR, 2.18; 95% CI, 1.06-4.48), intrapartum (cesarean delivery: aOR, 1.77; 95% CI, 1.01, 3.09), and infancy (antibiotic use: aOR, 2.30; 95% CI, 1.21-4.38; use of an acid suppressant: aOR, 6.05; 95% CI, 2.55-14.40) factors. We observed an inverse association between having a furry pet in infancy and EoE (aOR, 0.58; 95% CI, 0.34-0.97). No associations were observed for breast-feeding or maternal multivitamin or folic acid supplement use. Conclusion: Early-life factors, including maternal fever, preterm labor, cesarean delivery, and antibiotic or acid suppressant use in infancy, were associated with risk of pediatric EoE; having a pet in the home was protective. These results add to growing evidence that implicate early-life exposures in EoE pathogenesis.	[Jensen, Elizabeth T.] Wake Forest Univ, Dept Epidemiol & Prevent, Publ Hlth Sci, Winston Salem, NC 27157 USA; [Jensen, Elizabeth T.; Dellon, Evan S.] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Dept Med, Chapel Hill, NC USA; [Dellon, Evan S.] Univ N Carolina, Sch Med, Ctr Esophageal Dis & Swallowing, Chapel Hill, NC USA; [Kuhl, Jonathan T.; Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Kuhl, Jonathan T.; Rothenberg, Marc E.] Univ Cincinnati, Sch Med, Dept Pediat, Cincinnati, OH USA; [Martin, Lisa J.] Univ Cincinnati, Sch Med, Div Genet, Cincinnati, OH USA	Wake Forest University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Jensen, ET (corresponding author), Wake Forest Univ, Div Publ Hlth Sci, Dept Epidemiol & Prevent, Sch Med, Ctr Blvd, Winston Salem, NC 27157 USA.	ejensen@wakehealth.edu	Martin, Lisa/E-2425-2016	Martin, Lisa/0000-0001-8702-9946; Jensen, Elizabeth/0000-0003-2704-6634	American College of Gastroenterology-Clinical Research Award [R01 DK101856]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK101856] Funding Source: NIH RePORTER	American College of Gastroenterology-Clinical Research Award; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the American College of Gastroenterology-Clinical Research Award (to E.S.D. and E.T.J.) and R01 DK101856 (to E.S.D.).	Azad MB, 2016, BJOG-INT J OBSTET GY, V123, P983, DOI 10.1111/1471-0528.13601; Brown SB, 2014, NUTR REV, V72, P55, DOI 10.1111/nure.12080; Byberg KK, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-101; Calabrese C, 2005, AM J GASTROENTEROL, V100, P537, DOI 10.1111/j.1572-0241.2005.40476.x; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Collins MH, 2017, DIS ESOPHAGUS, V30, DOI 10.1111/dote.12470; Davis BP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86355; DeBrosse CW, 2010, J ALLERGY CLIN IMMUN, V126, P112, DOI 10.1016/j.jaci.2010.05.027; Dellon ES, 2014, GASTROENTEROL CLIN N, V43, P201, DOI 10.1016/j.gtc.2014.02.002; Dellon ES, 2014, CLIN GASTROENTEROL H, V12, P589, DOI 10.1016/j.cgh.2013.09.008; Dellon ES, 2013, AM J GASTROENTEROL, V108, P1854, DOI 10.1038/ajg.2013.363; Dellon ES, 2013, AM J GASTROENTEROL, V108, P679, DOI 10.1038/ajg.2013.71; Edwards MO, 2015, J ALLERGY CLIN IMMUN, V136, P581, DOI 10.1016/j.jaci.2015.05.005; Farre R, 2007, GUT, V56, P1191, DOI 10.1136/gut.2006.113688; Greenland S, 1999, EPIDEMIOLOGY, V10, P37, DOI 10.1097/00001648-199901000-00008; Herberth G, 2011, ALLERGY, V66, P1065, DOI 10.1111/j.1398-9995.2011.02587.x; Hruz P, 2011, GASTROENTEROLOGY, V140, pS238; Jensen ET, 2016, GASTROENTEROLOGY, V150, pS135, DOI 10.1016/S0016-5085(16)30555-8; Jensen Elizabeth T, 2016, Curr Treat Options Gastroenterol, V14, P39, DOI 10.1007/s11938-016-0083-1; Jensen ET, 2016, J PEDIATR GASTR NUTR, V62, P36, DOI 10.1097/MPG.0000000000000865; Jensen ET, 2015, BEST PRACT RES CL GA, V29, P721, DOI 10.1016/j.bpg.2015.06.008; Jensen ET, 2015, AM J GASTROENTEROL, V110, P626, DOI 10.1038/ajg.2014.316; Jensen ET, 2013, J PEDIATR GASTR NUTR, V57, P67, DOI 10.1097/MPG.0b013e318290d15a; Kedika RR, 2009, DIGEST DIS SCI, V54, P2312, DOI 10.1007/s10620-009-0951-9; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Kovacic MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023714; Lee E, 2015, ALLERGY ASTHMA IMMUN, V7, P167, DOI 10.4168/aair.2015.7.2.167; Lexmond WS, 2014, AM J GASTROENTEROL, V109, P646, DOI 10.1038/ajg.2014.12; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lodge CJ, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/176484; Loo EXL, 2015, INT ARCH ALLERGY IMM, V166, P273, DOI 10.1159/000381342; Martin LJ, 2015, J ALLERGY CLIN IMMUN, V135, P1519, DOI 10.1016/j.jaci.2015.03.004; Merwat SN, 2009, AM J GASTROENTEROL, V104, P1897, DOI 10.1038/ajg.2009.87; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Moawad FJ, 2016, CLIN GASTROENTEROL H, V14, P23, DOI 10.1016/j.cgh.2015.08.034; Molina-Infante J, 2016, GUT, V65, P524, DOI 10.1136/gutjnl-2015-310991; Molina-Infante J, 2011, CLIN GASTROENTEROL H, V9, P110, DOI 10.1016/j.cgh.2010.09.019; Mulder IE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028279; North ML, 2011, ANN ALLERG ASTHMA IM, V106, P355, DOI 10.1016/j.anai.2011.02.008; Pali-Scholl I, 2008, EXP TOXICOL PATHOL, V60, P337, DOI 10.1016/j.etp.2008.03.004; Patel AL, 2016, J PEDIATR GASTR NUTR, V62, P292, DOI 10.1097/MPG.0000000000000913; Pesce G, 2014, PEDIAT ALLERG IMM-UK, V25, P159, DOI 10.1111/pai.12160; Pistiner M, 2008, J ALLERGY CLIN IMMUN, V122, P274, DOI 10.1016/j.jaci.2008.05.007; Radano MC, 2014, J ALLER CL IMM-PRACT, V2, P475, DOI 10.1016/j.jaip.2014.02.018; Richiardi L, 2013, INT J EPIDEMIOL, V42, P1511, DOI 10.1093/ije/dyt127; Rosas-Salazar C, 2014, J ALLERGY CLIN IMMUN, V133, P357, DOI 10.1016/j.jaci.2013.09.003; Sandberg M, 2009, PEDIAT ALLERG IMM-UK, V20, P519, DOI 10.1111/j.1399-3038.2008.00794.x; Schokker D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100040; Seo JH, 2015, ALLERGY ASTHMA IMMUN, V7, P241, DOI 10.4168/aair.2015.7.3.241; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Slae M, 2015, DIGEST DIS SCI, V60, P3364, DOI 10.1007/s10620-015-3740-7; Spechler SJ, 2007, AM J GASTROENTEROL, V102, P1301, DOI 10.1111/j.1572-0241.2007.01179.x; Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282; Untersmayr E, 2005, FASEB J, V19, P656, DOI 10.1096/fj.04-3170fje; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; van Rhijn BD, 2012, GASTROENTEROLOGY, V142, pS1138; Veerappan GR, 2009, CLIN GASTROENTEROL H, V7, P420, DOI 10.1016/j.cgh.2008.10.009; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; Wen T, 2015, J ALLERGY CLIN IMMUN, V135, P187, DOI 10.1016/j.jaci.2014.08.043	59	63	63	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					214	222		10.1016/j.jaci.2017.05.018	http://dx.doi.org/10.1016/j.jaci.2017.05.018			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28601683	Green Accepted			2022-12-18	WOS:000419312200027
J	Smith, PK; Masilamani, M; Li, XM; Sampson, HA				Smith, Peter K.; Masilamani, Madhan; Li, Xiu-Min; Sampson, Hugh A.			The false alarm hypothesis: Food allergy is associated with high dietary advanced glycation end-products and proglycating dietary sugars that mimic alarmins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; alarmins; glycation; advanced glycated end-products; receptor for advanced glycated end-products	T-CELL-ACTIVATION; MAILLARD REACTION; DENDRITIC CELLS; MILK ALLERGY; URIC-ACID; PROTEIN GLYCATION; ORAL TOLERANCE; POTENTIAL ROLE; FREE-RADICALS; RISK-FACTORS	The incidence of food allergy has increased dramatically in the last few decades in westernized developed countries. We propose that the Western lifestyle and diet promote innate danger signals and immune responses through production of "alarmins.'' Alarmins are endogenous molecules secreted from cells undergoing nonprogrammed cell death that signal tissue and cell damage. High molecular group S (HMGB1) is a major alarmin that binds to the receptor for advanced glycation end-products (RAGE). Advanced glycation endproducts (AGEs) are also present in foods. We propose the "false alarm'' hypothesis, in which AGEs that are present in or formed from the food in our diet are predisposing to food allergy. The Western diet is high in AGEs, which are derived from cooked meat, oils, and cheese. AGEs are also formed in the presence of a high concentration of sugars. We propose that a diet high in AGEs and AGE-forming sugars results in misinterpretation of a threat from dietary allergens, promoting the development of food allergy. AGEs and other alarmins inadvertently prime innate signaling through multiple mechanisms, resulting in the development of allergic phenotypes. Current hypotheses and models of food allergy do not adequately explain the dramatic increase in food allergy in Western countries. Dietary AGEs and AGEforming sugars might be the missing link, a hypothesis supported by a number of convincing epidemiologic and experimental observations, as discussed in this article.	[Smith, Peter K.] Griffith Univ, Sch Med, 17-123 Nerang St, Southport, Qld 4215, Australia; [Masilamani, Madhan; Li, Xiu-Min; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA	Griffith University; Icahn School of Medicine at Mount Sinai	Smith, PK (corresponding author), Griffith Univ, Sch Med, 17-123 Nerang St, Southport, Qld 4215, Australia.	pksm@mac.com	li, xiu/GXV-1745-2022; Masilamani, Madhan/H-3691-2019	Masilamani, Madhan/0000-0001-8181-8848; Smith, Peter/0000-0002-2629-8963	National Institutes of Health, Food Allergy Research and Education; Sean Parker Foundation; Chris Burch Fund; Winston Wolkoff Fund	National Institutes of Health, Food Allergy Research and Education; Sean Parker Foundation; Chris Burch Fund; Winston Wolkoff Fund	X.-M. Li has consultant arrangements with Hong Kong University; has received grants from the National Institutes of Health, Food Allergy Research and Education, the Sean Parker Foundation, the Chris Burch Fund, and the Winston Wolkoff Fund; has a patent through Herbs Spring LLC; and has received royalties from UpToDate. H. A. Sampson holds 42.5% shares in Herbs Spring, LLC, a start-up that has supported the development of an herbal product for the treatment of food allergy, which in part might work through suppression of the alarmin system. The rest of the authors declare that they have no relevant conflicts of interest.	Agresti A, 2003, CURR OPIN GENET DEV, V13, P170, DOI 10.1016/S0959-437X(03)00023-6; Allen KJ, 2013, J ALLERGY CLIN IMMUN, V131, P1109, DOI 10.1016/j.jaci.2013.01.017; [Anonymous], 2013, UNH DEV WORLD FOOD M; [Anonymous], 2003, PROF FOOD CONS AM; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barrett JR, 2006, ENVIRON HEALTH PERSP, V114, pA352, DOI 10.1289/ehp.114-a352; Beeri MS, 2011, MECH AGEING DEV, V132, P583, DOI 10.1016/j.mad.2011.10.007; Berin MC, 2006, ALLERGY, V61, P64, DOI 10.1111/j.1398-9995.2006.01012.x; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; Birlouez-Aragon I, 2004, FOOD CHEM, V87, P253, DOI 10.1016/j.foodchem.2003.11.019; Blanc F, 2011, MOL NUTR FOOD RES, V55, P1887, DOI 10.1002/mnfr.201100251; Burks W, 1998, ALLERGY, V53, P725, DOI 10.1111/j.1398-9995.1998.tb03967.x; Buttari B, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/574029; Buttari B, 2011, BLOOD, V117, P6152, DOI 10.1182/blood-2010-12-325514; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Cerami C, 1997, P NATL ACAD SCI USA, V94, P13915, DOI 10.1073/pnas.94.25.13915; Chen, 2013, FOOD SCI HUM WELL, V2, P146, DOI [DOI 10.1016/J.FSHW.2013.08.002, 10.1016/j.fshw.2013.08.002]; Chen YL, 2008, J IMMUNOL, V181, P4272, DOI 10.4049/jimmunol.181.6.4272; Chung SY, 2001, J AGR FOOD CHEM, V49, P3911, DOI 10.1021/jf001186o; COATES ME, 1967, NATURE, V213, P307, DOI 10.1038/213307a0; Cohen-Or I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017974; Corzo-Martinez M, 2012, INT J FOOD MICROBIOL, V153, P420, DOI 10.1016/j.ijfoodmicro.2011.12.006; DeChristopher LR, 2016, PUBLIC HEALTH NUTR, V19, P123, DOI 10.1017/S1368980015000865; Delatour T, 2009, J CHROMATOGR A, V1216, P2371, DOI 10.1016/j.chroma.2009.01.011; Diesner SC, 2012, PEDIAT ALLERG IMM-UK, V23, P210, DOI 10.1111/j.1399-3038.2011.01259.x; Dittrich R, 2006, J AGR FOOD CHEM, V54, P6924, DOI 10.1021/jf060905h; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Dumitriu IE, 2005, J IMMUNOL, V174, P7506, DOI 10.4049/jimmunol.174.12.7506; Ellwood P, 2001, EUR RESPIR J, V17, P436, DOI 10.1183/09031936.01.17304360; Ellwood P, 2013, THORAX, V68, P351, DOI 10.1136/thoraxjnl-2012-202285; Finkelstein A, 1905, MONATSSCHRIFT KINDER, V4, P65; Fritz G, 2011, TRENDS BIOCHEM SCI, V36, P625, DOI 10.1016/j.tibs.2011.08.008; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; Ge JB, 2005, ARTERIOSCL THROM VAS, V25, P2157, DOI 10.1161/01.ATV.0000181744.58265.63; Gruber P, 2004, J AGR FOOD CHEM, V52, P4002, DOI 10.1021/jf035458+; Gruber C, 2009, EXPERT REV CLIN IMMU, V5, P1, DOI 10.1586/1744666X.5.1.1; Gupta RS, 2012, CLIN PEDIATR, V51, P856, DOI 10.1177/0009922812448526; Han KY, 2011, INT ARCH ALLERGY IMM, V155, P64, DOI 10.1159/000327298; Hara K, 2014, J IMMUNOL, V192, P4032, DOI 10.4049/jimmunol.1400110; He S. H., 2005, Journal of Food Distribution Research, V36, P79; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; Hilmenyuk T, 2010, IMMUNOLOGY, V129, P437, DOI 10.1111/j.1365-2567.2009.03199.x; Humphrey AL, 2015, J ALLERGY CLIN IMMUN, V135, pAB255, DOI 10.1016/j.jaci.2014.12.1774; Ibrahim ZA, 2013, MOL IMMUNOL, V56, P739, DOI 10.1016/j.molimm.2013.07.008; Kalapos MP, 2008, CHEM-BIOL INTERACT, V171, P251, DOI 10.1016/j.cbi.2007.11.009; Kang JH, 2003, TOXICOL LETT, V145, P181, DOI 10.1016/S0378-4274(03)00305-9; Kant R, 2011, MICROB BIOTECHNOL, V4, P323, DOI 10.1111/j.1751-7915.2010.00215.x; Kim BS, 2013, CURR OPIN IMMUNOL, V25, P738, DOI 10.1016/j.coi.2013.07.013; Kong J, 2015, ALLERGY, V70, P495, DOI 10.1111/all.12579; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Kumar R, 2009, J ALLERGY CLIN IMMUN, V124, P1031, DOI 10.1016/j.jaci.2009.06.052; Kuo CH, 2013, ALLERGY, V68, P870, DOI 10.1111/all.12162; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Lee JB, 2016, J ALLERGY CLIN IMMUN, V137, P1216, DOI 10.1016/j.jaci.2015.09.019; Li XM, 2014, J AGR FOOD CHEM, V62, P12152, DOI 10.1021/jf504132x; Lv LS, 2011, CHEM RES TOXICOL, V24, P579, DOI 10.1021/tx100457h; Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Manfredi AA, 2008, J IMMUNOL, V180, P2270, DOI 10.4049/jimmunol.180.4.2270; Martin PE, 2013, CLIN EXP ALLERGY, V43, P642, DOI 10.1111/cea.12092; Martino D, 2015, J ALLERGY CLIN IMMUN, V135, P1319, DOI 10.1016/j.jaci.2014.12.1933; Masilamani M, 2011, J ALLERGY CLIN IMMUN, V128, P1242, DOI 10.1016/j.jaci.2011.05.009; McNaughton S., EATING BEHAV URBAN R; Mericq V, 2010, DIABETES CARE, V33, P2232, DOI 10.2337/dc10-1058; Millien VO, 2013, SCIENCE, V341, P792, DOI 10.1126/science.1240342; Mills DJS, 2008, J APPL MICROBIOL, V105, P706, DOI 10.1111/j.1365-2672.2008.03783.x; Milutinovic PS, 2012, AM J PATHOL, V181, P1215, DOI 10.1016/j.ajpath.2012.06.031; Mondoulet L, 2005, J AGR FOOD CHEM, V53, P4547, DOI 10.1021/jf050091p; Moon WanKi, 1999, Agribusiness (New York), V15, P411, DOI 10.1002/(SICI)1520-6297(199922)15:3&lt;411::AID-AGR8&gt;3.0.CO;2-M; Mueller GA, 2013, ALLERGY, V68, P1546, DOI 10.1111/all.12261; Mullins RJ, 2010, CLIN EXP ALLERGY, V40, P1523, DOI 10.1111/j.1365-2222.2010.03573.x; Mullins RJ, 2007, MED J AUSTRALIA, V186, P618, DOI 10.5694/j.1326-5377.2007.tb01077.x; Mullins RJ, 2009, ANN ALLERG ASTHMA IM, V103, P488, DOI 10.1016/S1081-1206(10)60265-7; Nagel G, 2010, THORAX, V65, P516, DOI 10.1136/thx.2009.128256; Nakamura A, 2005, J AGR FOOD CHEM, V53, P7559, DOI 10.1021/jf0502045; Nakamura A, 2006, J AGR FOOD CHEM, V54, P9529, DOI 10.1021/jf061070d; Nakamura S, 2008, FOOD CHEM, V109, P538, DOI 10.1016/j.foodchem.2007.12.075; Oczypok EA, 2015, J ALLERGY CLIN IMMUN, V136, P747, DOI 10.1016/j.jaci.2015.03.011; Okada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044338; Perrier C, 2011, CLIN EXP ALLERGY, V41, P20, DOI 10.1111/j.1365-2222.2010.03639.x; Perrone L, 2015, J ALZHEIMERS DIS, V45, P965, DOI 10.3233/JAD-140720; Pischetsrieder M, 2012, AMINO ACIDS, V42, P1111, DOI 10.1007/s00726-010-0775-0; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P255, DOI 10.1016/j.jaci.2007.04.027; Price CL, 2004, DIABETES, V53, P1452, DOI 10.2337/diabetes.53.6.1452; Prusak AM, 2014, ACTA SCI POLON-TECHN, V13, P321, DOI 10.17306/J.AFS.2014.3.10; Ramasamy R, 2005, GLYCOBIOLOGY, V15, p16R, DOI 10.1093/glycob/cwi053; Ramasamy R, 2008, ANN NY ACAD SCI, V1126, P7, DOI 10.1196/annals.1433.056; Reitsma M, 2014, MOL NUTR FOOD RES, V58, P194, DOI 10.1002/mnfr.201300204; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Robertson CF, 2004, MED J AUSTRALIA, V180, P273, DOI 10.5694/j.1326-5377.2004.tb05924.x; Saavedra JM, 2013, ANN NUTR METAB, V62, P27, DOI 10.1159/000351538; Sang S, 2007, CHEM RES TOXICOL, V20, P1862, DOI 10.1021/tx700190s; Scanlon ST, 2015, CLIN EXP ALLERGY, V45, P9, DOI 10.1111/cea.12464; Sebekova K, 2008, ANN NY ACAD SCI, V1126, P177, DOI 10.1196/annals.1433.049; Sehra S, 2015, J ALLERGY CLIN IMMUN, V136, P433, DOI 10.1016/j.jaci.2015.01.021; Sessa L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086903; Shao X, 2008, CHEM RES TOXICOL, V21, P2042, DOI 10.1021/tx800227v; Sick E, 2010, BRIT J PHARMACOL, V161, P442, DOI 10.1111/j.1476-5381.2010.00905.x; Steyn NP, 2003, B WORLD HEALTH ORGAN, V81, P599; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sudo N, 1997, J IMMUNOL, V159, P1739; Taheri-Kafrani A, 2009, J AGR FOOD CHEM, V57, P4974, DOI 10.1021/jf804038t; Thornley S, 2011, PRIM CARE RESP J, V20, P75, DOI 10.4104/pcrj.2010.00087; Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457; Ullah MA, 2014, J ALLERGY CLIN IMMUN, V134, P440, DOI 10.1016/j.jaci.2013.12.1035; Uribarri J, 2005, ANN NY ACAD SCI, V1043, P461, DOI 10.1196/annals.1333.052; Uribarri J, 2010, J AM DIET ASSOC, V110, P911, DOI 10.1016/j.jada.2010.03.018; van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5; Vissers YM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023998; Vlassara H, 2002, P NATL ACAD SCI USA, V99, P15596, DOI 10.1073/pnas.242407999; Wood LG, 2012, AM J CLIN NUTR, V96, P534, DOI 10.3945/ajcn.111.032623; Ye XJ, 2010, FOOD CHEM, V121, P1039, DOI 10.1016/j.foodchem.2010.01.045; YIM HS, 1995, J BIOL CHEM, V270, P28228; Yu Linda Chia-Hui, 2012, J Allergy (Cairo), V2012, P596081, DOI 10.1155/2012/596081; Zitman-Gal T, 2012, J STEROID BIOCHEM, V132, P1, DOI 10.1016/j.jsbmb.2012.04.003	119	63	67	0	39	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2017	139	2					429	437		10.1016/j.jaci.2016.05.040	http://dx.doi.org/10.1016/j.jaci.2016.05.040			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EO9IM	27544741	hybrid			2022-12-18	WOS:000397002400007
J	Salter, BM; Oliveria, JP; Nusca, G; Smith, SG; Watson, RM; Comeau, M; Sehmi, R; Gauvreau, GM				Salter, Brittany M.; Oliveria, John Paul; Nusca, Graeme; Smith, Steve G.; Watson, Rick M.; Comeau, Micheal; Sehmi, Roma; Gauvreau, Gail M.			Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophils; allergic asthma; thymic stromal lymphopoietin; epithelium-derived cytokines; CD203c; T(H)2 cytokines	EXPRESSION; CHALLENGE; RESPONSES; PROMOTES; BLOOD; CELLS; CHEMOKINES; HEALTHY	Background: Thymic stromal lymphopoietin (TSLP) released after antigenic stimulation of allergic asthmatic airways is a key initiator of type 2 inflammation. Basophils are important effectors of allergic inflammation in the airways. Murine basophils have been shown to respond to TSLP independently of IL-3 by increasing functional thymic stromal lymphopoietin receptor (TSLPR) expression. Objective: The purpose of this study was to investigate the effect of TSLP stimulation on human basophil function. Methods: Ten patients with mild allergic asthma underwent diluent and allergen inhalation challenges. Peripheral blood and sputum samples were collected at baseline and 7 and 24 hours after challenge, and bone marrow samples were collected at baseline and 24 hours after challenge to measure basophil TSLPR expression. In vitro experiments were conducted on purified human basophils to measure the effect of TSLP on degranulation, expression of activation markers and T(H)2 cytokines, and eotaxin-induced shape change. Results: Allergen inhalation increased basophil numbers in the airways and significantly upregulated the expression of activation markers, T(H)2 intracellular cytokines, and receptors for TSLP, IL-3, and eotaxin in blood, bone marrow, and sputum basophils. In vitro stimulation with TSLP primed basophil migration to eotaxin and induced rapid and sustained basophil activation mediated directly through TSLPR and indirectly through an IL-3-mediated basophil autocrine loop. Basophils responded to TSLP at a similar magnitude and potency as the well-described basophil-activating stimuli IL-3 and anti-IgE. Conclusion: Our findings indicate that basophil activation during early-and late-phase responses to inhaled allergen might be driven at least in part by TSLP.	[Salter, Brittany M.; Oliveria, John Paul; Nusca, Graeme; Smith, Steve G.; Watson, Rick M.; Gauvreau, Gail M.] McMaster Univ, Dept Med, Hamilton, ON HSC 3U26, Canada; [Comeau, Micheal] Amgen Inc, Dept Inflammat Res, Seattle, WA USA; [Sehmi, Roma] St Josephs, Firestone Inst Resp Hlth, Hamilton, ON, Canada	McMaster University; Amgen; McMaster University	Gauvreau, GM (corresponding author), McMaster Univ, 1200 Main St West, Hamilton, ON HSC 3U26, Canada.	gauvreau@mcmaster.ca	Oliveria, John-Paul/AAH-8080-2020	Oliveria, John-Paul/0000-0002-7192-7634; Smith, Steven/0000-0001-9928-117X	Genentech; Sanofi; CSL Pharma	Genentech(Roche HoldingGenentech); Sanofi(Sanofi-Aventis); CSL Pharma	G. M. Gauvreau has received research support from Genentech, Sanofi, and CSL Pharma. The rest of the authors declare that they have no relevant conflicts of interest.	Agrawal R, 2014, CLIN EXP ALLERGY, V44, P1266, DOI 10.1111/cea.12390; Allakhverdi A, 2014, FRONT IMMUNOL, V4, P1; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; Demehri S, 2014, CLIN EXP ALLERGY, V44, P851, DOI 10.1111/cea.12270; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Dorman SC, 2005, J ALLERGY CLIN IMMUN, V115, P501, DOI 10.1016/j.jaci.2004.11.017; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; Giacomin PR, 2012, J IMMUNOL, V189, P4371, DOI 10.4049/jimmunol.1200691; Hauswirth AW, 2007, INT J IMMUNOPATH PH, V20, P267, DOI 10.1177/039463200702000207; Hui CCK, 2014, IMMUN INFLAMM DIS, V2, P44, DOI 10.1002/iid3.20; Ling P, 2004, BRIT J PHARMACOL, V142, P161, DOI 10.1038/sj.bjp.0705729; Miazgowicz MM, 2009, EXPERT REV CLIN IMMU, V5, P547, DOI 10.1586/ECI.09.45; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Ocmant A, 2005, CYTOKINE, V31, P375, DOI 10.1016/j.cyto.2005.06.007; Schroeder JT, 2009, J IMMUNOL, V182, P2432, DOI 10.4049/jimmunol.0801782; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Stirling RG, 2001, AM J RESP CRIT CARE, V164, P1403, DOI 10.1164/ajrccm.164.8.2010002; Sturm EM, 2010, CYTOM PART B-CLIN CY, V78B, P308, DOI 10.1002/cyto.b.20526; Tedeschi A, 1989, J IMMUNOL, V142, P3527; Watson BM, 2013, AM J RESP CRIT CARE, V187; Watson B, 2014, EXPERT OPIN THER TAR, V18, P771, DOI 10.1517/14728222.2014.915314; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Zhang KQ, 2007, AM J PHYSIOL-LUNG C, V293, pL375, DOI 10.1152/ajplung.00045.2007	27	63	64	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1636	1644		10.1016/j.jaci.2015.03.039	http://dx.doi.org/10.1016/j.jaci.2015.03.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	25962901				2022-12-18	WOS:000366044300026
J	Holzinger, D; Fassl, SK; de Jager, W; Lohse, P; Rohrig, UF; Gattorno, M; Omenetti, A; Chiesa, S; Schena, F; Austermann, J; Vogl, T; Kuhns, DB; Holland, SM; Rodriguez-Gallego, C; Lopez-Almaraz, R; Arostegui, JI; Colino, E; Roldan, R; Fessatou, S; Isidor, B; Poignant, S; Ito, K; Epple, HJ; Bernstein, JA; Jeng, M; Frankovich, J; Lionetti, G; Church, JA; Ong, PY; LaPlant, M; Abinun, M; Skinner, R; Bigley, V; Sachs, UJ; Hinze, C; Hoppenreijs, E; Ehrchen, J; Foell, D; Chae, JJ; Ombrello, A; Aksentijevich, I; Sunderkoetter, C; Roth, J				Holzinger, Dirk; Fassl, Selina Kathleen; de Jager, Wilco; Lohse, Peter; Roehrig, Ute F.; Gattorno, Marco; Omenetti, Alessia; Chiesa, Sabrina; Schena, Francesca; Austermann, Judith; Vogl, Thomas; Kuhns, Douglas B.; Holland, Steven M.; Rodriguez-Gallego, Carlos; Lopez-Almaraz, Ricardo; Arostegui, Juan I.; Colino, Elena; Roldan, Rosa; Fessatou, Smaragdi; Isidor, Bertrand; Poignant, Sylvaine; Ito, Koichi; Epple, Hans-Joerg; Bernstein, Jonathan A.; Jeng, Michael; Frankovich, Jennifer; Lionetti, Geraldina; Church, Joseph A.; Ong, Peck Y.; LaPlant, Mona; Abinun, Mario; Skinner, Rod; Bigley, Venetia; Sachs, Ulrich J.; Hinze, Claas; Hoppenreijs, Esther; Ehrchen, Jan; Foell, Dirk; Chae, Jae Jin; Ombrello, Amanda; Aksentijevich, Ivona; Sunderkoetter, Cord; Roth, Johannes			Single amino acid charge switch defines clinically distinct proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1)-associated inflammatory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hyperzincemia and hypercalprotectinemia; myeloid-related protein 8/14; calprotectin; S100 proteins; zinc; proline-serine-threonine phosphatase-interacting protein 1; pyogenic arthritis; pyoderma gangrenosum, and acne syndrome; genotype; phenotype; autoinflammation	JUVENILE IDIOPATHIC ARTHRITIS; PAPA SYNDROME; PYODERMA-GANGRENOSUM; ZINC-METABOLISM; RECEPTOR 4; PYOGENIC ARTHRITIS; INTERFERON-GAMMA; GENE-EXPRESSION; IN-VITRO; T-CELLS	Background: Hyperzincemia and hypercalprotectinemia (Hz/Hc) is a distinct autoinflammatory entity involving extremely high serum concentrations of the proinflammatory alarmin myeloid-related protein (MRP) 8/14 (S100A8/S100A9 and calprotectin). Objective: We sought to characterize the genetic cause and clinical spectrum of Hz/Hc. Methods: Proline-serine-threonine phosphatase-interacting protein 1 (PSTPIP1) gene sequencing was performed in 14 patients with Hz/Hc, and their clinical phenotype was compared with that of 11 patients with pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome. PSTPIP1-pyrin interactions were analyzed by means of immunoprecipitation and Western blotting. A structural model of the PSTPIP1 dimer was generated. Cytokine profiles were analyzed by using the multiplex immunoassay, and MRP8/14 serum concentrations were analyzed by using an ELISA. Results: Thirteen patients were heterozygous for a missense mutation in the PSTPIP1 gene, resulting in a p.E250K mutation, and 1 carried a mutation resulting in p. E257K. Both mutations substantially alter the electrostatic potential of the PSTPIP1 dimer model in a region critical for protein-protein interaction. Patients with Hz/Hc have extremely high MRP8/14 concentrations (2045 +/- 1300 mu g/mL) compared with those with PAPA syndrome (116 +/- 74 mu g/mL) and have a distinct clinical phenotype. A specific cytokine profile is associated with Hz/Hc. Hz/Hc mutations altered protein binding of PSTPIP1, increasing interaction with pyrin through phosphorylation of PSTPIP1. Conclusion: Mutations resulting in charge reversal in the y-domain of PSTPIP1 (E -> K) and increased interaction with pyrin cause a distinct autoinflammatory disorder defined by clinical and biochemical features not found in patients with PAPA syndrome, indicating a unique genotype-phenotype correlation for mutations in the PSTPIP1 gene. This is the first inborn autoinflammatory syndrome in which inflammation is driven by uncontrolled release of members of the alarmin family.	[Holzinger, Dirk; Fassl, Selina Kathleen; Austermann, Judith; Vogl, Thomas; Roth, Johannes] Univ Munster, Inst Immunol, D-48149 Munster, Germany; [Holzinger, Dirk; Austermann, Judith; Vogl, Thomas; Hinze, Claas; Ehrchen, Jan; Foell, Dirk; Sunderkoetter, Cord; Roth, Johannes] Univ Munster, Univ Hosp Muenster, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany; [Holzinger, Dirk; Foell, Dirk] Univ Munster, Univ Childrens Hosp Muenster, Dept Paediat Rheumatol & Immunol, D-48149 Munster, Germany; [de Jager, Wilco; Hinze, Claas] Univ Med Ctr Utrecht, Dept Paediat Immunol, Lab Translat Immunol, Utrecht, Netherlands; [Lohse, Peter] Univ Munich, Dept Clin Chem Grosshadern, D-81377 Munich, Germany; [Roehrig, Ute F.] Swiss Inst Bioinformat, Mol Modeling Grp, Lausanne, Switzerland; [Gattorno, Marco; Omenetti, Alessia; Chiesa, Sabrina; Schena, Francesca] G Gaslini Sci Inst, Div Pediat 2, Genoa, Italy; [Kuhns, Douglas B.] Leidos Biomed Res, Frederick, MD USA; [Holland, Steven M.] NIAID, NIH, Bethesda, MD USA; [Rodriguez-Gallego, Carlos] Hosp Univ Son Espases, Dept Immunol, Palma De Mallorca, Spain; [Lopez-Almaraz, Ricardo] Hosp Univ Canarias, Dept Pediat, San Cristobal la Laguna, Spain; [Arostegui, Juan I.] Hosp Clin IDIBAPS, Dept Immunol CDB, Barcelona, Spain; [Colino, Elena] Complejo Hosp Univ Insular Materno Infant, Dept Paediat, Las Palmas Gran Canaria, Spain; [Roldan, Rosa] Hosp Univ Reina Sofia, Dept Pediat Rheumatol, Cordoba, Spain; [Fessatou, Smaragdi] Univ Athens, Sch Med, ATTIKON Hosp, Dept Pediat 3, GR-10679 Athens, Greece; [Isidor, Bertrand] Ctr Hosp Univ, Serv Genet Med, Nantes, France; [Poignant, Sylvaine] CH Cholet, Serv Pediat, Cholet, France; [Ito, Koichi] Nagoya City Univ, Grad Sch Med Sci, Dept Pediat & Neonatol, Nagoya, Aichi, Japan; [Epple, Hans-Joerg] Charite, Dept Gastroenterol Infect Dis & Rheumatol, D-13353 Berlin, Germany; [Bernstein, Jonathan A.; Jeng, Michael; Frankovich, Jennifer] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; [Lionetti, Geraldina] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Church, Joseph A.; Ong, Peck Y.] Univ So Calif, Keck Sch Med, Div Clin Immunol & Allergy, Childrens Hosp Los Angeles, Los Angeles, CA 90033 USA; [Church, Joseph A.; Ong, Peck Y.] Univ So Calif, Keck Sch Med, Dept Pediat, Los Angeles, CA 90033 USA; [LaPlant, Mona] Childrens Hosp & Clin Minnesota, St Paul, MN USA; [Abinun, Mario] Great North Childrens Hosp, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Abinun, Mario] Great North Childrens Hosp, Childrens BMT Unit, Newcastle Upon Tyne, Tyne & Wear, England; [Abinun, Mario] Newcastle Univ, Inst Clin Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Skinner, Rod] Royal Victoria Infirm, Great North Childrens Hosp, Dept Paediat & Adolescent Haematol & Oncol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Skinner, Rod] Royal Victoria Infirm, Great North Childrens Hosp, Childrens BMT Unit, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Skinner, Rod] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Bigley, Venetia] Newcastle Univ, Sch Med, Human Dendrit Cell Lab, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Sachs, Ulrich J.] Univ Giessen, Inst Clin Immunol & Transfus Med, Giessen, Germany; [Hinze, Claas] Deutsch Zentrum Kinder & Jugendrheumatol, Garmisch Partenkirchen, Germany; [Hoppenreijs, Esther] St Maartens Clin, Dept Paediat Paediat Rheumatol, Nijmegen, Netherlands; [Hoppenreijs, Esther] Radboud Univ Nijmegen, Ctr Med, NL-6525 ED Nijmegen, Netherlands; [Ehrchen, Jan; Sunderkoetter, Cord] Univ Hosp Muenster, Dept Dermatol, Munster, Germany; [Chae, Jae Jin; Ombrello, Amanda; Aksentijevich, Ivona] NHGRI, NIH, Bethesda, MD 20892 USA; [Ehrchen, Jan; Sunderkoetter, Cord] Univ Hosp Muenster, Dept Translat Dermatoinfectiol, Munster, Germany	University of Munster; University of Munster; University of Munster; Utrecht University; Utrecht University Medical Center; University of Munich; Swiss Institute of Bioinformatics; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Hospital Universitari Son Espases; Universidad de la Laguna; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Athens Medical School; National & Kapodistrian University of Athens; University Hospital Attikon; Nantes Universite; CHU de Nantes; Nagoya City University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Stanford University; University of California System; University of California San Francisco; Children's Hospital Los Angeles; University of Southern California; University of Southern California; Children's Hospitals & Clinics of Minnesota; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Justus Liebig University Giessen; Sint Maartens Clinic; Radboud University Nijmegen; University of Munster; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Munster	Roth, J (corresponding author), Univ Munster, Inst Immunol, D-48149 Munster, Germany.	rothj@uni-muenster.de	Omenetti, Alessia/K-5975-2016; Aksentijevich, Ivona/AAF-1335-2019; Fessatou, Smaragdi/AAH-1592-2021; RODRIGUEZ-GALLEGO, CARLOS/AAB-7516-2022; Almaraz, Ricardo López/X-2931-2019; Isidor, Bertrand/AAJ-3456-2021; Ong, Peck Y/AAE-2944-2021; Schena, Francesca/AAA-9214-2020; Jeng, Michael R./AAM-3183-2020; Gattorno, Marco/AAL-2974-2020; Chiesa, Sabrina/AAN-7877-2020; Bigley, Venetia/AAU-9738-2020; Sachs, Ulrich/GSI-7824-2022	Omenetti, Alessia/0000-0002-8220-0385; Almaraz, Ricardo López/0000-0001-5521-9892; Isidor, Bertrand/0000-0001-6480-126X; Ong, Peck Y/0000-0002-6664-463X; Schena, Francesca/0000-0002-5868-7699; Gattorno, Marco/0000-0003-0704-1916; Bigley, Venetia/0000-0002-3017-2474; Fassl, Selina/0000-0002-6356-5012; Holzinger, Dirk/0000-0002-8062-8820; Ombrello, Amanda/0000-0001-5563-9416; Hinze, Claas/0000-0001-9247-4729; Arostegui, Juan Ignacio/0000-0003-4757-504X; Rodriguez-Gallego, Carlos/0000-0002-4344-8644; Roehrig, Ute/0000-0002-4676-4087; Jeng, Michael/0000-0001-8200-8484; Sunderkotter, Cord/0000-0002-2929-145X; de Jager, Wilco/0000-0002-0014-0682; Chiesa, Sabrina/0000-0002-0392-1927	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Instituters of Health, Department of Health and Haman Services; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; "Fondo de Investigaciones Sanitarias,'' Ministerio de Economia y Competitividad [PI06/1031, PI10/01718]; European Regional Development Fund European Social Fund FEDER-FSE; Interdisciplinary Centre for Clinical Research University of Munster; German Research Foundation [SFB1009]; Bundesministerium fur Bildung und Forschung (AID-NET) [01GM08100]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000646, ZIAAI000647] Funding Source: NIH RePORTER; Wellcome Trust [101155/Z/13/Z] Funding Source: researchfish	Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Instituters of Health, Department of Health and Haman Services; National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); "Fondo de Investigaciones Sanitarias,'' Ministerio de Economia y Competitividad; European Regional Development Fund European Social Fund FEDER-FSE; Interdisciplinary Centre for Clinical Research University of Munster; German Research Foundation(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung (AID-NET)(Federal Ministry of Education & Research (BMBF)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)	Supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Instituters of Health, Department of Health and Haman Services (to S.M.H.) and in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. Also supported by "Fondo de Investigaciones Sanitarias,'' Ministerio de Economia y Competitividad (PI06/1031, PI10/01718), with the funding of European Regional Development Fund European Social Fund FEDER-FSE, the Interdisciplinary Centre for Clinical Research University of Munster, the German Research Foundation (SFB1009), and the Bundesministerium fur Bildung und Forschung (AID-NET, project 01GM08100).	Bao B, 2011, BIOCHEM BIOPH RES CO, V407, P703, DOI 10.1016/j.bbrc.2011.03.084; Beck FWJ, 2006, NUTRITION, V22, P1045, DOI 10.1016/j.nut.2006.08.001; Besecker BY, 2011, AM J CLIN NUTR, V93, P1356, DOI 10.3945/ajcn.110.008417; Chae JJ, 2011, IMMUNITY, V34, P755, DOI 10.1016/j.immuni.2011.02.020; Cooper KM, 2008, MOL BIOL CELL, V19, P3180, DOI 10.1091/mbc.E08-02-0225; Cortesio CL, 2010, ARTHRITIS RHEUM-US, V62, P2556, DOI 10.1002/art.27521; de Jager W, 2005, J IMMUNOL METHODS, V300, P124, DOI 10.1016/j.jim.2005.03.009; Demidowich AP, 2012, ARTHRITIS RHEUM-US, V64, P2022, DOI 10.1002/art.34332; Fessatou S, 2005, J PEDIAT HEMATOL ONC, V27, P477, DOI 10.1097/01.mph.0000179958.19524.9c; Frosch M, 2000, ARTHRITIS RHEUM-US, V43, P628, DOI 10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X; Frosch M, 2009, ARTHRITIS RHEUM-US, V60, P883, DOI 10.1002/art.24349; Gaetke LM, 1997, AM J PHYSIOL-ENDOC M, V272, pE952, DOI 10.1152/ajpendo.1997.272.6.E952; Guerois R, 2002, J MOL BIOL, V320, P369, DOI 10.1016/S0022-2836(02)00442-4; Hayashi K, 2008, LIFE SCI, V83, P6, DOI 10.1016/j.lfs.2008.04.022; Henne WM, 2007, STRUCTURE, V15, P839, DOI 10.1016/j.str.2007.05.002; Hesker PR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051105; Holzinger D, 2012, ANN RHEUM DIS, V71, P974, DOI 10.1136/annrheumdis-2011-200598; Isidor B, 2009, ACTA PAEDIATR, V98, P410, DOI 10.1111/j.1651-2227.2008.01092.x; Lee H, 2012, CLIN EXP RHEUMATOL, V30, P452; Lindor NM, 1997, MAYO CLIN PROC, V72, P611; Loser K, 2010, NAT MED, V16, P713, DOI 10.1038/nm.2150; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MADURA JD, 1995, COMPUT PHYS COMMUN, V91, P57, DOI 10.1016/0010-4655(95)00043-F; Marzano AV, 2013, JAMA DERMATOL, V149, P762, DOI 10.1001/jamadermatol.2013.2907; Melo F, 1998, J MOL BIOL, V277, P1141, DOI 10.1006/jmbi.1998.1665; Newton RA, 1998, J IMMUNOL, V160, P1427; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Prasad AS, 2006, TRANSL RES, V148, P325, DOI 10.1016/j.trsl.2006.07.008; Prasad AS, 1997, P ASSOC AM PHYSICIAN, V109, P68; Rammes A, 1997, J BIOL CHEM, V272, P9496; Reil A, 2013, TRANSFUSION, V53, P2145, DOI 10.1111/trf.12086; Roth J, 2003, TRENDS IMMUNOL, V24, P155, DOI 10.1016/S1471-4906(03)00062-0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sampson B, 2002, LANCET, V360, P1742, DOI 10.1016/S0140-6736(02)11683-7; Schellevis MA, 2011, ANN RHEUM DIS, V70, P1168, DOI 10.1136/ard.2009.126185; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Shoham NG, 2003, P NATL ACAD SCI USA, V100, P13501, DOI 10.1073/pnas.2135380100; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; Smith EJ, 2010, CURR GENOMICS, V11, P519, DOI 10.2174/138920210793175921; Song XY, 2011, NAT IMMUNOL, V12, P1151, DOI 10.1038/ni.2155; Sugiura T, 2006, ACTA PAEDIATR, V95, P857, DOI 10.1080/08035250500482255; Tsou TC, 2011, J HAZARD MATER, V196, P335, DOI 10.1016/j.jhazmat.2011.09.035; van Lent PLEM, 2008, ANN RHEUM DIS, V67, P1750, DOI 10.1136/ard.2007.077800; Viemann D, 2005, BLOOD, V105, P2955, DOI 10.1182/blood-2004-07-2520; Vogl T, 2004, BLOOD, V104, P4260, DOI 10.1182/blood-2004-02-0446; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Waite AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006147; Wieringa FT, 2004, EUR J CLIN NUTR, V58, P1498, DOI 10.1038/sj.ejcn.1601998; Wittkowski H, 2008, PEDIAT RHEUMATOL S1, V6, pP208; Wittkowski H, 2011, ANN RHEUM DIS, V70, P2075, DOI 10.1136/ard.2011.152496; Yang HL, 2006, J IMMUNOL, V176, P5898, DOI 10.4049/jimmunol.176.10.5898; Yu JW, 2007, MOL CELL, V28, P214, DOI 10.1016/j.molcel.2007.08.029; Yu JW, 2013, J BIOL CHEM, V288, P11378, DOI 10.1074/jbc.M112.448795; Zindl CL, 2013, P NATL ACAD SCI USA, V110, P12768, DOI 10.1073/pnas.1300318110	54	63	67	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1337	1345		10.1016/j.jaci.2015.04.016	http://dx.doi.org/10.1016/j.jaci.2015.04.016			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	26025129	Green Accepted, Bronze			2022-12-18	WOS:000364787200024
J	Safholm, J; Manson, ML; Bood, J; Delin, I; Orre, AC; Bergman, P; Al-Ameri, M; Dahlen, SE; Adner, M				Safholm, Jesper; Manson, Martijn L.; Bood, Johan; Delin, Ingrid; Orre, Ann-Charlotte; Bergman, Per; Al-Ameri, Mamdoh; Dahlen, Sven-Erik; Adner, Mikael			Prostaglandin E-2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin-exacerbated respiratory disease; asthma; COX products; E prostanoid receptor; explanted human tissue model; human bronchi; pharmacologic testing; prostanoid receptors; thromboxane receptor	ALLERGEN-INDUCED BRONCHOCONSTRICTION; ASPIRIN-SENSITIVE ASTHMA; HUMAN ISOLATED BRONCHUS; INDUCED CONTRACTION; STIMULATED RELEASE; HISTAMINE-RELEASE; INHALED PGE(2); EP2 RECEPTORS; SMOOTH-MUSCLE; TP-RECEPTORS	Background: Inhaled prostaglandin (PG) E-2 might inhibit asthmatic responses, but the mechanisms involved remain undefined. Objective: We sought to characterize the direct and indirect effects of PGE(2) on human small airways with particular reference to the receptors mediating the responses. Methods: Contraction and relaxation were studied in isolated human bronchi with an inner diameter of 1 mm or less. Results: Low concentrations of PGE(2) (0.01-1 mmol/L) relaxed the bronchi precontracted by histamine. The bronchodilator response was inhibited by the E prostanoid (EP) subtype 4 receptor antagonist ONO-AE3-208 but unaffected by the EP2 receptor antagonist PF-04418948. Higher concentrations of PGE(2) (10-100 mu mol/L) contracted the small airways. However, the TP receptor agonists U-46,619, PGF(2 alpha), and PGD(2) were more potent than PGE(2.) Moreover, the bronchoconstrictor responses to PGE(2) and all other tested prostanoids, including the EP1/EP3 receptor agonist 17-phenyl trinor PGE(2) and the partial FP receptor agonist AL-8810, were uniformly abolished by the TP receptor antagonist SQ-29,548. In the presence of TP and EP4 antagonists, PGE(2) inhibited the mast cell-mediated bronchoconstriction resulting from anti-IgE challenge. Measurement of the release of histamine and cysteinyl leukotrienes documented that this bronchoprotective action of PGE(2) was mediated by the EP2 receptor, unrelated to bronchodilation, and increased with time of exposure. Conclusion: The pharmacology of PGE(2) in isolated human small airways was different from its profile in animal models. This first demonstration of powerful EP2 receptor-mediated inhibition of IgE-dependent contractions in human airways introduces a new selective target for the treatment of asthma. This EP2 control of mast cell-mediated bronchoconstriction is presumably exaggerated in patients with aspirin-exacerbated respiratory disease.	[Safholm, Jesper; Manson, Martijn L.; Bood, Johan; Delin, Ingrid; Dahlen, Sven-Erik; Adner, Mikael] Karolinska Inst, Inst Environm Med, Unit Expt Asthma & Allergy Res, SE-17177 Stockholm, Sweden; [Safholm, Jesper; Manson, Martijn L.; Bood, Johan; Delin, Ingrid; Dahlen, Sven-Erik; Adner, Mikael] Karolinska Inst, Ctr Allergy Res, SE-17177 Stockholm, Sweden; [Bergman, Per] Karolinska Inst, Dept Mol Med & Surg MMK, SE-17177 Stockholm, Sweden; [Orre, Ann-Charlotte; Bergman, Per; Al-Ameri, Mamdoh] Karolinska Univ Hosp, Dept Cardiothorac Surg & Anesthesiol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Safholm, J (corresponding author), Karolinska Inst, Inst Environm Med, Unit Expt Asthma & Allergy Res, Scheeles Vag 1, SE-17177 Stockholm, Sweden.	jesper.safholm@ki.se	Manson, Martijn/GQI-3438-2022; Manson, Martijn L/AAE-8606-2019	Manson, Martijn L/0000-0002-5508-8615; Safholm, Jesper/0000-0003-1922-8104	Medical Research Council; Heart Lung Foundation; Vardal Foundation; Stockholm County Council Research Funds (ALF); Swedish Strategic Research Foundation; Konsul Th. C Berghs research foundation; KI-SciLifeLab collaborations on Translational Medicine (ChAMP); ERC COST action [BM 1201]; Karolinska Institutet	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Heart Lung Foundation(Swedish Heart-Lung Foundation); Vardal Foundation; Stockholm County Council Research Funds (ALF); Swedish Strategic Research Foundation(Swedish Foundation for Strategic Research); Konsul Th. C Berghs research foundation; KI-SciLifeLab collaborations on Translational Medicine (ChAMP); ERC COST action; Karolinska Institutet(Karolinska Institutet)	Supported by the Medical Research Council, the Heart Lung Foundation, the Vardal Foundation, the Stockholm County Council Research Funds (ALF), the Swedish Strategic Research Foundation, Konsul Th. C Berghs research foundation, the KI-SciLifeLab collaborations on Translational Medicine (ChAMP), ERC COST action BM 1201, and Karolinska Institutet.	Adner M, 1996, EUR RESPIR J, V9, P351, DOI 10.1183/09031936.96.09020351; Andersson CK, 2009, THORAX, V64, P297, DOI 10.1136/thx.2008.101683; ANGGARD E, 1965, J BIOL CHEM, V240, P3518; ARMOUR CL, 1989, EUR J PHARMACOL, V165, P215, DOI 10.1016/0014-2999(89)90715-2; BEASLEY RCW, 1989, J APPL PHYSIOL, V66, P1685, DOI 10.1152/jappl.1989.66.4.1685; Benyahia C, 2012, PULM PHARMACOL THER, V25, P115, DOI 10.1016/j.pupt.2011.12.012; Billot X, 2003, BIOORG MED CHEM LETT, V13, P1129, DOI 10.1016/S0960-894X(03)00042-8; BJORCK T, 1993, PULM PHARMACOL, V6, P87, DOI 10.1006/pulp.1993.1012; BLACK JL, 1986, PROSTAGLANDINS, V32, P25, DOI 10.1016/0090-6980(86)90139-5; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; BRECHT T, 1987, PROSTAGLANDINS, V33, P51, DOI 10.1016/0090-6980(87)90048-7; Buckley J, 2011, THORAX, V66, P1029, DOI 10.1136/thx.2010.158568; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; COLEMAN RA, 1989, BRIT J PHARMACOL, V96, P688, DOI 10.1111/j.1476-5381.1989.tb11869.x; Daham K, 2014, J ALLERGY CLIN IMMUN, V134, P306, DOI 10.1016/j.jaci.2013.12.002; Dahlen B, 2001, NEW ENGL J MED, V344, P142, DOI 10.1056/NEJM200101113440215; ELLIS JL, 1994, AM J RESP CRIT CARE, V150, P717, DOI 10.1164/ajrccm.150.3.8087342; Feng CL, 2006, BLOOD, V107, P3243, DOI 10.1182/blood-2005-07-2772; GARDINER PJ, 1975, PROSTAGLANDINS, V10, P607, DOI 10.1016/S0090-6980(75)80007-4; Griffin BW, 1999, J PHARMACOL EXP THER, V290, P1278; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; Harrington LS, 2008, FASEB J, V22, P4005, DOI 10.1096/fj.08-107979; Hartert TV, 2000, AM J RESP CRIT CARE, V162, P637, DOI 10.1164/ajrccm.162.2.9904038; Kay LJ, 2006, BRIT J PHARMACOL, V147, P707, DOI 10.1038/sj.bjp.0706664; Knight DA, 1997, EUR J PHARMACOL, V319, P261, DOI 10.1016/S0014-2999(96)00870-9; Kuehn HS, 2011, IMMUNOL LETT, V141, P45, DOI 10.1016/j.imlet.2011.07.002; Maher SA, 2009, AM J RESP CRIT CARE, V180, P923, DOI 10.1164/rccm.200903-0388OC; MATHE AA, 1971, NATURE-NEW BIOL, V230, P215, DOI 10.1038/newbio230215a0; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138, DOI 10.1164/ajrccm.149.5.8173753; MILLER WL, 1975, PROSTAGLANDINS, V9, P9, DOI 10.1016/S0090-6980(75)80113-4; Murray J J, 1985, Trans Assoc Am Physicians, V98, P275; NIALS AT, 1993, CARDIOVASC DRUG REV, V11, P165, DOI 10.1111/j.1527-3466.1993.tb00274.x; NOREL X, 1991, BRIT J PHARMACOL, V104, P591, DOI 10.1111/j.1476-5381.1991.tb12474.x; OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; PEACHELL PT, 1988, J IMMUNOL, V140, P571; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Safholm J, 2013, BRIT J PHARMACOL, V168, P794, DOI 10.1111/j.1476-5381.2012.02189.x; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; SLADEK K, 1993, EUR RESPIR J, V6, P391; SWEATMAN WJ, 1968, NATURE, V217, P69, DOI 10.1038/217069a0; Szczeklik A, 1996, AM J RESP CRIT CARE, V153, P567, DOI 10.1164/ajrccm.153.2.8564099; van den Berge M, 2011, CHEST, V139, P412, DOI 10.1378/chest.10-1210; Wang XS, 2006, ALLERGY, V61, P503, DOI 10.1111/j.1398-9995.2006.01043.x	46	63	64	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1232	+		10.1016/j.jaci.2015.04.002	http://dx.doi.org/10.1016/j.jaci.2015.04.002			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	25962903				2022-12-18	WOS:000364787200011
J	Li, JJ; Tay, HL; Maltby, S; Xiang, Y; Eyers, F; Hatchwell, L; Sci, BB; Zhou, H; Toop, HD; Morris, JC; Nair, P; Mattes, J; Foster, PS; Yang, M				Li, Jing Jing; Tay, Hock L.; Maltby, Steven; Xiang, Yang; Eyers, Fiona; Hatchwell, Luke; Sci, B. Biomed; Zhou, Hong; Toop, Hamish D.; Morris, Jonathan C.; Nair, Parameswaran; Mattes, Joerg; Foster, Paul S.; Yang, Ming			MicroRNA-9 regulates steroid-resistant airway hyperresponsiveness by reducing protein phosphatase 2A activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MicroRNA; pulmonary macrophages; innate immunity; protein phosphatase 2A; steroid-resistant airway hyperresponsiveness	GLUCOCORTICOID-RECEPTOR PHOSPHORYLATION; PULMONARY MACROPHAGES; INFLAMMATORY SUBTYPES; INTERFERON-GAMMA; EMERGING ROLES; INDUCED ASTHMA; MECHANISMS; EXPRESSION; ACTIVATION; DISEASE	Background: Steroid-resistant asthma is a major clinical problem that is linked to activation of innate immune cells. Levels of IFN-gamma and LPS are often increased in these patients. Cooperative signaling between IFN-gamma/LPS induces macrophage-dependent steroid-resistant airway hyperresponsiveness (AHR) in mouse models. MicroRNAs (miRs) are small noncoding RNAs that regulate the function of innate immune cells by controlling mRNA stability and translation. Their role in regulating glucocorticoid responsiveness and AHR remains unexplored. Objective: IFN-gamma and LPS synergistically increase the expression of miR-9 in macrophages and lung tissue, suggesting a role in the mechanisms of steroid resistance. Here we demonstrate the role of miR-9 in IFN-gamma/LPS-induced inhibition of dexamethasone (DEX) signaling in macrophages and in induction of steroid-resistant AHR. Methods: MiRNA-9 expression was assessed by means of quantitative RT-PCR. Putative miR-9 targets were determined in silico and confirmed in luciferase reporter assays. miR-9 function was inhibited with sequence-specific antagomirs. The efficacy of DEX was assessed by quantifying glucocorticoid receptor (GR) cellular localization, protein phosphatase 2A (PP2A) activity, and AHR. Results: Exposure of pulmonary macrophages to IFN-gamma/LPS synergistically induced miR-9 expression; reduced levels of its target transcript, protein phosphatase 2 regulatory subunit B (B56) delta isoform; attenuated PP2A activity; and inhibited DEX-induced GR nuclear translocation. Inhibition of miR-9 increased both PP2A activity and GR nuclear translocation in macrophages and restored steroid sensitivity in multiple models of steroid-resistant AHR. Pharmacologic activation of PP2A restored DEX efficacy and inhibited AHR. MiR-9 expression was increased in sputum of patients with neutrophilic but not those with eosinophilic asthma. Conclusion: MiR-9 regulates GR signaling and steroid-resistant AHR. Targeting miR-9 function might be a novel approach for the treatment of steroid-resistant asthma.	[Li, Jing Jing; Tay, Hock L.; Maltby, Steven; Xiang, Yang; Eyers, Fiona; Zhou, Hong; Foster, Paul S.; Yang, Ming] Univ Newcastle, Sch Biomed Sci & Pharm, Prior Res Ctr Asthma & Resp Dis, Callaghan, NSW 2308, Australia; [Hatchwell, Luke; Mattes, Joerg] Univ Newcastle, Discipline Paediat & Child Hlth, Prior Res Ctr Asthma & Resp Dis, Sch Med & Publ Hlth,Fac Hlth, Callaghan, NSW 2308, Australia; Hunter Med Res Inst, Callaghan, NSW, Australia; [Xiang, Yang] Cent South Univ, Dept Physiol, Xiangya Sch Med, Changsha, Hunan, Peoples R China; [Toop, Hamish D.; Morris, Jonathan C.] Univ New S Wales, Sch Chem, Sydney, NSW, Australia; [Nair, Parameswaran] McMaster Univ, Firestone Inst Resp Hlth, St Josephs Healthcare, Hamilton, ON L8S 4L8, Canada; [Nair, Parameswaran] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada	University of Newcastle; University of Newcastle; Hunter Medical Research Institute; University of Newcastle; Central South University; University of New South Wales Sydney; McMaster University; McMaster University	Yang, M (corresponding author), Univ Newcastle, Sch Biomed Sci & Pharm, Immunol & Microbiol, Level 2,HMRI Bldg, Callaghan, NSW 2308, Australia.	Paul.Foster@newcastle.edu.au; Ming.Yang@newcastle.edu.au	Morris, Jonathan C/A-9923-2008; Foster, Paul/G-5057-2013; MATTES, JOERG/M-5179-2019; Toop, Hamish/AAV-8207-2020	Morris, Jonathan C/0000-0002-5109-9069; Toop, Hamish/0000-0003-4637-4764; , Paul/0000-0002-0827-8299; Zhou, Hong/0000-0003-2004-4572; Maltby, Steven/0000-0003-1240-5964	National Health and Medical Research Council of Australia; Australian Research Council; Cooperative Research Centre for Asthma and Airways; University of Newcastle; Canadian Institutes of Health Research	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); Cooperative Research Centre for Asthma and Airways(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); University of Newcastle; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Supported by the National Health and Medical Research Council of Australia, the Australian Research Council, the Cooperative Research Centre for Asthma and Airways, the University of Newcastle, and the Canadian Institutes of Health Research.	Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Ahn JH, 2007, P NATL ACAD SCI USA, V104, P2979, DOI 10.1073/pnas.0611532104; Ahn JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026292; Almeida MI, 2010, CELL RES, V20, P603, DOI 10.1038/cr.2010.70; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Barnes Peter J, 2009, Lancet, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106; Chen WW, 2008, MOL ENDOCRINOL, V22, P1754, DOI 10.1210/me.2007-0219; Collison A, 2013, NAT MED, V19, P232, DOI 10.1038/nm.3049; Collison A, 2011, J ALLERGY CLIN IMMUN, V128, P160, DOI 10.1016/j.jaci.2011.04.005; Collison A, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-29; Currie GP, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b494; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; Dilda F, 2012, VET J, V192, P514, DOI 10.1016/j.tvjl.2011.08.018; Foster PS, 2013, IMMUNOL REV, V253, P198, DOI 10.1111/imr.12058; Galliher-Beckley AJ, 2009, IUBMB LIFE, V61, P979, DOI 10.1002/iub.245; Gibson PG, 2009, THORAX, V64, P369, DOI 10.1136/thx.2008.109710; Hafner M, 2011, NAT STRUCT MOL BIOL, V18, P1181, DOI 10.1038/nsmb.2170; Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102; Hansbro NG, 2008, PHARMACOL THERAPEUT, V117, P313, DOI 10.1016/j.pharmthera.2007.11.002; Hatchwell L, 2014, J ALLERGY CLIN IMMUN, V133, P1720, DOI 10.1016/j.jaci.2013.11.014; Iborra M, 2012, AUTOIMMUN REV, V11, P305, DOI 10.1016/j.autrev.2010.07.002; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kobayashi Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027627; Kotani A, 2009, BLOOD, V114, P4169, DOI 10.1182/blood-2008-12-191619; Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Leucht C, 2008, NAT NEUROSCI, V11, P641, DOI 10.1038/nn.2115; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li JJ, 2010, J IMMUNOL, V185, P4401, DOI 10.4049/jimmunol.1001039; Lodish HF, 2008, NAT REV IMMUNOL, V8, P120, DOI 10.1038/nri2252; Loewen GM, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-145; Louis JV, 2011, P NATL ACAD SCI USA, V108, P6957, DOI 10.1073/pnas.1018777108; Ma N, 2012, J CELL BIOCHEM, V113, P1, DOI 10.1002/jcb.23341; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; McCarthy N, 2010, NAT REV GENET, V11, P8, DOI 10.1038/nrg2722; Mohamed JS, 2010, J BIOL CHEM, V285, P29336, DOI 10.1074/jbc.M110.101147; O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957; Oglesby IK, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-148; Pekow JR, 2012, INFLAMM BOWEL DIS, V18, P187, DOI 10.1002/ibd.21691; Plaisance V, 2006, J BIOL CHEM, V281, P26932, DOI 10.1074/jbc.M601225200; Plank M, 2013, CLIN EXP ALLERGY, V43, P981, DOI [10.1111/cea.12135, 10.1111/cea.12170]; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Saddoughi SA, 2013, EMBO MOL MED, V5, P105, DOI 10.1002/emmm.201201283; Saito S, 1999, BIOCHEM BIOPH RES CO, V259, P471, DOI 10.1006/bbrc.1999.0790; Sawicka E, 2003, J IMMUNOL, V171, P6206, DOI 10.4049/jimmunol.171.11.6206; Shanley TP, 2001, J IMMUNOL, V166, P966, DOI 10.4049/jimmunol.166.2.966; Shibata M, 2008, J NEUROSCI, V28, P10415, DOI 10.1523/JNEUROSCI.3219-08.2008; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2005, AM J RESP CRIT CARE, V172, P559, DOI 10.1164/rccm.200503-369OC; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; Simpson JL, 2009, PHARMACOL THERAPEUT, V124, P86, DOI 10.1016/j.pharmthera.2009.06.004; Switzer CH, 2011, ONCOGENE, V30, P2504, DOI 10.1038/onc.2010.622; ten Hacken NHT, 1998, EUR RESPIR J, V11, P312, DOI 10.1183/09031936.98.11020312; Uchida S, 2008, EUR J NEUROSCI, V27, P2250, DOI 10.1111/j.1460-9568.2008.06218.x; Wan HY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-16; Wang Y, 2011, GENOMICS, V98, P445, DOI 10.1016/j.ygeno.2011.09.004; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yang M, 2010, CLIN EXP ALLERGY, V40, P163, DOI 10.1111/j.1365-2222.2009.03393.x; Yang M, 2012, J LEUKOCYTE BIOL, V91, P557, DOI 10.1189/jlb.0711357; Yang M, 2009, J IMMUNOL, V182, P5107, DOI 10.4049/jimmunol.0803468; Yu UY, 2010, BMB REP, V43, P263, DOI 10.5483/BMBRep.2010.43.4.263; Zhang JH, 2011, J MOL CELL CARDIOL, V51, P337, DOI 10.1016/j.yjmcc.2011.05.019	69	63	69	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					462	473		10.1016/j.jaci.2014.11.044	http://dx.doi.org/10.1016/j.jaci.2014.11.044			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25772595				2022-12-18	WOS:000359004900028
J	Su, WR; Wan, Q; Huang, JW; Han, LH; Chen, XQ; Chen, GH; Olsen, N; Zheng, SG; Liang, D				Su, Wenru; Wan, Qian; Huang, Jingwen; Han, Longhui; Chen, Xiaoqing; Chen, Guihua; Olsen, Nancy; Zheng, Song Guo; Liang, Dan			Culture medium from TNF-alpha-stimulated mesenchymal stem cells attenuates allergic conjunctivitis through multiple antiallergic mechanisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; mesenchymal stem cells; stems cells; B cells; mast cells; histamine; allergic conjunctivitis	CONTACT HYPERSENSITIVITY; MURINE MODEL; VE-CADHERIN; INFLAMMATION; RECEPTOR; RESPONSES; TRANSPLANTATION; RECONSTRUCTION; SUPPRESSION; MATURATION	Background: The immunomodulatory and anti-inflammatory functions of mesenchymal stem cells (MSCs) have been demonstrated in several autoimmune/inflammatory diseases, but their contribution to allergic conjunctivitis and underlying antiallergic mechanisms remain elusive. Objective: We sought to explore the clinical application of MSCs to experimental allergic conjunctivitis (EAC) and its underlying antiallergic mechanisms. Methods: Culture medium from TNF-alpha-stimulated, bone marrow-derived MSCs (MSC-CMT) was administered topically to mice with EAC, and the related allergic symptoms and biological changes were evaluated. Murine spleen-derived B cells, bone marrow-derived mast cells (MCs), and lung vascular endothelial cells were cultured in vitro to investigate the antiallergic MSC-CMT mechanisms. Results: Topical instillation of MSC-CMT significantly attenuated the clinical symptoms of short ragweed pollen-induced EAC, with a significant decrease in inflammatory cell frequency, nuclear factor kB p65 expression, and TNF-alpha and IL-4 production. In vitro MSC-CMT significantly inhibited the activation of MCs and B-cell IgE release and reduced histamine-induced vascular hyperpermeability. During EAC, MSC-CMT treatment also decreased IgE production, histamine release, enrichment and activation of MCs, and conjunctival vascular hyperpermeability. The MSC-CMT-mediated inhibition of B cells, MCs, and histamine and its antiallergic effects during EAC were abrogated when MSCs were pretreated with COX2 small interfering RNA. Conclusions: Our findings provide compelling evidence that MSC-CMT inhibits EAC through COX2-dependent multiple antiallergic mechanisms and support the use of MSC-CMT as a novel strategy for treating allergic conjunctivitis.	[Su, Wenru; Wan, Qian; Huang, Jingwen; Han, Longhui; Chen, Xiaoqing; Liang, Dan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China; [Su, Wenru; Chen, Guihua; Zheng, Song Guo] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Clin Immunol, Guangzhou 510275, Guangdong, Peoples R China; [Chen, Xiaoqing; Olsen, Nancy; Zheng, Song Guo] Penn State Univ, Hershey Coll Med, Dept Med, Div Rheumatol, Hershey, PA USA	Sun Yat Sen University; Sun Yat Sen University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Liang, D (corresponding author), 54 Xianlie South Rd, Guangzhou 510060, Guangdong, Peoples R China.	szheng1@hmc.psu.edu; liangd631004@163.com	chen, xia/GXM-5435-2022; chen, xi/GXH-3653-2022; chen, xia/GYR-3948-2022	Su, Wenru/0000-0002-0506-6362	Natural Science Foundation of China [81271051, 81300740]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059103] Funding Source: NIH RePORTER	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Natural Science Foundation of China (81271051) and the Natural Science Foundation of China (81300740).	Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007; Azari AA, 2013, JAMA-J AM MED ASSOC, V310, P1721, DOI 10.1001/jama.2013.280318; Bielory L, 2012, ALLERGY ASTHMA PROC, V33, P129, DOI 10.2500/aap.2012.33.3525; Brown JM, 2011, CLIN EXP ALLERGY, V41, P526, DOI 10.1111/j.1365-2222.2010.03685.x; Cho KS, 2009, STEM CELLS, V27, P259, DOI 10.1634/stemcells.2008-0283; Chuang YC, 2011, CYTOKINE, V54, P222, DOI 10.1016/j.cyto.2011.01.013; Goodwin M, 2011, STEM CELLS, V29, P1137, DOI 10.1002/stem.656; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Guo M, 2008, AM J PHYSIOL-CELL PH, V294, pC977, DOI 10.1152/ajpcell.90607.2007; Heo SC, 2011, J INVEST DERMATOL, V131, P1559, DOI 10.1038/jid.2011.64; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Jensen Bettina M, 2006, Curr Protoc Immunol, VChapter 3, DOI 10.1002/0471142735.im0323s74; Jiang TS, 2010, MOL VIS, V16, P1304; Kabashima K, 2003, NAT MED, V9, P744, DOI 10.1038/nm872; Kim HS, 2013, GASTROENTEROLOGY, V145, P1392, DOI 10.1053/j.gastro.2013.08.033; Kim SS, 2009, CELL TISSUE RES, V336, P59, DOI 10.1007/s00441-009-0766-1; Krause P, 2009, BLOOD, V113, P2451, DOI 10.1182/blood-2008-05-157123; KUEHN HS, 2010, CURR PROTOC IMMUNOL, pCH7; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; La Rosa M, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-18; Lan WW, 2012, OCUL SURF, V10, P137, DOI 10.1016/j.jtos.2012.04.001; Le Blanc K, 2012, NAT REV IMMUNOL, V12, P383, DOI 10.1038/nri3209; Leonardi S, 2007, ALLERGY ASTHMA PROC, V28, P287, DOI 10.2500/aap.2007.28.2955; Li DQ, 2011, J ALLERGY CLIN IMMUN, V128, P1318, DOI 10.1016/j.jaci.2011.06.041; Liu PF, 2014, GENET MOL RES, V13, P7992, DOI 10.4238/2014.September.29.12; Ma S, 2014, CELL DEATH DIFFER, V21, P216, DOI 10.1038/cdd.2013.158; Ma YL, 2006, STEM CELLS, V24, P315, DOI 10.1634/stemcells.2005-0046; Magone MT, 1998, CLIN IMMUNOL IMMUNOP, V87, P75, DOI 10.1006/clin.1997.4507; Meller D, 2011, DTSCH ARZTEBL INT, V108, P243, DOI 10.3238/arztebl.2011.0243; MerayoLloves J, 1996, J ALLERGY CLIN IMMUN, V97, P1129, DOI 10.1016/S0091-6749(96)70268-3; Nemeth K, 2010, P NATL ACAD SCI USA, V107, P5652, DOI 10.1073/pnas.0910720107; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Oh JY, 2008, STEM CELLS, V26, P1047, DOI 10.1634/stemcells.2007-0737; Ono SJ, 2005, J ALLERGY CLIN IMMUN, V115, P118, DOI 10.1016/j.jaci.2004.10.042; Pan Q, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009327.pub2; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; RHEINS LA, 1987, CELL IMMUNOL, V106, P33, DOI 10.1016/0008-8749(87)90147-X; Salem HK, 2010, STEM CELLS, V28, P585, DOI 10.1002/stem.269; Spaggiari GM, 2009, BLOOD, V113, P6576, DOI 10.1182/blood-2009-02-203943; Sturm EM, 2008, J IMMUNOL, V181, P7273, DOI 10.4049/jimmunol.181.10.7273; Su WR, 2011, STEM CELLS, V29, P1849, DOI 10.1002/stem.738; Su WR, 2012, J ALLERGY CLIN IMMUN, V130, P444, DOI 10.1016/j.jaci.2012.05.011; Ueta M, 2009, J ALLERGY CLIN IMMUN, V123, P466, DOI 10.1016/j.jaci.2008.09.044; Winter MC, 2004, AM J PHYSIOL-LUNG C, V287, pL816, DOI 10.1152/ajplung.00056.2004; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yao CC, 2009, NAT MED, V15, P633, DOI 10.1038/nm.1968; Yao L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030842; Ye J, 2006, EYE, V20, P482, DOI 10.1038/sj.eye.6701913; Young AL, 2004, EYE, V18, P609, DOI 10.1038/sj.eye.6700721; Zaslona Z, 2014, J ALLERGY CLIN IMMUN, V133, P379, DOI 10.1016/j.jaci.2013.07.037	51	63	65	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2015	136	2					423	+		10.1016/j.jaci.2014.12.1926	http://dx.doi.org/10.1016/j.jaci.2014.12.1926			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CO2RS	25652765				2022-12-18	WOS:000359004900024
J	Grimshaw, KEC; Maskell, J; Oliver, EM; Morris, RCG; Foote, KD; Mills, ENC; Margetts, BM; Roberts, G				Grimshaw, Kate E. C.; Maskell, Joe; Oliver, Erin M.; Morris, Ruth C. G.; Foote, Keith D.; Mills, E. N. Clare; Margetts, Barrie M.; Roberts, Graham			Diet and food allergy development during infancy: Birth cohort study findings using prospective food diary data	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; double-blind; placebo-controlled food challenge; principal component analysis; infant feeding; prospective food diary data	FISH-OIL SUPPLEMENTATION; COWS MILK FORMULA; VITAMIN-D STATUS; NUTRITIONAL INTERVENTION; EUROPEAN COUNTRIES; RESPIRATORY HEALTH; CONTROLLED-TRIAL; ATOPIC DISEASE; DOUBLE-BLIND; CHILDHOOD	Background: After an era of only considering the allergenic properties of the infant diet and allergy outcomes, emerging data suggest that the overall composition of the infant diet might be a more important factor in the development of allergic disease. Objective: We sought to assess the relationship between infant dietary patterns in the first year of life and development of food allergy by age 2 years. Methods: We performed a nested, case-control, within-cohort study. Mothers kept prospective food diaries for the first year of life, with resultant diet data coded in a unique manner to produce new variables, which were then analyzed by using principal component analysis to identify infant feeding patterns within the study subjects. Results: Principal component analysis of diet diary data from 41 infants given a diagnosis of food allergy based on results of double-blind, placebo-controlled food challenges in the first 2 years of life and their 82 age-matched control subjects provided an early infant diet pattern and an ongoing diet pattern. There was no difference between the study groups for the early infant diet pattern, but for the ongoing diet pattern, there was a significant difference between the groups (P = .001). This ongoing dietary pattern was characterized by higher intake of fruits, vegetables, and home-prepared foods, with control infants having a significantly higher healthy infant diet dietary pattern score than children who had a food allergy. Conclusions: An infant diet consisting of high levels of fruits, vegetables, and home-prepared foods is associated with less food allergy by the age of 2 years.	[Grimshaw, Kate E. C.; Oliver, Erin M.; Roberts, Graham] Univ Southampton, Clin & Expt Sci Acad Unit, Fac Med, Southampton SO9 5NH, Hants, England; [Maskell, Joe] Univ Southampton, Southampton SO9 5NH, Hants, England; [Morris, Ruth C. G.] Univ Hosp Southampton NHS Fdn Trust, Wellcome Trust Clin Res Facil, Southampton, Hants, England; [Foote, Keith D.] Hampshire Hosp Fdn Trust, Winchester, Hants, England; [Mills, E. N. Clare] Univ Manchester, Inst Inflammat & Repair, Manchester Acad Hlth Sci Ctr, Manchester Inst Biotechnol, Manchester M13 9PL, Lancs, England; [Margetts, Barrie M.] Univ Southampton, Primary Care & Populat Sci Acad Unit, Fac Med, Southampton SO9 5NH, Hants, England	University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Manchester; University of Southampton	Grimshaw, KEC (corresponding author), Southampton Gen Hosp, Clin & Expt Sci Acad Unit, Mailpoint 803,Level F,South Acad Block,Tremona Rd, Southampton SO16 6YD, Hants, England.	kecg@soton.ac.uk		Roberts, Graham/0000-0003-2252-1248; Grimshaw, Kate/0000-0003-3649-7963	UK Food Standards Agency [TO7046]; UK Food Standards Agency as part of the EU EuroPrevall Project [FOOD-CT-2005-514000]	UK Food Standards Agency; UK Food Standards Agency as part of the EU EuroPrevall Project	Supported by the UK Food Standards Agency (Project TO7046) as part of the EU EuroPrevall Project (contract no. FOOD-CT-2005-514000).	American Academy of Pediatrics, START SOL FOODS; Arvaniti F, 2011, PEDIAT ALLERG IMM-UK, V22, P283, DOI 10.1111/j.1399-3038.2010.01113.x; Bekkers MBM, 2012, EUR RESPIR J, V39, P1468, DOI 10.1183/09031936.00094511; Bender AE, 1966, INT J FOOD SCI TECH, V1, P261; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Burney P, 2010, ALLERGY, V65, P1182, DOI 10.1111/j.1398-9995.2010.02346.x; Calder PC, 2009, BRIT J NUTR, V101, pS1, DOI 10.1017/S0007114509377867; Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S, DOI 10.1093/ajcn/80.6.1717S; Carlsen KCL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043214; Chatzi L, 2007, THORAX, V62, P677, DOI 10.1136/thx.2006.069419; Department of Health, 2009, HLTH CHILD PROGR PRE; Department of Health, 2009, FEED YOUR BAB BIRTH; Department of Health, 2004, INF FEED REC; Dunstan JA, 2012, ALLERGY, V67, P50, DOI 10.1111/j.1398-9995.2011.02714.x; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Erkkola M, 2009, CLIN EXP ALLERGY, V39, P875, DOI 10.1111/j.1365-2222.2009.03234.x; Fein SB, 2008, PEDIATRICS, V122, pS25, DOI 10.1542/peds.2008-1315b; Fergusson D M, 1994, Pediatr Allergy Immunol, V5, P44, DOI 10.1111/j.1399-3038.1994.tb00347.x; Furuhjelm C, 2009, ACTA PAEDIATR, V98, P1461, DOI 10.1111/j.1651-2227.2009.01355.x; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; Gale CR, 2009, J CHILD PSYCHOL PSYC, V50, P816, DOI 10.1111/j.1469-7610.2008.02029.x; Grimshaw KEC, 2006, P NUTR SOC, V65, P412, DOI 10.1079/PNS2006516; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; HODGE L, 1994, AUST NZ J MED, V24, P727, DOI 10.1111/j.1445-5994.1994.tb01793.x; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Holst B, 2008, CURR OPIN BIOTECH, V19, P73, DOI 10.1016/j.copbio.2008.03.003; HOST A, 1991, ALLERGY PROC, V12, P227, DOI 10.2500/108854191778879287; Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002; Jordan I, 2013, EUR J NUTR, V52, P905, DOI 10.1007/s00394-012-0398-1; Kajosaari M, 1991, Adv Exp Med Biol, V310, P453; Keil T, 2010, ALLERGY, V65, P482, DOI 10.1111/j.1398-9995.2009.02171.x; Kleinman RE, 2000, PEDIATRICS, V106, P1274; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Lodge CJ, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/176484; Matheson MC, 2007, J ALLERGY CLIN IMMUN, V120, P1051, DOI 10.1016/j.jaci.2007.06.030; McBride D, 2012, PEDIAT ALLERG IMM-UK, V23, P230, DOI 10.1111/j.1399-3038.2011.01254.x; Northstone K, 2005, EUR J CLIN NUTR, V59, P751, DOI 10.1038/sj.ejcn.1602136; Public Health England, 2021, MCCANCE WIDDOWSONS C; Robinson S, 2007, BRIT J NUTR, V98, P1029, DOI 10.1017/S0007114507750936; Rosenlund H, 2011, J ALLERGY CLIN IMMUN, V127, P1219, DOI 10.1016/j.jaci.2010.11.019; SAARINEN UM, 1979, LANCET, V2, P163; Santos AF, 2012, PEDIAT ALLERG IMM-UK, V23, P698, DOI 10.1111/pai.12025; Schiess S, 2010, J PEDIATR GASTR NUTR, V50, P92, DOI 10.1097/MPG.0b013e31819f1ddc; Schnappinger M, 2009, ANN NUTR METAB, V54, P67, DOI 10.1159/000207357; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; STINTZING G, 1979, ACTA PAEDIATR SCAND, V68, P383, DOI 10.1111/j.1651-2227.1979.tb05024.x; The Department of Health, 2009, PREGN BOOK; Vassallo MF, 2010, J ALLERGY CLIN IMMUN, V126, P217, DOI 10.1016/j.jaci.2010.06.011; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521	53	63	63	0	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					511	519		10.1016/j.jaci.2013.05.035	http://dx.doi.org/10.1016/j.jaci.2013.05.035			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	23891269				2022-12-18	WOS:000332397100027
J	Otsuka, A; Doi, H; Egawa, G; Maekawa, A; Fujita, T; Nakamizo, S; Nakashima, C; Nakajima, S; Watanabe, T; Miyachi, Y; Narumiya, S; Kabashima, K				Otsuka, Atsushi; Doi, Hiromi; Egawa, Gyohei; Maekawa, Akiko; Fujita, Tomoko; Nakamizo, Satoshi; Nakashima, Chisa; Nakajima, Saeko; Watanabe, Takeshi; Miyachi, Yoshiki; Narumiya, Shuh; Kabashima, Kenji			Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; filaggrin; JTC801; keratinocyte differentiation	FLAKY TAIL MICE; SKIN; BARRIER; GENE; DIFFERENTIATION; CORNEUM; MODEL; RISK; MUTATIONS; RESPONSES	Background: Nonsense mutations in filaggrin (FLG) represent a significant genetic factor in the cause of atopic dermatitis (AD). Objective: It is of great importance to find drug candidates that upregulate FLG expression and to determine whether increased FLG expression controls the development of AD. Methods: We screened a library of bioactives by using an FLG reporter assay to find candidates that promoted FLG mRNA expression using a human immortalized keratinocyte cell line (HaCaT). We studied the effect of the compound on keratinocytes using the human skin equivalent model. We examined the effect of the compound on AD-like skin inflammation in NC/Nga mice. Results: JTC801 promoted FLG mRNA and protein expression in both HaCaT and normal human epidermal keratinocytes. Intriguingly, JTC801 promoted the mRNA and protein expression levels of FLG but not the mRNA levels of other makers for keratinocyte differentiation, including loricrin, keratin 10, and transglutaminase 1, in a human skin equivalent model. In addition, oral administration of JTC801 promoted the protein level of Flg and suppressed the development of AD-like skin inflammation in NC/Nga mice. Conclusion: This is the first observation that the compound, which increased FLG expression in human and murine keratinocytes, attenuated the development of AD-like skin inflammation in mice. Our findings provide evidence that modulation of FLG expression can be a novel therapeutic target for AD.	[Otsuka, Atsushi; Doi, Hiromi; Egawa, Gyohei; Nakamizo, Satoshi; Nakashima, Chisa; Nakajima, Saeko; Miyachi, Yoshiki; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto 6068507, Japan; [Otsuka, Atsushi; Watanabe, Takeshi] Kyoto Univ, Grad Sch Med, Ctr Innovat Immunoregulat Technol & Therapeut, Kyoto 6068507, Japan; [Maekawa, Akiko; Fujita, Tomoko; Narumiya, Shuh] Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University	Kabashima, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, 54 Shogoin Kawara, Kyoto 6068507, Japan.	kaba@kuhp.kyoto-u.ac.jp	Nakamizo, Satoshi/ABH-2121-2021; Nakajima, Saeko/AAB-1577-2021; Kabashima, Kenji/G-2521-2014	Nakamizo, Satoshi/0000-0001-9332-0369; Otsuka, Atsushi/0000-0001-7365-947X; Egawa, Gyohei/0000-0002-6101-4719; Nakajima, Saeko/0000-0003-0831-1447; Kabashima, Kenji/0000-0002-0773-0554	Ministry of Education, Culture, Sports, Science, and Technology; Ministry of Health, Labor, and Welfare of Japan; AK project at Kyoto University	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); AK project at Kyoto University	Supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labor, and Welfare of Japan and a clinical research grant from the AK project at Kyoto University.	Andoh T, 2004, J INVEST DERMATOL, V123, P196, DOI 10.1111/j.0022-202X.2004.22704.x; Brown SJ, 2012, J INVEST DERMATOL, V132, P98, DOI 10.1038/jid.2011.342; Chavanas S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003408; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fujita T, 2011, J INVEST DERMATOL, V131, P1660, DOI 10.1038/jid.2011.123; HAAKE AR, 1991, J INVEST DERMATOL, V96, P71, DOI 10.1111/1523-1747.ep12515868; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kabashima K, 2012, DERMATOL SIN, V30, P142, DOI 10.1016/j.dsi.2012.07.003; Kabashima-Kubo R, 2012, J DERMATOL SCI, V67, P37, DOI 10.1016/j.jdermsci.2012.04.004; Kamata Y, 2009, J BIOL CHEM, V284, P12829, DOI 10.1074/jbc.M807908200; Katagiri C, 2003, J DERMATOL SCI, V31, P29, DOI 10.1016/S0923-1811(02)00137-8; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kezic S, 2012, J ALLERGY CLIN IMMUN, V129, P1031, DOI 10.1016/j.jaci.2011.12.989; Mabuchi T, 2003, EUR J NEUROSCI, V17, P1384, DOI 10.1046/j.1460-9568.2003.02575.x; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Moniaga CS, 2013, AM J PATHOL, V182, P841, DOI 10.1016/j.ajpath.2012.11.039; Moniaga Catharina Sagita, 2011, Inflammation & Allergy Drug Targets, V10, P477; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Nakai K, 2012, AM J PATHOL, V181, P969, DOI 10.1016/j.ajpath.2012.06.005; Nakamura K, 1999, FEBS LETT, V445, P9, DOI 10.1016/S0014-5793(99)00087-3; Otsuka A, 2012, J EUR ACAD DERMATOL, V26, P527, DOI 10.1111/j.1468-3083.2011.04091.x; Otsuka A, 2013, ACTA DERM-VENEREOL, V93, P88, DOI 10.2340/00015555-1329; Otsuka A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025538; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pellerin L, 2013, J ALLERGY CLIN IMMUN, V131, P1094, DOI 10.1016/j.jaci.2012.12.1566; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Proksch E, 2008, EXP DERMATOL, V17, P1063, DOI 10.1111/j.1600-0625.2008.00786.x; Rawlings A.V., 2004, DERMATOL THER, V17, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/s004030050080; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Suto H, 1999, INT ARCH ALLERGY IMM, V120, P70, DOI 10.1159/000053599; Szarvas S, 2003, J CLIN ANESTH, V15, P234, DOI 10.1016/S0952-8180(02)00501-9; Tokura Y, 2010, J DERMATOL SCI, V58, P1, DOI 10.1016/j.jdermsci.2010.02.008; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; Wang XW, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng154; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004	43	63	68	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					139	+		10.1016/j.jaci.2013.07.027	http://dx.doi.org/10.1016/j.jaci.2013.07.027			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24055295				2022-12-18	WOS:000329105700019
J	Szefler, SJ; Chmiel, JF; Fitzpatrick, AM; Giacoia, G; Green, TP; Jackson, DJ; Nielsen, HC; Phipatanakul, W; Raissy, HH				Szefler, Stanley J.; Chmiel, James F.; Fitzpatrick, Anne M.; Giacoia, George; Green, Thomas P.; Jackson, Daniel J.; Nielsen, Heber C.; Phipatanakul, Wanda; Raissy, Hengameh H.			Asthma across the ages: Knowledge gaps in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma natural history; asthma progression; asthma biomarkers; childhood asthma; asthma pharmacotherapy	RESPIRATORY-SYNCYTIAL-VIRUS; EXHALED BREATH CONDENSATE; NITRIC-OXIDE SYNTHASE; 1ST 6 YEARS; YOUNG-CHILDREN; PRESCHOOL-CHILDREN; LUNG-FUNCTION; AIRWAY INFLAMMATION; EARLY-LIFE; HIGH-RISK	The Eunice Kennedy Shriver National Institute of Child Health and Human Development convened an Asthma Group in response to the Best Pharmaceuticals for Children Act. The overall goal of the Best Pharmaceuticals for Children Act Program is to improve pediatric therapeutics through preclinical and clinical drug trials that lead to drug-labeling changes. Although significant advances have been made in the understanding and management of asthma in adults with appropriately labeled medications, less information is available on the management of asthma in children. Indeed, many medications are inadequately labeled for use in children. In general, the younger the child, the less information there is available to guide clinicians. Because asthma often begins in early childhood, it is incumbent on us to continue to address the primary questions raised in this review and carefully evaluate the medications used to manage asthma in children. Meanwhile, continued efforts should be made in defining effective strategies that reduce the risk of exacerbations. If the areas of defined need are addressed in the coming years, namely prevention of exacerbations and progression of disease, as well as primary intervention, we will see continuing reduction in asthma mortality and morbidity along with improved quality of life for children with asthma.	[Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat & Pharmacol, Denver, CO 80206 USA; [Szefler, Stanley J.] Univ Colorado, Sch Med, Denver, CO USA; [Chmiel, James F.] Rainbow Babies & Childrens Hosp, Univ Hosp, Cleveland, OH 44106 USA; [Chmiel, James F.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Fitzpatrick, Anne M.] Emory Univ, Atlanta Ctr Dev Lung Biol, Dept Pediat & Childrens Healthcare, Atlanta, GA 30322 USA; [Giacoia, George] Natl Inst Child Hlth & Dev, Bethesda, MD USA; [Green, Thomas P.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Jackson, Daniel J.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA; [Nielsen, Heber C.] Tufts Univ, Sch Med, Tufts Med Ctr, Floating Hosp Children, Boston, MA 02111 USA; [Phipatanakul, Wanda] Harvard Univ, Boston Childrens Hosp, Boston, MA USA; [Phipatanakul, Wanda] Harvard Univ, Sch Med, Boston, MA USA; [Raissy, Hengameh H.] Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Emory University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; University of Wisconsin System; University of Wisconsin Madison; Floating Hospital For Children; Tufts Medical Center; Tufts University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of New Mexico	Szefler, SJ (corresponding author), Natl Jewish Hlth, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	szeflers@njhealth.org		Fitzpatrick, Anne/0000-0002-2933-5926; Nielsen, Heber/0000-0002-9382-0539; Szefler, Stanley/0000-0002-6911-3199	National Heart, Lung, and Blood Institute (NHLBI) AsthmaNet grant [U10 HL098177]; CTSA award [UL1TR000439, UL1TR000454]; AsthmaNet grant [U10 HL098103]; University of Wisconsin CTSA grant through the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) [UL1TR000427]; NHLBI AsthmaNet grant [U10 HL098102, U10 HL098075]; Harvard Catalyst/the Harvard Clinical and Translational Science Center (NIH Award) [UL1 RR 025758]; Harvard University; National Center for Research Resources; National Center for Advancing Translational Sciences of the NIH [UL1 TR000041]; NHLBI [5U10 HL098075-02]; Colorado CTSA grant from the NCRR/NIH [UL1 RR025780]; NIH/NCATS [UL1 TR000154];  [R21 HL097231]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000154, UL1TR000427, UL1TR001082, UL1TR000454, UL1TR000439, KL2TR000428, UL1TR000041] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758, UL1RR025780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL098090, R21HL097231, U10HL098177, U10HL098102, U10HL098103, U10HL098075] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI) AsthmaNet grant; CTSA award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); AsthmaNet grant; University of Wisconsin CTSA grant through the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS); NHLBI AsthmaNet grant; Harvard Catalyst/the Harvard Clinical and Translational Science Center (NIH Award)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard University; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Colorado CTSA grant from the NCRR/NIH; NIH/NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	J.F.C. is supported by National Heart, Lung, and Blood Institute (NHLBI) AsthmaNet grant U10 HL098177 and CTSA award UL1TR000439. A. M. F. is supported by AsthmaNet grant U10 HL098103 and CTSA award UL1TR000454. D. J. J. was supported by the University of Wisconsin CTSA grant UL1TR000427 through the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS). H. C. N. is supported by R21 HL097231. W. P. is supported by NHLBI AsthmaNet grant U10 HL098102. This work was conducted with the support of Harvard Catalyst/the Harvard Clinical and Translational Science Center (NIH Award no. UL1 RR 025758) and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University, and its affiliated academic health care centers; and the National Center for Research Resources or the NIH. H. H. R. is supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the NIH through grant no. UL1 TR000041 and NHLBI-funded Clinical Centers for the NHLBI AsthmaNet grant 5U10 HL098075-02. S. J. S. is supported by NHLBI AsthmaNet grant U10 HL098075 and supported in part by Colorado CTSA grant UL1 RR025780 from the NCRR/NIH and UL1 TR000154 from NIH/NCATS.	Akinbami LJ, 2012, J ALLERGY CLIN IMMUN, V129, pS49, DOI 10.1016/j.jaci.2011.12.984; Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; Aysola R, 2010, J MAGN RESON IMAGING, V32, P1379, DOI 10.1002/jmri.22388; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P287, DOI 10.1016/j.jaci.2012.04.025; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bizzintino J, 2011, EUR RESPIR J, V37, P1037, DOI 10.1183/09031936.00092410; Blaisdell CJ, 2002, J ASTHMA, V39, P567, DOI 10.1081/JAS-120014921; Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Busse WW, 2012, J ALLERGY CLIN IMMUN, V129, pS1, DOI 10.1016/j.jaci.2011.12.985; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Caffarelli C, 2012, RESPIRATION, V84, P291, DOI 10.1159/000341969; Carraro S, 2010, EUR RESPIR J, V35, P1364, DOI 10.1183/09031936.00074909; Castro-Rodriguez JA, 2011, J ALLERGY CLIN IMMUN, V127, P1082, DOI 10.1016/j.jaci.2011.01.024; Castro-Rodriguez JA, 2010, J ALLERGY CLIN IMMUN, V126, P212, DOI 10.1016/j.jaci.2010.06.032; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Cloutier MM, 2012, J ALLERGY CLIN IMMUN, V129, pS24, DOI 10.1016/j.jaci.2011.12.980; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; de Blic J, 2004, J ALLERGY CLIN IMMUN, V113, P94, DOI 10.1016/j.jaci.2003.10.045; Diaz-Vazquez C, 2009, PEDIAT ALLERG IMM-UK, V20, P601, DOI 10.1111/j.1399-3038.2008.00827.x; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983; Green SA, 2004, THORAX, V59, P100, DOI 10.1136/thorax.2003.006825; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P956, DOI 10.1016/j.jaci.2011.06.027; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Guo FH, 1998, ENVIRON HEALTH PERSP, V106, P1119, DOI 10.2307/3433973; Guxens M., 2013, J ALLERGY CLIN IMMUN; Hartling L, 2012, PEDIATRICS, V129, pS112, DOI 10.1542/peds.2012-0055C; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596, DOI 10.1136/bmj.308.6944.1596; Ingram JL, 2012, J ALLERGY CLIN IMMUN, V130, P829, DOI 10.1016/j.jaci.2012.06.034; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kalliola S, 2013, J ALLERGY CLIN IMMUN, V131, P730, DOI 10.1016/j.jaci.2013.01.005; Keskin O, 2012, ALLERGOL IMMUNOPATHO; Kimes D, 2004, ENVIRON RES, V94, P7, DOI 10.1016/S0013-9351(03)00046-X; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Krawiec ME, 2001, AM J RESP CRIT CARE, V163, P1338, DOI 10.1164/ajrccm.163.6.2005116; Krishnan JA, 2012, J ALLERGY CLIN IMMUN, V129, pS124, DOI 10.1016/j.jaci.2011.12.981; Kurlandsky LE, 2013, PEDIAT ALLER IMM PUL, V26, P35, DOI 10.1089/ped.2012.0201; Laumbach RJ, 2012, J ALLERGY CLIN IMMUN, V129, P3, DOI 10.1016/j.jaci.2011.11.021; Lim J, 2011, J FAM PSYCHOL, V25, P137, DOI 10.1037/a0022452; Liu L, 2011, CHEST, V139, P328, DOI 10.1378/chest.10-0163; Lopez-Guisa JM, 2012, J ALLERGY CLIN IMMUN, V129, P990, DOI 10.1016/j.jaci.2011.11.035; Malmstrom K, 2011, THORAX, V66, P157, DOI 10.1136/thx.2010.139246; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2011, LANCET, V377, P650, DOI 10.1016/S0140-6736(10)62145-9; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Naji N, 2013, RESP MED, V107, P503, DOI 10.1016/j.rmed.2012.12.022; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; National Asthma Education and Prevention Program, 2008, J ALLERGY CLIN IMMUN, V121, P1330; Newth CJL, 2012, J PEDIATR-US, V161, P214, DOI 10.1016/j.jpeds.2012.02.041; O'Brian AL, 2012, J ALLERGY CLIN IMMUN, V129, P1162, DOI 10.1016/j.jaci.2011.11.046; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; O'Reilly R, 2013, J ALLERGY CLIN IMMUN, V131, P1024, DOI 10.1016/j.jaci.2012.08.044; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Pando S, 2010, PHARMACOTHERAPY, V30, P1109, DOI 10.1592/phco.30.11.1109; Pao CS, 2002, AM J RESP CRIT CARE, V166, P945, DOI 10.1164/rccm.200203-265OC; Payne DNR, 2004, THORAX, V59, P862, DOI 10.1136/thx.2003.017244; Pickerd N, 2013, PEDIATR PULM, V48, P160, DOI 10.1002/ppul.22584; Plotnick LH, 2000, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000060, 10.1002/14651858.CD000060]; Rabinovitch N, 2006, J ALLERGY CLIN IMMUN, V118, P635, DOI 10.1016/j.jaci.2006.05.011; Rand CS, 2012, J ALLERGY CLIN IMMUN, V129, pS136, DOI 10.1016/j.jaci.2011.12.987; Rao DR, 2012, J ASTHMA, V49, P586, DOI 10.3109/02770903.2012.690481; Rheims S, 2008, PLOS MED, V5, P1223, DOI 10.1371/journal.pmed.0050166; Rodrigo GJ, 2005, THORAX, V60, P740, DOI 10.1136/thx.2005.040444; Saglani S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-46; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Schirm E, 2006, BRIT J CLIN PHARMACO, V62, P383, DOI 10.1111/j.1365-2125.2006.02699.x; Searing DA, 2011, CURR OPIN PEDIATR, V23, P314, DOI 10.1097/MOP.0b013e3283461926; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Szefler SJ, 2012, J ALLERGY CLIN IMM S, V129, pS9; Szefler SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1043, DOI 10.1016/j.jaci.2007.08.063; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Tang H, 2010, EUR RESPIR J, V35, P757, DOI 10.1183/09031936.00034409; Teper AM, 2005, AM J RESP CRIT CARE, V171, P587, DOI 10.1164/rccm.200408-1088OC; Tepper RS, 2012, J ALLERGY CLIN IMMUN, V129, pS65, DOI 10.1016/j.jaci.2011.12.986; Tsartsali L, 2011, THORAX, V66, P280, DOI 10.1136/thx.2010.149799; Wedes SH, 2011, J PEDIATR-US, V159, P248, DOI 10.1016/j.jpeds.2011.01.029; Williams K, 2012, PEDIATRICS, V129, pS153, DOI 10.1542/peds.2012-0055I; Wilson SR, 2012, J ALLERGY CLIN IMMUN, V129, pS88, DOI 10.1016/j.jaci.2011.12.988; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Wu PS, 2011, EXPERT REV ANTI-INFE, V9, P731, DOI [10.1586/eri.11.92, 10.1586/ERI.11.92]; Yasuda H, 2004, CHEST, V125, P2160, DOI 10.1378/chest.125.6.2160; Yasuda H, 2002, THORAX, V57, P779, DOI 10.1136/thorax.57.9.779; Zeiger RS, 2011, NEW ENGL J MED, V365, P1990, DOI 10.1056/NEJMoa1104647; Zhang JY, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-50	105	63	64	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					3	15		10.1016/j.jaci.2013.10.018	http://dx.doi.org/10.1016/j.jaci.2013.10.018			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24290281	Green Accepted, Bronze			2022-12-18	WOS:000329105700001
J	Oka, T; Rios, EJ; Tsai, M; Kalesnikoff, J; Galli, SJ				Oka, Tatsuya; Rios, Eon J.; Tsai, Mindy; Kalesnikoff, Janet; Galli, Stephen J.			Rapid desensitization induces internalization of antigen-specific IgE on mouse mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; antigen; basophil; degranulation; desensitization; IgE; mast cell; rapid desensitization; receptor internalization; rush desensitization	FC-EPSILON-RI; HUMAN BASOPHILS; HYPERSENSITIVITY REACTIONS; DRUG HYPERSENSITIVITY; CYTOKINE PRODUCTION; DEGRANULATION; RESPONSES; SURVIVAL; RECEPTOR; ALLERGY	Background: Rapid desensitization transiently prevents severe allergic reactions, allowing administration of life-saving therapies in previously sensitized patients. However, the mechanisms underlying successful rapid desensitization are not fully understood. Objectives: We sought to investigate whether the mast cell (MC) is an important target of rapid desensitization in mice sensitized to exhibit IgE-dependent passive systemic anaphylaxis in vivo and to investigate the antigen specificity and underlying mechanisms of rapid desensitization in our mouse model. Methods: C57BL/6 mice (in vivo) or primary isolated C57BL/6 mouse peritoneal mast cells (PMCs; in vitro) were passively sensitized with antigen-specific anti-2,4-dinitrophenyl IgE, anti-ovalbumin IgE, or both. MCs were exposed over a short period of time to increasing amounts of antigen (2,4-dinitrophenyl-human serum albumin or ovalbumin) in the presence of extracellular calcium in vitro or by means of intravenous administration to sensitized mice in vivo before challenging the mice with or exposing the PMCs to optimal amounts of specific or irrelevant antigen. Results: Rapidly exposing mice or PMCs to progressively increasing amounts of specific antigen inhibited the development of antigen-induced hypothermia in sensitized mice in vivo and inhibited antigen-induced PMC degranulation and prostaglandin D2 synthesis in vitro. Such MC hyporesponsiveness was induced antigen-specifically and was associated with a significant reduction in antigen-specific IgE levels on MC surfaces. Conclusions: Rapidly exposing MCs to progressively increasing amounts of antigen can both enhance the internalization of antigen-specific IgE on the MC surface and also desensitize these cells in an antigen-specific manner in vivo and in vitro.	[Oka, Tatsuya; Rios, Eon J.; Tsai, Mindy; Kalesnikoff, Janet; Galli, Stephen J.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Lane Bldg,L-235,300 Pasteur Dr, Stanford, CA 94305 USA.	sgalli@stanford.edu		Tsai, Mindy/0000-0002-8421-4721	National Institutes of Health (NIH) [AI070813, AI023990, CA072074]; NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023990, R01AI023990, R01AI070813] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health (AI070813, AI023990, and CA072074; to S.J.G.).; Disclosure of potential conflict of interest: T. Oka has been supported by one or more grants from the National Institutes of Health (NIH; AI070813, AI023990, and CA072074) and is employed by Daiichi-Sankyo Co, Ltd. M. Tsai and S. J. Galli have been supported by one or more grants from the NIH (AI070813, AI023990, and AI072074). J. Kalesnikoff has been supported by one or more grants from the NIH, is employed by Stanford University, and has received one or more payments for lecturing from or is on the speakers' bureau for UC Berkeley Extension. E. J. Rios declares no relevant conflicts of interest.	Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Castells M, 2012, CANCER IMMUNOL IMMUN, V61, P1575, DOI 10.1007/s00262-012-1273-x; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Cernadas JR, 2010, ALLERGY, V65, P1357, DOI 10.1111/j.1398-9995.2010.02441.x; EBERLEINKONIG B, 1995, CLIN EXP ALLERGY, V25, P704, DOI 10.1111/j.1365-2222.1995.tb00007.x; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Gonzalez-Espinosa C, 2003, J EXP MED, V197, P1453, DOI 10.1084/jem.20021806; ISHIZAKA T, 1985, J IMMUNOL, V135, P492; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kalesnikoff J, 2007, BLOOD, V109, P5308, DOI 10.1182/blood-2007-01-067363; Kitaura J, 2004, J IMMUNOL, V173, P4317, DOI 10.4049/jimmunol.173.7.4317; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; Lam V, 2003, BLOOD, V102, P1405, DOI 10.1182/blood-2002-10-3176; MacGlashan D, 2000, BIOCHEM PHARMACOL, V60, P1717, DOI 10.1016/S0006-2952(00)00490-1; MacGlashan D, 2012, CLIN EXP ALLERGY, V42, P1060, DOI 10.1111/j.1365-2222.2012.04013.x; MACGLASHAN DW, 1981, J IMMUNOL, V127, P2410; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Morales AR, 2005, ANN ALLERG ASTHMA IM, V94, P575, DOI 10.1016/S1081-1206(10)61136-2; Oka T, 2004, AM J PHYSIOL-CELL PH, V286, pC256, DOI 10.1152/ajpcell.00197.2003; Oka T, 2012, LAB INVEST, V92, P1472, DOI 10.1038/labinvest.2012.116; Pandey V, 2004, J IMMUNOL, V172, P4048, DOI 10.4049/jimmunol.172.7.4048; Piliponsky AM, 2010, AM J PATHOL, V176, P926, DOI 10.2353/ajpath.2010.090342; Plewako H, 2006, INT ARCH ALLERGY IMM, V141, P346, DOI 10.1159/000095461; Reber LL, 2012, TRENDS IMMUNOL, V33, P613, DOI 10.1016/j.it.2012.09.008; Ring J, 2010, CHEM IMMUNOL ALLERGY, V95, P201, DOI 10.1159/000315953; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Romano A, 2011, J ALLERGY CLIN IMMUN, V127, pS67, DOI 10.1016/j.jaci.2010.11.047; Sancho-Serra MD, 2011, EUR J IMMUNOL, V41, P1004, DOI 10.1002/eji.201040810; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; SHALIT M, 1995, CLIN EXP ALLERGY, V25, P896, DOI 10.1111/j.1365-2222.1995.tb00033.x; SHALIT M, 1993, IMMUNOLOGY, V79, P319; Skripak JM, 2008, PEDIAT ALLERG IMM-UK, V19, P368, DOI 10.1111/j.1399-3038.2008.00723.x; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021	38	63	64	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					922	+		10.1016/j.jaci.2013.05.004	http://dx.doi.org/10.1016/j.jaci.2013.05.004			27	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23810240	Green Accepted			2022-12-18	WOS:000325096500020
J	Brough, HA; Makinson, K; Penagos, M; Maleki, SJ; Cheng, H; Douiri, A; Stephens, AC; Turcanu, V; Lack, G				Brough, Helen A.; Makinson, Kerry; Penagos, Martin; Maleki, Soheila J.; Cheng, Hsiaopo; Douiri, Abdel; Stephens, Alick C.; Turcanu, Victor; Lack, Gideon			Distribution of peanut protein in the home environment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut; sensitization; allergy; environment; dust; aerosolized; airborne; saliva; hand; ELISA; validation	ALLERGEN; CHILDREN; PREVALENCE; SCHOOLS; DUST; RISK; FOOD	Background: To halt the increase in peanut allergy, we must determine how children become sensitized to peanut. High household peanut consumption used as an indirect marker of environmental peanut exposure is associated with the development of peanut allergy. Objective: We sought to validate a method to quantify environmental peanut exposure, to determine how peanut is transferred into the environment after peanut consumption, and to determine whether environmental peanut persists despite cleaning. Methods: After initial comparative studies among 3 ELISA kits, we validated and used the Veratox polyclonal peanut ELISA to assess peanut protein concentrations in dust and air and on household surfaces, bedding, furnishings, hand wipes, and saliva. Results: The Veratox polyclonal peanut ELISA had the best rate of recovery of an independent peanut standard. We demonstrated 100% sensitivity and specificity and a less than 15% coefficient of variation for intra-assay, interassay, and interoperator variability. There was high within-home correlation for peanut protein levels in dust and household surface wipes. Airborne peanut levels were lower than the limit of quantitation for the Veratox polyclonal peanut ELISA in a number of simulated scenarios, except for a brief period directly above peanuts being deshelled. Peanut protein persisted on hands and in saliva 3 hours after peanut consumption. Peanut protein was completely removed from granite tables after cleaning with detergent, and levels were reduced but still present after detergent cleaning of laminate and wooden table surfaces, pillows, and sofa covers. Conclusions: Peanut spread easily around the home and might be resistant to usual cleaning methods. Peanut protein can be transferred into the environment by means of hand transfer and saliva but is unlikely to be aerosolized.	[Brough, Helen A.; Makinson, Kerry; Penagos, Martin; Stephens, Alick C.; Turcanu, Victor; Lack, Gideon] Kings Coll London, MRC, Dept Paediat Allergy, London, England; [Brough, Helen A.; Makinson, Kerry; Penagos, Martin; Stephens, Alick C.; Turcanu, Victor; Lack, Gideon] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, Div Asthma Allergy & Lung Biol, London, England; [Brough, Helen A.; Makinson, Kerry; Penagos, Martin; Stephens, Alick C.; Turcanu, Victor; Lack, Gideon] Guys & St Thomas NHS Fdn Trust, London SE1 7EH, England; [Brough, Helen A.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England; [Maleki, Soheila J.; Cheng, Hsiaopo] USDA, Agr Res Serv, So Reg Res Ctr, New Orleans, LA USA; [Douiri, Abdel] Kings Coll London, Sch Med, Dept Publ Hlth Sci, London, England	University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of Southampton; United States Department of Agriculture (USDA); University of London; King's College London	Lack, G (corresponding author), Guys & St Thomas NHS Fdn Trust, Childrens Allergy Unit, 2nd Fl,Stairwell B,South Wing,Westminster Bridge, London SE1 7EH, England.	Gideon.lack@kcl.ac.uk		Douiri, Abdel/0000-0002-4354-4433; Penagos, Martin/0000-0002-9488-194X; Lack, Gideon/0000-0001-7350-4021	National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's & St Thomas' NHS Foundation Trust; King's College London; Medical Research Council; Department of Health through the NIHR comprehensive Biomedical Research Centre award; King's College Hospital NHS Foundation Trust; Anaphylaxis Campaign; National Peanut Board; Sodilac; Novartis; Nestle Nutrition; GlaxoSmithKline; Serono Symposia International Foundation; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish	National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's & St Thomas' NHS Foundation Trust; King's College London(General Electric); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health through the NIHR comprehensive Biomedical Research Centre award; King's College Hospital NHS Foundation Trust; Anaphylaxis Campaign; National Peanut Board; Sodilac; Novartis(Novartis); Nestle Nutrition(Nestle SA); GlaxoSmithKline(GlaxoSmithKline); Serono Symposia International Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	Supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's & St Thomas' NHS Foundation Trust and King's College London and the Medical Research Council.; H. A. Brough, K. Makinson, and V. Turcanu have received research support from the Department of Health through the NIHR comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. S. J. Maleki is on the Scientific Advisory Council to the National Peanut Board. G. Lack has received research support from the Department of Health through the NIHR comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust; is on the DBV Technologies Scientific Advisory Board; has received consultancy fees from the Anaphylaxis Campaign and National Peanut Board; has received lecture fees from Sodilac, Novartis, Nestle Nutrition, GlaxoSmithKline, and Serono Symposia International Foundation; and has stock/options in DBV Technologies. The rest of the authors declare that they have no relevant conflicts of interest.	Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Boeniger M F, 2001, Appl Occup Environ Hyg, V16, P660, DOI 10.1080/104732201750175861; Brough H, 2009, ALLERGY, V64, P543; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; DYBENDAL T, 1994, ALLERGY, V49, P210, DOI 10.1111/j.1398-9995.1994.tb02651.x; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2012, VAL AN PROC TEXT MET, VQ2; Johnson R, 2010, ANN ALLERG ASTHMA IM, V105, pA15; Jones R. T., 1996, Journal of Allergy and Clinical Immunology, V97, P423, DOI 10.1016/S0091-6749(96)81179-1; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; Maloney JM, 2006, J ALLERGY CLIN IMMUN, V118, P719, DOI 10.1016/j.jaci.2006.05.017; Mason K, 2001, ALLERGY, V56, P1012, DOI 10.1034/j.1398-9995.2001.00358.x; Nogueira MCL, 2004, J AOAC INT, V87, P1480; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Schmitt DA, 2010, J AGR FOOD CHEM, V58, P1138, DOI 10.1021/jf902694j; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; Sheehan WJ, 2012, J ALLERGY CLIN IMMUN, V129, pAB236, DOI 10.1016/j.jaci.2011.12.166; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Taylor AV, 2000, J ALLERGY CLIN IMMUN, V105, P166, DOI 10.1016/S0091-6749(00)90192-1; Taylor SL, 2009, FOOD CHEM TOXICOL, V47, P1198, DOI 10.1016/j.fct.2009.02.011; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; Van Boxtel EL, 2006, J AGR FOOD CHEM, V54, P7180, DOI 10.1021/jf061433+; WITTEMAN AM, 1995, INT ARCH ALLERGY IMM, V107, P566, DOI 10.1159/000237100; Zeleny R, 2010, FOOD CHEM, V123, P1343, DOI 10.1016/j.foodchem.2010.06.018	27	63	64	2	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					623	629		10.1016/j.jaci.2013.02.035	http://dx.doi.org/10.1016/j.jaci.2013.02.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23608728				2022-12-18	WOS:000323612000014
J	Tse, SM; Gold, DR; Sordillo, JE; Hoffman, EB; Gillman, M; Rifas-Shiman, SL; Fuhlbrigge, AL; Tantisira, KG; Weiss, ST; Litonjua, AA				Tse, Sze Man; Gold, Diane R.; Sordillo, Joanne E.; Hoffman, Elaine B.; Gillman, MatthewW.; Rifas-Shiman, Sheryl L.; Fuhlbrigge, Anne L.; Tantisira, Kelan G.; Weiss, Scott T.; Litonjua, Augusto A.			Diagnostic accuracy of the bronchodilator response in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; bronchodilator response; diagnosis	LUNG-FUNCTION; CHILDHOOD ASTHMA; PREDICTORS; RESPONSIVENESS	Background: The bronchodilator response (BDR) reflects the reversibility of airflow obstruction and is recommended as an adjunctive test to diagnose asthma. The validity of the commonly used definition of BDR, a 12% or greater change in FEV1 from baseline, has been questioned in childhood. Objectives: We sought to examine the diagnostic accuracy of the BDR test by using 3 large pediatric cohorts. Methods: Cases include 1041 children with mild-to-moderate asthma from the Childhood Asthma Management Program. Control subjects (nonasthmatic and nonwheezing) were chosen from Project Viva and Home Allergens, 2 population-based pediatric cohorts. Receiver operating characteristic curves were constructed, and areas under the curve were calculated for different BDR cutoffs. Results: A total of 1041 cases (59.7% male; mean age, 8.9 +/- 2.1 years) and 250 control subjects (46.8% male; mean age, 8.7 +/- 1.7 years) were analyzed, with mean BDRs of 10.7% +/- 10.2% and 2.7% +/- 8.4%, respectively. The BDR test differentiated asthmatic patients from nonasthmatic patients with a moderate accuracy (area under the curve, 73.3%). Despite good specificity, a cutoff of 12% was associated with poor sensitivity (35.6%). A cutoff of less than 8% performed significantly better than a cutoff of 12% (P = .03, 8% vs 12%). Conclusions: Our findings highlight the poor sensitivity associated with the commonly used 12% cutoff for BDR. Although our data show that a threshold of less than 8% performs better than 12%, given the variability of this test in children, we conclude that it might be not be appropriate to choose a specific BDR cutoff as a criterion for the diagnosis of asthma.	[Tse, Sze Man; Gold, Diane R.; Sordillo, Joanne E.; Fuhlbrigge, Anne L.; Tantisira, Kelan G.; Weiss, Scott T.; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Tse, Sze Man; Gold, Diane R.; Sordillo, Joanne E.; Fuhlbrigge, Anne L.; Tantisira, Kelan G.; Weiss, Scott T.; Litonjua, Augusto A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA; [Tse, Sze Man] Massachusetts Gen Hosp, Dept Pediat, Div Pediat Pulm Med, Boston, MA 02114 USA; [Hoffman, Elaine B.] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Gillman, MatthewW.; Rifas-Shiman, Sheryl L.] Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, Cambridge, MA 02138 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Tse, SM (corresponding author), Channing Labs, 181 Long Wood Ave, Boston, MA 02115 USA.	reszt@channing.harvard.edu		Litonjua, Augusto/0000-0003-0422-5875	National Heart, Lung, and Blood Institute [NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, 16052]; General Clinical Research Center from the National Center for Research Resources [M01RR00051, M01RR0099718-24, M01RR02719-14, RR00036]; National Institutes of Health [P50 HL67664, U01 HL65899, T32 HL07427]; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases/R01 grant [AI035786]; National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute (NHLBI); NHLBI; Agency for Healthcare Research and Quality; NIH;  [R01 HL064925];  [R01 HD034568]; DIVISION OF LUNG DISEASES [N01HR016045, N01HR016052, N01HR016047, N01HR016044, N01HR016048, N01HR016049, N01HR016046, N01HR016050, N01HR016051] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD034568, R01HD034568] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064925, P50HL067664, T32HL007427, U01HL065899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); General Clinical Research Center from the National Center for Research Resources; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Allergy and Infectious Diseases/R01 grant; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Childhood Asthma Management Program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. Additional support for this research came from grants P50 HL67664, U01 HL65899, and T32 HL07427 from the National Institutes of Health and the National Heart, Lung, and Blood Institute. Home Allergens is funded by National Institute of Allergy and Infectious Diseases/R01 grant AI035786. Project Viva is funded by R01 HL064925 and R01 HD034568.; S. M. Tse, M. W. Gillman, and K. G. Tantisira have been supported by/have received one or more grants from or have one or more grants pending with the National Institutes of Health (NIH). D. R. Gold has been supported by one or more grants from the National Institute of Allergy and Infectious Diseases. A. L. Fuhlbrigge has been supported by one or more grants from and has received support for travel from the National Heart, Lung, and Blood Institute (NHLBI); is a Board member for Merck; has consultancy arrangements with Merck, GlaxoSmithKline, ICON Medical Imaging, Sunovion, the Lovelace Respiratory Research Institute, and Dmagi; and has received one or more grants from or has one or more grants pending with the NHLBI and the Agency for Healthcare Research and Quality. A. A. Litonjua has been supported by one or more grants from the NIH and has received royalties from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.	Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Benton AS, 2010, J ASTHMA, V47, P728, DOI 10.3109/02770903.2010.491142; BRAND PLP, 1992, THORAX, V47, P429, DOI 10.1136/thx.47.6.429; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Choudhry S, 2010, PHARMACOGENET GENOM, V20, P351, DOI 10.1097/FPC.0b013e328337f992; Duan QL, 2013, PHARMACOGENOMICS J, V13, P130, DOI 10.1038/tpj.2011.56; Duan QL, 2011, AM J RESP CRIT CARE, V183, P449, DOI 10.1164/rccm.201005-0758OC; Dundas I, 2005, THORAX, V60, P13, DOI 10.1136/thx.2004.029934; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Galant SP, 2007, J PEDIATR-US, V151, P457, DOI 10.1016/j.jpeds.2007.05.004; Gillman MW, 2004, J PEDIATR-US, V144, P240, DOI 10.1016/j.jpeds.2003.10.064; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Holt EW, 2008, J ALLERGY CLIN IMMUN, V121, P1175, DOI 10.1016/j.jaci.2008.02.015; KERSTJENS HAM, 1993, THORAX, V48, P722, DOI 10.1136/thx.48.7.722; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; LORBER DB, 1978, AM REV RESPIR DIS, V118, P855; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Paull K, 2005, PEDIATR PULM, V39, P311, DOI 10.1002/ppul.20161; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Puckett JL, 2010, PEDIATR PULM, V45, P174, DOI 10.1002/ppul.21172; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Sharma S, 2008, J ALLERGY CLIN IMMUN, V122, P921, DOI 10.1016/j.jaci.2008.09.004; Shin YH, 2012, CAN RESPIR J, V19, P273, DOI 10.1155/2012/560323; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tan WC, 2012, THORAX, V67, P718, DOI 10.1136/thoraxjnl-2011-201445; Tantisira KG, 2006, J ALLERGY CLIN IMMUN, V117, P1264, DOI 10.1016/j.jaci.2006.01.050; Vu LTT, 2010, PEDIATR PULM, V45, P380, DOI 10.1002/ppul.21201; WAALKENS HJ, 1993, EUR RESPIR J, V6, P645; WEIR DC, 1991, THORAX, V46, P43, DOI 10.1136/thx.46.1.43	32	63	63	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					554	+		10.1016/j.jaci.2013.03.031	http://dx.doi.org/10.1016/j.jaci.2013.03.031			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23683464	Green Accepted, Green Submitted			2022-12-18	WOS:000323612000005
J	Fuertes, E; Brauer, M; MacIntyre, E; Bauer, M; Bellander, T; von Berg, A; Berdel, D; Brunekreef, B; Chan-Yeung, M; Gehring, U; Herbarth, O; Hoffmann, B; Kerkhof, M; Klumper, C; Koletzko, S; Kozyrskyj, A; Kull, I; Heinrich, J; Melen, E; Pershagen, G; Postma, D; Tiesler, CMT; Carlsten, C				Fuertes, Elaine; Brauer, Michael; MacIntyre, Elaina; Bauer, Mario; Bellander, Tom; von Berg, Andrea; Berdel, Dietrich; Brunekreef, Bert; Chan-Yeung, Moira; Gehring, Ulrike; Herbarth, Olf; Hoffmann, Barbara; Kerkhof, Marjan; Kluemper, Claudia; Koletzko, Sibylle; Kozyrskyj, Anita; Kull, Inger; Heinrich, Joachim; Melen, Erik; Pershagen, Goran; Postma, Dirkje; Tiesler, Carla M. T.; Carlsten, Chris		TAG Study Grp	Childhood allergic rhinitis, traffic-related air pollution, and variability in the GSTP1, TNF, TLR2, and TLR4 genes: Results from the TAG Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood allergic rhinitis; air pollution; genetics; interaction; TNF; TLR4	TUMOR-NECROSIS-FACTOR; S-TRANSFERASE P1; LAND-USE REGRESSION; RISK-FACTORS; ASTHMA; ALPHA; POLYMORPHISM; CHILDREN; ASSOCIATION; SYMPTOMS	Background: Associations between traffic-related air pollution (TRAP) and allergic rhinitis remain inconsistent, possibly because of unexplored gene-environment interactions. Objective: In a pooled analysis of 6 birth cohorts (N-total = 15,299), we examined whether TRAP and genetic polymorphisms related to inflammation and oxidative stress predict allergic rhinitis and sensitization. Methods: Allergic rhinitis was defined with a doctor diagnosis or reported symptoms at age 7 or 8 years. Associations between nitrogen dioxide, particulate matter 2.5 (PM2.5) mass, PM2.5 absorbance, and ozone, estimated for each child at the year of birth, and single nucleotide polymorphisms within the GSTP1, TNF, TLR2, or TLR4 genes with allergic rhinitis and aeroallergen sensitization were examined with logistic regression. Models were stratified by genotype and interaction terms tested for gene-environment associations. Results: Point estimates for associations between nitrogen dioxide, PM2.5 mass, and PM2.5 absorbance with allergic rhinitis were elevated, but only that for PM2.5 mass was statistically significant (1.37 [1.01, 1.86] per 5 mu g/m(3)). This result was not robust to single-cohort exclusions. Carriers of at least 1 minor rs1800629 (TNF) or rs1927911 (TLR4) allele were consistently at an increased risk of developing allergic rhinitis (1.19 [1.00, 1.41] and 1.24 [1.01, 1.53], respectively), regardless of TRAP exposure. No evidence of gene-environment interactions was observed. Conclusion: The generally null effect of TRAP on allergic rhinitis and aeroallergen sensitization was not modified by the studied variants in the GSTP1, TNF, TLR2, or TLR4 genes. Children carrying a minor rs1800629 (TNF) or rs1927911 (TLR4) allele may be at a higher risk of allergic rhinitis.	[Fuertes, Elaine; Brauer, Michael; MacIntyre, Elaina; Carlsten, Chris] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada; [Fuertes, Elaine; MacIntyre, Elaina; Heinrich, Joachim; Tiesler, Carla M. T.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany; [Brauer, Michael; Chan-Yeung, Moira; Carlsten, Chris] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Bauer, Mario] UFZ Helmholtz Ctr Environm Res, Dept Environm Immunol, Leipzig, Germany; [Bellander, Tom; Kull, Inger; Melen, Erik; Pershagen, Goran] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [von Berg, Andrea; Berdel, Dietrich] Marien Hosp Wesel, Dept Pediat, Wesel, Germany; [Brunekreef, Bert; Gehring, Ulrike] Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; [Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Herbarth, Olf] Univ Leipzig, Fac Med Environm Med & Hyg, D-04109 Leipzig, Germany; [Hoffmann, Barbara; Kluemper, Claudia] Univ Dusseldorf, IUF Leibniz Res Inst Environm Med, Dusseldorf, Germany; [Hoffmann, Barbara] Univ Dusseldorf, Fac Med, Dusseldorf, Germany; [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, GRIAC Inst, Dept Epidemiol, Groningen, Netherlands; [Koletzko, Sibylle] Univ Munich, Dr von Hauner Childrens Hosp, Div Paediat Gastroenterol & Hepatol, Munich, Germany; [Kozyrskyj, Anita] Women & Childrens Hlth Res Inst, Fac Med & Dent, Dept Pediat, Edmonton, AB, Canada; [Kozyrskyj, Anita] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Kull, Inger] Karolinska Inst, Dept Clin Sci & Educ, Stockholm, Sweden; [Kull, Inger; Melen, Erik] Sachs Children & Youth Hosp, Stockholm, Sweden; [Postma, Dirkje] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9700 AB Groningen, Netherlands; [Postma, Dirkje] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma & COPD, Groningen, Netherlands; [Tiesler, Carla M. T.] Univ Munich, Dr von Hauner Childrens Hosp, Div Metab Dis & Nutr Med, Munich, Germany	University of British Columbia; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of British Columbia; Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Karolinska Institutet; St. Marien Hospital; Utrecht University; Utrecht University; Utrecht University Medical Center; Leipzig University; Heinrich Heine University Dusseldorf; Leibniz Institut fur Umweltmedizinische Forschung (IUF); Heinrich Heine University Dusseldorf; University of Groningen; University of Munich; University of Alberta; Karolinska Institutet; University of Groningen; University of Groningen; University of Munich	Carlsten, C (corresponding author), 2775 Laurel St, Vancouver, BC V6H 0A5, Canada.	carlsten@mail.ubc.ca	Brauer, Michael/Y-2810-2019; Bauer, Mario/AAZ-7540-2021; Heinrich, Joachim/N-1720-2013	Brauer, Michael/0000-0002-9103-9343; Heinrich, Joachim/0000-0002-9620-1629; Pershagen, Goran/0000-0002-9701-1130; Gehring, Ulrike/0000-0003-3612-5780; brunekreef, bert/0000-0001-9908-0060; Bauer, Michaela/0000-0001-8717-3278; Kull, Inger/0000-0001-6096-3771; Fuertes, Elaine/0000-0003-0205-9025	AllerGen Networks of Centres of Excellence; German Research Society; German Environmental Agency; EU; BMBF grant from the Childhood Foundation; Swedish Research Council; Swedish Research Council FORMAS; Nestle Nutrition Institute; Swedish Heart-Lung Foundation; Stiftelsen Frimurare Barnhuset i Stockholm; Stockholm County Council; Swedish Environmental Protection Agency; Swedish Society for Medical Research	AllerGen Networks of Centres of Excellence; German Research Society(German Research Foundation (DFG)); German Environmental Agency; EU(European Commission); BMBF grant from the Childhood Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Research Council FORMAS(Swedish Research CouncilSwedish Research Council Formas); Nestle Nutrition Institute(Nestle SA); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Stiftelsen Frimurare Barnhuset i Stockholm; Stockholm County Council(Stockholm County Council); Swedish Environmental Protection Agency; Swedish Society for Medical Research	M. Brauer has been supported by one or more grants fromand has received support for travel from the AllerGen Networks of Centres of Excellence. E. Fuertes has been supported by one or more grants from the AllerGen Networks of Centres of Excellence and has received support for travel fromthe Canadian Institutes of Health Research (Sir Frederick Banting and Charles Best Canada Graduate Scholarship). B. Hoffmann has consultancy arrangements with Health Effects Institut; has received one or more grants from or has one or more grants pending with the German Research Society, German Environmental Agency, EU; and has received one or more payments for lecturing from or is on the speakers' bureau for MSE class University of Mainz. S. Koletzko has been supported by a BMBF grant from the Childhood Foundation. E. MacIntyre has been supported by one or more grants from the AllerGen Networks of Centres of Excellence. G. Pershagen has been supported by one or more grants from the Swedish Research Council, Swedish Research Council FORMAS. A. von Berg has received one or more payments for lecturing from or is on the speakers' bureau for the Nestle Nutrition Institute. T. Bellander has been supported by one or more grants from and has received support for travel from the Swedish Research Council FORMAS, the Swedish Heart-Lung Foundation, Stiftelsen Frimurare Barnhuset i Stockholm, the Stockholm County Council, the Swedish Environmental Protection Agency, and the Swedish Society for Medical Research and has received one or more grants from or has one or more grants pending with the Swedish EPA, the Swedish Research Council FORMAS, and the Swedish Transport Authority. D. Postma has consultancy arrangements with AstraZeneca, Boehringer Ingelheim, GSK, Nycomed, and Teva; has received one or more grants from or has one or more grants pending with Chiesi, GSK, and AstraZeneca; and has received one or more payments for lecturing fromor is on the speakers' bureau for AstraZeneca, Chiesi, and Nycomed. The rest of the authors declare that they have no relevant conflicts of interest.	Ait-Khaled N, 2009, ALLERGY, V64, P123, DOI 10.1111/j.1398-9995.2008.01884.x; Allen RW, 2011, ATMOS ENVIRON, V45, P369, DOI 10.1016/j.atmosenv.2010.10.002; Almqvist C, 2005, CLIN EXP ALLERGY, V35, P612, DOI 10.1111/j.1365-2222.2005.02243.x; Anderson HR, 2010, OCCUP ENVIRON MED, V67, P293, DOI 10.1136/oem.2009.048785; [Anonymous], 2005, HLTH EFFECTS TRANSPO; APMoSPHERE, 2007, AIR POLL MOD SUPP PO; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bjorksten B, 2008, PEDIAT ALLERG IMM-UK, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Braback L, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-17; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Brunekreef B, 2003, EUR RESPIR J, V21, P913, DOI 10.1183/09031936.03.00014903; Carlsten C, 2012, CURR OPIN ALLERGY CL, V12, P455, DOI 10.1097/ACI.0b013e328357cc55; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Emenius G, 2003, OCCUP ENVIRON MED, V60, P876, DOI 10.1136/oem.60.11.876; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Fuertes E, 2012, CHILDHOOD ALLERGIC R; Gao ZW, 2010, APPL CLIN GENET, V3, P109, DOI 10.2147/TACG.S8380; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Gentile DA, 2004, HUM IMMUNOL, V65, P347, DOI 10.1016/j.humimm.2004.01.014; Gerbase MW, 2011, CLIN EXP ALLERGY, V41, P1579, DOI 10.1111/j.1365-2222.2011.03807.x; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gilliland FD, 2006, AM J RESP CRIT CARE, V174, P1335, DOI 10.1164/rccm.200509-1424OC; Gruzieva O, 2012, J ALLERGY CLIN IMMUN, V129, P240, DOI 10.1016/j.jaci.2011.11.001; Hafkamp-de Groen E, 2012, J EPIDEMIOL COMMUN H, V66, P1017, DOI 10.1136/jech-2011-200333; Heinrich J, 2004, CURR OPIN ALLERGY CL, V4, P341, DOI 10.1097/00130832-200410000-00003; Hemminki E, 1996, ACTA OBSTET GYN SCAN, V75, P19, DOI 10.3109/00016349609033278; Henderson SB, 2007, ENVIRON SCI TECHNOL, V41, P2422, DOI 10.1021/es0606780; Hochadel M, 2006, ATMOS ENVIRON, V40, P542, DOI 10.1016/j.atmosenv.2005.09.067; Hoek G, 2002, ATMOS ENVIRON, V36, P4077, DOI 10.1016/S1352-2310(02)00297-2; Holloway JW, 2012, RESPIROLOGY, V17, P590, DOI 10.1111/j.1440-1843.2012.02164.x; Iwasaki M, 2003, J ALLERGY CLIN IMMUN, V112, P134, DOI 10.1067/mai.2003.1554; Kaiser HB, 2004, ALLERGY ASTHMA PROC, V25, P7; Kauffmann F, 2012, J ALLERGY CLIN IMMUN, V130, P1229, DOI 10.1016/j.jaci.2012.10.038; Kerkhof M, 2010, THORAX, V65, P690, DOI 10.1136/thx.2009.119636; Kim WK, 2012, J ALLERGY CLIN IMMUN, V130, P421, DOI 10.1016/j.jaci.2012.04.052; Kozyrskyj AL, 2009, ALLERGY, V64, P1185, DOI 10.1111/j.1398-9995.2009.02033.x; Lee YL, 2004, CLIN EXP ALLERGY, V34, P1707, DOI 10.1111/j.1365-2222.2004.02099.x; Li YF, 2006, AM J RESP CRIT CARE, V173, P970, DOI 10.1164/rccm.200508-1256OC; Louis E, 1998, CLIN EXP IMMUNOL, V113, P401; Marshall Gailen D, 2004, J Am Osteopath Assoc, V104, pS1; Marshall JD, 2008, ATMOS ENVIRON, V42, P1359, DOI 10.1016/j.atmosenv.2007.08.012; Melen E, 2008, ENVIRON HEALTH PERSP, V116, P1077, DOI 10.1289/ehp.11117; Minhas K, 2010, J INVEST ALLERG CLIN, V20, P563; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103a; Nonaka M, 1996, AM J RESP CRIT CARE, V153, P1675, DOI 10.1164/ajrccm.153.5.8630619; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI 10.1097/EDE.0b013e31816a1ce3; Riccio AN, 2002, CLIN EXP ALLERGY, V32, P422, DOI 10.1046/j.1365-2222.2002.01315.x; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Ruijsbroek A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-225; Salam MT, 2007, THORAX, V62, P1050, DOI 10.1136/thx.2007.080127; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Senthilselvan A, 2008, ANN ALLERG ASTHMA IM, V100, P463, DOI 10.1016/S1081-1206(10)60472-3; Slama R, 2010, REPROD TOXICOL, V30, P600, DOI 10.1016/j.reprotox.2010.07.001; Tager I., 2010, TRAFFIC RELATED AIR; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Wu H, 2007, ENVIRON HEALTH PERSP, V115, P616, DOI 10.1289/ehp.9740; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Yang IA, 2005, AM J RESP CRIT CARE, V171, P171, DOI 10.1164/rccm.200402-194OC; Zhu SK, 2000, AM J RESP CRIT CARE, V161, P1655, DOI 10.1164/ajrccm.161.5.9906086; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521	66	63	66	1	59	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					342	+		10.1016/j.jaci.2013.03.007	http://dx.doi.org/10.1016/j.jaci.2013.03.007			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23639307				2022-12-18	WOS:000322631700011
J	Thompson, BR; Douglass, JA; Ellis, MJ; Kelly, VJ; O'Hehir, RE; King, GG; Verbanck, S				Thompson, Bruce R.; Douglass, Jo A.; Ellis, Matthew J.; Kelly, Vanessa J.; O'Hehir, Robyn E.; King, Gregory G.; Verbanck, Sylvia			Peripheral lung function in patients with stable and unstable asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; acinar airways; peripheral gas mixing	VENTILATION HETEROGENEITY; COMPUTED-TOMOGRAPHY; AIRWAY INVOLVEMENT; NITROGEN WASHOUT; DISTAL LUNG; INFLAMMATION; ADULTS; ACINAR; VALUES; SLOPE	Background: Exacerbations of asthma are thought to be caused by airflow obstruction resulting from airway inflammation, bronchospasm, and mucus plugging. Histologic evidence suggests the small airways, including acinar air spaces, are involved; however, this has not been corroborated in vivo by measurements of peripheral small-airway function. Objective: We sought to determine whether asthma severity is linked to small-airway function, particularly in patients with acute severe asthma. Methods: Eighteen subjects admitted for an asthma exacerbation underwent lung function testing, including measures of acinar ventilation heterogeneity (S-acin) and conductive ventilation heterogeneity (S-cond) using the multiple-breath nitrogen washout. Treatment requirement was defined according to Global Initiative for Asthma scores. Data were compared with those obtained in 19 patients with stable asthma. Results: For the asthma exacerbation group, the median FEV1 was 59% of predicted value (95% CI, 45% to 75% of predicted value), the median S-cond value was 185% of predicted value (95% CI, 119% to 245% of predicted value), and the median S-acin value was 225% of predicted value (95% CI, 143% to 392% of predicted value). FEV1 (percent predicted) was correlated with S-acin (percent predicted) values (Spearman rho = -0.67, P =.006) but not with S-cond (percent predicted) values (P >.1). The Global Initiative for Asthma score was significantly related to S-acin (percent predicted) (Spearman rho = 0.59, P = .016) but not to S-cond (percent predicted) values (P >.1). The unstable group was characterized by considerably lower forced vital capacity (P <. 001) and higher S-cond (P =.001) values than the unstable group. In a subgroup of 11 unstable patients who could be reviewed after 4 weeks, FEV1, forced vital capacity, S-acin, and S-cond values showed marked improvements. Conclusion: Our findings suggest that unstable asthma is characterized by a combined abnormality in the acinar and conductive lung zones, both of which are partly reversible. Functional abnormality in the acinar lung zone in particular showed a direct correlation with airflow obstruction and treatment requirement in patients with acute severe asthma.	[Thompson, Bruce R.; Ellis, Matthew J.; O'Hehir, Robyn E.] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic 3004, Australia; [Thompson, Bruce R.; Ellis, Matthew J.; O'Hehir, Robyn E.] Monash Univ, Melbourne, Vic 3004, Australia; [Thompson, Bruce R.; Ellis, Matthew J.; O'Hehir, Robyn E.; King, Gregory G.] Cooperat Res Ctr Asthma & Airways, Sydney, NSW, Australia; [Douglass, Jo A.] Royal Melbourne Hosp, Dept Clin Immunol & Allergy, Parkville, Vic 3050, Australia; [Douglass, Jo A.] Univ Melbourne, Parkville, Vic 3052, Australia; [Kelly, Vanessa J.] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA; [Kelly, Vanessa J.] Harvard Univ, Sch Med, Boston, MA USA; [King, Gregory G.] Woolcock Inst Med Res, Sydney, NSW, Australia; [Verbanck, Sylvia] Vrije Univ Brussel, Acad Hosp, Div Resp, Brussels, Belgium	Florey Institute of Neuroscience & Mental Health; Monash University; Royal Melbourne Hospital; University of Melbourne; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Sydney; Woolcock Institute of Medical Research; Vrije Universiteit Brussel	Thompson, BR (corresponding author), Alfred Hosp, Dept Allergy Immunol & Resp Med, Lung Funct Lab, Commercial Rd, Melbourne, Vic 3004, Australia.	b.thompson@alfred.org.au	Verbanck, Sylvia/L-7849-2016; O'Hehir, Robyn E/H-3627-2011	Verbanck, Sylvia/0000-0003-0231-2756; O'Hehir, Robyn E/0000-0002-3489-7595; Douglass, Jo/0000-0002-1200-8048; Thompson, Bruce/0000-0002-5885-0652	Cooperative Research Centre for Asthma and Airways; National Health and Medical Research Council, Australia; National Health and Medical Research Council; AstraZeneca; GlaxoSmithKline,; Novartis; Pharmaxis; Pharmaxis, and the Asthma Foundation	Cooperative Research Centre for Asthma and Airways(Australian GovernmentDepartment of Industry, Innovation and ScienceCooperative Research Centres (CRC) Programme); National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); AstraZeneca(AstraZeneca); GlaxoSmithKline,(GlaxoSmithKline); Novartis(Novartis); Pharmaxis; Pharmaxis, and the Asthma Foundation	Support for this study was provided by the Cooperative Research Centre for Asthma and Airways and the National Health and Medical Research Council, Australia.; Disclosure of potential conflict of interest: B. R. Thompson, M. J. Ellis, V. J. Kelly, R. E. O'Hchir, and S. Verbanck have received grants from the National Health and Medical Research Council and the Cooperative Research Centre for Asthma and Airways. J. A. Douglass has received grants from the National Health and Medical Research Council and the Cooperative Research Centre for Asthma and Airways; is on an advisory board for Novartis; has received payment for lectures from AstraZeneca, GlaxoSmithKline, and Novartis; and has received royalties from Health Press Limited. G. G. King has received grants from the National Health and Medical Research Council, GlaxoSmithKline, Boehringer Ingelheim, Pharmaxis, and the Asthma Foundation; has received travel support from GlaxoSmithKline, Novartis, AstraZeneca, Boehringer Ingelheim, and Pfizer; has received subject payments for clinical trials from Pharmaxis; and is part of a consultancy agreement between GlaxoSmithKline, Novartis, AstraZeneca, Boehringer Ingelheim, Pfizer, and the Woolcock Institute of Medical Research, and his research group receives an unrestricted allocation as part of the monies received from the consultancy agreements.	Berry M, 2005, EUR RESPIR J, V25, P986, DOI 10.1183/09031936.05.00132404; Bourdin A, 2006, ALLERGY, V61, P85, DOI 10.1111/j.1398-9995.2006.00970.x; COOPER DM, 1983, J APPL PHYSIOL, V54, P1125, DOI 10.1152/jappl.1983.54.4.1125; Corsico A, 2003, J APPL PHYSIOL, V95, P441, DOI 10.1152/japplphysiol.01018.2002; Cosio MG, 2006, AM J RESP CRIT CARE, V174, P847, DOI 10.1164/rccm.200607-960ED; Downie SR, 2007, THORAX, V62, P684, DOI 10.1136/thx.2006.069682; Farah CS, 2012, J ALLERGY CLIN IMMUN, V130, P61, DOI 10.1016/j.jaci.2012.02.015; Farah CS, 2012, J ALLERGY CLIN IMMUN, V129, P381, DOI 10.1016/j.jaci.2011.11.017; Global Initiative for Asthma (GINA), 2011, GLOB STRAT ASTHM MAN; Gustafsson PM, 2007, PEDIATR PULM, V42, P168, DOI 10.1002/ppul.20554; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hansen JE, 2006, CHEST, V129, P369, DOI 10.1378/chest.129.2.369; Hasegawa M, 2006, AM J RESP CRIT CARE, V173, P1309, DOI 10.1164/rccm.200601-037OC; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; King GG, 2005, RESP PHYSIOL NEUROBI, V148, P165, DOI 10.1016/j.resp.2005.05.001; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Lutchen KR, 1997, J APPL PHYSIOL, V83, P1192, DOI 10.1152/jappl.1997.83.4.1192; Macleod KA, 2009, THORAX, V64, P33, DOI 10.1136/thx.2007.095018; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518, DOI 10.1164/ajrccm.162.4.9909044; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Shimizu K, 2011, RESP MED, V105, P1275, DOI 10.1016/j.rmed.2011.04.007; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Stuart-Andrews CR, 2012, J APPL PHYSIOL, V112, P1073, DOI 10.1152/japplphysiol.00372.2011; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Thorpe CW, 1997, J APPL PHYSIOL, V82, P1616, DOI 10.1152/jappl.1997.82.5.1616; Verbanck S, 1999, AM J RESP CRIT CARE, V159, P1545, DOI 10.1164/ajrccm.159.5.9809017; VERBANCK S, 1990, J APPL PHYSIOL, V69, P2269, DOI 10.1152/jappl.1990.69.6.2269; Verbanck S, 2003, J APPL PHYSIOL, V94, P1380, DOI 10.1152/japplphysiol.00588.2002; Verbanck S, 2006, J ALLERGY CLIN IMMUN, V118, P340, DOI 10.1016/j.jaci.2006.04.056; Verbanck S, 2012, THORAX, V67, P789, DOI 10.1136/thoraxjnl-2011-201484; Verbanck S, 2010, J ALLERGY CLIN IMMUN, V125, P611, DOI 10.1016/j.jaci.2009.10.053; Wang CB, 2008, J MAGN RESON IMAGING, V28, P80, DOI 10.1002/jmri.21408	37	63	63	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2013	131	5					1322	1328		10.1016/j.jaci.2013.01.054	http://dx.doi.org/10.1016/j.jaci.2013.01.054			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	144AU	23561802	Bronze			2022-12-18	WOS:000318912200007
J	Lu, KD; Breysse, PN; Diette, GB; Curtin-Brosnan, J; Aloe, C; Williams, DL; Peng, RD; McCormack, MC; Matsui, EC				Lu, Kim D.; Breysse, Patrick N.; Diette, Gregory B.; Curtin-Brosnan, Jean; Aloe, Charles; Williams, D'Ann L.; Peng, Roger D.; McCormack, Meredith C.; Matsui, Elizabeth C.			Being overweight increases susceptibility to indoor pollutants among urban children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; overweight; obesity; indoor pollutants childhood asthma; inner-city asthma	INNER-CITY CHILDREN; BODY-MASS INDEX; AIR-POLLUTION; UNITED-STATES; OBESITY; ASSOCIATION; SEVERITY; SYMPTOMS; MORBIDITY; EXPOSURE	Background: Both being overweight and exposure to indoor pollutants, which have been associated with worse health of asthmatic patients, are common in urban minority populations. Whether being overweight is a risk factor for the effects of indoor pollutant exposure on asthma health is unknown. Objectives: We sought to examine the effect of weight on the relationship between indoor pollutant exposure and asthma health in urban minority children. Methods: One hundred forty-eight children (age, 5-17 years) with persistent asthma were followed for 1 year. Asthma symptoms, health care use, lung function, pulmonary inflammation, and indoor pollutants were assessed every 3 months. Weight category was based on body mass index percentile. Results: Participants were predominantly African American (91%) and had public health insurance (85%). Four percent were underweight, 52% were normal weight, 16% were overweight, and 28% were obese. Overweight or obese participants had more symptoms associated with exposure to fine particulate matter measuring less than 2.5 mu m in diameter (PM2.5) than normal-weight participants across a range of asthma symptoms. Overweight or obese participants also had more asthma symptoms associated with nitrogen dioxide (NO2) exposure than normal-weight participants, although this was not observed across all types of asthma symptoms. Weight did not affect the relationship between exposure to coarse particulate matter measuring between 2.5 and 10 mu m in diameter and asthma symptoms. Relationships between indoor pollutant exposure and health care use, lung function, or pulmonary inflammation did not differ by weight. Conclusion: Being overweight or obese can increase susceptibility to indoor PM2.5 and NO2 in urban children with asthma. Interventions aimed at weight loss might reduce asthma symptom responses to PM2.5 and NO2, and interventions aimed at reducing indoor pollutant levels might be particularly beneficial in overweight children. (J Allergy Clin Immunol 2013; 131:1017-23.)	[Lu, Kim D.] Johns Hopkins Sch Med, Div Pediat Resp Sci, Baltimore, MD USA; [Diette, Gregory B.; McCormack, Meredith C.] Johns Hopkins Sch Med, Div Pulm & Crit Care Med, Dept Pediat, Baltimore, MD USA; [Breysse, Patrick N.; Williams, D'Ann L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; [Peng, Roger D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Curtin-Brosnan, Jean; Aloe, Charles; Matsui, Elizabeth C.] Johns Hopkins Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine	Matsui, EC (corresponding author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	ematsui@jhmi.edu		Matsui, Elizabeth/0000-0001-8134-5593; Koehl, Rachelle/0000-0002-7797-7456; Ayers, Andrew/0000-0001-5305-7156; McCormack, Meredith/0000-0003-1702-3201; Pham, Hewlett/0000-0003-0330-6104	National Institute of Environmental Health Sciences [P50ES015903, P01ES018176]; Environmental Protection Agency [R832139]; National Institute of Allergy and Infectious Diseases [R01AI070630]; Johns Hopkins University School of Medicine General Clinical Research Center from the National Center for Research Resources/ National Institutes of Health [M01-RR00052]; National Institutes of Health (NIH); National Institute of Environmental Health Sciences (NIEHS); US Environmental Protection Agency; GlaxoSmithKline; royalties from Springer Publishing; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL072748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES018176, R01ES019560, K24ES021098, P50ES015903] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Environmental Protection Agency(United States Environmental Protection Agency); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Johns Hopkins University School of Medicine General Clinical Research Center from the National Center for Research Resources/ National Institutes of Health; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); US Environmental Protection Agency(United States Environmental Protection Agency); GlaxoSmithKline(GlaxoSmithKline); royalties from Springer Publishing; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Institute of Environmental Health Sciences (P50ES015903, P01ES018176), the Environmental Protection Agency (R832139), the National Institute of Allergy and Infectious Diseases (R01AI070630), and the Johns Hopkins University School of Medicine General Clinical Research Center (grant no. M01-RR00052) from the National Center for Research Resources/ National Institutes of Health.; Disclosure of potential conflict of interest: P. N. Breysse has received a grant from the National Institutes of Health (NIH). G. B. Diette has received grants from the NIH, the National Institute of Environmental Health Sciences (NIEHS), and the US Environmental Protection Agency and has consultant arrangements with GlaxoSmithKline and Fenzian. R. D. Peng has received grants from the NIH and receives royalties from Springer Publishing. M. C. McCormack has received a grant from the NIEHS and has consultant arrangements with Alexza Pharmaceuticals. E. C. Matsui has received a grant from the NIH and received the Phadia Research Foundation Award. The rest of the authors declare that they have no relevant conflicts of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bennett WD, 2004, J APPL PHYSIOL, V97, P821, DOI 10.1152/japplphysiol.01403.2003; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Breysse Patrick N, 2010, Proc Am Thorac Soc, V7, P102, DOI 10.1513/pats.200908-083RM; Breysse PN, 2005, ENVIRON RES, V98, P167, DOI 10.1016/j.envres.2004.07.018; Carroll CL, 2006, PEDIATR CRIT CARE ME, V7, P527, DOI 10.1097/01.PCC.0000243749.14555.E8; Clerisme-Beaty EM, 2009, J ALLERGY CLIN IMMUN, V124, P207, DOI 10.1016/j.jaci.2009.05.034; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607, DOI 10.1289/ehp.021100607; Fessler MB, 2009, J ALLERGY CLIN IMMUN, V124, P967, DOI 10.1016/j.jaci.2009.08.005; Forno E, 2011, J ALLERGY CLIN IMMUN, V127, P741, DOI 10.1016/j.jaci.2010.12.010; Grammer LC, 2010, J ASTHMA, V47, P491, DOI 10.3109/02770901003801980; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hansel NN, 2008, ENVIRON HEALTH PERSP, V116, P1428, DOI 10.1289/ehp.11349; Holguin F, 2010, J APPL PHYSIOL, V108, P754, DOI 10.1152/japplphysiol.00702.2009; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11; Lang AM, 2010, ACTA PAEDIATR, V99, P404, DOI 10.1111/j.1651-2227.2009.01625.x; McCormack MC, 2009, ENVIRON HEALTH PERSP, V117, P294, DOI 10.1289/ehp.11770; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Quinto KB, 2011, J ALLERGY CLIN IMMUN, V128, P964, DOI 10.1016/j.jaci.2011.06.031; Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Sutherland ER, 2009, J ALLERGY CLIN IMMUN, V123, P1328, DOI 10.1016/j.jaci.2009.04.005; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Taylor B, 2008, THORAX, V63, P14, DOI 10.1136/thx.2007.082784; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, P1163, DOI 10.1016/j.jaci.2008.12.1126; Weinmayr G, 2010, ENVIRON HEALTH PERSP, V118, P449, DOI 10.1289/ehp.0900844	35	63	64	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1017	+		10.1016/j.jaci.2012.12.1570	http://dx.doi.org/10.1016/j.jaci.2012.12.1570			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23403052	Bronze, Green Accepted			2022-12-18	WOS:000317187200008
J	Murota, H; Izumi, M; Abd El-Latif, MIA; Nishioka, M; Terao, M; Tani, M; Matsui, S; Sano, S; Katayama, I				Murota, Hiroyuki; Izumi, Mayuko; Abd El-Latif, Mostafa I. A.; Nishioka, Megumi; Terao, Mika; Tani, Mamori; Matsui, Saki; Sano, Shigetoshi; Katayama, Ichiro			Artemin causes hypersensitivity to warm sensation, mimicking warmth-provoked pruritus in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Artemin; fibroblast; substance P; atopic dermatitis; itch; nerve fiber; warmth	NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; SUBSTANCE-P; SKIN; RECEPTOR; GDNF; FAMILY; ITCH; NOCICEPTION; EXPRESSION	Background: Itch impairs the quality of life for many patients with dermatoses, especially atopic dermatitis (AD), and is frequently induced by a warm environment. Objective: To determine the mechanism underlying itch induction by warmth, we focused on artemin, a member of glial cell line-derived neurotrophic factors (GDNFs). Methods: A gene array assay revealed that artemin was expressed in substance P-treated dermal fibroblasts. The expression of artemin in healthy and AD-lesional skin was evaluated with immunohistochemistry and in situ hybridization. The impact of fibroblast-derived artemin on the proliferation and morphology of neural cell was investigated in vitro. To confirm the involvement of artemin in skin sensibility, wild-type and GDNF family receptor alpha 3 knockout mice were employed for sensory examination. Results: Artemin-expressing fibroblasts accumulated in skin lesions of patients with AD. Artemin induced cell proliferation of a neuroblastoma cell line in vitro, and intradermal injection of artemin in mice resulted in peripheral nerve sprouting and thermal hyperalgesia. Artemin-treated mice demonstrated scratching behavior in a warm environment, but mice deficient for GDNF family receptor alpha 3, a potent artemin receptor, did not show this behavior. Furthermore, the escaping response to heat stimulus was attenuated in GDNF family receptor alpha 3 knockout mice, suggesting that artemin may contribute to sensitivity to heat. Conclusion: These data suggest that dermal fibroblasts secrete artemin in response to substance P, leading to abnormal peripheral innvervation and thermal hyperalgesia. We hypothesize that artemin lowers the threshold of temperature-dependent itch sensation and might therefore be a novel therapeutic target for treating pruritic skin disorders, including AD. (J Allergy Clin Immunol 2012;130:671-82.)	[Murota, Hiroyuki; Izumi, Mayuko; Abd El-Latif, Mostafa I. A.; Nishioka, Megumi; Terao, Mika; Tani, Mamori; Matsui, Saki; Katayama, Ichiro] Osaka Univ, Grad Sch Med, Dept Dermatol, Course Integrated Med, Suita, Osaka 5650871, Japan; [Abd El-Latif, Mostafa I. A.] Cairo Univ, Dept Dermatol, Cairo, Egypt; [Sano, Shigetoshi] Kochi Univ, Dept Dermatol, Kochi, Japan	Osaka University; Egyptian Knowledge Bank (EKB); Cairo University; Kochi University	Murota, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Dermatol, Course Integrated Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	h-murota@derma.med.osaka-u.ac.jp		attia, mostafa/0000-0003-3619-7522	Ministry of Education, Culture, Sports, Science and Technology, Japan; Grants-in-Aid for Scientific Research [24590726] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Bae SJ, 2002, INT ARCH ALLERGY IMM, V127, P316, DOI 10.1159/000057749; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Beltrani VS, 1999, J ALLERGY CLIN IMMUN, V104, pS87, DOI 10.1016/S0091-6749(99)70050-3; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P598, DOI 10.1067/mai.2003.174; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; Dou YC, 2006, ARCH DERMATOL RES, V298, P31, DOI 10.1007/s00403-006-0657-1; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Elitt CM, 2006, J NEUROSCI, V26, P8578, DOI 10.1523/JNEUROSCI.2185-06.2006; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HEYER G, 1995, ACTA DERM-VENEREOL, V75, P348; Hong J, 2011, SEMIN CUTAN MED SURG, V30, P71, DOI 10.1016/j.sder.2011.05.002; Honma Y, 2002, NEURON, V35, P267, DOI 10.1016/S0896-6273(02)00774-2; Hosogi M, 2006, PAIN, V126, P16, DOI 10.1016/j.pain.2006.06.003; Ikoma A, 2006, NAT REV NEUROSCI, V7, P535, DOI 10.1038/nrn1950; Katayama I, 1997, J DERMATOL SCI, V15, P201, DOI 10.1016/S0923-1811(97)00608-7; Koblenzer CS, 1999, J ALLERGY CLIN IMMUN, V104, pS109, DOI 10.1016/S0091-6749(99)70052-7; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Lai Xi-nan, 2003, Chin J Traumatol, V6, P350; Lambiase A, 1997, J ALLERGY CLIN IMMUN, V100, P408, DOI 10.1016/S0091-6749(97)70256-2; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Malin SA, 2006, J NEUROSCI, V26, P8588, DOI 10.1523/JNEUROSCI.1726-06.2006; Mallet C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012748; Micera A, 2001, P NATL ACAD SCI USA, V98, P6162, DOI 10.1073/pnas.101130898; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Murota H, 2003, ARTHRITIS RHEUM, V48, P1117, DOI 10.1002/art.10896; Murota Hiroyuki, 2010, Allergology International, V59, P345, DOI 10.2332/allergolint.10-OA-0182; NEMEROFF CB, 1979, P NATL ACAD SCI USA, V76, P5368, DOI 10.1073/pnas.76.10.5368; Nishino J, 1999, NEURON, V23, P725, DOI 10.1016/S0896-6273(01)80031-3; Schmelz M, 2002, J DERMATOL SCI, V28, P91, DOI 10.1016/S0923-1811(01)00167-0; Schuhknecht B, 2011, BRIT J DERMATOL, V165, P85, DOI 10.1111/j.1365-2133.2011.10306.x; Silvian L, 2006, BIOCHEMISTRY-US, V45, P6801, DOI 10.1021/bi060035x; Sin AZ, 2001, J ALLERGY CLIN IMMUN, V108, P387; Terao M, 2010, EXP DERMATOL, V19, P38, DOI 10.1111/j.1600-0625.2009.00973.x; Trupp M, 1997, J NEUROSCI, V17, P3554; Wahlgren C F, 1991, Acta Derm Venereol Suppl (Stockh), V165, P1; Weigelt N, 2010, J CUTAN PATHOL, V37, P578, DOI 10.1111/j.1600-0560.2009.01484.x; Wilson SR, 2011, NAT NEUROSCI, V14, P595, DOI 10.1038/nn.2789	39	63	66	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					671	+		10.1016/j.jaci.2012.05.027	http://dx.doi.org/10.1016/j.jaci.2012.05.027			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22770266	Bronze			2022-12-18	WOS:000308463500016
J	Masilamani, M; Wei, J; Bhatt, S; Paul, M; Yakir, S; Sampson, HA				Masilamani, Madhan; Wei, John; Bhatt, Shiven; Paul, Misu; Yakir, Stefanie; Sampson, Hugh A.			Soybean isoflavones regulate dendritic cell function and suppress allergic sensitization to peanut	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; soybean; isoflavones; genistein; daidzein; dendritic cells; T cells	NEUTROPHIL CHEMOTACTIC FACTOR; NATURAL-KILLER-CELLS; GUINEA-PIG MODEL; CHOLERA-TOXIN; F-1 GENERATIONS; RECEPTOR-ALPHA; SOY GENISTEIN; IN-VITRO; INHIBITOR; DIFFERENTIATION	Background: Although peanut and soybean proteins share extensive amino acid sequence homology, the incidence and severity of allergic reactions to soy are much less than those to peanut. Soybeans are rich in anti-inflammatory isoflavones and are the most common source of isoflavones in the human food supply. Objective: We hypothesized that the active isoflavones in the gut milieu are capable of modulating immune responses to dietary antigens by regulating dendritic cell (DC) function. Methods: We tested this hypothesis in a murine model of peanut allergy and in human monocyte-derived dendritic cells (MDDCs). C3H/HeJ mice were fed a diet containing genistein and daidzein. The mice were sensitized and challenged with peanut, and the anaphylactic symptoms were compared with those of mice fed a soy-free diet. Human MDDCs were activated with cholera toxin in the presence of isoflavones. The surface expression of DC activation markers and DC-mediated effector functions were analyzed by means of flow cytometry. Results: Dietary isoflavones significantly reduced the anaphylactic symptoms and mast cell degranulation in vivo after peanut challenge. Serum peanut-specific antibodies were markedly reduced in mice fed the isoflavone diet. Isoflavones inhibited cholera toxin-induced DC maturation in the mesenteric lymph nodes and human MDDCs and subsequent DC-mediated CD4(+) T-cell function in vitro. Conclusions: These data suggest that dietary isoflavones suppress allergic sensitization and protect against peanut allergy in vivo. Dietary supplementation of soybean isoflavones could be a novel strategy to prevent the development of allergic reactions to food. (J Allergy Clin Immunol 2011;128:1242-50.)	[Masilamani, Madhan; Wei, John; Bhatt, Shiven; Paul, Misu; Yakir, Stefanie; Sampson, Hugh A.] Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, New York, NY 10029 USA; [Masilamani, Madhan; Sampson, Hugh A.] Mt Sinai Sch Med, Inst Immunol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Masilamani, M (corresponding author), Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, Anbg 17-40, New York, NY 10029 USA.	madhan.masilamani@mssm.edu	Masilamani, Madhan/H-3691-2019	Masilamani, Madhan/0000-0001-8181-8848; Bhatt, Shiven/0000-0001-5030-2347	Jaffe Food Allergy Institute, Mount Sinai School of Medicine	Jaffe Food Allergy Institute, Mount Sinai School of Medicine	Supported by the Jaffe Food Allergy Institute, Mount Sinai School of Medicine.	Agostoni C, 2006, J PEDIATR GASTR NUTR, V42, P352, DOI 10.1097/01.mpg.0000189358.38427.cd; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BACHERT C, 1995, EUR ARCH OTO-RHINO-L, V252, pS44, DOI 10.1007/BF02484434; Badger TM, 2009, AM J CLIN NUTR, V89, pS1668, DOI 10.3945/ajcn.2009.26736U; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barnes S, 2010, LYMPHAT RES BIOL, V8, P89, DOI 10.1089/lrb.2009.0030; Beardslee TA, 2000, INT ARCH ALLERGY IMM, V123, P299, DOI 10.1159/000053642; Berin MC, 2009, MUCOSAL IMMUNOL, V2, P24, DOI 10.1038/mi.2008.72; Blazquez AB, 2008, J IMMUNOL, V180, P4441, DOI 10.4049/jimmunol.180.7.4441; Bogunovic M, 2009, IMMUNITY, V31, P513, DOI 10.1016/j.immuni.2009.08.010; Braun MC, 1999, J EXP MED, V189, P541, DOI 10.1084/jem.189.3.541; Cecilia M, 2008, J ALLERGY CLIN IMMUN, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Chalubinski M, 2006, ALLERGY, V61, P1326, DOI 10.1111/j.1398-9995.2006.01135.x; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Cheong H, 1998, ARCH PHARM RES, V21, P478, DOI 10.1007/BF02974647; Cooke PS, 2006, J NUTR, V136, P704, DOI 10.1093/jn/136.3.704; Cordle CT, 2004, J NUTR, V134, p1213S, DOI 10.1093/jn/134.5.1213S; Day AJ, 2000, FEBS LETT, V468, P166, DOI 10.1016/S0014-5793(00)01211-4; Day AJ, 1998, FEBS LETT, V436, P71, DOI 10.1016/S0014-5793(98)01101-6; Dodge IL, 2003, J IMMUNOL, V170, P4457, DOI 10.4049/jimmunol.170.9.4457; Duan W, 2003, AM J RESP CRIT CARE, V167, P185, DOI 10.1164/rccm.200205-420OC; Fallon PG, 2001, J IMMUNOL, V166, P2712, DOI 10.4049/jimmunol.166.4.2712; Faries MB, 2001, BLOOD, V98, P2489, DOI 10.1182/blood.V98.8.2489; Gagliardi MC, 2000, EUR J IMMUNOL, V30, P2394, DOI 10.1002/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO;2-Y; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; Guo TL, 2002, TOXICOLOGY, V172, P205, DOI 10.1016/S0300-483X(02)00005-7; Guo TL, 2002, TOXICOL APPL PHARM, V181, P219, DOI 10.1006/taap.2002.9418; Hauber HP, 2004, INT ARCH ALLERGY IMM, V134, P79, DOI 10.1159/000078384; Hendrich S, 2002, J CHROMATOGR B, V777, P203, DOI 10.1016/S1570-0232(02)00347-1; HUNTLEY JF, 1990, PARASITE IMMUNOL, V12, P85, DOI 10.1111/j.1365-3024.1990.tb00938.x; Kalhan R, 2008, CLIN EXP ALLERGY, V38, P103, DOI 10.1111/j.1365-2222.2007.02862.x; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Lissin LW, 2000, J AM COLL CARDIOL, V35, P1403; LOPEZ AF, 1986, J EXP MED, V163, P1085, DOI 10.1084/jem.163.5.1085; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; Merritt RJ, 2004, J NUTR, V134, p1220S, DOI 10.1093/jn/134.5.1220S; Miyake Y, 2005, J ALLERGY CLIN IMMUN, V115, P1176, DOI 10.1016/j.jaci.2005.02.016; NEWLANDS GFJ, 1993, BIOCHEM J, V294, P127, DOI 10.1042/bj2940127; NEWLANDS GFJ, 1987, IMMUNOLOGY, V62, P629; Orgaard A, 2008, EXP BIOL MED, V233, P1066, DOI 10.3181/0712-MR-347; Osterfeld H, 2010, J ALLERGY CLIN IMMUN, V125, P469, DOI 10.1016/j.jaci.2009.09.054; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pons L, 2004, J ALLERGY CLIN IMMUN, V114, P915, DOI 10.1016/j.jaci.2004.06.049; Regal JF, 2000, P SOC EXP BIOL MED, V223, P372, DOI 10.1046/j.1525-1373.2000.22353.x; Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Sakai T, 2008, J MED INVESTIG, V55, P167, DOI 10.2152/jmi.55.167; Sanchez J, 2011, INDIAN J MED RES, V133, P153; Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S; Setchell KDR, 1997, LANCET, V350, P23, DOI 10.1016/S0140-6736(96)09480-9; SHI J, 2009, ORL J OTO-RHINO-LARY, V72, P256; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Sicherer SH, 2000, ALLERGY, V55, P515, DOI 10.1034/j.1398-9995.2000.00119.x; Smith LJ, 2004, J ASTHMA, V41, P833, DOI 10.1081/JAS-200038447; SMYTH MJ, 1991, J IMMUNOL, V146, P3815; Strom BL, 2001, JAMA-J AM MED ASSOC, V286, P807, DOI 10.1001/jama.286.7.807; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; van Ree R, 2004, CURR OPIN ALLERGY CL, V4, P235, DOI [10.1097/00130832-200406000-00017, 10.1097/01.all.0000129457.27092.8f]; Wallaert B, 2002, ALLERGY, V57, P405, DOI 10.1034/j.1398-9995.2002.13527.x; Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668; WHEELER ME, 1988, J CLIN INVEST, V82, P1211, DOI 10.1172/JCI113718; Wilson S, 2005, NUTR REV, V63, P47, DOI [10.1111/j.1753-4887.2005.tb00121.x, 10.1301/nr.2005.feb.47-58]; XU X, 1995, J NUTR, V125, P2307, DOI 10.1093/jn/125.9.2307; Yamasaki M, 2007, CANCER SCI, V98, P1740, DOI 10.1111/j.1349-7006.2007.00595.x; Yellayi S, 2003, J ENDOCRINOL, V176, P267, DOI 10.1677/joe.0.1760267; Yellayi S, 2002, P NATL ACAD SCI USA, V99, P7616, DOI 10.1073/pnas.102650199; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; Zhang T, 2008, CLIN EXP ALLERGY, V38, P1808, DOI 10.1111/j.1365-2222.2008.03075.x; Zhang Y, 1999, J NUTR, V129, P399, DOI 10.1093/jn/129.2.399	74	63	68	0	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1242	U583		10.1016/j.jaci.2011.05.009	http://dx.doi.org/10.1016/j.jaci.2011.05.009			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21696815				2022-12-18	WOS:000298342700013
J	Ferrer, M; Gamboa, P; Sanz, ML; Goikoetxea, MJ; Cabrera-Freitag, P; Javaloyes, G; Berroa, F; Kaplan, AP				Ferrer, Marta; Gamboa, Pedro; Sanz, Maria L.; Goikoetxea, Maria Jose; Cabrera-Freitag, Paula; Javaloyes, Gracia; Berroa, Felicia; Kaplan, Allen P.			Omalizumab is effective in nonautoimmune urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FC-EPSILON-RI; BASOPHIL ACTIVATION; CD63 EXPRESSION		[Ferrer, Marta; Sanz, Maria L.; Goikoetxea, Maria Jose; Cabrera-Freitag, Paula; Javaloyes, Gracia; Berroa, Felicia] Clin Univ Navarra Med Sch, Dept Allergy, Pamplona, Spain; [Gamboa, Pedro] Hosp Basurto, Allergy Serv, Bilbao, Spain; [Kaplan, Allen P.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	University of Navarra; Basurto Hospital; Medical University of South Carolina	Ferrer, M (corresponding author), Clin Univ Navarra Med Sch, Dept Allergy, Pamplona, Spain.	mferrerp@unav.es	Ferrer, Marta/C-4319-2016; Goikoetxea, Maria Jose/AAJ-9054-2021	Ferrer, Marta/0000-0001-8495-1302; Goikoetxea, Maria Jose/0000-0003-2213-6999				Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Gamboa PM, 2003, ALLERGY, V58, P312, DOI 10.1034/j.1398-9995.2003.00096.x; Gomez G, 2007, J IMMUNOL, V179, P1353, DOI 10.4049/jimmunol.179.2.1353; Luquin E, 2005, CLIN EXP ALLERGY, V35, P456, DOI 10.1111/j.1365-2222.2005.02212.x; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Mlynek A, 2008, ALLERGY, V63, P777, DOI 10.1111/j.1398-9995.2008.01726.x; Oliver JM, 2010, INT ARCH ALLERGY IMM, V151, P275, DOI 10.1159/000250436; Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x; Zuberbier T, 2009, ALLERGY, V64, P1417, DOI 10.1111/j.1398-9995.2009.02179.x	9	63	63	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1300	1302		10.1016/j.jaci.2010.12.1085	http://dx.doi.org/10.1016/j.jaci.2010.12.1085			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21315432				2022-12-18	WOS:000290018600029
J	Prickett, SR; Voskamp, AL; Dacumos-Hill, A; Symons, K; Rolland, JM; O'Hehir, RE				Prickett, Sara R.; Voskamp, Astrid L.; Dacumos-Hill, April; Symons, Karen; Rolland, Jennifer M.; O'Hehir, Robyn E.			Ara h 2 peptides containing dominant CD4(+) T-cell epitopes: Candidates for a peanut allergy therapeutic	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; Ara h 2; T-cell epitope; peptide; immunotherapy	IGE-BINDING EPITOPES; MUTATIONAL ANALYSIS; FOOD ALLERGY; BEE VENOM; HLA-DP; IMMUNOTHERAPY; IDENTIFICATION; MECHANISMS; RISK; DERMATOPHAGOIDES	Background: Peanut allergy is a life-threatening condition; there is currently no cure. Although whole allergen extracts are used for specific immunotherapy for many allergies, they can cause severe reactions, and even fatalities, in peanut allergy. Objective: This study aimed to identify short, T-cell epitope-based peptides that target allergen-specific CD4(+) T cells but do not bind IgE as candidates for safe peanut-specific immunotherapy. Methods: Multiple CD4(+) T-cell lines specific for the major peanut allergen Ara h 2 were generated from PBMCs of 16 HLA-diverse subjects with peanut allergy by using 5,6-carboxyfluorescein diacetate succinimidylester-based methodology. Proliferation and ELISPOT assays were used to identify dominant epitopes recognized by T-cell lines and to confirm recognition by peripheral blood T cells of epitope-based peptides modified for therapeutic production. HLA restriction of core epitope recognition was investigated by using anti-HLA blocking antibodies and HLA genotyping. Serum-IgE peptide-binding was assessed by dot-blot. Results: Five dominant CD4(+) T-cell epitopes were identified in Ara h 2. In combination, these were presented by HLA-DR, HLA-DP, and HLA-DQ molecules and recognized by T cells from all 16 subjects. Three short peptide variants containing these T-cell epitopes were designed with cysteine-to-serine substitutions to facilitate stability and therapeutic production. Variant peptides showed HLA-binding degeneracy, did not bind peanut-specific serum IgE, and could directly target T(H)2-type T cells in peripheral blood of subjects with allergy. Conclusion: Short CD4(+) T-cell epitope-based Ara h 2 peptides were identified as novel candidates for a T-cell-targeted peanut-specific immunotherapy for an HLA-diverse population. (J Allergy Clin Immunol 2011;127:608-15.)	[Prickett, Sara R.; Voskamp, Astrid L.; Dacumos-Hill, April; Symons, Karen; O'Hehir, Robyn E.] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic 3004, Australia; [Prickett, Sara R.; Voskamp, Astrid L.; Dacumos-Hill, April; Rolland, Jennifer M.; O'Hehir, Robyn E.] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia	Florey Institute of Neuroscience & Mental Health; Monash University	O'Hehir, RE (corresponding author), Alfred Hosp, Dept Allergy Immunol & Resp Med, Commercial Rd, Melbourne, Vic 3004, Australia.	robyn.ohehir@monash.edu	Rolland, Jennifer/E-7543-2011; O'Hehir, Robyn E/H-3627-2011	O'Hehir, Robyn E/0000-0002-3489-7595	Ilhan Food Allergy Foundation; National Health and Medical Research Council of Australia	Ilhan Food Allergy Foundation; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	Supported by grants from the Ilhan Food Allergy Foundation and the National Health and Medical Research Council of Australia.	Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Akdis M, 2009, CURR OPIN IMMUNOL, V21, P700, DOI 10.1016/j.coi.2009.07.012; Albrecht M, 2009, J ALLERGY CLIN IMMUN, V124, P328, DOI 10.1016/j.jaci.2009.05.031; Alexander C, 2005, ALLERGY, V60, P1269, DOI 10.1111/j.1398-9995.2005.00885.x; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Bateman EAL, 2008, CLIN EXP ALLERGY, V38, P1760, DOI 10.1111/j.1365-2222.2008.03098.x; Blanc F, 2009, CLIN EXP ALLERGY, V39, P1277, DOI 10.1111/j.1365-2222.2009.03294.x; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Campbell JD, 2009, J EXP MED, V206, P1535, DOI 10.1084/jem.20082901; De Jong EC, 1998, CLIN EXP ALLERGY, V28, P743, DOI 10.1046/j.1365-2222.1998.00301.x; de Leon Maria P., 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000208; de Leon MP, 2003, CLIN EXP ALLERGY, V33, P1273, DOI 10.1046/j.1365-2222.2003.01761.x; Eiwegger T, 2006, CLIN EXP ALLERGY, V36, P1281, DOI 10.1111/j.1365-2222.2006.02565.x; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Glaspole IN, 2005, ALLERGY, V60, P35, DOI 10.1111/j.1398-9995.2004.00608.x; HIGGINS JA, 1994, J ALLERGY CLIN IMMUN, V93, P891, DOI 10.1016/0091-6749(94)90383-2; HIGGINS JA, 1992, J ALLERGY CLIN IMMUN, V90, P749, DOI 10.1016/0091-6749(92)90098-M; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Hong SJ, 1999, J ALLERGY CLIN IMMUN, V104, P473, DOI 10.1016/S0091-6749(99)70396-9; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kammerer R, 1997, J ALLERGY CLIN IMMUN, V100, P96, DOI 10.1016/S0091-6749(97)70200-8; Kay AB, 2004, SPRINGER SEMIN IMMUN, V25, P391, DOI 10.1007/s00281-003-0146-y; Kemp AS, 2008, MED J AUSTRALIA, V188, P503, DOI 10.5694/j.1326-5377.2008.tb01761.x; King N, 2005, MOL NUTR FOOD RES, V49, P963, DOI 10.1002/mnfr.200500073; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Larche M, 2008, CLIN EXP ALLERGY, V38, P1709, DOI 10.1111/j.1365-2222.2008.03112.x; Larche M, 2007, ALLERGY, V62, P325, DOI 10.1111/j.1398-9995.2006.01309.x; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; Mannering SI, 2005, J IMMUNOL METHODS, V298, P83, DOI 10.1016/j.jim.2005.01.001; McDermott RA, 2007, CLIN EXP ALLERGY, V37, P752, DOI 10.1111/j.1365-2222.2007.02701.x; Middleton D, 2003, TISSUE ANTIGENS, V61, P403, DOI 10.1034/j.1399-0039.2003.00062.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Mullins RJ, 2009, J ALLERGY CLIN IMMUN, V123, P689, DOI 10.1016/j.jaci.2008.12.1116; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; O'Hehir RE, 2007, CURR MED CHEM, V14, P2235, DOI 10.2174/092986707781696609; O'Hehir RE, 2007, LANCET, V370, P483, DOI 10.1016/S0140-6736(07)61228-8; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Palmer GW, 2005, CLIN IMMUNOL, V115, P302, DOI 10.1016/j.clim.2005.02.011; Pumphrey R, 2004, CURR OPIN ALLERGY CL, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Rabjohn P, 2002, INT ARCH ALLERGY IMM, V128, P15, DOI 10.1159/000057999; Ramos ML, 2009, PLANT MOL BIOL, V69, P325, DOI 10.1007/s11103-008-9428-z; Rolland JM, 2009, PHARMACOL THERAPEUT, V121, P273, DOI 10.1016/j.pharmthera.2008.11.007; Ruiter B, 2007, INT ARCH ALLERGY IMM, V143, P119, DOI 10.1159/000098660; Sampson MA, 2006, J ALLERGY CLIN IMMUN, V117, P1440, DOI 10.1016/j.jaci.2006.03.009; Scadding G, 2009, J ASTHMA, V46, P322, DOI 10.1080/02770900902785729; Shek LP, 2010, J ALLERGY CLIN IMMUN, V126, pe7; Shek LPC, 2010, J ALLERGY CLIN IMMUN, V126, P324, DOI 10.1016/j.jaci.2010.06.003; Shreffler WG, 2006, ANN ALLERG ASTHMA IM, V96, P865, DOI 10.1016/S1081-1206(10)61351-8; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Tanabe S, 2007, CURR PROTEIN PEPT SC, V8, P109, DOI 10.2174/138920307779941569; Thyagarajan A, 2010, J ALLERGY CLIN IMMUN, V126, P31, DOI 10.1016/j.jaci.2010.05.012; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042; VERHOEF A, 1993, INT IMMUNOL, V5, P1589, DOI 10.1093/intimm/5.12.1589; Woodfolk JA, 2007, J ALLERGY CLIN IMMUN, V119, P280, DOI 10.1016/j.jaci.2006.11.008; Yun J, 2009, INTERN MED J, V39, P475, DOI 10.1111/j.1445-5994.2009.01967.x	63	63	73	1	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					608	U554		10.1016/j.jaci.2010.09.027	http://dx.doi.org/10.1016/j.jaci.2010.09.027			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	730FG	21093025				2022-12-18	WOS:000288018400008
J	Rosenthal, LA; Avila, PC; Heymann, PW; Martin, RJ; Miller, EK; Papadopoulos, NG; Peebles, RS; Gern, JE				Rosenthal, Louis A.; Avila, Pedro C.; Heymann, Peter W.; Martin, Richard J.; Miller, E. Kathryn; Papadopoulos, Nikolaos G.; Peebles, R. Stokes, Jr.; Gern, James E.		Amer Acad Allergy Asthma & Immunol	Viral respiratory tract infections and asthma: The course ahead	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Viral respiratory tract infections; asthma; wheezing; asthma onset; asthma exacerbations; respiratory tract viruses; rhinovirus; respiratory syncytial virus; allergy	SYNCYTIAL VIRUS-INFECTION; HIGH-RISK CHILDREN; HUMAN RHINOVIRUS; CHILDHOOD ASTHMA; AIRWAY INFLAMMATION; INTERMITTENT ASTHMA; INFANCY; ILLNESSES; EXACERBATIONS; BRONCHIOLITIS	Inquiries into the relationships between viral respiratory tract illnesses and the inception and exacerbation of asthma are being facilitated by recent advances in research approaches and technology. In this article we identify important knowledge gaps and future research questions, and we discuss how new investigational tools, including improved respiratory tract virus detection techniques, will permit current and future researchers to define these relationships and the host, virus, developmental, and environmental mechanisms that regulate them. A better understanding of these processes should facilitate the development of improved strategies for the prevention and treatment of virus-induced wheezing illnesses and asthma exacerbations and, possibly, the ultimate goal of discovering effective approaches for the primary prevention of asthma. (J Allergy Clin Immunol 2010;125:1212-7.)	[Rosenthal, Louis A.; Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI 53792 USA; [Rosenthal, Louis A.; Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53792 USA; [Avila, Pedro C.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Heymann, Peter W.] Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA USA; [Martin, Richard J.] Natl Jewish Hlth, Dept Med, Denver, CO USA; [Miller, E. Kathryn] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Peebles, R. Stokes, Jr.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Papadopoulos, Nikolaos G.] Univ Athens, Dept Allergy, Pediat Clin 2, GR-10679 Athens, Greece	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Northwestern University; Feinberg School of Medicine; University of Virginia; National Jewish Health; Vanderbilt University; Vanderbilt University; National & Kapodistrian University of Athens	Rosenthal, LA (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, 600 Highland Ave,K4-948 CSC 9988, Madison, WI 53792 USA.	lar@medicine.wisc.edu	Papadopoulos, Nikolaos/ABE-1774-2021; N.G., Papadopoulos/L-8670-2013	Papadopoulos, Nikolaos/0000-0002-4448-3468; N.G., Papadopoulos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-2508-3872	National Institutes of Health/National Institute of Allergy and Infectious Diseases [AI070503]; Genentech; National Institutes of Health (NIH); Cove Point Foundation; NIH/National Heart, Lung, and Blood Institute; Thrasher and Vanderbilt Clinical and Translational Research Scholars; AstraZeneca; Merck; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070503] Funding Source: NIH RePORTER	National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Genentech(Roche HoldingGenentech); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cove Point Foundation; NIH/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Thrasher and Vanderbilt Clinical and Translational Research Scholars; AstraZeneca(AstraZeneca); Merck(Merck & Company); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by a grant front the National Institutes of Health/National Institute of Allergy and Infectious Diseases (AI070503).; Disclosure of potential conflict of interest: L. A. Rosenthal has declared that he has no conflict of interest. P. C. Avila has received research support from Genentech. P. W. Heymann has received research support front the National Institutes of Health (NIH) and the Cove Point Foundation. R. J. Martin has consulted for Adelphi, Abbott, Schering-Plough, Novartis, Genentech, Nitoc, Teva, Coviden, AstraZeneca, Kalobios, and Sepracor and has received research support from the NIH/National Heart, Lung, and Blood Institute. E. K. Miller has received research support from Thrasher and Vanderbilt Clinical and Translational Research Scholars. N. G. Papadopoulos is on advisory boards for Merck and GlaxoSmithKline and has received honoraria for talks from Novartis. R. S. Peebles has received research support from the NIH. J. E. Gem is on the scientific advisory board for and has stock options for 3V Bioseiences, has consulted for and has stock options for EraGen Biosciences, has consulted for Synairgen and Centocor. and has received research support from AstraZeneca and Merck.	Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; DeSantis TZ, 2003, BIOINFORMATICS, V19, P1461, DOI 10.1093/bioinformatics/btg200; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Farquhar H, 2009, J ALLERGY CLIN IMMUN, V124, P649, DOI 10.1016/j.jaci.2009.07.037; Hansbro NG, 2008, PHARMACOL THERAPEUT, V117, P313, DOI 10.1016/j.pharmthera.2007.11.002; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Kaiser L, 2006, AM J RESP CRIT CARE, V174, P1392, DOI 10.1164/rccm.200604-489OC; Kistler A, 2007, J INFECT DIS, V196, P817, DOI 10.1086/520816; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lau SKP, 2007, J CLIN MICROBIOL, V45, P3655, DOI 10.1128/JCM.01254-07; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Litonjua AA, 2009, CURR OPIN ALLERGY CL, V9, P202, DOI 10.1097/ACI.0b013e32832b36cd; McErlean P, 2007, J CLIN VIROL, V39, P67, DOI 10.1016/j.jcv.2007.03.012; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Miller EK, 2009, J ALLERGY CLIN IMMUN, V123, P98, DOI 10.1016/j.jaci.2008.10.007; Moore ML, 2009, J VIROL, V83, P4185, DOI 10.1128/JVI.01853-08; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Newcomb DC, 2008, AM J RESP CRIT CARE, V177, P1111, DOI 10.1164/rccm.200708-1243OC; Palmenberg AC, 2009, SCIENCE, V324, P55, DOI 10.1126/science.1165557; Panickar J, 2009, NEW ENGL J MED, V360, P329, DOI 10.1056/NEJMoa0804897; Papadopoulos NG, 2008, PEDIAT ALLERG IMM-UK, V19, P51, DOI 10.1111/j.1399-3038.2008.00767.x; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Robertson CF, 2007, AM J RESP CRIT CARE, V175, P323, DOI 10.1164/rccm.200510-1546OC; Rosenthal LA, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-122; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Simoes EAF, 2007, J PEDIATR-US, V151, P34, DOI 10.1016/j.jpeds.2007.02.032; Thomsen SF, 2009, AM J RESP CRIT CARE, V179, P1091, DOI 10.1164/rccm.200809-1471OC; Tortorolo L, 2005, AM J RESP CRIT CARE, V172, P233, DOI 10.1164/rccm.200412-1693OC; Wenzel SE, 2002, AM J MED, V112, P627, DOI 10.1016/S0002-9343(02)01095-1; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Yoo Jennifer, 2007, Proc Am Thorac Soc, V4, P277, DOI 10.1513/pats.200702-033AW	36	63	66	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1212	1217		10.1016/j.jaci.2010.04.002	http://dx.doi.org/10.1016/j.jaci.2010.04.002			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20513518	Green Accepted, Bronze, Green Published			2022-12-18	WOS:000278831000005
J	Crotty, MP; Taylor, SL				Crotty, Matthew P.; Taylor, Steve L.			Risks associated with foods having advisory milk labeling	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGIC CHILD; ANAPHYLAXIS; INGESTION		[Crotty, Matthew P.; Taylor, Steve L.] Univ Nebraska, Dept Food Sci & Technol, Food Allergy Res & Resource Program, Lincoln, NE 68583 USA	University of Nebraska System; University of Nebraska Lincoln	Crotty, MP (corresponding author), Univ Nebraska, Dept Food Sci & Technol, Food Allergy Res & Resource Program, Lincoln, NE 68583 USA.	staylor2@unl.edu	Taylor, Steve L./V-1341-2019; Crotty, Matthew/AAM-1102-2021	Crotty, Matthew/0000-0002-6353-2958				GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; Hefle SL, 2007, J ALLERGY CLIN IMMUN, V120, P171, DOI 10.1016/j.jaci.2007.04.013; Laoprasert N, 1998, J FOOD PROTECT, V61, P1522, DOI 10.4315/0362-028X-61.11.1522; Levin ME, 2005, PEDIATRICS, V116, P1223, DOI 10.1542/peds.2005-0020; Taylor SL, 2006, CURR OPIN ALLERGY CL, V6, P186, DOI 10.1097/01.all.0000225158.75521.ad; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Taylor SL, 2007, COMPR REV FOOD SCI F, V6, P36, DOI 10.1111/j.1541-4337.2007.00016.x	7	63	63	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					935	937		10.1016/j.jaci.2009.12.003	http://dx.doi.org/10.1016/j.jaci.2009.12.003			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20227750				2022-12-18	WOS:000276787900021
J	Skoner, D; Gentile, D; Bush, R; Fasano, MB; McLaughlin, A; Esch, RE				Skoner, David; Gentile, Deborah; Bush, Robert; Fasano, Mary Beth; McLaughlin, Anne; Esch, Robert E.			Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinoconjunctivitis; maximum tolerable dose; medication score; subcutaneous immunotherapy; sublingual immunotherapy; symptom score	PEDIATRIC-PATIENTS; CLINICAL-TRIALS; EFFICACY; GRASS; RHINITIS; ASTHMA; METAANALYSIS; RESPONSES; CHILDREN; SAFETY	Background: Specific allergen immunotherapy is most often delivered subcutaneously, but sublingual immunotherapy may confer greater benefit in terms of tolerability and safety, accessibility, and improved antigen delivery. Objective: This randomized, double-blind, placebo-controlled trial was conducted to identify a safe and effective maintenance dose range of sublingual standardized glycerinated short ragweed pollen extract in adults with ragweed-induced rhinoconjunctivitis. Methods: In May 2006, a total of 115 patients with ragweed-induced rhinoconjunctivitis were randomly allocated to placebo (n = 40), medium-dose extract (4.8 mu g Amb a 1/d; n = 39), or high-dose extract (48 mu g Amb a 1/d; n = 36). In a 1-day (rush) dose-escalation regimen, ragweed pollen extract was administered sublingually in incremental doses until maximum tolerable or scheduled dose was reached and then maintained during the ragweed pollen season. Patient diaries were used to monitor nasal and ocular symptoms and medication. The primary endpoint was symptom score. Results: Both active treatment groups achieved a 15% reduction in total rhinoconjunctivitis symptom scores compared with placebo during the entire ragweed pollen season, but the difference was not statistically significant (P > .10) However, in an analysis of covariance correcting for preseasonal symptoms, both mean daily symptom scores (0.19 +/- 1.16 vs 1.00 +/- 2.30) and medication scores (0.0003 +/- 1.64 vs 0.63 +/- 1.06) for the entire pollen season were significantly reduced in the high-dose versus placebo groups, respectively (P <= .05). Ragweed-specific IgG, IgG(4), and IgA antibodies were increased after treatment in the medium- and high-dose groups and not the placebo group. Frequency of adverse events was similar between, the placebo and treatment groups, but oral-mucosal adverse events occurred more often with treatment. Conclusion: Standardized glycerinated short ragweed pollen extract administered sublingually at maintenance doses of 4.8 to 48 mu g Amb a 1/d was safe and can induce favorable clinical and immunologic changes in ragweed-sensitive subjects. However, additional trials are needed to establish efficacy. (J Allergy Clin Immunol 2010;125:660-6.)	[Skoner, David; Gentile, Deborah] Drexel Univ, Coll Med, Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; [Bush, Robert] Univ Wisconsin, Sch Med & Publ Hlth, William S Middleton Mem Vet Adm Hosp, Madison, WI 53706 USA; [Fasano, Mary Beth] Univ Iowa, Hosp & Clin, Iowa City, IA 52242 USA; [McLaughlin, Anne] Welborn Clin Res Ctr, Evansville, IN USA; [Esch, Robert E.] Greer Labs Inc, Lenoir, NC USA	Allegheny General Hospital; Drexel University; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Iowa	Skoner, D (corresponding author), Drexel Univ, Coll Med, Allegheny Gen Hosp, 320 EN Ave, Pittsburgh, PA 15212 USA.	dskoner@wpahs.org		Fasano, Mary/0000-0001-8468-1605	Greer Laboratories, Inc; Novartis Pharmaceuticals Corp; Schering Plough; Greer Laboratories; NIH; Lev Pharmaceuticals; Merck; Pharming; GlaxoSmithKline; Map Pharmaceuticals	Greer Laboratories, Inc; Novartis Pharmaceuticals Corp(Novartis); Schering Plough(Merck & CompanySchering Plough Corporation); Greer Laboratories; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lev Pharmaceuticals; Merck(Merck & Company); Pharming; GlaxoSmithKline(GlaxoSmithKline); Map Pharmaceuticals	Editorial support was funded by Greer Laboratories, Inc.; Disclosure of potential conflict of interest: D. Skoner is on the speakers' bureau for AstraZeneca, GlaxoSmithKline, Merck. Inc, and Novartis Pharmaceutical Corp; receives research support from Novartis Pharmaceuticals Corp, and Schering Plough; and is a consultant for Merck, Inc. D. Gentile receives research support from Greer Laboratories. R. Bush invests in TEVA Pharmaceuticals and receives research support from the NIH and Greer Laboratories. M. B. Fasano receives research support from Greer Laboratories, Lev Pharmaceuticals, and CSL-Behring and is on the Board of Directors for ABAI. A. McLaughlin receives research support from Greer, Lev Pharmaceuticals, Merck, Pharming, GlaxoSmithKline, Novartis, and Map Pharmaceuticals and receives speakers' honoraria from Merck, Schering. GlaxoSmithKline, AstraZeneca, and Sanofi-Aventis. R. E. Esch is employed by Greer Laboratories.	Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Bordignon V, 2006, ANN ALLERG ASTHMA IM, V97, P158, DOI 10.1016/S1081-1206(10)60006-3; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425, DOI 10.1016/S1081-1206(10)61408-1; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Calderon MA, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001936.PUB2; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Clark J, 2007, ALLERGY, V62, P1023, DOI 10.1111/j.1398-9995.2007.01469.x; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; Cox L, 2007, CURR ALLERGY ASTHM R, V7, P410, DOI 10.1007/s11882-007-0063-6; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; DOYLE WJ, 1994, J ALLERGY CLIN IMMUN, V93, P236; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Esch RE, 2008, CURR OPIN OTOLARYNGO, V16, P260, DOI 10.1097/MOO.0b013e3282fc706f; Esch RE, 2008, ANN ALLERG ASTHMA IM, V100, P475, DOI 10.1016/S1081-1206(10)60474-7; Finegold I, 2007, ALLERGY ASTHMA PROC, V28, P44, DOI 10.2500/aap.2007.28.2971; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Frew AJ, 1999, J ALLERGY CLIN IMMUN, V104, P267, DOI 10.1016/S0091-6749(99)70362-3; Garcia-Marcos Luis, 2007, Inflammation & Allergy Drug Targets, V6, P117; Keskin O, 2006, PEDIATR ALLERGY IMMU, V17, P396, DOI 10.1111/j.1399-3038.2006.00442.x; Klimek L, 2005, OTOLARYNG HEAD NECK, V133, P538, DOI 10.1016/j.otohns.2005.07.020; Leatherman BD, 2007, OTOLARYNG HEAD NECK, V136, pS1, DOI 10.1016/j.otohns.2006.11.057; Malling HJ, 2006, ALLERGY, V61, P24, DOI 10.1111/j.1398-9995.2006.01158.x; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Pfaar O, 2008, ANN ALLERG ASTHMA IM, V100, P256, DOI 10.1016/S1081-1206(10)60451-6; RAJAKULASINGAM K, 2003, MIDDLETONS ALLERGY P, P644; Rossi RE, 2007, VACCINE, V25, P957, DOI 10.1016/j.vaccine.2006.08.040; Subiza J, 2008, CLIN EXP ALLERGY, V38, P987, DOI 10.1111/j.1365-2222.2008.02995.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wilson DR, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002893	35	63	64	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					660	666		10.1016/j.jaci.2009.12.931	http://dx.doi.org/10.1016/j.jaci.2009.12.931			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20153030	Bronze			2022-12-18	WOS:000275883200023
J	von Bubnoff, D; Andres, E; Hentges, F; Bieber, T; Michel, T; Zimmer, J				von Bubnoff, Dagmar; Andres, Emmanuel; Hentges, Francois; Bieber, Thomas; Michel, Tatiana; Zimmer, Jacques			Natural killer cells in atopic and autoimmune diseases of the skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Natural killer cells; skin; allergy; autoimmunity	HUMAN NK CELLS; HUMAN HAIR FOLLICLE; T-CELL; DENDRITIC CELLS; IFN-GAMMA; INTERFERON-GAMMA; GENE-EXPRESSION; INTERLEUKIN 22; INHIBITORY RECEPTORS; ADAPTIVE IMMUNITY	Natural killer (NK) cells are best known for their ability to recognize and kill tumor cells and virally infected cells and for their ability to produce large amounts of some cytokines, such as IEFN-gamma. Recent research has substantially expanded our view on the function of NK cells in the immune system in health and disease. In addition to the better-studied functions in cancer and autoimmunity, contributions from NK cells to allergies and various skin diseases have emerged. We briefly recount the traditional NK cell functions before focusing on their roles in atopic dermatitis, psoriasis, alopecia areata, and pemphigus vulgaris. Although this field is still developing, strong data are available that indicate NK cell involvement. In patients with allergic diseases, the production of T(H)2 cytokines by NK cells contributes to the known immune deviation. In patients with psoriasis, their pathophysiologic role seems to be especially the production of IFN-gamma. NK cell overactivation can be found in patients with alopecia areata and pemphigus vulgaris. Many details are still unclear; however, we believe that there is solid evidence that NK cells actively participate in a number of diseases that have not been traditionally linked to this type of lymphocyte. (J Allergy Clin Immunol 2010;125:60-8.)	[Hentges, Francois; Michel, Tatiana; Zimmer, Jacques] CRP Sante, Lab Immunogenet & Allergol, L-1526 Luxembourg, Luxembourg; [von Bubnoff, Dagmar; Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, D-5300 Bonn, Germany; [Andres, Emmanuel] Univ Hosp Strasbourg, Dept Internal Med, Med Clin B, Strasbourg, France	Luxembourg Institute of Health; University of Bonn; CHU Strasbourg	Zimmer, J (corresponding author), CRP Sante, Lab Immunogenet & Allergol, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg.	jacques.zimmer@crp-sante.lu	Andres, E/AAY-3767-2020; Andres, Emmanuel/AAX-1502-2020	Andres, Emmanuel/0000-0002-7914-7616; Michel, Tatiana/0000-0002-0146-9236; Zimmer, Jacques/0000-0002-7118-6944	Ministry of Culture, Higher Education, and Research (MCESR), Luxembourg; National Research Fund (FNR), Luxembourg	Ministry of Culture, Higher Education, and Research (MCESR), Luxembourg; National Research Fund (FNR), Luxembourg(Luxembourg National Research Fund)	Supported by grants from the Ministry of Culture, Higher Education, and Research (MCESR), Luxembourg, and the National Research Fund (FNR), Luxembourg.	Akkoc T, 2008, J ALLERGY CLIN IMMUN, V121, P652, DOI 10.1016/j.jaci.2007.12.1171; Aktas E, 2005, CLIN EXP IMMUNOL, V140, P301, DOI 10.1111/j.1365-2249.2005.02777.x; Alecu M, 2009, J EUR ACAD DERMATOL, V23, P288, DOI 10.1111/j.1468-3083.2008.03035.x; Anderson SK, 2001, IMMUNOL REV, V181, P79, DOI 10.1034/j.1600-065X.2001.1810106.x; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Arnon TI, 2005, NAT IMMUNOL, V6, P515, DOI 10.1038/ni1190; Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A; Assarsson E, 2004, J IMMUNOL, V173, P174, DOI 10.4049/jimmunol.173.1.174; BAADSGAARD O, 1986, ACTA DERM-VENEREOL, V66, P266; Benghiat Fleur Samantha, 2009, Transplant Rev (Orlando), V23, P11, DOI 10.1016/j.trre.2008.08.007; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Boniface K, 2008, IMMUNOL REV, V226, P132, DOI 10.1111/j.1600-065X.2008.00714.x; Bos JD, 2005, BRIT J DERMATOL, V152, P1098, DOI 10.1111/j.1365-2133.2005.06645.x; Brandt CS, 2009, J EXP MED, V206, P1495, DOI 10.1084/jem.20090681; Brillard E, 2007, EXP HEMATOL, V35, P416, DOI 10.1016/j.exphem.2006.12.004; Brodin P, 2009, TRENDS IMMUNOL, V30, P143, DOI 10.1016/j.it.2009.01.006; Buentke E, 2002, J INVEST DERMATOL, V119, P850, DOI 10.1046/j.1523-1747.2002.00132.x; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Cameron AL, 2003, BRIT J DERMATOL, V149, P160, DOI 10.1046/j.1365-2133.2003.05319.x; Cameron AL, 2002, ARCH DERMATOL RES, V294, P363, DOI 10.1007/s00403-002-0349-4; Campbell DE, 1999, CLIN EXP IMMUNOL, V115, P377; Carayannopoulos LN, 2004, CURR OPIN IMMUNOL, V16, P26, DOI 10.1016/j.coi.2003.11.003; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Cetin ED, 2009, AM J DERMATOPATH, V31, P53, DOI 10.1097/DAD.0b013e318185a66e; Chiarini C, 2008, AM J CLIN PATHOL, V130, P526, DOI 10.1309/NG60Y7V0WNUFH4LA; Christoph T, 2000, BRIT J DERMATOL, V142, P862, DOI 10.1046/j.1365-2133.2000.03464.x; Colonna M, 2009, IMMUNITY, V31, P15, DOI 10.1016/j.immuni.2009.06.008; Cooper MA, 2009, EMBO REP, V10, P1103, DOI 10.1038/embor.2009.203; Cooper MA, 2009, P NATL ACAD SCI USA, V106, P1915, DOI 10.1073/pnas.0813192106; de Cid R, 2009, NAT GENET, V41, P211, DOI 10.1038/ng.313; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; Deniz G, 2008, J IMMUNOL, V180, P850, DOI 10.4049/jimmunol.180.2.850; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Elias PM, 2008, J ALLERGY CLIN IMMUN, V121, P1337, DOI 10.1016/j.jaci.2008.01.022; Eyerich K, 2008, J INVEST DERMATOL, V128, P2640, DOI 10.1038/jid.2008.139; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fehniger TA, 1999, J IMMUNOL, V162, P4511; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Fernandez NC, 2005, BLOOD, V105, P4416, DOI 10.1182/blood-2004-08-3156; Freyschmidt-Paul P, 2006, BRIT J DERMATOL, V155, P515, DOI 10.1111/j.1365-2133.2006.07377.x; Gilhar A, 2006, AUTOIMMUN REV, V5, P64, DOI 10.1016/j.autrev.2005.07.001; Gilhar A, 2002, J INVEST DERMATOL, V119, P384, DOI 10.1046/j.1523-1747.2002.01812.x; Giuliani M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002241; Gregoire C, 2007, IMMUNOL REV, V220, P169, DOI 10.1111/j.1600-065X.2007.00563.x; Hanna J, 2004, J CLIN INVEST, V114, P1612, DOI 10.1172/JCI200422787; Homey Bernhard, 2007, Chem Immunol Allergy, V93, P181, DOI 10.1159/000100895; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Ito T, 2005, J INVEST DERMATOL, V125, P1139, DOI 10.1111/j.0022-202X.2005.23927.x; Ito T, 2004, AM J PATHOL, V164, P623, DOI 10.1016/S0002-9440(10)63151-3; Ito T, 2008, J INVEST DERMATOL, V128, P1196, DOI 10.1038/sj.jid.5701183; Kalkunte SS, 2009, J IMMUNOL, V182, P4085, DOI 10.4049/jimmunol.0803769; Kane KP, 2001, IMMUNOL REV, V181, P104, DOI 10.1034/j.1600-065X.2001.1810108.x; Katsuta M, 2006, J IMMUNOL, V176, P7736, DOI 10.4049/jimmunol.176.12.7736; Kawakami Y, 2009, J EXP MED, V206, P1219, DOI 10.1084/jem.20082835; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kheradmand T, 2008, J LEUKOCYTE BIOL, V83, P1128, DOI 10.1189/jlb.0907626; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Kimura K, 2008, INT J PSYCHOPHYSIOL, V70, P63, DOI 10.1016/j.ijpsycho.2008.05.580; Kisich KO, 2008, J ALLERGY CLIN IMMUN, V122, P62, DOI 10.1016/j.jaci.2008.04.022; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Koning H, 1996, PEDIATR RES, V40, P363, DOI 10.1203/00006450-199609000-00001; La Gruta NL, 2001, AUTOIMMUNITY, V34, P147, DOI 10.3109/08916930109001962; Lambiase A, 2007, MOL VIS, V13, P1562; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; Lo CKC, 2008, ARTHRITIS RHEUM, V58, P2700, DOI 10.1002/art.23760; Louten J, 2009, J ALLERGY CLIN IMMUN, V123, P1004, DOI 10.1016/j.jaci.2009.04.003; Lowes MA, 2008, J INVEST DERMATOL, V128, P1207, DOI 10.1038/sj.jid.5701213; Loza MJ, 2002, BLOOD, V99, P1273, DOI 10.1182/blood.V99.4.1273; Luci C, 2009, NAT IMMUNOL, V10, P75, DOI 10.1038/ni.1681; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Maroof A, 2008, IMMUNITY, V29, P295, DOI 10.1016/j.immuni.2008.06.012; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; McGonagle D, 2006, PLOS MED, V3, P1242, DOI 10.1371/journal.pmed.0030297; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; NICKOLOFF BJ, 1991, ARCH DERMATOL, V127, P871, DOI 10.1001/archderm.127.6.871; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; O'Connor GM, 2006, IMMUNOLOGY, V117, P1, DOI 10.1111/j.1365-2567.2005.02256.x; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Ottaviani C, 2006, EUR J IMMUNOL, V36, P118, DOI 10.1002/eji.200535243; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Paus R, 2003, J INVEST DERM SYMP P, V8, P188, DOI 10.1046/j.1087-0024.2003.00807.x; Peritt D, 1998, J IMMUNOL, V161, P5821; Poli A, 2009, IMMUNOLOGY, V126, P458, DOI 10.1111/j.1365-2567.2008.03027.x; Purwar R, 2006, J INVEST DERMATOL, V126, P1043, DOI 10.1038/sj.jid.5700085; RANKI A, 1984, J INVEST DERMATOL, V83, P7, DOI 10.1111/1523-1747.ep12261627; Raulet DH, 2006, NAT REV IMMUNOL, V6, P520, DOI 10.1038/nri1863; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Reich K, 2005, LANCET, V366, P1367, DOI 10.1016/S0140-6736(05)67566-6; Riccieri V, 2000, LUPUS, V9, P333, DOI 10.1191/096120300678828460; Rieg S, 2005, J IMMUNOL, V174, P8003, DOI 10.4049/jimmunol.174.12.8003; Roark CL, 2008, CURR OPIN IMMUNOL, V20, P353, DOI 10.1016/j.coi.2008.03.006; Roy S, 2008, J IMMUNOL, V180, P1729, DOI 10.4049/jimmunol.180.3.1729; Ruckert R, 1998, J INVEST DERMATOL, V111, P25, DOI 10.1046/j.1523-1747.1998.00228.x; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Satoh-Takayama N, 2008, IMMUNITY, V29, P958, DOI 10.1016/j.immuni.2008.11.001; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V107, P171, DOI 10.1067/mai.2001.111850; Schuster M, 2000, AM J RESP CRIT CARE, V161, P558, DOI 10.1164/ajrccm.161.2.9812021; Shimada Y, 1999, J ALLERGY CLIN IMMUN, V104, P163, DOI 10.1016/S0091-6749(99)70128-4; Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928; Stern JNH, 2008, CLIN EXP IMMUNOL, V152, P472, DOI 10.1111/j.1365-2249.2008.03638.x; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Takahashi H, 2007, J INVEST DERMATOL, V127, P324, DOI 10.1038/sj.jid.5700527; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Vivier E, 2009, NAT REV IMMUNOL, V9, P229, DOI 10.1038/nri2522; von Bubnoff D, 2001, J ALLERGY CLIN IMMUN, V108, P329, DOI 10.1067/mai.2001.117457; Walker C, 1998, J IMMUNOL, V161, P1962; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Wollenberg A, 2002, J INVEST DERMATOL, V118, P327, DOI 10.1046/j.0022-202x.2001.01665.x; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wollenberg A, 2007, CLIN REV ALLERG IMMU, V33, P35, DOI 10.1007/s12016-007-0032-9; Yokoyama WM, 2004, ANNU REV IMMUNOL, V22, P405, DOI 10.1146/annurev.immunol.22.012703.104711; Zaba LC, 2009, J INVEST DERMATOL, V129, P79, DOI 10.1038/jid.2008.194; Zenewicz LA, 2008, EUR J IMMUNOL, V38, P3265, DOI 10.1002/eji.200838655; Zhang C, 2006, CELL MOL IMMUNOL, V3, P241; Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505; Zhou RB, 2007, J IMMUNOL, V178, P2141, DOI 10.4049/jimmunol.178.4.2141; Zingoni A, 2004, J IMMUNOL, V173, P3716, DOI 10.4049/jimmunol.173.6.3716	126	63	65	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					60	68		10.1016/j.jaci.2009.11.020	http://dx.doi.org/10.1016/j.jaci.2009.11.020			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	20109737				2022-12-18	WOS:000273660500006
J	Gronlund, H; Adedoyin, J; Commins, SP; Platts-Mills, TAE; van Hage, M				Gronlund, Hans; Adedoyin, Justus; Commins, Scott P.; Platts-Mills, Thomas A. E.; van Hage, Marianne			The carbohydrate galactose-alpha-1,3-galactose is a major IgE-binding epitope on cat IgA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SPECIFICITY; ALLERGENS		[Gronlund, Hans; Adedoyin, Justus; van Hage, Marianne] Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden; [Commins, Scott P.; Platts-Mills, Thomas A. E.] Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Karolinska Institutet; University of Virginia	Gronlund, H (corresponding author), Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden.	hans.gronlund@ki.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Platts-Mills, Thomas/0000-0002-1263-329X; Gronlund, Hans/0000-0003-4882-7624	NIAID NIH HHS [K08 AI085190, L30 AI080151-02, L30 AI080151, K08 AI085190-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI085190] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adedoyin J, 2006, J IMMUNOL METHODS, V310, P117, DOI 10.1016/j.jim.2006.01.001; Adedoyin J, 2007, J ALLERGY CLIN IMMUN, V119, P640, DOI 10.1016/j.jaci.2006.11.637; Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; Gronlund H, 2003, J BIOL CHEM, V278, P40144, DOI 10.1074/jbc.M301416200; Macher BA, 2008, BBA-GEN SUBJECTS, V1780, P75, DOI 10.1016/j.bbagen.2007.11.003	9	63	66	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1189	1191		10.1016/j.jaci.2009.03.011	http://dx.doi.org/10.1016/j.jaci.2009.03.011			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19362358	Bronze, Green Accepted			2022-12-18	WOS:000266309400036
J	Marsden, PA; Smith, JA; Kelsall, AA; Owen, E; Naylor, JR; Webster, D; Sumner, H; Alam, U; McGuinness, K; Woodcock, AA				Marsden, Paul A.; Smith, Jaclyn A.; Kelsall, Angela A.; Owen, Emily; Naylor, Jonathan R.; Webster, Deborah; Sumner, Helen; Alam, Uazman; McGuinness, Kevin; Woodcock, Ashley A.			A comparison of objective and subjective measures of cough in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cough; asthma; objective cough monitoring; quality of life	RESPIRATORY-DISEASES; REFLEX SENSITIVITY; VARIANT ASTHMA; ADULTS; CHALLENGE; SYMPTOMS; LIFE; QUESTIONNAIRE; METHACHOLINE; ZAFIRLUKAST	Background: Cough is widely recognized as a key symptom in the diagnosis and the monitoring of asthma, but little is known about how best to assess cough in asthma. Objective: To determine how objective cough rates correlate with subjective measures of cough in asthma. Methods: We studied 56 subjects, median age 42.0 years (range, 28.5-71), 34 (60.7%) female, with asthma. Subjects performed cough reflex sensitivity testing (concentration of citric acid causing 2 and 5 coughs [C2 and C5]), 24-hour fully ambulatory cough recordings, subjectively scored the severity of their cough (visual analog scales and 0-5 score) and completed a cough-related quality of life questionnaire (Leicester Cough Questionnaire). Ambulatory cough recordings were manually counted and reported in cough seconds per hour (cs/h). Results: The median time spent coughing was 2.6 cs/h (range, 0.0-14.2), with subjects spending more time coughing by day (median, 3.9 cs/h [0.0-18.5]) than by night (median, 0.3 cs/h [0.0-8.7]; P < .001). A weak inverse relationship was seen between day cough rates and log(10)C2 (r = -0.39; P = .03) but not log(10)C5 (r = 4.08; P = .65). Objective time spent coughing was also weak-moderately associated with subjective cough scores and visual analog scales, and most strongly correlated with cough-related quality of life (r = -0.54; P < .001). Conclusion: Subjective measures of cough and cough reflex sensitivity are poor surrogates for objective cough frequency in asthma. When designing studies to assess interventions for cough in asthma, we advocate a combination of both objective measures of cough and cough-related quality of life. (J Allergy Clin Immunol 2008;122:903-7.)	[Marsden, Paul A.; Kelsall, Angela A.; Owen, Emily; Naylor, Jonathan R.; Webster, Deborah; Alam, Uazman; McGuinness, Kevin] Univ S Manchester Hosp, N W Lung Res Ctr, Natl Hlth Serv Fdn Trust, Manchester M23 9LT, Lancs, England; [Smith, Jaclyn A.; Sumner, Helen; Woodcock, Ashley A.] Univ Manchester, Resp Res Grp, Manchester M13 9PL, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Manchester	Marsden, PA (corresponding author), Univ S Manchester Hosp, N W Lung Res Ctr, Natl Hlth Serv Fdn Trust, Southmoor Rd, Manchester M23 9LT, Lancs, England.	Paul.A.Marsden@manchester.ac.uk	Alam, Uazman/I-9173-2019	Alam, Uazman/0000-0002-3190-1122; Woodcock, Ashley/0000-0002-5428-8578; Smith, Jaclyn/0000-0001-8837-4928	North West Lung Research Centre Endowment Fund; Schering-Plough; AstraZeneca; Medical Research Council [G0701918] Funding Source: researchfish; MRC [G0701918] Funding Source: UKRI	North West Lung Research Centre Endowment Fund; Schering-Plough(Merck & CompanySchering Plough Corporation); AstraZeneca(AstraZeneca); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the North West Lung Research Centre Endowment Fund.; Disclosure of potential conflict of interest: J. A. Smith is a consultant for Schering-Plough, receives grant support from Schering-Plough. and is an inventor on a cough-monitoring patent owned by the University Hospital of South Manchester Trust, patent licensed to Vitalograph Ltd. A. A. Woodcock is a consultant for GlaxoSmithKline. Chiesi, and Schering-Plough; receives grant support front Schering-Plough and AstraZeneca; and is a co-inventor of an ambulatory cough monitor patent owned by the University Hospital of South Manche (er and licensed by Vitalograph Ltd. The rest of the authors have declared that they have no conflict of interest.	Birring SS, 2003, THORAX, V58, P339, DOI 10.1136/thorax.58.4.339; Braido F, 2006, J INVEST ALLERG CLIN, V16, P110; *BRIT THOR SOC, 2005, BTS SIGN GUID MAN AS; Chang AB, 2007, PULM PHARMACOL THER, V20, P371, DOI 10.1016/j.pupt.2006.10.004; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; de Marco R, 2006, J ALLERGY CLIN IMMUN, V117, P1249, DOI 10.1016/j.jaci.2006.03.019; Decalmer SC, 2007, THORAX, V62, P329, DOI 10.1136/thx.2006.067413; Di Franco A, 2001, PULM PHARMACOL THER, V14, P35, DOI 10.1006/pupt.2000.0264; Dicpinigaitis PV, 2002, J ASTHMA, V39, P291, DOI 10.1081/JAS-120002285; Dicpinigaitis PV, 1999, J ASTHMA, V36, P265, DOI 10.3109/02770909909075410; French CT, 2002, CHEST, V121, P1123, DOI 10.1378/chest.121.4.1123; *GINA, 2007, GLOB STRAT ASTHM MAN; HSU JY, 1994, EUR RESPIR J, V7, P1246, DOI 10.1183/09031936.94.07071246; Irwin RS, 1997, ARCH INTERN MED, V157, P1981, DOI 10.1001/archinte.157.17.1981; Janson C, 2001, EUR RESPIR J, V18, P647, DOI 10.1183/09031936.01.00098701; Kelsall A, 2008, EUR RESPIR J, V32, P175, DOI 10.1183/09031936.00101307; Langley SJ, 2003, ANN ALLERG ASTHMA IM, V91, P398, DOI 10.1016/S1081-1206(10)61688-2; Manfreda J, 2001, CAN MED ASSOC J, V164, P995; McGarvey LPA, 1998, THORAX, V53, P738, DOI 10.1136/thx.53.9.738; Osman LM, 2001, THORAX, V56, P138, DOI 10.1136/thorax.56.2.138; Polley L, 2008, CHEST, V134, P295, DOI 10.1378/chest.07-0141; Smith J, 2006, J ALLERGY CLIN IMMUN, V117, P831, DOI 10.1016/j.jaci.2005.09.055; SMITH J, 2004, THESIS U MANCHESTER; Smith JA, 2006, THORAX, V61, P425, DOI 10.1136/thx.2005.050963; SMITH JA, 2002, AM J RESP CRIT CARE, V165, pA832; Smith J, 2006, CHEST, V130, P379, DOI 10.1016/S0012-3692(15)51851-5; Teeter JG, 1998, CHEST, V113, P272, DOI 10.1378/chest.113.2.272; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	28	63	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2008	122	5					903	907		10.1016/j.jaci.2008.08.029	http://dx.doi.org/10.1016/j.jaci.2008.08.029			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	372ZF	18842290	Bronze			2022-12-18	WOS:000260940100007
J	Castigli, E; Wilson, SA; Elkhal, A; Ozcan, E; Garibyan, L; Geha, RS				Castigli, Emanuela; Wilson, Stephen A.; Elkhal, Abdallah; Ozcan, Esra; Garibyan, Lilit; Geha, Raif S.			Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD40; transmembrane activator and calcium modulator and cyclophilin ligand interactor; common variable immunodeficiency; plasma cell; immunoglobulin; B cells	COMMON VARIABLE IMMUNODEFICIENCY; BAFF; APRIL; TACI; RECEPTOR; RECOMBINATION; EXPRESSION; MATURATION; GENERATION; MECHANISM	Background: Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) is a receptor used by B cell-activating factor of the TNF family and a proliferation-inducing ligand (APRIL) to induce isotype switching independently of CD40 and is mutated in patients with common variable immunodeficiency. Objective: We sought to determine whether TACI and CD40 cooperate in inducing class switch recombination and immunoglobulin production. Methods: Naive mouse B cells were stimulated with suboptimal concentrations of anti-CD40 plus IL-4 in the presence or absence of APRIL or anti-TACI IgG, and IgE production was measured by means of ELISA. mRNA for Cy-l and C epsilon germ-line transcripts, activation-induced cytidine deaminase, and mature gamma(1) and F transcripts were measured by means of RT-PCR. Plasmablasts were enumerated by using syndecan-l/ CD138 staining. Interferon regulatory factor 4, B lymphocyte-induced maturation protein 1, and IL6 mRNA expression was measured by using quantitative PCR. Results: TACI ligation enhanced IgG, and IgE secretion by naive murine B cells stimulated by anti-CD40 plus IL-4, with little effect on B-cell proliferation or class switch recombination. In contrast, TACI ligation of anti-CD40 plus IL-4-stimulated B cells induced a significant increase in syndecans-1/CD138-positive cells. TACI ligation caused a modest but significant increase in the expression of interferon regulatory factor 4, with no detectable change in B lymphocyte-induced maturation protein 1 expression. Conclusion: TACI and CD40 signaling converge to promote B-cell differentiation into plasmablasts. Clinical implications: Our data suggest that TACI dysfunction could contribute to the impaired antibody response to T-dependent antigens in common variable immunodeficiency.	Childrens Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University	Geha, RS (corresponding author), Childrens Hosp, Div Immunol, 1 Blackfan Circle, Boston, MA 02115 USA.	Raif.Geha@childrens.harvard.edu	Garibyan, Lilit/AAR-1638-2020		NIAID NIH HHS [AI031136, R21 AI065762-01, P01 AI031541, R01 AI031136, U19 AI031541, AI065762, AI031541, R21 AI065762-02, R21 AI065762, N01AI30070] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031541, U19AI031541, N01AI030070, P01AI031541, R21AI065762, R01AI031136] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahonen CL, 2002, NAT IMMUNOL, V3, P451, DOI 10.1038/ni792; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000; Castigli E, 2007, NAT GENET, V39, P430, DOI 10.1038/ng0407-430; Cunningham-Rundles C, 2005, NAT REV IMMUNOL, V5, P880, DOI 10.1038/nri1713; FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Hasbold J, 2004, NAT IMMUNOL, V5, P55, DOI 10.1038/ni1016; He B, 2004, J IMMUNOL, V173, P4479, DOI 10.4049/jimmunol.173.7.4479; Hendriks J, 2005, CELL DEATH DIFFER, V12, P637, DOI 10.1038/sj.cdd.4401647; Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309; Jabara HH, 2005, J ALLERGY CLIN IMMUN, V115, P856, DOI 10.1016/j.jaci.2005.01.020; Jabara HH, 2002, IMMUNITY, V17, P265, DOI 10.1016/S1074-7613(02)00394-1; Klein U, 2006, NAT IMMUNOL, V7, P773, DOI 10.1038/ni1357; Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Mongini PKA, 2006, J IMMUNOL, V176, P6736, DOI 10.4049/jimmunol.176.11.6736; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Ng LG, 2006, EUR J IMMUNOL, V36, P1837, DOI 10.1002/eji.200635956; Ni CZ, 2004, J IMMUNOL, V173, P7394, DOI 10.4049/jimmunol.173.12.7394; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Ohkubo Y, 2005, J IMMUNOL, V174, P7703, DOI 10.4049/jimmunol.174.12.7703; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Sakurai D, 2007, BLOOD, V109, P2961, DOI 10.1182/blood-2006-08-041772; Sakurai D, 2007, EUR J IMMUNOL, V37, P110, DOI 10.1002/eji.200636623; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Sciammas R, 2006, IMMUNITY, V25, P225, DOI 10.1016/j.immuni.2006.07.009; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; von Bulow GU, 2001, IMMUNITY, V14, P573, DOI 10.1016/S1074-7613(01)00130-3; Wols HAM, 2002, J IMMUNOL, V169, P4213, DOI 10.4049/jimmunol.169.8.4213; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Xu SL, 2001, MOL CELL BIOL, V21, P4067, DOI 10.1128/MCB.21.12.4067-4074.2001	33	63	65	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					885	891		10.1016/j.jaci.2007.06.012	http://dx.doi.org/10.1016/j.jaci.2007.06.012			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17689597	Green Accepted			2022-12-18	WOS:000250157700024
J	Sever, ML; Arbes, SJ; Gore, JC; Santangelo, RG; Vaughn, B; Mitchell, H; Schal, C; Zeldin, DC				Sever, Michelle L.; Arbes, Samuel J., Jr.; Gore, J. Chad; Santangelo, Richard G.; Vaughn, Ben; Mitchell, Herman; Schal, Coby; Zeldin, Darryl C.			Cockroach allergen reduction by cockroach control alone in low-income urban homes: A randomized control trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroaches; cockroach allergen; Bla g 1; Bla g 2; indoor allergens; intervention trial	INTEGRATED PEST-MANAGEMENT; INNER-CITY HOMES; ENVIRONMENTAL INTERVENTION; ASTHMA; COMMUNITY; ABATEMENT; EXPOSURE; CHILDREN; BLA-G-1	Background: We previously reported significant reductions in cockroach allergen concentrations in urban homes by reducing cockroach infestations. Objective: To determine the effectiveness of pest control performed by professional entomologists, compared with commercial companies, in reducing cockroach allergen. Methods: This 3-arm randomized controlled trial enrolled 60 cockroach-infested homes in North Carolina. Homes were randomly assigned to a control group or 1 of 2 treatment groups. Treatment 1 had insecticide baits placed by entomologists from North Carolina State University. Treatment 2 received pest control from a randomly assigned commercial company. Vacuumed dust sampling and cockroach trapping were conducted at 0, 6, and 12 months. Dust samples were analyzed by ELISA. Results: In treatment 1 homes, there were significant reductions in geometric mean trap counts compared with control and treatment 2 homes at 12 months. Relative to control, significant 12-month reductions in Bla g 1 were evident in treatment I homes at all sampled sites, except bedroom floor. From baseline to month 12, geometric mean Bla g 1 concentrations (U/g) decreased from 64.2 to 5.6 in kitchen, 10.6 to 1.1 in living room, 10.7 to 1.9 on bedroom floor, and 3.6 to 2.3 in bed. Treatment 2 homes showed no significant 12-month allergen reductions versus control. Conclusion: Reductions in Bla g 1 in cockroach-infested homes can be achieved by reducing infestations; however, the magnitude of allergen reduction is dependent on the thoroughness and effectiveness of cockroach eradication efforts. Clinical implications: Elimination of cockroaches is an effective method for reducing exposure to cockroach allergen.	NIEHS, NIH, Div Intramural Res, Res Triangle Pk, NC 27709 USA; N Carolina State Univ, Dept Entomol, Raleigh, NC 27695 USA; Rho Inc, Chapel Hill, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; North Carolina State University; Rho	Zeldin, DC (corresponding author), NIEHS, NIH, Div Intramural Res, POB 12233,MD D2-01, Res Triangle Pk, NC 27709 USA.	zeldin@nielis.nih.gov	Zeldin, Darryl C/Y-7091-2018; Schal, Coby/A-8717-2010	Zeldin, Darryl C/0000-0002-2087-7307; Schal, Coby/0000-0001-7195-6358; Sever, Michelle/0000-0002-2435-1214	Intramural NIH HHS [Z01 ES025041-10] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025041] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V113, P109, DOI 10.1016/j.jaci.2003.10.042; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Brenner BL, 2003, ENVIRON HEALTH PERSP, V111, P1649, DOI 10.1289/ehp.6069; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842, DOI 10.1016/S0091-6749(99)70296-4; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gore JC, 2007, ANNU REV ENTOMOL, V52, P439, DOI 10.1146/annurev.ento.52.110405.091313; Levy JI, 2006, SOC SCI MED, V63, P2191, DOI 10.1016/j.socscimed.2006.05.006; Miller DM, 2004, J ECON ENTOMOL, V97, P559, DOI 10.1603/0022-0493-97.2.559; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; Rogers L, 2002, CHEST, V122, P1580, DOI 10.1378/chest.122.5.1580; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SCHAL C, 1990, ANNU REV ENTOMOL, V35, P521, DOI 10.1146/annurev.en.35.010190.002513; Wang CL, 2006, J ECON ENTOMOL, V99, P879, DOI 10.1603/0022-0493-99.3.879; Wickham J.C, 1995, UNDERSTANDING CONTRO, P109; Williams LW, 1999, J ALLERGY CLIN IMMUN, V104, P702, DOI 10.1016/S0091-6749(99)70346-5	16	63	63	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					849	855		10.1016/j.jaci.2007.07.003	http://dx.doi.org/10.1016/j.jaci.2007.07.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17825893	Green Accepted			2022-12-18	WOS:000250157700019
J	Lerch, M; Keller, M; Britschgi, M; Kanny, G; Tache, V; Schmid, DA; Beeler, A; Gerber, BO; Luethi, M; Bircher, AJ; Christiansen, C; Pichler, WJ				Lerch, Marianne; Keller, Monika; Britschgi, Markus; Kanny, Gisele; Tache, Valerie; Schmid, Daphne A.; Beeler, Andreas; Gerber, Basil O.; Luethi, Michael; Bircher, Andreas J.; Christiansen, Cathrine; Pichler, Werner J.			Cross-reactivity patterns of T cells specific for iodinated contrast media	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						contrast media; hypersensitivity; T-cell fine; T-cell clone; cross-reactivity; precursor frequency	ALLERGIC CONTACT-DERMATITIS; HYPERSENSITIVITY REACTIONS; DRUG HYPERSENSITIVITY; POVIDONE-IODINE; SKIN-TESTS; ACTIVATION; FREQUENCY	Background: Approximately 3% of patients exposed to iodinated contrast media develop delayed hypersensitivity reactions. Objective: We wanted to better understand the molecular basis of contrast media cross-reactivity. Methods: Cross-reactivity was assessed by skin testing and measurement of T-cell activation (CD69 upregulation) and proliferation (H-3-thymidine uptake, 5,6-carboxyfluorescein diacetate succinimidyl ester staining) of PBMCs, T-cell lines, and T-cell clones of 2 patients with delayed hypersensitivity reactions to iohexol and iomeprol, respectively. Thirteen different contrast media and potassium iodide were compared. Results: Skin testing and analyses of PBMCs, T-cell lines, and clones showed broad cross-reactivity in both patients. Broad as well as more restricted cross-reactivity patterns were found in iohexol-specific and iomeprol-specific CD4(+) T-cell clones, whereas 1 iomeprol-specific CD8(+) T-cell clone showed no cross-reactivity at all. The reactivity to equimolar concentrations of iohexol and its dimer iodixanol was very similar, suggesting that the dimer was not more stimulatory than its monomer. Consistently low reactivity to iobitridol was found in both patients, but never to iodide. A frequency analysis of contrast medium-specific peripheral T cells gave values between 0.6% (iomeprol) and 0.05% (iobitridol). Conclusion: Clinically observed cross-reactivity between different contrast media is a result of the presence of contrast media-specific T cells, some of which show a broad cross-reactivity pattern. Iodide ions, known to be present at low concentration in contrast media solutions, do not seem to be the causative moiety. Clinical implications: Detailed in vitro analysis might help identify noncross-reactive contrast media.	Univ Bern, Clin Rheumatol & Clin Immunol Allergol, Inselspital, CH-3010 Bern, Switzerland; Univ Hosp Nancy, Dept Internal Med, Nancy, France; Univ Basel Hosp, Dept Dermatol, Allergy Unit, CH-4031 Basel, Switzerland; GE Healthcare, Res & Dev, Oslo, Norway	University of Bern; CHU de Nancy; Universite de Lorraine; University of Basel; General Electric	Pichler, WJ (corresponding author), Univ Bern, Clin Rheumatol & Clin Immunol Allergol, Inselspital, PKT2 D572, CH-3010 Bern, Switzerland.	werner.pichler@insel.ch	Lerch, Michael/AAC-8551-2019; Kanny, Gisèle/AHA-8910-2022	Lerch, Michael/0000-0002-2406-9972; Britschgi, Markus/0000-0001-6151-4257; Lerch, Marianne/0000-0001-8603-3310; Pichler, Werner J./0000-0002-8117-359X				Barbaud A, 2001, CONTACT DERMATITIS, V45, P321, DOI 10.1034/j.1600-0536.2001.450601.x; Beeler A, 2006, J ALLERGY CLIN IMMUN, V117, P455, DOI 10.1016/j.jaci.2005.10.030; Bircher AJ, 2006, AKTUEL DERMATOL, V32, P44, DOI 10.1055/s-2005-921136; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; Brockow K, 2005, TOXICOLOGY, V209, P189, DOI 10.1016/j.tox.2004.12.032; Brockow K, 2005, ALLERGY, V60, P150, DOI 10.1111/j.1398-9995.2005.00745.x; Brockow K, 2002, ALLERGY, V57, P45; Brockow K, 1999, J ALLERGY CLIN IMMUN, V104, P1107, DOI 10.1016/S0091-6749(99)70096-5; Christiansen C, 2000, EUR RADIOL, V10, P1965, DOI 10.1007/s003300000543; Christiansen C, 2005, TOXICOLOGY, V209, P185, DOI 10.1016/j.tox.2004.12.020; Courvoisier S, 1998, ALLERGY, V53, P1221, DOI 10.1111/j.1398-9995.1998.tb03846.x; Depta JPH, 2003, CURR OPIN ALLERGY CL, V3, P261, DOI 10.1097/01.all.0000083951.99396.30; GENEVEE C, 1992, EUR J IMMUNOL, V22, P1261, DOI 10.1002/eji.1830220522; Kanny G, 2005, J ALLERGY CLIN IMMUN, V115, P179, DOI 10.1016/j.jaci.2004.09.012; Lachapelle JM, 2005, CONTACT DERMATITIS, V52, P9, DOI 10.1111/j.0105-1873.2005.00479.x; LASSER EC, 1994, AM J ROENTGENOL, V162, P523, DOI 10.2214/ajr.162.3.8109489; Lee SK, 2005, CONTACT DERMATITIS, V52, P184, DOI 10.1111/j.0105-1873.2005.00499.x; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Nishioka K, 2000, CONTACT DERMATITIS, V42, P90, DOI 10.1034/j.1600-0536.2000.042002090.x; Reddy M, 2004, J IMMUNOL METHODS, V293, P127, DOI 10.1016/j.jim.2004.07.006; Romano A, 2005, TOXICOLOGY, V209, P169, DOI 10.1016/j.tox.2004.12.016; Romano A, 2002, RADIOLOGY, V225, P466, DOI 10.1148/radiol.2251011654; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; Vernassiere C, 2004, CONTACT DERMATITIS, V50, P359, DOI 10.1111/j.0105-1873.2004.00367.x; von Greyerz S, 1999, J IMMUNOL, V162, P595; Zanni MP, 1997, J IMMUNOL, V158, P1139	26	63	64	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1529	1536		10.1016/j.jaci.2007.02.007	http://dx.doi.org/10.1016/j.jaci.2007.02.007			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17412404				2022-12-18	WOS:000247232800032
J	Dijkstra, A; Howard, TD; Vonk, JM; Ampleford, EJ; Lange, LA; Bleecker, ER; Meyers, DA; Postma, DS				Dijkstra, A; Howard, TD; Vonk, JM; Ampleford, EJ; Lange, LA; Bleecker, ER; Meyers, DA; Postma, DS			Estrogen receptor 1 polymorphisms are associated with airway hyperresponsiveness and lung function decline, particularly in female subjects with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						estrogen receptor 1; gene polymorphism; asthma; airway hyperresponsiveness; lung function decline; sex	ESTROGEN-RECEPTOR-ALPHA; HORMONE REPLACEMENT THERAPY; PULMONARY-FUNCTION; FOLLOW-UP; RHEUMATOID-ARTHRITIS; GENE POLYMORPHISMS; RISK-FACTORS; EXPRESSION; WOMEN; POPULATION	Background: Sex hormones may contribute to the higher prevalence and severity of adult asthma in women compared with men. Objective: Sequence variants in the estrogen receptor a gene (ESRI) may alter estrogen action in asthma. Methods: Two hundred asthma probands and their families (n = 1249) were genotyped for 5 single nucleotide polymorphisms (SNPs) in the ESRI gene (intervening sequence 1 [IVS1]-1505A/G, IVS1-1415T/C, IVS1-397C/T, IVS1-351G/A and exon 1 +30T/C). Association with asthma and bronchial hyperresponsiveness (BHR) were tested. In the asthma probands, association of SNPs with BHR severity and annual FEV1 decline were determined. Results: No SNP was associated with asthma. IVS1-397 was significantly associated with the presence of BHR (P =.02) and interacted with sex; female subjects with the CT or TT genotype were at risk (P =.01). In asthma probands, all SNPs were associated with FEV1 decline. Exon1 +30 CT and TT group had an excess decline of 11.6 mL/y (P =.03) and 15.7 mL/y (P =.01), respectively, compared with the CC group. Of the IVS1 polymorphisms, IVS1-351G/A showed the strongest association, with the AA group having excess decline of 16.1 mL/y (P =.01) compared with the GG group. In subanalyses by sex, these associations were significant only in female subjects. Conclusion: ESR1 gene variants may affect development of BHR, particularly in female subjects. They may also lead to a more rapid lung function loss in patients with asthma, and in female subjects specifically. This may result from altered estrogen action, which affects lung development and/or airway remodeling. Further studies on ESR1 gene variations are important to understand better the origin of sex differences in asthma. Clinical implications: Variations in the gene encoding estrogen receptor a are associated with BHR and a more rapid annual lung function decline., especially in female subjects. Even though this has no diagnostic or clinical implication, it may open avenues for future sex-specific treatment in asthma.	Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9700 RB Groningen, Netherlands; Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol & Stat, NL-9700 RB Groningen, Netherlands; Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC USA	University of Groningen; University of Groningen; Wake Forest University; Wake Forest Baptist Medical Center	Postma, DS (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Hanzepl 1,POB 30-001, NL-9700 RB Groningen, Netherlands.	d.s.postma@int.umcg.nl	Vonk, Judith M/ABA-3009-2020; Vonk, Judith/K-8477-2019	Vonk, Judith M/0000-0001-7531-4547; Vonk, Judith/0000-0001-7531-4547				Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Abramson M, 1996, Respirology, V1, P291, DOI 10.1111/j.1440-1843.1996.tb00045.x; CARR BR, 1979, J CLIN ENDOCR METAB, V49, P346, DOI 10.1210/jcem-49-3-346; Cortazzo P, 2002, BIOCHEM BIOPH RES CO, V293, P537, DOI 10.1016/S0006-291X(02)00226-7; Cutolo M, 2002, ANN NY ACAD SCI, V966, P131, DOI 10.1111/j.1749-6632.2002.tb04210.x; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055; ELIASSON O, 1986, J ALLERGY CLIN IMMUN, V77, P87, DOI 10.1016/0091-6749(86)90328-3; Fagan JK, 2001, ANN ALLERG ASTHMA IM, V86, P177, DOI 10.1016/S1081-1206(10)62688-9; Fasco MJ, 2002, MOL CELL ENDOCRINOL, V188, P125, DOI 10.1016/S0303-7207(01)00750-X; Ferrero V, 2003, ARTERIOSCL THROM VAS, V23, P2223, DOI 10.1161/01.ATV.0000101181.81022.BF; Flores-Delgado G, 2001, BIOCHEM BIOPH RES CO, V283, P661, DOI 10.1006/bbrc.2001.4827; GODDEN DJ, 1994, AM J RESP CRIT CARE, V149, P106, DOI 10.1164/ajrccm.149.1.8111567; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10, DOI 10.1164/ajrccm/148.1.10; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; Hamano N, 1998, ALLERGY ASTHMA PROC, V19, P263, DOI 10.2500/108854198778557773; Herrington DM, 2002, CIRCULATION, V105, P1879, DOI 10.1161/01.CIR.0000016173.98826.88; Herrington DM, 2002, NEW ENGL J MED, V346, P967, DOI 10.1056/NEJMoa012952; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Ioannidis JPA, 2002, J BONE MINER RES, V17, P2048, DOI 10.1359/jbmr.2002.17.11.2048; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Kos-Kudla B, 2000, J CLIN PHARM THER, V25, P461, DOI 10.1046/j.1365-2710.2000.00310.x; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Logginidou H, 2000, CHEST, V117, P25, DOI 10.1378/chest.117.1.25; Lu H, 2002, ARTERIOSCL THROM VAS, V22, P817, DOI 10.1161/01.ATV.0000014424.18209.21; Massaro D, 2004, AM J PHYSIOL-LUNG C, V287, pL1154, DOI 10.1152/ajplung.00228.2004; Massaro GD, 1996, AM J PHYSIOL-LUNG C, V270, pL110, DOI 10.1152/ajplung.1996.270.1.L110; MASSARO GD, 1995, P NATL ACAD SCI USA, V92, P1105, DOI 10.1073/pnas.92.4.1105; Mollerup S, 2002, LUNG CANCER, V37, P153, DOI 10.1016/S0169-5002(02)00039-9; Oguzulgen IK, 2002, J ASTHMA, V39, P517, DOI 10.1081/JAS-120004921; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734, DOI 10.1164/ajrccm.157.6.9606088; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267, DOI 10.1164/ajrccm.155.4.9105065; Phiel KL, 2005, IMMUNOL LETT, V97, P107, DOI 10.1016/j.imlet.2004.10.007; Rijcken B, 1996, AM J RESP CRIT CARE, V154, pS246, DOI 10.1164/ajrccm/154.6_Pt_2.S246; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; Schaubel D, 1996, J ASTHMA, V33, P255, DOI 10.3109/02770909609055366; Strachan DP, 1996, BRIT MED J, V312, P1195; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; Ushiyama T, 1999, ANN RHEUM DIS, V58, P7, DOI 10.1136/ard.58.1.7; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; VANDERLENDE R, 1972, SCAND J RESPIR DIS, V53, P218; Vrieze A, 2003, J ALLERGY CLIN IMMUN, V112, P271, DOI 10.1067/mai.2003.1676; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58, DOI 10.1164/ajrccm/145.1.58; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; Zhao XJ, 2001, THORAX, V56, P205, DOI 10.1136/thorax.56.3.205	47	63	66	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					604	611		10.1016/j.jaci.2005.11.023	http://dx.doi.org/10.1016/j.jaci.2005.11.023			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522460				2022-12-18	WOS:000236263100016
J	Poole, JA; Meng, JF; Reff, M; Spellman, MC; Rosenwasser, LJ				Poole, JA; Meng, JF; Reff, M; Spellman, MC; Rosenwasser, LJ			Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD23; lumiliximab; antigen-presenting cell; T-cell response; costimulatory molecule	AFFINITY IGE RECEPTOR; B-CELLS; ALVEOLAR MACROPHAGES; HUMAN-LYMPHOCYTES; IMMUNOGLOBULIN-E; HLA-DR; EXPRESSION; CD23; FC-EPSILON-RII/CD23; COSTIMULATION	Background: CD23 plays a role in the regulation of IgE production and allergy-induced immune and inflammatory responses. A novel anti-CD23 monoclonal antibody, lumiliximab, is a potential therapeutic antibody recently demonstrated to be safe in human beings. Objective: This study investigated the effects of lumiliximab on allergen-induced immune responses from atopic subjects compared with blocking HLA-DR and costimulatory molecules, CD80 and CD86. Methods: Allergen-stimulated PBMCs from atopic subjects were pretreated with lumiliximab or antibodies to CD80, CD86, and HLA-DR. Cultures were analyzed for cell proliferation and IL-1 beta, TNF-alpha, and IL-5 cytokine secretion. An allergen-specific T-cell line was developed and analyzed for lymphocyte proliferation. in response to allergen with or without lumiliximab. Lumiliximab's effect on CD86 expression was evaluated by flow cytometry in the U937 monocytic cell line. Results: Lumiliximab reduced allergen-induced PBMC proliferation by 50% (n = 6; P = .006). In addition, cultures pretreated with lumiliximab had a reduction in the proinflammatory cytokines IL-1 beta (P < .003) and TNF-ci (P = .05) and the T(H)2 cytokine IL-5 (P = .002). Blocking CD86 resulted in greater reduction in proliferation than lumiliximab (P = .003) but similar effects in cytokine secretion. The anti-CD80 blocking antibody had no effect on cytokine production but did reduce proliferation. Furthermore, the addition of lumiliximab to cytokine stimulated U937 cells reduced surface expression of CD86 (P = .012). Conclusion: These results indicate that the anti-CD23 mAb, lumiliximab, may be involved in modulating antigen presenting cells and reducing T(H)2-type immune responses. The use of this antibody may provide clinical benefit for treating allergic diseases.	Univ Colorado, Hlth Sci Ctr, Div Clin Immunol & Allergy, Natl Jewish Med & Res Ctr,Dept Med, Denver, CO 80202 USA; Biogen Idec Inc, San Diego, CA USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Biogen	Poole, JA (corresponding author), Univ Nebraska, Med Ctr, Nebraska Med Ctr 985300, Omaha, NE 68198 USA.	japoole@unmc.edu			NIGMS NIH HHS [1 U01 GM/HL-61376-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdelilah SG, 1998, INT IMMUNOL, V10, P395, DOI 10.1093/intimm/10.4.395; Balbo P, 2001, CLIN EXP ALLERGY, V31, P625, DOI 10.1046/j.1365-2222.2001.01068.x; BONNEFOY JY, 1988, J EXP MED, V167, P57, DOI 10.1084/jem.167.1.57; BORISH L, 1991, J IMMUNOL, V146, P63; BORISH L, 1992, CLIN EXP ALLERGY, V22, P984, DOI 10.1111/j.1365-2222.1992.tb03025.x; Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460; CAMPBELL KA, 1992, EUR J IMMUNOL, V22, P2107, DOI 10.1002/eji.1830220822; Carreno BM, 2002, ANNU REV IMMUNOL, V20, P29, DOI 10.1146/annurev.immunol.20.091101.091806; CHIHARA J, 1991, ANN ALLERGY, V67, P429; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; DELESPESSE G, 1986, EUR J IMMUNOL, V16, P1043, DOI 10.1002/eji.1830160903; FLORESROMO L, 1990, EUR J IMMUNOL, V20, P2465, DOI 10.1002/eji.1830201116; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; GAGRO A, 1993, INT ARCH ALLERGY IMM, V101, P203, DOI 10.1159/000236520; Gounni AS, 2001, FASEB J, V15, P940, DOI 10.1096/fj.00-0378com; Greenfield EA, 1998, CRIT REV IMMUNOL, V18, P389, DOI 10.1615/CritRevImmunol.v18.i5.10; GURKA G, 1989, J ALLERGY CLIN IMMUN, V83, P945, DOI 10.1016/0091-6749(89)90110-3; Hakonarson H, 1999, J ALLERGY CLIN IMMUN, V104, P575, DOI 10.1016/S0091-6749(99)70326-X; Harkins MS, 2003, ANN ALLERG ASTHMA IM, V91, P567, DOI 10.1016/S1081-1206(10)61536-0; Hofer MF, 1998, J ALLERGY CLIN IMMUN, V101, P96, DOI 10.1016/S0091-6749(98)70199-X; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; Karagiannis SN, 2001, IMMUNOLOGY, V103, P319, DOI 10.1046/j.1365-2567.2001.01238.x; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Larche M, 1998, J IMMUNOL, V161, P6375; LAWRENCE DA, 1975, J CLIN INVEST, V55, P368, DOI 10.1172/JCI107940; Nakamura T, 2000, INT J IMMUNOPHARMACO, V22, P131, DOI 10.1016/S0192-0561(99)00068-5; RABATIC S, 1993, CLIN EXP IMMUNOL, V94, P337; Rosenwasser LJ, 2003, J ALLERGY CLIN IMMUN, V112, P563, DOI 10.1067/mai.2003.1709; Sano H, 1999, P ASSOC AM PHYSICIAN, V111, P82, DOI 10.1046/j.1525-1381.1999.09668.x; SARFATI M, 1988, J IMMUNOL, V141, P2195; SHERR E, 1989, J IMMUNOL, V142, P481; Ten RM, 1999, J IMMUNOL, V163, P3851; Tsicopoulos A, 2000, CLIN EXP ALLERGY, V30, P602; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; WILLIAMS J, 1992, J IMMUNOL, V149, P2823; Yamaoka KA, 1996, INT IMMUNOL, V8, P479, DOI 10.1093/intimm/8.4.479	37	63	70	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					780	788		10.1016/j.jaci.2005.07.007	http://dx.doi.org/10.1016/j.jaci.2005.07.007			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210051				2022-12-18	WOS:000235686600011
J	Saito, J; Inoue, K; Sugawara, A; Yoshikawa, M; Watanabe, K; Ishida, T; Ohtsuka, Y; Munakata, M				Saito, J; Inoue, K; Sugawara, A; Yoshikawa, M; Watanabe, K; Ishida, T; Ohtsuka, Y; Munakata, M			Exhaled nitric oxide as a marker of airway inflammation for an epidemiologic study in schoolchildren	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exhaled nitric aside; wheeze; IgE; atopy; asthma; spirometry	BRONCHOALVEOLAR LAVAGE; RESPIRATORY-TRACT; ASTHMA; HYPERRESPONSIVENESS; HEALTHY; INDUCTION; SYNTHASE; GROWTH	Background: Exhaled nitric oxide (eNO) levels are increased in airway inflammatory disorders, such as asthma. Objective: We sought to determine whether eNO could serve as a noninvasive marker of allergic airway inflammation for an epidemiologic study in schoolchildren. Methods: Two hundred seventy-eight schoolchildren aged 10 to 12 years answered a modified American Thoracic Society questionnaire, and eNO levels and pulmonary function were measured. In 246 subjects serum nonspecific IgE levels and levels of IgE specific to house dust mite, cat, cedar, and mold were also measured. Correlation analysis was used to examine eNO levels, nonspecific IgE levels, antigen-specific IgE levels, and pulmonary function. In addition, we compared these variables between subjects with (recurrent wheezers) and without (nonwheezers) recurrent wheeze. Finally, multiple logistic regression analysis was used to find possible predictors for recurrent wheezers. Results: eNO showed significant positive correlations with nonspecific IgE (r = 0.62, P < .001) and mite-specific IgE (r = 0.74, P < .001) and weak positive correlations with specific IgE to cat and cedar. Only eNO showed a weak but significant inverse correlation with pulmonary function (% FEV1, P = .035; FEV1/forced vital capacity, P = .018). eNO, nonspecific IgE, and mite-specific IgE levels in recurrent wheezers were greater (P < .001), and % FEV1 was less (P = .06) when compared with values seen in nonwheezers. Finally, eNO was determined by means of multiple logistic regression analysis to be the best predictor for recurrent wheezers compared with other variables (odds ratio, 11.2; 95% CI, 1.33-94.0). Conclusion: eNO can be used in epidemiologic studies as a noninvasive marker of allergic airway inflammation in schoolchildren.	Fukushima Med Univ, Sch Med, Dept Pulm Med, Fukushima 9601295, Japan	Fukushima Medical University	Saito, J (corresponding author), Fukushima Med Univ, Sch Med, Dept Pulm Med, 1 Hikarigaoka, Fukushima 9601295, Japan.	junpei@fmu.ac.jp						[Anonymous], 1999, Am J Respir Crit Care Med, V160, P2104; Bont L, 2001, PEDIATR INFECT DIS J, V20, P277, DOI 10.1097/00006454-200103000-00012; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308, DOI 10.1164/ajrccm.162.4.9910051; Brusasco V, 1998, THORAX, V53, P992, DOI 10.1136/thx.53.11.992; Byrnes CA, 1997, PEDIATR PULM, V24, P312; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; Deykin A, 2002, AM J RESP CRIT CARE, V165, P1597, DOI 10.1164/rccm.2201081; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; Esposito S, 2000, EUR RESPIR J, V16, P1142, DOI 10.1034/j.1399-3003.2000.16f21.x; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69, DOI 10.1164/ajrccm.159.1.9804134; Gibson PG, 2001, AM J RESP CRIT CARE, V164, P977, DOI 10.1164/ajrccm.164.6.9910053; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Henriksen AH, 2000, EUR RESPIR J, V15, P849, DOI 10.1034/j.1399-3003.2000.15e07.x; Henriksen AH, 2001, RESP MED, V95, P122, DOI 10.1053/rmed.2000.1004; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903a; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894, DOI 10.1164/ajrccm.151.6.7767537; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Lundberg JON, 1996, ARCH DIS CHILD, V75, P323, DOI 10.1136/adc.75.4.323; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800, DOI 10.1164/ajrccm.152.2.7633745; Moody A, 2000, J ALLERGY CLIN IMMUN, V105, P895, DOI 10.1067/mai.2000.105318; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911, DOI 10.1164/ajrccm.159.3.9802108; SMITH DL, 1993, AM REV RESPIR DIS, V148, P523, DOI 10.1164/ajrccm/148.2.523; Steerenberg PA, 2003, THORAX, V58, P242, DOI 10.1136/thorax.58.3.242; Stevenson EC, 1997, CLIN EXP ALLERGY, V27, P1027, DOI 10.1111/j.1365-2222.1997.tb01254.x; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; 2002, EUR RESP J, V20, P223; 2001, AM J RESP CRIT CARE, V163, P1470	33	63	68	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					512	516		10.1016/j.jaci.2004.05.033	http://dx.doi.org/10.1016/j.jaci.2004.05.033			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356549				2022-12-18	WOS:000223799600006
J	Munthe-Kaas, MC; Carlsen, KH; Helms, PJ; Gerritsen, J; Whyte, M; Feijen, M; Skinningsrud, B; Main, M; Kwong, GNM; Lie, BA; Carlsen, KCL; Undlien, DE				Munthe-Kaas, MC; Carlsen, KH; Helms, PJ; Gerritsen, J; Whyte, M; Feijen, M; Skinningsrud, B; Main, M; Kwong, GNM; Lie, BA; Carlsen, KCL; Undlien, DE			CTLA-4 polymorphisms in allergy and asthma and the T(H)1/T(H)2 paradigm	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; atopy; IgE; bronchial hyperresponsiveness; FEV1; genetic analysis; CTLA-4 polymorphisms; association study	IGE LEVELS; ASSOCIATION; GENE; SUSCEPTIBILITY; DIFFERENTIATION; LINKAGE; CELLS	Background: Several genomic regions are reported to be associated with the development of asthma and allergy, including chromosome 2q33. This region harbors the candidate gene cytotoxic T-lymphocyte antigen 4 (CTLA-4), an important regulator of T-cell activation and differentiation. Objective: We sought to explore possible associations between CTLA-4 polymorphisms and allergy and asthma. Methods: Seven single nucleotide polymorphisms (SNPs; MH30, -1147CT, +49AG, CT60, JO31, JO30, JO27_1) in CTLA-4 were analyzed for associations with total serum IgE, allergic sensitization (positive skin prick test to common allergens), bronchial hyperresponsiveness (BHR) to methacholine, asthma, and lung function (FEV1% of predicted) in 364 asthmatic families from 3 European countries. Results: Transmission disequilibrium test analysis showed that several SNPs were significantly associated with serum IgE levels, allergy, asthma, and FEV1% predicted below 80%, but not with BHR, and CTLA-4 polymorphisms of potentially direct pathogenic significance in atopic disorders were identified. Conclusion: We identified associations between 4 newly discovered SNPs in the CTLA-4 gene and serum IgE levels, allergy, asthma, and reduced lung function, but not BHR, suggesting an important role for CTLA-4 in atopy and reduced lung function in asthmatic subjects rather than asthma per se. The particular SNP alleles found positively associated with our phenotypes were recently shown to be associated negatively with autoimmune disorders. Although a skewing toward a T(H)1 reactivity pattern is believed to characterize autoimmune diseases, atopic diseases are considered T(H)2-mediated. Hence, our data suggest a role for CTLA-4 polymorphisms in determining the T(H)1/T(H)2 balance and identify CTLA-4 signaling as a potential therapeutic target in atopic disease.	Univ Oslo, Ulleval Univ Hosp, Dept Pediat, N-0407 Oslo, Norway; Univ Oslo, Ulleval Univ Hosp, Inst Med Genet, N-0407 Oslo, Norway; Natl Hosp, Volksentoppen BKL, Oslo, Norway; Univ Aberdeen, Dept Child Hlth, Aberdeen, Scotland; Univ Groningen, Ctr Med, Dept Pediat, Groningen, Netherlands; Univ Sheffield, Sch Med & Biomed Sci, Royal Hallamshire Hosp, Acad Unit Resp Med, Sheffield, S Yorkshire, England; Rikshospitalet Univ Hosp, Inst Immunol, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; National Hospital Norway; University of Aberdeen; University of Groningen; University of Sheffield; University of Oslo; National Hospital Norway	Munthe-Kaas, MC (corresponding author), Univ Oslo, Ulleval Univ Hosp, Dept Pediat, N-0407 Oslo, Norway.	m.c.munthe-kaas@ioks.uio.no	Whyte, Moira/E-6210-2010					[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; [Anonymous], 2000, J Pediatr, V137, P470; Bour-Jordan H, 2003, NAT IMMUNOL, V4, P182, DOI 10.1038/ni884; Cardwell CR, 2003, DIABETES CARE, V26, P2568, DOI 10.2337/diacare.26.9.2568; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Deurloo DT, 2001, AM J RESP CELL MOL, V25, P751, DOI 10.1165/ajrcmb.25.6.4607; EWENS WJ, 1995, AM J HUM GENET, V57, P455; Grohmann U, 2003, TRENDS MOL MED, V9, P133, DOI 10.1016/S1471-4914(03)00026-1; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; Heinzmann A, 2000, EUR J IMMUNOGENET, V27, P57, DOI 10.1046/j.1365-2370.2000.00198.x; Hizawa N, 2001, J ALLERGY CLIN IMMUN, V108, P74, DOI 10.1067/mai.2001.116119; Howard TD, 2002, J ALLERGY CLIN IMMUN, V110, P743, DOI 10.1067/mai.2002.128723; Jaffar Z, 1999, AM J RESP CELL MOL, V20, P153, DOI 10.1165/ajrcmb.20.1.3255; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kato T, 2000, J IMMUNOL, V164, P3554, DOI 10.4049/jimmunol.164.7.3554; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Kristiansen OP, 2000, GENES IMMUN, V1, P170, DOI 10.1038/sj.gene.6363655; Lee SY, 2002, CHEST, V122, P171, DOI 10.1378/chest.122.1.171; Marsh DG, 1997, NAT GENET, V15, P389; Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957; Mattila PS, 2002, DIABETES CARE, V25, P865, DOI 10.2337/diacare.25.5.865; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; O'Shea JJ, 2002, NAT IMMUNOL, V3, P506, DOI 10.1038/ni0602-506; Oaks MK, 2000, CELL IMMUNOL, V201, P144, DOI 10.1006/cimm.2000.1649; PHAGOO SB, 1991, CLIN EXP ALLERGY, V21, P589, DOI 10.1111/j.1365-2222.1991.tb00851.x; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Walunas TL, 1998, J IMMUNOL, V160, P3855; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502, DOI 10.1164/ajrccm/148.6_Pt_1.1502; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Yang KD, 2004, CLIN EXP ALLERGY, V34, P32, DOI 10.1111/j.1365-2222.2004.01776.x	35	63	68	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					280	287		10.1016/j.jaci.2004.03.050	http://dx.doi.org/10.1016/j.jaci.2004.03.050			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	847OU	15316504				2022-12-18	WOS:000223405600011
J	Kawano, T; Matsuse, H; Kondo, Y; Machida, I; Saeki, S; Tomari, S; Mitsuta, K; Obase, Y; Fukushima, C; Shimoda, T; Kohno, S				Kawano, T; Matsuse, H; Kondo, Y; Machida, I; Saeki, S; Tomari, S; Mitsuta, K; Obase, Y; Fukushima, C; Shimoda, T; Kohno, S			Cysteinyl leukotrienes induce nuclear factor kappa B activation and RANTES production in a murine model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						leukotrienes; cytokines; nuclear factor kappa B; RANTES; inflammation	RECEPTOR ANTAGONIST; AIRWAY INFLAMMATION; HUMAN EOSINOPHILS; CYTOKINE RANTES; CELLS; EXPRESSION; PRANLUKAST; CHEMOKINE; HYPERRESPONSIVENESS; PROLIFERATION	Background: It has been demonstrated that both cysteinyl leukotrienes (eysLTs) and cytokines are involved in the pathophysiology of bronchial asthma. Nonetheless, the exact mechanism involved in the interaction between these 2 molecules has yet to be determined. Objective: The aim of the present study was to determine the effects of cysLTs on allergic airway inflammation and allergen-specific cytokine production in a murine model of asthma. Methods: Four groups of BALB/c mice (control mice, Dermatophagoides fatinae allergen-sensitized mice, pranlukast cysLT receptor antagonist-treated allergen-sensitized mice, and dexamethasone-treated allergen-sensitized mice) were examined. Results: Allergen-sensitized mice exhibited increased airway responsiveness and inflammation. Pranlukast-treated mice showed significant attenuation of these changes concomitant with reduction of T(H)2 cytokine and IFN-gamma production by isolated lung mononuclear cells (MNCs). A much stronger inhibition of all cytokines was noted in dexamethasone-treated mice. Pranlukast also significantly inhibited production of RANTES and activation of nuclear factor kappaB (NF-kappaB) in the isolated lung MNCs. Leukotriene D-4 stimulated isolated lung MNCs to produce RANTES but not any other cytokines and also activated NF-kappaB in these cells. Conclusions: Our results suggest that cysLTs activate NF-kappaB and induce RANTES production from isolated lung MNCs, which in turn might cause migration of eosinophils and activated T lymphocytes into the airway.	Nagasaki Univ, Sch Med, Dept Internal Med 2, Nagasaki 8528501, Japan	Nagasaki University	Matsuse, H (corresponding author), Nagasaki Univ, Sch Med, Dept Internal Med 2, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.							ALAM R, 1993, J IMMUNOL, V150, P3442; Altman LC, 1998, J ALLERGY CLIN IMMUN, V102, P50, DOI 10.1016/S0091-6749(98)70054-5; Anthonsen MW, 2001, J BIOL CHEM, V276, P30527, DOI 10.1074/jbc.M008481200; Appay V, 2001, TRENDS IMMUNOL, V22, P83, DOI 10.1016/S1471-4906(00)01812-3; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BARES PJ, 2001, J ALLERGY CLIN IMMUN, V108, pS72; BITTLEMAN DB, 1994, AM J RESP CRIT CARE, V150, pS72, DOI 10.1164/ajrccm/150.5_Pt_2.S72; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAYER JM, 1993, AM REV RESPIR DIS, V148, P70; DEVERGNE O, 1994, J EXP MED, V179, P1689, DOI 10.1084/jem.179.5.1689; Drasen JM, 1987, AM REV RESPIR DIS, V136, P368; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Hirata N, 1998, AM J RESP CELL MOL, V18, P12, DOI 10.1165/ajrcmb.18.1.2704; Hisada T, 1999, AM J RESP CRIT CARE, V160, P571, DOI 10.1164/ajrccm.160.2.9810101; Ihaku D, 1999, J ALLERGY CLIN IMMUN, V104, P1147, DOI 10.1016/S0091-6749(99)70006-0; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; Menard G, 2000, AM J RESP CELL MOL, V23, P572, DOI 10.1165/ajrcmb.23.4.4152; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Obase Y, 2001, ANN ALLERG ASTHMA IM, V87, P43, DOI 10.1016/S1081-1206(10)62321-6; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PILEWSKI JM, 1993, AM REV RESP DIS S, V148, P31; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; Tohda Y, 1999, CLIN EXP ALLERGY, V29, P1532; Tomari S, 2001, ANN ALLERG ASTHMA IM, V87, P156, DOI 10.1016/S1081-1206(10)62212-0; UUNDERWOOD DC, 1996, AM J RESP CRIT CARE, V154, P850; van Puijenbroek AAFL, 1999, CYTOKINE, V11, P104, DOI 10.1006/cyto.1998.0404; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739	38	63	64	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					369	374		10.1067/mai.2003.1636	http://dx.doi.org/10.1067/mai.2003.1636			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	709WY	12897744				2022-12-18	WOS:000184650600022
J	Sorensen, B; Streib, JE; Strand, M; Make, B; Giclas, PC; Fleshner, M; Jones, JF				Sorensen, B; Streib, JE; Strand, M; Make, B; Giclas, PC; Fleshner, M; Jones, JF			Complement activation in a model of chronic fatigue syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exercise; allergy; pathogenesis; symptom production; chronic fatigue syndrome; complement activation; eosinophilic cationic protein	STRUCTURED CLINICAL INTERVIEW; IMMUNOLOGICAL ABNORMALITIES; PHYSICAL-ACTIVITY; RHEUMATOID-ARTHRITIS; EXERCISE; DEPRESSION; ALLERGY; HEALTH; CULTURES; DISEASE	Background: A need exists to identify biological markers in chronic fatigue syndrome (CFS). Objective: To use an exercise and/or allergen challenge to induce the symptoms of CFS and to identify a biological marker that correlates with these symptoms. Methods: Patients with CFS (n = 32) and age-matched, normal control patients (n = 29) exercised for 20 minutes on a stationary bike at 70% of their predicted max work load (Watts). Patients from each group with positive skin test results were also challenged with intranasally administered relevant allergens. Symptoms were recorded for 2 weeks before and I week after each challenge, using 3 different instruments. Blood samples vi ere taken before, and 0, 1, 6, and 24 hours after challenges. Levels of complement split products, cell-associated cytokines, and eosinophilic cationic protein were measured. Mean preexercise and postexercise symptom scores were evaluated for each group. Results: Exercise challenge induced significant increases of the complement split product C4a, but not C3a or C5a, at 6 hours after exercise only in the CFS group (P < .01), regardless of allergy status. Mean symptom scores were significantly increased after exercise through the use of a daily diary (P < .03) and a weekly diary (P < .01) for the CFS group only. Mean scores for the Multidimensional Fatigue Inventory categories "reduced activity" and "mental fatigue" were significantly increased in the CFS group only (P < .04 and P < .02, respectively). Conclusions: Exercise challenge may be a valuable tool in the development of diagnostic criteria and tests for CFS. Establishment of a role for complement activation products as markers or participants in production of illness require further study.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO USA; Natl Jewish Med & Res Ctr, Dept Biostat, Denver, CO USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; Natl Jewish Med & Res Ctr, Diagnost Complement Lab, Denver, CO USA; Univ Colorado, Dept Kinesiol & Appl Physiol, Boulder, CO USA; Univ Colorado, Ctr Neurosci, Boulder, CO 80309 USA	National Jewish Health; National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Jones, JF (corresponding author), 1400 Jackson St,K913, Denver, CO 80206 USA.		Strand, Matt/AAU-3762-2021	Strand, Matt/0000-0002-9083-5989; Fleshner, Monika/0000-0002-0470-0827	NCRR NIH HHS [M01-RR00051] Funding Source: Medline; NIAID NIH HHS [R01-AI48555] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048555] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER E, 1994, CLIN INFECT DIS, V18, pS136, DOI 10.1093/clinids/18.Supplement_1.S136; Bearne LM, 2002, RHEUMATOLOGY, V41, P157, DOI 10.1093/rheumatology/41.2.157; Borish L, 1998, J ALLERGY CLIN IMMUN, V102, P222, DOI 10.1016/S0091-6749(98)70090-9; Buchwald D, 1997, J RHEUMATOL, V24, P372; CHAO CC, 1991, CYTOKINE, V3, P292, DOI 10.1016/1043-4666(91)90497-2; Conti F, 1996, ALLERGY, V51, P124; Daltroy LH, 1995, BRIT J RHEUMATOL, V34, P1064; DUFAUX B, 1989, CLIN CHIM ACTA, V179, P45, DOI 10.1016/0009-8981(89)90021-1; DUFAUX B, 1991, INT J SPORTS MED, V12, P38; Dunn AL, 2001, MED SCI SPORT EXER, V33, pS587, DOI 10.1097/00005768-200106001-00027; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GUPTA S, 1991, SCAND J IMMUNOL, V33, P319, DOI 10.1111/j.1365-3083.1991.tb01777.x; Gupta S, 1999, INT J MOL MED, V3, P209; KLIMAS NG, 1990, J CLIN MICROBIOL, V28, P1403, DOI 10.1128/JCM.28.6.1403-1410.1990; Konstantinov K, 1996, J CLIN INVEST, V98, P1888, DOI 10.1172/JCI118990; Kowal K, 2002, ALLERGY ASTHMA PROC, V23, P35; LLOYD A, 1992, CLIN EXP IMMUNOL, V87, P76; LLOYD AR, 1989, MED J AUSTRALIA, V151, P122, DOI 10.5694/j.1326-5377.1989.tb139594.x; Meyer T, 2000, SPORTS MED, V30, P269, DOI 10.2165/00007256-200030040-00003; Mostert S, 2002, MULT SCLER J, V8, P161, DOI 10.1191/1352458502ms779oa; Paluska SA, 2000, SPORTS MED, V29, P167, DOI 10.2165/00007256-200029030-00003; Patarca R, 2001, ANN NY ACAD SCI, V933, P185; ROBBNICHOLSON LC, 1989, BRIT J RHEUMATOL, V28, P500; Salmon P, 2001, CLIN PSYCHOL REV, V21, P33, DOI 10.1016/S0272-7358(99)00032-X; Shephard PJ, 1997, EXERC IMMUNOL REV, V3, P53; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SMITH JK, 1990, ANN ALLERGY, V65, P304; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Steinberg P, 1996, J ALLERGY CLIN IMMUN, V97, P119, DOI 10.1016/S0091-6749(96)70290-7; STRAUS SE, 1988, J ALLERGY CLIN IMMUN, V81, P791, DOI 10.1016/0091-6749(88)90933-5; Visser J, 2001, J NEUROIMMUNOL, V119, P343, DOI 10.1016/S0165-5728(01)00400-3; Vollmer-Conna U, 1998, AUST NZ J PSYCHIAT, V32, P523, DOI 10.3109/00048679809068326; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Yates Herbert A., 2002, Journal of the American Osteopathic Association, V102, P267	35	63	63	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					397	403		10.1067/mai.2003.1615	http://dx.doi.org/10.1067/mai.2003.1615			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	709WY	12897748	Bronze			2022-12-18	WOS:000184650600026
J	Hamilton, RG				Hamilton, RG			Clinical laboratory assessment of IgE - Reply	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							LATEX		Johns Hopkins Univ, Ctr Asthma & Allergy, Baltimore, MD 21224 USA	Johns Hopkins University	Hamilton, RG (corresponding author), Johns Hopkins Univ, Ctr Asthma & Allergy, Room 1A20,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.							Ebo DG, 1997, J ALLERGY CLIN IMMUN, V100, P618, DOI 10.1016/S0091-6749(97)70165-9; Ebo DG, 2003, J ALLERGY CLIN IMMUN, V111, P1414, DOI 10.1067/mai.2003.1519; Hamilton RG, 2003, J ALLERGY CLIN IMMUN, V111, P1414, DOI 10.1067/mai.2003.1520; Hamilton RG, 2002, J ALLERGY CLIN IMMUN, V110, pS47, DOI 10.1067/mai.2002.125334	4	63	65	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1414	1416		10.1067/mai.2003.1520	http://dx.doi.org/10.1067/mai.2003.1520			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ					2022-12-18	WOS:000183424700041
J	Lee, KS; Jin, SM; Kim, HJ; Lee, YC				Lee, KS; Jin, SM; Kim, HJ; Lee, YC			Matrix metalloproteinase inhibitor regulates inflammatory cell migration by reducing ICAM-1 and VCAM-1 expression in a murine model of toluene diisocyanate-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						toluene diisocyanate; matrix metalloproteinase; asthma; adhesion molecules; cytokines	ADHESION MOLECULE-1 ICAM-1; BASEMENT-MEMBRANE; TISSUE INHIBITOR; IN-VITRO; MATRIX-METALLOPROTEINASE-9; INFILTRATION	Background: Matrix metalloproteinase-9 (MMP-9) has been reported to play a crucial role in the transmigration of neutrophils, lymphocytes, and eosinophils. Neutrophils, eosinophils, and lymphocytes migrate from the blood to the lungs in response to inflammatory mediators produced in the airways and are subsequently released into the circulation. This traffic is mediated by adhesion molecules. However, little is known about the migration of inflammatory cells through the endothelial and epithelial basement membranes in toluene diisocyanate (TDI)-induced asthma. Objectives: An aim of this study was to evaluate the effect of MMP inhibitors on the expression of ICAM-1 and VCAM-1 in the migration of inflammatory cells in a murine model of TDI-induced asthma. Methods: We used a marine model to investigate TDI-induced asthma to examine the possible involvement of ICAM-1 and VCAM-1 in the pathogenesis of that disease and the effect of MMP inhibitors on the expression of ICAM-1 and VCAM-1. Results: In mice, the following typical pathophysiologic features develop in the lungs: increased numbers of inflammatory cells and increased expression of MMP-9, ICAM-1, and VCAM-1 mRNA and protein. Administration of MMP inhibitors reduced the increased numbers of inflammatory cells and the increased expression of ICAM-1 and VCAM-1 mRNA expression and protein. In addition, MMP inhibitors significantly abrogated the increased expression of IL-1beta, IL-4, and TNF-alpha mRNA in lung tissues and levels of IL-1beta IL-4, and TNF-alpha in bronchoalveolar lavage fluids after TDI inhalation. Conclusions: These results suggest that MMP inhibitors regulate inflammatory cell migration by reducing ICAM-1 and VCAM-1 expression and possibly also by suppressing IL-1beta, IL-4, and TNF-alpha expression.	Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Ctr Allerg Immune Dis, Chonju 561712, South Korea; Chonbuk Natl Univ, Sch Med, Dept Urol, Chonju 561712, South Korea	Jeonbuk National University; Jeonbuk National University	Lee, YC (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Ctr Allerg Immune Dis, 634-18 Keumamdong, Chonju 561712, South Korea.							BOSCHETTO P, 1988, J ALLERGY CLIN IMMUN, V80, P261; Bosse M, 1999, AM J RESP CRIT CARE, V159, P596, DOI 10.1164/ajrccm.159.2.9802045; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BUSSE WW, 1993, AM REV RESPIR DIS, V147, P520; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Hirata N, 1998, AM J RESP CELL MOL, V18, P12, DOI 10.1165/ajrcmb.18.1.2704; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; Kumagai K, 1999, J IMMUNOL, V162, P4212; Lee YC, 2001, J ALLERGY CLIN IMMUN, V108, P1021, DOI 10.1067/mai.2001.120132; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298, DOI 10.1164/ajrccm.159.4.9708080; LEPPERT D, 1995, J IMMUNOL, V154, P4379; MAPP CE, 1987, B EUR PHYSIOPATH RES, V23, P583; Mautino G, 1997, AM J RESP CELL MOL, V17, P583, DOI 10.1165/ajrcmb.17.5.2562; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; MONTEFORT S, 1992, EUR RESPIR J, V5, P815; MONTEFORT S, 1991, RESP MED, V85, P91, DOI 10.1016/S0954-6111(06)80284-2; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4, DOI 10.1165/ajrcmb.12.1.7529029; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851	26	63	71	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1278	1284		10.1067/mai.2003.1501	http://dx.doi.org/10.1067/mai.2003.1501			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789230				2022-12-18	WOS:000183424700018
J	Stafford, RS; Ma, J; Finkelstein, SN; Haver, K; Cockburn, I				Stafford, RS; Ma, J; Finkelstein, SN; Haver, K; Cockburn, I			National trends in asthma visits and asthma pharmacotherapy, 1978-2002	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma visits; asthma pharmacotherapy; inhaled corticosteroids; bronchodilators; controller-to-reliever ratio; evidence-based guidelines	INHALED STEROIDS; GENERAL-PRACTICE; UNITED-STATES; DRUG-THERAPY; GUIDELINES; MANAGEMENT; CARE; BRONCHODILATOR; MORTALITY; CHILDREN	Background: Research is limited on physicians' compliance with recent clinical guidelines for asthma treatment. Objective: Our purpose was to investigate the relationships among clinical guidelines, asthma pharmacotherapy, and office-based visits through use of nationally representative data. Methods: Nationally representative data on prescribing patterns by office-based US physicians were extracted from the National Disease and Therapeutic Index. We tracked 19782002 trends in the frequency of asthma visits and patterns of asthma pharmacotherapy, focusing on the use of controller and reliever medications. Results: The estimated annual number of asthma visits in the United States increased continuously from 1978 through 1990 (18 million visits); since 1990, it has remained relatively stable. Controller medication use increased 8-fold between 1978 and 2002, inhaled corticosteroids manifesting the biggest increases. The use of reliever medications, particularly short-acting oral beta(2)-agonists, decreased modestly over this period. The aggregate use of controllers (83% of visits) superseded that of relievers (80%) for the first time in 2001. Improved appropriateness of asthma pharmacotherapy was also suggested by an increase in the controller-to-reliever ratio, which reached 92% in 2002. Xanthines, which once dominated asthma therapy (63% of visits in 1978), were used in only 2% of visits in 2002. More recent drug entrants have been adopted rapidly, single-entity long-acting inhaled beta(2)-agonists being used in 9% of visits and leukotriene modifiers in 24% of visits in 2002. Conclusion: Asthma pharmacotherapy has changed extensively in the past 25 years. Practices over the last decade are increasingly consistent with evidence-based guidelines. These changes in medication use might have contributed to the lack of a recent increase in asthma visits.	Stanford Univ, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA; MIT, Program Pharmaceut Ind, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Dept Pediat, Pulm Unit, Boston, MA 02114 USA; Boston Univ, Sch Management, Boston, MA 02215 USA	Stanford University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Boston University	Stafford, RS (corresponding author), Stanford Univ, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA.		Cockburn, Iain M/G-9524-2013; Stafford, Randall/F-3974-2017	Cockburn, Iain M/0000-0003-2034-0187; Stafford, Randall/0000-0003-1805-1271	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS013405] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; BAUMAN A, 1995, RESP MED, V89, P665, DOI 10.1016/0954-6111(95)90133-7; Bjorksten B, 2000, CLIN EXP ALLERGY, V30, P73; BOSCO LA, 1987, J ALLERGY CLIN IMMUN, V80, P398, DOI 10.1016/0091-6749(87)90058-3; Boulet LP, 1998, CHEST, V113, P587, DOI 10.1378/chest.113.3.587; Burney P., 1997, ASTHMA; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Frischer M, 1999, PUBLIC HEALTH, V113, P247, DOI 10.1038/sj.ph.1900583; Global Initiative for Asthma, 2002, GLOB STRAT ASTHM MAN; Goodman DC, 1999, PEDIATRICS, V104, P187, DOI 10.1542/peds.104.2.187; Jacobson GA, 1996, J CLIN PHARM THER, V21, P317, DOI 10.1111/j.1365-2710.1996.tb00025.x; Jain P, 1996, DRUGS, V52, P1, DOI 10.2165/00003495-199600526-00003; Jans MP, 2001, INT J QUAL HEALTH C, V13, P17, DOI 10.1093/intqhc/13.1.17; Joyce DP, 1999, CAN FAM PHYSICIAN, V45, P1707; Kemp JP, 1998, J ASTHMA, V35, P601, DOI 10.3109/02770909809048963; KESTEN S, 1993, J ALLERGY CLIN IMMUN, V92, P499, DOI 10.1016/0091-6749(93)90073-O; Laumann JM, 1998, ANN PHARMACOTHER, V32, P1290, DOI 10.1345/aph.18147; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; Majeed A, 1999, J PUBLIC HEALTH MED, V21, P395, DOI 10.1093/pubmed/21.4.395; *NAT ASTHM ED PROG, 1997, EXP PAN REP 2 GUID D; *NAT ASTHM ED PROG, 1991, EXP PAN REP GUID DIA; *NAT ASTHM ED PROG, 2002, EX SUMM NAEPP EXP PA; Nestor A, 1998, ANN ALLERG ASTHMA IM, V81, P327, DOI 10.1016/S1081-1206(10)63124-9; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Reddy P, 2001, ANN PHARMACOTHER, V35, P682; Shelley M, 2000, J CLIN EPIDEMIOL, V53, P1217, DOI 10.1016/S0895-4356(00)00249-3; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; Terr AI, 1996, ANN ALLERG ASTHMA IM, V76, P273, DOI 10.1016/S1081-1206(10)63441-2; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; WOOLCOCK AJ, 1997, CIBA F SYMP, V206, P57; WOOLCOCK AJ, 1997, CIBA F SYMP, V206, P34	31	63	64	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					729	735		10.1067/mai.2003.177	http://dx.doi.org/10.1067/mai.2003.177			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	667WW	12704350				2022-12-18	WOS:000182258500009
J	Deslee, G; Charbonnier, AS; Hammad, H; Angyalosi, G; Tillie-Leblond, I; Mantovani, A; Tonnel, AB; Pestel, J				Deslee, G; Charbonnier, AS; Hammad, H; Angyalosi, G; Tillie-Leblond, I; Mantovani, A; Tonnel, AB; Pestel, J			Involvement of the mannose receptor in the uptake of Der p 1, a major mite allergen, by human dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; mannose receptor; uptake; house dust mite; allergy	EOSINOPHILIC AIRWAY INFLAMMATION; CYSTEINE PROTEASE ACTIVITY; DERMATOPHAGOIDES-PTERONYSSINUS; ANTIGEN PRESENTATION; LANGERHANS CELLS; INHALED ANTIGEN; II PRESENTATION; DOWN-REGULATION; DC-SIGN; T-CELLS	Background: Immature dendritic cells (DCs) take up antigens in peripheral tissues and, after antigen processing, mature to efficiently stimulate T cells in secondary lymph nodes. In allergic airway diseases DCs have been shown to be involved in the induction and maintenance of a T(H)2-type profile. Objective: The present study was undertaken to determine pathways of Der p 1 (a house dust mite allergen) uptake by human DCs and to compare Der p I uptake between DCs from patients with house dust mite allergy and DCs from healthy donors. Methods: Monocyte-derived DCs (MD-DCs) were obtained from patients with house dust mite allergy (n = 13) and healthy donors (n = 11). Der p 1 was labeled with rhodamine. Der p 1 uptake by MD-DCs was analyzed by means of flow cytometry and confocal microscopy. Results: Rhodamine-labeled Der p I was demonstrated to be taken up by MD-DCs in a dose-, time-, and temperature-dependent manner. The involvement of the mannose receptor (MR) in the Der p I uptake was demonstrated by using (1) inhibitors of the MR-mediated endocytosis (mannan and blocking anti-MR mAb), which inhibited the Der p I uptake from 40% to 50%, and (2) confocal microscopy showing the colocalization of rhodamine-labeled Der p 1 with FITC-dextran. Interestingly, compared with DCs from healthy donors, DCs from allergic patients expressed more MR and were more efficient in Der p 1 uptake. Conclusion: These results suggest that the MR could play a key role in the Der p 1 allergen uptake by DCs and in the pathogenesis of allergic diseases in dust mite-sensitive patients.	Inst Pasteur, INSERM U416, F-59019 Lille, France; Inst Biol, Lille, France; CHRU, Hop A Calmette, Dept Pneumol, Lille, France; Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, I-20157 Milan, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Pestel, J (corresponding author), Inst Pasteur, INSERM U416, 1 Rue Prof Calmette,BP 245, F-59019 Lille, France.		Mantovani, Alberto/HCI-7449-2022; Hammad, Hamida/J-9391-2015; DESLEE, Gaëtan/G-2625-2013	Mantovani, Alberto/0000-0001-5578-236X; Hammad, Hamida/0000-0003-3762-8603; DESLEE, Gaëtan/0000-0002-4919-5916				Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BELLINI A, 1993, CHEST, V103, P997, DOI 10.1378/chest.103.4.997; Buentke E, 2000, CLIN EXP ALLERGY, V30, P1759, DOI 10.1046/j.1365-2222.2000.00937.x; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Cochand L, 1999, AM J RESP CELL MOL, V21, P547, DOI 10.1165/ajrcmb.21.5.3785; Comoy EE, 1998, J IMMUNOL, V160, P2456; Engering AJ, 1997, ADV EXP MED BIOL, V417, P183; Fanger NA, 1997, J IMMUNOL, V158, P3090; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; INABA K, 1993, J EXP MED, V178, P479, DOI 10.1084/jem.178.2.479; Kato M, 2000, INT IMMUNOL, V12, P1511, DOI 10.1093/intimm/12.11.1511; King C, 1998, J IMMUNOL, V161, P3645; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Longoni D, 1998, INT J CLIN LAB RES, V28, P162, DOI 10.1007/s005990050037; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Maurer D, 1998, J IMMUNOL, V161, P2731; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Noirey N, 2000, J ALLERGY CLIN IMMUN, V105, P1194, DOI 10.1067/mai.2000.106545; Okano M, 2001, J ALLERGY CLIN IMMUN, V108, P101, DOI 10.1067/mai.2001.115757; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schulz O, 1997, EUR J IMMUNOL, V27, P584, DOI 10.1002/eji.1830270303; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; SOUSA CRE, 1993, J EXP MED, V178, P509, DOI 10.1084/jem.178.2.509; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; Svensson M, 1997, J IMMUNOL, V158, P4229; Tan MCAA, 1997, EUR J IMMUNOL, V27, P2426, DOI 10.1002/eji.1830270942; Taylor M E, 2001, Results Probl Cell Differ, V33, P105; Valladeau J, 2000, IMMUNITY, V12, P71, DOI 10.1016/S1074-7613(00)80160-0; van Oort E, 2002, EUR J BIOCHEM, V269, P671, DOI 10.1046/j.0014-2956.2001.02700.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang JY, 1996, CLIN EXP IMMUNOL, V106, P367, DOI 10.1046/j.1365-2249.1996.d01-838.x	40	63	68	1	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					763	770		10.1067/mai.2002.129121	http://dx.doi.org/10.1067/mai.2002.129121			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417886				2022-12-18	WOS:000179082500012
J	Kopp, MV; Brauburger, J; Riedinger, F; Beischer, D; Ihorst, G; Kamin, W; Zielen, S; Bez, C; Friedrichs, F; von Berg, A; Gerhold, K; Hamelmann, E; Hultsch, T; Kuehr, J				Kopp, MV; Brauburger, J; Riedinger, F; Beischer, D; Ihorst, G; Kamin, W; Zielen, S; Bez, C; Friedrichs, F; von Berg, A; Gerhold, K; Hamelmann, E; Hultsch, T; Kuehr, J			The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; anti-IgE; Omalizumab; children; sensitization; rhinoconjunctivitis; specific immunotherapy; leukotrienes; Cellular Allergen Stimulation Test-ELISA; therapy	HUMAN BASOPHILS; AIRWAY HYPERRESPONSIVENESS; MONOCLONAL-ANTIBODY; IMMUNOTHERAPY; EXPRESSION; OMALIZUMAB; MEDIATORS; EFFICACY; RECEPTOR; ASTHMA	Background: Binding of allergens with IgE to the IgE receptors on mast cells and basophils results in the release of inflammatory mediators as sulfidoleukotrienes (SLTs), triggering allergic cascades that result in allergic symptoms, such as asthma and rhinitis. Objective: We sought to investigate whether anti-IgE (Omalizumab), a humanized monoclonal anti-IgE antibody, in addition to specific immunotherapy (SIT) affects the leukotriene pathway. Methods: Ninety-two children (age range, 6-17 years) with sensitization to birch and grass pollens and with seasonal allergic rhinitis were included in a phase 111, placebo-controlled, multi-center clinical study. All subjects were randomized to one of 4 treatment groups. Two groups subcutaneously received birch SIT and 2 groups received grass SIT for at least 14 weeks before the start of the birch pollen season. After 12 weeks of SIT titration, placebo or anti-IgE was added for 24 weeks. The primary clinical efficacy variable was symptom load (ie, the sum of daily symptom severity score and rescue medication score during pollen season). Blood samples taken at baseline and at the end of study treatment after the grass pollen season were used for separation of leukocytes in this substudy. After in vitro stimulation of the blood cells with grass and birch pollen allergens, SLT release (LTC4, LTD4, and LTE4) was quantified by using the ELISA technique. Results: Before the study treatment, SLT release to birch and grass pollen exposure did not differ significantly among the 4 groups. Under treatment with anti-IgE + SIT-grass (n = 23), a lower symptom load occurred during the pollen season compared to placebo + SIT-grass (n = 24, P = .012). The same applied to both groups receiving birch SIT (n = 23 and n = 22, respectively; P = .03). At the end of treatment, the combination of anti-IgE plus grass SIT, as well as anti-IgE plus birch SIT, resulted in significantly lower SLT release after stimulation with the corresponding allergen (416 ng/L [5th-95th percentile, 1-1168] and 207 ng/L [1-860 ng/L], respectively) compared with placebo plus SIT (2490 ng/L [384-6587 ng/L], P = .001; 2489 ng/L [1-5670 ng/L], P = .001). In addition, treatment with anti-IgE was also followed by significantly lower SLT releases to the allergens unrelated to SIT (grass SIT: 300 ng/L [1-2432 ng/L] in response to birch allergen; birch SIT: 1478 ng/L [1-4593 ng/L] in response to grass pollen) in comparison with placebo (grass SIT: 1850 ng/L [1-5499 ng/L], P = .001; birch SIT: 2792 ng/L [154-5839 ng/L], P = .041. Conclusion: Anti-IgE therapy reduces leukotriene release of peripheral leukocytes stimulated with allergen in children with allergic rhinitis undergoing allergen immunotherapy independent of the type of SIT allergen used.	Univ Freiburg, Childrens Hosp, D-79106 Freiburg, Germany; Novartis Pharma GmbH, Res Grp, Nurnberg, Germany; Novartis Pharma AG, Basel, Switzerland	University of Freiburg; Novartis; Novartis	Kopp, MV (corresponding author), Univ Freiburg, Childrens Hosp, Mathildenstr 1, D-79106 Freiburg, Germany.		Hamelmann, Eckard/AAJ-9124-2021; Zielen, Stefan/AAD-7243-2020; Ihorst, Gabriele/AAA-7445-2021					Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Bisgaard H, 2001, ALLERGY, V56, P7, DOI 10.1034/j.1398-9995.56.s66.2.x; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; DAHLEN B, 1995, CLIN EXP ALLERGY, V25, P50, DOI 10.1111/j.1365-2222.1995.tb00422.x; DEWECK AL, 1993, ALLERGY CLIN IMMUNOL, V5, P9; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Ferrer M, 1998, J INVEST ALLERG CLIN, V8, P277; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; HOLGATE S T, 1985, Clinical Immunology Reviews, V4, P241; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; KURIMOTO Y, 1991, EUR J IMMUNOL, V21, P361, DOI 10.1002/eji.1830210217; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Milgrom H, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e36; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Saarinen JV, 2001, ALLERGY, V56, P58, DOI 10.1034/j.1398-9995.2001.00833.x; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Tanaka H, 2001, J ALLERGY CLIN IMMUN, V107, P331, DOI 10.1067/mai.2001.112275; Wang DY, 2000, AM J RHINOL, V14, P325, DOI 10.2500/105065800781329483; WHITE MV, 1992, J ALLERGY CLIN IMMUN, V90, P699, DOI 10.1016/0091-6749(92)90155-U; Withers NJ, 2000, RESP MED, V94, P391, DOI 10.1053/rmed.1999.0746	28	63	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					728	735		10.1067/mai.2002.128804	http://dx.doi.org/10.1067/mai.2002.128804			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417881				2022-12-18	WOS:000179082500007
J	Horner, AA; Takabayashi, K; Beck, L; Sharma, B; Zubeldia, J; Baird, S; Tuck, S; Libet, L; Spiegelberg, HL; Liu, FT; Raz, E				Horner, AA; Takabayashi, K; Beck, L; Sharma, B; Zubeldia, J; Baird, S; Tuck, S; Libet, L; Spiegelberg, HL; Liu, FT; Raz, E			Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunostimulatory; DNA; CpG motif; immunotherapy; anaphylaxis	RAGWEED HAY-FEVER; CPG OLIGODEOXYNUCLEOTIDES; DENDRITIC CELLS; BACTERIAL-DNA; IMMUNOTHERAPY; RESPONSES; ANTIGEN; ASTHMA; ACTIVATION; MATURATION	Background: Immunotherapy has gradually fallen out of favor for the treatment of many allergic diseases because of the overall convenience, safety, and efficacy of medications. However, investigations suggest that allergen/immunostimulatory sequence oligodeoxynucleotide (ISS-ODN) conjugates (AICs) might have improved safety and efficacy compared with allergen extracts. Objective: We determined whether changes in the ISS-ODN conjugation ratio would effect the immunogenicity and allergenicity of AIC. Methods: Immunogenicity was determined by means of AIC vaccination of mice, followed by analysis of antigen-specific antibody and cytokine responses. The allergenicity of AIC was determined in mast cell release studies and in marine models of anaphylaxis and the Arthus reaction. Results: AIC induced a stronger immune response than allergen alone or allergen mixed with ISS-ODN, but higher-level ISS-ODN conjugation reduced its immunogenicity modestly. In mast cell degranulation studies AIC was approximately 100-fold less allergenic than native allergen, with stepwise increases in the ODN conjugation ratio leading to stepwise decreases in allergenicity. In anaphylaxis studies death rates were reduce from 100% with native allergen challenge to as low as 0% with high-ratio ISS-ODN AIC challenge. Similar results were obtained in an Arthus reaction model. Conclusion: These investigations establish that AIC is both significantly more immunogenic and less allergenic than native allergens and the techniques used might have further utility for the standardization and optimization of AIC formulations for use in allergic patients.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; La Jolla Inst Allergy & Immunol, San Diego, CA USA; Dynavax Technol Corp, Berkeley, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; La Jolla Institute for Immunology	Raz, E (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Liu, FU-TONG/A-5749-2019; Zubeldia, Jose M./H-3518-2016	Liu, FU-TONG/0000-0002-3354-1001; Zubeldia, Jose M./0000-0003-3110-274X	NIAID NIH HHS [AI01490, AI40682] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI040682, K08AI001490] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Akdis CA, 2001, MICROBES INFECT, V3, P891, DOI 10.1016/S1286-4579(01)01449-6; Creticos PS, 2000, J ALLERGY CLIN IMMUN, V105, pS70, DOI 10.1016/S0091-6749(00)90645-6; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; Creticos PS, 2001, J ALLERGY CLIN IMMUN, V107, pS216; CRETICOS PS, 1997, ALLERGY, P726; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P413, DOI 10.1067/mai.2002.126660; Horner AA, 2001, J IMMUNOL, V167, P1584, DOI 10.4049/jimmunol.167.3.1584; Horner AA, 2001, IMMUNOL REV, V179, P102, DOI 10.1034/j.1600-065X.2001.790111.x; Horner AA, 2000, J ALLERGY CLIN IMMUN, V106, P349, DOI 10.1067/mai.2000.107933; JUTEL M, 1995, J IMMUNOL, V154, P4187; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Marquardt DL, 2000, J ALLERGY CLIN IMMUN, V105, P500, DOI 10.1067/mai.2000.104942; Mellerup MT, 2000, CLIN EXP ALLERGY, V30, P1423, DOI 10.1046/j.1365-2222.2000.00910.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; NORMAN PS, 1984, J ALLERGY CLIN IMMUN, V73, P782, DOI 10.1016/0091-6749(84)90448-2; Park Y, 2001, J ALLERGY CLIN IMMUN, V108, P570; Santeliz JV, 2002, J ALLERGY CLIN IMMUN, V109, P455, DOI 10.1067/mai.2002.122156; Shirota H, 2000, J IMMUNOL, V164, P5575, DOI 10.4049/jimmunol.164.11.5575; Shirota H, 2001, J IMMUNOL, V167, P66, DOI 10.4049/jimmunol.167.1.66; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tighe H, 2000, EUR J IMMUNOL, V30, P1939, DOI 10.1002/1521-4141(200007)30:7<1939::AID-IMMU1939>3.0.CO;2-#; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; Winther L, 2000, ALLERGY, V55, P818, DOI 10.1034/j.1398-9995.2000.00367.x	30	63	72	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					413	420		10.1067/mai.2002.126660	http://dx.doi.org/10.1067/mai.2002.126660			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209088				2022-12-18	WOS:000177936900011
J	Gutzmer, R; Langer, K; Lisewski, M; Mommert, S; Rieckborn, D; Kapp, A; Werfel, T				Gutzmer, R; Langer, K; Lisewski, M; Mommert, S; Rieckborn, D; Kapp, A; Werfel, T			Expression and function of histamine receptors 1 and 2 on human monocyte-derived dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine; H1 receptor; H2 receptor; dendritic cells	LANGERHANS CELLS; CALCIUM MOBILIZATION; CA2+ MOBILIZATION; ATOPIC-DERMATITIS; GENE-EXPRESSION; BLOOD MONOCYTES; ACTIVATION; GAMMA; NEUTROPHILS; MACROPHAGES	Background: Histamine is a well-known mediator of inflammatory and allergic reactions and has immunomodulatory capacities. There is increasing evidence that dendritic cells as professional antigen-presenting cells play a major role in the development of allergic reactions. However, a possible link between histamine and dendritic cells has not been investigated thus far. Objective: We investigated the effect of histamine on human monocyte-derived dendritic cells (MoDCs). Methods: Expression of histamine H1 and H2 receptors (H1R and H2R) on MoDCs was assessed by means of RT-PCR and flow cytometry. Functional exploration of these receptors was performed by monitoring the increase of intracellular calcium levels (H1R), cyclic adenosine monophosphate formation (H2R), F-actin polymerization, and IL-12p70 production. Results: MoDCs express both H1R and H2R. Stimulation of dendritic cells with histamine resulted in F-actin polymerization and cyclic adenosine monophosphate production through H2R. Influx of calcium could not be detected after stimulation of dendritic cells with histamine under conditions in which histamine induced calcium influx in monocytes. Histamine and H1R and H2R agonists downregulated IL-12p70 production of prestimulated MoDCs. Conclusion: MoDCs express histamine HI and H2 receptors. Our results indicate chemotactic (F-actin polymerization) and immunomodulatory (inhibition of IL-12p70 production) effects of histamine on MoDCs. Therefore histamine might represent a link between immediate-type hypersensitivity reactions and cellular inflammation in allergic disease (eg. in atopic dermatitis).	Hannover Med Univ, Dept Dermatol & Allergol, D-30449 Hannover, Germany	Hannover Medical School	Gutzmer, R (corresponding author), Hannover Med Univ, Dept Dermatol & Allergol, Ricklinger Str 5, D-30449 Hannover, Germany.		Werfel, Thomas/B-6921-2012	Kapp, Alexander/0000-0002-1748-6276				Arad G, 1996, CELL IMMUNOL, V170, P149, DOI 10.1006/cimm.1996.0145; Banu Y, 1999, J EXP MED, V189, P673, DOI 10.1084/jem.189.4.673; Bieber T, 1997, IMMUNOL TODAY, V18, P311, DOI 10.1016/S0167-5699(97)01046-3; Caron G, 2001, J IMMUNOL, V166, P6000, DOI 10.4049/jimmunol.166.10.6000; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; DESHAZO RD, 1982, J ALLERGY CLIN IMMUN, V69, P429, DOI 10.1016/0091-6749(82)90117-8; DICKENSON JM, 1993, BIOCHEM J, V292, P409, DOI 10.1042/bj2920409; DOHLSTEN M, 1988, SCAND J IMMUNOL, V27, P527, DOI 10.1111/j.1365-3083.1988.tb02379.x; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; Elsner J, 1996, J CELL PHYSIOL, V167, P548, DOI 10.1002/(SICI)1097-4652(199606)167:3<548::AID-JCP18>3.3.CO;2-Y; HARRIS JN, 1994, INT J IMMUNOPHARMACO, V16, P633, DOI 10.1016/0192-0561(94)90136-8; HERSHKOVIZ R, 1994, J LEUKOCYTE BIOL, V56, P495, DOI 10.1002/jlb.56.4.495; HOWARD TH, 1984, J CELL BIOL, V98, P1265, DOI 10.1083/jcb.98.4.1265; Ikeda H, 1997, ACTA OTO-LARYNGOL, V117, P864, DOI 10.3109/00016489709114216; ITO K, 1995, AM J PHYSIOL-LUNG C, V268, pL63, DOI 10.1152/ajplung.1995.268.1.L63; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kalinski P, 1998, J IMMUNOL, V161, P2804; Kirchhoff K, 2001, IMMUNOLOGY, V103, P210, DOI 10.1046/j.1365-2567.2001.01197.x; Kohka H, 2000, J IMMUNOL, V164, P6640, DOI 10.4049/jimmunol.164.12.6640; Kraft S, 1998, J IMMUNOL, V161, P1000; Krouwels FH, 1998, AM J RESP CELL MOL, V18, P721, DOI 10.1165/ajrcmb.18.5.2909; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; Lovenberg TW, 1999, MOL PHARMACOL, V55, P1101, DOI 10.1124/mol.55.6.1101; Maurer D, 1998, J IMMUNOL, V161, P2731; Niisato N, 1996, BIOCHEM PHARMACOL, V52, P1015, DOI 10.1016/0006-2952(96)00417-0; Niisato N, 1996, J PERIODONTAL RES, V31, P113, DOI 10.1111/j.1600-0765.1996.tb00472.x; Paltauf-Doburzynska J, 2000, J PHYSIOL-LONDON, V524, P701, DOI 10.1111/j.1469-7793.2000.00701.x; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; RADERMECKER M, 1989, INT ARCH ALLER A IMM, V88, P197, DOI 10.1159/000234784; Rasmussen R., 2001, RAPID CYCLE REAL TIM, P21, DOI [10.1007/978-3-642-59524-0_3, DOI 10.1007/978-3-642-59524-0_3]; SEIFERT R, 1994, N-S ARCH PHARMACOL, V349, P355, DOI 10.1007/BF00170880; TAYLOR RS, 1991, J IMMUNOL, V147, P3794; van der Pouw Kraan TCTM, 1998, J CLIN INVEST, V102, P1866, DOI 10.1172/JCI3692; VANNIER E, 1991, J EXP MED, V174, P281, DOI 10.1084/jem.174.1.281; Wang KY, 2000, FEBS LETT, V473, P345, DOI 10.1016/S0014-5793(00)01560-X; Werfel T, 2000, J IMMUNOL, V165, P6599, DOI 10.4049/jimmunol.165.11.6599; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596	37	63	68	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					524	531		10.1067/mai.2002.121944	http://dx.doi.org/10.1067/mai.2002.121944			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11898002				2022-12-18	WOS:000174586400022
J	Reider, N; Reider, D; Ebner, S; Holzmann, S; Herold, M; Fritsch, P; Romani, N				Reider, N; Reider, D; Ebner, S; Holzmann, S; Herold, M; Fritsch, P; Romani, N			Dendritic cells contribute to the development of atopy by an insufficiency in IL-12 production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; T(H)1/T(H)2; IL-12; IL-10; atopy; CD123; IL-4; IL-5; IL-13	AIRWAY HYPERRESPONSIVENESS; T-CELLS; CYTOKINE; INTERLEUKIN-12; ACTIVATION; MATURATION; RESPONSES; CD40; CAPACITY; INNATE	Background: IL-12 is a crucial factor in the development and course of allergic diseases. By virtue of their IL-12 production, dendritic cells (DCs) are potent inducers of T(H)1 responses. However, distinct subsets of DCs have also been shown to induce T(H)2 differentiation. Objective: We hypothesized that DCs from atopic and nonatopic individuals might differ in their propensity to skew T-cell responses to either the T(H)1 type or the TH2 type. To this end, we investigated the cytokine patterns produced by DCs from atopic and nonatopic individuals, and we attempted to clarify whether this could be due to different DC lineages or, alternatively, to different microenvironmental factors. Methods: DCs were generated from lymphocyte-depleted PBMCs from atopic and nonatopic donors and fully matured with monocyte-conditioned medium. Production of IL-4, IL-5, IL-10, IL-12, and IL-13 in response to CD40 ligation was measured with ELISA. DC subsets were identified in PBMCs from freshly drawn blood by 3-color flow cytometry. Results: Compared with DCs from healthy donors, monocyte-derived DCs from atopic patients produced less bioactive IL-12 and IL-10. DC production of IL-4, IL-13, and IL-5 was not detected. Relatively more CD123(+) DCs, corresponding to T(H)2-inducing "DC2s," were found in PBMCs from atopic patients. Conclusion: The data suggest that in addition to the described abnormalities in the patients' T-cell populations, DCs might also critically contribute to the atopic/allergic T(H)1 outcome in the patient and thus to the disease.	Univ Innsbruck, Dept Internal Med, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Dermatol, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Romani, N (corresponding author), Univ Innsbruck, Dept Dermatol, Anichstr 35, A-6020 Innsbruck, Austria.			Romani, Nikolaus/0000-0003-1614-9128; Ebner, Susanne/0000-0002-0394-9620				Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bellinghausen I, 2000, J ALLERGY CLIN IMMUN, V105, P988, DOI 10.1067/mai.2000.105526; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; De Wit D, 2000, J ALLERGY CLIN IMMUN, V105, P346, DOI 10.1016/S0091-6749(00)90086-1; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Ebner S, 2001, J IMMUNOL, V166, P633, DOI 10.4049/jimmunol.166.1.633; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; GATELY MK, 1995, CURRENT PROTOCOLS IM; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hochrein H, 2000, J EXP MED, V192, P823, DOI 10.1084/jem.192.6.823; Hyland ME, 1999, CLIN EXP ALLERGY, V29, P1467; Kalinski P, 1997, J IMMUNOL, V159, P28; Kalinski P, 2000, J IMMUNOL, V165, P1877, DOI 10.4049/jimmunol.165.4.1877; Kalinski P, 1999, J IMMUNOL, V162, P3231; Kapsenberg ML, 1996, INT ARCH ALLERGY IMM, V110, P107, DOI 10.1159/000237274; Kapsenberg ML, 2000, AM J RESP CRIT CARE, V162, pS76, DOI 10.1164/ajrccm.162.supplement_2.ras-4; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; OHMEN JD, 1995, J IMMUNOL, V154, P1956; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; Ono SJ, 2000, ANNU REV IMMUNOL, V18, P347, DOI 10.1146/annurev.immunol.18.1.347; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Rieser C, 1997, J EXP MED, V186, P1603, DOI 10.1084/jem.186.9.1603; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; Varga EM, 2000, J IMMUNOL, V165, P2877, DOI 10.4049/jimmunol.165.5.2877; Vieira PL, 2000, J IMMUNOL, V164, P4507, DOI 10.4049/jimmunol.164.9.4507	38	63	64	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					89	95		10.1067/mai.2002.120556	http://dx.doi.org/10.1067/mai.2002.120556			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799371				2022-12-18	WOS:000173739300014
J	Burgel, PR; Escudier, E; Coste, A; Dao-Pick, T; Ueki, IF; Takeyama, K; Shim, JJ; Murr, AH; Nadel, JA				Burgel, PR; Escudier, E; Coste, A; Dao-Pick, T; Ueki, IF; Takeyama, K; Shim, JJ; Murr, AH; Nadel, JA			Relation of epidermal growth factor receptor expression to goblet cell hyperplasia in nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway epithelium; mucin MUC5AC; epidermal growth factor receptor; nasal polyps; neutrophils; eosinophils	NECROSIS-FACTOR-ALPHA; MESSENGER-RNA EXPRESSION; EGF RECEPTOR; LUNG-TISSUE; TNF-ALPHA; NEUTROPHILS; EOSINOPHILS; PROTEIN; AIRWAYS; ACTIVATION	Background: Because the epidermal growth factor receptor (EGFR) system regulates mucin production in airway epithelium, we hypothesized a role for this system in mucus hypersecretion that occurs in nasal polyposis. Objective: We examined the relationship between goblet cell hyperplasia, EGFR expression, and inflammatory mediators produced by eosinophils and neutrophils in nasal polyp tissues, Methods: Nasal polyp tissue samples from 8 patients and nasal turbinate biopsy specimens from 6 normal control subjects were examined for alcian blue/PAS staining, mucin MUC5AC (MUC5AC), and EGFR immunoreactivity and EGFR gene expression (in situ hybridization). We also examined the role of eosinophils and neutrophils in goblet cell hyperplasia, Results: In control nasal mucosa alcian blue/periodic acid-Schiff- and MUC5AC-stained areas were 18.40% +/- 1.31% and 21.89% +/- 1.43%, respectively. In polyps the alcian blue/periodic acid-Schiff- and MUC5AC-stained areas were 51.30% +/- 5.85% and 52.07% +/- 6.58%, which was significantly larger than that found in control subjects (each comparison, P < .01). Four of 6 control specimens expressed EGFR messenger RNA and protein weakly in the epithelium. In polyps 4 of 8 specimens expressed EGFR gene and EGFR protein strongly; the EGFR-stained area was greater in hyperplastic than in pseudostratified epithelium. TNF-<alpha> immunoreactivity, expressed in eosinophils, was increased in EGFR-positive polyps compared with EGFR-negative polyps, suggesting a role for TNF-alpha in EGFR expression. Neutrophils were increased in the epithelium of EGFR-positive compared with EGFR-negative polyps, suggesting a role for these cells in mucin expression and in goblet cell degranulation, Conclusion: These data suggest a role for EGFR cascade in the regulation of goblet cell mucins in nasal polyps. Proof of concept will require clinical studies using selective EGFR inhibitors.	Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Otolaryngol, San Francisco, CA 94143 USA; Grp Hosp Pitie Salpetriere, Serv Histol, AP HP, F-75634 Paris, France; Hop Intercommunal & Henri Mondor, Serv Otorhinolaryngol & Chirurg Cervico Faciale, AP HP, Creteil, France	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHI Creteil	Nadel, JA (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA.			COSTE, Andre/0000-0002-8386-3455; Burgel, Pierre Regis/0000-0003-0903-9828				Aust MR, 1997, AM J RHINOL, V11, P293, DOI 10.2500/105065897781446685; BREZILLON S, 1995, LAB INVEST, V72, P191; Coste A, 1996, ACTA OTO-LARYNGOL, V116, P755, DOI 10.3109/00016489609137920; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dusi S, 1996, J IMMUNOL, V157, P4615; ELOVIC A, 1994, J ALLERGY CLIN IMMUN, V93, P864, DOI 10.1016/0091-6749(94)90379-4; FINOTTO S, 1994, J IMMUNOL, V153, P2278; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUNDT M, 1992, EUR J IMMUNOL, V22, P811, DOI 10.1002/eji.1830220327; KAKOI H, 1987, ACTA OTO-LARYNGOL, V103, P137, DOI 10.3109/00016488709134709; KRAJINA Z, 1987, ACTA OTO-LARYNGOL, V103, P435; LEE HM, 2000, AM J RESP CRIT CARE, V161, pA320; Lou YP, 1998, AM J RESP CRIT CARE, V157, P1927, DOI 10.1164/ajrccm.157.6.9709113; LUND VJ, 1995, BRIT MED J, V311, P1411, DOI 10.1136/bmj.311.7017.1411; MADTES DK, 1994, AM J RESP CELL MOL, V11, P540, DOI 10.1165/ajrcmb.11.5.7524566; OHKAWARA Y, 1992, AM J RESP CELL MOL, V7, P385, DOI 10.1165/ajrcmb/7.4.385; PALUDETTI G, 1983, Rhinology (Utrecht), V21, P347; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; SOZZANI S, 1994, BLOOD, V84, P3895, DOI 10.1182/blood.V84.11.3895.bloodjournal84113895; STOOP AE, 1993, J ALLERGY CLIN IMMUN, V91, P616, DOI 10.1016/0091-6749(93)90267-J; Takeyama K, 2000, J IMMUNOL, V164, P1546, DOI 10.4049/jimmunol.164.3.1546; Takeyama K, 1998, AM J PHYSIOL-LUNG C, V275, pL294, DOI 10.1152/ajplung.1998.275.2.L294; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; VOYNOW JA, 1994, AM J RESP CELL MOL, V11, P742, DOI 10.1165/ajrcmb.11.6.7946402; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; XING Z, 1993, AM J PATHOL, V143, P1009	29	63	67	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					705	712		10.1067/mai.2000.109823	http://dx.doi.org/10.1067/mai.2000.109823			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031341				2022-12-18	WOS:000089980600014
J	Skoner, DP				Skoner, DP			Complications of allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Conference on Advances in Allergic Diseases - An Update for the New Millennium	FEB 11, 1999	WASHINGTON, D.C.			allergic rhinitis; eustachian tube obstruction; middle ears underpressure; otitis media with effusion; sinusitis	EUSTACHIAN-TUBE OBSTRUCTION; ACUTE OTITIS-MEDIA; INFLAMMATORY MEDIATORS; FOLLOW-UP; SINUSITIS; ASTHMA; NASAL; INFECTION; CHALLENGE; CHILDREN	Upper and lower respiratory diseases, including asthma, sinusitis, and otitis media with effusion, frequently complicate allergic rhinitis, The close association of nasal allergies with these conditions has been supported by extensive epidemiologic evidence. Similar models have been proposed to explain the pathophysiologic links between allergic rhinitis and both sinusitis and otitis media with effusion. In these models, inflammation caused by nasal allergy and/or viral infection leads to obstruction, fluid accumulation, bacterial infection, and acute disease. If these diseases are unsuccessfully treated, a chronic state of inflammation, obstruction, and infection develops that can cause mucosal damage and, ultimately, chronic disease. A number of studies have investigated the roles and interactions of viruses and allergens in the development of otitis media with effusion. Diagnosing and prophylactically treating nasal allergies in patients with this condition may help prevent recurrent episodes and improve the response to therapy.	Childrens Hosp Pittsburgh, Dept Allergy & Immunol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Skoner, DP (corresponding author), Childrens Hosp Pittsburgh, Dept Allergy & Immunol, 3705 5th Ave, Pittsburgh, PA 15213 USA.							BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BUCHMAN CA, 1995, J INFECT DIS, V172, P1348, DOI 10.1093/infdis/172.5.1348; BUSSE WW, 1988, J ALLERGY CLIN IMMUN, V81, P770, DOI 10.1016/0091-6749(88)90930-X; DOYLE WJ, 1994, ANN OTO RHINOL LARYN, V103, P59, DOI 10.1177/000348949410300111; Fireman P, 1997, J ALLERGY CLIN IMMUN, V99, pS787, DOI 10.1016/S0091-6749(97)70130-1; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; Heikkinen T, 1999, NEW ENGL J MED, V340, P260, DOI 10.1056/NEJM199901283400402; Kapsali T, 1997, J ALLERGY CLIN IMMUN, V99, P556; KNIGHT LC, 1992, CLIN OTOLARYNGOL, V17, P308, DOI 10.1111/j.1365-2273.1992.tb01002.x; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x; RACHELEFSKY G S, 1991, Journal of Allergy and Clinical Immunology, V87, P219, DOI 10.1016/0091-6749(91)91603-Q; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; REILLY JS, 1990, OTOLARYNG HEAD NECK, V103, P856, DOI 10.1177/01945998901030S504; SAVOLAINEN S, 1989, ALLERGY, V44, P116, DOI 10.1111/j.1398-9995.1989.tb02234.x; SETTIPANE GA, 1986, OTOLARYNG HEAD NECK, V94, P470, DOI 10.1177/019459988609400411; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SHAPIRO GG, 1988, J ALLERGY CLIN IMMUN, V82, P935, DOI 10.1016/0091-6749(88)90036-X; SHAPIRO GG, 1991, PEDIATRICS, V87, P311; SKONER DP, 1986, ARCH OTOLARYNGOL, V112, P840; SKONER DP, 1990, ANN ALLERGY, V65, P206; SKONER DP, 1987, J ALLERGY CLIN IMMUN, V79, P27, DOI 10.1016/S0091-6749(87)80012-X; SKONER DP, 1995, CLIN EXP ALLERGY, V25, P561, DOI 10.1111/j.1365-2222.1995.tb01095.x; SKONER DP, 1988, ARCH OTOLARYNGOL, V114, P1131; SKONER DP, 1988, AM J RHINOL, V2, P155; SKONER DP, 1989, AM J RHINOL, V3, P53; STILLWAGON PK, 1987, ANN ALLERGY, V58, P442; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; TOMONAGA K, 1988, ACTA OTO-LARYNGOL, P41; TURNER BW, 1992, J ALLERGY CLIN IMMUN, V90, P474, DOI 10.1016/0091-6749(92)90172-X	30	63	66	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	2	S			S605	S609		10.1067/mai.2000.106150	http://dx.doi.org/10.1067/mai.2000.106150			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	328QU	10856165				2022-12-18	WOS:000087862200003
J	Pucci, N; Lombardi, E; Novembre, E; Farina, S; Bernardini, R; Rossi, E; Favilli, T; Vierucci, A				Pucci, N; Lombardi, E; Novembre, E; Farina, S; Bernardini, R; Rossi, E; Favilli, T; Vierucci, A			Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: Correlation with disease activity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; eosinophil cationic protein; eosinophil protein X; eosinophils	CHILDHOOD ASTHMA; ECP; PATHOGENESIS; NEUROTOXIN; MARKERS; ECZEMA	Background: Eosinophil cationic protein (ECP) and eosinophil protein X (EPX) or eosinophil-derived neurotoxin (EDN) are released by eosinophil granulocytes in allergic diseases. Serum ECP (s-ECP) levels have been correlated with disease activity in atopic dermatitis (AD) in adults and young patients, and high urinary EPX (u-EPX) levels in asthmatic patients seem to reflect active disease. A relationship between AD severity and u-EPX concentration in young children has not been previously studied. Objective: This study was performed to evaluate whether the severity of AD in infants and young children was correlated with s-ECP and u-EPX levels. Methods: Fifty-four infants and children (mean age, 17.7 months; range, 4-48 months) with AD and without other allergic conditions were evaluated. The severity of AD was measured by using the SCORAD index. S-ECP, serum total IgE, serum-specific IgE for common allergens, and peripheral blood eosinophil counts (PBECs) were determined. In forty-two children u-EPX was also measured. Seven age-matched control patients underwent the same determinations. Results: S-ECP and u-EPX were significantly higher in children with AD than in control children (mean, 23.9 vs 3.5 mu g/dL [P < .001] and 57.7 vs 6.0 mu g/mmol creatinine [P < .001]). A significant correlation was found between SCORAD and s-ECP (P = .002), u-EPX (P = .01), and PBECs (P = .01) and between symptom index and uEPX (P = .0004), PBECs were strongly correlated to s-ECP and u-EPX (P < .0001). However, 5 patients with moderate and severe AD (11.9%) showed low levels of s-ECP, u-EPX, and PBECs. Conclusion: S-ECP and u-EPX were useful markers of AD activity in infants and young children. When taken together, the two determinations could give more information about the clinical course of the illness. Some patients seemed to have clinical exacerbations without an involvement of eosinophils and their products.	Univ Florence, Anna Meyer Hosp, Dept Pediat, Allergy & Clin Immunol Unit, I-50132 Florence, Italy	University of Florence	Pucci, N (corresponding author), Univ Florence, Anna Meyer Hosp, Dept Pediat, Allergy & Clin Immunol Unit, Via Luca Giordano 13, I-50132 Florence, Italy.		Lombardi, Enrico/K-3356-2016	Lombardi, Enrico/0000-0003-4749-9091				Akdis CA, 1999, INT ARCH ALLERGY IMM, V118, P140, DOI 10.1159/000024051; BELTRANIV S, 1996, ATOPIC DERMATITIS PA; Cheng JF, 1997, J ALLERGY CLIN IMMUN, V99, P683, DOI 10.1016/S0091-6749(97)70031-9; Cottin V, 1998, J ALLERGY CLIN IMMUN, V101, P116, DOI 10.1016/S0091-6749(98)70202-7; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; DEVILLER P, 1991, CLIN CHIM ACTA, V201, P105, DOI 10.1016/0009-8981(91)90031-7; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Fujisawa T, 1998, CLIN EXP ALLERGY, V28, P19; Furue Masutaka, 1994, Journal of Dermatological Science, V7, P89, DOI 10.1016/0923-1811(94)90081-7; GLEICH GJ, 1992, INFLAMMATION BASIC P, P663; Halmerbauer G, 1997, ALLERGY, V52, P765, DOI 10.1111/j.1398-9995.1997.tb01236.x; HAMANN KJ, 1990, GENOMICS, V7, P535, DOI 10.1016/0888-7543(90)90197-3; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HIROHITO K, 1998, ALLERGY PRINCIPLES P, P242; KAGI MK, 1992, DERMATOLOGY, V185, P88, DOI 10.1159/000247419; KAPP A, 1993, ALLERGY, V48, P1, DOI 10.1111/j.1398-9995.1993.tb02167.x; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; Kristjansson S, 1996, J ALLERGY CLIN IMMUN, V97, P1179, DOI 10.1016/S0091-6749(96)70182-3; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; Lugosi E, 1997, ALLERGY, V52, P584, DOI 10.1111/j.1398-9995.1997.tb02605.x; Marks GB, 1998, CLIN EXP ALLERGY, V28, P1345; MUSGROVE K, 1976, BRIT J DERMATOL, V95, P365, DOI 10.1111/j.1365-2133.1976.tb00837.x; Oosaki R, 1998, CLIN EXP ALLERGY, V28, P1138; OTT NL, 1994, J ALLERGY CLIN IMMUN, V94, P120, DOI 10.1016/0091-6749(94)90078-7; PAGANELLI R, 1991, INT ARCH ALLER A IMM, V96, P175, DOI 10.1159/000235490; REIMERT CM, 1993, ACTA TROP, V54, P1, DOI 10.1016/0001-706X(93)90063-H; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; SCHAUER U, 1995, ALLERGY, V50, P126; Shirakawa S, 1998, Arerugi, V47, P1240; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; SUR S, 1988, J LEUKOCYTE BIOL, V63, P715; Vanto T, 1998, ALLERGY, V53, P415, DOI 10.1111/j.1398-9995.1998.tb03915.x; WELLER PF, 1991, NEW ENGL J MED, V324, P1110	34	63	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				353	357		10.1016/S0091-6749(00)90087-3	http://dx.doi.org/10.1016/S0091-6749(00)90087-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669858	Bronze			2022-12-18	WOS:000085402200022
J	Piacentini, GL; Bodini, A; Costella, S; Vicentini, L; Peroni, D; Zanolla, L; Boner, AL				Piacentini, GL; Bodini, A; Costella, S; Vicentini, L; Peroni, D; Zanolla, L; Boner, AL			Allergen avoidance is associated with a fall in exhaled nitric oxide in asthmatic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nitric oxide; asthma; antigen avoidance; mites	MITE		Univ Verona, Policlin Borgo Roma, Pediat Clin, I-37134 Verona, Italy; Ist Pio XII, Belluno, Italy; Univ Verona, Dept Cardiol, I-37100 Verona, Italy	University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona	Piacentini, GL (corresponding author), Univ Verona, Policlin Borgo Roma, Pediat Clin, I-37134 Verona, Italy.		Peroni, Diego G/K-4002-2018; Peroni, Diego/K-8795-2016	Peroni, Diego/0000-0002-0234-1373; Zanolla, Luisa/0000-0002-3626-9699				ALVING K, 1993, EUR RESPIR J, V6, P1368; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Kharitonov SA, 1996, CURR OPIN ANAESTH, V9, P542	5	63	65	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1323	1324		10.1016/S0091-6749(99)70031-X	http://dx.doi.org/10.1016/S0091-6749(99)70031-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589019				2022-12-18	WOS:000084289200031
J	Wiedermann, U; Jahn-Schmid, B; Bohle, B; Repa, A; Renz, H; Kraft, D; Ebner, C				Wiedermann, U; Jahn-Schmid, B; Bohle, B; Repa, A; Renz, H; Kraft, D; Ebner, C			Suppression of antigen-specific T- and B-cell responses by intranasal or oral administration of recombinant Bet v 1, the major birch pollen allergen, in a murine model of type I allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; birch pollen; Bet v 1; tolerance suppression; in vivo animal model; BALB c	AUTOIMMUNE MYASTHENIA-GRAVIS; MUCOSAL TOLERANCE; IMMUNE-RESPONSE; INHALED ANTIGEN; IGE RESPONSES; INDUCTION; MICE; INHIBITION; OVALBUMIN; INHALATION	Background: Mucosal (nasal or oral) administration of soluble protein antigens induces a state of antigen-specific immunologic hyporesponsiveness. Several studies have shown that induction of mucosal tolerance can prevent the onset or reduce the severity of certain T-H1-mediated experimental autoimmune diseases. Only a few studies describe similar results for type I allergies, which are caused by excessive T-H2 cell activities. Objective: We sought to investigate whether mucosal tolerance induction would also be efficient in preventing an allergic type I immune response. Methods: A murine model of inhalative type I allergy, leading to sensitization to birth pollen and its major allergen Bet v 1 in BALB/c mice, was used. Recombinant Bet v 1 was nasally or orally applied in low doses before sensitization. At the time of death, immediate-type skin tests were performed. Blood was taken, and serum was used for measurement of allergen-specific antibodies. Spleen cell cultures were performed to determine cytokine production (IL-4, IL-5, IL-10, and IFN-gamma), as well as levels of TGF-beta mRNA. Results: Both nasal and oral administration of minimal doses of recombinant Bet v 1 before aerosol sensitization with birch pollen suppressed the allergen-specific antibody production of all isotypes. Consequently, the in vivo type I skin test responses to the allergen were negative in the tolerized, in contrast to the sensitized, group. Moreover, allergen-specific lymphoproliferative responses and cytokine production in vitro (ie, IFN-gamma, IL-4 IL-5, and IL-10) were markedly reduced. In contrast, expression of TGF-beta mRNA was markedly increased in spleen cells from nasally tolerized animals, indicating regulatory mechanisms for tolerance induction. Conclusion: We conclude from the present study that nasal, as well as oral, administration of recombinant allergen is an effective way to prevent allergen-specific T- and B-cell responses in a T-H2 model.	Univ Vienna, Inst Gen & Expt Pathol, Div Immunopathol, A-1090 Vienna, Austria; Agr Univ Vienna, Ctr Ultrastruct Res, A-1180 Vienna, Austria; Charite Virchow Klinikum, Inst Lab Med & Pathobiochem, Berlin, Germany	University of Vienna; University of Natural Resources & Life Sciences, Vienna; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wiedermann, U (corresponding author), Univ Vienna, Inst Gen & Expt Pathol, Div Immunopathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.			Bohle, Barbara/0000-0002-5105-7985; Wiedermann, Ursula/0000-0002-1302-3223				AROEIRA LS, 1995, SCAND J IMMUNOL, V41, P319, DOI 10.1111/j.1365-3083.1995.tb03573.x; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; FISHMANLOBELL J, 1994, EUR J IMMUNOL, V24, P2720, DOI 10.1002/eji.1830241122; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; GARSIDE P, 1995, J IMMUNOL, V154, P5649; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Haneda K, 1997, J IMMUNOL, V159, P4484; HOLT PG, 1981, IMMUNOLOGY, V42, P409; HOYNE G, 1996, INT IMMUNOL, V7, P335; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; Lowrey JA, 1998, INT ARCH ALLERGY IMM, V116, P93, DOI 10.1159/000023931; MA CG, 1995, J NEUROIMMUNOL, V58, P51, DOI 10.1016/0165-5728(94)00187-S; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MELAMED D, 1994, EUR J IMMUNOL, V24, P1974, DOI 10.1002/eji.1830240906; Melamed D, 1996, INT IMMUNOL, V8, P717, DOI 10.1093/intimm/8.5.717; Metzler B, 1996, ANN NY ACAD SCI, V778, P228, DOI 10.1111/j.1749-6632.1996.tb21131.x; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Strobel S, 1998, IMMUNOL TODAY, V19, P173, DOI 10.1016/S0167-5699(97)01239-5; Tian JD, 1996, J EXP MED, V183, P1561, DOI 10.1084/jem.183.4.1561; vanHalteren AG, 1997, J IMMUNOL, V159, P3009; WANG ZY, 1994, CELL IMMUNOL, V157, P353, DOI 10.1006/cimm.1994.1233; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144; Wolvers DAW, 1997, IMMUNOLOGY, V92, P328, DOI 10.1046/j.1365-2567.1997.00356.x; Wu XM, 1998, EUR J IMMUNOL, V28, P134, DOI 10.1002/(SICI)1521-4141(199801)28:01<134::AID-IMMU134>3.0.CO;2-3; Xiao BG, 1997, CLIN IMMUNOL IMMUNOP, V85, P119, DOI 10.1006/clin.1997.4432; Yasue M, 1997, CELL IMMUNOL, V181, P30, DOI 10.1006/cimm.1997.1184; ZHANG ZYJ, 1990, J IMMUNOL, V145, P2489	37	63	66	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1202	1210		10.1016/S0091-6749(99)70200-9	http://dx.doi.org/10.1016/S0091-6749(99)70200-9			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359907				2022-12-18	WOS:000080929500034
J	Nelson, HS; Busse, WW; deBoisblanc, BP; Berger, WE; Noonan, MJ; Webb, DR; Wolford, JP; Mahajan, PS; Hamedani, AG; Shah, T; Harding, SM				Nelson, HS; Busse, WW; deBoisblanc, BP; Berger, WE; Noonan, MJ; Webb, DR; Wolford, JP; Mahajan, PS; Hamedani, AG; Shah, T; Harding, SM			Fluticasone propionate powder: Oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	FEB 19-26, 1997	SAN FRANCISCO, CA	Amer Acad Allergy Asthma & Immunol		asthma; Diskus; fluticasone propionate; oral corticosteroid-sparing	STEROID-DEPENDENT ASTHMA; OF-LIFE; QUESTIONNAIRE; OSTEOPOROSIS; CYCLOSPORINE; METHOTREXATE; PHARMACOLOGY; THERAPY; AEROSOL	Background: Many patients with severe asthma are dependent on oral corticosteroids for maintenance control of their disease. Treatments that allow patients to be weaned off oral corticosteroids may help to minimize the risk of side effects associated with their chronic use. Objective: This study evaluated whether inhaled fluticasone propionate powder could maintain pulmonary function while reducing the dose of oral prednisone in patients with chronic, severe asthma. Methods: Oral prednisone-dependent (5 to 40 mg/day) adolescents and adults with asthma (n = 111; mean FEV1 = 61% of predicted value) were randomized to placebo or twice daily fluticasone propionate 500 or 1000 mu g administered by means of a multidose powder inhaler for 16 weeks in a double-blind, parallel-group study, Patients underwent controlled prednisone reduction on the basis of predetermined asthma stability criteria. Results: Oral prednisone was eliminated by 75% and 89% of patients in the twice daily 500 and 1000 mu g fluticasone propionate groups, respectively, versus 9% of the placebo group (P < .001). FEV1, morning and evening peak expiratory flow, asthma symptoms, albuterol use, and nighttime awakenings improved with fluticasone propionate treatment, achieving statistical significance (P less than or equal to .009) primarily in the 1000 mu g twice daily group. Hypothalamic-pituitary-adrenal axis suppression observed at baseline improved when patients were weaned off oral prednisone to fluticasone propionate. Adverse events ascribed to drug treatment were primarily topical effects of inhaled corticosteroids or those associated with prednisone withdrawal. Patient quality of life assessed by means of the Asthma Quality of Life Questionnaire was clinically and significantly improved after fluticasone propionate treatment (P less than or equal to .003). Conclusion: Fluticasone propionate powder (500 or 1000 mu g twice daily) effectively improved lung function, adrenal function, and asthma-specific quality of life in patients with severe chronic asthma previously treated with oral prednisone while allowing most patients to be weaned off oral corticosteroid therapy.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Wisconsin, Ctr Clin Canc, Madison, WI USA; Louisiana State Univ, Med Ctr, New Orleans, LA USA; So Calif Res Ctr, Mission Viejo, CA USA; Allergy Associates PC, Portland, OR USA; Allergy & Asthma Associates, Kirkland, WA USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	National Jewish Health; University of Wisconsin System; University of Wisconsin Madison; Louisiana State University System; GlaxoSmithKline	Nelson, HS (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St,Room A107, Denver, CO 80206 USA.							Adachi JD, 1997, NEW ENGL J MED, V337, P382, DOI 10.1056/NEJM199708073370603; ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; Barnes NC, 1998, RESP MED, V92, P95, DOI 10.1016/S0954-6111(98)90039-7; Bernstein IL, 1996, J ALLERGY CLIN IMMUN, V98, P317, DOI 10.1016/S0091-6749(96)70156-2; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; DYER PD, 1991, J ALLERGY CLIN IMMUN, V88, P208, DOI 10.1016/0091-6749(91)90330-Q; ERZURUM SC, 1991, ANN INTERN MED, V114, P353, DOI 10.7326/0003-4819-114-5-353; Esmailpour N, 1997, EUR RESPIR J, V10, P1496, DOI 10.1183/09031936.97.10071496; Gross GN, 1998, AM J MANAG CARE, V4, P233; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; Harding SM, 1997, ADV THER, V14, P153; HOGGER P, 1994, STEROIDS, V59, P597, DOI 10.1016/0039-128X(94)90054-X; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; LACRONIQUE J, 1991, EUR RESPIR J, V4, P807; LI JTC, IN PRESS J ALLERGY C; LIEBERMAN P, 1972, J ALLERGY CLIN IMMUN, V49, P329, DOI 10.1016/0091-6749(72)90131-5; MALTON A, 1995, EUR J CLIN RES, V7, P177; Nelson H, 1998, J ALLERGY CLIN IMMUN, V101, pS11; NIEROP G, 1992, THORAX, V47, P349, DOI 10.1136/thx.47.5.349; *NIH, 1997, NIH PUBL; NIZANKOWSKA E, 1995, EUR RESPIR J, V8, P1091, DOI 10.1183/09031936.95.08071091; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Okamoto LJ, 1996, ANN ALLERG ASTHMA IM, V76, P455, DOI 10.1016/S1081-1206(10)63463-1; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; POLGAR G, 1971, PULMONARY FUNCTION T, P12; REID IR, 1989, CLIN ENDOCRINOL, V30, P83, DOI 10.1111/j.1365-2265.1989.tb03730.x; ROSENHALL L, 1982, EUR J RESPIR DIS, V63, P154; RUTTENVANMOLKEN MPMH, 1995, EUR RESPIR J, V8, P888; SMITH ND, 1993, DRUG INF J, V27, P617; TRUHAN AP, 1987, ANN ALLERGY, V58, P326; Wasserman SI, 1996, J ASTHMA, V33, P265, DOI 10.3109/02770909609055367	37	63	69	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				267	275		10.1016/S0091-6749(99)70501-4	http://dx.doi.org/10.1016/S0091-6749(99)70501-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	167JW	9949318				2022-12-18	WOS:000078630100014
J	Kraft, M; Vianna, E; Martin, RJ; Leung, DYM				Kraft, M; Vianna, E; Martin, RJ; Leung, DYM			Nocturnal asthma is associated with reduced glucocorticoid receptor binding affinity and decreased steroid responsiveness at night	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoid receptors; nocturnal asthma; circadian rhythm	PRIMARY CORTISOL RESISTANCE; INFLAMMATION	Background: The mechanisms for heightened nocturnal inflammation in patients with nocturnal asthma (NA) are not well understood. Objective: We sought to determine the glucocorticoid receptor (GR) characteristics and steroid responsiveness in subjects with NA. Methods: Eleven subjects with NA, 12 subjects with nonnocturnal asthma (NNA), and 16 nonasthmatic control subjects underwent blood sampling at 4 PM and 4 AM in a random order separated by 1 week. GR binding affinity was measured in PBMCs by using a [H-3]-dexamethasone (DX) radioligand binding assay and Scatchard analysis. The capacity of hydrocortisone (HC) and DX to suppress proliferation of PBMCs stimulated with PHA was also determined. Results: The subjects with NA exhibited a significantly lower CR binding affinity at 4 AM, detected by an elevated dissociation constant (Kd) of 22.2 +/- 1.6 nmol/L compared with Ed at 1 PM (10.9 +/- 0.7 nmol/L; P = .0001). The GR lid of the NNA and control groups did not change significantly from 4 PM to 4 AM, Within the NA group, there was also a significant inverse correlation between the absolute FEV1 at 4 AM and the Kd at 4 AM (r = -0.65, P = .04). PBMCs from subjects with NA exhibited less suppression of PBMC proliferation with HC and DX at 4 AM compared with that at 4 PM (P = .0001 and .03 for HC and DX? respectively). There were no circadian changes in suppression of PBMC proliferation in either the NNA or control groups. Conclusion: GR binding affinity and steroid responsiveness exhibit a circadian variation in subjects with NA, with a reduced GR binding affinity and suppression of PBMC proliferation at 4 AM that is not observed in normal subjects or asthmatic subjects without nocturnal exacerbation. These observations may contribute to nocturnal airway inflammation by inhibiting the antiinflammatory effects of glucocorticoids.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kraft, M (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St,Room J107, Denver, CO 80206 USA.		Vianna, Elcio/I-2508-2016	Vianna, Elcio/0000-0003-1902-6326	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, K08HL003343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03343, HL36577] Funding Source: Medline; NIAMS NIH HHS [AR-41256] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adcock IM, 1996, EUR RESPIR J, V9, P160, DOI 10.1183/09031936.96.09010160; ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BORISH L, 1992, J IMMUNOL, V149, P3078; CHROUSOS GP, 1982, J CLIN INVEST, V69, P1261, DOI 10.1172/JCI110565; CHROUSOS GP, 1993, ANN INTERN MED, V119, P1113, DOI 10.7326/0003-4819-119-11-199312010-00009; Cochran WG., 1989, AMES IOWA STATE U PR, V8; CRABTREE GR, 1981, METHODS HEMATOLOGY, V2, P252; HERRSCHER RF, 1992, J CLIN INVEST, V90, P596, DOI 10.1172/JCI115898; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; JARJOUR NN, 1995, AM J RESP CRIT CARE, V152, P1474, DOI 10.1164/ajrccm.152.5.7582279; KAM JC, 1993, J IMMUNOL, V151, P3460; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Kraft M, 1998, CHRONOBIOL INT, V15, P85, DOI 10.3109/07420529808998672; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; MALCHOFF CD, 1990, J CLIN ENDOCR METAB, V70, P503, DOI 10.1210/jcem-70-2-503; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MARTIN RJ, 1990, AM REV RESPIR DIS, V141, P33, DOI 10.1164/ajrccm/141.1.33; Nimmagadda SR, 1997, AM J RESP CRIT CARE, V155, P87, DOI 10.1164/ajrccm.155.1.9001294; *SAS I STAT, 1997, CHANG ENB REL 6 12; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SPAHN JD, 1995, AM J RESP CRIT CARE, V151, P1709, DOI 10.1164/ajrccm.151.6.7767511; VIANNA EO, 1997, AM J RESP CRIT CARE, V155, pA887; WELLER FR, 1986, J ALLERGY CLIN IMMUN, V78, P423, DOI 10.1016/0091-6749(86)90028-X; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; WERNER S, 1992, J CLIN ENDOCR METAB, V75, P1005, DOI 10.1210/jc.75.4.1005; WILSON SJ, 1996, AM J RESP CRIT CARE, V153, pA878	27	63	64	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				66	71		10.1016/S0091-6749(99)70527-0	http://dx.doi.org/10.1016/S0091-6749(99)70527-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893187				2022-12-18	WOS:000078112300011
J	Armentia, A; Lombardero, M; Callejo, A; Santos, JMM; Gil, FJM; Vega, J; Arranz, ML; Martinez, C				Armentia, A; Lombardero, M; Callejo, A; Santos, JMM; Gil, FJM; Vega, J; Arranz, ML; Martinez, C			Occupational asthma by Anisakis simplex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anisakis simplex; occupational asthma; allergy to fish; fish flour	PROTEINS	Background: No cases of occupational asthma caused by the inhalation of antigens from Anisakis simplex have been published. Objective: The purpose of this study was to evaluate the possibility that A simplex ran play a role in the asthma experienced by 2 workers when handling fish and fish flour. Methods: Skin prick and bronchial challenge tests with A simplex were performed. We also carried out measurements of specific IgE to A simplex and immunoblotting. Results: Both patients had strong positive skin test responses, challenge test responses, and specific IgE to A simplex. Immunoblotting showed that both patients also had IgE against several hands in the fish flour extract, suggesting contamination by Anisakis allergens. Conclusion: These 2 patients provide evidence for occupational asthma caused by A simplex, based on in vivo and in vitro tests for Anisakis-specific IgE.	Hosp Rio Hortega, Serv Alergia, Valladolid 47010, Spain; Hosp Rio Hortega, Serv Bioquim, Valladolid 47010, Spain; ALK ABELLO, Madrid, Spain	Hospital del Rio Hortega; Hospital del Rio Hortega; ALK-Abello AS	Armentia, A (corresponding author), Hosp Rio Hortega, Serv Alergia, Cardenal Torquemada SN, Valladolid 47010, Spain.		Martin-Gil, Francisco Javier/C-4696-2013; Armentia, Alicia/GLS-3358-2022	Martin-Gil, Francisco Javier/0000-0003-4989-6197; ARMENTIA, ALICIA/0000-0002-4165-4305				ARMENTIA A, 1992, ANN ALLERGY, V68, P398; Armentia A, 1997, J ASTHMA, V34, P369, DOI 10.3109/02770909709055378; AUDICANA MT, 1995, J ALLERGY CLIN IMMUN, V96, P558, DOI 10.1016/S0091-6749(95)70301-2; CHATHAM M, 1982, CHEST, V82, P15, DOI 10.1378/chest.82.1.15; Estrada Rodriguez J L, 1997, Allergol Immunopathol (Madr), V25, P95; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; HARGREAV.FE, 1966, LANCET, V1, P445; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Perteguer MJ, 1996, INT J PARASITOL, V26, P105, DOI 10.1016/0020-7519(95)00111-5; SAKANARI JA, 1990, J PARASITOL, V76, P625, DOI 10.2307/3282971; SANCHEZMADRID F, 1984, J IMMUNOL METHODS, V73, P367, DOI 10.1016/0022-1759(84)90412-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	13	63	63	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1998	102	5					831	834		10.1016/S0091-6749(98)70024-7	http://dx.doi.org/10.1016/S0091-6749(98)70024-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	139MR	9819301				2022-12-18	WOS:000077033400018
J	Cameron, LA; Durham, SR; Jacobson, MR; Masuyama, K; Juliusson, S; Gould, HJ; Lowhagen, O; Minshall, EM; Hamid, OA				Cameron, LA; Durham, SR; Jacobson, MR; Masuyama, K; Juliusson, S; Gould, HJ; Lowhagen, O; Minshall, EM; Hamid, OA			Expression of IL-4, C epsilon RNA, and I epsilon RNA in the nasal mucosa of patients with seasonal rhinitis: Effect of topical corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; C epsilon; I epsilon; IL-4; allergic rhinitis; topical corticosteroids	COLONY-STIMULATING FACTOR; CYTOKINE MESSENGER-RNA; HUMAN B-CELLS; FLUTICASONE PROPIONATE; LOCAL PRODUCTION; IGE ANTIBODIES; T-CELLS; IMMUNOGLOBULIN-E; REGION GENES; HAY-FEVER	Background: Nasal allergen provocation has demonstrated that allergen-induced rhinitis is associated with an increase in local IL-4 mRNA and IgE heavy chain (C epsilon) and IgE heavy chain promoter (I epsilon) RNA and that pretreatment with topical glucocorticosteroids inhibits the increase in these transcripts. Objective; This study was undertaken ta determine whether observations made after acute allergen provocation can be extended to the case of chronic exposure experienced during the pollen season. Methods: Biopsy specimens were obtained from the inferior turbinate of 33 pollen-sensitive subjects with allergic rhinitis before and during pollen season. Patients were randomized in a double-blind fashion and treated with either topical steroids (200 mu g fluticasone propionate twice daily; n = 16) or matched placebo nasal sprag (n = 17) before the pollen season. Alkaline phospatase anti-alkaline phosphatase immunocytochemistry was used to identify B cells (CD20(+)), and in situ hybridization was used to detect IL-4, C epsilon and I epsilon RNA(+) cells. Results: Baseline examination revealed IL-4 and C epsilon RNA but virtually no I epsilon RNA(+) cells in the nasal mucosa. Analysis revealed a significant difference in the expression of C epsilon and I epsilon RNA(+) cells (p < 0.001). Biopsy specimens taken after antigen exposure exhibited highly significant increases in placebo-treated (p < 0.001) but not steroid-treated patients. In both groups, the number of CD20(+) cells was unchanged when preexposure and postexposure biopsy specimens were compared. Conclusions: These results show strong support for the hypothesis that IgE class switching occurs locally within the nasal mucosa of subjects with seasonal allergic rhinitis and that this response can be inhibited through strategies directed against local IgE production.	McGill Univ, Meakins Christie Labs, Quebec City, PQ H2X 2P2, Canada; Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6LY, England; Univ London Kings Coll, Randall Inst, London WC2R 2LS, England; Sahlgrenska Hosp, Allergy Clin, Gothenburg, Sweden	McGill University; Imperial College London; Royal Brompton Hospital; University of London; King's College London; Sahlgrenska University Hospital	Hamid, OA (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain, Quebec City, PQ H2X 2P2, Canada.			Gould, Hannah/0000-0003-0411-688X				ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; DELPRETE G, 1988, J IMMUNOL, V140, P4193; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128, DOI 10.1159/000237525; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; DURHAM SR, 1992, J IMMUNOL, V148, P2390; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GESSNER A, 1994, INFECT IMMUN, V62, P411; GILLON J, 1981, IMMUNOL TODAY, V2, P80, DOI 10.1016/0167-5699(81)90035-9; GROSS A, 1993, J IMMUNOL, V150, P2112; HUGGINS KG, 1975, LANCET, V2, P148; ILLIUM P, 1978, ACTA OTOLARYNGOL, V86, P135; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KIMATA H, 1995, J IMMUNOL, V154, P3557; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; LUTZKER S, 1988, CELL, V53, P77; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MASUYAMA K, 1995, J ALLERGY CLIN IMMUN, V95, P300; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NONOYAMA S, 1993, J EXP MED, V178, P1097, DOI 10.1084/jem.178.3.1097; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; RAK S, 1994, CLIN EXP ALLERGY, V24, P930, DOI 10.1111/j.1365-2222.1994.tb02724.x; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; ROTHMAN P, 1990, MOL CELL BIOL, V10, P1672, DOI 10.1128/MCB.10.4.1672; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; VAMEY VA, 1992, AM REV RESPIR DIS, V146, P170; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5	35	63	67	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					330	336		10.1016/S0091-6749(98)70244-1	http://dx.doi.org/10.1016/S0091-6749(98)70244-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525448				2022-12-18	WOS:000072593900009
J	Teuber, SS; Brown, RL; Haapanen, LAD				Teuber, SS; Brown, RL; Haapanen, LAD			Allergenicity of gourmet nut oils processed by different methods	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; oils; tree nuts; peanut	FOOD; CHILDREN	Background: No information is available on allergenicity of tree nut oils, and information oil peanut oils has been conflicting. Many of the nut oils now on the market undergo minimal processing and mag contain residual antigen. Objective: This study was carried out to determine whether several of the new ''gourmet'' tree nut oils, as well as peanut oils, contain residual proteins that could bind IgE from sera of patients with allergy. Methods: Several brands of walnut, almond, hazelnut, pistachio, and macadamia nut oils were examined, Peanut oils, both unrefined oils (which have been shown to contain allergenic proteins) and refined oils (without previously demonstrable allergens), were also examined to confirm reproducibility of immunoreactivity as reported by other investigators. Oils were extracted with O.2 mol/L ammonium bicarbonate, and protein concentrations in the aqueous extracts were measured, IgE binding was assayed by slot-blot and Western immunoblotting. Pooled sera from patients with a history of systemic reactions to various tree nuts or peanuts were used as appropriate. Results: The oil extracts known to be from oils that had undergone less processing at lower temperatures tended to demonstrate qualitatively greater IgE binding and higher protein concentrations. Conclusion: Tree nut and peanut oils may pose a threat to patients with allergy, depending on the method of manufacture and processing.	NO CALIF HEALTHCARE SYST, DEPT VET AFFAIRS, PLEASANT HILL, CA USA		Teuber, SS (corresponding author), UNIV CALIF DAVIS, SCH MED, DEPT INTERNAL MED, DIV RHEUMATOL ALLERGY & CLIN IMMUNOL, DAVIS, CA 95616 USA.				PHS HHS [35747-10] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; CHIU JT, 1991, J ALLERGY CLIN IMMUN, V88, P414, DOI 10.1016/0091-6749(91)90106-X; HOFFMAN DR, 1994, J ALLERGY CLIN IMMUN, V93, P801, DOI 10.1016/0091-6749(94)90262-3; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; KEATING MU, 1990, J ALLERGY CLIN IMMUN, V86, P41, DOI 10.1016/S0091-6749(05)80121-6; KLURFELD DM, 1987, LIPIDS, V22, P667, DOI 10.1007/BF02533947; Moneret-Vautrin D A, 1994, Pediatr Allergy Immunol, V5, P184, DOI 10.1111/j.1399-3038.1994.tb00236.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; TATTRIE NH, 1973, J I CAN SCI TECHNOL, V6, P289; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4	10	63	66	0	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					502	507		10.1016/S0091-6749(97)70077-0	http://dx.doi.org/10.1016/S0091-6749(97)70077-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111495				2022-12-18	WOS:A1997WU27400013
J	Barnes, PJ				Barnes, PJ			Neuroeffector mechanisms: The interface between inflammation and neuronal responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adrenergic nervous system; asthma; cholinergic pathways; nonadrenergic noncholinergic pathways neurogenic inflammation; sensory nerves; symptoms	GUINEA-PIG AIRWAYS; BRADYKININ-INDUCED BRONCHOCONSTRICTION; VASOACTIVE-INTESTINAL-PEPTIDE; INHIBITORY NANC NERVES; NITRIC-OXIDE; SUBSTANCE-P; NEUTRAL ENDOPEPTIDASE; RECEPTOR ANTAGONIST; SMOOTH-MUSCLE; CHOLINERGIC NEUROTRANSMISSION	There is a complex relation between inflammation and neural control of the airways. Cholinergic neurotransmission may be enhanced by inflammatory mediators; cholinergic nerves are the dominant neural pathway for bronchoconstriction in humans. Anticholinergic drugs are more effective in acute severe asthma than in chronic asthma, Suggesting that cholinergic mechanisms may be important in exacerbations. Several possible abnormalities in adrenergic control in asthma have been proposed and may be caused by the inflammatory process. Adrenergic nerves do not have direct control of airway smooth muscle but may influence bronchomotor tone in several ways, such as adrenergic neural control of the bronchial vasculature or a secondary effect on cholinergic neurotransmission. Nonadrenergic noncholinergic (NANC) mechanisms mediate both bronchoconstriction and bronchodilation, and a defect in NANC bronchodilatation has been suggested to operate in severe asthma. Relatively little is known about the properties of airway sensory (afferent) nerves in human beings. They are thought to be involved in symptoms of cough and chest tightness, and the threshold for their activation is lowered in conditions of chronic inflammation. In addition retrograde activation of sensory nerves by a local axon reflex, resulting in the release of peptides, may contribute to inflammation of the airways. Neurogenic inflammation is probably not relevant to mild asthma, however, but it may be more important in severe disease such as brittle asthma.			Barnes, PJ (corresponding author), NATL HEART & LUNG INST, DEPT THORAC MED, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND.			Barnes, Peter/0000-0002-5122-4018				ADCOCK IM, 1993, J MOL ENDOCRINOL, V11, P1, DOI 10.1677/jme.0.0110001; BAI TR, 1991, AM REV RESPIR DIS, V143, P441, DOI 10.1164/ajrccm/143.2.441; BAI TR, 1992, AM J RESP CELL MOL, V6, P647, DOI 10.1165/ajrcmb/6.6.647; BARANIUK J N, 1991, American Review of Respiratory Disease, V143, pA40; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1391, DOI 10.1164/ajrccm/144.6.1391; BARNES PJ, 1992, THORAX, V47, P979, DOI 10.1136/thx.47.11.979; BARNES PJ, 1990, TRENDS PHARMACOL SCI, V11, P185, DOI 10.1016/0165-6147(90)90112-L; BARNES PJ, 1992, PHYSIOL REV, V72, P699, DOI 10.1152/physrev.1992.72.3.699; BARNES PJ, 1986, J ALLERGY CLIN IMMUN, V77, P791, DOI 10.1016/0091-6749(86)90375-1; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; BARNES PJ, 1990, MOL ASPECTS MED, V11, P351, DOI 10.1016/0098-2997(90)90003-K; BARNES PJ, 1993, THORAX, V48, P195, DOI 10.1136/thx.48.3.195; BARNES PJ, 1994, NEUROPEPTIDES RESPIR, P285; BELVISI MG, 1991, EUR J PHARMACOL, V198, P219, DOI 10.1016/0014-2999(91)90626-2; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BELVISI MG, 1992, J APPL PHYSIOL, V73, P2505, DOI 10.1152/jappl.1992.73.6.2505; BELVISI MG, 1993, EUR J PHARMACOL, V231, P97, DOI 10.1016/0014-2999(93)90689-F; BELVISI MG, 1993, AM REV RESPIR DIS, V147, pA286; CHEUNG D, 1992, AM REV RESPIR DIS, V145, P1275, DOI 10.1164/ajrccm/145.6.1275; CHUN GL, 1991, BRIT J PHARMACOL, V102, P91, DOI 10.1111/j.1476-5381.1991.tb12137.x; COLERIDGE HM, IN PRESS AUTONOIC CO; DANIELE RP, 1992, AM REV RESPIR DIS, V145, P1230, DOI 10.1164/ajrccm/145.5.1230; DIXON CMS, 1989, BRIT J CLIN PHARMACO, V27, P831, DOI 10.1111/j.1365-2125.1989.tb03446.x; FOX AJ, 1995, NEUROSCIENCE, V67, P741, DOI 10.1016/0306-4522(95)00115-Y; FOX AJ, 1995, J PHYSIOL-LONDON, V482, P179, DOI 10.1113/jphysiol.1995.sp020508; FOX AJ, 1993, J PHYSIOL-LONDON, V469, P21, DOI 10.1113/jphysiol.1993.sp019802; FOX AJ, 1995, AM J RESP CRIT CARE, V151, pA110; FROSSARD N, 1989, J PHARMACOL EXP THER, V248, P292; GOLDIE RG, 1986, BRIT J CLIN PHARMACO, V22, P669, DOI 10.1111/j.1365-2125.1986.tb02956.x; GRANDORDY BM, 1994, LIFE SCI, V54, P185, DOI 10.1016/0024-3205(94)00587-7; HAMID QA, 1991, EUR J PHARM-MOLEC PH, V206, P133, DOI 10.1016/0922-4106(91)90021-9; ICHINOSE M, 1992, LANCET, V340, P1248, DOI 10.1016/0140-6736(92)92948-F; IND PW, 1989, AM REV RESPIR DIS, V139, P1390, DOI 10.1164/ajrccm/139.6.1390; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; KUO HP, 1990, J PHYSIOL-LONDON, V431, P629, DOI 10.1113/jphysiol.1990.sp018351; LAMMERS JWJ, 1989, AM REV RESPIR DIS, V139, P446, DOI 10.1164/ajrccm/139.2.446; LAMMERS JWJ, 1989, J APPL PHYSIOL, V67, P856, DOI 10.1152/jappl.1989.67.2.856; LAMMERS JWJ, 1992, EUR RESPIR J, V5, P239; LEI YH, 1992, BRIT J PHARMACOL, V105, P261, DOI 10.1111/j.1476-5381.1992.tb14243.x; LILLY CM, 1995, AM J RESP CRIT CARE, V151, P548, DOI 10.1164/ajrccm.151.2.7531100; LOTVALL JO, 1991, ALLERGY, V46, P105, DOI 10.1111/j.1398-9995.1991.tb00552.x; MAK JCW, 1992, AM J RESP CELL MOL, V7, P344, DOI 10.1165/ajrcmb/7.3.344; MAK JCW, 1990, AM REV RESPIR DIS, V141, P1559, DOI 10.1164/ajrccm/141.6.1559; MAK JCW, 1988, PEPTIDES, V9, P957, DOI 10.1016/0196-9781(88)90073-3; MATSUSE T, 1991, AM REV RESPIR DIS, V144, P368, DOI 10.1164/ajrccm/144.2.368; MINETTE PAH, 1989, J APPL PHYSIOL, V67, P2461, DOI 10.1152/jappl.1989.67.6.2461; MIURA M, 1992, AM REV RESPIR DIS, V145, P70, DOI 10.1164/ajrccm/145.1.70; MOLFINO NA, 1993, AM REV RESPIR DIS, V148, P1238, DOI 10.1164/ajrccm/148.5.1238; NADEL JA, 1991, EUR RESPIR J, V4, P745; NICHOL G M, 1990, American Review of Respiratory Disease, V141, pA663; NIEBER K, 1992, J ALLERGY CLIN IMMUN, V90, P646, DOI 10.1016/0091-6749(92)90138-R; OKAYAMA M, 1994, AM J RESP CRIT CARE, V149, P76, DOI 10.1164/ajrccm.149.1.8111602; OLLERENSHAW S, 1989, NEW ENGL J MED, V320, P1244, DOI 10.1056/NEJM198905113201904; OLLERENSHAW SL, 1991, EUR RESPIR J, V4, P673; PATEL HJ, 1995, AM J RESP CRIT CARE, V152, P872, DOI 10.1164/ajrccm.152.3.7663798; SAKAMOTO T, 1993, EUR J PHARMACOL, V231, P31, DOI 10.1016/0014-2999(93)90680-G; SPINA D, 1989, BRIT J PHARMACOL, V97, P701, DOI 10.1111/j.1476-5381.1989.tb12006.x; STRETTON D, 1992, P NATL ACAD SCI USA, V89, P1325, DOI 10.1073/pnas.89.4.1325; TOMAKI M, 1995, AM J RESP CRIT CARE, V151, P613; TSUKAGOSHI H, 1995, J APPL PHYSIOL, V78, P1015, DOI 10.1152/jappl.1995.78.3.1015; TSUKAGOSHI H, 1995, J APPL PHYSIOL, V78, P921, DOI 10.1152/jappl.1995.78.3.921; UNDEM BJ, 1991, INT ARCH ALLER A IMM, V94, P319, DOI 10.1159/000235394; VERLEDEN GM, 1991, AM REV RESPIR DIS, V143, P114, DOI 10.1164/ajrccm/143.1.114; WARD JK, 1993, J CLIN INVEST, V92, P736, DOI 10.1172/JCI116644; WIDDICOMBE JG, 1990, ARCH INT PHARMACOD T, V303, P83; WIDDICOMBE JG, 1991, ASTHMA ITS PATHOLOGY, P327	67	63	64	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	2	S			S73	S81		10.1016/S0091-6749(96)80132-1	http://dx.doi.org/10.1016/S0091-6749(96)80132-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VW140	8939180				2022-12-18	WOS:A1996VW14000015
J	Lefort, J; Bachelet, CM; Leduc, D; Vargaftig, BB				Lefort, J; Bachelet, CM; Leduc, D; Vargaftig, BB			Effect of antigen provocation of IL-5 transgenic mice on eosinophil mobilization and bronchial hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bone marrow; bronchoalveolar lavage; corticosteroids; lungs; IL-5; mice	CELL-MEDIATED INDUCTION; MAJOR BASIC-PROTEIN; AIRWAY HYPERREACTIVITY; TRACHEAL EPITHELIUM; LYMPHOCYTES-T; ASTHMA; RESPONSIVENESS; INTERLEUKIN-5; INFLAMMATION; MOUSE	We investigated whether allergen-induced eosinophil recruitment into mouse airways modifies the in vivo bronchopulmonary responses to standard agonists, an adaptation of a technique described for larger animals. Swiss, CBA, and IL-5 transgenic mice were immunized with ovalbumin and challenged intranasally after 14 days. Immunization alone was followed by increased eosinophil counts in bone marrow and blood, whereas antigenic challenge induced eosinophil infiltration in lungs and bronchoalveolar lavage fluid, which was suppressed by dexamethasone. Despite the high eosinophil counts, no bronchopulmonary hyperreactivity to methacholine or serotonin was detected 3 to 96 hoots after antigenic provocation. Our results demonstrate that immunization augments the production of eosinophils by mice, which is further increased by antigenic challenge, brit that eosinophil overproduction and lung infiltration, per se, are not sufficient to induce bronchopulmonary hyperreactivity, even in constitutively hypereosinophilic IL-5 transgenic mice.	INST PASTEUR,UNITE PHARMACOL CELLULAIRE,INSERM,URA 285,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Vargaftig, Bernardo Boris B.B.J./C-3323-2013; BACHELET, Claude-Marie/T-7946-2019	BACHELET, Claude-Marie/0000-0001-9852-0378				ALTMAN LC, 1981, J CLIN INVEST, V67, P28, DOI 10.1172/JCI110024; AMORIM C, 1994, ANN NY ACAD SCI, V725, P34; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; CORRIS PA, 1993, LANCET, V341, P1369, DOI 10.1016/0140-6736(93)90941-9; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FRIGAS E, 1980, LAB INVEST, V42, P35; GARSSEN J, 1993, AM REV RESPIR DIS, V147, P307, DOI 10.1164/ajrccm/147.2.307; GARSSEN J, 1991, AM REV RESPIR DIS, V144, P931, DOI 10.1164/ajrccm/144.4.931; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; HIGA A, 1990, INT ARCH ALLER A IMM, V91, P239, DOI 10.1159/000235123; HUDSON G, 1966, BONE MARROW REACTION, P86; ISSEKUTZ TB, 1989, INT J IMMUNOPHARMACO, V11, P725, DOI 10.1016/0192-0561(89)90126-4; KIRUCHI Y, 1994, J IMMUNOL METHODS, V167, P289; LAITINEN LA, 1991, AM REV RESPIR DIS, V143, P423, DOI 10.1164/ajrccm/143.2.423; LARSEN GL, 1992, J CLIN INVEST, V89, P747, DOI 10.1172/JCI115651; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948, DOI 10.1164/ajrccm/137.4.948; LEVITT RC, 1988, FASEB J, V2, P2605, DOI 10.1096/fasebj.2.10.3384240; MARTIN TR, 1993, J CLIN INVEST, V91, P1176, DOI 10.1172/JCI116277; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; PRETOLANI M, 1994, AM J RESP CRIT CARE, V149, P1167, DOI 10.1164/ajrccm.149.5.8173756; RENZ H, 1993, J EXP MED, V177, P1175, DOI 10.1084/jem.177.4.1175; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65, DOI 10.1164/ajrccm.149.1.8111600; SAMTER M, 1953, BLOOD, V8, P1078, DOI 10.1182/blood.V8.12.1078.1078; SILVA JRLE, 1993, AM J RESP CELL MOL, V9, P44, DOI 10.1165/ajrcmb/9.1.44; STRATH M, 1992, EXP HEMATOL, V20, P229; TAKAMOTO M, 1993, PARASITE IMMUNOL, V15, P493, DOI 10.1111/j.1365-3024.1993.tb00636.x; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; WALKER C, 1991, J IMMUNOL, V146, P1829; WALLEN N, 1991, J IMMUNOL, V147, P3490; WANG JM, 1993, CLIN EXP IMMUNOL, V93, P323, DOI 10.1111/j.1365-2249.1993.tb08180.x; ZUCKERFRANKLIN D, 1976, J HISTOCHEM CYTOCHEM, V24, P1270, DOI 10.1177/24.12.63511	38	63	65	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					788	799		10.1016/S0091-6749(96)80157-6	http://dx.doi.org/10.1016/S0091-6749(96)80157-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613636				2022-12-18	WOS:A1996UA97500010
J	Stellato, C; deCrescenzo, G; Patella, V; Mastronardi, P; Mazzarella, B; Marone, G				Stellato, C; deCrescenzo, G; Patella, V; Mastronardi, P; Mazzarella, B; Marone, G			Human basophil mast cell releasability .11. Heterogeneity of the effects of contrast media on mediator release	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; contrast media; histamine; leukotriene C-4; mast cells; prostaglandin D-2; tryptase	HISTAMINE-RELEASE; ANAPHYLACTOID REACTIONS; RADIOCONTRAST MEDIA; PLASMA HISTAMINE; TRYPTASE; ACTIVATION; LEUKOTRIENES; INVITRO	Background: The activation of basophils and mast cells plays a role in the pathogenesis of anaphylactoid reactions occurring during the administration of iodinated radiocontrast media. Methods: We compared the effects of three contrast media (CM), Hexabrix (sodium and meglumine salts of ioxaglic acids), Telebrix (sodium and meglumine salts of ioxitalamic acid), and Optiray (ioversol) on the release of performed (histamine and tryptase) and de novo synthesized (prostaglandin D-2 and leukotriene C-4) mediators from human basophils and mast cells isolated from lung, skin, and heart tissue. The commercial preparations were evaluated in parallel with the pure substances. Mannitol was used a positive control inducing histamine release (HR) by hyperosmolar stimulation. Results: Hexabrix (0.1 to 0.3 mol/L), Telebrix (0.1 to 0.5 mol/L), Optiray (0.2 to 0.5 mol/L), and the corresponding pure substances concentration-dependently induced HR from basophils. A positive correlation was found between CM osmolality and HR from basophils. Mast cells isolated from different anatomic sites responded differently to the three CM. Hexabrix and Optiray induced histamine and trytase release from human lung mast cells, but not from human skin mast cells. No correlation was found between the osmolality of CM and HR from human lung mast cells. There was a significant correlation between the percent of histamine and tryptase release induced by CM from human lung mast cells. None of the CM induced the de novo synthesis of Leukotriene C-4 or prostaglandin D-2 from basophils or mast cells. The kinetics of HR caused by CM differed according to the drug used and the cell (basophils or human lung mast cells) examined. CM-induced HR from basophils and human lung mast cells was temperature-dependent, partially influenced by extracellular Ca2+ concentrations, and mot modified by preincubation of basophils with IL-2 or IL-3. Conclusion: These results provide evidence of the heterogeneity of the effects of CM on mediator release from human basophils and mast cells from different anatomic sites. They also suggest that hyperosmolarity may be an important factor in the activation of basophils by CM, but less relevant for mast cells. CM induce only the release of performed mediators. The measurement of plasma trytase might be clinically useful for monitoring adverse reactions caused by CM.	UNIV NAPLES FEDERICO II, SCH MED, DIV CLIN IMMUNOL & ALLERGY, I-80131 NAPLES, ITALY; UNIV NAPLES FEDERICO II, SCH MED, DEPT ANESTHESIOL, I-80131 NAPLES, ITALY	University of Naples Federico II; University of Naples Federico II			Stellato, Cristiana/P-3001-2015	Stellato, Cristiana/0000-0002-1294-8355; Patella, Vincenzo/0000-0001-5640-6446				AMON EU, 1990, INT ARCH ALLER A IMM, V92, P203; ANSELL G, 1982, CONTRAST MEDIA RADIO, P7; ASSEM ESK, 1983, BRIT J RADIOL, V56, P647, DOI 10.1259/0007-1285-56-669-647; BENYON RC, 1989, BRIT J PHARMACOL, V97, P898, DOI 10.1111/j.1476-5381.1989.tb12030.x; BIELORY L, 1985, INT ANESTHESIOL CLIN, V23, P97; BUSH WH, 1991, AM J ROENTGENOL, V157, P1153, DOI 10.2214/ajr.157.6.1950858; CASOLARO V, 1989, AM REV RESPIR DIS, V139, P1375, DOI 10.1164/ajrccm/139.6.1375; EGGLESTON PA, 1987, AM REV RESPIR DIS, V135, P1043; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; ENNIS M, 1991, AGENTS ACTIONS, V33, P26, DOI 10.1007/BF01993118; ENNIS M, 1992, SPEC C ISS, pC177; ERFFMEYER JE, 1985, J ALLERGY CLIN IMMUN, V75, P401, DOI 10.1016/0091-6749(85)90079-X; FINDLAY SR, 1981, J CLIN INVEST, V67, P1604, DOI 10.1172/JCI110195; GERBER KH, 1982, CIRCULATION, V65, P1307, DOI 10.1161/01.CIR.65.7.1307; GILBERT HS, 1975, BLOOD, V46, P279; GREENBERGER PA, 1991, J ALLERGY CLIN IMMUN, V87, P867, DOI 10.1016/0091-6749(91)90135-B; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P600, DOI 10.1016/0091-6749(84)90113-1; HAYES EC, 1983, J IMMUNOL, V131, P429; KALINER M, 1982, J ALLERGY CLIN IMMUN, V69, P283, DOI 10.1016/S0091-6749(82)80005-5; KALINER M, 1984, INVEST RADIOL, V19, P116, DOI 10.1097/00004424-198403000-00007; KALSNER S, 1984, SCIENCE, V223, P1435, DOI 10.1126/science.6701530; KURIMOTO Y, 1989, J EXP MED, V170, P467, DOI 10.1084/jem.170.2.467; LAROCHE D, 1991, ANESTHESIOLOGY, V75, P945, DOI 10.1097/00000542-199112000-00004; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; LIEBERMAN P, 1992, IMMUNOL ALLERGY CLIN, V12, P649; MACDONALD SM, 1989, J IMMUNOL, V142, P3527; MARONE G, 1988, ANN NY ACAD SCI, V524, P321; OLIN T, 1986, ACTA RADIOL DIAGN, V27, P257, DOI 10.1177/028418518602700301; PATELLA V, 1995, J IMMUNOL, V154, P2855; PATELLA V, 1990, J IMMUNOL, V145, P3054; RICE MC, 1983, J ALLERGY CLIN IMMUN, V72, P180, DOI 10.1016/0091-6749(83)90527-4; SALEM DN, 1986, AM J MED, V80, P382, DOI 10.1016/0002-9343(86)90710-2; SCHEFLER WC, 1984, STAT HLTH PROFESSION; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SCHROR K, 1978, N-S ARCH PHARMACOL, V302, P61, DOI 10.1007/BF00586598; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SHULMAN KL, 1993, J IMMUNOTHER, V13, P208, DOI 10.1097/00002371-199304000-00008; SIMON RA, 1979, J ALLERGY CLIN IMMUN, V63, P281, DOI 10.1016/0091-6749(79)90114-3; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; STELLATO C, 1991, BRIT J ANAESTH, V67, P751, DOI 10.1093/bja/67.6.751; TENNANT JR, 1964, TRANSPLANTATION, V2, P685, DOI 10.1097/00007890-196411000-00001; VIGORITO C, 1983, J CARDIOVASC PHARM, V5, P531, DOI 10.1097/00005344-198307000-00004; VIGORITO C, 1986, CIRCULATION, V73, P1175, DOI 10.1161/01.CIR.73.6.1175; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2	46	63	66	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1996	97	3					838	850		10.1016/S0091-6749(96)80162-X	http://dx.doi.org/10.1016/S0091-6749(96)80162-X			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UA975	8613641				2022-12-18	WOS:A1996UA97500015
J	DESJARDINS, A; MALO, JL; LARCHEVEQUE, J; CARTIER, A; MCCANTS, M; LEHRER, SB				DESJARDINS, A; MALO, JL; LARCHEVEQUE, J; CARTIER, A; MCCANTS, M; LEHRER, SB			OCCUPATIONAL IGE-MEDIATED SENSITIZATION AND ASTHMA CAUSED BY CLAM AND SHRIMP	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						BRONCHIAL DISEASES; ENVIRONMENTAL MONITORING; HYPOSENSITIVITY; OCCUPATIONAL DISEASES; RAST	CRAB-PROCESSING WORKERS; INHALED HISTAMINE; HYPERSENSITIVITY; CRUSTACEA; ALLERGEN	Background: To confirm occupational asthma caused by clam and shrimp in a food company worker; the following investigation was planned in 60 other exposed workers (56 participants). Methods: Before the production period of clam and shrimp, a medical and occupational questionnaire was carried out and skin and RAST resting were done with common inhalants and clam, shrimp, crab, and lobster extracts. During the production period environmental monitoring was performed with personal and general samplers; inhalation testing with methacholine was proposed to subjects with immediate skin reactivity to clam, shrimp, or befit. After the production period, all subjects with an immediate skin reaction to clam, shrimp, or both and either a history of rhinoconjunctivitis, asthma, or bronchial hyperresponsiveness were seen by a specialist. Results: Including the index case in whom occupational asthma to clam and shrimp had been confirmed, four (7%) subjects had a history of rhinoconjunctivitis and two (4%) had a history of asthma during the period of clam production, whereas three (5%) subjects had rhinoconjunctivitis and two (4%) had asthma during the shrimp production. Three (5%) subjects had immediate skin reactivity to clam, and nine (16%) subjects to shrimp. Four (7%) subjects had increased specific IgE antibodies (RAST binding greater than or equal to 3%) to clam and eight (14%) to shrimp. Significant associations were found between immunologic reactivity to clam and shrimp on the one hand and to crab and lobster on the other Environmental monitoring demonstrated clam and shrimp on the air sampling filters. Occupational asthma caused by clam was confirmed by specific inhalation challenges in one subject in addition to the index case. These two subjects had skin reactivity and increased specific IgE antibodies to clam, shrimp ol both. Conclusion: By including the initial subject the prevalence of immediate sensitization is 5% to 7% to clam and 14% to 16% to shrimp. Two (4%) subjects had occupational asthma caused by clam, and one (2%) had occupational asthma caused by shrimp.	HOP SACRE COEUR, DEPT CHEST MED, MONTREAL, PQ H4J 1C5, CANADA; TULANE UNIV, SCH MED, DEPT MED, NEW ORLEANS, LA 70112 USA; FONDS RECH SANTE QUEBEC, QUEBEC CITY, PQ, CANADA; UNIV MONTREAL, SCH MED, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal; Tulane University; Universite de Montreal								[Anonymous], 1987, AM REV RESPIR DIS, V136, P1285; Bernstein David I., 1993, P103; Bernstein David I., 1993, P373; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; Carino M, 1985, Med Lav, V76, P471; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P344, DOI 10.1016/S0091-6749(86)80087-2; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; CLOUTIER Y, 1989, EUR RESPIR J, V2, P769; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49, DOI 10.1159/000236802; DAUL CB, 1993, CLIN REV ALLERG, V11, P201; DAUL CB, 1993, MOL BIOL IMMUNOLOGY, P219; GADDIE J, 1980, LANCET, V2, P1350; JYO T, 1980, OCCUPATIONAL ASTHMA, P209; Malo Jean-Luc, 1993, P145; MALO JL, 1993, CLIN REV ALLERG, V11, P223; MALO JL, 1990, AM REV RESPIR DIS, V142, P1359, DOI 10.1164/ajrccm/142.6_Pt_1.1359; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MUSMAND JJ, 1993, CLIN EXP ALLERGY, V23, P722, DOI 10.1111/j.1365-2222.1993.tb00359.x; ONEIL C, 1993, CLIN REV ALLERG, V11, P183; SHANTI KN, 1993, J IMMUNOL, V151, P5354	23	63	68	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				608	617		10.1016/S0091-6749(95)70259-8	http://dx.doi.org/10.1016/S0091-6749(95)70259-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499677	Bronze			2022-12-18	WOS:A1995TG52800006
J	CIPRANDI, G; PRONZATO, C; RICCA, V; BAGNASCO, M; CANONICA, GW				CIPRANDI, G; PRONZATO, C; RICCA, V; BAGNASCO, M; CANONICA, GW			EVIDENCE OF INTERCELLULAR-ADHESION MOLECULE-1 EXPRESSION ON NASAL EPITHELIAL-CELLS IN ACUTE RHINOCONJUNCTIVITIS CAUSED BY POLLEN EXPOSURE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						RHINOCONJUNCTIVITIS; POLLEN ALLERGY; ADHESION MOLECULES; CD54; EPITHELIAL CELLS; INFLAMMATORY CELLS	CONJUNCTIVAL PROVOCATION TEST; ALLERGIC SUBJECTS; LATE-PHASE; ICAM-1; INFLAMMATION; ASTHMA; CHALLENGE; CYTOKINES; RHINITIS; LIGAND	Rhinoconjunctivitis caused by pollen allergy is characterized by typical signs and symptoms and mucosal infiltration by inflammatory cells during pollen season. It has been recently demonstrated that the adhesion molecule system is deeply involved in cell-to-cell interaction during inflammatory response consequent to allergic reactions. The aim of this study was to evaluate the expression of intercellular adhesion molecule-1 (ICAM-1 or CD54) on nasal epithelial cells, before and during natural seasonal exposure, in 10 allergic patients (Parietaria judaica-sensitized) and in 10 healthy volunteers, correlating this parameter with clinical and cytologic involvement. Nasal epithelial cells of allergic subjects showed a significant expression of CD54 during pollen season (p < 0.001). On the contrary, no CD54 expression was observed out of pollen season. In healthy volunteers no CD54 expression was observed both before and during pollen season. Cytologic evaluation demonstrated an infiltration by eosinophils (mainly activated [EG2+]), (p < 0.001), neutrophils (p < 0.001), and metachromatic cells (p < 0.001) during pollen season only in allergic subjects. Therefore results indicate that seasonal allergic rhinitis is characterized by an infiltration of inflammatory cells correlated with CD54 expression on nasal epithelial cells. This phenomenon is specific, being restricted only to allergic patients during pollen season.	UNIV GENOA,DIMI,DEPT INTERNAL MED,ALLERGY & CLIN IMMUNOL SERV,I-16132 GENOA,ITALY	University of Genoa			canonica, giorgio walter/ABF-2037-2020; Ciprandi, Giorgio/G-7462-2012	canonica, giorgio walter/0000-0001-8467-2557; Ciprandi, Giorgio/0000-0001-7016-8421				ADAMS DH, 1989, LANCET, V2, P1122; BAGNASCO M, 1993, SEP EUR AC ALL CLIN; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; Barnes P J, 1991, Clin Exp Allergy, V21 Suppl 1, P80, DOI 10.1111/j.1365-2222.1991.tb01710.x; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BIERER BE, 1988, FASEB J, V2, P2584, DOI 10.1096/fasebj.2.10.2838364; BONINI S, 1990, J ALLERGY CLIN IMMUN, V886, P69; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROWN PH, 1991, LANCET, V338, P590, DOI 10.1016/0140-6736(91)90605-O; CANONICA GW, 1991, ALLERGY CLIN IMMUN S, V1, P28; CIPRANDI G, 1993, ALLERGY, V48, P421, DOI 10.1111/j.1398-9995.1993.tb00740.x; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P1227, DOI 10.1016/0091-6749(93)90327-C; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; CIPRANDI G, 1991, INT ARCH ALLER A IMM, V96, P344, DOI 10.1159/000235519; CIPRANDI G, 1992, ALLERGY, V47, P309, DOI 10.1111/j.1398-9995.1992.tb02059.x; CIPRANDI G, 1992, LANCET, V339, P1173; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DOUGHERTY GJ, 1988, EUR J IMMUNOL, V18, P35, DOI 10.1002/eji.1830180107; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FAULL RJ, 1989, TRANSPLANTATION, V48, P226, DOI 10.1097/00007890-198908000-00009; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; KRENSKY AM, 1983, J IMMUNOL, V131, P64; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEMANSKE RF, 1988, ALLERGY PRINCIPLES P, P224; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; MAKGOBA MW, 1989, IMMUNOL TODAY, V10, P417, DOI 10.1016/0167-5699(89)90039-X; MAKGOBA MW, 1988, NATURE, V331, P86, DOI 10.1038/331086a0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393, DOI 10.1165/ajrcmb/7.4.393; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OFOSUAPPIAH W, 1989, SCAND J IMMUNOL, V29, P1517; PROUD D, 1990, J ALLERGY CLIN IMMUN, V85, P896, DOI 10.1016/0091-6749(90)90075-F; SOBEL RA, 1990, AM J PATHOL, V136, P1309; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VOLPES R, 1990, HEPATOLOGY, V12, P59, DOI 10.1002/hep.1840120110; WEETMAN AP, 1990, EUR J IMMUNOL, V20, P271, DOI 10.1002/eji.1830200207; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851	39	63	63	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					738	746		10.1016/0091-6749(94)90182-1	http://dx.doi.org/10.1016/0091-6749(94)90182-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930308				2022-12-18	WOS:A1994PM27300013
J	CHAN, SC; REIFSNYDER, D; BEAVO, JA; HANIFIN, JM				CHAN, SC; REIFSNYDER, D; BEAVO, JA; HANIFIN, JM			IMMUNOCHEMICAL CHARACTERIZATION OF THE DISTINCT MONOCYTE CYCLIC AMP-PHOSPHODIESTERASE FROM PATIENTS WITH ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS (AD); CHROMATOFOCUSING; IMMUNOADSORPTION; MONONUCLEAR LEUKOCYTES (MNLS); PHOSPHODIESTERASE (PDE); ANTI-PDE MONOCLONAL ANTIBODIES	NUCLEOTIDE PHOSPHODIESTERASE; POSSIBLE MECHANISM; LEUKOCYTE	Background: Previous findings have suggested that the immunopathology of patients with atopic dermatitis (AD) results from altered cellular responses caused by cyclic nucleotide regulatory abnormalities. One such defect is the increased degradation of the second messenger, cyclic adenosine monophosphate (cAMP), by elevated cAMP-phosphodiesterase (PDE) activity in patients with AD. Methods: We used two monoclonal antibodies to identify the major PDE isoform in AD blood monocytes. We have also characterized the abnormal PDE activity by means of chromatofocusing and sucrose gradient centrifugation. Results: The chromatofocusing technique allowed the separation of a PDE-containing fraction (isoelectric point = 6.1) from AD monocytes but not from normal cells. This monocyte fraction accounted for most of the elevated leukocyte-PDE activity and was a cytosolic, cAMP-specific, low Michaelis constant, calcium-calmodulin-dependent enzyme, inhibited by the cAMP-PDE inhibitor, Ro 20-1724. The majority of the PDE activity in this chromatofocused fraction was immunoadsorbed by the solid-phase immobilized antibodies against calcium-calmodulin-dependent PDE. Conclusions: The increased degradation of cAMP by a unique form of PDE may cause defective regulation of intracellular functions of AD monocytes, leading to the characteristic hyperreactive immune and inflammatory events. Characterization of PDE isoenzymes from different leukocyte subpopulations may allow further expansion of cell-directed therapy for inflammatory disease.	OREGON HLTH SCI UNIV, DEPT DERMATOL, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA; UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA	Oregon Health & Science University; University of Washington; University of Washington Seattle					NIADDK NIH HHS [AM21723] Funding Source: Medline; NIAID NIH HHS [AI 15557, AI 18615] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM021723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015557, R01AI018615] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beavo J., 1990, CYCLIC NUCLEOTIDE PH, P3; BEAVO JA, 1970, J BIOL CHEM, V245, P5649; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUSSE WW, 1979, J INVEST DERMATOL, V73, P184, DOI 10.1111/1523-1747.ep12581674; BUTCHER RW, 1962, J BIOL CHEM, V237, P1244; BUTLER JM, 1983, J ALLERGY CLIN IMMUN, V71, P490, DOI 10.1016/0091-6749(83)90467-0; CHAN SC, 1993, J LAB CLIN MED, V121, P44; COOPER KD, 1985, J INVEST DERMATOL, V84, P477, DOI 10.1111/1523-1747.ep12272486; COOPER KD, 1985, ACTA DERM-VENEREOL, P41; DAVIS BJ, 1959, J HISTOCHEM CYTOCHEM, V7, P297; GIUSTINA TA, 1984, J ALLERGY CLIN IMMUN, V74, P252, DOI 10.1016/0091-6749(84)90254-9; GMELIGMEYLING F, 1980, J IMMUNOL METHODS, V33, P1, DOI 10.1016/0022-1759(80)90077-0; GREWE SR, 1982, J ALLERGY CLIN IMMUN, V70, P452, DOI 10.1016/0091-6749(82)90008-2; HANIFIN JM, 1988, DRUG DEVELOP RES, V13, P123, DOI 10.1002/ddr.430130205; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; HESKEL NS, 1984, J AM ACAD DERMATOL, V11, P422, DOI 10.1016/S0190-9622(84)70184-8; HOLDEN CA, 1989, J AM ACAD DERMATOL, V21, P69, DOI 10.1016/S0190-9622(89)70150-X; HOLDEN CA, 1986, J INVEST DERMATOL, V87, P372, DOI 10.1111/1523-1747.ep12524844; HUANG CY, 1981, P NATL ACAD SCI-BIOL, V78, P871, DOI 10.1073/pnas.78.2.871; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; PARKER CW, 1977, J INVEST DERMATOL, V68, P302, DOI 10.1111/1523-1747.ep12494569; PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393; SAFKO MJ, 1981, J ALLERGY CLIN IMMUN, V68, P218, DOI 10.1016/0091-6749(81)90187-1; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69	27	63	63	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1993	91	6					1179	1188		10.1016/0091-6749(93)90321-6	http://dx.doi.org/10.1016/0091-6749(93)90321-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LG740	8389777	Bronze			2022-12-18	WOS:A1993LG74000010
J	RATNER, PH; PAULL, BR; FINDLAY, SR; HAMPEL, F; MARTIN, B; KRAL, KM; ROGENES, PR				RATNER, PH; PAULL, BR; FINDLAY, SR; HAMPEL, F; MARTIN, B; KRAL, KM; ROGENES, PR			FLUTICASONE PROPIONATE GIVEN ONCE DAILY IS AS EFFECTIVE FOR SEASONAL ALLERGIC RHINITIS AS BECLOMETHASONE DIPROPIONATE GIVEN TWICE DAILY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FLUTICASONE PROPIONATE; BECLOMETHASONE DIPROPIONATE; INTRANASAL CORTICOSTEROIDS; SEASONAL ALLERGIC RHINITIS; COMPLIANCE		Fluticasone propionate was compared with beclomethasone dipropionate for the treatment of allergic rhinitis in a multicenter, double-blind, randomized, placebo-controlled study during the mountain cedar (Juniperus ashei) pollination season in central Texas. Adults (n = 313) with moderate to severe symptoms were treated with fluticasone propionate aqueous nasal spray 200 mug once a day or beclomethasone dipropionate aqueous nasal spray 168 mug twice a day or placebo for 2 weeks. Fluticasone propionate administered once daily and beclomethasone dipropionate administered twice daily were equally effective as assessed by clinician- and patient-rated scores for nasal obstruction, rhinorrhea, sneezing, and nasal itching throughout the treatment and follow-up periods. Both regimens were more effective than placebo. Adverse events were related to topical administration and were similar in frequency and nature in all three treatment groups. Fluticasone propionate and beclomethasone dipropionate displayed a similar safety profile that did not differ from placebo. We conclude that fluticasone propionate aqueous nasal spray administered as 200 mug once daily in the morning is as safe and effective as beclomethasone dipropionate aqueous nasal spray administered as 168 mug twice daily for seasonal allergic rhinitis.			RATNER, PH (corresponding author), SYLVANA RES, 7711 LOUIS PASTEUR, SUITE 406, SAN ANTONIO, TX 78229 USA.							BELLING U, 1990, Clinical and Experimental Allergy, V20, P98; BRONSKY EA, 1987, IMMUNOL ALLERGY PRAC, V9, P165; BUSSE W, 1988, J ALLERGY CLIN IMMUN, V82, P890, DOI 10.1016/0091-6749(88)90031-0; DARNELL R, 1990, Clinical and Experimental Allergy, V20, P101; DOLOVICH J, 1990, RESP MED, V84, P31, DOI 10.1016/S0954-6111(08)80005-4; ESTELLE F, 1989, DRUGS, V38, P313, DOI 10.2165/00003495-198938020-00010; FINDLAY SR, 1986, J ALLERGY CLIN IMMUN, V77, P116, DOI 10.1016/0091-6749(86)90333-7; LAFORCE C, 1991, Journal of Allergy and Clinical Immunology, V87, P153, DOI 10.1016/0091-6749(91)91343-R; LANDIS JR, 1978, INT STAT REV, V46, P237, DOI 10.2307/1402373; LIEBERMAN P, 1988, HOSP PRACT, V23, P117; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P221, DOI 10.1016/S0091-6749(05)80069-7; MELTZER EO, 1987, IMMUNOL ALLERGY CLIN, V7, P57; NACLERIO RM, 1988, J ALLERGY CLIN IMMUN, V82, P927; NATHAN RA, 1991, ANN ALLERGY, V67, P332; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; REINBERG A, 1988, J ALLERGY CLIN IMMUN, V81, P51, DOI 10.1016/0091-6749(88)90220-5; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; VANAS A, 1991, ANN ALLERGY, V67, P156; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5	22	63	64	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	1				285	291		10.1016/S0091-6749(05)80005-3	http://dx.doi.org/10.1016/S0091-6749(05)80005-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP520	1527313				2022-12-18	WOS:A1992JP52000003
J	SCHUMACHER, MJ; SCHMIDT, JO; EGEN, NB; DILLON, KA				SCHUMACHER, MJ; SCHMIDT, JO; EGEN, NB; DILLON, KA			BIOCHEMICAL VARIABILITY OF VENOMS FROM INDIVIDUAL EUROPEAN AND AFRICANIZED HONEYBEES (APIS-MELLIFERA)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						VENOM; HONEYBEE; MELITTIN; PHOSPHOLIPASE; AFRICANIZED; BIOLOGIC VARIABILITY; ISOELECTRIC FOCUSING	BEE; HYMENOPTERA	To study biochemical differences between venom from individual honeybees, venom sacs from 103 European (EU) bees and 92 Africanized bees representing 12 different colonies were dissected, and the dry weight (DW) of venom from each bee was determined. Venom from each of these bees was studied with isoelectric focusing and functional assays for phospholipase A2 and melittin. Phospholipase concentrations in individual EU bee venoms varied between 1.8% and 27.4% (wt/wt). The melittin concentration in EU bee venom varied less and, on the average, was found to be much lower than previously reported. There was an eightfold to ninefold difference between lowest and highest venom sac DW contents, suggesting the possibility of highly variable venom delivery from bee stings. One EU bee contained > 300-mu-g of venom, three times the recommended maintenance dose for venom immunotherapy. Isoelectric focusing also demonstrated large differences between individual bees, with respect to major and minor components of their venoms. Africanized bees contained significantly less venom but more phospholipase than did EU bees. Bee venoms from different colonies differed in their DW content and in their concentrations of phospholipase and melittin. The results are relevant to the uncertainty of responses from sting challenges and field stings in allergic patients and massive stinging attacks on normal subjects.	USDA,CARL HAYDEN BEE RES CTR,TUCSON,AZ 85719; UNIV ARIZONA,COLL AGR,DEPT VET SCI,TUCSON,AZ 85724	United States Department of Agriculture (USDA); University of Arizona	SCHUMACHER, MJ (corresponding author), UNIV ARIZONA,HLTH SCI CTR,DEPT PEDIAT,STEELE MEM CHILDRENS RES CTR,TUCSON,AZ 85724, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041068] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM41068] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banks B.E.C., 1986, P329; EGEN NB, 1984, TOXICON, V22, P653, DOI 10.1016/0041-0101(84)90005-9; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; NELSON DR, 1990, J ALLERGY CLIN IMMUN, V85, P80, DOI 10.1016/0091-6749(90)90225-S; OWEN MD, 1990, TOXICON, V28, P813, DOI 10.1016/S0041-0101(09)80004-4; OWEN MD, 1983, TOXICON, V21, P171, DOI 10.1016/0041-0101(83)90061-2; Schmidt J.O., 1986, P425; SCHMIDT JO, 1986, TOXICON, V24, P907, DOI 10.1016/0041-0101(86)90091-7; SCHUMACHER MJ, 1990, AM J TROP MED HYG, V43, P79, DOI 10.4269/ajtmh.1990.43.79	11	63	65	1	12	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1992	90	1					59	65		10.1016/S0091-6749(06)80011-4	http://dx.doi.org/10.1016/S0091-6749(06)80011-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JE255	1629508	Bronze			2022-12-18	WOS:A1992JE25500007
J	BALLAS, ZK; TURNER, JM; TURNER, DA; GOETZMAN, EA; KEMP, JD				BALLAS, ZK; TURNER, JM; TURNER, DA; GOETZMAN, EA; KEMP, JD			A PATIENT WITH SIMULTANEOUS ABSENCE OF CLASSICAL NATURAL-KILLER-CELLS (CD3-, CD16+, AND NKH1+) AND EXPANSION OF CD3+, CD4-, CD8-, NKH1+ SUBSET	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,COLL MED,DEPT OBSTET & GYNECOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PATHOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,IOWA CITY VET ADM,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa	BALLAS, ZK (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,SW34J,GH,IOWA CITY,IA 52242, USA.			Ballas, Zuhair/0000-0001-5569-1230; Knaack, Aaron/0000-0001-7712-1415				ALLISON JP, 1987, ANNU REV IMMUNOL, V5, P503, DOI 10.1146/annurev.iy.05.040187.002443; BALLAS ZK, 1983, EUR J IMMUNOL, V13, P279, DOI 10.1002/eji.1830130403; BALLAS ZK, 1987, J IMMUNOL, V138, P1647; BAND H, 1987, SCIENCE, V238, P682, DOI 10.1126/science.3672118; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BOYUM A, 1976, SCAND J IMMUNOL   S5, V5, P9; BUKOWSKI JF, 1983, J IMMUNOL, V131, P1531; DAMLE NK, 1987, J IMMUNOL, V138, P1779; FITZGERALD PA, 1986, IMMUNOBIOLOGY NATURA, P107; FLEISHER G, 1982, J PEDIATR-US, V100, P727, DOI 10.1016/S0022-3476(82)80572-6; GARCIAPENARRUBIA P, 1989, J EXP MED, V169, P99, DOI 10.1084/jem.169.1.99; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HERBERMAN RB, 1981, SCIENCE, V214, P24, DOI 10.1126/science.7025208; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; LANIER LL, 1986, J IMMUNOL, V137, P2735; LANIER LL, 1986, J IMMUNOL, V136, P4480; Lopez C, 1982, NK CELLS OTHER NATUR, P1445; ORTALDO JR, 1984, ANNU REV IMMUNOL, V2, P359, DOI 10.1146/annurev.iy.02.040184.002043; ORTALDO JR, 1984, J IMMUNOL, V133, P779; PHILLIPS JH, 1986, J EXP MED, V164, P814, DOI 10.1084/jem.164.3.814; QUINNAN GV, 1982, NEW ENGL J MED, V307, P7, DOI 10.1056/NEJM198207013070102; RITZ J, 1988, ADV IMMUNOL, V42, P181, DOI 10.1016/S0065-2776(08)60845-7; RITZ J, 1985, SCIENCE, V228, P1540, DOI 10.1126/science.2409597; ROOK RH, 1983, J CLIN IMMUNOL, V3, P156; SONDEL PM, 1986, J IMMUNOL, V137, P502; SULLIVAN JL, 1980, SCIENCE, V210, P543, DOI 10.1126/science.6158759; TARGAN SR, 1983, J IMMUNOL, V130, P2671; TRINCHIERI G, 1987, CRC CR REV ONCOL-HEM, V7, P219, DOI 10.1016/S1040-8428(87)80009-4; TRINCHIERI G, 1984, LAB INVEST, V50, P489; VANDEGRIEND RJ, 1984, J IMMUNOL, V132, P3185	31	63	63	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1990	85	2					453	459		10.1016/0091-6749(90)90155-W	http://dx.doi.org/10.1016/0091-6749(90)90155-W			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CP511	2303649	Bronze			2022-12-18	WOS:A1990CP51100006
J	FOKKENS, WJ; VROOM, TM; RIJNTJES, E; MULDER, PGH				FOKKENS, WJ; VROOM, TM; RIJNTJES, E; MULDER, PGH			FLUCTUATION OF THE NUMBER OF CD-1(T6)-POSITIVE DENDRITIC CELLS, PRESUMABLY LANGERHANS CELLS, IN THE NASAL-MUCOSA OF PATIENTS WITH AN ISOLATED GRASS-POLLEN ALLERGY BEFORE, DURING, AND AFTER THE GRASS-POLLEN SEASON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SLOTERVAART HOSP,DEPT PATHOL,AMSTERDAM,NETHERLANDS; LEYENBURG HOSP,DEPT OTORHINOLARYNGOL,THE HAGUE,NETHERLANDS; ERASMUS UNIV,DEPT BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	Slotervaart Hospital; Erasmus University Rotterdam	FOKKENS, WJ (corresponding author), UNIV HOSP ROTTERDAM,DEPT OTORHINOLARYNGOL,DR MOLEWATERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS.		Fokkens, Wytske WJ/ABF-2185-2020					FELTKAMPVROOM TM, 1970, J CLIN PATHOL, V23, P188, DOI 10.1136/jcp.23.2.188; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; FOKKENS WJ, 1989, ALLERGY, V44, P167, DOI 10.1111/j.1398-9995.1989.tb02257.x; FOKKENS WJ, IN PRESS CLIN OTOLAR; HASHIMOTO K, 1968, ARCH DERMATOL, V97, P450, DOI 10.1001/archderm.97.4.450; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; KONRAD K, 1973, ARCH DERMATOL FORSCH, V246, P70, DOI 10.1007/BF00595489; LERCH PG, 1983, HUM IMMUNOL, V6, P13, DOI 10.1016/0198-8859(83)90070-8; LI CY, 1972, J HISTOCHEM CYTOCHEM, V20, P1049, DOI 10.1177/20.12.1049; MURPHY GF, 1985, ARCH DERMATOL RES, V278, P126, DOI 10.1007/BF00409219; MURPHY GF, 1985, HUM PATHOL, V16, P103, DOI 10.1016/S0046-8177(85)80057-5; ROWDEN G, 1979, BRIT J DERMATOL, V100, P531, DOI 10.1111/j.1365-2133.1979.tb05578.x; SILBERBERG I, 1973, ACTA DERM-VENEREOL, V53, P1; SILBERBERG I, 1976, J INVEST DERMATOL, V66, P210, DOI 10.1111/1523-1747.ep12482139; STREILEIN JW, 1982, J EXP MED, V155, P863, DOI 10.1084/jem.155.3.863; UNDERWOOD JCE, 1981, INTRO BIOPSY INTERPR	16	63	64	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1989	84	1					39	43		10.1016/0091-6749(89)90176-0	http://dx.doi.org/10.1016/0091-6749(89)90176-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AG120	2754144				2022-12-18	WOS:A1989AG12000007
J	WU, CH; LAN, JL				WU, CH; LAN, JL			COCKROACH HYPERSENSITIVITY - ISOLATION AND PARTIAL CHARACTERIZATION OF MAJOR ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											WU, CH (corresponding author), VET GEN HOSP,DEPT INTERNAL MED,DIV ALLERGY IMMUNOL & RHEUMATOL,VACRS,TAICHUNG 40705,TAIWAN.							AUKRUST L, 1980, ADV ALLERGOLOGY APPL, P475; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH RK, 1983, J ALLERGY CLIN IMMUN, V71, P239, DOI 10.1016/0091-6749(83)90105-7; CHANG JL, 1983, J ALLERGY CLIN IMMUN, V71, P161, DOI 10.1016/0091-6749(83)90413-X; CORBI AL, 1984, INT ARCH ALLER A IMM, V74, P318, DOI 10.1159/000233567; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; FORD SA, 1985, INT ARCH ALLER A IMM, V78, P15, DOI 10.1159/000233855; HOZ F, 1986, INT ARCH ALLER A IMM, V79, P238; HUSSAIN R, 1981, J ALLERGY CLIN IMMUN, V67, P217, DOI 10.1016/0091-6749(81)90064-6; JOHNSTONE A, 1982, IMMUNOCHEMISTRY PRAC, P44; JONES GS, 1986, CLIN RES, V34, pA888; KANG B, 1985, CLIN REV ALLERG, V3, P363, DOI 10.1007/BF02993001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; ONEIL CE, 1986, J ALLERGY CLIN IMMUN, V77, P130; TOVEY ER, 1984, INT ARCH ALLER A IMM, V75, P322, DOI 10.1159/000233641; TOVEY ER, 1985, INT ARCH ALLER A IMM, V76, P82, DOI 10.1159/000233667; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; WEEKE B, 1974, ACTA ALLERGOL, V29, P402, DOI 10.1111/j.1398-9995.1974.tb01661.x; WEEKE B, 1973, SCAND J IMMUNOL, V2, P149, DOI 10.1111/j.1365-3083.1973.tb03796.x	21	63	64	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				727	735		10.1016/0091-6749(88)90071-1	http://dx.doi.org/10.1016/0091-6749(88)90071-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	3192860	Bronze			2022-12-18	WOS:A1988R170800003
J	NELSON, HS; HIRSCH, SR; OHMAN, JL; PLATTSMILLS, TAE; REED, CE; SOLOMON, WR				NELSON, HS; HIRSCH, SR; OHMAN, JL; PLATTSMILLS, TAE; REED, CE; SOLOMON, WR			RECOMMENDATIONS FOR THE USE OF RESIDENTIAL AIR-CLEANING DEVICES IN THE TREATMENT OF ALLERGIC RESPIRATORY-DISEASES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											NELSON, HS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, 1400 JACKSON ST, DENVER, CO 80206 USA.							BEAUMONT F, 1984, ANN ALLERGY, V53, P486; BOWLER SD, 1985, ANN ALLERGY, V55, P498; CARPENTER GB, 1985, J ALLERGY CLIN IMMUN, V75, P121, DOI 10.1016/0091-6749(85)90201-5; Cohen MB, 1927, J LAB CLIN MED, V13, P59; CRIEP LH, 1936, J ALLERGY, V7, P120; EKWO EE, 1983, CHEST, V84, P662, DOI 10.1378/chest.84.6.662; FINDLAY SR, 1983, AM REV RESPIR DIS, V128, P1008; FRIEDLAENDER S, 1954, Ann Allergy, V12, P419; GAY LN, 1933, JAMA-J AM MED ASSOC, V100, P82; HIRSCH DJ, 1978, J ALLERGY CLIN IMMUN, V62, P22, DOI 10.1016/0091-6749(78)90067-2; HIRSCH SR, 1976, ANN ALLERGY, V36, P30; KING JG, 1973, RESPIR CARE, V18, P160; KOOISTRA JB, 1978, J ALLERGY CLIN IMMUN, V61, P315, DOI 10.1016/0091-6749(78)90053-2; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; KRANZ P, 1963, J ALLERGY, V34, P155, DOI 10.1016/0021-8707(63)90068-6; LAWRENCE JC, 1981, J HYG-CAMBRIDGE, V86, P203, DOI 10.1017/S0022172400068923; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; LOFCOE NM, 1971, ARCH ENVIRON HEALTH, V22, P230; MITCHELL EA, 1980, LANCET, V2, P559; MURRAY AB, 1983, PEDIATRICS, V71, P418; Nelson T, 1933, J AMER MED ASSOC, V100, P1385, DOI 10.1001/jama.1933.02740180007003; OFFERMANN FJ, 1984, LBL16659; OHMAN JL, 1987, J ALLERGY CLIN IMMUN, V79, P955, DOI 10.1016/0091-6749(87)90246-6; PLATTSMILLS TAE, 1985, ANN ALLERGY, V55, P419; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; Rappaport BZ, 1932, J AMER MED ASSOC, V98, P1861, DOI 10.1001/jama.1932.02730480011003; REED CE, 1985, CHEST, V87, pS40; RICHMAN PG, 1984, J ALLERGY CLIN IMMUN, V73, P590, DOI 10.1016/0091-6749(84)90516-5; SCHERR MS, 1977, W VA MED J, V73, P144; SILVERMAN L, 1956, AIR CONDITIONING DEC, P75; SMALL WS, 1957, J ALLERGY, V28, P455; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P305, DOI 10.1016/0091-6749(80)90160-8; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V56, P235, DOI 10.1016/0091-6749(75)90095-0; SOLOMON WR, 1984, J ALLERGY CLIN IMMUN, V74, P674, DOI 10.1016/0091-6749(84)90228-8; SPENGLER JD, 1983, SCIENCE, V221, P9, DOI 10.1126/science.6857273; SPIEGELMAN J, 1961, ANN ALLERGY, V19, P613; SPIEGELMAN J, 1963, J ALLERGY, V34, P426, DOI 10.1016/0021-8707(63)90007-8; STOCKHAM JD, PERFORMANCE PORTABLE; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; Trasoff A, 1936, J LAB CLIN MED, V22, P147; van Leeuwen W S, 1924, Proc R Soc Med, V17, P19; Vaughan W.T., 1933, J ALLERGY, V5, P37, DOI [10.1016/S0021-8707(33)90168-9, DOI 10.1016/S0021-8707(33)90168-9]; VERRALL B, IN PRESS ANN ALLERGY; VILLAVECES JW, 1977, ANN ALLERGY, V38, P400; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; WHITBY KT, 1983, ASHRAE T A B, V89; ZWEMER RJ, 1973, ANN ALLERGY, V31, P284; 1982, NEW SHELTER      JUL, P48; 1986, ALLERGY RELIEF   APR, P4; 1985, CONSUMER REPORTS JAN, P7; 1982, CONSUMER RES     APR, P25; 1986, NEW SHELTER      JAN, P64	53	63	63	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					661	669		10.1016/0091-6749(88)90980-3	http://dx.doi.org/10.1016/0091-6749(88)90980-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3171006				2022-12-18	WOS:A1988Q639900020
J	ZAKRZEWSKA, JM; IVANYI, L				ZAKRZEWSKA, JM; IVANYI, L			INVITRO LYMPHOCYTE-PROLIFERATION BY CARBAMAZEPINE, CARBAMAZEPINE-10, 11-EPOXIDE, AND OXCARBAZEPINE IN THE DIAGNOSIS OF DRUG-INDUCED HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UCL EASTMAN DENT HOSP, INST DENT SURG, DEPT CLIN PATHOL & ORAL IMMUNOL, 256 GRAYS INN RD, LONDON WC1X 8LD, ENGLAND; UCL EASTMAN DENT HOSP, DEPT ORAL MED, LONDON WC1X 8LD, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London			Zakrzewska, Joanna M./AAC-7378-2020	Zakrzewska, Joanna M./0000-0001-7805-5851				BREATHNACH SM, 1982, CLIN EXP DERMATOL, V7, P585, DOI 10.1111/j.1365-2230.1982.tb02481.x; CRILL WE, 1973, ANN INTERN MED, V79, P844, DOI 10.7326/0003-4819-79-6-844; DELAFUENTE JC, 1985, DRUG INTEL CLIN PHAR, V19, P114, DOI 10.1177/106002808501900206; EMRICH HM, 1985, J AFFECT DISORDERS, V8, P243, DOI 10.1016/0165-0327(85)90022-9; HOUWERZIJL J, 1977, CLIN EXP IMMUNOL, V29, P272; PHILBERT A, 1986, IRISH J MED SCI, V155, P297; ROBERTS DL, 1981, ARCH DERMATOL, V117, P273, DOI 10.1001/archderm.117.5.273; SILLANPAA M, 1981, ACTA NEUROL SCAND, V64, P5; TOMSON T, 1984, ARCH NEUROL-CHICAGO, V41, P598, DOI 10.1001/archneur.1984.04210080006004; VIROLAIN.M, 1971, CLIN EXP IMMUNOL, V9, P429	10	63	64	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					110	115		10.1016/0091-6749(88)90059-0	http://dx.doi.org/10.1016/0091-6749(88)90059-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3392362	Bronze			2022-12-18	WOS:A1988P400400018
J	SHEFFER, AL; FEARON, DT; AUSTEN, KF				SHEFFER, AL; FEARON, DT; AUSTEN, KF			HEREDITARY ANGIOEDEMA - A DECADE OF MANAGEMENT WITH STANOZOLOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	SHEFFER, AL (corresponding author), BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL IMMUNOL,75 FRANCIS ST,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI023401, R01AI022531, R37AI022531] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22531, AI-36110, AI-23401] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOSTONI A, 1980, J ALLERGY CLIN IMMUN, V65, P75, DOI 10.1016/0091-6749(80)90181-5; ARNOLD A, 1959, P SOC EXP BIOL MED, V102, P184; BAGHERI SA, 1974, ANN INTERN MED, V81, P610, DOI 10.7326/0003-4819-81-5-610; CICARDI M, 1983, J ALLERGY CLIN IMMUN, V68, P294; DAVIS PJ, 1974, JOHNS HOPKINS MED J, V135, P391; DECK HP, 1963, EXP MOL PATHOL S2, V2, P115; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GORDON BS, 1970, AM J CLIN PATHOL, V33, P156; HOSEA SW, 1980, ANN INTERN MED, V93, P809, DOI 10.7326/0003-4819-93-6-809; KEELE DK, 1967, AM J DIS CHILD, V113, P422, DOI 10.1001/archpedi.1967.02090190068004; PITTS JS, 1978, J LAB CLIN MED, V92, P501; Rosse W F, 1976, Trans Assoc Am Physicians, V89, P122; Schoenlank W, 1916, VIRCHOWS ARCH PATH A, V222, P358; SHEFFER AL, 1981, J ALLERGY CLIN IMMUN, V68, P181, DOI 10.1016/0091-6749(81)90181-0; SHEFFER AL, 1977, ANN INTERN MED, V86, P306, DOI 10.7326/0003-4819-86-3-306; SHEFFER AL, 1979, J ALLERGY CLIN IMMUN, V64, P275, DOI 10.1016/0091-6749(79)90144-1; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739; ZAK FG, 1950, AM J PATHOL, V26, P1	18	63	64	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					855	860		10.1016/S0091-6749(87)80277-4	http://dx.doi.org/10.1016/S0091-6749(87)80277-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	3693762	Bronze			2022-12-18	WOS:A1987L502000014
J	MOOTE, DW; LLOYD, DA; MCCOURTIE, DR; WELLS, GA				MOOTE, DW; LLOYD, DA; MCCOURTIE, DR; WELLS, GA			INCREASE IN GASTROESOPHAGEAL REFLUX DURING METHACHOLINE-INDUCED BRONCHOSPASM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN ONTARIO,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,LONDON N6A 3K7,ONTARIO,CANADA; UNIV WESTERN ONTARIO,DEPT MED,GASTROENTEROL SECT,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario)								BERQUIST WE, 1981, J ALLERGY CLIN IMMUN, V67, P407, DOI 10.1016/0091-6749(81)90087-7; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHERNOW B, 1979, DIGEST DIS SCI, V24, P839, DOI 10.1007/BF01324899; CHRISTENSEN J, 1976, ARCH INTERN MED, V136, P532, DOI 10.1001/archinte.136.5.532; CLEMENCON G H, 1961, Gastroenterologia, V95, P110; DODDS WJ, 1976, ARCH INTERN MED, V136, P515, DOI 10.1001/archinte.136.5.515; MANSFIELD LE, 1978, ANN ALLERGY, V41, P224; MAYS EE, 1976, JAMA-J AM MED ASSOC, V236, P2626, DOI 10.1001/jama.236.23.2626; MENDELSON CL, 1946, AM J OBSTET GYNECOL, V52, P191; MERMOD E, 1887, REV MED SUISSE ROMAN, V7, P422; NELSON HS, 1984, J ALLERGY CLIN IMMUN, V73, P547, DOI 10.1016/0091-6749(84)90509-8; PELLEGRINI CA, 1979, SURGERY, V86, P110; REICH SB, 1977, J NUCL MED, V18, P1079; SINGH V, 1983, J ASTHMA, V20, P241, DOI 10.3109/02770908309077083; SPAULDING HS, 1982, J ALLERGY CLIN IMMUN, V69, P516, DOI 10.1016/0091-6749(82)90176-2; WOLF S, 1985, J ALLERGY CLIN IMMUN, V75, P171, DOI 10.1016/0091-6749(85)90403-8; [No title captured]	17	63	64	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	1				619	623		10.1016/0091-6749(86)90079-5	http://dx.doi.org/10.1016/0091-6749(86)90079-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5682	3534050				2022-12-18	WOS:A1986E568200010
J	BUSH, RK; TAYLOR, SL; BUSSE, W				BUSH, RK; TAYLOR, SL; BUSSE, W			A CRITICAL-EVALUATION OF CLINICAL-TRIALS IN REACTIONS TO SULFITES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,FOOD RES INST,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	BUSH, RK (corresponding author), WILLIAM S MIDDLETON MEM VET ADM HOSP,2500 OVERLOOK TERRACE,MADISON,WI 53705, USA.							ALTMAN LC, 1985, J ALLERGY CLIN IMMUN, V75, P144, DOI 10.1016/0091-6749(85)90293-3; BAKER GJ, 1982, AUST NZ J MED, V12, P213; BAKER GJ, 1981, MED J AUSTRALIA, V2, P644; BOUSHEY HA, 1982, J ALLERGY CLIN IMMUN, V69, P335, DOI 10.1016/0091-6749(82)90142-7; BUSH RK, AM J MED; DELOHERY J, 1984, AM REV RESPIR DIS, V130, P1027; Evelyn J., 1664, RELATION CIDER SEV S, P24; FISHER AA, 1975, CUTIS, V16, P691; FLAHERTY M, 1985, J ALLERGY CLIN IMMUN, V75, P198, DOI 10.1016/0091-6749(85)90510-X; FREEDMAN BJ, 1977, CLIN ALLERGY, V7, P407, DOI 10.1111/j.1365-2222.1977.tb01471.x; GOLDFARB F, 1984, J ALLERGY CLIN IMMUN, V73, P135; Habenicht HA, 1983, IMMUNOL ALLERGY PRAC, V5, P25; HARKONEN H, 1983, AM REV RESPIR DIS, V128, P890; HOWLAND WC, 1985, J ALLERGY CLIN IMMUN, V75, P145, DOI 10.1016/0091-6749(85)90296-9; HUANG AS, 1984, NEW ENGL J MED, V311, P542; JACOBSEN D W, 1984, Journal of Allergy and Clinical Immunology, V73, P135; KOCHEN J, 1973, PEDIATRICS, V52, P145; KOEPKE J W, 1984, Journal of Allergy and Clinical Immunology, V73, P135; KOEPKE JW, 1984, JAMA-J AM MED ASSOC, V251, P2982, DOI 10.1001/jama.251.22.2982; KOEPKE JW, 1982, ANN ALLERGY, V48, P258; KOEPKE JW, 1983, J ALLERGY CLIN IMMUN, V72, P504, DOI 10.1016/0091-6749(83)90588-2; MATHISON DA, 1985, CHEST, V87, pS50, DOI 10.1378/chest.87.1.50S; MEGGS WJ, 1985, J ALLERGY CLIN IMMUN, V75, P144, DOI 10.1016/0091-6749(85)90295-7; MONIERWILLIAMS GW, 1927, 433 MIN HLTH RPT, P1; PRENNER BM, 1976, ANN ALLERGY, V37, P180; Ripper M., 1892, J PRAKT CHEM, V46, P428, DOI 10.1002/prac.18920460131; Schwartz H, 1984, IMMUNOL ALLERGY PRAC, V6, P29; SCHWARTZ HJ, 1984, J ALLERGY CLIN IMMUN, V74, P511, DOI 10.1016/0091-6749(84)90387-7; SCHWARTZ HJ, 1983, J ALLERGY CLIN IMMUN, V71, P487, DOI 10.1016/0091-6749(83)90466-9; SETTIPANE GA, 1984, N ENGL REG ALLERGY P, V4, P304; SEYAL M A, 1984, Journal of Allergy and Clinical Immunology, V73, P135; SIMON R, 1984, Journal of Allergy and Clinical Immunology, V73, P136; SIMON R A, 1982, Journal of Allergy and Clinical Immunology, V69, P118; SIMON RA, 1984, J ALLERGY CLIN IMMUN, V74, P623, DOI 10.1016/0091-6749(84)90116-7; SONIN L, 1985, J ALLERGY CLIN IMMUN, V75, P67, DOI 10.1016/0091-6749(85)90014-4; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P469, DOI 10.1016/0091-6749(84)90380-4; Taylor S L, 1986, Adv Food Res, V30, P1, DOI 10.1016/S0065-2628(08)60347-X; TAYLOR SL, 1985, J ALLERGY CLIN IMMUN, V75, P198, DOI 10.1016/0091-6749(85)90509-3; TOWNS SJ, 1984, PEDIATRICS, V73, P631; TWAROG FJ, 1982, JAMA-J AM MED ASSOC, V248, P2030, DOI 10.1001/jama.248.16.2030; WANG BC, 1984, ANESTH ANALG, V63, P445; WERTH GR, 1982, J ALLERGY CLIN IMMUN, V70, P143, DOI 10.1016/0091-6749(82)90243-3; WITEK TJ, 1984, CHEST, V86, P592, DOI 10.1378/chest.86.4.592; 1985, REEXAMINATION GRAS S, P1	45	63	63	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	2	S			191	202		10.1016/0091-6749(86)90012-6	http://dx.doi.org/10.1016/0091-6749(86)90012-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2997	3722647				2022-12-18	WOS:A1986D299700012
J	WALD, JA; FRIEDMAN, BF; FARR, RS				WALD, JA; FRIEDMAN, BF; FARR, RS			AN IMPROVED PROTOCOL FOR THE USE OF TROLEANDOMYCIN (TAO) IN THE TREATMENT OF STEROID-REQUIRING ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206	National Jewish Health								EITCHES RW, 1985, AM J DIS CHILD, V139, P264, DOI 10.1001/archpedi.1985.02140050058022; ENGEL MF, 1963, SOUTHERN MED J, V56, P1279, DOI 10.1097/00007611-196311000-00017; ENGLER RJM, 1985, J ALLERGY CLIN IMMUN, V75, P395, DOI 10.1016/0091-6749(85)90078-8; ITKIN IH, 1970, J ALLERGY, V45, P146, DOI 10.1016/0021-8707(70)90124-3; KAPLAN MA, 1959, ANTIBIOTICS ANN 1958, P273; MENDOZA GR, 1985, J ALLERGY CLIN IMMUN, V71, P135; ONG KS, 1978, J ALLERGY CLIN IMMUN, V62, P115, DOI 10.1016/0091-6749(78)90088-X; SPECTOR SL, 1974, J ALLERGY CLIN IMMUN, V54, P367, DOI 10.1016/0091-6749(74)90027-X; SZEFLER SJ, 1980, J ALLERGY CLIN IMMUN, V66, P447, DOI 10.1016/0091-6749(80)90004-4; SZEFLER SJ, 1982, CLIN PHARMACOL THER, V32, P166, DOI 10.1038/clpt.1982.143; TICKTIN HE, 1962, NEW ENGL J MED, V267, P964, DOI 10.1056/NEJM196211082671905; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; ZEIGER RS, 1980, J ALLERGY CLIN IMMUN, V66, P438, DOI 10.1016/0091-6749(80)90003-2; ZEIGER RS, 1985, BRONCHIAL ASTHMA, P714	14	63	63	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				36	43		10.1016/0091-6749(86)90112-0	http://dx.doi.org/10.1016/0091-6749(86)90112-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3487564				2022-12-18	WOS:A1986D299600007
J	BIERMAN, CW; SPIRO, SG; PETHERAM, I				BIERMAN, CW; SPIRO, SG; PETHERAM, I			CHARACTERIZATION OF THE LATE RESPONSE IN EXERCISE-INDUCED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UCL, SCH MED, RAYNE INST, DIV PULM MED, LONDON, ENGLAND	University of London; King's College London; University College London; UCL Medical School								BIERMAN C W, 1975, Pediatrics, V56, P847; BIERMAN CW, 1980, J ALLERGY CLIN IMMUN, V65, P206; BIERMAN CW, 1977, MUSCULAR EXERCISE LU, P301; CROPP GJA, 1977, MUSCULAR EXERCISE LU, P265; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DENDOV I, 1982, AM REV RESPIR DIS, V125, P530; EGGLESTON PA, 1976, J ALLERGY CLIN IMMUN, V58, P414, DOI 10.1016/0091-6749(76)90122-6; FELDMAN CH, 1982, AM REV RESPIR DIS, V125, P191; GODFREY S, 1975, J ALLERGY CLIN IMMUN, V56, P1, DOI 10.1016/0091-6749(75)90029-9; GODFREY S, 1977, MUSCULAR EXERCISE LU, P247; KAY AB, 1982, J ALLERGY CLIN IMMUN, V70, P317, DOI 10.1016/0091-6749(82)90019-7; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; MCNEILL RS, 1966, Q J MED, V35, P55; SHEPHARD RJ, 1968, B WORLD HEALTH ORGAN, V38, P757; SPIRO SG, 1981, THORAX, V36, P852, DOI 10.1136/thx.36.11.852; WEILERRAVELL D, 1981, J ALLERGY CLIN IMMUN, V67, P391, DOI 10.1016/0091-6749(81)90085-3	19	63	63	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	5					701	706		10.1016/0091-6749(84)90233-1	http://dx.doi.org/10.1016/0091-6749(84)90233-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TT169	6501742	Bronze			2022-12-18	WOS:A1984TT16900008
J	LAM, S; TAN, F; CHAN, H; CHANYEUNG, M				LAM, S; TAN, F; CHAN, H; CHANYEUNG, M			RELATIONSHIP BETWEEN TYPES OF ASTHMATIC REACTION, NONSPECIFIC BRONCHIAL REACTIVITY, AND SPECIFIC IGE ANTIBODIES IN PATIENTS WITH RED CEDAR ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV BRITISH COLUMBIA,DEPT MED,DIV RESP,VANCOUVER V6T 1W5,BC,CANADA	University of British Columbia								BRYANT DH, 1976, CLIN ALLERGY, V6, P523, DOI 10.1111/j.1365-2222.1976.tb01937.x; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1094; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; POPA VT, 1980, J ALLERGY CLIN IMMUN, V65, P389, DOI 10.1016/0091-6749(80)90218-3; STEEL RGD, 1960, PRINCIPLES PROCEDURE, P277; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x	10	63	63	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	2					134	139		10.1016/0091-6749(83)90520-1	http://dx.doi.org/10.1016/0091-6749(83)90520-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD959	6350407				2022-12-18	WOS:A1983RD95900005
J	TING, S; DUNSKY, EH; LAVKER, RM; ZWEIMAN, B				TING, S; DUNSKY, EH; LAVKER, RM; ZWEIMAN, B			PATTERNS OF MAST-CELL ALTERATIONS AND INVIVO MEDIATOR RELEASE IN HUMAN ALLERGIC SKIN REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN, SCH MED, DEPT MED, ALLERGY & IMMUNOL SECT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014332] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-14332, AI-07031] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; CLARK RAF, 1975, J EXP MED, V142, P1462, DOI 10.1084/jem.142.6.1462; DUNSKY EH, 1977, J ALLERGY CLIN IMMUN, V59, P142, DOI 10.1016/0091-6749(77)90216-0; DUNSKY EH, 1978, J ALLERGY CLIN IMMUN, V62, P127, DOI 10.1016/0091-6749(78)90091-X; FELARCA AB, 1971, J ALLERGY CLIN IMMUN, V48, P125, DOI 10.1016/0091-6749(71)90007-8; HASHIMOT.K, 1966, J INVEST DERMATOL, V46, P139, DOI 10.1038/jid.1966.23; KALINER M, 1978, AM REV RESPIR DIS, V118, P1015; KALINER M, 1973, NEW ENGL J MED, V289, P277, DOI 10.1056/NEJM197308092890601; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; KAY AB, 1971, J IMMUNOL, V107, P899; LEVINE MI, 1975, J ALLERGY CLIN IMMUN, V55, P276, DOI 10.1016/0091-6749(75)90147-5; LEVY DA, 1973, J LAB CLIN MED, V81, P291; LEWIS RA, 1975, J IMMUNOL, V114, P87; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1979, MAST CELL ITS ROLE H; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; ORANGE RP, 1971, J EXP MED, V134, pS136; ORR TSC, 1977, SCAND J RESPIR DIS, P1; PALADE GE, 1952, J EXP MED, V95, P285, DOI 10.1084/jem.95.3.285; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; TROTTER CM, 1973, CLIN ALLERGY, V3, P411, DOI 10.1111/j.1365-2222.1973.tb01349.x; VENABLE JH, 1965, J CELL BIOL, V25, P407, DOI 10.1083/jcb.25.2.407; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	26	63	63	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	5					417	423		10.1016/0091-6749(80)90122-0	http://dx.doi.org/10.1016/0091-6749(80)90122-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KQ965	6160172				2022-12-18	WOS:A1980KQ96500011
J	GUESDON, JL; THIERRY, R; AVRAMEAS, S				GUESDON, JL; THIERRY, R; AVRAMEAS, S			MAGNETIC ENZYME IMMUNOASSAY FOR MEASURING HUMAN IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LOUIS PASTEUR, FAC MED, BACTERIOL LAB, STRASBOURG, FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	GUESDON, JL (corresponding author), INST PASTEUR, DEPT BIOL MOLEC, UNITE IMMUNOCYTOCHIM, F-75724 PARIS, FRANCE.							ARBESMAN CE, 1972, J ALLERGY CLIN IMMUN, V49, P72, DOI 10.1016/0091-6749(72)90058-9; AVRAMEAS S, 1969, IMMUNOCHEMISTRY, V6, P43, DOI 10.1016/0019-2791(69)90177-3; AVRAMEAS S, 1969, IMMUNOCHEMISTRY, V6, P53, DOI 10.1016/0019-2791(69)90178-5; CAMPBELL DH, 1970, METHOD IMMUNOL, P189; CENTIFAN.YM, 1971, J IMMUNOL, V107, P608; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; GUESDON JL, 1977, IMMUNOCHEMISTRY, V14, P443, DOI 10.1016/0019-2791(77)90170-7; GUESDON JL, 1976, J IMMUNOL METHODS, V11, P129, DOI 10.1016/0022-1759(76)90140-X; GUESDON JL, 1976, CLIN EXP IMMUNOL, V25, P180; HOFFMAN DR, 1973, J ALLERGY CLIN IMMUN, V51, P303, DOI 10.1016/0091-6749(73)90132-2; JOHANSSON SG, 1968, IMMUNOLOGY, V14, P265; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; NEZLIN RS, 1973, IMMUNOCHEMISTRY, V10, P681, DOI 10.1016/0019-2791(73)90211-5; ROWE DS, 1969, B WORLD HEALTH ORGAN, V40, P613; SALMON SE, 1969, J IMMUNOL, V103, P129; STEFANI DV, 1972, PROBL HAEMATOL USSR, V12, P44; WELTMAN JK, 1976, J ALLERGY CLIN IMMUN, V58, P426, DOI 10.1016/0091-6749(76)90123-8	17	63	68	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	1					23	27		10.1016/0091-6749(78)90469-4	http://dx.doi.org/10.1016/0091-6749(78)90469-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EH112	338662				2022-12-18	WOS:A1978EH11200004
J	BENVENISTE, J; EGIDO, J; GUTIERREZMILLET, V; CAMUSSI, G				BENVENISTE, J; EGIDO, J; GUTIERREZMILLET, V; CAMUSSI, G			DETECTION OF IMMEDIATE HYPERSENSITIVITY IN RABBITS BY DIRECT BASOPHIL DEGRANULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP NECKER,INSERM,NEPHROL CLIN U25,F-75730 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Camussi, Giovanni/J-7624-2016	Camussi, Giovanni/0000-0003-2795-232X				BARBARO JF, 1966, P SOC EXP BIOL MED, V122, P1245; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BOSEILA AWA, 1959, STAIN TECHNOL, V34, P335, DOI 10.3109/10520295909114701; BOSEILA AWA, 1959, ACTA MED SCAND, V163, P525; CAMUSSI J, IN PRESS; COOPER JR, 1966, J CLIN PATHOL, V19, P402, DOI 10.1136/jcp.19.4.402; GILBERT HS, 1975, BLOOD, V46, P279; HENSON PM, 1970, J EXP MED, V131, P287, DOI 10.1084/jem.131.2.287; HIRSCH SR, 1972, J ALLERGY CLIN IMMUN, V50, P338, DOI 10.1016/0091-6749(72)90037-1; HIRSCH SR, 1974, J ALLERGY CLIN IMMUN, V53, P303, DOI 10.1016/0091-6749(74)90110-9; KLOPSTOCK A, 1962, Isr Med J, V21, P216; MONERETVAUTRAIN DA, 1974, REV FR ALLERGOL, V14, P121, DOI 10.1016/S0335-7457(74)80024-9; MOORE JE, 1953, P SOC EXP BIOL MED, V82, P601; OVARY Z, 1961, IMMUNOLOGICAL METHOD, P259; SHELLEY WB, 1961, NATURE, V191, P1056, DOI 10.1038/1911056a0; SIRAGANIAN RP, 1969, J ALLERGY, V43, P167	16	63	63	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	4					271	279		10.1016/0091-6749(77)90047-1	http://dx.doi.org/10.1016/0091-6749(77)90047-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DB886	66241				2022-12-18	WOS:A1977DB88600001
J	GILLESPIE, DN; NAKAJIMA, S; GLEICH, GJ				GILLESPIE, DN; NAKAJIMA, S; GLEICH, GJ			DETECTION OF ALLERGY TO NUTS BY RADIOALLERGOSORBENT TEST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MAYO CLIN & MAYO GRAD SCH MED,DEPT MICROBIOL,ROCHESTER,MN; MAYO CLIN & MAYO GRAD SCH MED,ALLERGIC DIS RES LAB,ROCHESTER,MN; MAYO CLIN & MAYO GRAD SCH MED,DEPT PEDIAT,ROCHESTER,MN; MAYO CLIN & FDN,ROCHESTER,MN 55901; MAYO CLIN & MAYO GRAD SCH MED,DEPT MED,ROCHESTER,MN; MAYO CLIN & MAYO GRAD SCH MED,DEPT IMMUNOL,ROCHESTER,MN	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								AAS K, 1971, J ALLERGY CLIN IMMUN, V48, P134, DOI 10.1016/0091-6749(71)90008-X; ANCOMA CR, 1950, CALIFORNIA MEDICAL J, V73, P476; BERG T, 1971, INT ARCH ALLER A IMM, V40, P770, DOI 10.1159/000230461; Bryan W T, 1971, Otolaryngol Clin North Am, V4, P523; BULLOCK JD, 1968, ANN ALLERGY, V26, P177; COCA AF, 1943, FAMILIAL NON REAGINI, P96; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; HADDAD ZH, 1972, J ALLERGY CLIN IMMUN, V49, P210, DOI 10.1016/0091-6749(72)90084-X; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; INGELFINGER FJ, 1949, NEW ENGL J MED, V241, P303, DOI 10.1056/NEJM194908252410805; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; PARISH WE, 1974, PROGR IMMUNOLOGY 2, V4, P19; POPA V, 1966, J ALLERG, V37, P321; SCHUR S, 1974, J ALLERGY CLIN IMMUN, V54, P174, DOI 10.1016/0091-6749(74)90054-2; SHELDON JM, 1967, MANUAL CLINICAL ALLE, P196; SHIODA H, 1966, J ALLERGY, V37, P321, DOI 10.1016/0021-8707(66)90131-6; Vaughan WT, 1936, J LAB CLIN MED, V21, P1278; VAUGHAN WT, 1930, J ALLERGY, V1, P385; WIDE L, 1967, LANCET, V2, P1105; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P109, DOI 10.1016/0091-6749(72)90006-1; YUNGINGER JW, 1973, J CLIN INVEST, V52, P1268, DOI 10.1172/JCI107294	22	63	63	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	4					302	309		10.1016/0091-6749(76)90086-5	http://dx.doi.org/10.1016/0091-6749(76)90086-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BM689	1262606				2022-12-18	WOS:A1976BM68900003
J	SOLOMON, WR				SOLOMON, WR			VOLUMETRIC STUDY OF WINTER FUNGUS PREVALENCE IN AIR OF MIDWESTERN HOMES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,MED SCH,DEPT INTERN MED,DIV ALLERGY,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan								Ackermann H W, 1969, Mykosen, V12, P309; ANDERSEN AA, 1958, J BACTERIOL, V76, P471, DOI 10.1128/JB.76.5.471-484.1958; Benson F.B., 1972, INDOOR OUTDOOR AIR P; GRAVESEN S, 1972, ACTA ALLERGOL, V27, P337, DOI 10.1111/j.1398-9995.1972.tb01433.x; GREGORY P H, 1953, Acta Allergol, V6, P168, DOI 10.1111/j.1398-9995.1953.tb03483.x; GREGORY PH, 1973, MICROBIOLOGY ATMOSPH, P207; JONES EA, 1971, ANN ALLERGY, V29, P525; LEFCOE NM, 1971, ARCH ENVIRON HEALTH, V22, P230, DOI 10.1080/00039896.1971.10665836; MALLEA M, 1974, REV FR ALLERGOL, V14, P31, DOI 10.1016/S0335-7457(74)80004-3; MAUNSELL K, 1952, INT ARCH ALLER A IMM, V3, P93, DOI 10.1159/000227952; MORROW MB, 1964, ANN ALLERGY, V22, P575; OGDEN EC, 1974, MANUAL SAMPLING AIRB, P47; ONIONS AHS, 1967, 107 COMM MYC I MYC P; PADY SM, 1960, MYCOLOGIA, V52, P347, DOI 10.2307/3756022; RICHARDS M, 1954, J ALLERGY, V25, P429, DOI 10.1016/0021-8707(54)90007-6; SCHAFFER N, 1953, J ALLERGY, V24, P348, DOI 10.1016/0021-8707(53)90180-4; SHERMAN H, 1964, NEW YORK STATE J MED, V64, P2533; SOLOMON WR, 1970, J ALLERGY, V45, P1, DOI 10.1016/0021-8707(70)90012-2; SOLOMON WR, 1974, J ALLERGY CLIN IMMUN, V54, P222, DOI 10.1016/0091-6749(74)90064-5; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V56, P235, DOI 10.1016/0091-6749(75)90095-0; SOLOMON WR, 1967, MANUAL CLINICAL ALLE; SOSMAN JA, 1974, J ALLERGY CLIN IMMUN, V53, P71; SWAEBLY MA, 1952, J ALLERGY, V23, P370, DOI 10.1016/0021-8707(52)90058-0; SWEET LC, 1971, J ALLERGY CLIN IMMUN, V48, P171, DOI 10.1016/0091-6749(71)90013-3; Van der Werff PJ, 1958, MOULD FUNGI BRONCHIA	25	63	64	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	57	1					46	55		10.1016/0091-6749(76)90078-6	http://dx.doi.org/10.1016/0091-6749(76)90078-6			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BC141	942733				2022-12-18	WOS:A1976BC14100006
J	Camiolo, M; Gauthier, M; Kaminski, N; Ray, A; Wenzel, SE				Camiolo, Matthew; Gauthier, Marc; Kaminski, Naftali; Ray, Anuradha; Wenzel, Sally E.			Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; ACE2; coronavirus; SARS-CoV-2; asthma; interferon; viral response; Type-2 low	GENE-EXPRESSION; CORONAVIRUS; CYTOSCAPE; ONTOLOGY; PACKAGE; TOOL	Background: More than 300 million people carry a diagnosis of asthma, with data to suggest that they are at a higher risk for infection or adverse outcomes from severe acute respiratory syndrome coronavirus 2. Asthma is remarkably heterogeneous, and it is currently unclear how patient-intrinsic factors may relate to coronavirus disease 2019. Objective: We sought to identify and characterize subsets of patients with asthma at increased risk for severe acute respiratory syndrome coronavirus 2 infection. Methods: Participants from 2 large asthma cohorts were stratified using clinically relevant parameters to identify factors related to angiotensin-converting enzyme-2 (ACE2) expression within bronchial epithelium. ACE-2 correlated gene signatures were used to interrogate publicly available databases to identify upstream signaling events and novel therapeutic targets. Results: Stratifying by type 2 inflammatory biomarkers, we identified subjects who demonstrated low peripheral blood eosinophils accompanied by increased expression of the severe acute respiratory syndrome coronavirus 2 receptor ACE2 in bronchial epithelium. Genes highly correlated with ACE2 overlapped with type 1 and 2 IFN signatures, normally induced by viral infections. T-cell recruitment and activation within bronchoalveolar lavage cells of ACE2-high subjects was reciprocally increased. These patients demonstrated characteristics corresponding to risk factors for severe coronavirus disease 2019, including male sex, history of hypertension, low peripheral blood, and elevated bronchoalveolar lavage lymphocytes. Conclusions: ACE2 expression is linked to upregulation of viral response genes in a subset of type 2 low patients with asthma with characteristics resembling known risk factors for severe coronavirus disease 2019. Therapies targeting the IFN family and T-cell activating factors may therefore be of benefit in a subset of patients.	[Camiolo, Matthew; Gauthier, Marc; Ray, Anuradha; Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; [Kaminski, Naftali] Yale Sch Med, Pulm Crit Care & Sleep Med, New Haven, CT USA; [Ray, Anuradha; Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA; [Wenzel, Sally E.] Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Dept Environm Med & Occupat Hlth, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wenzel, SE (corresponding author), Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Dept Environm Med & Occupat Hlth, Pittsburgh, PA USA.; Wenzel, SE (corresponding author), Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Environm Med & Occupat Hlth, 4126 Publ Hlth,130 DeSoto St, Pittsburgh, PA 15261 USA.	swenzel@pitt.edu		Camiolo, Matthew/0000-0002-9085-6552; Kaminski, Naftali/0000-0001-5917-4601	National Institutes of Health (NIH) [P01AI106684, R01HL113956, R01AI048927, U10HL109152, F32HL14741501]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by the National Institutes of Health (NIH) (grant no. P01AI106684 to A.R. and S.E.W., grant no. R01HL113956 to A.R., and grant no. R01AI048927 to A.R.), NIH grant number U10HL109152 (to S.E.W.), and NIH grant number F32HL14741501 (to M.C.).	[Anonymous], 2011, PLOS BIOL, V9, DOI [10.1371/journal.pbio.1001046, DOI 10.1371/JOURNAL.PBIO.1001046]; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bhakta NR, 2018, AM J RESP CRIT CARE, V197, P313, DOI 10.1164/rccm.201706-1070OC; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Buhl AL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01162; Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055; Charrad M, 2014, J STAT SOFTW, V61, P1; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Gauthier M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94580; Han H, 2018, NUCLEIC ACIDS RES, V46, pD380, DOI 10.1093/nar/gkx1013; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009; Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005; Kalinka Alex T, 2011, Bioinformatics, V27, P2011, DOI 10.1093/bioinformatics/btr311; Kanneganti TD, 2018, NAT REV IMMUNOL, V18, P483, DOI 10.1038/s41577-018-0027-1; Kreft L, 2017, NUCLEIC ACIDS RES, V45, pW490, DOI 10.1093/nar/gkx376; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Laresgoiti U, 2013, NUCLEIC ACIDS RES, V41, P10185, DOI 10.1093/nar/gkt821; Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034; Lesurf R, 2016, NUCLEIC ACIDS RES, V44, pD126, DOI 10.1093/nar/gkv1203; Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757; Li QL, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100375; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Modena BD, 2017, AM J RESP CRIT CARE, V195, P1449, DOI 10.1164/rccm.201607-1407OC; Modena BD, 2014, AM J RESP CRIT CARE, V190, P1363, DOI 10.1164/rccm.201406-1099OC; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0; Queen D, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00317; Raundhal M, 2015, J CLIN INVEST, V125, P3037, DOI 10.1172/JCI80911; Ray A, 2020, PHYSIOL REV, V100, P983, DOI 10.1152/physrev.00023.2019; Roan F, 2019, J CLIN INVEST, V129, P1441, DOI 10.1172/JCI124606; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Rouillard AD, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw100; Sajuthi Satria P, 2020, bioRxiv, DOI 10.1101/2020.04.09.034454; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236; Stathias V, 2020, NUCLEIC ACIDS RES, V48, pD431, DOI 10.1093/nar/gkz1023; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Toki S, 2020, ALLERGY, V75, P1606, DOI 10.1111/all.14196; Trifilo MJ, 2003, J VIROL, V77, P4004, DOI 10.1128/JVI.77.7.4004-4014.2003; Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	52	62	63	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2020	146	2					315	+		10.1016/j.jaci.2020.05.051	http://dx.doi.org/10.1016/j.jaci.2020.05.051			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MZ0TA	32531372	Green Published, Bronze			2022-12-18	WOS:000558835000016
J	Michaudel, C; Mackowiak, C; Maillet, I; Fauconnier, L; Akdis, CA; Sokolowska, M; Dreher, A; Tan, HTT; Quesniaux, VF; Ryffel, B; Togbe, D				Michaudel, Chloe; Mackowiak, Claire; Maillet, Isabelle; Fauconnier, Louis; Akdis, Cezmi A.; Sokolowska, Milena; Dreher, Anita; Tan, Hern-Tze Tina; Quesniaux, Valerie F.; Ryffel, Bernhard; Togbe, Dieudonnee			Ozone exposure induces respiratory barrier biphasic injury and inflammation controlled by IL-33	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ozone; ST2; IL-33; AHR; E-cadherin; inflammation; neutrophils	INDUCED AIRWAY HYPERRESPONSIVENESS; INDUCED LUNG INFLAMMATION; PUBLIC-HEALTH BENEFITS; INNATE LYMPHOID-CELLS; OXIDATIVE STRESS; INTERLEUKIN-33; RESPONSES; CYTOKINE; RECEPTOR; MICE	Background: IL-33 plays a critical role in regulation of tissue homeostasis, injury, and repair. Whether IL-33 regulates neutrophil recruitment and functions independently of airways hyperresponsiveness (AHR) in the setting of ozone-induced lung injury and inflammation is unclear. Objective: We sought to examine the role of the IL-33/ST2 axis in lung inflammation on acute ozone exposure in mice. Methods: ST2- and 1133 deficient, IL-33 citrine reporter, and C57BL/6 (wild-type) mice underwent a single ozone exposure (1 ppm for 1 hour) in all studies. Cell recruitment in lung tissue and the bronchoalveolar space, inflammatory parameters, epithelial barrier damage, and airway hyperresponsiveness (AHR) were determined. Results: We report that a single ozone exposure causes rapid disruption of the epithelial barrier within 1 hour, followed by a second phase of respiratory barrier injury with increased neutrophil recruitment, reactive oxygen species production, AHR, and IL-33 expression in epithelial and myeloid cells in wild-type mice. In the absence of IL-33 or IL-33 receptor/ST2, epithelial cell injury with protein leak and myeloid cell recruitment and inflammation are further increased, whereas the tight junction proteins E-cadherin and zonula occludens 1 and reactive oxygen species expression in neutrophils and AHR are diminished. ST2 neutralization recapitulated the enhanced ozone-induced neutrophilic inflammation. However, myeloid cell depletion using GR-1 antibody reduced ozone-induced lung inflammation, epithelial cell injury, and protein leak, whereas administration of recombinant mouse IL-33 reduced neutrophil recruitment in 1133 deficient mice. Conclusion: Data demonstrate that ozone causes an immediate barrier injury that precedes myeloid cell mediated inflammatory injury under the control of the IL-33/ST2 axis. Thus IL-33/ST2 signaling is critical for maintenance of intact epithelial barrier and inflammation.	[Michaudel, Chloe; Mackowiak, Claire; Maillet, Isabelle; Quesniaux, Valerie F.; Ryffel, Bernhard; Togbe, Dieudonnee] Univ Orleans, CNRS, UMR 7355, Lab Expt & Mol Immunol & Neurogenet INEM, Orleans, France; [Fauconnier, Louis; Togbe, Dieudonnee] ArtImmune SAS, Orleans, France; [Akdis, Cezmi A.; Sokolowska, Milena; Dreher, Anita; Tan, Hern-Tze Tina] Swiss Inst Allergy & Asthma Res, Davos, Switzerland; [Akdis, Cezmi A.; Sokolowska, Milena; Dreher, Anita; Tan, Hern-Tze Tina] CK CARE, Davos, Switzerland; [Tan, Hern-Tze Tina] Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Kubang Kerian, Malaysia; [Ryffel, Bernhard] Univ Cape Town, Div Immunol, Inst Infect Dis & Mol Med IDM, Cape Town, South Africa; [Ryffel, Bernhard] Univ Cape Town, Fac Hlth Sci, SAMRC, Immunol & Infect Dis, Cape Town, South Africa; [Ryffel, Bernhard] Sun Yat Sen Univ Guangzhou, Hosp 3, Dept Clin Immunol, Guangzhou, Guangdong, Peoples R China	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Orleans; Swiss Institute of Allergy & Asthma Research; Universiti Sains Malaysia; University of Cape Town; University of Cape Town; Sun Yat Sen University	Ryffel, B; Togbe, D (corresponding author), Artimmune, Orleans, France.; Ryffel, B; Togbe, D (corresponding author), Univ Orleans, CNRS, UMR7355, Expt & Mol Immunol & Neurogenet, Orleans, France.	bryffel@cnrs-orleans.fr; dtogbe@cnrs-orleans.fr	Togbe, Dieudonnee/AAE-1135-2020; Akdis, Cezmi/AAV-4844-2020	Togbe, Dieudonnee/0000-0001-6658-414X; Akdis, Cezmi/0000-0001-8020-019X; Mackowiak, Claire/0000-0003-1267-5905; Sokolowska, Milena/0000-0001-9710-6685; Michaudel, Chloe/0000-0001-7189-2729	Centre National de la Recherche Scientifique (CNRS); French Institute of Health and Medical Research (INSERM); European Regional Development Fund (FEDER) [2016-00110366]; la Region Centre (Respir_Ozone) [2014-00091905]	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); French Institute of Health and Medical Research (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); European Regional Development Fund (FEDER)(European Commission); la Region Centre (Respir_Ozone)	Supported by Centre National de la Recherche Scientifique (CNRS), the French Institute of Health and Medical Research (INSERM), the European Regional Development Fund (FEDER no. 2016-00110366), and la Region Centre (Respir_Ozone, no2014-00091905).	Akdis M, 2016, J ALLERGY CLIN IMMUN, V138, P984, DOI 10.1016/j.jaci.2016.06.033; Al-Hegelan M, 2011, IMMUNOL RES, V49, P173, DOI 10.1007/s12026-010-8180-z; Alves JC, 2010, NAT MED, V16, P708, DOI 10.1038/nm.2156; Barker JS, 2015, J TOXICOL ENV HEAL A, V78, P397, DOI 10.1080/15287394.2014.971924; Besnard AG, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004607; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Borthwick LA, 2016, SEMIN IMMUNOPATHOL, V38, P517, DOI 10.1007/s00281-016-0559-z; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004; Che LQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep18680; Chen GL, 2015, CELL PHYSIOL BIOCHEM, V35, P2111, DOI 10.1159/000374017; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Feng FF, 2016, ENVIRON TOXICOL, V31, P2016, DOI 10.1002/tox.22202; Fu AKY, 2016, P NATL ACAD SCI USA, V113, pE2705, DOI 10.1073/pnas.1604032113; Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049; Guabiraba R, 2014, MUCOSAL IMMUNOL, V7, P1079, DOI 10.1038/mi.2013.124; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Hardman CS, 2013, EUR J IMMUNOL, V43, P488, DOI 10.1002/eji.201242863; Hollingsworth John W, 2007, Proc Am Thorac Soc, V4, P240, DOI 10.1513/pats.200701-023AW; Ivanov AI, 2013, INT REV CEL MOL BIO, V303, P27, DOI 10.1016/B978-0-12-407697-6.00002-7; Ji M, 2011, ENVIRON RES LETT, V6, DOI 10.1088/1748-9326/6/2/024006; Jiang HR, 2012, EUR J IMMUNOL, V42, P1804, DOI 10.1002/eji.201141947; Johnston RA, 2007, AM J RESP CELL MOL, V37, P477, DOI 10.1165/rcmb.2006-0315OC; Kumagai K, 2016, AM J RESP CELL MOL, V54, P782, DOI 10.1165/rcmb.2015-0118OC; Kurt OK, 2016, CURR OPIN PULM MED, V22, P138, DOI 10.1097/MCP.0000000000000248; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Ledford DK, 2012, J ALLERGY CLIN IMMUN, V130, P24, DOI 10.1016/j.jaci.2012.02.055; Lefrancais E, 2014, P NATL ACAD SCI USA, V111, P15502, DOI 10.1073/pnas.1410700111; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Li BWS, 2013, IMMUNOLOGY, V140, P281, DOI 10.1111/imm.12153; Li D, 2014, J ALLERGY CLIN IMMUN, V134, P1422, DOI 10.1016/j.jaci.2014.05.011; Li F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080782; Li JH, 2012, J ALLERGY CLIN IMMUN, V130, P22, DOI 10.1016/j.jaci.2012.02.047; Li ZW, 2013, J BIOCHEM MOL TOXIC, V27, P3, DOI 10.1002/jbt.21453; Liew FY, 2012, ANN RHEUM DIS, V71, P101, DOI 10.1136/annrheumdis-2011-200589; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Madouri F, 2015, J MOL CELL BIOL, V7, P351, DOI 10.1093/jmcb/mjv012; Manzer R, 2008, AM J RESP CELL MOL, V38, P318, DOI 10.1165/rcmb.2007-0250OC; Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370; Mathews JA, 2017, ENVIRON HEALTH PERSP, V125, P246, DOI 10.1289/EHP272; Mathews JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131236; Mattila Pirkko, 2011, Clin Transl Allergy, V1, P5, DOI 10.1186/2045-7022-1-5; Michaudel C, 2016, AM J CLIN EXP IMMUNO, V5, P33; Miller RL, 2014, J ALLERGY CLIN IMMUN, V134, P1001, DOI 10.1016/j.jaci.2014.07.064; Mizutani N, 2014, J IMMUNOL, V192, P1372, DOI 10.4049/jimmunol.1301538; MOLOFSKY AB, 2015, IMMUNITY, V42, P1005, DOI [DOI 10.1016/j.immuni.2015.06.006, DOI 10.1016/J.IMMUNI.2015.06.006]; Molofsky AB, 2015, IMMUNITY, V43, P161, DOI 10.1016/j.immuni.2015.05.019; Monticelli LA, 2015, P NATL ACAD SCI USA, V112, P10762, DOI 10.1073/pnas.1509070112; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Nadeem A, 2014, PULM PHARMACOL THER, V29, P31, DOI 10.1016/j.pupt.2014.06.001; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Pain M, 2014, EUR RESPIR REV, V23, P118, DOI 10.1183/09059180.00004413; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977; Pinart M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058452; Qiu CA, 2013, IMMUNOLOGY, V138, P76, DOI 10.1111/imm.12020; Roversi P, 2013, J BIOL CHEM, V288, P18789, DOI 10.1074/jbc.M112.420331; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sedhom MAK, 2013, GUT, V62, P1714, DOI 10.1136/gutjnl-2011-301785; Steelant B, 2016, J ALLERGY CLIN IMMUN, V137, P1043, DOI 10.1016/j.jaci.2015.10.050; Sugita K, 2018, J ALLERGY CLIN IMMUN, V141, P300, DOI 10.1016/j.jaci.2017.02.038; Sunil VR, 2013, TOXICOL SCI, V133, P309, DOI 10.1093/toxsci/kft071; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Van Dyken SJ, 2014, IMMUNITY, V40, P414, DOI 10.1016/j.immuni.2014.02.003; Voter KZ, 2001, INHAL TOXICOL, V13, P465, DOI 10.1080/08958370151131837; Wieczfinska J, 2015, ANTIOXID REDOX SIGN, V23, P428, DOI 10.1089/ars.2013.5783; Wiegman CH, 2015, J ALLERGY CLIN IMMUN, V136, P769, DOI 10.1016/j.jaci.2015.01.046; Williams AS, 2007, J APPL PHYSIOL, V103, P1189, DOI 10.1152/japplphysiol.00172.2007; Williams AS, 2015, AM J PHYSIOL-LUNG C, V308, pL1168, DOI 10.1152/ajplung.00393.2014; Williams L, 2008, J PSYCHOSOM RES, V64, P63, DOI 10.1016/j.jpsychores.2007.06.008; Yang Q, 2016, J ALLERGY CLIN IMMUN, V137, P571, DOI 10.1016/j.jaci.2015.06.037	73	62	63	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2018	142	3					942	958		10.1016/j.jaci.2017.11.044	http://dx.doi.org/10.1016/j.jaci.2017.11.044			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GS5RJ	29331644	hybrid			2022-12-18	WOS:000443726500026
J	Mukherjee, M; Bulir, DC; Radford, K; Kjarsgaard, M; Huang, CM; Jacobsen, EA; Ochkur, SI; Catuneanu, A; Lamothe-Kipnes, H; Mahony, J; Lee, JJ; Lacy, P; Nair, PK				Mukherjee, Manali; Bulir, David C.; Radford, Katherine; Kjarsgaard, Melanie; Huang, Chynna Margaret; Jacobsen, Elizabeth A.; Ochkur, Sergei I.; Catuneanu, Ana; Lamothe-Kipnes, Hanah; Mahony, James; Lee, James J.; Lacy, Paige; Nair, Parameswaran K.			Sputum autoantibodies in patients with severe eosinophilic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; eosinophilia; autoantibodies; sputum; eosinophil degranulation; eosinophil peroxidase; autoimmunity; anti-nuclear antibodies	LYMPHOID-TISSUE; RHEUMATOID-ARTHRITIS; NASAL POLYPS; T-CELLS; B-CELL; AUTOIMMUNITY; DEGRANULATION; LYMPHOPENIA; PEROXIDASE; ANTIBODIES	Background: The persistence of eosinophils in sputum despite high doses of corticosteroids indicates disease severity in asthmatic patients. Chronic inflamed airways can lose tolerance over time to immunogenic entities released on frequent eosinophil degranulation, which further contributes to disease severity and necessitates an increase in maintenance corticosteroids. Objectives: We sought to investigate the possibility of a polyclonal autoimmune event in the airways of asthmatic patients and to identify associated clinical and molecular characteristics. Methods: The presence of autoantibodies against eosinophil peroxidase (EPX) and anti-nuclear antibodies was investigated in patients with eosinophilic asthma maintained on high-dose corticosteroids, prednisone, or both. The ability of sputum immunoglobulins to induce eosinophil degranulation in vitro was assessed. In addition, the associated inflammatory microenvironment in patients with detectable autoantibodies was examined. Results: We report a "polyclonal'' autoimmune event occurring in the airways of prednisone-dependent asthmatic patients with increased eosinophil activity, recurrent pulmonary infections, or both, as evident by the concomitant presence of sputum anti-EPX and anti-nuclear antibodies of the IgG subtype. Extensive cytokine profiling of sputum revealed a T(H)2-dominated microenvironment (eotaxin-2, IL-5, IL-18, and IL-13) and increased signalling molecules that support the formation of ectopic lymphoid structures ( B-cell activating factor and B cell-attracting chemokine 1). Immunoprecipitated sputum immunoglobulins from patients with increased autoantibody levels triggered eosinophil degranulation in vitro, with release of extensive histone-rich extracellular traps, an event unsuppressed by dexamethasone and possibly contributing to the steroid-unresponsive nature of these eosinophilic patients. Conclusion: This study identifies an autoimmune endotype of severe asthma that can be identified by the presence of sputum autoantibodies against EPX and autologous cellular components.	[Mukherjee, Manali; Radford, Katherine; Kjarsgaard, Melanie; Huang, Chynna Margaret; Nair, Parameswaran K.] McMaster Univ, Div Respirol, Hamilton, ON, Canada; [Bulir, David C.; Lee, James J.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Jacobsen, Elizabeth A.; Ochkur, Sergei I.; Lee, James J.] Mayo Clin, Div Pulm Med, Scottsdale, AZ USA; [Catuneanu, Ana; Lamothe-Kipnes, Hanah; Lacy, Paige] Univ Alberta, Dept Med, Edmonton, AB, Canada	McMaster University; McMaster University; Mayo Clinic; Mayo Clinic Phoenix; University of Alberta	Nair, PK (corresponding author), St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	parames@mcmaster.ca	Lacy, Paige/A-6021-2010; Mukherjee, Manali/AAE-2778-2020	Lacy, Paige/0000-0001-8885-6011; Mukherjee, Manali/0000-0002-7924-7211; Jacobsen, Elizabeth A./0000-0003-2956-753X	Canada Research Chair program; Ontario Thoracic Society	Canada Research Chair program(Canada Research Chairs); Ontario Thoracic Society	Supported by the Canada Research Chair program and the Ontario Thoracic Society.	BARRETT SP, 1995, EUR J IMMUNOL, V25, P238, DOI 10.1002/eji.1830250139; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Brusselle GG, 2013, NAT MED, V19, P977, DOI 10.1038/nm.3300; Chan YC, 2014, J ALLERGY CLIN IMMUN, V134, P1394, DOI 10.1016/j.jaci.2014.06.029; De Schryver E, 2016, J ALLERGY CLIN IMMUN, V138, P893, DOI 10.1016/j.jaci.2016.03.040; Gleeson PA, 1996, IMMUNOL REV, V149, P97, DOI 10.1111/j.1600-065X.1996.tb00901.x; GUEIRARD P, 1991, J AUTOIMMUN, V4, P517, DOI 10.1016/0896-8411(91)90163-7; Hori S, 2003, ADV IMMUNOL, V81, P331, DOI 10.1016/S0065-2776(03)81008-8; Jabri B, 2015, NAT REV IMMUNOL, V15, P771, DOI 10.1038/nri3919; KANEKO M, 1995, J CLIN INVEST, V95, P2813, DOI 10.1172/JCI117986; Kato A, 2013, J ALLERGY CLIN IMMUN, V131, P933, DOI 10.1016/j.jaci.2013.02.023; Kim JT, 1999, J IMMUNOL, V162, P4253; KITA H, 1991, J ALLERGY CLIN IMMUN, V87, P70, DOI 10.1016/0091-6749(91)90214-9; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Mauri C, 2014, IMMUNITY, V41, P878, DOI 10.1016/j.immuni.2014.12.003; McLachlan SM, 2007, THYROID, V17, P939, DOI 10.1089/thy.2007.0169; Morissette MC, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-49; Mukherjee M, 2017, ALLERGY ASTHMA CL IM, V13, DOI 10.1186/s13223-016-0174-5; Mukherjee M, 2015, LANCET RESP MED, V3, P824, DOI 10.1016/S2213-2600(15)00419-1; Mukherjee M, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-32; Nair P, 2013, ALLERGY, V68, P1177, DOI 10.1111/all.12206; Nair P, 2014, NEW ENGL J MED, V371, P1249, DOI 10.1056/NEJMe1408614; Nair P, 2013, J ALLERGY CLIN IMMUN, V132, P81, DOI 10.1016/j.jaci.2013.05.007; Olnes MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23002; Persson C, 2014, AM J RESP CRIT CARE, V189, P628, DOI 10.1164/rccm.201311-2069OE; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Randall TD, 2010, ADV IMMUNOL, V107, P187, DOI [10.1016/S0065-2776(10)07002-1, 10.1016/B978-0-12-381300-8.00007-1]; Rangel-Moreno J, 2006, J CLIN INVEST, V116, P3183, DOI 10.1172/JCI28756; Sallusto F, 2009, MICROBES INFECT, V11, P620, DOI 10.1016/j.micinf.2009.04.004; Salomonsson S, 2002, SCAND J IMMUNOL, V55, P336, DOI 10.1046/j.1365-3083.2002.01058.x; Sato A, 1996, AM J RESP CRIT CARE, V154, P1903, DOI 10.1164/ajrccm.154.6.8970384; Schulze-Koops H, 2004, ARTHRITIS RES THER, V6, P178, DOI 10.1186/ar1208; SZCZEKLIK A, 1995, AM J RESP CRIT CARE, V152, P1753, DOI 10.1164/ajrccm.152.6.8520733; Tan BK, 2011, J ALLERGY CLIN IMMUN, V128, P1198, DOI 10.1016/j.jaci.2011.08.037; Ueki S, 2016, J ALLERGY CLIN IMMUN, V137, P258, DOI 10.1016/j.jaci.2015.04.041; Ueki S, 2013, BLOOD, V121, P2074, DOI 10.1182/blood-2012-05-432088; Vodounon CA, 2014, ALLERGY ASTHMA CL IM, V10, DOI 10.1186/1710-1492-10-14; Wang JG, 2006, ARCH BIOCHEM BIOPHYS, V445, P256, DOI 10.1016/j.abb.2005.10.008; Weiler CR, 1996, J LEUKOCYTE BIOL, V60, P493, DOI 10.1002/jlb.60.4.493; Wenzel SE, 2012, AM J RESP CRIT CARE, V186, P501, DOI 10.1164/rccm.201203-0476OC	40	62	64	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1269	1279		10.1016/j.jaci.2017.06.033	http://dx.doi.org/10.1016/j.jaci.2017.06.033			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	28751233	Bronze			2022-12-18	WOS:000429197800013
J	Hoshino, A; Okada, S; Yoshida, K; Nishida, N; Okuno, Y; Ueno, H; Yamashita, M; Okano, T; Tsumura, M; Nishimura, S; Sakata, S; Kobayashi, M; Nakamura, H; Kamizono, J; Mitsui-Sekinaka, K; Ichimura, T; Ohga, S; Nakazawa, Y; Takagi, M; Imai, K; Shiraishi, Y; Chiba, K; Tanaka, H; Miyano, S; Ogawa, S; Kojima, S; Nonoyama, S; Morio, T; Kanegane, H				Hoshino, Akihiro; Okada, Satoshi; Yoshida, Kenichi; Nishida, Naonori; Okuno, Yusuke; Ueno, Hiroo; Yamashita, Motoi; Okano, Tsubasa; Tsumura, Miyuki; Nishimura, Shiho; Sakata, Sonoko; Kobayashi, Masao; Nakamura, Haruna; Kamizono, Junji; Mitsui-Sekinaka, Kanako; Ichimura, Takuya; Ohga, Shouichi; Nakazawa, Yozo; Takagi, Masatoshi; Imai, Kohsuke; Shiraishi, Yuichi; Chiba, Kenichi; Tanaka, Hiroko; Miyano, Satoru; Ogawa, Seishi; Kojima, Seiji; Nonoyama, Shigeaki; Morio, Tomohiro; Kanegane, Hirokazu			Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acute lymphoblastic leukemia; autoimmune disease; B-cell deficiency; common lymphoid progenitor; DNA binding; dysgammaglobulinemia; germline mutation; Ikaros; IKZF1; nuclear localization	B-CELL DIFFERENTIATION; LYMPHOBLASTIC-LEUKEMIA; ZINC FINGERS; IKAROS; LEUKEMOGENESIS; ACTIVATION; DEFECTS; SYSTEM; STAGE	Background: Ikaros, which is encoded by IKZF1, is a transcriptional factor that play a critical role in hematopoiesis. Somatic IKZF1 alterations are known to be involved in the pathogenesis of leukemia in human subjects. Recently, immunodeficiency caused by germline IKZF1 mutation has been described. Objective: We sought to describe the clinical and immunologic phenotypes of Japanese patients with heterozygous IKZF1 mutations. Methods: We performed whole-exome sequencing in patients from a dysgammaglobulinemia or autoimmune disease cohort and used a candidate gene approach in 4 patients. Functional and laboratory studies, including detailed lymphopoiesis/hematopoiesis analysis in the bone marrow, were performed. Results: Nine patients from 6 unrelated families were identified to have heterozygous germline mutations in IKZF1. Age of onset was 0 to 20 years (mean, 7.4 years). Eight of 9 patients presented with dysgammaglobulinemia accompanied by B-cell deficiency. Four of 9 patients had autoimmune disease, including immune thrombocytopenic purpura, IgA vasculitis, and systemic lupus erythematosus. Nonautoimmune pancytopenia was observed in 1 patient. All of the mutant Ikaros protein demonstrated impaired DNA binding to the target sequence and abnormal diffuse nuclear localization. Flow cytometric analysis of bone marrow revealed reduced levels of common lymphoid progenitors and normal development of pro-B to pre-B cells. Conclusions: Germline heterozygous IKZF1 mutations cause dysgammaglobulinemia; hematologic abnormalities, including B-cell defect; and autoimmune diseases.	[Hoshino, Akihiro; Nishida, Naonori] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pediat, Toyama, Japan; [Hoshino, Akihiro; Yamashita, Motoi; Okano, Tsubasa; Morio, Tomohiro; Kanegane, Hirokazu] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Pediat & Dev Biol, Tokyo, Japan; [Takagi, Masatoshi; Imai, Kohsuke] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Community Pediat Perinatal & Maternal Med, Tokyo, Japan; [Okada, Satoshi; Tsumura, Miyuki; Nishimura, Shiho; Sakata, Sonoko; Kobayashi, Masao] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pediat, Hiroshima, Japan; [Yoshida, Kenichi; Ueno, Hiroo; Ogawa, Seishi] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan; [Okuno, Yusuke; Kojima, Seiji] Nagoya Univ, Grad Sch Med, Dept Pediat, Nagoya, Aichi, Japan; [Nakamura, Haruna] Natl Mie Hosp, Dept Pediat, Tsu, Mie, Japan; [Kamizono, Junji] Kitakyushu City Yahata Hosp, Dept Pediat, Kitakyushu, Fukuoka, Japan; [Mitsui-Sekinaka, Kanako; Nonoyama, Shigeaki] Natl Def Med Coll, Dept Pediat, Tokorozawa, Saitama, Japan; [Ichimura, Takuya; Ohga, Shouichi] Yamaguchi Univ, Grad Sch Med, Dept Pediat, Ube, Yamaguchi, Japan; [Nakazawa, Yozo] Shinshu Univ, Sch Med, Dept Pediat, Matsumoto, Nagano, Japan; [Shiraishi, Yuichi; Chiba, Kenichi; Miyano, Satoru] Univ Tokyo, Inst Med Sci, Human Genome Ctr, Lab DNA Informat Anal, Tokyo, Japan; [Tanaka, Hiroko; Miyano, Satoru] Univ Tokyo, Inst Med Sci, Human Genome Ctr, Lab Sequence Anal, Tokyo, Japan	University of Toyama; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Hiroshima University; Kyoto University; Nagoya University; National Defense Medical College - Japan; Yamaguchi University; Shinshu University; University of Tokyo; University of Tokyo	Kanegane, H (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Pediat & Dev Biol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	hkanegane.ped@tmd.ac.jp	Ogawa, Seishi/AAE-7088-2019; Okada, Satoshi/B-8901-2011; 岡野, 翼/AAU-8246-2021; Ueno, Hiroo/AAJ-7175-2020; Okuno, Yusuke/C-9082-2009; Imai, Kohsuke/Q-2602-2015; Yamashita, Motoi/ABB-5789-2021	Okada, Satoshi/0000-0002-4622-5657; Okuno, Yusuke/0000-0003-3139-9272; Imai, Kohsuke/0000-0003-2132-8403; Yoshida, Kenichi/0000-0003-4612-2778; Miyano, Satoru/0000-0002-1753-6616; Morio, Tomohiro/0000-0002-9259-1025	Research on Measures for Intractable Disease Project; Ministry of Education, Culture, Sports, Science, and Technology of Japan; Ministry of Health, Labour, and Welfare of Japan; Grants-in-Aid for Scientific Research [26461570, 15K09640, 17K10112, 26221308] Funding Source: KAKEN	Research on Measures for Intractable Disease Project; Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by the Research on Measures for Intractable Disease Project (to S.K.) and grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to T.M. and H.K.) and the Ministry of Health, Labour, and Welfare of Japan (to S.N.).	Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Casero D, 2015, NAT IMMUNOL, V16, P1282, DOI 10.1038/ni.3299; Cazzaniga G, 2011, BLOOD, V118, P5559, DOI 10.1182/blood-2011-07-366542; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Dumortier A, 2006, MOL CELL BIOL, V26, P209, DOI 10.1128/MCB.26.1.209-220.2006; Goldman FD, 2012, PEDIATR BLOOD CANCER, V58, P591, DOI 10.1002/pbc.23160; Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472; Hirata O, 2013, HAEMATOLOGICA, V98, P1641, DOI 10.3324/haematol.2013.083741; Honda F, 2012, NAT IMMUNOL, V13, P369, DOI 10.1038/ni.2234; John LB, 2011, MOL IMMUNOL, V48, P1272, DOI 10.1016/j.molimm.2011.03.006; Kirstetter P, 2002, EUR J IMMUNOL, V32, P720, DOI 10.1002/1521-4141(200203)32:3<720::AID-IMMU720>3.0.CO;2-P; Klug A, 2010, Q REV BIOPHYS, V43, P1, DOI 10.1017/S0033583510000089; Kuehn HS, 2016, NEW ENGL J MED, V374, P1032, DOI 10.1056/NEJMoa1512234; Lana T, 2015, LEUKEMIA, V29, P2107, DOI 10.1038/leu.2015.78; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; Nomura K, 2000, BLOOD, V96, P610; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Schjerven H, 2013, NAT IMMUNOL, V14, P1073, DOI 10.1038/ni.2707; Schwickert TA, 2014, NAT IMMUNOL, V15, P283, DOI 10.1038/ni.2828; Tarbox JA, 2014, J CLIN IMMUNOL, V34, P594, DOI 10.1007/s10875-014-0038-z; Trageser D, 2009, J EXP MED, V206, P1739, DOI 10.1084/jem.20090004; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wolfe SA, 2001, STRUCTURE, V9, P717, DOI 10.1016/S0969-2126(01)00632-3	27	62	64	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					223	231		10.1016/j.jaci.2016.09.029	http://dx.doi.org/10.1016/j.jaci.2016.09.029			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27939403	Bronze			2022-12-18	WOS:000404542000022
J	Yancey, SW; Ortega, HG; Keene, ON; Mayer, B; Gunsoy, NB; Brightling, CE; Bleecker, ER; Haldar, P; Pavord, ID				Yancey, Steven W.; Ortega, Hector G.; Keene, Oliver N.; Mayer, Bhabita; Gunsoy, Necdet B.; Brightling, Christopher E.; Bleecker, Eugene R.; Haldar, Pranabashis; Pavord, Ian D.			Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antiasthmatic agents; exacerbation; emergency service; hospital; IL-5; mepolizumab; severe eosinophilic asthma; meta-analysis	EXACERBATIONS; THERAPY; HETEROGENEITY; STATEMENT; SAFETY; DREAM; LUNG	Background: Studies show that mepolizumab can reduce the frequency of clinically significant exacerbations in patients with severe eosinophilic asthma, compared with placebo. However, important events such as hospitalizations and emergency room visits are rare and difficult to characterize in single studies. Objective: We sought to compare hospitalization or hospitalization and/or emergency room visit rates in patients with severe eosinophilic asthma treated with mepolizumab or placebo in addition to standard of care for at least 24 weeks. Methods: This study was conducted and reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. PubMed and the GSK Clinical Study Register were searched for suitable studies. The primary end points were the rate of exacerbations requiring hospitalization and the rate of exacerbations requiring hospitalization/emergency room visit. The proportion of patients with 1 or more event was also assessed. All mepolizumab doses were combined and individual patient-level data were analyzed. Results: Four studies (n = 1388) were eligible for inclusion. Mepolizumab significantly reduced the rate of exacerbations requiring hospitalization (relative rate, 0.49; 95% CI, 0.30-0.80; P = .004) and hospitalization/emergency room visit (relative rate, 0.49; 95% CI, 0.33-0.73; P < .001) versus placebo. Significant reductions of 45% and 38% were also observed for the proportion of patients experiencing 1 or more hospitalization and hospitalization and/or emergency room visit, respectively. Conclusions: Mepolizumab approximately halved exacerbations requiring hospitalization and/or emergency room visits compared with placebo in patients with severe eosinophilic asthma. This treatment addresses a key outcome in a patient population with a high unmet need (GSK Study 204664).	[Yancey, Steven W.; Ortega, Hector G.] GSK, Resp Therapeut Area, Res Triangle Pk, NC USA; [Keene, Oliver N.; Mayer, Bhabita; Gunsoy, Necdet B.] GSK, Clin Stat, Stockley Pk, Uxbridge, Middx, England; [Brightling, Christopher E.; Haldar, Pranabashis] Univ Leicester, Inst Lung Hlth, Leicester, Leics, England; [Bleecker, Eugene R.] Wake Forest Sch Med, Ctr Genom & Personalized Med, Winston Salem, NC USA; [Pavord, Ian D.] Univ Oxford, Nuffield Dept Med, Resp Med Unit, Oxford OX1 2JD, England	GlaxoSmithKline; GlaxoSmithKline; University of Leicester; Wake Forest University; University of Oxford	Yancey, SW (corresponding author), 5 Moore Dr,POB 13398, Res Triangle Pk, NC 27709 USA.	steve.w.yancey@gsk.com		Keene, Oliver/0000-0003-0016-9773; Ortega, Hector/0000-0002-2632-6370; brightling, chris/0000-0002-9345-4903; Haldar, Pranabashis/0000-0002-1572-5421; Pavord, Ian/0000-0002-4288-5973	GSK [204664, MEA112997, NCT01000506, MEA115588, NCT01691521, MEA115575, NCT01691508, CRT110184, ISRCTN75169762, 204644]	GSK(GlaxoSmithKline)	The meta-analysis (study ID 204664) and studies in this meta-analysis (MEA112997 [NCT01000506], MEA115588 [NCT01691521], MEA115575 [NCT01691508], and CRT110184 [ISRCTN75169762]) were funded by GSK (study no. 204644). Medical writing support by Fishawack Indicia Ltd was also funded by GSK.	Alvarez G G, 2005, Can Respir J, V12, P265; Antoniu SA, 2009, EXPERT OPIN INV DRUG, V18, P869, DOI [10.1517/13543780902922678 , 10.1517/13543780902922678]; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Chuang-Stein C, 2011, PHARM STAT, V10, P3, DOI 10.1002/pst.397; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Custovic A, 2013, ALLERGY, V68, P1520, DOI 10.1111/all.12275; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; GSK, 2014, MULT OP LAB DOS RANG; GSK, 2016, MEA115661 MULT OP LA; GSK, 2015, PGX7530 GEN MEP SB24; GSK, 2015, MET SPONS STUD MEA11; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2014, J ALLERGY CLIN IMMUN, V133, P921, DOI 10.1016/j.jaci.2013.11.026; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hessel PA, 1999, ANN ALLERG ASTHMA IM, V83, P362, DOI 10.1016/S1081-1206(10)62832-3; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Liu Yang, 2013, Biomed Res Int, V2013, P839683, DOI 10.1155/2013/839683; McDonough AK, 2008, CURR OPIN RHEUMATOL, V20, P131, DOI 10.1097/BOR.0b013e3282f51031; Menzella F, 2015, MULTIDISCIP RESP MED, V10, DOI 10.1186/2049-6958-10-1; Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382; Metcalfe C, 2006, STAT MED, V25, P165, DOI 10.1002/sim.2310; Moher David, 2009, Ann Intern Med, V151, P264, DOI [10.1136/bmj.b2535, 10.1016/j.ijsu.2010.02.007]; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Ortega HG, 2016, LANCET RESP MED, V4, P549, DOI 10.1016/S2213-2600(16)30031-5; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Powell C, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010834.pub2; Prazma CM, 2014, THORAX, V69, P1141, DOI 10.1136/thoraxjnl-2014-205581; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Roufosse FE, 2013, J ALLERGY CLIN IMMUN, V131, P461, DOI 10.1016/j.jaci.2012.07.055; Sarnes E, 2011, CLIN THER, V33, P1413, DOI 10.1016/j.clinthera.2011.09.009; Schleich F, 2014, RESP MED, V108, P1723, DOI 10.1016/j.rmed.2014.10.007; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Zeiger RS, 2016, J ALLER CL IMM-PRACT, V4, P120, DOI 10.1016/j.jaip.2015.08.003	39	62	65	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2017	139	4					1167	+		10.1016/j.jaci.2016.08.008	http://dx.doi.org/10.1016/j.jaci.2016.08.008			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ER4LR	27726946	Green Published, hybrid			2022-12-18	WOS:000398771800012
J	Srivastava, KD; Siefert, A; Fahmy, TM; Caplan, MJ; Li, XM; Sampson, HA				Srivastava, Kamal D.; Siefert, Alyssa; Fahmy, Tarek M.; Caplan, Michael J.; Li, Xiu-Min; Sampson, Hugh A.			Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; anaphylaxis; mice; IgE; immunotherapy; nanoparticle	BIODEGRADABLE NANOPARTICLES; CPG OLIGODEOXYNUCLEOTIDES; INDUCTION; TOLERANCE; RESPONSES; MODULATION; EFFICACY; REGIMEN; HUMANS; FAHF-2	Background: Treatments to reverse peanut allergy remain elusive. Current clinical approaches using peanut oral/sublingual immunotherapy are promising, but concerns about safety and long-term benefit remain a barrier to wide use. Improved methods of delivering peanut-specific immunotherapy are needed. Objective: We sought to investigate the efficacy and safety of peanut oral immunotherapy using CpG-coated poly(lactic-coglycolic acid) nanoparticles containing peanut extract (CpG/PN-NPs) in a murine model of peanut allergy. Methods: C3H/HeJ mice were rendered peanut allergic by means of oral sensitization with peanut and cholera toxin. Mice were then subjected to 4 weekly gavages with CpG/PN-NPs, vehicle (PBS), nanoparticles alone, peanut alone, CpG nanoparticles, or peanut nanoparticles. Untreated mice served as naive controls. After completing therapy, mice underwent 5 monthly oral peanut challenges. Anaphylaxis was evaluated by means of visual assessment of symptom scores and measurement of body temperature and plasma histamine levels. Peanut-specific serum IgE, IgG(1), and IgG(2a) levels were measured by using ELISA, as were cytokine recall responses in splenocyte cultures. Results: Mice with peanut allergy treated with CpG/PN-NPs but not vehicle or other treatment components were significantly protected from anaphylaxis to all 5 oral peanut challenges, as indicated by lower symptom scores, less change in body temperature, and a lower increase of plasma histamine levels. Importantly, CpG/PN-NP treatment did not cause anaphylactic reactions. Treatment was associated with a sustained and significant decrease in peanut-specific IgE/IgG(1) levels and an increase in peanut-specific IgG(2a) levels. Compared with vehicle control animals, peanut recall responses in splenocyte cultures from nanoparticle-treated mice showed significantly decreased levels of TH2 cytokines (IL-4, IL-5, and IL-13) but increased IFN-gamma levels in cell supernatants. Conclusions: Preclinical findings indicate that peanut oral immunotherapy with CpG/PN-NPs might be a valuable strategy for peanut-specific immunotherapy in human subjects.	[Srivastava, Kamal D.; Li, Xiu-Min; Sampson, Hugh A.] Icahn Sch Med Mt Sinai, Pediat Allergy & Immunol, New York, NY USA; [Srivastava, Kamal D.; Li, Xiu-Min; Sampson, Hugh A.] Jaffe Food Allergy Inst, New York, NY USA; [Siefert, Alyssa; Fahmy, Tarek M.] Yale Univ, Dept Biomed Engn, New Haven, CT USA; [Fahmy, Tarek M.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA; [Caplan, Michael J.] Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT USA	Icahn School of Medicine at Mount Sinai; Yale University; Yale University; Yale University	Sampson, HA (corresponding author), Icahn Sch Med Mt Sinai, Jaffe Food Allergy Inst, Dept Pediat, Box 1198, New York, NY 10029 USA.	hugh.sampson@mssm.edu	li, xiu/GXV-1745-2022	Caplan, Michael/0000-0001-5768-4405	Allertein Therapeutics; KL2 Faculty Scholar Award from Mount Sinai CTSA [KL2TR000069]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000069] Funding Source: NIH RePORTER	Allertein Therapeutics; KL2 Faculty Scholar Award from Mount Sinai CTSA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	Supported by a grant from Allertein Therapeutics (to X.-M.L.). K.D.S. was partially supported by a KL2 Faculty Scholar Award KL2TR000069 from Mount Sinai CTSA.	Anagnostou K, 2011, CLIN EXP ALLERGY, V41, P1273, DOI 10.1111/j.1365-2222.2011.03699.x; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bayne K, 1998, ANN NY ACAD SCI, V862, P105, DOI 10.1111/j.1749-6632.1998.tb09122.x; Blumchen K, 2010, J ALLERGY CLIN IMMUN, V126, P83, DOI 10.1016/j.jaci.2010.04.030; Burton OT, 2014, J ALLERGY CLIN IMMUN, V134, P1310, DOI 10.1016/j.jaci.2014.05.042; Campbell JD, 2014, THORAX, V69, P565, DOI 10.1136/thoraxjnl-2013-204605; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; De Castro C, 2010, METHOD ENZYMOL, V480, P89, DOI 10.1016/S0076-6879(10)80005-9; Demento SL, 2010, J IMMUNOL, V185, P2989, DOI 10.4049/jimmunol.1000768; Diwan Manish, 2004, Current Drug Delivery, V1, P405, DOI 10.2174/1567201043334597; Fahmy TM, 2005, BIOMATERIALS, V26, P5727, DOI 10.1016/j.biomaterials.2005.02.025; Finkelman FD, 2010, CURR OPIN IMMUNOL, V22, P783, DOI 10.1016/j.coi.2010.10.005; Greenhawt MJ, 2013, ALLERGY ASTHMA PROC, V34, P197, DOI 10.2500/aap.2013.34.3661; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Horner AA, 2002, J ALLERGY CLIN IMMUN, V110, P413, DOI 10.1067/mai.2002.126660; Horner AA, 2000, J ALLERGY CLIN IMMUN, V106, P349, DOI 10.1067/mai.2000.107933; Hunter Z, 2014, ACS NANO, V8, P2148, DOI 10.1021/nn405033r; Jimenez-Saiz R, 2011, J AGR FOOD CHEM, V59, P13195, DOI 10.1021/jf202963r; Kawakita A, 2012, ALLERGY, V67, P371, DOI 10.1111/j.1398-9995.2011.02777.x; Kim EH, 2013, J ALLERGY CLIN IMMUN, V132, P476, DOI 10.1016/j.jaci.2013.02.017; Kulis M, 2013, MOL NUTR FOOD RES, V57, P906, DOI 10.1002/mnfr.201200410; Kumar G, 2012, CRIT REV THER DRUG, V29, P149, DOI 10.1615/CritRevTherDrugCarrierSyst.v29.i2.20; Le TM, 2008, ALLERGY, V63, P910, DOI 10.1111/j.1398-9995.2008.01688.x; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V129, P1579, DOI 10.1016/j.jaci.2012.04.009; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Lutsiak MEC, 2006, J PHARM PHARMACOL, V58, P739, DOI 10.1211/jpp.58.6.0004; Mondoulet L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031967; Nurmatov U, 2012, COCHRANE DB SYST REV, V9; Pali-Scholl I, 2013, EUR J PHARM BIOPHARM, V85, P656, DOI 10.1016/j.ejpb.2013.03.003; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; Reisacher WR, 2011, INT FORUM ALLERGY RH, V1, P390, DOI 10.1002/alr.20074; Sah H, 2013, INT J NANOMED, V8, P747, DOI 10.2147/IJN.S40579; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Senti G, 2009, CLIN EXP ALLERGY, V39, P562, DOI 10.1111/j.1365-2222.2008.03191.x; Sheikh A, 2012, PRIM CARE RESP J, V21, P41, DOI 10.4104/pcrj.2011.00071; Silva AL, 2015, VACCINE, V33, P847, DOI 10.1016/j.vaccine.2014.12.059; Silva JM, 2013, J CONTROL RELEASE, V168, P179, DOI 10.1016/j.jconrel.2013.03.010; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Skripak JM, 2008, PEDIAT ALLERG IMM-UK, V19, P368, DOI 10.1111/j.1399-3038.2008.00723.x; Smit JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028917; Srivastava KD, 2012, ANN ALLERG ASTHMA IM, V108, P351, DOI 10.1016/j.anai.2012.03.008; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; TALBOT RW, 1984, DIGEST DIS SCI, V29, P1015, DOI 10.1007/BF01311253; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Varshney P, 2011, J ALLERGY CLIN IMMUN, V127, P654, DOI 10.1016/j.jaci.2010.12.1111; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042	47	62	65	1	31	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					536	+		10.1016/j.jaci.2016.01.047	http://dx.doi.org/10.1016/j.jaci.2016.01.047			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27130858	Bronze			2022-12-18	WOS:000380835800025
J	Desai, A; Jung, MY; Olivera, A; Gilfillan, AM; Prussin, C; Kirshenbaum, AS; Beaven, MA; Metcalfe, DD				Desai, Avanti; Jung, Mi-Yeon; Olivera, Ana; Gilfillan, Alasdair M.; Prussin, Calman; Kirshenbaum, Arnold S.; Beaven, Michael A.; Metcalfe, Dean D.			IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cells; signal transducer and activator of transcription 3; suppressor of cytokine signaling 3; stem cell factor; IL-6; mastocytosis	FC-EPSILON-RI; SOLUBLE INTERLEUKIN-6 RECEPTOR; PERIPHERAL-BLOOD; COLORECTAL-CANCER; EXPRESSION; GROWTH; SOCS3; DISEASE; GENE; HYPERMETHYLATION	Background: IL-6, levels of which are reported to be increased in association with mastocytosis, asthma, and urticaria, is used in conjunction with stem cell factor to generate CD34(+) cell-derived primary human mast cell (HuMC) cultures. Despite these associations, the effects on and mechanisms by which prolonged exposure to IL-6 alters HuMC numbers and function are not well understood. Objectives: We sought to study the effect of IL-6 on HuMC function, the mechanisms by which IL-6 exerts its effects, and the relationship of these findings to mastocytosis. Methods: HuMCs were cultured in stem cell factor with or without IL-6. Responses to FceRI aggregation and expression of proteases and receptors, including the soluble IL-6 receptor (sIL-6R), were then quantitated. Epigenetic changes in suppressor of cytokine signaling 3 (SOCS3) were determined by using methylation-specific PCR. Serum samples from healthy control subjects and patients with mastocytosis were assayed for IL-6, tryptase, and sIL-6R. Results: IL-6 enhanced mast cell (MC) proliferation, maturation, and reactivity after FceRI aggregation. IL-6 reduced expression of SOCS3, which correlated with methylation of the SOCS3 promoter and increased expression and activation of signal transducer and activator of transcription 3. IL-6 also suppressed constitutive production of sIL-6R, and serum levels of sIL-6R were similarly reduced in patients with mastocytosis. Conclusion: IL-6 increases MC proliferation and formation of a more reactive phenotype enabled by suppressing proteolytic cleavage of sIL-6R from IL-6R and downregulation of the SOCS3 autoinhibitory pathway. We suggest IL-6 blockade might ameliorate MC-related symptoms and pathology in patients with MC-related diseases associated with increased IL-6 levels, including mastocytosis.	[Desai, Avanti; Jung, Mi-Yeon; Olivera, Ana; Gilfillan, Alasdair M.; Prussin, Calman; Kirshenbaum, Arnold S.; Metcalfe, Dean D.] NIAID, Lab Allerg Dis, NIH, Rm 11C208,Bldg 10, Bethesda, MD 20892 USA; [Beaven, Michael A.] NHLBI, Lab Mol Immunol, NIH, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Desai, A (corresponding author), NIAID, Lab Allerg Dis, NIH, Rm 11C208,Bldg 10, Bethesda, MD 20892 USA.	avanti.desai@nih.gov			Division of Intramural Research Programs of the National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute, National Institutes of Health; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000249, ZIAAI001206, ZIAAI000965] Funding Source: NIH RePORTER	Division of Intramural Research Programs of the National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Division of Intramural Research Programs of the National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute, National Institutes of Health.	Babon JJ, 2014, SEMIN IMMUNOL, V26, P13, DOI 10.1016/j.smim.2013.12.004; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Brockow K, 2005, CLIN IMMUNOL, V115, P216, DOI 10.1016/j.clim.2005.01.011; Brockow K, 2010, CHEM IMMUNOL ALLERGY, V95, P110, DOI 10.1159/000315946; Caughey GH, 2011, ADV EXP MED BIOL, V716, P212, DOI 10.1007/978-1-4419-9533-9_12; Cruse G, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-2; Edwards ST, 2005, J PATHOL, V206, P279, DOI 10.1002/path.1780; Egler RA, 2008, CLIN CANCER RES, V14, P7028, DOI 10.1158/1078-0432.CCR-07-5017; Esparza-Gordillo J, 2013, J ALLERGY CLIN IMMUN, V132, P371, DOI 10.1016/j.jaci.2013.01.057; Fourouclas N, 2008, HAEMATOL-HEMATOL J, V93, P1635, DOI 10.3324/haematol.13043; Fujii K, 2001, J DERMATOL, V28, P248, DOI 10.1111/j.1346-8138.2001.tb00126.x; Galicia JC, 2004, GENES IMMUN, V5, P513, DOI 10.1038/sj.gene.6364120; Garbers C, 2014, BBA-MOL BASIS DIS, V1842, P1485, DOI 10.1016/j.bbadis.2014.05.018; Garbers C, 2011, J BIOL CHEM, V286, P14804, DOI 10.1074/jbc.M111.229393; Gilfillan AM, 2011, CRIT REV IMMUNOL, V31, P475, DOI 10.1615/CritRevImmunol.v31.i6.30; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Hirano T, 1998, Int Rev Immunol, V16, P249; Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Hundley TR, 2004, BLOOD, V104, P2410, DOI 10.1182/blood-2004-02-0631; Isomoto H, 2007, GASTROENTEROLOGY, V132, P384, DOI 10.1053/j.gastro.2006.10.037; Isomoto H, 2009, DIGESTION, V79, P2, DOI 10.1159/000167859; Jones SA, 2005, J INTERF CYTOK RES, V25, P241, DOI 10.1089/jir.2005.25.241; Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158; Kasperska-Zajac A, 2011, CLIN EXP ALLERGY, V41, P1386, DOI 10.1111/j.1365-2222.2011.03789.x; Kikuchi T, 2002, CYTOKINE, V20, P200, DOI 10.1006/cyto.2002.2010; Kinoshita T, 1999, BLOOD, V94, P496, DOI 10.1182/blood.V94.2.496.414k19_496_508; Kirshenbaum Arnold S, 2006, Methods Mol Biol, V315, P105; Kirshenbaum AS, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-45; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; Kuehn Hye Sun, 2010, Curr Protoc Immunol, VChapter 7, DOI 10.1002/0471142735.im0738s91; Lappalainen J, 2007, CLIN EXP ALLERGY, V37, P1404, DOI 10.1111/j.1365-2222.2007.02778.x; Li Y, 2012, CARCINOGENESIS, V33, P1889, DOI 10.1093/carcin/bgs214; Lindemann C, 2011, ACTA NEUROPATHOL, V122, P241, DOI 10.1007/s00401-011-0832-0; Ludwig A, 2005, COMB CHEM HIGH T SCR, V8, P161, DOI 10.2174/1386207053258488; Ma HT, 2009, CRIT REV IMMUNOL, V29, P155, DOI 10.1615/CritRevImmunol.v29.i2.40; Mayado A, 2015, LEUKEMIA; Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340; Misiak-Tloczek A, 2009, APMIS, V117, P558, DOI 10.1111/j.1600-0463.2009.02518.x; Morales JK, 2010, GENES IMMUN, V11, P599, DOI 10.1038/gene.2010.35; Morjaria JB, 2011, THORAX, V66, P537, DOI 10.1136/thx.2010.136523; NAKAHATA T, 1995, BIOLOGICAL AND MOLECULAR ASPECTS OF MAST CELL AND BASOPHIL DIFFERENTIATION AND FUNCTION, P13; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Okugawa Y, 2010, BRIT J CANCER, V103, P787, DOI 10.1038/sj.bjc.6605827; Peake NJ, 2006, RHEUMATOLOGY, V45, P1485, DOI 10.1093/rheumatology/kel154; Pierconti F, 2011, PROSTATE, V71, P318, DOI 10.1002/pros.21245; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Saito H, 1996, J IMMUNOL, V157, P343; Scheller J, 2014, SEMIN IMMUNOL, V26, P2, DOI 10.1016/j.smim.2013.11.002; Schoeler D, 2003, J INVEST DERMATOL, V120, P795, DOI 10.1046/j.1523-1747.2003.12126.x; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Smrz D, 2013, EUR J IMMUNOL, V43, P1873, DOI 10.1002/eji.201243214; Starr R, 1998, INT J BIOCHEM CELL B, V30, P1081, DOI 10.1016/S1357-2725(98)00067-3; Stevens RL, 2007, IMMUNOL REV, V217, P155, DOI 10.1111/j.1600-065X.2007.00525.x; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Tkaczyk C, 2002, J IMMUNOL METHODS, V268, P239, DOI 10.1016/S0022-1759(02)00210-7; Tokita T, 2007, INT J ONCOL, V30, P689; Traum D, 2012, J LEUKOCYTE BIOL, V91, P427, DOI 10.1189/jlb.0411209; Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Yoshimura A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00020	64	62	63	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1863	+		10.1016/j.jaci.2015.09.059	http://dx.doi.org/10.1016/j.jaci.2015.09.059			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26774658	Bronze, Green Accepted			2022-12-18	WOS:000377527200028
J	Picard, M; Pur, L; Caiado, J; Giavina-Bianchi, P; Galvao, VR; Berlin, ST; Campos, SM; Matulonis, UA; Castells, MC				Picard, Matthieu; Pur, Leyla; Caiado, Joana; Giavina-Bianchi, Pedro; Galvao, Violeta Regnier; Berlin, Suzanne T.; Campos, Susana M.; Matulonis, Ursula A.; Castells, Mariana C.			Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Taxane; paclitaxel; docetaxel; hypersensitivity; skin test; allergy; risk stratification; desensitization; challenge	RAPID DESENSITIZATION; CONTRAST-MEDIA; PACLITAXEL; ANAPHYLAXIS; DOCETAXEL; CANCER; CHEMOTHERAPY; PROTOCOL; SAFETY; CARBOPLATIN	Background: The optimal approach to patients with hypersensitivity reactions (HSRs) to taxanes has not been established. Objective: We sought to assess the safety and efficacy of risk stratification based on the severity of the initial HSR and skin testing for guiding taxane reintroduction in patients with an HSR to these agents. Methods: Data on 164 patients treated for a taxane-related HSR from April 2011 to August 2014 at the Dana-Farber Cancer Institute and Brigham and Women's Hospital were collected retrospectively. Patients were re-exposed to taxanes either through desensitization, challenge, or regular infusion based on the severity of the initial HSR and skin test response. Depending on the initial risk stratification and tolerance to re-exposure, patients were then treated with shorter desensitization protocols, challenge, or both with the aim of resuming regular infusions, except in patients with a severe immediate initial HSR. Results: Of 138 patients desensitized, 29 (21%) had an immediate and 20 (14%) had a delayed HSR with the procedure. Of 49 patients challenged, 2 (4%) had a mild immediate and 1 (2%) had a delayed HSR with the procedure. No patients had a severe immediate HSR with desensitization or challenge. Thirty-six (22%) patients eventually resumed regular infusions. These patients were more likely to have negative skin test responses and to have experienced a delayed or mild immediate initial HSR. Conclusions: Risk stratification based on the severity of the initial HSR and skin testing to guide taxane reintroduction is safe and allows a significant number of patients to resume regular infusions.	[Picard, Matthieu; Pur, Leyla; Caiado, Joana; Giavina-Bianchi, Pedro; Galvao, Violeta Regnier; Castells, Mariana C.] Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, 1 Jimmy Fund Way,Smith Bldg, Boston, MA 02115 USA; [Berlin, Suzanne T.; Campos, Susana M.; Matulonis, Ursula A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute	Castells, MC (corresponding author), Brigham & Womens Hosp, 1 Jimmy Fund Way,Smith Bldg, Boston, MA 02115 USA.	mcastells@partners.org	Ozyigit, Leyla Pur/O-9045-2015	Ozyigit, Leyla Pur/0000-0002-7113-9988	Ovations for the Cure of Ovarian Cancer	Ovations for the Cure of Ovarian Cancer	Supported by Ovations for the Cure of Ovarian Cancer.	Alvarez-Cuesta E, 2015, ALLERGY, V70, P784, DOI 10.1111/all.12620; [Anonymous], 2011, ALLERGY ASTHMA PROC, V32, P79, DOI 10.2500/aap.2011.32.3409; Banerji A, 2014, J ALLER CL IMM-PRACT, V2, P428, DOI 10.1016/j.jaip.2014.04.010; Bookman MA, 1997, ANN ONCOL, V8, P611, DOI 10.1023/A:1008207025430; Brennan PJ, 2009, J ALLERGY CLIN IMMUN, V124, P1259, DOI 10.1016/j.jaci.2009.09.009; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brown SGA, 2013, J ALLERGY CLIN IMMUN, V132, P1141, DOI 10.1016/j.jaci.2013.06.015; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; ENRIGHT T, 1989, ANN ALLERGY, V62, P302; Fader AN, 2009, INT J GYNECOL CANCER, V19, P1281, DOI 10.1111/IGC.0b013e3181a38e2f; Feldweg AM, 2005, GYNECOL ONCOL, V96, P824, DOI 10.1016/j.ygyno.2004.11.043; Gastaminza G, 2011, J INVEST ALLERG CLIN, V21, P108; Jerschow E, 2014, J ALLERGY CLIN IMMUN, V134, P1318, DOI 10.1016/j.jaci.2014.08.018; KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107; Kwon JS, 2002, GYNECOL ONCOL, V84, P420, DOI 10.1006/gyno.2001.6546; Madrigal-Burgaleta R, 2013, ALLERGY, V68, P853, DOI 10.1111/all.12105; Markman M, 2000, J CLIN ONCOL, V18, P102, DOI 10.1200/JCO.2000.18.1.102; Morgan RJ, 2013, J NATL COMPR CANC NE, V11, P1199, DOI 10.6004/jnccn.2013.0142; O'Cathail SM, 2013, INT J GYNECOL CANCER, V23, P1318, DOI 10.1097/IGC.0b013e31829f1799; Picard M, 2015, CLIN REV ALLERG IMMU, V49, P177, DOI 10.1007/s12016-014-8416-0; Picard M, 2014, J ALLERGY CLIN IMMUN, V133, pAB152, DOI 10.1016/j.jaci.2013.12.557; Garcia AP, 2010, J INVEST ALLERG CLIN, V20, P170; Raisch DW, 2011, EXPERT OPIN DRUG SAF, V10, P521, DOI 10.1517/14740338.2011.582865; SCHRIJVERS D, 1993, ANN ONCOL, V4, P610, DOI 10.1093/oxfordjournals.annonc.a058599; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Timoney JP, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.2566; Valent P, 2013, ALLERGY, V68, P417, DOI 10.1111/all.12126; Vanhaelen M, 2002, PLANTA MED, V68, P36, DOI 10.1055/s-2002-19865; Vasey PA, 2004, JNCI-J NATL CANCER I, V96, P1682, DOI 10.1093/jnci/djh323; WEISS RB, 1990, J CLIN ONCOL, V8, P1263, DOI 10.1200/JCO.1990.8.7.1263; Weiszhar Z, 2012, EUR J PHARM SCI, V45, P492, DOI 10.1016/j.ejps.2011.09.016; Wheatley LM, 2015, J ALLERGY CLIN IMMUN, V136, P262, DOI 10.1016/j.jaci.2015.05.027; Yamamoto Y, 2011, ONCOTARGETS THER, V4, P123, DOI 10.2147/OTT.S13836	35	62	64	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1154	+		10.1016/j.jaci.2015.10.039	http://dx.doi.org/10.1016/j.jaci.2015.10.039			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26725998	Bronze			2022-12-18	WOS:000373351200023
J	Sears, MR				Sears, Malcolm R.			Predicting asthma outcomes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; birth cohorts; longitudinal phenotypes; lung function; persistence; prediction; remission; wheezing	CHILDHOOD ASTHMA; LUNG-FUNCTION; HIGH-RISK; BRONCHIAL HYPERRESPONSIVENESS; INHALED CORTICOSTEROIDS; AIRWAY RESPONSIVENESS; WHEEZING PHENOTYPES; PRESCHOOL-CHILDREN; NATURAL-HISTORY; EARLY-ONSET	This review addresses predictors of remission or persistence of wheezing and asthma from early childhood through adulthood. Early childhood wheezing is common, but predicting who will remit or have persistent childhood asthma remains difficult. By adding parental history of asthma and selected infant biomarkers to the history of recurrent wheezing, the Asthma Predictive Index and its subsequent modifications provide better predictions of persistence than simply the observation of recurrent wheeze. Sensitization, especially to multiple allergens, increases the likelihood of development of classic childhood asthma. Remission is more likely in male subjects and those with milder disease (less frequent and less severe symptoms), less atopic sensitization, a lesser degree of airway hyperresponsiveness, and no concomitant allergic disease. Conversely, persistence is linked strongly to allergic sensitization, greater frequency and severity of symptoms, abnormal lung function, and a greater degree of airway hyperresponsiveness. A genetic risk score might predict persistence more accurately than family history. Remission of established adult asthma is substantially less common than remission during childhood and adolescence. Loss of lung function can begin early in life and tracks through childhood and adolescence. Despite therapy which controls symptoms and exacerbations, the outcomes of asthma appear largely resistant to pharmacologic therapy.	[Sears, Malcolm R.] McMaster Univ, Fac Hlth Sci, Dept Med, de Groote Sch Med, Hamilton, ON L8N 3Z5, Canada	McMaster University	Sears, MR (corresponding author), St Josephs Healthcare Hamilton, Firestone Inst Resp Hlth, T3219,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	searsm@mcmaster.ca						Amin P, 2014, J ALLER CL IMM-PRACT, V2, P709, DOI 10.1016/j.jaip.2014.08.009; Andersson M, 2013, PEDIATRICS, V132, pE435, DOI 10.1542/peds.2013-0741; Belgrave DCM, 2014, AM J RESP CRIT CARE, V189, P1101, DOI 10.1164/rccm.201309-1700OC; Belgrave DCM, 2013, J ALLERGY CLIN IMMUN, V132, P575, DOI 10.1016/j.jaci.2013.05.041; Belsky DW, 2013, LANCET RESP MED, V1, P453, DOI 10.1016/S2213-2600(13)70101-2; Bender B., 2009, J PEDIAT, V154, P682; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brand PLP, 2011, J ALLERGY CLIN IMMUN, V127, P293, DOI 10.1016/j.jaci.2010.10.012; Castro-Rodriguez JA, 2011, CURR OPIN ALLERGY CL, V11, P157, DOI 10.1097/ACI.0b013e3283464c4a; Caudri D, 2013, CLIN EXP ALLERGY, V43, P1395, DOI 10.1111/cea.12173; Caudri D, 2009, J ALLERGY CLIN IMMUN, V124, P903, DOI 10.1016/j.jaci.2009.06.045; Chang TS, 2013, J ALLER CL IMM-PRACT, V1, P152, DOI 10.1016/j.jaip.2012.10.008; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Gershon A, 2012, J ALLERGY CLIN IMMUN, V129, P679, DOI 10.1016/j.jaci.2011.11.014; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Grad R, 2012, J ALLERGY CLIN IMMUN, V130, P299, DOI 10.1016/j.jaci.2012.05.022; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Holloway JW, 2010, J ALLERGY CLIN IMMUN, V126, P200, DOI 10.1016/j.jaci.2010.06.006; Holm M, 2007, EUR RESPIR J, V30, P62, DOI 10.1183/09031936.00121705; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; Kerkhof M, 2014, J ALLERGY CLIN IMMUN, V133, P68, DOI 10.1016/j.jaci.2013.06.004; Leonardi NA, 2011, J ALLERGY CLIN IMMUN, V127, P1466, DOI 10.1016/j.jaci.2011.03.001; Martin PE, 2011, J ALLERGY CLIN IMMUN, V127, P1473, DOI 10.1016/j.jaci.2011.02.041; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; Neuman A, 2014, PEDIAT ALLERG IMM-UK, V25, P380, DOI 10.1111/pai.12223; OSWALD H, 1994, BRIT MED J, V309, P95, DOI 10.1136/bmj.309.6947.95; Panettieri RA, 2008, J ALLERGY CLIN IMMUN, V121, P607, DOI 10.1016/j.jaci.2008.01.006; Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018; Riiser A, 2012, AM J RESP CRIT CARE, V186, P493, DOI 10.1164/rccm.201112-2235OC; Roel E, 2009, INT J MED SCI, V6, P348; Ronmark E, 1999, THORAX, V54, P611, DOI 10.1136/thx.54.7.611; Savenije OEM, 2012, J ALLERGY CLIN IMMUN, V130, P325, DOI 10.1016/j.jaci.2012.05.007; Sears MR, 2012, AM J RESP CRIT CARE, V186, P469, DOI 10.1164/rccm.201207-1258ED; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SEARS MR, 1994, BRIT MED J, V309, P72, DOI 10.1136/bmj.309.6947.72; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Subbarao P, 2009, CAN MED ASSOC J, V181, pE181, DOI 10.1503/cmaj.080612; Szefler S, 2000, NEW ENGL J MED, V343, P1054; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811, DOI 10.1164/ajrccm/147.4.811; Tai A, 2014, J ALLERGY CLIN IMMUN, V133, P1572, DOI 10.1016/j.jaci.2013.12.1033; Tantisira KG, 2008, AM J RESP CRIT CARE, V178, P325, DOI 10.1164/rccm.200708-1174OC; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; To T, 2007, ARCH PEDIAT ADOL MED, V161, P1197, DOI 10.1001/archpedi.161.12.1197; Vink NM, 2010, J ALLERGY CLIN IMMUN, V126, P498, DOI 10.1016/j.jaci.2010.06.018; Vonk JM, 2004, THORAX, V59, P925, DOI 10.1136/thx.2003.016246	52	62	68	0	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					829	836		10.1016/j.jaci.2015.04.048	http://dx.doi.org/10.1016/j.jaci.2015.04.048			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	26449797				2022-12-18	WOS:000362976300001
J	Smith, SG; Gugilla, A; Mukherjee, M; Merim, K; Irshad, A; Tang, W; Kinoshita, T; Watson, B; Oliveria, JP; Comeau, M; O'Byrne, PM; Gauvreau, GM; Sehmi, R				Smith, Steven G.; Gugilla, Akash; Mukherjee, Manali; Merim, Kayla; Irshad, Anam; Tang, Wei; Kinoshita, Takashi; Watson, Brittany; Oliveria, John-Paul; Comeau, Mike; O'Byrne, Paul M.; Gauvreau, Gail M.; Sehmi, Roma			Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hematopoietic progenitor cells; thymic stromal lymphopoietin; asthma	BONE-MARROW; EOSINOPHIL PROGENITORS; AIRWAY INFLAMMATION; SPUTUM EOSINOPHILIA; RESPONSES; DISEASE; CORTICOSTEROIDS; FACTOR-1-ALPHA; INTERLEUKIN-13; EXACERBATIONS	Background: Thymic stromal lymphopoietin (TSLP) and IL-33 are considered important initiators of type 2 immunity. In asthmatic patients allergic inflammatory responses are associated with increased lung homing of bone marrow-derived CD34(+) hematopoietic progenitor cells (HPCs), which include eosinophil lineage-committed progenitor cells. In this study we investigated the role of TSLP and IL-33 in the recruitment of progenitor cells to the airways in asthmatic subjects. Objectives: We sought (i) to examine the effect of allergen inhalation challenge on expression levels of receptors for TSLP (thymic stromal lymphopoietin receptor [TSLPR] and CD127) and IL-33 (ST2) and (ii) investigate the functional effects of these cytokines on HPCs. Methods: Consenting patients with mild atopic asthma (n = 19) with an FEV1 of 70% or greater and methacholine PC20 of 16 mg/mL or less were recruited. Blood-and sputum-extracted progenitors were phenotyped by flow cytometry before and 24 hours after allergen challenge. Functional responses, including cytokine production and migration to TSLP and IL-33, were assessed in vitro. Results: Significant increases in mature eosinophil, HPC, and eosinophil lineage-committed progenitor cell counts in sputum were observed 24 hours after allergen and were associated with a significant allergen-induced increase in HPCs expressing TSLPR, CD127, and ST2. Pre-exposure to TSLP and IL-33 primed the migration of HPCs to a potent progenitor cell chemoattractant, stromal cell-derived factor 1 alpha (CXCL12). Incubation with TSLP and IL-33 stimulated significant production of IL-5 and IL-13, but not IL-4, by HPCs. This priming effect was inhibited by blocking antibodies to TSLPR and ST2, respectively, and IL-13 receptor alpha 1 in both scenarios. Conclusions: In allergic asthmatic responses increased lung homing of HPCs may be orchestrated by TSLP and IL-33 through an IL-13-dependent axis.	[Smith, Steven G.; Gugilla, Akash; Mukherjee, Manali; Merim, Kayla; Irshad, Anam; Sehmi, Roma] St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada; [Tang, Wei; Kinoshita, Takashi; Watson, Brittany; Oliveria, John-Paul; O'Byrne, Paul M.; Gauvreau, Gail M.] McMaster Univ, Dept Med, Asthma Res Grp, Hamilton, ON, Canada; [Comeau, Mike] Amgen Inc, Inflammat Res, Seattle, WA USA	McMaster University; McMaster University; Amgen	Sehmi, R (corresponding author), St Josephs Hosp, Firestone Inst Resp Hlth, Luke Wing,Rm L314-6,50 Charlton Ave East, Hamilton, ON L8N 4A6, Canada.	sehmir@mcmaster.ca	Oliveria, John-Paul/AAH-8080-2020; Mukherjee, Manali/AAE-2778-2020	Oliveria, John-Paul/0000-0002-7192-7634; Mukherjee, Manali/0000-0002-7924-7211; O'Byrne, Paul/0000-0003-0979-281X; Smith, Steven/0000-0001-9928-117X	Father Sean O'Sullivan Postdoctoral Research Fellowship Award; Canadian Lung Association	Father Sean O'Sullivan Postdoctoral Research Fellowship Award; Canadian Lung Association	S.G.S. is a recipient of the Father Sean O'Sullivan Postdoctoral Research Fellowship Award. R.S. is supported by a research grant from the Canadian Lung Association.	Allakhyerdi Z, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00461; Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; BOUSQUET J, 1995, INT ARCH ALLERGY IMM, V107, P211, DOI 10.1159/000236980; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Cameron L, 2000, J IMMUNOL, V164, P1538, DOI 10.4049/jimmunol.164.3.1538; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Dorman SC, 2005, J ALLERGY CLIN IMMUN, V115, P501, DOI 10.1016/j.jaci.2004.11.017; Dorman SC, 2004, AM J RESP CRIT CARE, V169, P573, DOI 10.1164/rccm.200307-1004OC; Doyle TM, 2011, EUR RESPIR J, V38, P679, DOI 10.1183/09031936.00133210; Gauvreau GM, 2009, CLIN EXP ALLERGY, V39, P1297, DOI 10.1111/j.1365-2222.2009.03325.x; Gauvreau Gail M, 2005, Expert Rev Clin Immunol, V1, P87, DOI 10.1586/1744666X.1.1.87; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Harada M, 2011, AM J RESP CELL MOL, V44, P787, DOI 10.1165/rcmb.2009-0418OC; Holtzman MJ, 2014, NAT REV IMMUNOL, V14, P686, DOI 10.1038/nri3739; Hui CCK, 2014, IMMUN INFLAMM DIS, V2, P44, DOI 10.1002/iid3.20; Hunninghake GM, 2010, ALLERGY, V65, P1566, DOI 10.1111/j.1398-9995.2010.02415.x; Imaoka H, 2011, CLIN EXP ALLERGY, V41, P1740, DOI 10.1111/j.1365-2222.2011.03816.x; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Kim YK, 1999, AM J RESP CELL MOL, V20, P388, DOI 10.1165/ajrcmb.20.3.3060; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406, DOI 10.1164/ajrccm.163.2.9912091; Menzies-Gow A, 2003, J ALLERGY CLIN IMMUN, V111, P714, DOI 10.1067/mai.2003.1382; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Punia N, 2012, CLIN EXP ALLERGY, V42, P255, DOI 10.1111/j.1365-2222.2011.03889.x; Reijmerink NE, 2008, J ALLERGY CLIN IMMUN, V122, P651, DOI 10.1016/j.jaci.2008.06.030; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi Roma, 2009, P421, DOI 10.1007/978-4-431-88315-9_25; Semlali A, 2010, J ALLERGY CLIN IMMUN, V125, P844, DOI 10.1016/j.jaci.2010.01.044; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Sivapalan N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109991; Southam DS, 2005, J ALLERGY CLIN IMMUN, V115, P95, DOI 10.1016/j.jaci.2004.09.022; van Veen IH, 2009, J ALLERGY CLIN IMMUN, V124, P615, DOI 10.1016/j.jaci.2009.06.029; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wysoczynski M, 2005, BLOOD, V105, P40, DOI 10.1182/blood-2004-04-1430; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	45	62	65	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1594	1602		10.1016/j.jaci.2014.12.1918	http://dx.doi.org/10.1016/j.jaci.2014.12.1918			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25656998				2022-12-18	WOS:000355933400023
J	Janssen, E; Morbach, H; Ullas, S; Bannock, JM; Massad, C; Menard, L; Barlan, I; Lefranc, G; Su, H; Dasouki, M; Al-Herz, W; Keles, S; Chatila, T; Geha, RS; Meffre, E				Janssen, Erin; Morbach, Henner; Ullas, Sumana; Bannock, Jason M.; Massad, Christopher; Menard, Laurence; Barlan, Isil; Lefranc, Gerard; Su, Helen; Dasouki, Majed; Al-Herz, Waleed; Keles, Sevgi; Chatila, Talal; Geha, Raif S.; Meffre, Eric			Dedicator of cytokinesis 8-deficient patients have a breakdown in peripheral B-cell tolerance and defective regulatory T cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dedicator of cytokinesis 8; autoimmunity; B-cell tolerance; regulatory T cells	DOCK8 DEFICIENCY; AUTOANTIBODY PRODUCTION; TRANSPLANTATION; EXPRESSION; LIGAND; LYMPHOCYTE; EXPANSION; PROFILES; REMOVAL; BAFF	Background: Dedicator of cytokinesis 8 (DOCK8) deficiency is typified by recurrent infections, increased serum IgE levels, eosinophilia, and a high incidence of allergic and autoimmune manifestations. Objective: We sought to determine the role of DOCK8 in the establishment and maintenance of human B-cell tolerance. Methods: Autoantibodies were measured in the plasma of DOCK8-deficient patients. The antibody-coding genes from new emigrant/transitional and mature naive B cells were cloned and assessed for their ability to bind self-antigens. RegulatoryT(Treg) cells in the blood were analyzed by means of flow cytometry, and their function was tested by examining their capacity to inhibit the proliferation of CD4(+)CD25(-) effector T cells. Results: DOCK8-deficient patients had increased levels of autoantibodies in their plasma. We determined that central B-cell tolerance did not require DOCK8, as evidenced by the normally low frequency of polyreactive new emigrant/transitional B cells in DOCK8-deficient patients. In contrast, autoreactive B cells were enriched in the mature naive B-cell compartment, revealing a defective peripheral B-cell tolerance checkpoint. In addition, we found that Treg cells were decreased and exhibited impaired suppressive activity in DOCK8-deficient patients. Conclusions: Our data support a critical role for DOCK8 in Treg cell homeostasis and function and the enforcement of peripheral B-cell tolerance.	[Janssen, Erin; Ullas, Sumana; Keles, Sevgi; Chatila, Talal; Geha, Raif S.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Janssen, Erin; Chatila, Talal; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Morbach, Henner; Bannock, Jason M.; Massad, Christopher; Menard, Laurence; Meffre, Eric] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA; [Barlan, Isil] Marmara Univ, Istanbul, Turkey; [Lefranc, Gerard] Univ Montpellier, IMGT, F-34059 Montpellier, France; [Lefranc, Gerard] CNRS, Inst Human Genet, Montpellier, France; [Su, Helen] NIH, Human Immunol Dis Unit, Bethesda, MD 20892 USA; [Dasouki, Majed] Univ Kansas, Med Ctr, Div Genet Endocrinol & Metab, Dept Pediat, Kansas City, MO USA; [Dasouki, Majed] Univ Kansas, Med Ctr, Div Genet Endocrinol & Metab, Dept Internal Med, Kansas City, MO USA; [Al-Herz, Waleed] Kuwait Univ, Fac Med, Dept Pediat, Safat 13060, Kuwait; [Keles, Sevgi] Necmettin Erbakan Univ, Meram Med Fac, Div Pediat Immunol & Allergy, Konya, Turkey	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Yale University; Marmara University; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; National Institutes of Health (NIH) - USA; University of Kansas; University of Kansas; Kuwait University; Necmettin Erbakan University; Selcuk University	Geha, RS (corresponding author), Boston Childrens Hosp, One Blackfan St, Boston, MA 02115 USA.	raif.geha@childrens.harvard.edu; eric.meffre@yale.edu	Su, Helen C/H-9541-2015	Su, Helen C/0000-0002-5582-9110; Chatila, Talal/0000-0001-7439-2762; Janssen, Erin/0000-0002-0687-2550	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI061093, AI071087, AI082713, AI095848, AI100315, HL059561, 5K 12HD052896]; Manton Foundation; German Research Foundation [DFG MO2160/2-1]; Dubai-Harvard Foundation for Medical Research; Jeffrey Modell Foundation; Intramural Research Program of the NIH; NIAID; Kuwait Foundation for the Advancement of Sciences [2010-1302-05]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052896] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI082713, ZIAAI001193, R21AI095848, R01AI071087, P01AI061093, R01AI100315] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Manton Foundation; German Research Foundation(German Research Foundation (DFG)); Dubai-Harvard Foundation for Medical Research; Jeffrey Modell Foundation; Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Kuwait Foundation for the Advancement of Sciences(Kuwait Foundation for the Advancement of Sciences (KFAS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grants AI061093, AI071087, AI082713, and AI095848 (to E.M.); AI100315 and HL059561 (to R.S.G.); and 5K 12HD052896 (to E.J.), as well as by grants from the Manton Foundation (to E.J.), German Research Foundation grant DFG MO2160/2-1 (to H.M.), the Dubai-Harvard Foundation for Medical Research and the Jeffrey Modell Foundation (to R.S.G.), the Intramural Research Program of the NIH, NIAID (to H.S.), and the Kuwait Foundation for the Advancement of Sciences 2010-1302-05 (to W.A.-H.).	Al Khatib S, 2009, J ALLERGY CLIN IMMUN, V124, P342, DOI 10.1016/j.jaci.2009.05.004; Al-Herz W, 2012, CLIN IMMUNOL, V143, P266, DOI 10.1016/j.clim.2012.03.002; Alsum Z, 2013, J CLIN IMMUNOL, V33, P55, DOI 10.1007/s10875-012-9769-x; Barlogis V, 2011, J ALLERGY CLIN IMMUN, V128, P420, DOI 10.1016/j.jaci.2011.03.025; Bittner TC, 2010, KLIN PADIATR, V222, P351, DOI 10.1055/s-0030-1265135; Booth NJ, 2010, J IMMUNOL, V184, P4317, DOI 10.4049/jimmunol.0903781; Boztug H, 2012, PEDIATR HEMAT ONCOL, V29, P585, DOI 10.3109/08880018.2012.714844; Bradley LM, 2005, TRENDS IMMUNOL, V26, P172, DOI 10.1016/j.it.2005.01.004; Christensen SR, 2005, J EXP MED, V202, P321, DOI 10.1084/jem.20050338; d'Hennezel E, 2011, J IMMUNOL, V186, P6788, DOI 10.4049/jimmunol.1100269; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Gatz SA, 2011, BONE MARROW TRANSPL, V46, P552, DOI 10.1038/bmt.2010.169; Ghost S, 2012, CLIN IMMUNOL, V145, P259, DOI 10.1016/j.clim.2012.10.003; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Halverson R, 2004, NAT IMMUNOL, V5, P645, DOI 10.1038/ni1076; Herve M, 2007, J EXP MED, V204, P1583, DOI 10.1084/jem.20062287; Hoyer BF, 2004, J EXP MED, V199, P1577, DOI 10.1084/jem.20040168; Isnardi I, 2008, IMMUNITY, V29, P746, DOI 10.1016/j.immuni.2008.09.015; Isnardi I, 2010, BLOOD, V115, P5026, DOI 10.1182/blood-2009-09-243071; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Jackson SW, 2014, J IMMUNOL, V192, P4525, DOI 10.4049/jimmunol.1400098; Janssen E, 2014, CLIN IMMUNOL, V150, P220, DOI 10.1016/j.clim.2013.12.006; Kinnunen T, 2013, J CLIN INVEST, V123, P2737, DOI 10.1172/JCI68775; Kinnunen T, 2013, BLOOD, V121, P1595, DOI 10.1182/blood-2012-09-457465; Li QZ, 2007, CLIN EXP IMMUNOL, V147, P60, DOI 10.1111/j.1365-2249.2006.03251.x; Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572; McDonald DR, 2010, J ALLERGY CLIN IMMUN, V126, P1304, DOI 10.1016/j.jaci.2010.07.034; Meffre E, 2004, J EXP MED, V199, P145, DOI 10.1084/jem.20031550; Meffre E, 2011, ANN NY ACAD SCI, V1246, P1, DOI 10.1111/j.1749-6632.2011.06347.x; Menard L, 2011, J CLIN INVEST, V121, P3635, DOI 10.1172/JCI45790; Metin A, 2012, PEDIATR TRANSPLANT, V16, P398, DOI 10.1111/j.1399-3046.2011.01641.x; Meyers G, 2011, P NATL ACAD SCI USA, V108, P11554, DOI 10.1073/pnas.1102600108; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Ng YS, 2004, J EXP MED, V200, P927, DOI 10.1084/jem.20040920; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Romberg N, 2013, J CLIN INVEST, V123, P4283, DOI 10.1172/JCI69854; Saadoun D, 2013, ARTHRITIS RHEUM-US, V65, P1085, DOI 10.1002/art.37828; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sanal O, 2012, J CLIN IMMUNOL, V32, P698, DOI 10.1007/s10875-012-9664-5; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Scholz JL, 2013, LUPUS, V22, P350, DOI 10.1177/0961203312469453; Su HC, 2010, CURR OPIN ALLERGY CL, V10, P515, DOI 10.1097/ACI.0b013e32833fd718; Terrier B, 2011, J IMMUNOL, V187, P6550, DOI 10.4049/jimmunol.1102022; Walter GJ, 2013, ARTHRITIS RHEUM-US, V65, P627, DOI 10.1002/art.37832; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506	47	62	63	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1365	1374		10.1016/j.jaci.2014.07.042	http://dx.doi.org/10.1016/j.jaci.2014.07.042			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25218284	Green Accepted			2022-12-18	WOS:000346075400019
J	Li, YY; Li, CW; Chao, SS; Yu, FG; Yu, XM; Liu, J; Yan, Y; Shen, L; Gordon, W; Shi, L; Wang, DY				Li, Ying Ying; Li, Chun Wei; Chao, Siew Shuen; Yu, Feng Gang; Yu, Xue Min; Liu, Jing; Yan, Yan; Shen, Liang; Gordon, William; Shi, Li; Wang, De Yun			Impairment of cilia architecture and ciliogenesis in hyperplastic nasal epithelium from nasal polyps	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Impairments of cilia architecture; nasal polyps; hyperplasia	CHRONIC RHINOSINUSITIS; BEAT FREQUENCY; UP-REGULATION; IN-VITRO; CELLS; EXPRESSION; DISEASES; FOXJ1; CP110; INFLAMMATION	Background: Aberrant airway epithelial remodeling is one of the cardinal histopathologic features of inflammatory airway diseases, but whether it alters the mucociliary apparatus remains unknown. Objective: We sought to investigate the morphologic pattern of motile cilia and ciliogenesis-associated makers in hyperplastic nasal epithelium from nasal polyps (NPs) both in vivo and in vitro. Methods: Biopsy specimens obtained from patients with NPs (n = 44) and inferior turbinate from healthy control subjects (n = 38) were analyzed by using scanning electron microscopy, immunofluorescence staining, single-cell (cytospin) staining, quantitative real-time PCR, and human nasal epithelial stem/progenitor cell culture and differentiation. Results: Abnormal cilia architecture (untidy, overly dense, and lengthened) was more commonly observed in patients with NPs by using scanning electron microscopy. Ectopic lengthened cilia were visualized by means of immunofluorescence (patients with NPs: 6.33 mu m [5.51-7.43 mu m] vs control subjects: 3.73 mu m [3.50-4.27 mu m], P < .0001), at the site of epithelial hyperplasia in isolated single cells (patients with NPs: 6.55 +/- 0.23 mu m vs control subjects 4.89 +/- 0.24 mu m, P < .0001), and in differentiated ciliated cells derived from human nasal epithelial stem/progenitor cells (patients with NPs: 9.20 +/- 0.56 mu m vs control subjects: 5.21 +/- 0.37 mu m, P < .0001). Ciliary beat frequency was found to be significantly slower in patients with NPs than control subjects in vitro. Both protein and mRNA levels of ciliogenesis-associated markers (centrosomal protein 110 [CP110], forkhead box J1 [Foxj1], and P73 isoform with an N-terminal transactivation domain [TAp73]) were significantly increased in patients with NPs versus those seen in control subjects and were positively correlated with cilia length. Conclusion: For the first time, this study demonstrates for that motile cilia impairment is a co-condition of epithelial hyperplasia in patients with NPs, and this impairment of function is a likely cause of chronic mucosal inflammation or infection (eg, biofilm) observed in patients with chronic rhinosinusitis.	[Li, Ying Ying; Li, Chun Wei; Chao, Siew Shuen; Yu, Feng Gang; Liu, Jing; Yan, Yan; Wang, De Yun] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, Singapore 119228, Singapore; [Yu, Xue Min; Shi, Li] Shandong Univ, Qilu Hosp, Dept Otolaryngol, Shanghai, Peoples R China; [Shen, Liang] Natl Univ Singapore, Biostat Unit, Singapore 119228, Singapore; [Gordon, William] Univ Calif Irvine, Dept Med & Biol Chem, Irvine, CA USA; [Shi, Li] Shandong Univ, Minist Hlth, Lab Otorhinolaryngol, Shanghai, Peoples R China	National University of Singapore; Shandong University; National University of Singapore; University of California System; University of California Irvine; Shandong University	Wang, DY (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, 1E Kent Ridge Rd, Singapore 119228, Singapore.	shili126@sina.com; entwdy@nus.edu.sg			National Medical Research Council (NMRC) [CIRG12Nov033]; Singapore Immunology Network (SIgN) of Singapore [SIgN 10-028]; National Nature Science Foundation of China [81170897]	National Medical Research Council (NMRC)(National Medical Research Council, Singapore); Singapore Immunology Network (SIgN) of Singapore; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	Supported by grants from the National Medical Research Council (NMRC; CIRG12Nov033) and from the Singapore Immunology Network (SIgN; SIgN 10-028) of Singapore and the National Nature Science Foundation of China (grant awarded number 81170897).	Avasthi P, 2012, DIFFERENTIATION, V83, pS30, DOI 10.1016/j.diff.2011.11.015; Biedlingmaier JF, 1998, OTOLARYNG HEAD NECK, V118, P165, DOI 10.1016/S0194-5998(98)80005-3; Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; DEVALIA JL, 1993, RESP MED, V87, P405, DOI 10.1016/0954-6111(93)90064-7; Eley L, 2005, CURR OPIN GENET DEV, V15, P308, DOI 10.1016/j.gde.2005.04.008; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gavet O, 2010, DEV CELL, V18, P533, DOI 10.1016/j.devcel.2010.02.013; Gomperts BN, 2007, AM J RESP CELL MOL, V37, P339, DOI 10.1165/rcmb.2006-0400OC; Han DM, 2009, AM J RHINOL ALLERGY, V23, P610, DOI 10.2500/ajra.2009.23.3401; Hartig Sean M, 2013, Curr Protoc Mol Biol, VChapter 14, DOI 10.1002/0471142727.mb1415s102; Hsu J, 2013, J ALLERGY CLIN IMMUN, V131, pe1; Hsu J, 2013, J ALLERGY CLIN IMMUN, V131, P977, DOI 10.1016/j.jaci.2013.01.028; Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001; Lai YY, 2011, J ALLERGY CLIN IMMUN, V128, P1207, DOI 10.1016/j.jaci.2011.09.001; Leopold PL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008157; Li CW, 2012, ALLERGY, V67, P732, DOI 10.1111/j.1398-9995.2012.02811.x; Li CW, 2009, THORAX, V64, P306, DOI 10.1136/thx.2008.106096; Li CW, 2011, J ALLERGY CLIN IMMUN, V127, P765, DOI 10.1016/j.jaci.2010.12.011; Li CW, 2013, CURR ALLERGY ASTHM R, V13, P209, DOI 10.1007/s11882-012-0328-6; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McCulloch C.M., 2008, WILEY SERIES PROBABI, V2nd; Reimer A, 1978, Acta Otolaryngol Suppl, V356, P1; Roy S, 2009, BIOESSAYS, V31, P694, DOI 10.1002/bies.200900031; Sisson JH, 2003, J MICROSC-OXFORD, V211, P103, DOI 10.1046/j.1365-2818.2003.01209.x; Spektor A, 2007, CELL, V130, P678, DOI 10.1016/j.cell.2007.06.027; Tomasini R, 2009, P NATL ACAD SCI USA, V106, P797, DOI 10.1073/pnas.0812096106; Tomkova K, 2008, NEOPLASMA, V55, P177; TOSKALA E, 1995, J LARYNGOL OTOL, V109, P509, DOI 10.1017/S0022215100130580; Tsang WY, 2008, DEV CELL, V15, P187, DOI 10.1016/j.devcel.2008.07.004; Yan Y, 2013, CURR OPIN OTOLARYNGO, V21, P263, DOI 10.1097/MOO.0b013e32835f80a0; You YJ, 2004, AM J PHYSIOL-LUNG C, V286, pL650, DOI 10.1152/ajplung.00170.2003; Yu FG, 2012, LARYNGOSCOPE, V122, P1463, DOI 10.1002/lary.23320; Yu XW, 2008, NAT GENET, V40, P1445, DOI 10.1038/ng.263; Yu XM, 2013, HISTOPATHOLOGY, V63, P686, DOI 10.1111/his.12211; Zhao XN, 2012, AM J RHINOL ALLERGY, V26, P345, DOI 10.2500/ajra.2012.26.3794	36	62	67	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2014	134	6					1282	1292		10.1016/j.jaci.2014.07.038	http://dx.doi.org/10.1016/j.jaci.2014.07.038			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AW1UG	25201258				2022-12-18	WOS:000346075400010
J	Romberg, N; Morbach, H; Lawrence, MG; Kim, S; Kang, I; Holland, SM; Milner, JD; Meffre, E				Romberg, Neil; Morbach, Henner; Lawrence, Monica G.; Kim, Sanghyun; Kang, Insoo; Holland, Steven M.; Milner, Joshua D.; Meffre, Eric			Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC MUCOCUTANEOUS CANDIDIASIS; APOPTOSIS; INDUCTION; TRANS		[Romberg, Neil] Yale Univ, Sch Med, Dept Pediat, Div Allergy & Clin Immunol, New Haven, CT 06510 USA; [Morbach, Henner; Meffre, Eric] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA; [Kim, Sanghyun; Kang, Insoo] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Lawrence, Monica G.; Milner, Joshua D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA; [Kim, Sanghyun] Kangwon Natl Univ, Coll Med, Chunchon, South Korea	Yale University; Yale University; Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Kangwon National University	Romberg, N (corresponding author), Yale Univ, Sch Med, Dept Pediat, Div Allergy & Clin Immunol, New Haven, CT 06510 USA.	neil.romberg@yale.edu		Romberg, Neil/0000-0002-1881-5318	Intramural NIH HHS Funding Source: Medline; NIAID NIH HHS [AI095848, R01 AI071087, AI071087, R21 AI095848, P01 AI061093, AI061093, U19 AI082713, AI082713] Funding Source: Medline; NICHD NIH HHS [K12HD0141401-10] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI061093, R21AI095848, R01AI071087, ZIAAI001183, U19AI082713] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Hirahara K, 2012, IMMUNITY, V36, P1017, DOI 10.1016/j.immuni.2012.03.024; Liu LY, 2011, J EXP MED, V208, P1635, DOI 10.1084/jem.20110958; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Niitsu N, 2002, LEUKEMIA RES, V26, P745, DOI 10.1016/S0145-2126(01)00202-8; Sironi JJ, 2004, J BIOL CHEM, V279, P4066, DOI 10.1074/jbc.M307774200; van de Veerdonk FL, 2011, NEW ENGL J MED, V365, P54, DOI 10.1056/NEJMoa1100102	7	62	62	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1691	1693		10.1016/j.jaci.2013.01.004	http://dx.doi.org/10.1016/j.jaci.2013.01.004			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23403048	Green Accepted			2022-12-18	WOS:000320532800030
J	Carolan, BJ; Sutherland, ER				Carolan, Brendan J.; Sutherland, E. Rand			Clinical phenotypes of chronic obstructive pulmonary disease and asthma: Recent advances	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Biomarker; biopsy; cluster analysis	LUNG-FUNCTION DECLINE; AIR-FLOW OBSTRUCTION; BODE INDEX; SEVERE EXACERBATIONS; CLUSTER-ANALYSIS; COPD PHENOTYPES; FEATURES; OVERLAP; RISK; TIME	Asthma and chronic obstructive pulmonary disease (COPD) are prevalent obstructive lung diseases, both of which are characterized by airflow limitation. Although both represent distinct pathogenic entities, there can be significant clinical and physiologic overlap between the 2 disorders, creating potential management difficulties for clinicians. Although practice guidelines for both conditions outline diagnostic and management strategies, asthma and COPD are highly heterogeneous, and the symptoms of many patients remain poorly controlled despite adherence to current guidelines. Recent advances in phenotyping studies have elucidated heterogeneity in these airway diseases and might represent the best opportunity to enhance diagnosis, predict outcomes, and personalize treatments in patients with asthma and those with COPD. This review will focus on recent advances in describing phenotypic heterogeneity in asthma and COPD, including the evaluation of multiple clinical variables, molecular biomarkers, physiologic and radiologic data, and factors associated with disease progression and frequent exacerbations. (J Allergy Clin Immunol 2013;131:627-34.)	[Carolan, Brendan J.; Sutherland, E. Rand] Natl Jewish Hlth, Dept Med, Denver, CO USA; [Carolan, Brendan J.; Sutherland, E. Rand] Univ Colorado, Sch Med, Denver, CO USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sutherland, ER (corresponding author), 1400 Jackson St,J-201, Denver, CO 80206 USA.	sutherlande@njhealth.org			Forest Laboratories; GlaxoSmithKline; Merck/Schering-Plough; Novartis; Dey; Genentech; Boehringer Ingelheim; National Institutes of Health	Forest Laboratories; GlaxoSmithKline(GlaxoSmithKline); Merck/Schering-Plough(Merck & CompanySchering Plough Corporation); Novartis(Novartis); Dey; Genentech(Roche HoldingGenentech); Boehringer Ingelheim(Boehringer Ingelheim); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	E. R. Sutherland has received consultancy fees from Forest Laboratories, GlaxoSmithKline, Merck/Schering-Plough, Novartis, Dey, and Genentech; is employed by National Jewish Health; has received research support from Boehringer Ingelheim, Novartis, and the National Institutes of Health; and has received payment for developing educational presentations from Genentech. B.J. Carolan declares that he has no relevant conflicts of interest.	Agusti A, 2011, AM J RESP CRIT CARE, V183, P1129, DOI 10.1164/rccm.201009-1414PP; Bafadhel M, 2011, AM J RESP CRIT CARE, V184, P662, DOI 10.1164/rccm.201104-0597OC; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Barr RG, 2010, NEW ENGL J MED, V362, P217, DOI 10.1056/NEJMoa0808836; Burgel PR, 2010, EUR RESPIR J, V36, P531, DOI 10.1183/09031936.00175109; Burgel PR, 2012, EUR RESPIR J, V40, P495, DOI 10.1183/09031936.00228511; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Cote CG, 2005, EUR RESPIR J, V26, P630, DOI 10.1183/09031936.05.00045505; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Donaldson GC, 2010, CHEST, V137, P1091, DOI 10.1378/chest.09-2029; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; DORNHORST AC, 1955, LANCET, V1, P1185; Everitt BS, 2011, CLUSTER ANAL, DOI DOI 10.1002/9780470977811; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Garcia-Aymerich J, 2011, THORAX, V66, P430, DOI 10.1136/thx.2010.154484; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Good JT, 2012, CHEST, V141, P599, DOI 10.1378/chest.11-0741; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Halpin DMG, 2011, LUNG, V189, P261, DOI 10.1007/s00408-011-9301-8; Han MLK, 2011, RADIOLOGY, V261, P274, DOI 10.1148/radiol.11110173; Hardin M, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-127; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Soler-Cataluna JJ, 2012, ARCH BRONCONEUMOL, V48, P331, DOI 10.1016/j.arbres.2011.12.009; Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017; Martinez CH, 2012, THORAX, V67, P399, DOI 10.1136/thoraxjnl-2011-201185; Martinez FJ, 2008, AM J RESP CRIT CARE, V178, P491, DOI 10.1164/rccm.200709-1383OC; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nishimura M, 2012, AM J RESP CRIT CARE, V185, P44, DOI 10.1164/rccm.201106-0992OC; Ong KC, 2005, CHEST, V128, P3810, DOI 10.1378/chest.128.6.3810; Parr David G, 2011, Proc Am Thorac Soc, V8, P338, DOI 10.1513/pats.201101-014RM; Regan EA, 2010, COPD, V7, P32, DOI 10.3109/15412550903499522; Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608, DOI 10.1164/ajrccm.161.5.9908022; Vestbo J, 2012, AM J RESP CRIT CARE; Vestbo J, 2011, NEW ENGL J MED, V365, P1184, DOI 10.1056/NEJMoa1105482; Wells JM, 2012, NEW ENGL J MED, V367, P913, DOI 10.1056/NEJMoa1203830; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 2012, AM J RESP CRIT CARE, V186, P501, DOI 10.1164/rccm.201203-0476OC; Wood LG, 2012, CHEST, V142, P86, DOI 10.1378/chest.11-1838; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Wu AC, 2011, CHEST, V140, P100, DOI 10.1378/chest.10-2794	45	62	63	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					627	634		10.1016/j.jaci.2013.01.010	http://dx.doi.org/10.1016/j.jaci.2013.01.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23360757				2022-12-18	WOS:000315587800001
J	Perzanowski, MS; Chew, GL; Divjan, A; Jung, KH; Ridder, R; Tang, DL; Diaz, D; Goldstein, IF; Kinney, PL; Rundle, AG; Camann, DE; Perera, FP; Miller, RL				Perzanowski, Matthew S.; Chew, Ginger L.; Divjan, Adnan; Jung, Kyung Hwa; Ridder, Robert; Tang, Deliang; Diaz, Diurka; Goldstein, Inge F.; Kinney, Patrick L.; Rundle, Andrew G.; Camann, David E.; Perera, Frederica P.; Miller, Rachel L.			Early-life cockroach allergen and polycyclic aromatic hydrocarbon exposures predict cockroach sensitization among inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bla g 2; cockroach; polycyclic aromatic hydrocarbon; IgE; allergy; inner-city; GSTM; GSTP	S-TRANSFERASE M1; NEW-YORK-CITY; ENVIRONMENTAL TOBACCO-SMOKE; DIESEL EXHAUST PARTICLES; DNA ADDUCT LEVELS; HOUSE-DUST MITE; IN-VIVO; PARTICULATE MATTER; INDOOR ALLERGENS; AIR-POLLUTION	Background: Sensitization to cockroach is one of the strongest identified risk factors for greater asthma morbidity in low-income urban communities; however, the timing of exposures relevant to the development of sensitization has not been elucidated fully. Furthermore, exposure to combustion byproducts, including polycyclic aromatic hydrocarbons (PAHs), can augment the development of allergic sensitization. Objective: We sought to test the hypotheses that domestic cockroach allergen measured prenatally would predict cockroach sensitization in early childhood and that this association would be greater for children exposed to higher PAH concentrations. Methods: Dominican and African American pregnant women living in New York City were enrolled. In the third trimester expectant mothers wore personal air samplers for measurement of 8 nonvolatile PAHs and the semivolatile PAH pyrene, and dust was collected from homes for allergen measurement. Glutathione-S-transferase mu 1 (GSTM1) gene polymorphisms were measured in children. Allergen-specific IgE levels were measured from the children at ages 2, 3, 5, and 7 years. Results: Bla g 2 in prenatal kitchen dust predicted cockroach sensitization at the ages of 5 to 7 years (adjusted relative risk [RR], 1.15; P = .001; n = 349). The association was observed only among children with greater than (RR, 1.22; P = .001) but not less than (RR, 1.07; P = .24) the median sum of 8 nonvolatile PAH levels. The association was most pronounced among children with higher PAH levels and null for the GSTM1 gene (RR, 1.54; P = .001). Conclusions: Prenatal exposure to cockroach allergen was associated with a greater risk of allergic sensitization. This risk was increased by exposure to nonvolatile PAHs, with children null for the GSTM1 mutation particularly vulnerable. (J Allergy Clin Immunol 2013;131:886-93.)	[Perzanowski, Matthew S.; Chew, Ginger L.; Divjan, Adnan; Jung, Kyung Hwa; Ridder, Robert; Tang, Deliang; Diaz, Diurka; Goldstein, Inge F.; Kinney, Patrick L.; Rundle, Andrew G.; Perera, Frederica P.; Miller, Rachel L.] Columbia Univ, CCCEH, New York, NY 10032 USA; [Perzanowski, Matthew S.; Chew, Ginger L.; Divjan, Adnan; Tang, Deliang; Diaz, Diurka; Kinney, Patrick L.; Perera, Frederica P.; Miller, Rachel L.] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Jung, Kyung Hwa; Ridder, Robert; Miller, Rachel L.] Columbia Univ, Div Pulm, Dept Med, Coll Phys & Surg, New York, NY 10032 USA; [Goldstein, Inge F.; Rundle, Andrew G.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Camann, David E.] Southwest Res Inst, San Antonio, TX USA; [Miller, Rachel L.] Columbia Univ, Dept Pediat, Div Pediat Allergy & Immunol, Coll Phys & Surg, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Southwest Research Institute; Columbia University	Perzanowski, MS (corresponding author), Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, 722 W 168th St,11th Floor, New York, NY 10032 USA.	mp2217@columbia.edu	Rundle, Andrew G/A-5282-2009	Rundle, Andrew G/0000-0003-0211-7707; Divjan, Adnan/0000-0002-8895-5965	National Institutes of Environmental Health Sciences (NIEHS) [P01 ES09600, RO1ES08977, R01ES13163, RO1ES11158, P30 ES009089, P50ES015905, R03ES013308]; US Environmental Protection Agency (EPA) [R827027, RD832141, RD834509]; Bauman Family Foundation; Gladys & Roland Harriman Foundation, New York Community Trust; Educational Foundation of America; New York Times Company Foundation; Schmidt Family Foundation; Johnson Family Foundation, Rockefeller Financial Services; Horace W. Goldsmith Foundation; Beldon Fund; John Merck Fund; V. Kann Rasmussen Foundation; National Institutes of Health (NIH); EPA; US Department of Housing and Urban Development; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009600, R01ES013163, R03ES013308, R01ES011158, R01ES008977, P30ES009089, P50ES015905] Funding Source: NIH RePORTER	National Institutes of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); US Environmental Protection Agency (EPA)(United States Environmental Protection Agency); Bauman Family Foundation; Gladys & Roland Harriman Foundation, New York Community Trust; Educational Foundation of America; New York Times Company Foundation; Schmidt Family Foundation; Johnson Family Foundation, Rockefeller Financial Services; Horace W. Goldsmith Foundation; Beldon Fund; John Merck Fund; V. Kann Rasmussen Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EPA(United States Environmental Protection Agency); US Department of Housing and Urban Development; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Institutes of Environmental Health Sciences (NIEHS; grants P01 ES09600, RO1ES08977, R01ES13163, RO1ES11158, P30 ES009089, P50ES015905, and R03ES013308), the US Environmental Protection Agency (EPA; grants R827027, RD832141, and RD834509), the Bauman Family Foundation, the Gladys & Roland Harriman Foundation, New York Community Trust, the Educational Foundation of America, the New York Times Company Foundation, the Schmidt Family Foundation, the Johnson Family Foundation, Rockefeller Financial Services, the Horace W. Goldsmith Foundation, the Beldon Fund, the John Merck Fund, and the V. Kann Rasmussen Foundation.; M. S. Perzanowski has been supported by one or more grants from the National Institutes of Health (NIH) and from the EPA, has received one or more grants from or has one or more grants pending with the US Department of Housing and Urban Development, and has received one or more payments for travel/accommodations/meeting expenses from Indoor Biotechnologies. P. L. Kinney has been supported by one or more grants from the NIH. A. G. Rundle has been supported by one or more grants from the NIH and is a Board member for EHE International. F. P. Perera has been supported by one or more grants from the National Institutes of Environmental Health Sciences. R. L. Miller has been supported by one or more grants from the NIH and the EPA. The rest of the authors declare that they have no relevant conflicts of interest.	Antens CJM, 2006, CLIN EXP ALLERGY, V36, P1525, DOI 10.1111/j.1365-2222.2006.02603.x; Arand M, 1996, ANAL BIOCHEM, V236, P184, DOI 10.1006/abio.1996.0153; Bommel H, 2000, J ALLERGY CLIN IMMUN, V105, P796, DOI 10.1067/mai.2000.105124; Bommel H, 2003, INT IMMUNOPHARMACOL, V3, P1371, DOI 10.1016/S1567-5769(03)00135-8; Chang Carolyn, 2010, Clin Mol Allergy, V8, P11, DOI 10.1186/1476-7961-8-11; Chew GL, 2008, J ALLERGY CLIN IMMUN, V121, P240, DOI 10.1016/j.jaci.2007.08.024; Chew GL, 2005, INDOOR AIR, V15, P228, DOI 10.1111/j.1600-0668.2005.00363.x; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536, DOI 10.1164/ajrccm.157.5.9708011; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Cornell AG, 2012, J EXPO SCI ENV EPID, V22, P258, DOI 10.1038/jes.2012.3; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183, DOI 10.1016/S0091-6749(99)70011-4; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Donohue KM, 2008, J ALLERGY CLIN IMMUN, V122, P914, DOI 10.1016/j.jaci.2008.08.034; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Filep S, 2012, ALLERGY, V67, P235, DOI 10.1111/j.1398-9995.2011.02750.x; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Ginsberg G, 2009, J TOXICOL ENV HEAL B, V12, P389, DOI 10.1080/10937400903158375; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Hu X, 1997, ARCH BIOCHEM BIOPHYS, V345, P32, DOI 10.1006/abbi.1997.0269; Jung KH, 2012, ANN ALLERG ASTHMA IM, V109, P249, DOI 10.1016/j.anai.2012.07.019; Jung KH, 2010, ATMOS ENVIRON, V44, P4545, DOI 10.1016/j.atmosenv.2010.08.024; Kass D, 2009, ENVIRON HEALTH PERSP, V117, P1219, DOI 10.1289/ehp.0800149; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; KIMATA H, 1992, J EXP MED, V176, P1227, DOI 10.1084/jem.176.4.1227; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Mastrangelo G, 1996, ENVIRON HEALTH PERSP, V104, P1166, DOI 10.2307/3432909; Melen E, 2008, ENVIRON HEALTH PERSP, V116, P1077, DOI 10.1289/ehp.11117; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995, DOI 10.1164/ajrccm.164.6.2011107; Miller RM, 2004, LIBR J, V129, P126; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Olmedo O, 2011, J ALLERGY CLIN IMMUN, V128, P284, DOI 10.1016/j.jaci.2011.02.044; Perera FP, 1997, SCIENCE, V278, P1068, DOI 10.1126/science.278.5340.1068; Perzanowski MS, 2010, THORAX, V65, P118, DOI 10.1136/thx.2009.121459; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Porter M, 2007, AM J RESP CELL MOL, V37, P706, DOI 10.1165/rcmb.2007-0199OC; Rauh VA, 2004, NEUROTOXICOL TERATOL, V26, P373, DOI 10.1016/j.ntt.2004.01.002; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Rojas M, 2000, CARCINOGENESIS, V21, P35, DOI 10.1093/carcin/21.1.35; Rosa MJ, 2011, RESP MED, V105, P869, DOI 10.1016/j.rmed.2010.11.022; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Rundle A, 2012, AM J EPIDEMIOL, V175, P1163, DOI 10.1093/aje/kwr455; Samuelsen M, 2008, TOXICOLOGY, V246, P124, DOI 10.1016/j.tox.2008.01.001; Seamonds D, BOTTOM BARREL DIRTIE; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Sundberg K, 1998, CARCINOGENESIS, V19, P433, DOI 10.1093/carcin/19.3.433; Togias A, 2010, J ALLERGY CLIN IMMUN, V125, P540, DOI 10.1016/j.jaci.2010.01.040; Tonne CC, 2004, ENVIRON HEALTH PERSP, V112, P754, DOI 10.1289/ehp.5955; Torrent M, 2006, J ALLERGY CLIN IMMUN, V118, P742, DOI 10.1016/j.jaci.2006.04.059; Yoshida T, 2010, TOXICOL LETT, V199, P383, DOI 10.1016/j.toxlet.2010.10.002	54	62	65	0	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					886	+		10.1016/j.jaci.2012.12.666	http://dx.doi.org/10.1016/j.jaci.2012.12.666			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23391330	Green Published, Green Accepted			2022-12-18	WOS:000315587800033
J	Parvaneh, N; Casanova, JL; Notarangelo, LD; Conley, ME				Parvaneh, Nima; Casanova, Jean-Laurent; Notarangelo, Luigi Daniele; Conley, Mary Ellen			Primary immunodeficiencies: A rapidly evolving story	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Primary immunodeficiencies; combined immunodeficiencies; well-defined syndromes with immunodeficiency; predominantly antibody defects; defects of immune dysregulation; congenital defects of phagocytes; defects in innate immunity; autoinflammatory disorders; mutation detection	GENERALIZED PUSTULAR PSORIASIS; HERPES-SIMPLEX ENCEPHALITIS; HERMANSKY-PUDLAK-SYNDROME; KILLER-CELL DEFICIENCY; PHOSPHOLIPASE-C-GAMMA; T-CELL; CONGENITAL ASPLENIA; INFLAMMATORY SKIN; TYROSINE KINASE; BOWEL-DISEASE	The characterization of primary immunodeficiencies (PIDs) in human subjects is crucial for a better understanding of the biology of the immune response. New achievements in this field have been possible in light of collaborative studies; attention paid to new phenotypes, infectious and otherwise; improved immunologic techniques; and use of exome sequencing technology. The International Union of Immunological Societies Expert Committee on PIDs recently reported on the updated classification of PIDs. However, new PIDs are being discovered at an ever-increasing rate. A series of 19 novel primary defects of immunity that have been discovered after release of the International Union of Immunological Societies report are discussed here. These new findings highlight the molecular pathways that are associated with clinical phenotypes and suggest potential therapies for affected patients. (J Allergy Clin Immunol 2013;131:314-23.)	[Parvaneh, Nima] Univ Tehran Med Sci, Childrens Med Ctr, Pediat Infect Dis Res Ctr, Tehran, Iran; [Parvaneh, Nima] Univ Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Tehran, Iran; [Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, Rockefeller Branch, New York, NY 10021 USA; [Casanova, Jean-Laurent] Univ Paris 05, Necker Med Sch, Necker Branch, Lab Human Genet Infect Dis, Paris, France; [Casanova, Jean-Laurent] INSERM, U980, Paris, France; [Notarangelo, Luigi Daniele] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Notarangelo, Luigi Daniele] Harvard Univ, Sch Med, Childrens Hosp Boston, Manton Ctr Orphan Dis Res, Boston, MA USA; [Conley, Mary Ellen] Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN USA; [Conley, Mary Ellen] Le Bonheur Childrens Hosp, Memphis, TN USA	Tehran University of Medical Sciences; Tehran University of Medical Sciences; Rockefeller University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Tennessee System; University of Tennessee Health Science Center	Parvaneh, N (corresponding author), Childrens Med Ctr, Pediat Infect Dis Res Ctr, 62 Gharib St, Tehran 14194, Iran.	nparvaneh@tums.ac.ir	Parvaneh, Nima/A-2523-2010; Notarangelo, Luigi D/F-9718-2016; Casanova, Jean-Laurent/I-3418-2017	Parvaneh, Nima/0000-0002-3397-9716; Notarangelo, Luigi D/0000-0002-8335-0262; Casanova, Jean-Laurent/0000-0002-7782-4169	National Institutes of Health (NIH); Pfizer; Merck; NIH; March of Dimes; Jeffrey Modell Foundation; Immune Deficiency Foundation	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer(Pfizer); Merck(Merck & Company); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes(March of Dimes); Jeffrey Modell Foundation; Immune Deficiency Foundation	J.-L. Casanova has received grants from the National Institutes of Health (NIH); has been a consultant for Pfizer, GlaxoSmithKline, NovImmune, Biogenldec, Merck, and Sanofi-Aventis; and has grants/grants pending from Pfizer and Merck. L. D. Notarangelo is a board member for the Immune Disease Institute, is employed by Children's Hospital Boston, has grants/grants pending with the NIH, the March of Dimes, and the Jeffrey Modell Foundation; and has received payment for lectures, including service on speakers' bureaus for the WAS foundation. M. E. Conley is employed by the University of Tennessee, has received grants/grants pending from the NIH and the March of Dimes, has received payment for lectures from the Immune Deficiency Foundation, and is receiving royalties from the Southern Bio for monoclonal antibodies. N. Parvaneh declares no relevant conflicts of interest.	Abdollahpour H, 2012, BLOOD, V119, P3450, DOI 10.1182/blood-2011-09-378158; Aiuti A, 1999, EUR J IMMUNOL, V29, P1823, DOI 10.1002/(SICI)1521-4141(199906)29:06<1823::AID-IMMU1823>3.0.CO;2-B; Al-Herz W, 2012, CLIN IMMUNOL, V144, P24, DOI 10.1016/j.clim.2012.05.003; Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; Al-Muhsen S, 2008, J ALLERGY CLIN IMMUN, V122, P1043, DOI 10.1016/j.jaci.2008.10.037; Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; ALDRICH RA, 1954, PEDIATRICS, V13, P133; Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; Asokan R, 2006, J IMMUNOL, V177, P383, DOI 10.4049/jimmunol.177.1.383; Augey F, 2006, EUR J DERMATOL, V16, P669, DOI 10.1684/ejd.2006.0003; Badolato R, 2007, J ALLERGY CLIN IMMUN, V120, P735, DOI 10.1016/j.jaci.2007.08.039; Badolato R, 2012, BLOOD, V119, P3185, DOI 10.1182/blood-2012-01-404350; Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031; Belmont JW, 2004, CURR OPIN CARDIOL, V19, P216, DOI 10.1097/00001573-200405000-00005; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Blaydon DC, 2011, NEW ENGL J MED, V365, P1502, DOI 10.1056/NEJMoa1100721; Bochman ML, 2009, MICROBIOL MOL BIOL R, V73, P652, DOI 10.1128/MMBR.00019-09; Bogunovic D, 2012, SCIENCE, V337, P1684, DOI 10.1126/science.1224026; Borst J, 2005, CURR OPIN IMMUNOL, V17, P275, DOI 10.1016/j.coi.2005.04.004; Bustamante J, 2011, NAT IMMUNOL, V12, P213, DOI 10.1038/ni.1992; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Casanova JL, 2007, SCIENCE, V317, P617, DOI 10.1126/science.1142963; Casanova JL, 2004, NAT REV IMMUNOL, V4, P55, DOI 10.1038/nri1264; Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P541; Conley ME, 2012, J EXP MED, V209, P463, DOI 10.1084/jem.20112533; Conley ME, 2011, ANN NY ACAD SCI, V1238, P1, DOI 10.1111/j.1749-6632.2011.06212.x; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Crequer A, 2012, J CLIN IMMUNOL; Crequer A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044010; Crequer A, 2012, J CLIN INVEST, V122, P3239, DOI 10.1172/JCI62949; Cullinane AR, 2011, AM J HUM GENET, V88, P778, DOI 10.1016/j.ajhg.2011.05.009; Curcio C, 2007, J PATHOL, V211, P67, DOI 10.1002/path.2088; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DCunha J, 1996, J IMMUNOL, V157, P4100; de Beaucoudrey L, 2010, MEDICINE, V89, P381, DOI 10.1097/MD.0b013e3181fdd832; de la Fuente MA, 2007, P NATL ACAD SCI USA, V104, P926, DOI 10.1073/pnas.0610275104; de Souza N, 2007, DEVELOPMENT, V134, P691, DOI 10.1242/dev.02767; Dell'Angelica EC, 2004, CURR OPIN CELL BIOL, V16, P458, DOI 10.1016/j.ceb.2004.05.001; Dinarello C, 2010, NAT IMMUNOL, V11, P973, DOI 10.1038/ni1110-973; Dorn T, 2007, BLOOD, V109, P2346, DOI 10.1182/BLOOD-2006-04-019034; Durfee LA, 2010, MOL CELL, V38, P722, DOI 10.1016/j.molcel.2010.05.002; Eidenschenk C, 2006, AM J HUM GENET, V78, P721, DOI 10.1086/503269; Eidenschenk C, 2006, J IMMUNOL, V177, P8835, DOI 10.4049/jimmunol.177.12.8835; Etzioni A, 2005, J PEDIATR-US, V146, P423, DOI 10.1016/j.jpeds.2004.11.022; Farrar JE, 1996, CLIN IMMUNOL IMMUNOP, V81, P271, DOI 10.1006/clin.1996.0188; Fearon DT, 2000, ANNU REV IMMUNOL, V18, P393, DOI 10.1146/annurev.immunol.18.1.393; Fruman DA, 2010, CURR TOP MICROBIOL, V346, P225, DOI 10.1007/82_2010_39; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; Funami K, 2008, J BIOL CHEM, V283, P18283, DOI 10.1074/jbc.M801013200; Funami K, 2007, J IMMUNOL, V179, P6867, DOI 10.4049/jimmunol.179.10.6867; Gallego MD, 2006, INT IMMUNOL, V18, P221, DOI 10.1093/intimm/dxh310; Gilbert B, 2002, EUR J PEDIATR, V161, P368, DOI 10.1007/s00431-002-0965-1; Gineau L, 2012, J CLIN INVEST, V122, P821, DOI 10.1172/JCI61014; Goldbach-Mansky R, 2009, J ALLERGY CLIN IMMUN, V124, P1141, DOI 10.1016/j.jaci.2009.11.016; Goldman FD, 1998, J CLIN INVEST, V102, P421, DOI 10.1172/JCI3205; Gorska MM, 2012, CURR ALLERGY ASTHM R, V12, P396, DOI 10.1007/s11882-012-0281-4; Gorska MM, 2012, BLOOD, V119, P1399, DOI 10.1182/blood-2011-04-350686; Gorska MM, 2010, J IMMUNOL, V184, P4488, DOI 10.4049/jimmunol.0903115; Gorska MM, 2009, J IMMUNOL, V183, P1675, DOI 10.4049/jimmunol.0900792; Gorska MM, 2004, J EXP MED, V199, P369, DOI 10.1084/jem.20030589; Granados EL, 2002, J CLIN INVEST, V110, P1029, DOI 10.1172/JCI200215658; Haddad E, 2001, BLOOD, V97, P33, DOI 10.1182/blood.V97.1.33; Hambleton S, 2011, NEW ENGL J MED, V365, P127, DOI 10.1056/NEJMoa1100066; Hauck F, 2012, J ALLERGY CLIN IMMUN, V130, P1144, DOI 10.1016/j.jaci.2012.07.029; Herman M, 2012, J EXP MED, V209, P1567, DOI 10.1084/jem.20111316; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Hubert P, 2000, INT IMMUNOL, V12, P449, DOI 10.1093/intimm/12.4.449; Hughes CR, 2012, J CLIN INVEST, V122, P814, DOI 10.1172/JCI60224; IVEMARK B I, 1955, Acta Paediatr Suppl, V44, P7; Kanegane H, 2005, J CLIN IMMUNOL, V25, P491, DOI 10.1007/s10875-005-5370-x; Koss M, 2012, DEV CELL, V22, P913, DOI 10.1016/j.devcel.2012.02.009; Lanzi G, 2012, J EXP MED, V209, P29, DOI 10.1084/jem.20110896; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Laurence J, 1996, J CLIN INVEST, V97, P672, DOI 10.1172/JCI118464; Lazarczyk M, 2008, J EXP MED, V205, P35, DOI 10.1084/jem.20071311; Le Bras S, 2009, P NATL ACAD SCI USA, V106, P7519, DOI 10.1073/pnas.0806410106; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mahlaoui N, 2011, J PEDIATR-US, V158, P142, DOI 10.1016/j.jpeds.2010.07.027; Marrakchi S, 2011, NEW ENGL J MED, V365, P620, DOI 10.1056/NEJMoa1013068; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Morgan NV, 2011, J CLIN INVEST, V121, P695, DOI 10.1172/JCI41931; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; MYERSON RM, 1956, NEW ENGL J MED, V254, P1131, DOI 10.1056/NEJM195606142542406; Nehme NT, 2012, BLOOD, V119, P3458, DOI 10.1182/blood-2011-09-378364; Nolte MA, 2009, IMMUNOL REV, V229, P216, DOI 10.1111/j.1600-065X.2009.00774.x; Ombrello MJ, 2012, NEW ENGL J MED, V366, P330, DOI 10.1056/NEJMoa1102140; Onoufriadis A, 2011, AM J HUM GENET, V89, P432, DOI 10.1016/j.ajhg.2011.07.022; Orange JS, 2012, J CLIN INVEST, V122, P798, DOI 10.1172/JCI62620; Orth G, 2008, CURR TOP MICROBIOL, V321, P59; Patterson RL, 2005, TRENDS BIOCHEM SCI, V30, P688, DOI 10.1016/j.tibs.2005.10.005; Picard C, 2003, CURR OPIN ALLERGY CL, V3, P451, DOI 10.1097/01.all.0000104457.09202.c0; Pitha-Rowe IF, 2007, CYTOKINE GROWTH F R, V18, P409, DOI 10.1016/j.cytogfr.2007.06.017; Ramoz N, 2002, NAT GENET, V32, P579, DOI 10.1038/ng1044; Roger PM, 1999, CLIN INFECT DIS, V28, P1012, DOI 10.1086/514739; ROSE V, 1975, BRIT HEART J, V37, P840; Salmond RJ, 2009, IMMUNOL REV, V228, P9, DOI 10.1111/j.1600-065X.2008.00745.x; Salzer E, 2013, HAEMATOLOGICA, V98, P473, DOI 10.3324/haematol.2012.068791; Sancho-Shimizu V, 2007, CURR OPIN ALLERGY CL, V7, P495, DOI 10.1097/ACI.0b013e3282f151d2; Sancho-Shimizu V, 2011, CURR OPIN VIROL, V1, P487, DOI 10.1016/j.coviro.2011.10.016; Sancho-Shimizu V, 2011, J CLIN INVEST, V121, P4889, DOI 10.1172/JCI59259; Sawabe T, 2001, INT J MOL MED, V7, P609; Scheller J, 2011, TRENDS IMMUNOL, V32, P380, DOI 10.1016/j.it.2011.05.005; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Szakonyi G, 2001, SCIENCE, V292, P1725, DOI 10.1126/science.1059118; Thiel J, 2012, J ALLERGY CLIN IMMUN, V129, P801, DOI 10.1016/j.jaci.2011.09.027; Tybulewicz VLJ, 2009, NAT REV IMMUNOL, V9, P630, DOI 10.1038/nri2606; van Montfrans JM, 2012, J ALLERGY CLIN IMMUN, V129, P787, DOI 10.1016/j.jaci.2011.11.013; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; van Zelm MC, 2010, J CLIN INVEST, V120, P1265, DOI 10.1172/JCI39748; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; Viguier M, 2010, ANN INTERN MED, V153, P66, DOI 10.7326/0003-4819-153-1-201007060-00030; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Wada H, 2001, CIRCULATION, V103, P743; Wang JW, 2004, ONCOGENE, V23, P4089, DOI 10.1038/sj.onc.1207567; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Wei ML, 2006, PIGM CELL RES, V19, P19, DOI 10.1111/j.1600-0749.2005.00289.x; Whitley Richard J., 2002, Curr Treat Options Neurol, V4, P231, DOI 10.1007/s11940-002-0040-2; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; WISKOTT A, 1937, MONATSSCHR KINDERH, V68, P212; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; ZELICKSON BD, 1991, ARCH DERMATOL, V127, P1339, DOI 10.1001/archderm.127.9.1339; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhou Q, 2012, AM J HUM GENET, V91, P713, DOI 10.1016/j.ajhg.2012.08.006; Zhu LR, 2006, EUR J HUM GENET, V14, P17, DOI 10.1038/sj.ejhg.5201506	132	62	65	0	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					314	323		10.1016/j.jaci.2012.11.051	http://dx.doi.org/10.1016/j.jaci.2012.11.051			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23374262				2022-12-18	WOS:000314661500006
J	Chang, PJ; Bhavsar, PK; Michaeloudes, C; Khorasani, N; Chung, KF				Chang, Po-Jui; Bhavsar, Pankaj K.; Michaeloudes, Charalambos; Khorasani, Nadia; Chung, Kian Fan			Corticosteroid insensitivity of chemokine expression in airway smooth muscle of patients with severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway smooth muscle; asthma; corticosteroid insensitivity; CX3CL1; CCL11; CXCL8	PROTEIN MAP KINASE; N-TERMINAL KINASE; GLUCOCORTICOID-RECEPTOR; EOTAXIN EXPRESSION; TNF-ALPHA; T-CELLS; PHOSPHORYLATION; ACTIVATION; RESISTANCE; RELEASE	Background: Patients with severe asthma are less responsive to the beneficial effects of corticosteroid therapy. Objective: We investigated whether corticosteroid insensitivity was present in airway smooth muscle cells (ASMCs) of patients with severe asthma. Methods: ASMCs cultured from bronchial biopsy specimens of nonasthmatic control subjects (n = 12) and patients with nonsevere (n = 10) or severe (n = 10) asthma were compared for the effect of dexamethasone on suppression of TNF-alpha- and IFN-gamma-induced CCL11 (eotaxin), CXCL8 (IL-8), and CX3CL1 (fractalkine) expression. The mechanisms of corticosteroid insensitivity are also determined. Results: CCL11 release was higher in ASMCs of patients with nonsevere but not severe asthma and nonasthmatic control subjects; CXCL8 and CX3CL1 release were similar in all groups. In patients with severe asthma, dexamethasone caused less suppression of CCL11 and CXCL8 release induced by TNF-alpha. Dexamethasone potentiated TNF-alpha- and IFN-gamma-induced CX3CL1 release equally in all 3 groups. TNF-alpha-induced phosphorylated p38 mitogen-activated protein kinase levels were increased in ASMCs from patients with severe asthma compared with those from patients with nonsevere asthma and nonasthmatic subjects, whereas TNF-alpha-induced phosphorylated c-Jun N-terminal kinase and phosphorylated extracellular signal-related kinase levels were increased in all asthmatic groups. Ap38 inhibitor increased the inhibitory effect of dexamethasone. Conclusions: ASMCs of patients with severe asthma are corticosteroid insensitive; this might be secondary to heightened p38 mitogen-activated protein kinase levels. (J Allergy Clin Immunol 2012; 130:877-85.)	[Chang, Po-Jui; Bhavsar, Pankaj K.; Michaeloudes, Charalambos; Khorasani, Nadia; Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; [Chang, Po-Jui; Bhavsar, Pankaj K.; Michaeloudes, Charalambos; Khorasani, Nadia; Chung, Kian Fan] Royal Brompton NHS Fdn Trust, Biomed Res Unit, London, England; [Chang, Po-Jui] Chang Gung Univ, Dept Thorac Med, Chang Gung Mem Hosp Linkou, Coll Med, Tao Yuan, Taiwan	Imperial College London; Royal Brompton Hospital; Chang Gung Memorial Hospital; Chang Gung University	Chung, KF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk	Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012; Michaeloudes, Charalambos/H-5816-2013	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Michaeloudes, Charalambos/0000-0002-4107-4028	Wellcome Trust [085935]; Asthma UK [08/041]; Respiratory Disease Biomedical Research Unit at the Royal Brompton NHS Foundation Trust; Imperial College London; GlaxoSmithKline; Medical Research Council UK; Asthma UK; Wellcome Trust; Medical Research Council [G0801056B] Funding Source: researchfish	Wellcome Trust(Wellcome Trust); Asthma UK; Respiratory Disease Biomedical Research Unit at the Royal Brompton NHS Foundation Trust; Imperial College London(General Electric); GlaxoSmithKline(GlaxoSmithKline); Medical Research Council UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by project grants from the Wellcome Trust (085935), Asthma UK (08/041), and the Respiratory Disease Biomedical Research Unit at the Royal Brompton NHS Foundation Trust and Imperial College London. K.F.C. is a Senior Investigator of the National Institute for Health Research, United Kingdom.; P.K. Bhavsar has received support from GlaxoSmithKline. K.F. Chung is a consultant for Gilead; is an Advisory Board member for GlaxoSmithKline and Merck; has been supported by one or more grants from the Medical Research Council UK, Asthma UK, and the Wellcome Trust; and has received support from GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.	Banerjee A, 2008, BRIT J PHARMACOL, V155, P84, DOI 10.1038/bjp.2008.232; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Chan V, 2006, AM J RESP CRIT CARE, V174, P379, DOI 10.1164/rccm.200509-1420OC; Chung KF, 1999, BRIT J PHARMACOL, V127, P1145, DOI 10.1038/sj.bjp.0702660; Chung KF, 2011, CHEST, V139, P1470, DOI 10.1378/chest.10-1914; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; El-Shazly A, 2006, J IMMUNOL, V176, P1860, DOI 10.4049/jimmunol.176.3.1860; Garin A, 2002, BIOCHEM J, V368, P753, DOI 10.1042/BJ20020951; Heaney LG, 2005, LANCET, V365, P974, DOI 10.1016/S0140-6736(05)71087-4; Hew M, 2010, INTERN MED J, V40, P323, DOI 10.1111/j.1445-5994.2010.02192.x; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Ji GP, 2010, BIOCHEM BIOPH RES CO, V391, P547, DOI 10.1016/j.bbrc.2009.11.095; John AE, 2009, J IMMUNOL, V183, P4682, DOI 10.4049/jimmunol.0803832; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; John M, 1997, J IMMUNOL, V158, P1841; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474, DOI 10.1164/ajrccm.164.3.2010109; Johnson SR, 1997, TRENDS PHARMACOL SCI, V18, P288, DOI 10.1016/S0165-6147(97)01092-4; Li LB, 2004, J ALLERGY CLIN IMMUN, V114, P1059, DOI 10.1016/j.jaci.2004.08.005; Liu WM, 2008, J ALLERGY CLIN IMMUN, V121, P893, DOI 10.1016/j.jaci.2008.02.004; Macedo P, 2009, CLIN EXP ALLERGY, V39, P1668, DOI 10.1111/j.1365-2222.2009.03319.x; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Oltmanns U, 2008, PULM PHARMACOL THER, V21, P292, DOI 10.1016/j.pupt.2007.07.001; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Proceedings of the ATS workshop on refractory asthma, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Rimaniol AC, 2003, J ALLERGY CLIN IMMUN, V112, P1139, DOI 10.1016/j.jaci.2003.09.041; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Shen F, 2011, J CELL BIOCHEM, V112, P756, DOI 10.1002/jcb.23002; Sousa AR, 1999, J ALLERGY CLIN IMMUN, V104, P565, DOI 10.1016/S0091-6749(99)70325-8; Stirling RG, 2001, ALLERGY, V56, P825, DOI 10.1034/j.1398-9995.2001.00143.x; Sukkar MB, 2004, AM J PHYSIOL-LUNG C, V287, pL1230, DOI 10.1152/ajplung.00014.2004; Szatmary Z, 2004, J BIOL CHEM, V279, P43708, DOI 10.1074/jbc.M406568200; Trian T, 2007, J EXP MED, V204, P3173, DOI 10.1084/jem.20070956; Tsitoura DC, 2004, J CLIN INVEST, V113, P619, DOI 10.1172/JCI200418975; Wang SW, 1999, INFLAMM RES, V48, P533, DOI 10.1007/s000110050499; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025	41	62	65	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					877	+		10.1016/j.jaci.2012.07.017	http://dx.doi.org/10.1016/j.jaci.2012.07.017			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017MT	22947346	Green Accepted			2022-12-18	WOS:000309594800006
J	Rosas-Salazar, C; Apter, AJ; Canino, G; Celedon, JC				Rosas-Salazar, Christian; Apter, Andrea J.; Canino, Glorisa; Celedon, Juan C.			Health literacy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; health literacy; literacy; numeracy; health outcomes	DISPARITIES; INFORMATION; ADULTS; CARE; READABILITY; KNOWLEDGE; EDUCATION; NUMERACY; OUTCOMES; IMPACT	The report "Healthy people'' from the US Department of Health and Human Services defines health literacy (HL) as follows: "The degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.'' The same report identifies asthma as a public health problem of high priority. Unfortunately, impaired HL is prevalent in our society, and patients with low HL and asthma face multiple challenges as they attempt to manage their disease. Indeed, the National Asthma Education and Prevention Program's current guidelines require patients to have considerable HL and self-management skills. Numerous studies have linked inadequate literacy with poor health outcomes. Unlike many sociodemographic variables, HL can potentially be addressed in the health care setting. The purpose of this review is to raise awareness of the problem, summarize the current evidence linking HL and asthma, and offer strategies to strengthen the communication between patients and health care providers to decrease asthma health disparities. In addition, we discuss potential future directions for research in this field. (J Allergy Clin Immunol 2012;129:935-42.)	[Rosas-Salazar, Christian; Celedon, Juan C.] Univ Pittsburgh, Div Pediat Pulm Med Allergy & Immunol, Childrens Hosp Pittsburgh UPMC, Pittsburgh, PA 15260 USA; [Apter, Andrea J.] Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; [Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA; [Canino, Glorisa] Univ Puerto Rico, Dept Pediat, San Juan, PR 00936 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Pennsylvania; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Celedon, JC (corresponding author), 4401 Penn Ave, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu	Rosas-Salazar, Christian/AAC-8571-2021	Rosas-Salazar, Christian/0000-0001-6644-5780	National Institutes of Health/National Heart, Lung, and Blood Institute	National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	A. J. Apter receives research support from the National Institutes of Health/National Heart, Lung, and Blood Institute. J. C. Celedon is on the advisory board for Genentech and receives research support from the National Institutes of Health/National Heart, Lung, and Blood Institute. The rest of the authors declare that they have no relevant conflicts of interest.	Adams RJ, 2009, J ALLERGY CLIN IMMUN, V124, P601, DOI 10.1016/j.jaci.2009.05.035; Apter AJ, 2006, J ASTHMA, V43, P705, DOI 10.1080/02770900600925585; Apter AJ, 2009, PATIENT EDUC COUNS, V75, P386, DOI 10.1016/j.pec.2009.01.003; Apter AJ, 2008, J GEN INTERN MED, V23, P2117, DOI 10.1007/s11606-008-0803-x; Baker DW, 1999, PATIENT EDUC COUNS, V38, P33, DOI 10.1016/S0738-3991(98)00116-5; Baptist AP, 2011, J ASTHMA, V48, P133, DOI 10.3109/02770903.2010.535880; Berkman N. D., 2004, LITERACY HLTH OUTCOM; Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005; Birru MS, 2004, J MED INTERNET RES, V6, P66, DOI 10.2196/jmir.6.3.e25; Cabana MD, 2005, J ALLERGY CLIN IMMUN, V115, P1225, DOI 10.1016/j.jaci.2005.03.004; Canino G, 2009, J ALLERGY CLIN IMMUN, V123, P1209, DOI 10.1016/j.jaci.2009.02.043; Center for Disease Control and Prevention, NAT ASTHM CONTR PROG; Davis T C, 1993, Fam Med, V25, P391; Davis TC, 1998, HEALTH EDUC BEHAV, V25, P613, DOI 10.1177/109019819802500508; DeWalt DA, 2007, AMBUL PEDIATR, V7, P25, DOI 10.1016/j.ambp.2006.10.001; DeWalt Darren A, 2009, Pediatrics, V124 Suppl 3, pS265, DOI 10.1542/peds.2009-1162B; Federman AD, 2010, J ASTHMA, V47, P620, DOI 10.3109/02770901003702816; Forbis SG, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e52; Gazmararian JA, 2003, PATIENT EDUC COUNS, V51, P267, DOI 10.1016/S0738-3991(02)00239-2; Horner S D, 2000, J Community Health Nurs, V17, P15, DOI 10.1207/S15327655JCHN1701_02; Institute of Medicine, 2011, HLTH LIT IMPL HLTH C; Institute of Medicine, 2004, HLTH LITERACY PRESCR; Macy ML, 2011, PEDIATR EMERG CARE, V27, P469, DOI 10.1097/PEC.0b013e31821c98a8; Mancuso CA, 2006, J ASTHMA, V43, P41, DOI 10.1080/02770900500447052; Mancuso CA, 2006, J GEN INTERN MED, V21, P813, DOI 10.1111/j.1525-1497.2006.00528.x; Martin LT, 2011, JAMA-J AM MED ASSOC, V306, P874, DOI 10.1001/jama.2011.1212; National Academy on an Aging Society, HLTH LIT FACT SHEETS; National Asthma Education and Prevention Program, 2007, EXP PAN REP 3 GUID D; National Center for Education Statistics, 2005, NAT ASS AD LIT NAAL; Paasche-Orlow MK, 2007, AM J HEALTH BEHAV, V31, pS19; Paasche-Orlow MK, 2005, AM J RESP CRIT CARE, V172, P980, DOI 10.1164/rccm.200409-1291OC; Parikh NS, 1996, PATIENT EDUC COUNS, V27, P33, DOI 10.1016/0738-3991(95)00787-3; PARKER RM, 1995, J GEN INTERN MED, V10, P537, DOI 10.1007/BF02640361; Parker RM, 1999, JAMA-J AM MED ASSOC, V281, P552; Poureslami Iraj M, 2007, MedGenMed, V9, P40; Roberts NJ, 2010, PATIENT EDUC COUNS, V80, P141, DOI 10.1016/j.pec.2009.09.040; Robinson LD, 2008, J NATL MED ASSOC, V100, P892, DOI 10.1016/S0027-9684(15)31401-2; Rosenfeld L, 2011, PATIENT EDUC COUNS, V82, P110, DOI 10.1016/j.pec.2010.02.023; Rudd Rima E, 2004, Health Promot Pract, V5, P334, DOI 10.1177/1524839903257771; Shone LP, 2009, PATIENT EDUC COUNS, V75, P368, DOI 10.1016/j.pec.2009.01.004; Smith H, 1998, BRIT MED J, V317, P264, DOI 10.1136/bmj.317.7153.264; Sobel RM, 2009, J COMMUN HEALTH, V34, P321, DOI 10.1007/s10900-009-9153-9; Sudore RL, 2006, J GEN INTERN MED, V21, P806, DOI 10.1111/j.1525-1497.2006.00539.x; US Department of Health and Human Services, 2000, HLTH PEOPL 2010; Vargas PA, 2010, J ASTHMA, V47, P889, DOI 10.3109/02770903.2010.497887; Villaire M., 2007, HLTH LITERACY PRIMAR; Weiss BD, 2005, ANN FAM MED, V3, P514, DOI 10.1370/afm.405; Weiss BD., 2007, HLTH LITERACY MANUAL; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008; Wittich AR, 2007, J ASTHMA, V44, P51, DOI 10.1080/02770900601125672; Wood MR, 2010, J PEDIATR NURS, V25, P418, DOI 10.1016/j.pedn.2009.05.003	51	62	62	3	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					935	942		10.1016/j.jaci.2012.01.040	http://dx.doi.org/10.1016/j.jaci.2012.01.040			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	917AP	22326486				2022-12-18	WOS:000302144600007
J	Sturm, GJ; Hemmer, W; Hawranek, T; Lang, R; Ollert, M; Spillner, E; Blank, S; Bokanovic, D; Aberer, W				Sturm, Gunter J.; Hemmer, Wolfgang; Hawranek, Thomas; Lang, Roland; Ollert, Markus; Spillner, Edzard; Blank, Simon; Bokanovic, Danijela; Aberer, Werner			Detection of IgE to recombinant Api m 1 and rVes v 5 is valuable but not sufficient to distinguish bee from wasp venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Sturm, Gunter J.; Bokanovic, Danijela; Aberer, Werner] Med Univ Graz, Dept Dermatol, Div Environm Dermatol & Venerol, Graz, Austria; [Hemmer, Wolfgang] Floridsdorf Allergy Ctr, Vienna, Austria; [Hawranek, Thomas; Lang, Roland] Paracelsus Private Med Univ, Dept Dermatol, Salzburg, Austria; [Ollert, Markus] Biederstein Tech Univ Munchen, Dept Dermatol & Allergy, Munich, Germany; [Spillner, Edzard; Blank, Simon] Univ Hamburg, Dept Chem, Inst Biochem & Mol Biol, Hamburg, Germany	Medical University of Graz; Paracelsus Private Medical University; Technical University of Munich; University of Hamburg	Sturm, GJ (corresponding author), Med Univ Graz, Dept Dermatol, Div Environm Dermatol & Venerol, Graz, Austria.	gunter.sturm@medunigraz.at	Blank, Simon/M-7708-2013; Spillner, E./G-3799-2010	Ollert, Markus W./0000-0002-8055-0103; spillner, edzard/0000-0003-0999-5254				Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V127, P265, DOI 10.1016/j.jaci.2010.06.042; Korosec P, 2009, CLIN EXP ALLERGY, V39, P1730, DOI 10.1111/j.1365-2222.2009.03347.x; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Seismann Henning, 2010, Clin Mol Allergy, V8, P7, DOI 10.1186/1476-7961-8-7; Seismann H, 2010, MOL IMMUNOL, V47, P799, DOI 10.1016/j.molimm.2009.10.005; Sturm GJ, 2007, ALLERGY, V62, P884, DOI 10.1111/j.1398-9995.2007.01413.x	7	62	62	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					247	248		10.1016/j.jaci.2011.02.021	http://dx.doi.org/10.1016/j.jaci.2011.02.021			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21439627				2022-12-18	WOS:000292245600044
J	Bisgaard, H; Pipper, CB; Bonnelykke, K				Bisgaard, Hans; Pipper, Christian Bressen; Bonnelykke, Klaus			Endotyping early childhood asthma by quantitative symptom assessment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; young children; patterns; endotypes; ORMDL3; symptoms	LEUKOTRIENE RECEPTOR ANTAGONIST; PRESCHOOL-CHILDREN; RESPIRATORY SYMPTOMS; BIRTH COHORT; INFANTS; VIDEO; PHENOTYPES; PARENTS; WHEEZE; AIRWAY	Background: Asthmatic symptoms in young children reflect a heterogeneous group of diseases. Symptoms remain the primary end-point in both research and clinical management, but there is a need for standardized symptom assessment. Objective: We sought to explore endotyping of early childhood asthma by prospective daily diary recordings of globally assessed symptoms during the first 6 years of life. Methods: Globally assessed troublesome lung symptoms were recorded in daily diaries during the first 6 years of life in the Copenhagen Prospective Studies on Asthma in Childhood birth cohort born of mothers with asthma. Symptom recordings adjusted for missing values were used to categorize children based on the temporal symptom pattern. We propose an alternative approach of quantitating symptom frequency and longitudinal assessment of age-at-onset to segment children. These different methods were compared by estimating the risk from the well-established genetic risk variants of ORMDL3. Results: Six years of daily diary recordings were available in 307 children (75% of the birth cohort). We confirmed the archetypal temporal categories of transient early, persistent, and late-onset troublesome lung symptoms based on 3-year periods, finding no benefit from a finer temporal categorization of 2- or 1-year periods. Restricting categorization to symptoms during the summer improved specificity at the expense of sensitivity. Our alternative approach quantitating symptom frequency and age-at-onset exhibited a more powerful association with ORMDL3, whereas the study power was lost by restricting to doctor-verified wheeze. Conclusions: We propose a novel method for endotyping of early childhood asthma based on the frequency and age-of-onset of globally assessed troublesome lung symptoms analyzed longitudinally. This method showed the closest association with genetic variants, hence underlying molecular mechanisms and endotypes. (J Allergy Clin Immunol 2011;127:1155-64.)	[Bisgaard, Hans] Univ Copenhagen, DK-2820 Copenhagen, Denmark; Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, DK-2820 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen	Bisgaard, H (corresponding author), Univ Copenhagen, Ledreborg Alle 34, DK-2820 Copenhagen, Denmark.	Bisgaard@copsac.com	Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592; Pipper, Christian Bressen/0000-0003-0261-616X; Bonnelykke, Klaus/0000-0003-2003-1018	Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden)		Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; BISGAARD H, 1990, LANCET, V336, P649, DOI 10.1016/0140-6736(90)92147-A; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P126, DOI 10.1164/ajrccm.160.1.9811024; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2010, BMJ-BRIT MED J, V341; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Bush A, 2009, NEW ENGL J MED, V360, P409, DOI 10.1056/NEJMe0808951; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Cane RS, 2001, ARCH DIS CHILD, V84, P31, DOI 10.1136/adc.84.1.31; Crane J, 2003, EUR RESPIR J, V21, P455, DOI 10.1183/09031936.03.00041403; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Knorr B, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e48; Kocevar VS, 2004, CHEST, V125, P1680, DOI 10.1378/chest.125.5.1680; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MESLIER N, 1995, EUR RESPIR J, V8, P1942, DOI 10.1183/09031936.95.08111942; Michel G, 2006, EUR RESPIR J, V28, P1124, DOI 10.1183/09031936.06.00008406; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Mohangoo AD, 2010, PEDIATR PULM, V45, P500, DOI 10.1002/ppul.21208; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Smith JA, 2008, AM J RESP CRIT CARE, V177, P1358, DOI 10.1164/rccm.200709-1419OC; Sorensen M, 2007, BIOMARKERS, V12, P38, DOI 10.1080/13547500600943148; Thomsen SF, 2010, J ALLERGY CLIN IMMUN, V126, P626, DOI 10.1016/j.jaci.2010.06.017; Van Sickle D, 2005, EUR RESPIR J, V26, P829, DOI 10.1183/09031936.05.00027205; Warren P, 2006, LANCET, V368, P1416, DOI 10.1016/S0140-6736(06)69596-2; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8	32	62	62	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1155	U428		10.1016/j.jaci.2011.02.007	http://dx.doi.org/10.1016/j.jaci.2011.02.007			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21439619				2022-12-18	WOS:000290018600009
J	Valenta, R; Niespodziana, K; Focke-Tejkl, M; Marth, K; Huber, H; Neubauer, A; Niederberger, V				Valenta, Rudolf; Niespodziana, Katarzyna; Focke-Tejkl, Margit; Marth, Katharina; Huber, Hans; Neubauer, Angela; Niederberger, Verena			Recombinant allergens: What does the future hold?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergen-specific immunotherapy; recombinant allergen	GRASS-POLLEN ALLERGEN; HAY-FEVER; IMMUNOTHERAPY; VACCINATION; PEPTIDES; VACCINES; BET-V-1	This year we are celebrating not only the centenary of allergen-specific immunotherapy but also the 10-year anniversary of the first administration of recombinant allergen-based vaccines to allergic patients. By using recombinant DNA technology, defined and safe allergy vaccines can be produced that allow us to overcome many, if not all, of the problems associated with the use of natural allergen extracts, such as insufficient quality, allergenic activity, and poor immunogenicity. Here we provide an update of clinical studies with recombinant allergen-based vaccines, showing that some of these vaccines have undergone successful clinical evaluation up to phase III studies. Furthermore, we introduce a strategy for allergen-specific immunotherapy based on recombinant fusion proteins consisting of viral carrier proteins and allergen-derived peptides without allergenic activity, which holds the promise of being free of side effects and eventually being useful for prophylactic vaccination. (J Allergy Clin Immunol 2011;127:860-4.)	[Valenta, Rudolf; Focke-Tejkl, Margit; Marth, Katharina] Med Univ Vienna, Christian Doppler Lab Allergy Res, A-1090 Vienna, Austria; [Valenta, Rudolf; Niespodziana, Katarzyna] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, A-1090 Vienna, Austria; [Niederberger, Verena] Med Univ Vienna, Dept ENT, A-1090 Vienna, Austria; [Huber, Hans; Neubauer, Angela] Biomay AG, Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Valenta, R (corresponding author), Med Univ Vienna, Christian Doppler Lab Allergy Res, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at		Valenta, Rudolf/0000-0001-5944-3365	Austrian Science Fund (FWF) [F1815, F1818]; Christian Doppler Research Association; Biomay, Vienna, Austria	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Christian Doppler Research Association; Biomay, Vienna, Austria	Supported by grants F1815 and F1818 of the Austrian Science Fund (FWF), by the Christian Doppler Research Association, and by a research grant from Biomay, Vienna, Austria.; Disclosure of potential conflict of interest: R. Valenta receives research support from the Austrian Science Fund, the Christian Doppler Research Association, Biomay, and Phadia and has provided legal consultation services/expert witness testimony in cases related to allergy diagnostics and allergy therapeutics. V. Niederberger receives research support from the Austrian Science Fund. The rest of the authors have declared that they have no conflict of interest.	Campana R, 2008, J ALLERGY CLIN IMMUN, V121, P528, DOI 10.1016/j.jaci.2007.09.014; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Edlmayr J, 2009, J IMMUNOL, V182, P6298, DOI 10.4049/jimmunol.0713622; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; KATZ DH, 1970, J EXP MED, V132, P261, DOI 10.1084/jem.132.2.261; KLIMEK L, 2005, ALLERGY CLIN IMMUN S, V1, P15; Kundig TM, 2006, J ALLERGY CLIN IMMUN, V117, P1470, DOI 10.1016/j.jaci.2006.01.040; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Linhart B, 2005, J ALLERGY CLIN IMMUN, V115, P1010, DOI 10.1016/j.jaci.2004.12.1142; MARSH DG, 1970, IMMUNOLOGY, V18, P705; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niespodziana K, 2011, J ALLERGY C IN PRESS; Noon L, 1911, LANCET, V1, P1572; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pree I, 2010, CLIN EXP ALLERGY, V40, P1346, DOI 10.1111/j.1365-2222.2010.03548.x; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; RAK S, 2009, 27 C EUR AC ALL CLIN; TWAROCH T, 2011, J ALLERGY C IN PRESS; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; Winther L, 2009, J ALLERGY CLIN IMMUN, V123, pS215, DOI 10.1016/j.jaci.2008.12.822	24	62	74	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					860	864		10.1016/j.jaci.2011.02.016	http://dx.doi.org/10.1016/j.jaci.2011.02.016			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21458656	Bronze			2022-12-18	WOS:000289055800005
J	Price, D; Martin, RJ; Barnes, N; Dorinsky, P; Israel, E; Roche, N; Chisholm, A; Hillyer, EV; Kemp, L; Lee, AJ; von Ziegenweidt, J; Colice, G				Price, David; Martin, Richard J.; Barnes, Neil; Dorinsky, Paul; Israel, Elliot; Roche, Nicolas; Chisholm, Alison; Hillyer, Elizabeth V.; Kemp, Linda; Lee, Amanda J.; von Ziegenweidt, Julie; Colice, Gene			Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: A real-world observational study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; database; fluticasone; hydrofluoroalkane-beclomethasone; inhaled corticosteroid; observational study	MILD PERSISTENT ASTHMA; HFA-BECLOMETHASONE; CHLOROFLUOROCARBON BECLOMETHASONE; CONTROLLED-TRIALS; INHALED STEROIDS; LUNG DEPOSITION; SMALL AIRWAYS; BUDESONIDE; PROPIONATE; FORMOTEROL	Background: Long-term randomized trials comparing asthma outcomes between inhaled corticosteroids in real-world populations are lacking. As such, rigorously conducted observational studies to complement the findings of randomized trials are needed. Objective: We sought to compare asthma-related outcomes over 1 year as recorded in a large primary care database for patients aged 5 to 60 years receiving a first prescription (initiation population) or dose increase (step-up population) of hydrofluoroalkane (HFA)-beclomethasone or fluticasone. Methods: We used a retrospective matched cohort study in which patients were matched on baseline demographic and disease severity measures. Coprimary outcomes were asthma control (a composite measure comprising no unplanned visit or hospitalization for asthma, oral corticosteroids, or antibiotics for lower respiratory tract infection) and exacerbation rate. Results: More than 80% of patients in each population achieved asthma control; 10% and 16% of patients in the initiation and step-up populations, respectively, received add-on or combination therapy during the year. Fluticasone was prescribed at significantly higher doses than HFA-beclomethasone for both populations (P <=.001). In the initiation population (n = 1319 in each cohort) the adjusted odds ratio for achieving asthma control with HFA-beclomethasone was 1.30 (95% CI, 1.02-1.65) relative to fluticasone. In the step-up population (cohorts: n 5 250) the adjusted odds ratio for achieving asthma control with HFA-beclomethasone was 1.22 (95% CI, 0.66-2.26). Exacerbation rates were similar between cohorts. Conclusions: In a real-world setting patients receiving HFA-beclomethasone had a similar or better chance of achieving asthma control at lower prescribed doses than with fluticasone. (J Allergy Clin Immunol 2010;126:511-8.)	[Price, David] Univ Aberdeen, Ctr Acad Primary Care, Foresterhill Hlth Ctr, Aberdeen AB25 2AY, Scotland; [Price, David; Chisholm, Alison; Hillyer, Elizabeth V.; Kemp, Linda; von Ziegenweidt, Julie] Res Real Life, Norwich, Norfolk, England; [Martin, Richard J.] Natl Jewish Hlth, Denver, CO USA; [Barnes, Neil] Barts & London NHS Trust, London Chest Hosp, Barts, England; [Dorinsky, Paul] Teva Global Resp Res & Dev, Horsham, PA USA; [Israel, Elliot] Brigham & Womens Hosp, Boston, MA 02115 USA; [Israel, Elliot] Harvard Univ, Sch Med, Boston, MA USA; [Roche, Nicolas] Hop Hotel Dieu, Paris, France; [Lee, Amanda J.] Univ Aberdeen, Sect Populat Hlth, Aberdeen AB9 1FX, Scotland; [Colice, Gene] Washington Hosp Ctr, Washington, DC 20010 USA; [Colice, Gene] George Washington Univ, Sch Med, Washington, DC USA	University of Aberdeen; National Jewish Health; Barts Health NHS Trust; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Aberdeen; MedStar Washington Hospital Center; George Washington University	Price, D (corresponding author), Univ Aberdeen, Ctr Acad Primary Care, Foresterhill Hlth Ctr, Westburn Rd, Aberdeen AB25 2AY, Scotland.	david@respiratoryresearch.org	Roche, Nicolas/AAP-4445-2021; Roche, Nicolas/AAE-9206-2021; Price, David/H-2837-2019	Price, David/0000-0002-9728-9992; roche, nicolas/0000-0002-3162-5033; Hillyer, Elizabeth/0000-0003-3022-5692; Chisholm, Alison/0000-0001-9197-8159	Merck Co, Inc; Teva Pharmaceuticals Limited; Boehringer Ingelheim; GlaxoSmithKline; Merck; Sharpe and Dohme; Pfizer; Schering-Plough; Altana Pharma; Chiesi; UK National Health Centre; Aerocrine; AstraZeneca; Novartis; Teva; NHLBI/NIH; Aerovance; Amgen; Ception Therapeutics; Genentech; Icagen; Johnson Johnson; MedImmune; National Institutes of Health	Merck Co, Inc(Merck & Company); Teva Pharmaceuticals Limited(Teva Pharmaceutical Industries); Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Sharpe and Dohme; Pfizer(Pfizer); Schering-Plough(Merck & CompanySchering Plough Corporation); Altana Pharma; Chiesi(Chiesi Pharmaceuticals Inc); UK National Health Centre; Aerocrine; AstraZeneca(AstraZeneca); Novartis(Novartis); Teva(Teva Pharmaceutical Industries); NHLBI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Aerovance; Amgen(Amgen); Ception Therapeutics; Genentech(Roche HoldingGenentech); Icagen; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); MedImmune(AstraZenecaMedimmune); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Access to data from the General Practice Research Database was funded by Merck & Co, Inc, and the analysis was funded by Teva Pharmaceuticals Limited.; Disclosure of potential conflict of interest: D. Price is a consultant for Aerocrine, Boehringer Ingelheim, Dey Pharmaceuticals, GlaxoSmithKline, Merck, Merck Generics, Sharpe and Dohme, Novartis, Schering-Plough, Teva, Bayer (antibiotic study design); has spoken at meetings sponsored by Boehringer Ingelheim, GlaxoSmithKline, Merck, Sharpe and Dohme, Pfizer, Schering-Plough, Altana Pharma, and Chiesi; has received research support from UK National Health Centre, Aerocrine, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Sharpe and Dohme, Novartis, Pfizer, Schering-Plough, and Teva. R. J. Martin is a lecturer and consultant for Teva; is a consultant for AstraZeneca, Novartis/Genentech, Schering, Cypress BioScience, Phase to Phase and Common Health, and the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH); and has received research support from the NHLBI/NIH. N. Barnes has provided lectured consultancy for GlaxoSmithKline, AstraZeneca, Chiesi, Boehringer, Teva, and Nycomed and has received research support from GlaxoSmithKline, Novartis, and Schering-Plough. E. Israel is a consultant for Abbott, Amgen, Cowen & Co, GlaxoSmithKline, Icagen, MedImmune, Merck, NewMentor, NKT Therapeutics, Ono Pharmaceuticals US, Pulmatrix, Schering-Plough, and Teva Specialty Pharmaceuticals and has received research support from Aerovance, Amgen, Ception Therapeutics, Genentech, Icagen, Johnson & Johnson, MedImmune, National Institutes of Health, and Novartis. E. V. Hillyer has done freelance writing for Merck, Aerocrine, and Teva Sante (France). G. Colice has served as a consultant/speaker for Teva, Dey, BT, GlaxoSmithKline, Vakera, Skye Pharma, and MedImmune and has served as an expert witness on the topic of long-acting beta-agonists. The rest of the authors have declared that they have no conflict of interest.	Aubier M, 2001, RESP MED, V95, P212, DOI 10.1053/rmed.2000.1025; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Black PN, 2000, EUR J CLIN PHARMACOL, V56, P431, DOI 10.1007/s002280000140; *BOST COLL DRUG SU, BOST COLL DRUG SURV; British Thoracic Society / Scottish Intercollegiate Guidelines Network, 2009, BRIT GUID MAN ASTHM; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Fairfax A, 2001, ANN ALLERG ASTHMA IM, V86, P575, DOI 10.1016/S1081-1206(10)62907-9; Fanta CH, 2009, NEW ENGL J MED, V360, P1002, DOI 10.1056/NEJMra0804579; Gibson PG, 2007, J ALLERGY CLIN IMMUN, V119, P344, DOI 10.1016/j.jaci.2006.10.043; Global Strategy for Asthma Management and Prevention, 2009, GLOB STRAT ASTHM MAN; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258, DOI 10.1016/S0091-6749(99)70043-6; Hall Jason, 2003, N Z Med J, V116, pU563; Herland K, 2005, RESP MED, V99, P11, DOI 10.1016/j.rmed.2004.03.026; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1551, DOI 10.1164/ajrccm.163.7.2008013; Lasserson TJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005309.pub3; Leach CL, 2005, J AEROSOL MED, V18, P379, DOI 10.1089/jam.2005.18.379; Leach CL, 2002, CHEST, V122, P510, DOI 10.1378/chest.122.2.510; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Martin RJ, 2002, J ALLERGY CLIN IMMUN, V109, pS447, DOI 10.1067/mai.2002.121409; Masoli M, 2004, THORAX, V59, P16; National Asthma Education and Prevention Program, 2007, HYPERLIPIDAEMIA; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Schirm E, 2006, BRIT J CLIN PHARMACO, V62, P383, DOI 10.1111/j.1365-2125.2006.02699.x; Shepherd J, 2008, HEALTH TECHNOL ASSES, V12, P1; Sindi A, 2009, CHEST, V136, P145, DOI 10.1378/chest.08-2149; Thomas M, 2003, EXPERT OPIN PHARMACO, V4, P351, DOI 10.1517/14656566.4.3.351; Thongngarm T, 2005, J ASTHMA, V42, P257, DOI 10.1081/JAS-200057888; Travers J, 2007, THORAX, V62, P219, DOI 10.1136/thx.2006.066837; Turner S, 2009, ARCH DIS CHILD, V94, P16, DOI 10.1136/adc.2008.140681; Verbanck S, 2006, J ALLERGY CLIN IMMUN, V118, P340, DOI 10.1016/j.jaci.2006.04.056; Virchow JC, 2008, RESP MED, V102, P10, DOI 10.1016/j.rmed.2007.07.031; Weatherall M, 2010, THORAX, V65, P39, DOI 10.1136/thx.2009.116608; Wijesinghe M, 2009, EUR RESPIR J, V34, P803, DOI 10.1183/09031936.00159708; Wong ICK, 2005, BRIT J CLIN PHARMACO, V59, P750, DOI 10.1111/j.1365-2125.2005.02450.x; Yamaguchi M, 2009, PULM PHARMACOL THER, V22, P326, DOI 10.1016/j.pupt.2009.01.005; GEN PRACTICE RES DAT	40	62	64	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					511	U186		10.1016/j.jaci.2010.06.040	http://dx.doi.org/10.1016/j.jaci.2010.06.040			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20692026				2022-12-18	WOS:000281512500016
J	Lange, NE; Rifas-Shiman, SL; Camargo, CA; Gold, DR; Gillman, MW; Litonjua, AA				Lange, Nancy E.; Rifas-Shiman, Sheryl L.; Camargo, Carlos A., Jr.; Gold, Diane R.; Gillman, Matthew W.; Litonjua, Augusto A.			Maternal dietary pattern during pregnancy is not associated with recurrent wheeze in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; dietary pattern; Mediterranean diet; healthy diet; principal components; childhood wheeze; pregnancy	MAJOR CHRONIC DISEASE; OBSTRUCTIVE PULMONARY-DISEASE; GUIDELINES-FOR-AMERICANS; MEDITERRANEAN DIET; VITAMIN-D; ANTIOXIDANT INTAKE; FOOD-CONSUMPTION; ASTHMA; RISK; ECZEMA	Background: The rise in asthma prevalence over the last few decades may be a result of changes in prenatal or early-life environment, including maternal diet during pregnancy. Previous studies have found associations between individual foods or nutrients consumed during pregnancy and asthma or wheeze in children, but these may be confounded by overall dietary pattern. Objective: To determine whether overall maternal dietary pattern during pregnancy is associated with recurrent wheeze in children. Methods: A total of 1376 mother-infant pairs from Project Viva, a longitudinal prebirth cohort, who had responses for food frequency questionnaires in the first and second trimester and outcome data at 3 years of age were included. Multivariable logistic regression was used to look at associations between dietary pattern and the primary outcome of recurrent wheeze at 3 years. Overall dietary pattern was examined by using Mediterranean diet score, Alternate Healthy Eating Index modified for pregnancy (AHEI-P), and principal components analysis to look at Western and Prudent diets. Results: None of these dietary patterns was associated with the primary outcome of recurrent wheeze in children in either the crude or the multivariable model (multivariable model, odds ratio per 1-point increase in Mediterranean diet, 0.98 [95% CI, 0.89-1.08]; AHEI-P, 1.07 [0.87-1.30]; Prudent, 1.02 [0.83-1.26]; Western, 0.98 [0.81-1.19]). Conclusion: Overall dietary pattern during pregnancy is not associated with recurrent wheeze in this cohort. Maternal intake of individual nutrients may be more important determinants of offspring wheeze-associated illness than is dietary pattern. (J Allergy Clin Immunol 2010;126:250-5.)	[Lange, Nancy E.; Camargo, Carlos A., Jr.; Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Lange, Nancy E.; Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Lange, Nancy E.; Gold, Diane R.; Litonjua, Augusto A.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA; [Rifas-Shiman, Sheryl L.; Gillman, Matthew W.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA; [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Gillman, Matthew W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Lange, NE (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	nlange@partners.org	Camargo, Carlos A./C-2145-2008	Camargo, Carlos A./0000-0002-5071-7654; Litonjua, Augusto/0000-0003-0422-5875	NIH [HL61907, HL64925, HD34568, AI35786, HL68041, HL007427]; AstraZeneca; Dey; GlaxoSmithKline; Merck; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD034568, R01HD034568] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064925, R01HL061907, K24HL068041, T32HL007427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786, R56AI035786] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AstraZeneca(AstraZeneca); Dey; GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by NIH HL61907, HL64925, HD34568, AI35786, HL68041, and HL007427.; C. A. Camargo Jr is a consultant and speaker for AstraZeneca; is on the advisory board for Dey; is a consultant, is a speaker, and is on the advisory board for GlaxoSmithKline; is a speaker of Merck; is a consultant and is on the advisory board for Novartis; and has received research support from the National Institutes of Health, AstraZeneca, Dey, GlaxoSmithKline, and Merck. D. R. Gold has received research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Baker Elizabeth A, 2006, Prev Chronic Dis, V3, pA76; Bakolis I, 2010, ALLERGY, V65, P606, DOI 10.1111/j.1398-9995.2009.02215.x; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez JA, 2008, J PEDIATR-US, V152, P823, DOI 10.1016/j.jpeds.2008.01.003; Chatzi L, 2008, THORAX, V63, P507, DOI 10.1136/thx.2007.081745; Chatzi L, 2007, THORAX, V62, P677, DOI 10.1136/thx.2006.069419; de Batlle J, 2008, ALLERGY, V63, P1310, DOI 10.1111/j.1398-9995.2008.01722.x; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Devereux G, 2006, AM J RESP CRIT CARE, V174, P499, DOI 10.1164/rccm.200512-1946OC; Fawzi WW, 2004, ANN EPIDEMIOL, V14, P754, DOI 10.1016/j.annepidem.2004.03.001; Fung TT, 2007, DIABETES CARE, V30, P1753, DOI 10.2337/DC06-2581; Garcia-Marcos L, 2007, THORAX, V62, P503, DOI 10.1136/thx.2006.060020; Gillman MW, 2005, NEW ENGL J MED, V353, P1848, DOI 10.1056/NEJMe058187; Gillman MW, 2004, J PEDIATR-US, V144, P240, DOI 10.1016/j.jpeds.2003.10.064; Hooper R, 2010, BRIT J NUTR, V103, P1354, DOI 10.1017/S0007114509993266; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Jacobs DR, 2003, AM J CLIN NUTR, V78, p508S, DOI 10.1093/ajcn/78.3.508S; Joshi S, 2007, EARLY HUM DEV, V83, P789, DOI 10.1016/j.earlhumdev.2007.09.007; Kennedy E, 1996, J AM DIET ASSOC, V96, P234, DOI 10.1016/S0002-8223(96)00072-7; Kleinbaum D, 1988, APPL REGRESSION ANAL; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Litonjua AA, 2006, AM J CLIN NUTR, V84, P903, DOI 10.1093/ajcn/84.4.903; Lu Z, 2007, J STEROID BIOCHEM, V103, P642, DOI 10.1016/j.jsbmb.2006.12.010; Ly NP, 2006, PEDIATRICS, V117, pE1132, DOI 10.1542/peds.2005-2271; Martindale S, 2005, AM J RESP CRIT CARE, V171, P121, DOI 10.1164/rccm.200402-220OC; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; McCullough ML, 2000, AM J CLIN NUTR, V72, P1223; McCullough ML, 2000, AM J CLIN NUTR, V72, P1214; McCullough ML, 2002, AM J CLIN NUTR, V76, P1261, DOI 10.1093/ajcn/76.6.1261; Miyake Y, 2010, ALLERGY, V65, P758, DOI 10.1111/j.1398-9995.2009.02267.x; Miyake Y, 2009, THORAX, V64, P815, DOI 10.1136/thx.2009.115931; Navarro-Alarcon M, 2008, SCI TOTAL ENVIRON, V400, P115, DOI 10.1016/j.scitotenv.2008.06.024; Northstone K, 2008, EUR J CLIN NUTR, V62, P471, DOI 10.1038/sj.ejcn.1602741; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Radesky JS, 2008, PAEDIATR PERINAT EP, V22, P47, DOI 10.1111/j.1365-3016.2007.00899.x; Rifas-Shiman SL, 2009, J AM DIET ASSOC, V109, P1004, DOI 10.1016/j.jada.2009.03.001; Rifas-Shiman SL, 2006, PAEDIATR PERINAT EP, V20, P35, DOI 10.1111/j.1365-3016.2006.00691.x; Robison R, 2010, CURR OPIN ALLERGY CL, V10, P139, DOI 10.1097/ACI.0b013e32833667a8; Romieu I, 2007, CLIN EXP ALLERGY, V37, P518, DOI 10.1111/j.1365-2222.2007.02685.x; Romieu I, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-122; Salam MT, 2005, J ASTHMA, V42, P513, DOI 10.1081/JAS-200067619; Sausenthaler S, 2007, AM J CLIN NUTR, V85, P530; Shaheen SO, 2009, THORAX, V64, P411, DOI 10.1136/thx.2008.104703; Taveras EM, 2008, J ALLERGY CLIN IMMUN, V121, P1161, DOI 10.1016/j.jaci.2008.03.021; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Tricon S., 2006, Clinical and Experimental Allergy Reviews, V6, P117, DOI 10.1111/j.1365-2222.2006.00114.x; Varraso R, 2009, EUR RESPIR J, V33, P33, DOI 10.1183/09031936.00130807; Varraso R, 2007, THORAX, V62, P786, DOI 10.1136/thx.2006.074534; Varraso R, 2007, AM J CLIN NUTR, V86, P488, DOI 10.1093/ajcn/86.2.488; WHITELAW A, 1988, BRIT MED BULL, V44, P1037, DOI 10.1093/oxfordjournals.bmb.a072288; Willers SM, 2007, THORAX, V62, P773, DOI 10.1136/thx.2006.074187; Willers SM, 2008, AM J RESP CRIT CARE, V178, P124, DOI 10.1164/rccm.200710-1544OC; Willett W, 2012, NUTR EPIDEMIOLOGY	54	62	63	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					250	U13		10.1016/j.jaci.2010.05.009	http://dx.doi.org/10.1016/j.jaci.2010.05.009			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20584543	Green Accepted			2022-12-18	WOS:000281203800008
J	Kariyawasam, HH; Pegorier, S; Barkans, J; Xanthou, G; Aizen, M; Ying, S; Kay, AB; Lloyd, CM; Robinson, DS				Kariyawasam, Harsha H.; Pegorier, Sophie; Barkans, Julia; Xanthou, Georgina; Aizen, Maxine; Ying, Sun; Kay, A. Barry; Lloyd, Clare M.; Robinson, Douglas S.			Activin and transforming growth factor-beta signaling pathways are activated after allergen challenge in mild asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; activin-A; TGF-beta(1)	TGF-BETA; AIRWAY HYPERRESPONSIVENESS; BINDING-PROTEIN; MESSENGER-RNA; T-CELLS; EXPRESSION; CYTOKINE; RECEPTOR; NEUTROPHILS; FOLLISTATIN	Background: Both transforming growth factor (TGF)-beta 1 and activin-A have been implicated in airway remodeling in asthma, but the modulation of their specific signaling pathways after disease activation remains undefined. Objective: To define the expression kinetics of TGF-beta(1), activin-A ligands, and follistatin (a natural activin inhibitor), their type I and type II receptors (activin-like kinase[ALK]-1, ALK-5, ALK-4, TbRII, and ActRIIA/RIIB) and activation of signaling (via phosphorylated (p) Smad2), in the asthmatic airway after allergen challenge. Methods: Immunohistochemistry was performed on bronchial biopsies from 15 mild atopic patients with asthma (median age, 25 years; median FEV1% predicted, 97%) at baseline and 24 hours after allergen inhalation. Functional effects of activin-A were evaluated by using cultured normal human bronchial epithelial (NHBE) cells. Results: pSmad2(+) epithelial cells increased at 24 hours (P = .03), and pSmad2 was detected in submucosal cells. No modulation of activin-A, follistatin, or TGF-beta(1) expression was demonstrated. Activin receptor 1 cells increased after allergen challenge: ALK-4 in epithelium (P = .04) and submucosa (P = .04), and ActRIIA in epithelium (P = .01). The TGF-beta receptor ALK-5 expression was minimal in the submucosa at baseline and after challenge and was downregulated in the epitheliumafter challenge (P = .02), whereas ALK-1 and T beta RII expression in the submucosa increased after allergen challenge (P = .03 and P = .004, respectively). ALK-1 and ALK-4 expression by T cells was increased after allergen challenge. Activin-A induced NHBE cell proliferation, was produced by NHBE cells in response to TNF-alpha, and downregulated TNF-alpha and IL-13-induced chemokine production by NHBE cells. Conclusion: Both TGF-beta and activin signaling pathways are activated on allergen provocation in asthma. Activin-A may contribute to resolution of inflammation. (J Allergy Clin Immunol 2009;124:454-62.)	[Kariyawasam, Harsha H.; Pegorier, Sophie; Barkans, Julia; Aizen, Maxine; Kay, A. Barry; Lloyd, Clare M.; Robinson, Douglas S.] Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, Fac Med, London SW7 2AZ, England; [Kariyawasam, Harsha H.; Barkans, Julia; Aizen, Maxine; Robinson, Douglas S.] Univ London Imperial Coll Sci Technol & Med, Allergy & Clin Immunol Sect, Natl Heart & Lung Inst, Fac Med, London SW7 2AZ, England; [Kariyawasam, Harsha H.; Pegorier, Sophie; Barkans, Julia; Aizen, Maxine; Ying, Sun; Kay, A. Barry; Lloyd, Clare M.; Robinson, Douglas S.] Univ London Imperial Coll Sci Technol & Med, MRC, Natl Heart & Lung Inst, Fac Med, London SW7 2AZ, England; [Kariyawasam, Harsha H.; Pegorier, Sophie; Barkans, Julia; Aizen, Maxine; Ying, Sun; Kay, A. Barry; Lloyd, Clare M.; Robinson, Douglas S.] Univ London Imperial Coll Sci Technol & Med, Asthma UK Ctr Allerg Mech Asthma, Natl Heart & Lung Inst, Fac Med, London SW7 2AZ, England; [Xanthou, Georgina] Acad Athens, Biomed Res Fdn, Athens, Greece	Imperial College London; Imperial College London; Imperial College London; Imperial College London; University of London; King's College London; Academy of Athens	Kay, AB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, Fac Med, Sir Alexander Fleming Bldg,S Kensington Campus, London SW7 2AZ, England.	a.b.kay@imperial.ac.uk	Xanthou, Georgina/AAH-8682-2019	Lloyd, Clare/0000-0001-8977-6726	Imperial College Trust Fund; Wellcome Trust; Medical Research Council [G0400503B] Funding Source: researchfish; Asthma UK [08/022] Funding Source: researchfish	Imperial College Trust Fund; Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	Supported by the Imperial College Trust Fund. D.S.R. was supported by a Wellcome Trust leave award for clinical academics. C.M.L. is a Wellcome Trust Senior Fellow. Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.	Adachi Y, 1997, AM J PHYSIOL-LUNG C, V273, pL701, DOI 10.1152/ajplung.1997.273.3.L701; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Aoki F, 2005, AM J RESP CRIT CARE, V172, P713, DOI 10.1164/rccm.200412-1620OC; Balzar S, 2005, J ALLERGY CLIN IMMUN, V115, P110, DOI 10.1016/j.jaci.2004.09.034; BRANDES ME, 1991, J IMMUNOL, V147, P1600; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Chu HW, 2000, J ALLERGY CLIN IMMUN, V106, P1115; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Gawa K, 2006, J IMMUNOL, V177, P6787, DOI 10.4049/jimmunol.177.10.6787; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; Huber S, 2009, J IMMUNOL, V182, P4633, DOI 10.4049/jimmunol.0803143; Jones KL, 2004, J ENDOCRINOL, V181, P307, DOI 10.1677/joe.0.1810307; Jones KL, 2007, P NATL ACAD SCI USA, V104, P16239, DOI 10.1073/pnas.0705971104; Karagiannidis C, 2006, J ALLERGY CLIN IMMUN, V117, P111, DOI 10.1016/j.jaci.2005.09.017; Kariyawasam HH, 2008, AM J RESP CRIT CARE, V177, P1074, DOI 10.1164/rccm.200709-1376OC; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Khalil N, 2002, EXP LUNG RES, V28, P233, DOI 10.1080/019021402753570527; Leigh R, 2008, J ALLERGY CLIN IMMUN, V121, P1238, DOI 10.1016/j.jaci.2008.01.067; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Ling EM, 2002, CLIN EXP ALLERGY, V32, P175, DOI 10.1046/j.1365-2222.2002.01287.x; Nakao A, 2002, J ALLERGY CLIN IMMUN, V110, P873, DOI 10.1067/mai.2002.129236; Phipps S, 2004, AM J RESP CELL MOL, V31, P626, DOI 10.1165/rcmb.2004-0193OC; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Robson NC, 2008, BLOOD, V111, P2733, DOI 10.1182/blood-2007-03-080994; Rosendahl A, 2001, AM J RESP CELL MOL, V25, P60, DOI 10.1165/ajrcmb.25.1.4396; Sadick H, 2005, HAEMATOLOGICA, V90, P818; Scherner O, 2007, J BIOL CHEM, V282, P13934, DOI 10.1074/jbc.M611062200; Schmidt-Weber CB, 2007, J ALLERGY CLIN IMMUN, V120, P247, DOI 10.1016/j.jaci.2007.06.039; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sulyok S, 2004, MOL CELL ENDOCRINOL, V225, P127, DOI 10.1016/j.mce.2004.07.011; Torrego A, 2007, THORAX, V62, P307, DOI 10.1136/thx.2006.063487	34	62	64	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					454	462		10.1016/j.jaci.2009.06.022	http://dx.doi.org/10.1016/j.jaci.2009.06.022			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19733294	Green Accepted			2022-12-18	WOS:000274315900009
J	Bonilla, FA				Bonilla, Francisco A.			Intravenous immunoglobulin: Adverse reactions and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Intravenous immunoglobulin; adverse effects			Childrens Hosp Boston, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Bonilla, FA (corresponding author), Childrens Hosp Boston, 300 Longwood Ave, Boston, MA 02115 USA.	francisco.bonilla@childrens.harvard.edu						Ahsan N, 1998, J NEPHROL, V11, P157; Berger M, 2004, CLIN IMMUNOL, V112, P1, DOI 10.1016/j.clim.2004.02.002; Brennan VM, 2003, CLIN EXP IMMUNOL, V133, P247, DOI 10.1046/j.1365-2249.2003.02199.x; Horn J, 2007, CLIN IMMUNOL, V122, P156, DOI 10.1016/j.clim.2006.10.002; Rare Diseases Clinical Research Network, 2019, PRIM IMM DEF TREATM	5	62	68	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2008	122	6					1238	1239		10.1016/j.jaci.2008.08.033	http://dx.doi.org/10.1016/j.jaci.2008.08.033			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	383ZA	18842292				2022-12-18	WOS:000261711800034
J	Mehra, R; Redline, S				Mehra, Reena; Redline, Susan			Sleep apnea: A proinflammatory disorder that coaggregates with obesity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sleep apnea; obesity; inflammation; asthma	POSITIVE AIRWAY PRESSURE; C-REACTIVE PROTEIN; SOLUBLE INTERLEUKIN-6 RECEPTOR; OXIDATIVE STRESS; RISK-FACTORS; INTERMITTENT HYPOXIA; CARDIOVASCULAR RISK; DAYTIME SLEEPINESS; LIPID-PEROXIDATION; INSULIN-RESISTANCE	Both obesity and sleep apnea are prevalent health conditions that frequently coaggregate. Obesity-associated inflammation may influence asthma control; the relation of sleep apnea to asthma or allergic rhinitis may be bidirectional. Both obesity and sleep apnea are associated with augmented levels of inflammation and oxidative stress, and it is biologically plausible that the proinflammatory effects of one disorder influence the expression of the other disorder. This article elucidates mechanistic associations among obesity, sleep apnea, and systemic inflammation; highlights interrelationships between these factors with cardiopulmonary disease; and identifies specific areas for future research directions.			Mehra, R (corresponding author), Case Western Reserve Univ, 11100 Euclid Ave, Cleveland, OH 44106 USA.	mehrar@ameritecht.net	Mehra, Reena/ABA-5710-2021	Mehra, Reena/0000-0002-6222-2675	NCI NIH HHS [U54 CA116867, 1U54CA116867, U54 CA116867-04] Funding Source: Medline; NHLBI NIH HHS [K23 HL079114-01A2, K23 HL079114, K23 HL079114-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA116867] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL079114] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adner M, 2002, BRIT J PHARMACOL, V137, P971, DOI 10.1038/sj.bjp.0704928; Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Alzoghaibi Mohammed A, 2005, Sleep Breath, V9, P119, DOI 10.1007/s11325-005-0022-1; Barcelo A, 2006, EUR RESPIR J, V27, P756, DOI 10.1183/09031936.06.00067605; Barreiro E, 2007, THORAX, V62, P1095, DOI 10.1136/thx.2006.069963; Carpagnano GE, 2003, CHEST, V124, P1386, DOI 10.1378/chest.124.4.1386; Carpagnano GE, 2002, CHEST, V122, P1162, DOI 10.1378/chest.122.4.1162; CHAN CS, 1988, AM REV RESPIR DIS, V137, P1502, DOI 10.1164/ajrccm/137.6.1502; Ciftci TU, 2004, CYTOKINE, V28, P87, DOI 10.1016/j.cyto.2004.07.003; Depalo A, 2008, J INTERN MED, V263, P70, DOI 10.1111/j.1365-2796.2007.01875.x; Devouassoux G, 2007, J ALLERGY CLIN IMMUN, V119, P597, DOI 10.1016/j.jaci.2006.11.638; Dikmenoglu N, 2006, SLEEP MED, V7, P255, DOI 10.1016/j.sleep.2005.12.005; Drager LF, 2007, AM J RESP CRIT CARE, V176, P706, DOI 10.1164/rccm.200703-500OC; Dyugovskaya L, 2003, AM J RESP CRIT CARE, V168, P242, DOI 10.1164/rccm.200210-1226OC; FITZPATRICK MF, 1993, EUR RESPIR J, V6, P531; Gami AS, 2003, ENDOCRIN METAB CLIN, V32, P869, DOI 10.1016/S0889-8529(03)00069-0; Goldbart AD, 2005, AM J RESP CRIT CARE, V172, P364, DOI 10.1164/rccm.200408-1064OC; Gozal D, 2007, AM J RESP CRIT CARE, V176, P188, DOI 10.1164/rccm.200610-1519OC; Guerrero M, 2001, Sleep Breath, V5, P93, DOI 10.1007/s11325-001-0093-6; Guidry UC, 2001, AM J RESP CRIT CARE, V164, P933, DOI 10.1164/ajrccm.164.6.2001092; GUILLEMINAULT C, 1988, EUR RESPIR J, V1, P902; Harsch IA, 2004, AM J RESP CRIT CARE, V169, P156, DOI 10.1164/rccm.200302-206OC; Hoffmann MS, 2007, ANTIOXID REDOX SIGN, V9, P661, DOI 10.1089/ars.2007.1589; Ip MSM, 2000, AM J RESP CRIT CARE, V162, P2166, DOI 10.1164/ajrccm.162.6.2002126; Ip MSM, 2000, CHEST, V118, P580, DOI 10.1378/chest.118.3.580; Knuiman M, 2006, CHEST, V130, P1779, DOI 10.1378/chest.130.6.1779; Kobayashi K, 2006, CHEST, V129, P632, DOI 10.1378/chest.129.3.632; Kokura S, 2000, CIRC RES, V86, P205, DOI 10.1161/01.RES.86.2.205; KRESYUN V I, 1991, Ukrainskii Biokhimicheskii Zhurnal, V63, P59; Kripke DF, 2002, ARCH GEN PSYCHIAT, V59, P131, DOI 10.1001/archpsyc.59.2.131; Larkin EK, 2005, CIRCULATION, V111, P1978, DOI 10.1161/01.CIR.0000161819.76138.5E; Larsson LG, 2001, RESP MED, V95, P423, DOI 10.1053/rmed.2001.1054; Lavie L, 2004, SLEEP, V27, P123; Lavie L, 2002, AM J RESP CRIT CARE, V165, P1624, DOI 10.1164/rccm.20110-040OC; Mehra R, 2006, ARCH INTERN MED, V166, P1725, DOI 10.1001/archinte.166.16.1725; Minoguchi K, 2006, EUR RESPIR J, V28, P378, DOI 10.1183/09031936.06.00084905; Montgomery S, 2006, INT J PSYCHIAT CLIN, V10, P5, DOI 10.1080/13651500600637049; Nayak AS, 2002, ALLERGY ASTHMA PROC, V23, P359; Ng DK, 2006, ALLERGY ASTHMA PROC, V27, P240, DOI 10.2500/aap.2006.27.2855; Patel SR, 2006, AM J EPIDEMIOL, V164, P947, DOI 10.1093/aje/kwj280; Peppard PE, 2000, JAMA-J AM MED ASSOC, V284, P3015, DOI 10.1001/jama.284.23.3015; PETROSYAN M, 2007, SLEEP BREATH    1211; Polotsky VY, 2003, J PHYSIOL-LONDON, V552, P253, DOI 10.1113/jphysiol.2003.048173; Punjabi NM, 2007, SLEEP, V30, P29, DOI 10.1093/sleep/30.1.29; Punjabi NM, 2005, J APPL PHYSIOL, V99, P1998, DOI 10.1152/japplphysiol.00695.2005; Redline S, 1999, AM J RESP CRIT CARE, V159, P1527, DOI 10.1164/ajrccm.159.5.9809079; Robinson GV, 2004, THORAX, V59, P777, DOI 10.1136/thx.2003.018739; Ryan S, 2005, CIRCULATION, V112, P2660, DOI 10.1161/CIRCULATIONAHA.105.556746; Sanders MH, 2003, AM J RESP CRIT CARE, V167, P7, DOI 10.1164/rccm.2203046; Schulz R, 2000, AM J RESP CRIT CARE, V162, P566, DOI 10.1164/ajrccm.162.2.9908091; Shinagawa K, 2007, AM J RESP CRIT CARE, V175, P136, DOI 10.1164/rccm.200608-1097OC; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; Steiner S, 2005, CARDIOLOGY, V104, P92, DOI 10.1159/000086729; Sulit LG, 2005, AM J RESP CRIT CARE, V171, P659, DOI 10.1164/rccm.200403-398OC; Svatikova A, 2005, EUR HEART J, V26, P2435, DOI 10.1093/eurheartj/ehi440; Svatikova A, 2004, AM J PHYSIOL-REG I, V287, pR284, DOI 10.1152/ajpregu.00241.2004; Taheri S, 2007, SLEEP, V30, P991, DOI 10.1093/sleep/30.8.991; Tam CS, 2007, SLEEP, V30, P723, DOI 10.1093/sleep/30.6.723; TECULESCU DB, 1992, PEDIATR PULM, V13, P239, DOI 10.1002/ppul.1950130412; Thomas PS, 1999, THORAX, V54, P352, DOI 10.1136/thx.54.4.352; Vgontzas AN, 1997, J CLIN ENDOCR METAB, V82, P1313, DOI 10.1210/jc.82.5.1313; Vgontzas AN, 2000, J CLIN ENDOCR METAB, V85, P1151, DOI 10.1210/jc.85.3.1151; von Kanel R, 2007, CHEST, V131, P733, DOI 10.1378/chest.06-2006; Wali SO, 1998, SLEEP, V21, P290; Yamauchi M, 2005, CHEST, V127, P1674, DOI 10.1378/chest.127.5.1674; Yeh HC, 2008, DIABETES CARE, V31, P741, DOI 10.2337/dc07-1464; Yokoe T, 2003, CIRCULATION, V107, P1129, DOI 10.1161/01.CIR.0000052627.99976.18; YOKOYAMA A, 1995, CLIN EXP IMMUNOL, V100, P325; Yokoyama A, 1997, AM J RESP CRIT CARE, V156, P1688, DOI 10.1164/ajrccm.156.5.9610070; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 2001, ARCH INTERN MED, V161, P1514, DOI 10.1001/archinte.161.12.1514	72	62	68	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1096	1102		10.1016/j.jaci.2008.04.002	http://dx.doi.org/10.1016/j.jaci.2008.04.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18466782	Green Accepted			2022-12-18	WOS:000255961700003
J	Real, FG; Svanes, C; Omenaas, ER; Anto, JM; Plana, E; Janson, C; Jarvis, D; Zemp, E; Wjst, M; Leynaert, B; Sunyer, J				Real, Francisco Gomez; Svanes, Cecilie; Omenaas, Ernst Reidar; Anto, Josep Maria; Plana, Este; Janson, Christer; Jarvis, Deborah; Zemp, Elisabeth; Wjst, Matthias; Leynaert, Benedicte; Sunyer, Jordi			Menstrual irregularity and asthma and lung function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						irregular menstruation; oligomenorrhea; asthma; lung function; allergy; body mass index; physical activity; insulin resistance; ECRHS	OLIGOMENORRHEA AND/OR HIRSUTISM; POLYCYSTIC-OVARY-SYNDROME; SELF-REPORTED SYMPTOMS; BIRTH COHORT 1966; HEALTH SURVEY-II; INSULIN-RESISTANCE; CARDIOVASCULAR-DISEASE; VENTILATORY FUNCTION; DIABETES-MELLITUS; WOMEN	Background: Oligomenorrhea was associated with more asthma (Respiratory Health in Northern Europe study), but a possible association with lung function has not been investigated previously. Objective: To investigate whether oligomenorrhea was related to lung function and asthma, and whether body mass index and physical activity modified associations. Methods: Women age 28 to 44 years (n = 1631) participating in the European Community Respiratory Health Survey were included. Women who were taking exogenous sex hormones, were pregnant, or had recently given birth were excluded. Results: Long or irregular menstrual cycles were reported by 313 women (19%). Oligomenorrhea was significantly associated with more asthma symptoms (odds ratio [OR], 1.76; 95% CI, 1.29-2.40), allergic asthma (OR, 2.46; 95% CI, 1.43-4.23), and lower forced vital capacity (FVC; adjusted difference, 63 mL; 95% CI. -124 to -1). When excluding women using asthma medication, very lean women, or women exercising daily, these associations remained significant. Effects of oligomenorrbea Were additive to those of body mass index (BMI) on asthma and FVC. Asthma symptoms increased significantly with BMI. FVC and FEV1 increased with BMI until 25 kg/m(2) and thereafter decreased with increasing BMI. Excluding women exercising daily, asthma symptoms increased significantly with decreasing physical activity (OR, 1.09; 95% CI, 1.001-1.19) per category of physical activity) independently of oligomenorrhea. Among women exercising daily, oligomenorrhea, predicted very high risk for asthma symptoms (OR, 12.6; 95% CI, 3.7-43). Conclusion: Women with oligomenorrhea have reduced lung function and more asthma, particularly allergic asthma, independent of BMI and physical activity. Airways pathology may have not only a hormonal but also a metabolic component. Clinical implications: Women with oligomenorrhea should be investigated with regard to asthma and lung function. Underlying metabolic disturbance should be considered in asthma.	Haukeland Hosp, Dept Gynecol & Obstet, N-5021 Bergen, Norway; Haukeland Hosp, Clin Res Ctr, N-5021 Bergen, Norway; Haukeland Hosp, Dept Thorac Med, N-5021 Bergen, Norway; Inst Municipal Invest Med, Environm Resp Res Unit, Barcelona, Spain; Univ Bergen, Inst Med, Resp Res Grp, Bergen, Norway; Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; Kings Coll London, Dept Publ Hlth Sci, London, England; Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; Natl Res Ctr Environm & Hlth, Forschungszentrum Umwelt & Gesundheit, Neuherberg, Germany; Inst Natl Sante Rech Med U700, Fac Med Xavier Bichat, Paris, France	University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Haukeland University Hospital; University of Bergen; Uppsala University; University of London; King's College London; University of Basel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Real, FG (corresponding author), Haukeland Hosp, Dept Gynecol & Obstet, N-5021 Bergen, Norway.	francisco.real@med.uib.no	Jarvis, Deborah/E-6494-2011; Svanes, Cecilie/N-7556-2017; Sunyer, Jordi/G-6909-2014; Anto, J M/H-2676-2014; Leynaert, Benedicte/N-5251-2018	Svanes, Cecilie/0000-0001-8512-5192; Sunyer, Jordi/0000-0002-2602-4110; Anto, J M/0000-0002-4736-8529; Leynaert, Benedicte/0000-0001-5045-2492; Gomez Real, Francisco/0000-0001-5407-3270; Jarvis, Deborah/0000-0002-1753-3896				Akerman MJH, 2004, J ASTHMA, V41, P521, DOI 10.1081/JAS-120037651; Chinn S, 2005, LANCET, V365, P1629, DOI 10.1016/S0140-6736(05)66511-7; Chinn S, 1998, THORAX, V53, P984, DOI 10.1136/thx.53.11.984; Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013; Dandona P, 2004, J CLIN ENDOCR METAB, V89, P5043, DOI 10.1210/jc.2004-0436; Davis WA, 2004, DIABETES CARE, V27, P752, DOI 10.2337/diacare.27.3.752; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Engstrom G, 2003, J INTERN MED, V253, P574, DOI 10.1046/j.1365-2796.2003.01138.x; FARQUHAR CM, 1994, AUST NZ J OBSTET GYN, V34, P67, DOI 10.1111/j.1479-828X.1994.tb01041.x; FERMANDES AR, 2005, J PEDIAT ADOLESC GYN, V18, P269; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; Garamszegi C, 1998, J PSYCHOSOM OBST GYN, V19, P165, DOI 10.3109/01674829809025694; GRODSTEIN F, 1993, EPIDEMIOLOGY, V4, P151, DOI 10.1097/00001648-199303000-00011; Hastie T, 1995, Stat Methods Med Res, V4, P187, DOI 10.1177/096228029500400302; Haver MC, 2003, AM J OBSTET GYNECOL, V188, P1189, DOI 10.1067/mob.2003.311; Hull M G, 1987, Gynecol Endocrinol, V1, P235, DOI 10.3109/09513598709023610; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Kelly CCJ, 2001, J CLIN ENDOCR METAB, V86, P2453, DOI 10.1210/jc.86.6.2453; Kos-Kudla B, 2000, J CLIN PHARM THER, V25, P461, DOI 10.1046/j.1365-2710.2000.00310.x; LANGE P, 1989, EUR RESPIR J, V2, P14; Lawlor DA, 2004, DIABETOLOGIA, V47, P195, DOI 10.1007/s00125-003-1310-6; Lazarus R, 1998, EUR RESPIR J, V12, P641, DOI 10.1183/09031936.98.12030641; Lazarus R, 1998, EUR RESPIR J, V12, P635, DOI 10.1183/09031936.98.12030635; Mishra V, 2004, INT J OBESITY, V28, P1048, DOI 10.1038/sj.ijo.0802700; Pekkanen J, 2005, EUR RESPIR J, V26, P28, DOI 10.1183/09031936.05.00120104; POLSON DW, 1988, LANCET, V1, P870; Puder JJ, 2005, J CLIN ENDOCR METAB, V90, P6014, DOI 10.1210/jc.2005-1002; Romieu I, 2001, EPIDEMIOL REV, V23, P268, DOI 10.1093/oxfordjournals.epirev.a000806; Rubin RN, 2004, AM J RESP CRIT CARE, V169, P393, DOI 10.1164/rccm.200301-055OC; Rubio RL, 1988, ALLERGOL IMMUNOPATH, V16, P263; Schneider Marcie B, 2003, J Pediatr Adolesc Gynecol, V16, P89, DOI 10.1016/S1083-3188(03)00008-1; Shaaban R, 2007, THORAX, V62, P403, DOI 10.1136/thx.2006.068205; Shaheen SO, 1999, THORAX, V54, P396, DOI 10.1136/thx.54.5.396; Solomon CG, 2002, J CLIN ENDOCR METAB, V87, P2013, DOI 10.1210/jc.87.5.2013; Solomon CG, 2001, JAMA-J AM MED ASSOC, V286, P2421, DOI 10.1001/jama.286.19.2421; SPEROFFL, 1999, CLIN GYNECOLOGIE END; Svanes C, 2005, THORAX, V60, P445, DOI 10.1136/thx.2004.032615; Taponen S, 2003, J CLIN ENDOCR METAB, V88, P141, DOI 10.1210/jc.2002-020982; Taponen S, 2004, J CLIN ENDOCR METAB, V89, P2114, DOI 10.1210/jc.2003-031720; Xu BZ, 2002, EUR J PUBLIC HEALTH, V12, P166, DOI 10.1093/eurpub/12.3.166	40	62	63	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					557	564		10.1016/j.jaci.2007.04.041	http://dx.doi.org/10.1016/j.jaci.2007.04.041			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17604090	Bronze			2022-12-18	WOS:000249505400013
J	Wu, H; Romieu, I; Sienra-Monge, JJ; del Rio-Navarro, BE; Anderson, DM; Jenchura, CA; Li, HL; Ramirez-Aguilar, M; Lara-Sanchez, ID; London, SJ				Wu, Hao; Romieu, Isabelle; Sienra-Monge, Juan-Jose; del Rio-Navarro, Blanca Estela; Anderson, Daniel M.; Jenchura, Charlotte A.; Li, Huiling; Ramirez-Aguilar, Matiana; Lara-Sanchez, Irma del Carmen; London, Stephanie J.			Genetic variation in S-nitrosoglutathione reductase (GSNOR) and childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alcohol dehydrogenase 5; allergy; asthma; formaldehyde dehydrogenase; genetic predisposition to disease; nitric oxide; single nucleotide polymorphism; S-nitrosoglutathione; S-nitrosoglutathione reductase; S-nitrosothiol	CASE-PARENT TRIADS; NITRIC-OXIDE; BRONCHODILATOR; ASSOCIATION; GENOTYPE; POLYMORPHISMS; CHILDREN; AIRWAY	Background: S-nitrosothiols are potent endogenous bronchodilators depleted in asthmatic airway lining fluid. S-nitrosoglutathione reductase (GSNOR; also known as alcohol dehydrogenase 5 or formaldehyde dehydrogenase) catalyzes the metabolism of S-nitrosoglutathione (GSNO) and controls intracellular levels of S-nitrosothiols. GSNOR knockout mice have increased lung S-nitrosothiol levels and are therefore protected from airway hyperresponsiveness after methacholine or allergen challenge. Objective: We sought to investigate whether genetic variation in GSNOR is associated with childhood asthma and atopy. Methods: We genotyped 5 tagging and 2 additional single nucleotide polymorphisms (SNPs) in GSNOR in 532 nuclear families consisting of asthmatic children aged 4 to 17 years and both parents in Mexico City. Atopy was determined by means of skin prick testing. Results: Carrying 1 or 2 copies of the minor allele of SNP rs1154404 was associated with decreased risk of asthma (relative risk [RR], 0.77; 95% CI, 0.61-0.97; P = .028 for 1 copy and RR, 0.66; 95% CI, 0.44-0.99; P = .046 for 2 copies). Homozygosity for the minor allele of SNP rs28730619 was associated with increased risk of asthma (RR, 1.60; 95% CI, 1.13-2.26; P = .0077). Haplotype analyses supported the single SNP findings. GSNOR SNPs were not associated with the degree of atopy. Conclusion: This is the first study of genetic polymorphisms in GSNOR and asthma. These data suggest that genetic variation in GSNOR might play a role in asthma susceptibility. Clinical implications: The association of GSNOR polymorphisms with asthma suggests a potential therapeutic target.	NIEHS, Natl Inst Hlth, Dept Hlth & Human Serv, Div Intramural Res,Lab Resp Biol, Res Triangle Pk, NC 27709 USA; NIEHS, Natl Inst Hlth, Dept Hlth & Human Serv, Div Intramural Res,Epidemiol Branch, Res Triangle Pk, NC 27709 USA; Hosp Infantil Mexico Dr Federico Gomez, Mexico City, DF, Mexico; Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Hospital Infantil de Mexico Federico Gomez; Instituto Nacional de Salud Publica	London, SJ (corresponding author), NIEHS, Natl Inst Hlth, Dept Hlth & Human Serv, Div Intramural Res,Lab Resp Biol, POB 12233,MD A3-05, Res Triangle Pk, NC 27709 USA.	london2@niehs.nih.gov	London, Stephanie/C-3734-2019	London, Stephanie/0000-0003-4911-5290	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES049019, Z01ES025045] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 ES049019-12, Z01 ES049019] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AAS K, 1973, INT ARCH ALLER A IMM, V45, P57, DOI 10.1159/000231002; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Belousov Yevgeniy S., 2004, Human Genomics, V1, P209; *BTS SIGN, 2003, THORAX S1, V28; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Edenberg HJ, 2000, PROG NUCLEIC ACID RE, V64, P295, DOI 10.1016/S0079-6603(00)64008-4; Fang KH, 2000, AM J PHYSIOL-LUNG C, V279, pL716, DOI 10.1152/ajplung.2000.279.4.L716; FOLERTS G, 2006, CURR PHARM DESIGN, V12, P3221; Gaston B, 1998, LANCET, V351, P1317, DOI 10.1016/S0140-6736(97)07485-0; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gerard C, 2005, SCIENCE, V308, P1560, DOI 10.1126/science.1114163; Gjessing HK, 2006, ANN HUM GENET, V70, P382, DOI 10.1111/j.1469-1809.2005.00218.x; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Henderson EM, 2005, TRENDS MOL MED, V11, P481, DOI 10.1016/j.molmed.2005.09.009; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; HUR MW, 1992, GENE, V121, P305, DOI 10.1016/0378-1119(92)90135-C; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Kacmarek RM, 1996, AM J RESP CRIT CARE, V153, P128, DOI 10.1164/ajrccm.153.1.8542105; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kistner EO, 2004, GENET EPIDEMIOL, V27, P33, DOI 10.1002/gepi.20001; Lake SL, 2004, ANN HUM GENET, V68, P55, DOI 10.1046/j.1529-8817.2003.00073.x; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Li HL, 2006, J ALLERGY CLIN IMMUN, V117, P119, DOI 10.1016/j.jaci.2005.09.026; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; *NHLBI, 1998, POCKET GUIDE ASTHMA; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Perez-Padilla R, 2003, PEDIATR PULM, V35, P177, DOI 10.1002/ppul.10232; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Spahn JD, 2004, AM J RESP CRIT CARE, V169, P784, DOI 10.1164/rccm.200309-1234OE; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Umbach DH, 2000, AM J HUM GENET, V66, P251, DOI 10.1086/302707; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Weinberg CR, 1998, AM J HUM GENET, V62, P969, DOI 10.1086/301802; Wilcox AJ, 1998, AM J EPIDEMIOL, V148, P893	40	62	62	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2007	120	2					322	328		10.1016/j.jaci.2007.04.022	http://dx.doi.org/10.1016/j.jaci.2007.04.022			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	198VF	17543375	Green Accepted			2022-12-18	WOS:000248654900016
J	de Halleux, S; Stura, E; VanderElst, L; Carlier, V; Jacquemin, M; Saint-Remy, JM				de Halleux, S; Stura, E; VanderElst, L; Carlier, V; Jacquemin, M; Saint-Remy, JM			Three-dimensional structure and IgE-binding properties of mature fully active Der p1, a clinically relevant major allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; cysteine protease; Dermatophagoides; Der p 1; structure	DUST MITE ALLERGEN; CYSTEINE PROTEASE ACTIVITY; DER-P-1	Background: Der p 1 is a 25-kd allergen with cysteine protease activity. Sensitization to Der p 1 affects a large proportion of individuals with allergy, resulting in rhinitis, asthma, and/or atopic dermatitis. Objective: We determined the Der p 1 crystallographic structure to understand the relationships among structure, function, and allergenicity. Methods: Recombinant pro-Der p 1 was produced in Pichia pastoris and allowed to mature spontaneously before purification by a 2-step procedure. Protease activity was checked by using a fluorogenic peptide substrate. Allergenicity was analysed by IgE binding assays and basophil activation test. The determination of the 3-dimensional structure was obtained by X-ray crystallography at 1.9 angstrom resolution. Results: The recombinant protein is fully active and expresses an allergenicity equivalent to its natural counterpart. Der p 1 exhibits a cysteine protease fold typical of the papain family, has a magnesium binding site, and forms dimers with a large interface. The crystal lattice shows that the dimers are tightly packed in a compact double layer of proteins. Such all assembly likely exists in dry fecal pellets, the natural form of allergen exposure, and appears ideal to interact with cell surf. ace and trigger allergic inflammation. Conclusion: We present here the 3-dimensional structural features of mature fully active Der p 1, one of the main allergens involved in human allergic diseases. This opens the possibility to evaluate the importance of enzymatic activity in pathology and possible new therapeutic interventions.	Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	KU Leuven; CEA; UDICE-French Research Universities; Universite Paris Saclay	Saint-Remy, JM (corresponding author), Univ Leuven, Ctr Mol & Vasc Biol, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	jeanmarie.saint-remy@med.kuleuven.be	Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118				Akdis CA, 2000, INT ARCH ALLERGY IMM, V121, P261, DOI 10.1159/000024352; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Asokananthan N, 2002, J IMMUNOL, V169, P4572, DOI 10.4049/jimmunol.169.8.4572; Billson J, 1998, BIOORG MED CHEM LETT, V8, P993, DOI 10.1016/S0960-894X(98)00151-6; Brown A, 2003, AM J RESP CELL MOL, V29, P381, DOI 10.1165/rcmb.2003-0060OC; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Collins SP, 1996, CLIN EXP ALLERGY, V26, P36, DOI 10.1111/j.1365-2222.1996.tb00054.x; GREENE WK, 1992, MOL IMMUNOL, V29, P257, DOI 10.1016/0161-5890(92)90107-9; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; JEANNIN P, 1992, MOL IMMUNOL, V29, P739, DOI 10.1016/0161-5890(92)90184-Y; John RJ, 2000, CLIN EXP ALLERGY, V30, P784, DOI 10.1046/j.1365-2222.2000.00840.x; Kraft S, 2004, INT ARCH ALLERGY IMM, V135, P62, DOI 10.1159/000080231; Magi M, 2004, J ALLERGY CLIN IMMUN, V114, P545, DOI 10.1016/j.jaci.2004.04.014; Meno K, 2005, J IMMUNOL, V175, P3835, DOI 10.4049/jimmunol.175.6.3835; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI [10.1093/nar/gkh071, 10.1093/nar/gkp971]; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Smith WA, 2001, J ALLERGY CLIN IMMUN, V107, P985, DOI 10.1067/mai.2001.114652; Takai T, 2005, BIOCHEM BIOPH RES CO, V328, P944, DOI 10.1016/j.bbrc.2005.01.051; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Tsumoto K, 2004, BIOTECHNOL PROGR, V20, P1301, DOI 10.1021/bp0498793	22	62	67	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					571	576		10.1016/j.jaci.2005.11.032	http://dx.doi.org/10.1016/j.jaci.2005.11.032			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	025JY	16522455				2022-12-18	WOS:000236263100011
J	Kalach, N; Soulaines, P; de Boissieu, D; Dupont, C				Kalach, N; Soulaines, P; de Boissieu, D; Dupont, C			A pilot study of the usefulness and safety of a ready-to-use atopy patch test (Diallertest) versus a comparator (Finn Chamber) during cow's milk allergy in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk allergy; children; ready-to-use atopy patch test	SKIN-PRICK; FOOD ALLERGY; DIAGNOSTIC-ACCURACY; IGE; INFANTS; RAST; IDENTIFICATION; CHALLENGES; CHILDHOOD; ECZEMA	Background: Patch testing is used in the diagnosis of food allergy, especially during delayed manifestations. Objective: A ready-to-use atopy patch test (APT), the Diallertest, was compared with another APT device, the Finn Chamber, in pediatric cow's milk allergy. Methods: This prospective study involved 49 children (34.3 +/- 17 [mean +/- SD] months of age), with cow's milk allergy manifested by atopic dermatitis (10.2%), digestive manifestations (40.8%), or both (49%). All children underwent both APT techniques, with a reading 72 hours after application, followed by a milk elimination diet for 4 to 6 weeks and open cow's milk challenge. Results: A positive result was seen in 22 (44.8%) versus 13 (26.5%) patients with the ready-to-use and the comparator APTs, respectively. No side effects were recorded. Both techniques were concordant in 67.3% of patients. Of the total 41 open cow's milk challenges, 60.9% had positive results, with 8 patients lost to follow-up. The performances of the ready-to-use and comparator APTs were as follows: sensitivity, 76% (95% CI, 59.2% to 92.7%) versus 44% (95% CI, 24.5% to 63.4%; P = .02); specificity, 93.8% (95% CI, 81.9% to 100%) versus 93.8% (95% CI, 81.9% to 100%); positive predictive value, 95 % (95% CI, 85.4% to 100 %; 1 false-positive result) versus 91.7% (95% CI, 76% to 100%; 1 false-positive result); negative predictive value, 71.4% (95% CI, 52% to 90.7%; 6 false-negative results) versus 51.7% (95% Cl, 33.5% to 69.8%; 14 false-negative results); and test accuracy, 82.9% (95% Cl, 71.3% to 94.5%) versus 63.4% (95% CI, 48.6% to 78.1 %; P = .05). Conclusion: The ready-to-use APT exhibited a good sensitivity and specificity, with no side effects.	Cochin St Vincent de Paul Hosp, Dept Pediat Neonatol, Pediat Gastroenterol & Nutr Unit, F-75674 Paris 14, France; Catholic Univ Lille, St Vincent de Paul Hosp, Clin Pediat St Antoine, Lille, France; Univ Paris 05, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kalach, N (corresponding author), Cochin St Vincent de Paul Hosp, Dept Pediat Neonatol, Pediat Gastroenterol & Nutr Unit, 82 Ave Denfert Rochereau, F-75674 Paris 14, France.	kalach.nicolas@ghicl.net						ANDRE F, 1992, REV FR ALLERGOL, V32, P11, DOI 10.1016/S0335-7457(05)80171-6; Bahna S L, 1995, Pediatr Allergy Immunol, V6 Suppl 8, P49; BHALLA RB, 1982, ADV INTERPRETATION C, P295; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; de Boissieu D, 2004, J PEDIATR-US, V145, P716, DOI 10.1016/j.jpeds.2004.06.052; de Boissieu D, 2003, J PEDIATR-US, V142, P203, DOI 10.1067/mpd.2003.92; deBoissieu D, 1997, J PEDIATR-US, V131, P744, DOI 10.1016/S0022-3476(97)70104-5; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Jarvinen KM, 2003, CLIN EXP ALLERGY, V33, P1060, DOI 10.1046/j.1365-2222.2003.01741.x; JOHANSSON SGO, 1976, CLIN ALLERGY, V6, P91, DOI 10.1111/j.1365-2222.1976.tb01417.x; Kekki OM, 1997, ALLERGY, V52, P755, DOI 10.1111/j.1398-9995.1997.tb01234.x; Majamaa H, 1999, ALLERGY, V54, P346, DOI 10.1034/j.1398-9995.1999.00834.x; MOISAN V, 1990, REV FR ALLERGOL, V30, P233, DOI 10.1016/S0335-7457(05)80261-8; Moneret-Vautrin DA, 1998, J ALLERGY CLIN IMMUN, V101, pS87; Niggemann B, 2001, J ALLERGY CLIN IMMUN, V108, P1053, DOI 10.1067/mai.2001.120192; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Niggemann B, 2000, ALLERGY, V55, P281, DOI 10.1034/j.1398-9995.2000.00464.x; Niggemann Bodo, 2002, Indian Journal of Pediatrics, V69, P57, DOI 10.1007/BF02723778; Rietschel RL, 1996, LANCET, V347, P1202, DOI 10.1016/S0140-6736(96)90731-X; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; Saarinen KM, 2001, CLIN EXP ALLERGY, V31, P423, DOI 10.1046/j.1365-2222.2001.01015.x; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Stromberg L, 2002, ACTA PAEDIATR, V91, P1044, DOI 10.1080/080352502760311520; Turjanmaa K, 2002, Allerg Immunol (Paris), V34, P95; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7	30	62	62	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1321	1326		10.1016/j.jaci.2005.08.033	http://dx.doi.org/10.1016/j.jaci.2005.08.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337466				2022-12-18	WOS:000235687000025
J	Baudouin, C; Liang, H; Bremond-Gignac, D; Hamard, P; Hreiche, R; Creuzot-Garcher, C; Warnet, JM; Brignole-Baudouin, F				Baudouin, C; Liang, H; Bremond-Gignac, D; Hamard, P; Hreiche, R; Creuzot-Garcher, C; Warnet, JM; Brignole-Baudouin, F			CCR4 and CCR5 expression in conjunctival specimens as differential markers of T(H)1/T(H)2 in ocular surface disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology	APR 24-29, 2004	Ft Lauderdale, FL	Assoc Res Vis & Ophthalmol		CCR4; CCR5; conjunctiva; flow cytometry; glaucoma; HLA-DR; impression cytology; Sjogren syndrome; T(H)1; T(H)2	INFLAMMATORY MARKERS; EPITHELIAL-CELLS; T-CELLS; TH2; EYE	Background: Accurate inflammatory mechanisms in chronic ocular surface diseases (OSDs) cannot routinely be assessed. New techniques for investigating ocular surface inflammatory pathways are of major importance. Objective: To investigate the expressions of CCR4 and CCR5, known to be related to the T(H)2 and T(H)1 systems, respectively, and HLA-DR in conjunctival impression cytology specimens from patients with chronic OSDs. Methods: In this case-controlled study, impression cytology specimens were taken in a series of patients with vernal keratoconjunctivitis (n = 21), giant papillary conjunctivitis (n = 6), or keratoconjunctivitis sicca (KCS; n = 17), or receiving topical antiglaucoma treatments (n = 31), and from 20 normal subjects. Conjunctival cells were incubated with mAbs to CCR4, CCR5, CD45, and HLA-DR to quantify conjunctival inflammation in a masked manner using flow cytometry. Results: HLA-DR was higher in the glaucoma and KCS groups than in allergic and normal eyes. CCR4 was overexpressed in allergy and glaucoma, whereas CCR5 was higher in the KCS and glaucomatous groups. CD45 was expressed by only few cells in all groups, with almost no significant differences. CCR4 expression was negatively correlated with CCR5 and HLA-DR, whereas CCR5 was positively correlated with HLA-DR. Conclusion: This study confirms the overexpression of chemokine receptors by the conjunctival epithelium in OSDs. CCR4 and CCR5 expression may vary according to the immune pathway involved. Accurate mechanisms in ocular surface inflammatory reactions-that is, those related to the T(H)1 or T(H)2 systems-could be differentiated by CCR4/CCR5 profiles. Our results also suggest that long-term use of topical treatments may stimulate both systems.	Quinze Vingts Natl Ophthalmol Hosp, Dept Ophthalmol, F-75012 Paris, France; Univ Versailles, Hop Ambroise Pare, APHP, Paris Ouest Sch Med, F-78000 Versailles, France; INSERM, U598, Inst Biomed Cordeliers, Paris, France; Univ Paris 07, Robert Debre Hosp, APHP, Dept Ophthalmol, F-75221 Paris 05, France; Univ Paris 05, Fac Biol & Pharmacol Sci, Dept Toxicol, F-75270 Paris 06, France; Burgundi Univ, Univ Hosp Dijon, Dept Ophthalmol, Dijon, France	CHNO des Quinze-Vingts; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU Dijon Bourgogne; Universite de Bourgogne	Baudouin, C (corresponding author), Quinze Vingts Natl Ophthalmol Hosp, Dept Ophthalmol, 28 Rue Charenton, F-75012 Paris, France.	baudouin@quinze-vingts.fr	Liang, Hong/V-4518-2019	Liang, Hong/0000-0002-0579-8651; BRIGNOLE-BAUDOUIN, FRANCOISE/0000-0002-2006-5384; BREMOND-GIGNAC, Dominique/0000-0002-3563-5482; Baudouin, Christophe/0000-0003-1743-6698				Andrew DP, 2001, J IMMUNOL, V166, P103, DOI 10.4049/jimmunol.166.1.103; Baudouin C, 1997, INVEST OPHTH VIS SCI, V38, P1458; Baudouin C, 2000, GRAEF ARCH CLIN EXP, V238, P900, DOI 10.1007/s004170000179; Baudouin C, 2004, OPHTHALMOLOGY, V111, P2186, DOI 10.1016/j.ophtha.2004.06.023; Bielory L, 2000, J ALLERGY CLIN IMMUN, V106, P805, DOI 10.1067/mai.2000.111029; Bielory L, 2004, CURR OPIN ALLERGY CL, V4, P421, DOI 10.1097/00130832-200410000-00014; Bonini S, 2004, EYE, V18, P345, DOI 10.1038/sj.eye.6700675; Brignole F, 2000, INVEST OPHTH VIS SCI, V41, P1356; Calder VL, 1999, CLIN EXP ALLERGY, V29, P1214; Debbasch C, 2001, INVEST OPHTH VIS SCI, V42, P2525; El-Asrar Ahmed M. Abu, 2001, British Journal of Ophthalmology, V85, P1357, DOI 10.1136/bjo.85.11.1357; Fujishima H, 1997, INVEST OPHTH VIS SCI, V38, P1350; Leonardi A, 1999, INVEST OPHTH VIS SCI, V40, P3036; Leonardi A, 2002, PROG RETIN EYE RES, V21, P319, DOI 10.1016/S1350-9462(02)00006-X; Luo LH, 2004, INVEST OPHTH VIS SCI, V45, P4293, DOI 10.1167/iovs.03-1145; Matsuura N, 2004, CURR EYE RES, V29, P235, DOI 10.1080/02713680490516738; MIYAZAKI D, 2005, J CLIN INVEST, V13, P1; Ono SJ, 2005, J ALLERGY CLIN IMMUN, V115, P118, DOI 10.1016/j.jaci.2004.10.042; Pisella PJ, 2004, INVEST OPHTH VIS SCI, V45, P1360, DOI 10.1167/iovs.03-1067; Sood A, 2003, INVEST OPHTH VIS SCI, V44, pU205; Tsubota K, 1999, INVEST OPHTH VIS SCI, V40, P28; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; Yanagita M, 1999, J IMMUNOL, V162, P3559; Yeaman GR, 2004, IMMUNOLOGY, V113, P524, DOI 10.1111/j.1365-2567.2004.01990.x	24	62	65	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					614	619		10.1016/j.jaci.2005.05.033	http://dx.doi.org/10.1016/j.jaci.2005.05.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	017IE	16159632				2022-12-18	WOS:000235686500022
J	Menge, T; Lalive, PH; von Budingen, HC; Cree, B; Hauser, SL; Genain, CP				Menge, T; Lalive, PH; von Budingen, HC; Cree, B; Hauser, SL; Genain, CP			Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						galactocerebroside; myelin antigens; autoantibody; multiple sclerosis; experimental allergic encephalomyelitis	MYELIN OLIGODENDROCYTE GLYCOPROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; BASIC-PROTEIN; ANTIMYELIN ANTIBODIES; IMMUNE-RESPONSES; DEMYELINATION; AUGMENTATION; LESIONS; SERUM	Background: Galactocerebroside, the major glycolipid of central nervous system myelin, is a known target for pathogenic demyelinating antibody responses in experimental allergic encephalomyelitis (EAE), the animal model of multiple sclerosis (MS). Objective: To address the importance of anti-galactocerebroside (alpha-GalC) antibodies in MS and to evaluate them as biomarkers of disease. Methods: alpha-GalC IgGs were quantified from sera of patients with MS and in marmoset EAE by a new immunosorbent assay. Results: We report a significant difference in serum alpha-GalC IgG titers between patients with relapsing-remitting (RR)-MS and healthy controls (HCs; P < .001). The frequencies of alpha-GalC antibody-positive subjects (alpha-GalC titers >= mean HC titers + 3 SD) are also significantly elevated in RR-MS compared with HC (40% vs 0%; P = .0033). Immunoaffinity purified alpha-GalC IgGs from human serum bind to cultured human oligodendrocytes, indicating that the ELISA detects a biologically relevant epitope. Corroborating these findings, alpha-GalC antibody responses in marmoset EAE were similarly found to be specifically associated with the RR forms and not the peracute or progressive forms, in contrast with other anti-myelin antibodies (P = .0256). Conclusion: (1) alpha-GalC antibodies appear MS-specific and are not found in healthy subjects, unlike antibodies against myelin proteins; (2) when present, alpha-GalC antibodies identify mostly RR-MS and may be an indicator of ongoing disease activity. This novel assay is a suitable and valuable method to increase accuracy of diagnosis and disease staging in MS.	Univ Calif San Francisco, Dept Neurol, Neuroimmunol Labs, San Francisco, CA 94143 USA; Univ Zurich, Neurol Klin, Zurich, Switzerland	University of California System; University of California San Francisco; University of Zurich	Genain, CP (corresponding author), Univ Calif San Francisco, Dept Neurol, Neuroimmunol Labs, C-440,513 Parnassus Ave, San Francisco, CA 94143 USA.	claudeg@itsa.ucsf.edu	Lalive, Patrice/AAM-5861-2020; Hauser, Stephen L/J-2978-2016	von Budingen, H.-Christian/0000-0003-0159-6662	NIAID NIH HHS [AI43073-11] Funding Source: Medline; NINDS NIH HHS [NS4678-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043073] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMOR S, 1994, J IMMUNOL, V153, P4349; Battistini L, 1996, J NEUROIMMUNOL, V67, P145; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Berger T, 2003, NEW ENGL J MED, V349, P139, DOI 10.1056/NEJMoa022328; Bernard CCA, 1997, J MOL MED-JMM, V75, P77, DOI 10.1007/s001090050092; Brex PA, 2002, NEW ENGL J MED, V346, P158, DOI 10.1056/NEJMoa011341; Fierz W, 1988, Ann N Y Acad Sci, V540, P360, DOI 10.1111/j.1749-6632.1988.tb27099.x; Frohman EM, 2003, NEUROLOGY, V61, P602, DOI 10.1212/01.WNL.0000082654.99838.EF; FRY JM, 1974, SCIENCE, V183, P540, DOI 10.1126/science.183.4124.540; Genain CP, 1995, J CLIN INVEST, V96, P2966, DOI 10.1172/JCI118368; ICHIOKA T, 1988, NEUROCHEM RES, V13, P203, DOI 10.1007/BF00971533; KASAI N, 1986, J NEUROL SCI, V75, P33, DOI 10.1016/0022-510X(86)90048-1; Lampasona V, 2004, NEUROLOGY, V62, P2092, DOI 10.1212/01.WNL.0000127615.15768.AE; Lily O, 2004, BRAIN, V127, P269, DOI 10.1093/brain/awh031; Lindert RB, 1999, BRAIN, V122, P2089, DOI 10.1093/brain/122.11.2089; LININGTON C, 1988, AM J PATHOL, V130, P443; LOLLI F, 1993, J NEUROIMMUNOL, V44, P69, DOI 10.1016/0165-5728(93)90269-5; Lumsden CE, 1970, HDB CLINICAL NEUROLO, P217; Mantegazza R, 2004, INT IMMUNOL, V16, P559, DOI 10.1093/intimm/dxh056; MASSACESI L, 1995, ANN NEUROL, V37, P519, DOI 10.1002/ana.410370415; Menon KK, 1997, J NEUROCHEM, V69, P214; MOORE GRW, 1984, LAB INVEST, V51, P416; Morris-Downes MM, 2002, J NEUROIMMUNOL, V125, P114, DOI 10.1016/S0165-5728(02)00040-1; Nakajima H, 2001, PROTEIN EXPRES PURIF, V22, P267, DOI 10.1006/prep.2001.1449; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RAINE CS, 1981, J NEUROL SCI, V52, P117, DOI 10.1016/0022-510X(81)90140-4; RAINE CS, 1981, LAB INVEST, V45, P174; Reindl M, 1999, BRAIN, V122, P2047, DOI 10.1093/brain/122.11.2047; Robinson WH, 2003, PROTEOMICS, V3, P2077, DOI 10.1002/pmic.200300583; Rosenbluth J, 1999, J NEUROCYTOL, V28, P397, DOI 10.1023/A:1007021916210; ROSTAMI AM, 1987, ANN NEUROL, V22, P381, DOI 10.1002/ana.410220316; SAIDA T, 1979, ACTA NEUROPATHOL, V48, P19, DOI 10.1007/BF00691786; SCHLUESENER HJ, 1987, J IMMUNOL, V139, P4016; Shamshiev A, 1999, EUR J IMMUNOL, V29, P1667, DOI 10.1002/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; TABIRA T, 1985, J NEUROL SCI, V67, P201, DOI 10.1016/0022-510X(85)90116-9; Von Budingen HC, 2001, J CLIN IMMUNOL, V21, P155	37	62	65	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					453	459		10.1016/j.jaci.2005.03.023	http://dx.doi.org/10.1016/j.jaci.2005.03.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083805				2022-12-18	WOS:000235686400033
J	Xepapadaki, P; Papadopoulos, NG; Bossios, A; Manoussakis, E; Manousakas, T; Saxoni-Papageorgiou, P				Xepapadaki, P; Papadopoulos, NG; Bossios, A; Manoussakis, E; Manousakas, T; Saxoni-Papageorgiou, P			Duration of postviral airway hyperresponsiveness in children with asthma: Effect of atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway hyperresponsiveness; atopy	RESPIRATORY VIRAL-INFECTIONS; RHINOVIRUS INFECTION; COMMON COLD; VIRUS; INFLAMMATION; RESPONSIVENESS; CHILDHOOD; BRONCHOPROVOCATION; HYPERREACTIVITY; EXACERBATIONS	Background: Respiratory viruses induce asthma exacerbations and airway hyperresponsiveness (AHR). Atopy is an important risk factor for asthma persistence. Objective: We sought to evaluate whether atopy is a risk factor for prolonged AHR after upper respiratory tract infections (URIs). Methods: Twenty-five children (13 atopic and 12 nonatopic children) with intermittent virus-induced asthma were studied. Clinical evaluation, skin prick tests, methacholine bronchoprovocation, questionnaires, and a nasal wash specimen were obtained at baseline. For 9 months, subjects completed diary cards with respiratory symptoms. During their first reported cold, a nasal wash specimen was obtained. Methacholine provocation was performed 10 days and 5, 7, 9, and 11 weeks later. In case a new cold developed, the provocation schedule was followed from the beginning. Results: Viruses were detected in 17 (68%) of 25 patients during their first cold, with rhinovirus being most commonly identified (82%). AHR increased significantly 10 days after the URI, equally in both groups (P = .67), and remained so up to the fifth week. Duration of AHR in subjects experiencing a single URI ranged from 5 to 11 weeks, without a significant difference between groups. In the duration of the study, atopic children experienced more colds and asthma exacerbations than nonatopic children. Thus for duration of AHR, significant prolongation was noted in the atopic group when assessed cumulatively. Conclusion: In asthmatic children the duration of AHR after a single natural cold is 5 to 11 weeks. However, an increased rate of symptomatic cold and asthma episodes in atopic children is associated with considerable cumulative prolongation of AHR, which might help explain the role of atopy as a risk factor for asthma persistence.	UPC Res Labs, Goudi 11527, Greece; Univ Athens, Allergy Unit, Pediat Clin 2, Athens, Greece	National & Kapodistrian University of Athens	Xepapadaki, P (corresponding author), UPC Res Labs, 13 Levadias, Goudi 11527, Greece.	panvik@hol.gr	Bossios, Apostolos/ABH-8262-2020; N.G., Papadopoulos/L-8670-2013; Bossios, Apostolos/A-1720-2008; Papadopoulos, Nikolaos/ABE-1774-2021	Bossios, Apostolos/0000-0002-0494-2690; N.G., Papadopoulos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-2508-3872				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Arruda LK, 2005, CURR OPIN ALLERGY CL, V5, P153, DOI 10.1097/01.all.0000162308.89857.6c; Avila PC, 2000, J ALLERGY CLIN IMMUN, V106, P829, DOI 10.1067/mai.2000.111027; Bardin PG, 1996, EUR RESPIR J, V9, P2250, DOI 10.1183/09031936.96.09112250; Boulet LP, 2003, AM J RESP CRIT CARE, V167, P371, DOI 10.1164/rccm.200111-084PP; Brooks GD, 2003, AM J RESP CRIT CARE, V168, P1091, DOI 10.1164/rccm.200306-737OC; Busse WW, 2000, J ALLERGY CLIN IMMUN, V105, P889, DOI 10.1067/mai.2000.106378; Cain H, 2001, CLIN CHEST MED, V22, P651, DOI 10.1016/S0272-5231(05)70058-7; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282; Christodoulopoulos P, 2001, J ALLERGY CLIN IMMUN, V107, P586, DOI 10.1067/mai.2001.114883; Cockcroft DW, 2001, AM J RESP CRIT CARE, V163, P1514, DOI 10.1164/ajrccm.163.7.2103055b; COME JM, 2002, LANCET, V359, P831; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100, DOI 10.1164/ajrccm.160.1.9808074; FOLKERTS G, 1995, AM J RESP CRIT CARE, V151, P1666; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1872, DOI 10.1164/ajrccm.155.6.9196088; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Grunberg K, 1997, AM J RESP CRIT CARE, V155, P833; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Jafri HS, 2004, J INFECT DIS, V189, P1856, DOI 10.1086/386372; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kluijver JC, 2003, AM J RESP CRIT CARE, V168, P1174, DOI 10.1164/rccm/200212-1520OC; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LOUISPHILIPPE B, 2003, CURR ALLERGY ASTHM R, V3, P166; Lowe L, 2004, CURR ALLERGY ASTHM R, V4, P159, DOI 10.1007/s11882-004-0062-9; Martinez FD, 2001, J ALLERGY CLIN IMMUN, V107, pS449, DOI 10.1067/mai.2001.114993; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; *NAT I HLTH NAT HE, 2002, PUBLICATION; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Papadopoulos NG, 2002, ALLERGY, V57, P295; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Papadopoulos NG, 1999, J MED VIROL, V58, P100, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;100::AID-JMV16&gt;3.0.CO;2-D; Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-118BC; Papadopoulos NG, 1999, J VIROL METHODS, V80, P179, DOI 10.1016/S0166-0934(99)00045-2; Papadopoulos NG, 2002, CLIN EXP ALLERGY, V32, P537, DOI 10.1046/j.0954-7894.2002.01313.x; Papadopoulos NG, 2003, CURR OPIN ALLERGY CL, V3, P39, DOI 10.1097/01.all.0000053266.39029.b4; Parry DE, 2000, J ALLERGY CLIN IMMUN, V105, P692, DOI 10.1067/mai.2000.104785; Postma DS, 2000, AM J RESP CRIT CARE, V162, pS118, DOI 10.1164/ajrccm.162.supplement_2.ras-13; Prescott SL, 2003, ALLERGY, V58, P864, DOI 10.1034/j.1398-9995.2003.00231.x; Schwarze J, 2002, EUR RESPIR J, V19, P341, DOI 10.1183/09031936.02.00254302; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P949, DOI 10.1111/j.1365-2222.1993.tb00280.x; Skoner DP, 1996, AM J RESP CRIT CARE, V154, P661, DOI 10.1164/ajrccm.154.3.8810602; Smart JM, 2001, PEDIATR ALLERGY IMMU, V12, P181, DOI 10.1034/j.1399-3038.2001.012004181.x; Sub-committee on Skin tests of the European Academy of Allergy and Clinical Immunology, 1989, ALLERGY, V44, P1; Trigg CJ, 1996, CLIN EXP ALLERGY, V26, P665, DOI 10.1111/j.1365-2222.1996.tb00593.x; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; Walter MJ, 2002, J CLIN INVEST, V110, P165, DOI 10.1172/JCI200214345; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; WARNER JO, 1998, PEDIAT ALLERGY IMMUN, V9, P55; Weiss ST, 2000, AM J RESP CRIT CARE, V162, P50, DOI 10.1164/ajrccm.162.1.9811005	54	62	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					299	304		10.1016/j.jaci.2005.04.007	http://dx.doi.org/10.1016/j.jaci.2005.04.007			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083783	Green Published, Bronze			2022-12-18	WOS:000235686400010
J	Miyake, Y; Sasaki, S; Ohya, Y; Miyamoto, S; Matsunaga, I; Yoshida, T; Hirota, Y; Oda, H				Miyake, Y; Sasaki, S; Ohya, Y; Miyamoto, S; Matsunaga, I; Yoshida, T; Hirota, Y; Oda, H		Osaka Maternal Child Hlth Study Gr	Soy, isoflavones, and prevalence of allergic rhinitis in Japanese women: The Osaka Maternal and Child Health Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; cross-sectional study; isoflavones; Japanese women; soy	FATTY-ACID INTAKE; HAY-FEVER; ASTHMA; RHINOCONJUNCTIVITIS; CONSUMPTION; DISORDERS; NUTRITION; PREGNANCY; TEENAGERS; CYTOKINES	Background: It has been hypothesized that isoflavones reduce the risk of many chronic diseases, but there are no data on the effects of dietary soy and isoflavone consumption on allergic disorders. Objective: This cross-sectional study examined the relationship between dietary soy products and isoflavone intake and the prevalence of allergic rhinitis. Methods: Study subjects were 1002 Japanese pregnant women. Allergic rhinitis (including cedar pollinosis) was defined as present if subjects had received drug treatment at some point during the previous 12 months. Adjustment was made for age; gestation; parity, cigarette smoking; passive smoking at home and at work; indoor domestic pets; family history of asthma, atopic eczema, and allergic rhinitis;, family income; education; mite allergen level in house dust, changes in diet in the previous month; season when data were collected; and body mass index. Results: Compared with dietary intake of total soy product, soy protein, daidzein, and genistein in the first quartile, consumption of these substances in the fourth quartile was independently associated with a reduced prevalence of allergic rhinitis, although no significant dose-response relationships were observed. A clear inverse linear trend for miso intake across quartiles was found, whereas the adjusted odds ratio for comparison of the highest with the lowest quartile was not statistically significant. Consumption of tofu, tofu products, fermented soybeans, boiled soybeans, and miso soup was not related to the prevalence (of allergic rhinitis. Conclusion: A high intake of so, and isoflavones may be associated with a reduced prevalence of allergic rhinitis.	Fukuoka Univ, Sch Med, Dept Publ Hlth, Fukuoka 8140180, Japan; Natl Inst Hlth & Nutr, Project Sci Evaluat Dietary Reference Intakes, Tokyo, Japan; Natl Ctr Child Hlth & Dev, Div Allergy, Dept Med Specialties, Tokyo, Japan; Osaka City Univ, Sch Med, Dept Publ Hlth, Osaka, Japan; Osaka Prefectural Inst Publ Hlth, Osaka 537, Japan	Fukuoka University; National Institute of Health & Nutrition - Japan; National Center for Child Health & Development - Japan; Osaka Metropolitan University; Osaka Prefectural Institute of Public Health	Miyake, Y (corresponding author), Fukuoka Univ, Sch Med, Dept Publ Hlth, Fukuoka 8140180, Japan.	miyake-y@cis.fukuoka-u.ac.jp	Miyake, Yoshihiro/ABF-1774-2020	Miyake, Yoshihiro/0000-0003-1244-4488				Anthony MS, 1998, AM J CLIN NUTR, V68, p1390S, DOI 10.1093/ajcn/68.6.1390S; Bingham SA, 1998, BRIT J NUTR, V79, P393, DOI 10.1079/BJN19980068; Bolte G, 2001, AM J RESP CRIT CARE, V163, P277, DOI 10.1164/ajrccm.163.1.2006004; Chaouat G, 2004, INT ARCH ALLERGY IMM, V134, P93, DOI 10.1159/000074300; Chen XW, 2002, BIOCHEM BIOPH RES CO, V295, P417, DOI 10.1016/S0006-291X(02)00667-8; Constantinou AI, 2001, NUTR CANCER, V41, P75, DOI 10.1207/S15327914NC41-1&amp;2_10; Dunder T, 2001, ALLERGY, V56, P425, DOI 10.1034/j.1398-9995.2001.056005425.x; Farchi S, 2003, EUR RESPIR J, V22, P772, DOI 10.1183/09031936.03.00006703; FOTSIS T, 1995, J NUTR, V125, pS790, DOI 10.1093/jn/125.suppl_3.790S; Greendale GA, 2002, AM J EPIDEMIOL, V155, P746, DOI 10.1093/aje/155.8.746; Huang SL, 2001, CLIN EXP ALLERGY, V31, P259, DOI 10.1046/j.1365-2222.2001.00938.x; Huang SL, 2001, CLIN EXP ALLERGY, V31, P1875, DOI 10.1046/j.1365-2222.2001.01222.x; Jenkins DJA, 2002, METABOLISM, V51, P919, DOI 10.1053/meta.2002.33352; Kimira M, 1998, J Epidemiol, V8, P168; Knoferl MW, 2001, AM J PHYSIOL-CELL PH, V281, pC1131, DOI 10.1152/ajpcell.2001.281.4.C1131; KONISHI E, 1994, J MED ENTOMOL, V31, P394, DOI 10.1093/jmedent/31.3.394; LI ZG, 1993, CLIN EXP RHEUMATOL, V11, P157; Messina MJ, 1999, AM J CLIN NUTR, V70, p439S, DOI 10.1093/ajcn/70.3.439s; Miyake Y, 2004, ACTA PAEDIATR, V93, P380, DOI [10.1111/j.1651-2227.2004.tb02965.x, 10.1080/08035250410022819]; Miyake Y, 2003, CLIN EXP ALLERGY, V33, P312, DOI 10.1046/j.1365-2222.2003.t01-1-01607.x; Miyake Yoshihiro, 2002, J Epidemiol, V12, P418; Nafstad P, 2003, J ASTHMA, V40, P343, DOI 10.1081/JAS-120018633; Nagata C, 2002, AM J EPIDEMIOL, V156, P824, DOI 10.1093/aje/kwf118; Nagel G, 2003, ALLERGY, V58, P1277, DOI 10.1046/j.1398-9995.2003.00296.x; Nikov GN, 2000, ENVIRON HEALTH PERSP, V108, P867, DOI 10.2307/3434995; Okuda M, 2003, ANN ALLERG ASTHMA IM, V91, P288, DOI 10.1016/S1081-1206(10)63532-6; Palmer GW, 2002, ANN ALLERG ASTHMA IM, V89, P350, DOI 10.1016/S1081-1206(10)62034-0; Philpott CM, 2004, CLIN OTOLARYNGOL, V29, P138, DOI 10.1111/j.1365-2273.2004.00801.x; Sasaki S, 2000, J NUTR SCI VITAMINOL, V46, P285, DOI 10.3177/jnsv.46.285; Sasaki S, 1998, J Epidemiol, V8, P203; *STAT BUR MIN PUBL, 2002, POSTS TEL JAP 2000 P; Strachan DP, 1997, PEDIAT ALLERG IMM-UK, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Takai T, 1997, MOL IMMUNOL, V34, P255, DOI 10.1016/S0161-5890(97)00020-5; Trak-Fellermeier MA, 2004, EUR RESPIR J, V23, P575, DOI 10.1183/09031936.04.00074404; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Wakai K, 2001, ANN EPIDEMIOL, V11, P59, DOI 10.1016/S1047-2797(00)00182-4; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Yamamoto S, 2003, J NATL CANCER I, V95, P906, DOI 10.1093/jnci/95.12.906	39	62	65	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1176	1183		10.1016/j.jaci.2005.02.016	http://dx.doi.org/10.1016/j.jaci.2005.02.016			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940131				2022-12-18	WOS:000229815400011
J	Stempel, DA; McLaughin, TP; Stanford, RH; Fuhlbrigge, AL				Stempel, DA; McLaughin, TP; Stanford, RH; Fuhlbrigge, AL			Patterns of asthma control: A 3-year analysis of patient claims	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; asthma control; administrative claim; asthma variability; controller medications	AIRWAY INFLAMMATION; COST	Background: The goal of asthma therapy is to maintain consistent control. Objective: We sought to examine the patterns of asthma control recorded over 3 years using administrative claims and resource utilization definition. Methods: We performed a retrospective observational study with a nationally representative patient-level database containing pharmacy and medical claims. Patients with asthma (International Classification of Diseases, Ninth Revision-Clinical Modification code 493.xx), patients undergoing treatment with at least 1 asthma medication, and patients with 36 months of continuous claims coverage during the calendar years 1996 through 2002 were identified. A total of 63,324 patients were included in the study. Patients were classified as having controlled asthma in year 1 if they had less than 4 claims for a short-acting beta(2)-agonist, no claims for an OCS, and no asthma-related emergency department visits or hospitalizations. Patients were then followed over the next 8 quarters (2 years) to observe whether control was maintained. Control during a quarter was defined with the same criteria, except the reliever threshold was adjusted to 2 or more claims per quarter. Results: Thirty-nine thousand ninety-five (57%) patients were defined as having controlled asthma during year 1. During the 2-year follow-up period, a range of 10% to 14% of these patients with controlled asthma met the criteria of uncontrolled asthma during any given quarter. Overall, 46,227 (73%) patients identified met the criteria for uncontrolled asthma at least once during the 3-year period. Conclusions: This study demonstrates that almost 75% of asthmatic patients experience an uncontrolled asthma episode 1 or more times over a 3-year period. Furthermore, we found that significant fluctuations in asthma control exist, even in patients with prior controlled asthma.	Informed NW, Seattle, WA USA; Univ Washington, Seattle, WA 98195 USA; NDC Hlth, Phoenix, AZ USA; GlaxoSmithKline, Res Triangle Pk, NC USA; Harvard Univ, Sch Med, Boston, MA USA	University of Washington; University of Washington Seattle; GlaxoSmithKline; Harvard University; Harvard Medical School	Stempel, DA (corresponding author), Informed NW, Seattle, WA USA.	econmed@msn.com						Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Juniper EF, 1997, ALLERGY, V52, P971, DOI 10.1111/j.1398-9995.1997.tb02416.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Lee J, 2001, AM J MANAG CARE, V7, pS103; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; PRENDERGRAFT TB, 2003, J ALLERGY CLIN IMM S, V111, pS267; Stempel DA, 2004, CHEST, V126, P75, DOI 10.1378/chest.126.1.75; Stempel DA, 2001, RESP MED, V95, P992, DOI 10.1053/rmed.2001.1185; Stempel DA, 1997, ANN ALLERG ASTHMA IM, V79, P517, DOI 10.1016/S1081-1206(10)63059-1; *SYMM HLTH DAT SYS, 2002, EP TREATM GROUPS US; *US DEP HHS, 1997, NAT I HLTH PUBL; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Yazdani C, 2001, CLIN THER, V23, P1672, DOI 10.1016/S0149-2918(01)80136-3	17	62	63	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					935	939		10.1016/j.jaci.2005.01.054	http://dx.doi.org/10.1016/j.jaci.2005.01.054			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867848				2022-12-18	WOS:000229055100006
J	Hunt, LW; Frigas, E; Butterfield, JH; Kita, H; Blomgren, J; Dunnette, SL; Offord, KP; Gleich, GJ				Hunt, LW; Frigas, E; Butterfield, JH; Kita, H; Blomgren, J; Dunnette, SL; Offord, KP; Gleich, GJ			Treatment of asthma with nebulized lidocaine: A randomized, placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; glitcocorticoids; lidocaine; eosinophils	INHALED LIGNOCAINE; PLASMA EXUDATION; GLUCOCORTICOIDS; RESPONSES; INHALATION; ANESTHESIA; SURVIVAL	Background: In 2 prior uncontrolled studies, nebulized lidocaine reduced oral glucocorticoid use in patients with severe glucocorticoid-dependent asthma. Objective: We tested the safety and efficacy of nebulized lidocaine in a randomized, placebo-controlled study in patients with mild-to-moderate asthma. Methods: We recruited 50 subjects (25 receiving lidocaine and 25 receiving placebo); all had a prebronchodilator FEV1 of 64% to 125% of predicted normal value and were treated with daily inhaled glucocorticoids (but not systemic glucocorticoids) and bronchodilators for at least 2 months. Before treatment, subjects monitored their symptoms and peak How values and maintained their medications for 2 weeks. At initiation, subjects inhaled either nebulized placebo (saline) or lidocaine (4%, 100 mg) 4 times daily. All subjects were instructed to reduce their inhaled glucocorticoid dosage by one half each week for 3 weeks and to discontinue glucocorticoid treatment at week 4. The subjects continued the nebulized lidocaine or placebo for a total of 8 weeks, monitored their symptoms, and used bronchodilators to control symptoms. Results: Indicators of asthma severity showed benefit for the lidocaine-treated group: changes in FEV1 (P less than or equal to .001), nighttime awakenings (P less than or equal to .02), symptoms (P less than or equal to .010), bronchodilator use (P less than or equal to .010), and blood eosinophil counts (P less than or equal to .020). Subjects in both groups reduced use of inhaled glucocorticoids comparably. Subjects receiving nebulized placebo showed increases in their symptom scores, bronchodilator use (P less than or equal to .05 for both), and blood eosinophil counts (P less than or equal to .01) and decreases in FEV1 (P less than or equal to .001). Conclusion: Nebulized lidocaine provided effective and safe therapy in subjects with mild-to-moderate asthma.	Mayo Clin & Mayo Fdn, Mayo Grad Sch Med, Dept Internal Med, Div Allerg Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch Med, Div Biostat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch Med, Dept Immunol, Allerg Dis Res Lab, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Gleich, GJ (corresponding author), Univ Utah, Dept Dermatol, Sch Med, 4B454,30 North 1900 East, Salt Lake City, UT 84132 USA.				NIAID NIH HHS [AI 34577] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034577, U01AI034577] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bankers-Fulbright JL, 1998, J IMMUNOL, V160, P5546; Bjorck S, 2002, PHARMACOL TOXICOL, V90, P173, DOI 10.1034/j.1600-0773.2002.900401.x; BOYE NP, 1979, SCAND J RESPIR DIS, V60, P105; CAIRE N, 1989, CLIN EXP ALLERGY, V19, P65, DOI 10.1111/j.1365-2222.1989.tb02346.x; CARRYER HM, 1950, J ALLERGY, V21, P282, DOI 10.1016/0021-8707(50)90059-1; CHINN WM, 1977, CHEST, V71, P346, DOI 10.1378/chest.71.3.346; Decco ML, 1999, ANN ALLERG ASTHMA IM, V82, P29, DOI 10.1016/S1081-1206(10)62656-7; ERJEFALT I, 1993, AM REV RESPIR DIS, V148, P695, DOI 10.1164/ajrccm/148.3.695; ERJEFALT I, 1991, AM REV RESPIR DIS, V143, P1008, DOI 10.1164/ajrccm/143.5_Pt_1.1008; FISH JE, 1979, RESPIRATION, V37, P201, DOI 10.1159/000194028; Groeben H, 2000, CHEST, V118, P509, DOI 10.1378/chest.118.2.509; Harrison TW, 1998, RESP MED, V92, P1359, DOI 10.1016/S0954-6111(98)90142-1; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; Hunt LW, 1996, MAYO CLIN PROC, V71, P361, DOI 10.4065/71.4.361; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; LAMAS AM, 1991, J IMMUNOL, V147, P254; MCALPINE LG, 1989, CHEST, V96, P1012, DOI 10.1378/chest.96.5.1012; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MIKAWA K, 1994, ANESTHESIOLOGY, V81, P689, DOI 10.1097/00000542-199409000-00023; MILLER WC, 1975, AM REV RESPIR DIS, V111, P739; *NAT ASTHM ED PREV, 1997, PUBL NAT ASTHM ED PR; *NIH, 1997, NIH PUBL; Ohnishi T, 1996, CLIN EXP IMMUNOL, V104, P325, DOI 10.1046/j.1365-2249.1996.32737.x; Okada S, 1998, J IMMUNOL, V160, P4010; Rosario NA, 2000, ANN ALLERG ASTHMA IM, V85, P245, DOI 10.1016/S1081-1206(10)62475-1; SCHIMMER BP, 1996, GOODMAN GILMANS PHAR, P1475; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; Taniguchi T, 1996, CRIT CARE MED, V24, P642, DOI 10.1097/00003246-199604000-00016; WALLEN N, 1991, J IMMUNOL, V147, P3490; WEISS EB, 1977, CHEST, V72, P429, DOI 10.1378/chest.72.4.429	31	62	70	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					853	859		10.1016/j.jaci.2004.02.039	http://dx.doi.org/10.1016/j.jaci.2004.02.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	818UC	15131566	Bronze			2022-12-18	WOS:000221269000006
J	Burgess, JK; Carlin, S; Pack, RA; Arndt, GM; Au, WW; Johnson, PRA; Black, JL; Hunt, NH				Burgess, JK; Carlin, S; Pack, RA; Arndt, GM; Au, WW; Johnson, PRA; Black, JL; Hunt, NH			Detection and characterization of OX40 ligand expression in human airway smooth muscle cells: A possible role in asthma?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cell-surface molecules; inflammation; OX40 ligand; human airway smooth muscle cells	CD4 T-CELLS; GROWTH-FACTOR; CYTOKINE DIFFERENTIATION; COSTIMULATORY MOLECULE; ALLERGIC INFLAMMATION; DNA-SYNTHESIS; MURINE MODEL; TH2 CELLS; ACTIVATION; RECEPTOR	Background: The airway smooth muscle (ASM) cell, originally thought of as a passive structural cell, is now well recognized as an active participant in the pathologic events that occur during persistent asthma. Cell-surface molecules play an important role in the development of an immune response. A number of cell-surface molecules are expressed on ASM cells, and these might contribute to the inflammatory reaction. Objective: The purpose of this study was to determine whether OX40 ligand (OX40L), a molecule known to be involved in T-cell activation, was present on the ASM cell surface. Methods: We used real-time RT-PCR to detect mRNA expression and flow cytometry, ELISA, and immunoprecipitation to detect the presence of cell-surface protein on ASM cells isolated from asthmatic and nonasthmatic individuals. ELISAs and Western blotting were used to determine the functional outcomes of engagement of OX40L. Results: OX40L was present on both asthmatic and nonasthmatic ASM cells. Engagement of OX40L with recombinant OX40:Fc resulted in a significantly greater increase in release of IL-6 from ASM cells of asthmatic patients than from ASM cells of nonasthmatic patients (P < .01). Ligation of OX40L resulted in a rapid translocation of protein kinase C beta(2) to the cell membrane. Conclusion: Because the receptor for OX40L, OX40, is expressed on CD4(+) T cells within 48 hours of stimulation through the T-cell receptor, elucidation of the cross-talk between OX40 and OX40L could be very important in understanding the interaction of cells present in the inflamed airways of an asthmatic patient.	Univ Sydney, Dept Pharmacol, Resp Res Grp, Sydney, NSW 2006, Australia; Woolcock Inst Med Res, Sydney, NSW, Australia; Johnson & Johnson Res Pty Ltd, Eveleigh, NSW, Australia; Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; Woolcock Institute of Medical Research; Johnson & Johnson; University of Sydney	Burgess, JK (corresponding author), Univ Sydney, Dept Pharmacol, Resp Res Grp, Bosch Bldg D05, Sydney, NSW 2006, Australia.		Hunt, Nick H/A-3636-2011; Burgess, Janette K/A-3597-2010; Black, Judith L/C-6559-2008; Burgess, Janette/M-7117-2019	Burgess, Janette/0000-0001-9868-9966				Arestides RSS, 2002, EUR J IMMUNOL, V32, P2874, DOI 10.1002/1521-4141(2002010)32:10<2874::AID-IMMU2874>3.0.CO;2-4; Baba E, 2001, J IMMUNOL, V167, P875, DOI 10.4049/jimmunol.167.2.875; Black JL, 2001, AM J RESP CRIT CARE, V164, pS63, DOI 10.1164/ajrccm.164.supplement_2.2106059; BOUSQUET J, 1995, INT ARCH ALLERGY IMM, V107, P211, DOI 10.1159/000236980; Burgess JK, 1998, BLOOD, V92, P2366, DOI 10.1182/blood.V92.7.2366.2366_2366_2373; Burgess JK, 2003, AM J RESP CRIT CARE, V167, P71, DOI 10.1164/rccm.200205-416OC; CALDERHEAD DM, 1993, J IMMUNOL, V151, P5261; Carlin S, 2000, AM J RESP CELL MOL, V23, P555, DOI 10.1165/ajrcmb.23.4.4197; Carlin S, 1999, AM J PHYSIOL-LUNG C, V276, pL506, DOI 10.1152/ajplung.1999.276.3.L506; Chen AI, 1999, IMMUNITY, V11, P689, DOI 10.1016/S1074-7613(00)80143-0; DURANDARCZYNSKA W, 1993, HISTOCHEMISTRY, V100, P465, DOI 10.1007/BF00267827; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Flynn S, 1998, J EXP MED, V188, P297, DOI 10.1084/jem.188.2.297; Gokmen-Polar Y, 1998, J BIOL CHEM, V273, P20261, DOI 10.1074/jbc.273.32.20261; Gramaglia I, 1998, J IMMUNOL, V161, P6510; Hakonarson H, 2001, J IMMUNOL, V166, P293, DOI 10.4049/jimmunol.166.1.293; HICKS C, 1994, J IMMUNOL METHODS, V170, P83, DOI 10.1016/0022-1759(94)90248-8; Hirst SJ, 2000, CLIN EXP ALLERGY, V30, P54, DOI 10.1046/j.1365-2222.30.s1.1.x; Hoshino A, 2003, EUR J IMMUNOL, V33, P861, DOI 10.1002/eji.200323455; Hughes JM, 2000, MEDIAT INFLAMM, V9, P93, DOI 10.1080/096293500411550; Jember AGH, 2001, J EXP MED, V193, P387, DOI 10.1084/jem.193.3.387; JOHNSON PRA, 1995, AM J PHYSIOL-LUNG C, V269, pL514, DOI 10.1152/ajplung.1995.269.4.L514; KILEY SC, 1995, J CELL SCI, V108, P1003; Lane P, 2000, J EXP MED, V191, P201, DOI 10.1084/jem.191.2.201; Lazaar AL, 1998, J IMMUNOL, V161, P3120; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Lee JH, 2001, AM J PHYSIOL-LUNG C, V280, pL1019, DOI 10.1152/ajplung.2001.280.5.L1019; Matsumura Y, 1999, J IMMUNOL, V163, P3007; Matsumura Y, 1997, ARCH DERMATOL RES, V289, P653, DOI 10.1007/s004030050255; MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332; Murata K, 2000, J EXP MED, V191, P365, DOI 10.1084/jem.191.2.365; Ohshima Y, 1997, J IMMUNOL, V159, P3838; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; SanchezGuerrero IM, 1997, EUR RESPIR J, V10, P2091, DOI 10.1183/09031936.97.10092091; Sukkar MB, 2000, MEDIAT INFLAMM, V9, P161, DOI 10.1080/09629350020008673; Triantafilou M, 2001, CYTOMETRY, V43, P279, DOI 10.1002/1097-0320(20010401)43:4<279::AID-CYTO1060>3.0.CO;2-B; UYTTENHOVE C, 1988, J EXP MED, V167, P1417, DOI 10.1084/jem.167.4.1417; Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119; Weinberg AD, 1999, J IMMUNOL, V162, P1818	39	62	69	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					683	689		10.1016/j.jaci.2003.12.311	http://dx.doi.org/10.1016/j.jaci.2003.12.311			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100674				2022-12-18	WOS:000220956600016
J	Rowe, J; Heaton, T; Kusel, M; Suriyaarachchi, D; Serralha, M; Holt, BJ; de Klerk, N; Sly, PD; Holt, PG				Rowe, J; Heaton, T; Kusel, M; Suriyaarachchi, D; Serralha, M; Holt, BJ; de Klerk, N; Sly, PD; Holt, PG			High IFN-gamma production by CD8(+) T cells and early sensitization among infants at high risk of atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; infants; cytokines; CD8(+) T cells	BLOOD MONONUCLEAR-CELLS; INTERFERON-GAMMA; CORD-BLOOD; POSTNATAL MATURATION; PERTUSSIS VACCINE; TH2 CELLS; ALLERGEN; CHILDREN; ASTHMA; IL-4	Background: High genetic risk (HR) of atopy among unstratified populations of infants is associated with attenuated IFN-gamma responses. However, the role of IFN-gamma in progression from HR status to active disease is less clear. Objective: To identify immune function markers in neonates with HR that are associated with positive atopic outcomes at 2 years. Methods: Cord blood mononuclear cells (CBMCs) were collected from 175 children with HR and cryopreserved. The children were assessed for atopy by skin prick at 0.5 and 2 years. CBMCs were thawed and stimulated with allergens and mitogens PHA and staphylococcal enterotoxin B (SEB), and cytokine responses were determined. Results: No correlations were observed between allergen specific CBMC responses and atopic outcomes. In contrast, sensitization was strongly associated with polyclonal IFN-gamma responses to both PHA (P=.002) and SEB (P =.005), and also with SEB-induced IL-5 (P=.05), IL-10 (P =.02), and IL-13 (P =.01). Logistic regression analysis identified elevated PHA-induced IFN-gamma and SEB-induced IL-13 responses as the strongest independent predictors of atopy development. Cell separation studies confirmed CD8(+) T cells as the source of similar to90 % of IFN-gamma production. Conclusions: IFN-gamma produced by CD8(+) T cells may synergize with T(H)2 cytokines in driving atopy development in children with HR.	Telethon Inst Child Hlth Res, Div Cell Biol, Perth, WA 6872, Australia; Univ Western Australia, Fac Med & Dent, Ctr Child Hlth Res, Perth, WA 6009, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Holt, PG (corresponding author), Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, Perth, WA 6872, Australia.	patrick@ichr.uwa.edu.au	Holt, Patrick G/H-1548-2011; de Klerk, Nicholas H/D-8388-2016; Sly, Peter D/F-1486-2010	Holt, Patrick G/0000-0003-1193-0935; de Klerk, Nicholas H/0000-0001-9223-0767; Sly, Peter D/0000-0001-6305-2201; Serralha, Michael/0000-0002-0121-2879				Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BYRON KA, 1994, CLIN EXP ALLERGY, V24, P878, DOI 10.1111/j.1365-2222.1994.tb01810.x; Coffman RL, 1999, CURR TOP MICROBIOL, V238, P1; Essayan DM, 1996, J ALLERGY CLIN IMMUN, V98, P1035, DOI 10.1016/S0091-6749(96)80188-6; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Hanifin JM., 1980, ACTA DERM-VENEREOL, V92, P44; Heaton T, 2003, ALLERGY, V58, P252, DOI 10.1034/j.1398-9995.2003.00088.x; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325, DOI 10.1165/ajrcmb.16.3.9070618; HOEGER PH, 1992, J INFECT DIS, V165, P1064, DOI 10.1093/infdis/165.6.1064; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P1117, DOI 10.1067/mai.2000.105804; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Lee SY, 2001, ANN ALLERG ASTHMA IM, V86, P659, DOI 10.1016/S1081-1206(10)62295-8; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790, DOI 10.1164/ajrccm.161.6.9906130; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; O'Sullivan S, 2001, AM J RESP CRIT CARE, V164, P560, DOI 10.1164/ajrccm.164.4.2102018; Ohshima Y, 1997, J IMMUNOL, V158, P629; Piccinni MP, 1996, EUR J IMMUNOL, V26, P2293, DOI 10.1002/eji.1830261004; Pohl D, 1997, ALLERGY, V52, P732, DOI 10.1111/j.1398-9995.1997.tb01230.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 2000, ALLERGY, V55, P470; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Rowe J, 2001, J INFECT DIS, V184, P80, DOI 10.1086/320996; Seneviratne SL, 2002, J CLIN INVEST, V110, P1283, DOI 10.1172/JCI200215753; Sharp MJ, 2003, CLIN EXP ALLERGY, V33, P435, DOI 10.1046/j.1365-2222.2003.01627.x; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; van der Velden VHJ, 2001, CLIN EXP ALLERGY, V31, P997, DOI 10.1046/j.1365-2222.2001.01176.x; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x	38	62	64	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					710	716		10.1016/j.jaci.2003.12.585	http://dx.doi.org/10.1016/j.jaci.2003.12.585			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100678				2022-12-18	WOS:000220956600020
J	Chrischilles, E; Ahrens, R; Kuehl, A; Kelly, K; Thorne, P; Burmeister, L; Merchant, J				Chrischilles, E; Ahrens, R; Kuehl, A; Kelly, K; Thorne, P; Burmeister, L; Merchant, J			Asthma prevalence and morbidity among rural Iowa schoolchildren	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; screening; rural; farm	SCREENING QUESTIONNAIRE; ALLERGIC DISEASES; URBAN CHILDREN; HAY-FEVER; SCHOOL; FARM; ADOLESCENTS	Background: There are conflicting findings about the prevalence of asthma among farm and nonfarm children. Objectives: We sought to estimate asthma prevalence and morbidity and determine differences between farm and nonfarm children. Methods: The study population consisted of all children aged 6 to 14 years enrolled in 10 school districts in 2 noncontiguous rural Iowa counties from 2000 through 2002. The mailed parental screening questionnaire included the International Study of Asthma and Allergies in Childhood core questionnaire, items from the Functional Severity Index, and items on physician diagnosis and medication and urgent care use. Results: The response rate was 86.6%. The 12-month prevalence of wheeze was 19.1 %. Self-reported physician diagnosis of asthma was reported by 13.4%. On multivariable analysis controlling for age, sex, and county, children who lived on farms were less likely than those who lived in town to have ever wheezed (odds ratio, 0.71; 95% CI, 0.58-0.87) or to have wheezed during the past year (odds ratio, 0.77; 95% CI, 0.60-0.98). However, this protective association with farming was only observed in one of the study counties. Among those who wheezed, farm and nonfarm children were equally likely to have been given a diagnosis of asthma and had comparable morbidity. Conclusion: By using a standardized questionnaire with a high response rate in this large, rural, population-based study, asthma prevalence rivaled that in large Midwestern cities. Unmeasured risk factors might account for the apparent protective effect in Keokuk County. These findings cast doubt on a protective effect of rural life for the development of childhood asthma.	Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Coll Publ Hlth, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA; Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa	Chrischilles, E (corresponding author), Univ Iowa, Coll Publ Hlth, Dept Epidemiol, 200 Hawkins Dr, Iowa City, IA 52242 USA.		Kelly, Kevin M./O-5485-2019; Kelly, Kevin M/E-2716-2013	Kelly, Kevin M./0000-0002-9177-1454; Kelly, Kevin M/0000-0002-9177-1454; Thorne, Peter/0000-0002-5045-0929; Chrischilles, Elizabeth/0000-0002-1843-1955	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009607, P30ES005605] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30-ES05605, ES09607] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asher MI, 1998, EUR RESPIR J, V12, P315; Asher MI, 1998, CLIN EXP ALLERGY, V28, P52; Bauer EJ, 1999, J SCHOOL HEALTH, V69, P12, DOI 10.1111/j.1746-1561.1999.tb02335.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; DOUWES J, 2002, MODERN IND HYGIENE, V4; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563, DOI 10.1164/ajrccm.161.5.9908119; Frank PI, 2001, BRIT J GEN PRACT, V51, P117; Frank TL, 1999, EUR RESPIR J, V14, P1190, DOI 10.1183/09031936.99.14511909; Freeman NCG, 2002, AM J PUBLIC HEALTH, V92, P45, DOI 10.2105/AJPH.92.1.45; Glasgow NJ, 2001, MED J AUSTRALIA, V174, P384, DOI 10.5694/j.1326-5377.2001.tb143338.x; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; KOLNAAR BGM, 1994, FAM PRACT, V11, P133, DOI 10.1093/fampra/11.2.133; Merchant JA, 2002, J RURAL HEALTH, V18, P521, DOI 10.1111/j.1748-0361.2002.tb00919.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; ROSIER MJ, 1994, AM J RESP CRIT CARE, V149, P1434, DOI 10.1164/ajrccm.149.6.8004295; Schenker MB, 1998, AM J RESP CRIT CARE, V158, pS1; SIERSTED HC, 1998, BRIT MED J, V316, P613; Tong S, 1999, Aust J Rural Health, V7, P18, DOI 10.1046/j.1440-1584.1999.00195.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; WILLIAMS JK, 1995, J SCHOOL HEALTH, V65, P234, DOI 10.1111/j.1746-1561.1995.tb03371.x; Yawn BP, 2001, J RURAL HEALTH, V17, P32, DOI 10.1111/j.1748-0361.2001.tb00252.x	23	62	64	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					66	71		10.1016/j.jaci.2003.09.037	http://dx.doi.org/10.1016/j.jaci.2003.09.037			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	760MP	14713909				2022-12-18	WOS:000187837900008
J	Hao, MQ; Comier, S; Wang, MY; Lee, JJ; Nel, A				Hao, MQ; Comier, S; Wang, MY; Lee, JJ; Nel, A			Diesel exhaust particles exert acute effects on airway inflammation and function in murine allergen provocation models	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						diesel exhaust particle; airway hyperreactivity; asthma; mouse models	PARTICULATE; ASTHMA; HYPERRESPONSIVENESS; RESPONSIVENESS; EXPRESSION; MICE; ENHANCEMENT; ASSOCIATION; CHALLENGE; POLLUTION	Background: Epidemiologic studies show that sudden surges in ambient particulate matter (PM) levels can trigger acute asthma exacerbations. Although diesel exhaust particles (DEPs) act as an adjuvant for allergic sensitization, this is a delayed response and does not explain acute PM effects on airway hyperreactivity (AHR). Objective: Our aim was to determine the acute effects of DEPs on AHR using a mouse model. Methods: Three protocols were developed, 2 of which require OVA sensitization, whereas the third was OVA independent. In the mild sensitization protocol BALB/c mice receive intraperitoneal OVA without alum and are then challenged with aerosolized OVA with or without DEPs. In the postchallenge model DEPs are delivered after OVA challenge to animals sensitized by intraperitoneal OVA plus alum. In the third protocol nebulizer DEPs were also delivered to IL-5-overexpressing mice that exhibit constitutive airway inflammation. Animals were subjected to whole-body plethysmography (WBP) and then killed for performance of bronchoalveolar lavage, histology, and serology. Results: DEP delivery concomitant with OVA challenge or after the induction of airway inflammation with this allergen induced increased AHR in models 1 and 2, respectively. Although these animals showed DEP-induced inflammation and mucus production in the intermediary airways, there was no effect on OVA-specific IgE or T(H)2 cytokine production. In the IL-5 transgenic mice it was possible to induce similar effects with DEPs in the absence of an allergen. Conclusion: We demonstrate that DEPs induced AHR independent of their adjuvant effects, suggesting the use of these models to study the mechanism or mechanisms of acute asthma exacerbation by means of PM.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol & Allergy, Los Angeles, CA 90095 USA; Mayo Clin, Div Pulm Med, Scottsdale, AZ USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Mayo Clinic; Mayo Clinic Phoenix	Nel, A (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol & Allergy, 10833 Le Conte Ave,52-175 CHS, Los Angeles, CA 90095 USA.		Cormier, Stephania A/I-7382-2017; Nel, Andre E/J-2808-2012	Cormier, Stephania A/0000-0002-6050-6172; 	NHLBI NIH HHS [HL65228] Funding Source: Medline; NIAID NIH HHS [P01-AI50495] Funding Source: Medline; NIAMS NIH HHS [F32 AR08545] Funding Source: Medline; NIEHS NIH HHS [R01-ES10553] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR008545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010553] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Borchers MT, 2001, AM J PHYSIOL-LUNG C, V280, pL813, DOI 10.1152/ajplung.2001.280.4.L813; D'Amato G, 2002, ALLERGY, V57, P30, DOI 10.1034/j.1398-9995.57.s72.5.x; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Deurloo DT, 2001, AM J RESP CELL MOL, V25, P751, DOI 10.1165/ajrcmb.25.6.4607; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Ichinose T, 2002, TOXICOLOGY, V180, P293, DOI 10.1016/S0300-483X(02)00420-1; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Li N, 2002, J IMMUNOL, V169, P4531, DOI 10.4049/jimmunol.169.8.4531; Lim HB, 1998, FREE RADICAL BIO MED, V25, P635, DOI 10.1016/S0891-5849(98)00073-2; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024, DOI 10.1016/S0091-6749(99)70084-9; Polosa R, 1999, Can Respir J, V6, P436; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; Takano H, 1998, IMMUNOPHARM IMMUNOT, V20, P329, DOI 10.3109/08923979809038548; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; Veronesi B, 1999, TOXICOL APPL PHARM, V154, P106, DOI 10.1006/taap.1998.8567; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Walters DM, 2001, AM J RESP CRIT CARE, V164, P1438, DOI 10.1164/ajrccm.164.8.2007121; Whitekus MJ, 2002, J IMMUNOL, V168, P2560, DOI 10.4049/jimmunol.168.5.2560; WJST M, 1993, BRIT MED J, V307, P596, DOI 10.1136/bmj.307.6904.596	25	62	64	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					905	914		10.1016/j.jaci.2003.07.005	http://dx.doi.org/10.1016/j.jaci.2003.07.005			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743BV	14610479	Green Published, Bronze			2022-12-18	WOS:000186553300012
J	Verster, JC; Volkerts, ER; van Oosterwijck, AWAA; Aarab, M; Bijtjes, SIR; De Weert, AM; Eijken, EJE; Verbaten, MN				Verster, JC; Volkerts, ER; van Oosterwijck, AWAA; Aarab, M; Bijtjes, SIR; De Weert, AM; Eijken, EJE; Verbaten, MN			Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						levocetirizine; diphenhydramine; memory; attention; psychomotor; mood; antihistamine	PSYCHOMETRIC TEST-PERFORMANCE; HEALTHY ADULT VOLUNTEERS; HISTAMINE-INDUCED WHEAL; DAYTIME SLEEPINESS; ALLERGIC RHINITIS; DOUBLE-BLIND; CETIRIZINE; LORATADINE; ANTIHISTAMINES; FLARE	Central nervous system adverse effects, such as sedation, often accompany the use of first-generation antihistamines. These effects might interfere with memory functioning and psychomotor performance. Levocetirizine was recently introduced as a new antihistamine said to be free from sedative effects. Objective: We sought to investigate the effects of levocetirizine (5 mg), diphenhydramine (50 mg), and placebo on memory and psychomotor performance after acute (day 1) and subchronic (day 4) daily administration in 48 healthy volunteers (24 men and 24 women). Methods: This study was a double-blind, placebo-controlled, randomized clinical trial. Treatments were administrated on days 1, 2, 3, and 4, 3 hours before the start of the laboratory test battery (performed on days 1 and 4), comprising a word-learning test, the Sternberg Memory Scanning Test, a tracking test (easy and hard version), and a divided attention test (tracking and memory scanning simultaneously). Statistical analyses were performed separately for days 1 and 4 by using analysis of variance. Results: On day 1, diphenhydramine significantly impaired tracking performance (easy: F-19,F-0 = 25.9, P <.0001; hard: F-1,F-90 = 20.5, P <.0001) and divided attention (tracking: F-1,F-90 = 23.8, P <.0001; memory scanning: F-1,F-90 = 22.0, P <.0001). Results on word-learning tests and Sternberg Memory Scanning Tests were not significantly impaired. On day 4, the effects of diphenhydramine did not reach significance. In contrast, on both days I and 4, levocetirizine did not significantly impair laboratory test performance. Conclusion: The results show that memory, attention, and tracking performance are unaffected after acute and subchronic administration of levocetirizine (5 mg), whereas diphenhydramine (50 mg) significantly affected divided attention and tracking after acute administration.	Univ Utrecht, Inst Pharmaceut Sci, Dept Psychopharmacol, NL-3508 TB Utrecht, Netherlands	Utrecht University	Verster, JC (corresponding author), Univ Utrecht, Inst Pharmaceut Sci, Dept Psychopharmacol, POB 80082, NL-3508 TB Utrecht, Netherlands.		Verster, Joris C/A-9017-2008	Verster, Joris/0000-0002-6455-2096				Benedetti MS, 2001, EUR J CLIN PHARMACOL, V57, P571; Clough GF, 2001, ALLERGY, V56, P985, DOI 10.1034/j.1398-9995.2001.00204.x; Devalia JL, 2001, ALLERGY, V56, P50, DOI 10.1034/j.1398-9995.2001.00726.x; Gillard M, 2002, INFLAMM RES, V51, pS77; Gillard M, 2002, INFLAMM RES, V51, pS79; Gillard M, 2002, MOL PHARMACOL, V61, P391, DOI 10.1124/mol.61.2.391; Gilmore TM, 1996, AM J IND MED, V30, P234; Grant JA, 2002, ANN ALLERG ASTHMA IM, V88, P190, DOI 10.1016/S1081-1206(10)61995-3; Hindmarch I, 2001, CURR MED RES OPIN, V17, P241, DOI 10.1185/0300799019117011; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; Kay GG, 2001, ALLERGY ASTHMA PROC, V22, P281; Leynadier F, 2001, Acta Otorhinolaryngol Belg, V55, P305; MATTILA MJ, 1986, EUR J CLIN PHARMACOL, V31, P291, DOI 10.1007/BF00981126; MOSKOWITZ H, 1988, CUTIS, V42, P14; Nicholson AN, 1998, AVIAT SPACE ENVIR MD, V69, P166; OHANLON JF, 1995, ALLERGY, V50, P234, DOI 10.1111/j.1398-9995.1995.tb01140.x; Ramaekers JG, 2000, BRIT MED J, V321, P572, DOI 10.1136/bmj.321.7260.572; RAMAEKERS JG, 1992, EUR J CLIN PHARMACOL, V42, P363; SCHWEITZER PK, 1994, J ALLERGY CLIN IMMUN, V94, P716, DOI 10.1016/0091-6749(94)90179-1; Simons FER, 1995, ANN ALLERG ASTHMA IM, V75, P507; Storms W, 1997, J ALLERGY CLIN IMMUN, V99, pS820, DOI 10.1016/S0091-6749(97)80042-5; VOLKERTS ER, 1992, HUM PSYCHOPHARM CLIN, V7, P227, DOI 10.1002/hup.470070402; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; Wang DY, 2001, ALLERGY, V56, P339, DOI 10.1034/j.1398-9995.2001.00775.x; WITEK TJ, 1992, J ALLERGY CLIN IMMUN, V90, P953, DOI 10.1016/0091-6749(92)90468-H; WITEK TJ, 1995, ANN ALLERG ASTHMA IM, V74, P419	26	62	65	2	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					623	627		10.1067/mai.2003.63	http://dx.doi.org/10.1067/mai.2003.63			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	656YW	12642847	Bronze			2022-12-18	WOS:000181639500028
J	Kusunoki, T; Sugai, M; Katakai, T; Omatsu, Y; Iyoda, T; Inaba, K; Nakahata, T; Shimizu, A; Yokota, Y				Kusunoki, T; Sugai, M; Katakai, T; Omatsu, Y; Iyoda, T; Inaba, K; Nakahata, T; Shimizu, A; Yokota, Y			T(H)2 dominance and defective development of a CD8(+) dendritic cell subset in Id2-deficient mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Id2; basic helix-loop-helix factor; T(H)1; T(H)2; dendtritic cell	HELIX INHIBITOR ID2; IN-VIVO; TRANSCRIPTION FACTOR; MYELOID PROGENITOR; LYMPHOID ORGANS; DIFFERENTIATION; CD8-ALPHA(+); COMMITMENT; RELB; POPULATIONS	Background: Although the T(H)1/T(H)2 balance is important in many clinical situations, the regulatory mechanisms in vivo have not been well elucidated. Objective: We sought to characterize the immunologic status of mice lacking Id2, an inhibitor of basic helix-loop-helix transcription factors. Methods: We analyzed serum immunoglobulin levels, gene-expression profiles in the spleen, T(H)1/T(H)2 balance, and dendritic cell (DC) populations of Id2(-/-) mice. Results: Serum levels of T(H)2-mediated IgG1 and IgE were increased more than 10-fold in Id2(-/-) mice without antigenic stimulation. Gene-expression analysis in Id2(-/-) splenocytes revealed enhanced expression of T(H)2-related genes, such as IL-4, and reduced expression of T(H)1-related genes, including IFN-gamma and IL-12. Intracellular cytokine staining also confirmed that Id2(-/-) splenic CD4(+) T cells are substantially skewed to T(H)2 cells. However, Id2(-/-) naive CD4(+) T cells differentiated into T(H)1 cells comparably with wild-type T cells under the appropriate culture conditions. Id2(-/-) mice displayed a selective and remarkable reduction of the CD8alpha(+)DC subset,which is known to induce preferential T(H)1 differentiation. Conclusion: Id2 is an indispensable regulator of the T(H)1/T(H)2 balance, possibly through the proper development of CD8alpha(+) DCs, and could be a novel target to treat allergic diseases.	Fukui Med Univ, Dept Biochem, Fukui 9101193, Japan; Kyoto Univ Hosp, Translat Res Ctr, Kyoto 606, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Anim Dev & Physiol, Kyoto, Japan; Kyoto Univ, Ctr Mol Biol & Genet, Kyoto, Japan; Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan	University of Fukui; Kyoto University; Kyoto University; Kyoto University; Kyoto University	Yokota, Y (corresponding author), Fukui Med Univ, Dept Biochem, 23-3 Shimoaizuki, Fukui 9101193, Japan.		Kusunoki, Takashi/AAE-5512-2019; Katakai, Tomoya/AAX-1434-2021	Katakai, Tomoya/0000-0002-4290-7028; Omatsu, Yoshiki/0000-0002-6212-0441; Sugai, Manabu/0000-0003-1668-7647				Anderson KL, 2000, J IMMUNOL, V164, P1855, DOI 10.4049/jimmunol.164.4.1855; Ardavin C, 2001, TRENDS IMMUNOL, V22, P691, DOI 10.1016/S1471-4906(01)02059-2; Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bjorck P, 2001, BLOOD, V98, P3520, DOI 10.1182/blood.V98.13.3520; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; del Hoyo GM, 2002, BLOOD, V99, P999, DOI 10.1182/blood.V99.3.999; del Hoyo GM, 2002, NATURE, V415, P1043, DOI 10.1038/4151043a; Guerriero A, 2000, BLOOD, V95, P879, DOI 10.1182/blood.V95.3.879.003k13_879_885; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Ikawa T, 2001, P NATL ACAD SCI USA, V98, P5164, DOI 10.1073/pnas.091537598; Iyoda T, 2002, J EXP MED, V195, P1289, DOI 10.1084/jem.20020161; Katakai T, 1998, INT IMMUNOL, V10, P1325, DOI 10.1093/intimm/10.9.1325; Maldonado-Lopez R, 2001, SEMIN IMMUNOL, V13, P275, DOI 10.1006/smim.2001.0323; Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587; Maldonado-Lopez R, 2001, J IMMUNOL, V167, P4345, DOI 10.4049/jimmunol.167.8.4345; Manz MG, 2001, BLOOD, V97, P3333, DOI 10.1182/blood.V97.11.3333; Merad M, 2000, BLOOD, V96, P1865, DOI 10.1182/blood.V96.5.1865.h8001865_1865_1872; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Norton JD, 2000, J CELL SCI, V113, P3897; Ohteki T, 1999, J EXP MED, V189, P1981, DOI 10.1084/jem.189.12.1981; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Satoskar AR, 1999, J IMMUNOL, V162, P6747; Spits H, 2000, J EXP MED, V192, P1775, DOI 10.1084/jem.192.12.1775; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Traver D, 2000, SCIENCE, V290, P2152, DOI 10.1126/science.290.5499.2152; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; Vremec D, 2000, J IMMUNOL, V164, P2978, DOI 10.4049/jimmunol.164.6.2978; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Wang MD, 1998, J IMMUNOL, V160, P1098; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4; Wu L, 2001, BLOOD, V98, P3376, DOI 10.1182/blood.V98.12.3376; Wu L, 1997, IMMUNITY, V7, P483, DOI 10.1016/S1074-7613(00)80370-2; Yokota Y, 2001, ONCOGENE, V20, P8290, DOI 10.1038/sj.onc.1205090; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	41	62	64	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					136	142		10.1067/mai.2003.29	http://dx.doi.org/10.1067/mai.2003.29			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532109	Bronze			2022-12-18	WOS:000180465500021
J	Baramki, D; Koester, J; Anderson, AJ; Borish, L				Baramki, D; Koester, J; Anderson, AJ; Borish, L			Modulation of T-cell function by R- and (S)-isomers of albuterol: Anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						albuterol; beta-adrenergic receptor; racemic; T lymphocyte; cytokine; apoptosis; proliferation	BETA(2)-ADRENERGIC RECEPTOR; BETA-ADRENOCEPTOR; RACEMIC ALBUTEROL; INTERFERON-GAMMA; S-ALBUTEROL; ENANTIOMERS; BETA(2)-AGONISTS; LEVALBUTEROL; INHIBITION; SALBUTAMOL	Background: beta(2)-Adrenergic agonists interact with specific receptors on T lymphocytes to mediate anti-inflammatory activities. However, anti-inflammatory effects are not observed when beta-adrenergic agonists are administered in vivo as racemates. Objective: We hypothesized that anti-inflammatory influences are mediated by the (R)-isomer and are masked in the additional presence of the (S)-isomer. Methods: Antigen-specific T-cell lines were generated in the presence of recombinant human IL-2 and tetanus with or without varying concentrations of (R)- and (S)-isomers of albuterol alone or in combination. Parallel lines were generated in the presence of propranolol. Cells were briefly pulsed with PHA and evaluated for proliferation, apoptosis, and cytokine secretion. Results: (R)-Albuterol significantly inhibited T-cell proliferation (77.0% +/- 9.7% of control at 10(-8) mol/L and 61.1% +/- 9.0% at 10(-7) mol/L). No influence was observed with (S)albuterol alone. However, the addition of (S)-albuterol to (R)albuterol mediated a dose-dependent increase in proliferation. At equivalent concentrations of the 2 isomers, proliferation was unchanged from the control, whereas at 10(-6) mol/L (S)albuterol, proliferation was enhanced. Both the inhibitory effects of (R)-albuterol alone and the stimulating influence of (R)- plus (S)-albuterol were blocked in the additional presence of propranolol. (R)-Albuterol at 10-8 mol/L inhibited IL-2 and IFN-gamma production. Racemic albuterol (10-8 mol/L each) had no influence on cytokine production; however, the combination of 10-8 mol/L (R)-albuterol with 10-6 (S)-albuterol stimulated production of IL-2 and IL-13. No effects were observed on apoptosis or cell viability. Conclusion: These studies confirm the P-adrenergic receptor-specific anti-inflammatory effects of (R)-albuterol. The racemate had minimal influences on proliferation or cytokine production. The presence of excess (S)-albuterol resulted in proinflammatory influences. We hypothesize that the (S)-isomer functions as an inverse agonist to switch the function of the beta(2)-adrenergic receptor.	Univ Virginia, Asthma & Allergy Dis Ctr, Beirne Carter Ctr Immunol Res, Dept Med, Charlottesville, VA 22908 USA; Sepracor Inc, Marlborough, MA USA	University of Virginia; Dainippon Sumitomo Pharmaceutical Company; Sunovion Pharmaceuticals Inc.	Borish, L (corresponding author), Univ Virginia, Asthma & Allergy Dis Ctr, Beirne Carter Ctr Immunol Res, Dept Med, Box 801355, Charlottesville, VA 22908 USA.				NIAID NIH HHS [K24 AI001793-03, AI01793, AI/HL47737] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047737, K24AI001793] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal S, 1999, J ALLERGY CLIN IMMUN, V103, P990, DOI 10.1016/S0091-6749(99)70168-5; AGRAWAL DK, 2000, AM J RESP CRIT CARE, V161, pA191; AndradeMena CE, 1997, J NEUROIMMUNOL, V76, P10, DOI 10.1016/S0165-5728(97)00015-5; BETZ M, 1991, J IMMUNOL, V146, P108; Borger P, 1998, AM J RESP CELL MOL, V19, P400, DOI 10.1165/ajrcmb.19.3.2765; Borger P, 1998, J ALLERGY CLIN IMMUN, V101, P231, DOI 10.1016/S0091-6749(98)70388-4; Busse WW, 1999, J ALLERGY CLIN IMMUN, V103, pS136; Chidiac P, 1996, MOL PHARMACOL, V50, P662; Cho S, 2000, J ALLERGY CLIN IMMUN, V105, pS22, DOI 10.1016/S0091-6749(00)90495-0; COCKCROFT DW, 1995, J ALLERGY CLIN IMMUN, V96, P44, DOI 10.1016/S0091-6749(95)70031-5; Cockcroft DW, 1999, J ALLERGY CLIN IMMUN, V103, P1049, DOI 10.1016/S0091-6749(99)70178-8; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; de Vries B, 2000, BRIT J PHARMACOL, V131, P915, DOI 10.1038/sj.bjp.0703664; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Gawchik SM, 1999, J ALLERGY CLIN IMMUN, V103, P615, DOI 10.1016/S0091-6749(99)70233-2; GRIESE M, 1988, EUR J CLIN INVEST, V18, P213, DOI 10.1111/j.1365-2362.1988.tb02416.x; Gumbhir-Shah K, 1999, PULM PHARMACOL THER, V12, P353, DOI 10.1006/pupt.1999.0217; Handley D, 1999, J ALLERGY CLIN IMMUN, V104, pS69, DOI 10.1016/S0091-6749(99)70276-9; Handley D A, 2000, Curr Opin Pulm Med, V6, P43, DOI 10.1097/00063198-200001000-00009; Holen E, 1998, APMIS, V106, P849, DOI 10.1111/j.1699-0463.1998.tb00231.x; Israel E, 2000, J ALLERGY CLIN IMMUN, V105, pS23, DOI 10.1016/S0091-6749(00)90497-4; Johansson F, 1996, CLIN REV ALLERG IMMU, V14, P57, DOI 10.1007/BF02772203; Kaminuma O, 1996, J PHARMACOL EXP THER, V279, P240; Krouwels FH, 1998, AM J RESP CELL MOL, V18, P721, DOI 10.1165/ajrcmb.18.5.2909; Leff AR, 1997, PULM PHARMACOL THER, V10, P97, DOI 10.1006/pupt.1997.0082; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Milligan G, 1997, TRENDS PHARMACOL SCI, V18, P468, DOI 10.1016/S0165-6147(97)90685-4; Mitra S, 1998, MOL PHARMACOL, V53, P347, DOI 10.1124/mol.53.3.347; Mohede ICM, 1996, INT J IMMUNOPHARMACO, V18, P193, DOI 10.1016/0192-0561(96)00008-2; Moore RH, 1998, CHEST, V113, P1095, DOI 10.1378/chest.113.4.1095; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V102, P943, DOI 10.1016/S0091-6749(98)70332-X; NELSON HS, 1995, NEW ENGL J MED, V333, P499, DOI 10.1056/NEJM199508243330807; PaninaBordignon P, 1997, J CLIN INVEST, V100, P1513, DOI 10.1172/JCI119674; Penn RB, 1996, CLIN REV ALLERG IMMU, V14, P37, DOI 10.1007/BF02772201; PerrinFayolle M, 1996, CLIN REV ALLERG IMMU, V14, P139, DOI 10.1007/BF02772208; Ramer-Quinn DS, 1997, J IMMUNOL, V159, P4857; Schmekel B, 1999, EUR RESPIR J, V13, P1230, DOI 10.1034/j.1399-3003.1999.13f04.x; SCHRECK DM, 2001, ANN EMERG MED, V38, pS10; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; TRUITT TJ, 2001, AM J RESP CRIT CARE, V163, pA644; Volcheck GW, 1998, J ALLERGY CLIN IMMUN, V101, pS35; Yamaguchi H, 1996, CLIN REV ALLERG IMMU, V14, P47, DOI 10.1007/BF02772202	42	62	67	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					449	454		10.1067/mai.2002.122159	http://dx.doi.org/10.1067/mai.2002.122159			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11897990				2022-12-18	WOS:000174586400011
J	Kanegane, H; Futatani, T; Wang, Y; Nomura, K; Shinozaki, K; Matsukura, H; Kubota, T; Tsukada, S; Miyawaki, T				Kanegane, H; Futatani, T; Wang, Y; Nomura, K; Shinozaki, K; Matsukura, H; Kubota, T; Tsukada, S; Miyawaki, T			Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						X-linked agammaglobulinemia; Bruton's tyrosine kinase; hypogammaglobulinemia; B cells; flow cytometry; genetic analysis; obligate carrier	BRUTONS-TYROSINE-KINASE; DEFICIENT EXPRESSION; B-CELLS; BTK; PROTEIN; FAMILY; IMMUNODEFICIENCY; PHENOTYPE; XLA	Background: X-linked agammaglobulinemia (XLA), caused by mutations in Bruton's tyrosine kinase (BTK), is the most common form of inherited antibody deficiency. We previously reported that a flow cytometric evaluation of BTK expression in monocytes could easily detect XLA as well as its carrier. Objective: Our purpose was to perform further flow cytometric analysis in additional XLA families in Japan. Methods: In all, 106 hypogammaglobulinemic males (from 91 families) of various ages with a lack of mature B cells (<1%) were investigated. Results: Flow cytometric assessment revealed the deficient BTK expression status in 78 families (93 patients), and mutations in BTK were identified in 76 or 78 families with presumed XLA. Of the patients with normal BTK expression, 2 showed missense mutations in which the normal amount of altered BTK transcript would cause the XLA phenotype. As many as 30% of these patients with XLA were clinically or genetically recognized beyond 5 years of age. Higher concentrations (>300 mg/dL) of serum IgG were evident in the cases diagnosed among adults, seemingly preventing severe infections. Fifty-seven of 70 mothers of patients with BTK deficiency were diagnosed as obligate carriers on the basis of a bimodal BTK expression pattern. Nine of the remaining 13 mothers showing nonmosaic BTK expression had no mutations in 2 alleles; surprisingly, the other 4 mothers had the mutated alleles. Conclusions: A diagnostic approach based on flow cytometric assessment for XLA should be initially considered in genetic investigation of antibody deficiencies, regardless or the patient's age.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Pediat, Toyama 9300194, Japan; Shinshu Univ, Sch Med, Dept Clin & Mol Genet, Matsumoto, Nagano 390, Japan; Osaka Univ, Sch Med, Dept Mol Med, Suita, Osaka 565, Japan	University of Toyama; Shinshu University; Osaka University	Miyawaki, T (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Pediat, 2630 Sugitani, Toyama 9300194, Japan.							ANKER R, 1989, J EXP MED, V169, P2109, DOI 10.1084/jem.169.6.2109; Busque L, 1996, BLOOD, V88, P59; Bykowsky MJ, 1996, AM J HUM GENET, V58, P477; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Conley ME, 2000, CLIN REV ALLERG IMMU, V19, P183, DOI 10.1385/CRIAI:19:2:183; Conley ME, 1998, AM J HUM GENET, V62, P1034, DOI 10.1086/301828; Conley ME, 1998, CURR OPIN IMMUNOL, V10, P399, DOI 10.1016/S0952-7915(98)80112-X; CONLEY ME, 1994, HUM MOL GENET, V3, P1751, DOI 10.1093/hmg/3.10.1751; CONLEY ME, 1996, IMMUNOLOGIC DISORDER, P201; DeWeers M, 1997, CLIN EXP IMMUNOL, V107, P235, DOI 10.1111/j.1365-2249.1997.296-ce1185.x; Futatani T, 1998, BLOOD, V91, P595; Futatani T, 2001, BRIT J HAEMATOL, V114, P141, DOI 10.1046/j.1365-2141.2001.02905.x; Gaspar HB, 1998, CLIN EXP IMMUNOL, V111, P334; Hashimoto S, 1999, INTERNAL MED, V38, P722, DOI 10.2169/internalmedicine.38.722; Hashimoto S, 1996, BLOOD, V88, P561, DOI 10.1182/blood.V88.2.561.bloodjournal882561; Hashimoto S, 1999, BLOOD, V94, P2357, DOI 10.1182/blood.V94.7.2357.419k40_2357_2364; Kanegane H, 2000, CLIN EXP IMMUNOL, V120, P512, DOI 10.1046/j.1365-2249.2000.01244.x; Kornfeld SJ, 1997, J ALLERGY CLIN IMMUN, V100, P702, DOI 10.1016/S0091-6749(97)70176-3; Kornfeld SJ, 1996, MOL MED, V2, P619, DOI 10.1007/BF03401645; KORNFELD SJ, 1994, NEW ENGL J MED, V331, P949; Kubota T, 1999, HUM GENET, V104, P49, DOI 10.1007/s004390050909; Nomura K, 2000, BLOOD, V96, P610; Nonoyama S, 1998, J IMMUNOL, V161, P3925; Ochs HD, 1996, MEDICINE, V75, P287, DOI 10.1097/00005792-199611000-00001; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Sakamoto M, 2001, AM J MED GENET, V99, P234, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1159>3.0.CO;2-M; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; TSUKADA S, 1994, CURR OPIN IMMUNOL, V6, P623, DOI 10.1016/0952-7915(94)90151-1; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 1998, NUCLEIC ACIDS RES, V26, P242, DOI 10.1093/nar/26.1.242; Vihinen M, 1999, HUM MUTAT, V13, P280, DOI 10.1002/(SICI)1098-1004(1999)13:4<280::AID-HUMU3>3.0.CO;2-L	33	62	67	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					1012	1020		10.1067/mai.2001.120133	http://dx.doi.org/10.1067/mai.2001.120133			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742281				2022-12-18	WOS:000172938400019
J	Piliponsky, AM; Pickholtz, D; Gleich, GJ; Levi-Schaffer, F				Piliponsky, AM; Pickholtz, D; Gleich, GJ; Levi-Schaffer, F			Human eosinophils induce histamine release from antigen-activated rat peritoneal mast cells: A possible role for mast cells in late-phase allergic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rat peritoneal mast cells; eosinophils; major basic protein; IgE-dependent activation; IgE-independent activation; histamine; heparin; pertussis toxin	MAJOR BASIC-PROTEIN; COLONY-STIMULATING FACTOR; AIRWAY HYPERRESPONSIVENESS; CATIONIC PROTEIN; GRANULE; LUNG; HEPARIN; INFILTRATION; INHIBITION; EXOCYTOSIS	Background: Mast cells and eosinophils are believed to interact during the late and the chronic stages of allergic inflammation. Objective: In this study we investigated whether eosinophils can cause activation and consequent histamine release of already challenged mast cells, a situation likely to take place during the allergic late-phase reaction. Methods: Rat peritoneal mast cells presensitized with IgE anti-dinitrophenol-human serum albumin and challenged by dinitrophenol-human serum albumin or compound 48/80 were incubated with either eosinophil sonicate or major basic protein (MBP), Eosinophils were purified from the peripheral (> 98%) blood of mildly allergic patients. Heparin and pertussis toxin and different extracellular Ca2+ concentrations were used to modulate mast cell reactivation by MBP, Histamine release was assessed as a marker of mast cell activation. Results: IgE-challenged mast cells were sensitive to reactivation induced by eosinophil sonicate and MBP, Reactivation was not cytotoxic for the mast cells, Mast cells previously challenged with compound 48/80 did not respond to subsequent MBP activation. Furthermore, heparin and pertussis toxin both inhibited mast cell reactivation induced by MBP, The ability of eosinophil sonicate and MBP to activate mast cells was not significantly affected at the different Ca2+ concentrations, Conclusions: In summary, we have shown a direct activating activity of eosinophils, partially due to MBP, toward IgE-challenged and immunologically desensitized mast cells. This suggests that in vivo mast cells can be reactivated during a late-phase reaction to release histamine by a non-IgE-dependent mechanism.	Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol,Hasassah Med Sch, IL-91120 Jerusalem, Israel; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA	Hebrew University of Jerusalem; Mayo Clinic; Mayo Clinic	Levi-Schaffer, F (corresponding author), Hebrew Univ Jerusalem, Fac Med, Sch Pharm, Dept Pharmacol,Hasassah Med Sch, IL-91120 Jerusalem, Israel.			Levi-Schaffer, Francesca/0000-0003-0620-2810				ACKERMAN SJ, 1983, J IMMUNOL, V131, P2977; Ahmed T, 1997, AM J RESP CRIT CARE, V155, P1848, DOI 10.1164/ajrccm.155.6.9196085; ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; ARM JP, 1992, ADV IMMUNOL, V51, P323, DOI 10.1016/S0065-2776(08)60491-5; Barata LT, 1998, J ALLERGY CLIN IMMUN, V101, P222, DOI 10.1016/S0091-6749(98)70387-2; BARKER RL, 1991, J CLIN INVEST, V88, P798, DOI 10.1172/JCI115379; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P649, DOI 10.1016/0091-6749(91)90159-L; Bressler RB, 1997, J ALLERGY CLIN IMMUN, V99, P508, DOI 10.1016/S0091-6749(97)70078-2; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GAGA M, 1991, J IMMUNOL, V147, P816; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1986, P NATL ACAD SCI USA, V83, P3146, DOI 10.1073/pnas.83.10.3146; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GUO CB, 1994, AM J RESP CELL MOL, V10, P384, DOI 10.1165/ajrcmb.10.4.7510984; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Heaney LG, 1998, CLIN EXP ALLERGY, V28, P196; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Levi-Schaffer F, 1998, J IMMUNOL, V160, P5554; LEVISCHAFFER F, 1990, EUR J IMMUNOL, V20, P2609, DOI 10.1002/eji.1830201213; LEVISCHAFFER F, 1990, J IMMUNOL, V145, P3418; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; Molinari JF, 1998, AM J RESP CRIT CARE, V157, P887, DOI 10.1164/ajrccm.157.3.9708027; MOUSLI M, 1990, TRENDS PHARMACOL SCI, V11, P358, DOI 10.1016/0165-6147(90)90179-C; Nadel JA, 1998, AM J RESP CRIT CARE, V157, pS130, DOI 10.1164/ajrccm.157.4.nhlb1-11; Niitsuma A, 1996, GEN PHARMACOL, V27, P123, DOI 10.1016/0306-3623(95)00082-8; OKAYAMA Y, 1994, J ALLERGY CLIN IMMUN, V93, P900, DOI 10.1016/0091-6749(94)90384-0; Okayama Y, 1998, EUR J IMMUNOL, V28, P708, DOI 10.1002/(SICI)1521-4141(199802)28:02<708::AID-IMMU708>3.0.CO;2-A; ORTNER MJ, 1981, BIOCHEM PHARMACOL, V30, P283, DOI 10.1016/0006-2952(81)90055-1; Patella V, 1996, J IMMUNOL, V157, P1219; Rochester CL, 1996, J IMMUNOL, V156, P4449; SAITO H, 1987, J IMMUNOL, V138, P3927; SHAFF RE, 1979, ANAL BIOCHEM, V94, P425, DOI 10.1016/0003-2697(79)90385-3; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; SUZUKINISHIMURA T, 1995, GEN PHARMACOL, V26, P117; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P764, DOI 10.1016/0091-6749(94)90185-6; ZHEUTLIN LM, 1984, J IMMUNOL, V133, P2180; Zweiman B, 1997, J ALLERGY CLIN IMMUN, V100, P104, DOI 10.1016/S0091-6749(97)70201-X	43	62	65	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					993	1000		10.1067/mai.2001.114656	http://dx.doi.org/10.1067/mai.2001.114656			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398076				2022-12-18	WOS:000169454800009
J	Chapman, MD; Wood, RA				Chapman, MD; Wood, RA			The role and remediation allergens in of animal allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						animal allergens; cat allergens; mammalian allergens	FEL-D-I; DOUBLE-BLIND PLACEBO; DUST MITE ALLERGENS; T-CELL EPITOPES; CAT-ALLERGEN; MAJOR ALLERGEN; DOMESTIC CAT; AERODYNAMIC CHARACTERISTICS; ENVIRONMENTAL CHALLENGE; AIRBORNE CONCENTRATIONS	Animal allergens are common causes of both acute and chronic allergic disease. The most important animal allergens are derived from mammals, principally cats, dogs, rats, mice, horses, and cows, which secrete or excrete allergens into the environment. Allergic sensitization may occur at home or in the workplace. Cat and dog allergens commonly cause allergies in the home and affect the general population. Laboratory animal handlers often have allergic reactions to rats and mice. Cow dander allergy is usually caused by occupational exposure and occurs in farmers and farm workers. Horse allergy occurs among people who regularly handle horses, either professionally or for recreational purposes. Over the past 20 years, the major animal allergens have been defined and characterized with regard to their molecular structure, immunogenicity, and environmental distribution. One remarkable finding has been the fact that must of the mammalian allergens that have thus far been cloned belong to a single family of proteins called the lipocalins, In addition to these molecular similarities, it has also been shown that most of the animal allergens are quite similar with regard to their aerodynamic properties. Although much is yet to be learned, progress is being made in our knowledge regarding the steps that may be necessary to control exposure to these allergens through environmental modifications in both homes and occupational settings. These measures include source control, air filtration devices, barrier devices, removal of carpeting and other reservoirs, and, in some cases, washing of the animal.	Univ Virginia, Div Clin Immunol & Allergy, Charlottesville, VA 22908 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA	University of Virginia; Johns Hopkins University	Chapman, MD (corresponding author), Univ Virginia, Div Clin Immunol & Allergy, Bldg MR4,Rm 5060,Box 225,Lane Rd, Charlottesville, VA 22908 USA.			Chapman, Martin/0000-0002-0845-3632				Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; AOYAMA K, 1992, BRIT J IND MED, V49, P41; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; Avner DB, 1997, J ALLERGY CLIN IMMUN, V100, P307, DOI 10.1016/S0091-6749(97)70242-2; BLAND SM, 1986, J OCCUP ENVIRON MED, V28, P1151; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Bollinger ME, 1998, J ALLERGY CLIN IMMUN, V101, P124, DOI 10.1016/S0091-6749(98)70203-9; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; Chapman MD, 1999, J ALLERGY CLIN IMMUN, V103, pS122; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHARPIN C, 1994, CLIN EXP ALLERGY, V24, P1174, DOI 10.1111/j.1365-2222.1994.tb03325.x; CORN M, 1988, ANN OCCUP HYG     S1, V32, P435; Counsell CM, 1996, J ALLERGY CLIN IMMUN, V98, P884, DOI 10.1016/S0091-6749(96)80004-2; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589, DOI 10.1136/oem.51.9.589; Custovic A, 1998, THORAX, V53, P33, DOI 10.1136/thx.53.1.33; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164, DOI 10.1111/j.1365-2222.1994.tb03323.x; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; DYNBENDA T, 1992, CLIN EXP ALLERGY, V22, P1100; EGGLESTON PA, 1995, AM J RESP CRIT CARE, V151, P640; EGGLESTON PA, 1990, J ALLERGY CLIN IMMUN, V86, P63, DOI 10.1016/S0091-6749(05)80124-1; EGGLESTON PA, 1989, J ALLERGY CLIN IMMUN, V84, P347, DOI 10.1016/0091-6749(89)90419-3; Flower DR, 1996, BIOCHEM J, V318, P1; Gregoire C, 1996, J BIOL CHEM, V271, P32951, DOI 10.1074/jbc.271.51.32951; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; GURKA G, 1989, J ALLERGY CLIN IMMUN, V83, P945, DOI 10.1016/0091-6749(89)90110-3; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hodson T, 1999, J ALLERGY CLIN IMMUN, V103, P581, DOI 10.1016/S0091-6749(99)70227-7; Ichikawa K, 1999, J ALLERGY CLIN IMMUN, V103, pS184; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KLUCKA CV, 1995, J ALLERGY CLIN IMMUN, V95, P1164, DOI 10.1016/S0091-6749(95)70072-2; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; Lascombe MB, 2000, J BIOL CHEM, V275, P21572, DOI 10.1074/jbc.M002854200; Litonjua AA, 1997, AM J RESP CRIT CARE, V156, P23, DOI 10.1164/ajrccm.156.1.9608072; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; LOWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V77, P497, DOI 10.1016/0091-6749(86)90185-5; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; Mantyjarvi R, 1996, J ALLERGY CLIN IMMUN, V97, P1297, DOI 10.1016/S0091-6749(96)70198-7; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; MUNIR AKM, 1994, ALLERGY, V49, P508, DOI 10.1111/j.1398-9995.1994.tb01121.x; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1982, J ALLERGY CLIN IMMUN, V69, P320; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; OHMAN JL, 1974, J IMMUNOL, V113, P1668; OHMAN JL, 1977, J ALLERGY CLIN IMMUN, V60, P317, DOI 10.1016/0091-6749(77)90112-9; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 2001, IN PRESS LANCET; PRICE JA, 1990, CLIN EXP ALLERGY, V20, P71, DOI 10.1111/j.1365-2222.1990.tb02778.x; PUROHIT A, 1999, ACI INT, V11, P207; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Rouvinen J, 1999, J BIOL CHEM, V274, P2337, DOI 10.1074/jbc.274.4.2337; SAKAGUCHI M, 1990, LAB ANIM SCI, V40, P613; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; Sicherer SH, 1997, J ALLERGY CLIN IMMUN, V99, P798, DOI 10.1016/S0091-6749(97)80014-0; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278; SPITZAUER S, 1993, INT ARCH ALLERGY IMM, V100, P60, DOI 10.1159/000236389; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388, DOI 10.1164/ajrccm.151.5.7735590; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4; VAILES LD, 1994, J ALLERGY CLIN IMMUN, V93, P22, DOI 10.1016/0091-6749(94)90229-1; van der Heide S, 1999, J ALLERGY CLIN IMMUN, V104, P447, DOI 10.1016/S0091-6749(99)70391-X; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; VANDERBREMPT X, 1991, J ALLERGY CLIN IMMUN, V87, P595, DOI 10.1016/0091-6749(91)90020-O; VANHOF W, 1997, J BIOL CHEM, V272, P1837; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Vaughan JW, 2000, J ALLERGY CLIN IMMUN, V105, pS363, DOI 10.1016/S0091-6749(00)91493-3; VENABLES KM, 1988, BRIT J IND MED, V45, P667; Virtanen T, 1999, INT ARCH ALLERGY IMM, V120, P247, DOI 10.1159/000024277; Warner JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; WOOD RA, 1995, AM J RESP CRIT CARE, V151, P315, DOI 10.1164/ajrccm.151.2.7842184; WOOD RA, 1992, J ALLERGY CLIN IMMUN, V89, P126, DOI 10.1016/S0091-6749(05)80049-1; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P1002, DOI 10.1016/S0091-6749(99)70170-3; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110; WOOD RA, 1994, PROVOCATION TESTING; WOODFOLK JA, 1995, J ALLERGY CLIN IMMUN, V96, P325, DOI 10.1016/S0091-6749(95)70051-X; WOODFOLK JA, 1994, J ALLERGY CLIN IMMUN, V94, P19, DOI 10.1016/0091-6749(94)90066-3; Wu SY, 1999, J BIOL CHEM, V274, P170, DOI 10.1074/jbc.274.1.170; Zeiler T, 1999, J IMMUNOL, V162, P1415; ZIELONKA TM, 1994, CLIN EXP ALLERGY, V24, P1169, DOI 10.1111/j.1365-2222.1994.tb03324.x	92	62	65	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3		S			S414	S421		10.1067/mai.2001.113672	http://dx.doi.org/10.1067/mai.2001.113672			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	418KR	11242602	Bronze			2022-12-18	WOS:000167891800003
J	Posadas, SJ; Leyva, L; Torres, MJ; Rodriguez, JL; Bravo, I; Rosal, M; Fernandez, J; Juarez, C; Blanca, M				Posadas, SJ; Leyva, L; Torres, MJ; Rodriguez, JL; Bravo, I; Rosal, M; Fernandez, J; Juarez, C; Blanca, M			Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; drug reactions; T(H)1; T(H)2; cytokines	T-CELL ACTIVATION; PERIPHERAL-BLOOD; ATOPIC-DERMATITIS; RESISTANT ASTHMA; GENE-EXPRESSION; MESSENGER-RNA; INDIVIDUALS; INTERLEUKIN-5; EOSINOPHILS; MECHANISMS	Background: The mechanisms involved in adverse drug reactions with an immunologic basis (ADRIB) can be antibody dependent, mainly IgE or T cell dependent (sensitized T cells), These mechanisms are regulated by a number of cytokines, including IL-2, IL-4, IL-5, IFN-gamma, and TNF-alpha, which follow the classical T(H)1/T(H)2 immunologic paradigm. Although evidence for this has been seen in ex vivo studies, the results are heterogeneous, and few in vivo studies have been carried out in subjects with ADRIB. Objective: We studied a group of patients who experienced either immediate reactions (n = 10) or nonimmediate reactions (n = 9) to drugs to determine the cytokine pattern profile during the acute stage of the response, as well as after recovery. Methods: PBMCs were taken at different time intervals of 24 hours or less and 7, 15, and 30 days after the onset of the reaction, and the specific cytokine transcription and production were determined by using quantitative competitive RT-PCR and ELISA, respectively, Results: There was a transient polarized pattern corresponding to a T(H)1 response with IL-2, IFN-gamma, and TNF-alpha in nonimmediate reactions and to a T(H)2 response with IL-4 in immediate reactions. Conclusions: This is the first in vivo demonstration of these T(H)1/T(H)2 patterns in subjects with ADRIB and confirms that an immunologic process is occurring related to the mechanisms involved in the pathologic manifestation. These findings are relevant to the understanding of the pathophysiologic mechanisms involved in ADRIB, suggesting that further studies in this direction are warranted.	Hosp Univ La Paz, Allergy Serv, Madrid 28046, Spain; Carlos Haya Hosp, Res Unit Allerg Dis, Malaga, Spain; Elche Hosp, Allergy Unit, Alicante, Spain; Carlos Haya Hosp, Dept Internal Med, Malaga, Spain; Civil Hosp, Emergency Unit, Malaga, Spain	Hospital Universitario La Paz; Hospital Carlos Haya; Hospital Carlos Haya	Blanca, M (corresponding author), Hosp Univ La Paz, Allergy Serv, Paseo de la Castellana 261, Madrid 28046, Spain.		POSADAS, SINFORIANO J/H-8075-2013; Leyva, Laura/R-2187-2019; Torres, Maria/GVU-3391-2022; Leyva, Laura/B-5574-2019; Torres, María José/T-3518-2017; Fernandez, Javier/B-6425-2018	POSADAS, SINFORIANO J/0000-0003-0014-1957; Leyva, Laura/0000-0003-0620-9625; Leyva, Laura/0000-0003-0620-9625; Torres, María José/0000-0001-5228-471X; Fernandez, Javier/0000-0003-1065-7199				ADI A, 1991, AM REV RESPIR DIS, V143, P533; AMOS HE, 1976, ALLERGIC DRUG REACTI, P64; BRANDER C, 1995, J IMMUNOL, V155, P2670; Brugnolo F, 1999, J IMMUNOL, V163, P1053; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coleman JW, 1998, IMMUNOL TODAY, V19, P196, DOI 10.1016/S0167-5699(97)01231-0; CORRIGAN CJ, 1988, LANCET, V1, P1129; CORRIGAN CJ, 1995, AM J RESP CELL MOL, V12, P567, DOI 10.1165/ajrcmb.12.5.7742019; Demoly P, 1998, THORAX, V53, P1063, DOI 10.1136/thx.53.12.1063; DOI S, 1994, CLIN EXP ALLERGY, V24, P854, DOI 10.1111/j.1365-2222.1994.tb01808.x; EIERMAN DF, 1989, J IMMUNOL, V142, P1970; Ferry B, 1997, CLIN EXP IMMUNOL, V110, P410, DOI 10.1046/j.1365-2249.1997.4361452.x; GARSIDE P, 1995, IMMUNOL TODAY, V16, P220, DOI 10.1016/0167-5699(95)80162-6; GERBLICH AA, 1984, NEW ENGL J MED, V310, P1349, DOI 10.1056/NEJM198405243102103; GOJEAU JC, 1994, NEW ENGL J MED, V331, P1272; Gonzalez FJ, 1997, J ALLERGY CLIN IMMUN, V100, P135, DOI 10.1016/S0091-6749(97)70205-7; Gonzalez FJ, 1997, INT ARCH ALLERGY IMM, V113, P345, DOI 10.1159/000237597; HERSHKOVIZ R, 1994, J IMMUNOL, V153, P554; HERTL M, 1995, J INVEST DERMATOL, V105, pS95, DOI 10.1038/jid.1995.19; Ho KKL, 1998, CLIN EXP ALLERGY, V28, P889; Katagiri K, 1997, CLIN EXP IMMUNOL, V108, P289, DOI 10.1046/j.1365-2249.1997.d01-1015.x; Kemeny DM, 1998, CURR OPIN IMMUNOL, V10, P628, DOI 10.1016/S0952-7915(98)80080-0; Lara-Marquez ML, 1998, J ALLERGY CLIN IMMUN, V101, P699, DOI 10.1016/S0091-6749(98)70180-0; Leung DYM, 1998, ANN NY ACAD SCI, V840, P735, DOI 10.1111/j.1749-6632.1998.tb09612.x; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Leyva L, 2000, J ALLERGY CLIN IMMUN, V105, P157, DOI 10.1016/S0091-6749(00)90191-X; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Padovan E, 1997, EUR J IMMUNOL, V27, P1303, DOI 10.1002/eji.1830270602; Padovan E, 1996, EUR J IMMUNOL, V26, P42, DOI 10.1002/eji.1830260107; PICKER LJ, 1995, BLOOD, V86, P1408, DOI 10.1182/blood.V86.4.1408.bloodjournal8641408; Schauer U, 1996, IMMUNOL TODAY, V17, P305, DOI 10.1016/0167-5699(96)30020-0; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schwiebert LA, 1996, J ALLERGY CLIN IMMUN, V97, P143, DOI 10.1016/S0091-6749(96)80214-4; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; Sugita Y, 1997, BRIT J DERMATOL, V136, P393, DOI 10.1111/j.1365-2133.1997.tb14952.x; SULLIVAN TJ, 1993, ALLERGY PRINCIPLES P, V2, P1726; Szepietowski JC, 1997, BRIT J DERMATOL, V137, P195, DOI 10.1046/j.1365-2133.1997.18051888.x; Torres MJ, 1998, CLIN EXP ALLERGY, V28, P1264; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; YU DTY, 1980, J EXP MED, V151, P91, DOI 10.1084/jem.151.1.91	42	62	65	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					769	776		10.1067/mai.2000.109828	http://dx.doi.org/10.1067/mai.2000.109828			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031349				2022-12-18	WOS:000089980600022
J	Swystun, VA; Gordon, JR; Davis, EB; Zhang, XB; Cockcroft, DW				Swystun, VA; Gordon, JR; Davis, EB; Zhang, XB; Cockcroft, DW			Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						beta-agonists; allergen; asthma; mast cell; tryptase; eosinophils	EXERCISE-INDUCED BRONCHOCONSTRICTION; BETA-ADRENERGIC RECEPTORS; AIRWAY RESPONSIVENESS; INHALED ALBUTEROL; BRONCHODILATOR SUBSENSITIVITY; BRONCHIAL RESPONSIVENESS; REDUCED PROTECTION; SALMETEROL; AGONIST; INHIBITION	Background: Increased asthmatic responses to allergen, both early and late, have been demonstrated after regular use of beta(2)-agonists in as few as 7 days. Desensitization of beta(2)-adrenergic receptors on airway mast cells may contribute to this effect by allowing greater release of mast cell mediator on allergen-induced degranulation, Tryptase released from lung mast cells can be measured in serum 1 hour after allergen challenge and serves as a marker of mast cell degranulation. Objective: To examine the effect of regular treatment with salbutamol, a beta(2)-agonist, on mast cell mediator release after allergen challenge and its influence on the early asthmatic response (EAR) and the Late allergic response, we measured the EAR, serum tryptase levels, the 7-hour FEV1, and sputum tryptase levels and cell profiles. Methods: We conducted a placebo-controlled, double-blind, randomized cross-over comparison of treatments for 10 days with either a salbutamol metered-dose inhaler (100 mu g, 2 puffs 4 times daily) or a matched placebo inhaler with at least a 7-day washout between treatments, Atopic subjects (n = 14) with mild-to-moderate asthma performed same-dose allergen inhalation tests after both treatments 12 to 15 hours after the last dose of study inhaler. Baseline and 7-hour FEV1 and the EAR to allergen were measured by using spirometry; venous blood was drawn at 1 hour for analysis of serum tryptase; and sputum was induced and collected at 1 and 7 hours, Results: Salbutamol treatment resulted in a significantly greater EAR (20% +/- 1.6% [SEM] vs 15% +/- 2.1%; P = .047); increased I-hour serum tryptase levels (9.09 +/- 1.57 vs 7.52 +/- 1.12 mu g/L; P = .011); increased proportions of eosinophils in the 7-hour sputum sample (39.1% +/- 5.1% vs 28.4% +/- 4.4%; P < .05); increased proportion of metachromatic cells in the 7-hour sputum sample (4.4% +/- 1.1% vs 2.2% +/- 0.6%; P = .032); and lower 7-hour FEV1 (2.77 +/-:0.18 vs 2.97 +/- 0.20 L; P = .014), Baseline FEV1 was not significantly different after salbutamol treatment compared with values after placebo treatment (2.90 +/- 0.20 vs 3.00 +/- 0.19 L; P = .11). Conclusion: Regular 10-day treatment with salbutamol increases the allergen-induced release of mediator from airway mast cells, and this is reflected in an increased EAR to allergen. Late-pbase responses to allergen were also enhanced, as demonstrated by decreased 7-hour FEV1 and increased eosinophilia and percentage of metachromatic cells in the 7-hour sputum sample. Increased allergen-induced mast cell degranulation could, in part, explain the increased asthmatic responses to allergen after beta(2)-agonist treatment and could contribute to the deterioration of asthma control that is associated with regular use of beta(2)-agonist by potentiating allergic inflammation.	Univ Saskatchewan, Royal Univ Hosp, Div Resp Med, Dept Physiol, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Royal Univ Hosp, Div Resp Med, Dept Vet Microbiol, Saskatoon, SK S7N 0W0, Canada	University of Saskatchewan; University of Saskatchewan	Cockcroft, DW (corresponding author), Univ Saskatchewan, Royal Univ Hosp, Div Resp Med, Dept Physiol, 5th Floor Ellis Hall, Saskatoon, SK S7N 0W0, Canada.		Gordon, John/D-7621-2013	Gordon, John/0000-0003-3830-8070				Adcock IM, 1996, EUR RESPIR J, V9, P160, DOI 10.1183/09031936.96.09010160; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, P838, DOI 10.1164/ajrccm.152.3.7663795; Bhagat R, 1996, J ALLERGY CLIN IMMUN, V97, P47, DOI 10.1016/S0091-6749(96)70282-8; Bissonnette EY, 1997, J ALLERGY CLIN IMMUN, V100, P825, DOI 10.1016/S0091-6749(97)70280-X; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; CHONG LK, 1995, AM J RESP CELL MOL, V13, P540, DOI 10.1165/ajrcmb.13.5.7576689; CHURCH MK, 1987, BRIT J PHARMACOL, V90, P421, DOI 10.1111/j.1476-5381.1987.tb08972.x; CHURCH MK, 1999, J ALLERGY CLIN IMMUN, V103, P155; COCKCROFT DW, 1995, AM J RESP CRIT CARE, V152, P1485, DOI 10.1164/ajrccm.152.5.7582281; COCKCROFT DW, 1995, J ALLERGY CLIN IMMUN, V96, P44, DOI 10.1016/S0091-6749(95)70031-5; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; COCKCROFT DW, 1997, CAN RESPIR J, V4, P37; Coqueret O, 1996, EUR RESPIR J, V9, P220, DOI 10.1183/09031936.96.09020220; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Giannini D, 1996, CHEST, V110, P1452, DOI 10.1378/chest.110.6.1452; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; Hayes MJ, 1996, AM J RESP CRIT CARE, V154, P1277, DOI 10.1164/ajrccm.154.5.8912736; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; MANOLITSAS ND, 1995, AM J RESP CRIT CARE, V151, P1925, DOI 10.1164/ajrccm.151.6.7767541; McGraw DW, 1997, J BIOL CHEM, V272, P7338, DOI 10.1074/jbc.272.11.7338; MEYER JM, 1993, ANN PHARMACOTHER, V27, P1478, DOI 10.1177/106002809302701214; NEWNHAM DM, 1994, AM J MED, V97, P29, DOI 10.1016/0002-9343(94)90045-0; Nielson CP, 1998, AM J RESP CRIT CARE, V157, P184, DOI 10.1164/ajrccm.157.1.9704070; NISHIKAWA M, 1994, AM J RESP CELL MOL, V10, P91, DOI 10.1165/ajrcmb.10.1.8292387; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; PIN I, 1992, AM REV RESPIR DIS, V145, P1265, DOI 10.1164/ajrccm/145.6.1265; PIN I, 1992, THORAX, V152, P53; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; TORPHY TJ, 1995, J BIOL CHEM, V270, P23596; TURKI J, 1995, AM J PHYSIOL, V269, pL708; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VATHENEN AS, 1988, LANCET, V1, P554	41	62	64	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				57	64						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337ZH	10887306				2022-12-18	WOS:000088393300008
J	Djukanovic, R				Djukanovic, R			Asthma: A disease of inflammation and repair	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; mucosal inflammation; airway remodeling	NEUTROPHIL CHEMOTACTIC FACTOR; BRONCHOALVEOLAR LAVAGE FLUID; AIR-FLOW OBSTRUCTION; CD8(+) T-CELLS; SUBEPITHELIAL FIBROSIS; BRONCHIAL-MUCOSA; CD44 ISOFORMS; INTERLEUKIN-8; ENDOTHELIN; CYTOKINES	Mucosal inflammation and more recently airway remodeling continue to be a focus of interest when considering both the pathophysiology and treatment of asthma. Although a number of candidate genes relevant to inflammatory cell action have been identified and linked to atopy and airway hyperresponsiveness, it is important to understand genetic factors that might determine the extent of tissue remodeling. The mechanisms regulating the allergic responses in the airways are complex, involving antigen presenting cells and T lymphocytes, which process antigens and orchestrate the response, and mast cells and eosinophils as effector cells. Abundant evidence also points to a proinflammatory role for structural cells, including epithelial and endothelial cells, and smooth muscle. Because of the complex nature of the inflammatory changes in asthma, the exact relation between individual inflammatory cells and their mediators on the one hand and hyperresponsiveness of the airways and clinical manifestations on the other remains unclear. The same applies to the phenomenon of airway remodeling because it is uncertain exactly how the different components of restructuring affect the airway physiology. If progress is to be made in the treatment of asthma, further efforts will be needed to understand the regulation and link between the mechanisms causing inflammation and those leading to fibrotic changes.	Univ Southampton, Immunopharmacol Grp, Southampton SO9 5NH, Hants, England	University of Southampton	Djukanovic, R (corresponding author), Univ Southampton, Southampton Gen Hosp, Level D,Ctr Block, Southampton SO16 6YD, Hants, England.			Djukanovic, Ratko/0000-0001-6039-5612				BAGGIOLINI M, 1992, INT ARCH ALLERGY IMM, V99, P196, DOI 10.1159/000236247; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865, DOI 10.1164/ajrccm.152.3.7663797; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BROADDUS VC, 1992, AM REV RESPIR DIS, V146, P825, DOI 10.1164/ajrccm/146.4.825; BRUIJNZEEL PLB, 1993, CLIN EXP ALLERGY, V23, P97, DOI 10.1111/j.1365-2222.1993.tb00304.x; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CONLON K, 1995, EUR J IMMUNOL, V25, P644, DOI 10.1002/eji.1830250303; CONLON K, 1995, EUR J IMMUNOL, V25, P751, DOI 10.1002/eji.1830250319; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; DEAN TP, 1993, PEDIATR RES, V34, P159, DOI 10.1203/00006450-199308000-00010; Djukanovic R, 1997, AM J RESP CRIT CARE, V155, P826, DOI 10.1164/ajrccm.155.3.9117012; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; DJUKANOVIC R, 1995, INT ARCH ALLERGY IMM, V107, P389, DOI 10.1159/000237047; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; GLASSBERG MK, 1994, AM J RESP CELL MOL, V10, P316, DOI 10.1165/ajrcmb.10.3.7509612; KAHALEH MB, 1991, ARTHRITIS RHEUM, V34, P978, DOI 10.1002/art.1780340807; KEMENY DM, 1994, IMMUNOL TODAY, V15, P107, DOI 10.1016/0167-5699(94)90152-X; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; LABERGE S, 1995, J IMMUNOL, V155, P2902; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14, DOI 10.1165/ajrcmb.16.1.8998074; LOUIS R, 1997, AM J RESP CRIT CARE, V155, P446; LYNCH DA, 1993, RADIOLOGY, V188, P829, DOI 10.1148/radiology.188.3.8351357; MACDONALD IG, 1933, ANN INTERN MED, V6, P253; MAGGI E, 1994, J EXP MED, V180, P489, DOI 10.1084/jem.180.2.489; MICHAEL PP, 1935, J ALLERGY, V6, P150; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MONTEFORT S, 1993, CLIN EXP ALLERGY, V23, P185, DOI 10.1111/j.1365-2222.1993.tb00880.x; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084, DOI 10.1164/ajrccm/146.4.1084; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Redington A. E., 1993, Thorax, V48, P1081; REDINGTON AE, 1995, AM J RESP CRIT CARE, V151, P1034; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Redington AE, 1997, J ALLERGY CLIN IMMUN, V100, P544, DOI 10.1016/S0091-6749(97)70148-9; Richman-Eisenstat JB, 1993, AM J PHYSIOL, V264, P413; RIEBER EP, 1994, J EXP MED, V179, P1385, DOI 10.1084/jem.179.4.1385; ROCHE WR, 1989, LANCET, V1, P520; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SCHACHTER EN, 1984, CHEST, V85, P623, DOI 10.1378/chest.85.5.623; Shute JK, 1997, AM J RESP CRIT CARE, V155, P1877, DOI 10.1164/ajrccm.155.6.9196089; SHUTE JK, 1995, INT ARCH ALLERGY IMM, V107, P340, DOI 10.1159/000237022; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; Stanciu LA, 1997, J ALLERGY CLIN IMMUN, V100, P373, DOI 10.1016/S0091-6749(97)70251-3; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; VILLAR MTA, 1993, AM REV RESPIR DIS, V147, pA242; WARRINGA RAJ, 1993, J ALLERGY CLIN IMMUN, V91, P1198, DOI 10.1016/0091-6749(93)90323-8; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363	56	62	62	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S522	S526		10.1016/S0091-6749(00)90055-1	http://dx.doi.org/10.1016/S0091-6749(00)90055-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286JG	10669536				2022-12-18	WOS:000085439600013
J	Benlounes, N; Candalh, C; Matarazzo, P; Dupont, C; Heyman, M				Benlounes, N; Candalh, C; Matarazzo, P; Dupont, C; Heyman, M			The time-course of milk antigen-induced TNF-alpha secretion differs according to the clinical symptoms in children with cow's milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; cytokines; biological lest; predictive test	TUMOR-NECROSIS-FACTOR; HUMAN WHOLE-BLOOD; PROTEIN INTOLERANCE; ATOPIC-DERMATITIS; LYMPHOCYTE-PROLIFERATION; SENSITIVE ENTEROPATHY; MONONUCLEAR-CELLS; FOOD CHALLENGES; MANIFESTATIONS; ADOLESCENTS	Background: TNF-alpha secretion by blood mononuclear cells stimulated with cow's milk proteins is significantly higher in infants with active cow's milk allergy (CMA) manifested by digestive symptoms than in children who have recovered from CMA. Objective: The current study was undertaken to analyze the kinetics of TNF-alpha secretion and to evaluate the usefulness of the measurement of TNF-alpha release in whole blood cultures in the prediction of clinical outcome after milk challenge, Methods: Blood samples were obtained from 83 children maintained on a cow's milk-free diet and examined just before a cow's milk provocation. Children were divided into 4 groups according to clinical outcome: group I (active CMA with cutaneous symptoms), group II (active CMA with predominantly digestive symptoms), group III (children recovered from CMA), and group IV (control), The kinetics of TNF-alpha secretion was measured in blood cultured for 1 to 5 days at different cow's milk protein concentrations, Results: On day 1 TNF-alpha secretion was significantly higher in group I (485 [453] pg/mL, mean [SD], P < .005) and in group II (269 [102] pg/mL, P < .005) than that observed in groups III and IV (149 [95] and 87 [71] pg/mL, respectively). Then TNF-alpha was rapidly degraded and a second peak of secretion was observed on day 5 but only in group II (278 [221] pg/mL), whereas in groups I, III, and IV a low secretion was observed (70 [61], 45 [40], and 11 [12] pg/mL, respectively, P < .02), Conclusion: These results show that the pattern of TNF-alpha secretion in response to cow's milk proteins is different in CMA infants with cutaneous or digestive symptoms and suggest that TNF-alpha release might predict clinical relapse on challenge.	Hop St Vincent de Paul, F-75674 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Heyman, M (corresponding author), Fac Necker Enfants Malad, INSERM, E9925, 156 Rue Vaugirard, F-75730 Paris 15, France.							ALLEN JN, 1992, J LAB CLIN MED, V119, P538; ASHKENAZI A, 1980, PEDIATRICS, V66, P399; Baehler P, 1996, CLIN EXP ALLERGY, V26, P254, DOI [10.1046/j.1365-2222.1996.d01-310.x, 10.1111/j.1365-2222.1996.tb00089.x]; Benlounes N, 1996, J ALLERGY CLIN IMMUN, V98, P781, DOI 10.1016/S0091-6749(96)70127-6; Benlounes N, 1997, CLIN EXP ALLERGY, V27, P942, DOI 10.1111/j.1365-2222.1997.tb01237.x; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; CORTI A, 1994, J IMMUNOL METHODS, V177, P191, DOI 10.1016/0022-1759(94)90156-2; DEFORGE LE, 1991, BIOCHEM BIOPH RES CO, V174, P18, DOI 10.1016/0006-291X(91)90478-P; DEGROOTE D, 1992, CYTOKINE, V4, P239, DOI 10.1016/1043-4666(92)90062-V; DUPONT C, 1989, J PEDIATR GASTR NUTR, V8, P459, DOI 10.1097/00005176-198905000-00007; EIGENMANN PA, 1995, J ALLERGY CLIN IMMUN, V96, P549, DOI 10.1016/S0091-6749(95)70300-4; ELSASSERBEILE U, 1991, J IMMUNOL METHODS, V139, P191, DOI 10.1016/0022-1759(91)90188-L; Hankard GF, 1997, J PEDIATR GASTR NUTR, V25, P79, DOI 10.1097/00005176-199707000-00013; HEYMAN M, 1994, GASTROENTEROLOGY, V106, P1514, DOI 10.1016/0016-5085(94)90405-7; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; HILL DJ, 1988, CLIN ALLERGY, V18, P469, DOI 10.1111/j.1365-2222.1988.tb02897.x; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; Hoffman KM, 1997, J ALLERGY CLIN IMMUN, V99, P360, DOI 10.1016/S0091-6749(97)70054-X; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; KONDO N, 1993, J ALLERGY CLIN IMMUN, V91, P658, DOI 10.1016/0091-6749(93)90272-H; Majamaa H, 1996, CLIN EXP ALLERGY, V26, P181, DOI 10.1111/j.1365-2222.1996.tb00078.x; MATARAZZO P, 1997, J PEDIAT GASTROENTER, V24, P467; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; Michalsky MP, 1997, SHOCK, V7, P139, DOI 10.1097/00024382-199702000-00010; NAGATA S, 1995, J PEDIATR GASTR NUTR, V20, P44, DOI 10.1097/00005176-199501000-00008; Netea MG, 1996, CYTOKINE, V8, P739, DOI 10.1006/cyto.1996.0098; Pesce G, 1996, INT ARCH ALLERGY IMM, V110, P233, DOI 10.1159/000237292; PHILLIPS AD, 1979, GUT, V20, P509, DOI 10.1136/gut.20.6.509; RODRIGUEZ P, 1995, CYTOKINE, V7, P441, DOI 10.1006/cyto.1995.0060; SAALMAN R, 1995, SCAND J IMMUNOL, V42, P140, DOI 10.1111/j.1365-3083.1995.tb03637.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; *SAS I, 1994, SAS US GUID; SAVILAHTI E, 1992, J PEDIATR GASTR NUTR, V14, P108, DOI 10.1097/00005176-199201000-00022; SETRAKIAN JC, 1994, ARCH SURG-CHICAGO, V129, P187; Suomalainen H, 1994, Pediatr Allergy Immunol, V5, P20, DOI 10.1111/j.1399-3038.1994.tb00214.x; TAINIO VM, 1990, ALLERGY, V45, P189, DOI 10.1111/j.1398-9995.1990.tb00482.x; VANKESSEL KPM, 1991, J IMMUNOL, V147, P3862	39	62	66	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				863	869		10.1016/S0091-6749(99)70300-3	http://dx.doi.org/10.1016/S0091-6749(99)70300-3			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518834				2022-12-18	WOS:000083281200021
J	Bochner, BS; Bickel, CA; Taylor, ML; MacGlashan, DW; Gray, PW; Raport, CJ; Godiska, R				Bochner, BS; Bickel, CA; Taylor, ML; MacGlashan, DW; Gray, PW; Raport, CJ; Godiska, R			Macrophage-derived chemokine induces human eosinophil chemotaxis in a CC chemokine receptor 3- and CC chemokine receptor 4-independent manner	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; chemokines; chemotaxis; macrophage-derived chemokine	MOLECULAR-CLONING; EOTAXIN RECEPTOR; FUNCTIONAL-CHARACTERIZATION; DENDRITIC CELLS; HUMAN BASOPHILS; EXPRESSION; CHEMOATTRACTANT; RANTES; MCP-4; INFLAMMATION	Background: Chemokines are believed to contribute to selective cell recruitment, Macrophage-derived chemokine (MDC) is a CC chemokine that causes chemotaxis of dendritic cells, monocytes, and activated natural killer cells. MDC binds to CC chemokine receptor 4 (CCR4) but not to CCR1, CCR2, CCR3, CCR5, CCR6, or CCR7, Objective: Our aim was to determine the in vitro activity of MDC on human eosinophils by using chemotaxis and calcium flux assays. Methods: Eosinophils were purified from peripheral blood of allergic donors, and chemotactic activity of MDC and other CC chemokines was compared in microchemotaxis chamber assays. The role of CCR3 in these assays was determined by using a CCR3-bIocking antibody. Measurements of cytosolic Ca++ mobilization were performed by using fura-2AM labeling, with eosinophils and cell lines transfected with CCR3 or CCR4. Eosinophil expression of CCR3 and CCR4 mRNA was determined by using RT-PCR, Results: MDC (0.1 to 100 nmol/L) caused dose-dependent chemotaxis of purified human eosinophils (maximum similar to 3-fold control). Compared with other CC chemokines, the potency and efficacy for eosinophil chemotaxis were similar for MDC and eotaxin but were less than that observed for RANTES, monocyte chemoattractant protein (MCP)-4, and eotaxin-2, Although MDC can act by means of CCR4 RT-PCR analysis failed to reveal CCR4 mRNA in eosinophils, Effects of MDC on eosinophils was also independent of CCR3, as a blocking mAb to CCR3 failed to inhibit MDC-induced chemotaxis, Furthermore, CCR3-transfected human embryonic kidney cells labeled with Fura-2AM exhibited a rapid rise in intracellular free calcium after stimulation with eotaxin, eotaxin-2, or MCP-B but not with MDC. Eosinophils cultured for 72 hours in 10 ng/mL IL-5 also demonstrated increased intracellular free calcium after stimulation with eotaxin-2 or MCP-4, but not with up to 100 nmol/L MDC, Conclusion: MDC is a CCR3- and CCR4-independent activator of eosinophil chemotaxis, but it does not appear to elicit measurable cytosolic calcium elevations during these responses. MDC appears to act by means of another receptor in addition to CCR4 and may therefore contribute to eosinophil accumulation without working through CCR1 to CCR7.	Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Sch Med, Div Clin Immunol,Dept Med, Baltimore, MD 21224 USA; ICOS Corp, Bothell, WA USA	Johns Hopkins University; Johns Hopkins Medicine; Icos Corporation	Bochner, BS (corresponding author), Johns Hopkins Univ, Johns Hopkins Asthma & Allergy Ctr, Sch Med, Div Clin Immunol,Dept Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.		Godiska, Ronald/V-7489-2017	Godiska, Ronald/0000-0003-0101-6365	NHLBI NIH HHS [HL49545] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049545] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Beck LA, 1997, J IMMUNOL, V159, P2962; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOCHNER BS, 1997, ALLERGY, P251; Chang MS, 1997, J BIOL CHEM, V272, P25229, DOI 10.1074/jbc.272.40.25229; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; EBISAWA M, 1994, J IMMUNOL, V153, P2153; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; MACGLASHAN D, 1991, J IMMUNOL, V147, P2259; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; MCCOLL SR, 1993, J IMMUNOL, V150, P4550; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sozzani S, 1997, J IMMUNOL, V159, P1993; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Stellato C, 1997, J CLIN INVEST, V99, P926, DOI 10.1172/JCI119257; TOMIOKA K, 1993, J IMMUNOL, V151, P4989; Uguccioni M, 1996, J EXP MED, V183, P2379, DOI 10.1084/jem.183.5.2379; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667	33	62	63	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	1				527	532		10.1016/S0091-6749(99)70481-1	http://dx.doi.org/10.1016/S0091-6749(99)70481-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	176WU	10069890	Bronze			2022-12-18	WOS:000079175700025
J	Hamilos, DL; Thawley, SE; Kramper, MA; Kamil, A; Hamid, QA				Hamilos, DL; Thawley, SE; Kramper, MA; Kamil, A; Hamid, QA			Effect of intranasal fluticasone on cellular infiltration, endothelial adhesion molecule expression, and proinflammatory cytokine mRNA in nasal polyp disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyps; sinusitis; Fluticasone; cytokine; inflammation	EOSINOPHIL CATIONIC PROTEIN; NF-KAPPA-B; AIRWAY INFLAMMATION; TNF-ALPHA; MONOCLONAL-ANTIBODIES; BRONCHIAL BIOPSIES; MESSENGER-RNA; P-SELECTIN; T-CELLS; ASTHMA	Background: Nasal polyp (NP) disease demonstrates a gradual response to treatment with intranasal steroids. We hypothesized that various inflammatory features that promote NP eosinophilia would show a differential sensitivity to treatment with intranasal fluticasone. Objectives: We conducted a double-blind, placebo-controlled trial of 4 weeks of intranasal fluticasone propionate or matching placebo to assess their effectiveness in reducing NP inflammatory cells, expression of endothelial vascular cell adhesion molecule (VCAM)-1 and P-selectin, and expression of cytokines involved in induction of a group of adhesion molecules (ie, IL-4, IL-13, TNF-alpha, and IL-1 beta). Methods: Twenty subjects (9 women and II men) with severe chronic sinusitis and NP were studied. Systemic and intranasal steroids were withheld for a minimum of I month and 2 weeks, respectively, before the study. Biopsy specimens of NPs were obtained 1 week before and 4 weeks after treatment with intranasal fluticasone 100 mu g or placebo per nostril administered twice daily. Biopsy specimens were snap frozen for immunostaining or fixed in paraformaldehyde for in situ hybridization. Pretreatment to posttreatment results were analyzed with Wilcoxon's signed-rank test. Results: Fluticasone treatment significantly reduced NP eosinophilia (P = .02) and CD4(+) T lymphocytes (P = .02). Eosinophils expressing the marker EG2 were more significantly reduced (P = .007). Fluticasone also reduced the expression of P-selectin (P = .005) and the number of IL-4 and IL-13 mRNA(+) cells (P = .02 and .05, respectively). In contrast, fluticasone did not significantly reduce expression of endothelial VCAM-1 or the number of TNF-alpha or IL-1 beta mRNA(+) cells in the polyps. Conclusions: We conclude that intranasal fluticasone reduced NP inflammation but that expression of proinflammatory cytokines and endothelial VCAM-1 were relatively unaffected by fluticasone treatment. These latter inflammatory features may contribute to the persistence of NP disease despite intranasal steroid treatment.	Washington Univ, Sch Med, Div Allergy Immunol, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Otolaryngol Ear Nose & Throat Surg, St Louis, MO 63110 USA; McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ, Canada; McGill Univ, Meakins Christie Labs, Dept Pathol, Montreal, PQ, Canada	Washington University (WUSTL); Washington University (WUSTL); McGill University; McGill University	Hamilos, DL (corresponding author), Washington Univ, Sch Med, Div Allergy Immunol, Dept Med, 660 S Euclid Ave, St Louis, MO 63110 USA.							Adachi T, 1996, J ALLERGY CLIN IMMUN, V98, pS207, DOI 10.1016/S0091-6749(96)70068-4; Barks JL, 1997, J IMMUNOL, V159, P4532; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; BOOTH H, 1995, AM J RESP CRIT CARE, V152, P45, DOI 10.1164/ajrccm.152.1.7599861; BOURKE GJ, 1985, INTERPRETATION USES; CHURCHILL L, 1993, AM REV RESPIR DIS, V148, pS83, DOI 10.1164/ajrccm/148.6_Pt_2.S83; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DOLOVICH J, 1990, RHINITIS ASTHMA SIMI, P233; FREW AJ, 1988, J IMMUNOL, V141, P4158; Fukuda T, 1996, AM J RESP CELL MOL, V14, P84, DOI 10.1165/ajrcmb.14.1.8534490; Gille J, 1997, J CLIN INVEST, V99, P492, DOI 10.1172/JCI119184; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443, DOI 10.1165/ajrcmb.15.4.8879177; HAMILOS DL, 1992, J ALLERGY CLIN IMMUN, V91, P39; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Holmberg K, 1997, ANN ALLERG ASTHMA IM, V78, P270, DOI 10.1016/S1081-1206(10)63180-8; IADEMARCO MF, 1995, J CLIN INVEST, V95, P264, DOI 10.1172/JCI117650; JAHNSEN FL, 1995, AM J RESP CELL MOL, V12, P624, DOI 10.1165/ajrcmb.12.6.7539273; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Johnson M, 1996, J ALLERGY CLIN IMMUN, V97, P169, DOI 10.1016/S0091-6749(96)80217-X; KANAI N, 1994, AM J RESP CRIT CARE, V150, P1094, DOI 10.1164/ajrccm.150.4.7921442; Kitayama J, 1997, J IMMUNOL, V159, P3929; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LUKACS NW, 1995, J IMMUNOL, V154, P5411; MOQBEL R, 1992, CLIN EXP ALLERGY, V22, P265, DOI 10.1111/j.1365-2222.1992.tb03082.x; MOSER R, 1992, J IMMUNOL, V149, P1432; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; Read MA, 1996, J IMMUNOL, V157, P3472; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; ROTHENBERG MW, 1987, SCIENCE, V137, P645; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V82, P950, DOI 10.1016/0091-6749(88)90038-3; SPRY CJF, 1985, INT ARCH ALLER A IMM, V77, P252, DOI 10.1159/000233803; SYMON FA, 1994, J EXP MED, V180, P371, DOI 10.1084/jem.180.1.371; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; THORNHILL MH, 1991, J IMMUNOL, V146, P592; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; Yao LB, 1996, J EXP MED, V184, P81, DOI 10.1084/jem.184.1.81; Ying S, 1997, J IMMUNOL, V158, P5050	42	62	71	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				79	87		10.1016/S0091-6749(99)70529-4	http://dx.doi.org/10.1016/S0091-6749(99)70529-4			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893189				2022-12-18	WOS:000078112300013
J	Hofer, MF; Jirapongsananuruk, O; Trumble, AE; Leung, DYM				Hofer, MF; Jirapongsananuruk, O; Trumble, AE; Leung, DYM			Upregulation of B7.2, but not B7.1, on B cells from patients with allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cells; asthma; costimulatory molecules; interleukin	B7-2 COSTIMULATORY MOLECULES; CYTOKINE PRODUCTION; RECEPTOR CD23; ANTIGEN; INTERLEUKIN-4; EXPRESSION; ACTIVATION; DISEASE; IL-4; DIFFERENTIATION	Background: Allergic asthma is associated with T-H2-like cell responses and increased IgE production. Recent studies in mice have suggested that the costimulatory molecule B7.2 (CD86) may influence the development of T-H2 cells. Objective: We sought to determine the potential role of B7.2 in patients with asthma. Methods: We performed an analysis of B cells from patients with allergic asthma and healthy control subjects for expression of B7.1 and B7.2 on B cells using five-parameter flow cytometry, Results: We report that atopic patients with asthma who are exposed to allergens have significantly (p < 0.005) higher levels of B7.2 expression on B cells than atopic asthmatic subjects not exposed to allergen in vivo or nonatopic control subjects, In contrast, there vc ere no differences in B7.1 (CD80) expression among the three study subject groups, When peripheral blood mononuclear cells from asthmatic patients or normal control subjects were stimulated with IL-4 or IL-13, the expression of B7.2, but not B7.1, was significantly increased (p < 0.005) on B cells, Interferon-gamma or IL-12 did not affect the expression of either molecule, The functional significance of B7.2 induction by IL-4 in allergic disease was suggested by the increased expression of this molecule on CD23(+), but not CD23(-), B cells. Conclusion: These results indicate that the same B cell involved in allergen presentation also expresses the costimulatory molecule B7.2 and support the hypothesis that this molecule is an important costimulatory molecule in allergic responses, the expression of which can be modulated by T-H2-like cytokines.	Natl Jewish Med & REs Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Leung, DYM (corresponding author), Natl Jewish Med & REs Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.			Jirapongsananuruk, Orathai/0000-0002-1603-1106	NHLBI NIH HHS [HL37260, HL36577] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577, R01HL037260, R37HL037260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; DEBOER M, 1993, EUR J IMMUNOL, V23, P3120, DOI 10.1002/eji.1830231212; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; Gause WC, 1997, J IMMUNOL, V158, P4082; HALPERN M, 1993, INT ARCH ALLERGY IMM, V100, P197, DOI 10.1159/000236411; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; KIM KM, 1988, PEDIATR RES, V24, P254, DOI 10.1203/00006450-198808000-00023; KING CL, 1995, EUR J IMMUNOL, V25, P587, DOI 10.1002/eji.1830250242; Krinzman SJ, 1996, J CLIN INVEST, V98, P2693, DOI 10.1172/JCI119093; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LANIER LL, 1995, J IMMUNOL, V154, P97; LEDBETTER JA, 1990, BLOOD, V75, P1531; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LENSCHOW DJ, 1994, J IMMUNOL, V153, P1990; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LIFE P, 1995, EUR J IMMUNOL, V25, P333, DOI 10.1002/eji.1830250205; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; MCARTHUR JG, 1993, J EXP MED, V178, P1645, DOI 10.1084/jem.178.5.1645; MONDINO A, 1996, J LEUKOCYTE BIOL, V53, P805; MUDDE GC, 1995, IMMUNOL TODAY, V16, P380, DOI 10.1016/0167-5699(95)80005-0; Natesan M, 1996, J IMMUNOL, V156, P2783; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; Paterson RLK, 1996, EUR J IMMUNOL, V26, P1979, DOI 10.1002/eji.1830260902; Reiser H, 1996, NEW ENGL J MED, V335, P1369, DOI 10.1056/NEJM199610313351807; REISER H, 1992, P NATL ACAD SCI USA, V89, P271, DOI 10.1073/pnas.89.1.271; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SEDER RA, 1994, J EXP MED, V179, P299, DOI 10.1084/jem.179.1.299; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; THOMPSON CB, 1995, CELL, V81, P979, DOI 10.1016/S0092-8674(05)80001-7; Tsuyuki S, 1997, J EXP MED, V185, P1671, DOI 10.1084/jem.185.9.1671	33	62	72	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				96	102		10.1016/S0091-6749(98)70199-X	http://dx.doi.org/10.1016/S0091-6749(98)70199-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449507				2022-12-18	WOS:000071539800015
J	Kimura, M; Tsuruta, S; Yoshida, T				Kimura, M; Tsuruta, S; Yoshida, T			Correlation of house dust mite-specific lymphocyte proliferation with IL-5 production, eosinophilia, and the severity of symptoms in infants with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; infants; house dust mite; lymphocyte proliferation; IL-5; eosinophils; flow cytometry	T-CELL RESPONSES; DERMATOPHAGOIDES-FARINAE; INTERFERON-GAMMA; IGE PRODUCTION; ALLERGENS; PTERONYSSINUS; DISEASE; RISK	Because house dust mite (HDM)-specific IgE antibody (IgE-RAST) is usually not detectable in infants with atopic dermatitis (AD), HDM has not been regarded as the cause of infantile AD. The level of HDM-specific lymphocyte proliferation (expressed as stimulation index measured by Bow cytometry [SIF]), however, was found to be markedly elevated in AD infants. This suggests that the sensitization of T cells to HDM extract occurs even in infancy. Moreover, the level of HDM-SIF is correlated closely with the severity of infantile AD, suggesting that HDM is a major cause of this disease not only in adults and children but also in infants, Although the level of HDM-SIF did not correlate with the level of HDM-specific IgE-RAST in infants with AD, it did intimately correlate with the absolute number of peripheral blood eosinophils, Because T lymphocytes are known to secrete some cytokines, such as IL-5, that enhance the proliferation of eosinophils, we measured the IL-5 production by peripheral blood mononuclear cells in infants with AD on stimulation with HDM extract, The amount of IL-5 production is significantly higher in infants with AD, as well as in children with AD, than that found in nonatopic control subjects. Moreover, the level of IL-5 production is correlated closely with the level of HDM-SIF in infants with AD. Taken together, these results suggest that HDMs play an important role in the development of infantile AD by inducing IL-5 production from HDM-specific T lymphocytes.	Shizuoka Childrens Hosp, Dept Allergy & Clin Immunol, Shizuoka 420, Japan		Kimura, M (corresponding author), Shizuoka Childrens Hosp, Dept Allergy & Clin Immunol, Urushiyama 860, Shizuoka 420, Japan.							CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COFFMAN RL, 1986, J IMMUNOL, V136, P949; ComansBitter WM, 1997, J PEDIATR-US, V130, P388, DOI 10.1016/S0022-3476(97)70200-2; HAIDA M, 1985, J ALLERGY CLIN IMMUN, V75, P686, DOI 10.1016/0091-6749(85)90094-6; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; HIRATANI M, 1981, J ALLERGY CLIN IMMUN, V68, P205, DOI 10.1016/0091-6749(81)90185-8; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; Martin LB, 1996, INT ARCH ALLERGY IMM, V109, P207, DOI 10.1159/000237239; MITCHELL EB, 1982, LANCET, V1, P127; Miyasato Minoru, 1996, Journal of Dermatology (Tokyo), V23, P382; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; RAJKA G, 1989, ACTA DERM-VENEREOL, P13; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SLY RM, 1996, NELSON TXB PEDIAT, P641; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; WALKER C, 1993, CLIN EXP ALLERGY, V23, P145, DOI 10.1111/j.1365-2222.1993.tb00310.x; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137	23	62	63	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				84	89		10.1016/S0091-6749(98)70197-6	http://dx.doi.org/10.1016/S0091-6749(98)70197-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449505				2022-12-18	WOS:000071539800013
J	Ebo, DG; Stevens, WJ; Bridts, CH; DeClerck, LS				Ebo, DG; Stevens, WJ; Bridts, CH; DeClerck, LS			Latex-specific IgE, skin testing, and lymphocyte transformation to latex in latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; latex; lymphocyte proliferation; skin test	CONTACT URTICARIA; RUBBER; PREVALENCE; ANTIBODIES; DIAGNOSIS	Background: This study was designed to determine the discriminative value of latex-specific IgE tests, latex skin tests, and lymphocyte transformation tests (LTTs) to latex in 38 patients with latex allergy (12 nonatopic and 26 atopic) and 44 control subjects (24 nonatopic and 20 atopic). We also evaluated the recommended positive cutoff (i.e., 0.35 kU/L) of both in vitro latex-IgE tests. Methods: Latex-specific IgE levels were determined by the Immuno-CAP (Upjohn-Pharmacia) and the ALaSTAT-RIA (Diagnostic Products Corp.) assays, Skin tests and LTTs were performed with a nonammoniated latex extract (DPC). Sensitivities and specificities were defined according to the 95th percentile value of nonatopic control subjects, For the in vitro IgE tests, sensitivity and specificity were also calculated by using the proposed positive threshold of 0.35 kU/L. Sensitivities and specificities of both cutoffs were compared. Results: Compared with a clinical history of latex allergy and according to the 95th percentile value of nonatopic control subjects (0.44 kU/L), latex-specific IgE determined by the Immuno-CAP assay achieved a sensitivity of 97% and a specificity of 86%. For the ALaSTAT-RIA assay, with 0.54 kU/L as the 95th percentile threshold value in nonatopic control subjects, sensitivity was 100%, and specificity was 83%. According to the threshold value of 0.35 kU/L, a sensitivity of 97% and a specificity of 83% for the Immuno-CAP assay and a sensitivity of 100% and a specificity of 33% for the ALaSTAT-RIA assay were observed. The latex skin test reached a sensitivity of 97% and a specificity of 100%. The LTT to latex showed a sensitivity of 39% and a specificity of 95%. No relation between symptoms and latex-specific IgE tests, latex skin tests, or LTTs nas found. Conclusions: Our results confirm that latex skin tests and latex-specific IgE assessments are sensitive and specific methods for establishing the diagnosis of latex allergy, although the specificity of the ALaSTAT-RIA assay was very low when interpreted according to the threshold of 0.35 kU/L. The LTT to nonammoniated latex is too insensitive for diagnosis of allergy to latex This reemphasizes that in order to evaluate the sensitivity and specificity of diagnostic procedures, one should always include an appropriate control group.	UNIV ANTWERP,DEPT IMMUNOL ALLERGOL & RHEUMATOL,B-2610 ANTWERP,BELGIUM	University of Antwerp			EBO, Didier/H-4894-2016; BRIDTS, Chris HM/M-7933-2016	EBO, Didier/0000-0003-0672-7529; BRIDTS, Chris HM/0000-0002-3324-7320				BONNEKOH B, 1992, JAMA-J AM MED ASSOC, V267, P2603, DOI 10.1001/jama.267.19.2603; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; FUCHS T, 1992, ALLERGY PROC, V13, P61, DOI 10.2500/108854192778878881; Grimm A., 1927, KLIN WOCHENSCHR, V6, P1479, DOI 10.1007/BF017185344.; HOLZMAN RS, 1993, ANESTH ANALG, V76, P635; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V91, P1128, DOI 10.1016/0091-6749(93)90314-6; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; Magera B., 1996, Journal of Allergy and Clinical Immunology, V97, P322, DOI 10.1016/S0091-6749(96)80777-9; MONERETVAUTRIN DA, 1991, ANESTHESIOLOGY, V74, P391, DOI 10.1097/00000542-199102000-00048; MURALI PS, 1994, J LAB CLIN MED, V124, P638; Ownby DR, 1996, J ALLERGY CLIN IMMUN, V97, P1188, DOI 10.1016/S0091-6749(96)70183-5; Plebani M, 1996, ALLERGY, V51, P407, DOI 10.1111/j.1398-9995.1996.tb04638.x; RaulfHeimsoth M, 1996, J ALLERGY CLIN IMMUN, V98, P640, DOI 10.1016/S0091-6749(96)70098-2; REINHEIMER G, 1995, ANN ALLERG ASTHMA IM, V74, P184; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; Stern G, 1927, KLIN WOCHENSCHR, V6, P1096; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43, DOI 10.7326/0003-4819-122-1-199501010-00007; *TASK FORC ALL REA, 1993, J ALLERGY CLIN IMMUN, V92, P16; TURJANMAA K, 1989, ALLERGY, V44, P181, DOI 10.1111/j.1398-9995.1989.tb02259.x; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; VANBEVER HP, 1993, CLIN EXP ALLERGY, V23, P661, DOI 10.1111/j.1365-2222.1993.tb01792.x	24	62	64	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1997	100	5					618	623		10.1016/S0091-6749(97)70165-9	http://dx.doi.org/10.1016/S0091-6749(97)70165-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YG202	9389291				2022-12-18	WOS:A1997YG20200008
J	Garcia, M; Moneo, I; Audicana, MT; delPozo, MD; Munoz, D; Fernandez, E; Diez, J; Etxenagusia, MA; Ansotegui, IJ; deCorres, LF				Garcia, M; Moneo, I; Audicana, MT; delPozo, MD; Munoz, D; Fernandez, E; Diez, J; Etxenagusia, MA; Ansotegui, IJ; deCorres, LF			The use of IgE immunoblotting as a diagnostic tool in Anisakis simplex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anisakis simplex; parasite; fish; allergy; IgE immunoblotting; IgE; urticaria; anaphylaxis		Background: The fish parasite Anisakis simplex is the etiologic agent of anisakiasis and induces IgE-mediated reactions. Skin prick tests (SPTs) and the measurement of specific IgE to A. simplex were, in our experience, not valid tools with which to discriminate between allergic and nonallergic patients because many control subjects also had positive results. Objective: The study was carried out to assess the usefulness of IgE immunoblotting in the diagnosis of allergy to A, simplex. Methods: We have studied 61 patients with acute symptoms of urticaria, angioedema, or anaphylaxis and positive specific IgE to A, simplex. According to the anamnesis, time interval between ingestion of fish and clinical onset of symptoms, and exclusion of other causes of allergy, three different groups of patients were established: group A (allergic), group NA (nonallergic), and group D (doubtful), Fifty-one healthy donors were included as control subjects (group C). IgE immunoblotting with A. simplex whole-body extract was performed in all patients and control subjects. Results: Four patterns of immunoblotting were observed: type 1, with a group of several bands of medium molecular weight and others of low molecular weight; type 2, two or more bands of medium molecular weight; type 3, only one band of medium molecular weight; type 4, without any band. There was a significant predominance of blotting type 1 in group A and type 4 in group C. Conclusion: These data suggest that IgE immunoblotting is the most useful approach to A. simplex allergy diagnosis.	HOSP SANTIAGO APOSTOL, SERV ALERGOL, DEPT ALLERGY & IMMUNOL, E-01004 VITORIA, SPAIN; HLTH INST CARLOS 3, DEPT IMMUNOL, MADRID, SPAIN				Fernandez, Eduardo/S-8206-2016	Fernandez, Eduardo/0000-0002-7052-6011				Allen JE, 1996, INT ARCH ALLERGY IMM, V109, P3, DOI 10.1159/000237225; AUDICANA MT, 1995, J ALLERGY CLIN IMMUN, V96, P558, DOI 10.1016/S0091-6749(95)70301-2; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; deCorres LF, 1996, J INVEST ALLERG CLIN, V6, P315; delPozo MD, 1996, J ALLERGY CLIN IMMUN, V97, P977, DOI 10.1016/S0091-6749(96)80073-X; DESOWITZ RS, 1985, T ROY SOC TROP MED H, V79, P256, DOI 10.1016/0035-9203(85)90351-7; IGLESIAS R, 1993, PARASITE IMMUNOL, V15, P243, DOI 10.1111/j.1365-3024.1993.tb00607.x; Iglesias R, 1996, PARASITOL RES, V82, P378, DOI 10.1007/s004360050131; ISHIKURA H, 1996, INT ARCH ALLERGY IMM, V109, P3; Kasuya S, 1992, Arerugi, V41, P106; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; KASUYA S, 1989, ACI NEWS, V1, P13; KENNEDY MW, 1988, MOL BIOCHEM PARASIT, V31, P35, DOI 10.1016/0166-6851(88)90143-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MONEO I, 1995, OCCUP MED-OXFORD, V45, P151, DOI 10.1093/occmed/45.3.151; ONEIL C, 1993, CLIN REV ALLERG, V11, P183; PEREIRA J, 1992, ALGUNOS ASPECTOS EPI, P23; PETIT C, 1989, METHOD ENZYMOL, V178, P144; 1990, ENCUESTA NUTRICIONAL, P29	20	62	65	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1997	99	4					497	501		10.1016/S0091-6749(97)70076-9	http://dx.doi.org/10.1016/S0091-6749(97)70076-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WU274	9111494				2022-12-18	WOS:A1997WU27400012
J	Spahn, JD; Landwehr, LP; Nimmagadda, S; Surs, W; Leung, DYM; Szefler, SJ				Spahn, JD; Landwehr, LP; Nimmagadda, S; Surs, W; Leung, DYM; Szefler, SJ			Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						steroid-resistant asthma; pharmacotherapy; glucocorticoid receptor; T lymphocytes	T ACTIVATION; BUDESONIDE	Background: Glucocorticoids are important medications used to control the airway inflammation associated with asthma. Synthetic glucocorticoids vary in their binding affinity for the glucocorticoid receptor (GCR). Methods: We compared hydrocortisone, beclomethasone dipropionate, triamcinolone acetonide, flunisolide, and budesonide with regard to their capacity to inhibit phytohemagglutinin-induced peripheral blood mononuclear cell proliferation from six patients with steroid-sensitive asthma and seven patients with steroid-resistant asthma. Peripheral blood mononuclear cell GCR binding affinities for dexamethasone and budesonide were also determined for both patient groups by using a radioligand binding assay and Scatchard analysis. Results: Dose-dependent inhibition was demonstrated for all glucocorticoids in both patient groups, with the steroid-resistant group requiring approximately 2 log-fold more glucocorticoids for an equivalent degree of inhibition. The mean concentrations necessary to cause 50% inhibition of lymphocyte proliferation (IC(50)s) for the steroid-sensitive group ranged from 2 x 10(-10) mol/L for budesonide to 7 x 10(-8) mol/L for hydrocortisone, whereas the mean IC50 for the steroid-resistant group ranged from approximately 2 x 10(-8) mol/L for budesonide to greater than 10(-6) mol/L for hydrocortisone. In addition, a significant correlation was noted between the degree of inhibition of lymphocyte proliferation (IC50) and the binding affinity of dexamethasone to the GCR Patients with steroid-resistant asthma have been shown to have a reduced GCR binding affinity. The GCR binding affinity fdr budesonide was significantly higher in both groups (i.e., lower dissociation constant) than that obtained for dexamethasone. Conclusion: These data suggest that glucocorticoids such as budesonide, by virtue of their high GCR binding affinities and greater ability to suppress lymphocyte proliferation, may therefore be beneficial in the management of difficult-to-control asthma.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV ALLERGY CLIN IMMUNOL, DENVER, CO 80206 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV CLIN PHARMACOL, DENVER, CO 80206 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, DENVER, CO 80262 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Nimmagadda, Sai/0000-0003-0653-1323	NCRR NIH HHS [RR-00051] Funding Source: Medline; NHLBI NIH HHS [HL-36577] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036577] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGERTOFT L, 1993, ARCH DIS CHILD, V69, P130, DOI 10.1136/adc.69.1.130; ALVAREZ J, 1992, J ALLERGY CLIN IMMUN, V89, P714, DOI 10.1016/0091-6749(92)90379-G; Brattsand R., 1992, NEW DRUGS ASTHMA, V2, P193; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970, DOI 10.1164/ajrccm/141.4_Pt_1.; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1026, DOI 10.1164/ajrccm/144.5.page; CRABTREE GR, 1981, METHODS HEMATOLOGY, V2, P252; KAM JC, 1993, J IMMUNOL, V151, P3460; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; LIPWORTH BJ, 1993, PHARMACOL THERAPEUT, V58, P173, DOI 10.1016/0163-7258(93)90049-J; POZNANSKY MC, 1984, CLIN SCI, V67, P639, DOI 10.1042/cs0670639; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SPAHN JD, 1995, SEVERE ASTHMA PATHOG, P497; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839	14	62	63	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1996	98	6	1				1073	1079		10.1016/S0091-6749(96)80194-1	http://dx.doi.org/10.1016/S0091-6749(96)80194-1			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WB378	8977508				2022-12-18	WOS:A1996WB37800012
J	Mantyjarvi, R; Parkkinen, S; Rytkonen, M; Pentikainen, J; Pelkonen, J; Rautiainen, J; Zeiler, T; Virtanen, T				Mantyjarvi, R; Parkkinen, S; Rytkonen, M; Pentikainen, J; Pelkonen, J; Rautiainen, J; Zeiler, T; Virtanen, T			Complementary DNA cloning of the predominant allergen of bovine dander: A new member in the lipocalin family	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bovine; allergen; cDNA cloning sequence; lipocalin; IgE binding	SEQUENCE-ANALYSIS; PROTEIN; PURIFICATION; ORIGIN	Background: A number of allergenic proteins in animal danders have been characterized at the molecular level, but little is known of their biologic functions. We have found that the prevalence of IgE antibodies among patients with cattle-associated asthma is highest against a dander protein referred to as BDA20. Objective: The study was performed to characterize the molecular structure of BDA20,* the predominant allergen in bovine dander. Methods: Clones encoding allergens were identified and isolated from a complementary DNA library by immunoblotting and DNA hybridization and sequenced. Recombinant proteins were produced in Escherichia coli. Immunoreactivity of the recombinant proteins and amino acid sequences of peptides obtained from native BDA20 after Lys-C cleavage were used to identify, clones coding for BDA20. Results: In this article we report the cDNA and amino acid sequences of BDA20. Homology comparisons showed that BDA20 belongs to the family of lipocalins. Conclusions: The results link a dander allergen to a group of functionally important proteins. Lipocalins are present in various body fluids and secretions of several animal species in which they function as carriers of small hydrophobic molecules, such as retinoids and pheromones. If allergenicity proves to be a property shared by lipocalins, our results will have considerable implications for allergen research.			Mantyjarvi, R (corresponding author), UNIV KUOPIO,DEPT CLIN MICROBIOL,POB 1627,FIN-70211 KUOPIO,FINLAND.			Rytkonen-Nissinen, Marja/0000-0002-2014-8315				CLARK AJ, 1984, EMBO J, V3, P1045, DOI 10.1002/j.1460-2075.1984.tb01925.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; LORUSSO JR, 1986, J ALLERGY CLIN IMMUN, V78, P928, DOI 10.1016/0091-6749(86)90242-3; MCDONALD B, 1989, J ALLERGY CLIN IMMUN, V83, P251; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; NORTH ACT, 1991, BIOCH SOC S, V57, P35; PARKKINEN S, 1995, J ALLERGY CLIN IMMUN, V95, P1255, DOI 10.1016/S0091-6749(95)70083-8; PRAHL P, 1982, INT ARCH ALLER A IMM, V67, P293, DOI 10.1159/000233036; PRICE JA, 1987, CLIN ALLERGY, V17, P43, DOI 10.1111/j.1365-2222.1987.tb02318.x; RAUTALAHTI M, 1987, EUR J RESPIR DIS, V71, P155; Sambrook J, 1989, MOL CLONING LAB MANU; SCHOU C, 1993, CLIN EXP ALLERGY, V23, P7, DOI 10.1111/j.1365-2222.1993.tb02477.x; SCHUMACHER MJ, 1980, MOL IMMUNOL, V17, P1087, DOI 10.1016/0161-5890(80)90105-4; SIVAPRASADARAO A, 1993, BIOCHEM SOC T, V21, P619, DOI 10.1042/bst0210619; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; UNTERMAN RD, 1981, P NATL ACAD SCI-BIOL, V78, P3478, DOI 10.1073/pnas.78.6.3478; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; WALLS AF, 1983, ALLERGY, V38, P419, DOI 10.1111/j.1398-9995.1983.tb05085.x; WEEKE B, 1983, SCAND J IMMUNOL S10, V17, P265; YLONEN J, 1994, ALLERGY, V49, P707, DOI 10.1111/j.1398-9995.1994.tb02091.x; YLONEN J, 1992, INT ARCH ALLERGY IMM, V99, P112, DOI 10.1159/000236343; YLONEN J, 1994, J ALLERGY CLIN IMMUN, V93, P851, DOI 10.1016/0091-6749(94)90377-8	23	62	63	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1297	1303		10.1016/S0091-6749(96)70198-7	http://dx.doi.org/10.1016/S0091-6749(96)70198-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648026	Bronze			2022-12-18	WOS:A1996VD60700018
J	AHLROTH, M; ALENIUS, H; TURJANMAA, K; MAKINENKILJUNEN, S; REUNALA, T; PALOSUO, T				AHLROTH, M; ALENIUS, H; TURJANMAA, K; MAKINENKILJUNEN, S; REUNALA, T; PALOSUO, T			CROSS-REACTING ALLERGENS IN NATURAL-RUBBER LATEX AND AVOCADO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IGE; NATURAL RUBBER LATEX; AVOCADO; CROSS-REACTIVITY; IMMUNOBLOTTING; IMMUNOBLOT INHIBITION; RAST INHIBITION; PRICK TESTS	CONTACT URTICARIA; GLOVE CONTACT; ANAPHYLAXIS; ANTIGENS	Background: An association between allergy to latex and avocado has been reported but the responsible cross-reacting allergens have not been identified or characterized. Methods: Immunoblotting, immunoblot inhibition, and RAST inhibition methods were used to study class-reactive proteins between natural rubber latex (NRL) and avocado. Sera from 18 patients with previously verified later allergy were used as the source of IgE antibodies, and II of the patients underwent skin prick testing with fresh avocado. Results: Fourteen of the 18 sera (78%) had IgE antibodies that bound to a total of 17 avocado proteins with apparent molecular weights ranging from 16 to 91 kd. Ten most strongly reacting sera were used for immunoblot inhibition studies. When NRL proteins were used as soluble inhibitors, binding of lgE antibodies to solid-phase avocado proteins was inhibited in a dose-dependent manner: 100 mu g of NRL proteins inhibited IgE binding to 15 of the 17 avocado proteins, and 10 mu g caused inhibition to 13 protein bands. Comparably, soluble avocado proteins were able to inhibit IgE binding to solid-phase NRL. Corresponding RAST inhibitions were performed with two patient sera; in both, avocado inhibited IgE binding to NRL and in one NRL proteins inhibited IgE binding to avocado. Skin prick test responses to fresh avocado were positive in seven of the II patients with latex allergy who were tested. Conclusions: The large number of inhibitable proteins in immunoblot experiments and clinical observations from skin prick tests suggest considerable immunologic cross-reactivity between NRL and avocado. The observed cross-reacting protein components may be responsible for the recently reported type I hypersensitivity reactions to NRL, and avocado in patients with a preexisting allergy to either allergen.	NATL PUBL HLTH INST,DEPT IMMUNOBIOL,SF-00300 HELSINKI,FINLAND; UNIV TAMPERE,DEPT CLIN SCI,SF-33520 TAMPERE,FINLAND; UNIV TAMPERE,DEPT DERMATOL,SF-33101 TAMPERE,FINLAND; UNIV HELSINKI,HOSP SKIN & ALLERG DIS,HELSINKI,FINLAND	Finland National Institute for Health & Welfare; Tampere University; Tampere University; University of Helsinki				Alenius, Harri/0000-0003-0106-8923				ALENIUS H, 1991, INT ARCH ALLER A IMM, V96, P376, DOI 10.1159/000235525; ALENIUS H, UNPUB CROSS REACTIVI; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; CEUPPENS JL, 1992, LANCET, V339, P493, DOI 10.1016/0140-6736(92)91101-D; CHAMBEYRON C, 1992, ALLERGY, V47, P92, DOI 10.1111/j.1398-9995.1992.tb05094.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; FROSCH PJ, 1986, CONTACT DERMATITIS, V14, P241, DOI 10.1111/j.1600-0536.1986.tb01233.x; LAVAUD F, 1992, LANCET, V339, P492, DOI 10.1016/0140-6736(92)91100-M; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; MORALES C, 1989, CLIN EXP ALLERGY, V19, P425, DOI 10.1111/j.1365-2222.1989.tb02409.x; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1990, ANN ALLERGY, V65, P411; SUSSMAN GL, 1991, JAMA-J AM MED ASSOC, V265, P2844, DOI 10.1001/jama.265.21.2844; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P241, DOI 10.1111/j.1600-0536.1988.tb02920.x; TURJANMAA K, 1988, DERMATOL CLIN, V6, P47, DOI 10.1016/S0733-8635(18)30688-0; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1990, LANCET, V336, P1588, DOI 10.1016/0140-6736(90)93372-V; WARPINSKI JR, 1991, ALLERGY PROC, V12, P95, DOI 10.2500/108854191779011846; Yman L, 1975, Dev Biol Stand, V29, P151	21	62	63	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					167	173		10.1016/S0091-6749(95)70004-8	http://dx.doi.org/10.1016/S0091-6749(95)70004-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636053	Bronze			2022-12-18	WOS:A1995RQ00100004
J	DEANDRADE, AD; CHARPIN, D; BIRNBAUM, J; LANTEAUME, A; CHAPMAN, M; VERVLOET, D				DEANDRADE, AD; CHARPIN, D; BIRNBAUM, J; LANTEAUME, A; CHAPMAN, M; VERVLOET, D			INDOOR ALLERGEN LEVELS IN DAY NURSERIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						HOUSE DUST MITE; CAT; DOG; COCKROACH; DAY NURSERIES; ENVIRONMENT; ALLERGY; HOUSING	FEL-D-I; DUST MITE ALLERGENS; DER-P-I; HOUSE-DUST; F-I; RISK-FACTORS; SCHOOL DUST; ASTHMA; EXPOSURE; CHILDREN	Background: Because allergic sensitization seems to occur especially during infancy, we decided to evaluate such an exposure in day nurseries. Methods: Thirty day nurseries in Marseilles, which were selected at random, were visited during 2 weeks in April 1993. Routine cleaning includes daily cleaning of smooth floors, weekly laundering of sheets, and monthly cleaning of soft toys. Mattresses are encased in synthetic covers. Dust samples were collected from four settings: infants' mattresses and pillows, smooth floors, and soft toys. Levels of mite, cockroach, cat, and dog allergens were analyzed with a monoclonal antibody-based ELISA. Results: Mite allergen levels were lower than the proposed threshold level for sensitization (2 mu g/gm of dust) on 94% of mattresses and soft toys and on 100% of floors and pillows. Cat allergen levels in mattresses ranged from less than 0.1 to 4.5 mu g/gm dust. On floors, cat allergen levels ranged from less than 0.1 to 2.4 mu g/gm dust. Only 10% of pillows and soft toys had levels greater than 2 mu g/gm of dust. Fel d I levels were significantly higher (p < 0.03) in mattresses from nurseries with curtains and were correlated with the percentage of children with a cat at home. In almost all day nurseries cockroach allergen (Bla g I and Bla g II) levels were very low. Only three samples from mattresses had clog allergen levels greater than 2 mu g of Can f I allergen per gram of dust. On floors the level was always lower than 2 mu g/gm. Conclusions: These data clearly show that indoor allergen levels are much lower in day nurseries than in most houses. Most samples contain allergen levels below threshold levels for sensitization. Thus children of atopic parents are less likely to become sensitized to indoor allergens in day nurseries than in their own homes. In addition, this study emphasizes the efficacy of avoidance measures such as use of synthetic protective mattress covers, frequent washing of sheets and soft toys, and avoidance of carpets and curtains.	HOP ST MARGUERITE, DEPT MALAD RESP, SERV PNEUMOALLERGOL, F-13277 MARSEILLE 9, FRANCE; UNIV VIRGINIA, HLTH SCI CTR, DIV CLIN IMMUNOL & ALLERGY, CHARLOTTESVILLE, VA USA	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Virginia			Dornelas de Andrade, Armele/AAO-7337-2021	Dornelas de Andrade, Armele/0000-0001-9430-4395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032557] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-32557] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; DYBENDAL T, 1992, CLIN EXP ALLERGY, V22, P1100, DOI 10.1111/j.1365-2222.1992.tb00136.x; DYBENDAL T, 1994, ALLERGY, V49, P210, DOI 10.1111/j.1398-9995.1994.tb02651.x; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; ENBERG RN, 1993, ANN ALLERGY, V70, P471; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GREEN WF, 1992, J ALLERGY CLIN IMMUN, V89, P1196, DOI 10.1016/0091-6749(92)90305-L; INGRAM JM, 1995, IN PRESS J ALLERGY C; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V78, P398, DOI 10.1016/0091-6749(86)90024-2; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; SCHOU C, 1991, J ALLERGY CLIN IMMUN, V88, P847, DOI 10.1016/0091-6749(91)90240-O; SHAMIE S, 1990, Journal of Allergy and Clinical Immunology, V85, P226; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; VANDERBREMPT X, 1991, J ALLERGY CLIN IMMUN, V87, P595, DOI 10.1016/0091-6749(91)90020-O; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x	23	62	62	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1995	95	6					1158	1163		10.1016/S0091-6749(95)70071-4	http://dx.doi.org/10.1016/S0091-6749(95)70071-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RD309	7797783	Bronze			2022-12-18	WOS:A1995RD30900002
J	SAKAGUCHI, M; INOUYE, S; IRIE, T; MIYAZAWA, H; WATANABE, M; YASUEDA, H; SHIDA, T; NITTA, H; CHAPMAN, MD; SCHOU, C; AALBERSE, RC				SAKAGUCHI, M; INOUYE, S; IRIE, T; MIYAZAWA, H; WATANABE, M; YASUEDA, H; SHIDA, T; NITTA, H; CHAPMAN, MD; SCHOU, C; AALBERSE, RC			AIRBORNE CAT (FEL-D-I), DOG (CAN-F-I), AND MITE (DER-I AND DER-II) ALLERGEN LEVELS IN THE HOMES OF JAPAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AIRBORNE; CAT; DOG; MITE; ALLERGEN	DERMATOPHAGOIDES-FARINAE; AFFINITY PURIFICATION; DUST; ASTHMA; MOUSE; HOUSE; AIR	We measured the airborne and floor dust allergen levels of the cat (Fel d I), dog (Can f I), and mite (Der I and Der II) allergens in 13 houses. Airborne allergens were sampled with a low-noise air sampler for 5 to 7 days in the living rooms where the inhabitants were living as usuaL. The mean levels of airborne Fel d I and Can f I in houses with cats or dogs were 5960 and 2880 pg/m3, respectively, which were about 160 and 100 times higher than levels of airborne Der L In floor dust the mean levels of Fel d I and Can f I were 322 and 236 mug/gm fine dust, respectively which were 59 and 10 times higher than the levels of Der L These results suggest that the airborne cat and dog allergens might be important sources of allergens for persons who live in a house with those animals, because the absolute allergen levels in both the air and dust are significantly higher than those of mite.	INST PUBL HLTH,DEPT ARCHITECTURAL HYG ENGN & HOUSING,TOKYO 108,JAPAN; KYORIN UNIV,DEPT MED TECHNOL,MITAKA,TOKYO 181,JAPAN; UNIV TOKYO,DEPT HUMAN ECOL,TOKYO 113,JAPAN; NATL SAGAMIHARA HOSP & RES CTR RHEUMATOL ALLERGY,CLIN RES CTR ALLERGY & RHEUMATOL,SAGAMIHARA,JAPAN; NATL INST ENVIRONM STUDIES,DIV REG ENVIRONM,YATABE,IBARAKI 305,JAPAN; UNIV VIRGINIA,DIV ALLERGY & CLIN IMMUNOL,CHARLOTTESVILLE,VA 22903; ALK RES,HORSHOLM,DENMARK; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,DEPT ALLERGY,CENT LAB,AMSTERDAM,NETHERLANDS	Kyorin University; University of Tokyo; National Institute for Environmental Studies - Japan; University of Virginia	SAKAGUCHI, M (corresponding author), NATL INST HLTH,DEPT EPIDEMIOL,TOYAMA 1-23-1,SHINJUKU KU,TOKYO 162,JAPAN.		Inouye, Sharon/R-7216-2019	Chapman, Martin/0000-0002-0845-3632				CHAPMAN MD, 1988, J IMMUNOL, V140, P812; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LOWENSTEIN H, 1985, ALLERGY, V40, P430, DOI 10.1111/j.1398-9995.1985.tb02682.x; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; OHMAN JL, 1987, J ALLERGY CLIN IMMUN, V79, P955, DOI 10.1016/0091-6749(87)90246-6; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; SAKAGUCHI M, 1989, J IMMUNOL METHODS, V116, P181, DOI 10.1016/0022-1759(89)90202-0; SAKAGUCHI M, 1989, INT ARCH ALLER A IMM, V90, P190, DOI 10.1159/000235022; SAKAGUCHI M, 1992, ALLERGY, V47, P55, DOI 10.1111/j.1398-9995.1992.tb02250.x; SCHOU C, 1991, J ALLERGY CLIN IMMUN, V88, P847, DOI 10.1016/0091-6749(91)90240-O; SCHOU C, 1991, CLIN EXP ALLERGY, V21, P321, DOI 10.1111/j.1365-2222.1991.tb01663.x; SOLOMON WR, 1988, ALLERGY PRINCIPLES P, P212; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; SWANSON MC, 1990, AM REV RESPIR DIS, V141, P1578, DOI 10.1164/ajrccm/141.6.1578; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; VANDERBREMPT X, 1991, J ALLERGY CLIN IMMUN, V87, P596; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; YASUEDA H, 1989, INT ARCH ALLER A IMM, V90, P182, DOI 10.1159/000235021; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214, DOI 10.1159/000234137; YASUEDA H, 1989, INT ARCH ALLER A IMM, V88, P402, DOI 10.1159/000234724	23	62	63	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					797	802		10.1016/0091-6749(93)90056-L	http://dx.doi.org/10.1016/0091-6749(93)90056-L			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258613				2022-12-18	WOS:A1993ML89300004
J	PIACENTINI, GL; MARTINATI, L; FORNARI, A; COMIS, A; CARCERERI, L; BOCCAGNI, P; BONER, AL				PIACENTINI, GL; MARTINATI, L; FORNARI, A; COMIS, A; CARCERERI, L; BOCCAGNI, P; BONER, AL			ANTIGEN AVOIDANCE IN A MOUNTAIN ENVIRONMENT - INFLUENCE ON BASOPHIL RELEASABILITY IN CHILDREN WITH ALLERGIC-ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; ALTITUDE; ANTIGEN AVOIDANCE; BASOPHIL; RELEASABILITY	HISTAMINE-RELEASE; BRONCHIAL HYPERREACTIVITY	Background: The influence of natural antigen avoidance in an environment free of relevant allergens (Istituto Pio XII, Misurina, Italian Alps, 1756 m) and of antigen exposure (sea level) on basophil releasability as well as on bronchial hyperreactivity (BHR) and specific IgE serum level, were investigated in a group of children with asthma who were allergic to Dermatophagoides pteronyssinus. Methods: Twenty allergic children with asthma participated in the study. Spontaneous and antigen-induced histamine release, BHR, and serum IgE were investigated at the time of admission, after 40 and 80 days of antigen avoidance, and after 15 days of exposure at sea level. Results: Significant drops in antigen-induced basophil histamine release, BHR, and specific IgE serum level but not in spontaneous basophil histamine release were observed after 40 days of antigen avoidance and were confirmed at a further evaluation after 40 more days. After 15 days of antigen exposure at sea level, specific antigen-induced basophil histamine release, BHR, and serum IgE but not spontaneous basophil histamine release increased promptly, even if not significantly. Conclusion: In children with allergic asthma, antigen-induced basophil releasability BHR, and specific IgE serum levels appear to be modifiable by periods of antigen avoidance or exposure.	UNIV VERONA, DEPT PEDIAT, I-37100 VERONA, ITALY; UNIV VERONA, DEPT IMMUNOL & INFECT, I-37100 VERONA, ITALY; IST PIO XII, MISURINA, ITALY	University of Verona; University of Verona								AKAGI K, 1989, J ALLERGY CLIN IMMUN, V83, P742, DOI 10.1016/0091-6749(89)90009-2; BONER AL, 1985, ANN ALLERGY, V54, P42; CHARPIN D, 1988, CHEST, V93, P758, DOI 10.1378/chest.93.4.758; GAMBOA PM, 1989, ALLERGOL IMMUNOPATH, V17, P73; GILBERT HS, 1975, BLOOD, V46, P279; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; ISHIZAKA K, 1989, ADV IMMUNOL, V47, P1; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; KORSGAARD J, 1989, 14 WORKSH MIT ALL C; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; NEIJENS HJ, 1982, CLIN ALLERGY, V12, P577, DOI 10.1111/j.1365-2222.1982.tb02556.x; NEIJENS HJ, 1980, CLIN ALLERGY, V10, P535, DOI 10.1111/j.1365-2222.1980.tb02134.x; PERONI DG, 1991, EUR RESPIR J, V4, pS507; PLATTSMILLS TAE, 1982, LANCET, V2, P675; ROSENTHAL RR, 1979, J ALLERGY CLIN IMMUN, V64, P564, DOI 10.1016/0091-6749(79)90013-7; SIRAGANIAN RP, 1976, J ALLERGY CLIN IMMUN, V57, P525, DOI 10.1016/0091-6749(76)90003-8; VERLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290; WHAN U, 1990, ALLERGY, V45, P109	18	62	62	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1993	92	5					644	650		10.1016/0091-6749(93)90006-2	http://dx.doi.org/10.1016/0091-6749(93)90006-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MG982	7693784				2022-12-18	WOS:A1993MG98200004
J	HUTCHESON, PS; REJENT, AJ; SLAVIN, RG				HUTCHESON, PS; REJENT, AJ; SLAVIN, RG			VARIABILITY IN PARAMETERS OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS IN PATIENTS WITH CYSTIC-FIBROSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ABPA; ASPERGILLUS ANTIBODIES; CYSTIC FIBROSIS	DIAGNOSIS	Seventy-nine patients with cystic fibrosis (CF) were evaluated and were followed in a longitudinal, prospective fashion during a 6-year period for the development of immune parameters indicating Aspergillus fumigatus (Af) sensitization and allergic bronchopulmonary aspergillosis (ABPA). Although four patients developed frank ABPA, there was considerable variability in immune parameters in non-ABPA. Twenty-four patients became skin test positive to Af with none losing skin reactivity. Twenty-five patients developed serum precipitins to Af, whereas 12 patients lost their precipitins. Of 15 patients with an elevated total serum IgE of greater-than-or-equal-to 2 SD, five demonstrated a marked decline of at least 40%. Three of 16 patients with IgE-Af became negative, whereas eight of 27 patients lost their IgG-Af. None of these patients had received corticosteroid therapy that could have accounted for the findings. Thus, patients with CF frequently lose evidence of Af sensitivity spontaneously without corticosteroid intervention. The diagnosis of ABPA in CF should not be based solely on serology and skin test results, since at any point in time, patients with CF may demonstrate variable responses to Af.	ST LOUIS UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63104	Saint Louis University	HUTCHESON, PS (corresponding author), ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,1402 S GRAND BLVD,ROOM R209,ST LOUIS,MO 63104, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030652] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30652] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BHALLA RB, 1982, ADV INTERPRETATION C, P295; BRUETON MJ, 1980, ARCH DIS CHILD, V55, P348, DOI 10.1136/adc.55.5.348; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; GREENBERGER PA, 1988, ALLERGY PRINCIPLES P, P1219; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; LAUFER P, 1984, J ALLERGY CLIN IMMUN, V73, P44, DOI 10.1016/0091-6749(84)90482-2; MEARNS M, 1967, LANCET, V1, P53; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; ROSENBERG M, 1977, ANN INTERN MED, V86, P405, DOI 10.7326/0003-4819-86-4-405; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SLAVIN RG, 1989, CURRENT THERAPY RESP, P147; TIETZ NW, 1982, FUNDAMENTALS CLIN CH, P1094	12	62	64	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				390	394		10.1016/0091-6749(91)90102-T	http://dx.doi.org/10.1016/0091-6749(91)90102-T			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126	1890268	Bronze			2022-12-18	WOS:A1991GG12600034
J	POLOSA, R; PHILLIPS, GD; RAJAKULASINGAM, K; HOLGATE, ST				POLOSA, R; PHILLIPS, GD; RAJAKULASINGAM, K; HOLGATE, ST			THE EFFECT OF INHALED IPRATROPIUM BROMIDE ALONE AND IN COMBINATION WITH ORAL TERFENADINE ON BRONCHOCONSTRICTION PROVOKED BY ADENOSINE 5'-MONOPHOSPHATE AND HISTAMINE IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							AMP-INDUCED BRONCHOCONSTRICTION; BRONCHIAL REACTIVITY; SODIUM CROMOGLYCATE; GANGLIONIC BLOCKADE; NEDOCROMIL SODIUM; ATOPIC SUBJECTS; MAST-CELLS; COLD AIR; ATROPINE; INHIBITION	The aim of this study was to investigate the effect of terfenadine, an antihistamine, 180 mg orally, the anticholinergic drug, ipratropium bromide (IB), 0.5 mg nebulized aerosol, the combination of these two drugs, and placebo tablets and aerosol on histamine- and adenosine 5'-monophosphate (AMP)-induced bronchoconstriction in a randomized, double-blind fashion. Airway response was evaluated as FEV1. After placebo, the geometric mean (GM) provocative concentration causing a 20% in FEV1 from the postsaline baseline value (PC20) for histamine and AMP was 0.63 and 5 mg/ml, respectively. Terfenadine displaced the FEV1 concentration-response curves obtained with both histamine (GM PC20 values increasing to 26.92 mg/ml) and AMP (GM PC20 values increasing to 26.7 mg/ml) to the right. IB had a small, but significant, protective effect against the fall in FEV1 produced by histamine and AMP, the GM PC20 values increasing to 1.69 and to 12.6 mg/ml, respectively. Terfenadine and IB in combination produced protection against histamine and AMP that was more than the production produced by either drug alone, the GM PC20 values increasing to 54.76 and 47.7 mg/ml, respectively. There was no correlation between degree of bronchodilatation induced by active treatments and concentration ratios for AMP or histamine. These data suggest that histamine release and vagal reflexes both contribute to AMP-induced bronchoconstriction in clinical asthma in man.			POLOSA, R (corresponding author), SOUTHAMPTON GEN HOSP,MED 1,LEVEL D,CTR BLOCK TREMONA RD,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							ALTMAN DG, 1986, LANCET, V2, P307; BEASLEY R, 1987, AM REV RESPIR DIS, V136, P1140, DOI 10.1164/ajrccm/136.5.1140; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHANYEUNG M, 1977, CHEST, V71, P320, DOI 10.1378/chest.71.3.320; CHURCH MK, 1991, ASTHMA ITS PATHOLOGY, P561; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; CRIMI N, 1989, J ALLERGY CLIN IMMUN, V83, P921, DOI 10.1016/0091-6749(89)90106-1; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; EISER NM, 1982, B EUR PHYSIOPATHOL R, V17, P449; FISH JE, 1977, AM REV RESPIR DIS, V115, P371; GUSTAFSSON LE, 1986, EUR J PHARMACOL, V120, P179, DOI 10.1016/0014-2999(86)90538-8; HAHN HL, 1978, J APPL PHYSIOL, V44, P144, DOI 10.1152/jappl.1978.44.2.144; HOLTZMAN MJ, 1980, AM REV RESPIR DIS, V122, P17; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; IHKE E, 1990, CHEST, V97, P46; LEWIS RA, 1984, DRUGS LUNG, P63; MANN JS, 1985, AM REV RESPIR DIS, V132, P1; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; OBYRNE PM, 1985, J ALLERGY CLIN IMMUN, V76, P97, DOI 10.1016/0091-6749(85)90810-3; OKAYAMA M, 1986, AM REV RESPIR DIS, V133, pA93; PATEL KR, 1987, J ALLERGY CLIN IMMUN, V79, P355, DOI 10.1016/0091-6749(87)90155-2; PAUWELS RA, 1987, AM REV RESPIR DIS, V136, P374, DOI 10.1164/ajrccm/136.2.374; PEACHELL PT, 1988, AM REV RESPIR DIS, V138, P1143, DOI 10.1164/ajrccm/138.5.1143; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; PHILLIPS GD, 1989, AM REV RESPIR DIS, V139, P463, DOI 10.1164/ajrccm/139.2.463; PHILLIPS GD, 1989, CLIN EXP ALLERGY, V19, P405, DOI 10.1111/j.1365-2222.1989.tb02406.x; PHILLIPS GD, 1989, EUR RESPIR J, V2, P210; POLOSA R, 1990, IMMUNOLOGY ALLERGY C, P363; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RICHARDS R, 1989, CLIN EXP ALLERGY, V19, P285, DOI 10.1111/j.1365-2222.1989.tb02385.x; SHEPPARD D, 1982, J APPL PHYSIOL, V53, P169, DOI 10.1152/jappl.1982.53.1.169; SHEPPARD D, 1984, J ALLERGY CLIN IMMUN, V73, P82, DOI 10.1016/0091-6749(84)90488-3; SHEPPARD D, 1983, J APPL PHYSIOL, V54, P130, DOI 10.1152/jappl.1983.54.1.130; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; WOLKOVE N, 1981, ANN ALLERGY, V47, P311; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823	36	62	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1991	87	5					939	947		10.1016/0091-6749(91)90415-K	http://dx.doi.org/10.1016/0091-6749(91)90415-K			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FM095	1673977				2022-12-18	WOS:A1991FM09500005
J	MYGIND, N				MYGIND, N			NASAL POLYPOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							FINE-STRUCTURE; CELLS		RIGSHOSP,DEPT ALLERGY,DK-2100 COPENHAGEN,DENMARK	Rigshospitalet; University of Copenhagen	MYGIND, N (corresponding author), RIGSHOSP,DEPT OTORHINOLARYNGOL,DK-2100 COPENHAGEN,DENMARK.							CAPLIN I., 1971, ANN ALLERGY, V29, P63; CAUNA N, 1972, ANN OTO RHINOL LARYN, V81, P41, DOI 10.1177/000348947208100105; Drake-Lee AS, 1989, RHINITIS MECH MANAGE, P141; DRAKELEE AB, 1984, J ROY SOC MED, V77, P120, DOI 10.1177/014107688407700210; DRAKELEE AB, 1984, J LARYNGOL OTOL, V98, P285, DOI 10.1017/S0022215100146584; DRETTNER B, 1982, Rhinology (Utrecht), V20, P149; HARTWIG S, 1988, J LARYNGOL OTOL, V102, P148, DOI 10.1017/S0022215100104372; Jankowski R, 1989, Rhinol Suppl, V8, P51; Jantti-Alanko S, 1989, Rhinol Suppl, V8, P59; KARLSSON G, 1982, Rhinology (Utrecht), V20, P144; KUNZELMANN K, 1989, PFLUG ARCH EUR J PHY, V415, P172, DOI 10.1007/BF00370589; LAROCCA LM, 1989, ANN ALLERGY, V63, P508; LARSEN PL, 1989, LARYNGOSCOPE, V99, P1274; LEVINE HL, 1990, LARYNGOSCOPE, V100, P79; LILDHOLDT T, 1988, ACTA OTO-LARYNGOL, V105, P140, DOI 10.3109/00016488809119457; MANIGLIA AJ, 1989, LARYNGOSCOPE, V99, P276; MYGIND N, 1974, ACTA OTO-LARYNGOL, V78, P436, DOI 10.3109/00016487409126377; MYGIND N, 1975, Clinical Allergy, V5, P159, DOI 10.1111/j.1365-2222.1975.tb01848.x; RHUNO J, 1990, J ALLERGY CLIN IMMUN, V86, P946; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SETTIPANE GA, 1984, RHINITIS, P133; SLAVIN RG, 1988, ALLERGY PRINCIPLES P, P1291; SORENSEN H, 1977, Rhinology (Utrecht), V15, P121; STOOP AE, 1989, J ALLERGY CLIN IMMUN, V84, P734, DOI 10.1016/0091-6749(89)90302-3; VENGE P, 1990, RHINITIS ASTHMA SIMI, P188; Yamashita T, 1989, Rhinol Suppl, V8, P15	26	62	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1990	86	6	1				827	829		10.1016/S0091-6749(05)80142-3	http://dx.doi.org/10.1016/S0091-6749(05)80142-3			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EQ045	2262640				2022-12-18	WOS:A1990EQ04500001
J	KLEMENTSSON, H; ANDERSSON, M; PIPKORN, U				KLEMENTSSON, H; ANDERSSON, M; PIPKORN, U			ALLERGEN-INDUCED INCREASE IN NONSPECIFIC NASAL REACTIVITY IS BLOCKED BY ANTIHISTAMINES WITHOUT A CLEAR-CUT RELATIONSHIP TO EOSINOPHIL INFLUX	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LUND HOSP,DEPT OTORHINOLARYNGOL,S-22185 LUND,SWEDEN	Lund University; Skane University Hospital								ANDERSSON M, 1989, ALLERGY, V44, P342, DOI 10.1111/j.1398-9995.1989.tb00456.x; ANDERSSON M, 1987, ALLERGY, V42, P631, DOI 10.1111/j.1398-9995.1987.tb00395.x; ANDERSSON M, 1989, ACTA OTO-LARYNGOL, V107, P270, DOI 10.3109/00016488909127508; ANDERSSON M, 1988, CLIN ALLERGY, V18, P189, DOI 10.1111/j.1365-2222.1988.tb02858.x; ANDERSSON M, 1989, J ALLERGY CLIN IMMUN, V82, P1019; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BORUM P, 1979, J ALLERGY CLIN IMMUN, V63, P253, DOI 10.1016/0091-6749(79)90109-X; BROFELDT S, 1986, AM REV RESPIR DIS, V133, P1138; COCKCROFT DW, 1982, CLIN ALLERGY, V2, P503; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DEVOS C, 1989, INT ARCH ALLER A IMM, V88, P212, DOI 10.1159/000234789; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FREIGAS E, 1980, LAB INVEST, V42, P35; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GRONBORG H, 1986, CLIN ALLERGY, V16, P597, DOI 10.1111/j.1365-2222.1986.tb01999.x; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HOLMBERG K, 1989, ALLERGY, V44, P281, DOI 10.1111/j.1398-9995.1989.tb01070.x; KLEMENTSSON H, IN PRESS CLIN EXP AL; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; MALM L, 1985, ALLERGIC VASOMOTOR R, P140; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; NICHOLSON AN, 1982, BRIT J CLIN PHARMACO, V13, P199, DOI 10.1111/j.1365-2125.1982.tb01356.x; PATEL KR, 1987, J ALLERGY CLIN IMMUN, V79, P355, DOI 10.1016/0091-6749(87)90155-2; PIPKORN U, 1988, J IMMUNOL METHODS, V112, P37, DOI 10.1016/0022-1759(88)90030-0; PIPKORN U, 1987, ALLERGIC VASOMOTOR R, P149; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; RAPHAEL GD, 1989, AM REV RESPIR DIS, V139, P791, DOI 10.1164/ajrccm/139.3.791; SNYDER SH, 1987, ANN ALLERGY, V59, P4; WIHL JA, 1986, ALLERGY, V41, P357, DOI 10.1111/j.1398-9995.1986.tb00313.x	30	62	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				466	472		10.1016/S0091-6749(05)80201-5	http://dx.doi.org/10.1016/S0091-6749(05)80201-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	1977780				2022-12-18	WOS:A1990EG45400005
J	TURKELTAUB, PC; GERGEN, PJ				TURKELTAUB, PC; GERGEN, PJ			THE RISK OF ADVERSE REACTIONS FROM PERCUTANEOUS PRICK-PUNCTURE ALLERGEN SKIN TESTING, VENIPUNCTURE, AND BODY MEASUREMENTS - DATA FROM THE 2ND NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY 1976-80 (NHANES-II)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,CTR BLDG,RM 2-58,3700 E W HIGHWAY,HYATTSVILLE,MD 20782; US FDA,CTR BIOL EVALUAT & RES,ALLERGEN PROD LAB,BETHESDA,MD 20014	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); US Food & Drug Administration (FDA)			turkeltaub, paul/U-7729-2019; turkeltaub, paul/AAG-6160-2019	turkeltaub, paul/0000-0002-7350-1469				BOUSQUET J, 1988, ALLERGY PRINCIPLES P, P424; Braunwald E., 1987, HARRISONS PRINCIPLES; DONOHUE D, 1981, CLIN PRACTICE BLOOD, P199; GERGEN PJ, 1986, DHHS PHS861685 NAT C; GUNTER EW, 1981, LABORATORY PROCEDURE; HENRY JB, 1984, TODD SANFORD DAVIDSO; KLEINKNECHT RA, 1987, BEHAV RES THER, V25, P175, DOI 10.1016/0005-7967(87)90043-X; KLEINKNECHT RA, 1988, BEHAV RES THER, V26, P303, DOI 10.1016/0005-7967(88)90082-4; LOCKEY RF, 1989, J ALLERGY CLIN IMMUN, V84, P967, DOI 10.1016/0091-6749(89)90396-5; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; MCDOWELL A, 1981, DHHS PHS811317 NAT C; PATTERSON R, 1985, ALLERGIC DISEASES DI; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; THYER BA, 1985, J CLIN PSYCHOL, V41, P451, DOI 10.1002/1097-4679(198507)41:4<451::AID-JCLP2270410402>3.0.CO;2-O; WYNGAARDEN JB, 1988, CECIL TXB MED; [No title captured]	16	62	63	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				886	890		10.1016/0091-6749(89)90384-9	http://dx.doi.org/10.1016/0091-6749(89)90384-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2600322				2022-12-18	WOS:A1989CG29300005
J	MELTZER, EO				MELTZER, EO			EVALUATING RHINITIS - CLINICAL, RHINOMANOMETRIC, AND CYTOLOGIC ASSESSMENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF SAN DIEGO,SCH MED,RES CTR,LA JOLLA,CA 92093	University of California System; University of California San Diego	MELTZER, EO (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,ALLERGY & ASTHMA MED GRP,LA JOLLA,CA 92093, USA.							MELTZER EO, 1983, PEDIATR CLIN N AM, V30, P847; MELTZER EO, 1985, J RESPIR DIS, V6, P100; ORGEL HA, 1986, J ALLERGY CLIN IMMUN, V77, P858, DOI 10.1016/0091-6749(86)90384-2; WELCH MJ, 1985, ANN ALLERGY, V55, P577; YOUNG P, 1980, US PHS NIH DIHN80388	5	62	66	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	2	S			900	908		10.1016/0091-6749(88)90032-2	http://dx.doi.org/10.1016/0091-6749(88)90032-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R2353	3057042				2022-12-18	WOS:A1988R235300003
J	HAAKFRENDSCHO, M; DINARELLO, C; KAPLAN, AP				HAAKFRENDSCHO, M; DINARELLO, C; KAPLAN, AP			RECOMBINANT HUMAN INTERLEUKIN-1 BETA CAUSES HISTAMINE-RELEASE FROM HUMAN BASOPHILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY STONY BROOK,HLTH SCI CTR,DEPT MED,DIV ALLERGY RHEUMATOL & CLIN IMMUNOL,T-16-040,STONY BROOK,NY 11794; TUFTS UNIV,NEW ENGLAND MED CTR,DIV EXPTL MED,BOSTON,MA 02111	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Tufts Medical Center; Tufts University								ALAM R, 1984, ANN ALLERGY, V53, P66; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BOWLIN TL, 1984, J IMMUNOL, V133, P2001; BUSSE WW, 1983, J ALLERGY CLIN IMMUN, V71, P382, DOI 10.1016/0091-6749(83)90066-0; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; EZEUMUZIE IC, 1983, AGENTS ACTIONS, V13, P222; GOETZL EJ, 1984, IMMUNOLOGY, V53, P227; HAAKFRENDSCHO M, 1987, J ALLERGY CLIN IMMUN, V79, P171; HAAKFRENDSCHO M, 1986, J ALLERGY CLIN IMMUN, V77, P230; HAMAGUCHI Y, 1987, J EXP MED, V165, P268, DOI 10.1084/jem.165.1.268; IHLE JN, 1983, J IMMUNOL, V131, P282; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LIU MC, 1986, J IMMUNOL, V136, P2588; MOSMANN TR, 1986, P NATL ACAD SCI USA, V83, P5654, DOI 10.1073/pnas.83.15.5654; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; RAZIN E, 1984, J IMMUNOL, V132, P1479; SARFATI M, 1986, IMMUNOLOGY, V59, P569; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; SMITH CA, 1986, P NATL ACAD SCI USA, V83, P1857, DOI 10.1073/pnas.83.6.1857; SUBRAMANIAN N, 1987, J IMMUNOL, V138, P271; THUESON DO, 1979, J IMMUNOL, V123, P633; THUESON DO, 1979, J IMMUNOL, V123, P626	27	62	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1988	82	2					218	223		10.1016/0091-6749(88)91002-0	http://dx.doi.org/10.1016/0091-6749(88)91002-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P8741	3261306				2022-12-18	WOS:A1988P874100012
J	MULLER, UR; MORRIS, T; BISCHOF, M; FRIEDLI, H; SKARVIL, F				MULLER, UR; MORRIS, T; BISCHOF, M; FRIEDLI, H; SKARVIL, F			COMBINED ACTIVE AND PASSIVE IMMUNOTHERAPY IN HONEYBEE-STING ALLERGY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INST CLIN & EXPTL TUMOR RES,BERN,SWITZERLAND; SWISS RED CROSS,CENT LAB,CH-3000 BERN 22,SWITZERLAND		MULLER, UR (corresponding author), ZIEGLERSPITAL,DIV MED,CH-3007 BERN,SWITZERLAND.							AALBERSE RC, 1983, J IMMUNOL, V130, P722; ADKINSON NF, 1980, J ALLERGY CLIN IMMUN, V65, P1, DOI 10.1016/0091-6749(80)90169-4; AUKRUST L, 1982, ALLERGY, V37, P265, DOI 10.1111/j.1398-9995.1982.tb01909.x; BARANDUN S, 1962, VOX SANG, V7, P157, DOI 10.1111/j.1423-0410.1962.tb03240.x; BOUSQUET J, 1984, Journal of Allergy and Clinical Immunology, V73, P188; CLAYTON WF, 1983, CLIN ALLERGY, V13, P123, DOI 10.1111/j.1365-2222.1983.tb02579.x; EINARSSON R, 1982, ALLERGY, V37, P273, DOI 10.1111/j.1398-9995.1982.tb01910.x; HEINER DC, 1980, J ALLERGY CLIN IMMUN, V65, P201; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JARISCH R, 1980, WIEN KLIN WOCHENSC S, V92, P1; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LIGHT WC, 1976, CLIN ALLERGY, V6, P293, DOI 10.1111/j.1365-2222.1976.tb01909.x; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1985, INT ARCH ALLER A IMM, V77, P201, DOI 10.1159/000233786; MULLER U, 1982, INT ARCH ALLER A IMM, V68, P320; PATRIZZI R, 1979, ALLERGY, V34, P249, DOI 10.1111/j.1398-9995.1979.tb01705.x; SKVARIL F, 1984, INT ARCH ALLER A IMM, V73, P330, DOI 10.1159/000233493; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P500, DOI 10.1016/0091-6749(82)90174-9; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; WETTERWALD A, 1985, INT ARCH ALLER A IMM, V77, P195, DOI 10.1159/000233784	21	62	63	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				115	122		10.1016/0091-6749(86)90123-5	http://dx.doi.org/10.1016/0091-6749(86)90123-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3722631				2022-12-18	WOS:A1986D299600018
J	WEILER, JM; FREIMAN, P; SHARATH, MD; METZGER, WJ; SMITH, JM; RICHERSON, HB; BALLAS, ZK; HALVERSON, PC; SHULAN, DJ; MATSUO, S; WILSON, RL				WEILER, JM; FREIMAN, P; SHARATH, MD; METZGER, WJ; SMITH, JM; RICHERSON, HB; BALLAS, ZK; HALVERSON, PC; SHULAN, DJ; MATSUO, S; WILSON, RL			SERIOUS ADVERSE REACTIONS TO PROTAMINE SULFATE - ARE ALTERNATIVES NEEDED	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,DEPT ANAESTHESIOL,IOWA CITY,IA 52242	University of Iowa; University of Iowa				Knaack, Aaron/0000-0001-7712-1415; Ballas, Zuhair/0000-0001-5569-1230				ANDERSEN JM, 1981, AM J HOSP PHARM, V38, P701, DOI 10.1093/ajhp/38.5.701; BJORAKER D G, 1982, Anesthesiology (Hagerstown), V57, pA7, DOI 10.1097/00000542-198209001-00007; BULL BS, 1975, J THORAC CARDIOV SUR, V69, P685; BULL BS, 1975, J THORAC CARDIOV SUR, V69, P674; CAPLAN SN, 1976, NEW ENGL J MED, V295, P172; CASTANEDA AR, 1966, J THORAC CARDIOV SUR, V52, P716, DOI 10.1016/S0022-5223(19)43382-5; CHARGAFF E, 1938, J BIOL CHEM, V122, P153; CHENOWETH DE, 1981, NEW ENGL J MED, V304, P497, DOI 10.1056/NEJM198102263040901; COBB CA, 1982, SURG NEUROL, V17, P245, DOI 10.1016/0090-3019(82)90112-4; DOOLAN L, 1981, ANAESTH INTENS CARE, V9, P147, DOI 10.1177/0310057X8100900209; FADALI MA, 1974, ANN SURG, V180, P232, DOI 10.1097/00000658-197408000-00018; FEHR J, 1983, CLIN IMMUNOL IMMUNOP, V29, P7, DOI 10.1016/0090-1229(83)90002-8; GODAL HC, 1960, SCAND J CLIN LAB INV, V12, P446; GRANT J A, 1984, Journal of Allergy and Clinical Immunology, V73, P180; HAGEDORS H. C., 1936, Journal of the American Medical Association, V106, P177; Hattersley P., 1966, JAMA-J AM MED ASSOC, V196, P150; HERZIG GP, 1972, BLOOD-J HEMATOL, V39, P554, DOI 10.1182/blood.V39.4.554.554; HEYNS AD, 1980, THROMB HAEMOSTASIS, V44, P65; HOLLAND CL, 1984, CLIN CARDIOL, V7, P157, DOI 10.1002/clc.4960070305; JACKSON DR, 1970, ANGIOLOGY, V21, P295, DOI 10.1177/000331977002100502; JAQUES L. B., 1938, ACTA MED SCAND SUPPL, V90, P190; JAQUES LB, 1949, BRIT J PHARM CHEMOTH, V4, P135, DOI 10.1111/j.1476-5381.1949.tb00526.x; JASTRZEBSKI J, 1974, THORAX, V29, P534, DOI 10.1136/thx.29.5.534; KELLY JF, 1978, J ALLERGY CLIN IMMUN, V62, P181, DOI 10.1016/0091-6749(78)90104-5; KNAPE JTA, 1981, ANESTHESIOLOGY, V55, P324, DOI 10.1097/00000542-198109000-00025; LAKIN JD, 1978, J ALLERGY CLIN IMMUN, V61, P102, DOI 10.1016/0091-6749(78)90232-4; LANGER R, 1982, SCIENCE, V217, P261, DOI 10.1126/science.7089564; LOWENSTEIN E, 1983, ANESTHESIOLOGY, V59, P470, DOI 10.1097/00000542-198311000-00022; MASONE R, 1982, Anesthesiology (Hagerstown), V57, pA6, DOI 10.1097/00000542-198209001-00006; MOORTHY SS, 1980, ANESTH ANALG, V59, P77; NORDSTROM L, 1978, ACTA ANAESTH SCAND, V22, P195, DOI 10.1111/aas.1978.22.3.195; OLINGER GN, 1980, ANN THORAC SURG, V29, P20, DOI 10.1016/S0003-4975(10)61620-7; RENT R, 1975, J IMMUNOL, V114, P120; REYNOLDS EF, 1982, EXTRAPHARMACOPEIA, P390; REYNOLDS EF, 1982, EXTRAPHARMACOPOEIA, P843; SAMUEL T, 1978, CLIN EXP IMMUNOL, V33, P261; SAMUEL T, 1977, CLIN EXP IMMUNOL, V30, P181; SANCHEZ MB, 1982, LANCET, V1, P1243; SCHNITZLER S, 1981, AGENTS ACTIONS, V11, P73, DOI 10.1007/BF01991461; SHARATH MD, J THORAC CARDIOVASC; Shelley WB, 1942, P SOC EXP BIOL MED, V50, P300; SIEGEL J, 1974, J EXP MED, V140, P631, DOI 10.1084/jem.140.3.631; TAKADA A, 1980, THROMB RES, V18, P847, DOI 10.1016/0049-3848(80)90207-8; Thompson W. H., 1900, Z PHYSIOL CHEM, V29, P1; Tocantins LM, 1943, P SOC EXP BIOL MED, V54, P94; TUNG KSK, 1975, CLIN EXP IMMUNOL, V20, P93; VONTZ FK, 1982, AM SURGEON, V48, P549; WEILER JM, 1978, J EXP MED, V147, P409, DOI 10.1084/jem.147.2.409	48	62	68	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	2					297	303		10.1016/0091-6749(85)90061-2	http://dx.doi.org/10.1016/0091-6749(85)90061-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABZ05	2857186				2022-12-18	WOS:A1985ABZ0500011
J	SCHLEIMER, RP; MACGLASHAN, DW; PETERS, SP; NACLERIO, R; PROUD, D; ADKINSON, NF; LICHTENSTEIN, LM				SCHLEIMER, RP; MACGLASHAN, DW; PETERS, SP; NACLERIO, R; PROUD, D; ADKINSON, NF; LICHTENSTEIN, LM			INFLAMMATORY MEDIATORS AND MECHANISMS OF RELEASE FROM PURIFIED HUMAN BASOPHILS AND MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239	Johns Hopkins University								ADAMS GK, 1979, J IMMUNOL, V122, P555; ADAMS GK, UNPUB EFFECTS FENOTE; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; CAULFIELD JP, 1980, J CELL BIOL, V85, P299, DOI 10.1083/jcb.85.2.299; CONTI MA, 1980, FED PROC, V39, P1569; CRETICOS PS, 1983, J ALLERGY CLIN IMMUN, V71, P90, DOI 10.1016/0091-6749(83)90129-X; CREWS FT, 1980, BIOCHEM BIOPH RES CO, V93, P42, DOI 10.1016/S0006-291X(80)80243-9; CUSHLEY, 1983, BR J CLIN PHARM, V15, P161; CUSHLEY MJ, 1983, PHARM ASTHMA, P109; DAERON M, 1982, J IMMUNOL, V129, P1212; DORSCH W, 1982, J ALLERGY CLIN IMMUN, V70, P236, DOI 10.1016/0091-6749(82)90059-8; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; FLOWER RJ, 1979, NATURE, V278, P456, DOI 10.1038/278456a0; FOX CC, 1984, J IMMUNOL, V132, P2177; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P160, DOI 10.1016/0091-6749(82)90037-9; HIRATA F, 1980, P NATL ACAD SCI-BIOL, V77, P2533, DOI 10.1073/pnas.77.5.2533; HONG SL, 1976, P NATL ACAD SCI USA, V73, P1730, DOI 10.1073/pnas.73.5.1730; ISHIZAKA T, 1983, J IMMUNOL, V130, P2357; ISHIZAKA T, 1980, P NATL ACAD SCI-BIOL, V77, P1903, DOI 10.1073/pnas.77.4.1903; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; KENNERLY DA, 1979, J IMMUNOL, V122, P152; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; LANDRY FJ, 1983, J IMMUNOL METHODS, V63, P329, DOI 10.1016/S0022-1759(83)80006-4; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LEWIS RA, 1974, J EXP MED, V140, P1133, DOI 10.1084/jem.140.5.1133; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LEWIS RA, 1981, BIOCH ACUTE ALLERGIC, P239; LICHTENS.LM, 1968, SCIENCE, V161, P902, DOI 10.1126/science.161.3844.902; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MACGLASHAN DW, 1980, J IMMUNOL, V124, P2519; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MARONE G, 1979, J IMMUNOL, V123, P1473; NACLERIO R, 1984, Journal of Allergy and Clinical Immunology, V73, P148; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1984, ARCH OTOLARYNGOL, V110, P25; NEWBALL HH, 1981, INT ARCH ALLER A IMM, V66, P165, DOI 10.1159/000232894; PELIKAN Z, 1982, ANN ALLERGY, V49, P200; PEPYS J, 1974, CLIN ALLERGY, V4, P13, DOI 10.1111/j.1365-2222.1974.tb01358.x; PETERS SP, 1982, AM REV RESPIR DIS, V126, P1034; PETERS SP, 1984, J IMMUNOL, V132, P1972; PIENKOWSKI MM, UNPUB HISTAMINE PROS; PINCKARD RN, UNPUB; POOTHULLIL J, 1976, J ALLERGY CLIN IMMUN, V57, P164, DOI 10.1016/0091-6749(76)90035-X; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; PROUD D, 1982, CLIN RES, V30, P165; PROUD D, 1984, FED PROC, V43, P1807; ROBERTS LJ, 1980, NEW ENGL J MED, V303, P1400, DOI 10.1056/NEJM198012113032405; Schild H, 1937, Q J EXP PHYSIOL, V26, P165; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1983, CLIN REV ALLERG, V1, P327; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; SCHULMAN ES, 1983, J IMMUNOL, V131, P1936; SCHWARTZ LB, 1981, J BIOL CHEM, V256; STEEL L, 1979, J ALLERGY CLIN IMMUN, V64, P287, DOI 10.1016/0091-6749(79)90146-5; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880	63	62	62	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					473	481		10.1016/0091-6749(84)90381-6	http://dx.doi.org/10.1016/0091-6749(84)90381-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN620	6208229				2022-12-18	WOS:A1984TN62000003
J	SHANAHAN, F; LEE, TDG; BIENENSTOCK, J; BEFUS, AD				SHANAHAN, F; LEE, TDG; BIENENSTOCK, J; BEFUS, AD			THE INFLUENCE OF ENDORPHINS ON PERITONEAL AND MUCOSAL MAST-CELL SECRETION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,MED CTR 4H18,DEPT PATHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA; MCMASTER UNIV,MED CTR,DEPT MED,HOST RESISTANCE PROGRAM,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University; McMaster University			Befus, Dean/C-5561-2009	Befus, Dean/0000-0002-1611-2897; Shanahan, Fergus/0000-0003-0467-0936				BATCHELOR KW, 1979, MAST CELL ITS ROLE H, P47; BEFUS AD, 1979, IMMUNOLOGY, V38, P95; BEFUS AD, 1982, J IMMUNOL, V128, P2475; BEFUS AD, 1979, EXP PARASITOL, V47, P1; BEFUS AD, 1982, IN VIVO IMMUNOLOGY H, P521; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; BRANDT NJ, 1980, NEW ENGL J MED, V303, P914, DOI 10.1056/NEJM198010163031604; ELLIS HV, 1970, J PHARMACOL EXP THER, V175, P627; Enerback L., 1981, MONOGR ALLERGY, V17, P222; ERJAVEC F, 1981, N-S ARCH PHARMACOL, V317, P67, DOI 10.1007/BF00506259; FADEN AI, 1980, J INFECT DIS, V142, P229, DOI 10.1093/infdis/142.2.229; FJELLNER B, 1981, ACTA DERM-VENEREOL, V61, P245; GOLDSTEIN DJ, 1983, ANN INTERN MED, V98, P30, DOI 10.7326/0003-4819-98-1-30; GROSMAN N, 1982, AGENTS ACTIONS, V12, P417, DOI 10.1007/BF01965920; GROSMAN N, 1981, AGENTS ACTIONS, V2, P196; IMURA H, 1981, ANNU REV PHYSIOL, V43, P265, DOI 10.1146/annurev.ph.43.030181.001405; JOHNSON AR, 1973, P SOC EXP BIOL MED, V142, P1252; LEWIS RA, 1981, NATURE, V293, P103, DOI 10.1038/293103a0; MELANDER A, 1977, ACTA MED SCAND, V201, P257; MORLEY JE, 1982, JAMA-J AM MED ASSOC, V247, P2379, DOI 10.1001/jama.247.17.2379; PEARCE FL, 1982, J IMMUNOL, V128, P2481; PEPYS J, 1979, MAST CELL ITS ROLE H; ROY PD, 1980, BIOCHEM J, V191, P233, DOI 10.1042/bj1910233; RUITENBERG EJ, 1982, INT ARCH ALLER A IMM, V67, P233, DOI 10.1159/000233024; SHANAHAN F, 1983, FED PROC, V42, P1343; STROBEL S, 1981, J CLIN PATHOL, V34, P851, DOI 10.1136/jcp.34.8.851; VUOLTEENAHO O, 1980, LIFE SCI, V27, P57, DOI 10.1016/0024-3205(80)90019-3; ZIOUDROU C, 1979, J BIOL CHEM, V254, P2446	28	62	63	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	4					499	504		10.1016/0091-6749(84)90385-3	http://dx.doi.org/10.1016/0091-6749(84)90385-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN620	6208230				2022-12-18	WOS:A1984TN62000007
J	BLUESTONE, CD				BLUESTONE, CD			EUSTACHIAN-TUBE FUNCTION - PHYSIOLOGY, PATHO-PHYSIOLOGY, AND ROLE OF ALLERGY IN PATHOGENESIS OF OTITIS-MEDIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PITTSBURGH,SCH MED,OTITIS MEDIA RES CTR,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	BLUESTONE, CD (corresponding author), CHILDRENS HOSP,DEPT OTOLARYNGOL,PITTSBURGH,PA 15213, USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE001697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016337] Funding Source: NIH RePORTER; NIDCR NIH HHS [5P01 DE01697] Funding Source: Medline; NINDS NIH HHS [5P01 NS16337] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTI PWR, 1970, LARYNGOSCOPE, V80, P735, DOI 10.1288/00005537-197005000-00005; ASCHAN G K, 1952, Acta Soc Med Ups, V57, P1; ASCHAN GUNNAR, 1955, ACTA SOC MED UPSALIENSIS, V60, P131; BAUER F, 1975, J LARYNGOL OTOL, V89, P63, DOI 10.1017/S0022215100080087; BEERY QC, 1979, LARYNGOSCOPE, V89, P1446, DOI 10.1002/lary.5540890910; BEERY QC, 1975, LARYNGOSCOPE, V85, P1976, DOI 10.1288/00005537-197512000-00003; BERNSTEIN JM, 1981, OTOLARYNG HEAD NECK, V89, P874, DOI 10.1177/019459988108900534; BERRY QC, 1980, ANN OTO RHINOL LARYN, V89, P28; Bluestone C D, 1972, Cleft Palate J, V9, P93; Bluestone C D, 1972, Cleft Palate J, V9, P183; BLUESTONE CD, 1975, LARYNGOSCOPE, V85, P113, DOI 10.1288/00005537-197501000-00009; BLUESTONE CD, 1975, ANN OTO RHINOL LARYN, V84, P333, DOI 10.1177/000348947508400308; BLUESTONE CD, 1973, LARYNGOSCOPE, V83, P594, DOI 10.1288/00005537-197304000-00015; BLUESTONE CD, 1978, PEDIATRICS, V61, P753; BLUESTONE CD, 1972, LARYNGOSCOPE, V82, P1654, DOI 10.1288/00005537-197209000-00009; BLUESTONE CD, 1971, ANN OTO RHINOL LARYN, V80, P1; BLUESTONE CD, 1974, ANN OTO RHINOL LARYN, V83, P27, DOI 10.1177/0003489474083S1103; BLUESTONE CD, 1976, ANN OTO RHINOL LARYN, V85, P182, DOI 10.1177/00034894760850S235; BLUESTONE CD, 1977, LARYNGOSCOPE, V87, P493; Brooks D., 1969, INT AUDIOL, V8, P563; BYLANDER A, 1980, ANN OTO RHINOL LARYN, V89, P20, DOI 10.1177/00034894800890S308; CANTEKIN EI, 1979, ANN OTO RHINOL LARYN, V88, P40, DOI 10.1177/000348947908800108; CANTEKIN EI, 1977, ANN OTO RHINOL LARYN, V86, P1; CANTEKIN EI, 1980, ANN OTO RHINOL LARYN, V89, P71, DOI 10.1177/00034894800890S320; Compere W E Jr, 1970, Otolaryngol Clin North Am, V3, P45; COMPERE WE, 1960, ARCHIV OTOLARYNGOL, V71, P386; DOYLE WJ, 1980, ANN OTO RHINOL LARYN, V89, P34, DOI 10.1177/00034894800890S311; DOYLE WJ, 1980, ANN OTO RHINOL LARYN, V89, P41, DOI 10.1177/00034894800890S312; DRAPER WL, 1967, LARYNGOSCOPE, V77, P636, DOI 10.1288/00005537-196704000-00016; ELBROND O, 1976, ARCH OTOLARYNGOL, V102, P538; ELNER A, 1972, ACTA OTO-LARYNGOL, V74, P191, DOI 10.3109/00016487209128440; ELNER A, 1977, ACTA OTO-LARYNGOL, V83, P25, DOI 10.3109/00016487709128807; ELNER A, 1971, ACTA OTO-LARYNGOL, V72, P320, DOI 10.3109/00016487109122489; FISCHER TJ, 1978, PEDIATRICS, V62, P443; FRIEDMAN PA, 1983, J ALLERGY CLIN IMMUN, V71, P442; HONJO I, 1979, ACTA OTO-LARYNGOL, V87, P84, DOI 10.3109/00016487909126391; Ingelstedt S, 1967, ACTA OTO-LARYNGOL, V228, P1; INGELSTEDT S, 1967, ACTA OTO-LARYNGOL, V228, P31; JERGER J, 1970, ARCHIV OTOLARYNGOL, V92, P311; JOHSON B, 1969, ACTA OTOLARYNGOL, V68, P271; KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022; LAFAYE R, 1974, ANN OTOLARYNGOL CHIR, V91, P665; MCNICOLL WD, 1979, J LARYNGOL OTOL, V93, P357, DOI 10.1017/S0022215100087132; ODOI H, 1971, LARYNGOSCOPE, V81, P1242, DOI 10.1288/00005537-197108000-00007; PAPARELLA M M, 1970, Annals of Otology Rhinology and Laryngology, V79, P766; PARADISE JL, 1969, PEDIATRICS, V44, P35; PARADISE JL, 1974, PEDIATRICS, V53, P48; PERLMAN HB, 1951, AMA ARCH OTOLARYNGOL, V53, P370; Rich AR, 1920, B JOHNS HOPKINS HOSP, V31, P206; RIU R, 1966, PHYSL TROMPE EUSTACH; ROGERS R L, 1962, Laryngoscope, V72, P456; Stool S E, 1967, Cleft Palate J, V4, P99; Taylor G D, 1972, Laryngoscope, V82, P771, DOI 10.1288/00005537-197205000-00002; WITTENBORG MH, 1963, AMER J ROENTGENOL RA, V89, P1194	54	62	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	3					242	251		10.1016/0091-6749(83)90027-1	http://dx.doi.org/10.1016/0091-6749(83)90027-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RH938	6886258				2022-12-18	WOS:A1983RH93800003
J	PATTERSON, R; ZEISS, CR; PRUZANSKY, JJ				PATTERSON, R; ZEISS, CR; PRUZANSKY, JJ			IMMUNOLOGY AND IMMUNOPATHOLOGY OF TRIMELLITIC ANHYDRIDE PULMONARY REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University					NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COOMBS RRA, 1975, CLIN ASPECTS IMMUNOL, pCH25; PATTERSON R, 1981, INT ARCH ALLER A IMM, V66, P332, DOI 10.1159/000232838; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1259; PATTERSON R, 1978, J CLIN INVEST, V62, P971, DOI 10.1172/JCI109226; PATTERSON R, 1981, J CLIN IMMUNOL, V1, P181, DOI 10.1007/BF00922761; TURNER ES, 1980, CLIN EXP IMMUNOL, V39, P470; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; ZEISS CR, 1980, INT ARCH ALLER A IMM, V61, P380	8	62	62	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	1					19	23		10.1016/0091-6749(82)90196-8	http://dx.doi.org/10.1016/0091-6749(82)90196-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NY715	7086000				2022-12-18	WOS:A1982NY71500007
J	MURANAKA, M; NAKAJIMA, K; SUZUKI, S				MURANAKA, M; NAKAJIMA, K; SUZUKI, S			BRONCHIAL RESPONSIVENESS TO ACETYLCHOLINE IN PATIENTS WITH BRONCHIAL-ASTHMA AFTER LONG-TERM TREATMENT WITH GOLD SALT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MURANAKA, M (corresponding author), UNIV TOKYO,FAC MED,DEPT MED & PHYS THERAPY,BUNKYO KU,TOKYO 113,JAPAN.							American Rheumatism Association, 1973, ARTHRITIS RHEUM, V16, P353; [Anonymous], 1960, ANN RHEUM DIS, V19, P95; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; DUDAN A, 1932, SCHWEIZ MED WOCHENSC, V4, P96; HARTH M, 1977, CLIN EXP IMMUNOL, V27, P357; ISHIZAKI T, 1965, DIAGNOSIS TREATMENT, V53, P750; LIPSKY PE, 1977, J CLIN INVEST, V59, P455, DOI 10.1172/JCI108660; LORBER A, 1978, ARTHRITIS RHEUM, V21, P785, DOI 10.1002/art.1780210708; MAKINO S, 1964, JAP J ALLERGY, V13, P32; MATSUMURA T, 1969, J ASTHMA RES, V4, P205; MONTAGNA CP, 1936, DEUT MED WOCHENSCHR, V50, P2055; MURANAKA M, 1974, J ALLERGY CLIN IMMUN, V54, P32, DOI 10.1016/S0091-6749(74)80006-0; MURANAKA M, 1978, ANN ALLERGY, V40, P132; NORN S, 1971, Acta Pharmacologica et Toxicologica Supplementum, V30, P13; Okatani Y, 1970, JPN MED J, V2432, P17; PENNEYS NS, 1974, J INVEST DERMATOL, V63, P356, DOI 10.1111/1523-1747.ep12680840; PERSELLIN RH, 1966, ARTHRITIS RHEUM-US, V9, P57, DOI 10.1002/art.1780090107; REED CE, 1978, ALLERGY PRINCIPLES P, P659; SHIDA T, 1973, EXCERPTA MEDICA  300, P19; SUGIHARA H, 1959, JPN J CLIN MED, V17, P443; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; UGAI K, 1979, ARTHRITIS RHEUM, V22, P1352, DOI 10.1002/art.1780221206; VERNONROBERTS B, 1973, ANN RHEUM DIS, V32, P301, DOI 10.1136/ard.32.4.301; ZVAIFLER NJ, 1979, ARTHRITIS ALLIED CON, P335	25	62	62	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	5					350	356		10.1016/0091-6749(81)90079-8	http://dx.doi.org/10.1016/0091-6749(81)90079-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ563	6785336				2022-12-18	WOS:A1981LQ56300004
J	MCLEAN, JA; MATHEWS, KP; SOLOMON, WR; BRAYTON, PR; CIARKOWSKI, AA				MCLEAN, JA; MATHEWS, KP; SOLOMON, WR; BRAYTON, PR; CIARKOWSKI, AA			EFFECT OF HISTAMINE AND METHACHOLINE ON NASAL AIRWAY-RESISTANCE IN ATOPIC AND NONATOPIC SUBJECTS - COMPARISON WITH BRONCHIAL CHALLENGE AND SKIN-TEST RESPONSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN, MED CTR, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan								BOUHUYS A, 1967, AM REV RESPIR DIS, V95, P89; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CLAIRMONT AA, 1973, ANN OTO RHINOL LARYN, V82, P69, DOI 10.1177/000348947308200115; CURRY JJ, 1946, J CLIN INVEST, V25, P785, DOI 10.1172/JCI101764; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; DUBOIS AB, 1958, J CLIN INVEST, V37, P1746, DOI 10.1172/JCI103767; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FARMER L, 1945, J ALLERGY, V16, P44, DOI 10.1016/0021-8707(45)90038-4; FELARCA AB, 1966, J ALLERGY, V37, P223, DOI 10.1016/0021-8707(66)90117-1; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; GROBLER NJ, 1966, REACTIVITY NASAL RES; HALL LJ, 1968, ANN OTO RHINOL LARYN, V77, P1120, DOI 10.1177/000348946807700610; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P27, DOI 10.1159/000227898; JACKSON RT, 1973, CLIN PEDIATR, V12, P559, DOI 10.1177/000992287301200918; KALINER M, 1976, J ALLERGY CLIN IMMUN, V57, P213; KRAMAR J, 1975, INT ARCH ALLER A IMM, V49, P341, DOI 10.1159/000231415; LESKOWITZ S, 1961, J ALLERGY, V32, P152, DOI 10.1016/0021-8707(61)90068-5; LOWELL FC, 1948, J ALLERGY, V19, P172, DOI 10.1016/0021-8707(48)90050-1; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MALCOMSON K G, 1959, J Laryngol Otol, V73, P73, DOI 10.1017/S0022215100054980; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V58, P563, DOI 10.1016/0091-6749(76)90202-5; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V57, P153, DOI 10.1016/0091-6749(76)90034-8; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; RADERMECKER PM, 1955, INT ARCH ALLER A IMM, V27, P213; ROSENTHAL RR, 1975, J ALLERGY CLIN IMMUN, V56, P338, DOI 10.1016/0091-6749(75)90127-X; SALEM H, 1972, ARCHIV OTOLARYNGOL, V96, P524; SOLOMON WR, 1965, J ALLERGY, V36, P62, DOI 10.1016/0021-8707(65)90033-X; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; Tiffeneau R, 1958, Acta Allergol Suppl (Copenh), V5, P187; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P358, DOI 10.1016/0091-6749(76)90093-2; VARGAFTIG BB, 1974, EUR J PHARMACOL, V25, P216, DOI 10.1016/0014-2999(74)90053-3	33	62	62	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	2					165	170		10.1016/0091-6749(77)90220-2	http://dx.doi.org/10.1016/0091-6749(77)90220-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CV622	833381				2022-12-18	WOS:A1977CV62200012
J	TURKELTAUB, PC; NORMAN, PS; CREPEA, S				TURKELTAUB, PC; NORMAN, PS; CREPEA, S			TREATMENT OF RAGWEED HAY-FEVER WITH AN INTRANASAL SPRAY CONTAINING FLUNISOLIDE, A NEW SYNTHETIC CORTICOSTEROID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SYNTEX CORP,PALO ALTO,CA; JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,ONEILL RES LABS,BALTIMORE,MD 21239	Syntex Corporation; Johns Hopkins University			turkeltaub, paul/AAG-6160-2019; turkeltaub, paul/U-7729-2019	turkeltaub, paul/0000-0002-7350-1469				BROSTOFF J, 1969, J ALLERGY, V44, P77, DOI 10.1016/0021-8707(69)90003-3; HARRIS DM, 1975, POSTGRAD MED J, V51, P20; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; MARTIN LE, 1975, POSTGRAD MED J, V51, P11; MILLER FF, 1975, ANN ALLERGY, V34, P107; MYGIND N, 1973, BRIT MED J, V4, P464, DOI 10.1136/bmj.4.5890.464; NORMAN PS, 1967, J ALLERGY, V40, P57, DOI 10.1016/0021-8707(67)90060-3; NORMAN PS, 1969, J ALLERGY, V44, P129, DOI 10.1016/0021-8707(69)90137-3; NORMAN PS, 1965, J ALLERGY, V36, P284, DOI 10.1016/0021-8707(65)90087-0; NORMAN PS, 1966, J ALLERGY, V38, P93, DOI 10.1016/0021-8707(66)90048-7; NORMAN PS, 1966, INT ENCY PHARM THERA, P639; WILSON L, 1974, POSTGRAD MED J, V50, P7	12	62	62	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	5					597	606		10.1016/0091-6749(76)90206-2	http://dx.doi.org/10.1016/0091-6749(76)90206-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CL088	789436				2022-12-18	WOS:A1976CL08800008
J	HOEHNE, JH; REED, CE				HOEHNE, JH; REED, CE			WHERE IS ALLERGIC REACTION IN RAGWEED ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		Dixon WE, 1903, J PHYSIOL-LONDON, V29, P97; HATCH TF, 1964, PULMONARY DEPOSITION; ITKIN JH, 1970, J ALLERG, V45, P178; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KNOX RB, 1970, NATURE, V225, P1066, DOI 10.1038/2251066a0; MILLS JE, 1970, BRIT J PHARMACOL, V39, P724, DOI 10.1111/j.1476-5381.1970.tb09898.x; NADEL JA, 1962, J APPL PHYSIOL, V17, P861, DOI 10.1152/jappl.1962.17.6.861; RALL JE, 1945, J LAB CLIN MED, V30, P953; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; WIDDICOMBE JG, 1970, ARCH INTERN MED, V126, P311, DOI 10.1001/archinte.126.2.311	10	62	62	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	1					36	&		10.1016/0091-6749(71)90053-4	http://dx.doi.org/10.1016/0091-6749(71)90053-4			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J8503	5282887				2022-12-18	WOS:A1971J850300006
J	Dudeck, A; Koberle, M; Goldmann, O; Meyer, N; Dudeck, J; Lemmens, S; Rohde, M; Roldan, NG; Dietze-Schwonberg, K; Orinska, Z; Medina, E; Hendrix, S; Metz, M; Zenclussen, AC; von Stebut, E; Biedermann, T				Dudeck, Anne; Koeberle, Martin; Goldmann, Oliver; Meyer, Nicole; Dudeck, Jan; Lemmens, Stefanie; Rohde, Manfred; Roldan, Nestor Gonzalez; Dietze-Schwonberg, Kirsten; Orinska, Zane; Medina, Eva; Hendrix, Sven; Metz, Martin; Zenclussen, Ana Claudia; von Stebut, Esther; Biedermann, Tilo			Mast cells as protectors of health	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cell; innate immunity; infection; mast cell protease; tumor; pregnancy; venom; toxin; central nervous system trauma	DENGUE VIRUS-INFECTION; TUMOR-NECROSIS-FACTOR; NATURAL-KILLER-CELLS; INFLUENZA-A VIRUS; NEUTROPHIL RECRUITMENT; LEISHMANIA-MAJOR; HOST-DEFENSE; T-CELLS; CUTANEOUS LEISHMANIASIS; ANTIMICROBIAL ACTIVITY	Mast cells (MCs), which are well known for their effector functions in T(H)2-skewed allergic and also autoimmune inflammation, have become increasingly acknowledged for their role in protection of health. It is now clear that they are also key modulators of immune responses at interface organs, such as the skin or gut. MCs can prime tissues for adequate inflammatory responses and cooperate with dendritic cells in T-cell activation. They also regulate harmful immune responses in trauma and help to successfully orchestrate pregnancy. This review focuses on the beneficial effects of MCs on tissue homeostasis and elimination of toxins or venoms. MCs can enhance pathogen clearance in many bacterial, viral, and parasitic infections, such as through Toll-like receptor 2-triggered degranulation, secretion of antimicrobial cathelicidins, neutrophil recruitment, or provision of extracellular DNA traps. The role of MCs in tumors is more ambiguous; however, encouraging new findings show they can change the tumor microenvironment toward antitumor immunity when adequately triggered. Uterine tissue remodeling by alpha-chymase (mast cell protease [MCP] 5) is crucial for successful embryo implantation. MCP-4 and the tryptase MCP-6 emerge to be protective in central nervous system trauma by reducing inflammatory damage and excessive scar formation, thereby protecting axon growth. Last but not least, proteases, such as carboxypeptidase A, released by Fc epsilon RI-activated MCs detoxify an increasing number of venoms and endogenous toxins. A better understanding of the plasticity of MCs will help improve these advantageous effects and hint at ways to cut down detrimental MC actions.	[Dudeck, Anne; Dudeck, Jan] Otto von Guericke Univ, Med Fac, Inst Mol & Clin Immunol, Hlth Campus Immunol Infectiol & Inflammat, Magdeburg, Germany; [Koeberle, Martin; Biedermann, Tilo] Tech Univ Munich, Dept Dermatol & Allergol, Biedersteinerstr 29, D-80802 Munich, Germany; [Goldmann, Oliver; Medina, Eva] Helmholtz Ctr Infect Res, Infect Immunol Res Grp, Braunschweig, Germany; [Rohde, Manfred] Helmholtz Ctr Infect Res, Cent Facil Microscopy, Braunschweig, Germany; [Meyer, Nicole; Zenclussen, Ana Claudia] Otto von Guericke Univ, Med Fac, Expt Obstet & Gynecol, Magdeburg, Germany; [Lemmens, Stefanie; Hendrix, Sven] Hasselt Univ, Biomed Res Inst, Dept Morphol, Diepenbeek, Belgium; [Roldan, Nestor Gonzalez] German Ctr Lung Res DZL, Jr Grp Allergobiochem, Res Ctr Borstel, Leibniz Lung Ctr,ARCN, Munich, Germany; [Orinska, Zane] German Ctr Lung Res DZL, Div Expt Pneumol, Res Ctr Borstel, Leibniz Lung Ctr,ARCN, Munich, Germany; [Dietze-Schwonberg, Kirsten; von Stebut, Esther] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Dermatol, Mainz, Germany; [Metz, Martin] Charite, Klin Dermatol Venerol & Allergol, Berlin, Germany; [von Stebut, Esther] Univ Cologne, Dept Dermatol, Cologne, Germany; [Biedermann, Tilo] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, EKA, Neuherberg, Germany	Otto von Guericke University; Technical University of Munich; Helmholtz Association; Helmholtz-Center for Infection Research; Helmholtz Association; Helmholtz-Center for Infection Research; Otto von Guericke University; Hasselt University; Johannes Gutenberg University of Mainz; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Cologne; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Biedermann, T (corresponding author), Tech Univ Munich, Dept Dermatol & Allergol, Biedersteinerstr 29, D-80802 Munich, Germany.	Tilo.Biedermann@tum.de	Zenclussen, Ana/AAE-8760-2020; Köberle, Martin/HCI-8264-2022; Metz, Martin/B-8799-2009; Dudeck, Anne/ABB-3498-2020; Hendrix, Sven/F-4059-2010	Zenclussen, Ana/0000-0003-3544-4552; Köberle, Martin/0000-0001-6825-2667; Metz, Martin/0000-0002-4070-9976; Dudeck, Anne/0000-0002-1311-9620; Hendrix, Sven/0000-0003-2344-7369; Biedermann, Tilo/0000-0002-5352-5105; Meyer, Nicole/0000-0002-7990-2175	Priority Programme of the Deutsche Forschungsgemeinschaft (DFG) SPP 1394: Mast cells - promoters of health and modulators of disease	Priority Programme of the Deutsche Forschungsgemeinschaft (DFG) SPP 1394: Mast cells - promoters of health and modulators of disease(German Research Foundation (DFG))	This article was published as part of a supplement sponsored by the members of the Priority Programme of the Deutsche Forschungsgemeinschaft (DFG) SPP 1394: Mast cells - promoters of health and modulators of disease.	Abdul-Wahid A, 2016, INT J CANCER, V139, P841, DOI 10.1002/ijc.30121; Abel J, 2011, J INNATE IMMUN, V3, P495, DOI 10.1159/000327714; Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Agrawal SS, 2011, EUR J CONTRACEP REPR, V16, P142, DOI 10.3109/13625187.2010.548882; Agrawal SS, 2009, EUR J CONTRACEP REPR, V14, P444, DOI 10.3109/13625180903258695; Akahoshi M, 2011, J CLIN INVEST, V121, P4180, DOI 10.1172/JCI46139; Amaral MM, 2007, J IMMUNOL, V179, P3425, DOI 10.4049/jimmunol.179.6.3425; Anderson E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01532; Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; Ashina K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132367; Ball E, 2006, J PATHOL, V208, P535, DOI 10.1002/path.1927; Becker M, 2015, CELL MOL IMMUNOL, V12, P192, DOI 10.1038/cmi.2014.73; BENYON RC, 1991, J IMMUNOL, V147, P2253; Bidri M, 1997, PARASITE IMMUNOL, V19, P475, DOI 10.1046/j.1365-3024.1997.d01-153.x; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Bilo MB, 2011, ALLERGY, V66, P35, DOI 10.1111/j.1398-9995.2011.02630.x; Bot I, 2007, CIRCULATION, V115, P2516, DOI 10.1161/CIRCULATIONAHA.106.660472; Bradding P, 2018, IMMUNOL REV, V282, P198, DOI 10.1111/imr.12626; BRANDON JM, 1979, EUR J PHARMACOL, V57, P171, DOI 10.1016/0014-2999(79)90362-5; Bulfone-Paus S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00394; Burke SM, 2008, BLOOD, V111, P5467, DOI 10.1182/blood-2007-10-118547; Cangussu SD, 2009, MEM I OSWALDO CRUZ, V104, P918, DOI 10.1590/S0074-02762009000600017; Ch'ng S, 2006, MODERN PATHOL, V19, P149, DOI 10.1038/modpathol.3800474; Chacon-Salinas R, 2011, J IMMUNOL, V186, P25, DOI 10.4049/jimmunol.1001657; Chu YT, 2015, IMMUNOLOGY, V146, P163, DOI 10.1111/imm.12492; Conti P, 2016, MULT SCLER RELAT DIS, V5, P77, DOI 10.1016/j.msard.2015.11.005; Crawford G, 2018, NAT IMMUNOL, V19, P859, DOI 10.1038/s41590-018-0161-8; Croy BA, 2006, IMMUNOL REV, V214, P161; Dawicki W, 2010, J IMMUNOL, V184, P2116, DOI 10.4049/jimmunol.0803894; De Filippo K, 2013, BLOOD, V121, P4930, DOI 10.1182/blood-2013-02-486217; De Leo Bianca, 2017, F1000Res, V6, P667, DOI 10.12688/f1000research.11432.1; Descatoire M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01265; Di Nardo A, 2003, J IMMUNOL, V170, P2274, DOI 10.4049/jimmunol.170.5.2274; Di Nardo A, 2008, J IMMUNOL, V180, P7565, DOI 10.4049/jimmunol.180.11.7565; Dimitriadou V, 1997, ANTICANCER RES, V17, P1541; Doener F, 2013, INT IMMUNOL, V25, P553, DOI 10.1093/intimm/dxt019; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Dudeck A, 2011, EUR J IMMUNOL, V41, P1883, DOI 10.1002/eji.201040994; Dudeck J, 2017, J EXP MED, V214, P3791, DOI 10.1084/jem.20160783; Dudeck J, 2015, CELL REP, V13, P399, DOI 10.1016/j.celrep.2015.08.078; Duncan LM, 1998, J CUTAN PATHOL, V25, P11, DOI 10.1111/j.1600-0560.1998.tb01683.x; Ebert S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004100; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Ekoff M, 2007, BLOOD, V110, P3209, DOI 10.1182/blood-2007-02-073957; Esquivel A, 2017, AM J RESP CRIT CARE, V196, P985, DOI 10.1164/rccm.201701-0120OC; Feger F, 2002, TRENDS IMMUNOL, V23, P151, DOI 10.1016/S1471-4906(01)02156-1; Feyerabend TB, 2011, IMMUNITY, V35, P832, DOI 10.1016/j.immuni.2011.09.015; Furuta T, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001505; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Galli Stephen J, 2017, Trans Am Clin Climatol Assoc, V128, P193; Galli SJ, 2011, NAT IMMUNOL, V12, P1035, DOI 10.1038/ni.2109; Garcia-Rodriguez KM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01290; Gendrin C, 2018, J ALLERGY CLIN IMMUN, V142, P120, DOI 10.1016/j.jaci.2017.07.042; GIBBONS AFE, 1972, BIOL REPROD, V6, P193, DOI 10.1093/biolreprod/6.2.193; Goldmann O, 2016, CELL MICROBIOL, V18, P807, DOI 10.1111/cmi.12550; Graham AC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00238; Graham AC, 2013, J IMMUNOL, V190, P4676, DOI 10.4049/jimmunol.1202096; Gri G, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00120; Grujic M, 2017, ONCOTARGET, V8, P25066, DOI 10.18632/oncotarget.15339; Guzik TJ, 2005, CLIN EXP ALLERGY, V35, P448, DOI 10.1111/j.1365-2222.2005.02210.x; Harris NL, 2017, IMMUNITY, V47, P1024, DOI 10.1016/j.immuni.2017.11.015; Hendriksen E, 2017, NEUROSCI BIOBEHAV R, V79, P119, DOI 10.1016/j.neubiorev.2017.05.001; Hendrix S, 2013, FASEB J, V27, P920, DOI 10.1096/fj.12-204800; Hepworth MR, 2012, GUT MICROBES, V3, P476, DOI 10.4161/gmic.21507; Holzel M, 2016, CANCER RES, V76, P251, DOI 10.1158/0008-5472.CAN-15-1090; Hosoda M, 2002, J IMMUNOL, V169, P1482, DOI 10.4049/jimmunol.169.3.1482; Hu YX, 2012, J VIROL, V86, P3347, DOI 10.1128/JVI.06053-11; Huang B, 2008, BLOOD, V112, P1269, DOI 10.1182/blood-2008-03-147033; Huang CF, 1998, J IMMUNOL, V160, P1910; Huber M, 2019, J ALLERGY CLIN IMMUN, V144, pS31, DOI 10.1016/j.jaci.2019.02.004; Jensen F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014409; Jin YX, 2007, DEV NEUROSCI-BASEL, V29, P373, DOI 10.1159/000105478; Johnzon CF, 2016, AM J PATHOL, V186, P4, DOI 10.1016/j.ajpath.2015.06.024; Josset L, 2012, J VIROL, V86, P7192, DOI 10.1128/JVI.00563-12; Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204; Kaesler S, 2012, EUR J IMMUNOL, V42, P831, DOI 10.1002/eji.201141690; Kantor DB, 2016, J ALLERGY CLIN IMMUN, V138, P1467, DOI 10.1016/j.jaci.2016.04.044; Kempuraj D, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00703; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; King CA, 2002, J VIROL, V76, P8408, DOI 10.1128/JVI.76.16.8408-8419.2002; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; Kneilling M, 2009, BLOOD, V114, P1696, DOI 10.1182/blood-2008-11-187682; Koberle M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00106; Komi DEA, 2018, CLIN REV ALLERG IMMU, V54, P432, DOI 10.1007/s12016-017-8646-z; Kondeti V, 2016, J ALLERGY CLIN IMMUN, V137, P289, DOI 10.1016/j.jaci.2015.06.030; Koraka P, 2003, J MED VIROL, V70, P91, DOI 10.1002/jmv.10358; Kostka SL, 2009, J IMMUNOL, V182, P3039, DOI 10.4049/jimmunol.0713598; Kroner J, 2017, J BONE MINER RES, V32, P2431, DOI 10.1002/jbmr.3234; Landskron G, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/149185; Lemmermann NAW, 2017, CELL MOL IMMUNOL, V14, P479, DOI 10.1038/cmi.2017.23; Lilla JN, 2011, BLOOD, V118, P6930, DOI 10.1182/blood-2011-03-343962; Liu AY, 2013, J IMMUNOL, V190, P1758, DOI 10.4049/jimmunol.1202567; Liu FT, 2011, CLIN REV ALLERG IMMU, V41, P298, DOI 10.1007/s12016-011-8252-4; Lu FL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00363; Maciel Thiago T, 2015, F1000Prime Rep, V7, P09, DOI 10.12703/P7-09; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; da Silva EZM, 2014, J HISTOCHEM CYTOCHEM, V62, P698, DOI 10.1369/0022155414545334; Marichal T, 2013, CANCER IMMUNOL RES, V1, P269, DOI 10.1158/2326-6066.CIR-13-0119; Marichal T, 2013, IMMUNITY, V39, P963, DOI 10.1016/j.immuni.2013.10.005; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Maurer M, 2004, NATURE, V432, P512, DOI 10.1038/nature03085; Maurer M, 2006, FASEB J, V20, P2460, DOI 10.1096/fj.06-5860com; Mazzoni A, 2006, J IMMUNOL, V177, P3577, DOI 10.4049/jimmunol.177.6.3577; McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022; Mehdawi L, 2016, ACTA ONCOL, V55, P1434, DOI 10.1080/0284186X.2016.1198493; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Meyer N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00711; Meyer N, 2017, SCI REP-UK, V7, DOI 10.1038/srep45106; Michaloudi HC, 1999, J ANAT, V195, P577, DOI 10.1046/j.1469-7580.1999.19540577.x; Migalovich-Sheikhet H, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00238; Morrison J, 2017, J VIROL, V91, DOI 10.1128/JVI.00617-17; Morrison J, 2014, J VIROL, V88, P10556, DOI 10.1128/JVI.00570-14; Mukai K, 2018, IMMUNOL REV, V282, P121, DOI 10.1111/imr.12634; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Naqvi N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12753-1; Narla S, 2018, ANN ALLERG ASTHMA IM, V120, P66, DOI 10.1016/j.anai.2017.10.019; Nascimento NG, 2010, TOXICON, V55, P343, DOI 10.1016/j.toxicon.2009.08.009; Nelissen S, 2014, NEUROBIOL DIS, V62, P260, DOI 10.1016/j.nbd.2013.09.012; Nelissen S, 2013, ACTA NEUROPATHOL, V125, P637, DOI 10.1007/s00401-013-1092-y; Nigrovic PA, 2008, AM J PATHOL, V173, P1693, DOI 10.2353/ajpath.2008.080407; Oldford SA, 2015, MOL IMMUNOL, V63, P113, DOI 10.1016/j.molimm.2014.02.020; Orinska Z, 2005, BLOOD, V106, P978, DOI 10.1182/blood-2004-07-2656; Otsuka A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025538; Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x; Paul C, 2016, EUR J IMMUNOL, V46, P114, DOI 10.1002/eji.201545613; Pejler G, 2010, BLOOD, V115, P4981, DOI 10.1182/blood-2010-01-257287; Pennock JL, 2006, CHEM IMMUNOL ALLERGY, V90, P128, DOI 10.1159/000088885; Peschke K, 2014, CELL REP, V8, P1300, DOI 10.1016/j.celrep.2014.07.046; Pijnenborg R, 2006, PLACENTA, V27, P939, DOI 10.1016/j.placenta.2005.12.006; PIJNENBORG R, 1991, BRIT J OBSTET GYNAEC, V98, P648, DOI 10.1111/j.1471-0528.1991.tb13450.x; Piliponsky AM, 2008, NAT MED, V14, P392, DOI 10.1038/nm1738; Piliponsky AM, 2018, IMMUNOL REV, V282, P188, DOI 10.1111/imr.12623; Podlech J, 2015, MED MICROBIOL IMMUN, V204, P327, DOI 10.1007/s00430-015-0386-1; Portales-Cervantes L, 2017, J INNATE IMMUN, V9, P94, DOI 10.1159/000450576; PROFET M, 1991, Q REV BIOL, V66, P23, DOI 10.1086/417049; Purwar R, 2012, NAT MED, V18, P1248, DOI 10.1038/nm.2856; Rabenhorst A, 2012, BLOOD, V120, P2042, DOI 10.1182/blood-2012-03-415638; Reber LL, 2012, TRENDS IMMUNOL, V33, P613, DOI 10.1016/j.it.2012.09.008; Reitz M, 2017, MUCOSAL IMMUNOL, V10, P481, DOI 10.1038/mi.2016.56; REYNOLDS DS, 1988, J BIOL CHEM, V263, P12783; Rigoni A, 2015, CANCER MICROENVIRON, V8, P167, DOI 10.1007/s12307-014-0152-8; Roldan NG, 2016, EUR J IMMUNOL, V46, P432, DOI 10.1002/eji.201545879; Roy A, 2014, J BIOL CHEM, V289, P237, DOI 10.1074/jbc.M112.435156; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Salamonsen LA, 1999, REV REPROD, V4, P11; Sandeep M, 2014, INDIAN J EXP BIOL, V52, P1165; Sayed BA, 2008, ANNU REV IMMUNOL, V26, P705, DOI 10.1146/annurev.immunol.26.021607.090320; Sayed BA, 2010, J IMMUNOL, V184, P6891, DOI 10.4049/jimmunol.1000126; Scheb-Wetzel M, 2014, INFECT IMMUN, V82, P4496, DOI 10.1128/IAI.02114-14; Schmerse F, 2014, REPRODUCTION, V147, P781, DOI 10.1530/REP-13-0570; Schneider LA, 2007, J EXP MED, V204, P2629, DOI 10.1084/jem.20071262; Schubert N, 2015, ARTHRITIS RHEUMATOL, V67, P903, DOI 10.1002/art.38996; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Skokos D, 2003, J IMMUNOL, V170, P3037, DOI 10.4049/jimmunol.170.6.3037; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; SPICER SS, 1960, J HISTOCHEM CYTOCHEM, V8, P18, DOI 10.1177/8.1.18; St John AL, 2013, ELIFE, V2, DOI 10.7554/eLife.00481; St John AL, 2011, P NATL ACAD SCI USA, V108, P9190, DOI 10.1073/pnas.1105079108; STARKEY JR, 1988, INT J CANCER, V42, P48, DOI 10.1002/ijc.2910420110; Starkl P, 2016, J ALLERGY CLIN IMMUN, V137, P246, DOI 10.1016/j.jaci.2015.08.005; Stelekati E, 2009, IMMUNITY, V31, P665, DOI 10.1016/j.immuni.2009.08.022; Stone SF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002326; Sutherland RE, 2008, J IMMUNOL, V181, P5598, DOI 10.4049/jimmunol.181.8.5598; Trivedi NN, 2010, AM J RESP CELL MOL, V42, P257, DOI 10.1165/rcmb.2009-0324RT; Troupin A, 2016, J IMMUNOL, V197, P4382, DOI 10.4049/jimmunol.1600846; Vangansewinkel T, 2016, FASEB J, V30, P2040, DOI 10.1096/fj.201500114R; Visciano C, 2015, ONCOGENE, V34, P5175, DOI 10.1038/onc.2014.441; Voehringer D, 2008, J IMMUNOL, V180, P4742, DOI 10.4049/jimmunol.180.7.4742; von Kockritz-Blickwede M, 2008, BLOOD, V111, P3070, DOI 10.1182/blood-2007-07-104018; von Stebut E, 2003, BLOOD, V101, P210, DOI 10.1182/blood-2002-03-0921; Vukman KV, 2016, PARASITE IMMUNOL, V38, P45, DOI 10.1111/pim.12295; Wang ZP, 2012, J IMMUNOL, V188, P345, DOI 10.4049/jimmunol.1101703; Watanabe K, 2009, PARASITE, V16, P209, DOI 10.1051/parasite/2009163209; Weber FC, 2015, J EXP MED, V212, P15, DOI 10.1084/jem.20130062; Wezel A, 2015, ATHEROSCLEROSIS, V241, P289, DOI 10.1016/j.atherosclerosis.2015.05.028; Woidacki K, 2015, SCI REP-UK, V5, DOI 10.1038/srep13938; Woidacki K, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00029; Woldacki K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.214; WORDINGER RJ, 1985, J REPROD FERTIL, V73, P451, DOI 10.1530/jrf.0.0730451; Zarnegar B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00310; Ziemka-Nalecz M, 2017, J NEUROPATH EXP NEUR, V76, P644, DOI 10.1093/jnen/nlx046	183	61	63	4	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4		S	SI		S4	S18		10.1016/j.jaci.2018.10.054	http://dx.doi.org/10.1016/j.jaci.2018.10.054			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8GI	30468774	Green Submitted, Green Published, hybrid, Green Accepted			2022-12-18	WOS:000488805000002
J	Gernez, Y; de Jesus, AA; Alsaleem, H; Macaubas, C; Roy, A; Lovell, D; Jagadeesh, KA; Alehashemi, S; Erdman, L; Grimley, M; Talarico, S; Bacchetta, R; Lewis, DB; Canna, SW; Laxer, RM; Mellins, ED; Goldbach-Mansky, R; Weinacht, KG				Gernez, Yael; de Jesus, Adriana A.; Alsaleem, Hanouf; Macaubas, Claudia; Roy, Amitava; Lovell, Daniel; Jagadeesh, Karthik A.; Alehashemi, Sara; Erdman, Laura; Grimley, Michael; Talarico, Susanna; Bacchetta, Rosa; Lewis, David B.; Canna, Scott W.; Laxer, Ron M.; Mellins, Elizabeth D.; Goldbach-Mansky, Raphaela; Weinacht, Katja G.			Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1 beta inhibition	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INTERLEUKIN-18		[Gernez, Yael; Lewis, David B.] Stanford Sch Med, Div Allergy & Immunol, Dept Pediat, Stanford, CA 94305 USA; [Macaubas, Claudia; Mellins, Elizabeth D.] Stanford Sch Med, Div Human Gene Therapy, Dept Pediat, Stanford, CA 94305 USA; [Bacchetta, Rosa; Weinacht, Katja G.] Stanford Sch Med, Dept Pediat, Div Stem Cell Transplantat & Regenerat Med, Stanford, CA 94305 USA; [de Jesus, Adriana A.; Alehashemi, Sara; Goldbach-Mansky, Raphaela] NIAID, Translat Autoinflammatory Dis Sect, Lab Clin Immunol & Microbiol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Alsaleem, Hanouf; Erdman, Laura; Talarico, Susanna; Laxer, Ron M.] Univ Toronto, Dept Pediat Rheumatol, Toronto, ON, Canada; [Alsaleem, Hanouf; Erdman, Laura; Talarico, Susanna; Laxer, Ron M.] Hosp Sick Children, Toronto, ON, Canada; [Roy, Amitava] NIAID, BCBB, OCICB Rocky Mt Labs, NIH, Hamilton, MT USA; [Lovell, Daniel] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA; [Grimley, Michael] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH 45229 USA; [Jagadeesh, Karthik A.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Canna, Scott W.] UPMC, Childrens Hosp Pittsburgh, RK Mellon Inst, Dept Pediat,Div Rheumatol, Pittsburgh, PA USA	Stanford University; Stanford University; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gernez, Y (corresponding author), Stanford Sch Med, Div Allergy & Immunol, Dept Pediat, Stanford, CA 94305 USA.; Weinacht, KG (corresponding author), Stanford Sch Med, Dept Pediat, Div Stem Cell Transplantat & Regenerat Med, Stanford, CA 94305 USA.	yaelg@stanford.edu; kgw1@stanford.edu	Erdman, Laura/ABB-6936-2021	Erdman, Laura/0000-0001-8142-825X; Alehashemi, Sara/0000-0002-6531-6108; Mellins, Elizabeth/0000-0003-2577-139X	Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001220] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported in part by the Intramural Research Program of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.	Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Carrega P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9280; Chen F, 2000, CURR BIOL, V10, P758, DOI 10.1016/S0960-9822(00)00571-6; de Jesus AA, 2015, ANNU REV IMMUNOL, V33, P823, DOI 10.1146/annurev-immunol-032414-112227; Di Meo S, 2014, CLIN CANCER RES, V20, P585, DOI 10.1158/1078-0432.CCR-13-2240; Glatzer T, 2013, IMMUNITY, V38, P1223, DOI 10.1016/j.immuni.2013.05.013; Johnson JL, 2012, J BIOL CHEM, V287, P5764, DOI 10.1074/jbc.M111.336487; Kuhns DB, 2016, BLOOD, V128, P2135, DOI 10.1182/blood-2016-03-706028; Martinelli S, 2018, AM J HUM GENET, V102, P309, DOI 10.1016/j.ajhg.2017.12.015; Qadir MI, 2015, CHEM BIOL DRUG DES, V86, P432, DOI 10.1111/cbdd.12556; Standing ASI, 2017, J EXP MED, V214, P59, DOI 10.1084/jem.20161228; Wada T, 2014, CYTOKINE, V65, P74, DOI 10.1016/j.cyto.2013.09.007; Weiss ES, 2018, BLOOD, V131, P1442, DOI 10.1182/blood-2017-12-820852	13	61	63	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2019	144	4					1122	+		10.1016/j.jaci.2019.06.017	http://dx.doi.org/10.1016/j.jaci.2019.06.017			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JB8FZ	31271789	Green Accepted			2022-12-18	WOS:000488803900028
J	Jahreis, S; Trump, S; Bauer, M; Bauer, T; Thurmann, L; Feltens, R; Wang, Q; Gu, L; Grutzmann, K; Roder, S; Averbeck, M; Weichenhan, D; Plass, C; Sack, U; Borte, M; Dubourg, V; Schuurmann, G; Simon, JC; von Bergen, M; Hackermuller, J; Eils, R; Lehmann, I; Polte, T				Jahreis, Susanne; Trump, Saskia; Bauer, Mario; Bauer, Tobias; Thuermann, Loreen; Feltens, Ralph; Wang, Qi; Gu, Lei; Gruetzmann, Konrad; Roeder, Stefan; Averbeck, Marco; Weichenhan, Dieter; Plass, Christoph; Sack, Ulrich; Borte, Michael; Dubourg, Virginie; Schueuermann, Gerrit; Simon, Jan C.; von Bergen, Martin; Hackermueller, Joerg; Eils, Roland; Lehmann, Irina; Polte, Tobias			Maternal phthalate exposure promotes allergic airway inflammation over 2 generations through epigenetic modifications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Airway inflammation; asthma; phthalates; epigenetics; T cells	T-CELL NUMBERS; PRENATAL EXPOSURE; DNA METHYLATION; CORD BLOOD; ASTHMA; CHILDREN; METABOLISM; DNAZYME; HEALTH; FRIEND	Background: Prenatal and early postnatal exposures to environmental factors are considered responsible for the increasing prevalence of allergic diseases. Although there is some evidence for allergy-promoting effects in children because of exposure to plasticizers, such as phthalates, findings of previous studies are inconsistent and lack mechanistic information. Objective: We investigated the effect of maternal phthalate exposure on asthma development in subsequent generations and their underlying mechanisms, including epigenetic alterations. Methods: Phthalate metabolites were measured within the prospective mother-child cohort Lifestyle and Environmental Factors and Their Influence on Newborns Allergy Risk (LINA) and correlated with asthma development in the children. A murine transgenerational asthma model was used to identify involved pathways. Results: In LINA maternal urinary concentrations of mono-nbutyl phthalate, a metabolite of butyl benzyl phthalate (BBP), were associated with an increased asthma risk in the children. Using a murine transgenerational asthma model, we demonstrate a direct effect of BBP on asthma severity in the offspring with a persistently increased airway inflammation up to the F2 generation. This disease-promoting effect was mediated by BBP-induced global DNA hypermethylation in CD4(+) T cells of the offspring because treatment with a DNA-demethylating agent alleviated exacerbation of allergic airway inflammation. Thirteen transcriptionally downregulated genes linked to promoter or enhancer hypermethylation were identified. Among these, the GATA-3 repressor zinc finger protein 1 (Zfpm1) emerged as a potential mediator of the enhanced susceptibility for T(H)2-driven allergic asthma. Conclusion: These data provide strong evidence that maternal BBP exposure increases the risk for allergic airway inflammation in the offspring by modulating the expression of genes involved in T(H)2 differentiation through epigenetic alterations.	[Jahreis, Susanne; Trump, Saskia; Bauer, Mario; Thuermann, Loreen; Gruetzmann, Konrad; Roeder, Stefan; Lehmann, Irina; Polte, Tobias] UFZ Helmholtz Ctr Environm Res Leipzig Halle, Dept Environm Immunol, Leipzig, Germany; [Feltens, Ralph; von Bergen, Martin] UFZ Helmholtz Ctr Environm Res Leipzig Halle, Dept Mol Syst Biol, Leipzig, Germany; [Dubourg, Virginie; Hackermueller, Joerg] UFZ Helmholtz Ctr Environm Res Leipzig Halle, Young Investigators Grp Bioinformat & Transcript, Dept Mol Syst Biol, Leipzig, Germany; [Schueuermann, Gerrit] UFZ Helmholtz Ctr Environm Res Leipzig Halle, Dept Ecol Chem, Leipzig, Germany; [Jahreis, Susanne; Averbeck, Marco; Simon, Jan C.; Polte, Tobias] Univ Leipzig, Med Ctr, Dept Dermatol Venerol & Allergol, Leipzig, Germany; [Bauer, Tobias; Wang, Qi; Gu, Lei; Eils, Roland] German Canc Res Ctr, Div Theoret Bioinformat, Heidelberg, Germany; [Weichenhan, Dieter; Plass, Christoph] German Canc Res Ctr, Div Epigen & Canc Risk Factors, Heidelberg, Germany; [Sack, Ulrich] Univ Leipzig, Med Fac, Inst Clin Immunol, Leipzig, Germany; [von Bergen, Martin] Univ Leipzig, Fac Biosci Pharm & Psychol, Inst Biochem, Leipzig, Germany; [Borte, Michael] St Georg Childrens Hosp, Municipal Hosp, Leipzig, Germany; [Schueuermann, Gerrit] Tech Univ Bergakad Freiberg, Inst Organ Chem, Freiberg, Germany; [von Bergen, Martin] Aalborg Univ, Dept Chem & Biosci, Aalborg, Denmark; [Trump, Saskia; Eils, Roland] Heidelberg Univ, Inst Pharm & Mol Biotechnol, Heidelberg, Germany; [Trump, Saskia; Eils, Roland] Heidelberg Univ, Bioquant Ctr, Heidelberg, Germany; [Eils, Roland] Heidelberg Univ, German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC, Heidelberg, Germany; [Jahreis, Susanne] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Infect Hematol Oncol, Jena, Germany; [Gu, Lei] Harvard Med Sch, Dept Cell Biol, Boston, MA USA	Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Leipzig University; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Leipzig University; Leipzig University; Leipzig University; Technical University Freiberg; Aalborg University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Hans Knoll Institute (HKI); Harvard University; Harvard Medical School	Polte, T (corresponding author), Helmholtz Univ, UFZ Helmholtz Ctr Environm Res Leipzig Halle, Res Grp Expt Allergy & Immunol, Permoserstr 15, Leipzig, Germany.	tobias.polte@ufz.de	von Bergen, Martin/D-7960-2011; Jahreis, Susanne/AAA-9826-2020; Thürmann, Loreen/AAD-4716-2022; Sack, Ulrich/J-6301-2015; Gu, Lei/GWQ-6785-2022; Eils, Roland/B-6121-2009; Schüürmann, Gerrit/E-7962-2017; Hackermüller, Jörg/F-2494-2016; Bauer, Mario/AAZ-7540-2021; Trump, Saskia/ABG-5182-2021	von Bergen, Martin/0000-0003-2732-2977; Thürmann, Loreen/0000-0003-1109-1924; Sack, Ulrich/0000-0002-7813-0492; Eils, Roland/0000-0002-0034-4036; Schüürmann, Gerrit/0000-0002-3789-1703; Hackermüller, Jörg/0000-0003-4920-7072; Bauer, Tobias/0000-0002-4961-3639; Lehmann, Irina/0000-0001-8875-5587; Trump, Saskia/0000-0002-9894-1807; Wang, Qi/0000-0002-6420-1720	Helmholtz Association grant [VG-NG-337]; LIFE-Leipzig Research Center for Civilization Diseases [LIFE-007-D7]; Helmholtz Initiative for Personalized Medicine (iMed); DFG [SFB 1052]	Helmholtz Association grant(Helmholtz Association); LIFE-Leipzig Research Center for Civilization Diseases; Helmholtz Initiative for Personalized Medicine (iMed); DFG(German Research Foundation (DFG))	Supported by the Helmholtz Association grant VG-NG-337, the LIFE-Leipzig Research Center for Civilization Diseases (LIFE-007-D7), and the Helmholtz Initiative for Personalized Medicine (iMed). M.v.B. was funded by the DFG SFB 1052.	Adibi JJ, 2008, ENVIRON HEALTH PERSP, V116, P467, DOI 10.1289/ehp.10749; Alessandrini F, 2006, J ALLERGY CLIN IMMUN, V117, P824, DOI 10.1016/j.jaci.2005.11.046; Bauer T, 2016, MOL SYST BIOL, V12, DOI 10.15252/msb.20156520; Bertelsen RJ, 2013, ENVIRON HEALTH PERSP, V121, P251, DOI 10.1289/ehp.1205256; Bonisch U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039817; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Braun JM, 2013, CURR OPIN PEDIATR, V25, P247, DOI 10.1097/MOP.0b013e32835e1eb6; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Dick S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006554; Dodson RE, 2012, ENVIRON HEALTH PERSP, V120, P935, DOI 10.1289/ehp.1104052; Du W, 2014, BLOOD, V123, P1938, DOI 10.1182/blood-2013-09-528018; EIGENBERG DA, 1986, J TOXICOL ENV HEALTH, V17, P445, DOI 10.1080/15287398609530839; European Food Safety Initiative, 2005, OP SCI PAN FOOD ADD; Feltens R, 2015, J CHROMATOGR SEP TEC, V6, P290, DOI DOI 10.4172/2157-7064.1000290; Franck U, 2014, ENVIRON INT, V73, P393, DOI 10.1016/j.envint.2014.08.013; Gascon M, 2015, J ALLERGY CLIN IMMUN, V135, P370, DOI 10.1016/j.jaci.2014.09.030; Hackermuller J, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r48; Herberth G, 2014, J ALLERGY CLIN IMMUN, V133, P543, DOI 10.1016/j.jaci.2013.06.036; Hinz D, 2010, CLIN EXP ALLERGY, V40, P419, DOI 10.1111/j.1365-2222.2009.03434.x; Hoffmann S, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r34; Homburg U, 2015, J ALLERGY CLIN IMMUN, V136, P797, DOI 10.1016/j.jaci.2015.02.018; Kabesch M, 2014, CURR OPIN ALLERGY CL, V14, P62, DOI 10.1097/ACI.0000000000000025; Kitamura N, 2011, INT ARCH ALLERGY IMM, V155, P53, DOI 10.1159/000327292; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Kurata H, 2002, J IMMUNOL, V168, P4538, DOI 10.4049/jimmunol.168.9.4538; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Chisaguano AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078245; Martin M., 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Martino D, 2011, CHEST, V139, P640, DOI 10.1378/chest.10-1800; Nativelle C, 1999, FOOD CHEM TOXICOL, V37, P905, DOI 10.1016/S0278-6915(99)00071-X; Pearce N, 2006, INT J TUBERC LUNG D, V10, P125; Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055; Petzold S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100468; Polte T, 2006, J CLIN INVEST, V116, P1025, DOI 10.1172/JCI23792; Polte T, 2008, J ALLERGY CLIN IMMUN, V122, P1022, DOI 10.1016/j.jaci.2008.09.014; Polte T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8554; Rajesh P, 2014, J ENDOCRINOL, V223, P47, DOI 10.1530/JOE-14-0111; Reiprich M, 2013, ALLERGY, V68, P481, DOI 10.1111/all.12121; Rissman EF, 2014, ENDOCRINOLOGY, V155, P2770, DOI 10.1210/en.2014-1123; Robinson Lacey, 2015, Curr Environ Health Rep, V2, P379, DOI 10.1007/s40572-015-0066-8; Schutze N, 2010, AM J RESP CRIT CARE, V181, P1188, DOI 10.1164/rccm.200909-1350OC; Sekaran S, 2015, J CELL BIOCHEM, V116, P1466, DOI 10.1002/jcb.25108; Tachdjian R, 2009, J EXP MED, V206, P2191, DOI 10.1084/jem.20091480; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Vinson C, 2012, EPIGENOMICS-UK, V4, P655, DOI [10.2217/EPI.12.55, 10.2217/epi.12.55]; Wagner JR, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r37; Wang IJ, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0060-x; Wang Q, 2013, NAT PROTOC, V8, P2022, DOI 10.1038/nprot.2013.118; Weisse K, 2013, ALLERGY, V68, P220, DOI 10.1111/all.12081; Whyatt RM, 2014, ENVIRON HEALTH PERSP, V122, P1141, DOI 10.1289/ehp.1307670; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Zhou MX, 2001, J EXP MED, V194, P1461, DOI 10.1084/jem.194.10.1461	53	61	63	3	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					741	753		10.1016/j.jaci.2017.03.017	http://dx.doi.org/10.1016/j.jaci.2017.03.017			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	28392331	hybrid, Green Published			2022-12-18	WOS:000424410800030
J	Sasaki, M; Koplin, JJ; Dharmage, SC; Field, MJ; Sawyer, SM; McWilliam, V; Peters, RL; Gurrin, LC; Vuillermin, PJ; Douglass, J; Pezic, A; Brewerton, M; Tang, MLK; Patton, GC; Allen, KJ				Sasaki, Mari; Koplin, Jennifer J.; Dharmage, Shyamali C.; Field, Michael J.; Sawyer, Susan M.; McWilliam, Vicki; Peters, Rachel L.; Gurrin, Lyle C.; Vuillermin, Peter J.; Douglass, Jo; Pezic, Angela; Brewerton, Maia; Tang, Mimi L. K.; Patton, George C.; Allen, Katrina J.			Prevalence of clinic-defined food allergy in early adolescence: The SchoolNuts study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; adolescence; anaphylaxis; peanut allergy; tree nut allergy; prevalence; population	NATURAL-HISTORY; HYPERSENSITIVITY; PREDICTORS; CHALLENGES; AVOIDANCE; TEENAGERS; CRITERIA; INFANTS; ASTHMA; LIFE	Background: Rising rates of food-induced anaphylaxis have recently been shown in the adolescent age group, following earlier descriptions of a rise in children younger than 5 years. However, few population-based studies have examined the prevalence of food allergy in adolescence using objective measures such as oral food challenge (OFC). Objective: We sought to determine the prevalence of food allergy among a population-based sample of 10- to 14-year-old adolescents using clinical evaluation including OFC to confirm the diagnosis. Methods: Schools were randomly selected from greater metropolitan Melbourne, Australia. Students aged 10 to 14 years, and their parents, were asked to complete a questionnaire regarding the adolescent's food allergy or food-related reactions. Clinic evaluation, which consisted of skin prick tests and OFC where eligible, was undertaken if students were suspected to have current food allergy from parent response. Among 9816 students assessed, 5016 had complete parent response and clinic evaluation when eligible. An additional 4800 students had student questionnaires only. Results: The prevalence of clinic-defined current food allergy based on history, sensitization data, and OFC results was 4.5% (95% CI, 3.9-5.1), with the most common food triggers being peanut, 2.7% (95% CI, 2.3-3.2), and tree nut, 2.3% (95% CI, 1.9-2.8). Among the additional group of 4800 adolescents who had only self-reported food allergy status available, the prevalence of self-reported current food allergy was 5.5% (95% CI, 4.9-6.2), with peanut, 2.8% (95% CI, 2.3-3.3), and tree nut, 2.3% (95% CI, 1.9-2.8), the most common. Conclusions: Approximately 1 in 20 10- to 14-year-old school students in Melbourne has current food allergy. This high prevalence suggests that the previously reported rise in food-induced anaphylaxis in this age group may reflect an increasing prevalence of food allergy rather than simply increased reporting of anaphylaxis.	[Sasaki, Mari; Koplin, Jennifer J.; Dharmage, Shyamali C.; Field, Michael J.; Sawyer, Susan M.; McWilliam, Vicki; Peters, Rachel L.; Gurrin, Lyle C.; Vuillermin, Peter J.; Pezic, Angela; Brewerton, Maia; Tang, Mimi L. K.; Patton, George C.; Allen, Katrina J.] Univ Melbourne, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Dharmage, Shyamali C.; Gurrin, Lyle C.] Univ Melbourne, Sch Populat & Global Hlth, Parkville, Vic, Australia; [Sawyer, Susan M.; McWilliam, Vicki; Tang, Mimi L. K.; Patton, George C.; Allen, Katrina J.] Royal Childrens Hosp, Parkville, Vic, Australia; [Vuillermin, Peter J.] Deakin Univ, Barwon Hlth, Child Hlth Res Unit, Geelong, Vic, Australia; [Vuillermin, Peter J.] Deakin Univ, Sch Med, Geelong, Vic, Australia; [Douglass, Jo] Royal Melbourne Hosp, Dept Clin Immunol & Allergy, Parkville, Vic, Australia; [Douglass, Jo] Univ Melbourne, Parkville, Vic, Australia; [Tang, Mimi L. K.; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia; [Allen, Katrina J.] Univ Manchester, Manchester, Lancs, England	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; Deakin University; Deakin University; Royal Melbourne Hospital; University of Melbourne; University of Melbourne; University of Manchester	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Ribeiro, Ana Cristina/HHN-7466-2022; Tang, Mimi/ABD-8350-2020; McWilliam, Vicki/S-9462-2019; Allen, Katrina/I-4361-2018; Patton, George C/B-5246-2013	Ribeiro, Ana Cristina/0000-0002-0493-8376; Tang, Mimi/0000-0002-3839-5293; Allen, Katrina/0000-0002-1921-4493; Patton, George C/0000-0001-5039-8326; McWilliam, Vicki/0000-0002-5000-2181; Peters, Rachel/0000-0002-2411-6628; Koplin, Jennifer/0000-0002-7576-5142; Gurrin, Lyle/0000-0001-7052-1969; Sasaki, Mari/0000-0003-1590-3838; Douglass, Jo/0000-0002-1200-8048	National Health and Medical Research Council of Australia [APP1047396]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by the National Health and Medical Research Council of Australia (grant no. APP1047396).	Australian Curriculum AaRA, 2016, IND COMM SOC ADV; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1, DOI 10.1016/S1081-1206(10)60305-5; Kaya A, 2013, PEDIAT ALLERG IMM-UK, V24, P456, DOI 10.1111/pai.12097; Koplin JJ, 2012, J ALLERGY CLIN IMMUN, V129, P1145, DOI 10.1016/j.jaci.2011.09.044; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Little D., 2002, STAT ANAL MISSING DA; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; McWilliam V, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0555-8; Monks H, 2010, CLIN EXP ALLERGY, V40, P1533, DOI 10.1111/j.1365-2222.2010.03586.x; Mullins RJ, 2015, J ALLERGY CLIN IMMUN, V136, P367, DOI 10.1016/j.jaci.2015.05.009; Nwaru BI, 2014, ALLERGY, V69, P992, DOI 10.1111/all.12423; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Panjari M, 2016, CLIN EXP ALLERGY, V46, P602, DOI 10.1111/cea.12699; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Peters RL, 2017, J ALLERGY CLIN IMMUN, V140, P145, DOI 10.1016/j.jaci.2017.02.019; Peters RL, 2015, J ALLERGY CLIN IMMUN, V135, P1257, DOI 10.1016/j.jaci.2015.01.002; Peters RL, 2014, J ALLERGY CLIN IMMUN, V133, P485, DOI 10.1016/j.jaci.2013.11.032; Peters RL, 2012, PEDIAT ALLERG IMM-UK, V23, P347, DOI 10.1111/j.1399-3038.2011.01237.x; Peters RL, 2015, J ALLERGY CLIN IMMUN, V135, pe1; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, P956, DOI 10.1016/j.jaci.2014.10.021; Winberg A, 2016, ACTA PAEDIATR, V105, P206, DOI 10.1111/apa.13253; Winberg A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131804	25	61	61	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2018	141	1					391	+		10.1016/j.jaci.2017.05.041	http://dx.doi.org/10.1016/j.jaci.2017.05.041			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR8GH	28755784				2022-12-18	WOS:000419312200044
J	Gurrola, J; Borish, L				Gurrola, Jose, II; Borish, Larry			Chronic rhinosinusitis: Endotypes, biomarkers, and treatment response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; endotypes; biomarkers	PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; SALINE NASAL IRRIGATION; TASTE RECEPTOR T2R38; DOUBLE-BLIND; STAPHYLOCOCCUS-AUREUS; MUCOCILIARY CLEARANCE; EOSINOPHILIC ASTHMA; SINUS MICROBIOTA; ORAL STEROIDS	It is increasingly recognized that chronic rhinosinusitis (CRS) comprises a spectrum of different diseases with distinct clinical presentations and pathogenic mechanisms. Defining the distinct phenotypes and endotypes of CRS affects prognosis and, most importantly, is necessary as the basis for making therapeutic decisions. The need for individualized definitions of pathogenic mechanisms before initiating therapy extends to virtually all therapeutic considerations. This is clearly crucial with antibiotics, where, barring an influence from their off-target anti-inflammatory pharmacologic effects, an understanding of the role of the individual biome predicts likelihood of therapeutic benefit. However, this need for identifying individual phenotypes and endotypes also extends to the agent that is currently considered the mainstay of treatment of CRS, specifically glucocorticoids. As with asthma, it is recognized that a large minority of patients with CRS have a steroid-resistant phenotype, identification of which will preclude use of these agents with their potential side effects. Identification of endotypes is also becoming increasingly imperative because targeted biotherapeutic agents, such as anti-IgE and anti-cytokine antibodies, are becoming available. These agents are likely to benefit patients in whom the targeted mediator is not only expressed but demonstrably driving a central mechanism in that patient. In summary, the treatment of CRS is at an exciting crossroad. On the positive side, numerous therapeutics are in development that seem likely to have a positive effect in our patients with this condition. The challenge is that these therapies will require targeted individualized treatments based on identifying subjects with the relevant endotype.	[Gurrola, Jose, II] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA USA; [Borish, Larry] Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA USA; [Borish, Larry] Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA USA	University of California System; University of California San Francisco; University of Virginia; University of Virginia	Gurrola, J (corresponding author), 2233 Post St,3rd Floor,Box 1225, San Francisco, CA 94115 USA.	jose.gurrola@ucsf.edu		Gurrola II, Jose/0000-0001-6801-5768	National Institutes of Health [UO1AI123337, UO1AI100799]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	L.B. was supported by National Institutes of Health grants UO1AI123337 and UO1AI100799.	Adappa ND, 2014, INT FORUM ALLERGY RH, V4, P3, DOI 10.1002/alr.21253; Adappa ND, 2013, INT FORUM ALLERGY RH, V3, P184, DOI 10.1002/alr.21140; Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Alandejani T, 2009, OTOLARYNG HEAD NECK, V141, P114, DOI 10.1016/j.otohns.2009.01.005; Andersson DI, 2014, NAT REV MICROBIOL, V12, P465, DOI 10.1038/nrmicro3270; Andersson DI, 2010, NAT REV MICROBIOL, V8, P260, DOI 10.1038/nrmicro2319; [Anonymous], 2016, TACKLING DRUG RESIST; Bachert C, 2016, JAMA-J AM MED ASSOC, V315, P469, DOI 10.1001/jama.2015.19330; Bachert C, 2017, J ALLERGY CLIN IMMUN, V140, P1024, DOI 10.1016/j.jaci.2017.05.044; Bachert C, 2016, J ALLER CL IMM-PRACT, V4, P621, DOI 10.1016/j.jaip.2016.05.004; Bachert Claus, 2015, GMS Curr Top Otorhinolaryngol Head Neck Surg, V14, pDoc09, DOI 10.3205/cto000124; Bachmann G, 2000, EUR ARCH OTO-RHINO-L, V257, P537, DOI 10.1007/s004050000271; Boase S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-210; BROWN HM, 1958, LANCET, V2, P1245; Carey RM, 2015, INT FORUM ALLERGY RH, V5, P808, DOI 10.1002/alr.21568; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Chiu AG, 2008, AM J RHINOL, V22, P34, DOI 10.2500/ajr.2008.22.3122; Cope EK, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0266-6; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Cowan DC, 2010, THORAX, V65, P384, DOI 10.1136/thx.2009.126722; De Greve G, 2017, CLIN TRANSL ALLERGY, V7, DOI 10.1186/s13601-017-0157-8; Desrosiers M, 2007, AM J RHINOL, V21, P149, DOI 10.2500/ajr.2007.21.3007; Desrosiers M, 2007, AM J RHINOL, V21, P527, DOI 10.2500/ajr.2007.21.3069; Dunford C, 2000, Nurs Stand, V15, P63; Farag AA, 2013, INT FORUM ALLERGY RH, V3, P276, DOI 10.1002/alr.21116; FitzGerald JM, 2016, LANCET, V388, P2128, DOI [10.1016/s0140-6736(16)31322-8, 10.1016/S0140-6736(16)31322-8]; Fokkens WJ, 2012, RHINOLOGY, V50, P1, DOI 10.4193/Rhin20.600; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1067/MAI.2002.130051; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Gevaert P, 2013, J ALLERGY CLIN IMMUN, V131, P110, DOI 10.1016/j.jaci.2012.07.047; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; Gunel C, 2017, LARYNGOSCOPE, V127, P794, DOI 10.1002/lary.26415; Hanania NA, 2015, THORAX, V70, P748, DOI 10.1136/thoraxjnl-2014-206719; HARTWIG S, 1988, J LARYNGOL OTOL, V102, P148, DOI 10.1017/S0022215100104372; Hauptman G, 2007, OTOLARYNG HEAD NECK, V137, P815, DOI 10.1016/j.otohns.2007.07.034; Hauser LJ, 2015, INT FORUM ALLERGY RH, V5, P3, DOI 10.1002/alr.21428; Head K, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011994.pub2; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; Hoggard M, 2017, INT FORUM ALLERGY RH, V7, P230, DOI 10.1002/alr.21871; Huang A, 2013, CURR OPIN OTOLARYNGO, V21, P31, DOI 10.1097/MOO.0b013e32835bc4ab; Huck W, 1993, Arch Fam Med, V2, P497, DOI 10.1001/archfami.2.5.497; Jervis-Bardy J, 2012, INT FORUM ALLERGY RH, V2, P111, DOI 10.1002/alr.20106; Kim JS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167369; Kwakman PHS, 2010, FASEB J, V24, P2576, DOI 10.1096/fj.09-150789; Lee JT, 2014, AM J RHINOL ALLERGY, V28, P29, DOI 10.2500/ajra.2014.28.3988; Lee RJ, 2014, J CLIN INVEST, V124, P1393, DOI 10.1172/JCI72094; Lee RJ, 2012, J CLIN INVEST, V122, P4145, DOI 10.1172/JCI64240; Lee VS, 2017, INT FORUM ALLERGY RH, V7, P365, DOI 10.1002/alr.21898; LEGENT F, 1994, CHEMOTHERAPY, V40, P8, DOI 10.1159/000239310; Lim M, 2008, AM J RHINOL, V22, P381, DOI 10.2500/ajr.2008.22.3189; Liu CM, 2013, INT FORUM ALLERGY RH, V3, DOI 10.1002/alr.21195; Low TH, 2014, AM J RHINOL ALLERGY, V28, P225, DOI 10.2500/ajra.2014.28.4031; Lusby P E, 2002, J Wound Ostomy Continence Nurs, V29, P295, DOI 10.1067/mjw.2002.129073; Lusby PE, 2005, ARCH MED RES, V36, P464, DOI 10.1016/j.arcmed.2005.03.038; Mavric E, 2008, MOL NUTR FOOD RES, V52, P483, DOI 10.1002/mnfr.200700282; Milara J, 2015, J ALLERGY CLIN IMMUN, V135, P470, DOI 10.1016/j.jaci.2014.07.011; Moore O A, 2001, BMC Complement Altern Med, V1, P2, DOI 10.1186/1472-6882-1-2; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Soter ACPB, 2017, RHINOLOGY, V55, P175, DOI 10.4193/Rhino15.291; Pinto JM, 2010, RHINOLOGY, V48, P318, DOI [10.4193/Rhin09.144, 10.4193/Rhino09.144]; Pothoven KL, 2017, TISSUE BARRIERS, V5, DOI 10.1080/21688370.2017.1341367; Pynnonen MA, 2007, ARCH OTOLARYNGOL, V133, P1115, DOI 10.1001/archotol.133.11.1115; Rabago D, 2002, J FAM PRACTICE, V51, P1049; Ramakrishnan VR, 2015, J ALLERGY CLIN IMMUN, V136, P334, DOI 10.1016/j.jaci.2015.02.008; Rom DI, 2017, RHINOLOGY, V55, P90, DOI [10.4193/Rhino16.181, 10.4193/Rhin16.181]; Rudmik L, 2013, INT FORUM ALLERGY RH, V3, P281, DOI 10.1002/alr.21096; Shah AS, 2009, SCIENCE, V325, P1131, DOI 10.1126/science.1173869; Slavin Raymond G, 2005, J Allergy Clin Immunol, V116, pS13, DOI 10.1016/j.jaci.2005.09.048; Solares CA, 2006, AM J OTOLARYNG, V27, P161, DOI 10.1016/j.amjoto.2005.09.006; Soler ZM, 2013, INT FORUM ALLERGY RH, V3, P31, DOI 10.1002/alr.21064; Soyka MB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123163; Steinke JW, 2017, J ALLER CL IMM-PRACT, V5, P1582, DOI 10.1016/j.jaip.2017.04.009; Steinke JW, 2016, ANN ALLERG ASTHMA IM, V117, P234, DOI 10.1016/j.anai.2016.06.006; Steinke JW, 2012, ANN OTO RHINOL LARYN, V121, P579, DOI 10.1177/000348941212100904; Steinke JW, 2009, J ALLERGY CLIN IMMUN, V124, P1352, DOI 10.1016/j.jaci.2009.09.018; Stevens WW, 2015, AM J RESP CRIT CARE, V192, P682, DOI 10.1164/rccm.201412-2278OC; Talbot AR, 1997, LARYNGOSCOPE, V107, P500, DOI 10.1097/00005537-199704000-00013; Tan BK, 2017, J ALLERGY CLIN IMMUN, V139, P699, DOI 10.1016/j.jaci.2016.06.063; Thamboo A, 2011, J OTOLARYNGOL-HEAD N, V40, P238, DOI 10.2310/7070.2011.100235; Tomassen P, 2016, J ALLERGY CLIN IMMUN, V137, P1449, DOI 10.1016/j.jaci.2015.12.1324; Tuncer U, 2003, AURIS NASUS LARYNX, V30, P263, DOI 10.1016/S0385-8146(03)00051-8; Uren B, 2008, LARYNGOSCOPE, V118, P1677, DOI 10.1097/MLG.0b013e31817aec47; Vaidyanathan S, 2011, ANN INTERN MED, V154, P293, DOI 10.7326/0003-4819-154-5-201103010-00003; Valentine R, 2011, AM J RHINOL ALLERGY, V25, P323, DOI 10.2500/ajra.2011.25.3659; Van Zele T, 2004, J ALLERGY CLIN IMMUN, V114, P981, DOI 10.1016/j.jaci.2004.07.013; Van Zele T, 2010, J ALLERGY CLIN IMMUN, V125, P1069, DOI 10.1016/j.jaci.2010.02.020; Wallwork B, 2006, LARYNGOSCOPE, V116, P189, DOI 10.1097/01.mlg.0000191560.53555.08; Wang XD, 2016, J ALLERGY CLIN IMMUN, V138, P1344, DOI 10.1016/j.jaci.2016.05.041; Wen WP, 2012, J ALLERGY CLIN IMMUN, V129, P1522, DOI 10.1016/j.jaci.2012.01.079; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woods CM, 2015, INT FORUM ALLERGY RH, V5, P1104, DOI 10.1002/alr.21604	93	61	63	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1499	1508		10.1016/j.jaci.2017.10.006	http://dx.doi.org/10.1016/j.jaci.2017.10.006			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	29106996	Bronze			2022-12-18	WOS:000417206000003
J	Del Bel, KL; Ragotte, RJ; Saferali, A; Lee, S; Vercauteren, SM; Mostafavi, SA; Schreiber, RA; Prendiville, JS; Phang, MS; Halparin, J; Au, N; Dean, JM; Priatel, JJ; Jewels, E; Junker, AK; Rogers, PC; Seear, M; McKinnon, ML; Turvey, SE				Del Bel, Kate L.; Ragotte, Robert J.; Saferali, Aabida; Lee, Susan; Vercauteren, Suzanne M.; Mostafavi, Sara A.; Schreiber, Richard A.; Prendiville, Julie S.; Phang, Min S.; Halparin, Jessica; Au, Nicholas; Dean, John M.; Priatel, John J.; Jewels, Emily; Junker, Anne K.; Rogers, Paul C.; Seear, Michael; McKinnon, Margaret L.; Turvey, Stuart E.			JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ACUTE LYMPHOBLASTIC-LEUKEMIA; MODEL; MUTATIONS; DISEASE		[Del Bel, Kate L.; Ragotte, Robert J.; Saferali, Aabida; Lee, Susan; Schreiber, Richard A.; Prendiville, Julie S.; Phang, Min S.; Halparin, Jessica; Dean, John M.; Jewels, Emily; Junker, Anne K.; Rogers, Paul C.; Seear, Michael; Turvey, Stuart E.] Univ British Columbia, British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC, Canada; [Vercauteren, Suzanne M.; Au, Nicholas; Priatel, John J.] Univ British Columbia, British Columbia Childrens Hosp, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Mostafavi, Sara A.; McKinnon, Margaret L.] Univ British Columbia, British Columbia Childrens Hosp, Dept Med Genet, Vancouver, BC, Canada	BC Childrens Hospital; University of British Columbia; BC Childrens Hospital; University of British Columbia; BC Childrens Hospital; University of British Columbia	Turvey, SE (corresponding author), Univ British Columbia, British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC, Canada.; McKinnon, ML (corresponding author), Univ British Columbia, British Columbia Childrens Hosp, Dept Med Genet, Vancouver, BC, Canada.	mmckinnon@cw.bc.ca; sturvey@cw.bc.ca	Rogers, Paul/AAV-6876-2021; Turvey, Stuart/HGV-1191-2022	Rogers, Paul/0000-0002-1182-9231; McKinnon, Margaret/0000-0002-3161-414X; Priatel, John/0000-0001-8794-6306; Au, Nicholas/0000-0003-4009-3048; Ragotte, Robert/0000-0002-6463-1595; Turvey, Stuart/0000-0003-1599-1065; Del Bel, Kate/0000-0001-7669-9530	Canadian Institutes of Health Research; Canadian Allergy, Asthma and Immunology Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Allergy, Asthma and Immunology Foundation	S. E. Turvey holds the Aubrey J. Tingle Professorship in Pediatric Immunology and is a clinical scholar of the Michael Smith Foundation for Health Research. This work was supported in part by funding from the Canadian Institutes of Health Research and the Canadian Allergy, Asthma and Immunology Foundation.	Farwell KD, 2015, GENET MED, V17, P578, DOI 10.1038/gim.2014.154; Flex E, 2008, J EXP MED, V205, P751, DOI 10.1084/jem.20072182; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hornakova T, 2010, BLOOD, V115, P3287, DOI 10.1182/blood-2009-09-245498; Hornakova T, 2009, J BIOL CHEM, V284, P6773, DOI 10.1074/jbc.M807531200; Jameson JL, 2015, NEW ENGL J MED, V372, P2229, DOI 10.1056/NEJMsb1503104; Kleppe M, 2011, BLOOD, V117, P7090, DOI 10.1182/blood-2010-10-314286; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loh ML, 2015, PEDIATR BLOOD CANCER, V62, P1717, DOI 10.1002/pbc.25575; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Sabrautzki S, 2013, AM J PATHOL, V183, P352, DOI 10.1016/j.ajpath.2013.04.027; Springuel L, 2014, BLOOD, V124, P3924, DOI 10.1182/blood-2014-05-576652; Toms AV, 2013, NAT STRUCT MOL BIOL, V20, P1221, DOI 10.1038/nsmb.2673; Yasuda T, 2016, J CLIN INVEST, V126, P2064, DOI 10.1172/JCI82887	15	61	61	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					2016	+		10.1016/j.jaci.2016.12.957	http://dx.doi.org/10.1016/j.jaci.2016.12.957			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	28111307	Bronze			2022-12-18	WOS:000402724600043
J	Okubo, K; Masuyama, K; Imai, T; Okamiya, K; Stage, BS; Seitzberg, D; Konno, A				Okubo, Kimihiro; Masuyama, Keisuke; Imai, Toru; Okamiya, Kazuhiro; Stage, Brian Sonne; Seitzberg, Dorthe; Konno, Akiyoshi			Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy immunotherapy; sublingual immunotherapy tablet; house dust mite; allergy; allergic rhinitis; conjunctivitis; adolescent	DOUBLE-BLIND; FOLLOW-UP; ASTHMA	Background: The SQ house dust mite (HDM) sublingual immunotherapy (SLIT) tablet has been approved in 11 European countries and Japan for patients with HDM-induced respiratory allergic disease. Objective: This trial was conducted to confirm the efficacy and safety of the SQ HDM SLIT tablet in Japanese patients with moderate-to-severe HDM-induced allergic rhinitis (AR). Methods: The trial was a randomized, double-blind, placebo-controlled trial including 946 Japanese adults and adolescents (12-64 years). Subjects were randomly assigned to daily treatment with the SQ HDM SLIT tablet at a dose of 10,000 Japanese allergy units (JAU) or 20,000 JAU or to placebo (1: 1: 1). The primary end point was the total combined rhinitis score (TCRS), which is composed of AR symptom and medication scores during the efficacy evaluation period. Symptom and medication scores of AR and conjunctivitis, rhinitis quality of life, and symptom-free and symptom-severe days were evaluated as secondary end points. Results: Analysis of the primary end point demonstrated statistically significant reductions in TCRSs of 1.15 (22%, P < .001) in the 10,000-JAU group and 0.99 (19%, P <. 001) in the 20,000-JAU group compared with the placebo group. The statistically significant treatment effect was evident from 12 weeks of treatment onward. All secondary end points, except AR medication score, were statistically significant in favor of active treatment compared with placebo. Post hoc analysis of TCRSs in adolescents showed the same efficacy as in adults (P<.05). The treatment was well tolerated by both adults and adolescents. Conclusion: The trial confirmed the efficacy and safety profile of the SQ HDM SLIT tablet in Japanese adult and adolescent patients with moderate-to-severe HDM-induced AR. These data support the robust efficacy and safety profile of previously reported European data.	[Okubo, Kimihiro] Nippon Med Sch, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Tokyo, Japan; [Masuyama, Keisuke] Yamanashi Univ, Grad Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Kofu, Yamanashi, Japan; [Imai, Toru] Assoc Pollen Informat Japan, Tokyo, Japan; [Okamiya, Kazuhiro] Torii, Tokyo, Japan; [Stage, Brian Sonne; Seitzberg, Dorthe] ALK Abello, Horsholm, Denmark; [Konno, Akiyoshi] Southern Tohoku Gen Hosp, Allergy & Head & Neck Tumor Ctr, Fukushima, Japan	Nippon Medical School; University of Yamanashi; ALK-Abello AS	Okubo, K (corresponding author), Nippon Med Sch, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.	ent-kimi@nms.ac.jp			Torii	Torii	The authors present this publication on behalf of all the involved investigators. The trial was funded by Torii, and in this context the authors thank the clinical trial team at Torii for clinical project management, operational oversight, quality control, safety monitoring, data management, and statistics. Kazuhiro Okamiya, Torii, was responsible for medical writing, editorial, and journal submission assistance for this manuscript. We thank Susanna Dahlgreen and Kaare Lund from ALK-Abello for reviewing the manuscript.	Arlian Larry G, 2002, Curr Allergy Asthma Rep, V2, P401, DOI 10.1007/s11882-002-0074-2; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; Batard T, 2016, ALLERGY, V71, P220, DOI 10.1111/all.12796; Bergmann KC, 2014, J ALLERGY CLIN IMMUN, V133, P1608, DOI 10.1016/j.jaci.2013.11.012; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Canonica GW, 2009, WORLD ALLERGY ORGAN, V2, P233, DOI 10.1097/WOX.0b013e3181c6c379; Canonica GW, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-6; Corzo JL, 2014, J INVEST ALLERG CLIN, V24, P154; Demoly P, 2016, J ALLERGY CLIN IMMUN, V137, P444, DOI 10.1016/j.jaci.2015.06.036; Downie SR, 2004, ALLERGY, V59, P406, DOI 10.1111/j.1398-9995.2003.00420.x; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; European Medicines Agency, 2008, CHMPEWP185042006 EUR; FIELLER EC, 1954, J ROY STAT SOC B, V16, P175; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Henmar H, 2016, INT ARCH ALLERGY IMM, V169, P23, DOI 10.1159/000444016; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Marogna M, 2008, ANN ALLERG ASTHMA IM, V101, P206, DOI 10.1016/S1081-1206(10)60211-6; Marogna M, 2010, J ALLERGY CLIN IMMUN, V126, P969, DOI 10.1016/j.jaci.2010.08.030; Meier U, 2006, PHARM STAT, V5, P253, DOI 10.1002/pst.210; Mosbech H, 2015, ANN ALLERG ASTHMA IM, V114, P134, DOI 10.1016/j.anai.2014.11.015; Nolte H, 2015, J ALLERGY CLIN IMMUN, V135, P1494, DOI 10.1016/j.jaci.2014.12.1911; Okamoto Y, 2015, INT ARCH ALLERGY IMM, V166, P177, DOI 10.1159/000381059; Okubo Kimihiro, 2011, Allergology International, V60, P171, DOI [10.2332/allergolint.11-RAI-0334, 10.2332/allergolint. 11-RAI-0334]; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Takai T, 2015, ALLERGOL INT, V64, P181, DOI 10.1016/j.alit.2015.01.005; Thomas WR, 2010, ASIAN PAC J ALLERGY, V28, P211; Tovey ER, 2000, ACI INT, V12, P226; US Food and Drug Administration, 2013, BRIEF DOC ORAL 2013; US Food and Drug Administration, 2014, BRIEF DOC RAGW 2014; Virchow JC, 2016, JAMA-J AM MED ASSOC, V315, P1715, DOI 10.1001/jama.2016.3964	30	61	64	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2017	139	6					1840	+		10.1016/j.jaci.2016.09.043	http://dx.doi.org/10.1016/j.jaci.2016.09.043			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EW7VG	27864024	Bronze			2022-12-18	WOS:000402724600015
J	Tsujita, Y; Mitsui-Sekinaka, K; Imai, K; Yeh, TW; Mitsuiki, N; Asano, T; Ohnishi, H; Kato, Z; Sekinaka, Y; Zaha, K; Kato, T; Okano, T; Takashima, T; Kobayashi, K; Kimura, M; Kunitsu, T; Maruo, Y; Kanegane, H; Takagi, M; Yoshida, K; Okuno, Y; Muramatsu, H; Shiraishi, Y; Chiba, K; Tanaka, H; Miyano, S; Kojima, S; Ogawa, S; Ohara, O; Okada, S; Kobayashi, M; Morio, T; Nonoyama, S				Tsujita, Yuki; Mitsui-Sekinaka, Kanako; Imai, Kohsuke; Yeh, Tzu-Wen; Mitsuiki, Noriko; Asano, Takaki; Ohnishi, Hidenori; Kato, Zenichiro; Sekinaka, Yujin; Zaha, Kiyotaka; Kato, Tamaki; Okano, Tsubasa; Takashima, Takehiro; Kobayashi, Kaoru; Kimura, Mitsuaki; Kunitsu, Tomoaki; Maruo, Yoshihiro; Kanegane, Hirokazu; Takagi, Masatoshi; Yoshida, Kenichi; Okuno, Yusuke; Muramatsu, Hideki; Shiraishi, Yuichi; Chiba, Kenichi; Tanaka, Hiroko; Miyano, Satoru; Kojima, Seiji; Ogawa, Seishi; Ohara, Osamu; Okada, Satoshi; Kobayashi, Masao; Morio, Tomohiro; Nonoyama, Shigeaki			Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase delta syndrome-like immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Activated phosphatidylinositol 3-kinase delta syndrome; catalytic subunit p110 delta of phosphatidylinositol 3-kinase; phosphatase and tensin homolog; primary immunodeficiency disease	CXC CHEMOKINE RECEPTOR-5; GERMLINE MUTATIONS; EXCISION CIRCLES; TUMOR-SUPPRESSOR; COWDENS-SYNDROME; GUTHRIE CARDS; T-CELLS; GENE; QUANTIFICATION; IDENTIFICATION	Background: Activated phosphatidylinositol 3-kinase delta syndrome (APDS) is a recently discovered primary immunodeficiency disease (PID). Excess phosphatidylinositol 3-kinase (PI3K) activity linked to mutations in 2 PI3K genes, PIK3CD and PIK3R1, causes APDS through hyperphosphorylation of AKT, mammalian target of rapamycin (mTOR), and S6. Objective: This study aimed to identify novel genes responsible for APDS. Methods: Whole-exome sequencing was performed in Japanese patients with PIDs. Immunophenotype was assessed through flow cytometry. Hyperphosphorylation of AKT, mTOR, and S6 in lymphocytes was examined through immunoblotting, flow cytometry, and multiplex assays. Results: We identified heterozygous mutations of phosphatase and tensin homolog (PTEN) in patients with PIDs. Immunoblotting and quantitative PCR analyses indicated that PTEN expression was decreased in these patients. Patients with PTEN mutations and those with PIK3CD mutations, including a novel E525A mutation, were further analyzed. The clinical symptoms and immunologic defects of patients with PTEN mutations, including lymphocytic AKT, mTOR, and S6 hyperphosphorylation, resemble those of patients with APDS. Because PTEN is known to suppress the PI3K pathway, it is likely that defective PTEN results in activation of the PI3K pathway. Conclusion: PTEN loss-of-function mutations can cause APDS-like immunodeficiency because of aberrant PI3K pathway activation in lymphocytes.	[Tsujita, Yuki; Mitsui-Sekinaka, Kanako; Imai, Kohsuke; Sekinaka, Yujin; Zaha, Kiyotaka; Kato, Tamaki; Nonoyama, Shigeaki] Natl Def Med Coll, Dept Pediat, Saitama, Japan; [Imai, Kohsuke] TMDU, Dept Community Pediat Perinatal & Maternal Med, Tokyo, Japan; [Yeh, Tzu-Wen; Mitsuiki, Noriko; Okano, Tsubasa; Takashima, Takehiro; Kanegane, Hirokazu; Takagi, Masatoshi; Morio, Tomohiro] TMDU, Dept Pediat & Dev Biol, Tokyo, Japan; [Asano, Takaki; Okada, Satoshi; Kobayashi, Masao] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pediat, Hiroshima, Japan; [Ohnishi, Hidenori; Kato, Zenichiro] Gifu Univ, Grad Sch Med, Dept Pediat, Gifu, Japan; [Kato, Zenichiro] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, Struct Med, Gifu, Japan; [Kobayashi, Kaoru] Kuma Hosp, Dept Surg, Kobe, Hyogo, Japan; [Kimura, Mitsuaki] Shizuoka Childrens Hosp, Dept Allergy & Clin Immunol, Shizuoka, Japan; [Kunitsu, Tomoaki; Maruo, Yoshihiro] Shiga Univ Med Sci, Dept Pediat, Otsu, Shiga, Japan; [Yoshida, Kenichi; Ogawa, Seishi] Kyoto Univ, Dept Pathol & Tumor Biol, Kyoto, Japan; [Okuno, Yusuke; Muramatsu, Hideki; Kojima, Seiji] Nagoya Univ, Gradual Sch Med, Dept Pediat, Nagoya, Aichi, Japan; [Shiraishi, Yuichi; Chiba, Kenichi; Miyano, Satoru] Univ Tokyo, Inst Med Sci, Lab DNA Informat Anal, Ctr Human Genome, Tokyo, Japan; [Tanaka, Hiroko; Miyano, Satoru] Univ Tokyo, Inst Med Sci, Lab Sequence Anal, Ctr Human Genome, Tokyo, Japan; [Ohara, Osamu] Kazusa DNA Res Inst, Dev Technol Dept, Chiba, Japan	National Defense Medical College - Japan; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Hiroshima University; Gifu University; Gifu University; Kuma Hospital; Shiga University of Medical Science; Kyoto University; Nagoya University; University of Tokyo; University of Tokyo; Kazusa DNA Research Institute	Imai, K (corresponding author), Tokyo Med & Dent Univ, Dept Community Pediat Perinatal & Maternal Med, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	kimai.ped@tmd.ac.jp	Ogawa, Seishi/AAE-7088-2019; Muramatsu, Hideki/ABA-3376-2021; Ohara, Osamu/G-5448-2015; Imai, Kohsuke/Q-2602-2015; Muramatsu, Hideki/I-3763-2012; 岡野, 翼/AAU-8246-2021; Okada, Satoshi/B-8901-2011; Asano, Takaki/AAC-7757-2022; Okuno, Yusuke/C-9082-2009; Sekinaka, Yujin/K-4858-2019	Muramatsu, Hideki/0000-0002-8801-0021; Ohara, Osamu/0000-0002-3328-9571; Imai, Kohsuke/0000-0003-2132-8403; Okada, Satoshi/0000-0002-4622-5657; Asano, Takaki/0000-0003-1424-2433; Okuno, Yusuke/0000-0003-3139-9272; Sekinaka, Yujin/0000-0002-2497-3419; Morio, Tomohiro/0000-0002-9259-1025; Tsujita, Yuki/0000-0003-2486-5343; Yoshida, Kenichi/0000-0003-4612-2778	Ministry of Defense, Japan; Research on Measures for Intractable Diseases Project [H26-037, H23-012]; Ministry of Health, Labour and Welfare, Japan; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [26293250, 15K09640]; Practical Research for Rare/Intractable Diseases from Japan Agency for Medical Research and Development, AMED; Japan Foundation for Pediatric Research; Jeffrey Modell Foundation; Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics; Grants-in-Aid for Scientific Research [15H06186, 26461570] Funding Source: KAKEN	Ministry of Defense, Japan; Research on Measures for Intractable Diseases Project; Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Practical Research for Rare/Intractable Diseases from Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED)); Japan Foundation for Pediatric Research; Jeffrey Modell Foundation; Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported in part by the Ministry of Defense, Japan; the Research on Measures for Intractable Diseases Project (H26-037, H23-012): matching fund subsidy from the Ministry of Health, Labour and Welfare, Japan; the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan (26293250, 15K09640); the Practical Research for Rare/Intractable Diseases from Japan Agency for Medical Research and Development, AMED; the Japan Foundation for Pediatric Research; the Jeffrey Modell Foundation; the Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics; and Drs M. and W. Hirose, H. Matsuda, and H. Seto.	Amer M, 2011, INT J DERMATOL, V50, P516, DOI 10.1111/j.1365-4632.2010.04669.x; Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Browning MJ, 2015, J MED GENET, V52, P856, DOI 10.1136/jmedgenet-2015-103266; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; Crank MC, 2014, J CLIN IMMUNOL, V34, P272, DOI 10.1007/s10875-014-0012-9; Deau MC, 2014, J CLIN INVEST, V124, P3923, DOI 10.1172/JCI75746; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; FECHTELER T, 1995, J MOL BIOL, V253, P114, DOI 10.1006/jmbi.1995.0540; HALEVY S, 1985, ACTA DERM-VENEREOL, V65, P126; Hartman HN, 2015, J CLIN IMMUNOL, V35, P11, DOI 10.1007/s10875-014-0109-1; Hedge D, 2000, ARCH DIS CHILD, V82, P234, DOI 10.1136/adc.82.3.234; Kobayashi K, 2002, ENDOCR SURG, V19, P116; Kobayashi K, 2013, J JPN THYROID ASS, V4, P50; Kracker S, 2014, J ALLERGY CLIN IMMUN, V134, P233, DOI 10.1016/j.jaci.2014.02.020; Kunishima S, 2013, AM J HUM GENET, V92, P431, DOI 10.1016/j.ajhg.2013.01.015; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lucas CL, 2014, J EXP MED, V211, P2537, DOI 10.1084/jem.20141759; Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Morinishi Y, 2009, J PEDIATR-US, V155, P829, DOI 10.1016/j.jpeds.2009.05.026; Nakagawa N, 2011, J ALLERGY CLIN IMMUN, V128, P223, DOI 10.1016/j.jaci.2011.01.052; Oda H, 2014, AM J HUM GENET, V95, P121, DOI 10.1016/j.ajhg.2014.06.007; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; RILEY HD, 1960, PEDIATRICS, V26, P293; RUSCHAK PJ, 1981, ARCH DERMATOL, V117, P573, DOI 10.1001/archderm.117.9.573; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8	31	61	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1672	+		10.1016/j.jaci.2016.03.055	http://dx.doi.org/10.1016/j.jaci.2016.03.055			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27426521	Bronze			2022-12-18	WOS:000390019300023
J	Lynch, JP; Werder, RB; Simpson, J; Loh, Z; Zhang, V; Haque, A; Spann, K; Sly, PD; Mazzone, SB; Upham, JW; Phipps, S				Lynch, Jason P.; Werder, Rhiannon B.; Simpson, Jennifer; Loh, Zhixuan; Zhang, Vivian; Haque, Ashraful; Spann, Kirsten; Sly, Peter D.; Mazzone, Stuart B.; Upham, John W.; Phipps, Simon			Aeroallergen-induced IL-33 predisposes to respiratory virus-induced asthma by dampening antiviral immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pneumonia virus of mice; IL-33; type 2 innate lymphoid cell; antiviral; respiratory syncytial virus; interferon; plasmacytoid dendritic cell	PLASMACYTOID DENDRITIC CELLS; INDUCED INTERFERON-PRODUCTION; ALLERGIC LUNG INFLAMMATION; INNATE LYMPHOID-CELLS; HOUSE-DUST MITE; SYNCYTIAL VIRUS; RECEPTOR 7; EARLY-LIFE; PNEUMOVIRUS INFECTION; CHILDHOOD ASTHMA	Background: Frequent viral lower respiratory infections in early life are an independent risk factor for asthma onset. This risk and the development of persistent asthma are significantly greater in children who later become sensitized. Objective: We sought to elucidate the pathogenic processes that underlie the synergistic interplay between allergen exposures and viral infections. Methods: Mice were inoculated with a murine-specific Pneumovirus species (pneumonia virus of mice [PVM]) and exposed to low-dose cockroach extract (CRE) in early and later life, and airway inflammation, remodeling, and hyperreactivity assessed. Mice were treated with anti-IL-33 or apyrase to neutralize or block IL-33 release. Results: PVM infection or CRE exposure alone did not induce disease, whereas PVM/CRE coexposure acted synergistically to induce the hallmark features of asthma. CRE exposure during viral infection in early life induced a biphasic IL-33 response and impaired IFN-alpha and IFN-lambda production, which in turn increased epithelial viral burden, airway smooth muscle growth, and type 2 inflammation. These features were ameliorated when CRE-induced IL-33 release was blocked or neutralized, whereas substitution of CRE with exogenous IL-33 recapitulated the phenotype observed in PVM/CRE-coexposed mice. Mechanistically, IL-33 downregulated viperin and interferon regulatory factor 7 gene expression and rapidly degraded IL-1 receptor-associated kinase 1 expression in plasmacytoid dendritic cells both in vivo and in vitro, leading to Toll-like receptor 7 hyporesponsiveness and impaired IFN-alpha production. Conclusion: We identified a hitherto unrecognized function of IL-33 as a potent suppressor of innate antiviral immunity and demonstrate that IL-33 contributes significantly to the synergistic interplay between respiratory virus and allergen exposures in the onset and progression of asthma.	[Lynch, Jason P.; Werder, Rhiannon B.; Simpson, Jennifer; Loh, Zhixuan; Zhang, Vivian; Mazzone, Stuart B.; Phipps, Simon] Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; [Spann, Kirsten; Sly, Peter D.; Upham, John W.; Phipps, Simon] Univ Queensland, Australian Infect Dis Res Ctr, St Lucia, Qld, Australia; [Sly, Peter D.] Univ Queensland, Ctr Childrens Hlth Res, St Lucia, Qld, Australia; [Haque, Ashraful] QIMR Berghofer Med Inst, Brisbane, Qld, Australia; [Spann, Kirsten] Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld, Australia; [Upham, John W.] Univ Queensland, Princess Alexandra Hosp, Sch Med, Lung & Allergy Res Ctr, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland; Queensland University of Technology (QUT); University of Queensland	Phipps, S (corresponding author), Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia.	s.phipps@uq.edu.au	Werder, Rhiannon/AAL-5192-2021; Phipps, Simon/F-9170-2010; Upham, John/F-4420-2010; Sly, Peter D/F-1486-2010; Loh, Zhixuan/G-4104-2015; Spann, Kirsten/B-4524-2013; Lynch, Jason/G-2991-2016; Haque, Ashraful/H-8697-2014	Werder, Rhiannon/0000-0002-6432-4587; Phipps, Simon/0000-0002-7388-3612; Upham, John/0000-0002-0017-3433; Sly, Peter D/0000-0001-6305-2201; Loh, Zhixuan/0000-0002-4124-9502; Spann, Kirsten/0000-0003-0567-8382; Lynch, Jason/0000-0003-0889-2616; Haque, Ashraful/0000-0003-2260-0026; Mazzone, Stuart/0000-0001-5270-1333	Rebecca L. Cooper Medical Research Foundation; Australian Infectious Disease Research Excellence Award; Australian Research Council Future Fellowship	Rebecca L. Cooper Medical Research Foundation; Australian Infectious Disease Research Excellence Award; Australian Research Council Future Fellowship(Australian Research Council)	Supported by an equipment grant (Rebecca L. Cooper Medical Research Foundation), an Australian Infectious Disease Research Excellence Award awarded (to S.P., J.P.L, and J.W.U.) and an Australian Research Council Future Fellowship (to S.P.).	AHERNE W, 1970, J CLIN PATHOL, V23, P7, DOI 10.1136/jcp.23.1.7; Baraldo S, 2014, THORAX, V69, P772, DOI 10.1136/thoraxjnl-2013-204922; Bem RA, 2011, AM J PHYSIOL-LUNG C, V301, pL148, DOI 10.1152/ajplung.00065.2011; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Davidson S, 2011, J IMMUNOL, V186, P5938, DOI 10.4049/jimmunol.1002635; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Grotenboer NS, 2013, J ALLERGY CLIN IMMUN, V131, P856, DOI 10.1016/j.jaci.2012.11.028; Guo LY, 2015, NAT IMMUNOL, V16, P1051, DOI 10.1038/ni.3244; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hardman CS, 2013, EUR J IMMUNOL, V43, P488, DOI 10.1002/eji.201242863; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jackson DJ, 2014, AM J RESP CRIT CARE, V190, P1373, DOI 10.1164/rccm.201406-1039OC; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242, DOI 10.1164/ajrccm/139.1.242; James KM, 2013, J ALLERGY CLIN IMMUN, V132, P227, DOI 10.1016/j.jaci.2013.01.009; Kaiko GE, 2013, J ALLERGY CLIN IMMUN, V131, P1331, DOI 10.1016/j.jaci.2013.02.041; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Liu YC, 2012, J IMMUNOL, V188, P1019, DOI 10.4049/jimmunol.1102181; Llop-Guevara A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088714; Lynch JP, 2014, EUR RESPIR J, V43, P264, DOI 10.1183/09031936.00203412; McKenzie ANJ, 2014, IMMUNITY, V41, P366, DOI 10.1016/j.immuni.2014.09.006; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; O'Reilly R, 2013, J ALLERGY CLIN IMMUN, V131, P1024, DOI 10.1016/j.jaci.2012.08.044; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191; Phipps S, 2009, CLIN EXP ALLERGY, V39, P1920, DOI 10.1111/j.1365-2222.2009.03335.x; Pritchard AL, 2012, J IMMUNOL, V188, P5898, DOI 10.4049/jimmunol.1103507; Roponen M, 2010, EUR RESPIR J, V35, P64, DOI 10.1183/09031936.00172008; Saglani S, 2013, J ALLERGY CLIN IMMUN, V132, P676, DOI 10.1016/j.jaci.2013.04.012; Saitoh T, 2011, IMMUNITY, V34, P352, DOI 10.1016/j.immuni.2011.03.010; Sandig H, 2013, EUR J IMMUNOL, V43, P979, DOI 10.1002/eji.201242786; Savenije OE, 2014, J ALLERGY CLIN IMMUN, V134, P170, DOI 10.1016/j.jaci.2013.12.1080; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Spann KM, 2014, THORAX, V69, P918, DOI 10.1136/thoraxjnl-2013-204908; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stewart A, 2012, AM J RESP CRIT CARE, V185, P1035, DOI 10.1164/rccm.201203-0457ED; Swiecki M, 2010, IMMUNITY, V33, P955, DOI 10.1016/j.immuni.2010.11.020; Sykes A, 2014, THORAX, V69, P240, DOI 10.1136/thoraxjnl-2012-202909; Tjota MY, 2013, J CLIN INVEST, V123, P2287, DOI 10.1172/JCI63802; Traister RS, 2015, J ALLERGY CLIN IMMUN, V135, P92, DOI 10.1016/j.jaci.2014.06.023; Ullah MA, 2014, J ALLERGY CLIN IMMUN, V134, P440, DOI 10.1016/j.jaci.2013.12.1035; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Yagami A, 2010, J IMMUNOL, V185, P5743, DOI 10.4049/jimmunol.0903818	53	61	62	1	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1326	1337		10.1016/j.jaci.2016.02.039	http://dx.doi.org/10.1016/j.jaci.2016.02.039			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27236500	Bronze			2022-12-18	WOS:000389542700011
J	Lee, A; Chiu, YHM; Rosa, MJ; Jara, C; Wright, RO; Coull, BA; Wright, RJ				Lee, Alison; Chiu, Yueh-Hsiu Mathilda; Rosa, Maria Jose; Jara, Calvin; Wright, Robert O.; Coull, Brent A.; Wright, Rosalind J.			Prenatal and postnatal stress and asthma in children: Temporal- and sex-specific associations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Negative life events; perinatal stress; childhood asthma; sex- and temporal-specific effects	MATERNAL STRESS; EARLY-LIFE; CHILDHOOD ASTHMA; HPA AXIS; PREGNANCY; ENVIRONMENT; RESPONSES; EXPOSURE; SYSTEMS; IMMUNE	Background: Temporal- and sex-specific effects of perinatal stress have not been examined for childhood asthma. Objectives: We examined associations between prenatal and/or postnatal stress and children's asthma (n = 765) and effect modification by sex in a prospective cohort study. Methods: Maternal negative life events were ascertained prenatally and postpartum. Negative life event scores were categorized as 0, 1 to 2, 3 to 4, or = or greater to assess exposure-response relationships. We examined effects of prenatal and postnatal stress on children's asthma by age 6 years, modeling each as independent predictors, mutually adjusting for prenatal and postnatal stress, and finally considering interactions between prenatal and postnatal stress. Effect modification by sex was examined in stratified analyses and by fitting interaction terms. Results: When considering stress in each period independently, among boys, a dose-response relationship was evident for each level increase on the ordinal scale prenatally (odds ratio [OR], 1.38; 95% CI, 1.06-1.79; P value for trend = .03) and postnatally (OR, 1.53; 95% CI, 1.16-2.01; P value for trend = .001); among girls, only the postnatal trend was significant (OR, 1.60; 95% CI, 1.14-2.22; P value for trend = .005). Higher stress in both the prenatal and postnatal periods was associated with increased odds of receiving a diagnosis of asthma in girls (OR, 1.37; 95% CI, 0.98-1.91; P-interaction = .07) but not boys (OR, 1.08; 95% CI, 0.82-1.42; P-interaction = .61). Conclusions: Although boys were more vulnerable to stress during the prenatal period, girls were more affected by postnatal stress and cumulative stress across both periods in relation to asthma. Understanding sex and temporal differences in response to early-life stress might provide unique insight into the cause and natural history of asthma.	[Lee, Alison] Icahn Sch Med Mt Sinai, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA; [Chiu, Yueh-Hsiu Mathilda; Rosa, Maria Jose; Jara, Calvin; Wright, Robert O.] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA; [Wright, Robert O.; Wright, Rosalind J.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA; [Chiu, Yueh-Hsiu Mathilda; Wright, Rosalind J.] Icahn Sch Med Mt Sinai, Kravis Childrens Hosp, Dept Pediat, New York, NY 10029 USA; [Coull, Brent A.] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Coull, Brent A.] Harvard Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Wright, RJ (corresponding author), One Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	rosalind.wright@mssm.edu	Rosa, Maria José/AAX-6620-2020	Rosa, Maria José/0000-0002-1509-7664; Jara, Calvin/0000-0003-2852-6736; Chiu, Yueh-Hsiu Mathilda/0000-0003-1656-660X; Wright, Robert/0000-0003-1180-6459	Thrasher Research Fund Early Career Award; Chest Foundation Clinical Research Grant; Empire Clinical Research Investigator Program Award;  [R01 ES010932];  [U01 HL072494];  [R01 HL080674];  [P30 ES023515];  [P30 ES000002];  [T32 HD049311-09]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD049311] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080674, U01HL072494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010932, P30ES000002, P30ES023515] Funding Source: NIH RePORTER	Thrasher Research Fund Early Career Award; Chest Foundation Clinical Research Grant; Empire Clinical Research Investigator Program Award; ; ; ; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The Asthma Coalition on Community, Environment, and Social Stress (ACCESS) project has been funded by grants R01 ES010932, U01 HL072494, and R01 HL080674 (principal investigator: R.J.W.), and phenotyping and biostatistical support was funded by P30 ES023515 and P30 ES000002. During preparation of this manuscript, A.L. was supported by a Thrasher Research Fund Early Career Award (principal investigator: A.L.), a Chest Foundation Clinical Research Grant (principal investigator: A.L.), and an Empire Clinical Research Investigator Program Award (principal investigator: R.O.W.). M.J.R. was supported by T32 HD049311-09.	Ahanks N, 2001, J CLIN INVEST, V108, P1567; Appleton AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074691; Bale TL, 2011, STRESS, V14, P348, DOI 10.3109/10253890.2011.586447; Bale TL, 2010, BIOL PSYCHIAT, V68, P314, DOI 10.1016/j.biopsych.2010.05.028; Berry CA, 2006, PSYCHOL REP, V98, P123, DOI 10.2466/PRO.98.1.123-132; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Biswas Debajit K, 2005, Sci STKE, V2005, ppe27, DOI 10.1126/stke.2882005pe27; Bock J, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00011; Bronson SL, 2014, ENDOCRINOLOGY, V155, P2635, DOI 10.1210/en.2014-1040; Buss C, 2007, J NEUROSCI, V27, P2592, DOI 10.1523/JNEUROSCI.3252-06.2007; Casanello P, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00049; CHERTOK RJ, 1984, P SOC EXP BIOL MED, V176, P138; Chiu YHM, 2012, AM J RESP CRIT CARE, V186, P147, DOI 10.1164/rccm.201201-0162OC; Cohen Sheldon, 1995, MEASURING STRESS GUI, P3; Cookson H, 2009, J ALLERGY CLIN IMMUN, V123, P847, DOI 10.1016/j.jaci.2009.01.042; Dietert RR, 2000, ENVIRON HEALTH PERSP, V108, P483, DOI 10.2307/3454540; Dunn GA, 2011, HORM BEHAV, V59, P290, DOI 10.1016/j.yhbeh.2010.05.004; Enlow MB, 2014, EARLY HUM DEV, V90, P377, DOI 10.1016/j.earlhumdev.2014.04.007; Evans GW, 2004, AM PSYCHOL, V59, P77, DOI 10.1037/0003-066X.59.2.77; Fang F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027202; Farrell MR, 2013, PHYSIOL BEHAV, V122, P208, DOI 10.1016/j.physbeh.2013.04.002; Fox HC, 2009, HARVARD REV PSYCHIAT, V17, P103, DOI 10.1080/10673220902899680; Gabory A, 2013, BIOL SEX DIFFER, V4, DOI 10.1186/2042-6410-4-5; Giallo R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121459; Glover V, 2012, PHYSIOL BEHAV, V106, P736, DOI 10.1016/j.physbeh.2012.02.011; Glover V, 2010, NEUROSCI BIOBEHAV R, V35, P17, DOI 10.1016/j.neubiorev.2009.11.008; Groger N, 2016, BRAIN STRUCT FUNCT, V221, P679, DOI 10.1007/s00429-014-0889-3; Gryparis A, 2007, J R STAT SOC C-APPL, V56, P183, DOI 10.1111/j.1467-9876.2007.00573.x; Guxens M, 2014, J ALLERGY CLIN IMMUN, V133, P59, DOI 10.1016/j.jaci.2013.04.044; Haque A, 2002, AM STAT COMP SECT 20; Hartwig IRV, 2014, J MOL MED, V92, P1093, DOI 10.1007/s00109-014-1167-9; Hartwig IRV, 2014, J ALLERGY CLIN IMMUN, V134, P160, DOI 10.1016/j.jaci.2014.01.033; Hoffman CS, 2008, PAEDIATR PERINAT EP, V22, P587, DOI 10.1111/j.1365-3016.2008.00965.x; Holguin Fernando, 2013, Ann Am Thorac Soc, V10 Suppl, pS150, DOI 10.1513/AnnalsATS.201305-116AW; Jansson T, 2007, CLIN SCI, V113, P1, DOI 10.1042/CS20060339; Kaplan LA, 2008, EARLY HUM DEV, V84, P249, DOI 10.1016/j.earlhumdev.2007.06.004; Kinkead R, 2013, CURR PHARM DESIGN, V19, P4471, DOI 10.2174/1381612811319240012; Kozyrskyj AL, 2008, AM J RESP CRIT CARE, V177, P142, DOI 10.1164/rccm.200703-381OC; Lim R, 2014, AM J PHYSIOL-LUNG C, V307, pL141, DOI 10.1152/ajplung.00250.2013; Maccari S, 2014, J NEUROENDOCRINOL, V26, P707, DOI 10.1111/jne.12175; McLaughlin KA, 2015, P NATL ACAD SCI USA, V112, P5637, DOI 10.1073/pnas.1423363112; Minghetti L, 2013, J MATERN-FETAL NEO M, V26, P259, DOI 10.3109/14767058.2012.733751; Mueller BR, 2008, J NEUROSCI, V28, P9055, DOI 10.1523/JNEUROSCI.1424-08.2008; Myatt L, 2010, PLACENTA, V31, pS66, DOI 10.1016/j.placenta.2009.12.021; Myers HF, 2009, J BEHAV MED, V32, P9, DOI 10.1007/s10865-008-9181-4; Oken Emily, 2003, BMC Pediatr, V3, P6, DOI 10.1186/1471-2431-3-6; Pagliaccio D, 2015, NEUROIMAGE, V109, P1, DOI 10.1016/j.neuroimage.2015.01.017; Panagiotakopoulos L, 2014, FRONT NEUROENDOCRIN, V35, P285, DOI 10.1016/j.yfrne.2014.03.002; Peters JL, 2009, J ALLERGY CLIN IMMUN, V123, P1041, DOI 10.1016/j.jaci.2009.02.027; PrabhuDas M, 2015, NAT IMMUNOL, V16, P328, DOI 10.1038/ni.3131; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323, DOI 10.1289/ehp.02110s2323; Reyes M, 2011, ANN ALLERG ASTHMA IM, V107, P42, DOI 10.1016/j.anai.2011.03.004; Sampson RJ, 1999, AM SOCIOL REV, V64, P633, DOI 10.2307/2657367; Sandman CA, 2013, J PSYCHOSOM RES, V75, P327, DOI 10.1016/j.jpsychores.2013.07.009; Sandovici I, 2012, REPROD BIOMED ONLINE, V25, P68, DOI 10.1016/j.rbmo.2012.03.017; SAS Institute, 2008, 32471 SAS I; Shalowitz MU, 1998, HEALTH SERV RES, V33, P1381; Shaughnessy DT, 2014, ENVIRON HEALTH PERSP, V122, P1271, DOI 10.1289/ehp.1408418; Stark MJ, 2011, PLACENTA, V32, P865, DOI 10.1016/j.placenta.2011.08.010; Szefler SJ, 2014, J ALLERGY CLIN IMMUN, V133, P3, DOI 10.1016/j.jaci.2013.10.018; Thiele K, 2015, AM J PATHOL, V185, P2805, DOI 10.1016/j.ajpath.2015.06.019; Turcotte-Tremblay AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/201717; van de Loo KFE, 2016, EUR RESPIR J, V47, P133, DOI 10.1183/13993003.00299-2015; Veru F, 2014, STRESS, V17, P133, DOI 10.3109/10253890.2013.876404; Viau V, 2002, J NEUROENDOCRINOL, V14, P506, DOI 10.1046/j.1365-2826.2002.00798.x; von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776; Wells PG, 2009, TOXICOL SCI, V108, P4, DOI 10.1093/toxsci/kfn263; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Wright RJ, 1998, THORAX, V53, P1066, DOI 10.1136/thx.53.12.1066; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358, DOI 10.1164/ajrccm.165.3.2102016; Wright RJ, 2007, CHEST, V132, p757S, DOI 10.1378/chest.07-1904; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x; Wright RJ, 2013, AM J RESP CRIT CARE, V187, P1186, DOI 10.1164/rccm.201208-1530OC; Wright RJ, 2012, CHEM IMMUNOL ALLERGY, V98, P32, DOI 10.1159/000336496; Wright RJ, 2011, IMMUNOL ALLERGY CLIN, V31, P19, DOI 10.1016/j.iac.2010.09.011; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC; Wright RJ, 2008, CIENC SAUDE COLETIVA, V13, P1729, DOI 10.1590/S1413-81232008000600008; Yam KY, 2015, STRESS, V18, P328, DOI 10.3109/10253890.2015.1064890; Zhang C, 2014, TOXICOLOGY, V325, P74, DOI 10.1016/j.tox.2014.08.015	80	61	61	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					740	+		10.1016/j.jaci.2016.01.014	http://dx.doi.org/10.1016/j.jaci.2016.01.014			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	DY9ZM	26953156	Bronze, Green Accepted			2022-12-18	WOS:000385496000009
J	Slatter, MA; Engelhardt, KR; Burroughs, LM; Arkwright, PD; Nademi, Z; Skoda-Smith, S; Hagin, D; Kennedy, A; Barge, D; Flood, T; Abinun, M; Wynn, RF; Gennery, AR; Cant, AJ; Sansom, D; Hambleton, S; Torgerson, TR				Slatter, Mary A.; Engelhardt, Karin R.; Burroughs, Lauri M.; Arkwright, Peter D.; Nademi, Zohreh; Skoda-Smith, Suzanne; Hagin, David; Kennedy, Alan; Barge, Dawn; Flood, Terence; Abinun, Mario; Wynn, Robert F.; Gennery, Andrew R.; Cant, Andrew J.; Sansom, David; Hambleton, Sophie; Torgerson, Troy R.			Hematopoietic stem cell transplantation for CTLA4 deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IMMUNE DYSREGULATION; MUTATIONS; VARIANTS		[Slatter, Mary A.; Engelhardt, Karin R.; Nademi, Zohreh; Flood, Terence; Abinun, Mario; Gennery, Andrew R.; Cant, Andrew J.; Hambleton, Sophie] NHS Fdn Trust, Newcastle Tyne Hosp, Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Slatter, Mary A.; Nademi, Zohreh; Abinun, Mario; Gennery, Andrew R.; Cant, Andrew J.; Hambleton, Sophie] Univ Newcastle Tyne, Inst Cellular Med, Primary Immunodeficiency Grp, Newcastle Upon Tyne, Tyne & Wear, England; [Burroughs, Lauri M.; Skoda-Smith, Suzanne; Hagin, David; Torgerson, Troy R.] Univ Washington, Seattle, WA 98195 USA; [Burroughs, Lauri M.; Skoda-Smith, Suzanne; Hagin, David; Torgerson, Troy R.] Seattle Childrens Hosp, Seattle, WA USA; [Burroughs, Lauri M.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Arkwright, Peter D.; Wynn, Robert F.] Univ Manchester, Royal Manchester Childrens Hosp, Manchester, Lancs, England; [Kennedy, Alan; Sansom, David] Royal Free Hosp, UCL Inst Immun & Transplantat, London, England; [Barge, Dawn] Reg Immunol Lab, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Fred Hutchinson Cancer Center; Royal Manchester Children's Hospital; University of Manchester; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Slatter, MA (corresponding author), NHS Fdn Trust, Newcastle Tyne Hosp, Great North Childrens Hosp, Newcastle Upon Tyne, Tyne & Wear, England.; Slatter, MA (corresponding author), Univ Newcastle Tyne, Inst Cellular Med, Primary Immunodeficiency Grp, Newcastle Upon Tyne, Tyne & Wear, England.	mary.slatter@nuth.nhs.uk	Hagin, David/GRS-3442-2022	Sansom, David/0000-0001-6506-3115; Hambleton, Sophie/0000-0001-7954-3267; Kennedy, Alan/0000-0003-0384-3866	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL122173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R13AI094943] Funding Source: NIH RePORTER; The Sir Jules Thorn Charitable Trust [12JTA] Funding Source: researchfish; NHLBI NIH HHS [P01 HL122173, P01 HL122173] Funding Source: Medline; NIAID NIH HHS [R13 AI094943, R13 AI094943] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); The Sir Jules Thorn Charitable Trust; NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Burroughs LM, 2014, BIOL BLOOD MARROW TR, V20, P1996, DOI 10.1016/j.bbmt.2014.08.020; Chambers CA, 1997, IMMUNITY, V7, P885, DOI 10.1016/S1074-7613(00)80406-9; Choi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046688; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Niroula A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117380; Rao K, 2005, BLOOD, V105, P879, DOI 10.1182/blood-2004-03-0960; Schubert D, 2014, NAT MED, V20, P1410, DOI 10.1038/nm.3746; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Snowden JA, 2012, BRIT J HAEMATOL, V157, P742, DOI 10.1111/j.1365-2141.2012.09122.x	13	61	62	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2016	138	2					615	619		10.1016/j.jaci.2016.01.045	http://dx.doi.org/10.1016/j.jaci.2016.01.045			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DS5PY	27102614	Green Submitted, Bronze			2022-12-18	WOS:000380835800043
J	Platts-Mills, TAE; Schuyler, AJ; Erwin, EA; Commins, SP; Woodfolk, JA				Platts-Mills, Thomas A. E.; Schuyler, Alexander J.; Erwin, Elizabeth A.; Commins, Scott P.; Woodfolk, Judith A.			IgE in the diagnosis and treatment of allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergen particles; IgE antibodies; eosinophilic esophagitis; alpha-gal; IgG(4)	RED MEAT ALLERGY; DUST-MITE ALLERGEN; EOSINOPHILIC ESOPHAGITIS; RANDOMIZED-TRIAL; INDUCED ANAPHYLAXIS; ORAL IMMUNOTHERAPY; ASTHMATIC-CHILDREN; TICK BITES; ALPHA-GAL; CAT	Traditionally, the concept of allergy implied an abnormal response to an otherwise benign agent (eg, pollen or food), with an easily identifiable relationship between exposure and disease. However, there are syndromes in which the relationship between exposure to the relevant allergen and the ``allergic'' disease is not clear. In these cases the presence of specific IgE antibodies can play an important role in identifying the relevant allergen and provide a guide to therapy. Good examples include chronic asthma and exposure to perennial indoor allergens and asthma related to fungal infection. Finally, we are increasingly aware of forms of food allergy in which the relationship between exposure and the disease is delayed by 3 to 6 hours or longer. Three forms of food allergy with distinct clinical features are now well recognized. These are (1) anaphylactic sensitivity to peanut, (2) eosinophilic esophagitis related to cow's milk, and (3) delayed anaphylaxis to red meat. In these syndromes the immunology of the response is dramatically different. Peanut and galactose alpha-1,3-galactose (alpha-gal) are characterized by high- or very high- titer IgE antibodies for Ara h 2 and alpha-gal, respectively. By contrast, eosinophilic esophagitis is characterized by low levels of IgE specific for milk proteins with high- or very high- titer IgG(4) to the same proteins. The recent finding is that patients with alpha-gal syndrome do not have detectable IgG(4) to the oligosaccharide. Thus the serum results not only identify relevant antigens but also provide a guide to the nature of the immune response.	[Platts-Mills, Thomas A. E.; Schuyler, Alexander J.; Woodfolk, Judith A.] Univ Virginia, Asthma & Allergy Dis Ctr, Charlottesville, VA USA; [Erwin, Elizabeth A.] Nationwide Childrens Hosp, Ctr Innovat Pediat Practice, Columbus, OH USA; [Commins, Scott P.] Univ N Carolina, Div Rheumatol Allergy & Immunol, Chapel Hill, NC USA	University of Virginia; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University of North Carolina; University of North Carolina Chapel Hill	Platts-Mills, TAE (corresponding author), Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu		Platts-Mills, Thomas/0000-0002-1263-329X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI020565] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal NS, 2015, J ALLER CL IMM-PRACT, V3, P110, DOI 10.1016/j.jaip.2014.05.010; Bates D V, 1966, Health Phys, V12, P173; Brockow K, 2015, J ALLERGY CLIN IMMUN, V134, p[977, e4]; Bronnert M, 2012, CLIN EXP ALLERGY, V42, P1406, DOI 10.1111/j.1365-2222.2012.04035.x; Bunyavanich S, 2014, J ALLERGY CLIN IMMUN, V134, P753, DOI 10.1016/j.jaci.2014.05.050; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; Chinuki Y, 2016, ALLERGY, V71, P421, DOI 10.1111/all.12804; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Clayton F, 2014, GASTROENTEROLOGY, V147, P602, DOI 10.1053/j.gastro.2014.05.036; Coca A F, 1930, Bull N Y Acad Med, V6, P593; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Cornmins SP, 2012, AM J RESP CRIT CARE, V185, P723, DOI 10.1164/rccm.201111-2017OC; deBlay F, 1997, J ALLERGY CLIN IMMUN, V99, P107, DOI 10.1016/S0091-6749(97)70307-5; Denning DW, 2009, AM J RESP CRIT CARE, V179, P11, DOI 10.1164/rccm.200805-737OC; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; Du Toit G, 2016, NEW ENGL J MED, V374, P1435, DOI 10.1056/NEJMoa1514209; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Erwin E, 2015, J ALLERGY CLIN IMMUN, V3, p[896, e3]; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Erwin EA, 2016, J ALLERGY CLIN IMMUN; Erwin EA, 2007, J ALLERGY CLIN IMMUN, V119, P359, DOI 10.1016/j.jaci.2006.12.648; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; FORMAN SR, 1978, J ALLERGY CLIN IMMUN, V62, P131, DOI 10.1016/0091-6749(78)90096-9; Glatz M, 2015, ACTA DERM-VENEREOL, V95, P191, DOI 10.2340/00015555-1864; Gronlund H, 2009, J ALLERGY CLIN IMMUN, V123, P1189, DOI 10.1016/j.jaci.2009.03.011; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hales BJ, 2013, J ALLER CL IMM-PRACT, V1, P656, DOI 10.1016/j.jaip.2013.08.008; Hamsten C, 2013, J ALLERGY CLIN IMMUN, V132, P1431, DOI 10.1016/j.jaci.2013.07.050; Heymann Peter W, 2005, Pediatr Infect Dis J, V24, pS217, DOI 10.1097/01.inf.0000188164.33856.f9; Hilger C, 1997, ALLERGY, V52, P179, DOI 10.1111/j.1398-9995.1997.tb00972.x; Hilger C, 2016, ALLERGY, V71, P711, DOI 10.1111/all.12835; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; Hoyt AEW, 2016, J ALLERGY C IN PRESS; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; Jappe U, 2012, HAUTARZT, V63, P299, DOI 10.1007/s00105-011-2266-y; Kekki OM, 2013, PEDIAT ALLERG IMM-UK, V24, P244, DOI 10.1111/pai.12057; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Kennedy JL, 2012, CLIN EXP ALLERGY, V42, P659, DOI 10.1111/j.1365-2222.2011.03944.x; Konradsen JR, 2015, J ALLERGY CLIN IMMUN, V135, P616, DOI 10.1016/j.jaci.2014.08.026; Larche Mark, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS292, DOI 10.1513/AnnalsATS.201402-090AW; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419, DOI 10.1289/ehp.02110419; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Mullins RJ, 2012, J ALLERGY CLIN IMMUN, V129, P1334, DOI 10.1016/j.jaci.2012.02.038; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; OHMAN JL, 1973, J ALLERGY CLIN IMMUN, V52, P231, DOI 10.1016/0091-6749(73)90061-4; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2015, J ALLERGY CLIN IMMUN, V136, P3, DOI 10.1016/j.jaci.2015.03.048; Platts-Mills TAE, 2011, IMMUNOL REV, V242, P51, DOI 10.1111/j.1600-065X.2011.01021.x; Platts-Mills TAE, 2009, AM J RESP CRIT CARE, V180, P109, DOI 10.1164/rccm.200811-1756PR; Posthumus J, 2013, J ALLERGY CLIN IMMUN, V131, P923, DOI 10.1016/j.jaci.2012.12.665; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; Rispens T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055566; Ronmark E, 2009, J ALLERGY CLIN IMMUN, V124, P357, DOI 10.1016/j.jaci.2009.05.011; Sampson HA, 2003, CLIN DERMATOL, V21, P183, DOI 10.1016/S0738-081X(02)00363-2; Schuyler AJ, 2016, J ALLERGY CLIN IMMUN, V137, pAB232, DOI 10.1016/j.jaci.2015.12.943; Simon D, 2016, ALLERGY, V71, P611, DOI 10.1111/all.12846; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Soto-Quiros M, 2012, J ALLERGY CLIN IMMUN, V129, P1499, DOI 10.1016/j.jaci.2012.03.040; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Steinke JW, 2015, J ALLERGY CLIN IMMUN, V135, P589, DOI 10.1016/j.jaci.2014.12.1947; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510, DOI 10.5694/j.1326-5377.2009.tb02533.x; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; von Hertzen L, 2009, AM J RESP CRIT CARE, V180, P113, DOI 10.1164/rccm.200807-1001CO; Von Pirquet C., 1906, CLIN ASPECTS IMMUNOL; Ward GW, 1999, J ALLERGY CLIN IMMUN, V104, P541, DOI 10.1016/S0091-6749(99)70321-0; WARD GW, 1989, LANCET, V1, P859; WEARY PE, 1967, ARCH DERMATOL, V95, P400, DOI 10.1001/archderm.95.4.400; White T, 2014, COLD SPRING HARB PER, V4; Wise F, 1930, J AMER MED ASSOC, V95, P1504, DOI 10.1001/jama.1930.27210200002011a; Woodfolk JA, 1998, J BIOL CHEM, V273, P29489, DOI 10.1074/jbc.273.45.29489; Yokooji T, 2013, ALLERGOL INT, V62, P435, DOI 10.2332/allergolint.13-OA-0561; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396	79	61	62	0	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1662	1670		10.1016/j.jaci.2016.04.010	http://dx.doi.org/10.1016/j.jaci.2016.04.010			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	27264001	Green Submitted, Green Accepted, Bronze			2022-12-18	WOS:000377527200004
J	Ullah, MA; Revez, JA; Loh, ZX; Simpson, J; Zhang, VV; Bain, L; Varelias, A; Rose-John, S; Blumenthal, A; Smyth, MJ; Hill, GR; Sukkar, MB; Ferreira, MAR; Phipps, S				Ullah, Md Ashik; Revez, Joana A.; Loh, Zhixuan; Simpson, Jennifer; Zhang, Vivian; Bain, Lisa; Varelias, Antiopi; Rose-John, Stefan; Blumenthal, Antje; Smyth, Mark J.; Hill, Geoffrey R.; Sukkar, Maria B.; Ferreira, Manuel A. R.; Phipps, Simon			Allergen-induced IL-6 trans-signaling activates gamma delta T cells to promote type 2 and type 17 airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Tocilizumab; MR16-1; sgp130-Fc; eosinophils; neutrophils; IL-17; gamma delta T cell; allergy; endotype	SOLUBLE INTERLEUKIN-6 RECEPTOR; ASTHMA EXACERBATIONS; NEUTROPHILIC ASTHMA; CYTOKINE PRODUCTION; INDUCED SPUTUM; IN-VIVO; HYPERREACTIVITY; RESPONSES; IDENTIFICATION; CHILDREN	Background: A variant in the IL-6 receptor (IL-6R) gene increases asthma risk and is predicted to decrease IL-6 classic signaling and increase IL-6 trans-signaling. This suggests that inhibition of IL-6 trans-signaling, but not classic signaling, might suppress allergic airway inflammation. Objectives: We sought to determine whether IL-6 signaling contributes to (1) acute experimental asthma induced by clinically relevant allergens and (2) variation in asthma clinical phenotypes in asthmatic patients. Methods: Mice were sensitized to house dust mite (HDM) or cockroach at day 0, treated with IL-6R inhibitors at day 13, and challenged with the same allergen at days 14 to 17. End points were measured 3 hours after the final challenge. IL-6 and soluble IL-6 receptor (sIL-6R) expression in induced sputum of asthmatic patients was correlated with asthma clinical phenotypes. Results: Both HDM and cockroach induced a type 2/type 17 cytokine profile and mixed granulocytic inflammation in the airways. Both allergens increased IL-6 expression in the airways, but only cockroach induced sIL-6R expression. Therefore HDM challenge promoted IL-6 classic signaling but not trans-signaling; in this model treatment with anti-IL-6R did not suppress airway inflammation. In contrast, cockroach-induced inflammation involved activation of IL-6 trans-signaling and production of IL-17A by gamma delta T cells. Anti-IL-6R, selective blockade of sIL-6R, or gamma delta T-cell deficiency significantly attenuated cockroach-induced inflammation. Asthmatic patients with high airway IL-6 and sIL-6R levels were enriched for the neutrophilic and mixed granulocytic subtypes. Conclusion: Experimental asthma associated with both high IL-6 and high sIL-6R levels in the airways is attenuated by treatment with IL-6R inhibitors.	[Ullah, Md Ashik; Sukkar, Maria B.] Univ Sydney, Sydney Med Sch, Woolcock Inst Med Res, Sydney, NSW 2006, Australia; [Ullah, Md Ashik; Loh, Zhixuan; Simpson, Jennifer; Zhang, Vivian; Phipps, Simon] Univ Queensland, Sch Biomed Sci, Lab Resp Neurosci & Mucosal Immun, Brisbane, Qld, Australia; [Ullah, Md Ashik; Revez, Joana A.; Bain, Lisa; Varelias, Antiopi; Smyth, Mark J.; Hill, Geoffrey R.; Ferreira, Manuel A. R.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Rose-John, Stefan] Univ Kiel, Dept Biochem, Kiel, Germany; [Blumenthal, Antje] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia; [Smyth, Mark J.] Univ Queensland, Sch Med, Herston, Qld, Australia; [Hill, Geoffrey R.] Royal Brisbane Hosp, Dept Bone Marrow Transplantat, Brisbane, Qld, Australia; [Sukkar, Maria B.] Univ Technol Sydney, Grad Sch Hlth, Sch Pharm, Sydney, NSW 2007, Australia	University of Sydney; Woolcock Institute of Medical Research; University of Queensland; QIMR Berghofer Medical Research Institute; University of Kiel; University of Queensland; University of Queensland; Royal Brisbane & Women's Hospital; University of Technology Sydney	Phipps, S (corresponding author), Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia.	manuel.ferreira@qimrberghofer.edu.au; s.phipps@uq.edu.au	Smyth, Mark J/H-8709-2014; Varelias, Antiopi/A-6516-2015; Ullah, Ashik/N-6465-2017; Ferreira, Manuel A R/D-3609-2013; Sukkar, Maria B/L-6917-2013; Loh, Zhixuan/G-4104-2015; Phipps, Simon/F-9170-2010; Blumenthal, Antje/A-3608-2011; Revez, Joana/ABA-2920-2020; Hill, Geoffrey/O-2630-2016; Ullah, Ashik/G-3852-2010; Rose-John, Stefan/A-7998-2010	Smyth, Mark J/0000-0001-7098-7240; Ullah, Ashik/0000-0002-0025-1796; Ferreira, Manuel A R/0000-0001-9059-1825; Loh, Zhixuan/0000-0002-4124-9502; Phipps, Simon/0000-0002-7388-3612; Blumenthal, Antje/0000-0003-3673-7015; Revez, Joana/0000-0003-3204-5396; Hill, Geoffrey/0000-0003-2994-0429; Ullah, Ashik/0000-0002-0025-1796; Rose-John, Stefan/0000-0002-7519-3279; Sukkar, Maria/0000-0003-4591-2399; Varelias, Antiopi/0000-0002-3437-9659				Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Barkhausen T, 2011, CRIT CARE MED, V39, P1407, DOI 10.1097/CCM.0b013e318211ff56; Briso EM, 2008, J IMMUNOL, V180, P7102, DOI 10.4049/jimmunol.180.11.7102; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Cosmi L, 2010, J ALLERGY CLIN IMMUN, V125, P222, DOI 10.1016/j.jaci.2009.10.012; Cui ZH, 2003, AM J RESP CRIT CARE, V168, P1324, DOI 10.1164/rccm.200305-634OC.R1; Dennehy KM, 2008, EUR J IMMUNOL, V38, P500, DOI 10.1002/eji.200737741; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Ferreira RC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003444; Ferwerda G, 2008, CELL MICROBIOL, V10, P2058, DOI 10.1111/j.1462-5822.2008.01188.x; Gallo E, 2012, EUR J IMMUNOL, V42, P2322, DOI 10.1002/eji.201142227; Garbers C, 2014, BBA-MOL BASIS DIS, V1842, P1485, DOI 10.1016/j.bbadis.2014.05.018; Glanville N, 2013, MUCOSAL IMMUNOL, V6, P1091, DOI 10.1038/mi.2013.3; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Hahn YS, 2004, J IMMUNOL, V172, P2894, DOI 10.4049/jimmunol.172.5.2894; Hamzaoui A, 2002, MEDIAT INFLAMM, V11, P113, DOI 10.1080/09629350220131971; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hawkins GA, 2012, J ALLERGY CLIN IMMUN, V130, P510, DOI 10.1016/j.jaci.2012.03.018; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432-1327.2001.01867.x; Krug N, 2001, AM J RESP CELL MOL, V25, P125, DOI 10.1165/ajrcmb.25.1.4194; Lahn M, 2002, P NATL ACAD SCI USA, V99, P8850, DOI 10.1073/pnas.132519299; Lewkowich IP, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-122; Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020; Mayer A, 2014, EUR J IMMUNOL, V44, P3252, DOI 10.1002/eji.201444646; Melzer D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000072; Molfino NA, 1996, CLIN EXP IMMUNOL, V104, P144, DOI 10.1046/j.1365-2249.1996.d01-645.x; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Murdoch JR, 2010, AM J RESP CRIT CARE, V182, P464, DOI 10.1164/rccm.200911-1775OC; Neveu WA, 2009, J IMMUNOL, V183, P1732, DOI 10.4049/jimmunol.0802923; Nish SA, 2014, ELIFE, V3, DOI 10.7554/eLife.01949; Oleksy A, 2002, MICROB PATHOGENESIS, V32, P173, DOI 10.1006/mpat.2002.0491; Page K, 2008, J IMMUNOL, V180, P6317, DOI 10.4049/jimmunol.180.9.6317; Park SJ, 2004, J IMMUNOL, V173, P3844, DOI 10.4049/jimmunol.173.6.3844; Peters M, 1998, BLOOD, V92, P3495, DOI 10.1182/blood.V92.10.3495.422k47_3495_3504; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Raymond M, 2011, J ALLERGY CLIN IMMUN, V128, P192, DOI 10.1016/j.jaci.2011.04.029; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Schramm CM, 2000, AM J RESP CELL MOL, V22, P218, DOI 10.1165/ajrcmb.22.2.3620; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; Simpson JL, 2014, EUR RESPIR J, V43, P1067, DOI 10.1183/09031936.00105013; Sodenkamp J, 2012, IMMUNOBIOLOGY, V217, P996, DOI 10.1016/j.imbio.2012.01.015; Spinozzi F, 1996, ANN INTERN MED, V124, P223, DOI 10.7326/0003-4819-124-2-199601150-00005; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Ullah MA, 2014, J ALLERGY CLIN IMMUN, V134, P440, DOI 10.1016/j.jaci.2013.12.1035; Urboniene D, 2013, RESP MED, V107, P413, DOI 10.1016/j.rmed.2012.11.012; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Woolhouse IS, 2002, THORAX, V57, P667, DOI 10.1136/thorax.57.8.667; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	56	61	62	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					1065	1073		10.1016/j.jaci.2015.02.032	http://dx.doi.org/10.1016/j.jaci.2015.02.032			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25930193				2022-12-18	WOS:000362976300025
J	Havstad, S; Johnson, CC; Kim, H; Levin, AM; Zoratti, EM; Joseph, CLM; Ownby, DR; Wegienka, G				Havstad, Suzanne; Johnson, Christine Cole; Kim, Haejin; Levin, Albert M.; Zoratti, Edward M.; Joseph, Christine L. M.; Ownby, Dennis R.; Wegienka, Ganesa			Atopic phenotypes identified with latent class analyses at age 2 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; phenotype; latent class analysis; birth cohort	SEVERE ASTHMA; CLUSTER-ANALYSIS; SENSITIZATION; ASSOCIATIONS; EXPOSURE; RISK; LIFE; LUNG; IGE	Background: Atopic sensitization (ie, atopy) is the most commonly reported risk factor for asthma. Recent studies have begun to suggest that atopy, as conventionally defined, might be an umbrella term that obfuscates more specific allergic disease types. Objective: We sought to determine whether distinct and meaningful atopic phenotypes exist within a racially diverse birth cohort using 10 allergen-specific serum IgE (sIgE) measurements from children aged 2 years. Methods: Using the Wayne County Health, Environment, Allergy and Asthma Longitudinal Study (WHEALS) birth cohort (62% black), we analyzed sIgE data on 10 allergens (Dermatophagoides farinae, dog, cat, timothy grass, ragweed, Alternaria alternata, egg, peanut, milk, and German cockroach) obtained from 594 children at age 2 years. Conventional atopy was defined as at least 1 sIgE level of 0.35 IU/mL or greater. Results: A 4-class solution (latent class model) was the best fit. Class types were labeled "low to no sensitization" (76.9% of sample), "highly sensitized" (2.7%), "milk and egg dominated" (15.3%), and "peanut and inhalant(s)" (5.1%). Almost one third (32.2%) of the low to no sensitization group met the criteria for conventional atopy. The highly sensitized group was significantly associated with a doctor's diagnosis of asthma after age 4 years (odds ratio [OR], 5.3; 95% CI, 1.6-17.4), whereas the milk and egg dominated and peanut and inhalant(s) groups were not (ORs of 1.6 [95% CI, 0.8-3.0] and 1.8 [95% CI, 0.6-4.9], respectively). Children of black race were more likely to be in the 3 multisensitized groups (P = .04). Conclusion: Classification by sIgE patterns defined groups whose membership is more strongly associated with atopic dermatitis, wheeze, and asthma compared with conventional atopy.	[Havstad, Suzanne; Johnson, Christine Cole; Levin, Albert M.; Joseph, Christine L. M.; Wegienka, Ganesa] Georgia Regents Univ, Dept Publ Hlth Sci, Augusta, GA USA; [Kim, Haejin; Zoratti, Edward M.] Georgia Regents Univ, Henry Ford Hosp, Dept Internal Med, Div Allergy, Augusta, GA USA; [Ownby, Dennis R.] Georgia Regents Univ, Dept Pediat, Augusta, GA USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Havstad, S (corresponding author), 1 Ford Pl,3E, Detroit, MI 48202 USA.	shavsta1@hfhs.org			National Institutes of Health [R01 AI051598, P01 AI089473]; National Institutes of Health (NIH); NIH; Aspen Allergy Conference; National Institute of Allergy and Infectious Diseases (NIAID); NIAID; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI089473, R01AI050681] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Aspen Allergy Conference; National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants R01 AI051598 and P01 AI089473. Disclosure of potential conflict of interest: S. Havstad, A. M. Levin, D. R. Ownby, and G. Wegienka have received research support from the National Institutes of Health (NIH). C. C. Johnson has received research support from the NIH, has consulted for Sucampo Expert Panel Meeting and McNeil Expert Panel Meeting, and has received payment for lectures from the Aspen Allergy Conference. H. Kim and E. M. Zoratti have received research support from the National Institute of Allergy and Infectious Diseases (NIAID). C. L. M. Joseph has received research support and travel support from the NIAID.	Behbod B, 2013, ALLERGY, V68, P1410, DOI 10.1111/all.12254; Custovic A, 2013, CURR OPIN ALLERGY CL, V13, P173, DOI 10.1097/ACI.0b013e32835e82b6; Fitzpatrick AM, 2012, CURR OPIN ALLERGY CL, V12, P193, DOI 10.1097/ACI.0b013e32835090ac; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Garden FL, 2013, CLIN EXP ALLERGY, V43, P633, DOI 10.1111/cea.12095; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Havstad S, 2011, J ALLERGY CLIN IMMUN, V128, P880, DOI 10.1016/j.jaci.2011.06.039; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Joseph CLM, 2011, J ALLERGY CLIN IMMUN, V127, P1203, DOI 10.1016/j.jaci.2011.02.018; Just J, 2012, EUR RESPIR J, V40, P55, DOI 10.1183/09031936.00123411; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Mclachlan G., 2000, WILEY SER PROB STAT; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Muthen LK, 2013, MPLUS USERS GUIDE; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; Ownby DR, 2010, PEDIAT ALLERG IMM-UK, V21, P533, DOI 10.1111/j.1399-3038.2009.00918.x; Perry LM, 2009, ANN ALLERG ASTHMA IM, V103, P342, DOI 10.1016/S1081-1206(10)60535-2; Petersen Trond, 1995, HDB STAT MODELING SO, P453; Roberts G, 2012, CLIN EXP ALLERGY, V42, P1501, DOI 10.1111/j.1365-2222.2012.04074.x; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Smith JA, 2008, AM J RESP CRIT CARE, V177, P1358, DOI 10.1164/rccm.200709-1419OC; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Wegienka G, 2012, CLIN EXP ALLERGY, V42, P909, DOI 10.1111/j.1365-2222.2011.03946.x; Wegienka G, 2011, CLIN EXP ALLERGY, V41, P979, DOI 10.1111/j.1365-2222.2011.03747.x; Weinmayr G, 2013, CLIN EXP ALLERGY, V43, P223, DOI 10.1111/cea.12035; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yao WG, 2010, J ALLERGY CLIN IMMUN, V126, P483, DOI 10.1016/j.jaci.2010.06.028	29	61	62	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					722	+		10.1016/j.jaci.2014.01.022	http://dx.doi.org/10.1016/j.jaci.2014.01.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24636082	Green Accepted			2022-12-18	WOS:000341372400027
J	Jing, H; Zhang, Q; Zhang, Y; Hill, BJ; Dove, CG; Gelfand, EW; Atkinson, TP; Uzel, G; Matthews, HF; Mustillo, PJ; Lewis, DB; Kavadas, FD; Hanson, IC; Kumar, AR; Geha, RS; Douek, DC; Holland, SM; Freeman, AF; Su, HC				Jing, Huie; Zhang, Qian; Zhang, Yu; Hill, Brenna J.; Dove, Christopher G.; Gelfand, Erwin W.; Atkinson, T. Prescott; Uzel, Gulbu; Matthews, Helen F.; Mustillo, Peter J.; Lewis, David B.; Kavadas, Fotini D.; Hanson, I. Celine; Kumar, Ashish R.; Geha, Raif S.; Douek, Daniel C.; Holland, Steven M.; Freeman, Alexandra F.; Su, Helen C.			Somatic reversion in dedicator of cytokinesis 8 immunodeficiency modulates disease phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dedicator of cytokinesis 8; reversion; somatic repair; recombination; gene conversion; intragenic single crossover; T cell; natural killer cell; allergy; immunodeficiency	STEM-CELL TRANSPLANTATION; HYPER-IGE SYNDROME; DOCK8 DEFICIENCY; SURVIVAL; RECOMBINATION; MOSAICISM; KINETICS; HUMANS	Background: Autosomal recessive loss-of-function mutations in dedicator of cytokinesis 8 (DOCK8) cause a combined immunodeficiency characterized by atopy, recurrent infections, and cancer susceptibility. A genotype-phenotype explanation for the variable disease expression is lacking. Objective: We investigated whether reversions contributed to the variable disease expression. Methods: Patients followed at the National Institutes of Health's Clinical Center were studied. We performed detailed genetic analyses and intracellular flow cytometry to detect DOCK8 protein expression within lymphocyte subsets. Results: We identified 17 of 34 DOCK8-deficient patients who had germline mutations with variable degrees of reversion caused by somatic repair. Somatic repair of the DOCK8 mutations resulted from second-site mutation, original-site mutation, gene conversion, and intragenic crossover. Higher degrees of reversion were associated with recombination-mediated repair. DOCK8 expression was restored primarily within antigen-experienced T cells or natural killer cells but less so in naive T or B cells. Several patients exhibited multiple different repair events. Patients who had reversions were older and had less severe allergic disease, although infection susceptibility persisted. No patients were cured without hematopoietic cell transplantation. Conclusions: In patients with DOCK8 deficiency, only certain combinations of germline mutations supported secondary somatic repair. Those patients had an ameliorated disease course with longer survival but still had fatal complications or required hematopoietic cell transplantation. These observations support the concept that some DOCK8-immunodeficient patients have mutable mosaic genomes that can modulate disease phenotype over time.	[Jing, Huie; Zhang, Qian; Zhang, Yu; Dove, Christopher G.; Su, Helen C.] NIAID, Lab Host Def, Div Intramural Res, NIH, Bethesda, MD 20892 USA; [Uzel, Gulbu; Holland, Steven M.; Freeman, Alexandra F.] NIAID, Lab Clin Infect Dis, Div Intramural Res, NIH, Bethesda, MD 20892 USA; [Hill, Brenna J.; Douek, Daniel C.] NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; [Gelfand, Erwin W.] Natl Jewish Hlth, Div Cell Biol, Dept Pediat, Div Allergy & Immunol, Denver, CO USA; [Atkinson, T. Prescott] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA; [Mustillo, Peter J.] Nationwide Childrens Hosp, Div Infect Dis & Immunol, Columbus, OH USA; [Lewis, David B.] Stanford Univ, Div Immunol Allergy & Rheumatol, Dept Pediat, Stanford, CA 94305 USA; [Kavadas, Fotini D.] Alberta Childrens Prov Gen Hosp, Dept Pediat, Sect Clin Immunol & Allergy, Calgary, AB, Canada; [Kavadas, Fotini D.] Univ Calgary, Calgary, AB T2N 1N4, Canada; [Hanson, I. Celine] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Sect Allergy & Immunol, Houston, TX 77030 USA; [Kumar, Ashish R.] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA; [Kumar, Ashish R.] Univ Cincinnati, Cincinnati, OH 45221 USA; [Geha, Raif S.] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Geha, Raif S.] Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; [Geha, Raif S.] Harvard Univ, Sch Med, Boston, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Jewish Health; University of Alabama System; University of Alabama Birmingham; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Stanford University; Alberta Childrens Hospital; University of Calgary; University of Calgary; Baylor College of Medicine; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Su, HC (corresponding author), NIAID, Lab Host Def, Div Intramural Res, NIH, Bldg 10CRC,Rm 5W3940,10CRC Ctr Dr,MSC 1456, Bethesda, MD 20892 USA.	hsu@niaid.nih.gov	Kumar, Ashish/GRJ-3967-2022; Su, Helen C/H-9541-2015; Kumar, Ashish/GRR-3470-2022	Su, Helen C/0000-0002-5582-9110; Kumar, Ashish/0000-0002-4476-3494; Zhang, Qian/0000-0002-9040-3289	Intramural Research Program; Vaccine Research Center of the National Institutes of Health, National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001193, ZIAAI000646, ZIAAI000647] Funding Source: NIH RePORTER	Intramural Research Program; Vaccine Research Center of the National Institutes of Health, National Institute of Allergy and Infectious Diseases; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Intramural Research Program and the Vaccine Research Center of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.	Alsum Z, 2013, J CLIN IMMUNOL, V33, P55, DOI 10.1007/s10875-012-9769-x; Barlogis V, 2011, J ALLERGY CLIN IMMUN, V128, P420, DOI 10.1016/j.jaci.2011.03.025; Bittner TC, 2010, KLIN PADIATR, V222, P351, DOI 10.1055/s-0030-1265135; Boztug H, 2012, PEDIATR HEMAT ONCOL, V29, P585, DOI 10.3109/08880018.2012.714844; Chu EY, 2012, ARCH DERMATOL, V148, P79, DOI 10.1001/archdermatol.2011.262; Crawford G, 2013, BLOOD, V122, P2052, DOI 10.1182/blood-2013-02-482331; Dasouki M, 2011, CLIN IMMUNOL, V141, P128, DOI 10.1016/j.clim.2011.06.003; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Gatz SA, 2011, BONE MARROW TRANSPL, V46, P552, DOI 10.1038/bmt.2010.169; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Jongmans MCJ, 2012, AM J HUM GENET, V90, P426, DOI 10.1016/j.ajhg.2012.01.004; Kawai T, 2012, J CLIN IMMUNOL, V32, P690, DOI 10.1007/s10875-012-9684-1; Lai-Cheong JE, 2011, TRENDS MOL MED, V17, P140, DOI 10.1016/j.molmed.2010.11.003; Lambe T, 2011, EUR J IMMUNOL, V41, P3423, DOI 10.1002/eji.201141759; Macallan DC, 2005, BLOOD, V105, P3633, DOI 10.1182/blood-2004-09-3740; Macallan DC, 2003, EUR J IMMUNOL, V33, P2316, DOI 10.1002/eji.200323763; Metin A, 2012, PEDIATR TRANSPLANT, V16, P398, DOI 10.1111/j.1399-3046.2011.01641.x; Mizesko MC, 2013, J ALLERGY CLIN IMMUN, V131, P840, DOI 10.1016/j.jaci.2012.12.1568; Palendira U, 2012, J EXP MED, V209, P911, DOI 10.1084/jem.20112391; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Randall KL, 2009, NAT IMMUNOL, V10, P1283, DOI 10.1038/ni.1820; Sanal O, 2012, J CLIN IMMUNOL, V32, P698, DOI 10.1007/s10875-012-9664-5; Su HC, 2011, ANN NY ACAD SCI, V1246, P26, DOI 10.1111/j.1749-6632.2011.06295.x; Trifari S, 2010, J ALLERGY CLIN IMMUN, V125, P439, DOI 10.1016/j.jaci.2009.11.034; Wada T, 2008, CURR OPIN ALLERGY CL, V8, P510, DOI 10.1097/ACI.0b013e328314b651; Zhang Q, 2009, NEW ENGL J MED, V361, P2046, DOI 10.1056/NEJMoa0905506; Zhang Y, 2007, IMMUNOLOGY, V121, P258, DOI 10.1111/j.1365-2567.2007.02573.x	28	61	63	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2014	133	6					1667	1675		10.1016/j.jaci.2014.03.025	http://dx.doi.org/10.1016/j.jaci.2014.03.025			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AI2FI	24797421	Green Accepted			2022-12-18	WOS:000336672500020
J	Larsen, JM; Brix, S; Thysen, AH; Birch, S; Rasmussen, MA; Bisgaard, H				Larsen, Jeppe Madura; Brix, Susanne; Thysen, Anna Hammerich; Birch, Sune; Rasmussen, Morten Arendt; Bisgaard, Hans			Children with asthma by school age display aberrant immune responses to pathogenic airway bacteria as infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; bacteria; immune response; birth cohort	CHILDHOOD ASTHMA; INFLAMMATION; ASSOCIATION; COLONIZATION; EOSINOPHILIA; MEPOLIZUMAB; MECHANISMS; CYTOKINES; DISEASE; INNATE	Background: Asthma is a highly prevalent chronic lung disease that commonly originates in early childhood. Colonization of neonatal airways with the pathogenic bacterial strains Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae is associated with increased risk of later childhood asthma. We hypothesized that children with asthma have an abnormal immune response to pathogenic bacteria in infancy. Objective: We aimed to assess the bacterial immune response in asymptomatic infants and the association with later development of asthma by age 7 years. Methods: The Copenhagen Prospective Studies on Asthma in Childhood birth cohort was followed prospectively, and asthma was diagnosed at age 7 years. The immune response to H influenzae, M catarrhalis, and S pneumoniae was analyzed in 292 infants using PBMCs isolated and stored since the age of 6 months. The immune response was assessed based on the pattern of cytokines produced and T-cell activation. Results: The immune response to pathogenic bacteria was different in infants with asthma by 7 years of age (P = .0007). In particular, prospective asthmatic subjects had aberrant production of IL-5 (P = .008), IL-13 (P = .057), IL-17 (P = .001), and IL-10 (P = .028), whereas there were no differences in T-cell activation or peripheral T-cell composition. Conclusions: Children with asthma by school age exhibited an aberrant immune response to pathogenic bacteria in infancy. We propose that an abnormal immune response to pathogenic bacteria colonizing the airways in early life might lead to chronic airway inflammation and childhood asthma.	[Larsen, Jeppe Madura; Brix, Susanne; Thysen, Anna Hammerich] Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, DK-2800 Lyngby, Denmark; [Larsen, Jeppe Madura; Thysen, Anna Hammerich; Birch, Sune; Bisgaard, Hans] Univ Copenhagen, Copenhagen Univ Hosp, Copenhagen Prospect Studies Asthma Childhood, DK-2820 Copenhagen, Denmark; [Rasmussen, Morten Arendt] Univ Copenhagen, Fac Sci, Frederiksberg, Denmark	Technical University of Denmark; University of Copenhagen; University of Copenhagen	Bisgaard, H (corresponding author), Univ Copenhagen, Copenhagen Univ Hosp, Copenhagen Prospect Studies Asthma Childhood, Ledreborg Alle 34, DK-2820 Copenhagen, Denmark.	bisgaard@copsac.com	Larsen, Jeppe Madura/K-6518-2019; Bisgaard, Hans/N-4761-2016; Arendt, Morten/S-8843-2017; Rasmussen, Morten/AAE-9517-2020; Pedersen, Susanne Brix/B-3484-2009	Larsen, Jeppe Madura/0000-0003-1492-0708; Bisgaard, Hans/0000-0003-4131-7592; Arendt, Morten/0000-0001-7431-5206; Rasmussen, Morten/0000-0001-7431-5206; Pedersen, Susanne Brix/0000-0001-8951-6705; Thysen, Anna Hammerich/0000-0002-2914-1099	Lundbeck Foundation; Strategic Research Foundation; Pharmacy Foundation; Augustinus Foundation; Danish Medical Research Council; Danish Pediatric Asthma Centre; Danish Strategic Research Council; Danish State Budget; Capital Region of Denmark; Danish Council for Independent Research, Medical Sciences; Lundbeck Foundation [R16-2007-1694] Funding Source: researchfish	Lundbeck Foundation(Lundbeckfonden); Strategic Research Foundation; Pharmacy Foundation; Augustinus Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Pediatric Asthma Centre; Danish Strategic Research Council(Danske Strategiske Forskningsrad (DSF)); Danish State Budget; Capital Region of Denmark; Danish Council for Independent Research, Medical Sciences(Det Frie Forskningsrad (DFF)); Lundbeck Foundation(Lundbeckfonden)	The Copenhagen Prospective Studies on Asthma in Childhood (COPSAC) is funded by private and public research funds, all of which are listed at www.copsac.com. The Lundbeck Foundation, the Strategic Research Foundation, the Pharmacy Foundation of 1991, the Augustinus Foundation, the Danish Medical Research Council, and the Danish Pediatric Asthma Centre provided core support for COPSAC.; S. Brix has received research support from the Danish Strategic Research Council. H. Bisgaard has received research support from the Danish Strategic Research Council, the Lundbeck Foundation, the Danish State Budget, the Capital Region of Denmark, and the Danish Council for Independent Research, Medical Sciences. The rest of the authors declare that they have no relevant conflicts of interest.	Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Dubin PJ, 2008, IMMUNOL REV, V226, P160, DOI 10.1111/j.1600-065X.2008.00703.x; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Karakoc F, 2002, CLIN EXP ALLERGY, V32, P51, DOI 10.1046/j.0022-0477.2001.01273.x; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Ouyang WJ, 2011, ANNU REV IMMUNOL, V29, P71, DOI 10.1146/annurev-immunol-031210-101312; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Skytt N, 2012, J ALLERGY CLIN IMMUN, V130, P403, DOI 10.1016/j.jaci.2012.04.043; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Zhang Z, 2009, J CLIN INVEST, V119, P1899, DOI 10.1172/JCI36731	25	61	65	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1008	+		10.1016/j.jaci.2014.01.010	http://dx.doi.org/10.1016/j.jaci.2014.01.010			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24612682				2022-12-18	WOS:000333531700008
J	Holbrook, T; Keet, CA; Frischmeyer-Guerrerio, PA; Wood, RA				Holbrook, Teri; Keet, Corinne A.; Frischmeyer-Guerrerio, Pamela A.; Wood, Robert A.			Use of ondansetron for food protein-induced enterocolitis syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ORAL ONDANSETRON		[Holbrook, Teri; Keet, Corinne A.; Frischmeyer-Guerrerio, Pamela A.; Wood, Robert A.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA	Johns Hopkins University	Holbrook, T (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA.	rwood@jhmi.edu	Guerrerio, Pamela/S-9360-2019	Keet, Corinne/0000-0002-6585-239X				[Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Cheng A, 2011, PAED CHILD HEALT-CAN, V16, P177, DOI 10.1093/pch/16.3.177; Culy C R, 2001, Paediatr Drugs, V3, P441, DOI 10.2165/00128072-200103060-00007; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Ramsook C, 2002, ANN EMERG MED, V39, P397, DOI 10.1067/mem.2002.122706; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V115, P1	6	61	62	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1219	1220		10.1016/j.jaci.2013.06.021	http://dx.doi.org/10.1016/j.jaci.2013.06.021			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23890754				2022-12-18	WOS:000326235600026
J	Esparza-Gordillo, J; Schaarschmidt, H; Liang, LM; Cookson, W; Bauerfeind, A; Lee-Kirsch, MA; Nemat, K; Henderson, J; Paternoster, L; Harper, JI; Mangold, E; Nothen, MM; Ruschendorf, F; Kerscher, T; Marenholz, I; Matanovic, A; Lau, S; Keil, T; Bauer, CP; Kurek, M; Ciechanowicz, A; Macek, M; Franke, A; Kabesch, M; Hubner, N; Abecasis, G; Weidinger, S; Moffatt, M; Lee, YA				Esparza-Gordillo, Jorge; Schaarschmidt, Heidi; Liang, Liming; Cookson, William; Bauerfeind, Anja; Lee-Kirsch, Min-Ae; Nemat, Katja; Henderson, John; Paternoster, Lavinia; Harper, John I.; Mangold, Elisabeth; Nothen, Markus M.; Rueschendorf, Franz; Kerscher, Tamara; Marenholz, Ingo; Matanovic, Anja; Lau, Susanne; Keil, Thomas; Bauer, Carl-Peter; Kurek, Michael; Ciechanowicz, Andrzej; Macek, Milan; Franke, Andre; Kabesch, Michael; Hubner, Norbert; Abecasis, Goncalo; Weidinger, Stephan; Moffatt, Miriam; Lee, Young-Ae			A functional IL-6 receptor (IL6R) variant is a risk factor for persistent atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; persistent atopic dermatitis; prognosis; inflammation; soluble IL-6 receptor; single nucleotide polymorphism; longitudinal study; population-based cohort; candidate association study; genetic risk factor	ASTHMA; ASSOCIATION; DISEASE; BIRTH; CHILDREN; MECHANISMS; CHILDHOOD; MUTATIONS; BURDEN; ECZEMA	Background: Atopic dermatitis (AD) is a common inflammatory skin disease. Previous studies have revealed shared genetic determinants among different inflammatory disorders, suggesting that markers associated with immune-related traits might also play a role in AD. Objective: We sought to identify novel genetic risk factors for AD. Methods: We examined the results of all genome-wide association studies from a public repository and selected 318 genetic markers that were significantly associated with any inflammatory trait. These markers were considered candidates and tested for association with AD in a 3-step approach including 7 study populations with 7130 patients with AD and 9253 control subjects. Results: A functional amino acid change in the IL-6 receptor (IL-6R Asp358Ala; rs2228145) was significantly associated with AD (odds ratio [OR], 1.15; P = 5 x 10(-9)). Interestingly, investigation of 2 independent population-based birth cohorts showed that IL-6R 358Ala specifically predisposes to the persistent form of AD (ORpersistent AD = 1.22, P = .0008; ORtransient (AD) = 1.04, P = .54). This variant determines the balance between the classical membrane-bound versus soluble IL-6R signaling pathways. Carriers of 358Ala had increased serum levels of soluble IL-6R (P 5 4 3 10 214), with homozygote carriers showing a 2-fold increase. Moreover, we demonstrate that soluble IL-6R levels were higher in patients with AD than in control subjects (46.0 vs 37.8 ng/mL, P = .001). Additional AD risk variants were identified in RAD50, RUNX3, and ERBB3. Conclusion: Our study supports the importance of genetic variants influencing inflammation in the etiology of AD. Moreover, we identified a functional genetic variant in IL6R influencing disease prognosis and specifically predisposing to persistent AD.	[Esparza-Gordillo, Jorge; Kerscher, Tamara; Marenholz, Ingo; Matanovic, Anja; Lee, Young-Ae] Charite Univ Med Berlin, Pediat Allergol Expt & Clin Res Ctr, Berlin, Germany; [Esparza-Gordillo, Jorge; Bauerfeind, Anja; Rueschendorf, Franz; Kerscher, Tamara; Marenholz, Ingo; Matanovic, Anja; Hubner, Norbert; Lee, Young-Ae] Max Delbruck Ctr Mol Med, Berlin, Germany; [Schaarschmidt, Heidi; Franke, Andre] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany; [Liang, Liming] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Liang, Liming] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Cookson, William; Moffatt, Miriam] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Lee-Kirsch, Min-Ae; Nemat, Katja] Tech Univ Dresden, Klin Kinder & Jugendmed, Dresden, Germany; [Henderson, John; Paternoster, Lavinia] Univ Bristol, Dept Community Based Med, Bristol BS8 1TH, Avon, England; [Harper, John I.] Great Ormond St Hosp Sick Children, Dept Paediat Dermatol, London WC1N 3JH, England; [Mangold, Elisabeth; Nothen, Markus M.] Univ Bonn, Inst Human Genet, Bonn, Germany; [Nothen, Markus M.] Univ Bonn, Life & Brain Ctr, Dept Genom, Bonn, Germany; [Lau, Susanne] Charite, Berlin, Germany; [Keil, Thomas] Charite, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Bauer, Carl-Peter] Tech Univ Munich, Dept Pediat, D-80290 Munich, Germany; [Kurek, Michael] Pomeranian Med Univ, Dept Clin Allergol, Szczecin, Poland; [Ciechanowicz, Andrzej] Pomeranian Med Univ, Dept Lab Diagnost & Mol Med, Szczecin, Poland; [Macek, Milan] Charles Univ Prague, Med Sch & Fac 2, Hosp Motol, Dept Biol & Med Genet, Prague, Czech Republic; [Kabesch, Michael] Univ Childrens Hosp Regensburg KUNO, Dept Pediat Pneumol & Allergy, Regensburg, Germany; [Abecasis, Goncalo] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA; [Weidinger, Stephan] Univ Hosp Schleswig Holstein, Dept Dermatol Venereol & Allergy, Kiel, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Kiel; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Imperial College London; Technische Universitat Dresden; University of Bristol; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Bonn; University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Munich; Pomeranian Medical University; Pomeranian Medical University; Charles University Prague; Motol University Hospital; University of Michigan System; University of Michigan; University of Kiel; Schleswig Holstein University Hospital	Lee, YA (corresponding author), Charite Campus Buch, Pediat Allergol Expt & Clin Res Ctr, Lindenberger Weg 80, D-13125 Berlin, Germany.	yolee@mdc-berlin.de	Lee-Kirsch, Min Ae/C-5769-2018; Kabesch, Michael/AAB-5701-2020; Ciechanowicz, Andrzej/W-8594-2018; Kabesch, Michael/GZM-1583-2022; Cookson, William/HHC-1790-2022; Weidinger, Stephan/C-8461-2011; Franke, Andre/B-2151-2010; Paternoster, Lavinia/C-1292-2015	Ciechanowicz, Andrzej/0000-0002-3804-440X; Weidinger, Stephan/0000-0003-3944-252X; Franke, Andre/0000-0003-1530-5811; Paternoster, Lavinia/0000-0003-2514-0889; Abecasis, Goncalo/0000-0003-1509-1825; Nothen, Markus/0000-0002-8770-2464	German Ministry of Education and Research (BMBF); Wellcome Trust; ThermoFisher Scientific; Nutricia GmbH; Novartis Pharma AG; Bencard Allergie GmbH; UK Medical Research Council; European Union FP7 Programme; DFG; European Respiratory Society; EIAACI; American Thoracic Society; Novartis; GlaxoSmithKline; BMBF; European Union; BMBF-NGFN; Medical Research Council [MR/J012165/1, G0801056B, G9815508] Funding Source: researchfish; MRC [MR/J012165/1] Funding Source: UKRI	German Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Wellcome Trust(Wellcome Trust); ThermoFisher Scientific; Nutricia GmbH(Danone Nutricia); Novartis Pharma AG; Bencard Allergie GmbH; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union FP7 Programme; DFG(German Research Foundation (DFG)); European Respiratory Society; EIAACI; American Thoracic Society; Novartis(Novartis); GlaxoSmithKline(GlaxoSmithKline); BMBF(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); BMBF-NGFN(Federal Ministry of Education & Research (BMBF)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	J. Esparza-Gordillo, T. Kerscher, I. Marenholz, and A. Matanovic have received grants from the German Ministry of Education and Research (BMBF). W. Cookson and M. Moffatt have received grants from Wellcome Trust. K. Nemat has received payment for lectures from ThermoFisher Scientific, Nutricia GmbH, Novartis Pharma AG, HAL Allergy Group, and Bencard Allergie GmbH. J. Henderson has received grants from Wellcome Trust and UK Medical Research Council and has grants/grants pending from UK Medical Research Council and European Union FP7 Programme. M. M. Nothen is employed by the University of Bonn; has grants/grants pending with German Research Foundation (DFG), BMBF, and the National Institutes of Health; and has received payment for lectures, including service on speakers' bureaus, from Arztekammer Brandenburg. S. Lau has received grants from DFG, has consultant arrangements with Merck, and has received payment for lectures, including service on speakers' bureaus from SymbioPharm Euro. T. Keil has received grants from the DFG; is employed by Charite Berlin, Germany; and has grants/grants pending from EU MeDall and iFAAM. M. Macek has received grants from University Hospital Motol. M. Kabesch has received grants from the European Union, BMBF, and DFG; has received payment for lectures, including service on speakers' bureaus, for the European Respiratory Society, EIAACI, the American Thoracic Society, Novartis, and GlaxoSmithKline. N. Hubner has grants/grants pending from BMBF, European Union. S. Weidinger has received grants from BMBF-NGFN; is a board member for Astellas Atopic Dermatitis European Expert Committee and Novartis Study Board, Urticaria; has grants/grants pending from Excellence Cluster Inflammation at Interfaces, a grant from the Fritz Thyssen Stiftung, and two grants from DFG; and has received payment for lectures, including service on speakers' bureaus, for Novartis. Y.-A. Lee has received grants from BMBF and has grants/grants pending from DFG. The rest of the authors declare that they have no relevant conflicts of interest.	Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boyd A, 2012, INT J EPIDEMIOL; Carroll CL, 2005, PEDIATR DERMATOL, V22, P192, DOI 10.1111/j.1525-1470.2005.22303.x; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Estelle F, 2007, PEDIAT ALLERG IMM-UK, V18, P535, DOI 10.1111/j.1399-3038.2007.00558.x; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Galicia JC, 2004, GENES IMMUN, V5, P513, DOI 10.1038/sj.gene.6364120; Girolomoni G, 2003, ALLERGY, V58, P420, DOI 10.1034/j.1398-9995.2003.00112.x; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hawkins GA, 2012, J ALLERGY CLIN IMMUN, V130, P510, DOI 10.1016/j.jaci.2012.03.018; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jones SA, 2005, J IMMUNOL, V175, P3463, DOI 10.4049/jimmunol.175.6.3463; Krawczak M, 2006, COMMUNITY GENET, V9, P55, DOI 10.1159/000090694; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167, DOI 10.1067/mai.2000.107935; Margolis DJ, 2012, J ALLERGY CLIN IMMUN, V130, P912, DOI 10.1016/j.jaci.2012.07.008; Meding B, 2005, CONTACT DERMATITIS, V53, P308, DOI 10.1111/j.0105-1873.2005.00731.x; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; MULLBERG J, 1994, J IMMUNOL, V152, P4958; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Navarini AA, 2011, J ALLERGY CLIN IMMUN, V128, P1128, DOI 10.1016/j.jaci.2011.09.009; Patel AM, 2010, DRUG DES DEV THER, V4, P263, DOI 10.2147/DDDT.S14099; Peters AS, 2010, J ALLERGY CLIN IMMUN, V126, P590, DOI 10.1016/j.jaci.2010.06.020; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ridker PM, 2008, AM J HUM GENET, V82, P1185, DOI 10.1016/j.ajhg.2008.03.015; Schmitt J, 2010, J ALLERGY CLIN IMMUN, V125, P404, DOI 10.1016/j.jaci.2009.10.055; von Kobyletzki LB, 2012, BMC DERMATOL, V12, DOI 10.1186/1471-5945-12-11; Waetzig GH, 2012, EXPERT OPIN THER TAR, V16, P225, DOI 10.1517/14728222.2012.660307; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Zhernakova A, 2009, NAT REV GENET, V10, P43, DOI 10.1038/nrg2489	38	61	63	2	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					371	377		10.1016/j.jaci.2013.01.057	http://dx.doi.org/10.1016/j.jaci.2013.01.057			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	194KL	23582566				2022-12-18	WOS:000322631700014
J	Haddad, E; Leroy, S; Buckley, RH				Haddad, Elie; Leroy, Sandrine; Buckley, Rebecca H.			B-cell reconstitution for SCID: Should a conditioning regimen be used in SCID treatment?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; conditioning regimen; hematopoietic stem cell transplantation; B-cell function; immunoglobulin therapy	SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW-TRANSPLANTATION; TERM IMMUNE RECONSTITUTION; STEM-CELL; THYMIC OUTPUT; SINGLE-CENTER; DISEASE; ENGRAFTMENT; OUTCOMES	Bone marrow transplantation has resulted in life-saving sustained T-cell reconstitution in many infants with severe combined immunodeficiency (SCID), but correction of B-cell function has been more problematic. At the annual meeting of the Primary Immunodeficiency Treatment Consortium held in Boston, Massachusetts, on April 27, 2012, a debate was held regarding the use of pretransplantation conditioning versus no pretransplantation conditioning in an effort to address this problem. Reviews of the literature were made by both debaters, and there was agreement that there was a higher rate of B-cell chimerism and a lower number of patients who required ongoing immunoglobulin replacement therapy in centers that used pretransplantation conditioning. However, there were still patients who required immunoglobulin replacement in those centers, and therefore pretransplantation conditioning did not guarantee development of B-cell function. Dr Rebecca H. Buckley presented data on B-cell function according to the molecular defect of the patient, and showed that patients with IL-7 receptor alpha, ADA, and CD3 chain gene mutations can have normal B-cell function after transplantation with only host B cells. Dr Elie Haddad presented a statistical analysis of B-cell function in published reports and showed that only a conditioning regimen that contained busulfan was significantly associated with better B-cell function after transplantation. The question is whether the risk of immediate and long-term toxicity with use of busulfan is justified, particularly in patients with SCID with DNA repair defects and in very young newborns with SCID who will be detected by using newborn screening. (J Allergy Clin Immunol 2013; 131:994-1000.)	[Haddad, Elie] Univ Montreal, Dept Pediat, CHU St Justine Res Ctr, Montreal, PQ H3T 1C5, Canada; [Haddad, Elie] Univ Montreal, Dept Microbiol & Immunol, CHU St Justine Res Ctr, Montreal, PQ H3T 1C5, Canada; [Leroy, Sandrine] Inst Pasteur, Unit Epidemiol Emerging Dis, Paris, France; [Buckley, Rebecca H.] Duke Univ, Sch Med, Dept Pediat, Durham, NC USA; [Buckley, Rebecca H.] Duke Univ, Sch Med, Dept Immunol, Durham, NC USA	Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Duke University; Duke University	Haddad, E (corresponding author), Univ Montreal, Dept Pediat & Microbiol & Immunol, CHU St Justine Res Ctr, 3175 Chemin Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.	elie.haddad@umontreal.ca; buckL003@mc.duke.edu	Haddad, Elie/AAQ-4971-2020; Buckley, Rebecca/AAB-1578-2019	Haddad, Elie/0000-0003-2446-6879	U54 grant from the National Institute of Allergy and Infectious Diseases for the PIDTC [U54AI082973]; R13 grant [5R13AI094943]; National Institutes of Health (NIH); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI082973, R13AI094943] Funding Source: NIH RePORTER	U54 grant from the National Institute of Allergy and Infectious Diseases for the PIDTC; R13 grant; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a U54 grant U54AI082973 from the National Institute of Allergy and Infectious Diseases for the PIDTC, an R13 grant 5R13AI094943 in support of the 2012 annual meeting of the PIDTC, and the NIH Office of Rare Diseases Research of the National Center for Advancing Translational Sciences. E. H. is a scholar of the Fonds de Recherche en Sante du Quebec.; Disclosure of potential conflict of interest: R. H. Buckley has received grants from the National Institutes of Health (NIH), has received travel expenses from the NIH, has received fees for participation in review activities from the NIH, is employed by Duke University Medical Center, and has grants/grants pending from the NIH. E. Haddad and S. Leroy declare that they have no relevant conflicts of interest.	Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Bertrand Y, 1999, J PEDIATR-US, V134, P740, DOI 10.1016/S0022-3476(99)70291-X; Buckley RH, 2013, J CLIN IMMUNOL, V33, P96, DOI 10.1007/s10875-012-9797-6; Buckley RH, 2012, J ALLERGY CLIN IMMUN, V129, P597, DOI 10.1016/j.jaci.2011.12.964; Buckley RH, 2011, IMMUNOL RES, V49, P25, DOI 10.1007/s12026-010-8191-9; Buckley RH, 2010, J ALLERGY CLIN IMMUN, V125, P790, DOI 10.1016/j.jaci.2010.02.012; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DROR Y, 1993, BLOOD, V81, P2021; Dvorak CC, 2008, BIOL BLOOD MARROW TR, V14, P1125, DOI 10.1016/j.bbmt.2008.07.008; Friedrich W, 2007, IMMUNOL RES, V38, P165, DOI 10.1007/s12026-007-0030-2; Grunebaum E, 2006, JAMA-J AM MED ASSOC, V295, P508, DOI 10.1001/jama.295.5.508; Haddad E, 1999, BLOOD, V94, P2923, DOI 10.1182/blood.V94.8.2923.420k44_2923_2930; Haddad E, 1998, BLOOD, V91, P3646; HIMELSTEIN BP, 1993, J PEDIATR-US, V122, P289, DOI 10.1016/S0022-3476(06)80135-6; Koppelmans V, 2012, J CLIN ONCOL, V30, P1080, DOI 10.1200/JCO.2011.37.0189; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Neven B, 2009, BLOOD, V113, P4114, DOI 10.1182/blood-2008-09-177923; O'Marcaigh AS, 2001, BONE MARROW TRANSPL, V27, P703, DOI 10.1038/sj.bmt.1702831; OCHS HD, 1971, J CLIN INVEST, V50, P2559, DOI 10.1172/JCI106756; Patel NC, 2009, J ALLERGY CLIN IMMUN, V124, P1062, DOI 10.1016/j.jaci.2009.08.041; Patel NC, 2008, J ALLERGY CLIN IMMUN, V122, P1185, DOI 10.1016/j.jaci.2008.10.030; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; Recher M, 2011, BLOOD, V118, P6824, DOI 10.1182/blood-2011-06-362533; SANDERS JE, 1992, CURR CLIN O, P95; Sarzotti-Kelsoe M, 2009, BLOOD, V114, P1445, DOI 10.1182/blood-2009-01-199323; Slatter MA, 2008, J ALLERGY CLIN IMMUN, V121, P361, DOI 10.1016/j.jaci.2007.10.035; Titman P, 2008, BLOOD, V112, P3907, DOI 10.1182/blood-2008-04-151332; VANLEEUWEN JEM, 1994, BLOOD, V84, P3936, DOI 10.1182/blood.V84.11.3936.bloodjournal84113936	30	61	63	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					994	1000		10.1016/j.jaci.2013.01.047	http://dx.doi.org/10.1016/j.jaci.2013.01.047			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23465660	Green Accepted			2022-12-18	WOS:000317187200005
J	Solensky, R				Solensky, Roland			Allergy to beta-lactam antibiotics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CROSS-REACTIVITY; PENICILLIN; HISTORY; HYPERSENSITIVITY; RESENSITIZATION; CEPHALOSPORIN; CHILDREN; SAFETY		Corvallis Clin, Corvallis, OR 97330 USA		Solensky, R (corresponding author), Corvallis Clin, 3680 NW Samaritan Dr, Corvallis, OR 97330 USA.	roland.solensky@corvallisclinic.com						Apter AJ, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.10.052; Arroliga ME, 2003, INFECT CONT HOSP EP, V24, P347, DOI 10.1086/502212; Atanaskovic-Markovic M, 2009, J ALLERGY CLIN IMMUN, V124, P167, DOI 10.1016/j.jaci.2009.02.031; AUDICANA M, 1994, ALLERGY, V49, P108, DOI 10.1111/j.1398-9995.1994.tb00809.x; Daulat S, 2004, J ALLERGY CLIN IMMUN, V113, P1220, DOI 10.1016/j.jaci.2004.03.023; del Real GA, 2007, ANN ALLERG ASTHMA IM, V98, P355, DOI 10.1016/S1081-1206(10)60882-4; Frigas E, 2008, MAYO CLIN PROC, V83, P651, DOI 10.4065/83.6.651; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; Harris AD, 1999, AM J MED, V107, P166, DOI 10.1016/S0002-9343(99)00190-4; Hershkovich J, 2009, CLIN EXP ALLERGY, V39, P726, DOI 10.1111/j.1365-2222.2008.03180.x; Jost BC, 2006, ANN ALLERG ASTHMA IM, V97, P807, DOI 10.1016/S1081-1206(10)60973-8; Loo VG, 2005, NEW ENGL J MED, V353, P2442, DOI 10.1056/NEJMoa051639; Macy E, 2003, J ALLERGY CLIN IMMUN, V111, P1111, DOI 10.1067/mai.2003.1385; Macy E, 2002, ALLERGY, V57, P1151, DOI 10.1034/j.1398-9995.2002.23700.x; Macy Eric, 2009, Perm J, V13, P12; Martinez JA, 2003, ARCH INTERN MED, V163, P1905, DOI 10.1001/archinte.163.16.1905; Miranda A, 1996, J ALLERGY CLIN IMMUN, V98, P671, DOI 10.1016/S0091-6749(96)70101-X; Nadarajah K, 2005, ANN ALLERG ASTHMA IM, V95, P541, DOI 10.1016/S1081-1206(10)61016-2; Park M, 2006, ANN ALLERG ASTHMA IM, V97, P681, DOI 10.1016/S1081-1206(10)61100-3; Sade K, 2003, CLIN EXP ALLERGY, V33, P501, DOI 10.1046/j.1365-2222.2003.01638.x; Solensky R, 2002, ARCH INTERN MED, V162, P822, DOI 10.1001/archinte.162.7.822; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Torres MJ, 2001, ALLERGY, V56, P850, DOI 10.1034/j.1398-9995.2001.00089.x	24	61	63	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1442	+		10.1016/j.jaci.2012.08.021	http://dx.doi.org/10.1016/j.jaci.2012.08.021			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23195529				2022-12-18	WOS:000311641100040
J	Grad, R; Morgan, WJ				Grad, Roni; Morgan, Wayne J.			Long-term outcomes of early-onset wheeze and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; wheezing; lung function; airways hyperresponsiveness; atopy; outcomes; infancy; childhood; early onset	1ST 6 YEARS; INCREASED AIRWAY RESPONSIVENESS; LUNG-FUNCTION; CHILDHOOD ASTHMA; EARLY-LIFE; RHINOVIRUS ILLNESSES; RESPIRATORY ILLNESS; NATURAL-HISTORY; BIRTH COHORT; YOUNG-ADULTS	Evidence from longitudinal cohort studies demonstrates that wheezing that begins in early life and continues into the school years generally persists into adulthood. This persistent wheezing is associated with lung function deficits and airways hyperresponsiveness that appear to be established in the first few years of life. Allergic sensitization early in life, early-life infection with rhinovirus, or colonization with any of a number of bacteria have been associated with increased risk of persistent wheeze. Early life, whether in utero or in the first few years of life, presents a window of vulnerability during which airway injury results in persistent airways dysfunction. Available data further suggest that a second such window of vulnerability might be present in the preadolescent and adolescent years. Lung function growth patterns established by age 6 years generally continue into early adulthood to middle adulthood, typically leaving groups of subjects with wheezing that persists into or relapses during adulthood with a mean FEV1 of about 10% of predicted value less than their peers who do not wheeze. Subgroups of patients with persistent asthma, however, can have progressive decreases in lung function and enter adulthood with even lower lung function. The concern exists that these deficits in lung function apparent in early adulthood might put subjects at risk for the later development of chronic obstructive pulmonary disease. (J Allergy Clin Immunol 2012;130:299-307.)	[Grad, Roni] Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ 85724 USA; Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ 85724 USA	University of Arizona; University of Arizona	Grad, R (corresponding author), Univ Arizona, Coll Med, Dept Pediat, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	roni.grad@gmail.com			National Institutes of Health; Cystic Fibrosis Foundation; National Heart, Lung, and Blood Institute; American Academy of Allergy, Asthma Immunology; Elsevier; Genentech; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042268] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Academy of Allergy, Asthma Immunology; Elsevier; Genentech(Roche HoldingGenentech); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	R. Grad has received research support from the National Institutes of Health and is employed by the University of Arizona. W. J. Morgan has received research support from the National Institutes of Health, the Cystic Fibrosis Foundation, and the National Heart, Lung, and Blood Institute; has received consulting fees/honoraria and travel support from the American Academy of Allergy, Asthma & Immunology; has received travel support from Elsevier; has received consulting fees from Genentech and the Cystic Fibrosis Foundation; is employed by the University of Arizona; and has received textbook royalties from Elsevier.	Avila L, 2005, J ASTHMA, V42, P543, DOI 10.1080/02770900500214791; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Butland BK, 2007, ANN ALLERG ASTHMA IM, V98, P337, DOI 10.1016/S1081-1206(10)60879-4; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Forno E, 2012, J ALLERGY CLIN IMMUN; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P532, DOI 10.1016/j.jaci.2011.06.037; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Horak E, 2003, BRIT MED J, V326, P422, DOI 10.1136/bmj.326.7386.422; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Keil T, 2006, ALLERGY, V61, P1104, DOI 10.1111/j.1398-9995.2006.01167.x; Kurukulaaratchy RJ, 2003, EUR RESPIR J, V22, P767, DOI 10.1183/09031936.03.00005903; Kusel MMH, 2012, EUR RESPIR J, V39, P876, DOI 10.1183/09031936.00193310; Landrigan PJ, 2006, PEDIATRICS, V118, P2173, DOI 10.1542/peds.2006-0360; Lau S, 2003, EUR RESPIR J, V21, P834, DOI 10.1183/09031936.03.00037203; Limb SL, 2005, J ALLERGY CLIN IMMUN, V116, P1213, DOI 10.1016/j.jaci.2005.09.024; Limb SL, 2005, J ALLERGY CLIN IMMUN, V115, P61, DOI 10.1016/j.jaci.2004.09.032; Lodge CJ, 2011, J ALLERGY CLIN IMMUN, V128, P782, DOI 10.1016/j.jaci.2011.06.038; Marossy AE, 2007, AM J RESP CRIT CARE, V175, P355, DOI 10.1164/rccm.200607-1023OC; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1998, J ALLERGY CLIN IMMUN, V102, P915, DOI 10.1016/S0091-6749(98)70328-8; Martinez FD, 2011, J ALLERGY CLIN IMMUN, V128, P939, DOI 10.1016/j.jaci.2011.09.020; Martinez Fernando D, 2009, Proc Am Thorac Soc, V6, P272, DOI 10.1513/pats.200808-092RM; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Oostveen E, 2010, EUR RESPIR J, V35, P865, DOI 10.1183/09031936.00023409; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; Robinson PD, 2009, RESPIRATION, V78, P339, DOI 10.1159/000225373; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Strachan D, 1996, EUR RESPIR J, V9, pS42; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629, DOI 10.1164/ajrccm.154.6.8970346; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Torrent M, 2007, AM J RESP CRIT CARE, V176, P446, DOI 10.1164/rccm.200607-916OC; Turner SW, 2009, AM J RESP CRIT CARE, V179, P98, DOI 10.1164/rccm.200805-804OC; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; Weiss ST, 2000, AM J RESP CRIT CARE, V162, P50, DOI 10.1164/ajrccm.162.1.9811005; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	55	61	64	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					299	307		10.1016/j.jaci.2012.05.022	http://dx.doi.org/10.1016/j.jaci.2012.05.022			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22738675	Green Accepted			2022-12-18	WOS:000307002200007
J	James, KM; Peebles, RS; Hartert, TV				James, Kristina M.; Peebles, R. Stokes, Jr.; Hartert, Tina V.			Response to infections in patients with asthma and atopic disease: An epiphenomenon or reflection of host susceptibility?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; viral infections; bacterial infections; allergy; allergic rhinitis; atopic disease; immune function; immune system	RESPIRATORY SYNCYTIAL VIRUS; INVASIVE PNEUMOCOCCAL DISEASE; COMMUNITY-ACQUIRED PNEUMONIA; INNATE IMMUNE-RESPONSE; EPITHELIAL-CELLS; RISK-FACTORS; AIRWAY HYPERRESPONSIVENESS; MATERNAL SMOKING; DIESEL EXHAUST; POLYSACCHARIDE VACCINE	Associations between respiratory tract infections and asthma inception and exacerbations are well established. Infant respiratory syncytial virus and rhinovirus infections are known to be associated with an increased risk of asthma development, and among children with prevalent asthma, 85% of asthma exacerbations are associated with viral infections. However, the exact nature of this relationship remains unclear. Is the increase in severity of infections an epiphenomenon, meaning respiratory tract infections just appear to be more severe in patients with underlying respiratory disease, or instead a reflection of altered host susceptibility among persons with asthma and atopic disease? The main focus of this review is to summarize the available levels of evidence supporting or refuting the notion that patients with asthma or atopic disease have an altered susceptibility to selected pathogens, as well as discussing the biological mechanism or mechanisms that might explain such associations. Finally, we will outline areas in need of further research because understanding the relationships between infections and asthma has important implications for asthma prevention and treatment, including potential new pathways that might target the host immune response to select pathogens. (J Allergy Clin Immunol 2012;130:343-51.)	[James, Kristina M.; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Ctr Asthma & Environm Hlth Sci Res, Nashville, TN 37232 USA; [James, Kristina M.; Peebles, R. Stokes, Jr.; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hartert, TV (corresponding author), Vanderbilt Univ, Sch Med, Ctr Asthma & Environm Hlth Sci Res, 6107 Med Ctr E, Nashville, TN 37232 USA.	tina.hartert@vanderbilt.edu			National Institutes of Health; Merck Scientific Advisory Committee; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095227, K24AI077930] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Merck Scientific Advisory Committee; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	T. V. Hartert has received grants from the National Institutes of Health, has received consulting fees from the Merck Scientific Advisory Committee, has received fees for participation in review activities for the MedImmune Scientific Advisory Board for the REPORT study, and is employed by Vanderbilt University. The rest of the authors declare that they have no relevant conflicts of interest.	Ahn KM, 2005, J ASTHMA, V42, P745, DOI 10.1080/02770900500308023; Almirall J, 2008, EUR RESPIR J, V31, P1274, DOI 10.1183/09031936.00095807; Ansaldi F, 2005, J INT MED RES, V33, P490, DOI 10.1177/147323000503300503; Arkwright PD, 2000, CLIN EXP IMMUNOL, V122, P16, DOI 10.1046/j.1365-2249.2000.01338.x; Asquith KL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001339; Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Bramley AM, 1999, EUR RESPIR J, V14, P1061, DOI 10.1183/09031936.99.14510619; [Brigham and Women's hospital National Heart Lung and Blood Institute], RAND TRIAL MAT VIT D; Broeckaert F, 2000, ENVIRON HEALTH PERSP, V108, P533, DOI 10.2307/3454615; Cakebread JA, 2011, J ALLERGY CLIN IMMUN, V127, P1148, DOI 10.1016/j.jaci.2011.01.023; Cardozo DM, 2008, J MED MICROBIOL, V57, P185, DOI 10.1099/jmm.0.47470-0; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Chen S, 2007, J IMMUNOL, V179, P1634, DOI 10.4049/jimmunol.179.3.1634; Ciencewicki J, 2007, INHAL TOXICOL, V19, P1121, DOI 10.1080/08958370701665426; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Cunningham AF, 1998, EUR RESPIR J, V11, P345, DOI 10.1183/09031936.98.11020345; Dawood FS, 2011, PEDIATRICS, V128, pE27, DOI 10.1542/peds.2010-3343; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; DiFranza JR, 2004, PEDIATRICS, V113, P1007; DOYLE WJ, 1992, J ALLERGY CLIN IMMUN, V89, P968, DOI 10.1016/0091-6749(92)90219-R; Eldeirawi K, 2010, J ASTHMA, V47, P473, DOI 10.3109/02770901003759428; Fitzpatrick AM, 2008, J ALLERGY CLIN IMMUN, V121, P1372, DOI 10.1016/j.jaci.2008.03.008; Fitzpatrick AM, 2011, PEDIATR RES, V69, P154, DOI 10.1203/PDR.0b013e3182026370; Flohr C, 2009, CLIN EXP ALLERGY, V39, P20, DOI 10.1111/j.1365-2222.2008.03134.x; Foster S, 2003, IMMUNOLOGY, V108, P109, DOI 10.1046/j.1365-2567.2003.01539.x; Gern JE, 2008, PEDIATR INFECT DIS J, V27, pS97, DOI 10.1097/INF.0b013e318168b718; Gold DR, 2009, J ALLERGY CLIN IMMUN, V124, P1078, DOI 10.1016/j.jaci.2009.08.021; Gowdy K, 2008, TOXICOL APPL PHARM, V229, P310, DOI 10.1016/j.taap.2008.01.040; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Grigoryev DN, 2010, J ALLERGY CLIN IMMUN, V125, P153, DOI 10.1016/j.jaci.2009.10.024; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Han YY, 2009, PEDIAT ALLERG IMM-UK, V20, P748, DOI 10.1111/j.1399-3038.2009.00871.x; Hassantoufighi A, 2007, CLIN EXP IMMUNOL, V148, P218, DOI 10.1111/j.1365-2249.2007.03341.x; Henquell C, 2012, J CLIN VIROL, V53, P280, DOI 10.1016/j.jcv.2011.10.009; Hewson CA, 2010, EUR RESPIR J, V36, P1425, DOI 10.1183/09031936.00026910; Higaki S, 1999, INT J DERMATOL, V38, P265, DOI 10.1046/j.1365-4362.1999.00686.x; Hobson L, 2008, CLIN EXP IMMUNOL, V151, P359, DOI 10.1111/j.1365-2249.2007.03560.x; Isnard A, 2008, CURR GENOMICS, V9, P290, DOI 10.2174/138920208785133262; Jafri HS, 2004, J INFECT DIS, V189, P1856, DOI 10.1086/386372; Jaspers I, 2005, TOXICOL SCI, V85, P990, DOI 10.1093/toxsci/kfi141; Johnson TR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016458; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Juhn YJ, 2008, J ALLERGY CLIN IMMUN, V122, P719, DOI 10.1016/j.jaci.2008.07.029; Jung JA, 2010, J ALLERGY CLIN IMMUN, V125, P217, DOI 10.1016/j.jaci.2009.10.045; Kabesch M, 2004, CLIN EXP ALLERGY, V34, P340, DOI 10.1111/j.1365-2222.2004.01860.x; Karatekin G, 2009, EUR J CLIN NUTR, V63, P473, DOI 10.1038/sj.ejcn.1602960; KARMALI R, 1991, IMMUNOLOGY, V74, P589; Karmaus W, 2008, J ASTHMA, V45, P688, DOI 10.1080/02770900802178306; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Klemets P, 2010, THORAX, V65, P698, DOI 10.1136/thx.2009.132670; Kling S, 2005, CLIN EXP ALLERGY, V35, P672, DOI 10.1111/j.1365-2222.2005.02244.x; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Krasnowska Maryla, 1992, Archivum Immunologiae et Therapiae Experimentalis, V40, P75; Look DC, 2001, AM J PATHOL, V159, P2055, DOI 10.1016/S0002-9440(10)63057-X; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Lubbe J, 2003, AM J CLIN DERMATOL, V4, P641; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217, DOI 10.1016/S0091-6749(98)70386-0; MACEK V, 1994, AM J RESP CRIT CARE, V150, P7, DOI 10.1164/ajrccm.150.1.8025775; Macek V, 1999, Can Respir J, V6, P37; MacIntyre EA, 2010, PEDIATR INFECT DIS J, V29, pE96, DOI 10.1097/INF.0b013e3181fcd9e8; Malmstrom K, 2006, J ALLERGY CLIN IMMUN, V118, P591, DOI 10.1016/j.jaci.2006.04.032; Marin J, 2000, J INFECTION, V41, P69, DOI 10.1053/jinf.2000.0688; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563; Meyer EH, 2008, ANNU REV MED, V59, P281, DOI 10.1146/annurev.med.59.061506.154139; Miller EK, 2008, PEDIATRICS, V121, P1, DOI 10.1542/peds.2007-1053; Miller EK, 2012, AM J RESP CRIT CARE, V185, P508, DOI 10.1164/rccm.201108-1462OC; Miller EK, 2011, J ALLERGY CLIN IMMUN, V127, P883, DOI 10.1016/j.jaci.2010.11.041; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Morales E, 2012, EPIDEMIOLOGY, V23, P64, DOI 10.1097/EDE.0b013e31823a44d3; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Noakes PS, 2006, EUR RESPIR J, V28, P721, DOI 10.1183/09031936.06.00050206; Nuorti J. P., 2010, Morbidity and Mortality Weekly Report, V59, P1102; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; O'Regan GM, 2010, CLIN EXP ALLERGY, V40, P965, DOI 10.1111/j.1365-2222.2010.03522.x; O'Riordan S, 2010, CAN MED ASSOC J, V182, P39, DOI 10.1503/cmaj.091724; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517, DOI 10.1164/ajrccm.163.2.2004039; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Peebles RS, 2001, J MED VIROL, V63, P178, DOI 10.1002/1096-9071(20000201)63:2<178::AID-JMV1013>3.3.CO;2-F; Peisong G, 2004, GENES IMMUN, V5, P58, DOI 10.1038/sj.gene.6364030; Rezaee F, 2011, AM J RESP CELL MOL, V45, P277, DOI 10.1165/rcmb.2010-0121OC; Riedel F, 1997, EUR RESPIR J, V10, P639; RING J, 1992, ALLERGY, V47, P265, DOI 10.1111/j.1398-9995.1992.tb02051.x; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Runswick S, 2007, RESPIROLOGY, V12, P834, DOI 10.1111/j.1440-1843.2007.01175.x; Sadeghi K, 2006, EUR J IMMUNOL, V36, P361, DOI 10.1002/eji.200425995; Schafer T, 1997, J AM ACAD DERMATOL, V36, P550, DOI 10.1016/S0190-9622(97)70242-1; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Schwarze J, 2004, AM J RESP CRIT CARE, V169, P801, DOI 10.1164/rccm.200308-1203OC; Semple M, 2011, EUR RESP SOC ANN C N; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Sorkness RL, 1999, AM J RESP CRIT CARE, V160, P705, DOI 10.1164/ajrccm.160.2.9810002; Stefanaki C, 2010, INT J STD AIDS, V21, P723, DOI 10.1258/ijsa.2010.010225; Sutherland ER, 2010, J ALLERGY CLIN IMMUN, V126, P747, DOI 10.1016/j.jaci.2010.07.024; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Teepe J, 2010, EUR RESPIR J, V35, P1113, DOI 10.1183/09031936.00101509; Vinogradova Y, 2009, BRIT J GEN PRACT, V59, P742, DOI 10.3399/bjgp09X472629; Walter MJ, 2002, J CLIN INVEST, V110, P165, DOI 10.1172/JCI200214345; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wayse V, 2004, EUR J CLIN NUTR, V58, P563, DOI 10.1038/sj.ejcn.1601845; Williams JV, 1998, PEDIATR DERMATOL, V15, P194, DOI 10.1046/j.1525-1470.1998.1998015194.x; Wollenberg A, 2011, CLIN REV ALLERG IMMU, V41, P272, DOI 10.1007/s12016-010-8227-x; Wos M, 2008, AM J RESP CRIT CARE, V177, P1082, DOI 10.1164/rccm.200607-973OC; Wu Q, 2008, AM J RESP CRIT CARE, V177, P720, DOI 10.1164/rccm.200709-1387OC; Xatzipsaiti M, 2005, AM J RESP CRIT CARE, V172, P1037, DOI 10.1164/rccm.200502-315OC; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Zhang GC, 2009, AM J RESP CRIT CARE, V179, P205, DOI 10.1164/rccm.200803-438OC	116	61	64	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					343	351		10.1016/j.jaci.2012.05.056	http://dx.doi.org/10.1016/j.jaci.2012.05.056			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22846746	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000307002200012
J	Chu, SY; Horton, HM; Pong, E; Leung, IWL; Chen, H; Nguyen, DH; Bautista, C; Muchhal, US; Bernett, MJ; Moore, GL; Szymkowski, DE; Desjarlais, JR				Chu, Seung Y.; Horton, Holly M.; Pong, Erik; Leung, Irene W. L.; Chen, Hsing; Duc-Hanh Nguyen; Bautista, Cristina; Muchhal, Umesh S.; Bernett, Matthew J.; Moore, Gregory L.; Szymkowski, David E.; Desjarlais, John R.			Reduction of total IgE by targeted coengagement of IgE B-cell receptor and Fc gamma RIIb with Fc-engineered antibody	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; asthma; Fc epsilon RI; Fc gamma RIIb; humanized mice; IgE; inhibitory receptor; omalizumab; plasma cell; therapeutic antibody	ALLERGIC-ASTHMA; MONOCLONAL-ANTIBODIES; AFFINITY RECEPTOR; IMMUNOGLOBULIN-E; PLASMA-CELLS; MAST-CELLS; EPSILON-RI; IN-VIVO; THERAPY; INHIBITION	Background: Sequestration of IgE to prevent its binding to high-affinity IgE receptor Fc epsilon RI on basophils and mast cells is an effective therapy for allergic asthma. IgE production requires differentiation of activated IgE(+) B cells into plasma cells upon allergen sensitization. B-cell receptor signaling is suppressed by the inhibitory IgG Fc receptor Fc gamma RIIb; therefore, we reasoned that a therapeutic antibody that coengages Fc gamma RIIb and IgE B-cell receptor would not only sequester IgE but also suppress its production by blocking IgE(+) B-cell activation and differentiation to IgE-secreting plasma cells. Objective: To explore the effects of IgE sequestration versus IgE suppression by comparing omalizumab to Fc gamma RIIb-optimized anti-IgE antibodies in humanized mouse models of immunoglobulin production. Methods: By using a murine anti-IgE antibody as a template, we humanized, increased IgE binding, and modified its Fc domain to increase affinity for Fc gamma RIIb. We next compared effects of this antibody (XmAb7195) versus omalizumab on the secretion of IgE and other isotypes in human PBMC cultures and in PBMC-engrafted severe combined immunodeficiency mice. Results: Relative to omalizumab, XmAb7195 has a 5-fold higher affinity for human IgE and more than 400-fold higher affinity for Fc gamma RIIb. In addition to sequestering soluble IgE, XmAb7195 inhibited plasma cell differentiation and consequent human IgE production through coengagement of IgE B-cell receptor with Fc gamma RIIb. In PBMC-engrafted mice, XmAb7195 reduced total human IgE (but not IgG or IgM) levels by up to 40-fold relative to omalizumab. Conclusion: XmAb7195 acts by IgE sequestration coupled with an Fc gamma RIIb-mediated inhibitory mechanism to suppress the formation of IgE-secreting plasma cells and reduce both free and total IgE levels. (J Allergy Clin Immunol 2012; 129:1102-15.)	[Chu, Seung Y.; Horton, Holly M.; Pong, Erik; Leung, Irene W. L.; Chen, Hsing; Duc-Hanh Nguyen; Bautista, Cristina; Muchhal, Umesh S.; Bernett, Matthew J.; Moore, Gregory L.; Szymkowski, David E.; Desjarlais, John R.] Xencor Inc, Monrovia, CA USA		Szymkowski, DE (corresponding author), Xencor Inc, 111 W Lemon Ave, Monrovia, CA USA.	david.szymkowski@xencor.com		Szymkowski, David/0000-0002-8934-7902				Brightbill HD, 2010, J CLIN INVEST, V120, P2218, DOI 10.1172/JCI40141; Calame KL, 2003, ANNU REV IMMUNOL, V21, P205, DOI 10.1146/annurev.immunol.21.120601.141138; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Chu SY, 2008, MOL IMMUNOL, V45, P3926, DOI 10.1016/j.molimm.2008.06.027; Dharajiya N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009337; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Feichtner S, 2008, J IMMUNOL, V180, P5499, DOI 10.4049/jimmunol.180.8.5499; Fukuyama H, 2005, NAT IMMUNOL, V6, P99, DOI 10.1038/ni1151; Heyman B, 2003, IMMUNOL LETT, V88, P157, DOI 10.1016/S0165-2478(03)00078-6; Hochhaus G, 2003, CURR MED RES OPIN, V19, P491, DOI 10.1185/030079903125002171; HOOK WA, 1991, MOL IMMUNOL, V28, P631, DOI 10.1016/0161-5890(91)90132-4; Horton HM, 2008, CANCER RES, V68, P8049, DOI 10.1158/0008-5472.CAN-08-2268; Horton HM, 2011, J IMMUNOL, V186, P4223, DOI 10.4049/jimmunol.1003412; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; Jardieu PM, 1999, INT ARCH ALLERGY IMM, V118, P112, DOI 10.1159/000024043; KEEGAN AD, 1991, MOL IMMUNOL, V28, P1149, DOI 10.1016/0161-5890(91)90030-N; Kourtis G, 2010, J INVEST ALLERG CLIN, V20, P451; Lazar GA, 2007, MOL IMMUNOL, V44, P1986, DOI 10.1016/j.molimm.2006.09.029; Li FB, 2011, SCIENCE, V333, P1030, DOI 10.1126/science.1206954; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Moore GL, 2010, MABS-AUSTIN, V2, P181, DOI 10.4161/mabs.2.2.11158; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Ota T, 2009, J IMMUNOL, V182, P8110, DOI 10.4049/jimmunol.0900300; Pearson T, 2008, CURR TOP MICROBIOL, V324, P25; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PRESTA LG, 1993, J IMMUNOL, V151, P2623; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Richards JO, 2008, MOL CANCER THER, V7, P2517, DOI 10.1158/1535-7163.MCT-08-0201; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P308, DOI 10.1159/000237010; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P412, DOI 10.1159/000237058; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; TAKIZAWA F, 1992, J EXP MED, V176, P469, DOI 10.1084/jem.176.2.469; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Watanabe T, 2004, AM J RESP CRIT CARE, V169, P105, DOI 10.1164/rccm.200302-239OC; Xiang Z, 2007, NAT IMMUNOL, V8, P419, DOI 10.1038/ni1440	36	61	100	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1102	1115		10.1016/j.jaci.2011.11.029	http://dx.doi.org/10.1016/j.jaci.2011.11.029			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22257644				2022-12-18	WOS:000302144600027
J	Ruiter, B; Shreffler, WG				Ruiter, Bert; Shreffler, Wayne G.			The role of dendritic cells in food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dendritic cells; food allergy; innate immunity; T(H)2 differentiation; T(H)2 adjuvant; sensitization; tolerance; allergen-specific immunotherapy; Toll-like receptors; C-type lectin receptors	ANTIGEN-PRESENTING CELLS; IMMUNE-RESPONSES; EPITHELIAL-CELLS; ORAL TOLERANCE; T-CELLS; RETINOIC-ACID; IMMUNOTHERAPY; INDUCTION; INNATE; ADJUVANTS	In recent years, our understanding of the initiation of T(H)2-type immunity has increased significantly, yet the mechanism behind the induction of T(H)2 responses and allergic sensitization to food antigens largely remains an enigma. Dendritic cells (DCs) were first described almost 4 decades ago and have since been recognized as the most important antigen-presenting cells and crucial in the induction of T-cell differentiation. Here we discuss our current knowledge of the role of DCs in food allergy. In both murine models and allergic patients, characteristics of DCs have been identified that might play a role in sensitization to food and enhance susceptibility to food allergy. In addition, it has now been shown that several allergens, including some from foods, can directly activate DCs to induce T(H)2 skewing. Other cell types with innate immune functions, such as epithelial cells and basophils, might also be involved in sensing of food allergens in human subjects, and interaction of DCs with these cells might facilitate sensitization. DCs appear to play an important role in allergen-specific immunotherapy and could be an attractive target for tolerance induction in patients with food allergy. Further characterization of differences in DC responses between human food-allergic and nonallergic subjects is necessary to gain a better insight into the role of DCs in sensitization and tolerance to food allergens. (J Allergy Clin Immunol 2012;129:921-8.)	Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; Massachusetts Gen Hosp, Food Allergy Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ruiter, B (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Bldg 149,13th St, Charlestown, MA 02129 USA.	bruiter@partners.org; wshreffler@partners.org		Ruiter, Bert/0000-0003-3945-3202; Shreffler, Wayne/0000-0001-6465-137X	NCI NIH HHS [L40 CA117818] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Allam JP, 2010, J ALLERGY CLIN IMMUN, V126, P638, DOI 10.1016/j.jaci.2010.04.039; [Anonymous], 2010, J ALLERGY CLIN IMMUN, V126, pS5, DOI 10.1016/j.jaci.2010.10.007; Arques JL, 2008, MOL IMMUNOL, V45, P2177, DOI 10.1016/j.molimm.2007.12.004; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Behnecke A, 2009, J ALLERGY CLIN IMMUN, V124, P108, DOI 10.1016/j.jaci.2009.03.020; Blazquez AB, 2008, J IMMUNOL, V180, P4441, DOI 10.4049/jimmunol.180.7.4441; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Calderon MA, 2012, ALLERGY, V67, P302, DOI 10.1111/j.1398-9995.2011.02761.x; Cassani B, 2011, GASTROENTEROLOGY, V141, P2109, DOI 10.1053/j.gastro.2011.09.015; Cecilia M, 2008, J ALLERGY CLIN IMMUN, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Chambers SJ, 2004, IMMUNOLOGY, V112, P72, DOI 10.1111/j.1365-2567.2004.01846.x; Chen M, 2007, BLOOD, V109, P4360, DOI 10.1182/blood-2006-11-056424; Chen X, 2011, ALLERGY, V66, P1038, DOI 10.1111/j.1398-9995.2011.02585.x; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Dreschler K, 2011, J ALLERGY CLIN IMMUN, V127, P487, DOI 10.1016/j.jaci.2010.12.003; du Pre MF, 2011, ALLERGY, V66, P478, DOI 10.1111/j.1398-9995.2010.02519.x; Dunkin D, 2011, J ALLERGY CLIN IMMUN, V128, P1251, DOI 10.1016/j.jaci.2011.06.007; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Feng BS, 2008, J ALLERGY CLIN IMMUN, V122, P55, DOI 10.1016/j.jaci.2008.04.036; Frischmeyer-Guerrerio PA, 2011, CLIN EXP ALLERGY, V41, P61, DOI 10.1111/j.1365-2222.2010.03606.x; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Hall JA, 2011, IMMUNITY, V34, P435, DOI 10.1016/j.immuni.2011.03.003; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hilmenyuk T, 2010, IMMUNOLOGY, V129, P437, DOI 10.1111/j.1365-2567.2009.03199.x; Hsu SC, 2007, J ALLERGY CLIN IMMUN, V119, P1522, DOI 10.1016/j.jaci.2007.01.034; Hu J, 2011, IMMUNOLOGY, V132, P307, DOI 10.1111/j.1365-2567.2010.03396.x; Ilchmann A, 2010, J ALLERGY CLIN IMMUN, V125, P175, DOI 10.1016/j.jaci.2009.08.013; Iliev ID, 2009, MUCOSAL IMMUNOL, V2, P340, DOI 10.1038/mi.2009.13; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Iwasaki A, 2001, J IMMUNOL, V166, P4884, DOI 10.4049/jimmunol.166.8.4884; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Jyonouchi S, 2011, J ALLERGY CLIN IMMUN, V128, P102, DOI 10.1016/j.jaci.2011.02.026; Kool M, 2011, IMMUNITY, V35, P82, DOI 10.1016/j.immuni.2011.05.013; Koyasu S, 2011, IMMUNOLOGY, V132, P475, DOI 10.1111/j.1365-2567.2011.03413.x; Lebre MC, 2008, J ALLERGY CLIN IMMUN, V122, P969, DOI 10.1016/j.jaci.2008.08.028; Li DP, 2012, J EXP MED, V209, P109, DOI 10.1084/jem.20110399; Lombardi V, 2008, CLIN EXP ALLERGY, V38, P1819, DOI 10.1111/j.1365-2222.2008.03056.x; Maldonado RA, 2010, ADV IMMUNOL, V108, P111, DOI [10.1016/B978-0-12-380995-7.00004-5, 10.1016/S0065-2776(10)08004_1]; Man AL, 2004, J ALLERGY CLIN IMMUN, V113, P965, DOI 10.1016/j.jaci.2004.02.038; Manicassamy S, 2010, SCIENCE, V329, P849, DOI 10.1126/science.1188510; Mascarell L, 2007, VACCINE, V26, P108, DOI 10.1016/j.vaccine.2007.10.050; Masilamani M, 2011, J ALLERGY CLIN IMMUN, V128, P1242, DOI 10.1016/j.jaci.2011.05.009; Minnicozzi M, 2011, IMMUNOL REV, V242, P106, DOI 10.1111/j.1600-065X.2011.01025.x; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moingeon P, 2011, IMMUNOL ALLERGY CLIN, V31, P407, DOI 10.1016/j.iac.2011.03.001; Mousallem T, 2012, CLIN EXP IMMUNOL, V167, P26, DOI 10.1111/j.1365-2249.2011.04499.x; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Novak N, 2011, ALLERGY, V66, P22, DOI 10.1111/j.1398-9995.2011.02626.x; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, pe9; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Pochard P, 2010, J ALLERGY CLIN IMMUN, V126, P92, DOI 10.1016/j.jaci.2010.04.003; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Royer PJ, 2010, J IMMUNOL, V185, P1522, DOI 10.4049/jimmunol.1000774; Ruiter B, 2012, J ALLERGY CLIN IMMUN, V129, pAB243, DOI 10.1016/j.jaci.2011.12.043; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Smit JJ, 2011, CLIN EXP ALLERGY, V41, P890, DOI 10.1111/j.1365-2222.2011.03738.x; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Steinfelder S, 2009, J EXP MED, V206, P1681, DOI 10.1084/jem.20082462; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; Stoop JN, 2010, ARTHRITIS RHEUM-US, V62, P3656, DOI 10.1002/art.27756; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Takatsu K, 2009, ADV IMMUNOL, V101, P191, DOI 10.1016/S0065-2776(08)01006-7; Ternblay JN, 2007, J ALLERGY CLIN IMMUN, V120, P659, DOI 10.1016/j.jaci.2007.04.044; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x; Tversky JR, 2010, CLIN EXP ALLERGY, V40, P94, DOI 10.1111/j.1365-2222.2009.03388.x; Van Overtvelt L, 2008, INT ARCH ALLERGY IMM, V145, P152, DOI 10.1159/000108140; Van Overtvelt L, 2010, VACCINE, V28, P2986, DOI 10.1016/j.vaccine.2010.02.009; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; Wills-Karp M, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1.51.pe55; Yang PC, 2007, GASTROENTEROLOGY, V133, P1522, DOI 10.1053/j.gastro.2007.08.006; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhao CQ, 2010, ALLERGY, V65, P986, DOI 10.1111/j.1398-9995.2009.02295.x; Zhou YF, 2010, NAT MED, V16, P1128, DOI 10.1038/nm.2201	88	61	63	1	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					921	928		10.1016/j.jaci.2012.01.080	http://dx.doi.org/10.1016/j.jaci.2012.01.080			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22464669				2022-12-18	WOS:000302144600005
J	Patil, SP; Wang, J; Song, Y; Noone, S; Yang, N; Wallenstein, S; Sampson, HA; Li, XM				Patil, Sangita P.; Wang, Julie; Song, Ying; Noone, Sally; Yang, Nan; Wallenstein, Sylvan; Sampson, Hugh A.; Li, Xiu-Min			Clinical safety of Food Allergy Herbal Formula-2 (FAHF-2) and inhibitory effect on basophils from patients with food allergy: Extended phase I study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; Food Allergy Herbal Formula-2; basophil activation	HISTAMINE-RELEASING FACTOR; INDUCED ANAPHYLAXIS; ATOPIC-DERMATITIS; CD63 EXPRESSION; UP-REGULATION; DOUBLE-BLIND; MEDICINE; EFFICACY; TOLERABILITY; DIAGNOSIS	Background: Food allergy is a common and increasing health concern in westernized countries. No effective treatment is available, and accidental ingestion can be life-threatening. Food Allergy Herbal Formula-2 (FAHF-2) blocks peanut-induced anaphylaxis in a murine model of peanut-induced anaphylaxis. It was found to be safe and well tolerated in an acute phase I study of patients with food allergy. Objective: We sought to assess the safety of FAHF-2 in an extended phase I clinical trial and determine the potential effects on peripheral blood basophils from patients with food allergy. Methods: Patients in an open-label study received 3.3 g (6 tablets) of FAHF-2 three times a day for 6 months. Vital signs, physical examination results, laboratory data, pulmonary function test results, and electrocardiographic data were acquired at baseline and at 2-month intervals. During the course of the study, basophil activation and basophil and eosinophil numbers were evaluated by using CCR3/CD63 staining and flow cytometry. Results: Of 18 patients enrolled, 14 completed the study. No significant drug-associated differences in laboratory parameters, pulmonary function study results, or electrocardiographic findings before and after treatment were found. There was a significant reduction (P < .010) in basophil CD63 expression in response to ex vivo stimulation at month 6. There was also a trend toward a reduction in eosinophil and basophil numbers after treatment. Conclusion: FAHF-2 was safe and well tolerated and had an inhibitory effects on basophil numbers in an extended phase I clinical study. A controlled phase II study is warranted. (J Allergy Clin Immunol 2011;128:1259-65.)	[Patil, Sangita P.; Wang, Julie; Song, Ying; Noone, Sally; Yang, Nan; Sampson, Hugh A.; Li, Xiu-Min] Mt Sinai Sch Med, Div Pediat Allergy & Immunol, New York, NY 10029 USA; [Wallenstein, Sylvan] Mt Sinai Sch Med, Dept Prevent Med, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Li, XM (corresponding author), Mt Sinai Sch Med, Div Pediat Allergy & Immunol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	xiu-min.li@mssm.edu	Song, Ying/C-9949-2013; li, xiu/GXV-1745-2022	Song, Ying/0000-0001-7735-4008; 	Winston Wolkoff Integrative Medicine for Allergy and Immunology Foundation; National Institutes of Health [1R01AT001495-01A1, 2R01AT001495-05A1]; Food Allergy Initiative (FAI); National Institutes of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH); National Institutes of Health/National Institute of Allergy and Infectious Diseases [K23 AI083883]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI083883] Funding Source: NIH RePORTER	Winston Wolkoff Integrative Medicine for Allergy and Immunology Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food Allergy Initiative (FAI); National Institutes of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by the Food Allergy Initiative, the Winston Wolkoff Integrative Medicine for Allergy and Immunology Foundation, and National Institutes of Health grant 1R01AT001495-01A1 and 2R01AT001495-05A1 awarded to X.-M. Li. J.W. is funded in part by a grant from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (K23 AI083883).; H. A. Sampson is a consultant for Allertein Therapeutics, LLC; has received research support from the Food Allergy Initiative (FAI) and the National Institutes of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH); is a consultant and scientific advisor for the FAI; is a medical advisor for the Food Allergy & Anaphylaxis Network (FAAN); is a scientific advisor for the University of Nebraska FARRP; and is 45% owner of Herbal Springs, LLC. X.-M. Li has a consultant for the FAI; is a shareholder of Herbal Springs, LLC; and has received research support from the FAI and NIH. The rest of the authors have declared that they have no conflict of interest.	BANKS JR, 1986, J ALLERGY CLIN IMMUN, V78, P51, DOI 10.1016/0091-6749(86)90114-4; Barg W, 2008, J INVEST ALLERG CLIN, V18, P312; Bensky D, 1990, CHINESE HERBAL MED F; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Chan CK, 2006, PEDIAT ALLERG IMM-UK, V17, P316, DOI 10.1111/j.1399-3038.2006.00406.x; Chang TT, 2006, PHYTOTHER RES, V20, P342, DOI 10.1002/ptr.1843; Ducrest S, 2005, ALLERGY, V60, P1446, DOI 10.1111/j.1398-9995.2005.00910.x; Ebo DG, 2007, CYTOM PART B-CLIN CY, V72B, P196, DOI 10.1002/cyto.b.20142; FRANKLIN HR, 1994, ANN ONCOL, V5, P113, DOI 10.1093/oxfordjournals.annonc.a058760; Hausmann OV, 2011, ALLERGY, V66, P85, DOI 10.1111/j.1398-9995.2010.02431.x; Hon KLE, 2007, BRIT J DERMATOL, V157, P357, DOI 10.1111/j.1365-2133.2007.07941.x; Hsu CH, 2005, PEDIATR ALLERGY IMMU, V16, P76, DOI 10.1111/j.1399-3038.2005.00230.x; Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Kahlert H, 2008, INT ARCH ALLERGY IMM, V145, P193, DOI 10.1159/000109288; Kao ST, 2000, ALLERGY, V55, P1127, DOI 10.1034/j.1398-9995.2000.00728.x; Kepley CL, 2000, J IMMUNOL, V165, P5913, DOI 10.4049/jimmunol.165.10.5913; Kim EH, 2011, J ALLERGY CLIN IMMUN, V127, P640, DOI 10.1016/j.jaci.2010.12.1083; Li XM, 2009, CURR OPIN ALLERGY CL, V9, P161, DOI 10.1097/ACI.0b013e328329226f; Li XM, 2009, J ALLERGY CLIN IMMUN, V123, P297, DOI 10.1016/j.jaci.2008.12.026; Moneret-Vautrin DA, 1999, ANN ALLERG ASTHMA IM, V82, P33, DOI 10.1016/S1081-1206(10)62657-9; Nagao M, 2008, INT ARCH ALLERGY IMM, V146, P47, DOI 10.1159/000126061; Ocmant A, 2009, CLIN EXP ALLERGY, V39, P1234, DOI 10.1111/j.1365-2222.2009.03292.x; Ocmant A, 2007, J IMMUNOL METHODS, V320, P40, DOI 10.1016/j.jim.2006.12.002; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.12.1128, 10.1016/j.jaci.2008.09.051]; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Song Y, 2010, J ALLERGY CLIN IMMUN, V126, P1208, DOI 10.1016/j.jaci.2010.09.013; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; US Food and Drug Administration, 2004, GUID IND BOT DRUG PR; Vonakis BM, 2001, J ALLERGY CLIN IMMUN, V108, P822, DOI 10.1067/mai.2001.119159; Wang JL, 2007, CLIN EXP ALLERGY, V37, P651, DOI 10.1111/j.1365-2222.2007.02682.x; Wang JL, 2010, ANN ALLERG ASTHMA IM, V105, P75, DOI 10.1016/j.anai.2010.05.005; Wen MC, 2005, J ALLERGY CLIN IMMUN, V116, P517, DOI 10.1016/j.jaci.2005.05.029	36	61	67	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1259	U602		10.1016/j.jaci.2011.06.015	http://dx.doi.org/10.1016/j.jaci.2011.06.015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21794906	Green Accepted, Bronze			2022-12-18	WOS:000298342700015
J	Mushtaq, N; Ezzati, M; Hall, L; Dickson, I; Kirwan, M; Png, KMY; Mudway, IS; Grigg, J				Mushtaq, Naseem; Ezzati, Majid; Hall, Lucinda; Dickson, Iain; Kirwan, Michael; Png, Ken M. Y.; Mudway, Ian S.; Grigg, Jonathan			Adhesion of Streptococcus pneumoniae to human airway epithelial cells exposed to urban particulate matter	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Urban particulate matter; Streptococcus pneumoniae; adhesion; A549; primary human bronchial epithelial cells	HOSPITAL ADMISSIONS; OXIDATIVE STRESS; PARTICLES; POLLUTION; RECEPTOR; CHILDREN; INVASION; PM10; NEIGHBORHOODS; ASSOCIATION	Background: Epidemiologic studies report an association between pneumonia and urban particulate matter (PM) less than 10 microns (mu m) in aerodynamic diameter (PM10). Streptococcus pneumoniae is a common cause of bacterial pneumonia worldwide. To date, the mechanism whereby urban PM enhances vulnerability to S pneumoniae infection is unclear. Adhesion of S pneumoniae to host cells is a prerequisite for infection. Host-expressed proteins, including the receptor for platelet-activating factor (PAFR), are co-opted by S pneumoniae to adhere to lower airway epithelial cells. Objectives: To define whether inhalable urban PM enhances the adhesion of S pneumoniae to airway epithelial cells. Methods: A549 cells were cultured with PM10 from Leicester (United Kingdom [UK]) and PM10 and PM less than 2.5 mu m in aerodynamic diameter (PM2.5) from Accra (Ghana), then infected with S pneumoniae strain D39. Pneumococcal adhesion to human primary bronchial epithelial cells was also assessed. Bacterial adhesion was determined by quantitative culture and confocal microscopy. The role of oxidative stress was assessed by N-acetyl cysteine, and the role of PAFR was assessed by mRNA transcript level, receptor expression, and receptor blocking. Results: PM10 (UK) increased S pneumoniae adhesion to both A549 airway epithelial cells and human primary bronchial epithelial cells. PM10 (Ghana) and PM2.5 (Ghana) also increased adhesion. Culture of A549 cells by PM10 (UK) increased PAFR mRNA transcript level and PAFR expression. PM10 (UK)-stimulated adhesion to A549 cells was attenuated by a PAFR blocker and N-acetyl cysteine. Conclusion: Urban PM increases adhesion of S pneumoniae to human airway epithelial cells. PM-stimulated adhesion is mediated by oxidative stress and PAFR. (J Allergy Clin Immunol 2011;127:1236-42.)	[Grigg, Jonathan] Queen Mary Univ London, Ctr Paediat, Blizard Inst Cell & Mol Sci, Barts & London Sch Med & Dent, London E1 2AT, England; [Png, Ken M. Y.] Queen Mary Univ London, NanoVis Ctr, Sch Engn & Mat Sci, London E1 2AT, England; [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, London, England; [Mudway, Ian S.] Kings Coll London, Pharmaceut Sci Res Div, Sch Biomed & Hlth Sci, London WC2R 2LS, England	University of London; Queen Mary University London; University of London; Queen Mary University London; Imperial College London; University of London; King's College London	Grigg, J (corresponding author), Queen Mary Univ London, Ctr Paediat, Blizard Inst Cell & Mol Sci, Barts & London Sch Med & Dent, 4 Newark St, London E1 2AT, England.	j.grigg@qmul.ac.uk		Mudway, Ian/0000-0003-1239-5014; Grigg, Jonathan/0000-0003-3109-6028	Queen Mary University London; US National Science Foundation; Medical Research Council [G0801056B] Funding Source: researchfish	Queen Mary University London; US National Science Foundation(National Science Foundation (NSF)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by Queen Mary University London.; Disclosure of potential conflict of interest: M. Ezzati receives research support from the US National Science Foundation. The rest of the authors have declared that they have no conflict of interest.	Adedeji A, 2004, THORAX, V59, P542; [Anonymous], AIR QUALITY EUROPE; Arku RE, 2008, SCI TOTAL ENVIRON, V402, P217, DOI 10.1016/j.scitotenv.2008.04.042; Avadhanula V, 2006, J VIROL, V80, P1629, DOI 10.1128/JVI.80.4.1629-1636.2006; Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; Brown DM, 2007, AM J PHYSIOL-LUNG C, V292, pL1444, DOI 10.1152/ajplung.00162.2006; Bunn HJ, 2001, THORAX, V56, P932, DOI 10.1136/thorax.56.12.932; Calcabrini A, 2004, ENVIRON RES, V95, P82, DOI 10.1016/j.envres.2003.07.011; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; Cohen AJ., 2004, COMP QUANTIFICATION, P1353; Colbeck I, 2010, INDOOR AIR, V20, P40, DOI 10.1111/j.1600-0668.2009.00624.x; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Dherani M, 2008, B WORLD HEALTH ORGAN, V86, P390, DOI 10.2471/BLT.07.044529; Dionisio KL, 2010, ENVIRON SCI TECHNOL, V44, P2270, DOI 10.1021/es903276s; Donaldson K, 2003, FREE RADICAL BIO MED, V34, P1369, DOI 10.1016/S0891-5849(03)00150-3; Donaldson K, 2005, PART FIBRE TOXICOL, V2, DOI 10.1186/1743-8977-2-10; Farha Talal, 2005, Paediatr Respir Rev, V6, P76, DOI 10.1016/j.prrv.2005.03.001; Hammerschmidt S, 2005, INFECT IMMUN, V73, P4653, DOI 10.1128/IAI.73.8.4653-4667.2005; Isaacs KK, 2006, J AEROSOL MED, V19, P344, DOI 10.1089/jam.2006.19.344; Ishizuka S, 2001, AM J RESP CELL MOL, V24, P459, DOI 10.1165/ajrcmb.24.4.4248; Kim YJ, 2009, RESP MED, V103, P757, DOI 10.1016/j.rmed.2008.11.011; Kocbach A, 2005, SCI TOTAL ENVIRON, V346, P231, DOI 10.1016/j.scitotenv.2004.10.025; LeVan TD, 1997, BIOCHEM PHARMACOL, V54, P1007, DOI 10.1016/S0006-2952(97)00249-9; MacNee W, 2003, EUR RESPIR J, V21, p47S, DOI 10.1183/09031936.03.00403203; Medina-Ramon M, 2006, AM J EPIDEMIOL, V163, P579, DOI 10.1093/aje/kwj078; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mudway IS, 2005, PART FIBRE TOXICOL, V2, DOI 10.1186/1743-8977-2-6; Neupane B, 2010, AM J RESP CRIT CARE, V181, P47, DOI [10.1164/rccm.200901-0160oc, 10.1164/rccm.200901-0160OC]; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; Okada N, 1998, MICROBIOL-SGM, V144, P3079, DOI 10.1099/00221287-144-11-3079; OsornioVargas AR, 1996, AM J PHYSIOL-LUNG C, V271, pL93, DOI 10.1152/ajplung.1996.271.1.L93; Rhoden CR, 2004, TOXICOL SCI, V79, P296, DOI 10.1093/toxsci/kfh122; Rijneveld AW, 2004, J INFECT DIS, V189, P711, DOI 10.1086/381392; Sehlstedt M, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-21; Sigaud S, 2007, TOXICOL APPL PHARM, V223, P1, DOI 10.1016/j.taap.2007.04.014; Suzuki M, 2009, THORAX, V64, P484, DOI 10.1136/thx.2008.106385; van der Poll T, 2009, LANCET, V374, P1543, DOI 10.1016/S0140-6736(09)61114-4; Wardlaw T, 2006, LANCET, V368, P1048, DOI 10.1016/S0140-6736(06)69334-3; Weidenmaier C, 2008, NAT REV MICROBIOL, V6, P276, DOI 10.1038/nrmicro1861; Wilson R, 1996, EUR RESPIR J, V9, P1523, DOI 10.1183/09031936.96.09071523	41	61	62	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1236	U536		10.1016/j.jaci.2010.11.039	http://dx.doi.org/10.1016/j.jaci.2010.11.039			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21247619				2022-12-18	WOS:000290018600019
J	Holt, PG; Strickland, DH				Holt, Patrick G.; Strickland, Deborah H.			Interactions between innate and adaptive immunity in asthma pathogenesis: New perspectives from studies on acute exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; innate immunity; viral injection; dendritic cells; regulatory T cells	REGULATORY T-CELLS; ALLERGIC AIRWAY INFLAMMATION; THYMIC STROMAL LYMPHOPOIETIN; FC-EPSILON-RI; PLASMACYTOID DENDRITIC CELLS; AFFINITY IGE RECEPTOR; HOUSE-DUST MITE; EPITHELIAL-CELLS; RESPIRATORY-INFECTIONS; HOSPITAL ADMISSIONS	Asthma is a complex multigenic disease. The most frequently encountered form is atopic asthma, which is at its highest prevalence during childhood/young adulthood, and this represents the main focus of this review. The primary risk factor for atopic asthma is sensitization to perennial aeroallergens resulting from a failure to generate protective immunologic tolerance. This tolerance process is orchestrated by airway mucosal dendritic cells and normally results in programming of regulatory T cells, which inhibit activation of the T(H)2 memory cells that, among other activities, drive IgE production and prime the effector populations responsible for IgE-mediated tissue damage. Emerging evidence highlights the complexity of this process, in particular the iterative nature of the underlying interactions between innate and adaptive immune mechanisms in which virtually every signal emanating from one cellular compartment provokes an answering response from the other. To further complicate this picture, the local mesenchyme can also interpose signals to fine tune immune responses to optimally meet local microenvironmental needs. Perturbation of the balance between these interlinked innate and adaptive immune pathways is increasingly believed to be the basis for disease expression, and in the specific case of atopic asthma, the prototypic example of this (discussed below) is acute exacerbations triggered by viral infections. (J Allergy Clin Immunol 2010;125:963-72.)	[Holt, Patrick G.] Univ Western Australia, Div Cell Biol, Telethon Inst Child Hlth Res, Perth, WA 6872, Australia; Univ Western Australia, Ctr Child Hlth Res, Fac Med & Dent, Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Holt, PG (corresponding author), Univ Western Australia, Div Cell Biol, Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.	patrick@ichr.uwa.edu.au	Strickland, Deborah/AGV-6937-2022; Holt, Patrick G/H-1548-2011; strickland, deborah/K-4597-2019	Strickland, Deborah/0000-0003-0114-4201; Holt, Patrick G/0000-0003-1193-0935; 	National Health and Medical Research Council	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Work in the authors' laboratory is funded by the National Health and Medical Research Council.	Akbar AN, 2007, NAT REV IMMUNOL, V7, P231, DOI 10.1038/nri2037; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; ALBAS ABV, 1981, J EXP MED, V154, P235; ALBLAS ABV, 1979, J EXP MED, V149, P1504, DOI DOI 10.1004/JEM.149.6.1504; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373, DOI 10.4049/jimmunol.178.6.3373; Bosco A, 2009, J IMMUNOL, V182, P6011, DOI 10.4049/jimmunol.0804125; COME JM, 2002, LANCET, V359, P831; Cyr MM, 2001, CURR OPIN IMMUNOL, V13, P727, DOI 10.1016/S0952-7915(01)00286-2; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002; Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Goswami S, 2009, NAT IMMUNOL, V10, P496, DOI 10.1038/ni.1719; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; HARNMAD H, 2008, NAT REV IMMUNOL, V8, P193; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Hollams EM, 2009, J ALLERGY CLIN IMMUN, V124, P463, DOI 10.1016/j.jaci.2009.06.019; Holt PG, 2008, NAT REV IMMUNOL, V8, P142, DOI 10.1038/nri2236; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P255, DOI 10.1111/j.1365-2222.1989.tb02380.x; HOLT PG, 1994, J IMMUNOL, V153, P256; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Hung LY, 2008, CRIT REV IMMUNOL, V28, P269, DOI 10.1615/CritRevImmunol.v28.i4.10; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Jahnsen FL, 2006, J IMMUNOL, V177, P5861, DOI 10.4049/jimmunol.177.9.5861; Joetham A, 2007, J IMMUNOL, V178, P1433, DOI 10.4049/jimmunol.178.3.1433; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kearley J, 2008, J ALLERGY CLIN IMMUN, V122, P617, DOI 10.1016/j.jaci.2008.05.048; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Koraka P, 2003, J MED VIROL, V70, P91, DOI 10.1002/jmv.10358; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lee JH, 2007, CLIN EXP IMMUNOL, V148, P53, DOI 10.1111/j.1365-2249.2007.03329.x; Leech MD, 2007, J IMMUNOL, V179, P7050, DOI 10.4049/jimmunol.179.10.7050; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Lin YL, 2008, ALLERGY, V63, P67, DOI 10.1111/j.1398-9995.2007.01526.x; Maggi L, 2007, J ALLERGY CLIN IMMUN, V120, P429, DOI 10.1016/j.jaci.2007.05.002; Mahnke K, 2003, BLOOD, V101, P4862, DOI 10.1182/blood-2002-10-3229; MAURER D, 1995, J IMMUNOL, V154, P6285; Mcgee HS, 2009, AM J RESP CRIT CARE, V180, P211, DOI 10.1164/rccm.200809-1505OC; McWilliam AS, 1997, J VIROL, V71, P226, DOI 10.1128/JVI.71.1.226-236.1997; MCWILLIAM AS, 1994, J EXP MED, V179, P1331, DOI 10.1084/jem.179.4.1331; MOSMANN TR, 1994, SCIENCE, V265, P193, DOI 10.1126/science.8023139; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nakagome K, 2005, J IMMUNOL, V174, P6955, DOI 10.4049/jimmunol.174.11.6955; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Oriss TB, 2005, J IMMUNOL, V174, P854, DOI 10.4049/jimmunol.174.2.854; Papadopoulos NG, 2007, ALLERGY, V62, P457, DOI 10.1111/j.1398-9995.2007.01341.x; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785, DOI 10.1164/ajrccm.159.3.9801052; Rate A, 2009, J IMMUNOL, V182, P72, DOI 10.4049/jimmunol.182.1.72; Robays LJ, 2007, J IMMUNOL, V178, P5305, DOI 10.4049/jimmunol.178.8.5305; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Semper AE, 2003, J ALLERGY CLIN IMMUN, V112, P411, DOI 10.1067/mai.2003.1626; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Shevach EM, 2009, IMMUNITY, V30, P636, DOI 10.1016/j.immuni.2009.04.010; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P317; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Tamachi T, 2006, J ALLERGY CLIN IMMUN, V118, P606, DOI 10.1016/j.jaci.2006.04.051; Terashima A, 2008, J EXP MED, V205, P2727, DOI 10.1084/jem.20080698; Tiemessen MM, 2004, J ALLERGY CLIN IMMUN, V113, P932, DOI 10.1016/j.jaci.2003.12.016; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1046/j.1365-2222.1996.1095481.x; Vermaelen K, 2003, AM J RESP CELL MOL, V29, P405, DOI 10.1165/rcmb.2003-0008OC; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang YH, 2009, CLIN EXP ALLERGY, V39, P798, DOI 10.1111/j.1365-2222.2009.03241.x; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Weber KSC, 2001, EUR J IMMUNOL, V31, P2458, DOI 10.1002/1521-4141(200108)31:8<2458::AID-IMMU2458>3.3.CO;2-C; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; WELLIVER RC, 1982, J PEDIATR-US, V101, P889, DOI 10.1016/S0022-3476(82)80005-X; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Xatzipsalti M, 2008, CLIN EXP ALLERGY, V38, P466, DOI 10.1111/j.1365-2222.2007.02906.x; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	98	61	67	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					963	972		10.1016/j.jaci.2010.02.011	http://dx.doi.org/10.1016/j.jaci.2010.02.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20394979				2022-12-18	WOS:000277686700002
J	Caldwell, JM; Blanchard, C; Collins, MH; Putnam, PE; Kaul, A; Aceves, SS; Bouska, CA; Rothenberg, ME				Caldwell, Julie M.; Blanchard, Carine; Collins, Margaret H.; Putnam, Philip E.; Kaul, Ajay; Aceves, Seema S.; Bouska, Catherine A.; Rothenberg, Marc E.			Glucocorticoid-regulated genes in eosinophilic esophagitis: A role for FKBP51	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Glucocorticoids; eosinophilic esophagitis; FKBP51; IL-13; esophageal epithelial cells	FLUTICASONE PROPIONATE; IMMUNOPHILIN FKBP51; EPITHELIAL-CELLS; SQUIRREL-MONKEY; EXPRESSION; RESISTANCE; CHILDREN; OVEREXPRESSION; RECEPTOR; BIOAVAILABILITY	Background: Eosinophilic esophagitis (EE) involves marked accumulation of eosinophils in the esophageal mucosa that responds to swallowed fluticasone propionate (FP) in a subset of patients. Objectives: We aimed to uncover the mechanism of action of swallowed FP in patients with EE by providing evidence for a topical effect in the esophagus by identifying a molecular signature for FP exposure in vivo. Methods: Global microarray expression profiles, immunofluorescence microscopy, and cell signaling in esophageal tissue and cell lines were analyzed. Results: Thirty-two transcripts exhibited altered expression in patients who responded to swallowed FP treatment. Esophageal FK506-binding protein 5 (FKBP51) mRNA levels were increased (P<.05) in FP responders compared with those seen in control subjects and patients with untreated active EE. After FP treatment of esophageal epithelial cells, FKBP51 mRNA and protein levels were increased in a dose- and time-dependent manner by FP treatment in vitro. FP-induced FKBP51 was steroid receptor dependent because RU486 completely inhibited gene and protein induction. The half-life of FKBP51 mRNA was 16 to 18 hours independent of FP treatment. FKBP51 overexpression reduced FP action as assessed by FP inhibition of IL-13-induced eotaxin-3 promoter activity. Conclusions: Our results suggest that swallowed glucocorticoid treatment directly affects esophageal gene expression in patients with EE. In particular, increased FKBP51 transcript levels identify glucocorticoid exposure in vivo and distinguish FP responders from untreated patients with active EE and patients without EE. In addition, FKBP51 reduces glucocorticoid-mediated inhibition of IL-13 signaling in epithelial cells in vitro, suggesting that FKBP51 might influence FP responsiveness. We propose that esophageal FKBP51 levels have diagnostic and prognostic significance in patients with EE. (J Allergy Clin Immunol 2010;125:879-88.)	[Caldwell, Julie M.; Blanchard, Carine; Bouska, Catherine A.; Rothenberg, Marc E.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Coll Med, Cincinnati, OH 45229 USA; [Collins, Margaret H.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Pathol & Lab Med, Coll Med, Cincinnati, OH 45229 USA; [Aceves, Seema S.] Univ Calif San Diego, Rady Childrens Hosp, Div Allergy, San Diego, CA 92103 USA; [Aceves, Seema S.] Univ Calif San Diego, Rady Childrens Hosp, Div Immunol, San Diego, CA 92103 USA; [Aceves, Seema S.] Univ Calif San Diego, Rady Childrens Hosp, Div Pediat, San Diego, CA 92103 USA; [Aceves, Seema S.] Univ Calif San Diego, Rady Childrens Hosp, Div Med, San Diego, CA 92103 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of California System; University of California San Diego	Rothenberg, ME (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org			National Institutes of Health [RO1 DK76893, U19 A1070235]; American Heart Association [09POST2180041]; Food Allergy Project; Campaign Urging Research for Eosinophilic Disorders (CURED); Buckeye Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083450, U19AI070235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076893] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Food Allergy Project; Campaign Urging Research for Eosinophilic Disorders (CURED); Buckeye Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported in part by National Institutes of Health grant RO1 DK76893 and U19 A1070235, American Heart Association grant 09POST2180041, the Food Allergy Project, the Campaign Urging Research for Eosinophilic Disorders (CURED), and the Buckeye Foundation.; Disclosure of potential conflict of interest: J. M. Caldwell has received a postdoctoral grant from the American Heart Association. C. Blanchard has received research support from the National Institutes of Health. the Digestive Health Center CCHMC. and the American Partnership for Eosinophilic Disorders. M. H. Collins was a subcontractor as a clinical study central review pathologist for GlaxoSmithKline and Ception Therapeutics; was a consultant as a clinical study central review pathologist for Meritage Pharma; and is a Member of the Medical Advisory Panel for the American Partnership for Eosinophilic Diseases. S. S. Aceves has intellectual property patent royalties in Meritage Pharma and is on the Medical Advisory Board for the American Partnership for Eosinophilic Disorders, M. E. Rothenberg is a speaker and consultant for Merck; is a consultant for Centocor, Ception Therapeutics, Nycomed, and Array Biopharmra; has received research support from the National Institutes of Health, the Food Allergy and Anaphylaxis Network, and the Dana Foundation; is on the Medical Advisory Board for the American Partnership for Eosinophilic Disorders; and is on the Executive Council for the International Eosinophil Society. The rest of the authors have declared that they have no conflict of interest.	Baughman G, 1997, BIOCHEM BIOPH RES CO, V232, P437, DOI 10.1006/bbrc.1997.6307; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2005, INT J BIOCHEM CELL B, V37, P2559, DOI 10.1016/j.biocel.2005.06.010; Blanchard Carine, 2008, Gastrointest Endosc Clin N Am, V18, P133, DOI 10.1016/j.giec.2007.09.016; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Falcoz C, 2000, CLIN PHARMACOKINET, V39, P9, DOI 10.2165/00003088-200039001-00002; Franciosi JP, 2009, CLIN GASTROENTEROL H, V7, P415, DOI 10.1016/j.cgh.2008.10.006; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; GOLOLOBOVA M T, 1970, Byulleten' Eksperimental'noi Biologii i Meditsiny, V69, P97; Gunin AG, 1999, J GASTROENTEROL, V34, P661, DOI 10.1007/s005350050316; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; Hubler TR, 2004, CELL STRESS CHAPERON, V9, P243, DOI 10.1379/CSC-32R.1; Kino T, 2002, J ALLERGY CLIN IMMUN, V109, P609, DOI 10.1067/mai.2002. 123708; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Matsukura S, 2004, INT ARCH ALLERGY IMM, V134, P12, DOI 10.1159/000077787; MENARD D, 1987, ANAT REC, V217, P348, DOI 10.1002/ar.1092170405; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Scammell JG, 2001, GEN COMP ENDOCR, V124, P152, DOI 10.1006/gcen.2001.7696; Schaefer ET, 2008, CLIN GASTROENTEROL H, V6, P165, DOI 10.1016/j.cgh.2007.11.008; Schleimer Robert P, 2004, Proc Am Thorac Soc, V1, P222, DOI 10.1513/pats.200402-018MS; SCHWIEBERT LM, 1995, CELL IMMUNOL, V165, P12, DOI 10.1006/cimm.1995.1181; SHULL S, 1983, J BIOL CHEM, V258, P3364; Stellato C, 2007, J ALLERGY CLIN IMMUN, V120, P1247, DOI 10.1016/j.jaci.2007.10.041; Vermeer H, 2003, J CLIN ENDOCR METAB, V88, P277, DOI 10.1210/jc.2002-020354; Wan YH, 2002, MOL ENDOCRINOL, V16, P1204, DOI 10.1210/me.16.6.1204; Westberry JM, 2006, J STEROID BIOCHEM, V100, P34, DOI 10.1016/j.jsbmb.2006.03.004; Wochnik GM, 2005, J BIOL CHEM, V280, P4609, DOI 10.1074/jbc.M407498200; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; ZBORALSKE FF, 1984, IN VITRO CELL DEV B, V20, P109, DOI 10.1007/BF02626651	32	61	64	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					879	888		10.1016/j.jaci.2010.01.038	http://dx.doi.org/10.1016/j.jaci.2010.01.038			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20371398	Green Accepted			2022-12-18	WOS:000276787900014
J	Jin, C; Focke, M; Leonard, R; Jarisch, R; Altmann, F; Hemmer, W				Jin, Chunsheng; Focke, Margarete; Leonard, Renaud; Jarisch, Reinhart; Altmann, Friedrich; Hemmer, Wolfgang			Reassessing the role of hyaluronidase in yellow jacket venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alpha 1,3-Fucose; cross-reactive carbohydrate determinants; honeybee; hyaluronidase; Hymenoptera; N-linked glycans; venom allergy; Vespula species; yellow jacket	ANTIGENIC CROSS-REACTIVITY; N-LINKED OLIGOSACCHARIDES; HYMENOPTERA VENOM; BEE VENOM; CARBOHYDRATE DETERMINANTS; PROTEIN ALLERGENS; DOUBLE POSITIVITY; IMMUNOGLOBULIN-E; MAJOR ALLERGENS; INSECT CELLS	Background: Yellow jacket hyaluronidase (YJ-HYA) is considered a major allergen in yellow jacket allergy. It shows 50% homology with the hyaluronidase from honeybee venom, Api m 2. Recently, IgE binding to YJ-HYA and cross-reactivity with Api in 2 has been shown to be due to cross-reactive carbohydrate determinants (CCDs). Objective: We sought to quantify the importance of YJ-HYA in yellow jacket allergy and the cross-reactivity with Api in 2 by discriminating between carbohydrate and peptide epitopes. Methods: IgE binding to Vespula species venom was studied by means of Western blotting in 136 patients with yellow jacket allergy (31 in vitro single positive to yellow jacket venom and 105 in vitro double-positive to yellow jacket-honeybee). Inhibition studies were carried out with MUXF-BSA (isolated bromelain glycopeptides linked to bovine serum albumin) and purified Api in 2. Results: Among yellow jacket single-positive sera, only I of 31 bound with YJ-HYA, whereas this was the case in 87% of 105 double-positive sera. Of 83 patients in whom inhibitions were performed, 65% reacted with hyaluronidase through CCDs alone, 27% reacted with both CCDs and peptide epitopes, and 8% reacted only with the hyaluronidase peptide. The protein-specific reactivity with YJ-HYA was cross-inhibited by Api in 2 in 48% (14/29). Antigen 5 and phospholipase A, were each recognized by around 90% of sera from both groups, together identifying 97% of patients. Conclusion: Hyaluronidase is a minor yellow jacket venom allergen, and only 10% to 15% of patients with yellow jacket allergy are estimated to have IgE against the hyaluronidase protein. Peptide-specific cross-reactivity with Api in 2 occurs in half of these sera. Component-resolved diagnosis with antigen 5 and phospholipase would detect virtually all patients with yellow jacket venom allergy. (J Allergy Clin Immunol 2010;125:184-90.)	[Jarisch, Reinhart; Hemmer, Wolfgang] FAZ Floridsdorf Allergy Ctr, A-1210 Vienna, Austria; [Jin, Chunsheng; Leonard, Renaud; Altmann, Friedrich] Univ Nat Resources & Appl Life Sci, Dept Chem, Vienna, Austria; [Focke, Margarete] Med Univ Vienna, Inst Pathophysiol, Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; Medical University of Vienna	Hemmer, W (corresponding author), FAZ Floridsdorf Allergy Ctr, Franz Jonas Pl 8-6, A-1210 Vienna, Austria.	science@faz.at		Altmann, Friedrich/0000-0002-0112-7877; Leonard, Renaud/0000-0001-5023-1032	FAZ-Floridsdorf Allergy Centre; Austrian Science Foundation [S8803]	FAZ-Floridsdorf Allergy Centre; Austrian Science Foundation(Austrian Science Fund (FWF))	Supported by the FAZ-Floridsdorf Allergy Centre and grant S8803 from the Austrian Science Foundation.	Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; Egner W, 1998, CLIN EXP ALLERGY, V28, P26, DOI 10.1046/j.1365-2222.1998.00176.x; Hemmer W, 2004, CLIN EXP ALLERGY, V34, P460, DOI 10.1111/j.1365-2222.2004.01897.x; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1980, ANN ALLERGY, V45, P276; Hoffman DR, 2006, CLIN REV ALLERG IMMU, V30, P109, DOI 10.1385/CRIAI:30:2:109; HOFFMAN DR, 1986, J ALLERGY CLIN IMMUN, V78, P337, DOI 10.1016/S0091-6749(86)80086-0; HOFFMAN DR, 1984, J ALLERGY CLIN IMMUN, V74, P93, DOI 10.1016/0091-6749(84)90094-0; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Jin C, 2008, J ALLERGY CLIN IMMUN, V121, P185, DOI 10.1016/j.jaci.2007.07.047; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; KEMENY DM, 1984, EUR J BIOCHEM, V139, P217, DOI 10.1111/j.1432-1033.1984.tb07997.x; Kemparaju K, 2006, CELL BIOCHEM FUNCT, V24, P7, DOI 10.1002/cbf.1261; Kettner A, 1999, CLIN EXP ALLERGY, V29, P394, DOI 10.1046/j.1365-2222.1999.00492.x; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1983, MOL IMMUNOL, V20, P297, DOI 10.1016/0161-5890(83)90069-X; King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3; Kochuyt AM, 2005, CLIN EXP ALLERGY, V35, P441, DOI 10.1111/j.1365-2222.2005.02217.x; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; Kolarich D, 2005, FEBS J, V272, P5182, DOI 10.1111/j.1742-4658.2005.04841.x; Kolarich D, 2007, PROTEOMICS, V7, P1615, DOI 10.1002/pmic.200600800; KUBELKA V, 1995, GLYCOCONJUGATE J, V12, P77, DOI 10.1007/BF00731872; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; LU G, 1995, J BIOL CHEM, V270, P4457, DOI 10.1074/jbc.270.9.4457; Mari A, 2002, INT ARCH ALLERGY IMM, V129, P286, DOI 10.1159/000067591; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Muller U, 1997, CLIN EXP ALLERGY, V27, P915, DOI 10.1111/j.1365-2222.1997.tb01233.x; Muller UR, 2002, ALLERGY, V57, P570, DOI 10.1034/j.1398-9995.2002.02157.x; Muller UR., 1990, INSECT STING ALLERGY; Skov LK, 2006, ACTA CRYSTALLOGR D, V62, P595, DOI 10.1107/S0907444906010687; Soldatova LN, 1998, J ALLERGY CLIN IMMUN, V101, P691, DOI 10.1016/S0091-6749(98)70179-4; Soldatova LN, 2007, ALLERGY ASTHMA PROC, V28, P210, DOI 10.2500/aap.2007.28.2947; Tomiya N, 2004, GLYCOCONJUGATE J, V21, P343, DOI 10.1023/B:GLYC.0000046275.28315.87; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; WYPYCH JI, 1989, INT ARCH ALLER A IMM, V89, P60, DOI 10.1159/000234924	38	61	63	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					184	190		10.1016/j.jaci.2009.08.037	http://dx.doi.org/10.1016/j.jaci.2009.08.037			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	544MG	19910026				2022-12-18	WOS:000273660500022
J	Zeller, S; Rhyner, C; Meyer, N; Schmid-Grendelmeier, P; Akdis, CA; Crameri, R				Zeller, Sabine; Rhyner, Claudio; Meyer, Norbert; Schmid-Grendelmeier, Peter; Akdis, Cezrini A.; Crameri, Reto			Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic eczema; autoreactivity; self-antigens; IgE; mediator release; atopic dermatitis	CELL-MEDIATED AUTOIMMUNITY; SERUM IGE; CRYSTAL-STRUCTURE; CROSS-REACTIVITY; CDNA-CLONES; ALLERGEN; IDENTIFICATION; DERMATITIS; PROTEIN; KERATINOCYTES	Background: Atopic eczema (AE) is the most common chronic inflammatory skin disease. Recent data demonstrate the presence of autoreactive serum IgE antibodies correlating with the severity of the disease. Objective: Although several IgE-binding self-antigens have been reported, the whole repertoire of IgE-binding self-antigens is unknown. We aimed to estimate the repertoire size of autoreactive proteins related to AE and clone, produce, and characterize humoral and T-cell responses against novel self-antigens. Methods: Phage surface-displayed human cDNA libraries were enriched for clones binding to serum IgE from patients with AE and screened by using high-throughput technology. Selected clones were used to produce the encoded proteins, to test their IgE-binding ability in Western blots and ELISAs, and their ability to induce mediator release from basophils of sensitized individuals. Results: One hundred forty sequences encoding potential IgE-binding self-antigens associated with AE were identified. Sixteen sequences encoded already described self-antigens. Three new sequences showed homology with environmental allergens, 86 encoded known human proteins, 7 predicted proteins, and 28 showed sequence identity with genomic contigs. Immunoblotting and ELISA experiments demonstrated the presence of IgE antibodies in sera from patients with AE to 5 selected recombinant self-antigens and their ability to induce mediator release from basophils of patients with AE who have self-antigen-specific IgE antibodies. Conclusion: These data demonstrate a broad spectrum of at least 140 IgE-binding self-antigens associated with AE. By binding IgE antibodies or activating specific T cells, they might promote, perpetuate, or both existing skin inflammation. (J Allergy Clin Immunol 2009;124:278-85.)	[Zeller, Sabine; Rhyner, Claudio; Meyer, Norbert; Akdis, Cezrini A.; Crameri, Reto] Univ Zurich, Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; [Meyer, Norbert] Deutsch Hochgebirgsklin, Davos, Switzerland; [Schmid-Grendelmeier, Peter] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; University of Zurich; University Zurich Hospital	Crameri, R (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	crameri@siaf.uzh.ch	Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X	Swiss National Science Foundation [31-63381.00/2, 310000-114634/1]; OPO-Pharma Foundation, Zurich, Switzerland	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); OPO-Pharma Foundation, Zurich, Switzerland	Supported by Swiss National Science Foundation grants 31-63381.00/2 and 310000-114634/1 and by the OPO-Pharma Foundation, Zurich, Switzerland.	Akdis CA, 2006, ALLERGY, V61, P969, DOI 10.1111/j.1398-9995.2006.01153.x; Altrichter S, 2008, J INVEST DERMATOL, V128, P2232, DOI 10.1038/jid.2008.80; Appenzeller U, 1999, INT ARCH ALLERGY IMM, V118, P193, DOI 10.1159/000024064; Buhring HJ, 2004, INT ARCH ALLERGY IMM, V133, P317, DOI 10.1159/000077351; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; Crowe J, 1994, Methods Mol Biol, V31, P371; Dingermann Theo, 2008, Biotechnology Journal, V3, P90, DOI 10.1002/biot.200700214; Fluckiger S, 2002, J IMMUNOL, V168, P1267, DOI 10.4049/jimmunol.168.3.1267; Fluckiger S, 2002, EUR J IMMUNOL, V32, P10, DOI 10.1002/1521-4141(200201)32:1<10::AID-IMMU10>3.0.CO;2-I; Glaser AG, 2006, BIOCHEM J, V396, P41, DOI 10.1042/BJ20051708; HAMPTON STANLEY F., 1941, JOUR ALLERGY, V13, P63, DOI 10.1016/S0021-8707(41)90008-4; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Harbers M, 2008, GENOMICS, V91, P232, DOI 10.1016/j.ygeno.2007.11.004; Hemmann S, 1998, CLIN EXP ALLERGY, V28, P860, DOI 10.1046/j.1365-2222.1998.00329.x; Ichikawa S, 1998, J BIOL CHEM, V273, P356, DOI 10.1074/jbc.273.1.356; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kodzius R, 2003, COMB CHEM HIGH T SCR, V6, P147, DOI 10.2174/1386207033329751; Limacher A, 2007, J IMMUNOL, V178, P389, DOI 10.4049/jimmunol.178.1.389; MAIER E, 1994, J BIOTECHNOL, V35, P191, DOI 10.1016/0168-1656(94)90035-3; Mayer C, 1999, J EXP MED, V189, P1507, DOI 10.1084/jem.189.9.1507; Mittermann I, 2008, J INVEST DERMATOL, V128, P1451, DOI 10.1038/sj.jid.5701195; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; Natter S, 1998, FASEB J, V12, P1559, DOI 10.1096/fasebj.12.14.1559; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; PEARSON WR, 1991, GENOMICS, V11, P635, DOI 10.1016/0888-7543(91)90071-L; Rhyner C, 2004, METHODS, V32, P212, DOI 10.1016/j.ymeth.2003.08.003; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Sehra S, 2008, CRIT REV IMMUNOL, V28, P15, DOI 10.1615/CritRevImmunol.v28.i1.20; Simon F, 1944, J ALLERGY, V15, P338, DOI DOI 10.1016/S0021-8707(44)90143-7; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Sudheer PS, 2005, ANAESTHESIA, V60, P251, DOI 10.1111/j.1365-2044.2004.04086.x; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Weichel M, 2006, J ALLERGY CLIN IMMUN, V117, P676, DOI 10.1016/j.jaci.2005.11.040; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56, DOI 10.1159/000236803; Wopfner N, 2007, IMMUNOL ALLERGY CLIN, V27, P29, DOI 10.1016/j.iac.2006.10.003; Zeller S, 2008, INT ARCH ALLERGY IMM, V145, P87, DOI 10.1159/000108133	40	61	63	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					278	285		10.1016/j.jaci.2009.05.015	http://dx.doi.org/10.1016/j.jaci.2009.05.015			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19541355				2022-12-18	WOS:000268860400014
J	Rondon, C; Dona, I; Torres, MJ; Campo, P; Blanca, M				Rondon, Carmen; Dona, Inmaculada; Torres, Maria J.; Campo, Paloma; Blanca, Miguel			Evolution of patients with nonallergic rhinitis supports conversion to allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; comorbidities; evolution; nonallergic; quality of life; rhinitis	IDIOPATHIC RHINITIS; NASAL CHALLENGES; ASTHMA; IGE; PREVALENCE; ABSENCE; EPIDEMIOLOGY; COMMUNITY; GA(2)LEN; MUCOSAL	Background: Nonallergic rhinitis (NAR) affects a significant number of patients in clinical practice. However, the different entities involved within NAR require further study. Once allergy has been ruled out, most of these patients are not usually followed up in allergy clinics, despite the persistence of rhinitis symptoms. Thus few data are available concerning the natural evolution of these patients. Objective: We sought to re-evaluate over time the severity, accompanying disorders, and possible allergen sensitizations in subjects with NAR. Methods: A representative sample of 180 patients given diagnoses of NAR during 2000-2004 was re-evaluated in 2007 by using sociodemographic and clinical questionnaires, spirometry, skin prick testing, and measurement of specific IgE to common aeroallergens. Results: Patients with NAR generally experienced worsening disease (52%), with an increase in the persistence (12%) and severity of nasal symptoms (9%) and new comorbidities (24%) over time. The most frequent comorbidities at the re-evaluation were asthma (increasing from 32% to 55%) and conjunctivitis (from 28% to 43%), followed by chronic rhinosinusitis. Sensitization to aeroallergens not present at the initial evolution was detected by means of skin prick testing, serum specific IgE measurement, or both in 24% of the patients. Conclusions: Persistent moderate-to-severe rhinitis associated with asthma, conjunctivitis, or both and sensitization to aeroallergens are likely to appear at a later date in adults initially given diagnoses of NAR. A periodic re-evaluation of these patients might therefore be necessary. (J Allergy Clin Immunol 2009;123:1098-102.)	[Rondon, Carmen; Dona, Inmaculada; Torres, Maria J.; Campo, Paloma; Blanca, Miguel] Carlos Haya Hosp, Allergy Serv, Malaga, Spain	Hospital Carlos Haya	Rondon, C (corresponding author), Hosp Civil, Allergy Serv, Pabellon 6,Plaza Hosp Civil, Malaga 29009, Spain.	carmenrs61@gmail.com	Torres, Maria/GVU-3391-2022; Torres, María José/T-3518-2017	Torres, María José/0000-0001-5228-471X; RONDON SEGOVIA, CARMEN/0000-0003-0976-3402				Amin K, 2001, J ALLERGY CLIN IMMUN, V107, P249, DOI 10.1067/mai.2001.112266; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Bachert C, 2006, ALLERGY, V61, P693, DOI 10.1111/j.1398-9995.2006.01054.x; Berger G, 2007, ARCH OTOLARYNGOL, V133, P78, DOI 10.1001/archotol.133.1.78; Bodtger U, 2006, ALLERGY, V61, P712, DOI 10.1111/j.1398-9995.2006.01140.x; Bousquet J, 2008, ALLERGY, V63, P842, DOI 10.1111/j.1398-9995.2008.01715.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Braat JPM, 1998, AM J RESP CRIT CARE, V157, P1748, DOI 10.1164/ajrccm.157.6.9701016; Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Demoly P., 2003, MIDDLETONS ALLERGY P, P631; FOKKENS W, 2007, RHINOL S, V20, P1; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; Jessen M, 1997, ALLERGY, V52, P3, DOI 10.1111/j.1398-9995.1997.tb04876.x; KAM KL, 1994, ANN ALLERGY, V73, P329; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; LINDBERG S, 1993, ALLERGY, V48, P602, DOI 10.1111/j.1398-9995.1993.tb00756.x; Molgaard E, 2007, ALLERGY, V62, P1033, DOI 10.1111/j.1398-9995.2007.01355.x; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Nash DB, 2000, AM J MANAG CARE, V6, pS3; PEDERSEN PA, 1981, ALLERGY, V36, P375, DOI 10.1111/j.1398-9995.1981.tb01841.x; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Rondon C, 2008, ALLERGY, V63, P1352, DOI 10.1111/j.1398-9995.2008.01695.x; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Scadding GK, 2007, CLIN EXP ALLERGY, V37, P485, DOI 10.1111/j.1365-2222.2007.02675.x; Schatz M, 2007, ALLERGY, V62, P9, DOI 10.1111/j.1398-9995.2007.01548.x; Settipane Russell A, 2007, Clin Allergy Immunol, V19, P23; Van Wijk R. Gerth, 1994, Rhinology (Utrecht), V32, P119; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; Vignola AM, 1998, ALLERGY, V53, P833, DOI 10.1111/j.1398-9995.1998.tb03988.x; Wierzbicki DA, 2008, ANN ALLERG ASTHMA IM, V100, P533, DOI 10.1016/S1081-1206(10)60051-8; WRIGHT AL, 1994, PEDIATRICS, V94, P895	37	61	74	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1098	1102		10.1016/j.jaci.2009.02.018	http://dx.doi.org/10.1016/j.jaci.2009.02.018			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19361848				2022-12-18	WOS:000266309400018
J	McLean-Tooke, A; Barge, D; Spickett, GP; Gennery, AR				McLean-Tooke, Andrew; Barge, Dawn; Spickett, Gavin P.; Gennery, Andrew R.			Immunologic defects in 22q11.2 deletion syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						22q11.2 deletion syndrome; DiGeorge syndrome; lymphocyte count; autoimmunity; regulatory T cells; memory B cells	T-CELL HOMEOSTASIS; SELECTIVE IGM DEFICIENCY; DIGEORGE-SYNDROME; VELOCARDIOFACIAL SYNDROME; GENE-EXPRESSION; IMMUNE-RESPONSE; THYMIC OUTPUT; B-CELLS; NAIVE; AUTOIMMUNITY	Background: 22q11.2 Deletion syndrome, the most common congenital chromosome deletion syndrome, is associated with developmental defects including cardiac abnormalities and hypoplasia or abnormal migration of the thymus. These patients have variable defects in T-cell immunity with an increased incidence of infection and autoimmune disease. Objective: To investigate the immunologic constitution (if children with 22q11.2 deletion syndrome. Methods: We characterized the immunologic constitution of 27 children with 22q11.2 deletion syndrome and 54 healthy controls by flow-cytometric analysis of peripheral blood. lymphocyte populations. Results: Patients exhibited decreased T-cell numbers, although the normal age-related decrease in T-cell numbers was slower than in healthy children. There was a significant decrease in FoxP3(+) natural regulatory T (nTreg) cells with a strong correlation between nTreg cells and recent T-cell emigrants from the thymus, suggesting a link between the nTreg cell population and thymic function. Although total B-cell numbers were unaffected, patients showed a significantly decreased proportion of memory B cells in the B-cell pool. Conclusion: Lower nTreg cells in patients suggest that the generation and maintenance of these cells in children is related to thymic function. In addition to T-cell abnormalities classically seen in this syndrome, subtle defects in the B-cell compartment may also be seen.	[McLean-Tooke, Andrew; Barge, Dawn; Spickett, Gavin P.] Royal Victoria Infirm, Dept Immunol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Gennery, Andrew R.] Newcastle Univ, Dept Clin Med Sci Child Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	McLean-Tooke, A (corresponding author), Royal Victoria Infirm, Dept Immunol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	andymctooke@yahoo.co.uk	McLean-Tooke, Andrew/AAF-2568-2021	McLean-Tooke, Andrew/0000-0003-4307-0837				Al-Herz W, 2004, AM J MED GENET A, V127A, P99, DOI 10.1002/ajmg.a.20639; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Bourgeois C, 2006, IMMUNOL LETT, V107, P89, DOI 10.1016/j.imlet.2006.08.001; Brown JJ, 2004, J PEDIATR ENDOCR MET, V17, P1575; Chinen J, 2003, J ALLERGY CLIN IMMUN, V111, P573, DOI 10.1067/mai.2003.165; Dejaco C, 2006, IMMUNOLOGY, V117, P289, DOI 10.1111/j.1365-2567.2005.02317.x; Devriendt K, 1998, J MED GENET, V35, P789, DOI 10.1136/jmg.35.9.789-a; Finocchi A, 2006, PEDIATR ALLERGY IMMU, V17, P382, DOI 10.1111/j.1399-3038.2006.00409.x; Gennery AR, 2002, ARCH DIS CHILD, V86, P422, DOI 10.1136/adc.86.6.422; Goodship J, 1998, ARCH DIS CHILD, V79, P348, DOI 10.1136/adc.79.4.348; Holmes S, 2005, P NATL ACAD SCI USA, V102, P5519, DOI 10.1073/pnas.0501437102; Jameson SC, 2005, SEMIN IMMUNOL, V17, P231, DOI 10.1016/j.smim.2005.02.003; Jawad AF, 2001, J PEDIATR-US, V139, P715, DOI 10.1067/mpd.2001.118534; Junge S, 2007, EUR J IMMUNOL, V37, P3270, DOI 10.1002/eji.200636976; JUNKER AK, 1995, J PEDIATR-US, V127, P231, DOI 10.1016/S0022-3476(95)70300-4; Kanaya Y, 2006, CLIN EXP IMMUNOL, V144, P85, DOI 10.1111/j.1365-2249.2006.03038.x; Kimmig S, 2002, J EXP MED, V195, P789, DOI 10.1084/jem.20011756; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; Kobrynski LJ, 2007, LANCET, V370, P1443, DOI 10.1016/S0140-6736(07)61601-8; Kung SJ, 2007, ANN ALLERG ASTHMA IM, V99, P87, DOI 10.1016/S1081-1206(10)60627-8; Lavi RF, 2006, J ALLERGY CLIN IMMUN, V118, P1184, DOI 10.1016/j.jaci.2006.07.052; Liston A, 2007, CURR OPIN IMMUNOL, V19, P176, DOI 10.1016/j.coi.2007.02.005; McLean-Tooke A, 2008, CLIN EXP IMMUNOL, V151, P190, DOI 10.1111/j.1365-2249.2007.03536.x; Murray JM, 2003, IMMUNOL CELL BIOL, V81, P487, DOI 10.1046/j.1440-1711.2003.01191.x; Perez E, 2002, CURR OPIN PEDIATR, V14, P678, DOI 10.1097/00008480-200212000-00005; Piliero LM, 2004, BLOOD, V103, P1020, DOI 10.1182/blood-2003-08-2824; Pillai V, 2007, IMMUNOL LETT, V114, P9, DOI 10.1016/j.imlet.2007.08.012; Sakamoto O, 2004, PEDIATR INT, V46, P612, DOI 10.1111/j.1442-200x.2004.01940.x; Sediva A, 2005, MED SCI MONITOR, V11, pCR182; Sempowski GD, 2005, J CLIN IMMUNOL, V25, P462, DOI 10.1007/s10875-005-5635-4; Shi YH, 2003, CLIN IMMUNOL, V108, P128, DOI 10.1016/S1521-6616(03)00092-5; Smith CA, 1998, CLIN DIAGN LAB IMMUN, V5, P415, DOI 10.1128/CDLI.5.3.415-417.1998; Steffens CM, 2000, CLIN IMMUNOL, V97, P95, DOI 10.1006/clim.2000.4938; Sullivan KE, 1998, CLIN IMMUNOL IMMUNOP, V86, P141, DOI 10.1006/clin.1997.4463; Sullivan KE, 2002, CLIN DIAGN LAB IMMUN, V9, P1129, DOI 10.1128/CDLI.9.5.1129-1131.2002; Sullivan KE, 1997, ARTHRITIS RHEUM, V40, P430, DOI 10.1002/art.1780400307; Vos Q, 2000, IMMUNOL REV, V176, P154; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; Xiong N, 2007, IMMUNOL REV, V215, P15, DOI 10.1111/j.1600-065X.2006.00478.x; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547	40	61	67	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					362	367		10.1016/j.jaci.2008.03.033	http://dx.doi.org/10.1016/j.jaci.2008.03.033			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18485468				2022-12-18	WOS:000258426300024
J	Siebenhaar, F; Magerl, M; Peters, EMJ; Hendrix, S; Metz, M; Maurer, M				Siebenhaar, Frank; Magerl, Markus; Peters, Eva M. J.; Hendrix, Sven; Metz, Martin; Maurer, Marcus			Mast cell-driven skin inflammation is impaired in the absence of sensory nerves	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; sensory nerves; neuropeptides; allergic skin inflammation; urticaria	HAIR FOLLICLE INNERVATION; TUMOR-NECROSIS-FACTOR; SUBSTANCE-P; MURINE SKIN; ATOPIC-DERMATITIS; MOUSE MODEL; PEPTIDERGIC INNERVATION; GROWTH INHIBITION; DEPENDENT CHANGES; IMMUNE-RESPONSES	Background: Mast cells (MCs) and nerves can induce cutaneous inflammatory responses, both independently and by interacting with each other. However, little is known about the role of skin nerves and neuropeptides in the regulation of MC-mediated skin inflammation, and the contribution of MCs in neurogenic inflammation is still controversial. Objective: The aim of this study was to investigate the effects of cutaneous sensory nerves on MC-driven inflammatory responses. Methods: Passive cutaneous anaphylaxis, a model for type I allergic skin responses, was studied in the presence or absence of sensory nerves by using a murine model of selective cutaneous denervation. Results: Passive cutaneous anaphylaxis was significantly impaired in the absence of sensory nerves. This effect was not a result of an alteration of mast cell numbers in denervated skin. Moreover, IgE-mediated activation of mast cells was markedly decreased in denervated compared with normal skin. Notably, pretreatment of mice with selective antagonists of the neuropeptides substance P and/or calcitonin gene-related peptide also resulted in decreased inflammatory responses after MC activation. Conclusion: These data suggest that sensory skin nerves augment MC-driven inflammatory responses by releasing neuropeptides that increase MC degranulation.	[Siebenhaar, Frank; Magerl, Markus; Metz, Martin; Maurer, Marcus] Charite, Allergie Centrum Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany; [Peters, Eva M. J.] Charite, Neurosci Res Ctr, D-10117 Berlin, Germany; [Hendrix, Sven] Charite, Ctr Anat, Inst Cell Biol & Neurobiol, D-10117 Berlin, Germany; [Siebenhaar, Frank; Magerl, Markus; Metz, Martin; Maurer, Marcus] Univ Hosp Mainz, Dept Dermatol, Mainz, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University Hospital Mainz	Maurer, M (corresponding author), Charite, Allergie Centrum Charite, Dept Dermatol & Allergy, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de	Maurer, Marcus/ABG-2174-2020; Metz, Martin/M-5237-2013; Magerl, Markus/ABI-5335-2020; Metz, Martin/B-8799-2009; Hendrix, Sven/F-4059-2010	Maurer, Marcus/0000-0002-4121-481X; Metz, Martin/0000-0002-4070-9976; Magerl, Markus/0000-0001-9218-5468; Metz, Martin/0000-0002-4070-9976; Hendrix, Sven/0000-0003-2344-7369; Siebenhaar, Frank/0000-0003-4532-1644				ANSEL JC, 1993, J IMMUNOL, V150, P4478; Ansel JC, 1996, J INVEST DERMATOL, V106, P198, DOI 10.1111/1523-1747.ep12330326; Ansel JC, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P23, DOI 10.1038/jidsymp.1997.6; Arck PC, 2005, J MOL MED, V83, P386, DOI 10.1007/s00109-004-0627-z; Arck P, 2006, NEUROIMMUNOMODULAT, V13, P347, DOI 10.1159/000104863; Arck PC, 2006, J INVEST DERMATOL, V126, P1697, DOI 10.1038/sj.jid.5700104; BIENENSTOCK J, 1991, AM REV RESPIR DIS, V143, pS55, DOI 10.1164/ajrccm/143.3_Pt_2.S55; Biro T, 2005, EXP DERMATOL, V14, P225, DOI 10.1111/j.0906-6705.2005.0321a.x; BLENNERHASSETT MG, 1991, CELL TISSUE RES, V265, P121, DOI 10.1007/BF00318146; Blennerhassett MG, 1998, J NEUROBIOL, V35, P173, DOI 10.1002/(SICI)1097-4695(199805)35:2<173::AID-NEU4>3.0.CO;2-1; Botchkarev VA, 1997, ARCH DERMATOL RES, V289, P292, DOI 10.1007/s004030050195; Botchkarev VA, 1997, J COMP NEUROL, V386, P379, DOI 10.1002/(SICI)1096-9861(19970929)386:3<379::AID-CNE4>3.0.CO;2-Z; Botchkarev VA, 1999, J INVEST DERMATOL, V113, P878, DOI 10.1046/j.1523-1747.1999.00791.x; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; Downing JEG, 2000, IMMUNOL TODAY, V21, P281, DOI 10.1016/S0167-5699(00)01635-2; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2003, NAT IMMUNOL, V4, P1160, DOI 10.1038/ni1203-1160; GALLI SJ, 1987, AM J PATHOL, V127, P191; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gottwald Thomas, 1998, Wound Repair and Regeneration, V6, P8, DOI 10.1046/j.1524-475X.1998.60104.x; Hendrix S, 2007, J NEUROIMMUNOL, V184, P113, DOI 10.1016/j.jneuroim.2006.11.020; Henz BM, 2001, EXP DERMATOL, V10, P1, DOI 10.1034/j.1600-0625.2001.100101.x; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; HUA XY, 1993, J NEUROSCI, V13, P1947; Ito A, 2006, J PHARMACOL SCI, V102, P1, DOI 10.1254/jphs.CPJ06014X; Kakurai M, 2006, AM J PATHOL, V169, P1713, DOI 10.2353/ajpath.2006.060602; Karlsen TV, 2007, AM J PHYSIOL-HEART C, V292, pH1821, DOI 10.1152/ajpheart.00365.2006; Karmouty-Quintana H, 2007, BRIT J PHARMACOL, V150, P1022, DOI 10.1038/sj.bjp.0707168; Katsuno M, 2003, J DERMATOL SCI, V33, P55, DOI 10.1016/S0923-1811(03)00155-5; Kawana S, 2006, J DERMATOL SCI, V42, P47, DOI 10.1016/j.jdermsci.2005.12.004; KITAMURA Y, 1978, BLOOD, V52, P447; Lee WH, 2005, YONSEI MED J, V46, P8, DOI 10.3349/ymj.2005.46.1.8; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; Maurer M, 2005, EXP DERMATOL, V14, P923, DOI 10.1111/j.1600-0625.2005.00369.x; Maurer M, 2003, EXP DERMATOL, V12, P886, DOI 10.1111/j.0906-6705.2003.0109a.x; Maurer M, 1998, ARCH DERMATOL RES, V290, P574, DOI 10.1007/s004030050354; Maurer M, 2004, NATURE, V432, P512, DOI 10.1038/nature03085; Maurer M, 2006, FASEB J, V20, P2460, DOI 10.1096/fj.06-5860com; McQueen DS, 2007, BRIT J PHARMACOL, V151, P278, DOI 10.1038/sj.bjp.0707216; Metz M, 2007, TRENDS IMMUNOL, V28, P234, DOI 10.1016/j.it.2007.03.003; Metz M, 2006, SCIENCE, V313, P526, DOI 10.1126/science.1128877; Nakae S, 2006, J IMMUNOL, V176, P2238, DOI 10.4049/jimmunol.176.4.2238; Nakano A, 1997, J IMMUNOL, V159, P1987; Nassenstein C, 2006, BIOCHEM SOC T, V34, P591, DOI 10.1042/BST0340591; Nassenstein C, 2007, J ALLERGY CLIN IMMUN, V120, P1089, DOI 10.1016/j.jaci.2007.07.007; NAUKKARINEN A, 1994, INT J DERMATOL, V33, P361, DOI 10.1111/j.1365-4362.1994.tb01069.x; Oaklander AL, 2004, ANN NEUROL, V55, P639, DOI 10.1002/ana.20048; Ohmura T, 2004, INT ARCH ALLERGY IMM, V133, P389, DOI 10.1159/000077359; OLSSON Y, 1967, ACTA NEUROL SCAND, V43, P365, DOI 10.1111/j.1600-0404.1967.tb05739.x; Orinska Z, 2007, NAT MED, V13, P927, DOI 10.1038/nm1615; PAUS R, 1995, ARCH DERMATOL RES, V287, P500, DOI 10.1007/BF00373436; Peters EMJ, 2006, EXP DERMATOL, V15, P1, DOI 10.1111/j.0906-6705.2005.00372.x; Peters EMJ, 2005, BRAIN BEHAV IMMUN, V19, P252, DOI 10.1016/j.bbi.2004.08.005; Peters EMJ, 2001, J INVEST DERMATOL, V116, P236, DOI 10.1046/j.1523-1747.2001.01232.x; Peters EMJ, 2006, J INVEST DERMATOL, V126, P1937, DOI 10.1038/sj.jid.5700429; Plante S, 2006, J ALLERGY CLIN IMMUN, V117, P1321, DOI 10.1016/j.jaci.2005.12.1349; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; Remrod C, 2007, ARCH DERMATOL RES, V299, P85, DOI 10.1007/s00403-007-0745-x; Siebenhaar F, 2007, AM J PATHOL, V170, P1910, DOI 10.2353/ajpath.2007.060770; Siebenhaar F, 2007, J INVEST DERMATOL, V127, P1489, DOI 10.1038/sj.jid.5700704; Steinhoff M, 2003, ARCH DERMATOL, V139, P1479, DOI 10.1001/archderm.139.11.1479; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Steinhoff M, 2006, J INVEST DERMATOL, V126, P1705, DOI 10.1038/sj.jid.5700231; SUGIURA H, 1992, ACTA DERM-VENEREOL, P74; Suto H, 2006, J IMMUNOL, V176, P4102, DOI 10.4049/jimmunol.176.7.4102; Tsai M, 2005, CHEM IMMUNOL ALLERGY, V87, P179, DOI 10.1159/000087644; Van Nassauw L, 2007, AUTON NEUROSCI-BASIC, V133, P91, DOI 10.1016/j.autneu.2006.10.003; Weber A, 2003, BRIT J DERMATOL, V148, P224, DOI 10.1046/j.1365-2133.2003.05090.x; Weller K, 2006, FASEB J, V20, P2366, DOI 10.1096/fj.06-5837fje; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1988, J IMMUNOL, V140, P2356; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Zanini A, 2007, J ALLERGY CLIN IMMUN, V120, P329, DOI 10.1016/j.jaci.2007.04.021	74	61	64	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					955	961		10.1016/j.jaci.2007.11.013	http://dx.doi.org/10.1016/j.jaci.2007.11.013			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18158175				2022-12-18	WOS:000254884000021
J	Taher, YA; Piavaux, BJA; Gras, R; van Esch, BCAM; Hofman, GA; Bloksma, N; Henricks, PAJ; van Oosterhout, AJM				Taher, Yousef A.; Piavaux, Benoit J. A.; Gras, Renee; van Esch, Betty C. A. M.; Hofman, Gerard A.; Bloksma, Nanne; Henricks, Paul A. J.; van Oosterhout, Antoon J. M.			Indoleamine 2,3-dioxygenase-dependent tryptophan metabolites contribute to tolerance induction during allergen immunotherapy in a mouse model	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic asthma; immunotherapy; indoleamine 2,3-dioxygenase; tryptophan; kynurenine; dendritic cell; regulatory T cells; T(H)2 lymphocytes; hyperresponsiveness; eosinophilia; IgE; IL-10; suppression	GRASS-POLLEN IMMUNOTHERAPY; DENDRITIC CELLS; T-CELL; AIRWAY INFLAMMATION; KYNURENINE PATHWAY; INTERFERON-GAMMA; ASTHMA; INHIBITION; MICE; LYMPHOCYTES	Background: The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO) has been implicated in immune suppression and tolerance induction. Objective: We examined (1) whether IDO activity is required during tolerance induction by allergen immunotherapy or for the subsequent suppressive effects on asthma manifestations and (2) whether tryptophan depletion or generation of its downstream metabolites is involved. Methods: Ovalbumin (OVA)-sensitized and OVA-challenged BALB/c mice that display increased airway responsiveness to methacholine, serum OVA-specific IgE levels, bronchoalveolar eosinophilia, and T(H)2 cytokine levels were used as a model of allergic asthma. Sensitized mice received subcutaneous optimal (1 mg) or suboptimal (100 mu g) OVA immunotherapy. Results: Inhibition of IDO by 1-methyl-DL-tryptophan during immunotherapy, but not during inhalation challenge, partially reversed the suppressive effects of immunotherapy on airway eosinophilia and T(H)2 cytokine levels, whereas airway hyperresponsiveness and serum OVA-specific IgE levels remained suppressed. Administration of tryptophan during immunotherapy failed to abrogate its beneficial effects toward allergic airway inflammation. Interestingly, administration of tryptophan or its metabolites, kynurenine, 3-hydroxykynurenine, and xanthurenic acid, but not 3-hydroxyanthranilinic acid, quinolinic acid, and kynurenic acid, during suboptimal immunotherapy potentiated the reduction of eosinophilia. These effects coincided with reduced T(H)2 cytokine levels in bronchoalveolar lavage fluid, but no effects on IgE levels were detected. Conclusion: During immunotherapy, the tryptophan metabolites kynurenine, 3-hydroxykynurenine, and xanthurenic acid generated through IDO contribute to tolerance induction regarding T(H)2-dependent allergic airway inflammation.	[Taher, Yousef A.; Piavaux, Benoit J. A.; Gras, Renee; van Oosterhout, Antoon J. M.] Univ Groningen, Univ Med Ctr Groningen, Lab Allergol & Pulm Dis, NL-9700 RB Groningen, Netherlands; [Taher, Yousef A.; van Esch, Betty C. A. M.; Hofman, Gerard A.; Bloksma, Nanne; Henricks, Paul A. J.] Utrecht Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, Utrecht, Netherlands; [Bloksma, Nanne] Univ Utrecht, Fac Sci, Dept Biol, Utrecht, Netherlands	University of Groningen; Utrecht University; Utrecht University	van Oosterhout, AJM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Lab Allergol & Pulm Dis, POB 30-001, NL-9700 RB Groningen, Netherlands.	aj.m.van.oosterhout@path.umcg.nl	Piavaux, Benoit/G-6325-2014; Henricks, Paul/I-8255-2016	Piavaux, Benoit/0000-0002-7331-8031; van Esch, Betty/0000-0001-9961-750X				ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Agaugue S, 2006, J IMMUNOL, V177, P2061, DOI 10.4049/jimmunol.177.4.2061; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Belladonna ML, 2006, J IMMUNOL, V177, P130, DOI 10.4049/jimmunol.177.1.130; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Friberg M, 2002, INT J CANCER, V101, P151, DOI 10.1002/ijc.10645; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Grohmann U, 2003, J EXP MED, V198, P153, DOI 10.1084/jem.20030633; Grohmann U, 2001, J IMMUNOL, V167, P708, DOI 10.4049/jimmunol.167.2.708; Gurtner GJ, 2003, GASTROENTEROLOGY, V125, P1762, DOI 10.1053/j.gastro.2003.08.031; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Hessel EM, 2005, J EXP MED, V202, P1563, DOI 10.1084/jem.20050631; Heyliger SO, 1998, PHARMACOL RES, V38, P243, DOI 10.1006/phrs.1998.0362; HILAKIVICLARKE LA, 1991, DIABETES, V40, P1598, DOI 10.2337/diabetes.40.12.1598; Hylkema MN, 2002, CLIN EXP IMMUNOL, V129, P390, DOI 10.1046/j.1365-2249.2002.01938.x; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kang HS, 2003, J EXP MED, V198, P1643, DOI 10.1084/jem.20021784; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Kouskoff V, 2000, SCIENCE, V287, P2501, DOI 10.1126/science.287.5462.2501; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; LAPIN IP, 1976, VOP MED KHIM, V22, P600; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Mellor AL, 2003, J IMMUNOL, V171, P1652, DOI 10.4049/jimmunol.171.4.1652; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Platten M, 2005, SCIENCE, V310, P850, DOI 10.1126/science.1117634; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; Sakurai K, 2002, J NEUROIMMUNOL, V129, P186, DOI 10.1016/S0165-5728(02)00176-5; Stone TW, 2000, EUR J MED CHEM, V35, P179, DOI 10.1016/S0223-5234(00)00121-5; TAKIKAWA O, 1986, J BIOL CHEM, V261, P3648; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; van der Marel APJ, 2007, J IMMUNOL, V179, P894, DOI 10.4049/jimmunol.179.2.894; Van Oosterhout AJM, 1998, AM J RESP CELL MOL, V19, P622, DOI 10.1165/ajrcmb.19.4.3112m; VECSEI L, 1992, BRAIN RES BULL, V28, P233, DOI 10.1016/0361-9230(92)90184-Y; Vissers JLM, 2004, J ALLERGY CLIN IMMUN, V113, P1204, DOI 10.1016/j.jaci.2004.02.041; Wachholz PA, 2003, CLIN EXP ALLERGY, V33, P1171, DOI 10.1046/j.1365-2222.2003.01765.x; Weiner HL, 2001, NAT IMMUNOL, V2, P671, DOI 10.1038/90604; WERNER ER, 1987, BIOL CHEM H-S, V368, P1407, DOI 10.1515/bchm3.1987.368.2.1407	44	61	65	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					983	991		10.1016/j.jaci.2007.11.021	http://dx.doi.org/10.1016/j.jaci.2007.11.021			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18179817				2022-12-18	WOS:000254884000025
J	Bittner, C; Grassau, B; Frenzel, K; Baur, X				Bittner, Cordula; Grassau, Britta; Frenzel, Karsten; Baur, Xaver			Identification of wheat gliadins as an allergen family related to baker's asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						baker's asthma; wheat; gliadins; recombinant; alpha beta-gliadin; recombinant allergens; cDNA phage display	PHAGE DISPLAY; IN-VITRO; FLOUR; BINDING; IGE; ANTIBODIES; PROTEINS; SERA	Background: Flour is still one of the most common causes of occupational asthma worldwide. Thus far, little is known about the relevant allergens causing baker's asthma. Therefore the reliability of current diagnostic procedures is insufficient. Only few of the suspected causative wheat allergens have been hitherto characterized on the molecular level. Objective: The aim was to identify and characterize unknown wheat allergens related to baker's asthma to improve the reliability of diagnostic procedures. Methods: A wheat pJuFo cDNA phage display library was created and screened for IgE binding to wheat proteins with pooled sera from patients with baker's asthma. After identifying an alpha beta-gliadin, the frequency of sensitization was investigated by means of ELISA screening of 153 bakers' sera with the recombinant alpha beta-gliadin. Furthermore, the allergenicity of native total gliadin (alpha beta, gamma, omega) was analyzed by means of ImmunoCAP. Results: One cDNA clone was identified as an alpha beta-gliadin. Serum IgE antibodies to the recombinant allergen were found in 12% of bakers with occupational asthma. Of the asthmatic bakers, 33% showed sensitization to native total gliadin; 4% of them had negative results on routine IgE testing with wheat extract. Conclusions: Gliadins represent a newly discovered family of inhalable allergens in baker's asthma. This finding demonstrates that water-insoluble proteins might also represent causative allergens.	[Bittner, Cordula; Grassau, Britta; Baur, Xaver] Univ Hamburg, Ctr Med, Inst Occupat Med & Maritime Med ZIAM, D-20459 Hamburg, Germany; [Frenzel, Karsten] Univ Hamburg, Bioctr Klein Flottbek & Bot Garden, D-20459 Hamburg, Germany	University of Hamburg; University of Hamburg	Bittner, C (corresponding author), Univ Hamburg, Ctr Med, Inst Occupat Med & Maritime Med ZIAM, Seewartenstr 10, D-20459 Hamburg, Germany.	bittner@uke.uni-hamburg.de						Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; BALDO BA, 1978, CLIN ALLERGY, V8, P109, DOI 10.1111/j.1365-2222.1978.tb00456.x; Baur X, 1998, J ALLERGY CLIN IMMUN, V102, P984, DOI 10.1016/S0091-6749(98)70337-9; Baur X, 1998, CLIN EXP ALLERGY, V28, P1591; Baur X, 1998, ALLERGY, V53, P562, DOI 10.1111/j.1398-9995.1998.tb03931.x; BIETZ JA, 1977, CEREAL CHEM, V54, P1070; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P680; Brant A, 2005, OCCUP ENVIRON MED, V62, P395, DOI 10.1136/oem.2004.014639; Brisman J, 2002, OCCUP ENVIRON MED, V59, P498, DOI 10.1136/oem.59.7.498; Crameri R, 2002, Methods Mol Biol, V185, P461; GarciaCasado G, 1996, CLIN EXP ALLERGY, V26, P428, DOI 10.1046/j.1365-2222.1996.d01-326.x; GOMEZ L, 1990, FEBS LETT, V261, P85, DOI 10.1016/0014-5793(90)80642-V; Jensen-Jarolim E, 1999, INT ARCH ALLERGY IMM, V118, P224, DOI 10.1159/000024078; Kleber-Janke T, 2001, J CHROMATOGR B, V756, P295, DOI 10.1016/S0378-4347(01)00088-3; Latza U, 2005, AM J IND MED, V48, P144, DOI 10.1002/ajim.20186; Mittag D, 2004, MOL NUTR FOOD RES, V48, P380, DOI 10.1002/mnfr.200400016; Palosuo K, 2001, J ALLERGY CLIN IMMUN, V108, P634, DOI 10.1067/mai.2001.118602; Palosuo K, 2003, CURR OPIN ALLERGY CL, V3, P205, DOI [10.1097/00130832-200306000-00009, 10.1097/01.all.0000072717.82112.cc]; PRICHARD MG, 1985, CLIN ALLERGY, V15, P203, DOI 10.1111/j.1365-2222.1985.tb02274.x; Rozynek P, 2002, ALLERGY, V57, P463, DOI 10.1034/j.1398-9995.2002.23638.x; SanchezMonge R, 1997, CLIN EXP ALLERGY, V27, P1130, DOI 10.1046/j.1365-2222.1997.1340945.x; Sander I, 2001, J ALLERGY CLIN IMMUN, V107, P907, DOI 10.1067/mai.2001.113761; Sander I, 1999, ALLERGY, V54, P50; Sandiford CP, 1997, CLIN EXP ALLERGY, V27, P1120, DOI 10.1046/j.1365-2222.1997.1310936.x; WALSH BJ, 1985, J ALLERGY CLIN IMMUN, V76, P23, DOI 10.1016/0091-6749(85)90799-7; Watanabe J, 2004, BIOFACTORS, V22, P295, DOI 10.1002/biof.5520220157; Weichel M, 2006, J ALLERGY CLIN IMMUN, V117, P676, DOI 10.1016/j.jaci.2005.11.040; WEISS W, 1993, ELECTROPHORESIS, V14, P805, DOI 10.1002/elps.11501401126; Weiss W, 1997, ELECTROPHORESIS, V18, P826, DOI 10.1002/elps.1150180529	29	61	64	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					744	749		10.1016/j.jaci.2007.09.051	http://dx.doi.org/10.1016/j.jaci.2007.09.051			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18036646				2022-12-18	WOS:000253918900032
J	D'Amato, G; Cecchi, L; Liccardi, G				D'Amato, Gennaro; Cecchi, Lorenzo; Liccardi, Gennaro			Thunderstorm-related asthma: Not only grass pollen and spores	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY		[D'Amato, Gennaro; Liccardi, Gennaro] High Specialty Hosp A Cardarelli, Dept Resp Dis, Div resp & Allerg Dis, Naples, Italy; [Cecchi, Lorenzo] Univ Florence, Interdepartemental Ctr Bioclimatol, I-50121 Florence, Italy	Antonio Cardarelli Hospital; University of Florence	D'Amato, G (corresponding author), High Specialty Hosp A Cardarelli, Dept Resp Dis, Div resp & Allerg Dis, Naples, Italy.			Cecchi, Lorenzo/0000-0002-0658-2449				D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; D'Amato G, 2007, ALLERGY, V62, P11, DOI 10.1111/j.1398-9995.2006.01271.x; DAmato G, 1991, ALLERGENIC POLLEN PO, P113; DAMATO G, THUNDERSTOM ASS ASTH; Marks GB, 2007, J ALLERGY CLIN IMMUN, V120, P530, DOI 10.1016/j.jaci.2007.07.012; Pulimood TB, 2007, J ALLERGY CLIN IMMUN, V120, P610, DOI 10.1016/j.jaci.2007.04.045	6	61	63	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					537	538		10.1016/j.jaci.2007.10.046	http://dx.doi.org/10.1016/j.jaci.2007.10.046			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18155276				2022-12-18	WOS:000253337800048
J	Pedersen, SE; Bateman, ED; Bousquet, J; Busse, WW; Yoxall, S; Clark, TJ				Pedersen, Soren E.; Bateman, Eric D.; Bousquet, Jean; Busse, William W.; Yoxall, Sally; Clark, Tim J.			Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the gaining optimal asthama control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; salmeterollfluticasone propionate combination; asthma control; treatment response; smoking	BRONCHIAL HYPERRESPONSIVENESS; CIGARETTE-SMOKING; ASTHMA CONTROL; MILD ASTHMA; ATOPY; CORTICOSTEROIDS; POPULATION; AGE	Background: During the Gaining Optimal Asthma controL study, 3416 patients with uncontrolled asthma were randomized to receive salmeterol/fluticasone propionate combination (SFC) or fluticasone propionate (FP) for I year. Approximately two thirds of patients achieved well-controlled (WC) asthma, and one third continued to have asthma that was not well controlled (NWC). Objective: This analysis aimed to (1) identify factors influencing treatment response and (2) assess the clinical benefits of SFC and FP in patients with NWC asthma. Methods: Logistic regression analysis was used to investigate whether covariates influenced the achievement of at least WC asthma in the study population. In patients with NWC asthma, predefined criteria were used to assess improvements in 6 clinical outcomes. Results: Factors affecting the probability of having NWC asthma included smoking status (current vs never: odds ratio [OR], 2.757; 95% CI, 2.061-3.689; P <.0001; former vs never: OR, 1.274; 95% CI, 1.031-1.574; P = 0.0273), sex (women vs men: OR, 0.652; 95% CI, 0.527-0.806; P <.0001), history of inhaled corticosteroid use (no history vs history: OR, 0.546; 95% CI, 0.437-0.683; P <.0001), and treatment (FP vs SFC: OR, 1.972; 95% CI, 1.686-2.308; P <.0001). Of patients with NWC asthma, 86% to 96% showed improvements in I or more clinical outcomes. Conclusion: It is imperative for good asthma control that patients stop smoking. Patients who did not have at least WC asthma demonstrated clinical improvements in individual asthma outcomes. Clinical implications: Although not all patients can achieve guideline-defined control, long-term treatment with SFC or FP is associated with clinical improvements in nearly all patients, regardless of smoking history or inhaled corticosteroid use.	Univ So Denmark, Dept Pediat, Pediat Res Unit, Kolding Hosp, DK-6000 Kolding, Denmark; Univ Cape Town, Dept Med, Div Pulm, ZA-7925 Cape Town, South Africa; Hop Arnaud de Villeneuve, Montpellier, France; Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA; GlaxoSmithKline, Greenford, Middx, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	Kolding Hospital; University of Southern Denmark; University of Cape Town; Universite de Montpellier; CHU de Montpellier; University of Wisconsin System; University of Wisconsin Madison; GlaxoSmithKline; Imperial College London	Pedersen, SE (corresponding author), Univ So Denmark, Dept Pediat, Pediat Res Unit, Kolding Hosp, DK-6000 Kolding, Denmark.	spconsult@post1.tele.dk	Bousquet, Jean/O-4221-2019					Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bottema RW, 2005, IMMUNOL ALLERGY CLIN, V25, P621, DOI 10.1016/j.iac.2005.07.002; BRITTON J, 1994, EUR RESPIR J, V7, P881; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Dijkstra A, 2006, J ALLERGY CLIN IMMUN, V117, P604, DOI 10.1016/j.jaci.2005.11.023; *EUR AG EV MED PRO, CPMPEWP286399 EUR AG; *GLOB IN ASTH, 1998, NIH PUBL; Global Initiative for Asthma (GINA), GLOB STRAT ASTH MAN; HOSMER DW, 2000, APPL LOGIC REGRESSIO; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413, DOI 10.1164/ajrccm.156.5.9701060; Min JW, 2005, CHEST, V128, P3127, DOI 10.1378/chest.128.5.3127; *NIH, 1997, NIH PUBL; Schatz M, 2006, J ALLERGY CLIN IMMUN, V118, P1048, DOI 10.1016/j.jaci.2006.07.057; Thomson NC, 2005, CURR OPIN ALLERGY CL, V5, P57, DOI 10.1097/00130832-200502000-00011; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; TRIGG CJ, 1990, THORAX, V45, P866, DOI 10.1136/thx.45.11.866	21	61	62	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1036	1042		10.1016/j.jaci.2007.07.016	http://dx.doi.org/10.1016/j.jaci.2007.07.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17935765	Bronze			2022-12-18	WOS:000250973400009
J	Martin, L; Raison-Peyron, N; Nothen, MM; Cichon, S; Drouet, C				Martin, Ludovic; Raison-Peyron, Nadia; Noethen, Mcirkus M.; Cichon, Sven; Drouet, Christian			Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Orleans Hosp, Dept Dermatol, Orleans, France; French Reference Ctr Angioedema, Grenoble, France; Univ Montpellier, Dept Dermatol, F-34059 Montpellier, France; Univ Bonn, Dept Genom Life, D-5300 Bonn, Germany; Univ Bonn, Brain Ctr, D-5300 Bonn, Germany; Univ Bonn, Inst Human Genet, D-5300 Bonn, Germany; Univ Grenoble 1, CNRS, UMR 5525, Grenoble, France	Centre Hospitalier Regional d'Orleans; Universite de Montpellier; University of Bonn; University of Bonn; University of Bonn; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble Alpes (UGA)	Martin, L (corresponding author), Orleans Hosp, Dept Dermatol, Orleans, France.	ludovic.martin@chr-orleans.fr	Cichon, Sven/B-9618-2014; Nöthen, Markus/B-2027-2009; DROUET, Christian/J-8775-2019; Cichon, Sven/H-8803-2013; DROUET, Christian/AAE-5682-2020	Cichon, Sven/0000-0002-9475-086X; Nöthen, Markus/0000-0002-8770-2464; DROUET, Christian/0000-0003-1318-4278; Cichon, Sven/0000-0002-9475-086X; DROUET, Christian/0000-0003-1318-4278				Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Bork K, 2006, BRIT J DERMATOL, V154, P542, DOI 10.1111/j.1365-2133.2005.07048.x; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Cicardi M, 1999, AM J MED, V106, P650, DOI 10.1016/S0002-9343(99)00123-0; CICARDI M, 2004, J ALLERGY CLIN IMMUN, V114, pS55; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; DROUET C, 2004, J ALLERGY CLIN IMMUN, V114, pS65; FARSETTI A, 1995, ENDOCRINOLOGY, V136, P5076, DOI 10.1210/en.136.11.5076; Gupta S, 2004, ALLERGY, V59, P557, DOI 10.1111/j.1398-9995.2004.00428.x; Martin L, 2001, J ALLERGY CLIN IMMUN, V107, P747, DOI 10.1067/mai.2001.114242	11	61	61	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					975	977		10.1016/j.jaci.2007.07.002	http://dx.doi.org/10.1016/j.jaci.2007.07.002			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17825897	Bronze			2022-12-18	WOS:000250157700044
J	Janson, C; Asbjornsdottir, H; Birgisdottir, A; Sigurjonsdottir, RB; Gunnbjornsdottir, M; Gislason, D; Olafsson, I; Jogi, R; Gislason, T; Thjodleifsson, B				Janson, Christer; Asbjornsdottir, Hulda; Birgisdottir, Aida; Sigurjonsdottir, Rina Bjoerg; Gunnbjoernsdottir, Maria; Gislason, David; Olafsson, Isleifur; Joegi, Rain; Gislason, Thorarinn; Thjodleifsson, Bjarni			The effect of infectious burden on the prevalence of atopy and respiratory allergies in Iceland, Estonia, and Sweden	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; allergic asthnia; allergic rhinitis; hygiene hypothesis; infection; epidemology; Helicobacter pylori/immunology; hepatitis A/immunology; Chlamydia pneumoniae/immunology.; herpes simplex/immunology	HEPATITIS-A VIRUS; HELICOBACTER-PYLORI; HYGIENE HYPOTHESIS; HEALTH-SURVEY; EAST-GERMANY; EARLY-LIFE; HAY-FEVER; ASTHMA; CHILDREN; EXPOSURE	Background: Epidemiologic reports on the effect of microbe exposure on the development of atopy and allergic asthma are inconsistent. Objectives: The study investigates the association between serologic markers of infections and occurrence of atopy, allergic asthma, and rhinitis among adults in Iceland, Sweden, and Estonia. Methods: Individuals (n = 1249; mean age, 42 years) from Iceland. Sweden, and Estonia underwent a structured interview and blood sampling. Specific IgE was measured against 4 allergens, and IgG antibodies were measured against Helicobacter pylori, Toxoplasmosis gondii, hepatitis A virus, herpes simplex virus 1, Chlamydia pneumoniae, EBV, and cytomegalovirus. Results: Nonatopic subjects more often had positive serology for Helicobacter pylori, herpes simplex virus 1, Chlamydia pneumoniae, and cytomegalovirus. Having a low number (! 3) of IgG antibodies against the various infectious agents was an independent risk factor for atopy (odds ratio [OR], 1.43; 95% CI, 1.06-1.93), allergic asthma (OR, 1.82; 95% CI, 1.12-2.98), and allergic rhinitis (OR, 1.69; 95% CI, 1.21-2.37). The proportion of atopy that can be explained by a lower number (<= 3) of infections was 6.7% in Iceland, 9.2% in Estonia, and 16.4% in Sweden, and 6.7%, 48.2%, and 33.4% for allergic asthma, respectively. Conclusion: Our data are consistent with cumulative protective effect of infections against atopy and respiratory allergies irrespective of route of infection. Clinical implications: The study indicates what microbes or combination of microbes play a role in the complex interplay between hygiene and allergy and may contribute toward the understanding of the allergy epidemic.	Landspitali Univ Hosp, Dept Med, IS-101 Reykjavik, Iceland; Uppsala Univ, Akad Sjukhuset, Uppsala, Sweden; Univ Iceland, Fac Med, Reykjavik, Iceland; Landspitali Univ Hosp, Dept Clin Chem, Reykjavik, Iceland; Univ Tartu, Lung Clin, EE-50090 Tartu, Estonia	Landspitali National University Hospital; Uppsala University; Uppsala University Hospital; University of Iceland; Landspitali National University Hospital; University of Tartu	Thjodleifsson, B (corresponding author), Landspitali Univ Hosp, Dept Med, IS-101 Reykjavik, Iceland.	bjarnit@landspitali.is						ADLER SP, 1988, J PEDIATR-US, V112, P366, DOI 10.1016/S0022-3476(88)80314-7; Bamford KB, 1998, GASTROENTEROLOGY, V114, P482, DOI 10.1016/S0016-5085(98)70531-1; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bodner C, 1998, THORAX, V53, P28, DOI 10.1136/thx.53.1.28; Bodner C, 2000, THORAX, V55, P383, DOI 10.1136/thorax.55.5.383; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; Cremonini F, 2003, EUR J GASTROEN HEPAT, V15, P635, DOI 10.1097/00042737-200306000-00009; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Gonzalez-Quintela A, 2005, ALLERGY, V60, P98, DOI 10.1111/j.1398-9995.2005.00682.x; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Jarvis D, 2004, ALLERGY, V59, P1063, DOI 10.1111/j.1398-9995.2004.00539.x; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Kosunen TU, 2002, CLIN EXP ALLERGY, V32, P373, DOI 10.1046/j.1365-2222.2002.01330.x; Law M, 2005, BRIT MED J, V330, P1187, DOI 10.1136/bmj.38435.582975.AE; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87, DOI 10.1093/oxfordjournals.epirev.a036030; Linneberg A, 2003, J ALLERGY CLIN IMMUN, V111, P847, DOI 10.1067/mai.2003.1335; Malinovschi A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-92; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1999, LANCET, V354, P430, DOI 10.1016/S0140-6736(05)75853-0; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; McCune A, 2003, EUR J GASTROEN HEPAT, V15, P637, DOI 10.1097/00042737-200306000-00010; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Olafsdottir IS, 2005, THORAX, V60, P451, DOI 10.1136/thx.2004.035774; Radon K, 2004, CLIN EXP ALLERGY, V34, P1178, DOI 10.1111/j.1365-2222.2004.02005.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Sepp E, 2005, CLIN EXP ALLERGY, V35, P1141, DOI 10.1111/j.1365-2222.2005.02315.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; *UN HUM DEV IND, 2005, HUM DEV REP; Uter W, 2003, ALLERGY, V58, P580, DOI 10.1034/j.1398-9995.2003.00102.x; von Hertzen L, 2006, J ALLERGY CLIN IMMUN, V117, P151, DOI 10.1016/j.jaci.2005.07.028; von Hertzen LC, 2006, INT ARCH ALLERGY IMM, V140, P89, DOI 10.1159/000092251; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; Wickman M, 2005, ALLERGY, V60, P650, DOI 10.1111/j.1398-9995.2004.00764.x	47	61	62	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					673	679		10.1016/j.jaci.2007.05.003	http://dx.doi.org/10.1016/j.jaci.2007.05.003			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17586034				2022-12-18	WOS:000249505400029
J	Stern, DA; Riedler, J; Nowak, D; Braun-Fahrlander, C; Swoboda, I; Balic, N; Chen, KW; Vrtala, S; Gronlund, H; van Hage, M; Valenta, R; Spitzauer, S; Von Mutius, E; Vercelli, D				Stern, Debra A.; Riedler, Josef; Nowak, Dennis; Braun-Fahrlander, Charlotte; Swoboda, Ines; Balic, Nadja; Chen, Kuan-Wei; Vrtala, Susanne; Groenlund, Hans; van Hage, Marianne; Valenta, Rudolf; Spitzauer, Susanne; Von Mutius, Erika; Vercelli, Donata			Exposure to a farming environment has allergen-specific protective effects on T(H)2-dependent isotype switching in response to common inhalants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IgE; IgG; immunoglobulin switch region; farm exposure; immediate hypersensitivity; allergy; atopy	GRASS PHLEUM-PRATENSE; SERUM IGE LEVELS; SEQUENTIAL SWITCH; MAJOR ALLERGEN; CAT ALLERGEN; ASTHMA; CHILDREN; EPSILON; POLLEN; CELLS	Background: IgE synthesis by human B cells results from allergen-dependent, T(H)2-mediated isotype switching. Exposure to a farming environment protects against IgE responses. Objective: We reconstructed allergen-dependent switching patterns in vivo to identify the level or levels at which farm exposure acts to protect against atopy. Methods: Serum IgG1 to IgG4 and IgE to grass (rPhl p 1 and rPhl p 5), cat (rFel d 1), and mite (rDer p 2) were assessed by means of ELISA in the Allergy and Endotoxin study population (812 children). Farm exposure was defined as currently living on a farm, exposure to stables/farm milk in the first year of life, or both. Results: Farm exposure did not affect allergen-specific IgG2 and IgG3 levels but had complex allergen-specific effects on lgG1, IgG4, and IgE levels. Exposure protected against grass-specific responses at every step along the IgG1/IgG4/IgE switching pathway but had no significant effect on mite responses. Protection from cat responses was concentrated at the IgG1 level. For all allergens, failure to express IgG1 was associated with low prevalence of IgG4 or IgE responses. Notably, coexpression of IgG1, IgG4, and IgE to grass was associated with increased risk of allergic disease and higher IgE levels compared with production of lgG1 and IgE without IgG4, suggesting IgG4 coexpression marks stronger activation of T(H)2-dependent events. Conclusion: The protective effects of farm exposure were confined to TH2-dependent IgG1, IgG4, and IgE expression and were allergen and switch stage specific, suggesting that distinct mechanisms regulate individual steps within allergen-induced class switching in vivo. Clinical implications: Environmental interventions to prevent IgE expression might need to be tailored to specific allergens.	Univ Arizona, Arizona Resp Ctr, Arizona Hlth Sci Ctr, Funct Genom Lab,Coll Med, Tucson, AZ 85724 USA; Childrens Hosp, Schwarzach, Austria; Univ Munich, Inst Occupat & Environm Med, Munich, Germany; Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; Med Univ Vienna, Clin Inst Med & Chem Lab Diagnost, Vienna, Austria; Med Univ Vienna, Dept Pathophysiol, Ctr Physiol & Pathophysiol, Vienna, Austria; Karolinska Inst, Clin Immunol & Allergy Unit, Dept Med, Stockholm, Sweden; Univ Hosp, Stockholm, Sweden; Univ Childrens Hosp Munich, Munich, Germany; Univ Arizona, Dept Cell Biol, Coll Med, Tucson, AZ USA	University of Arizona; University of Arizona Health Sciences; University of Munich; University of Basel; Medical University of Vienna; Medical University of Vienna; Karolinska Institutet; University of Munich; University of Arizona	Vercelli, D (corresponding author), Univ Arizona, Arizona Resp Ctr, Arizona Hlth Sci Ctr, Funct Genom Lab,Coll Med, Rm 2349,1504 N Campbell Ave, Tucson, AZ 85724 USA.	donata@arc.arizona.edu	van Hage, Marianne/A-9678-2017; riedler, josef/AAQ-4666-2020	van Hage, Marianne/0000-0003-3091-1596; von Mutius, Erika/0000-0002-8893-4515; Valenta, Rudolf/0000-0001-5944-3365; Vrtala, Susanne/0000-0003-4250-8243; Chen, Kuan-Wei/0000-0001-5899-5766; Swoboda, Ines/0000-0002-9164-1721; Gronlund, Hans/0000-0003-4882-7624	NHLBI NIH HHS [HL67672] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067672, P50HL067672] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aghayan-Ugurluoglu R, 2000, J ALLERGY CLIN IMMUN, V105, P803, DOI 10.1067/mai.2000.104782; Aichberger KJ, 2005, J IMMUNOL, V175, P1286, DOI 10.4049/jimmunol.175.2.1286; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Gronlund H, 2003, J BIOL CHEM, V278, P40144, DOI 10.1074/jbc.M301416200; JABARA HH, 1993, J IMMUNOL, V151, P4528; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Linhart B, 2005, CURR OPIN IMMUNOL, V17, P646, DOI 10.1016/j.coi.2005.09.010; MILLS FC, 1992, J IMMUNOL, V149, P1075; Niederberger V, 2002, EUR J IMMUNOL, V32, P576, DOI 10.1002/1521-4141(200202)32:2<576::AID-IMMU576>3.0.CO;2-U; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; STEM D, 2004, NOVART FDN SYMP, V257, P25; Takhar P, 2005, J IMMUNOL, V174, P5024, DOI 10.4049/jimmunol.174.8.5024; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; ZHANG K, 1994, J IMMUNOL, V152, P3427	27	61	63	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					351	358		10.1016/j.jaci.2006.10.013	http://dx.doi.org/10.1016/j.jaci.2006.10.013			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17140649				2022-12-18	WOS:000244327900012
J	Busse, WW; Mitchell, H				Busse, William W.; Mitchell, Herman			Addressing issues of asthma in inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inner city; allergens	EXHALED NITRIC-OXIDE; CHILDHOOD ASTHMA; URBAN CHILDREN; EXPOSURE; MORBIDITY; COCKROACH; ALLERGEN; HOSPITALIZATION; POVERTY; RISK	For children living in the inner city, asthma tends to be more frequent and severe. Although the causes for this heightened severity of asthma are not clearly established, environmental allergens likely play a major role. To characterize, understand, and treat children with asthma living in the inner city better, the National Institutes of Allergy and Infectious Diseases of the National Institutes of Health established an Inner City Asthma Program in 1991. Over the past 15 years, 3 separate inner-city asthma research networks have been formed and funded by this institute. The work from these programs has led to important observations including evidence that environmental allergens, particularly cockroach, are important for sensitization and severity of asthma of the affected children. Furthermore, reductions in the allergen load can lead to improved asthma control. The most recent program, the Inner City Asthma Consortium, was formed in 2002 with a goal to develop immune-based therapy for children with asthma in the inner city and to determine mechanisms of these therapies as well as immunopathogenesis of asthma in these high-risk children. This article reviews these programs and how they have begun the effort to understand and treat children with asthma who live in inner cities better and what their findings mean in relationship to unique features of asthma in inner city children.	Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53792 USA; Rho Fed Syst Div Inc, Chapel Hill, NC USA	University of Wisconsin System; University of Wisconsin Madison	Busse, WW (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, J5-219 CSC 2454,600 Highland Ave, Madison, WI 53792 USA.	wwb@medicine.wisc.edu						Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; Deykin A, 2002, AM J RESP CRIT CARE, V165, P1597, DOI 10.1164/rccm.2201081; Etzel RA, 2003, PEDIATRICS, V112, P233; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; EVANS R, 1987, CHEST S, V91, P65; Galea S, 2005, ANNU REV PUBL HEALTH, V26, P341, DOI 10.1146/annurev.publhealth.26.021304.144708; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; Kharitonov SA, 2004, SWISS MED WKLY, V134, P175; Mansour ME, 2000, PEDIATRICS, V106, P512, DOI 10.1542/peds.106.3.512; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nicholas SW, 2005, AM J PUBLIC HEALTH, V95, P245, DOI 10.2105/AJPH.2004.042705; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Smith LA, 2005, PUBLIC HEALTH REP, V120, P109, DOI 10.1177/003335490512000203; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; WEISS KB, 1992, CHEST, V101, P362	23	61	64	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					43	49		10.1016/j.jaci.2006.10.021	http://dx.doi.org/10.1016/j.jaci.2006.10.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	127YL	17208585				2022-12-18	WOS:000243622200008
J	Wang, YF; McCusker, C				Wang, Yufa; McCusker, Christine			Neonatal exposure with LPS and/or allergen prevents experimental allergic airways disease: Development of tolerance using environmental antigens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergic rhinitis; developmental immunology; allergy prevention; animal model; T-regulatory cells; lipopolysaccharide	TOLL-LIKE RECEPTOR-4; BACTERIAL LIPOPOLYSACCHARIDE; IMMUNE-RESPONSES; MURINE MODEL; EARLY-LIFE; ENDOTOXIN EXPOSURE; REGULATORY CELLS; ATOPIC CHILDREN; DENDRITIC CELLS; HAY-FEVER	Background: Studies show that children in rural environments develop less asthma and allergic rhinitis than their urban counterparts. This may be a result, in part, of neonatal exposure to environmental antigens such as LPS and/or early exposure to allergens. Objective: This study examined the effects of neonatal allergen and/or LPS exposure on subsequent immune responses to allergen. Methods: Newborn mice were exposed to LPS and/or ovalbumin. At age 6 weeks, these animals were sensitized and challenged with ovalbumin, and airway inflammation, hyperresponsiveness, and cytokine expression were assessed. Results: Animals exposed to LPS in the neonatal period developed T cells expressing CD25 and IL-10 on sensitization and challenge. They demonstrated abrogation of airway hyperresponsiveness and significant decreases in IL-13 from bronchoalveolar lavage fluid and in specific IgE. IL-4-expressing spleen cells were also significantly decreased. Mice exposed in the neonatal period to ovalbumin demonstrated airway hyporesponsiveness after subsequent ovalbumin sensitization and challenge and did not produce specific IgE. In contrast, these animals showed increases in IFN-gamma. Animals exposed to both LPS and ovalbumin developed a response characterized by IL-10 and IFN-gamma-expressing T cells. Conclusion: This suggests that mucosal antigen exposure in the neonatal period results in inhibition of allergic responses to environmental allergens. Early LPS exposure directs mucosal responses toward tolerance, whereas ovalbumin exposure follows the T(H)1-type response on subsequent sensitization. Clinical implications: This study suggests that prevention of airways allergy may be best achieved by appropriate exposure of the airway mucosa early in life to environmental antigens.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Res Inst, Montreal Childrens Hosp, Montreal, PQ H2X 2P2, Canada	McGill University; McGill University	McCusker, C (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain, Montreal, PQ H2X 2P2, Canada.	christine.mccusker@mcgill.ca						Adkins B, 2002, J IMMUNOL, V169, P4998, DOI 10.4049/jimmunol.169.9.4998; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2003, INT ARCH ALLERGY IMM, V130, P108, DOI 10.1159/000069012; Amoudruz P, 2005, J ALLERGY CLIN IMMUN, V115, P1304, DOI 10.1016/j.jaci.2005.02.036; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Bottcher MF, 2004, J ALLERGY CLIN IMMUN, V114, P561, DOI 10.1016/j.jaci.2004.04.050; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Cochran JR, 2002, PEDIATR PULM, V34, P267, DOI 10.1002/ppul.10161; Cottrez F, 2000, J IMMUNOL, V165, P4848, DOI 10.4049/jimmunol.165.9.4848; Delayre-Orthez C, 2005, INT ARCH ALLERGY IMM, V138, P298, DOI 10.1159/000088867; Delayre-Orthez C, 2004, CLIN EXP ALLERGY, V34, P1789, DOI 10.1111/j.1365-2222.2004.02082.x; Doganci A, 2005, J CLIN INVEST, V115, P1388, DOI 10.1172/JCI200522433C1; Douwes J, 2004, J ALLERGY CLIN IMMUN, V114, P1051, DOI 10.1016/j.jaci.2004.08.004; Eisenbarth SC, 2004, CURR OPIN PEDIATR, V16, P659, DOI 10.1097/01.mop.0000145920.00101.e4; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gentile DA, 2004, ANN ALLERG ASTHMA IM, V92, P538, DOI 10.1016/S1081-1206(10)61761-9; Gerhold K, 2003, J ALLERGY CLIN IMMUN, V112, P389, DOI 10.1067/mai.2003.1646; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Jaffar Z, 2004, J IMMUNOL, V172, P3842, DOI 10.4049/jimmunol.172.6.3842; Kilpelainen M, 2002, ALLERGY, V57, P1130, DOI 10.1034/j.1398-9995.2002.23341.x; Levesque Benoit, 2004, Can Respir J, V11, P343; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Matsumoto K, 2005, RESPIROLOGY, V10, P18, DOI 10.1111/j.1440-1843.2005.00647.x; McCusker C, 2002, J ALLERGY CLIN IMMUN, V110, P891, DOI 10.1067/mai.2002.130048; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Peters M, 2006, THORAX, V61, P134, DOI 10.1136/thx.2005.049403; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Prescott SL, 2005, CLIN EXP ALLERGY, V35, P417, DOI 10.1111/j.1365-2222.2005.02171.x; Riedl MA, 2005, J IMMUNOL, V174, P7440, DOI 10.4049/jimmunol.174.11.7440; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rodriguez D, 2003, J IMMUNOL, V171, P1001, DOI 10.4049/jimmunol.171.2.1001; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Roponen M, 2005, J ALLERGY CLIN IMMUN, V116, P1048, DOI 10.1016/j.jaci.2005.08.039; Samsom JN, 2005, J IMMUNOL, V174, P5279, DOI 10.4049/jimmunol.174.9.5279; Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tulic MK, 2004, LANCET, V363, P1689, DOI 10.1016/S0140-6736(04)16253-3; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Tulic MK, 2002, INT ARCH ALLERGY IMM, V129, P119, DOI 10.1159/000065881; Uthoff H, 2003, J IMMUNOL, V171, P3485, DOI 10.4049/jimmunol.171.7.3485; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; von Mutius E, 2004, J ALLERGY CLIN IMMUN, V113, P373, DOI 10.1016/j.jaci.2003.12.040; Wang Y, 2005, CLIN EXP ALLERGY, V35, P1104, DOI 10.1111/j.1365-2222.2005.02301.x	49	61	72	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					143	151		10.1016/j.jaci.2006.03.020	http://dx.doi.org/10.1016/j.jaci.2006.03.020			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815150				2022-12-18	WOS:000239184800018
J	Mandron, M; Aries, MF; Brehm, RD; Tranter, HS; Acharya, KR; Charveron, M; Davrinche, C				Mandron, Marie; Aries, Marie-Francoise; Brehm, Rossalyn D.; Tranter, Howard S.; Acharya, K. Ravi; Charveron, Marie; Davrinche, Christian			Human dendritic cells conditioned with Staphylococcus aureus enterotoxin B promote T(H)2 cell polarization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; SFB; TLR; T-H cells polarization	TOLL-LIKE RECEPTOR-2; ATOPIC-DERMATITIS; IL-2 PRODUCTION; T-CELLS; INNATE; INTERLEUKIN-2; MATURATION; ASTHMA; TLR2	Background: Immune surveillance against microbes at sites of interface with environment involves immediate recognition of pathogen-associated molecular patterns by dendritic cells (DCs). According to their first-line position, DCs are key parameters for the establishment of an appropriate innate and adaptive response against pathogens to avoid disease development. Even though their role in pathogenesis is well known, bacterial toxins have been less examined for their ability to drive DC activation and T-cell polarization. Objective: We made the assumption that early conditioning of DCs with Stophylococcus aureus enterotoxins could take part in T-cell polarization. Methods: Human monocyte-derived DCs were stimulated with S aureus enterotoxin B (SEB) and characterized with respect to secretion of inflammatory cytokines and their ability to drive polarization of naive allogenic T cells. Results: We demonstrated that SEB induced maturation of DCs and that SEB-activated DCs secreted high levels of IL-2 but no IL-12p70, contrary to LPS-activated ones. Accordingly, we further showed that SEB-activated DCs were able to drive polarization of naive T cells into the T(H)2 subset. By using highly purified SEB and Toll-like receptor (TLR)-2 stably transfected Human Embryonic Kidney (HEK) 293 cells, we demonstrated for the first time the ability of SEB to induce TLR2 signaling. Furthermore, the involvement of SEB-TLR2 interaction in activation of dendritic cells was supported by neutralizing activity of anti-TLR2 antibodies. Conclusion: Altogether, our findings reinforce the notion that bacterial toxins may appear as new pathogen-associated molecular patterns, which could play a major role in inflammation and bacterial pathologies.	INSERM, U563, F-31024 Toulouse, France; Ctr Europeen Rech Peau & Epitheliums Revetement, Ctr Rech Pierre Fabre, Toulouse, France; Hlth Protect Agcy, Salisbury, Wilts, England; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Health Protection Agency; University of Bath	Davrinche, C (corresponding author), INSERM, U563, BP3028, F-31024 Toulouse, France.	davrinch@toulouse.inserm.fr		Acharya, K. Ravi/0000-0002-3009-4058				Aiba S, 2003, EXP DERMATOL, V12, P86, DOI 10.1034/j.1600-0625.2003.120111.x; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Arrode G, 2002, J VIROL, V76, P142, DOI 10.1128/JVI.76.1.142-150.2002; Bellocchio S, 2004, J IMMUNOL, V172, P3059, DOI 10.4049/jimmunol.172.5.3059; BREHM RD, 1990, APPL ENVIRON MICROB, V56, P1067, DOI 10.1128/AEM.56.4.1067-1072.1990; Chinen J, 2004, J ALLERGY CLIN IMMUN, V114, P398, DOI 10.1016/j.jaci.2004.05.036; Cote-Sierra J, 2004, P NATL ACAD SCI USA, V101, P3880, DOI 10.1073/pnas.0400339101; Delemarre FGA, 2001, J LEUKOCYTE BIOL, V69, P373; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Feau S, 2005, BLOOD, V105, P697, DOI 10.1182/blood-2004-03-1059; Granucci F, 2003, EMBO J, V22, P2546, DOI 10.1093/emboj/cdg261; Granucci F, 2003, J IMMUNOL, V170, P5075, DOI 10.4049/jimmunol.170.10.5075; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Laouini D, 2003, J ALLERGY CLIN IMMUN, V112, P981, DOI 10.1016/j.jaci.2003.07.007; LESTER MR, 1995, CLIN IMMUNOL IMMUNOP, V77, P332, DOI 10.1006/clin.1995.1160; LESTER MR, 1995, J IMMUNOL, V154, P6174; Netea MG, 2004, TRENDS MICROBIOL, V12, P484, DOI 10.1016/j.tim.2004.09.004; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, pS128, DOI DOI 10.1016/j.jaci.2003.09.032; OHMEN JD, 1995, J IMMUNOL, V154, P1956; Patel M, 2005, J IMMUNOL, V174, P7558, DOI 10.4049/jimmunol.174.12.7558; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Sing A, 2002, J EXP MED, V196, P1017, DOI 10.1084/jem.20020908; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304	26	61	64	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1141	1147		10.1016/j.jaci.2005.12.1360	http://dx.doi.org/10.1016/j.jaci.2005.12.1360			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675344				2022-12-18	WOS:000237436300028
J	Chaplin, DD				Chaplin, DD			Overview of the human immune response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adaptive immunity; atopy; dendritic cell; inflammation; innate immunity; toll-like receptors	TOLL-LIKE RECEPTORS; INNATE IMMUNITY; ASTHMA; IL-23; CELLS	The human immune system mobilizes a broad repertoire of innate and adaptive responses to protect against the universe of pathogens it encounters. Central to these protective responses are its mechanisms to distinguish self from nonself. This overview describes the major mechanisms used by the immune system to respond to invading microbes and identifies settings in which disturbed immune function exacerbates tissue injury.	Univ Alabama, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chaplin, DD (corresponding author), Univ Alabama, 845 19th St S,BBRB 276-11, Birmingham, AL 35294 USA.	dchaplin@uab.edu		Chaplin, David/0000-0002-1354-3069				Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Alam Rafeul, 2003, Journal of Allergy and Clinical Immunology, V111, pS476; Artis D, 2004, J IMMUNOL, V173, P5626, DOI 10.4049/jimmunol.173.9.5626; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; Bos JD, 2005, BRIT J DERMATOL, V152, P1098, DOI 10.1111/j.1365-2133.2005.06645.x; Chaplin David D., 2003, Journal of Allergy and Clinical Immunology, V111, pS442; de Jong EC, 2005, SPRINGER SEMIN IMMUN, V26, P289, DOI 10.1007/s00281-004-0167-1; Hayashi T, 2005, J IMMUNOL, V174, P5864, DOI 10.4049/jimmunol.174.9.5864; Hunter CA, 2005, NAT REV IMMUNOL, V5, P521, DOI 10.1038/nri1648; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Morgan BP, 2005, IMMUNOL LETT, V97, P171, DOI 10.1016/j.imlet.2004.11.010; Redecke V, 2004, J IMMUNOL, V172, P2739, DOI 10.4049/jimmunol.172.5.2739; Rottem Menachem, 2002, Dev Immunol, V9, P161, DOI 10.1080/1044667031000137638; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; Takeda K, 2004, J DERMATOL SCI, V34, P73, DOI 10.1016/j.jdermsci.2003.10.002; Woodland DL, 2003, CURR OPIN IMMUNOL, V15, P336, DOI 10.1016/S0952-7915(03)00037-2; Yokoyama WM, 2005, IMMUNOL RES, V32, P317, DOI 10.1385/IR:32:1-3:317	17	61	63	1	21	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		1			S430	S435		10.1016/j.jaci.2005.09.034	http://dx.doi.org/10.1016/j.jaci.2005.09.034			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	019VS	16455341				2022-12-18	WOS:000235865400002
J	Feleszko, W; Zawadzka-Krajewska, A; Matysiak, K; Lewandowska, D; Peradzynska, J; Dinh, QT; Hamelmann, E; Groneberg, DA; Kulus, M				Feleszko, W; Zawadzka-Krajewska, A; Matysiak, K; Lewandowska, D; Peradzynska, J; Dinh, QT; Hamelmann, E; Groneberg, DA; Kulus, M			Parental tobacco smoking is associated with augmented IL-13 secretion in children with allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; IL-13; smoking; pediatric asthma; IgE; environmental tobacco smoke; nasopharyngeal aspirates; IL-5; IL-12; IFN-gamma	RESPIRATORY SYNCYTIAL VIRUS; INDUCED SPUTUM; AIRWAY INFLAMMATION; CHILDHOOD ASTHMA; NASOPHARYNGEAL; HYPERREACTIVITY; INTERLEUKIN-13; CYTOKINES; CELL; INFECTIONS	Background: Exposure to environmental tobacco smoke (ETS) has been shown to increase symptoms of allergic bronchial asthma, but direct effects on the expression of inflammatory markers have not been demonstrated thus far. Objective: The aim of this study was to assess the correlation of ETS exposure with the expression of proinflammatory, mediators in airway secretions, including IFN-gamma and IL-12, as well as IL-5 and IL-13, in allergic asthmatic schoolchildren and healthy control subjects. Methods: By using the nasopharyngeal aspiration technique, airway secretions were collected from 24 atopic children with asthma (age, 6-16 years) and 26 healthy control subjects, and the concentration of cytokines was measured with immunoenzymatic methods. Results: IL-13 levels were highly increased in patients with asthma (P < .005), and parental tobacco smoke resulted in a significant increase in airway IL-13 secretion in these children compared with that seen in nonexposed children and healthy control subjects (median, 860 pg/mL vs 242 pg/ml, and 125 pg/mL, respectively). Furthermore, a positive correlation between IL-13 levels and serum IgE concentrations (r(s) = 0.55) was found in children with allergic asthma. Conclusions: These results indicate that ETS augments the expression and secretion of IL-13 in allergic asthma and that nasopharyngeal aspiration is a suitable method to assess cytokine measurements in airways in children. Measurements of IL-13 in secretions might be taken into account as a noninvasive marker of airway inflammation and to assess the detrimental effects of ETS.	Med Univ Warsaw, Dept Pediat Pneumonol, Childrens Hosp, PL-01184 Warsaw, Poland; Med Univ Warsaw, Dept Allergy, Childrens Hosp, PL-01184 Warsaw, Poland; Med Univ Warsaw, Unit Anaesthesiol, Childrens Hosp, PL-01184 Warsaw, Poland; Free Univ Berlin, Sch Med, Charite, Dept Pneumol & Immunol, D-1000 Berlin, Germany; Humboldt Univ, Berlin, Germany; Univ Med Berlin, Charite, Dept Pediat Pneumol & Immunol, Berlin, Germany	Medical University of Warsaw; Medical University of Warsaw; Medical University of Warsaw; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Feleszko, W (corresponding author), Med Univ Warsaw, Dept Pediat Pneumol & Allergy, Childrens Hosp, Ul Dzialdowska 1-3, PL-01184 Warsaw, Poland.	wfeleszko@kliniczny.pl	Kulus, Marek/W-4821-2018; Peradzynska, Joanna/V-6122-2018; Feleszko, Wojciech/ABH-2616-2020; Groneberg, David/A-5132-2018	Kulus, Marek/0000-0002-5360-4372; Peradzynska, Joanna/0000-0001-6587-0523; Feleszko, Wojciech/0000-0001-6613-2012; Groneberg, David/0000-0001-8551-6556				Bartalesi B, 2005, EUR RESPIR J, V25, P15, DOI 10.1183/09031936.04.00067204; Carlsen KCL, 2001, CURR OPIN ALLERGY CL, V1, P139; Chan-Yeung M, 2003, RESPIROLOGY, V8, P131, DOI 10.1046/j.1440-1843.2003.00453.x; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588, DOI 10.1164/ajrccm.159.2.9801022; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; DiFranza JR, 2004, PEDIATRICS, V113, P1007; Donovan CE, 1999, THORAX, V54, P938, DOI 10.1136/thx.54.10.938; Floreani A A, 1999, Curr Opin Pulm Med, V5, P38, DOI 10.1097/00063198-199901000-00007; Gibson PG, 2000, EUR RESPIR J, V16, P1008; Gibson PG, 1998, J ALLERGY CLIN IMMUN, V102, pS100, DOI 10.1016/S0091-6749(98)70039-9; *GLOB IN ASTHM, 1995, 023659 NIH; Greenfeder S, 2001, RESP RES, V2, P71, DOI 10.1186/rr41; Komai-Koma M, 2001, CLIN EXP ALLERGY, V31, P1441, DOI 10.1046/j.1365-2222.2001.01174.x; Krug N, 2001, AM J RESP CELL MOL, V25, P125, DOI 10.1165/ajrcmb.25.1.4194; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lemanske RF, 2002, PEDIATRICS, V109, P368; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; McKay A, 2004, CLIN EXP ALLERGY, V34, P904, DOI 10.1111/j.1365-2222.2004.01973.x; Nagayama Y, 2001, PEDIATR ALLERGY IMMU, V12, P318, DOI 10.1034/j.1399-3038.2001.0o044.x; *NAT ASTHM ED PREV, 2002, NAT I HTLH; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Oh JW, 2000, ALLERGY ASTHMA PROC, V21, P97, DOI 10.2500/108854100778250888; Oh JW, 2002, PEDIAT ALLERG IMM-UK, V13, P350, DOI 10.1034/j.1399-3038.2002.02018.x; Payne DNR, 2004, THORAX, V59, P862, DOI 10.1136/thx.2003.017244; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Seymour Brian W P, 2003, Clin Dev Immunol, V10, P35, DOI 10.1080/10446670310001598483; Seymour Brian W P, 2002, Dev Immunol, V9, P47, DOI 10.1080/1044667021000003989; Sheeran P, 1999, PEDIATR INFECT DIS J, V18, P115, DOI 10.1097/00006454-199902000-00007; Shoji S, 1998, J ASTHMA, V35, P243, DOI 10.3109/02770909809068214; Strachan DP, 1998, THORAX, V53, P117, DOI 10.1136/thx.53.2.117; Tutka Piotr, 2002, Int J Occup Med Environ Health, V15, P325; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xiang XY, 2002, J VIROL METHODS, V101, P127, DOI 10.1016/S0166-0934(01)00431-1; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	38	61	64	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					97	102		10.1016/j.jaci.2005.09.008	http://dx.doi.org/10.1016/j.jaci.2005.09.008			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387591				2022-12-18	WOS:000235687100016
J	Matsuda, K; Piliponsky, AM; Iikura, M; Nakae, S; Wang, EW; Dutta, SM; Kawakami, T; Tsai, M; Galli, SJ				Matsuda, K; Piliponsky, AM; Iikura, M; Nakae, S; Wang, EW; Dutta, SM; Kawakami, T; Tsai, M; Galli, SJ			Monomeric IgE enhances human mast cell chemokine production: ILA-4 augments and dexamethasone suppresses the response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						apoptosis; chemokines; monomeric IgE; sodium azide; umbilical cord blood-derived mast cells	FC-EPSILON-RI; MONOCYTE CHEMOATTRACTANT PROTEIN-1; UMBILICAL-CORD BLOOD; HIGH-AFFINITY; IMMUNOGLOBULIN-E; HUMAN BASOPHILS; UP-REGULATION; I EXPRESSION; RECEPTOR; ASTHMA	Background: Mouse monoclonal IgE antibodies can promote the survival of mouse bone marrow-derived cultured mast cells and induce the cells to secrete mediators in the absence of known specific antigen. Objective: To determine whether human IgE, in the absence of known specific antigen, had effects on the mediator secretion or survival of human mast cells. Methods: We tested whether human IgE induced human cord blood-derived mast cells to secrete mediators or enhanced their survival on withdrawal of stem cell factor. Results: Exposure to IgE, but not IgG, at concentrations as low as 2.5 mu g/mL significantly enhanced the release of IL-8 and monocyte chemoattractant protein 1, but not histamine or cysteinyl leukotrienes. However, under the conditions tested, chemokine production in response to IgE alone was significantly less than that induced when aliquots of the same IgE-sensitized populations of human mast cells were stimulated with anti-IgE. The production of IL-8 and monocyte chemoattractant protein 1 in response to either IgE alone or IgE and anti-IgE was enhanced by preincubation of the cells in IL-4 and was inhibited by preincubation of the cells with dexamethasone. By contrast, we did not detect any ability of IgE to enhance mast cell survival on withdrawal of stem cell factor. Conclusion: Exposure to human IgE in vitro in the absence of known specific antigen can enhance chemokine production by human mast cells, and this secretory response can be enhanced by preincubation of the mast cells with IL-4 and can be suppressed by dexamethasone.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA USA	Stanford University; La Jolla Institute for Immunology	Galli, SJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.	sgalli@stanford.edu	Kawakami, Toshiaki/O-1616-2015	Tsai, Mindy/0000-0002-8421-4721	NATIONAL CANCER INSTITUTE [R01CA072074] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL067674, P01HL067674] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023990, R01AI050209, R37AI023990] Funding Source: NIH RePORTER; NCI NIH HHS [CA72074] Funding Source: Medline; NHLBI NIH HHS [HL67674] Funding Source: Medline; NIAID NIH HHS [AI23990, AI50209] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Beeh KM, 2000, EUR RESPIR J, V16, P609, DOI 10.1034/j.1399-3003.2000.16d07.x; Borkowski TA, 2001, J IMMUNOL, V167, P1290, DOI 10.4049/jimmunol.167.3.1290; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Campbell EM, 1999, J IMMUNOL, V163, P2160; Cruse G, 2005, EUR RESPIR J, V25, P858, DOI 10.1183/09031936.05.00091704; Gilchrest H, 2003, LIFE SCI, V73, P2571, DOI 10.1016/S0024-3205(03)00607-6; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Hsu C, 1996, IMMUNOL LETT, V52, P129, DOI 10.1016/0165-2478(96)02599-0; Inamura H, 2002, INT ARCH ALLERGY IMM, V128, P142, DOI 10.1159/000059405; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kempuraj D, 1999, BLOOD, V93, P3338, DOI 10.1182/blood.V93.10.3338.410k05_3338_3346; KIMURA I, 1973, Clinical Allergy, V3, P195, DOI 10.1111/j.1365-2222.1973.tb01321.x; Kitaura J, 2003, P NATL ACAD SCI USA, V100, P12911, DOI 10.1073/pnas.1735525100; Kubo S, 2001, J IMMUNOL, V167, P3427, DOI 10.4049/jimmunol.167.6.3427; Lloyd CM, 2003, CURR OPIN PHARMACOL, V3, P443, DOI 10.1016/S1471-4892(03)00069-9; Lukacs NW, 2001, NAT REV IMMUNOL, V1, P108, DOI 10.1038/35100503; MacGlashan D, 2000, J LEUKOCYTE BIOL, V68, P479; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; NILSSON G, 1994, J IMMUNOL, V153, P3717; Ohashi Y, 1997, ANN ALLERG ASTHMA IM, V79, P213, DOI 10.1016/S1081-1206(10)63004-9; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Saito H, 1996, J IMMUNOL, V157, P343; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Szalai C, 2001, J ALLERGY CLIN IMMUN, V108, P375, DOI 10.1067/mai.2001.117930; Tachimoto H, 2002, INT ARCH ALLERGY IMM, V128, P18, DOI 10.1159/000059414; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; Toru H, 1996, INT IMMUNOL, V8, P1367; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Wilhelm S, 1997, IMMUNOL LETT, V59, P53, DOI 10.1016/S0165-2478(97)00099-0; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Xia HZ, 1997, J IMMUNOL, V159, P2911; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yamaguchi M, 1999, J IMMUNOL, V162, P5455	39	61	67	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1357	1363		10.1016/j.jaci.2005.08.042	http://dx.doi.org/10.1016/j.jaci.2005.08.042			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337471				2022-12-18	WOS:000235687000030
J	Taylor-Clark, TE; Kollarik, M; MacGlashan, DW; Undem, BJ				Taylor-Clark, TE; Kollarik, M; MacGlashan, DW; Undem, BJ			Nasal sensory nerve populations responding to histamine and capsaicin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						trigeminal; nasal symptoms; sensory nerve; C-fiber; histamine; capsaicin; substance P	EXPERIMENTAL ALLERGIC RHINITIS; GENE-RELATED PEPTIDE; GUINEA-PIG MODEL; SUBSTANCE-P; HORSERADISH-PEROXIDASE; TRIGEMINAL GANGLION; CENTRAL PROJECTIONS; NEURONS; MUCOSA; RECEPTORS	Background: Inflammation of the nasal mucosa leads to sneezing, nasal itch, rhinorrhea, and nasal blockage. Many of these symptoms are likely the result of nasal trigeminal sensory nerve stimulation by inflammatory mediators. Nasal challenge with the C-fiber stimulant capsaicin causes a different set of symptoms than those evoked by histamine, suggesting that these 2 stimuli may activate separate subpopulations of nasal sensory nerves. Objective: To investigate the trigeminal sensory nerves innervating the guinea pig nasal mucosa and to address specifically the hypothesis that histamine and capsaicin activate distinct subgroups of these nerves. Methods: Guinea pig trigeminal neurons (retrogradely labeled from the nasal mucosa) were assessed for their responses to histamine and capsaicin by studying changes in the intracellular free calcium concentration, and assessed for substance P immumoreactivity. Results: Only 60% of the nasal-specific trigeminal sensory neurons were found to be capsaicin-sensitive. Histamine stimulated only a subset (< 40%) of these capsaicin-sensitive neurons. No nasal-specific capsaicin-insensitive neurons responded to histamine, although about 10% of trigeminal ganglion neurons per se responded to histamine but not capsaicin. Immunohistochemical analysis revealed that most (about 60%) of the sensory neurons innervating the nasal mucosa did not express the neuropeptide substance P, including nearly all large-diameter neurons, but also a significant number of small-diameter neurons (presumably C-fiber neurons). Conclusion: Nasal neurons are not homogenous with respect to chemosensitivity or substance P content. It is likely that this heterogeneity in nasal afferent nerves underlies the differences in nasal responses to specific inflammatory mediators associated with the allergic reaction.	Johns Hopkins Univ, Sch Med, Div Clin Immunol, Dept Med, Baltimore, MD 21218 USA	Johns Hopkins University	Undem, BJ (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	bundem@jhmi.edu	Taylor-Clark, Thomas/I-6148-2012	Taylor-Clark, Thomas/0000-0002-5056-2699				Andrew D, 2001, NAT NEUROSCI, V4, P72, DOI 10.1038/82924; ANTON F, 1991, NEUROSCIENCE, V41, P617, DOI 10.1016/0306-4522(91)90354-Q; ASAKURA K, 1994, EUR ARCH OTO-RHINO-L, V251, P224, DOI 10.1007/BF00628428; Dinh QT, 2003, NEUROPEPTIDES, V37, P245, DOI 10.1016/S0143-4179(03)00065-9; Dutschmann M, 2002, PFLUG ARCH EUR J PHY, V444, P227, DOI 10.1007/s00424-002-0797-x; ECCLES R, 2003, UPPER LOWER RESP DIS, P87; Fukuda S, 2003, EUR J PHARMACOL, V476, P239, DOI 10.1016/S0014-2999(03)02188-5; GRUNDITZ T, 1994, ANAT EMBRYOL, V189, P327; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hill SJ, 1997, PHARMACOL REV, V49, P253; Hunter DD, 1998, NEUROSCIENCE, V83, P591, DOI 10.1016/S0306-4522(97)00324-2; Hunter DD, 2000, AM J RESP CRIT CARE, V161, P543, DOI 10.1164/ajrccm.161.2.9812083; IMAMURA T, 1992, AGENTS ACTIONS, V37, P245, DOI 10.1007/BF02028116; Kashiba H, 1999, MOL BRAIN RES, V66, P24, DOI 10.1016/S0169-328X(98)00346-5; Kim BM, 2004, NEUROSCI LETT, V361, P159, DOI 10.1016/j.neulet.2004.01.019; KIRKEGAARD J, 1983, BRIT J DIS CHEST, V77, P113, DOI 10.1016/0007-0971(83)90017-7; KOKUMAI S, 1992, INT ARCH ALLERGY IMM, V98, P256, DOI 10.1159/000236194; KONNO A, 1995, ANN OTO RHINOL LARYN, V104, P730, DOI 10.1177/000348949510400912; Konno A, 1996, ANN OTO RHINOL LARYN, V105, P648, DOI 10.1177/000348949610500811; LAWSON SN, 1993, BRAIN RES BULL, V30, P239, DOI 10.1016/0361-9230(93)90250-F; Lucier G E, 1988, J Chem Neuroanat, V1, P303; LUCIER GE, 1986, J COMP NEUROL, V247, P123, DOI 10.1002/cne.902470108; LUCIER GE, 1989, EXP NEUROL, V103, P83, DOI 10.1016/0014-4886(89)90189-1; MACGLASHAN D, 1989, J CELL BIOL, V109, P123, DOI 10.1083/jcb.109.1.123; Nicolson TA, 2002, NEUROSCIENCE, V110, P329, DOI 10.1016/S0306-4522(01)00561-9; PHILIP G, 1994, J ALLERGY CLIN IMMUN, V94, P1035, DOI 10.1016/0091-6749(94)90122-8; PIEDIMONTE G, 1993, J PHARMACOL EXP THER, V265, P36; Plevkova J, 2004, J Physiol Pharmacol, V55 Suppl 3, P101; Plevkova J, 2004, RESP PHYSIOL NEUROBI, V142, P225, DOI 10.1016/j.resp.2004.06.006; Schaefer ML, 2002, J COMP NEUROL, V444, P221, DOI 10.1002/cne.10143; Schmelz M, 2003, J NEUROPHYSIOL, V89, P2441, DOI 10.1152/jn.01139.2002; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; Sekizawa S, 1998, RESP PHYSIOL, V112, P13, DOI 10.1016/S0034-5687(98)00009-7; Sekizawa S, 1996, RESP PHYSIOL, V103, P211, DOI 10.1016/0034-5687(95)00091-7; SEKIZAWA S, 1994, RESP PHYSIOL, V96, P37, DOI 10.1016/0034-5687(94)90104-X; Sekizawa SI, 1996, RESP PHYSIOL, V106, P223, DOI 10.1016/S0034-5687(96)00085-0; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; Tai CF, 2003, CURR ALLERGY ASTHM R, V3, P215, DOI 10.1007/s11882-003-0042-5; TANI E, 1990, NEUROSCI LETT, V112, P1, DOI 10.1016/0304-3940(90)90312-W; TANI E, 1990, NEUROSCI LETT, V115, P171, DOI 10.1016/0304-3940(90)90450-N; Taylor-Clark T, 2005, CURR OPIN PHARMACOL, V5, P214, DOI 10.1016/j.coph.2004.12.004; Tiniakov RL, 2003, J APPL PHYSIOL, V94, P1821, DOI 10.1152/japplphysiol.00930.2002; TOTHKASA I, 1986, INT J CLIN PHARM RES, V6, P163; Wasner G, 2004, EUR J PAIN, V8, P179, DOI 10.1016/S1090-3801(03)00099-5; Widdicombe JG, 1996, CLIN EXP ALLERGY, V26, P32, DOI 10.1111/j.1365-2222.1996.tb00656.x	45	61	63	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1282	1288		10.1016/j.jaci.2005.08.043	http://dx.doi.org/10.1016/j.jaci.2005.08.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337460	Bronze			2022-12-18	WOS:000235687000019
J	Brisbon, N; Plumb, J; Brawer, R; Paxman, D				Brisbon, N; Plumb, J; Brawer, R; Paxman, D			The asthma and obesity epidemics: The role played by the built environment - a public health perspective	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; obesity; environment; built environment	AGE	Obesity and asthma have reached epidemic proportions in the United States. The reasons for these epidemics are complex, and the solutions to address them are many. This article explores the epidemics, their causes and consequences, associations and relationships, an expansion of the definition of the environment, and current national initiatives that address the components of the built and social environments that promote obesity and precipitate asthma.	Thomas Jefferson Univ, Dept Family Med, Philadelphia, PA USA; Thomas Jefferson Univ Hosp, Off Adv Populat Hlth, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Plumb, J (corresponding author), 1015 Walnut,Suite 401, Philadelphia, PA 19107 USA.	james.plumb@jefferson.edu		Brawer, Rickie/0000-0002-3566-5702				Daviglus ML, 2004, JAMA-J AM MED ASSOC, V292, P2743, DOI 10.1001/jama.292.22.2743; Fielding JE, 2002, AM J PREV MED, V22, P67; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gennuso J, 1998, ARCH PEDIAT ADOL MED, V152, P1197; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; *HLTH CAN DIV CHIL, 2002, NAT BUILT ENV; Orleans CT, 2003, ANN BEHAV MED, V25, P77, DOI 10.1207/S15324796ABM2502_02; Redd SC, 2002, AM J EPIDEMIOL, V155, P198, DOI 10.1093/aje/155.3.198; Srinivasan S, 2003, AM J PUBLIC HEALTH, V93, P1446, DOI 10.2105/AJPH.93.9.1446; Tantisira KG, 2001, THORAX, V56, P64; *US DEP HHS, 2001, HLTH PEOPL 2010	11	61	63	4	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1024	1028		10.1016/j.jaci.2005.02.020	http://dx.doi.org/10.1016/j.jaci.2005.02.020			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	925LR	15867861				2022-12-18	WOS:000229055100019
J	Hoffman, DR; Sakell, RH; Schmidt, M				Hoffman, DR; Sakell, RH; Schmidt, M			Sol i 1, the phospholipase allergen of imported fire ant venom	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fire ant; phospholipase; venom; cross-reactivity; carbohydrate; allergen	AMINO-ACID-SEQUENCES; ANTIGENIC CROSS-REACTIVITY; YELLOW JACKET VENOM; SOL-I-II; HYMENOPTERA VENOM; SOLENOPSIS-INVICTA; PANCREATIC LIPASE; VESPID VENOMS; WASP VENOMS; HORNET	Background: Sol i 1, the venom phospholipase of imported fire ant venom is an important allergen and exhibits some cross-reactivity with IgE antibodies from patients sensitized to other Hymenoptera venoms. Objective: To determine the primary structure of Sol i 1 and evaluate the roles of protein and carbohydrate epitopes in its cross-reactivity. Methods: Sol i 1 was purified from venom, proteolytic peptides prepared and amino acid sequences obtained. The cDNA for Sol i 1 was cloned, sequenced, and compared with sequences of other wasp venom phospholipases. The role of carbohydrate epitopes in the cross-reactivity with other Hymenoptera venoms was studied by RAST inhibition. Results: The sequence identified Sol i 1 as a lipase of the GX class, lipoprotein lipase superfamily, pancreatic lipase homologous family and RP2 subgroup phospholipases as are the vespid venom phospholipases. The 148 residues identified by amino acid sequencing represent about 48% of the translated cDNA sequence. Sol i 1 was 31-32% identical to yellow jacket phospholipases. The identical regions of sequence were clustered in the domain which forms the serine hydrolase active site. Mannosylated N-glyeans could completely inhibit binding of IgE from honeybee venom sensitized patients to Sol i 1. Inhibition by glycan of IgE binding from yellow jacket venom sensitized patients was low or absent for three of eight sera and substantial, but not complete for five sera. Conclusions: Sol i 1 is related to wasp venom phospholipases. Cross-reactivity with honeybee venom is caused by carbohydrate, whereas cross-reactivity with yellow jacket venom involves reactivity with both carbohydrate determinants of hyaluronidase and high molecular weight proteins and phospholipase protein determinants.	E Carolina Univ, Dept Pathol & Lab Med, Brody Sch Med, Greenville, NC 27834 USA; E Carolina Univ, Dept Biol, Greenville, NC 27834 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Hoffman, DR (corresponding author), E Carolina Univ, Dept Pathol & Lab Med, Brody Sch Med, Greenville, NC 27834 USA.	hoffmand@mail.ecu.edu						BORRIELLO F, 1990, NUCLEIC ACIDS RES, V18, P5481, DOI 10.1093/nar/18.18.5481; DUGI KA, 1992, J BIOL CHEM, V267, P25086; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; Fischer M, 2003, NUCLEIC ACIDS RES, V31, P319, DOI 10.1093/nar/gkg015; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hemmer W, 2004, CLIN EXP ALLERGY, V34, P460, DOI 10.1111/j.1365-2222.2004.01897.x; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; Hoffman D., 2003, MONOGRAPH INSECT ALL, P37; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1994, INT ARCH ALLERGY IMM, V104, P184, DOI 10.1159/000236728; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1979, ANN ALLERGY, V42, P224; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; LOMBARDO D, 1989, J MOL BIOL, V205, P259, DOI 10.1016/0022-2836(89)90380-X; MICKEL FS, 1989, J BIOL CHEM, V264, P12895; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NORDVALL SL, 1985, J ALLERGY CLIN IMMUN, V75, P122, DOI 10.1016/0091-6749(85)90207-6; Schmidt M, 2003, ALLERGY, V58, P342, DOI 10.1034/j.1398-9995.2003.00085.x; SCHMIDT M, 1993, FEBS LETT, V319, P138, DOI 10.1016/0014-5793(93)80053-W; Schmidt M, 2001, J ALLERGY CLIN IMMUN, V107, pS112; Schmidt M, 1996, J ALLERGY CLIN IMMUN, V98, P82, DOI 10.1016/S0091-6749(96)70229-4; SOLDATOVA L, 1993, FEBS LETT, V320, P145, DOI 10.1016/0014-5793(93)80080-E; [No title captured]	29	61	67	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					611	616		10.1016/j.jaci.2004.11.020	http://dx.doi.org/10.1016/j.jaci.2004.11.020			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753912				2022-12-18	WOS:000227687000027
J	Guajardo, JR; Schleifer, K; Daines, MO; Ruddy, RM; Aronow, BJ; Wills-Karp, M; Hershey, GKK				Guajardo, JR; Schleifer, K; Daines, MO; Ruddy, RM; Aronow, BJ; Wills-Karp, M; Hershey, GKK			Altered gene expression profiles in nasal respiratory epithelium reflect stable versus acute childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; childhood; microarray; genetics	ALLERGIC DISEASES; MOUSE MODEL; COMPLEMENT; EOSINOPHILS; IMMUNOLOGY; RECEPTOR; C3A	Background: Asthma is the most common chronic disease of childhood and has a strong genetic component. Objective: To identify gene expression signatures that reflect asthma-related processes and to determine whether these genes were similar or distinct between stable asthma and acute exacerbations in childhood, we profiled gene expression patterns in nasal respiratory epithelial cells. Methods: Children who had stable asthma (asthma-S; n = 10) and children experiencing an asthma exacerbation (asthma-E; n = 10) were recruited along with nonatopic children without asthma (n = 10). RNA was prepared from nasal respiratory epithelial cells isolated from each child, initially analyzed as pooled samples from the 3 groups, and further validated by using microarrays and RT-PCR with individual patient samples. Results: Distinct gene clusters were identifiable in individual and pooled asthma-S and asthma-E samples. Asthma-E samples demonstrated the strongest and most reproducible signatures, with 314 genes of 34,886 measured as present on the chip demonstrating induction or repression of greater than 2-fold with P < .05 in each of 4 individual samples. Asthma-S-regulated genes encompassed genes that overlapped with those of asthma-E but were fewer (166) and less consistent with respect to their behavior across the asthma-E patient samples. Conclusion: Exacerbated asthma status is readily distinguished based on the occurrence of strong gene expression signatures in nasal epithelial samples. Stable asthma status also exhibits differential signatures. The results suggest that there are independent gene expression signatures reflective of cells and genes poised or committed to activation by an asthma attack.	Cincinnati Childrens Hosp, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA; Cincinnati Childrens Hosp, Dept Pediat, Div Immunol, Cincinnati, OH 45229 USA; Cincinnati Childrens Hosp, Dept Pediat, Div Emergency Med, Cincinnati, OH 45229 USA; Cincinnati Childrens Hosp, Dept Pediat, Div Dev Biol & Pediat Informat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Hershey, GKK (corresponding author), Cincinnati Childrens Hosp, Dept Pediat, Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Gurjit.Hershey@chmcc.org	Aronow, Bruce J/F-8438-2012	Daines, Michael/0000-0003-2464-9034	NHLBI NIH HHS [R01 HL72987] Funding Source: Medline; NIAID NIH HHS [R01 AI46652-01A1, K08 AI053150] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI053150, R01AI046652] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Bates MD, 2002, GASTROENTEROLOGY, V122, P1467, DOI 10.1053/gast.2002.32975; Brutsche MH, 2002, J ALLERGY CLIN IMMUN, V109, P271, DOI 10.1067/mai.2002.121530; Drouin SM, 2001, J IMMUNOL, V167, P4141, DOI 10.4049/jimmunol.167.8.4141; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; GORDON A, 1999, MONOGRAPHS STAT APPL, P41; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Joseph CLM, 1998, J ALLERGY CLIN IMMUN, V101, P484, DOI 10.1016/S0091-6749(98)70355-0; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; Kunkel S L, 1999, Forum (Genova), V9, P339; Lee JH, 2001, AM J RESP CELL MOL, V25, P474, DOI 10.1165/ajrcmb.25.4.4522; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Matheson JM, 2001, CLIN EXP ALLERGY, V31, P1067, DOI 10.1046/j.1365-2222.2001.01125.x; McGill KA, 1998, PEDIATRICS, V102, P77, DOI 10.1542/peds.102.1.77; Meerschaert J, 1999, J IMMUNOL, V163, P6217; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; *NCI, 2002, MICR TRACK SYST NCI; Oda T, 2000, J BIOL CHEM, V275, P36781, DOI 10.1074/jbc.M006480200; Schneider E, 2002, TRENDS IMMUNOL, V23, P255, DOI 10.1016/S1471-4906(02)02215-9; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912; Zou J, 2002, GENOME BIOL, V3	31	61	69	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					243	251		10.1016/j.jaci.2004.10.032	http://dx.doi.org/10.1016/j.jaci.2004.10.032			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696077	Bronze			2022-12-18	WOS:000227043600006
J	Hajoui, O; Janani, R; Tulic, M; Joubert, P; Ronis, T; Hamid, Q; Zheng, H; Mazer, BD				Hajoui, O; Janani, R; Tulic, M; Joubert, P; Ronis, T; Hamid, Q; Zheng, H; Mazer, BD			Synthesis of IL-13 by human B lymphocytes: Regulation and role in IgE production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B lymphocytes; cytokines; IL-13; allergy; IgE	NASAL-MUCOSA; T-CELLS; INTRAVENOUS IMMUNOGLOBULIN; SIGNALING PATHWAYS; ALLERGIC-ASTHMA; GERMINAL CENTER; CD40 LIGAND; DIFFERENTIATION; INTERLEUKIN-13; EXPRESSION	Background: Our laboratory has demonstrated previously that human tonsillar B lymphocytes express IL-13 mRNA Objective: We sought to investigate IL-13 production by human B cells and the association between B cell-derived IL-13 and IgE secretion. Methods: Human B lymphocytes were isolated from tonsils and purified by means of rosetting with sheep RBCs or positive or negative selection with magnetic beads. They were stimulated with anti-CD40 antibodies with or without recombinant IL-4. Total mRNA was extracted, and IL-13 mRNA was measured by means of standard RT-PCR or by means of real-time PCR with commercially available primers. B cells were cultured with or without IL-13 neutralizing antibodies, and Cepsilon transcripts and supernatant IgE levels were measured. Results: IL-13 mRNA was detected in human B lymphocytes stimulated with anti-CD40 antibodies and IL-4 or IL-2 but not in unstimulated B cells. Real-time PCR demonstrated a 10- to 15-fold increase in IL-13 mRNA, maximizing at 36 hours. IL-13 protein was detected from B lymphocytes on day 3 and accumulated through day 7. The synthesis of IL-13 required both CD40 and IL-4 stimulation. The presence of IL-13 was confirmed by means of intracellular staining of cultured B lymphocytes and antigen-stimulated nasal biopsy specimens from atopic individuals. Addition of IL-13 neutralizing antibodies to purified B-cell cultures inhibited IgE production by up to 80% and diminished IgE (Cepsilon) transcripts by 50%. Conclusion: Human B lymphocytes express IL-13 mRNA after ligation of CD40 and the addition of cytokines. Human B lymphocytes produce significant IL-13, and neutralization of IL-13 impairs IgE synthesis. IL-13 might be an important autocrine growth factor for IgE-producing B lymphocytes.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Hlth Ctr, Childrens Hosp, Div Allergy & Immunol, Montreal, PQ H3A 2T5, Canada	McGill University; McGill University	Mazer, BD (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	Bruce.Mazer@McGill.ca	Tulic, Meri K/ABB-5138-2020; Tulic, Meri/P-6613-2016	Tulic, Meri K/0000-0002-2661-2369; Tulic, Meri/0000-0002-2661-2369; Ronis, Tova/0000-0003-3223-5069; Joubert, Philippe/0000-0001-7784-6387				Bastien Y, 1999, J IMMUNOL, V162, P5498; Bellinghausen I, 2003, IMMUNOLOGY, V108, P167, DOI 10.1046/j.1365-2567.2003.01576.x; Bergeron C, 2003, CLIN EXP ALLERGY, V33, P1389, DOI 10.1046/j.1365-2222.2003.01785.x; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Burdin N, 1997, METHODS, V11, P98, DOI 10.1006/meth.1996.0393; BURDIN N, 1995, J IMMUNOL, V154, P2533; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330, DOI 10.1016/S0091-6749(98)70244-1; Cerutti A, 1998, J IMMUNOL, V160, P2145; Dadgostar H, 2002, P NATL ACAD SCI USA, V99, P1497, DOI 10.1073/pnas.032665099; Dalwadi H, 2003, J IMMUNOL, V170, P1707, DOI 10.4049/jimmunol.170.4.1707; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; Hajoui O, 2002, J ALLERGY CLIN IMMUN, V109, pS319, DOI 10.1016/S0091-6749(02)82119-4; Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717; Hershey GKK, 2003, J ALLERGY CLIN IMMUN, V111, P677, DOI 10.1067/mai.2003.1333; Jeppson JD, 1998, J IMMUNOL, V161, P1738; Li HM, 1996, J IMMUNOL, V156, P4833; Li L, 1996, CELL IMMUNOL, V168, P133, DOI 10.1006/cimm.1996.0059; Macaulay AE, 1997, J IMMUNOL, V158, P4171; MALEFYT RD, 1995, INT IMMUNOL, V7, P1405, DOI 10.1093/intimm/7.9.1405; Oettgen HC, 2000, CURR OPIN IMMUNOL, V12, P618, DOI 10.1016/S0952-7915(00)00153-9; Palmer EM, 1997, J IMMUNOL, V158, P2654; Prieto J, 2001, CLIN EXP ALLERGY, V31, P791, DOI 10.1046/j.1365-2222.2001.01078.x; Sartori A, 1997, METHODS, V11, P116, DOI 10.1006/meth.1996.0395; Schultze JL, 1999, J EXP MED, V189, P1, DOI 10.1084/jem.189.1.1; Sigman K, 1998, J ALLERGY CLIN IMMUN, V102, P421, DOI 10.1016/S0091-6749(98)70130-7; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Tulic MK, 2004, LANCET, V363, P1689, DOI 10.1016/S0140-6736(04)16253-3; Tulic MK, 2002, J ALLERGY CLIN IMMUN, V110, P771, DOI 10.1067/mai.2002.128857; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Woerly G, 2002, J LEUKOCYTE BIOL, V72, P769; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Yanagihara Y, 1998, CLIN EXP IMMUNOL, V111, P136; Zhuang QL, 2001, J ALLERGY CLIN IMMUN, V108, P229, DOI 10.1067/mai.2001.116291	35	61	68	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					657	663		10.1016/j.jaci.2004.05.034	http://dx.doi.org/10.1016/j.jaci.2004.05.034			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	853AX	15356573				2022-12-18	WOS:000223799600029
J	Wisnewski, AV; Stowe, MH; Cartier, A; Liu, Q; Liu, J; Chen, L; Redlich, CA				Wisnewski, AV; Stowe, MH; Cartier, A; Liu, Q; Liu, J; Chen, L; Redlich, CA			Isocyanate vapor-induced antigenicity of human albumin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hexamethylene di-isocyanate; HDl; vapor; albumin; IgG; IgE; exposure; occupational asthma	TOLUENE DIISOCYANATE TDI; HUMAN SERUM-ALBUMIN; OCCUPATIONAL ASTHMA; IGE ANTIBODIES; HEXAMETHYLENE DIISOCYANATE; EXPOSED WORKERS; RAST; HYPERSENSITIVITY; RESPONSES; HSA	Background: The bioreactivity of isocyanate, a leading cause of occupational asthma, has led to uncertainty regarding the chemical's antigenicity and mechanisms that elicit immunopathology. Objective: To understand better the biologically relevant antigenic forms of hexamethylene diisocyanate (HDI), commonly used in the auto body industry. Methods: Human albumin was exposed to HDI vapors through a novel approach designed to model the air-liquid interface of the human airway. Vapor HDI-exposed albumin was characterized by electrophoresis, chemical substitution analysis, mass spectrometry, and serology studies on auto body shop workers (N = 203) and HDI asthmatics (N = 11). Results: HDI vapors caused significant changes in the shape and/or charge of human albumin, which differed from albumin exposed to liquid phase HDI, with lower isocyanate substitution ratios and distinct electrophoretic mobility. Specific sites of vapor HDI conjugation to albumin were identified at His(247) and Lys(414). Vapor HDI-exposed albumin was specifically recognized by the Immoral arm of the human immune system, with a strong dependence on albumin as the carrier. Vapor HDI-exposed albumin-specific IgG titers were significantly associated with HDI exposure (P = .001), and specific IgE was detectable in 55% (6/11) of isocyanate asthmatics versus 1.5% (3/203) of exposed healthy workers. Parallel studies using HDI-exposed albumin conjugates produced by previously published methods showed less significant associations of HDI-specific IgG and IgE with exposure and disease, respectively. Conclusion: HDI-albumin conjugates produced by novel vapor phase exposure methods may be more physiologically relevant than those produced by previously published methods and of greater utility, in characterizing the immune responses associated with HDI exposure and asthma.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada	Yale University; Universite de Montreal	Wisnewski, AV (corresponding author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,LCI-105, New Haven, CT 06520 USA.	adam.wisnewski@yale.edu		Chen, Liang/0000-0001-7300-6604	NCRR NIH HHS [M01 RR 00125] Funding Source: Medline; NHLBI NIH HHS [HL 62622, R01 HL062622-03, R01 HL062622] Funding Source: Medline; NIEHS NIH HHS [ES 00355] Funding Source: Medline; NIOSH CDC HHS [OH 3457] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [R01OH003457] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIOSH CDC HHS; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH))		Aul DJ, 1999, J ALLERGY CLIN IMMUN, V103, P749, DOI 10.1016/S0091-6749(99)70415-X; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; Baur X, 1996, INT ARCH ALLERGY IMM, V110, P332, DOI 10.1159/000237325; BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; Bernstein DI, 1997, JAMA-J AM MED ASSOC, V278, P1907, DOI 10.1001/jama.278.22.1907; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; COLIGAN JE, 1998, CURRENT PROTOCOLS IM; Cullinan P, 1998, CLIN EXP ALLERGY, V28, P668; DANKS JM, 1981, CLIN ALLERGY, V11, P161, DOI 10.1111/j.1365-2222.1981.tb01580.x; DESAYMARD C, 1975, EUR J IMMUNOL, V5, P541, DOI 10.1002/eji.1830050807; FORD WH, 1978, INT ARCH ALLER A IMM, V56, P136, DOI 10.1159/000232016; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; Gelamo EL, 2002, BBA-PROTEIN STRUCT M, V1594, P84, DOI 10.1016/S0167-4838(01)00287-4; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V86, P94, DOI 10.1016/S0091-6749(05)80128-9; GRAMMER LC, 1988, J ALLERGY CLIN IMMUN, V82, P627, DOI 10.1016/0091-6749(88)90975-X; GRUNEWALDER E, 1986, ALLERGY, V41, P203, DOI 10.1111/j.1398-9995.1986.tb00301.x; JIN R, 1988, CHEM RES TOXICOL, V1, P288, DOI 10.1021/tx00005a006; Karol M H, 1982, Fundam Appl Toxicol, V2, P108, DOI 10.1016/S0272-0590(82)80090-0; KAROL MH, 1995, ALLERGY, V50, P48, DOI 10.1111/j.1398-9995.1995.tb02482.x; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; KENNEDY AL, 1994, ARCH TOXICOL, V68, P434, DOI 10.1007/s002040050094; LISS GM, 1988, J ALLERGY CLIN IMMUN, V82, P55, DOI 10.1016/0091-6749(88)90051-6; Liu Q, 2003, ANN ALLERG ASTHMA IM, V90, P35, DOI 10.1016/S1081-1206(10)61647-X; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; NIELSEN J, 1988, J ALLERGY CLIN IMMUN, V82, P126, DOI 10.1016/0091-6749(88)90062-0; PAGGIARO PL, 1983, CLIN ALLERGY, V13, P75, DOI 10.1111/j.1365-2222.1983.tb02570.x; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847, DOI 10.1016/S0091-6749(99)70297-6; PEPYS J, 1972, Clinical Allergy, V2, P225, DOI 10.1111/j.1365-2222.1972.tb01287.x; PEZZINI A, 1984, CLIN ALLERGY, V14, P453, DOI 10.1111/j.1365-2222.1984.tb02229.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; Redlich CA, 2002, INT IMMUNOPHARMACOL, V2, P213, DOI 10.1016/S1567-5769(01)00174-6; Redlich CA, 2001, AM J IND MED, V39, P587, DOI 10.1002/ajim.1058; SCHEEL L D, 1964, Am Ind Hyg Assoc J, V25, P179, DOI 10.1080/00028896409342574; SELDEN AI, 1989, SCAND J WORK ENV HEA, V15, P234, DOI 10.5271/sjweh.1857; Son Minsik, 1998, Journal of Korean Medical Science, V13, P147; SPIAZZI A, 1991, ALLERGY, V46, P166, DOI 10.1111/j.1398-9995.1991.tb00565.x; Stone KL, 1998, ELECTROPHORESIS, V19, P1046, DOI 10.1002/elps.1150190620; Tarlo SM, 1999, J ALLERGY CLIN IMMUN, V103, P739, DOI 10.1016/S0091-6749(99)70413-6; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709, DOI 10.1016/S0091-6749(98)70181-2; TIIKKAINEN U, 1990, ALLERGY, V45, P497, DOI 10.1111/j.1398-9995.1990.tb00525.x; TSE CST, 1979, TOXICOL APPL PHARM, V51, P39, DOI 10.1016/0041-008X(79)90006-1; TSE CST, 1979, AM REV RESPIR DIS, V120, P829; VANDENPLAS O, 1993, J ALLERGY CLIN IMMUN, V91, P850, DOI 10.1016/0091-6749(93)90342-D; VANDENPLAS O, 1992, AM REV RESPIR DIS, V145, P582, DOI 10.1164/ajrccm/145.3.582; WASS U, 1989, J ALLERGY CLIN IMMUN, V83, P126, DOI 10.1016/0091-6749(89)90487-9; WELINDER H, 1988, CLIN ALLERGY, V18, P85, DOI 10.1111/j.1365-2222.1988.tb02847.x; Wikman H, 2002, PHARMACOGENETICS, V12, P227, DOI 10.1097/00008571-200204000-00007; Wisnewski AV, 2002, ENVIRON HEALTH PERSP, V110, P901, DOI 10.1289/ehp.02110901; Wisnewski AV, 1999, J ALLERGY CLIN IMMUN, V104, P341, DOI 10.1016/S0091-6749(99)70377-5	50	61	63	0	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1178	1184		10.1016/j.jaci.2004.03.009	http://dx.doi.org/10.1016/j.jaci.2004.03.009			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208602				2022-12-18	WOS:000222091000026
J	Hossain, MA; Ahmed, MS; Ghannoum, MA				Hossain, MA; Ahmed, MS; Ghannoum, MA			Attributes of Stachybotrys chartarum and its association with human disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						environment; mold; mycotoxin; Stachybotrys; building-related symptoms; stachylysin	SICK BUILDING SYNDROME; PULMONARY HEMORRHAGE; TOXIGENIC FUNGI; INDOOR MOLD; AIRWAYS INFLAMMATION; HOME DAMPNESS; EXPOSURE; HEALTH; LUNG; SPORES	Mold contamination and toxicities are not limited to crops and animals; they are also a concern in human health. Molds occur in outdoor and indoor environments, and water-damaged buildings harbor and provide substrate for several mold species. Of these, Stachybotrys chartarum poses a particular threat to occupants. Patients with building-related symptoms and infant idiopathic pulmonary hemorrhage often have histories of living in moldy, water-damaged buildings. Although a causal connection is far from being unequivocally proven, S chartarum has been associated with such clinical conditions. These illnesses could be attributed in part to mycotoxins released by S chartarum. Recently, a hemolysin released by this mold was found to be hemolytic in vitro and in vivo. In addition, allergenic proteins have been characterized from S chartarum. The exact mechanism of S chartarum pathogenesis has not yet been defined. Moreover, a causality-effect relation is not yet established. This review summarizes available information on the pathogenic attributes of S chartarum and calls for well-controlled objective studies.	Univ Hosp Cleveland, Ctr Med Mycol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH USA	University Hospitals of Cleveland; Case Western Reserve University	Ghannoum, MA (corresponding author), Univ Hosp Cleveland, Ctr Med Mycol, 11100 Euclid Ave, Cleveland, OH 44106 USA.							AKKMETELI MA, 1977, ANN NUTR ALIMENT, V31, P957; Andersson MA, 1997, APPL ENVIRON MICROB, V63, P387, DOI 10.1128/AEM.63.2.387-393.1997; [Anonymous], 2003, J OCCUP ENVIRON MED, V45, P470; [Anonymous], 1987, CAN J PUBLIC HEALTH, V78, pS1; ARUNDEL AV, 1986, ENVIRON HEALTH PERSP, V65, P351, DOI 10.2307/3430203; BAKAI SM, 1960, MYCOTOXICOSIS MAN AG, P163; Barnes C, 2002, ANN ALLERG ASTHMA IM, V89, P29, DOI 10.1016/S1081-1206(10)61907-2; Bondy GS, 2000, J TOXICOL ENV HEAL B, V3, P109, DOI 10.1080/109374000281113; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363, DOI 10.1164/ajrccm/140.5.1363; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P881; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P33; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P180; CIEGLER A, 1980, BIOSCIENCE, V30, P512, DOI 10.2307/1307970; Cooley JD, 1998, OCCUP ENVIRON MED, V55, P579, DOI 10.1136/oem.55.9.579; COOPER JAJ, 1998, FISHMANS PULMONARY D, P915; CORRIER DE, 1991, VET IMMUNOL IMMUNOP, V30, P73, DOI 10.1016/0165-2427(91)90010-A; DALES RE, 1991, AM REV RESPIR DIS, V143, P505, DOI 10.1164/ajrccm/143.3.505; Dales RE, 1999, ENVIRON HEALTH PERSP, V107, P481, DOI 10.1289/ehp.99107s3481; Dearborn DG, 1999, ENVIRON HEALTH PERSP, V107, P495, DOI 10.1289/ehp.99107s3495; Drobotko V. G., 1945, AMER REV SOVIET MED, V2, P238; DROBOTKO VG, 1946, VRACHEBNOE DELO, V26, P125; Elidemir O, 1999, PEDIATRICS, V104, P964, DOI 10.1542/peds.104.4.964; Engvall K, 2001, INT J TUBERC LUNG D, V5, P468; Engvall K, 2001, INT ARCH OCC ENV HEA, V74, P270, DOI 10.1007/s004200000218; ESCOULA L, 1988, MYCOPATHOLOGIA, V103, P153, DOI 10.1007/BF00436814; Etzel R, 1999, ENVIRON HEALTH PERSP, V107, P463; Etzel RA, 1998, ARCH PEDIAT ADOL MED, V152, P757; Forgacs J, 1972, MICROBIAL TOXINS, P95; GRANT C, 1989, INT BIODETERIOR, V25, P259, DOI 10.1016/0265-3036(89)90002-X; Gravesen S, 1999, ENVIRON HEALTH PERSP, V107, P505, DOI 10.1289/ehp.99107s3505; Gregory L, 2003, MYCOPATHOLOGIA, V156, P109; Hintikka EL, 1998, INDOOR AIR, P66; Hodgson MJ, 1998, J OCCUP ENVIRON MED, V40, P241, DOI 10.1097/00043764-199803000-00006; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161, DOI 10.1128/CMR.8.2.161; Hossain MA, 1997, J CLIN LAB ANAL, V11, P73, DOI 10.1002/(SICI)1098-2825(1997)11:2&lt;73::AID-JCLA1&gt;3.0.CO;2-L; HUNTER CA, 1988, INT BIODETERIOR, V24, P81, DOI 10.1016/0265-3036(88)90052-8; JARVIS BB, 1982, ACCOUNTS CHEM RES, V15, P388, DOI 10.1021/ar00084a002; Johanning E, 1996, INT ARCH OCC ENV HEA, V68, P207; Karunasena E, 2001, MYCOPATHOLOGIA, V150, P91, DOI 10.1023/A:1010920611811; KORNEEV NE, 1948, VETERINARIYA, V25, P36; Kuhn DM, 2003, CLIN MICROBIOL REV, V16, P144, DOI 10.1128/CMR.16.1.144-172.2003; Lee MG, 1999, J TOXICOL ENV HEAL A, V57, P459, DOI 10.1080/009841099157548; Mahmoudi M, 2000, J ASTHMA, V37, P191, DOI 10.3109/02770900009055442; MANN DD, 1983, AM J VET RES, V44, P1757; Menzies D, 1998, J ALLERGY CLIN IMMUN, V101, P38, DOI 10.1016/S0091-6749(98)70191-5; MILLER JD, 1988, INT BIODETERIOR, V24, P103, DOI 10.1016/0265-3036(88)90053-X; Miller JD, 2003, MED MYCOL, V41, P271, DOI 10.1080/1369378031000137350; Montana E, 1997, PEDIATRICS, V99, pE51, DOI 10.1542/peds.99.1.e5; Nagase M, 2002, IMMUNOL LETT, V84, P23, DOI 10.1016/S0165-2478(02)00127-X; Nielsen KF, 2003, FUNGAL GENET BIOL, V39, P103, DOI 10.1016/S1087-1845(03)00026-4; Nikulin M, 1996, INT J EXP PATHOL, V77, P213, DOI 10.1046/j.1365-2613.1996.9250323.x; Nikulin M, 1997, FUND APPL TOXICOL, V35, P182, DOI 10.1006/faat.1996.2274; Ormstad H, 2000, J TOXICOL ENV HEAL A, V61, P55, DOI 10.1080/00984100050116780; OTOKAWA M, 1983, DEV FOOD SCI, V4, P163; PITT JI, 1987, APPL ENVIRON MICROB, V53, P266, DOI 10.1128/AEM.53.2.266-269.1987; Pitt JI, 2000, MED MYCOL, V38, P17, DOI 10.1080/mmy.38.s1.17.22; PLATT SD, 1989, BRIT MED J, V298, P1673, DOI 10.1136/bmj.298.6689.1673; POLIAKOV AA, 1948, RUKOVODSTVO VET DEZI, P154; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877, DOI 10.4065/74.9.877; Rand TG, 2002, TOXICOL SCI, V65, P239, DOI 10.1093/toxsci/65.2.239; Rao CY, 2000, MYCOPATHOLOGIA, V149, P27, DOI 10.1023/A:1007239017018; REDDY RV, 1988, J FOOD PROTECT, V51, P32, DOI 10.4315/0362-028X-51.1.32; Ren P, 2001, ALLERGY, V56, P419, DOI 10.1034/j.1398-9995.2001.056005419.x; Rizzo Aldo F., 1992, Natural Toxins, V1, P106, DOI 10.1002/nt.2620010209; Rylander R, 1998, AM J RESP CRIT CARE, V158, P1685, DOI 10.1164/ajrccm.158.5.9712139; SAKAMOTO K, 1993, J ANTIBIOT, V46, P1788, DOI 10.7164/antibiotics.46.1788; SCHINDLER D, 1974, NATURE, V249, P38, DOI 10.1038/249038a0; SOBOTKA TJ, 1978, PHARMACOLOGY, V16, P287, DOI 10.1159/000136781; STUART BP, 1982, VET CLIN N AM-LARGE, V4, P377; Sudakin DL, 2003, TOXICOL LETT, V143, P97, DOI 10.1016/S0378-4274(03)00116-4; Takahashi T, 1997, MYCOPATHOLOGIA, V139, P23, DOI 10.1023/A:1006831111595; Taskinen T, 1997, ACTA PAEDIATR, V86, P1181, DOI 10.1111/j.1651-2227.1997.tb14841.x; Taskinen T, 1999, ACTA PAEDIATR, V88, P1373, DOI 10.1080/080352599750030112; Thorn J, 1998, AM J RESP CRIT CARE, V157, P1798, DOI 10.1164/ajrccm.157.6.9706081; Trout D, 2001, ENVIRON HEALTH PERSP, V109, P641, DOI 10.2307/3455040; Tuomi T, 2000, APPL ENVIRON MICROB, V66, P1899, DOI 10.1128/AEM.66.5.1899-1904.2000; Van Emon JM, 2003, J OCCUP ENVIRON MED, V45, P582, DOI 10.1097/01.jom.0000071503.96740.65; VERTINSKII KI, 1940, VETERINARIYA, V17, P61; Vesper SJ, 2002, INFECT IMMUN, V70, P2065, DOI 10.1128/IAI.70.4.2065-2069.2002; Vesper SJ, 2001, INFECT IMMUN, V69, P912, DOI 10.1128/IAI.69.2.912-916.2001; Vesper SJ, 1999, APPL ENVIRON MICROB, V65, P3175; Vesper SJ, 2000, APPL ENVIRON MICROB, V66, P2678, DOI 10.1128/AEM.66.6.2678-2681.2000; Viana ME, 2002, TOXICOL SCI, V70, P98, DOI 10.1093/toxsci/70.1.98; VONESSEN S, 1990, J TOXICOL-CLIN TOXIC, V28, P389, DOI 10.3109/15563659009038584; Wang JS, 1999, MUTAT RES-FUND MOL M, V424, P167, DOI 10.1016/S0027-5107(99)00017-2; Wilkins CK, 1998, PHARMACOL TOXICOL, V83, P112, DOI 10.1111/j.1600-0773.1998.tb01453.x; Withanage GSK, 2001, VET HUM TOXICOL, V43, P6; Yang GH, 2000, TOXICOL APPL PHARM, V164, P149, DOI 10.1006/taap.1999.8888; Yike I, 1999, APPL ENVIRON MICROB, V65, P88	90	61	63	2	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					200	208		10.1016/j.jaci.2003.12.018	http://dx.doi.org/10.1016/j.jaci.2003.12.018			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	773EX	14767429				2022-12-18	WOS:000188885700002
J	Grote, M; Valenta, R; Reichelt, R				Grote, M; Valenta, R; Reichelt, R			Abortive pollen germination: A mechanism of allergen release in birch, alder, and hazel revealed by immunogold electron microscopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pollen allergens; allergen release; immunogold electron microscopy; submicronic particles; Bet v 1	DIESEL EXHAUST PARTICLES; GRASS-POLLEN; IGE PRODUCTION; ASTHMA; BET-V-1; LOCALIZATION; EPITOPES; HORNBEAM; SMALLER	Background: Pollen from early-flowering trees (eg, birch, alder, hazel) represent major seasonal allergen sources. The effects of rain on the release of allergens from tree pollen has thus far not been studied at the ultrastructural level. Objective: This study was designed to investigate the effects of rain on the morphology of pollens from early-flowering trees and of potential rain-induced mechanisms of allergen release. Methods: Freshly collected pollen grains (birch, alder, and hazel) were exposed under controlled conditions to rainwater. Changes of pollen morphology and the release of allergens were analyzed by scanning electron microscopy. The release of allergen-bearing submicronic particles was studied by field emission scanning electron microscopy and transmission electron microscopy in conjunction with immunogold staining by using antibodies with specificity for the major allergens. Results: Scanning electron microscopy showed that freshly isolated pollen grains from birch, alder, and hazel have abortive germination in rainwater. Abortive pollen germination is characterized by the formation of short pollen tubes, which rupture at their tips and release micronic and submicronic particles containing major allergens. Immunogold transmission electron microscopy provided evidence that the allergens are transported through the pollen tubes during germination. Conclusions: Rainwater-induced release of allergen-bearing submicronic particles from abortively germinated tree pollens may represent a mechanism of allergen release, with important implications on the induction of asthma as well as on current methods for measuring environmental allergen exposure.	Univ Munster, Inst Med Phys & Biophys, D-48161 Munster, Germany; Univ Vienna, Dept Pathophysiol, Vienna, Austria	University of Munster; University of Vienna	Grote, M (corresponding author), Univ Munster, Inst Med Phys & Biophys, Robert Koch Str 31, D-48161 Munster, Germany.			Valenta, Rudolf/0000-0001-5944-3365				Behrendt H, 2001, CURR OPIN IMMUNOL, V13, P709, DOI 10.1016/S0952-7915(01)00283-7; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; Grote M, 1999, INT ARCH ALLERGY IMM, V118, P1, DOI 10.1159/000024024; GROTE M, 1993, J HISTOCHEM CYTOCHEM, V41, P745, DOI 10.1177/41.5.8468456; Grote M, 2001, J ALLERGY CLIN IMMUN, V108, P109, DOI 10.1067/mai.2001.116431; Grote M, 2000, J ALLERGY CLIN IMMUN, V105, P1140, DOI 10.1067/mai.2000.107044; Heo Y, 2001, TOXICOLOGY, V159, P143, DOI 10.1016/S0300-483X(00)00418-2; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Rantio-Lehtimaki A, 1991, ALLERGENIC POLLEN PO, P18; Razmovski V, 2000, J ALLERGY CLIN IMMUN, V105, P725, DOI 10.1067/mai.2000.105222; REED CE, 1985, CHEST, V87, pS40; REED CE, 1987, CHEST, V91, pS161, DOI 10.1378/chest.91.6.161S; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633, DOI 10.1046/j.1365-2222.1999.00567.x; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; Schappi GF, 1999, ALLERGY, V54, P478, DOI 10.1034/j.1398-9995.1999.00838.x; Schappi GF, 1997, SEX PLANT REPROD, V10, P315, DOI 10.1007/s004970050105; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Taylor PE, 2002, J ALLERGY CLIN IMMUN, V109, P51, DOI 10.1067/mai.2002.120759; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; VALENTA R, 1998, ALLERGEN IMMUNOTHERA, P85	29	61	61	0	19	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1017	1023		10.1067/mai.2003.1452	http://dx.doi.org/10.1067/mai.2003.1452			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	679DA	12743566				2022-12-18	WOS:000182904500016
J	Busse, W; Koenig, SM; Oppenheimer, J; Sahn, SA; Yancey, SW; Reilly, D; Edwards, LD; Dorinsky, PM				Busse, W; Koenig, SM; Oppenheimer, J; Sahn, SA; Yancey, SW; Reilly, D; Edwards, LD; Dorinsky, PM			Steroid-sparing effects of fluticasone propionate 100 mu g and salmeterol 50 mu g administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 mu g administered twice daily	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	68th Annual Meeting of the American-College-of-Chest-Physicians	NOV 02-07, 2002	SAN DIEGO, CA	Amer Coll Chest Physicians		fluticasone propionate; salmeterol; asthma; corticosteroid-sparing; inhaled corticosteroid; long-acting beta(2)-agonist	INHALED CORTICOSTEROIDS; TERM TREATMENT; DOUBLE-BLIND; LONG-TERM; ASTHMA; GLUCOCORTICOSTEROIDS; HOSPITALIZATION; EXACERBATIONS; INFLAMMATION; BUDESONIDE	Background: Concurrent use of an inhaled corticosteroid (ICS) and an inhaled long-acting beta(2)-agonist provides better overall asthma control than the use of higher doses of ICS alone. Objective: The purpose of this investigation was to determine whether fluticasone propionate (FP) combined with salmeterol in the Diskus device can be used to reduce the dose of ICS in patients currently stable on medium-dose ICS while maintaining asthma control. Methods: This was a randomized, double-blind, parallel group, 12- to 24-week trial consisting of a 3-part run-in period. The run-in period was designed to first establish FP 250 mug administered twice a day (bid) via Diskus as the minimum effective dose. During run-in period 1, patients received FP 220 mug bid or the equivalent for 10 to 14 days. Controlled patients moved to run-in period 2 (5-28 days), which assessed asthma stability on FP 100 mug bid administered via Diskus. Only patients who became unstable on FP 100 mug bid were eligible to enter run-in period 3 (26-30 days), during which they were placed on FP 250 mug bid and those regaining asthma control were eligible for randomization. The primary efficacy end-point was the proportion of patients who remained in the study with no evidence of worsening asthma. Secondary efficacy measures included FEV1, morning peak expiratory flow, percent of symptom-free days, and daily albuterol use. Results: Only 5% of patients treated with FP 100/salmeterol withdrew because of worsening asthma in the first 12 weeks; this compared with 7% in the FP 250 group. All patients from a subset of sites continued in the study for an additional 12 weeks; only an additional 1% of patients treated with either FP 100/salmeterol or FP 250 withdrew because of worsening asthma. Secondary efficacy measures confirmed primary effiacy results. Conclusion: In patients requiring FP250 bid for asthma stability, FP100/salmeterol bid was steroid-sparing, allowing a 60% reduction in the FP dose while maintaining overall asthma control.	Univ Wisconsin, Sch Med, Clin Res Unit K4 912 9988, Madison, WI 53792 USA; Univ Virginia, Charlottesville, VA USA; Pulm & Allergy Associates, Springfield, NJ USA; Med Univ S Carolina, Charleston, SC 29425 USA; GlaxoSmithKline, Res Triangle Pk, NC USA	University of Wisconsin System; University of Wisconsin Madison; University of Virginia; Medical University of South Carolina; GlaxoSmithKline	Busse, W (corresponding author), Univ Wisconsin, Sch Med, Clin Res Unit K4 912 9988, 600 Highland Ave, Madison, WI 53792 USA.			Edwards, Lisa/0000-0002-4867-2151				Adams RJ, 2001, PEDIATRICS, V107, P706, DOI 10.1542/peds.107.4.706; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Blais L, 1998, THORAX, V53, P1025, DOI 10.1136/thx.53.12.1025; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Chung KF, 1998, ALLERGY, V53, P7, DOI 10.1111/j.1398-9995.1998.tb04887.x; CRAPO R O, 1989, Respiratory Care, V34, P626; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; Kips JC, 2000, AM J RESP CRIT CARE, V161, P996, DOI 10.1164/ajrccm.161.3.9812056; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Li X, 1999, AM J RESP CRIT CARE, V160, P1493, DOI 10.1164/ajrccm.160.5.9811052; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41, DOI 10.1152/ajplung.1995.268.1.L41; Nielsen LP, 1999, RESP MED, V93, P863, DOI 10.1016/S0954-6111(99)90051-3; *NIH NAT HEART LUN, 1997, 2 NIH HEART LUNG BLO; Oddera S, 1998, RESPIRATION, V65, P199, DOI 10.1159/000029260; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Polgar G., 1971, PULMONARY FUNCTION T, P1; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Shapiro G, 2000, AM J RESP CRIT CARE, V161, P527, DOI 10.1164/ajrccm.161.2.9905091; Shrewsbury S, 2000, BMJ-BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Sin DD, 2001, EUR RESPIR J, V17, P380, DOI 10.1183/09031936.01.17303800; SUECHU M, 1999, EUR RESPIR J, V14, pS124; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; Wilding P, 1997, BRIT MED J, V314, P1441, DOI 10.1136/bmj.314.7092.1441	30	61	69	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					57	65		10.1067/mai.2003.38	http://dx.doi.org/10.1067/mai.2003.38			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	636PR	12532097				2022-12-18	WOS:000180465500009
J	de Lavareille, A; Roufosse, F; Schmid-Grendelmeier, P; Roumier, AS; Schandene, L; Cogan, E; Simon, HU; Goldman, M				de Lavareille, A; Roufosse, F; Schmid-Grendelmeier, P; Roumier, AS; Schandene, L; Cogan, E; Simon, HU; Goldman, M			High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						thymus and activation-regulated chemokine; hypereosinophilic syndrome; IL-5; T-cell lymphoma	T-CELLS; INTERLEUKIN-5; PROLIFERATION; EOSINOPHILIA	The idiopathic hypereosinophilic syndrome is associated with expansion of an IL-5-producing T-cell subset in a subgroup of patients. Identification of such patients is critical to adequate management because there is some evidence that they present an increased risk for development of T-cell lymphoma. Although the T(H)2-like cells often bear an aberrant surface phenotype and can readily be detected with flow cytometry, we now show that lymphocyte phenotyping might be normal in some cases. In contrast, serum thymus and activation-regulated chemokine levels are consistently increased in such patients compared with others with persistent idiopathic hypereosinophilia and could therefore represent a useful diagnostic tool.	Free Univ Brussels, Hop Erasme, Dept Immunol, B-1070 Brussels, Belgium; Free Univ Brussels, Hop Erasme, Dept Internal Med, B-1070 Brussels, Belgium; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Ctr Hosp Reg Univ Lille, Dept Immunol, F-59037 Lille, France; Inst Pasteur, INSERM, U547, F-59019 Lille, France; Univ Bern, Dept Pharmacol, Bern, Switzerland	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Swiss Institute of Allergy & Asthma Research; Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; University of Bern	Goldman, M (corresponding author), Free Univ Brussels, Hop Erasme, Dept Immunol, 808 Route Lennik, B-1070 Brussels, Belgium.		Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736; Cogan, Elie/0000-0003-2890-766X				Brugnoni D, 1996, BLOOD, V87, P1416, DOI 10.1182/blood.V87.4.1416.bloodjournal8741416; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; de Lavareille A, 2001, EUR J IMMUNOL, V31, P1037, DOI 10.1002/1521-4141(200104)31:4<1037::AID-IMMU1037>3.0.CO;2-#; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Kitano K, 1996, BRIT J HAEMATOL, V92, P315, DOI 10.1046/j.1365-2141.1996.d01-1482.x; O'Shea J J, 1987, Am J Med, V82, P539; Roufosse F, 2000, BRIT J HAEMATOL, V109, P540, DOI 10.1046/j.1365-2141.2000.02097.x; Sekiya T, 2000, J IMMUNOL, V165, P2205, DOI 10.4049/jimmunol.165.4.2205; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503	11	61	64	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					476	479		10.1067/mai.2002.127003	http://dx.doi.org/10.1067/mai.2002.127003			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209097				2022-12-18	WOS:000177936900020
J	Nagata, M; Saito, K; Tsuchiya, K; Sakamoto, Y				Nagata, M; Saito, K; Tsuchiya, K; Sakamoto, Y			Leukotriene D-4 upregulates eosinophil adhesion via the cysteinyl leukotriene 1 receptor	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; leukotriene D4; cell adhesion; adhesion molecules; leukotriene receptor antagonist	HYDROGEN-PEROXIDE; INFILTRATION; INFLAMMATION; MOLECULE-1; PRANLUKAST; ACTIVATION; D-4	Background: Eosinophils (EOS) are one of the cellular sources of cysteinyl leukotrienes (cysLTs) in allergic inflammation. There is evidence that cysLT(1) receptor antagonists possess anti-inflammatory properties in vivo in asthmatic airways. Although the exact mechanism of action remains unknown, cysLTs might regulate the cellular responses involved in allergic inflammation. Objective: The present study was undertaken to examine whether LTD4 modifies the adhesive property of EOS. Methods: EOS were isolated from the blood of healthy subjects. Their adhesion to tissue culture plates or recombinant human (rh) adhesion proteins was then examined in the presence or absence of LTD4. Results: LTD4 significantly augmented EOS adhesion to tissue culture plates (adhesion: 5.0% +/- 0.5% by medium control vs 9.1% +/- 1.2% by 1 mumol/L; P < .01; n = 10). The enhanced adhesion induced by, LTD4 was blocked by pranlukast, a cysLT(1) receptor antagonist, or an anti-beta(2) integrin antibody. Flow cytometry analysis revealed that LTD4 significantly enhanced the expression of CD11b and CD18 on the EOS surface. Finally, LTD4 augmented EOS adhesion to rh intercellular cell adhesion molecule I but not to rh vascular cell adhesion molecule I or fibronectin. Conclusions: The results suggest that LTD4 directly upregulates the adhesive property of EOS via the cysLT(1) receptor and beta(2) integrin. LTD4 generated from FOS or cells of some other type might contribute to the development of phenotypic change in airway EOS.	Saitama Med Sch, Dept Internal Med 2, Div Pulm, Moroyama, Saitama 3500495, Japan	Saitama Medical University	Nagata, M (corresponding author), Saitama Med Sch, Dept Internal Med 2, Div Pulm, 38 Morohongou, Moroyama, Saitama 3500495, Japan.							Bochner BS, 1997, J ALLERGY CLIN IMMUN, V100, P581, DOI 10.1016/S0091-6749(97)70158-1; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247, DOI 10.1164/ajrccm.155.4.9105062; ELLIOTT MJ, 1990, J IMMUNOL, V145, P167; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; HAMANN KJ, 2000, ASTHMA RHINITIS, P393; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; KITA H, 1995, J IMMUNOL, V154, P4749; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Macfarlane AJ, 2000, AM J RESP CRIT CARE, V161, P1553, DOI 10.1164/ajrccm.161.5.9906068; Nagata M, 1998, AM J RESP CELL MOL, V19, P158, DOI 10.1165/ajrcmb.19.1.3001; NAGATA M, 1995, J IMMUNOL, V155, P2194; Nagata M, 2000, IMMUNOLOGY, V101, P412, DOI 10.1046/j.1365-2567.2000.00123.x; Nakamura Y, 1998, THORAX, V53, P835, DOI 10.1136/thx.53.10.835; Pavord ID, 1999, AM J RESP CRIT CARE, V160, P1905, DOI 10.1164/ajrccm.160.6.9903114; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183, DOI 10.1002/jlb.55.2.183; Weller PF, 1997, J ALLERGY CLIN IMMUN, V100, P283, DOI 10.1016/S0091-6749(97)70237-9; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; Yoshida S, 2000, CLIN EXP ALLERGY, V30, P1008	25	61	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					676	680		10.1067/mai.2002.122841	http://dx.doi.org/10.1067/mai.2002.122841			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941318				2022-12-18	WOS:000175132600017
J	Pajno, GB; La Grutta, S; Barberio, G; Canonica, GW; Passalacqua, G				Pajno, GB; La Grutta, S; Barberio, G; Canonica, GW; Passalacqua, G			Harmful effect of immunotherapy in children with combined snail and mite allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; house dust mite; immunotherapy	POLLEN IMMUNOTHERAPY	Background: With respect to allergy, the possibility of cross-reactivity between snail and mite is well recognized, and anecdotal reports suggesting that allergen immunotherapy with mite extract can worsen snail-induced allergy exist. Objective: We describe the effect of immunotherapy in 4 children with snail-mite allergy. Methods: Four children (1 boy and 3 girls; 9-13 years of age) had consistent clinical histories (mild immediate respiratory symptoms after ingestion) and positive skin reactions for allergy to snail. They also had mite-induced asthma and were therefore prescribed subcutaneous specific immunotherapy and subsequently followed. Results: Several months (8-25) after starting immunotherapy, all children experienced life-threatening reactions, anaphylaxis, and respiratory failure after inadvertent ingestion of snail. Skin reactivity to the fresh food increased in all patients. Conclusions: This observation confirms that in patients with combined mite-snail allergy, immunotherapy should be avoided.	Univ Hosp, Pediat Div 2, Messina, Italy; Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy	AOU Policlinico Gaetano Martino; University of Genoa	Passalacqua, G (corresponding author), DIMI, Lgo R Benzi 10, I-16132 Genoa, Italy.		La Grutta, Stefania/N-3615-2014; canonica, giorgio walter/ABF-2037-2020	La Grutta, Stefania/0000-0001-8026-0715; canonica, giorgio walter/0000-0001-8467-2557				BANZET ML, 1992, REV FR ALLERGOL, V32, P198, DOI 10.1016/S0335-7457(05)80359-4; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; DEMAATBLEEKER F, 1995, ALLERGY, V50, P438, DOI 10.1111/j.1398-9995.1995.tb01174.x; KELSO JM, 1995, ANN ALLERG ASTHMA IM, V74, P391; MOLLER C, 1989, ANN ALLERGY, V62, P343; Peroni DG, 2000, PEDIATR ALLERGY IMMU, V11, P260, DOI 10.1034/j.1399-3038.2000.00001.x; SAMPSON HA, 1995, PROVOCATION TESTING, P623; vanRee R, 1996, ALLERGY, V51, P387, DOI 10.1111/j.1398-9995.1996.tb00147.x; vanRee R, 1996, ALLERGY, V51, P108, DOI 10.1111/j.1398-9995.1996.tb00043.x; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56, DOI 10.1159/000236803	10	61	61	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					627	629		10.1067/mai.2002.122844	http://dx.doi.org/10.1067/mai.2002.122844			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	543YZ	11941311	Bronze			2022-12-18	WOS:000175132600009
J	Sanders, SP; Siekierski, ES; Richards, SM; Porter, JD; Imani, F; Proud, D				Sanders, SP; Siekierski, ES; Richards, SM; Porter, JD; Imani, F; Proud, D			Rhinovirus infection induces expression of type 2 nitric oxide synthase in human respiratory epithelial cells in vitro and in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinovirus; common cold; asthma; epithelial cells; inducible nitric oxide synthase; nitric oxide; host defense	INHIBITS VIRAL REPLICATION; NF-KAPPA-B; VIRUS-INFECTION; ASTHMA; COLDS; INDUCTION; GENE; LINE; INTERLEUKIN-1; EXACERBATIONS	Background: Human rhinovirus (HRV) infections are the predominant cause of the common cold and are associated with exacerbations of asthma, Nitric oxide (NO) may play an important role in host defense by means of its potent antiviral properties. Objective: We sought to determine whether epithelial expression of type 2 nitric oxide synthase (NOS 2), which produces NO, is induced on rhinovirus infection in vitro and in vivo. Methods: Primary cultures of human airway epithelial cells were infected with HRV-16, and NOS 2 mRNA expression was assessed by conventional and real-time RT-PCR and NOS 2 protein by using Western blot analysis. Human subjects were also infected with HRV-16 in vivo, and mRNA for NOS 2 was assessed in nasal epithelial scrapings obtained before and after infection. Results: NOS 2 mRNA levels increased within 8 hours after HRV-16 infection of cultured cells and remained elevated up to 48 hours after infection. NOS 2 protein was elevated at 24 hours. Induction of NOS 2 did not occur with UV-inactivated HRV-16 but could be reproduced by using double-stranded RNA, indicating that induction was dependent on viral replication. Increased NOS 2 expression was also observed in nasal epithelial scrapings during symptomatic colds. Conclusion: Increased epithelial expression of NOS 2 mRNA occurs as part of the host response to HRV infection in vitro and in vivo. Given the antiviral effects of NO, we speculate that increased host production of NO may play an important role in host defense during HRV infections.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Sanders, SP (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.			Richards, Stephen M/0000-0002-7604-2368	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044696, P01AI037163] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61011] Funding Source: Medline; NIAID NIH HHS [AI44696, AI37163] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AROLA M, 1990, ANN OTO RHINOL LARYN, V99, P451, DOI 10.1177/000348949009900607; BARDIN PG, 1994, AM J RESP CELL MOL, V10, P207, DOI 10.1165/ajrcmb.10.2.8110476; CHURCHILL L, 1989, AM REV RESPIR DIS, V140, P449, DOI 10.1164/ajrccm/140.2.449; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Elewaut D, 1999, J IMMUNOL, V163, P1457; Gern JE, 2000, J ALLERGY CLIN IMMUN, V105, pS497, DOI 10.1016/S0091-6749(00)90050-2; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Guillemard E, 1996, ANTIMICROB AGENTS CH, V40, P1057, DOI 10.1128/AAC.40.4.1057; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; GWALTNEY JM, 1992, PROG MED VIROL, V39, P256; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Karupiah G, 1998, J VIROL, V72, P7703, DOI 10.1128/JVI.72.9.7703-7706.1998; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; KNIGHT V, 1964, PROG MED VIROL, V6, P1; Komatsu T, 1996, J NEUROIMMUNOL, V68, P101, DOI 10.1016/0165-5728(96)00083-5; Lin YL, 1997, J VIROL, V71, P5227, DOI 10.1128/JVI.71.7.5227-5235.1997; Linn SC, 1997, AM J PHYSIOL-GASTR L, V272, pG1499, DOI 10.1152/ajpgi.1997.272.6.G1499; Lopez-Guerrero JA, 1998, J VIROL, V72, P2538; Lowenstein CJ, 1996, J CLIN INVEST, V97, P1837, DOI 10.1172/JCI118613; MacLean A, 1998, J GEN VIROL, V79, P825, DOI 10.1099/0022-1317-79-4-825; Majano PL, 1998, J CLIN INVEST, V101, P1343, DOI 10.1172/JCI774; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MCHARDY VU, 1980, BRIT J DIS CHEST, V74, P228, DOI 10.1016/0007-0971(80)90048-0; Mikami S, 1996, BIOCHEM BIOPH RES CO, V220, P983, DOI 10.1006/bbrc.1996.0519; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Oleszak EL, 1997, J VIROL, V71, P3228, DOI 10.1128/JVI.71.4.3228-3235.1997; PROUD D, 1994, J INFECT DIS, V169, P1007, DOI 10.1093/infdis/169.5.1007; Rager KJ, 1998, J VIROL, V72, P1171, DOI 10.1128/JVI.72.2.1171-1176.1998; Reiss CS, 1998, J VIROL, V72, P4547, DOI 10.1128/JVI.72.6.4547-4551.1998; Rimmelzwaan GF, 1999, J VIROL, V73, P8880, DOI 10.1128/JVI.73.10.8880-8883.1999; Robinson NMK, 1999, EUR J CLIN INVEST, V29, P700; Samouilov A, 1998, ARCH BIOCHEM BIOPHYS, V357, P1, DOI 10.1006/abbi.1998.0785; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Sanders SP, 1999, P SOC EXP BIOL MED, V220, P123, DOI 10.1046/j.1525-1373.1999.d01-19.x; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; STELLATO C, 1995, J IMMUNOL, V155, P410; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Tsutsumi H, 1999, J LEUKOCYTE BIOL, V66, P99, DOI 10.1002/jlb.66.1.99; TURNER BW, 1992, J ALLERGY CLIN IMMUN, V90, P474, DOI 10.1016/0091-6749(92)90172-X; TURNER RB, 1982, J INFECT DIS, V145, P849, DOI 10.1093/infdis/145.6.849; XIE QW, 1994, J BIOL CHEM, V269, P4705; Zaragoza C, 1999, J IMMUNOL, V163, P5497	48	61	65	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					235	243		10.1067/mai.2001.112028	http://dx.doi.org/10.1067/mai.2001.112028			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	403YV	11174188				2022-12-18	WOS:000167071400008
J	Tejera, ML; Villalba, M; Batanero, E; Rodriguez, R				Tejera, ML; Villalba, M; Batanero, E; Rodriguez, R			Identification, isolation, and characterization of Ole e 7, a new allergen of olive tree pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Olea europaea; allergen; olive pollen allergy; Ole e 7; amino acid sequence	AMINO-ACID-SEQUENCE; MAJOR ALLERGEN; EUROPEA POLLEN; E-I; EXPRESSION; PROTEINS; CLONING; PURIFICATION; PROFILIN; OLE-E-3	Background: Olive tree (Olea europaea) pollen is an important cause of pollinosis in countries of the Mediterranean area and California. Objective: The aim of this study was to identify and purify a new allergen of olive tree pollen. Methods: Detection of a pollen allergen was done with individual allergic sera by immunoblotting and ELISA tests. Two allergenic fractions were isolated from olive pollen extract by using gel filtration and reverse-phase HPLC. Molecular characterization was achieved by acid hydrolysis and amino acid analysis, as well as by mass spectrometry, Sequencing of the N-terminal end of the allergen was carried out by Edman degradation of the polypeptide chain. Allergenic characterization was performed with sera from subjects with olive allergy by means of ELISA and immunoblotting after SDS-PAGE. Results: The new allergen Ole e 7 exhibits a high degree of polymorphism. Its molecular mass is in the range of 9875 d to 10,297 d. Twenty-one amino acid residues from the N-terminal end of 2 isoforms of the allergen have been sequenced revealing no homology with proteins contained in database banks. Ole e 7 has an average frequency of about 47% in patients with olive allergy, The strategy of purification of Ole e 7 can be useful on the isolation of new allergens. Conclusions: A new olive pollen allergen of clinical significance has been purified and characterized, contributing to the study of the complete allergogram of the olive tree pollen.	Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain	Complutense University of Madrid	Rodriguez, R (corresponding author), Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.		Villalba, María Teresa/AAW-1067-2020; Villalba, Mayte/K-5365-2014; RODRIGUEZ, ROSALIA/K-4993-2014	Villalba, María Teresa/0000-0002-0042-9953; RODRIGUEZ, ROSALIA/0000-0002-4280-3691				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Asturias JA, 1997, J ALLERGY CLIN IMMUN, V100, P365, DOI 10.1016/S0091-6749(97)70250-1; Batanero E, 1997, FEBS LETT, V410, P293, DOI 10.1016/S0014-5793(97)00582-6; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; BENCZE WL, 1957, ANAL CHEM, V29, P1193, DOI 10.1021/ac60128a025; Boluda L, 1998, J ALLERGY CLIN IMMUN, V101, P210, DOI 10.1016/S0091-6749(98)70385-9; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; Huecas S, 1999, EUR J BIOCHEM, V261, P539, DOI 10.1046/j.1432-1327.1999.00307.x; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUZURICA P, 1988, MOL IMMUNOL, V25, P337, DOI 10.1016/0161-5890(88)90028-4; Ledesma A, 1998, ALLERGY, V53, P520, DOI 10.1111/j.1398-9995.1998.tb04090.x; Ledesma A, 1998, EUR J BIOCHEM, V258, P454, DOI 10.1046/j.1432-1327.1998.2580454.x; LOMBARDERO M, 1992, J ALLERGY CLIN IMMUN, V89, P884, DOI 10.1016/0091-6749(92)90445-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACCHIA L, 1991, ALLERGENIC POLLEN PO, P87; VILLALBA M, 1990, BIOCHEM BIOPH RES CO, V172, P523, DOI 10.1016/0006-291X(90)90704-Q; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; WEBER K, 1969, J BIOL CHEM, V244, P4406; WHEELER AW, 1992, CLIN EXP ALLERGY, V22, P1052, DOI 10.1111/j.1365-2222.1992.tb00129.x; WHEELER AW, 1990, MOL IMMUNOL, V27, P631, DOI 10.1016/0161-5890(90)90005-K	22	61	67	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1999	104	4	1				797	802		10.1016/S0091-6749(99)70290-3	http://dx.doi.org/10.1016/S0091-6749(99)70290-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	248NG	10518824				2022-12-18	WOS:000083281200011
J	Gosset, P; Tillie-Leblond, I; Oudin, S; Parmentier, O; Wallaert, B; Joseph, M; Tonnel, AB				Gosset, P; Tillie-Leblond, I; Oudin, S; Parmentier, O; Wallaert, B; Joseph, M; Tonnel, AB			Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						chemokine; cytokine; IgE receptor; alveolar macrophage; allergic asthma	PERIPHERAL-BLOOD MONOCYTES; NECROSIS-FACTOR-ALPHA; HISTAMINE-RELEASING FACTOR; MONONUCLEAR PHAGOCYTES; ASTHMATIC-PATIENTS; DEPENDENT STIMULATION; INTERLEUKIN-10 IL-10; CHEMOTACTIC FACTOR; ATOPIC ASTHMA; EXPRESSION	Background: The alveolar macrophage (AM) expresses the low affinity IgE receptor and has the ability to produce not only several proinflammatory cytokines (TNF-alpha, IL-1, IL-6) but also antiinflammatory cytokines (IL-1 receptor antagonist [IL-1ra], IL-10), chemokines (IL-8, monocyte chemotactic protein-1 [MCP-1]), and macrophage inflammatory protein-1 alpha (MIP-1 alpha). Objective: The aim of this study was to evaluate the capacity of the AM from patients with allergic asthma and control subjects to produce chemokines and antiinflammatory versus proinflammatory cytokines after activation by IgE receptors and to define the role of CD23 in this activation. Methods: AMs mere collected by bronchoalveolar lavage from 13 patients with allergic asthma and 14 healthy subjects. Adherent AMs were activated either by the successive addition of IgE and anti-IgE or by monoclonal mouse IgG anti-CD23 or by a control monoclonal mouse antibody, TNF, IL-1 beta, IL-1ra, IL-10, IL-8, MCP-1, and MIP-1 alpha levels were evaluated in supernatants of AMs incubated for 18 hours and in some cases after 4 hours of incubation. Results: Activation by IgE and anti-IgE antibodies significantly increased the production of TNF, IL-1 beta, IL-8, MCP-1, MIP-1 alpha, and IL-IO in both control subjects and patients with asthma, whereas the increase for IL-1ra was only significant for the control subjects. Whereas F(ab) fragments of anti-CD23 antibodies inhibited IgE plus anti-IgG-induced cytokine production, activation by monoclonal IgG anti-CD23 antibodies reproduced the effect of IgE immune complexes. At 4 hours, the secretion of proinflammatory cytokines was increased by activation by IgE receptors, in contrast to antiinflammatory cytokines, In addition, analysis of the balance between proinflammatory and antiinflammatory cytokines showed that IgE-dependent activation largely favored the proinflammatory cytokines, particularly in patients with asthma. Conclusion: IgE-dependent activation by the Fc epsilon RII receptor upregulates the synthesis of both chemokines and antiinflammatory cytokines in addition to proinflammatory cytokines. However, IIR Is from patients with allergic asthma may promote airway inflammation after activation by IgE receptors through its preferential effect on proinflammatory cytokines.	Inst Pasteur, INSERM, U416, F-59019 Lille, France; Hop Calmette, Clin Malad Resp, Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille	Gosset, P (corresponding author), Inst Pasteur, INSERM, U416, BP245, F-59019 Lille, France.		Gosset, Philippe/C-6174-2018	Gosset, Philippe/0000-0002-4043-6429				ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; Armstrong L, 1996, THORAX, V51, P143, DOI 10.1136/thx.51.2.143; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BORISH L, 1992, J IMMUNOL, V149, P3078; BORISH L, 1991, J IMMUNOL, V146, P63; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Calhoun W, 1996, AM J RESP CRIT CARE, V153, pA881; DINARELLO CA, 1991, BLOOD, V77, P1627; Dugas N, 1996, EUR J IMMUNOL, V26, P1394, DOI 10.1002/eji.1830260632; FISHER E, 1992, BLOOD, V79, P2196; FULLER RW, 1986, CLIN EXP IMMUNOL, V65, P416; GALVEDEROCHEMONTEIX B, 1993, AM J RESP CELL MOL, V8, P160; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768, DOI 10.1164/ajrccm/146.3.768; GOSSET P, 1984, J ALLERGY CLIN IMMUN, V74, P827, DOI 10.1016/0091-6749(84)90186-6; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; GOSSET P, 1988, AM REV RESPIR DIS, V138, P40, DOI 10.1164/ajrccm/138.1.40; Gosset P, 1997, CLIN EXP ALLERGY, V27, P379; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; JARJOUR NN, 1996, AM J RESP CRIT CARE, V153, pA878; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; LIEBLER JM, 1994, J IMMUNOL, V152, P241; LIU FT, 1985, P NATL ACAD SCI USA, V82, P4100, DOI 10.1073/pnas.82.12.4100; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MELEWICZ FM, 1981, J IMMUNOL, V126, P1592; MOSSALAYI MD, 1994, INT IMMUNOL, V6, P931, DOI 10.1093/intimm/6.7.931; PANUSKA JR, 1995, J CLIN INVEST, V96, P2245; Powell N, 1996, EUR RESPIR J, V9, P2454, DOI 10.1183/09031936.96.09122454; RANKIN JA, 1992, AM REV RESPIR DIS, V145, P928, DOI 10.1164/ajrccm/145.4_Pt_1.928; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113, DOI 10.1165/ajrcmb.14.2.8630259; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; RUFF MR, 1981, LYMPHOKINE RES, V2, P35; TONNEL AB, 1983, LANCET, V1, P1406; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WARRINGA RAJ, 1991, BLOOD, V77, P2694; WHITE MV, 1989, IMMUNOL LETT, V22, P151, DOI 10.1016/0165-2478(89)90182-X; WILLEMS F, 1994, EUR J IMMUNOL, V24, P1007, DOI 10.1002/eji.1830240435; WILLIAMS J, 1992, J IMMUNOL, V149, P2823; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956	46	61	63	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1999	103	2	1				289	297		10.1016/S0091-6749(99)70504-X	http://dx.doi.org/10.1016/S0091-6749(99)70504-X			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167JW	9949321				2022-12-18	WOS:000078630100017
J	Kumagai, T; Yamanaka, T; Wataya, Y; Umetsu, A; Kawamura, N; Ikeda, K; Furukawa, H; Kimura, K; Chiba, S; Saito, S; Sugawara, N; Kurimoto, F; Sakaguchi, M; Inouye, S				Kumagai, T; Yamanaka, T; Wataya, Y; Umetsu, A; Kawamura, N; Ikeda, K; Furukawa, H; Kimura, K; Chiba, S; Saito, S; Sugawara, N; Kurimoto, F; Sakaguchi, M; Inouye, S			Gelatin-specific humoral and cellular immune responses in children with immediate- and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						gelatin allergy; measles vaccine; mumps vaccine; rubella vaccine; varicella vaccine; cellular immunology; IL-2 responsiveness; lymphocyte transformation; anaphylaxis	INTERLEUKIN-2 IL-2 RESPONSIVENESS; ALLERGEN-SPECIFIC INDUCTION; HEN EGG ALLERGY; LYMPHOCYTE-RESPONSES; INITIAL EVENTS; HYPERSENSITIVITY; IMMUNOTHERAPY; VACCINATION; ANTIBODY; INVITRO	Background: This study was designed to investigate the development of both cellular and humoral immune responses to gelatin in patients with vaccine-related immediate and nonimmediate reactions. Our purpose was to define the nature of the responses in the different clinical states. Methods: Six patients with immediate reactions and 21 patients with nonimmediate reactions after inoculation of various live vaccines were studied. Measurement of gelatin-specific IgE was performed in all subjects. Gelatin-specific T-cell responses detected by an in vitro lymphocyte proliferation assay and by an assay for IL-2 responsiveness were investigated to compare the immune response in patients with the two types of reaction. Results: till six patients with immediate reactions had IgE responses to gelatin, whereas none of the 21 patients with nonimmediate reactions had any anti-gelatin IgE. All of the six patients with immediate reactions and 17 of the 21 patients with nonimmediate reactions exhibited positive T-lymphocyte responses specific to gelatin. Conclusions: Immediate and nonimmediate reactions are caused by different types of allergy to gelatin, and cell-mediated immunity to gelatin mag play an important role in the pathogenesis of nonimmediate reactions.	PEDIAT ALLERGY & INFECT DIS SOC,SAPPORO,HOKKAIDO,JAPAN; SAPPORO MED UNIV,SCH MED,SAPPORO,HOKKAIDO,JAPAN; JIKEI UNIV,SCH MED,TOKYO,JAPAN; MITSUBISHI KAGAKU BIOCLIN LABS INC,TOKYO,JAPAN; NIH,TOKYO,JAPAN	Sapporo Medical University; Jikei University; Mitsubishi Kagaku Bio-Clinical Laboratories; National Institute of Health Sciences - Japan			Inouye, Sharon/R-7216-2019					AUKRUST L, 1980, ALLERGY, V35, P581, DOI 10.1111/j.1398-9995.1980.tb01808.x; BLACK PL, 1980, J ALLERGY CLIN IMMUN, V66, P394, DOI 10.1016/0091-6749(80)90119-0; BRUNING JW, 1982, HUM IMMUNOL, V5, P225, DOI 10.1016/0198-8859(82)90135-5; BUCKLEY RH, 1977, J ALLERGY CLIN IMMUN, V59, P70, DOI 10.1016/0091-6749(77)90180-4; FASANO MB, 1992, J PEDIATR-US, V120, P878, DOI 10.1016/S0022-3476(05)81953-5; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GIRARD JP, 1967, J ALLERGY, V39, P65, DOI 10.1016/0021-8707(67)90113-X; HIRATANI M, 1981, J ALLERGY CLIN IMMUN, V68, P205, DOI 10.1016/0091-6749(81)90185-8; JAMES JM, 1995, NEW ENGL J MED, V332, P1262, DOI 10.1056/NEJM199505113321904; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; MCEWEN J, 1983, MED J AUSTRALIA, V2, P503, DOI 10.5694/j.1326-5377.1983.tb122619.x; MIYAKE T, 1988, J JPN PEDIAT SOC, V92, P1502; MIYAKE T, 1986, J JPN PEDIAT SOC, V90, P1751; MOCHIZUKI Y, 1995, J JPN PEDIAT SOC, V99, P873; NOMA T, 1994, ANN ALLERGY, V73, P76; NOMA T, 1989, J ALLERGY CLIN IMMUN, V84, P255, DOI 10.1016/0091-6749(89)90333-3; NOMA T, 1990, ANN ALLERGY, V64, P33; OGURA H, 1995, INFECT IMMUN CHILD, V7, P115; POLLOCK TM, 1983, LANCET, V1, P753; ROMAGNANI S, 1973, Clinical Allergy, V3, P51, DOI 10.1111/j.1365-2222.1973.tb01309.x; SAKAGUCHI M, 1995, J ALLERGY CLIN IMMUN, V96, P563, DOI 10.1016/S0091-6749(95)70304-7; THURSTON A, 1987, J ROY COLL GEN PRACT, V37, P41; VANASPEREN PP, 1981, MED J AUSTRALIA, V2, P330; YOSHIZAWA I, 1989, J ALLERGY CLIN IMMUN, V84, P246, DOI 10.1016/0091-6749(89)90332-1	24	61	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					130	134		10.1016/S0091-6749(97)70204-5	http://dx.doi.org/10.1016/S0091-6749(97)70204-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257797				2022-12-18	WOS:A1997XP42800019
J	Rajakulasingam, K; Durham, SR; OBrien, F; Humbert, M; Barata, LT; Reece, L; Kay, AB; Grant, JA				Rajakulasingam, K; Durham, SR; OBrien, F; Humbert, M; Barata, LT; Reece, L; Kay, AB; Grant, JA			Enhanced expression of high-affinity IgE receptor (Fc epsilon RI) a chain in human allergen-induced rhinitis with co-localization to mast cells, macrophages, eosinophils, and dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; Fc epsilon RI receptors; IgE	EPIDERMAL LANGERHANS CELLS; MESSENGER-RNA EXPRESSION; ACTIVATED LYMPHOCYTES-T; ATOPIC-DERMATITIS; NASAL-MUCOSA; LATE-PHASE; CYTOKINE; ANTIBODIES; RESPONSES; PARASITES	Background: IgE-dependent activation of mast cells and basophils through the high-affinity IgE receptor (Fc epsilon RI) is involved in the pathogenesis of allergen-induced immediate and late responses. Objective: We investigated the expression and cellular distribution of Fc epsilon RI in the nasal mucosa after allergen challenge in patients with summer hay fever. Methods: Fourteen grass pollen-sensitive patients and seven normal control subjects underwent nasal challenge with grass pollen and allergen diluent in random order separated by 2 weeks. Nasal airway caliber was monitored by acoustic rhinometry, and nasal biopsy was performed at 6 hours. Messenger RNA for Fc epsilon RI was determined by using reverse-transcription polymerase chain reaction, and Fc epsilon RI protein-expression was determined by immunohistology with a mouse monoclonal antibody (22E7) and a rabbit polyclonal antibody (997) directed against the or subunit. Co-localization of Fc epsilon RI receptors was performed by using double-immunostaining methods. Results: In atopic subjects, there was a significant early decrease in nasal airway caliber, which extended up to 6 hours after allergen challenge. Fc epsilon RI mRNA levels were elevated at 6 hours (p = 0.03). Cells expressing Fc epsilon RI protein were increased in patients with atopic rhinitis compared with normal control subjects (p = 0.03). Further increases in Fc epsilon RI+ cells were observed after allergen challenge only in the atopic group (p = 0.02). Double immunohistochemistry revealed that the majority of Fc epsilon RI+ cells were mast cells (64%), followed by macrophages (20%), eosinophils (4%), and dendritic cells (2%), with 10% Fc epsilon RI+ cells being unidentified. Conclusions: Our results demonstrate increased Fc epsilon RI expression during allergen induced rhinitis and highlight a potential target for treatment.	HOP ANTOINE BECLERE, SERV PNEUMOL, CLAMART, FRANCE; UNIV TEXAS, MED BRANCH, DEPT ALLERGY & IMMUNOL, GALVESTON, TX 77550 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; University of Texas System; University of Texas Medical Branch Galveston	Rajakulasingam, K (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, DOVEHOUSE ST, LONDON SW3 6LY, ENGLAND.			Taborda Barata, Luis/0000-0001-6649-8890; Humbert, Marc/0000-0003-0703-2892				ALAM R, 1994, J IMMUNOL, V153, P3155; Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BRUYNZEELKOOMEN C, 1986, ARCH DERMATOL RES, V278, P199, DOI 10.1007/BF00412924; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; Gould H, 1991, Clin Exp Allergy, V21 Suppl 1, P138, DOI 10.1111/j.1365-2222.1991.tb01718.x; GOUNNI AS, 1994, J ALLERGY CLIN IMMUN, V94, P1214, DOI 10.1016/0091-6749(94)90334-4; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; GOUNNI AS, 1994, NATURE, V368, P473, DOI 10.1038/368473a0; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; ISHIZAKA T, 1978, J IMMUNOL, V120, P800; KOCHAN J, 1988, NUCLEIC ACIDS RES, V16, P3584, DOI 10.1093/nar/16.8.3584; LEUNG DYM, 1987, CLIN IMMUNOL IMMUNOP, V42, P328, DOI 10.1016/0090-1229(87)90021-3; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MAURER D, 1995, J IMMUNOL, V154, P6285; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OSTERHOFF B, 1994, J INVEST DERMATOL, V102, P315, DOI 10.1111/1523-1747.ep12371789; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; RAJAKULASINGAM K, 1992, J APPL PHYSIOL, V72, P1418, DOI 10.1152/jappl.1992.72.4.1418; SABAN R, 1994, J ALLERGY CLIN IMMUN, V94, P836, DOI 10.1016/0091-6749(94)90151-1; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TANAKA Y, 1995, ARCH DERMATOL RES, V287, P712, DOI 10.1007/BF01105794; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353	32	61	61	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					78	86		10.1016/S0091-6749(97)70198-2	http://dx.doi.org/10.1016/S0091-6749(97)70198-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257791				2022-12-18	WOS:A1997XP42800013
J	Laitinen, LA; Laitinen, A; Altraja, A; Virtanen, I; Kampe, M; Simonsson, BG; Karlsson, SE; Hakansson, L; Venge, P; Sillastu, H				Laitinen, LA; Laitinen, A; Altraja, A; Virtanen, I; Kampe, M; Simonsson, BG; Karlsson, SE; Hakansson, L; Venge, P; Sillastu, H			Section 1: Inflammatory determinants of asthma severity - Bronchial biopsy findings in intermittent or ''early'' asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchial biopsy; collagen; early asthma; eosinophils; tenascin	TENASCIN	Bronchial biopsy specimens from subjects with intermittent or ''early'' asthma were compared with specimens taken from healthy subjects. Patients with early asthma included those with seasonal asthma and occupational asthma. There was a small but statistically significant increase in the thickness of the subepithelial extracellular matrix protein tenascin in subjects with seasonal and occupational asthma compared with control subjects. Collagen types IV and VII were increased only in patients with occupational asthma. Eosinophils were the only inflammatory cells that were significantly increased in subjects with seasonal asthma compared with control subjects. These data show that inflammation is present in the airways of patients with early asthma, and the increase in tenascin expression in the basement membrane zone suggests that structural changes are also initiated at an early stage of the disease.	UNIV HELSINKI,INST BIOMED,DEPT ANAT,FIN-00014 HELSINKI,FINLAND; UPPSALA UNIV,DEPT LUNG MED & CLIN CHEM,UPPSALA,SWEDEN; LUND UNIV,DEPT LUNG MED,LUND,SWEDEN; TARTU STATE UNIV,DEPT PULM MED,EE-202400 TARTU,ESTONIA	University of Helsinki; Uppsala University; Lund University; University of Tartu	Laitinen, LA (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT MED,HAARTMANINKATU 4,FIN-00290 HELSINKI,FINLAND.							BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; ENGVALL E, 1986, J CELL BIOL, V103, P2457, DOI 10.1083/jcb.103.6.2457; HOWEEDY AA, 1990, LAB INVEST, V63, P798; KOSKELA K, 1996, CLIN EXP ALLERGY S1, V26, P1; KOVACS EJ, 1994, FASEB J, V8, P854, DOI 10.1096/fasebj.8.11.7520879; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LINNALA A, 1995, AM J RESP CELL MOL, V13, P578, DOI 10.1165/ajrcmb.13.5.7576694; MCGOWAN SE, 1992, FASEB J, V6, P2895, DOI 10.1096/fasebj.6.11.1644255; SAKAKURA T, 1994, PERSPECT DEV NEUROBI, V120, P1079	9	61	61	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1996	98	5	2	S			S3	S6		10.1016/S0091-6749(96)80122-9	http://dx.doi.org/10.1016/S0091-6749(96)80122-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VW140	8939170				2022-12-18	WOS:A1996VW14000002
J	Bernstein, IL; Bernstein, DI; Dubb, JW; Faiferman, I; Wallin, B; Bronsky, E; Spector, SL; Nathan, RA; Nelson, HS; Bardana, EJ; Blumenthal, MN; Bone, RC; Briggs, DD; Busse, WW; Campbell, SC; Condemi, JJ; Crain, MR; Grossman, J; Handley, GJ; Kemp, JP; Klaustermeyer, WB; Ledford, DK; Lockey, RF; Lopez, M; McNeil, DL; Metzger, WJ; Montanaro, A; Pinnas, JL; Schoenwetter, WF; Townley, RG; Valentine, MD; VanArsdel, PP; Vari, AJ; Weisberg, SC; Zeitz, HJ				Bernstein, IL; Bernstein, DI; Dubb, JW; Faiferman, I; Wallin, B; Bronsky, E; Spector, SL; Nathan, RA; Nelson, HS; Bardana, EJ; Blumenthal, MN; Bone, RC; Briggs, DD; Busse, WW; Campbell, SC; Condemi, JJ; Crain, MR; Grossman, J; Handley, GJ; Kemp, JP; Klaustermeyer, WB; Ledford, DK; Lockey, RF; Lopez, M; McNeil, DL; Metzger, WJ; Montanaro, A; Pinnas, JL; Schoenwetter, WF; Townley, RG; Valentine, MD; VanArsdel, PP; Vari, AJ; Weisberg, SC; Zeitz, HJ			A placebo-controlled multicenter study of auranofin in the treatment of Patients with corticosteroid-dependent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						auranofin; oral gold; steroid-dependent asthma; steroid-sparing; antiinflammatory effects of auranofin	BRONCHIAL-ASTHMA; DOUBLE-BLIND; GOLD SALT; METHOTREXATE; MODULATION; HISTAMINE; RELEASE; TRIAL	Background: Previous clinical studies have demonstrated that injectable gold salts and the oral gold compound auranofin, possess significant steroid-sparing effects in the treatment of asthma. Objectives: The objectives of this investigation were to determine whether auranofin could reduce oral corticosteroid requirements and to evaluate the safety of auranofin in the treatment of chronic corticosteroid-dependent asthma. Methods: Patients with asthma were eligible if they required at least 10 mg of prednisone per day for control and prevention of asthma exacerbations. Two hundred seventy-nine patients with chronic corticosteroid-dependent asthma (requiring greater than or equal to 10 mg/day) were randomized to receive auranofin, 3 mg twice daily or placebo during an 8-month clinical trial which was divided into three phases including: a 4-week baseline period (phase I), a 6-month double-blind treatment and steroid reduction period (phase II), and a 4-week posttreatment observation period during which steroid and auranofin doses ol placebo doses were maintained at levels achieved by the end of phase II (phase III). The primary efficacy variable was ''therapeutic success'' or reduction of daily corticosteroid use by 50% ol more. Results: The proportion of patients in the auranofin group achieving therapeutic success (41%) was significantly higher than that in the placebo group (27%) (p = 0.01). This effect was greatest in patients requiring 10 to 19 mg of oral prednisone per day at baseline (p < 0.001). In all treated patients, including those who did and did not complete the trial, significant I eduction (greater than or equal to 50% of baseline) in oral corticosteroid dosage was achieved in the auranofin group (60%) compared with the placebo group (32%) (p < 0.001). There were no significant differences between treatment groups in symptoms, concomitant medication use, or lung function. Mean serum total IgE levels decreased significantly from baseline in the auranofin group (-44.63 IU/ml) compared with the placebo group (p = 0.001). Gastrointestinal and cutaneous adverse events were greater in the auranofin group. Conclusions: Auranofin demonstrated a steroid-sparing effect without concomitant worsening of symptoms ol lung function and appeared to be more effective in patients dependent on 10 to 19 mg of prednisone per day. Therefore this study has demonstrated that auranofin is useful as a steroid-sparing agent in the treatment of chronic corticosteroid-dependent asthma.	SMITHKLINE BEECHAM,KING OF PRUSSIA,PA; ABBOTT LABS,ABBOTT PK,IL	GlaxoSmithKline; Abbott Laboratories	Bernstein, IL (corresponding author), UNIV CINCINNATI,COLL MED,DEPT MED,DIV IMMUNOL,231 BETHESDA AVE,ML 563,CINCINNATI,OH 45267, USA.							ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; BERNSTEIN DI, 1988, J ALLERGY CLIN IMMUN, V81, P6, DOI 10.1016/0091-6749(88)90213-8; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; DYER PD, 1991, J ALLERGY CLIN IMMUN, V88, P208, DOI 10.1016/0091-6749(91)90330-Q; ERZURUM SC, 1991, ANN INTERN MED, V114, P353, DOI 10.7326/0003-4819-114-5-353; HAFSTROM I, 1984, AGENTS ACTIONS, V15, P551, DOI 10.1007/BF01966773; LAITINEN LA, 1994, AM J RESP CRIT CARE, V150, pS87, DOI 10.1164/ajrccm/150.5_Pt_2.S87; MALO PE, 1986, J ALLERGY CLIN IMMUN, V77, P371, DOI 10.1016/S0091-6749(86)80120-8; MARONE G, 1986, AGENTS ACTIONS, V18, P100, DOI 10.1007/BF01987994; MURANAKA M, 1978, ANN ALLERGY, V40, P132; MURANAKA M, 1981, J ALLERGY CLIN IMMUN, V67, P350, DOI 10.1016/0091-6749(81)90079-8; NICROP G, 1992, THORAX, V47, P349; PARENTE JE, 1986, J RHEUMATOL, V13, P47; SIRACUSA A, 1993, J ALLERGY CLIN IMMUN, V92, P677, DOI 10.1016/0091-6749(93)90010-D; TAZAWA M, 1975, JAP J ALLERGY, V24, P42; WARD JR, 1983, ARTHRITIS RHEUM, V26, P1303, DOI 10.1002/art.1780261102; WOJTECKALUKASIK E, 1986, AGENTS ACTIONS, V18, P68, DOI 10.1007/BF01987985; 1987, AM REV RESPIR DIS, V136, P224	18	61	61	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					317	324		10.1016/S0091-6749(96)70156-2	http://dx.doi.org/10.1016/S0091-6749(96)70156-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757209				2022-12-18	WOS:A1996VC99500011
J	Nelson, HS; Knoetzer, J; Bucher, B				Nelson, HS; Knoetzer, J; Bucher, B			Effect of distance between sites and region of the body on results of skin prick tests	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HISTAMINE CONTROL; PERFORMANCE; DEVICES	Background: Two variables in skin prick testing were examined: the effect of a positive reaction to histamine or allergen on adjacent negative test sites and the relative size of reactions to allergen and histamine on the back and forearm. Methods: Fifty-two subjects were tested on the back and arm with an allergen extract to which they reacted with a wheal of 8 mm or greater in diameter and with 50% glycerin at sites ranging from 2 to 7.5 cm distant from the allergen test site. A similar study was performed in 50 subjects by using 1.8 mg/ml histamine base to produce the positive reaction. The data were analyzed for the effect of a positive reaction on an adjacent negative control site and also for the relative size of positive reactions on the back and forearm. Data from a second study were also examined for the difference in reactivity on the back and arm. In this study 77 subjects underwent skin prick testing (in duplicate) with seven allergen extracts, 50% glycerin, and 1.8 mg/ml histamine base on the forearm and back. Results: Positive reactions at the 50% glycerin sites were observed at a rate of 0.52% when defined as wheals of 3 mm in diameter or greater and at a rate of 1.11% when defined as flares of 10 mm in diameter or greater. There was no increase in the rate of false-positive reactions over the range of 2 to 5 cm distance from the sires of positive reactions to allergen or histamine. Fewer reactions were present at the 50% glycerin sites, 7.5 cm from the positive sites. The diameters of the reactions to allergen in the primary study were significantly (p < 0.001) smaller on the forearms than on rite back (27% less for the wheal and 14% less for the flare). The mean diameter of the wheals induced by histamine did not vary between back and arm (p = 0.3); however, the mean diameter of the flares on the forearm with histamine were 8% smaller than those on the back (p = 0.003). In the second study the reactions to cat extract (n = 59) were significantly smaller on the forearm than on the back (mean wheal diameter 16% less, mean flare diameter 14% less, p < 0.001 for both). The reactions to histamine (n = 76) in this study were also significantly smaller on the forearm (mean wheal diameter 6% less p = 0.027, and mean flare diameter 14% less, p < 0.001). Conclusion: If a relatively nontraumatic technique for skin testing is used adjacent positive test reaction sites of moderate size, which are 2 cm or more from the site of the prick test, are unlikely to cause false-positive reactions on either the back or forearm. Skin test reactivity is less notable on the forearm than on the back for both histamine and allergen. This effect was more pronounced for allergen tests (16% to 27% decrease in mean wheal diameter) than for histamine tests.			Nelson, HS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,DENVER,CO 80206, USA.							ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; ALEXANDER HL, 1930, J ALLERGY, V2, P23; BOUSQUET J, 1993, ALLERGY PRINCIPLES P, P573; Drebotg S, 1989, ALLERGY S10, V44, P22; KOLLER DY, 1992, ALLERGY, V47, P58, DOI 10.1111/j.1398-9995.1992.tb02251.x; NELSON HS, 1993, ANN ALLERGY, V71, P3; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P750, DOI 10.1016/0091-6749(93)90019-C; TERHO EO, 1989, ALLERGY, V44, P30, DOI 10.1111/j.1398-9995.1989.tb00442.x; TIPTON WR, 1980, ANN ALLERGY, V44, P204; VOORHORST R, 1973, ANN ALLERGY, V31, P137; VOORHORST R, 1980, ALLERGY, V35, P247, DOI 10.1111/j.1398-9995.1980.tb01762.x	11	61	65	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					596	601		10.1016/S0091-6749(96)70304-4	http://dx.doi.org/10.1016/S0091-6749(96)70304-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621844				2022-12-18	WOS:A1996TW08700004
J	Burks, AW; Fuchs, RL				Burks, AW; Fuchs, RL			Assessment of the endogenous allergens in glyphosate-tolerant and commercial soybean varieties	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PROTEINS		MONSANTO CO,AGR GRP,ST LOUIS,MO	Monsanto	Burks, AW (corresponding author), UNIV ARKANSAS MED SCI HOSP,ARKANSAS CHILDRENS HOSP,800 MARSHALL ST,LITTLE ROCK,AR 72202, USA.							BARRY G, 1992, BIOSYNTHESIS MOL REG, P139; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; OGAWA T, 1993, BIOSCI BIOTECH BIOCH, V57, P1030, DOI 10.1271/bbb.57.1030; PADGETTE SR, 1994, IN PRESS HERBICIDE R; THANH VH, 1976, J AGR FOOD CHEM, V24, P1117, DOI 10.1021/jf60208a030	5	61	67	0	13	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				1008	1010		10.1016/S0091-6749(95)70243-1	http://dx.doi.org/10.1016/S0091-6749(95)70243-1			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543735				2022-12-18	WOS:A1995TN12400023
J	WANG, JH; DEVALIA, JL; DUDDLE, JM; HAMILTON, SA; DAVIES, RJ				WANG, JH; DEVALIA, JL; DUDDLE, JM; HAMILTON, SA; DAVIES, RJ			EFFECT OF 6-HOUR EXPOSURE TO NITROGEN-DIOXIDE ON EARLY-PHASE NASAL RESPONSE TO ALLERGEN CHALLENGE IN PATIENTS WITH A HISTORY OF SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NITROGEN DIOXIDE (NO2); ALLERGIC RHINITIS; EOSINOPHIL CATIONIC PROTEIN; MAST CELL TRYPTASE; MYELOPEROXIDASE; INTERLEUKIN-8	EOSINOPHIL ACTIVATION; ASTHMATIC VOLUNTEERS; TRYPTASE LEVELS; IN-VITRO; PREVALENCE; CYTOKINES; INDICATOR; DISEASE; HEALTHY	Background: Recent studies have suggested that exposure to air pollutants may enhance the airway responsiveness of susceptible individuals to inhaled allergen. Methods: To investigate the effect of exposure to nitrogen dioxide (NO2) on nasal airways resistance (NAR) and inflammatory mediators in nasal lavage fluid eight subjects with a history of seasonal allergic rhinitis, who were rested out of season, were exposed in a randomized single-blind, crossover study to either air or 400 ppb NO2 for 6 hours. The charges in NAR and eosinophil cationic protein (ECP), mast cell tryptase (MCT), neutrophil myeloperoxidase (MPO), and interleukin-8 (IL-8) in nasal lavage fluid before and after exposure were evaluated. Another group of eight subjects with a history of seasonal allergic rhinitis were also randomized to exposure to air or 400 ppb NO2 for 6 hours and then challenged with allergen, before evaluation for changes in NAR and changes in ECP, MCT MPO, and IL-8 in nasal lavage fluid. Results: Exposure to air or NO2 did not alter either NAR or the levels of ECP, MCT, MPO, or IL-8 in nasal lavage fluid. Allergen challenge after exposure to both air and NO2 significantly (p < 0.05) increased levels of MCT, brit not MPO and IL-8, in the nasal lavage fluid. In addition, allergen challenge after exposure to NO2, but not air significantly increased levels of only ECP in nasal lavage fluid (p < 0.05). Conclusions: These results suggest that acute exposure to NO2, at concentrations found at the curbside in heavy traffic during episodes of pollution, may ''prime'' eosinophils for subsequent activation by allergen in individuals with a history of seasonal allergic rhinitis.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT RESP MED & ALLERGY,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London								ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; BASCOM R, 1990, AM REV RESPIR DIS, V1403, P594; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271, DOI 10.1165/ajrcmb/9.3.271; DEVALIA JL, 1993, EUR RESPIR J, V6, P1308; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; HILDING AC, 1972, ANN OTO RHINOL LARYN, V81, P422, DOI 10.1177/000348947208100314; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Kramer U, 1992, FORUM STADTE HYGIENE, V43, P82; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; LINN WS, 1986, ARCH ENVIRON HEALTH, V41, P292, DOI 10.1080/00039896.1986.9936699; LINN WS, 1985, ARCH ENVIRON HEALTH, V40, P234, DOI 10.1080/00039896.1985.10545925; LOZEWICZ S, 1992, J ALLERGY CLIN IMMUN, V89, P951, DOI 10.1016/0091-6749(92)90217-P; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; PEDEN DB, 1994, AM J RESP CRIT CARE, V149, pA154; RASMUSSEN TR, 1992, AM REV RESPIR DIS, V146, P654, DOI 10.1164/ajrccm/146.3.654; ROBINSON DS, 1993, THORAX, V48, P845, DOI 10.1136/thx.48.8.845; SANDSTROM T, 1991, EUR RESPIR J, V3, P332; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SOLOPERTO M, 1991, AM J PHYSIOL, V260, pL530, DOI 10.1152/ajplung.1991.260.6.L530; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; VENGE P, 1987, INT ARCH ALLER A IMM, V82, P333, DOI 10.1159/000234219; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133; WARRINGA RAJ, 1993, J ALLERGY CLIN IMMUN, V91, P1198, DOI 10.1016/0091-6749(93)90323-8; WILLIAMS ML, 1988, ATMOS ENVIRON, V22, P2819, DOI 10.1016/0004-6981(88)90449-0; 1994, AIR POLLUTION UK; 1993, ASPECTS AIR POLLUTIO; 1989, LONDON AIR POLLUTION	31	61	63	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1995	96	5	1				669	676		10.1016/S0091-6749(95)70266-0	http://dx.doi.org/10.1016/S0091-6749(95)70266-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TG528	7499684				2022-12-18	WOS:A1995TG52800013
J	BOULET, LP; GIGUERE, MC; MILOT, J; BROWN, J				BOULET, LP; GIGUERE, MC; MILOT, J; BROWN, J			EFFECTS OF LONG-TERM USE OF HIGH-DOSE INHALED STEROIDS ON BONE-DENSITY AND CALCIUM-METABOLISM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INHALED STEROIDS; BRONCHIAL ASTHMA; BONE DENSITY; CALCIUM METABOLISM; OSTEOCALCIN	BECLOMETHASONE DIPROPIONATE; DEPENDENT ASTHMATICS; ORAL PREDNISOLONE; BUDESONIDE; CORTICOSTEROIDS; COMPLICATIONS; TURNOVER; THERAPY; HYPERRESPONSIVENESS; OSTEOCALCIN	Background: Inhaled steroids are the mainstay in the antiinflammatory treatment of asthma. In the last few years, these agents have been used in increasing doses. Because high doses of inhaled steroids can reduce serum osteocalcin levels, there are concerns regarding their long-term effects on bone metabolism. Methods: We examined the effects of doses of 800 mu g/day or greater of beclomethasone or budesonide for more than 18 months in 37 asthmatic subjects (group A), matched to a control group of 37 asthmatic subjects using little or no inhaled steroids (< 500 mu g group B). All had a clinical evaluation measurements of expiratory flows, and determination of serum creatinine, calcium phosphate, gamma-glutamyl transpeptidase, alkaline phosphatase, cortisol, and osteocalcin levels. A 2-hour urinary sample was obtained for creatinine, calcium, phosphate, hydroxyproline, and cortisol measurements. Bone density was assessed at the lumbar spine level and at the hip with a Hologic-QDR-2000 osteodensitometer (Hologic, Boston Mass.). Results: The mean (+/-SD) daily dose of inhaled steroids over the last 2 years was 1140 +/- 353 mu g in group A (mean duration of use of >800 mu g/day, 34.2 +/- 13.0 months) and 89 +/- 98 mu g for group B (mean duration of use of <500 mu g/day, 15.7 +/- 18.8 months). The number of oral steroid treatments (<15 days) during the last 2 pears was small in the two groups, 0.92 +/- 1.27 in group A and 0.05 +/- 0.23 in group B (p > 0.05). The only differences between our two groups in terms of serum or urinary parameters were for mean osteocalcin level, which was lower in group A (2.16 +/- 1.09 ng/nl) than in group B (2.70 +/- 0.98 ng/ml) (p = 0.029), and in mean urinary phosphorous level, which was higher in group A (1.44 +/- 0.76 mmol/2 hr) than in group B (1.26 +/- 0.89 mmol/2 hr (p = 0.034). Mean urinary hydroxyproline levels were 15.51 +/- 6.98 mu mol/2 hr in group A and 13.53 +/- 7.13 mu mol/2 hr in group B (p > 0.05). Mean mineral bone densities of the lumbar spine and hip were similar in the two groups with values of 0.923 +/- 0.136 gm/cm(2) and 0.719 +/- 0.147 gm/cm(2) in group A and 0.933 +/- 0.154 gm/cm2 and 0.694 +/- 0.095 gm/cm(2) in group B (p > 0.05). The T and Z scores for lumbar spine were - 1.32 +/- 1.22 and -0.85 +/- 1.02 in group A and -1.19 +/- 1.33 and -0.72 +/- 1.08 in group B (p > 0.05). There was no correlation between the duration or dose of steroid use and bone density or osteocalcin. Although the serum osteocalcin level was lower in tire group of subjects using high-dose inhaled steroids, suggesting an osteoblastic depression, bone density was not significantly different compared with the control group. Conclusions: This study shows that although the serum osteocalcin level was lower and the urinary phosphorus level was higher in subjects using high-dose inhaled steroids for a mean of 34 months, compared with a control group, no significant difference in bone density or other markers of bone metabolism was found between the two groups.	UNIV LAVAL, CTR HOSP, QUEBEC CITY, PQ, CANADA	Laval University	BOULET, LP (corresponding author), HOP LAVAL, CTR PNEUMOL, UNITE RECH, 2725 CHEM ST FOY, Ste Foy G1V 4G5, PQ, CANADA.			Brown, Jacques/0000-0003-1910-788X				ADELROTH E, 1985, ALLERGY, V40, P58, DOI 10.1111/j.1398-9995.1985.tb04155.x; ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; [Anonymous], 1979, AM REV RESPIR DIS, V119, P831; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; DARWIN JP, 1960, ANN BIOCH, V1, P228; DESFORGES JF, 1991, NEW ENGL J MED, V324, P1105; DUTOIT JI, 1987, AM REV RESPIR DIS, V136, P1174, DOI 10.1164/ajrccm/136.5.1174; GEDDES DM, 1992, THORAX, V47, P404, DOI 10.1136/thx.47.6.404; GUNDBERG CM, 1985, CLIN CHEM, V31, P1720; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HODSMAN AB, 1991, J CLIN ENDOCR METAB, V72, P530, DOI 10.1210/jcem-72-3-530; JENNINGS BH, 1991, EUR J CLIN PHARMACOL, V41, P11, DOI 10.1007/BF00280099; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KONIG P, 1993, J PEDIATR-US, V122, P219, DOI 10.1016/S0022-3476(06)80116-2; LIEBERMAN P, 1972, J ALLERGY CLIN IMMUN, V49, P329, DOI 10.1016/0091-6749(72)90131-5; LUENGO M, 1991, EUR RESPIR J S14, V4, pA342; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MAUNSELL K, 1968, BMJ-BRIT MED J, V1, P661, DOI 10.1136/bmj.1.5593.661; MORRISON D, 1992, THORAX, V47, P418, DOI 10.1136/thx.47.6.418; PACKE GE, 1992, THORAX, V47, P414, DOI 10.1136/thx.47.6.414; SMITH MJ, 1983, THORAX, V38, P676, DOI 10.1136/thx.38.9.676; STEAD RJ, 1990, THORAX, V45, pA792; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V84, P688, DOI 10.1016/0091-6749(89)90297-2; TOOGOOD JH, 1990, AM REV RESPIR DIS, V141, pS89; TOOGOOD JH, 1988, AM REV RESPIR DIS, V138, P57, DOI 10.1164/ajrccm/138.1.57; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; TOOGOOD JH, 1991, ANN ALLERGY, V67, P87; TRUHAN AP, 1989, ANN ALLERGY, V62, P375; WEBB R, 1981, MED CLIN N AM, V65, P1073; WILLIAMS SJ, 1989, GLUCOCORTICOIDS MECH, P68; WOLFF AH, 1991, ANN ALLERGY, V67, P117; 1992, CLIN EXP ALLERGY S, V1, P1	34	61	63	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1994	94	5					796	803		10.1016/0091-6749(94)90145-7	http://dx.doi.org/10.1016/0091-6749(94)90145-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PR240	7963147				2022-12-18	WOS:A1994PR24000002
J	KENNEY, JS; BAKER, C; WELCH, MR; ALTMAN, LC				KENNEY, JS; BAKER, C; WELCH, MR; ALTMAN, LC			SYNTHESIS OF INTERLEUKIN-1-ALPHA, INTERLEUKIN-6, AND INTERLEUKIN-8 BY CULTURED HUMAN NASAL EPITHELIAL-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EPITHELIAL CELLS; INTERLEUKIN-1; INTERLEUKIN-6; INTERLEUKIN-8; ALLERGIC RHINITIS; EOSINOPHILIC NONALLERGIC RHINITIS	POTENT INFLAMMATORY CYTOKINES; NEUTROPHIL CHEMOTACTIC FACTOR; GENE-EXPRESSION; ANTIGEN CHALLENGE; NECROSIS-FACTOR; MESSENGER-RNA; IL-8; INVITRO; PRETREATMENT; ANTIBODIES	Nasal epithelium forms the initial barrier between the environment and the respiratory system and may be a potential source of proinflammatory interleukins, which contribute to the pathophysiology of allergic and nonallergic rhinitis. To explore this possibility, epithelium and cultured human nasal epithelial cells from nasal turbinates of patients undergoing surgery for treatment of upper airway obstruction were examined for the spontaneous expression of interleukin (TL)-1 alpha, IL-1 beta, IL-6, and IL-8. Human nasal epithelial cell lysates and culture supernatants were assayed by two-site ELISAs specific for IL-1 alpha, IL-1 beta, IL-6, or IL-8. Maximum concentrations of these cytokines in supernatants ranged from approximately 0.2 to 2 ng/ml for IL-1 alpha, 1.5 to 7 ng/ml for IL-6 and 100 to 3000 ng/ml for IL-8. IL-1 alpha was predominantly cell-associated, whereas most of the IL-8 and all of the IL-6 were detected in the supernatant. Little or no IL-1 beta was detected by ELISA in the supernatants or cell lysates. Whole tissue turbinates and isolated epithelium were also examined for IL-1 beta, IL-6, and IL-8 mRNA expression by Northern blot analysis. IL-6 and IL-8 mRNAs were detected, whereas IL-1 beta mRNA was not. Furthermore, IL-6 and IL-8 release from human nasal epithelial cell cultures was enhanced by addition to the cultures of lipopolysaccharide, and IL-6 release was inhibited by polymyxin B. Thus human nasal epithelium may be a major source of IL-1 alpha, IL-6, and IL-8 in allergic and nonallergic rhinitis. Production of those proinflammatory cytokines by epithelial cells of the nasal and sinus mucosa may contribute to the pathologic and clinical events that occur in these diseases.	UNIV WASHINGTON, DEPT MED, DIV ALLERGY & INFECT DIS, SEATTLE, WA 98195 USA; SYNTEX RES, INST IMMUNOL & BIOL SCI, PALO ALTO, CA USA	University of Washington; University of Washington Seattle; Syntex Corporation					NIEHS NIH HHS [NIEHS ES-05650] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005650] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAI K, 1992, ACI NEWS, V4, P113; AYARS GH, 1989, AM REV RESPIR DIS, V140, P125; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BECKER S, 1993, AM J RESP CELL MOL, V8, P20, DOI 10.1165/ajrcmb/8.1.20; CERAMI A, 1992, CLIN IMMUNOL IMMUNOP, V62, pS3, DOI 10.1016/0090-1229(92)90035-M; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLINS PD, 1991, J IMMUNOL, V146, P677; DEFORGE LE, 1992, J IMMUNOL, V148, P2133; DESPOT JE, 1987, IMMUNOL ALLERGY CLIN, V7, P37; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1989, CRIT REV IMMUNOL, V9, P1; DINARELLO CA, 1990, LYMPHOKINES IMMUNE R, P145; ELNER VM, 1990, AM J PATHOL, V136, P745; HAEGER EB, 1990, IMMUNOL ALLERGY CLIN, V10, P355; HIRANO T, 1992, CLIN IMMUNOL IMMUNOP, V62, pS60, DOI 10.1016/0090-1229(92)90042-M; HOLGATE ST, 1993, ALLERGY; JACOBS AL, 1992, ENDOCRINOLOGY, V131, P1037, DOI 10.1210/en.131.3.1037; KENNEY JS, 1987, J IMMUNOL, V138, P4236; KENNEY JS, 1990, LABORATORY METHODS I, V1, P231; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; LE PT, 1991, J EXP MED, V174, P1147, DOI 10.1084/jem.174.5.1147; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATTOLI S, 1992, CHEST, V101, pS27, DOI 10.1378/chest.101.3.27S; MAY LT, 1992, J BIOL CHEM, V267, P19698; MCMANUS MS, 1989, EXP LUNG RES, V15, P849, DOI 10.3109/01902148909069631; MORHENN VB, 1992, CYTOKINE, V4, P500, DOI 10.1016/1043-4666(92)90011-F; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; NEWTON RC, 1986, J LEUKOCYTE BIOL, V39, P299, DOI 10.1002/jlb.39.3.299; SANBORG CI, 1989, J LEUKOCYTE BIOL, V46, P417; SCHMOUDER RL, 1992, KIDNEY INT, V41, P191, DOI 10.1038/ki.1992.26; SHAMS N B K, 1989, Regional Immunology, V2, P136; VANDAMME J, 1990, J INVEST DERMATOL, V95, pS90; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253	39	61	62	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1994	93	6					1060	1067		10.1016/S0091-6749(94)70055-9	http://dx.doi.org/10.1016/S0091-6749(94)70055-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NT172	8006310				2022-12-18	WOS:A1994NT17200015
J	ANDRI, L; SENNA, G; BETTELI, C; GIVANNI, S; ANDRI, G; FALAGIANI, P				ANDRI, L; SENNA, G; BETTELI, C; GIVANNI, S; ANDRI, G; FALAGIANI, P			LOCAL NASAL IMMUNOTHERAPY FOR DERMATOPHAGOIDES-INDUCED RHINITIS - EFFICACY OF A POWDER EXTRACT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LOCAL IMMUNOTHERAPY; ALLERGIC RHINITIS; DERMATOPHAGOIDES; DOUBLE-BLIND STUDY	HOUSE DUST MITE; INTRANASAL IMMUNOTHERAPY; RAGWEED EXTRACT; IGE; SERUM	Background: Local nasal immunotherapy by means of an extract in ''macronized'' powder form was studied in allergic rhinitis to Dermatophagoides species. Methods: Twenty-four Dermatophagoides-sensitive patients were studied for 12 months in a double-blind controlled trial. Subjects were selected on the basis of a positive history, skin test, radioallergosorbent test, and intranasal challenge to Dermatophagoides antigen. Two 12-patient groups were selected at random; the first group was given active treatment, and the second received placebo. Results: After 6 months, the mean weekly symptom and medication scores were significantly lower in the treated group than in the control group. The treated group had a significant increase of specific nasal threshold to Dermatophagoides antigen after treatment. Adverse reactions to local nasal immunotherapy, which were limited to the upper respiratory tract, occurred very rarely and did not interfere with dose schedule. Conclusion: Local nasal immunotherapy in powder form may be a suitable alternative to the traditional subcutaneous immunotherapy in terms of clinical efficacy and safety.	MAIN HOSP,DEPT ALLERGOL,VERONA,ITALY; LOFARMA,PHARMACEUT LAB,MILAN,ITALY									ANDERSON MC, 1983, RAST INHIBITION PROC; ANDRI L, 1992, ALLERGY, V47, P318, DOI 10.1111/j.1398-9995.1992.tb02061.x; ANDRI L, 1992, ALLERGY S12, V47, P242; ARMITAGE P, 1971, STATISTICAL METHODS, P456; BACHERT C, 1988, LARYNGO RHINO OTOL, V67, P57, DOI 10.1055/s-2007-998449; BARDARE M, 1988, N ENGL REG ALLERGY P, V9, P257; CLARKE PS, 1987, ANN ALLERGY, V59, P25; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; CRIMI E, 1991, J ALLERGY CLIN IMMUN, V87, P721, DOI 10.1016/0091-6749(91)90395-5; DEUSCHL H, 1977, CLIN ALLERGY, V7, P315, DOI 10.1111/j.1365-2222.1977.tb01459.x; FOUCARD T, 1973, Clinical Allergy, V3, P91, DOI 10.1111/j.1365-2222.1973.tb01313.x; FOX PC, 1981, IMMUNOLOGY, V43, P227; GEORGITIS JW, 1986, INT ARCH ALLER A IMM, V81, P170, DOI 10.1159/000234127; GEORGITIS JW, 1983, J ALLERGY CLIN IMMUN, V71, P71, DOI 10.1016/0091-6749(83)90549-3; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V75, P496, DOI 10.1016/S0091-6749(85)80023-3; GHERSON G, 1988, N ENGL REG ALLERGY P, V9, P348; GURGENIDZE GV, 1990, ALLERGOL IMMUNOPATH, V18, P325; HOLT PG, 1981, IMMUNOLOGY, V42, P409; HORAK F, 1991, ALLERGEN IMMUNOTHERA, P109; JOHANSSON SGO, 1979, INT ARCH ALLER A IMM, V50, P447; MATHEWS KP, 1981, INT ARCH ALLER A IMM, V66, P218, DOI 10.1159/000232821; MCLEAN JA, 1978, J ALLERGY CLIN IMMUN, V63, P166; MEHTA S B, 1975, Clinical Allergy, V5, P279; MISTRELLO G, 1991, ALLERGY, V46, P52, DOI 10.1111/j.1398-9995.1991.tb00543.x; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P41, DOI 10.1016/0091-6749(81)90121-4; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V62, P314, DOI 10.1016/0091-6749(78)90164-1; SAIA B, 1989, ALLERGOLOGIE, V12, P114; SCHIANO S, 1986, USE ALLERGEN POWDER, P77; SCHUMACHER MJ, 1989, J ALLERGY CLIN IMMUN, V83, P711, DOI 10.1016/0091-6749(89)90001-8; SCHUMACHER MJ, 1981, ALLERGY, V37, P241; SEDGWICK JD, 1983, IMMUNOLOGY, V50, P625; STEWART GA, 1989, LANCET, V2, P154, DOI 10.1016/S0140-6736(89)90203-1; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; TRONOLONE M J, 1984, Journal of Allergy and Clinical Immunology, V73, P140; TSE KS, 1973, J ALLERGY CLIN IMMUN, V51, P208, DOI 10.1016/0091-6749(73)90140-1; WELSH PW, 1981, J ALLERGY CLIN IMMUN, V67, P237, DOI 10.1016/0091-6749(81)90067-1; WELSH PW, 1983, J ALLERGY CLIN IMMUN, V71, P454, DOI 10.1016/0091-6749(83)90461-X; WYPYCH J I, 1984, Journal of Allergy and Clinical Immunology, V73, P140; 1989, ALLERGY S10, V44, P27	40	61	61	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					987	996		10.1016/0091-6749(93)90211-W	http://dx.doi.org/10.1016/0091-6749(93)90211-W			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8491949				2022-12-18	WOS:A1993LC97800005
J	TERADA, N; KONNO, A; TADA, H; SHIROTORI, K; ISHIKAWA, K; TOGAWA, K				TERADA, N; KONNO, A; TADA, H; SHIROTORI, K; ISHIKAWA, K; TOGAWA, K			THE EFFECT OF RECOMBINANT HUMAN INTERLEUKIN-5 ON EOSINOPHIL ACCUMULATION AND DEGRANULATION IN HUMAN NASAL-MUCOSA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INTERLEUKIN-5; EOSINOPHIL; NASAL MUCOSA; SECRETORY IGA	PLATELET-ACTIVATING FACTOR; INVITRO; IL-5	Recombinant human interluekin-5 (rhIL-5) was administered repeatedly onto the nasal mucosa of individuals with Japanese cedar pollinosis outside the pollen season. The numbers of eosinophils and epithelial cells and the amount of eosinophil cationic protein (ECP), secretory IgA (S-IgA), and IgA in the nasal lavage fluid increased significantly after the application of rhIL-5. Responsiveness to histamine was also enhanced after the application. When S-IgA was administered onto the nasal mucosa after application of rhIL-5, the amount of ECP in the nasal lavage fluid was significantly more increased. The above findings together with the facts that IL-5 promotes production of IgA, that IgA receptors are present on eosinophils, and that rhIL-5 does not increase release of ECP from eosinophils isolated from the peripheral blood suggest that a series of possible reactions consisting of (1) IL-5-induced production of IgA from the immune-mediating cells, (2) binding of secretory components released from either serous glandular cells or epithelial cells of the nasal mucosa with IgA, (3) release of ECP from eosinophils induced by S-IgA and/or IgA, (4) epithelial damage to the nasal mucosa, and (5) development of nasal hyperreactivity to histamine.	CHIBA UNIV,SCH MED,DEPT OTORHINOLARYNGOL,CHIBA,JAPAN	Chiba University	TERADA, N (corresponding author), AKITA UNIV,SCH MED,DEPT OTORHINOLARYNGOL,1-1-1 HONDO,AKITA 010,JAPAN.							ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; BEAGLEY KW, 1989, J IMMUNOL, V141, P2305; CAPRON M, 1988, CR HEBD ACAD SCI, P397; FUJISAWA T, 1990, J IMMUNOL, V144, P642; FUJITA S, 1983, JPN J CLIN LAB AUTO, V8, P57; FUKUDA Y, 1991, J IMMUNOL METHODS, V143, P89, DOI 10.1016/0022-1759(91)90276-L; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; GULBENKIAN A R, 1991, Journal of Allergy and Clinical Immunology, V87, P206, DOI 10.1016/0091-6749(91)91548-8; HARRIMAN GR, 1988, J IMMUNOL, V140, P3033; KIMANI G, 1988, J IMMUNOL, V140, P3161; KONNO A, 1988, ORL TOKYO S, V7, P241; MACDONALD AJ, 1986, J ALLERGY CLIN IMMUN, V77, P227; NAGATA H, UNPUB EFFECT EPITHEL; NUMAO T, 1989, 7TH P S IMM TOK, P101; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; TAKAHASHI T, 1984, NIHON U DENT J, V58, P627; TERADA N, 1991, Japanese Journal of Allergology, V40, P181; TERADA N, 1988, J JPN RHINOL, V27, P28; TERADA N, 1990, 14 P WORLD C OT HEAD, P1765; TERADA N, 1989, J OTOLARYNGOL JPN, V92, P1337; TERADA N, IN PRESS PRACT OTOL; VENGE P, 1979, BRIT J HAEMATOL, V63, P253; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; YAMAGUCHI Y, 1988, J EXP MED, V167, P1737, DOI 10.1084/jem.167.5.1737	24	61	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					160	168		10.1016/0091-6749(92)90067-C	http://dx.doi.org/10.1016/0091-6749(92)90067-C			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1500623				2022-12-18	WOS:A1992JJ42300004
J	HENRIKSEN, JM; AGERTOFT, L; PEDERSEN, S				HENRIKSEN, JM; AGERTOFT, L; PEDERSEN, S			PROTECTIVE EFFECT AND DURATION OF ACTION OF INHALED FORMOTEROL AND SALBUTAMOL ON EXERCISE-INDUCED ASTHMA IN CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CHILDREN; BRONCHIAL ASTHMA; EXERCISE-INDUCED ASTHMA; BETA-2-ADRENOCEPTOR AGONIST; LONG-ACTING	VENTILATORY FUNCTIONS; REFRACTORY PERIOD; MEXICAN-AMERICAN; YOUNG-ADULTS; PREVENTION; AGONIST; METAPROTERENOL; DRUGS; WHITE; BLACK	The magnitude and duration of protection against exercise-induced asthma (EIA) afforded by salbutamol and the new, long-acting beta-2-agonist, formoterol, were compared in a double-blind, placebo-controlled crossover study. Twelve children with asthma and EIA (>25% fall from baseline at a pretrial exercise test) were studied on 3 different days receiving, in random order, either formoterol, 12-mu-g, salbutamol, 200-mu-g, or placebo by inhalation. The effect on EIA was evaluated by standardized treadmill-exercise tests repeated at the following times after medication: 1/2 hour (test 1), 3 hours (test 2), and, if the trial drug still demonstrated an effect, 51/2 hours (test 3) and 8 hours (test 4). The mean (SD) maximum percent fall in FEV1 at the pretrial test was 45% (14%). Placebo treatment had no effect on EIA. The mean (SD) maximum percent fall in FEV1 was 44% (14%) (test 1) and 39% (13%) (test 2) (not significant). Salbutamol offered good protection against EIA after 1/2 hour (percent fall in FEV1, 18% [18%]; p < 0.02) but was not significantly different from that of placebo after 3 hours, 39% (13%) fall in FEV1. Formoterol blocked EIA in all the children and demonstrated a significant effect in most children for at least 8 hours. The percent fall in FEV1 after the various tests were 8% (16%) (test 1), 10% (9%) (test 2), 18% (15%) (test 3), and 18% (7%) (test 4; N = 9) (all tests, p < 0.001). The mean duration of a 50% reduction in EIA was 11/2 hours for salbutamol and 61/2 hours for formoterol (p < 0.001). No side effects were observed. Inhaled formoterol was determined to be more effective and offered four to five times longer protection against EIA than salbutamol.	KOLDING SYGEHUS,DEPT PEDIAT,KOLDING,DENMARK	Kolding Hospital; University of Southern Denmark				Agertoft, Lone/0000-0001-6840-7921				ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; ARVIDSSON P, 1989, EUR RESPIR J, V2, P325; BECKER AB, 1989, J ALLERGY CLIN IMMUN, V84, P891, DOI 10.1016/0091-6749(89)90385-0; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; EGGLESTON PA, 1980, ALLERGIC DISEASES IN; FRANCIS PWJ, 1980, PEDIATRICS, V66, P103; GODFREY S, 1976, THORAX, V31, P137, DOI 10.1136/thx.31.2.137; GODFREY S, 1977, ASTHMA; HARTLEY JPR, 1980, THORAX, V35, P680, DOI 10.1136/thx.35.9.680; HENRIKSEN JM, 1981, ALLERGY, V36, P463, DOI 10.1111/j.1398-9995.1981.tb01857.x; HENRIKSEN JM, 1990, THESIS U AARHUS AARH; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; HSU KHK, 1979, J PEDIATR-US, V95, P192; JONES RS, 1976, ASTHMA CHILDREN; KONIG P, 1981, CLIN ALLERGY, V11, P597, DOI 10.1111/j.1365-2222.1981.tb02180.x; LOFDAHL CG, 1989, ALLERGY, V44, P264, DOI 10.1111/j.1398-9995.1989.tb01068.x; MCALPINE LG, 1990, RESP MED, V84, P293, DOI 10.1016/S0954-6111(08)80056-X; SCHOEFFEL RE, 1981, ANN ALLERGY, V46, P273; SHAPIRO GG, 1990, ANN ALLERGY, V64, P273; SILVERMAN M, 1973, THORAX, V28, P574, DOI 10.1136/thx.28.5.574; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SLY RM, 1984, J ALLERGY CLIN IMMUN, V73, P680, DOI 10.1016/0091-6749(84)90305-1; STEARNS DR, 1981, J APPL PHYSIOL, V50, P503, DOI 10.1152/jappl.1981.50.3.503	24	61	62	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1992	89	6					1176	1182		10.1016/0091-6749(92)90302-I	http://dx.doi.org/10.1016/0091-6749(92)90302-I			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HZ748	1351489				2022-12-18	WOS:A1992HZ74800013
J	MENON, P; RANDO, RJ; STANKUS, RP; SALVAGGIO, JE; LEHRER, SB				MENON, P; RANDO, RJ; STANKUS, RP; SALVAGGIO, JE; LEHRER, SB			PASSIVE CIGARETTE-SMOKE CHALLENGE STUDIES - INCREASE IN BRONCHIAL HYPERREACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ENVIRONMENTAL TOBACCO SMOKE; BRONCHIAL HYPERREACTIVITY	ALLERGEN-INDUCED INCREASE; LUNG-FUNCTION; INHALATION CHALLENGE; ASTHMATIC SUBJECTS; TOBACCO-SMOKE; RESPONSIVENESS; METHACHOLINE; REACTIVITY; CHILDREN	Degree and duration of bronchial hyperreactivity (BHR) after environmental tobacco smoke (ETS) inhalation was assessed in 31 smoke-sensitive subjects with asthma who exhibited lower airway symptoms on ETS exposure (group I) and 39 smoke-sensitive subjects without asthma who manifested only upper airway symptoms on cigarette-smoke exposure (group II). Subjects were challenged with ETS for 4 hours in a static-test chamber. The atmosphere was continuously monitored for airborne particulate levels (800 cpm), total suspended particulates (1266 +/- 283-mu-g/m3), and airborne nicotine levels (226 +/- 49-mu-g/m2). Methacholine challenges were performed before and serially after cigarette-smoke exposure, and the provocative dose causing a 20% fall in FEV1 was determined. Five of the 31 smoke-sensitive subjects with asthma and none of the smoke-sensitive subjects without asthma reacted to cigarette-smoke challenge (greater-than-or-equal-to 20% fall from baseline FEV1). Thirty-two percent (10/31) of the subjects with asthma demonstrated increased BHR at 6 hours, 29% (9/31) at 24 hours, and 13% (4/31) up to day 14 after ETS challenge. Of the subjects without asthma, 18% (7/39) demonstrated increased BHR at 6 hours, 10% (4/39) at 24 hours, and 8% (3/39) at 3 weeks. These studies demonstrated an increase in BHR after cigarette-smoke challenge in a number of study subjects (although they were clinically asymptomatic) and suggest that prolonged subclinical airway inflammation can occur in the absence of demonstrable change in airway caliber on exposure to ETS.	TULANE UNIV,SCH MED,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,1700 PERDIDO ST,NEW ORLEANS,LA 70112; TULANE UNIV,SCH MED,DEPT MED,PULM DIS SECT,NEW ORLEANS,LA 70112	Tulane University; Tulane University			Rando, Roy/AAN-6118-2020					BECKETT WS, 1988, AM REV RESPIR DIS, V137, P1499, DOI 10.1164/ajrccm/137.6.1499; BLACK JL, 1987, J ALLERGY CLIN IMMUN, V80, P39, DOI 10.1016/S0091-6749(87)80188-4; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DAHMS TE, 1981, CHEST, V80, P530, DOI 10.1378/chest.80.5.530; EATOUGH DJ, 1988, INDOOR AMBIENT AIR Q; GERRARD JW, 1980, AM REV RESPIR DIS, V122, P577; HENDRICK DJ, 1986, AM REV RESPIR DIS, V133, P600; KAUFFMANN F, 1986, AM REV RESPIR DIS, V134, P1172; LANG M, 1989, CHEST, V96, pS170; LEHRER SB, 1986, ANN ALLERGY, V56, P369; MACHADO L, 1985, ALLERGY, V40, P580, DOI 10.1111/j.1398-9995.1985.tb00886.x; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MENON PK, 1988, J ALLERGY CLIN IMMUN, V81, P324, DOI 10.1016/0091-6749(88)90857-3; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; OCONNOR GT, 1987, AM REV RESPIR DIS, V135, P800, DOI 10.1164/arrd.1987.135.4.800; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RANDO RJ, 1990, MAY AM IND HYG C ORL; SHEPHARD RJ, 1979, ENVIRON RES, V20, P392, DOI 10.1016/0013-9351(79)90015-X; SHEPPARD D, 1988, J CLIN INVEST, V81, P1111, DOI 10.1172/JCI113424; SHOJI S, 1987, CLIN RES, V35, P539; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V82, P331, DOI 10.1016/0091-6749(88)90003-6; STERLING TD, 1982, JAPCA J AIR WASTE MA, V32, P250, DOI 10.1080/00022470.1982.10465397; WIEDEMANN HP, 1986, CHEST, V89, P180, DOI 10.1378/chest.89.2.180; DHHS77157C PUBL	28	61	62	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					560	566		10.1016/0091-6749(92)90323-T	http://dx.doi.org/10.1016/0091-6749(92)90323-T			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1740586				2022-12-18	WOS:A1992HD75300008
J	OWNBY, DR; JOHNSON, CC; PETERSON, EL				OWNBY, DR; JOHNSON, CC; PETERSON, EL			MATERNAL SMOKING DOES NOT INFLUENCE CORD SERUM IGE OR IGD CONCENTRATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CORD SERUM; IGE; IGD; PARENTAL SMOKING; NEWBORN INFANTS	BLOOD IGE; CIGARETTE SMOKERS; TOBACCO-SMOKE; FOLLOW-UP; CHILDREN; ALLERGY; EXPOSURE; RISK; PREDICTION; BABIES	Increased cord blood IgE concentrations have been related to atopic risk in children, and a previous study reported increased cord blood IgE concentrations in smoking mothers. These associations suggest a relationship between maternal smoking during pregnancy and atopic risk. To evaluate this question, we prospectively studied parental smoking and cord blood IgE and IgD concentrations in a geographically defined group of women belonging to a health maintenance organization. Cord blood samples were obtained from 847 infants born to these women. Cotinine concentrations were measured in 114 cord blood samples to evaluate the veracity of the maternal smoking histories. Smoking during the prenatal period was reported by 144 mothers (17%) and 204 fathers (25%). Decreased birth weight and length were associated with maternal smoking (p < 0.001 for both), confirming previous studies. Neither maternal nor paternal smoking was found to be associated with IgE level in univariate or multivariate analyses. Maternal and paternal smoking was associated with IgD (p = 0.03 and p = 0.06, respectively) in univariate analysis. In multiple regression analysis controlling for potentially confounding variables, the association between paternal, but not maternal, smoking and IgD was sustained (p = 0.05 and p > 0.20, respectively). Our data do not demonstrate that maternal or paternal smoking increases cord blood IgE.	HENRY FORD HLTH SYST,DEPT INTERNAL MED,ALLERGY RES LAB,DETROIT,MI 48202; HENRY FORD HLTH SYST,DEPT BIOSTAT RES EPIDEMIOL & COMP,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital				Johnson, Christine Cole/0000-0002-6864-6604	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024156] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24156] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angioni A M, 1989, Paediatr Perinat Epidemiol, V3, P248, DOI 10.1111/j.1365-3016.1989.tb00376.x; BAHNA SL, 1983, CLIN EXP IMMUNOL, V51, P624; BAHNA SL, 1983, ALLERGY, V38, P57, DOI 10.1111/j.1398-9995.1983.tb00857.x; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; FERRIS BG, 1985, ENV HLTH PERSPECT, V63, P289; GELLERBERNSTEIN G, 1987, ALLERGY, V42, P85, DOI 10.1111/j.1398-9995.1987.tb02364.x; HAUS M, 1988, J ALLERGY CLIN IMMUN, V82, P179, DOI 10.1016/0091-6749(88)90997-9; HELM RM, 1986, J ALLERGY CLIN IMMUN, V77, P880, DOI 10.1016/0091-6749(86)90387-8; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; KIMPEN J, 1987, ARCH DIS CHILD, V62, P478, DOI 10.1136/adc.62.5.478; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; MAGNUSSON CGM, 1985, J ALLERGY CLIN IMMUN, V75, P513, DOI 10.1016/S0091-6749(85)80026-9; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; OWNBY DR, 1988, J ALLERGY CLIN IMMUN, V82, P634, DOI 10.1016/0091-6749(88)90976-1; PATTISHALL EN, 1985, AM J DIS CHILD, V139, P1101, DOI 10.1001/archpedi.1985.02140130039026; ROWE D S, 1970, Bulletin of the World Health Organization, V43, P607; ROWE MS, 1986, J ALLERGY CLIN IMMUN, V77, P714, DOI 10.1016/0091-6749(86)90416-1; THOMAS J, 1979, ANN ALLERGY, V43, P144; TSENG RYM, 1989, ACTA PAEDIATR SCAND, V78, P127, DOI 10.1111/j.1651-2227.1989.tb10900.x; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; ZETTERSTROM O, 1985, J ALLERGY CLIN IMMUN, V75, P594, DOI 10.1016/0091-6749(85)90035-1; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215	23	61	62	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1991	88	4					555	560		10.1016/0091-6749(91)90148-H	http://dx.doi.org/10.1016/0091-6749(91)90148-H			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GL049	1918722	Bronze			2022-12-18	WOS:A1991GL04900003
J	RAK, S; HAKANSON, L; VENGE, P				RAK, S; HAKANSON, L; VENGE, P			IMMUNOTHERAPY ABROGATES THE GENERATION OF EOSINOPHIL AND NEUTROPHIL CHEMOTACTIC ACTIVITY DURING POLLEN SEASON	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CENT HOSP VASTERAS,DEPT LUNG MED,VASTERAS,SWEDEN; UNIV HOSP UPPSALA,DEPT CLIN CHEM,INFLAMMAT RES LAB,UPPSALA,SWEDEN	Vasteras Central Hospital; Uppsala University; Uppsala University Hospital								AAS K, 1972, ACTA ALLERGOL, V27, P439; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DUNNILL MS, 1978, ALLERGY PRINCIPLES P, P678; GOSSET P, 1984, J ALLERGY CLIN IMMUN, V74, P827, DOI 10.1016/0091-6749(84)90186-6; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V83, P933, DOI 10.1016/0091-6749(89)90108-5; HAKANSSON L, 1980, SCAND J IMMUNOL, V11, P271, DOI 10.1111/j.1365-3083.1980.tb00235.x; HAKANSSON L, 1987, J LEUKOCYTE BIOL, V42, P689, DOI 10.1002/jlb.42.6.689; HOLGATE ST, 1985, CLIN ALLERGY, V15, P221, DOI 10.1111/j.1365-2222.1985.tb02279.x; HOLLINGSWORTH HM, 1984, AM REV RESPIR DIS, V130, P373; KAY AB, 1971, J IMMUNOL, V107, P899; KAY AB, 1970, CLIN EXP IMMUNOL, V7, P723; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379, DOI 10.1164/ajrccm/136.2.379; LEE TH, 1987, AM REV RESPIR DIS, V135, pS14; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LOWHAGEN O, 1983, EUR J RESPIR DIS, V64, P446; METZGER WJ, 1986, J ALLERGY CLIN IMMUN, V78, P282; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PAPAGEORGIOU N, 1983, J ALLERGY CLIN IMMUN, V72, P75, DOI 10.1016/0091-6749(83)90055-6; PARISH WE, 1982, CLIN ALLERGY, V12, P475, DOI 10.1111/j.1365-2222.1982.tb01646.x; PIPKORN U, 1982, THESIS U GOTHENBERG; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; TING S, 1981, J IMMUNOL, V127, P557; VENGE P, 1982, ALLERGY, V37, P55, DOI 10.1111/j.1398-9995.1982.tb04117.x; VENGE P, 1987, J ALLERGY CLIN IMMUN, V80, P679, DOI 10.1016/0091-6749(87)90287-9; VENGE P, 1985, GLUCOCORTICOSTEROIDS; WASSERMAN SI, 1982, CLIN EXP IMMUNOL, V47, P570; WILKINSON PC, 1974, CHEMOTAXIS INFLAMMAT	31	61	64	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					706	713		10.1016/S0091-6749(05)80174-5	http://dx.doi.org/10.1016/S0091-6749(05)80174-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	2229837				2022-12-18	WOS:A1990EJ63100002
J	VERDIANI, P; DICARLO, S; BARONTI, A				VERDIANI, P; DICARLO, S; BARONTI, A			DIFFERENT PREVALENCE AND DEGREE OF NONSPECIFIC BRONCHIAL HYPERREACTIVITY BETWEEN SEASONAL AND PERENNIAL RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											VERDIANI, P (corresponding author), OSPED GA PIZZETTI, DEPT PNEUMOL, DIV ALLERGOL & RESP PATHOPHYSIOL, VIALE CIMABUE 109, I-58100 GROSSETO, ITALY.							ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; BARONTI A, 1983, CURR THER RES CLIN E, V34, P142; BARONTI A, 1983, MED TORACICA, V5, P7; BOULET LP, 1989, ANN ALLERGY, V63, P114; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; COCKCROFT DW, 1985, ANN ALLERGY, V55, P857; COCKCROFT DW, 1983, LANCET, V2, P253; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; FAZZI P, 1982, EUR J RESPIR DIS, V63, P168; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; GNIAZDOWSKI R, 1979, ACTA OTO-LARYNGOL, V88, P257, DOI 10.3109/00016487909137167; GROSSMAN J, 1975, J ALLERGY CLIN IMMUN, V55, P49, DOI 10.1016/S0091-6749(75)80007-8; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; JOHNSTON.DE, 1968, AM J DIS CHILD, V115, P213, DOI 10.1001/archpedi.1968.02100010215010; MADONINI E, 1987, J ALLERGY CLIN IMMUN, V79, P358, DOI 10.1016/0091-6749(87)90156-4; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; MURRAY AB, 1983, PEDIATRICS, V71, P418; OREHEK J, 1976, B EUR PHYSIOPATH RES, V12, P565; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; STEPHENS NL, 1977, ASTHMA, V2, P147; STEVENS WJ, 1980, EUR J RESPIR DIS, V61, P203; TAKEYAMA H, 1985, J ALLERGY CLIN IMMUN, V75, P140, DOI 10.1016/0091-6749(85)90276-3; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; 1982, FISIOPATOLOGIA RESPI, V3, P3	33	61	62	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1990	86	4	1				576	582		10.1016/S0091-6749(05)80215-5	http://dx.doi.org/10.1016/S0091-6749(05)80215-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EG454	2229817				2022-12-18	WOS:A1990EG45400019
J	CALHOUN, WJ; BUSH, RK				CALHOUN, WJ; BUSH, RK			ENHANCED REACTIVE OXYGEN SPECIES METABOLISM OF AIRSPACE CELLS AND AIRWAY INFLAMMATION FOLLOW ANTIGEN CHALLENGE IN HUMAN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,DEPT MED,ALLERGY IMMUNOL SECT,MADISON,WI 53792; WILLIAM S MIDDLETON MEM VET ADM MED CTR,ALLERGY SECT,MADISON,WI 53705	University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	CALHOUN, WJ (corresponding author), UNIV WISCONSIN,DEPT MED,PULM & CRIT CARE MED SECT,H6 384 CSC,MADISON,WI 53792, USA.			Calhoun, William/0000-0001-7075-712X	PHS HHS [K08-01828] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOWSHER RR, 1983, J BIOL CHEM, V258, P2215; CALHOUN W J, 1987, American Review of Respiratory Disease, V135, pA224; CALHOUN WJ, 1988, J LAB CLIN MED, V112, P147; CALHOUN WJ, 1986, THORAX, V41, P266, DOI 10.1136/thx.41.4.266; CHANYEUNG M, 1988, CLIN ALLERGY, V18, P359, DOI 10.1111/j.1365-2222.1988.tb02883.x; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; DAMON M, 1989, American Review of Respiratory Disease, V139, pA304; DANIEL WW, 1983, BIOSTATISTICS F ANAL; DAVIS GS, 1990, AM REV RESPIR DIS, V141, pS183; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; FLINT KC, 1986, RESPIRATION, V50, P31, DOI 10.1159/000195099; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; HOLGATE ST, 1985, INT ARCH ALLER A IMM, V77, P47, DOI 10.1159/000233752; KROUTIL LA, 1987, J ALLERGY CLIN IMMUN, V80, P170, DOI 10.1016/0091-6749(87)90126-6; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LOWRY OH, 1951, J BIOL CHEM, V193, P265; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; RANKIN JA, 1984, J IMMUNOL, V132, P1993; SEDGWICK JB, 1988, J ALLERGY CLIN IMMUN, V81, P876, DOI 10.1016/0091-6749(88)90945-1; SHULT PA, 1985, J LAB CLIN MED, V106, P638; SPECTOR SL, 1983, PROVOCATIVE CHALLENG, P97; TAYLOR GW, 1989, LANCET, V1, P584; TONNEL AB, 1983, LANCET, V1, P1406; VONESSEN S, 1989, AM REV RESPIR DIS, V139, pA381	28	61	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1990	86	3	1				306	313		10.1016/S0091-6749(05)80092-2	http://dx.doi.org/10.1016/S0091-6749(05)80092-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EA859	2212406				2022-12-18	WOS:A1990EA85900003
J	MENSINGA, TT; SCHOUTEN, JP; RIJCKEN, B; WEISS, ST; SPEIZER, FE; VANDERLENDE, R				MENSINGA, TT; SCHOUTEN, JP; RIJCKEN, B; WEISS, ST; SPEIZER, FE; VANDERLENDE, R			THE RELATIONSHIP OF EOSINOPHILIA AND POSITIVE SKIN-TEST REACTIVITY TO RESPIRATORY SYMPTOM PREVALENCE IN A COMMUNITY-BASED POPULATION STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, JOINT DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV PULM, BOSTON, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	MENSINGA, TT (corresponding author), GRONINGEN STATE UNIV, DEPT EPIDEMIOL, ANTONIUS DEUSINGLAAN 1, 9713 AV GRONINGEN, NETHERLANDS.							ABAKER RJ, 1978, GLIM SYSTEM RELEASE; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1980, AM REV RESPIR DIS, V122, P709, DOI 10.1164/arrd.1980.122.5.709; BURROWS B, 1982, J ALLERGY CLIN IMMUN, V70, P199, DOI 10.1016/0091-6749(82)90042-2; CHANYEUNG M, 1984, AM J MED, V76, P31; CORRE F, 1971, LANCET, V2, P632; Cox D. R, 1977, ANAL BINARY DATA; CURRAN WS, 1961, ANN INTERN MED, V55, P777, DOI 10.7326/0003-4819-55-5-777; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; GLEICH GJ, 1988, HOSP PRACT, V1, P97; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; HELMAN N, 1975, AM J CLIN PATHOL, V63, P35; HERXHEIMER H, 1954, Acta Allergol, V7, P380, DOI 10.1111/j.1398-9995.1954.tb03534.x; HOWELL RW, 1970, LANCET, V2, P152, DOI 10.1016/S0140-6736(70)92736-4; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; PETITTI DB, 1986, AM J EPIDEMIOL, V123, P89, DOI 10.1093/oxfordjournals.aje.a114227; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; TAYLOR RG, 1985, THORAX, V40, P17, DOI 10.1136/thx.40.1.17; TELL GS, 1985, CIRCULATION, V72, P971, DOI 10.1161/01.CIR.72.5.971; VANDERLENDE R, 1972, SCAND J RESPIR DIS, V53, P218; VANDERLENDE R, 1969, THESIS ASSEN; VANDERLENDE R, 1969, BRONCHITIS, V3, P52; VANDERLENDE R, 1986, AEROSOLS RES RISK AS, P731; VEENING GJJ, 1958, THESIS THE HAGUE; WELLER PF, 1984, J ALLERGY CLIN IMMUN, V73, P1, DOI 10.1016/0091-6749(84)90474-3; 1967, GROUPE TRAVAIL BRONC; 1966, INSTRUCTIONS USE QUE	30	61	62	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					99	107		10.1016/S0091-6749(05)80129-0	http://dx.doi.org/10.1016/S0091-6749(05)80129-0			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2370392				2022-12-18	WOS:A1990DQ68800015
J	HATTEVIG, G; KJELLMAN, B; SIGURS, N; GRODZINSKY, E; HED, J; BJORKSTEN, B				HATTEVIG, G; KJELLMAN, B; SIGURS, N; GRODZINSKY, E; HED, J; BJORKSTEN, B			THE EFFECT OF MATERNAL AVOIDANCE OF EGGS, COWS MILK, AND FISH DURING LACTATION ON THE DEVELOPMENT OF IGE, IGG, AND IGA ANTIBODIES IN INFANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LINKOPING,CLIN IMMUNOL LAB,LINKOPING,SWEDEN; CENT HOSP BORAS,DEPT PEDIAT,BORAS,SWEDEN	Linkoping University	HATTEVIG, G (corresponding author), CENT HOSP SKOVDE,DEPT PEDIAT,S-54185 SKOVDE,SWEDEN.							AHLSTEDT S, 1983, INT ARCH ALLER A IMM, V71, P293, DOI 10.1159/000233410; BJORKSTEN B, 1984, CLIN REV ALLERG, V2, P95; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; CASIMIR G, 1985, J ALLERGY CLIN IMMUN, V75, P206, DOI 10.1016/0091-6749(85)90541-X; CHANDRA RK, 1985, CLIN ALLERGY, V15, P517, DOI 10.1111/j.1365-2222.1985.tb02304.x; DANNAEUS A, 1977, ACTA PAEDIATR SCAND, V66, P31, DOI 10.1111/j.1651-2227.1977.tb07803.x; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; DANNAEUS A, 1978, ACTA PAEDIATR SCAND, V67, P497, DOI 10.1111/j.1651-2227.1978.tb16360.x; FALTHMAGNUSSON K, 1988, J ALLERGY CLIN IMMUN, V81, P743, DOI 10.1016/0091-6749(88)91048-2; FALTHMAGNUSSON K, 1987, THESIS LINKOPING U L, P27; FALTHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P869; HAMBURGER RN, 1983, ANN ALLERGY, V51, P281; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; HATTEVIG G, 1987, ACTA PAEDIATR SCAND, V76, P349, DOI 10.1111/j.1651-2227.1987.tb10473.x; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; JARRETT EEE, 1977, LANCET, V2, P223; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P465, DOI 10.1111/j.1651-2227.1976.tb04915.x; LILJA G, UNPUB CLIN EXP ALLER; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MELLANDER L, 1986, CLIN EXP IMMUNOL, V63, P555; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; PARISH WE, 1970, LANCET, V2, P591; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; TURNER KJ, 1988, CLIN ALLERGY, V18, P331, DOI 10.1111/j.1365-2222.1988.tb02880.x; ZEIGER RS, 1986, J ALLERGY CLIN IMMUN, V78, P224, DOI 10.1016/0091-6749(86)90016-3	28	61	61	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				108	115		10.1016/0091-6749(90)90231-R	http://dx.doi.org/10.1016/0091-6749(90)90231-R			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299096				2022-12-18	WOS:A1990CM37800019
J	BOCK, SA				BOCK, SA			PROBABLE ALLERGIC REACTION TO CASEIN HYDROLYSATE FORMULA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter											BOCK, SA (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,DENVER,CO 80206, USA.							JARMOC LM, 1987, CLIN PEDIATR, V26, P154, DOI 10.1177/000992288702600312; SEBAN A, 1977, AM J CLIN NUTR, V30, P840, DOI 10.1093/ajcn/30.6.840	2	61	61	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1989	84	2					272	272						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL836	2760363	Bronze			2022-12-18	WOS:A1989AL83600020
J	FREELAND, HS; PIPKORN, U; SCHLEIMER, RP; BASCOM, R; LICHTENSTEIN, LM; NACLERIO, RM; PETERS, SP				FREELAND, HS; PIPKORN, U; SCHLEIMER, RP; BASCOM, R; LICHTENSTEIN, LM; NACLERIO, RM; PETERS, SP			LEUKOTRIENE-B4 AS A MEDIATOR OF EARLY AND LATE REACTIONS TO ANTIGEN IN HUMANS - THE EFFECT OF SYSTEMIC GLUCOCORTICOID TREATMENT INVIVO	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV PULM & CRIT CARE MED,804 COLL BLDG,PHILADELPHIA,PA 19107; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21205	Jefferson University; Johns Hopkins University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024509, P50AI020136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031891] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20136, AI-24509] Funding Source: Medline; NIAMS NIH HHS [AR31891] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRAY MA, 1983, BRIT MED BULL, V39, P249, DOI 10.1093/oxfordjournals.bmb.a071828; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FREELAND HS, 1988, AM REV RESPIR DIS, V138, P389, DOI 10.1164/ajrccm/138.2.389; HUNNINGHAKE GW, 1980, J CLIN INVEST, V66, P473, DOI 10.1172/JCI109878; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MARTIN TR, 1987, J CLIN INVEST, V80, P1114, DOI 10.1172/JCI113168; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357, DOI 10.1164/ajrccm/136.2.357; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; OBYRNE PM, 1985, J APPL PHYSIOL, V59, P1941, DOI 10.1152/jappl.1985.59.6.1941; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PIPKORN U, 1987, J CLIN INVEST, V80, P957, DOI 10.1172/JCI113188; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SCHLEIMER RP, 1985, ANNU REV PHARMACOL, V25, P381, DOI 10.1146/annurev.pharmtox.25.1.381; SHAK S, 1984, J BIOL CHEM, V259, P181; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; WARNER JA, 1987, BIOCHEM PHARMACOL, V36, P3195, DOI 10.1016/0006-2952(87)90632-0	20	61	62	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1989	83	3					634	642		10.1016/0091-6749(89)90076-6	http://dx.doi.org/10.1016/0091-6749(89)90076-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T8596	2466880				2022-12-18	WOS:A1989T859600010
J	VOLOVITZ, B; OSUR, SL; BERNSTEIN, JM; OGRA, PL				VOLOVITZ, B; OSUR, SL; BERNSTEIN, JM; OGRA, PL			LEUKOTRIENE-C4 RELEASE IN UPPER RESPIRATORY MUCOSA DURING NATURAL EXPOSURE TO RAGWEED IN RAGWEED-SENSITIVE CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP,DIV INFECT DIS,219 BRYANT ST,BUFFALO,NY 14222; CHILDRENS HOSP,DIV MICROBIOL LABS,BUFFALO,NY 14222; CHILDRENS HOSP,DIV ALLERGY & IMMUNOL,BUFFALO,NY 14222; SUNY BUFFALO,DEPT PEDIAT,BUFFALO,NY 14260; SUNY BUFFALO,DEPT MICROBIOL,BUFFALO,NY 14260; SUNY BUFFALO,DEPT OTOLARYNGOL,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015939] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-15939] Funding Source: Medline; NICHD NIH HHS [HD-19679] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATLURU D, 1984, J CLIN INVEST, V74, P1444, DOI 10.1172/JCI111556; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; CASEY L, 1982, LEUKOTRIENES OTHER L, P201; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CROMWELL O, 1981, LANCET, V2, P164; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; FERRERI NR, 1986, J IMMUNOL, V136, P4188; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; HANNA CJ, 1981, NATURE, V290, P343, DOI 10.1038/290343a0; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MATTHAY MA, 1984, J CLIN IMMUNOL, V4, P479, DOI 10.1007/BF00916578; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1986, CLIN ALLERGY, V16, P101, DOI 10.1111/j.1365-2222.1986.tb00753.x; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; OKUDA M, 1985, ANN ALLERGY, V54, P152; PETERS SP, 1984, J IMMUNOL, V132, P1972; RICKETTI AJ, 1983, ALLERGIC DISEASES, P207; SCOTT WA, 1983, FED PROC, V42, P129; STENMARK KR, 1983, NEW ENGL J MED, V309, P77, DOI 10.1056/NEJM198307143090204; TOGIAS AG, 1986, AM REV RESPIR DIS, V133, P1133; VOLOVITZ B, 1988, J PEDIATR-US, V112, P218, DOI 10.1016/S0022-3476(88)80058-1; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626	25	61	63	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1988	82	3	1				414	418		10.1016/0091-6749(88)90000-0	http://dx.doi.org/10.1016/0091-6749(88)90000-0			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q3229	3170989				2022-12-18	WOS:A1988Q322900014
J	TOWNLEY, RJ; HOPP, RJ				TOWNLEY, RJ; HOPP, RJ			INHALATION METHODS FOR THE STUDY OF AIRWAY RESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CREIGHTON UNIV, OMAHA, NE 68178 USA	Creighton University			Hopp, Russell/K-4578-2019					ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; Anderson S.D., 1985, AIRWAY RESPONSIVENES, P51; ANDERSON SD, 1985, CLIN REV ALLERG, V3, P427; ANDERSON SD, 1985, J ALLERGY CLIN IMMUN, V76, P763, DOI 10.1016/0091-6749(85)90745-6; BASCOM R, 1986, AM REV RESPIR DIS, V134, P248; BEWTRA A, 1984, ARCH INTERN MED, V144, P925, DOI 10.1001/archinte.144.5.925; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRUCE CA, 1975, J ALLERGY CLIN IMMUN, V56, P331, DOI 10.1016/0091-6749(75)90126-8; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CROPP GJA, 1979, J ALLERGY CLIN IMMUN, V64, P627, DOI 10.1016/0091-6749(79)90026-5; CROPP GJA, 1980, ATS NEWS         SPR, P11; CURRY JJ, 1947, J CLIN INVEST, V26, P430, DOI 10.1172/JCI101826; Cushley M J, 1983, Agents Actions Suppl, V13, P109; CUSS FM, 1986, LANCET, V2, P189; DAUTREBANDE L, 1941, PRESSE MED, V49, P942; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEVRIES K, 1982, BRONCHIAL HYPERREACT, P107; DOLOVICH MB, 1985, AIRWAY RESPONSIVENES, P9; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; ESCHENBACHER WL, 1985, AM REV RESPIR DIS, V131, P894; FELARCA AB, 1966, J ALLERGY, V37, P223, DOI 10.1016/0021-8707(66)90117-1; FINDLAY SR, 1980, AM REV RESPIR DIS, V122, P53; GODFREY S, 1975, J ALLERGY CLIN IMMUN, V56, P1, DOI 10.1016/0091-6749(75)90029-9; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P517, DOI 10.1016/0091-6749(86)90098-9; HARGREAVE FE, 1980, AIRWAY REACTIVITY ME, P145; HARGREAVE FE, 1984, ASTHMA PHYSL IMMUNOP, P263; HEATON RW, 1984, CHEST, V86, P810, DOI 10.1378/chest.86.6.810; HODGSON WC, 1984, CHEST, V85, P465, DOI 10.1378/chest.85.4.465; HOLROYDE MC, 1981, LANCET, V2, P17; ITKIN IH, 1967, J ALLERGY, V40, P245, DOI 10.1016/0021-8707(67)90087-1; KANG B, 1976, BMJ-BRIT MED J, V1, P867, DOI 10.1136/bmj.1.6014.867; LEWIS RA, 1982, CLIN SCI, V63, pP7; LOWELL FC, 1948, J ALLERGY, V19, P100, DOI 10.1016/0021-8707(48)90096-3; MALO JL, 1986, AM REV RESPIR DIS, V134, P990, DOI 10.1164/arrd.1986.134.5.990; MANN JS, 1985, AM REV RESPIR DIS, V132, P1; MATTOLI S, 1986, CHEST, V90, P726, DOI 10.1378/chest.90.5.726; MCLAUGHLIN FJ, 1983, PEDIATRICS, V72, P503; NAIR N, 1986, ANN ALLERGY, V56, P226; OBYRNE PM, 1985, AIRWAY RESPONSIVENES, P60; RAMSDALE EH, 1984, THORAX, V39, P912, DOI 10.1136/thx.39.12.912; REED C, 1983, ALLERGY PRINCIPLES P, P811; RIMMER J, 1986, CLIN ALLERGY, V16, P221, DOI 10.1111/j.1365-2222.1986.tb00769.x; ROSENTHAL RR, 1985, ALLERGY, pCH14; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285, DOI 10.1136/bmj.283.6302.1285; SHAW RJ, 1985, ALLERGY, V40, P48, DOI 10.1111/j.1398-9995.1985.tb04154.x; SIMONSSON BG, 1967, J CLIN INVEST, V46, P1812, DOI 10.1172/JCI105671; SMITH AP, 1975, CLIN SCI MOL MED, V48, P421, DOI 10.1042/cs0480421; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; SOUHRADA J, 1983, PROVOCATIVE CHALLENG, V2, P75; SPECTOR SL, 1975, J ALLERGY CLIN IMMUN, V56, P308, DOI 10.1016/0091-6749(75)90105-0; SWIFT DL, 1985, AIRWAY RESPONSIVENES, P1; TESSIER P, 1986, J ALLERGY CLIN IMMUN, V78, P379, DOI 10.1016/0091-6749(86)90021-7; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; TOWNLEY RG, 1976, J ALLERGY CLIN IMMUN, V57, P358, DOI 10.1016/0091-6749(76)90093-2; TOWNLEY RG, 1986, CLIN MED, pCH7; TOWNLEY RG, 1983, PROVOCATIVE CHALLENG, V1, P177; TRAUTLEIN JJ, 1979, J ALLERGY CLIN IMMUN, V64, P625, DOI 10.1016/0091-6749(79)90025-3; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WOOLCOCK AJ, 1986, AM REV RESPIR DIS, V133, pA177; WOOLCOCK AJ, 1985, AIRWAY RESPONSIVENES, P80; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	71	61	61	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1987	80	2					111	125		10.1016/0091-6749(87)90116-3	http://dx.doi.org/10.1016/0091-6749(87)90116-3			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	J6575	3301984	Bronze			2022-12-18	WOS:A1987J657500001
J	GREENBERGER, PA; PATTERSON, R				GREENBERGER, PA; PATTERSON, R			MANAGEMENT OF DRUG ALLERGY IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University			Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 11403] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG D, 1985, ANN INTERN MED, V103, P738, DOI 10.7326/0003-4819-103-5-738; DESWARTE D, 1985, ALLERGIC DISEASES DI, P505; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; JAFFE HS, 1983, LANCET, V2, P1109; JICK H, 1982, REV INFECT DIS, V4, P426; KLEMOLA E, 1970, Scandinavian Journal of Infectious Diseases, V2, P29, DOI 10.3109/inf.1970.2.issue-1.05; PEARSON RD, 1985, ANN INTERN MED, V103, P782, DOI 10.7326/0003-4819-103-5-782; PURDY BH, 1984, ANN INTERN MED, V100, P512, DOI 10.7326/0003-4819-100-4-512; SHEFFER AL, 1984, J ALLERGY CLIN IMMUN, V74, P580, DOI 10.1016/0091-6749(84)90110-6; SOGN DD, 1984, J ALLERGY CLIN IMMUN, V74, P589, DOI 10.1016/0091-6749(84)90111-8; VOLBERDING PA, 1985, ANN INTERN MED, V103, P729, DOI 10.7326/0003-4819-103-5-729; WRIGHT N, 1967, LANCET, V2, P1176; 1983, MMWR, V32, P309	13	61	61	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					484	488		10.1016/0091-6749(87)90366-6	http://dx.doi.org/10.1016/0091-6749(87)90366-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	3819229				2022-12-18	WOS:A1987G479500011
J	HAIDA, M; OKUDAIRA, H; OGITA, T; ITO, K; MIYAMOTO, T; NAKAJIMA, T; HONGO, O				HAIDA, M; OKUDAIRA, H; OGITA, T; ITO, K; MIYAMOTO, T; NAKAJIMA, T; HONGO, O			ALLERGENS OF THE HOUSE DUST MITE DERMATOPHAGOIDES-FARINAE - IMMUNOCHEMICAL STUDIES OF 4 ALLERGENIC FRACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC MED,DEPT IMMUNOL,WINNIPEG R3T 2N2,MANITOBA,CANADA; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT DERMATOL,TOKYO,JAPAN	University of Manitoba; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital	HAIDA, M (corresponding author), UNIV TOKYO,FAC MED,DEPT MED & PHYS THERAPY,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.							BILIOTTI G, 1975, CLIN ALLERGY, V1, P69; BULLOCK JD, 1972, AM J DIS CHILD, V123, P222, DOI 10.1001/archpedi.1972.02110090092010; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; Cooke RA, 1922, J IMMUNOL, V7, P147; DANDEU JP, 1982, IMMUNOLOGY, V46, P679; ISHII A, 1973, JPN J EXP MED, V43, P495; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; KLINMAN NR, 1969, CLIN EXP IMMUNOL, V4, P473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; LIND P, 1980, ALLERGY, V35, P227, DOI 10.1111/j.1398-9995.1980.tb01756.x; LIND P, 1981, P SCANDINAVIAN C ALL; MCALLEN MK, 1970, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.5708.501; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; MIYAMOTO T, 1974, J ALLERGY CLIN IMMUN, V53, P9, DOI 10.1016/0091-6749(74)90094-3; MIYAMOTO T, 1970, ANN ALLERGY, V28, P405; MIYAMOTO T, 1969, J ALLERGY, V44, P282, DOI 10.1016/0021-8707(69)90033-1; MIYAMOTO T, 1976, EXCERPTA MED INT C S, V414, P173; MORITA Y, 1975, ANN ALLERGY, V35, P361; NAKAGAWA T, 1977, INT ARCH ALLER A IMM, V55, P47, DOI 10.1159/000231907; PEPYS J, 1968, LANCET, V1, P270; ROMAGNANI S, 1976, INT ARCH ALLER A IMM, V50, P525, DOI 10.1159/000231557; Romagnani S, 1972, Clin Allergy, V2, P115, DOI 10.1111/j.1365-2222.1972.tb01276.x; SPIEKSMA FT, 1969, ACTA ALLERGOL, V24, P124, DOI 10.1111/j.1398-9995.1969.tb03762.x; STEWART GA, 1982, INT ARCH ALLER A IMM, V69, P224, DOI 10.1159/000233175; VANLEEUWEN S, 1925, Z IMMUNITATSFORSCH E, V43, P490; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; Voorhorst R., 1964, Allergie Asthma, V10, P329; WOODIEL NL, 1974, J ALLERGY CLIN IMMUN, V53, P278, DOI 10.1016/0091-6749(74)90106-7; Wrigley C.W., 1971, METHOD ENZYMOL, V22, P559	30	61	62	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	6					686	692		10.1016/0091-6749(85)90094-6	http://dx.doi.org/10.1016/0091-6749(85)90094-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ALA84	4008797				2022-12-18	WOS:A1985ALA8400009
J	FIELDS, DAS; PILLAR, J; DIAMANTIS, W; PERHACH, JL; SOFIA, RD; CHAND, N				FIELDS, DAS; PILLAR, J; DIAMANTIS, W; PERHACH, JL; SOFIA, RD; CHAND, N			INHIBITION BY AZELASTINE OF NONALLERGIC HISTAMINE-RELEASE FROM RAT PERITONEAL MAST-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WALLACE LABS,DEPT PHARMACOL,HALF ACRE RD,CRANBURY,NJ 08512									CHAND N, 1983, J ALLERGY CLIN IMMUN, V71, P149, DOI 10.1016/0091-6749(83)90365-2; CHAND N, 1982, INT J IMMUNOPHARMACO, V4, P342, DOI 10.1016/0192-0561(82)90327-7; CHAND N, 1983, EUR J PHARMACOL, V96, P227, DOI 10.1016/0014-2999(83)90311-4; CHAND N, 1983, PHARMACOLOGIST, V25, P181; DIAMANTIS W, 1982, PHARMACOLOGIST, V24, P200; Diamantis W., 1981, PHARMACOLOGIST, V23, P149; FIELDS DAS, 1981, PHARMACOLOGIST, V23, P161; FISCHER B, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1193; FOREMAN JC, 1981, ANNU REV PHARMACOL, V21, P63, DOI 10.1146/annurev.pa.21.040181.000431; KATAYAMA S, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1196; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; MANDI A, 1981, B EUR PHYSIOPATHOL R, V17, P5; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; ZECHEL HJ, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1184	14	61	66	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					400	403		10.1016/0091-6749(84)90415-9	http://dx.doi.org/10.1016/0091-6749(84)90415-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6199399				2022-12-18	WOS:A1984SK15500016
J	MCFADDEN, ER				MCFADDEN, ER			PATHOGENESIS OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review									BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	MCFADDEN, ER (corresponding author), BRIGHAM & WOMENS HOSP, SHIPLEY INST MED, BOSTON, MA 02115 USA.							ALLEGRA L, 1980, EUR J RESPIR DIS, V61, P41; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; AQUILINA AT, 1980, AM REV RESPIR DIS, V122, P3; AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; AYERS SM, 1970, CLIN PHARMACOL THER, V11, P337; BARNES PJ, 1983, AM REV RESPIR DIS, V127, P758; BARNES PJ, 1981, CLIN SCI, V61, P159, DOI 10.1042/cs0610159; BAROR O, 1977, J ALLERGY CLIN IMMUN, V60, P163, DOI 10.1016/0091-6749(77)90119-1; BEIL M, 1978, RESPIRATION, V35, P78, DOI 10.1159/000193863; BERNSTEIN IL, 1981, CLIN CHEST MED, V2, P255; BOUHUYS A, 1963, CLIN PHARMACOL THER, V4, P311; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRODY JS, 1972, J APPL PHYSIOL, V32, P160, DOI 10.1152/jappl.1972.32.2.160; BROWN R, 1978, J APPL PHYSIOL, V44, P150, DOI 10.1152/jappl.1978.44.2.150; BROWN R, 1977, J APPL PHYSIOL, V42, P221, DOI 10.1152/jappl.1977.42.2.221; BRUCE C, 1976, THORAX, V31, P724, DOI 10.1136/thx.31.6.724; BUNDGAARD A, 1982, EUR J RESPIR DIS, V63, P239; BUNDGAARD A, 1981, ALLERGY, V36, P385, DOI 10.1111/j.1398-9995.1981.tb01843.x; BUTCHER BT, 1977, J ALLERGY CLIN IMMUN, V59, P223, DOI 10.1016/0091-6749(77)90153-1; CABEZAS GA, 1971, J APPL PHYSIOL, V31, P651, DOI 10.1152/jappl.1971.31.5.651; CADE JF, 1971, LANCET, V2, P186; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHARLES TJ, 1979, CLIN SCI, V57, P39, DOI 10.1042/cs0570039; CHEN WY, 1977, RESPIRATION, V34, P305, DOI 10.1159/000193842; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAVIES RJ, 1983, ALLERGY PRINCIPLES P, P1037; DAVIS B, 1979, AM REV RESPIR DIS, V120, P547; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; DOUGLAS JS, 1973, J PHARMACOL EXP THER, V184, P169; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; FARRELL BP, 1980, AM REV RESPIR DIS, V121, P431; FISH JE, 1976, AM REV RESPIR DIS, V113, P579; FOLINSBEE LJ, 1980, AM REV RESPIR DIS, V121, P431, DOI 10.1164/arrd.1980.121.3.431; FORD RM, 1969, MED J AUSTRALIA, V1, P628, DOI 10.5694/j.1326-5377.1969.tb92346.x; FOSTER RW, 1968, BRIT J PHARMACOL, V33, P357, DOI 10.1111/j.1476-5381.1968.tb00996.x; FRANK NR, 1962, J APPL PHYSIOL, V17, P252, DOI 10.1152/jappl.1962.17.2.252; GADDIE J, 1972, British Journal of Diseases of the Chest, V66, P141, DOI 10.1016/S0007-0971(72)80036-6; GIRALDO B, 1969, ANN INTERN MED, V71, P479, DOI 10.7326/0003-4819-71-3-479; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GOLDSMITH J R, 1969, Journal of the Air Pollution Control Association, V19, P329; GOLDSTEIN IF, 1981, JAPCA J AIR WASTE MA, V31, P370, DOI 10.1080/00022470.1981.10465231; GREGG I, 1977, ASTHMA, P214; GRIECO MH, 1971, J ALLERGY CLIN IMMUN, V48, P143, DOI 10.1016/0091-6749(71)90009-1; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; GRIFFIN MP, 1982, J APPL PHYSIOL, V53, P1576, DOI 10.1152/jappl.1982.53.6.1576; GUERZON GM, 1979, AM REV RESPIR DIS, V119, P59; HACKNEY JD, 1978, ARCH ENVIRON HEALTH, V33, P176, DOI 10.1080/00039896.1978.10667330; HANNA CJ, 1981, NATURE, V290, P343, DOI 10.1038/290343a0; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; HIGENBOTTAM T, 1980, J APPL PHYSIOL, V49, P403, DOI 10.1152/jappl.1980.49.3.403; HOGG JC, 1982, CHEST, V82, pS8, DOI 10.1378/chest.82.1_Supplement.8S; HOLGATE ST, ASTHMA, V3; HOLROYDE MC, 1981, LANCET, V2, P17; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; HOLTZMAN MJ, 1980, AM REV RESPIR DIS, V122, P17; HORTON DJ, 1978, AM REV RESPIR DIS, V117, P1029; HOWARTH PH, 1982, THORAX, V37, P788; HUBER TE, 1954, AMA ARCH IND HYG OCC, V10, P399; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; IND PW, 1983, BRIT J PHARMACOL, V15, P14; INGRAM RH, 1977, J CLIN INVEST, V59, P696, DOI 10.1172/JCI108688; INNERSON LL, 1965, BRIT J PHARMACOL, V25, P18; ITKIN IH, 1967, J ALLERGY, V40, P245, DOI 10.1016/0021-8707(67)90087-1; JAMES L, 1976, J ALLERGY CLIN IMMUN, V57, P408, DOI 10.1016/0091-6749(76)90055-5; JUHLIN L, 1972, J ALLERGY CLIN IMMUN, V50, P92, DOI 10.1016/0091-6749(72)90004-8; KERR HD, 1979, ENVIRON RES, V19, P392, DOI 10.1016/0013-9351(79)90064-1; KERR JW, 1970, BMJ-BRIT MED J, V2, P139, DOI 10.1136/bmj.2.5702.139; KOENIG JQ, 1981, ENVIRON RES, V25, P340, DOI 10.1016/0013-9351(81)90036-0; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; KOUNIS NG, 1976, ANN ALLERGY, V37, P285; LAGUNOFF D, 1983, EXP LUNG RES, V4, P121, DOI 10.3109/01902148309055009; Laitinen L A, 1974, Scand J Respir Dis Suppl, V86, P1; LAITINEN LA, 1976, AM REV RESPIR DIS, V114, P291; LANGER I, 1967, J PHYSIOL-LONDON, V190, pP41; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1983, LANCET, V1, P520; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; LIEBERMAN P, 1978, J ALLERGY CLIN IMMUN, V62, P174, DOI 10.1016/0091-6749(78)90103-3; LINN WS, 1980, AM REV RESPIR DIS, V121, P243; LINN WS, 1978, AM REV RESPIR DIS, V117, P835; LOCKEY SD, 1977, ANN ALLERGY, V38, P206; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MATHE AA, 1976, ACTA PHYSL SCAND, V44, P1; MCFADDEN ER, 1980, J ALLERGY CLIN IMMUN, V66, P472, DOI 10.1016/0091-6749(80)90008-1; MCFADDEN ER, 1969, PSYCHOSOM MED, V31, P134, DOI 10.1097/00006842-196903000-00007; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MCNEILL RS, 1966, Q J MED, V35, P55; MCNEILL RS, 1966, AM J CARDIOL, V18, P473, DOI 10.1016/0002-9149(66)90072-5; MICHOUD MC, 1978, J APPL PHYSIOL, V45, P846, DOI 10.1152/jappl.1978.45.6.846; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; MORGAN DJR, 1982, CLIN ALLERGY, V12, P29; MURPHY RLH, 1976, BRONCHIAL ASTHMA MEC, P517; NADEL JA, 1976, BRONCHIAL ASTHMA MEC, P155; NAGAKURA T, 1983, AM REV RESPIR DIS, V128, P294; NEWBALL HH, 1973, J APPL PHYSIOL, V35, P552, DOI 10.1152/jappl.1973.35.4.552; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; ODRISCOLL BRC, 1982, THORAX, V37, P241, DOI 10.1136/thx.37.4.241; OGILVIE A. G., 1962, THORAX, V17, P183, DOI 10.1136/thx.17.3.183; OREHEK J, 1977, AM REV RESPIR DIS, V115, P937; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; PATEL KR, 1976, J ALLERGY CLIN IMMUN, V57, P285, DOI 10.1016/0091-6749(76)90084-1; PATTERSON R, 1977, J CLIN INVEST, V59, P217, DOI 10.1172/JCI108631; PAULET G, 1969, J PHYSIOL-PARIS, VS 61, P160; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; RICHARDSON J, 1976, J APPL PHYSIOL, V41, P764, DOI 10.1152/jappl.1976.41.5.764; RICHARDSON JB, 1979, AM REV RESPIR DIS, V119, P785; RICHARDSON PS, 1969, BMJ-BRIT MED J, V3, P143, DOI 10.1136/bmj.3.5663.143; ROSENTHAL RR, 1977, J APPL PHYSIOL, V42, P600, DOI 10.1152/jappl.1977.42.4.600; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V49, P6; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SETTIPANE GA, 1975, J ALLERGY CLIN IMMUN, V56, P215, DOI 10.1016/0091-6749(75)90092-5; SHEARD P, 1967, NATURE, V216, P283, DOI 10.1038/216283a0; SHEPPARD D, 1982, J APPL PHYSIOL, V53, P169, DOI 10.1152/jappl.1982.53.1.169; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; SHEPPARD D, 1981, AM REV RESPIR DIS, V124, P257; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; SIMONSSO BG, 1965, ACTA ALLERGOL, V20, P325, DOI 10.1111/j.1398-9995.1965.tb03068.x; SMITH LJ, 1976, J ALLERGY CLIN IMMUN, V58, P456, DOI 10.1016/0091-6749(76)90189-5; SNAPPER JR, 1978, J APPL PHYSIOL, V44, P738, DOI 10.1152/jappl.1978.44.5.738; SNASHALL PD, 1982, THORAX, V37, P118, DOI 10.1136/thx.37.2.118; SPECTOR S, 1976, AM REV RESPIR DIS, V113, P43; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1983, J ALLERGY CLIN IMMUN, V71, P156, DOI 10.1016/0091-6749(83)90396-2; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; TAKIZAWA T, 1971, AM REV RESPIR DIS, V104, P331, DOI 10.1164/arrd.1971.104.3.331; TAN Y, 1982, ANN ALLERGY, V48, P1; TARLO S, 1979, CLIN ALLERGY, V9, P293, DOI 10.1111/j.1365-2222.1979.tb01556.x; TATTERSFIELD AE, 1973, J APPL PHYSIOL, V35, P613, DOI 10.1152/jappl.1973.35.5.613; TOWNLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P427, DOI 10.1016/0091-6749(75)90061-5; VIDRUK EH, 1977, J APPL PHYSIOL, V43, P397, DOI 10.1152/jappl.1977.43.3.397; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; WEBER RW, 1979, J ALLERGY CLIN IMMUN, V64, P32, DOI 10.1016/0091-6749(79)90080-0; WEINER A, 1961, ANN ALLERGY, V19, P397; Weiss J W, 1982, Trans Assoc Am Physicians, V95, P30; WEISS JW, 1983, J ALLERGY CLIN IMMUN, V72, P140, DOI 10.1016/0091-6749(83)90521-3; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WEISS ST, AM REV RESPIR DIS; WELLIVER RC, 1983, J ALLERGY CLIN IMMUN, V72, P341, DOI 10.1016/0091-6749(83)90497-9; YOUNG WA, 1964, J APPL PHYSIOL, V19, P765, DOI 10.1152/jappl.1964.19.4.765; ZAID G, 1966, NEW ENGL J MED, V275, P580, DOI 10.1056/NEJM196609152751103; ZEIDBERG LD, 1961, AM REV RESPIR DIS, V84, P489	159	61	61	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	4					413	424		10.1016/0091-6749(84)90347-6	http://dx.doi.org/10.1016/0091-6749(84)90347-6			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SM089	6707390				2022-12-18	WOS:A1984SM08900001
J	HEMADY, Z; BLOMBERG, F; GELLIS, S; ROCKLIN, RE				HEMADY, Z; BLOMBERG, F; GELLIS, S; ROCKLIN, RE			IGE PRODUCTION INVITRO BY HUMAN-BLOOD MONONUCLEAR-CELLS - A COMPARISON BETWEEN ATOPIC AND NONATOPIC SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TUFTS UNIV,NEW ENGLAND MED CTR,DEPT MED,DIV ALLERGY,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,DEPT MED,DIV DERMATOL,BOSTON,MA 02111; BIOCELL LABS HB,UPPSALA,SWEDEN	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University								BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; FISER PM, 1979, J IMMUNOL, V123, P1788; GEHA RS, 1975, J CLIN INVEST, V56, P386, DOI 10.1172/JCI108103; GHORY AC, 1980, CLIN EXP IMMUNOL, V40, P581; ISHIZAKA K, 1978, IMMUNOL REV, V41, P109; KATZ DH, 1980, IMMUNOLOGY, V41, P1; LIMA M, 1981, CELL IMMUNOL, V64, P324, DOI 10.1016/0008-8749(81)90484-6; PATTERSON R, 1975, CLIN EXP IMMUNOL, V20, P265; PRYJMA J, 1980, CELL IMMUNOL, V50, P115, DOI 10.1016/0008-8749(80)90011-8; ROMAGNANI S, 1980, CLIN EXP IMMUNOL, V42, P579; ROMAGNANI S, 1980, CLIN EXP IMMUNOL, V42, P167; SAMPSON HA, 1981, J IMMUNOL, V127, P829; SAXON A, 1980, J CLIN INVEST, V65, P1457, DOI 10.1172/JCI109810; SAXON A, 1979, CLIN IMMUNOL IMMUNOP, V14, P974; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; TJIO AH, 1979, J IMMUNOL, V122, P2131; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5; ZURAW BL, 1981, J IMMUNOL, V127, P1169	20	61	61	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	3					324	330		10.1016/0091-6749(83)90087-8	http://dx.doi.org/10.1016/0091-6749(83)90087-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QH188	6826992				2022-12-18	WOS:A1983QH18800009
J	DORSCH, W; RING, J; REIMANN, HJ; GEIGER, R				DORSCH, W; RING, J; REIMANN, HJ; GEIGER, R			MEDIATOR STUDIES IN SKIN BLISTER FLUID FROM PATIENTS WITH DUAL SKIN REACTIONS AFTER INTRADERMAL ALLERGEN INJECTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MUNICH, DEPT DERMATOL, D-8000 MUNICH 2, FED REP GER; TECH UNIV MUNICH, DEPT INTERNAL MED, D-8000 MUNICH, FED REP GER; UNIV MUNICH, DEPT SURG, D-8000 MUNICH 2, FED REP GER	University of Munich; Technical University of Munich; University of Munich	DORSCH, W (corresponding author), UNIV MUNICH, KINDER POLIKLIN, DEPT PEDIAT, D-8000 MUNICH 2, FED REP GER.		Ring, Johannes/GLN-4341-2022	Ring, Johannes/0000-0001-8236-3152				Askenase P W, 1977, Prog Allergy, V23, P199, DOI 10.1159/000314242; BENVENISTE J, 1977, NATURE, V269, P170, DOI 10.1038/269170a0; BIANCO S, 1978, PHARMACOL RES COMMUN, V10, P657, DOI 10.1016/S0031-6989(78)80009-5; BIANCO S, 1979, PROSTAG LEUKOTR ESS, V3, P39, DOI 10.1016/0161-4630(79)90014-4; Black A K, 1976, Br J Pharmacol, V58, p317P; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BROCKLEHURST WE, 1968, BIOCH ACUTE ALLERGIC, P297; CHIGNARD M, 1979, NATURE, V279, P799, DOI 10.1038/279799a0; CURD JG, 1980, J EXP MED, V152, P742, DOI 10.1084/jem.152.3.742; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DORSCH W, 1980, PRAX KLIN PNEUMOL, V34, P461; DORSCH W, 1981, J ALLERGY CLIN IMMUN, V67, P117, DOI 10.1016/0091-6749(81)90006-3; DORSCH W, 1980, ALLERGY, V35, P503, DOI 10.1111/j.1398-9995.1980.tb01797.x; DORSCH W, 1982, AGENTS ACTIONS, V12, P113, DOI 10.1007/BF01965120; DORSCH W, ALLERGOLOGIE; DUNSKY EH, 1978, J ALLERGY CLIN IMMUN, V62, P127, DOI 10.1016/0091-6749(78)90091-X; Harris D N, 1980, Adv Prostaglandin Thromboxane Res, V6, P437; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; KRAVIS TC, 1977, J IMMUNOL, V118, P1569; LORENZ W, 1972, H-S Z PHYSIOL CHEM, V353, P911, DOI 10.1515/bchm2.1972.353.1.911; LOTNER GZ, 1980, J IMMUNOL, V124, P676; Mann K, 1976, Adv Exp Med Biol, V70, P65; MICHEL B, 1970, International Archives of Allergy and Applied Immunology, V39, P616; MONCADA S, 1978, PHARMACOL REV, V30, P293; NEWBALL HH, 1975, NATURE, V254, P635, DOI 10.1038/254635a0; Pepys J, 1973, Clin Allergy, V3, P1, DOI 10.1111/j.1365-2222.1973.tb01304.x; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; RATNOFF OD, 1971, THROMB DIATH HAEMO, V45, P109; RICHERSON HB, 1979, J ALLERGY CLIN IMMUN, V64, P67, DOI 10.1016/0091-6749(79)90085-X; RING J, 1979, INT ARCH ALLER A IMM, V58, P322, DOI 10.1159/000232208; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SHAIKH W, 1977, J ALLERGY CLIN IMMUN, V60, P242, DOI 10.1016/0091-6749(77)90138-5; SIESS W, 1981, THROMB HAEMOSTASIS, V45, P204; SMITH JA, 1980, J ALLERGY CLIN IMMUN, V65, P118, DOI 10.1016/0091-6749(80)90195-5; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Stalenheim G, 1979, Monogr Allergy, V14, P264; SVENSSON J, 1977, PROSTAGLANDINS, V14, P425, DOI 10.1016/0090-6980(77)90258-1; UMEMOTO L, 1976, J ALLERGY CLIN IMMUN, V58, P60, DOI 10.1016/0091-6749(76)90107-X; VARGAFTIG BB, 1980, EUR J PHARMACOL, V65, P185, DOI 10.1016/0014-2999(80)90391-X; VARGAFTIG BB, 1979, PROSTAGLANDINS, V18, P519; VERMEER BJ, 1979, J INVEST DERMATOL, V73, P303, DOI 10.1111/1523-1747.ep12531833; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905	44	61	61	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	4					236	242		10.1016/0091-6749(82)90059-8	http://dx.doi.org/10.1016/0091-6749(82)90059-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PL151	6181112				2022-12-18	WOS:A1982PL15100003
J	MATHISON, DA; STEVENSON, DD				MATHISON, DA; STEVENSON, DD			HYPERSENSITIVITY TO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS - INDICATIONS AND METHODS FOR ORAL CHALLENGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SCRIPPS CLIN & RES FDN,RES INST,DEPT CLIN RES,LA JOLLA,CA 92037	Scripps Research Institute								ABRAHAM AS, 1978, BRIT MED J, V1, P619; BASOMBA A, 1976, CLIN ALLERGY, V6, P269, DOI 10.1111/j.1365-2222.1976.tb01907.x; BIANCO S, 1977, IRCS (International Research Communications System) Medical Science Library Compendium, V5, P129; CHAFEE FH, 1967, J ALLERGY, V40, P65, DOI 10.1016/0021-8707(67)90099-8; COLLIER JL, COMMUNICATION; Cooke RA, 1919, J AMER MED ASSOC, V73, P759, DOI 10.1001/jama.1919.02610360029008; FARR RS, 1978, ANN INTERN MED, V59, P577; FINGL E, 1965, PHARMACOLOGICAL BASI, P22; JAKSCHIK B, 1976, CLIN RES, V24, pA575; KORDANSKY D, 1978, ANN INTERN MED, V88, P508, DOI 10.7326/0003-4819-88-4-508; MARTELLI NA, 1977, THORAX, V32, P684, DOI 10.1136/thx.32.6.684; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MICHAELSSON G, 1973, BRIT J DERMATOL, V88, P525, DOI 10.1111/j.1365-2133.1973.tb08014.x; OREHEK J, 1977, J ALLERGY CLIN IMMUN, V59, P414, DOI 10.1016/0091-6749(77)90003-3; PATRIARCA G, 1973, ANN ALLERGY, V31, P84; ROS AM, 1976, BRIT J DERMATOL, V95, P19, DOI 10.1111/j.1365-2133.1976.tb15532.x; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; SMITH AP, 1971, BRIT MED J, V2, P494, DOI 10.1136/bmj.2.5760.494; STEVENSON DD, 1976, CLIN ALLERGY, V6, P493, DOI 10.1111/j.1365-2222.1976.tb01934.x; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; VANE JR, 1976, J ALLERGY CLIN IMMUN, V58, P691, DOI 10.1016/0091-6749(76)90181-0; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANSELOW NA, 1967, ANN INTERN MED, V66, P567; WALKER JL, 1973, ADV BIOSCI, V9, P235; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2	27	61	64	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	6					669	674		10.1016/0091-6749(79)90036-8	http://dx.doi.org/10.1016/0091-6749(79)90036-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HX843	512263				2022-12-18	WOS:A1979HX84300024
J	DOLOVICH, J; LITTLE, DC				DOLOVICH, J; LITTLE, DC			CORRELATES OF SKIN-TEST REACTIONS TO BACILLUS-SUBTILIS ENZYME PREPARATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		Coombs RRA., 1968, CLIN ASPECTS IMMUNOL, V2, P575; DEBANNE MT, 1971, J ALLERGY CLIN IMMUN, V48, P212, DOI 10.1016/0091-6749(71)90067-4; DOLOVICH J, 1970, J ALLERGY, V45, P286, DOI 10.1016/0021-8707(70)90034-1; DOLOVICH J, 1971, J LAB CLIN MED, V77, P951; DOLOVICH J, UNPUBLISHED OBSERVAT; FIREMAN P, 1967, J ALLERGY, V40, P304, DOI 10.1016/0021-8707(67)90078-0; FLINDT MLH, 1969, LANCET, V1, P1177; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; GREENBERG M, 1970, BMJ-BRIT MED J, V2, P629, DOI 10.1136/bmj.2.5710.629; GUNTELBERG A. V., 1954, COMPT REND TRAV LAB CARLSBERG SER CHIM, V29, P36; ISHIZAKA K, 1970, CLIN EXP IMMUNOL, V6, P25; ISHIZAKA K, 1971, J ALLERGY, V47, P89; ISHIZAKA T, 1966, J IMMUNOL, V97, P716; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; NEWHOUSE ML, 1970, LANCET, V1, P689; OTTESEN M, 1960, CR TRAV LAB CARLSB, V32, P63; PEPYS J, 1969, LANCET, V1, P1181; PEPYS J, 1969, MONOGR ALLERGY, V4, P39; PEPYS J, 1968, CLINICAL ASPECTS IMM, P189; SALVAGGIO JE, 1970, NEW ENGL J MED, V283, P314, DOI 10.1056/NEJM197008062830610; SHAPIRO RS, 1971, J ALLERGY, V47, P76, DOI 10.1016/S0091-6749(71)80373-1; WICHER V, 1971, INT ARCH ALLER A IMM, V40, P779, DOI 10.1159/000230462; WICHER V, 1972, J ALLERGY CLIN IMMUN, V49, P59, DOI 10.1016/0091-6749(72)90124-8	23	61	61	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	1					43	&		10.1016/0091-6749(72)90122-4	http://dx.doi.org/10.1016/0091-6749(72)90122-4			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L3388	4257104				2022-12-18	WOS:A1972L338800006
J	TALAMO, RC				TALAMO, RC			ALPHA-ANTITRYPSIN IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BRISCOE WA, 1966, AM REV RESPIR DIS, V94, P529; ERIKSSON S, 1965, ACTA MED SCAND  S432, V177, P1; EVANS HE, 1970, AM REV RESPIR DIS, V101, P359; FAGERHOL MK, 1965, SCIENCE, V149, P986, DOI 10.1126/science.149.3687.986; FAGERHOL MK, 1969, ACTA ALLERGOL, V24, P107, DOI 10.1111/j.1398-9995.1969.tb03760.x; FAGERHOL MK, 1967, CLIN CHIM ACTA, V16, P199, DOI 10.1016/0009-8981(67)90181-7; FALK GA, 1971, AM REV RESPIR DIS, V103, P18; GANROT PO, 1967, SCAND J CLIN LAB INV, V19, P205, DOI 10.3109/00365516709090627; GANS H, 1967, CLIN CHIM ACTA, V17, P111, DOI 10.1016/0009-8981(67)90104-0; GOUGH J., 1949, JOUR ROY MICROSC SOC, V69, P231; HYSLOP NE, TO BE PUBLISHED; JANOFF A, 1970, LAB INVEST, V22, P228; JOHNSON A M, 1970, Pediatrics, V46, P921; JOHNSON MW, PERSONAL COMMUNICATI; KUEPPERS F, 1969, SCIENCE, V165, P899, DOI 10.1126/science.165.3896.899; KUEPPERS F, 1966, P SOC EXP BIOL MED, V121, P1207; KUEPPERS F, 1968, HUMANGENETIK, V6, P207, DOI 10.1007/BF00291864; KUEPPERS F, 1969, CLIN CHIM ACTA, V24, P401, DOI 10.1016/0009-8981(69)90111-9; LARSON RK, 1970, ANN INTERN MED, V72, P627, DOI 10.7326/0003-4819-72-5-627; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LAURELL CB, 1970, SCAND J CLIN LAB INV, V26, P345, DOI 10.3109/00365517009046244; LAURELL CB, 1965, J BIOCHEM, V10, P358; LEVINE BW, 1970, ANN INTERN MED, V73, P397, DOI 10.7326/0003-4819-73-3-397; LIEBERMA.J, 1969, NEW ENGL J MED, V281, P279, DOI 10.1056/NEJM196908072810601; LIEBERMAN J, 1971, S PROTEOLYSIS PULMON; MAKINO S, 1970, J LAB CLIN MED, V75, P742; MILLER F, 1969, AM J MED, V46, P615, DOI 10.1016/0002-9343(69)90080-1; PEDERSEN JT, 1969, DAN MED BULL, V16, P283; PIERCE J A, 1969, Clinical Research, V17, P477; SHARP H, 1971, S PROTEOLYSIS PULMON; SHARP HL, 1969, J LAB CLIN MED, V73, P934; STEVENS PM, IN PRESS; TALAMO RC, 1968, NEW ENGL J MED, V278, P345, DOI 10.1056/NEJM196802152780701; TALAMO RC, 1969, AM REV RESP DIS, V99, P998; TURINO GM, 1969, SCIENCE, V165, P709, DOI 10.1126/science.165.3894.709; TYLER HM, 1962, LANCET, V2, P432; WELCH MH, 1969, ANN INTERN MED, V71, P533, DOI 10.7326/0003-4819-71-3-533	37	61	61	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	4					240	&		10.1016/0091-6749(71)90072-8	http://dx.doi.org/10.1016/0091-6749(71)90072-8			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K5566					2022-12-18	WOS:A1971K556600008
J	Bozzi, G; Mangioni, D; Minoia, F; Aliberti, S; Grasselli, G; Barbetta, L; Castelli, V; Palomba, E; Alagna, L; Lombardi, A; Ungaro, R; Agostoni, C; Baldini, M; Blasi, F; Cesari, M; Costantino, G; Fracanzani, AL; Montano, N; Monzani, V; Pesenti, A; Peyvandi, F; Sottocorno, M; Muscatello, A; Filocamo, G; Gori, A; Bandera, A				Bozzi, Giorgio; Mangioni, Davide; Minoia, Francesca; Aliberti, Stefano; Grasselli, Giacomo; Barbetta, Laura; Castelli, Valeria; Palomba, Emanuele; Alagna, Laura; Lombardi, Andrea; Ungaro, Riccardo; Agostoni, Carlo; Baldini, Marina; Blasi, Francesco; Cesari, Matteo; Costantino, Giorgio; Fracanzani, Anna Ludovica; Montano, Nicola; Monzani, Valter; Pesenti, Antonio; Peyvandi, Flora; Sottocorno, Marcello; Muscatello, Antonio; Filocamo, Giovanni; Gori, Andrea; Bandera, Alessandra			Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SARS-CoV-2; COVID-19; hyperinflammation; anti-IL-1; anakinra; corticosteroids; methylprednisolone; immunomodulation; respiratory failure; mechanical ventilation		Background: Immunomodulants have been proposed to mitigate severe acute respiratory syndrome coronavirus 2-induced cytokine storm, which drives acute respiratory distress syndrome in coronavirus disease 2019 (COVID-19). Objective: We sought to determine efficacy and safety of the association of IL-1 receptor antagonist anakinra plus methylprednisolone in severe COVID-19 pneumonia with hyperinflammation. Methods: A secondary analysis of prospective observational cohort studies was carried out at an Italian tertiary health care facility. COVID-19 patients consecutively hospitalized (February 25, 2020, to March 30, 2020) with hyperinflammation (ferritin >1000 ng/mL and/or C-reactive protein >10 mg/dL) and respiratory failure (oxygen therapy from 0.4 FiO(2) Venturi mask to invasive mechanical ventilation) were evaluated to investigate the effect of high-dose anakinra plus methylprednisolone on survival. Patients were followed from study inclusion to day 28 or death. Crude and adjusted (sex, age, baseline PaO2:FiO2 ratio, Charlson index, baseline mechanical ventilation, hospitalization to inclusion lapse) risks were calculated (Cox proportional regression model). Results: A total of 120 COVID-19 patients with hyperinflammation (median age, 62 years; 80.0% males; median PaO2:FiO(2) ratio, 151; 32.5% on mechanical ventilation) were evaluated. Of these, 65 were treated with anakinra and methylprednisolone and 55 were untreated historical controls. At 28 days, mortality was 13.9% in treated patients and 35.6% in controls (Kaplan-Meier plots, P 5.005). Unadjusted and adjusted risk of death was significantly lower for treated patients compared with controls (hazard ratio, 0.33, 95% CI, 0.15-0.74, P 5.007, and HR, 0.18, 95% CI, 0.07-0.50, P 5.001, respectively). No significant differences in bloodstream infections or laboratory alterations were registered. Conclusions: Treatment with anakinra plus methylprednisolone may be a valid therapeutic option in COVID-19 patients with hyperinflammation and respiratory failure, also on mechanical ventilation. Randomized controlled trials including the use of either agent alone are needed to confirm these results.	[Bozzi, Giorgio; Mangioni, Davide; Castelli, Valeria; Palomba, Emanuele; Alagna, Laura; Lombardi, Andrea; Ungaro, Riccardo; Muscatello, Antonio; Gori, Andrea; Bandera, Alessandra] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Infect Dis Unit, Milan, Italy; [Mangioni, Davide] Univ Milan, Dept Med Biotechnol & Translat Med, Milan, Italy; [Minoia, Francesca; Agostoni, Carlo; Filocamo, Giovanni] Fdn IRCCS Ca Granda Osped Maggiore Policlin, UOC Pediat Media Intensita Cure, Milan, Italy; [Aliberti, Stefano; Blasi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Resp Unit, Milan, Italy; [Aliberti, Stefano; Blasi, Francesco] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Cyst Fibrosis Adult Ctr, Milan, Italy; [Aliberti, Stefano; Grasselli, Giacomo; Blasi, Francesco; Fracanzani, Anna Ludovica; Montano, Nicola; Pesenti, Antonio; Peyvandi, Flora; Gori, Andrea; Bandera, Alessandra] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy; [Grasselli, Giacomo; Costantino, Giorgio; Pesenti, Antonio] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Anesthesia Crit Care & Emergency, Milan, Italy; [Barbetta, Laura; Monzani, Valter] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Acute Med Unit, Milan, Italy; [Agostoni, Carlo; Cesari, Matteo; Costantino, Giorgio] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy; [Baldini, Marina] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Internal Med Unit, Milan, Italy; [Cesari, Matteo] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Geriatr Unit, Milan, Italy; [Fracanzani, Anna Ludovica] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Internal Med & Metab Dis Unit, Milan, Italy; [Montano, Nicola] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Internal Med Unit, Immunol & Allergol Unit, Milan, Italy; [Peyvandi, Flora] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Internal Med & Hemostasis & Thrombosis Unit, Milan, Italy; [Sottocorno, Marcello] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hosp Pharm, Milan, Italy; [Gori, Andrea; Bandera, Alessandra] Univ Milan, Ctr Multidisciplinary Res Hlth Sci, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Mangioni, D (corresponding author), IRCCS Ca Granda Osped Maggiore Policlin Fdn, Dept Internal Med, Infect Dis Unit, Via Francesco Sforza 35, I-20122 Milan, Italy.	davide.mangioni@unimi.it	Mangioni, Davide/AAC-3982-2022; Palomba, Emanuele/ABD-3357-2021; Bandera, Alessandra/AAC-6081-2022; Aliberti, Stefano/K-9115-2016; Minoia, Francesca/K-4951-2018; costantino, giorgio/AAC-6441-2022; Gori, Andrea/AAC-6078-2022; Lombardi, Andrea/U-4323-2019; Minoia, Francesca/AAB-8450-2022; Blasi, Francesco/O-5885-2017	Mangioni, Davide/0000-0002-7431-5019; Palomba, Emanuele/0000-0003-1386-6180; Aliberti, Stefano/0000-0002-0090-4531; Minoia, Francesca/0000-0002-5093-8422; costantino, giorgio/0000-0002-6391-3849; Lombardi, Andrea/0000-0002-0383-9579; Minoia, Francesca/0000-0002-5093-8422; Blasi, Francesco/0000-0002-2285-9970; BANDERA, ALESSANDRA/0000-0001-9440-4601				Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Fadel R, 2020, CLIN INFECT DIS, V71, P2114, DOI 10.1093/cid/ciaa601; Fearon WF, 2008, CIRCULATION, V117, P2577, DOI 10.1161/CIRCULATIONAHA.108.772491; Filocamo G, 2020, INT J INFECT DIS, V96, P607, DOI 10.1016/j.ijid.2020.05.026; Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8; Ingraham NE, 2020, LANCET RESP MED, V8, P544, DOI 10.1016/S2213-2600(20)30226-5; Johns Hopkins University, CTR SYST SCI ENG; King A, 2020, LANCET RHEUMATOL, V2, pE379, DOI 10.1016/S2665-9913(20)30160-0; Mehta P, 2020, LANCET RHEUMATOL, V2, pE358, DOI 10.1016/S2665-9913(20)30096-5; Pontali E, 2020, J ALLERGY CLIN IMMUN, V146, P213, DOI 10.1016/j.jaci.2020.05.002; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Ramiro S, 2020, ANN RHEUM DIS, V79, P1143, DOI 10.1136/annrheumdis-2020-218479; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	18	60	63	2	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2021	147	2					561	+		10.1016/j.jaci.2020.11.006	http://dx.doi.org/10.1016/j.jaci.2020.11.006		FEB 2021	10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QF1NF	33220354	Green Published, Bronze			2022-12-18	WOS:000616665800017
